PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	PATEL, HR; CHOI, HS; SYTKOWSKI, AJ				PATEL, HR; CHOI, HS; SYTKOWSKI, AJ			ACTIVATION OF 2 DISCRETE SIGNALING PATHWAYS BY ERYTHROPOIETIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MURINE ERYTHROLEUKEMIA-CELLS; C-MYC; ERYTHROID-DIFFERENTIATION; PROTEIN-PHOSPHORYLATION; RIBONUCLEIC-ACID; GENE-EXPRESSION; MESSENGER-RNA; OKADAIC ACID; T-CELLS; TRANSCRIPTION	Erythropoietin stimulation of erythroid cells induces a rapid increase in c-myc and decrease in c-myb mRNA levels. The signal pathway to c-myc requires activation of protein kinase C. We now report that erythropoietin down-regulates expression of c-myb via a discrete, serine/threonine-specific phosphatase-dependent pathway. The protein kinase C-blocker H7 completely prevents the c-myc response to erythropoietin, but has no effect on the c-myb response. In contrast, the phosphatase blocker okadaic acid prevents the c-myb response but not the c-myc response. This effect of okadaic acid on the c-myb response is concentration-dependent. Both the protein kinase C-dependent signal to c-myc and the phosphatase-dependent signal to c-myb regulate gene expression by a transcriptional arrest mechanism operative within the first intron of the respective protooncogenes. In contrast, the chemical inducer of differentiation, dimethyl sulfoxide, regulates expression of c-myc and c-myb without activation of these phosphatase- and kinase-dependent pathways.	HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT MED,DIV HEMATOL & ONCOL,BOSTON,MA 02215	Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038841] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38841] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY SC, 1991, J BIOL CHEM, V266, P24121; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; CHERN YJ, 1991, J BIOL CHEM, V266, P2009; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI HS, 1987, J BIOL CHEM, V262, P2933; CHOI HS, 1990, J BIOL CHEM, V265, P4143; de Both N J, 1978, Nature, V272, P626, DOI 10.1038/272626a0; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MUNOZ E, 1991, J IMMUNOL, V146, P136; NATALIS TM, 1991, NUCLEIC ACIDS RES, V19, P4301; PATEL MD, 1987, J BIOL CHEM, V262, P5831; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; QUELLE FW, 1991, J BIOL CHEM, V266, P609; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; SPANGLER R, 1991, J BIOL CHEM, V266, P681; SYTKOWSKI AJ, 1980, SCIENCE, V210, P74, DOI 10.1126/science.6932101; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706	23	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21300	21302						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328229				2022-12-27	WOS:A1992JV01100008
J	SAVARESE, DMF; RUSSELL, JT; FATATIS, A; LIOTTA, LA				SAVARESE, DMF; RUSSELL, JT; FATATIS, A; LIOTTA, LA			TYPE-IV COLLAGEN STIMULATES AN INCREASE IN INTRACELLULAR CALCIUM - POTENTIAL ROLE IN TUMOR-CELL MOTILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MELANOMA CELLS; INOSITOL TRISPHOSPHATE; EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; DICTYOSTELIUM-DISCOIDEUM; NEUTROPHIL CHEMOTAXIS; CYCLIC METABOLITE; PEPTIDE RECEPTOR; PLASMA-MEMBRANE	Type IV collagen (Coll IV), a component of the extracellular matrix, stimulates motility in the A2058 human melanoma cell line, a response that is inhibited by pertussis toxin (PT). Fibronectin (FN)-induced chemotaxis in this cell line is not affected by PT. To understand the mechanism of cellular signaling, single cell intracellular Ca2+ responses to Coll IV and FN were studied using Fura-2 and digital imaging fluorescence microscopy. Coll IV, at a dose that stimulates motility (100 mug/ml, 185 nM), induces a significant rise in cytosolic free Ca2+ concentration ([Ca2+]i) within 100 s. This response is not inhibited by PT. Treatment of the cells with FN 30 mug/ml (70 nM), a dose that stimulates near-maximal chemotaxis, does not increase [Ca2+]i appreciably. Removal of extracellular Ca2+ fails to inhibit the Coll IV-stimulated rise in Ca2+ in all cells. Depletion of extracellular Ca2+ and pretreatment of cells with Ca2+ channel blockers only partially inhibits Coll IV-induced motility. Depletion of intracellular Ca2+ inhibits both chemotaxis and the Coll IV-induced increase in intracellular Ca2+. Coll IV does not stimulate membrane phosphoinositide hydrolysis. We conclude that Coll IV treatment induces an inositol 1,4,5-trisphosphate-independent release of intracellular Ca2+ stores which appears to play a necessary role in the chemotactic response of A2058 cells but is not mediated by a PT-sensitive G-protein. This response is not seen in cells exposed to FN, suggesting different intracellular signaling mechanisms for stimulated motility between these two extracellular matrix molecules.	NCI,MED BRANCH,BETHESDA,MD 20892; NCI,PATHOL LAB,BETHESDA,MD 20892; NICHHD,DEV NEUROBIOL LAB,BETHESDA,MD 20892; POLICLIN NAPLES 2,IST FARMACOL,NAPLES,ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Universita della Campania Vanvitelli								AZNAVOORIAN S, 1990, J CELL BIOL, V110, P1427, DOI 10.1083/jcb.110.4.1427; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BOUCEK MM, 1976, SCIENCE, V193, P905, DOI 10.1126/science.948752; CHIEN JL, 1988, INT J PANCREATOL, V3, P113; CHUEH SH, 1987, J BIOL CHEM, V262, P13857; CYBULSKY AV, 1990, AM J PHYSIOL, V259, pF326, DOI 10.1152/ajprenal.1990.259.2.F326; DAWSON AP, 1985, FEBS LETT, V185, P147, DOI 10.1016/0014-5793(85)80759-6; ELFERINK JGR, 1985, BIOCHIM BIOPHYS ACTA, V846, P364, DOI 10.1016/0167-4889(85)90007-2; FLORMAN HM, 1989, DEV BIOL, V135, P133, DOI 10.1016/0012-1606(89)90164-4; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GODFRAIND T, 1981, J PHARMACOL EXP THER, V217, P510; GODFRAIND T, 1981, FED PROC, V40, P2866; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUIRGUIS R, 1987, NATURE, V329, P261, DOI 10.1038/329261a0; HALL AL, 1989, DEV BIOL, V136, P517, DOI 10.1016/0012-1606(89)90277-7; HARRIS H, 1987, NATURE, V330, P310, DOI 10.1038/330310a0; IMAI A, 1986, BIOCHEM J, V240, P341, DOI 10.1042/bj2400341; JEAN T, 1986, J BIOL CHEM, V261, P6414; KOHN EC, 1990, BIOCHEM BIOPH RES CO, V166, P757, DOI 10.1016/0006-291X(90)90874-M; KORCZAK B, 1989, CANCER RES, V49, P2597; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; LAM WC, 1981, AM J PATHOL, V104, P69; LASSING I, 1988, EXP CELL RES, V174, P1, DOI 10.1016/0014-4827(88)90136-X; LEE HC, 1989, J BIOL CHEM, V264, P1608; LESTER BR, 1989, CANCER RES, V49, P5940; LEVY AT, 1991, CANCER RES, V51, P439; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; LIOTTA LA, 1986, CANCER RES, V46, P1; LIPSCOMBE D, 1988, P NATL ACAD SCI USA, V85, P2398, DOI 10.1073/pnas.85.7.2398; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; MESHULAM T, 1986, J IMMUNOL, V137, P1954; MILLARD PJ, 1988, P NATL ACAD SCI USA, V85, P1854, DOI 10.1073/pnas.85.6.1854; MILNE JL, 1991, J CELL BIOL, V112, P103, DOI 10.1083/jcb.112.1.103; NAKAJIMA M, 1990, J NATL CANCER I, V82, P1890, DOI 10.1093/jnci/82.24.1890; NAKANO T, 1987, J BIOCHEM-TOKYO, V101, P1169, DOI 10.1093/oxfordjournals.jbchem.a121981; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; SCHACHT J, 1976, J NEUROCHEM, V27, P1119, DOI 10.1111/j.1471-4159.1976.tb00318.x; SEZZI ML, 1985, ANTICANCER RES, V5, P265; SMITH CD, 1985, J BIOL CHEM, V260, P5875; STRACKE ML, 1987, BIOCHEM BIOPH RES CO, V146, P339, DOI 10.1016/0006-291X(87)90730-3; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; TILLY BC, 1990, J CELL BIOL, V110, P1211, DOI 10.1083/jcb.110.4.1211; TSIEN RY, 1982, J CELL BIOL, V94, P324; Varani J, 1982, Cancer Metastasis Rev, V1, P17, DOI 10.1007/BF00049478; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0; ZABRENETZKY V, 1988, BIOCHEM J, V255, P1037, DOI 10.1042/bj2551037; ZIGMOND SH, 1988, CELL MOTIL CYTOSKEL, V9, P184, DOI 10.1002/cm.970090210	52	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21928	21935						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328249				2022-12-27	WOS:A1992JV01100103
J	BRUNKHORST, BA; STROHMEIER, G; LAZZARI, K; WEIL, G; MELNICK, D; FLEIT, HB; SIMONS, ER				BRUNKHORST, BA; STROHMEIER, G; LAZZARI, K; WEIL, G; MELNICK, D; FLEIT, HB; SIMONS, ER			DIFFERENTIAL ROLES OF FC-GAMMA-RII AND FC-GAMMA-RIII IN IMMUNE-COMPLEX STIMULATION OF HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER CELLS; SUPEROXIDE PRODUCTION; SIGNAL TRANSDUCTION; HUMAN-GRANULOCYTES; RESPIRATORY BURST; IMMUNE-COMPLEXES; MONOCLONAL-ANTIBODY; CYTOSOLIC CALCIUM; POTENTIAL CHANGES; HUMAN-LEUKOCYTES	Insoluble immune complexes (IIC) stimulate human neutrophils through Fcgamma receptors. Freshly isolated human neutrophils express two FcR subclasses, FcRII and FcRIII. We explored the role of FcRII and FcRIII in this activation process by selectively binding each FcR subclass with the Fab fragments of the respective anti-FcR monoclonal antibodies (MFab) before exposure to IIC. Correlation among liganded FcR subclass, IIC binding, and ensuant IIC stimulation was achieved with multiparameter flow cytometry. We utilized rhodamine-labeled anti-FcRIII and fluorescein-labeled IIC to study binding and observed the change in [Ca2+]i in the same cell with a Ca2+ indicator, Indo-1. Treatment with either anti-FcRII (IV.3) or anti-FcRIII (3G8) MFab decreased both the fraction of cells exhibiting a Ca2+ transient and the magnitude of that transient, although only anti-FcRIII but not anti-FcRII significantly inhibited the subsequent IIC binding. In addition, cells treated with anti-FcRII and then stimulated with IIC exhibited a decrease in both the intracellular Ca2+ transient and the later Ca2+ influx, whereas anti-FcRIII totally abolished the mobilization of intracellular Ca2+ without affecting the Ca2+ influx. Treatment with either anti-FcR MFab decreased the IIC-stimulated transmembrane potential change, oxidative burst, and elastase release. These studies indicate that freshly isolated neutrophils' Fc receptor subclasses have unique roles in the IIC-initiated stimulation and that full activation can only be achieved when both FcR subclasses are available.	SUNY STONY BROOK,SCH MED,DEPT PATHOL,STONY BROOK,NY 11794; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Boston University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019717] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031056] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL19717, HL07501] Funding Source: Medline; NIDDK NIH HHS [DK31056] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333; ANDERSON CL, 1986, IMMUNOL TODAY, V7, P264, DOI 10.1016/0167-5699(86)90007-1; ANDERSON CL, 1980, J IMMUNOL, V125, P2735; ANDERSON GP, 1990, BLOOD, V76, P1165; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BRUNKHORST BA, 1991, J BIOL CHEM, V266, P13035; CLARKSON SB, 1986, J EXP MED, V164, P474, DOI 10.1084/jem.164.2.474; COHEN HJ, 1978, J CLIN INVEST, V61, P1081, DOI 10.1172/JCI109007; COHEN L, 1983, J IMMUNOL, V131, P378; CROCKETTTORABI E, 1990, J IMMUNOL, V145, P3026; DOUGHERTY RW, 1984, BIOCHEM J, V222, P307, DOI 10.1042/bj2220307; ELSON RC, 1987, ESSENTIALS BIOSTATIS; FIESTER AJ, 1988, J IMMUNOL, V141, P243; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; GIERSCHIK P, 1986, J BIOL CHEM, V261, P8058; GRAZIANO RF, 1987, J IMMUNOL, V139, P3536; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HORNE WC, 1978, BLOOD, V51, P741; HUIZINGA TWJ, 1989, J IMMUNOL, V142, P2365; HUIZINGA TWJ, 1990, J IMMUNOL, V144, P1432; HUIZINGA TWJ, 1988, NATURE, V333, P667, DOI 10.1038/333667a0; JONES DH, 1985, J IMMUNOL, V135, P3348; JONES GS, 1981, J CELL PHYSIOL, V106, P75, DOI 10.1002/jcp.1041060109; KIMBERLY RP, 1990, J EXP MED, V171, P1239, DOI 10.1084/jem.171.4.1239; KORCHAK HM, 1984, J BIOL CHEM, V259, P4076; LANIER LL, 1988, J IMMUNOL, V141, P3478; LAZZARI KG, 1986, J BIOL CHEM, V261, P9710; LEW DP, 1989, EUR J CLIN INVEST, V19, P338, DOI 10.1111/j.1365-2362.1989.tb00240.x; LOONEY RJ, 1986, J EXP MED, V163, P826, DOI 10.1084/jem.163.4.826; LUNDJOHANSEN F, 1991, SCAND J IMMUNOL, V33, P261, DOI 10.1111/j.1365-3083.1991.tb01771.x; LUSCINSKAS FW, 1988, J CELL PHYSIOL, V134, P211, DOI 10.1002/jcp.1041340206; LYMAN CA, 1987, J INFECT DIS, V156, P770, DOI 10.1093/infdis/156.5.770; PAGONIS C, 1986, BIOCHEM PHARMACOL, V35, P237, DOI 10.1016/0006-2952(86)90520-4; PERUSSIA B, 1983, J EXP MED, V158, P1092, DOI 10.1084/jem.158.4.1092; PERUSSIA B, 1984, J IMMUNOL, V132, P1410; PETTY HR, 1989, J CELL PHYSIOL, V141, P598, DOI 10.1002/jcp.1041410319; PIERCE J, 1977, ANAL BIOCHEM, V81, P478, DOI 10.1016/0003-2697(77)90723-0; Ravetch J.V., 1990, FC RECEPTORS ACTION, P211; REIBMAN J, 1991, J IMMUNOL, V146, P988; ROBERTS PJ, 1990, J LEUKOCYTE BIOL, V48, P247, DOI 10.1002/jlb.48.3.247; ROSENBERG JS, 1985, CLIN CHEM, V319, P1444; SALMON JE, 1987, J EXP MED, V166, P1798, DOI 10.1084/jem.166.6.1798; SALMON JE, 1991, J IMMUNOL, V146, P997; SALVARAJ P, 1989, J IMMUNOL, V143, P3283; SHEN L, 1987, J IMMUNOL, V139, P534; SIMMONS D, 1988, NATURE, V333, P568, DOI 10.1038/333568a0; STUART SG, 1987, J EXP MED, V166, P1668, DOI 10.1084/jem.166.6.1668; TOSI MF, 1988, J IMMUNOL, V141, P2097; TRUETT AP, 1988, P NATL ACAD SCI USA, V85, P1549, DOI 10.1073/pnas.85.5.1549; UNKELESS JC, 1989, J CLIN INVEST, V83, P355, DOI 10.1172/JCI113891; VANDEWINKEL JGJ, 1991, J LEUKOCYTE BIOL, V49, P511, DOI 10.1002/jlb.49.5.511; WALKER BAM, 1991, J IMMUNOL, V146, P735; WHITIN JC, 1980, J BIOL CHEM, V255, P1874; WHITIN JC, 1981, J BIOL CHEM, V256, P8904; WILLIS HE, 1988, J IMMUNOL, V140, P234; YOUNG JDE, 1984, P NATL ACAD SCI-BIOL, V81, P5430, DOI 10.1073/pnas.81.17.5430	57	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20659	20666						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328206				2022-12-27	WOS:A1992JT97800025
J	QURESHI, SA; ALEXANDROPOULOS, K; RIM, M; JOSEPH, CK; BRUDER, JT; RAPP, UR; FOSTER, DA				QURESHI, SA; ALEXANDROPOULOS, K; RIM, M; JOSEPH, CK; BRUDER, JT; RAPP, UR; FOSTER, DA			EVIDENCE THAT HA-RAS MEDIATES 2 DISTINGUISHABLE INTRACELLULAR SIGNALS ACTIVATED BY V-SRC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHORBOL 12-MYRISTATE 13-ACETATE; NIH 3T3 CELLS; GENE-EXPRESSION; PHOSPHOLIPASE-D; EARLY RESPONSE; TRANSFORMATION; GTPASE; TRANSDUCTION; ONCOGENES	v-Src activates promoters under the control of 12-O-tetradecanoylphorbol-13-acetate (TPA) response elements (TREs) and serum response elements (SREs) via two distinguishable intracellular signaling mechanisms. The induction of TRE- and SRE-mediated gene expression by v-Src could be distinguished by a differential sensitivity to depleting cells of protein kinase C (PKC) and to a dominant negative Raf-1 mutant. Thus, PKC depletion and the dominant negative Raf-1 mutant were able to distinguish two intracellular signaling mechanisms activated by v-Src. Both of these v-Src-induced intracellular signals were sensitive to a dominant negative mutant of Ha-Ras. These data suggest that Ha-Ras functions to coordinately regulate multiple intracellular signaling mechanisms activated by v-Src.	CUNY HUNTER COLL, INST BIOMOLEC STRUCT & FUNCT, NEW YORK, NY 10021 USA; CUNY HUNTER COLL, DEPT BIOL SCI, NEW YORK, NY 10021 USA; NCI, FREDERICK CANC RES & DEV CTR, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21702 USA	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NATIONAL CANCER INSTITUTE [R01CA046677, R29CA046677] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RRO-3037-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BISHOP JM, 1984, RNA TUMOR VIRUSES, P999; BOCCKINO SB, 1985, J BIOL CHEM, V260, P4201; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; MARONEY AC, 1992, ONCOGENE, V7, P1207; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; NORI M, 1990, MOL CELL BIOL, V10, P4155, DOI 10.1128/MCB.10.8.4155; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; QURESHI SA, 1991, MOL CELL BIOL, V11, P102, DOI 10.1128/MCB.11.1.102; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; QURESHI SA, 1991, ONCOGENE, V6, P995; QURESHI SA, 1992, ONCOGENE, V7, P121; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SPANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017, DOI 10.1073/pnas.86.18.7017; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; Treisman R, 1990, Semin Cancer Biol, V1, P47; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	50	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17635	17639						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325443				2022-12-27	WOS:A1992JM22300027
J	HU, RM; LEVIN, ER; PEDRAM, A; FRANK, HJL				HU, RM; LEVIN, ER; PEDRAM, A; FRANK, HJL			ATRIAL-NATRIURETIC-PEPTIDE INHIBITS THE PRODUCTION AND SECRETION OF ENDOTHELIN FROM CULTURED ENDOTHELIAL-CELLS - MEDIATION THROUGH THE C-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION SYSTEM; SMOOTH-MUSCLE CELLS; HEART-FAILURE; MESSENGER-RNAS; GENE; RAT; ANGIOTENSIN; STIMULATION; HYDROLYSIS; EXPRESSION	Atrial natriuretic peptide (ANP) and endothelin-1 (ET-1) are vasoactive peptides produced in cells of the cardiovascular system. We examined the effects of ANP on ET-1 transcription, production (translation), and secretion in cultured bovine aortic endothelial cells (BAEC). ANP and C-ANP 4-23 (a specific ligand for the C or non-guanylate cyclase receptor) equipotently inhibited the synthesis of prepro-ET-1 and ET-1 proteins in BAEC by at least 50%. Both of these forms of ANP and another C receptor specific ligand, nanopiperazine ANP (11-15)-NH2, inhibited ET-1 secretion by as much as 55%. LY 83583, an inhibitor of ANP-induced cGMP generation, failed to reverse the ANP-induced inhibition of ET-1 secretion. This further indicated that the guanylate cyclase-linked B receptor is not involved. The decreased ET-1 secretion caused by C-ANP 4-23 was reversed by 8-bromo-cAMP or amiloride, which prevents ANP-induced inhibition of cAMP. We also found that ANP and C-ANP 4-23 augmented ET-1 mRNA levels in BAEC by prolonging the mRNA half-life. ANP or cycloheximide comparably inhibited ET-1 translation while increasing ET-1 mRNA levels, suggesting that the two events are related. These results indicate that ANP inhibits ET-1 protein production and secretion while stabilizing the ET-1 mRNA. The effects of ANP are mediated through the C receptor and are probably the result of ANP inhibiting the generation of cAMP. These findings suggest a potentially important new function for this receptor to mediate, in part, the interactions of ANP and ET in the vasculature.	LONG BEACH VET HOSP,MED SERV 111I,5901 E 7TH ST,LONG BEACH,CA 90822; UNIV CALIF IRVINE,DEPT MED,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT PHARMACOL,IRVINE,CA 92717	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine			Levin, Ellis/J-5402-2013		NICHD NIH HHS [HD-24401] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024401] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANANDSRIVASTAVA MB, 1991, BIOCHEM J, V278, P211, DOI 10.1042/bj2780211; ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; AUSBEL FM, 1989, CURRENT PROTOCOLS MO; BLOCH KD, 1989, J BIOL CHEM, V264, P10851; BOULANGER CM, 1991, J CARDIOVASC PHARM, V17, pS264, DOI 10.1097/00005344-199100177-00075; CAVERO PG, 1990, AM J PHYSIOL, V259, pF312, DOI 10.1152/ajprenal.1990.259.2.F312; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CLEVELAND D W, 1989, New Biologist, V1, P121; CODY RJ, 1986, J CLIN INVEST, V78, P1362, DOI 10.1172/JCI112723; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; EMORI T, 1991, HYPERTENSION, V18, P165, DOI 10.1161/01.HYP.18.2.165; GELFAND R, 1991, AM J PHYSIOL, V261, pR453; GOETZ KL, 1988, AM J PHYSIOL, V254, pE1, DOI 10.1152/ajpendo.1988.254.1.E1; HATTORI Y, 1991, METABOLISM, V40, P65; HIRATA M, 1989, BIOCHIM BIOPHYS ACTA, V1010, P346, DOI 10.1016/0167-4889(89)90060-8; INOUE A, 1989, J BIOL CHEM, V264, P14954; JOHNSON BG, 1991, J PHARMACOL EXP THER, V257, P720; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KOHNO M, 1991, J CLIN INVEST, V87, P1999, DOI 10.1172/JCI115228; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; LEVIN E R, 1991, Molecular and Cellular Neuroscience, V2, P189, DOI 10.1016/1044-7431(91)90044-O; LEVIN ER, 1991, ENDOCRINOLOGY, V128, P2925, DOI 10.1210/endo-128-6-2925; LEVIN ER, 1991, AM J PHYSIOL, V261, pE183; LEVIN ER, 1989, BIOCHEM BIOPH RES CO, V160, P807; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; ODONNELL ME, 1986, J BIOL CHEM, V261, P5461; OKOLICANY J, 1990, KIDNEY INT, V37, P342; RUBANYI GM, 1991, FASEB J, V5, P2713, DOI 10.1096/fasebj.5.12.1916094; SAIJONMAA O, 1990, BIOCHEM BIOPH RES CO, V173, P514, DOI 10.1016/S0006-291X(05)80064-6; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEIBINGER RJ, 1990, ENDOCRINOLOGY, V127, P119; SHAW G, 1986, CELL, V55, P1115; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; TSUNODA K, 1988, CIRC RES, V62, P155, DOI 10.1161/01.RES.62.1.155; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	38	125	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17384	17389						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324935				2022-12-27	WOS:A1992JL05300097
J	GERWINS, P; FREDHOLM, BB				GERWINS, P; FREDHOLM, BB			ATP AND ITS METABOLITE ADENOSINE ACT SYNERGISTICALLY TO MOBILIZE INTRACELLULAR CALCIUM VIA THE FORMATION OF INOSITOL 1,4,5-TRISPHOSPHATE IN A SMOOTH-MUSCLE CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEIN; FRTL-5 THYROID-CELLS; SIGNAL TRANSDUCTION SYSTEMS; PERTUSSIS TOXIN; PHOSPHOLIPASE-C; CYCLIC-AMP; PHOSPHOINOSITIDE TURNOVER; EXTRACELLULAR ATP; ADENYLATE-CYCLASE; CEREBRAL-CORTEX	Interactions between ATP and adenosine on the formation of inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) and mobilization of intracellular calcium were investigated in the smooth muscle cell line DDT1 MF-2. Activation of adenosine A1 receptors with adenosine or cyclopentyladenosine (CPA) or of nucleotide receptors with ATP increased both Ins(1,4,5)P3 formation and intracellular calcium concentrations. The A1 receptor-induced Ins(1,4,5)P3 formation (EC50) 10 nM) was antagonized by the A1 antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) and by pretreatment of the cells with pertussis toxin (PTX). ATP-stimulated Ins(1,4,5)P3 formation (EC50 21-mu-m) was attenuated, but still present, after PTX treatment. ATP and CPA had supraadditive effects on Ins(1,4,5)P3 accumulation and CPA increased ATP-induced Ins(1,4,5)P3 accumulation in a concentration-dependent manner with an EC50 of 3 nM, a concentration which per se had little or no effect on Ins(1,4,5)P3 accumulation. ATP (EC50 4-mu-M) and CPA (EC50 4 nM) both increased intracellular calcium levels. The effect of ATP was partially sensitive to PTX treatment, whereas the effect of CPA was blocked both by PTX and by DPCPX. Concentrations of ATP and CPA that by themselves were insufficient to raise intracellular calcium were able to do so when combined. The synergy between ATP and CPA on the mobilization of intracellular calcium was abolished after treatment of cells with PTX or when DPCPX was included in the experiment. Since ATP was metabolized by ecto-enzymes to ADP, AMP, and adenosine, we also examined whether adenosine formed from ATP could enhance the ATP effects on Ins(1,4,5)P3 accumulation. Indeed, the addition of the A1 receptor antagonist DPCPX or removal of endogenous adenosine by inclusion of adenosine deaminase in the experimental medium significantly attenuated the ATP response, and the two treatments did not have additive effects. The present study thus demonstrates that in a clonal cell line two types of receptors increase phospholipase C activity, but via different pathways; nucleotide receptors appeared to act via partially PTX-insensitive, and Al receptors via PTX-sensitive G-proteins. ATP and CPA are not only able per se to induce formation of Ins(1,4,5)P3 and mobilize intracellular calcium, but they also act synergistically. Finally, it is demonstrated that endogenous adenosine, possibly formed from the rapid breakdown of ATP, can significantly enhance some ATP effects.			GERWINS, P (corresponding author), KAROLINSKA INST, DEPT PHARMACOL, BOX 60400, S-10401 STOCKHOLM 60, SWEDEN.							ALEXANDER SPH, 1989, BRIT J PHARMACOL, V98, P1241, DOI 10.1111/j.1476-5381.1989.tb12670.x; ALI H, 1990, J BIOL CHEM, V265, P745; AREND LJ, 1988, AM J PHYSIOL, V255, pC581, DOI 10.1152/ajpcell.1988.255.5.C581; AREND LJ, 1989, AM J PHYSIOL, V256, pF1067, DOI 10.1152/ajprenal.1989.256.6.F1067; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOUSCAREL B, 1988, J BIOL CHEM, V263, P14913; BOYER JL, 1989, J BIOL CHEM, V264, P884; BRASS LF, 1986, J BIOL CHEM, V261, P6838; BRUNS RF, 1990, BIOL ACTIONS EXTRACE, V603, P211; BURNATOWSKAHLEDIN MA, 1991, AM J PHYSIOL, V260, pC143, DOI 10.1152/ajpcell.1991.260.1.C143; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; COCKCROFT S, 1989, BIOCHEM J, V263, P715, DOI 10.1042/bj2630715; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; DELAHUNTY TM, 1988, BIOCHEM J, V255, P69, DOI 10.1042/bj2550069; DUBYAK GR, 1988, J BIOL CHEM, V263, P18108; ELETR M, 1989, J NEUROSCI, V9, P1473; FINE J, 1989, BIOCHEM J, V263, P371, DOI 10.1042/bj2630371; FREDHOLM BB, 1988, TRENDS PHARMACOL SCI, V9, P130, DOI 10.1016/0165-6147(88)90194-0; GERWINS P, 1991, MOL PHARMACOL, V40, P149; GERWINS P, 1990, MOL PHARMACOL, V38, P660; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAGGBLAD J, 1987, NEUROSCI LETT, V82, P211, DOI 10.1016/0304-3940(87)90132-7; HILL SJ, 1987, BRIT J PHARMACOL, V91, P661, DOI 10.1111/j.1476-5381.1987.tb11260.x; HOITING B, 1990, EUR J PHARM-MOLEC PH, V189, P31, DOI 10.1016/0922-4106(90)90227-O; HOLLINGSWORTH EB, 1986, EUR J PHARMACOL, V122, P45, DOI 10.1016/0014-2999(86)90156-1; JOHNSON RM, 1987, J BIOL CHEM, V262, P17285; KENDALL DA, 1990, BRIT J PHARMACOL, V100, P37, DOI 10.1111/j.1476-5381.1990.tb12048.x; KENDALL DA, 1988, J NEUROCHEM, V50, P497, DOI 10.1111/j.1471-4159.1988.tb02939.x; KOHL C, 1990, BRIT J PHARMACOL, V101, P829, DOI 10.1111/j.1476-5381.1990.tb14165.x; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; LINDEN J, 1989, TRENDS PHARMACOL SCI, V10, P114, DOI 10.1016/0165-6147(89)90209-5; LONDOS C, 1980, P NATL ACAD SCI-BIOL, V77, P2551, DOI 10.1073/pnas.77.5.2551; NANOFF C, 1990, BRIT J PHARMACOL, V100, P63, DOI 10.1111/j.1476-5381.1990.tb12052.x; NAZAREA M, 1991, EUR J PHARM-MOLEC PH, V206, P47, DOI 10.1016/0922-4106(91)90145-8; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NORDSTEDT C, 1990, ANAL BIOCHEM, V189, P231, DOI 10.1016/0003-2697(90)90113-N; NORRIS JS, 1974, NATURE, V248, P422, DOI 10.1038/248422a0; OCONNOR SE, 1991, TRENDS PHARMACOL SCI, V12, P137, DOI 10.1016/0165-6147(91)90530-6; OKAJIMA F, 1990, J BIOL CHEM, V265, P21741; OKAJIMA F, 1988, ENDOCRINOLOGY, V123, P1035, DOI 10.1210/endo-123-2-1035; OKAJIMA F, 1989, FEBS LETT, V248, P145, DOI 10.1016/0014-5793(89)80450-8; OKAJIMA F, 1989, J BIOL CHEM, V264, P13029; OKAJIMA F, 1987, J BIOL CHEM, V262, P13483; PALMER S, 1990, METHODS INOSITIDE RE, P127; PFEILSCHIFTER J, 1990, CELL SIGNAL, V2, P129; PIROTTON S, 1987, J BIOL CHEM, V262, P17461; POBINER BF, 1985, J BIOL CHEM, V260, P6200; RAMKUMAR V, 1990, MOL PHARMACOL, V37, P149; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SCHWABE U, 1983, ADENOSINE ADENINE NU, P3; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VANCALKER D, 1979, J NEUROCHEM, V33, P999, DOI 10.1111/j.1471-4159.1979.tb05236.x; VONKUGELGEN I, 1991, TRENDS PHARMACOL SCI, V12, P319, DOI 10.1016/0165-6147(91)90587-I; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WATSON S, 1991, TRENDS PHARMACOL SCI, V12, P25	58	118	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16081	16087						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322890				2022-12-27	WOS:A1992JJ45800018
J	COOK, WJ; JEFFREY, LC; SULLIVAN, ML; VIERSTRA, RD				COOK, WJ; JEFFREY, LC; SULLIVAN, ML; VIERSTRA, RD			3-DIMENSIONAL STRUCTURE OF A UBIQUITIN-CONJUGATING ENZYME (E2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR CRYSTALLOGRAPHY; SACCHAROMYCES-CEREVISIAE; ALZHEIMERS-DISEASE; CARRIER PROTEIN; RAD6; GENE; ENCODES; DEGRADATION; RESOLUTION; REFINEMENT	The x-ray crystal structure of a recombinant ubiquitin-conjugating enzyme (E2) encoded by the UBC1 gene of the plant Arabidopsis thaliana has been determined with the use of multiple isomorphous replacement techniques and refined at 2.4-angstrom resolution by simulated annealing and restrained least-squares. This E2 is an alpha/beta-protein, with four alpha-helices and a four-stranded antiparallel beta-sheet. The NH2 and COOH termini, which may be important for interaction with other enzymes and substrates in the ubiquitin-conjugation pathway, are on the opposite side of the molecule from the cysteine residue that binds to the COOH terminus of ubiquitin. This structure should now allow for the rational analysis of E2 function by in vitro mutagenesis and facilitate the effective design of E2s with unique specificities or catalytic functions.	UNIV ALABAMA,CTR MACROMOLEC CRYSTALLOG,BIRMINGHAM,AL 35294; UNIV WISCONSIN,DEPT HORT,MADISON,WI 53706	University of Alabama System; University of Alabama Birmingham; University of Wisconsin System; University of Wisconsin Madison	COOK, WJ (corresponding author), UNIV ALABAMA,DEPT PATHOL,BIRMINGHAM,AL 35294, USA.				NINDS NIH HHS [NS-30374] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030374] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALL E, 1987, CELL, V51, P221, DOI 10.1016/0092-8674(87)90149-8; BERLETH ES, 1990, BIOCHEM BIOPH RES CO, V171, P705, DOI 10.1016/0006-291X(90)91203-5; BLOW DM, 1959, ACTA CRYSTALLOGR, V12, P794, DOI 10.1107/S0365110X59002274; BONNER WM, 1988, UBIQUITIN, P157; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; COOK WJ, 1992, J MOL BIOL, V223, P1183, DOI 10.1016/0022-2836(92)90270-T; DUNIGAN DD, 1988, VIROLOGY, V165, P310, DOI 10.1016/0042-6822(88)90691-5; ELLISON KS, 1991, J BIOL CHEM, V266, P24116; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HAAS AL, 1991, J BIOL CHEM, V266, P5104; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOWE J, 1988, J PATHOL, V155, P9, DOI 10.1002/path.1711550105; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORRISON A, 1988, MOL CELL BIOL, V8, P1179, DOI 10.1128/MCB.8.3.1179; PERRY G, 1987, P NATL ACAD SCI USA, V84, P3033, DOI 10.1073/pnas.84.9.3033; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; Rechsteiner M., 1988, UBIQUITIN; REYNOLDS P, 1985, P NATL ACAD SCI USA, V82, P168, DOI 10.1073/pnas.82.1.168; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; SULLIVAN ML, 1989, P NATL ACAD SCI USA, V86, P9861, DOI 10.1073/pnas.86.24.9861; SULLIVAN ML, 1991, J BIOL CHEM, V266, P23878; VANNOCKER S, 1991, P NATL ACAD SCI USA, V88, P10297, DOI 10.1073/pnas.88.22.10297; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; WANG BC, 1985, METHOD ENZYMOL, V115, P90; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	38	88	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15116	15121						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321826				2022-12-27	WOS:A1992JF08800090
J	PICKLES, RJ; CUTHBERT, AW				PICKLES, RJ; CUTHBERT, AW			FAILURE OF THAPSIGARGIN TO ALTER ION-TRANSPORT IN HUMAN SWEAT GLAND EPITHELIA WHILE INTRACELLULAR CA2+ CONCENTRATION IS RAISED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; DIVALENT-CATION ENTRY; ADRENAL CHROMAFFIN CELLS; CYSTIC-FIBROSIS TISSUES; PLASMA-MEMBRANE; CALCIUM ENTRY; INOSITOL TRISPHOSPHATE; SARCOPLASMIC-RETICULUM; CYTOSOLIC CALCIUM; TUMOR PROMOTER	Ca(i) in cultured human sweat gland epithelial monolayers was measured using Fura-2 fluorescence. Thapsigargin (Tg) caused a sustained increase in Ca(i), the rate of rise being slower but the magnitude greater than with the agonists lysylbradykinin and ATP. Tg caused an irreversible change such that even after it was removed Ca(i) was dependent on the ambient calcium concentration, consistent with the hypothesis that Ca2+ entry is controlled by the state of the intracellular stores. Calcium entry after Tg was not modified by nimodipine, omega-conotoxin, or BAY K8644 but could be blocked by low concentrations (0.5 mM) of La3+. High concentrations of La3+ (2 mM) caused an increase in the response to Tg, suggesting that membrane ATPase exerts a major Ca(i) lowering effect. Intracellular Ca2+ ion chelation with 1,2-bis(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid significantly blunted the response to Tg. Finally, Mn2+ entry rate into epithelial cells was doubled by Tg. In spite of the evidence that Tg raises Ca(i) to values greater and for longer than calcium requiring agonists only the latter affected transepithelial transport processes. It is shown that Tg neither affects transepithelial sodium transport nor chloride conductance, both of which increase in response to lysylbradykinin or ATP. It is concluded that spatio-temporal patterns of Ca(i) increase after Tg and other agonists are different.	UNIV CAMBRIDGE,DEPT PHARMACOL,TENNIS COURT RD,CAMBRIDGE CB2 1QJ,ENGLAND	University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BOND M, 1984, J PHYSIOL-LONDON, V355, P677, DOI 10.1113/jphysiol.1984.sp015445; BRAYDEN DJ, 1989, BRIT J PHARMACOL, V98, P809, DOI 10.1111/j.1476-5381.1989.tb14609.x; BRAYDEN DJ, 1988, J PHYSIOL-LONDON, V405, P657, DOI 10.1113/jphysiol.1988.sp017354; BRAYDEN DJ, 1991, BRIT J PHARMACOL, V102, P57, DOI 10.1111/j.1476-5381.1991.tb12132.x; BRAYDEN DJ, 1990, BRIT J CLIN PHARMACO, V29, P235, DOI 10.1111/j.1365-2125.1990.tb03625.x; CHEEK TR, 1989, J CELL BIOL, V109, P1219, DOI 10.1083/jcb.109.3.1219; CLANCY JP, 1990, AM J PHYSIOL, V258, pL25, DOI 10.1152/ajplung.1990.258.2.L25; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HENDERSON RM, 1991, PFLUG ARCH EUR J PHY, V418, P271, DOI 10.1007/BF00370526; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; KWAN CY, 1990, J BIOL CHEM, V265, P678; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LARSEN EH, 1990, J PHYSIOL-LONDON, V424, P109, DOI 10.1113/jphysiol.1990.sp018058; LEE CM, 1984, J CELL SCI, V72, P259; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MERRITT JE, 1988, J BIOL CHEM, V263, P6161; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; PANDOL SJ, 1990, J BIOL CHEM, V265, P12846; PICKLES RJ, 1991, EUR J PHARMACOL, V199, P77, DOI 10.1016/0014-2999(91)90639-8; PUTNEY JW, 1987, AM J PHYSIOL, V252, pG149, DOI 10.1152/ajpgi.1987.252.2.G149; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Quinton PM, 1987, KIDNEY INT S, V21, pS102; RANDRIAMAMPITA C, 1991, PFLUG ARCH EUR J PHY, V417, P633, DOI 10.1007/BF00372962; RASHATWAR SS, 1987, P NATL ACAD SCI USA, V84, P5685, DOI 10.1073/pnas.84.16.5685; RASMUSSEN U, 1978, ACTA PHARM SUEC, V15, P133; TAKEMURA H, 1990, CELL CALCIUM, V11, P11, DOI 10.1016/0143-4160(90)90044-U; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358	37	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14818	14825						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321817				2022-12-27	WOS:A1992JF08800049
J	ISHIKAWA, N; SHIMADA, N; MUNAKATA, Y; WATANABE, K; KIMURA, N				ISHIKAWA, N; SHIMADA, N; MUNAKATA, Y; WATANABE, K; KIMURA, N			ISOLATION AND CHARACTERIZATION OF A GENE ENCODING RAT NUCLEOSIDE DIPHOSPHATE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; TUMOR-METASTASIS; DROSOPHILA DEVELOPMENT; SEQUENCE-ANALYSIS; DNA-POLYMERASE; EMBRYO CELLS; BINDING; PROTEIN; TRANSCRIPTION; GDP	Two overlapping genomic clones for a rat nucleoside diphosphate kinase (NDP kinase) have been isolated and characterized. Complete sequencing of the genomic segment including the whole coding region for the enzyme revealed that the gene consists of four exons spanning 5.5 kilobase pairs. Primer extension analyses and ribonuclease protection assays indicated that the transcription may start from multiple sites with the major initiation site at 3 base pairs upstream from the translation initiation site, Met-1. Neither CAAT-box nor TATA-box could be assigned for each transcription initiation site, whereas five putative Sp1-binding sites (GC-boxes) were present in the 5'-flanking region. These features of the NDP kinase gene represent those of housekeeping genes. In genomic Southern blotting using a full-length rat NDP kinase cDNA as a probe, many positively hybridized fragments were detected. In support of this, five possible processed pseudogenes were identified in different DNA segments although many other NDP kinase-related genomic fragments remained to be characterized. These results demonstrate that the NDP kinase gene may consist of a multiple gene family.	TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL, DEPT MOLEC PATHOL, TOKYO 173, JAPAN; KYUSHU INST TECHNOL, FAC COMP SCI & SYST ENGN, DEPT BIOCHEM ENGN, IIZUKASHI, FUKUOKA 820, JAPAN	Tokyo Metropolitan Institute of Gerontology; Kyushu Institute of Technology	ISHIKAWA, N (corresponding author), TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL, DEPT MOLEC BIOL, 35-2 SAKAECHO, ITABASHI KU, TOKYO 173, JAPAN.							BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEERY DM, 1990, TRENDS GENET, V6, P173; HIRAYAMA R, 1991, J NATL CANCER I, V83, P1249, DOI 10.1093/jnci/83.17.1249; KEMLER I, 1990, FASEB J, V4, P1444, DOI 10.1096/fasebj.4.5.2407588; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIMUR AN, 1977, J BIOL CHEM, V252, P3829; KIMURA N, 1988, J BIOL CHEM, V263, P4647; KIMURA N, 1990, BIOCHEM BIOPH RES CO, V168, P99, DOI 10.1016/0006-291X(90)91680-Q; KIMURA N, 1988, BIOCHEM BIOPH RES CO, V151, P248, DOI 10.1016/0006-291X(88)90586-4; KIMURA N, 1979, J BIOL CHEM, V254, P3451; KIMURA N, 1985, BIOCHEM BIOPH RES CO, V131, P199, DOI 10.1016/0006-291X(85)91789-9; KIMURA N, 1990, J BIOL CHEM, V265, P15744; KIMURA N, 1983, J BIOL CHEM, V258, P2278; KIMURA N, 1983, J BIOL CHEM, V258, P2609; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LANDSCHULTZ WH, 1988, SCIENCE, V240, P1750; LEHNINGER AL, 1970, BIOCHEMISTRY-US, P306; LEMISCHKA I, 1982, NATURE, V300, P330, DOI 10.1038/300330a0; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LIM HM, 1988, GENE ANAL TECH, V5, P32, DOI 10.1016/0735-0651(88)90024-6; MACARREY JR, 1987, NATURE, V326, P501; MATHEWS CK, 1990, UCLA SYM BI, V133, P139; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; NICKERSON JA, 1984, J BIOL CHEM, V259, P1297; NONAKA M, 1989, J IMMUNOL, V142, P1377; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; PENNINGROTH SM, 1977, J MOL BIOL, V115, P643, DOI 10.1016/0022-2836(77)90108-5; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; RUGGIERI R, 1991, NATURE, V353, P390, DOI 10.1038/353390a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINGER M, 1991, GENES GENOMES, P498; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TENG DHF, 1991, NATURE, V353, P437, DOI 10.1038/353437a0; TESTA D, 1979, J BIOL CHEM, V254, P9075; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; WALTON GM, 1975, BIOCHIM BIOPHYS ACTA, V390, P231, DOI 10.1016/0005-2787(75)90344-5; YOUNG RA, 1981, CELL, V23, P451, DOI 10.1016/0092-8674(81)90140-9	58	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14366	14372						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321145				2022-12-27	WOS:A1992JD32500088
J	MACNICOL, M; SCHULMAN, H				MACNICOL, M; SCHULMAN, H			CROSS-TALK BETWEEN PROTEIN-KINASE-C AND MULTIFUNCTIONAL CA2+ CALMODULIN-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 CELLS; INOSITOL PHOSPHATES; CELLULAR SUBSTRATE; BINDING-PROTEIN; CA-2+; AUTOPHOSPHORYLATION; BRADYKININ; EXPRESSION; INFLUX	Protein kinase C (PKC) exhibits both negative and positive cross-talk with multifunctional Ca2+/calmodulin-dependent protein kinase (CaM kinase) in PC12 cells. PKC effects negative cross-talk by inhibiting the mobilization of intracellular Ca2+ stores and by inhibiting Ca2+ influx through voltage-sensitive Ca2+ channels. In the absence of cross-talk, Ca2+ influx induced by depolarization with 56 mM K+ stimulates CaM kinase and its autophosphorylation and converts up to 50% of the enzyme to a Ca2+-independent or autonomous species. Acute treatment with phorbol myristate acetate (PMA) elicits a parallel reduction in depolarization-induced Ca2+ influx and in generation of autonomous CaM kinase. Negative cross-talk also occurs during stimulation of the phosphatidylinositol signaling system with bradykinin, which activates both PKC and CaM kinase. The extent of CaM kinase activation is attenuated by the simultaneous activation of PKC; it is enhanced by prior down-regulation of PKC. PKC also exhibits positive cross-talk with CaM kinase. Submaximal activation of CaM kinase by ionomycin is potentiated by concurrent activation of PKC with PMA. Such PMA treatment is found to increase the level of cytosolic calmodulin. Enhanced activation of CaM kinase by PKC may result from PKC-mediated phosphorylation of calmodulin-binding proteins, such as neuromodulin and MARCKS, and the subsequent increase in the availability of previously bound calmodulin for activation of CaM kinase.	STANFORD UNIV,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305	Stanford University					NIGMS NIH HHS [GM40600] Funding Source: Medline; NIMH NIH HHS [MH48108] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048108] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DIVIRGILIO F, 1986, J BIOL CHEM, V261, P32; EXTON JH, 1990, J BIOL CHEM, V265, P1; FARAGO A, 1990, FEBS LETT, V268, P350, DOI 10.1016/0014-5793(90)81284-U; FASOLATO C, 1988, J BIOL CHEM, V263, P17350; FASOLATO C, 1990, J BIOL CHEM, V265, P20351; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HANSON PI, 1992, IN PRESS ANN REV BIO, V61; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; LICKTEIG R, 1988, J BIOL CHEM, V263, P19232; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MANGELS LA, 1990, MOL PHARMACOL, V37, P820; MARTIN TFJ, 1990, J BIOL CHEM, V265, P7623; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; RINK TJ, 1990, FEBS LETT, V268, P381, DOI 10.1016/0014-5793(90)81290-5; Schulman H, 1991, Curr Opin Neurobiol, V1, P43, DOI 10.1016/0959-4388(91)90009-V; Sharma R K, 1979, Adv Cyclic Nucleotide Res, V10, P187; Skene J H, 1990, Neurosci Res Suppl, V13, pS112, DOI 10.1016/0921-8696(90)90040-A; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; VANHOOFF COM, 1989, J CELL BIOL, V108, P1115, DOI 10.1083/jcb.108.3.1115; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002	32	99	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12197	12201						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1318312				2022-12-27	WOS:A1992HY94700082
J	LEYH, TS; VOGT, TF; SUO, Y				LEYH, TS; VOGT, TF; SUO, Y			THE DNA-SEQUENCE OF THE SULFATE ACTIVATION LOCUS FROM ESCHERICHIA-COLI K-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-L-SERINE; SALMONELLA-TYPHIMURIUM; CYSB PROTEIN; PENICILLIUM-CHRYSOGENUM; INVITRO INTERACTIONS; RHIZOBIUM-MELILOTI; CYSJIH PROMOTER; GENE; EXPRESSION; SULFURYLASE	The DNA sequence of the sulfate activation locus from Escherichia coli K-12 has been determined. The sequence includes the structural genes encoding the enzymes ATP sulfurylase (cysD and cysN) and APS kinase (cysC) which catalyze the synthesis of activated sulfate. These are the only genes known to reside in the sulfate activation operon. Consensus elements of the operon promoter were identified, and the start codons and open reading frames of the Cys polypeptides were determined. During this work, another gene, iap, was partially sequenced and mapped. The activity of ATP sulfurylase is stimulated by an intrinsic GTPase. Comparison of the primary sequences of CysN and Ef-Tu revealed that CysN has conserved many of the residues integral to the three-dimensional structure important for guanine nucleotide binding in Ef-Tu and RAS. nodP and nodQ, from Rhizobium meliloti, are essential for nodulation in leguminous plants. The Cys and Nod proteins are remarkably similar. NodP appears to be the smaller subunit of ATP sulfurylase. NodQ encodes homologues of both CysN and CysC; thus, these enzymes may be covalently associated in R. meliloti. The consensus GTP-binding sequences of NodQ and CysN are identical suggesting that NodQ encodes a regulatory GTPase.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	LEYH, TS (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031186] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43003-01] Funding Source: Medline; NIGMS NIH HHS [GM-31186] Funding Source: Medline; DRS NIH HHS [BRSG 613-4734] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); DRS NIH HHS		BEAUERLE PA, 1984, EMBO J, V3, P2209; BEAUERLE PA, 1987, J CELL BIOL, V105, P2655; BRAND SJ, 1984, NATURE, V309, P456, DOI 10.1038/309456a0; BRENDEL V, 1986, J BIOMOL STRUCT DYN, V3, P705, DOI 10.1080/07391102.1986.10508457; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; GAY NJ, 1983, NATURE, V301, P262, DOI 10.1038/301262a0; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; HERZOG V, 1985, European Journal of Cell Biology, V39, P399; HILTZ H, 1955, P NATL ACAD SCI USA, V41, P880; ISHINO Y, 1987, J BACTERIOL, V169, P5429, DOI 10.1128/jb.169.12.5429-5433.1987; JENSEN RT, 1982, J BIOL CHEM, V257, P5554; JEVONS FR, 1963, BIOCHEM J, V89, P621, DOI 10.1042/bj0890621; JONESMOR.MC, 1968, BIOCHEM J, V110, P589, DOI 10.1042/bj1100589; JONESMORTIMER MC, 1987, HEREDITY, V31, P213; KARP DR, 1983, J BIOL CHEM, V258, P12748; KREDICH NM, 1971, J BIOL CHEM, V246, P3474; KREDICH NM, 1987, ESCHERICHIA COLI SAL, V1, P419; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LEYH TS, 1988, J BIOL CHEM, V263, P2409; LEYH TS, 1992, J BIOL CHEM, V267, P542; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; MALO MS, 1990, GENE, V87, P127, DOI 10.1016/0378-1119(90)90504-K; MIZOBUCHI K, 1962, GENETICS, V47, P1617; MONROE RS, 1990, J BACTERIOL, V172, P6919, DOI 10.1128/jb.172.12.6919-6929.1990; MORITA T, 1986, J BIOL CHEM, V261, P4008; NAKATA A, 1982, GENE, V19, P313; OPPENHEIM DS, 1980, GENETICS, V95, P785; OSTROWSKI J, 1990, J BACTERIOL, V172, P779, DOI 10.1128/jb.172.2.779-785.1990; OSTROWSKI J, 1989, J BACTERIOL, V171, P130, DOI 10.1128/jb.171.1.130-140.1989; OSTROWSKI J, 1991, J BACTERIOL, V173, P2212, DOI 10.1128/JB.173.7.2212-2218.1991; RAIBAUD O, 1984, ANNU REV GENET, V18, P173, DOI 10.1146/annurev.ge.18.120184.001133; RENOSTO F, 1989, J BIOL CHEM, V264, P9433; ROBBINS PW, 1958, J BIOL CHEM, V233, P686; ROBBINS PW, 1957, J BIOL CHEM, V229, P837; SCHWARTZ RM, 1979, ATLAS PROTEIN SEQ S3, V5, P353; SCHWEDOCK J, 1990, NATURE, V348, P644, DOI 10.1038/348644a0; SCHWEDOCK J, 1989, Molecular Plant-Microbe Interactions, V2, P181, DOI 10.1094/MPMI-2-181; SEUBERT PA, 1985, ARCH BIOCHEM BIOPHYS, V240, P509, DOI 10.1016/0003-9861(85)90057-8; SHINE J, 1974, P NATL ACAD SCI USA, V71, P1341; SIEGEL LM, 1975, METABOLIC PATHWAYS, V7, P217; SUGAHARA K, 1979, P NATL ACAD SCI USA, V76, P6615, DOI 10.1073/pnas.76.12.6615; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; UNSWORTH CD, 1982, NATURE, V295, P519, DOI 10.1038/295519a0; VALENCIA A, 1991, P NATL ACAD SCI USA, V88, P5443, DOI 10.1073/pnas.88.12.5443; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; YAGER TD, 1987, ESCHERICHIA COLI SAL, V2, P1241; YATES JL, 1981, CELL, V21, P243	48	84	93	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10405	10410						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1316900				2022-12-27	WOS:A1992HV09000034
J	NISHIOKA, J; SUZUKI, K				NISHIOKA, J; SUZUKI, K			THE ROLE OF THE COOH-TERMINAL REGION OF ANTITHROMBIN-III - EVIDENCE THAT THE COOH-TERMINAL REGION OF THE INHIBITOR ENHANCES THE REACTIVITY OF THROMBIN AND FACTOR-XA WITH THE INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY ABNORMAL ANTITHROMBIN; HEPARIN-BINDING; ANTI-THROMBIN; PROTEIN-C; ACTIVE-SITE; IDENTIFICATION; SUBSTITUTION; MUTATION; VARIANT; DOMAIN	To elucidate the role of the COOH-terminal region of antithrombin III, we studied the effects of synthetic peptides corresponding to its sequence on the amidolytic and proteolytic activities of thrombin and Factor Xa in the presence or absence of the inhibitor, antithrombin III. The peptides ANRPFLVFI and IIFMGRVANP corresponding to residues Ala404 to Ile412 and Ile420 to Pro429, respectively, blocked the inhibition by antithrombin III. The effect of IIFMGRVANP was reduced in the presence of heparin. Both peptides at a concentration of 1 mM blocked complex formation between antithrombin III and thrombin or Factor Xa. The two peptides, particularly IIFMGRVANP, directly enhanced the amidolytic activity of thrombin and Factor Xa on the synthetic substrate Boc-Ala-Gly-Arg-MCA (where Boc is t-butoxycarbonyl and MCA is 4-methylcoumarin), which corresponds to residues P3-P1 of the reactive site of antithrombin III, and also on other substrates due to increased V(max). IIFMGRVANP also shortened the thrombin-induced fibrinogen clotting time, whereas ANRPFLVFI inhibited the thrombin-catalyzed activation of protein C both in the presence and absence of thrombomodulin. The direct effect of ANRPFLVFI and IIFMGRVANP on thrombin was confirmed by enhancement of the incorporation of dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide into thrombin. These findings suggest that the COOH-terminal region of antithrombin III interacts with thrombin and Factor Xa to increase the reactivity of the enzyme, which may enhance acyl-bond formation between the inhibitor and the enzyme.	MIE UNIV,SCH MED,DEPT MOLEC BIOL GENET DIS,TSU,MIE 514,JAPAN	Mie University								ASAKURA S, 1990, J BIOL CHEM, V265, P5135; ASAKURA S, 1989, J BIOL CHEM, V264, P13736; AUSTIN RC, 1991, BLOOD, V77, P2185; BJORK I, 1992, J BIOL CHEM, V267, P1976; BJORK I, 1982, J BIOL CHEM, V257, P2406; BOCK SC, 1988, BIOCHEMISTRY-US, V27, P6171, DOI 10.1021/bi00416a052; BOCK SC, 1989, THROMB HAEMOSTASIS, V62, P494; BRUNEL F, 1987, AM J HEMATOL, V25, P223, DOI 10.1002/ajh.2830250214; CHANDRA T, 1983, P NATL ACAD SCI-BIOL, V80, P1845, DOI 10.1073/pnas.80.7.1845; CHANG JY, 1986, J BIOL CHEM, V261, P1174; DUCHANGE N, 1987, THROMB RES, V45, P115, DOI 10.1016/0049-3848(87)90263-5; ERDJUMENT H, 1988, J BIOL CHEM, V263, P5589; FISH WW, 1979, EUR J BIOCHEM, V101, P31, DOI 10.1111/j.1432-1033.1979.tb04212.x; Furie B.C., 1976, Methods Enzymol, V45, P191; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KIKUMOTO R, 1984, BIOCHEMISTRY-US, V23, P85, DOI 10.1021/bi00296a014; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; KURACHI K, 1976, BIOCHEMISTRY-US, V15, P368, DOI 10.1021/bi00647a020; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNDBLAD RL, 1975, BIOCHEM BIOPH RES CO, V66, P482, DOI 10.1016/0006-291X(75)90536-7; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; NAKAGAWA M, 1991, THROMB RES, V64, P101, DOI 10.1016/0049-3848(91)90209-F; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; OLDS RJ, 1989, NUCLEIC ACIDS RES, V17, P10511, DOI 10.1093/nar/17.24.10511; OLDS RJ, 1992, BLOOD, V79, P1206, DOI 10.1182/blood.V79.5.1206.bloodjournal7951206; OWEN MC, 1987, BLOOD, V69, P1275; PERRY DJ, 1991, FEBS LETT, V285, P248, DOI 10.1016/0014-5793(91)80809-H; PETERSON CB, 1987, J BIOL CHEM, V262, P8061; PEWARCHUK WJ, 1990, THROMB RES, V59, P793, DOI 10.1016/0049-3848(90)90061-G; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; STEPHENS AW, 1987, J BIOL CHEM, V262, P1044; SUN XJ, 1989, J BIOL CHEM, V264, P11288; SUZUKI K, 1987, J BIOL CHEM, V262, P611; SUZUKI K, 1989, J BIOL CHEM, V264, P4872; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; SUZUKI K, 1991, J BIOL CHEM, V266, P18498; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255	37	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22224	22229						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331047				2022-12-27	WOS:A1992JW71900038
J	GAESTEL, M; BENNDORF, R; HAYESS, K; PRIEMER, E; ENGEL, K				GAESTEL, M; BENNDORF, R; HAYESS, K; PRIEMER, E; ENGEL, K			DEPHOSPHORYLATION OF THE SMALL HEAT-SHOCK PROTEIN HSP25 BY CALCIUM CALMODULIN-DEPENDENT (TYPE-2B) PROTEIN PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; EHRLICH ASCITES TUMOR; CATALYTIC SUBUNIT; SUBSTRATE-SPECIFICITY; MOLECULAR-CLONING; STRESS PROTEINS; ALPHA; PHOSPHORYLATION; CALCINEURIN; CELLS	The dephosphorylation of the mouse small heat shock protein hsp25 within an extract obtained from Ehrlich ascites tumor cells is inhibited by the calcium chelator EGTA and at concentrations of microcystin-LR which are characteristic for inhibition of calcium/calmodulin-dependent (2B type) protein phosphatases. Furthermore, the dephosphorylation of hsp25 in the cell-free system derived from Ehrlich ascites tumor could be increased specifically by addition of the calcium/calmodulin-dependent (2B type) protein phosphatase calcineurin. Dephosphorylation of the heat shock protein hsp25 is also obtained in an in vitro system containing phosphorylated recombinant hsp25, 1 mM Ca2+, calmodulin, and calcineurin specifying hsp25 as the direct substrate for this enzyme. The expression of two isoforms of the catalytic subunit of the mouse calcium/calmodulin-dependent (2B type) protein phosphatases in Ehrlich ascites tumor cells is demonstrated by polymerase chain reaction using specific oligonucleotide primers to the catalytic and calmodulin-binding domain, respectively. Northern blot analysis using the amplified fragments as probes shows that the mRNA of one isoform of the mouse calcium/calmodulin-dependent protein phosphatase is of medium abundance in EAT cells. These data suggest a calcium/calmodulin-dependent dephosphorylation of the small stress protein in EAT cells also in vivo. Since it is known that heat shock increases the intracellular calcium level and that thermotolerance is influenced by calcium chelators, ionophores, and anti-calmodulin drugs, the changes in the degree of hsp25 phosphorylation induced by thermal stress resulting in an altered thermoresistance could be explained at least partially by the calcium/calmodulin-dependent dephosphorylation through protein phosphatases 2B.			GAESTEL, M (corresponding author), MAX DELBRUCK CTR MOLEC MED,R ROSSLE STR 10,O-1115 BERLIN,GERMANY.		Gaestel, Matthias/A-6560-2013	Gaestel, Matthias/0000-0002-4944-4652				ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BEHLKE J, 1991, FEBS LETT, V288, P119, DOI 10.1016/0014-5793(91)81016-2; BENNDORF R, 1992, IN PRESS BIOCH BIOPH; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; CHIESA R, 1989, BIOCHEM BIOPH RES CO, V162, P1494, DOI 10.1016/0006-291X(89)90843-7; CHIESA R, 1990, FEBS LETT, V268, P222, DOI 10.1016/0014-5793(90)81013-E; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; CRETE P, 1990, RADIAT RES, V121, P320, DOI 10.2307/3577783; DEJONG WW, 1988, J BIOL CHEM, V263, P5141; ERIKSON E, 1988, 2ND MESSENGERS PHOSP, V12, P135; EVANS DP, 1990, J CELL PHYSIOL, V142, P615, DOI 10.1002/jcp.1041420323; EVANS DP, 1991, RADIAT RES, V127, P261, DOI 10.2307/3577940; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; GAESTEL M, 1989, EUR J BIOCHEM, V179, P209, DOI 10.1111/j.1432-1033.1989.tb14542.x; GUPTA RC, 1990, MOL CELL BIOCHEM, V97, P53; GUPTA RC, 1992, MOL CELL BIOCHEM, V267, P1846; GUY GR, 1991, J BIOL CHEM, V266, P14343; GUY GR, 1992, J BIOL CHEM, V267, P1846; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; ITO A, 1989, BIOCHEM BIOPH RES CO, V163, P1492, DOI 10.1016/0006-291X(89)91148-0; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KITAMURA K, 1991, J BIOCHEM-TOKYO, V109, P307; KLEE CB, 1983, METHOD ENZYMOL, V102, P227; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1988, RADIAT RES, V113, P426, DOI 10.2307/3577240; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MALHOTRA A, 1986, J CELL PHYSIOL, V128, P279, DOI 10.1002/jcp.1041280220; MURAMATSU T, 1992, P NATL ACAD SCI USA, V89, P529, DOI 10.1073/pnas.89.2.529; NOVER L, 1991, HEAT SHOCK RESPONSE, P41; OESTERREICH S, 1990, BIOMED BIOCHIM ACTA, V49, P219; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; PEZZI L, 1989, INT J BIOCHEM, V21, P791, DOI 10.1016/0020-711X(89)90212-7; POSAS F, 1989, NUCLEIC ACIDS RES, V17, P8369, DOI 10.1093/nar/17.20.8369; REGAZZI R, 1988, BIOCHEM BIOPH RES CO, V152, P62, DOI 10.1016/S0006-291X(88)80680-6; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; STEVENSON MA, 1986, BIOCHEM BIOPH RES CO, V137, P826, DOI 10.1016/0006-291X(86)91154-X; WILLIAMS KR, 1986, J BIOL CHEM, V261, P1890; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9	40	42	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21607	21611						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328240				2022-12-27	WOS:A1992JV01100055
J	KOHEN, R; KAKUNDA, A; RUBINSTEIN, A				KOHEN, R; KAKUNDA, A; RUBINSTEIN, A			THE ROLE OF CATIONIZED CATALASE AND CATIONIZED GLUCOSE-OXIDASE IN MUCOSAL OXIDATIVE DAMAGE INDUCED IN THE RAT JEJUNUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; POLYETHYLENE-GLYCOL; ENDOTHELIAL-CELLS; FREE-RADICALS; PROTECTION; PERMEABILITY; ANTIOXIDANT; ARTHRITIS; TRANSPORT	The successful prevention of hydrogen peroxide-induced damage to the rat jejunal mucosa by cationized catalase is described in this study. Biological damage was induced in a closed circulating intestinal loop of the rat by hydrogen peroxide and by hydroxyl radicals induced in situ via the metal-mediated Haber-Wiess reaction. The mucosal activity of lactate dehydrogenase and the amount of potassium ions were used to quantitatively characterize the tissue damage. Catalase was cationized by reacting it with N,N'-dimethyl-1,3-propanediamine to give a soluble product or with polyhistidine to give an insoluble product. The activity of the modified enzymes was assessed, and their ability to protect the rat jejunal mucosa against oxidative stress was studied. It was found that in all cases the cationized enzymes were superior to the native catalase in their shield capability. A significant protection against Fe(II)/H2O2 and ascorbie acid/copper ion-mediated damage was obtained when the cationized enzymes were used. In the presence of glucose, native glucose oxidase failed to cause damage in the rat jejunal mucosa; however, the cationized enzyme caused profound tissue injury. These findings indicate the potential therapeutic merit of cationized enzymes for the treatment of pathological processes in the intestine, whenever oxidative stress is involved.	HEBREW UNIV JERUSALEM,SCH PHARM,DAVID R BLOOM CTR PHARM,POB 12065,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem				Rubinstein, Abraham/0000-0001-6212-3725; Kohn, Ron/0000-0001-7268-9845				AMES BN, 1985, DIET HUMAN CARCINOGE, P25; BABBS CF, 1990, FREE RADICAL BIO MED, V8, P191, DOI 10.1016/0891-5849(90)90091-V; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CROSS CE, 1984, LANCET, V1, P1328; DANON D, 1972, J ULTRA MOL STRUCT R, V38, P500, DOI 10.1016/0022-5320(72)90087-1; FLIGIEL SEG, 1984, AM J PATHOL, V115, P375; GIBBS D, 1989, INFLAMMATION, V13, P465, DOI 10.1007/BF00914929; GINSBURG I, 1987, INFLAMMATION, V11, P489, DOI 10.1007/BF00915991; GRAF E, 1985, CANCER-AM CANCER SOC, V56, P717, DOI 10.1002/1097-0142(19850815)56:4<717::AID-CNCR2820560402>3.0.CO;2-4; GRANGER DN, 1986, VIEWPOINTS DIG DIS, V18, P13; GREENWALD RA, 1990, FREE RADICAL BIO MED, V8, P201, DOI 10.1016/0891-5849(90)90092-W; GRISHAM MB, 1990, INFLAMMATION, V14, P669, DOI 10.1007/BF00916370; GRISHAM MB, 1987, AM J PHYSIOL, V253, pG93, DOI 10.1152/ajpgi.1987.253.1.G93; HALLIWELL B, 1990, FREE RADICAL RES COM, V9, P1, DOI 10.3109/10715769009148569; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HIGSON FK, 1988, FREE RADICAL RES COM, V5, P107, DOI 10.3109/10715768809066918; ITOH M, 1985, GASTROENTEROLOGY, V88, P1162, DOI 10.1016/S0016-5085(85)80075-5; LEWIS LD, 1975, GASTROENTEROLOGY, V68, P1509; NAVOK T, 1984, BIOCHEM BIOPH RES CO, V122, P297, DOI 10.1016/0006-291X(84)90474-1; SCHALKWIJK J, 1985, J CLIN INVEST, V76, P198, DOI 10.1172/JCI111946; SHINAR E, 1983, J BIOL CHEM, V258, P1478; SMITH KR, 1989, PHARM RES-DORDR, V6, P466, DOI 10.1023/A:1015960205409; STOCKS SJ, 1986, ANAL BIOCHEM, V154, P232, DOI 10.1016/0003-2697(86)90520-8; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; TRIGUERO D, 1989, P NATL ACAD SCI USA, V86, P4761, DOI 10.1073/pnas.86.12.4761; TURRENS JF, 1984, J CLIN INVEST, V73, P87, DOI 10.1172/JCI111210; VANDENBERG WB, 1984, J CLIN INVEST, V74, P1850, DOI 10.1172/JCI111604; VARANI J, 1985, LAB INVEST, V53, P656; WARD PA, 1983, J CLIN INVEST, V72, P789, DOI 10.1172/JCI111050; WEISS SJ, 1981, J CLIN INVEST, V68, P714, DOI 10.1172/JCI110307; WOLFGANG GHI, 1991, TOXICOL APPL PHARM, V108, P321, DOI 10.1016/0041-008X(91)90121-T	32	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21349	21354						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328230				2022-12-27	WOS:A1992JV01100017
J	OGRADY, P; LIU, QJ; HUANG, SS; HUANG, JS				OGRADY, P; LIU, QJ; HUANG, SS; HUANG, JS			TRANSFORMING GROWTH-FACTOR-BETA (TGF-BETA) TYPE-V RECEPTOR HAS A TGF-BETA-STIMULATED SERINE THREONINE-SPECIFIC AUTOPHOSPHORYLATION ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; TYROSINE KINASE; BOVINE LIVER; BINDING-SITE; IDENTIFICATION; CELLS; SEQUENCE	The transforming growth factor beta (TGF-beta) type V receptor, a newly identified high molecular weight TGF-beta receptor (M(r) approximately 400,000) has been purified from bovine liver plasma membranes (O'Grady, P., Kuo, M.-D., Baldassare, J. J., Huang, S. S., and Huang, J. S. (1991) J. Biol Chem. 266, 8583-8589). The purified TGF-beta type V receptor underwent autophosphorylation at serine residues when incubated with [gamma-P-32] ATP in the presence of 0.1% beta-mercaptoethanol and 2.5 mM MnCl2. This phosphorylation was stimulated by preincubation with TGF-beta. The preferred exogenous substrate for the Ser/Thr-specific phosphorylation activity of the type V receptor was found to be bovine casein. The TGF-beta type V receptor could be affinity-labeled with 5'-p-[adenine-8-C-14]fluorosulfonylbenzoyl adenosine. Polylysine appeared to stimulate the autophosphorylation of the TGF-beta type receptor in the presence of [gamma-P-32]ATP and the incorporation of 5'-p-[adenine-8-C-14]fluorosulfonylbenzoyl adenosine into the TGF-beta type V receptor. The amino acid sequence analysis of the peptide fragments produced by cyanogen bromide cleavage of the purified TGF-beta type V receptor revealed that a peptide, namely CNBr-19, contained an amino acid sequence which shows homology to the putative ATP binding site of the receptors for activin, the Caenorhabditis elegans daf-1 gene product, and TGF-beta type II receptor (Lin, H. Y., Wang, Y.-F., Ng-Eaton, E., Weinberg, R. A., and Lodish, H. F. (1992) Cell 68, 775-785). These results suggest that the TGF-beta type V receptor is a Ser/Thr-specific protein kinase and belongs to the new class of membrane receptors associated with a Ser/Thr-specific protein kinase activity.	ST LOUIS UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, 1402 S GRAND BLVD, ST LOUIS, MO 63104 USA	Saint Louis University					NCI NIH HHS [CA 38808] Funding Source: Medline; NHLBI NIH HHS [HL 41782] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041782] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BASU M, 1984, NATURE, V311, P477, DOI 10.1038/311477a0; CHEIFETZ S, 1988, J BIOL CHEM, V263, P17225; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FUJITAYAMAGUCHI Y, 1989, BIOCHEM J, V263, P813, DOI 10.1042/bj2630813; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HASHIMOTO E, 1982, J BIOL CHEM, V257, P727; HUANG SS, 1986, J BIOL CHEM, V261, P9568; HUBLER L, 1992, BIOCHEM J, V281, P107, DOI 10.1042/bj2810107; KUO MD, 1990, J BIOL CHEM, V265, P16455; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATTHEWS LS, 1991, CELL, V65, P973; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; ODA Y, 1991, J BIOL CHEM, V266, P16791; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OGRADY P, 1991, BIOCHEM BIOPH RES CO, V179, P378, DOI 10.1016/0006-291X(91)91381-L; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SAGARINI PR, 1992, J BIOL CHEM, V267, P1048; STONE KL, 1988, TECHNIQUES PROTEIN C, P377; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; WALTON GM, 1985, METHOD ENZYMOL, V99, P206; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P442; ZOLLER MJ, 1979, J BIOL CHEM, V254, P8363	25	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21033	21037						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328218				2022-12-27	WOS:A1992JT97800082
J	LEMARCHAND, P; VAGLIO, M; MAUEL, J; MARKERT, M				LEMARCHAND, P; VAGLIO, M; MAUEL, J; MARKERT, M			TRANSLOCATION OF A SMALL CYTOSOLIC CALCIUM-BINDING PROTEIN (MRP-8) TO PLASMA-MEMBRANE CORRELATES WITH HUMAN NEUTROPHIL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; PHORBOL-MYRISTATE ACETATE; CELL-FREE SYSTEM; NADPH OXIDASE; INTRACELLULAR CALCIUM; ARACHIDONIC-ACID; KINASE-C; COMPONENTS; PURIFICATION	To further understand the mechanisms involved in phagocyte activation in general and in NADPH oxidase activation in particular, a polyclonal antibody was raised in rabbit against a partially purified oxidase preparation. The enzyme was solubilized from zymosan-activated human neutrophils and resting cells and separated by preparative isoelectric focusing electrophoresis. A polyclonal antibody was raised in rabbit against the pI 5.0 fraction, which had the maximum superoxide-producing capacity. Analysis of the polyclonal antibody revealed marked differences between activated and resting neutrophils. The antibody recognized in particular an 8-kDa protein (pS) in resting human neutrophil cytosol and in the membrane of zymosan-activated cells. A polyclonal antibody (anti-p8) was raised against the pure cytosolic p8 protein. This anti-p8 reacted not only with p8, but also with cytosolic proteins of 14 kDa and 6 kDa. N-terminal amino acid sequence analysis of p8 revealed homology with the calcium-binding myeloid related protein (MRP-8). Upon neutrophil activation, translocation of the 8- and 14-kDa proteins to the membrane was observed with stimuli known to depend on extracellular calcium. In calcium-depleted medium, the absence of translocation correlated with a depression of superoxide production, supporting a role for the calcium-binding protein in cellular activation.	BIOCHEM INST,CH-1066 EPALINGES,SWITZERLAND		LEMARCHAND, P (corresponding author), CHU VAUDOIS,CENT LAB CLIN CHEM,CH-1011 LAUSANNE,SWITZERLAND.		lemarchand, patricia/C-3247-2011	lemarchand, patricia/0000-0002-5330-2008				AMBRUSO DR, 1990, J BIOL CHEM, V265, P924; BABIOR BM, 1987, TRENDS BIOCHEM SCI, V12, P241, DOI 10.1016/0968-0004(87)90118-6; BALSINDE J, 1990, J IMMUNOL, V144, P4298; BATTEIGER B, 1982, J IMMUNOL METHODS, V55, P297, DOI 10.1016/0022-1759(82)90089-8; BOLSCHER BGJM, 1989, J CLIN INVEST, V83, P757, DOI 10.1172/JCI113954; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CLARK RA, 1987, J BIOL CHEM, V262, P4065; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; DOUSSIERE J, 1990, BIOCHEMISTRY-US, V29, P2225, DOI 10.1021/bi00461a004; EDGEWORTH J, 1991, J BIOL CHEM, V266, P7706; EDGEWORTH J, 1989, NATURE, V342, P189, DOI 10.1038/342189a0; FUJIMOTO S, 1989, J BIOL CHEM, V264, P21629; GABIG TG, 1990, J IMMUNOL, V145, P945; HEIERLI C, 1988, NEPHROL DIAL TRANSPL, V3, P773; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LEW PD, 1984, J CELL BIOL, V99, P1212, DOI 10.1083/jcb.99.4.1212; LIGETI E, 1988, BIOCHEMISTRY-US, V27, P193, DOI 10.1021/bi00401a029; MARKERT M, 1985, P NATL ACAD SCI USA, V82, P3144, DOI 10.1073/pnas.82.10.3144; MARKERT M, 1984, METHOD ENZYMOL, V105, P358; MURAO S, 1989, J BIOL CHEM, V264, P8356; NAKAMURA K, 1985, ANAL BIOCHEM, V148, P311, DOI 10.1016/0003-2697(85)90234-9; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SEIFERT R, 1987, EUR J BIOCHEM, V162, P563, DOI 10.1111/j.1432-1033.1987.tb10676.x; SHAAG D, 1990, BIOCHIM BIOPHYS ACTA, V1037, P405, DOI 10.1016/0167-4838(90)90044-G; SMOLEN JE, 1981, BIOCHIM BIOPHYS ACTA, V677, P512, DOI 10.1016/0304-4165(81)90267-1; SNYDERMAN R, 1986, J LEUKOCYTE BIOL, V40, P785, DOI 10.1002/jlb.40.6.785; TANAKA T, 1990, J BIOL CHEM, V265, P18717; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WILKINSON MM, 1988, J CELL SCI, V91, P221; WOLFSON M, 1985, J IMMUNOL, V135, P2057; ZWADLO G, 1988, CLIN EXP IMMUNOL, V72, P510	39	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19379	19382						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326551				2022-12-27	WOS:A1992JP59300056
J	JI, C; MARNETT, LJ				JI, C; MARNETT, LJ			OXYGEN RADICAL-DEPENDENT EPOXIDATION OF (7S,8S)-DIHYDROXY-7,8-DIHYDROBENZO[A]PYRENE IN MOUSE SKIN INVIVO - STIMULATION BY PHORBOL ESTERS AND INHIBITION BY ANTIINFLAMMATORY STEROIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR PROMOTER 12-O-TETRADECANOYLPHORBOL-13-ACETATE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; POLYCYCLIC AROMATIC-HYDROCARBONS; ANTIOXIDANT PROOXIDANT STATUS; METABOLIC-ACTIVATION; SUPEROXIDE-DISMUTASE; CHEMI-LUMINESCENCE; TOPICAL TREATMENT; EPIDERMAL-CELLS; DIOL-EPOXIDES	(7S,8S) - Dihydroxy - 7,8 - dihydrobenzo[a]pyrene ((+)-BP-7,8-diol) is epoxidized to (7S,8R)-dihydroxy-(9S,10R)-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene ((+)-syn-BPDE) by cytochrome P-450 isoenzymes and to (7S,8R)-dihydroxy-(9R,10S)-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene ((-)-anti-BPDE) by peroxyl free radicals. P-32 postlabeling analysis of the diastereomeric BPDE-DNA adducts was used to investigate the pathways of (+)-BP-7,8-diol oxidation in mouse skin in vivo. The pattern of deoxynucleoside 3',5'-bisphosphate adducts in epidermal scrapings from female CD-1 mice indicated that cytochrome P-450 was the major oxidant. Similar results were obtained when the tumor-promoting phorbol ester tetradecanoylphorbolacetate (TPA) was coadministered with (+)-BP-7,8-diol. However, when animals were pretreated with TPA 24 h before coadminsitration of TPA and (+)-BP-7,8-diol, the pattern of BPDE-DNA adducts indicated that peroxyl radicals made a major contribution to (+)-BP-7,8-diol epoxidation. Peroxyl radical-dependent epoxidation was maximal when the time between the two TPA administrations was 24-72 h. No increase in (-)-anti-BPDE-DNA was observed when the non-tumor-promoting phorbol ester 4-O-methyl-TPA was substituted for TPA. The calcium ionophore A23187 stimulated peroxyl radical generation when substituted for the first, but not the second, TPA treatment. The antiinflammatory steroid fluocinolone acetonide inhibited (-)-anti-BPDE-DNA adduct formation when coadministered with the first but not the second TPA treatment. These findings demonstrate the existence of two independent pathways of metabolic activation of (+)-BP-7,8-diol in mouse epidermis, one dependent on cytochrome P-450 and the other dependent on peroxyl free radicals. The results also suggest that repetitive topical administration of tumor-promoting phorbol esters remodels epidermal metabolism leading to a significant increase in free radical generation.	VANDERBILT UNIV, MED CTR,SCH MED,CTR MOLEC TOXICOL,DEPT BIOCHEM, AB HANCOCK JR MEM LAB CANC RES, NASHVILLE, TN 37232 USA	Vanderbilt University					NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER; NCI NIH HHS [CA47479] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAIRD WM, 1971, CANCER RES, V31, P1434; BIRNBOIM HC, 1986, CARCINOGENESIS, V7, P495, DOI 10.1093/carcin/7.3.495; Boutwel R. K., 1978, CARCINOGENESIS, V2, P49; BOYD JA, 1982, CANCER RES, V42, P2628; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; BYCZKOWSKI JZ, 1989, BIOCHEM BIOPH RES CO, V159, P1199, DOI 10.1016/0006-291X(89)92237-7; CANELLA K, 1991, CARCINOGENESIS, V12, P1109, DOI 10.1093/carcin/12.6.1109; CATALANO CE, 1987, BIOCHEMISTRY-US, V26, P8373, DOI 10.1021/bi00399a052; DEUTSCH J, 1978, P NATL ACAD SCI USA, V75, P3123, DOI 10.1073/pnas.75.7.3123; Dipple A., 1984, CHEM CARCINOGENS, P41; DIX TA, 1981, J AM CHEM SOC, V103, P6744, DOI 10.1021/ja00412a037; ELING T, 1986, CARCINOGENESIS, V7, P1957, DOI 10.1093/carcin/7.12.1957; ELING TE, 1990, ANNU REV PHARMACOL, V30, P1, DOI 10.1146/annurev.pa.30.040190.000245; FISCHER SM, 1985, CANCER RES, V45, P3130; FISCHER SM, 1986, CARCINOGENESIS, V7, P915, DOI 10.1093/carcin/7.6.915; FURSTENBERGER G, 1991, J BIOL CHEM, V266, P15738; GOLDSTEIN BD, 1981, CANCER LETT, V11, P257, DOI 10.1016/0304-3835(81)90117-8; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P391, DOI 10.1021/tx00022a001; GUPTA RC, 1985, CANCER RES, V45, P5656; HUBERMAN E, 1976, P NATL ACAD SCI USA, V73, P607, DOI 10.1073/pnas.73.2.607; KAPITULNIK J, 1978, CANCER RES, V38, P354; KENSLER T W, 1989, P233; KENSLER TW, 1987, TOXICOL APPL PHARM, V90, P337, DOI 10.1016/0041-008X(87)90341-3; KENSLER TW, 1986, ADV FREE RADICAL BIO, V2, P347, DOI 10.1016/S8755-9668(86)80019-9; MALLET WG, 1991, CARCINOGENESIS, V12, P521, DOI 10.1093/carcin/12.3.521; MARKS F, 1981, CANCER RES, V41, P696; Marnett L.J., 1986, CYTOCHROME P 450 STR, P29; MARNETT LJ, 1987, CARCINOGENESIS, V8, P1365, DOI 10.1093/carcin/8.10.1365; MARNETT LJ, 1979, FEBS LETT, V106, P13, DOI 10.1016/0014-5793(79)80684-5; MARNETT LJ, 1979, J BIOL CHEM, V254, P5077; MARNETT LJ, 1985, PLATELETS PHYSL PHAR, P187; METCALF JA, 1986, LABORATORY MANUAL NE, P150; MILLER JA, 1970, CANCER RES, V30, P559; MIYASAKI KT, 1991, ANAL BIOCHEM, V193, P38, DOI 10.1016/0003-2697(91)90040-Z; PANTHANANICKAL A, 1981, CHEM-BIOL INTERACT, V33, P239, DOI 10.1016/0009-2797(81)90044-2; PERCHELLET EM, 1989, CANCER RES, V49, P6193; POUND AW, 1967, AUST J EXP BIOL MED, V45, P507, DOI 10.1038/icb.1967.49; PRUESSSCHWARTZ D, 1989, CANCER RES, V49, P1732; PRYOR WA, 1986, ANNU REV PHYSIOL, V48, P657, DOI 10.1146/annurev.ph.48.030186.003301; REDDY AP, 1992, CHEM RES TOXICOL, V5, P26, DOI 10.1021/tx00025a006; REDDY AP, 1992, CHEM RES TOXICOL, V5, P19, DOI 10.1021/tx00025a005; REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543; REED GA, 1981, THESIS WAYNE STATE U; REINERS JJ, 1991, CARCINOGENESIS, V12, P2345, DOI 10.1093/carcin/12.12.2345; REINERS JJ, 1991, CARCINOGENESIS, V12, P2337, DOI 10.1093/carcin/12.12.2337; ROBINSON JM, 1984, BIOCHEM BIOPH RES CO, V122, P734, DOI 10.1016/S0006-291X(84)80095-9; RODRIGUES AD, 1991, CHEM RES TOXICOL, V4, P281, DOI 10.1021/tx00021a004; SCHWARZ JA, 1977, CHEM-BIOL INTERACT, V17, P331, DOI 10.1016/0009-2797(77)90096-5; SELIGER HH, 1982, PHOTOCHEM PHOTOBIOL, V36, P359, DOI 10.1111/j.1751-1097.1982.tb04387.x; SIMS P, 1974, NATURE, V252, P326, DOI 10.1038/252326a0; Sims P, 1974, Adv Cancer Res, V20, P165, DOI 10.1016/S0065-230X(08)60111-6; SIVARAJAH K, 1979, FEBS LETT, V106, P17, DOI 10.1016/0014-5793(79)80685-7; SLAGA TJ, 1982, J CELL BIOCHEM, V18, P99, DOI 10.1002/jcb.1982.240180109; SLAGA TJ, 1983, MODULATION MEDIATION, P10; Slaga TJ, 1978, CARCINOGENESIS, V2, P173; SOLANKI V, 1981, CARCINOGENESIS, V2, P1141, DOI 10.1093/carcin/2.11.1141; TAFFE BG, 1989, CARCINOGENESIS, V10, P1261, DOI 10.1093/carcin/10.7.1261; THAKKER DR, 1977, CHEM-BIOL INTERACT, V16, P281, DOI 10.1016/0009-2797(77)90108-9; THOMPSON S, 1976, J INVEST DERMATOL, V66, P108, DOI 10.1111/1523-1747.ep12481449; TROLL W, 1985, ANNU REV PHARMACOL, V25, P509, DOI 10.1146/annurev.pharmtox.25.1.509; TRUSH MA, 1991, FREE RADICAL BIO MED, V10, P201, DOI 10.1016/0891-5849(91)90077-G; TRUSH MA, 1985, P NATL ACAD SCI USA, V82, P5194, DOI 10.1073/pnas.82.15.5194; TRUSH MA, 1992, IN PRESS FOOD CHEM T; WEI HC, 1991, CANCER RES, V51, P4443; WOOD AW, 1976, J BIOL CHEM, V251, P4882	66	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17842	17848						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325452				2022-12-27	WOS:A1992JM22300057
J	TANG, BZ; NAZAR, RN				TANG, BZ; NAZAR, RN			UNBALANCED REGULATION OF THE RIBOSOMAL 5-S-RNA-BINDING PROTEIN IN SACCHAROMYCES-CEREVISIAE EXPRESSING MUTANT 5-S-RIBOSOMAL-RNAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; YEAST; DNA; SEQUENCE; REGION; GENES; PROMOTERS; ELEMENTS	A gene encoding the 5 S rRNA-binding protein (YL3) in yeast (Saccharomyces cerevisiae) was further characterized with respect to its chromosomal localization, the controlling sequence regions, and the influence of 5 S rRNA gene expression. Sequence and chromosome blot analyses localized the gene on chromosome XVI immediately downstream of a cytochrome oxidase assembly gene, COXII. S1 nuclease protection studies identified two major initiation sites, 20 and 65 nucleotides upstream of the coding sequence, and a single polyadenylation site, 98 nucleotides downstream of the stop codon. Northern blot analyses and S1 nuclease protection indicated a normal pattern of gene regulation in media supporting alternate rates of growth, but significantly unbalanced regulation was observed in the presence of mutant 5 S rRNA genes which under-produce RNA and result in reduced growth rates. The results suggest a co-ordinating regulatory mechanism which maintains appropriate levels of 5 S rRNA-protein complex; an internal control region-like sequence in the upstream region of the YL3 gene is consistent with this feedback mechanism.			TANG, BZ (corresponding author), UNIV GUELPH,DEPT MOLEC BIOL & GENET,GUELPH N1G 2W1,ONTARIO,CANADA.							BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P1881, DOI 10.1073/pnas.68.8.1881; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; CILIBERTO G, 1983, CELL, V32, P725, DOI 10.1016/0092-8674(83)90058-2; ELBARADI TTAL, 1986, CURR GENET, V10, P733, DOI 10.1007/BF00405095; FRIED HM, 1984, RECOMBINANT DNA CELL, P169; JOYCE CM, 1983, P NATL ACAD SCI-BIOL, V80, P1830, DOI 10.1073/pnas.80.7.1830; LEER RJ, 1985, NUCLEIC ACIDS RES, V13, P701, DOI 10.1093/nar/13.3.701; MAICAS E, 1990, NUCLEIC ACIDS RES, V18, P3387, DOI 10.1093/nar/18.11.3387; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; NAZAR RN, 1979, EUR J BIOCHEM, V102, P573, DOI 10.1111/j.1432-1033.1979.tb04274.x; NAZAR RN, 1991, BIOCHEM CELL BIOL, V69, P217, DOI 10.1139/o91-033; NAZAR RN, 1984, NUCLEIC ACIDS RES, V11, P3155; NOMURA M, 1984, ANN REV BIOCH, V53, P57; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELHAM HG, 1980, P NATL ACAD SCI USA, V77, P4679; PIELER T, 1987, CELL, V48, P91, DOI 10.1016/0092-8674(87)90359-X; PLANTA RJ, 1982, CELL NUCLEUS, V12, P213; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARROCKS AD, 1991, BIOTECHNIQUES, V10, P426; SIKORSKI RS, 1989, GENETICS, V122, P19; TANG BZ, 1991, J BIOL CHEM, V266, P6120; TEEM JL, 1984, NUCLEIC ACIDS RES, V12, P8295, DOI 10.1093/nar/12.22.8295; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; VANRYK DI, 1990, J BIOL CHEM, V265, P8377; VANRYK DI, 1992, J BIOL CHEM, P16177; WARNER JR, 1986, MICROBIOL SCI, V3, P341; WARNER JR, 1982, MOL BIOL YEAST SACCH, P529; YAGUCHI M, 1984, EUR J BIOCHEM, V139, P451, DOI 10.1111/j.1432-1033.1984.tb08026.x	30	8	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17738	17742						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325447				2022-12-27	WOS:A1992JM22300042
J	ZANG, LY; MISRA, HP				ZANG, LY; MISRA, HP			SUPEROXIDE RADICAL PRODUCTION DURING THE AUTOXIDATION OF 1-METHYL-4-PHENYL-2,3-DIHYDROPYRIDINIUM PERCHLORATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIGROSTRIATAL TOXIN 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; MONOAMINE-OXIDASE; SUBSTANTIA NIGRA; MPTP; METABOLITE; ION; PARKINSONISM; OXIDATION; N-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; BIOACTIVATION	1-Methyl-4-phenyl-2,3-dihydropyridinium perchlorate (MPDP+), an intermediate in the metabolism of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, was found to generate superoxide radicals during its autoxidation process. The generation of superoxide radicals was detected by their ability to reduce ferricytochrome c. Superoxide dismutase inhibited this reduction in a dose-dependent manner. The rate of reduction of ferricytochrome c was dependent not only on the concentration of MPDP+ but also on the pH of the system. Thus, the rate of autoxidation of MPDP+ and the sensitivity of this autoxidation to superoxide dismutase-inhibitable ferricytochrome c reduction were both augmented, as the pH was raised from 7.0 to 10.5. The rate constant (K(c)) for the reaction of superoxide radical with ferricytochrome c to form ferricytochrome c was found to be 3.48 x 10(5) m-1 s-1. The rate constant (K(MPDP+)) for the reaction of MPDP+ with ferricytochrome3+ c was found to be only 4.86 m-1 s-1. These results, in conjunction with complexities in the kinetics, lead to the proposal that autoxidation of MPDP+ proceeds by at least two distinct pathways, one of which involves the production of superoxide radicals and hence is inhibitable by superoxide dismutase. It is possible that the free radicals so generated could induce oxidative injury which may be central to the MPTP/MPDP+-induced neuropathy.	VIRGINIA POLYTECH INST & STATE UNIV, VIRGINIA MARYLAND REG COLL VET MED, DEPT BIOMED SCI, BLACKSBURG, VA 24061 USA; CHINESE ACAD SCI, BEIJING, PEOPLES R CHINA	Virginia Polytechnic Institute & State University; Chinese Academy of Sciences								BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; CAPELLOS C, 1972, KINETIC SYSTEMS, P6; CHACON JN, 1987, BIOCHEM BIOPH RES CO, V144, P957, DOI 10.1016/S0006-291X(87)80057-8; CHEVALET J, 1972, J ELECTROANAL CHEM, V39, P201, DOI 10.1016/S0022-0728(72)80488-1; CHIBA K, 1984, BIOCHEM BIOPH RES CO, V120, P574, DOI 10.1016/0006-291X(84)91293-2; CHIBA K, 1985, DRUG METAB DISPOS, V13, P342; CZAPSKI G, 1964, J PHYS CHEM-US, V68, P1169, DOI 10.1021/j100787a034; GESSNER W, 1985, FEBS LETT, V183, P345, DOI 10.1016/0014-5793(85)80807-3; GORDON S, 1963, J AM CHEM SOC, V85, P1375, DOI 10.1021/ja00893a002; GORDON S, 1964, J PHYS CHEM-US, V68, P1262, DOI 10.1021/j100787a520; HEIKKILA RE, 1984, NATURE, V311, P467, DOI 10.1038/311467a0; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; JOHANNESSEN JN, 1985, LIFE SCI, V36, P219, DOI 10.1016/0024-3205(85)90062-1; KLUGROTH D, 1973, J AM CHEM SOC, V95, P2786, DOI 10.1021/ja00790a007; KORTYTOWSKI W, 1987, BIOCHEM BIOPH RES CO, V144, P692, DOI 10.1016/S0006-291X(87)80020-7; KORYTOWSKI W, 1987, BIOCHEM BIOPH RES CO, V147, P354, DOI 10.1016/S0006-291X(87)80129-8; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LANGSTON JW, 1984, NEUROSCI LETT, V48, P87, DOI 10.1016/0304-3940(84)90293-3; LEUNG L, 1989, J ORG CHEM, V54, P1052, DOI 10.1021/jo00266a011; LEWIN R, 1984, SCIENCE, V225, P1460, DOI 10.1126/science.6433484; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; NAIMAN N, 1990, CHEM RES TOXICOL, V3, P133, DOI 10.1021/tx00014a008; PETERSON LA, 1985, J MED CHEM, V28, P1432, DOI 10.1021/jm00148a010; POIRIER J, 1985, BIOCHEM BIOPH RES CO, V131, P1284, DOI 10.1016/0006-291X(85)90230-X; POIRIER J, 1985, BIOCHEM BIOPH RES CO, V128, P25, DOI 10.1016/0006-291X(85)91639-0; RABANI J, 1969, J PHYS CHEM-US, V73, P3736, DOI 10.1021/j100845a030; SIMIC MG, 1975, BIOCHEM BIOPH RES CO, V62, P161, DOI 10.1016/S0006-291X(75)80118-5; TREVOR AJ, 1987, LIFE SCI, V40, P713, DOI 10.1016/0024-3205(87)90298-0; TREVOR AJ, 1988, TOXICOLOGY, V49, P513, DOI 10.1016/0300-483X(88)90037-6; WU E, 1988, CHEM RES TOXICOL, V1, P186, DOI 10.1021/tx00003a010; WU EY, 1986, LIFE SCI, V39, P1695, DOI 10.1016/0024-3205(86)90167-0; YONG VW, 1986, NEUROSCI LETT, V63, P56, DOI 10.1016/0304-3940(86)90012-1	32	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17547	17552						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325439				2022-12-27	WOS:A1992JM22300014
J	MINARD, KI; MCALISTERHENN, L				MINARD, KI; MCALISTERHENN, L			GLUCOSE-INDUCED DEGRADATION OF THE MDH2 ISOZYME OF MALATE-DEHYDROGENASE IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE FRUCTOSE-1,6-BISPHOSPHATASE; AMINO-ACID SEQUENCES; CATABOLITE INACTIVATION; PHOSPHOENOLPYRUVATE CARBOXYKINASE; REVERSIBLE INACTIVATION; DIRECTED MUTAGENESIS; GENE; PROTEIN; PHOSPHORYLATION; IMPORT	MDH2, the nonmitochondrial isozyme of malate dehydrogenase in Saccharomyces cerevisiae, was determined to be a target of glucose-induced proteolytic degradation. Shifting a yeast culture growing with acetate to medium containing glucose as a carbon source resulted in a 25-fold increase in turnover of MDH2. A truncated form of MDH2 lacking amino acid residues 1-12 was constructed by mutagenesis of the MDH2 gene and expressed in a haploid yeast strain containing a deletion disruption of the corresponding chromosomal gene. Measurements of malate dehydrogenase specific activity and determination of growth rates with diagnostic carbon sources indicated that the truncated form of MDH2 was expressed at authentic MDH2 levels and was fully active. However, the truncated enzyme proved to be less susceptible to glucose-induced proteolysis, exhibiting a 3.75-fold reduction in turnover rate following a shift to glucose medium. Rates of loss of activity for other cellular enzymes known to be subject to glucose inactivation were similarly reduced. An extended lag in attaining wild type rates of growth on glucose measured for strains expressing the truncated MDH2 enzyme represents the first evidence of a selective advantage for the phenomenon of glucose-induced proteolysis in yeast.	UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717	University of California System; University of California Irvine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033218] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33218] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATZPODIEN W, 1968, EUR J BIOCHEM, V7, P58, DOI 10.1111/j.1432-1033.1968.tb19573.x; BANASZAK LJ, 1975, ENZYMES, V11, P369; BEDWELL DM, 1987, MOL CELL BIOL, V7, P4038, DOI 10.1128/MCB.7.11.4038; BIRKTOFT JJ, 1983, J BIOL CHEM, V258, P472; BIRKTOFT JJ, 1989, BIOCHEM SOC T, V17, P301, DOI 10.1042/bst0170301; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; DAUM G, 1982, J BIOL CHEM, V257, P3028; DELAGUERRA R, 1988, FEBS LETT, V242, P149, DOI 10.1016/0014-5793(88)81004-4; DICKMAN ER, 1976, THESIS YESHIVA U NEW; ENTIAN KD, 1983, ARCH MICROBIOL, V134, P187, DOI 10.1007/BF00407756; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUNAGUMA T, 1985, BIOCHEM BIOPH RES CO, V130, P467, DOI 10.1016/0006-291X(85)90440-1; GANCEDO C, 1971, J BACTERIOL, V107, P401, DOI 10.1128/JB.107.2.401-405.1971; GANCEDO C, 1976, ARCH MICROBIOL, V109, P221, DOI 10.1007/BF00446632; GIETL C, 1990, P NATL ACAD SCI USA, V87, P5773, DOI 10.1073/pnas.87.15.5773; HAGELE E, 1978, EUR J BIOCHEM, V83, P67, DOI 10.1111/j.1432-1033.1978.tb12069.x; HERRERO P, 1985, ARCH MICROBIOL, V143, P216, DOI 10.1007/BF00411238; HOLZER H, 1976, TRENDS BIOCHEM SCI, V1, P178, DOI 10.1016/S0968-0004(76)80018-7; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOH T, 1987, J BIOL CHEM, V262, P15127; KIM KS, 1986, MOL CELL BIOL, V6, P1936, DOI 10.1128/MCB.6.6.1936; KOPETZKI E, 1987, BIOCHIM BIOPHYS ACTA, V912, P398, DOI 10.1016/0167-4838(87)90044-6; LAMPONI S, 1987, FEBS LETT, V216, P265, DOI 10.1016/0014-5793(87)80703-2; LENZ AG, 1980, FEBS LETT, V109, P271, DOI 10.1016/0014-5793(80)81103-3; LOPEZBOADO YS, 1987, ARCH MICROBIOL, V147, P231, DOI 10.1007/BF00463480; Maniatis T., 1982, MOL CLONING; MARCUS F, 1988, J BIOL CHEM, V263, P6058; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; MINARD KI, 1991, MOL CELL BIOL, V11, P370, DOI 10.1128/MCB.11.1.370; MULLER D, 1981, BIOCHEM BIOPH RES CO, V103, P926, DOI 10.1016/0006-291X(81)90899-8; POLAKIS ES, 1965, BIOCHEM J, V97, P298, DOI 10.1042/bj0970298; POLAKIS ES, 1965, BIOCHEM J, V97, P284, DOI 10.1042/bj0970284; RITTENHOUSE J, 1987, J BIOL CHEM, V262, P10114; RODERICK SL, 1986, J BIOL CHEM, V261, P9461; ROGERS DT, 1988, J BIOL CHEM, V263, P6051; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMPSON LM, 1989, J BIOL CHEM, V264, P12091; THOMPSON LM, 1988, BIOCHEMISTRY-US, V27, P8393, DOI 10.1021/bi00422a015; VALDESHEVIA MD, 1989, FEBS LETT, V258, P313, DOI 10.1016/0014-5793(89)81682-5; WITT I, 1966, BIOCHIM BIOPHYS ACTA, V128, P63, DOI 10.1016/0926-6593(66)90142-1; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	45	39	40	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17458	17464						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324938				2022-12-27	WOS:A1992JL05300108
J	MURPHY, AJ; HOOVER, JC				MURPHY, AJ; HOOVER, JC			INHIBITION OF THE NA,K-ATPASE BY FLUORIDE - PARALLELS WITH ITS INHIBITION OF THE SARCOPLASMIC-RETICULUM CAATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT ADENOSINE-TRIPHOSPHATASE; TRANSITION-STATE ANALOGS; CONFORMATIONAL TRANSITIONS; SLOW-BINDING; ATPASE; VANADATE; SODIUM; PUMP; ION; ACTIVATION	Addition of lithium fluoride to a suspension of Na,K-ATPase undergoing turnover produced a slow (minutes) complete loss of ouabain-sensitive ATPase activity. Persistence of the effect in the presence of deferoxamine showed that fluoride inhibits independent of aluminum. The time course of onset of inhibition was adequately fit by a function corresponding to a monophasic transformation with a pseudo first-order rate constant (k(obs)). This constant varied hyperbolically with [Mg2+] (half-maximal effect at 9 mM Mg2+), whereas it increased with no sign of approaching saturation as the square of [F-], implying that inhibition requires binding of two fluorides/ATPase. The value of k(obs) was found to be increased by > 10-fold in the presence of potassium ([K+]1/2 = 0.6 mM) or ouabain. Sodium, ATP, and ADP, which favor the E1 form of the enzyme, had a protective effect. These results implicate the potassium-occluded MgE2(K2) complex as the main fluoride-susceptible form. Protection by P(i) and orthovanadate suggests that fluoride exerts its effect at the phosphorylation site. Inhibition was reversible, although slowly, with t1/2 = 7 h at 37-degrees-C. Sodium greatly accelerated reversal (t1/2 = 3 min with 150 mM Na+ present), and potassium antagonized this acceleration. The value of k(obs) for reactivation increased steeply with [Na+], with the sodium dependence being about the same at pH 8.0 as at pH 7.4. All of these effects have parallels to effects of fluoride on the sarcoplasmic reticulum CaATPase (Murphy, A. J., and Coll, R. J. (1992) J. Biol. Chem. 267, 5229-5235).			MURPHY, AJ (corresponding author), UNIV PACIFIC,SCH DENT,DEPT BIOCHEM,SAN FRANCISCO,CA 94115, USA.				NIGMS NIH HHS [GM31083] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031083] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONNY B, 1990, FEBS LETT, V268, P277, DOI 10.1016/0014-5793(90)81027-L; ASKARI A, 1982, BIOCHEM BIOPH RES CO, V104, P1447, DOI 10.1016/0006-291X(82)91412-7; BEVINGTON PR, 1969, DATA REDUCTION ERROR, P4; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BOND GH, 1979, BIOCHEMISTRY-US, V18, P325, DOI 10.1021/bi00569a015; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CORNELIUS F, 1991, BIOCHIM BIOPHYS ACTA, V1071, P19, DOI 10.1016/0304-4157(91)90011-K; DUPUIS A, 1989, FEBS LETT, V255, P47, DOI 10.1016/0014-5793(89)81058-0; ESMANN M, 1985, BIOCHEM BIOPH RES CO, V127, P857, DOI 10.1016/S0006-291X(85)80022-X; FORBUSH B, 1987, J BIOL CHEM, V262, P11104; FRIEDEN C, 1980, BIOCHEMISTRY-US, V19, P5303, DOI 10.1021/bi00564a024; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GLYNN IM, 1982, J PHYSIOL-LONDON, V330, P17, DOI 10.1113/jphysiol.1982.sp014326; HORISBERGER JD, 1991, ANNU REV PHYSIOL, V53, P565, DOI 10.1146/annurev.physiol.53.1.565; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; LAHIRI AK, 1971, MOL PHARMACOL, V7, P46; LINDQUIST RN, 1973, J AM CHEM SOC, V95, P8762, DOI 10.1021/ja00807a043; LOLIS E, 1990, ANNU REV BIOCHEM, V59, P597, DOI 10.1146/annurev.bi.59.070190.003121; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MURPHY AJ, 1990, FEBS LETT, V263, P175, DOI 10.1016/0014-5793(90)80733-Y; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; MURPHY AJ, 1992, J BIOL CHEM, V267, P16990; OPIT LJ, 1966, BIOCHIM BIOPHYS ACTA, V120, P159, DOI 10.1016/0926-6585(66)90288-3; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PENZOTTI SC, 1972, MOL PHARMACOL, V8, P149; POST RL, 1975, J BIOL CHEM, V250, P691; POST RL, 1972, J BIOL CHEM, V247, P6530; ROBINSON JD, 1986, J BIOENERG BIOMEMBR, V18, P521, DOI 10.1007/BF00743148; SCHATZMANN HJ, 1953, HELV PHYSIOL PHARM A, V11, P346; SIMONS TJB, 1979, NATURE, V281, P337, DOI 10.1038/281337a0; SKOU JC, 1960, BIOCHIM BIOPHYS ACTA, V42, P6, DOI 10.1016/0006-3002(60)90746-0; SMITH RL, 1980, J BIOL CHEM, V255, P9852; STEIN WD, 1990, J THEOR BIOL, V147, P145, DOI 10.1016/S0022-5193(05)80049-9; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; STURMER W, 1989, J MEMBRANE BIOL, V110, P67, DOI 10.1007/BF01870994; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; WHITTAM R, 1964, NATURE, V203, P720, DOI 10.1038/203720a0; YOSHIDA H, 1968, BIOCHIM BIOPHYS ACTA, V150, P162, DOI 10.1016/0005-2736(68)90021-7	43	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16995	17000						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324918				2022-12-27	WOS:A1992JL05300043
J	NARAYANAN, CS; FUJIMOTO, J; GERASRAAKA, E; GERSHENGORN, MC				NARAYANAN, CS; FUJIMOTO, J; GERASRAAKA, E; GERSHENGORN, MC			REGULATION BY THYROTROPIN-RELEASING-HORMONE (TRH) OF TRH RECEPTOR MESSENGER-RNA DEGRADATION IN RAT PITUITARY GH3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; IRON-RESPONSIVE ELEMENT; STABILITY INVITRO; GENE-EXPRESSION; BINDING-PROTEIN; DOWN-REGULATION; PHORBOL ESTER; FREE SYSTEM; GM-CSF; DECAY	In rat pituitary GH3 cells, thyrotropin-releasing hormone (TRH) down-regulates TRH receptor (TRH-R) mRNA (Fujimoto, J., Straub, R. E., and Gershengorn, M. C. (1991) Mol. Endocrinol. 5, 1527-1532), at least in part, by stimulating its degradation (Fujimoto, J., Narayanan, C. S., Benjamin, J. E., Heinflink, M., and Gershengorn, M. C. (1992) Endocrinology 130, 1879-1884). Here we show that TRH regulates RNase activity in GH3 cells and that specific mRNA sequences are needed for in vivo regulation of TRH-R mRNA by TRH. TRH affected RNase activity in a biphasic manner with rapid stimulation (by 10 min) followed by a decrease to a rate slower than in control lysates within 6 h. This time course paralleled the effects of TRH on degradation of TRH-R mRNA in vivo. The regulated RNase activity was in a polysome-free fraction of the lysates and was not specific for TRH-R RNA. A truncated form of TRH-R RNA that was missing the entire 3'-untranslated region (TRHR-R5) was more stable than full-length TRH-R RNA (TRHR-WT). In contrast to TRHR-WT mRNA, TRHR-R5 mRNA and TRHR-D9 mRNA, which was missing the 143 nucleotides 5' of the poly(A) tail, were not down-regulated by TRH in stably transfected GH3 cells as their rates of degradation were not increased. These data show that TRH regulates RNase activity in GH3 cells, that the 3'-untranslated region bestows decreased stability on TRH-R mRNA and that the 3' end of the mRNA is necessary for regulation by TRH of TRH-R mRNA degradation. We present an hypothesis that explains specific regulation of TRH-R mRNA degradation by TRH in GH3 pituitary cells.	CORNELL UNIV,MED CTR,COLL MED,DEPT MED,DIV MOLEC BIOL,RM A328,1300 YORK AVE,NEW YORK,NY 10021; NEW YORK HOSP,NEW YORK,NY 10021	Cornell University; NewYork-Presbyterian Hospital					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043036] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43036] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATWATER JA, 1990, ANNU REV GENET, V24, P519; BELASCO JG, 1988, GENE, V72, P15, DOI 10.1016/0378-1119(88)90123-0; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BINDER R, 1989, J BIOL CHEM, V264, P16910; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1990, METHOD ENZYMOL, V181, P202; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; DEUTSCHER MP, 1988, TRENDS BIOCHEM SCI, V13, P136, DOI 10.1016/0968-0004(88)90070-9; DRUMMOND AH, 1986, J EXP BIOL, V124, P337; FUJIMOTO J, 1991, MOL ENDOCRINOL, V5, P1527, DOI 10.1210/mend-5-10-1527; FUJIMOTO J, 1992, ENDOCRINOLOGY, V130, P1879, DOI 10.1210/en.130.4.1879; GERSHENGORN MC, 1986, ANNU REV PHYSIOL, V48, P515; GERSHENGORN MC, 1978, J CLIN INVEST, V62, P937, DOI 10.1172/JCI109222; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HINKLE PM, 1975, BIOCHEMISTRY-US, V14, P3845, DOI 10.1021/bi00688a017; IMAI A, 1987, METHOD ENZYMOL, V141, P100; IZZO NJ, 1990, P NATL ACAD SCI USA, V87, P6268, DOI 10.1073/pnas.87.16.6268; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JACOBSON AB, 1984, NUCLEIC ACIDS RES, V12, P45, DOI 10.1093/nar/12.1Part1.45; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; LAVERRIERE JN, 1983, EMBO J, V2, P1493, DOI 10.1002/j.1460-2075.1983.tb01613.x; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MAYER JE, 1983, J BIOL CHEM, V258, P5340; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; ORON Y, 1987, SCIENCE, V238, P1406, DOI 10.1126/science.2825350; PASTORI RL, 1991, BIOCHEMISTRY-US, V30, P10490, DOI 10.1021/bi00107a018; PEI R, 1988, MOL CELL BIOL, V8, P2860, DOI 10.1128/MCB.8.7.2860; PELTZ SW, 1987, MOL CELL BIOL, V7, P4345, DOI 10.1128/MCB.7.12.4345; PEPPEL K, 1990, BIOTECHNIQUES, V9, P711; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1987, J BIOL CHEM, V262, P9374; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SORENSON CM, 1991, NUCLEIC ACIDS RES, V19, P4459, DOI 10.1093/nar/19.16.4459; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; WAGER RE, 1990, MOL CELL BIOL, V10, P5983, DOI 10.1128/MCB.10.11.5983; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	52	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17296	17303						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324930				2022-12-27	WOS:A1992JL05300085
J	MURPHY, BJ; CATTERALL, WA				MURPHY, BJ; CATTERALL, WA			PHOSPHORYLATION OF PURIFIED RAT-BRAIN NA+ CHANNEL RECONSTITUTED INTO PHOSPHOLIPID-VESICLES BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP-DEPENDENT PHOSPHORYLATION; SENSITIVE SODIUM-CHANNELS; SCORPION TOXIN BINDING; ALPHA-SUBUNIT; EXPRESSION; MODULATION; PURIFICATION; NEURONS; SITE	Phosphorylation of voltage-sensitive Na+ channels in neurons by protein kinase C slows Na+ channel inactivation and reduces peak Na+ currents. Na+ channels purified from rat brain and reconstituted into phospholipid vesicles under conditions that restore Na+ channel function were rapidly phosphorylated by protein kinase C on their 260-kDa alpha-subunit. The phosphorylation reaction required Ca2+, diolein, and phosphatidylserine for activation of protein kinase C, and the rate of phosphorylation of reconstituted Na+ channels was 3- to 4-fold faster than for Na+ channels in detergent solution. Phosphorylation was on serine residues in three distinct tryptic phosphopeptides designated A, B, and C. Up to 2.5 mol of phosphate were incorporated per mol of Na+ channel. Following maximum phosphorylation by protein kinase C, cAMP-dependent protein kinase was able to incorporate more than 2.25 mol of phosphate per mol of Na+ channel indicating that these two kinases phosphorylate distinct sites. However, prior phosphorylation by cAMP-dependent protein kinase prevented phosphorylation of phosphopeptide B indicating that both kinases phosphorylate the site in this peptide. Phosphopeptide B shown here to be phosphorylated by protein kinase C and phosphopeptide 7 previously shown to be phosphorylated by cAMP-dependent protein kinase co-migrate on two-dimensional phosphopeptide maps and evidently are identical. The reduction in peak Na+ currents caused by both protein kinase C and cAMP-dependent protein kinase may result from phosphorylation of this single common site.			MURPHY, BJ (corresponding author), UNIV WASHINGTON, SCH MED, DEPT PHARMACOL, SEATTLE, WA 98195 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015751] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15751] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGNEW WS, 1984, ANNU REV PHYSIOL, V46, P517; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BARCHI RL, 1988, ANNU REV NEUROSCI, V11, P445; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; COSTA MRC, 1982, J BIOL CHEM, V257, P7918; COSTA MRC, 1984, CELL MOL NEUROBIOL, V4, P291, DOI 10.1007/BF00733592; COSTA MRC, 1984, J BIOL CHEM, V259, P8210; DOUCET JP, 1990, ANAL BIOCHEM, V190, P209, DOI 10.1016/0003-2697(90)90182-9; FELLER DJ, 1985, J BIOL CHEM, V260, P1542; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; GORDON D, 1987, P NATL ACAD SCI USA, V84, P8682, DOI 10.1073/pnas.84.23.8682; HARTSHORNE RP, 1985, P NATL ACAD SCI USA, V82, P240, DOI 10.1073/pnas.82.1.240; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; LEVITAN IB, 1985, J MEMBRANE BIOL, V87, P177, DOI 10.1007/BF01871217; LI M, 1991, J CELL BIOL, V115, pA495; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; ROSSIE S, 1987, J BIOL CHEM, V262, P12735; ROSSIE S, 1989, J BIOL CHEM, V264, P14220; ROSSIE S, 1987, J BIOL CHEM, V262, P17530; ROSSIE S, 1987, ENZYMES, V18, P335; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; TAMKUN MM, 1984, J BIOL CHEM, V259, P1676; WALAAS SI, 1991, PHARMACOL REV, V43, P299; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836	33	38	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16129	16134						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322892				2022-12-27	WOS:A1992JJ45800025
J	WILDEN, PA; KAHN, CR; SIDDLE, K; WHITE, MF				WILDEN, PA; KAHN, CR; SIDDLE, K; WHITE, MF			INSULIN-RECEPTOR KINASE DOMAIN AUTOPHOSPHORYLATION REGULATES RECEPTOR ENZYMATIC FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; TYROSINE KINASE; BETA-SUBUNIT; PHOSPHORYLATION SITES; HYBRID RECEPTORS; SIGNAL TRANSDUCTION; TRANSFECTED CELLS; PROTEIN; REPLACEMENT; INVITRO	We have studied a series of insulin receptor molecules in which the 3 tyrosine residues which undergo autophosphorylation in the kinase domain of the beta-subunit (Tyr1158, Tyr1162, and Tyr1163) were replaced individually, in pairs, or all together with phenylalanine or serine by in vitro mutagenesis. A single-Phe replacement at each of these three positions reduced insulin-stimulated autophosphorylation of solubilized receptor by 45-60% of that observed with wild-type receptor. The double-Phe replacements showed a 60-70% reduction, and substitution of all 3 tyrosine residues with Phe or Ser reduced insulin-stimulated tyrosine autophosphorylation by >80%. Phosphopeptide mapping each mutant revealed that all remaining tyrosine autophosphorylation sites were phosphorylated normally following insulin stimulation, and no new sites appeared. The single-Phe mutants showed insulin-stimulated kinase activity toward a synthetic peptide substrate of 50-75% when compared with wild-type receptor kinase activity. Insulin-stimulated kinase activity was further reduced in the double-Phe mutants and barely detectable in the triple-Phe mutants. In contrast to the wild-type receptor, all of the mutant receptor kinases showed a significant reduction in activation following in vitro insulin-stimulated autophosphorylation. When studied in intact Chinese hamster ovary cells, insulin-stimulated receptor autophosphorylation and tyrosine phosphorylation of the cellular substrate pp185 in the single-Phe and double-Phe mutants was progressively lower with increased tyrosine replacement and did not exceed the basal levels in the triple-Phe mutants. However, all the mutant receptors, including the triple-Phe mutant, retained the ability to undergo insulin-stimulated Ser and Thr phosphorylation. Thus, full activation of the insulin receptor tyrosine kinase is dependent on insulin-stimulated Tris phosphorylation of the kinase domain, and the level of autophosphorylation in the kinase domain provides a mechanism for modulating insulin receptor kinase activity following insulin stimulation. By contrast, insulin stimulation of receptor phosphorylation on Ser and Thr residues by cellular serine/threonine kinases can occur despite markedly reduced tyrosine autophosphorylation.	HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	Harvard University; Harvard Medical School	WILDEN, PA (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02215 USA.		Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NIDDK NIH HHS [DK 33201, DK 36836, DK 38712] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038712, P30DK036836, R29DK038712, R55DK038712, R01DK033201] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHIN JE, 1991, J BIOL CHEM, V266, P15587; CHOU CK, 1987, J BIOL CHEM, V262, P1842; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; GOLDSTEIN BJ, 1991, ADV PROTEIN PHOSPHAT, V6; GOREN HJ, 1987, BIOCHEMISTRY-US, V26, P2374, DOI 10.1021/bi00382a044; GOTTSCHALK WK, 1991, J BIOL CHEM, V266, P8814; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; HERRERA R, 1986, J BIOL CHEM, V261, P1980; ISSAD T, 1991, BIOCHEM J, V275, P15, DOI 10.1042/bj2750015; KASUGA M, 1982, J BIOL CHEM, V257, P9891; KING MJ, 1990, BIOCHEM J, V266, P251, DOI 10.1042/bj2660251; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; MCCLAIN DA, 1991, MOL ENDOCRINOL, V5, P734, DOI 10.1210/mend-5-5-734; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; MYERS MG, 1991, J BIOL CHEM, V266, P10616; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; RODBARD D, 1980, CANCER, V46, P2907, DOI 10.1002/1097-0142(19801215)46:12+<2907::AID-CNCR2820461433>3.0.CO;2-6; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; SALE GJ, 1991, INSULIN RECEPTOR PHO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SBRACCIA P, 1991, DIABETES, V40, P295, DOI 10.2337/diabetes.40.2.295; SOOS MA, 1990, BIOCHEM J, V270, P383, DOI 10.1042/bj2700383; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUNG CK, 1989, J BIOL CHEM, V264, P18951; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TAVARE JM, 1991, BIOCHEM J, V274, P173, DOI 10.1042/bj2740173; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; TREADWAY JL, 1989, J BIOL CHEM, V264, P21450; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WHITE MF, 1989, J CELL BIOCHEM, V39, P429, DOI 10.1002/jcb.240390409; WHITE MF, 1985, J BIOL CHEM, V260, P9470; WHITE MF, 1991, J BIOENERG BIOMEMBR, V23, P63; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; ZHANG B, 1991, J BIOL CHEM, V266, P990	53	123	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16660	16668						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322912				2022-12-27	WOS:A1992JJ45800102
J	MENON, AK; STEVENS, VL				MENON, AK; STEVENS, VL			PHOSPHATIDYLETHANOLAMINE IS THE DONOR OF THE ETHANOLAMINE RESIDUE LINKING A GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR TO PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							VARIANT SURFACE GLYCOPROTEINS; GLYCOSYL-PHOSPHATIDYLINOSITOL ANCHOR; MEMBRANE-DERIVED OLIGOSACCHARIDES; SACCHAROMYCES-CEREVISIAE; TRYPANOSOMA-BRUCEI; PHOSPHOLIPASE-C; SN-1,2-DIACYLGLYCEROL CHOLINEPHOSPHOTRANSFERASE; STRUCTURAL CHARACTERIZATION; GLYCOLIPID PRECURSORS; RESISTANT GLYCOLIPIDS	Numerous cell surface glycoproteins from eukaryotic organisms including African trypanosomes and budding yeast (Saccharomyces cerevisiae), are anchored to the lipid bilayer by a glycophospholipid, glycosylphosphatidylinositol, covalently linked to the carboxyl terminus of the protein via a phosphoethanolamine bridge. In this paper we describe metabolic labeling experiments aimed at identifying the biosynthetic origin of the ethanolamine residue in the phosphoethanolamine bridge. Using yeast mutants generated by disruption of the ethanolaminephosphotransferase (EPT1) and cholinephosphotransferase (CPT1) genes, we report data consistent with the proposal that the ethanolamine residue is derived from phosphatidylethanolamine.	EMORY UNIV,ROLLINS RES CTR,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University	MENON, AK (corresponding author), ROCKEFELLER UNIV,MOLEC PARASITOL LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.			Menon, Anant Kumar/0000-0001-6924-2698	NIAID NIH HHS [AI28858, AI21531] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021531, R01AI028858] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BENNERT JT, 1981, BIOCHIM BIOPHYS ACTA, V666, P99; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORKENHAGEN L, 1961, J BIOL CHEM, V236, pPC28; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CONZELMANN A, 1991, CELL BIOL INT REP, V15, P863, DOI 10.1016/0309-1651(91)90038-K; CONZELMANN A, 1986, EMBO J, V5, P3291, DOI 10.1002/j.1460-2075.1986.tb04642.x; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; CONZELMANN A, 1990, EMBO J, V9, P653, DOI 10.1002/j.1460-2075.1990.tb08157.x; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; DOERING TL, 1989, J BIOL CHEM, V264, P11168; FATEMI SH, 1986, CELL, V46, P653, DOI 10.1016/0092-8674(86)90340-5; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIELD MC, 1991, J BIOL CHEM, V266, P8392; HIGGINS JA, 1989, BIOCHEM J, V259, P913, DOI 10.1042/bj2590913; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HJELMSTAD RH, 1988, J BIOL CHEM, V263, P19748; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P4357; HJELMSTAD RH, 1987, J BIOL CHEM, V262, P3909; HJELMSTAD RH, 1990, J BIOL CHEM, V265, P1755; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; JACKSON BJ, 1983, J BIOL CHEM, V258, P2394; KAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47; KENNEDY EP, 1961, FED PROC, V20, P934; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; KRAKOW JL, 1989, MOL BIOCHEM PARASIT, V36, P263, DOI 10.1016/0166-6851(89)90174-6; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MALGAT M, 1986, J LIPID RES, V27, P251; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MILLER KJ, 1987, J BACTERIOL, V169, P682, DOI 10.1128/jb.169.2.682-686.1987; MULLER G, 1991, EUR J BIOCHEM, V202, P299, DOI 10.1111/j.1432-1033.1991.tb16376.x; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SINGH N, 1991, MOL CELL BIOL, V11, P391, DOI 10.1128/MCB.11.1.391; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; ULLMAN MD, 1974, J BIOL CHEM, V249, P1506; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; VAI M, 1990, BIOCHIM BIOPHYS ACTA, V1038, P277, DOI 10.1016/0167-4838(90)90237-A; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027	51	122	124	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15277	15280						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322394				2022-12-27	WOS:A1992JG11300006
J	CAO, XM; MAHENDRAN, R; GUY, GR; TAN, YH				CAO, XM; MAHENDRAN, R; GUY, GR; TAN, YH			PROTEIN PHOSPHATASE INHIBITORS INDUCE THE SUSTAINED EXPRESSION OF THE EGR-1 GENE AND THE HYPERPHOSPHORYLATION OF ITS GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILMS-TUMOR LOCUS; ZINC-FINGER GENE; GROWTH-FACTORS; CALYCULIN-A; BINDING; ENCODES; PATHWAYS; SEQUENCE; KROX-24; INVITRO	The immediate-early gene Egr-1 is strongly and rapidly induced in human and mouse Balb/c fibroblasts by okadaic acid and calyculin A, both specific inhibitors of protein serine/threonine phosphatases 1 and 2A. In contrast to the transient induction of the Egr-1 gene by serum or phorbol 12-myristate 13-acetate, these phosphatase inhibitors stimulated a sustained induction of the Egr-1 gene. The induction is shown to occur transcriptionally and is sustained post- transcriptionally. Okadaic acid-induced Egr-1 mRNA is significantly more stable than serum-induced Egr-1 mRNA. The half-life of serum-induced Egr-1 mRNA is estimated to be 12 min, compared with a half life of 2 h for okadaic acid-induced Egr-1 mRNA. Okadaic acid also induced the expression of the related immediate-early genes Egr-2 and Egr-3 albeit to a lesser extent than Egr-1. Treatment of cells with okadaic acid and calyculin A also induced the synthesis of Egr-1 protein. The Egr-1 protein is weakly or not phosphorylated in quiescent cells, but multiple species of the phosphorylated forms of the Egr-1 protein are detected in cells treated with either of the phosphatase inhibitors. Simultaneous treatment of cells with TPA and okadaic acid synergistically induced Egr-1 gene expression, and H7 strongly inhibits this induction. Taken together, the results indicate that the induction of Egr-1 gene transcription and the phosphorylation of the induced Egr-1 protein are under the control of protein kinase(s) and protein phosphatase(s). The phosphorylation and dephosphorylation of Egr-1 protein may play a role in controlling cell growth.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,SIGNAL TRANSDUCT LAB,10 KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Mahendran, Ratha/B-3827-2012					ALEXANDRE C, 1991, ONCOGENE, V6, P1851; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO X, 1989, MOL CELL BIOL, V10, P1931; CAO XM, 1992, J BIOL CHEM, V267, P1345; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CURRAN T, 1987, ONCOGENE, V2, P79; GUY GR, 1991, J BIOL CHEM, V266, P14343; GUY GR, 1992, J BIOL CHEM, V267, P1846; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JAMIESON GA, 1989, J CELL PHYSIOL, V139, P262, DOI 10.1002/jcp.1041390207; JANSSENTIMMEN U, 1989, GENE, V80, P325, DOI 10.1016/0378-1119(89)90296-5; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEUNG TKC, 1987, J NEUROCHEM, V49, P232, DOI 10.1111/j.1471-4159.1987.tb03420.x; LIM RW, 1989, MOL CELL BIOL, V9, P1790, DOI 10.1128/MCB.9.4.1790; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Marzluff W F Jr, 1978, Methods Cell Biol, V19, P317; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MURPHY D, 1990, MOL ENDOCRINOL, V4, P1051, DOI 10.1210/mend-4-7-1051; PATWARDHAN S, 1991, ONCOGENE, V6, P917; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SUGANUMA M, 1990, CANCER RES, V50, P3521; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAKAI A, 1987, FEBS LETT, V217, P81, DOI 10.1016/0014-5793(87)81247-4; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; YOSHIDA M, 1989, GENOME, V31, P662, DOI 10.1139/g89-121	38	75	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12991	12997						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1320009				2022-12-27	WOS:A1992HZ48300089
J	MURO, AF; BERNATH, VA; KORNBLIHTT, AR				MURO, AF; BERNATH, VA; KORNBLIHTT, AR			INTERACTION OF THE -170-CYCLIC AMP RESPONSE ELEMENT WITH THE ADJACENT CCAAT BOX IN THE HUMAN FIBRONECTIN GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR ATF; LEUCINE ZIPPER PROTEINS; NUCLEAR FACTOR CREB; RNA POLYMERASE-II; CYCLIC-AMP; PREINITIATION COMPLEX; MOLECULAR-BIOLOGY; BINDING-PROTEINS; DNA ELEMENTS; CDNA CLONES	In the fibronectin gene promoter the cAMP response element (CRE) and the CCAAT box are separated by only 20 base pairs (bp), i.e. two turns of double helix. Binding of nuclear proteins to these elements, assessed by DNase I footprinting, differs in the different cell types. While in a variety of cells tested (HeLa, granulosa, brain, and adenocarcinoma) only CRE binding activity is observed, liver extracts show both CRE and CCAAT binding activities. Competitions with CRE oligonucleotides were able to prevent the binding of both liver factors, while competitions with CCAAT oligonucleotides only abolished the binding to the CCAAT box. Consistently, the occupation of the CCAAT box was reduced when the distance between the CRE and CCAAT elements was increased in a series of spacing mutants in which DNA fragments of 20, 28, or 44 bp were inserted, and in a construct where the CRE sequence was deleted. Furthermore, the mutants are less efficient than the wild type as templates for in vitro transcription elicited by liver nuclear extracts. Transcriptional activity decreases with the 20- and 28-bp insertions but is partially recovered with the 44-bp insertion. Partial purification of liver CRE- and CCAAT-binding proteins by high performance liquid chromatography on a Mono Q column and recombination of column fractions showed that a novel 73-kDa CRE-binding protein facilitates the association of the CCAAT-binding protein to the CCAAT site of the fibronectin gene.	UNIV BUENOS AIRES,FAC CIENCIAS EXACTAS & NAT,RA-1428 BUENOS AIRES,ARGENTINA	University of Buenos Aires	MURO, AF (corresponding author), UNIV BUENOS AIRES,CONSEJO NACL INVEST CIENT & TECN,RA-1428 BUENOS AIRES,ARGENTINA.		Muro, Andrés F/K-3156-2016	Muro, Andrés F/0000-0002-9628-0494; Kornblihtt, Alberto/0000-0003-4322-0831				BENBROOK DM, 1990, ONCOGENE, V5, P295; BERNATH VA, 1990, J BIOL CHEM, V265, P18219; BOWLUS CL, 1991, J BIOL CHEM, V266, P1122; Brenowitz M., 1989, CURRENT PROTOCOLS MO; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; DEAN DC, 1988, J CELL BIOL, V106, P2159, DOI 10.1083/jcb.106.6.2159; DEAN DC, 1989, MOL CELL BIOL, V9, P1498, DOI 10.1128/MCB.9.4.1498; DEAN DC, 1990, J BIOL CHEM, V265, P3522; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HUBSCHER U, 1987, NUCLEIC ACIDS RES, V15, P5486, DOI 10.1093/nar/15.13.5486; HYNES R, 1985, ANNU REV CELL BIOL, V1, P67, DOI 10.1146/annurev.cb.01.110185.000435; KORNBLIHTT AR, 1988, BIOL REV, V63, P465, DOI 10.1111/j.1469-185X.1988.tb00668.x; KUGLER W, 1988, NUCLEIC ACIDS RES, V16, P3156; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	34	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12767	12774						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1320003				2022-12-27	WOS:A1992HZ48300059
J	MEDCALF, RL				MEDCALF, RL			CELL-SPECIFIC AND GENE-SPECIFIC INTERACTIONS BETWEEN SIGNAL TRANSDUCTION PATHWAYS REVEALED BY OKADAIC ACID - STUDIES ON THE PLASMINOGEN ACTIVATING SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' FLANKING REGION; PHORBOL ESTER; TUMOR-PROMOTER; TISSUE-TYPE; PROTEIN-PHOSPHORYLATION; ENDOTHELIAL-CELLS; LYMPHOMA-CELLS; INHIBITOR; ELEMENT; RNA	The potential contribution of serine/threonine-specific protein phosphatases in the transcriptional regulation of plasminogen activator and plasminogen activator inhibitor gene expression was explored in human HT-1080 fibrosarcoma and U-937 monocyte-like cells using okadaic acid, a potent and specific inhibitor of phosphatases 1 and 2A (PP1 and PP2A). In both cell types okadaic acid induced plasminogen activator type 2 (PAI-2) gene transcription and mRNA and potentiated induction mediated by phorbol-12-myristate-13-acetate and tumor necrosis factor. Okadaic acid-mediated induction of PAI-2 was inhibited by 8-bromo-cAMP in HT-1080 cells but not in U-937 cells. Okadaic acid had opposite effects on urokinase (u-PA) gene expression in the two cell lines; u-PA mRNA and gene transcription was suppressed in HT-1080 cells but transiently induced in U-937 cells. Tissue-type PA (t-PA) mRNA, although undetectable in U-937 cells, was also suppressed by okadaic acid in HT-1080 cells. This effect was selective, as constitutive and phorbol-12-myristate-13-acetate-mediated expression of plasminogen activator inhibitor type 1 mRNA was not modulated by okadaic acid in either cell type. These results indicate that PP1 and PP2A protein phosphatases are involved in signal transduction pathways modulating PAI-2, u-PA, and t-PA, and furthermore, that okadaic acid interaction with the protein kinase C and A pathways are gene- and cell type-specific.			MEDCALF, RL (corresponding author), CHU VAUDOIS,SCH MED,CENT HEMATOL LAB,CH-1011 LAUSANNE,SWITZERLAND.		Medcalf, Robert L/E-9632-2011					ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BACHMANN F, 1987, THROMB DIATH HAEMO, P227; BARBER JR, 1987, MOL CELL BIOL, V7, P2001; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; CAJOT JF, 1989, J CELL BIOL, V109, P915, DOI 10.1083/jcb.109.2.915; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1982, NATURE, V296, P613, DOI 10.1038/296613a0; COHEN P, 1989, J BIOL CHEM, V264, P21435; COUSIN E, 1991, NUCLEIC ACIDS RES, V19, P3881, DOI 10.1093/nar/19.14.3881; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; ERDODI F, 1988, BIOCHEM BIOPH RES CO, V153, P156, DOI 10.1016/S0006-291X(88)81202-6; FISHER R, 1985, J BIOL CHEM, V260, P1223; GENTON C, 1987, J CELL BIOL, V104, P705, DOI 10.1083/jcb.104.3.705; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GRANT PJ, 1990, CLIN SCI, V78, P3, DOI 10.1042/cs0780003; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; ISSINGER OG, 1988, EMBO J, V7, P1621, DOI 10.1002/j.1460-2075.1988.tb02988.x; KIM SJ, 1990, CELL REGUL, V1, P269, DOI 10.1091/mbc.1.3.269; KRUITHOF EKO, 1988, BIOCHEM BIOPH RES CO, V156, P383, DOI 10.1016/S0006-291X(88)80852-0; KRUITHOF EKO, 1986, J BIOL CHEM, V261, P1207; LOSKUTOFF DJ, 1983, P NATL ACAD SCI-BIOL, V80, P2956, DOI 10.1073/pnas.80.10.2956; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; Maniatis T., 1982, MOL CLONING; MEDCALF RL, 1986, EMBO J, V5, P2217, DOI 10.1002/j.1460-2075.1986.tb04487.x; MEDCALF RL, 1988, J EXP MED, V168, P751, DOI 10.1084/jem.168.2.751; MEDCALF RL, 1988, J CELL BIOL, V106, P971, DOI 10.1083/jcb.106.3.971; MEDCALF RL, 1990, J BIOL CHEM, V265, P14618; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; NAGAMINE Y, 1991, EMBO J, V10, P117, DOI 10.1002/j.1460-2075.1991.tb07927.x; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; OHMURA T, 1990, INT IMMUNOL, V2, P1073, DOI 10.1093/intimm/2.11.1073; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SANTELL L, 1988, J BIOL CHEM, V263, P16802; SASSA T, 1989, BIOCHEM BIOPH RES CO, V159, P939, DOI 10.1016/0006-291X(89)92199-2; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; SCHLEUNING WD, 1987, MOL CELL BIOL, V7, P4564, DOI 10.1128/MCB.7.12.4564; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SCHONTHAL A, 1991, NEW BIOL, V3, P977; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; STOPPELLI MP, 1986, J CELL BIOL, V102, P1235, DOI 10.1083/jcb.102.4.1235; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; THEVENIN C, 1990, New Biologist, V2, P793; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; Witters LA, 1990, CURR OPIN CELL BIOL, V2, P212, DOI 10.1016/0955-0674(90)90009-4	53	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12220	12226						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1318313				2022-12-27	WOS:A1992HY94700085
J	GAROFALO, RS; BARENTON, B				GAROFALO, RS; BARENTON, B			FUNCTIONAL AND IMMUNOLOGICAL DISTINCTION BETWEEN INSULIN-LIKE GROWTH FACTOR-I RECEPTOR SUBTYPES IN KB CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOPHYSECTOMIZED RAT-LIVER; TYROSINE KINASE-ACTIVITY; NEURO-BLASTOMA CELLS; MONOCLONAL-ANTIBODIES; SOMATOMEDIN RECEPTOR; FACTOR-BINDING; BETA-SUBUNITS; PROTEINS; PHOSPHORYLATION; GLYCOSYLATION	Subtypes of insulin-growth factor I (IGF-I) receptors, including hybrid receptors containing insulin receptor alpha-beta-dimers associated with IGF-I receptor alpha-beta-dimers, have been described in a number of systems. The molecular basis of the multiple subtypes and their functional significance is not understood. Ligand-dependent phosphorylation of insulin and IGF-I receptors and immunoprecipitation with antipeptide and monoclonal antibodies have been used to characterize the subpopulations of these receptors in the human KB cell line. IGF-I receptors exhibit beta-subunits of 95 and 102 kDa in these cells. IGF-I receptors containing 102-kDa beta-subunits are immunoprecipitated by the IGF-I receptor-specific antibody alpha-IR3. Antibody alpha-IR3 does not appear to recognize a hybrid receptor in these cells. However, an antipeptide antibody against the carboxyl-terminal domain of the insulin receptor (AbP5) immunoprecipitates a population of receptors phosphorylated in response to IGF-I (1 nM) which contains both 95- and 102-kDa beta-subunits. These receptors must be hybrid complexes because AbP5 does not recognize the 102-kDa beta-subunit directly. The inability of antibody alpha-IR3 to recognize these complexes suggests that their IGF-I receptor alpha-subunits must differ from typical IGF-I receptor alpha-subunits either in primary sequence or conformation. Therefore, KB cells may contain more than one type of IGF-I receptor alpha-subunit. Hybrid IGF-I receptors can also be distinguished from homotypic IGF-I receptors by their responsiveness to IGF-II. Stimulation of autophosphorylation in hybrid IGF-I receptors by IGF-I is 3-4-fold greater than that seen in response to IGF-II. In contrast, IGF-I and IGF-II are nearly equipotent in stimulating autophosphorylation in the alpha-IR3-reactive receptor population. This suggests the existence of functionally distinct receptor subtypes which may differ in their ability to mediate the biological effects of IGF-II.	INRA,DIFFERENCIAT CELLULAIRE & CROISSANCE LAB,F-34060 MONTPELLIER,FRANCE	INRAE	GAROFALO, RS (corresponding author), SUNY HLTH SCI CTR,DEPT ANAT & CELL BIOL,450 CLARKSON AVE,BOX 5,BROOKLYN,NY 11203, USA.							ALEXANDRIDES TK, 1989, J BIOL CHEM, V264, P12922; BARENTON B, 1988, ENDOCRINOLOGY, V122, P2499, DOI 10.1210/endo-122-6-2499; BARENTON B, 1987, BIOCHEM BIOPH RES CO, V149, P555, DOI 10.1016/0006-291X(87)90403-7; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CASELLA SJ, 1986, J BIOL CHEM, V261, P9268; EAGLE H, 1955, P SOC EXP BIOL MED, V89, P362; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FLIER JS, 1985, BIOCHEM BIOPH RES CO, V127, P929, DOI 10.1016/S0006-291X(85)80033-4; GAROFALO RS, 1989, MOL CELL BIOL, V9, P2806, DOI 10.1128/MCB.9.7.2806; HEDO JA, 1983, J BIOL CHEM, V258, P20; HERRERA R, 1986, J BIOL CHEM, V261, P2489; HERRERA R, 1988, INSULIN RECEPTORS, P181; JACOBS S, 1983, P NATL ACAD SCI USA, V80, P1128; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KULL FC, 1983, J BIOL CHEM, V258, P6561; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MISRA P, 1986, J CLIN ENDOCR METAB, V63, P1400, DOI 10.1210/jcem-63-6-1400; MORGAN DO, 1986, BIOCHEMISTRY-US, V25, P5560, DOI 10.1021/bi00367a032; MORGAN DO, 1986, BIOCHEM BIOPH RES CO, V138, P1341, DOI 10.1016/S0006-291X(86)80430-2; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; OTA A, 1988, EUR J BIOCHEM, V174, P521, DOI 10.1111/j.1432-1033.1988.tb14130.x; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SHIMIZU M, 1986, AM J PHYSIOL, V251, pE611, DOI 10.1152/ajpendo.1986.251.5.E611; SOOS MA, 1989, BIOCHEM J, V263, P553, DOI 10.1042/bj2630553; TREADWAY JL, 1989, J BIOL CHEM, V264, P21450; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANWYK JJ, 1985, J CLIN ENDOCR METAB, V61, P639; WILDEN PA, 1989, BIOCHEMISTRY-US, V28, P9734, DOI 10.1021/bi00451a029; YU KT, 1984, J BIOL CHEM, V259, P5277	32	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11470	11475						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317868				2022-12-27	WOS:A1992HX16900081
J	GUERINI, D; MONTELL, C; KLEE, CB				GUERINI, D; MONTELL, C; KLEE, CB			MOLECULAR-CLONING AND CHARACTERIZATION OF THE GENES ENCODING THE 2 SUBUNITS OF DROSOPHILA-MELANOGASTER CALCINEURIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN PHOSPHATASE; SERINE-THREONINE PHOSPHATASES; CATALYTIC SUBUNIT; PHOSPHOPROTEIN PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; CELLULAR-REGULATION; OKADAIC ACID; CDNA CLONING; KINASE-II; CALMODULIN	Genomic clones containing the full coding sequences of the two subunits of the Ca2+/calmodulin-stimulated protein phosphatase, calcineurin, were isolated from a Drosophila melanogaster genomic library using highly conserved human cDNA probes. Three clones encoded a 19.3-kDa protein whose sequence is 88% identical to that of human calcineurin B, the Ca2+-binding regulatory subunit of calcineurin. The coding sequences of the Drosophila and human calcineurin B genes are 69% identical. Drosophila calcineurin B is the product of a single intron-less gene located at position 4F on the X chromosome. Drosophila genomic clones encoding a highly conserved region of calcineurin A, the catalytic subunit of calcineurin, were used to locate the calcineurin A gene at position 21 EF on the second chromosome of Drosophila and to isolate calcineurin A cDNA clones from a Drosophila embryonic cDNA library. The structure of the calcineurin A gene was determined by comparison of the genomic and cDNA sequences. Twelve exons, spread over a total of 6.6 kilobases, were found to encode a 64.6-kDa protein 73% identical to either human calcineurin Aalpha or beta. At the nucleotide level Drosophila calcineurin A cDNA is 67 and 65% identical to human calcineurin Aalpha and beta cDNAs, respectively. Major differences between human and Drosophila calcineurins A are restricted to the amino and carboxyl termini, including two stretches of repetitive sequences in the carboxyl-terminal third of the Drosophila molecule. Motifs characteristic of the putative catalytic centers of protein phosphatase-1 and -2A and calcineurin are almost perfectly conserved. The calmodulin-binding and auto-inhibitory domains, characteristic of all mammalian calcineurins A, are also conserved. A remarkable feature of the calcineurin A gene is the location of the intron/exon junctions at the boundaries of the functional domains and the apparent conservation of the intron/exon junctions from Drosophila to man.	NCI, BIOCHEM LAB, BETHESDA, MD 20892 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM & NEUROSCI, BALTIMORE, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University			Montell, Craig/AAH-3357-2021	Montell, Craig/0000-0001-5637-1482	NATIONAL EYE INSTITUTE [R01EY008117] Funding Source: NIH RePORTER; NEI NIH HHS [EY08117] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AITKEN A, 1982, FEBS LETT, V150, P314, DOI 10.1016/0014-5793(82)80759-X; AITKEN A, 1984, EUR J BIOCHEM, V139, P663, DOI 10.1111/j.1432-1033.1984.tb08055.x; AKIRA I, 1989, BIOCHEM BIOPH RES CO, V163, P1492; ASHBURNER M, 1991, DROSOPHILA INF SERVI, V69, P218; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN PTW, 1991, METHOD ENZYMOL, V201, P398; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GIRI PR, 1991, BIOCHEM BIOPH RES CO, V181, P252; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; GUERINI D, 1989, DNA-J MOLEC CELL BIO, V8, P675, DOI 10.1089/dna.1.1989.8.675; GUERINI D, 1991, ADV PROT PHOSPHATASE, V6, P391; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P16524; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KINCAID RL, 1991, ADV PROT PHOSPHATASE, V6, P73; KING MM, 1984, J BIOL CHEM, V259, P8847; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; Klee CB, 1985, ADV PROTEIN PHOSPHAT, P135; KUNO T, 1989, BIOCHEM BIOPH RES CO, V165, P1352, DOI 10.1016/0006-291X(89)92752-6; KUNO T, 1991, BIOCHEM BIOPH RES CO, V180, P1159, DOI 10.1016/S0006-291X(05)81188-X; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; MARTENSEN TM, 1989, BIOCHEMISTRY-US, V28, P9243, DOI 10.1021/bi00450a002; MCPARTLIN AE, 1991, BIOCHIM BIOPHYS ACTA, V1088, P308, DOI 10.1016/0167-4781(91)90069-X; MERAT DL, 1985, J BIOL CHEM, V260, P1053; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; MUKAI H, 1991, BIOCHEM BIOPH RES CO, V179, P1325, DOI 10.1016/0006-291X(91)91718-R; MURAMATSU T, 1992, P NATL ACAD SCI USA, V89, P529, DOI 10.1073/pnas.89.2.529; NISHIO H, 1992, BIOCHEM BIOPH RES CO, V182, P34, DOI 10.1016/S0006-291X(05)80108-1; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RAO J, 1989, J BIOL CHEM, V264, P1058; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUGIMOTO M, 1991, BIOCHEM BIOPH RES CO, V180, P1476, DOI 10.1016/S0006-291X(05)81362-2; VINCENT JB, 1990, FEBS LETT, V263, P265, DOI 10.1016/0014-5793(90)81389-6; WADZINSKI BE, 1990, J BIOL CHEM, V265, P21504; YOKOYAMA N, 1990, J BIOL CHEM, V265, P8170	50	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22542	22549						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331060				2022-12-27	WOS:A1992JW71900086
J	HOFFMAN, L; PRATT, G; RECHSTEINER, M				HOFFMAN, L; PRATT, G; RECHSTEINER, M			MULTIPLE FORMS OF THE 20-S MULTICATALYTIC AND THE 26-S UBIQUITIN ATP-DEPENDENT PROTEASES FROM RABBIT RETICULOCYTE LYSATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; OXIDANT-DAMAGED HEMOGLOBIN; SODIUM DODECYL-SULFATE; RAT SKELETAL-MUSCLE; RED BLOOD-CELLS; CLASS-II REGION; PROTEINASE COMPLEX; NEUTRAL ENDOPEPTIDASE; LINKED LMP; HUMAN MHC	We have used native gel electrophoresis followed by fluorogenic peptide overlay to identify multiple forms of rabbit reticulocyte multicatalytic protease (MCP) or 20 S protease, and two forms of rabbit 26 S ubiquitin/ATP-dependent protease. An abundant, fast-migrating 20 S complex (20 S(F)) possesses modest ability to hydrolyze the fluorogenic peptide succinyl-Leu-Leu-Val-Tyr-4-methyl-coumaryl-7-amide. In contrast, two minor, slower migrating species cleave the peptide at high rates. A unique 30-kDa polypeptide is associated with one of the active MCPs, and a 160-kDa subunit is associated with the other. Two electrophoretically distinct 26 S proteases can also be isolated from rabbit reticulocyte lysate. The faster migrating form, 26 S(F), is more resistant to inactivation by ATP depletion. Despite the differential response to nucleotides and the distinctive electrophoretic mobilities of 26 S(F) and 26 S(S), we have not identified any subunit differences between the two enzymes. In addition to active 26 S proteases, we have discovered and purified a proteolytically inactive particle that contains subunits characteristic of the 26 S protease (e.g. molecular masses between 30 and 110 kDa). Incubation of this protein complex with purified MCP and ATP results in the formation of the 26 S proteases.	UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah					NIGMS NIH HHS [GM37009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRIBAS J, 1990, J BIOL CHEM, V265, P13969; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; DAHLMANN B, 1985, BIOCHEM J, V228, P171, DOI 10.1042/bj2280171; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; DJABALLAH H, 1991, BIOCH SOC T S, V19, P291; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FAGAN JM, 1986, J BIOL CHEM, V261, P5705; GANOTH D, 1988, J BIOL CHEM, V263, P12412; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; HOUGH R, 1987, J BIOL CHEM, V262, P8303; Hough R. F., 1988, UBIQUITIN, P101, DOI 10.1007/978-1-4899-2049-2_5; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KOPP F, 1986, BIOCHIM BIOPHYS ACTA, V872, P253, DOI 10.1016/0167-4838(86)90278-5; LINGRELL J, 1972, PROTEIN BIOSYNTHESIS, P234; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MYKLES DL, 1991, ARCH BIOCHEM BIOPHYS, V288, P543, DOI 10.1016/0003-9861(91)90233-9; MYKLES DL, 1989, ARCH BIOCHEM BIOPHYS, V274, P216, DOI 10.1016/0003-9861(89)90433-5; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; ORLOWSKI M, 1991, BIOCHEMISTRY-US, V30, P5999, DOI 10.1021/bi00238a025; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P5211; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; RIVETT AJ, 1989, J BIOL CHEM, V264, P12215; SACCHETTA P, 1990, BIOCHIM BIOPHYS ACTA, V1037, P337, DOI 10.1016/0167-4838(90)90035-E; SEELIG A, 1991, BIOCHEM J, V280, P225, DOI 10.1042/bj2800225; SUZUKI K, 1987, TRENDS BIOCHEM SCI, V12, P103, DOI 10.1016/0968-0004(87)90048-X; TANAKA K, 1988, J BIOL CHEM, V263, P16209; TOMKINSON B, 1991, BIOCHEMISTRY-US, V30, P168, DOI 10.1021/bi00215a025; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; YAMAMOTO K, 1987, BIOCHEM BIOPH RES CO, V148, P267, DOI 10.1016/0006-291X(87)91105-3; ZOLFAGHARI R, 1987, ARCH BIOCHEM BIOPHYS, V258, P42, DOI 10.1016/0003-9861(87)90320-1	41	229	231	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22362	22368						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331052				2022-12-27	WOS:A1992JW71900060
J	LAMARCHE, AEP; ABATE, MI; CHAN, SHP; TRUMPOWER, BL				LAMARCHE, AEP; ABATE, MI; CHAN, SHP; TRUMPOWER, BL			ISOLATION AND CHARACTERIZATION OF COX12, THE NUCLEAR GENE FOR A PREVIOUSLY UNRECOGNIZED SUBUNIT OF SACCHAROMYCES-CEREVISIAE CYTOCHROME-C-OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARACOCCUS-DENITRIFICANS; EVOLUTIONARY ASPECTS; YEAST; PROTEIN; DNA; SEQUENCE; TRANSFORMATION; INHIBITOR; CLONING	We have cloned and sequenced COX12, the nuclear gene for subunit VIb of Saccharomyces cerevisiae cytochrome c oxidase. This subunit, which was previously not found in cytochrome c oxidase purified from S. cerevisiae, has a deduced amino acid sequence which is 41% identical to the sequences of subunits VIb of bovine and human cytochrome c oxidases. The chromosomal copy of COX12 was replaced with a plasmid-derived copy of COX12, in which the coding region for the suspected cytochrome oxidase subunit was replaced with the yeast URA3 gene. The resulting Ura+ deletion strain grew poorly at room temperature and was unable to grow at 37-degrees-C on ethanol/glycerol medium, whereas growth was normal at both temperatures on dextrose. This temperature-dependent, petite phenotype of the deletion strain was complemented to wild-type growth with a single copy plasmid carrying COX12. Cytochrome c oxidase activity in mitochondrial membranes from the cox12 deletion strain is decreased to 5-15% of that in membranes from the wild-type parent, and this activity is restored to normal when the cox12 deletion strain is complemented by the plasmid-borne COX12. Optical spectra of mitochondrial membranes from the cox12 deletion strain revealed that optically detectable cytochrome c oxidase is assembled at room temperature and at 37-degrees-C, although the heme a + a3 absorption is diminished approximately 50%. The N-terminal amino acid sequence of the protein encoded by COX12 is identical to the N-terminal sequence of a subunit found in yeast cytochrome c oxidase purified by a new procedure (Taanman, J.-W., and Capaldi, R. A. (1992) J. Biol. Chem. 267, 22481-22485). We conclude that COX12 encodes a subunit of yeast cytochrome c oxidase which is essential during assembly for full cytochrome c oxidase activity but apparently can be removed after the oxidase is assembled, with retention of oxidase activity. This is the first instance in which deletion of a subunit of cytochrome c oxidase results in assembly of optically detectable cytochrome c oxidase but having markedly diminished activity.	DARTMOUTH COLL,DEPT BIOCHEM,7200 VAIL BLDG,HANOVER,NH 03755; SYRACUSE UNIV,DEPT BIOL,SYRACUSE,NY 13244	Dartmouth College; Syracuse University								AGGELER R, 1990, J BIOL CHEM, V265, P16389; Ausubel FM, 1988, MOL REPROD DEV; BUSE G, 1991, J BIOENERG BIOMEMBR, V23, P269, DOI 10.1007/BF00762222; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HALIA T, 1991, EMBO J, V10, P2015; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HORSTMAN LL, 1970, J BIOL CHEM, V245, P1336; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KADENBACH B, 1991, J BIOENERG BIOMEMBR, V23, P321, DOI 10.1007/BF00762225; LJUNGDAHL PO, 1989, J BIOL CHEM, V264, P3723; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAARSE AC, 1984, EMBO J, V3, P2831, DOI 10.1002/j.1460-2075.1984.tb02216.x; Maniatis T, 1982, MOL CLONING LABORATO, P89; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MATSUBARA H, 1981, J BIOCHEM-TOKYO, V90, P1159, DOI 10.1093/oxfordjournals.jbchem.a133568; MATSUBARA H, 1981, J BIOCH, V94, P315; MULLER M, 1991, J BIOENERG BIOMEMBR, V23, P291, DOI 10.1007/BF00762223; PATTERSON TE, 1986, J BIOL CHEM, V261, P7192; PATTERSON TE, 1987, CYTOCHROME SYSTEMS M, P253; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SIKORSKI RS, 1989, GENETICS, V122, P19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAANMAN JW, 1992, J BIOL CHEM, V267, P22481; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAWICK JD, 1989, J BIOL CHEM, V264, P7005; TRUEBLOOD CE, 1988, MOL CELL BIOL, V8, P4537, DOI 10.1128/MCB.8.10.4537; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; VANDEROOST J, 1991, J BIOENERG BIOMEMBR, V23, P257, DOI 10.1007/BF00762221; VERDIER JM, 1990, YEAST, V6, P271, DOI 10.1002/yea.320060402; WRIGHT RM, 1986, J BIOL CHEM, V261, P7183; ZHO C, 1990, BIOTECHNIQUES, V8, P172	34	74	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22473	22480						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331057				2022-12-27	WOS:A1992JW71900076
J	XIA, ZX; DAI, WW; XIONG, JP; HAO, ZP; DAVIDSON, VL; WHITE, S; MATHEWS, FS				XIA, ZX; DAI, WW; XIONG, JP; HAO, ZP; DAVIDSON, VL; WHITE, S; MATHEWS, FS			THE 3-DIMENSIONAL STRUCTURES OF METHANOL DEHYDROGENASE FROM 2 METHYLOTROPHIC BACTERIA AT 2.6-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOBACTERIUM-EXTORQUENS AM1; NUCLEOTIDE-SEQUENCE; MACROMOLECULAR CRYSTALLOGRAPHY; PARACOCCUS-DENITRIFICANS; REFINEMENT; GENE; OXIDATION; SUBUNIT; SYSTEM; ERRORS	The structures of methanol dehydrogenase (MEDH) from two closely related methylotrophic bacteria, Methylophilus methylotrophus and W3A1, have been determined at 2.6-angstrom resolution. The molecule, a quinoprotein of molecular mass of about 138 kDa, contains two heavy (H) and two light (L) subunits of unknown sequence and two molecules of noncovalently associated pyrroloquinoline quinone. The two enzymes crystallize isomorphously in space group P2(1) with one H-2L2 heterotetramer in the asymmetric unit. The electron density map of the M. methylophilus enzyme was obtained by multiple isomorphous replacement with anomalous scattering and improved by solvent leveling and electron density averaging. For model building, the amino acid sequence of MEDH from Paracoccus denitrificans for the H subunit and from Methylobacterium extorquens AM1 for the L subunit were used to represent the unknown amino acid sequence. At the present time, 579 and 57 amino acid residues for the large and small subunits, respectively, have been fitted into the map. The phases for MEDH from M. methylophilus were used directly to analyze the W3A1 structure, and both structures were refined to R-factors (where R = SIGMA\F(o) - F(c)\/SIGMAF(o)) of 0.277 and 0.266, respectively. The L subunit contains a long alpha-helix and an extended N-terminal segment, both lying on the molecular surface of the H subunit. The H subunit contains eight antiparallel beta-sheets, each consisting of four strands arranged topologically like the letter W. The eight Ws are arranged circularly, forming the main disc-shaped body of the subunit, with some short helices and loops connecting the consecutive Ws, as well as some excursions within and between some of the Ws. The pyrroloquinoline quinone prosthetic group is located in the central channel of the large subunit near the surface of the molecule. The topology of the eight-W folding unit is similar to those of the six- and seven W folding units previously reported for three other proteins, neuraminidase, methylamine dehydrogenase, and galactose oxidase.	ACAD SINICA,SHANGHAI INST ORGAN CHEM,SHANGHAI 200032,PEOPLES R CHINA; UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,JACKSON,MS 39216; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110	Chinese Academy of Sciences; Shanghai Institute of Organic Chemistry, CAS; University of Mississippi; University of Mississippi Medical Center; Washington University (WUSTL)			White, Scott/C-6684-2008	Davidson, Victor/0000-0002-1966-7302; White, Scott/0000-0002-0202-6154	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031611, R01GM041574, R37GM041574] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41574, GM31611] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON DJ, 1988, J BACTERIOL, V170, P2254, DOI 10.1128/jb.170.5.2254-2262.1988; ANDERSON DJ, 1990, GENE, V90, P173, DOI 10.1016/0378-1119(90)90457-3; ANTHONY C, 1967, BIOCHEM J, V104, P960, DOI 10.1042/bj1040960; ANTHONY C, 1990, FEMS MICROBIOL LETT, V87, P209, DOI 10.1016/0378-1097(90)90456-Z; ANTHONY C, 1986, ADV MICROB PHYSIOL, V27, P113, DOI 10.1016/S0065-2911(08)60305-7; BETHGE PH, 1984, J APPL CRYSTALLOGR, V17, P215, DOI 10.1107/S0021889884011365; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; CHEN LY, 1991, FEBS LETT, V287, P163, DOI 10.1016/0014-5793(91)80041-Z; CHEN LY, 1992, PROTEINS, V14, P288, DOI 10.1002/prot.340140214; COX JM, 1992, BIOCHIM BIOPHYS ACTA, V1119, P97, DOI 10.1016/0167-4838(92)90240-E; DUINE JA, 1989, ANNU REV BIOCHEM, V58, P403; DUINE JA, 1980, EUR J BIOCHEM, V108, P187, DOI 10.1111/j.1432-1033.1980.tb04711.x; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; HARMS N, 1987, J BACTERIOL, V169, P3969, DOI 10.1128/jb.169.9.3969-3975.1987; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; INOUE T, 1989, J BACTERIOL, V171, P3115, DOI 10.1128/jb.171.6.3115-3122.1989; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONGEJAN JA, 1989, PQQ AND QUINOPROTEINS, P205; LIM LW, 1986, J MOL BIOL, V191, P141, DOI 10.1016/0022-2836(86)90431-6; MACHLIN SM, 1988, J BACTERIOL, V170, P4739, DOI 10.1128/jb.170.10.4739-4747.1988; MATTHEWS BW, 1975, ACTA CRYSTALLOGR A, V31, P480, DOI 10.1107/S0567739475001040; MCINTIRE WS, 1991, SCIENCE, V252, P981; NUNN DN, 1989, BIOCHEM J, V260, P857, DOI 10.1042/bj2600857; NUNN DN, 1988, BIOCHEM J, V256, P673, DOI 10.1042/bj2560673; REEKE GN, 1984, J APPL CRYSTALLOGR, V17, P125, DOI 10.1107/S0021889884011171; SALISBURY SA, 1979, NATURE, V280, P843, DOI 10.1038/280843a0; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; VANSPANNING RJM, 1991, J BACTERIOL, V173, P6948, DOI 10.1128/jb.173.21.6948-6961.1991; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; VELLIEUX FMD, 1989, EMBO J, V8, P2171, DOI 10.1002/j.1460-2075.1989.tb08339.x; WANG BC, 1985, METHOD ENZYMOL, V115, P90; XIA ZX, 1989, FEBS LETT, V258, P175, DOI 10.1016/0014-5793(89)81644-8	38	116	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22289	22297						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331050				2022-12-27	WOS:A1992JW71900048
J	SCHOLLMANN, C; GRUGEL, R; TATJE, D; HOPPE, J; FOLKMAN, J; MARME, D; WEICH, HA				SCHOLLMANN, C; GRUGEL, R; TATJE, D; HOPPE, J; FOLKMAN, J; MARME, D; WEICH, HA			BASIC FIBROBLAST GROWTH-FACTOR MODULATES THE MITOGENIC POTENCY OF THE PLATELET-DERIVED GROWTH-FACTOR (PDGF) ISOFORMS BY SPECIFIC UP-REGULATION OF THE PDGF ALPHA-RECEPTOR IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODY; ANGIOGENIC PROTEIN; SIGNALING COMPLEX; ENDOTHELIAL-CELLS; GENE-EXPRESSION; A-CHAIN; BETA; IDENTIFICATION; ASSOCIATION	Platelet-derived growth factor AA (PDGF AA), in contrast to PDGF AB and BB, is a poor mitogen for smooth muscle cells (SMC). However, together with basic fibroblast growth factor (bFGF) it acts synergistically on DNA synthesis of these cells. Northern blot analysis revealed that bFGF selectively increases the PDGF-receptor alpha-subtype (PDGF-R-alpha) mRNA level without a significant effect on the PDGF-R-beta mRNA level. The amount of PDGF-R-alpha protein is also selectively increased after stimulating SMC with bFGF as shown by immunoprecipitation of lysates from SMC with anti-PDGF-R-alpha antibodies. The number of binding sites for I-125-PDGF AA is more than doubled after bFGF-treatment, whereas the specific binding for PDGF AB and BB increased only by approximately 30 and 20%, respectively. The increase in the number of PDGF-R-alpha renders the SMC responsive for PDGF AA as demonstrated by the induction of the proto-oncogene c-fos as well as by an increased cell proliferation. The enhanced PDGF binding after bFGF treatment may in fact explain the observed synergistic behavior. These data are discussed with regard to a possible role of growth factor-induced transmodulation of receptor expression during atherogenesis.	UNIV FREIBURG, GODECKE AG, INST MOLEC CELL BIOL, MOOSWALDALLEE 1-9, W-7800 FREIBURG, GERMANY; HARVARD UNIV, SCH MED, DEPT ANAT & CELLULAR BIOL, BOSTON, MA 02115 USA; UNIV WURZBURG, BIOCENTER, INST PHYSIOL CHEM, W-8700 WURZBURG, GERMANY	University of Freiburg; Harvard University; Harvard Medical School; University of Wurzburg								ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; CHIOU WJ, 1989, J BIOL CHEM, V264, P21442; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; CORDONCARDO C, 1990, LAB INVEST, V63, P832; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DO MS, 1992, IN PRESS ONCOGENE; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FERNS GAA, 1991, AM J PATHOL, V138, P1045; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FRACKELTON AR, 1984, J BIOL CHEM, V259, P7909; GOSPODAROWICZ D, 1981, J CELL BIOL, V89, P568, DOI 10.1083/jcb.89.3.568; GRONWALD RGK, 1989, J BIOL CHEM, V264, P8120; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HART IK, 1989, DEVELOPMENT, V105, P595; HELDIN CH, 1985, MOL CELL ENDOCRINOL, V39, P169, DOI 10.1016/0303-7207(85)90061-9; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; HOPPE J, 1989, BIOCHEMISTRY-US, V28, P2956, DOI 10.1021/bi00433a032; HOPPE J, 1990, EUR J BIOCHEM, V187, P207, DOI 10.1111/j.1432-1033.1990.tb15296.x; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROSEN KM, 1990, BIOTECHNIQUES, V8, P398; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SACHINIDIS A, 1990, J BIOL CHEM, V265, P10238; SCHULZEOSTHOFF K, 1990, AM J PATHOL, V137, P85; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; Smits A, 1989, GROWTH FACTORS, V2, P1, DOI 10.3109/08977198909069076; TSUKAMOTO T, 1991, J BIOL CHEM, V266, P10143; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; WANG CY, 1990, MOL CELL BIOL, V10, P6781, DOI 10.1128/MCB.10.12.6781; Weich HA, 1990, GROWTH FACTORS, V2, P313, DOI 10.3109/08977199009078019; WEINMASTER G, 1990, EMBO J, V9, P915, DOI 10.1002/j.1460-2075.1990.tb08189.x; WILCOX JN, 1991, TRENDS CARDIOVAS MED, V1, P17, DOI 10.1016/1050-1738(91)90054-I; WINKLES JA, 1991, BIOCHEM BIOPH RES CO, V180, P519, DOI 10.1016/S0006-291X(05)81095-2; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346	58	77	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18032	18039						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325456				2022-12-27	WOS:A1992JM22300085
J	KIM, RA; WANG, JC				KIM, RA; WANG, JC			IDENTIFICATION OF THE YEAST TOP3 GENE-PRODUCT AS A SINGLE STRAND-SPECIFIC DNA TOPOISOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MITOTIC RECOMBINATION; BINDING-PROTEIN; OMEGA-PROTEIN; S-CEREVISIAE; SEQUENCES; CLONING; VECTORS; RDNA	The TOP3 gene of the yeast Saccharomyces cerevisiae was postulated to encode a DNA topoisomerase, based on its sequence homology to Escherichia coli DNA topoisomerase I and the suppression of the poor growth phenotype of top3 mutants by the expression of the E. coli enzyme (Wallis, J. W., Chrebet, G., Brodsky, G., Golfe, M., and Rothstein, R. (1989) Cell 58, 409-419). We have purified the yeast TOP3 gene product to near homogeneity as a 74-kDa protein from yeast cells lacking DNA topoisomerase I and overexpressing a plasmid-borne TOP3 gene linked to a phosphate-regulated yeast PHO5 gene promoter. The purified protein possesses a distinct DNA topoisomerase activity: similar to E. coli DNA topoisomerases I and III, it partially relaxes negatively but not positively supercoiled DNA. Several experiments, including the use of a negatively supercoiled heteroduplex DNA containing a 29-nucleotide single-stranded loop, indicate that the activity has a strong preference for single-stranded DNA. A protein-DNA covalent complex in which the 74-kDa protein is linked to a 5' DNA phosphoryl group has been identified, and the nucleotide sequences of 30 sites of DNA-protein covalent complex formation have been determined. These sequences differ from those recognized by E. coli DNA topoisomerase I but resemble those recognized by E. coli DNA topoisomerase III. Based on these results, the yeast TOP3 gene product can formally be termed S. cerevisiae DNA topoisomerase III. Analysis of supercoiling of intracellular yeast plasmids in various DNA topoisomerase mutants indicates that yeast DNA topoisomerase III has at most a weak activity in relaxing negatively supercoiled double-stranded DNA in vivo, in accordance with the characteristics of the purified enzyme.			KIM, RA (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.				NATIONAL CANCER INSTITUTE [R01CA047958] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024544, R37GM024544] Funding Source: NIH RePORTER; NCI NIH HHS [CA47958] Funding Source: Medline; NIGMS NIH HHS [GM 24544] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIMA K, 1983, NUCLEIC ACIDS RES, V11, P1657, DOI 10.1093/nar/11.6.1657; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; DEAN F, 1983, COLD SPRING HARB SYM, V47, P769; DEAN F, 1984, THESIS U CHICAGO; DEPEW RE, 1978, J BIOL CHEM, V253, P511; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; DUPLAY P, 1984, J BIOL CHEM, V259, P606; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GOTO T, 1985, P NATL ACAD SCI USA, V82, P7178, DOI 10.1073/pnas.82.21.7178; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; KIRKEGAARD K, 1985, J MOL BIOL, V185, P625, DOI 10.1016/0022-2836(85)90075-0; KUNG VT, 1977, J BIOL CHEM, V252, P5398; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; RADMAN M, 1991, BIOCHIMIE, V73, P357, DOI 10.1016/0300-9084(91)90101-6; RAYMOND W, 1990, THESIS HARVARD U; ROTHSTEIN R, 1987, MOL CELL BIOL, V7, P1198, DOI 10.1128/MCB.7.3.1198; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; TSE YC, 1980, J BIOL CHEM, V255, P5560; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JC, 1971, J MOL BIOL, V55, P532; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	33	112	123	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17178	17185						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324925				2022-12-27	WOS:A1992JL05300070
J	QUELLE, FW; QUELLE, DE; WOJCHOWSKI, DM				QUELLE, FW; QUELLE, DE; WOJCHOWSKI, DM			INTERLEUKIN-3, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR, AND TRANSFECTED ERYTHROPOIETIN RECEPTORS MEDIATE TYROSINE PHOSPHORYLATION OF A COMMON CYTOSOLIC PROTEIN (PP100) IN FDC-ER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; EXPRESSION CLONING; RAPID PHOSPHORYLATION; CYTOPLASMIC REGION; KINASE-ACTIVITY; BETA-CHAIN; GM-CSF; GROWTH; ACTIVATION; LINES	Receptors for the hematopoietic growth factors erythropoietin, interleukin 3 (IL-3), and granulocyte-macrophage colony-stimulating factor (GM-CSF) are members of a structurally related receptor superfamily. Interestingly, while none of these receptors encode tyrosine kinase activities, induced tyrosine phosphorylation has been observed in various responsive cells stimulated with each factor. Toward defining possible common transduction pathways which are activated by these three cytokines, we have studied induced protein phosphorylation in murine myeloid FDC-P1 cells stably transfected with an erythropoietin receptor cDNA (FDC-ER cells). FDC-ER cells proliferate in response to erythropoietin (Quelle, D. E., and Wojchowski, D. M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 4801-4805), and presently are shown to rapidly phosphorylate a M(r) 100,000 cytosolic protein (pp100) at tyrosine residues in response to this factor. Phosphorylation of pp100 also is induced in FDC-P1 and FDC-ER cells in response to IL-3 or GM-CSF. Importantly, quantitative analyses showed identical concentration dependencies for factor-induced pp100 phosphorylation and induced cell proliferation. Moreover, a selective loss of proliferative responsiveness to GM-CSF in FDC-ER cells was associated with a reduced capacity of GM-CSF to induce pp100 phosphorylation. Finally, limited differences in tryptic phosphopeptide maps of pp100 as isolated following exposure to erythropoietin, IL-3, or GM-CSF were observed, suggesting that these factors also may preferentially induce phosphorylation of pp100 at distinct sites. These findings are consistent with a role for pp100 as a common cytosolic transducer in the apparently convergent pathways of erythropoietin-, IL-3-, and GM-CSF-induced proliferation of myeloid progenitor cells.	PENN STATE UNIV, DEPT MOLEC & CELL BIOL, UNIV PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University				Quelle, Dawn/0000-0001-8776-0122; Quelle, Frederick/0000-0002-1184-6170	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040242] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44491] Funding Source: Medline; NIDDK NIH HHS [R29-DK40242] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGUSTINE JA, 1990, BIOCHIM BIOPHYS ACTA, V1052, P313, DOI 10.1016/0167-4889(90)90227-5; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; FRACKELTON AR, 1983, MOL CELL BIOL, V3, P1343, DOI 10.1128/MCB.3.8.1343; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GORDON JA, 1991, METHOD ENZYMOL, V201, P110; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; IHLE JN, 1982, J IMMUNOL, V129, P1377; ISFORT R, 1988, J BIOL CHEM, V263, P19203; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KANAKURA Y, 1991, BLOOD, V77, P243; KANAKURA Y, 1990, BLOOD, V76, P706; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; KURAMOCHI S, 1991, BIOCHEM BIOPH RES CO, V181, P1103, DOI 10.1016/0006-291X(91)92052-L; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINNEKIN D, 1990, BIOCHEM J, V271, P317, DOI 10.1042/bj2710317; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; QUELLE FW, 1991, J BIOL CHEM, V266, P609; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SALTZMAN EM, 1990, J BIOL CHEM, V265, P10138; SHACKELFORD DA, 1991, CELL REGUL, V2, P73, DOI 10.1091/mbc.2.1.73; SORENSEN PHB, 1989, BLOOD, V73, P406; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TUNER B, 1991, P NATL ACAD SCI USA, V88, P1227; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P6323, DOI 10.1073/pnas.88.14.6323; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	44	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17055	17060						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324920				2022-12-27	WOS:A1992JL05300051
J	MISEK, DE; SALTIEL, AR				MISEK, DE; SALTIEL, AR			AN INOSITOL PHOSPHATE GLYCAN DERIVED FROM A TRYPANOSOMA-BRUCEI GLYCOSYL-PHOSPHATIDYLINOSITOL MIMICS SOME OF THE METABOLIC ACTIONS OF INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLAR HEAD GROUP; VARIANT SURFACE GLYCOPROTEIN; DEPENDENT PROTEIN-KINASE; HEPATIC PLASMA-MEMBRANES; HORMONE-SENSITIVE LIPASE; EPIDERMAL GROWTH-FACTOR; FRUCTOSE 2,6-BISPHOSPHATE; RAT HEPATOCYTES; PYRUVATE-DEHYDROGENASE; OKADAIC ACID	Some of the acute actions of insulin may be mediated by an enzyme-modulating inositol phosphate glycan, produced by the insulin-sensitive hydrolysis of glycosyl-phosphatidylinositol (GPI) that is structurally similar to a membrane protein anchor. An inositol glycan fragment from the structurally characterized Trypanosoma brucei variant surface glycoprotein GPI anchor is evaluated for insulin-mimetic antilipolytic activity. The fragment specifically and dose-dependently inhibits isoproterenol-stimulated lipolysis. Like the effect of insulin, glycan-induced antilipolysis is blocked by the low K(m) cAMP phosphodiesterase inhibitor imazodan (CI-914) and the serine/threonine phosphatase inhibitor, okadaic acid, suggesting that the activation of both cAMP phosphodiesterase and serine/threonine protein phosphatases are necessary. Moreover, this fragment causes a specific and dose-dependent inhibition of both microsomal glucose-6-phosphatase (EC 3.1.3.9) and cytosolic fructose-1,6-bisphosphatase (EC 3.1.3.11) activity. Additionally, direct addition of the glycan to hepatocytes caused marked inhibition of glucose production from pyruvate. These results suggest that the direct modification of the activities of these two gluconeogenic enzymes by an inositol glycan may play a role in the inhibition of glucose output by insulin and provide the first evidence for the insulin-mimetic properties of a chemically characterized inositol glycan.	UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA; WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES DIV, DEPT SIGNAL TRANSDUCT, ANN ARBOR, MI 48105 USA	University of Michigan System; University of Michigan; Pfizer			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033804, R23DK033804] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33804] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEMANY S, 1987, NATURE, V330, P77, DOI 10.1038/330077a0; ALVAREZ JF, 1987, BIOCHEM BIOPH RES CO, V147, P765, DOI 10.1016/0006-291X(87)90996-X; ALVAREZ L, 1991, MOL ENDOCRINOL, V5, P1062, DOI 10.1210/mend-5-8-1062; ASSIMACOPOULOSJEANNET F, 1990, J BIOL CHEM, V265, P7202; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRUNI P, 1990, BIOCHEM BIOPH RES CO, V166, P765, DOI 10.1016/0006-291X(90)90875-N; BUTCHER RW, 1966, J BIOL CHEM, V241, P1651; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CROSS GAM, 1984, J CELL BIOCHEM, V24, P79, DOI 10.1002/jcb.240240107; DEGERMAN E, 1987, J BIOL CHEM, V262, P5797; EARDLEY DD, 1991, SCIENCE, V251, P78, DOI 10.1126/science.1824727; ELMAGHRABI MR, 1988, P NATL ACAD SCI USA, V85, P8430, DOI 10.1073/pnas.85.22.8430; ELMAGHRABI MR, 1991, J BIOL CHEM, V266, P2115; Ferguson M.A.J., 1987, NATO ASI Series Series H Cell Biology, V11, P19; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4963; Fleischer S, 1974, Methods Enzymol, V31, P6; GAULTON GN, 1991, DIABETES, V40, P1297, DOI 10.2337/diabetes.40.10.1297; GETTYS TW, 1990, SEC MESS PHOSPHOPROT, V13, P37; GOTTSCHALK WK, 1988, ARCH BIOCHEM BIOPHYS, V261, P175, DOI 10.1016/0003-9861(88)90116-6; GRANNER D, 1990, J BIOL CHEM, V265, P10173; HAMER MJ, 1990, BIOCHEM J, V269, P685, DOI 10.1042/bj2690685; HESS SL, 1991, J CELL BIOCHEM, V45, P374, DOI 10.1002/jcb.240450411; IGARASHI Y, 1987, BIOCHEM BIOPH RES CO, V145, P249, DOI 10.1016/0006-291X(87)91313-1; KELLY KL, 1986, FEBS LETT, V209, P238, DOI 10.1016/0014-5793(86)81119-X; KELLY KL, 1987, P NATL ACAD SCI USA, V84, P6404, DOI 10.1073/pnas.84.18.6404; KELLY KL, 1987, J BIOL CHEM, V262, P15285; KOJIMA I, 1990, J BIOL CHEM, V265, P16846; KONO T, 1973, J BIOL CHEM, V248, P7417; LARNER J, 1988, BIOCHEM BIOPH RES CO, V151, P1416, DOI 10.1016/S0006-291X(88)80520-5; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MANGANIELLO VC, 1990, 2ND MESSENGERS PHOSP, P147; MARTINY L, 1990, CELL SIGNAL, V2, P21, DOI 10.1016/0898-6568(90)90029-A; MATO JM, 1987, BIOCHEM BIOPH RES CO, V146, P764, DOI 10.1016/0006-291X(87)90595-X; MATO JM, 1987, J BIOL CHEM, V262, P2131; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MENON AK, 1988, J BIOL CHEM, V263, P1970; MERIDA I, 1988, FEBS LETT, V236, P251, DOI 10.1016/0014-5793(88)80325-9; MERIDA I, 1990, P NATL ACAD SCI USA, V87, P9421, DOI 10.1073/pnas.87.23.9421; MILLER TB, 1973, J BIOL CHEM, V248, P3483; MOR MA, 1981, FEBS LETT, V136, P131; NEWGARD CB, 1984, DIABETES, V33, P192, DOI 10.2337/diabetes.33.2.192; PILKIS SJ, 1975, J BIOL CHEM, V250, P6328; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PONTREMOLI S, 1982, ARCH BIOCHEM BIOPHYS, V218, P609, DOI 10.1016/0003-9861(82)90386-1; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROMERO G, 1990, P NATL ACAD SCI USA, V87, P1476, DOI 10.1073/pnas.87.4.1476; SALTIEL AR, 1986, P NATL ACAD SCI USA, V83, P5793, DOI 10.1073/pnas.83.16.5793; SALTIEL AR, 1987, BIOCHEM BIOPH RES CO, V149, P1084, DOI 10.1016/0006-291X(87)90519-5; SALTIEL AR, 1988, AM J PHYSIOL, V255, pC1, DOI 10.1152/ajpcell.1988.255.1.C1; SALTIEL AR, 1987, J BIOL CHEM, V262, P1116; SALTIEL AR, 1987, ENDOCRINOLOGY, V120, P967, DOI 10.1210/endo-120-3-967; SALTIEL AR, 1988, PHILOS T ROY SOC B, V320, P345, DOI 10.1098/rstb.1988.0081; SALTIEL AR, 1986, SCIENCE, V233, P967, DOI 10.1126/science.3016898; SHIBATA H, 1991, J BIOL CHEM, V266, P17948; SOLEY M, 1987, ARCH BIOCHEM BIOPHYS, V255, P136, DOI 10.1016/0003-9861(87)90303-1; SPAGNOLI D, 1983, ARCH BIOCHEM BIOPHYS, V226, P182, DOI 10.1016/0003-9861(83)90283-7; SPETH M, 1981, BIOCHEM BIOPH RES CO, V99, P134, DOI 10.1016/0006-291X(81)91723-X; STRALFORS P, 1984, P NATL ACAD SCI-BIOL, V81, P3317, DOI 10.1073/pnas.81.11.3317; STRALFORS P, 1989, EUR J BIOCHEM, V182, P379, DOI 10.1111/j.1432-1033.1989.tb14842.x; SUZUKI S, 1984, BIOCHEM BIOPH RES CO, V118, P40, DOI 10.1016/0006-291X(84)91064-7; TAKETA K, 1965, J BIOL CHEM, V240, P651; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P2861; VARGAS AM, 1990, J BIOL CHEM, V265, P15368; VILLALBA M, 1988, BIOCHIM BIOPHYS ACTA, V968, P69, DOI 10.1016/0167-4889(88)90045-6; WIELAND O, 1957, BIOCHEM Z, V329, P313; Williams J.M., 1975, ADV CARBOHYD CHEM, V31, P9, DOI [10.1016/S0065-2318(08)60294-2, DOI 10.1016/S0065-2318(08)60294-2]; WITTERS LA, 1988, J BIOL CHEM, V263, P8027; WITTERS LA, 1988, BIOCHEM BIOPH RES CO, V153, P992, DOI 10.1016/S0006-291X(88)81326-3	72	75	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16266	16273						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322896				2022-12-27	WOS:A1992JJ45800044
J	SPEAR, DH; KUTSUNAI, SY; CORRELL, CC; EDWARDS, PA				SPEAR, DH; KUTSUNAI, SY; CORRELL, CC; EDWARDS, PA			MOLECULAR-CLONING AND PROMOTER ANALYSIS OF THE RAT-LIVER FARNESYL DIPHOSPHATE SYNTHASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; PYROPHOSPHATE SYNTHETASE; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A SYNTHASE; COORDINATE REGULATION; BINDING PROTEINS; MEVALONIC ACID; MESSENGER-RNA; SEQUENCE; DNA; TRANSCRIPTION	The isolation and characterization of the rat genomic clone encoding the cholesterogenic enzyme farnesyl diphosphate (FPP) synthase is reported. The gene is localized on a 15-kilobase (kb) genomic fragment, spans approximately 12 kb and contains eight exons. Sequences containing from 3.9 kb to 132 base pairs (bp) of the putative promoter were joined to the coding region of the bacterial reporter gene chloramphenicol acetyltransferase (CAT). The CAT activities or CAT mRNA levels of the hybrid genes were determined following either transient transfections into human hepatoma HepG2 cells or stable transfections into Chinese hamster ovary cells. The transient transfections identified a 319-bp fragment that was required for a 4-fold induction in the absence of sterols. Sequence analysis of this region showed it contained five potential copies of the sterol regulatory element (SRE-1) (Smith, J. R., Osborne, T. F., Brown, M. S., Goldstein, J. L., and Gil, G. (1988) J. Biol. Chem. 263, 18480-18487) previously identified in the promoters of the 3-hydroxy-3-methyl-coenzyme A (HMG-CoA) reductase, HMG-CoA synthase, and low density lipoprotein receptor genes. Further mutational and deletion analysis of the FPP synthase promoter-CAT constructs followed by stable transfection and primer extension of the CAT mRNA levels indicated that these potential SRE-1 regulatory elements were not involved in the sterol-mediated transcriptional regulation of the gene. Our analyses have identified a 115-bp region that is required for the transcriptional induction of FPP synthase in the absence of sterols. These results suggest that the FPP synthase gene may be regulated at the transcriptional level by a different mechanism than other sterol regulated genes.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DIV CARDIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568] Funding Source: Medline; NIGMS NIH HHS [GMO7185] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTON NK, 1979, NATURE, V282, P864, DOI 10.1038/282864a0; ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ASHBY MN, 1989, J BIOL CHEM, V264, P635; BECK LA, 1988, J CELL BIOL, V107, P1307, DOI 10.1083/jcb.107.4.1307; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FAUST JR, 1980, J BIOL CHEM, V255, P6546; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HEINZMANN C, 1989, GENOMICS, V5, P493, DOI 10.1016/0888-7543(89)90015-3; JAMES MJ, 1980, J BIOL CHEM, V255, P16; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KINGSTON RE, 1989, CURRENT PROTOCOLS MO; LEVIN MS, 1989, BIOCHIM BIOPHYS ACTA, V1003, P293, DOI 10.1016/0005-2760(89)90235-X; Maniatis T., 1982, MOL CLONING; NIELSEN DA, 1983, P NATL ACAD SCI USA, V80, P1598; OLSON RE, 1983, VITAM HORM, V40, P1, DOI 10.1016/S0083-6729(08)60431-8; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; POULTER CD, 1981, BIOSYNTHESIS ISOPREN, V1, P162; RILLING HC, 1985, STEROLS BILE ACIDS, P17; ROSSER DSE, 1989, J BIOL CHEM, V264, P12653; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; TSONIS PA, 1988, NUCLEIC ACIDS RES, V16, P7745, DOI 10.1093/nar/16.15.7745; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607; WOLDA SL, 1988, J BIOL CHEM, V263, P5997	33	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14462	14469						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321149				2022-12-27	WOS:A1992JD32500102
J	DESOUZA, SJ; BRENTANI, R				DESOUZA, SJ; BRENTANI, R			COLLAGEN BINDING-SITE IN COLLAGENASE CAN BE DETERMINED USING THE CONCEPT OF SENSE-ANTISENSE PEPTIDE INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPATHIC COMPLEMENTARITY APPROACH; MATRIX METALLOPROTEINASE-3; FIBROBLAST COLLAGENASE; RECOGNITION PROPERTIES; TISSUE INHIBITOR; CELLS; GENE; STROMELYSIN; RECEPTOR; SEQUENCE	Tissue degradation and invasion are hallmarks of the metastatic phenotype. While several extracellular matrix components can be digested by proteases, degradation of interstitial collagen is selectively initiated by collagenase. It is obvious that inhibitors of collagenase activity would be extremely useful in preventing tissue destruction and tumor cell invasion and thus prove invaluable therapeutic agents. We describe here the possible development of such inhibitors through the use of the principle of complementary hydropathy. A peptide was deduced from the nucleotide sequence complementary to that coding for the region in interstitial collagen surrounding the bond between Gly775 and Ile776 which is cleaved by the enzyme. Labeled collagen binds specifically and quantitatively to this peptide. A polyclonal mouse serum raised against this peptide recognized purified human collagenase, was able to immunoprecipitate collagenase from cultured human keratinocyte supernatants and was effective in inhibiting collagenolytic activity with a K(i app) = 0.3-mu-M.	LUDWIG INST CANC RES,RUA PROFESSOR ANTONIO PRUDENTE 109 4,BR-01509 SAO PAULO,BRAZIL	Ludwig Institute for Cancer Research			de Souza, Sandro Jose/AAG-6270-2020					ALVAREZ OA, 1990, J NATL CANCER I, V82, P589, DOI 10.1093/jnci/82.7.589; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN B, 1988, BIOCHEMISTRY-US, V27, P6751, DOI 10.1021/bi00418a016; BLALOCK JE, 1984, BIOCHEM BIOPH RES CO, V121, P203, DOI 10.1016/0006-291X(84)90707-1; BOST KL, 1985, P NATL ACAD SCI USA, V82, P1372, DOI 10.1073/pnas.82.5.1372; BRENTANI RR, 1988, P NATL ACAD SCI USA, V85, P364, DOI 10.1073/pnas.85.2.364; BRENTANI RR, 1990, RECEPTOR PURIFICATIO, V1, P451; BRENTANI RR, 1990, J MOL EVOL, V3, P239; BRENTANI RR, 1988, J THEOR BIOL, V135, P459; BRIGIDO MD, 1990, IMMUNOL LETT, V24, P191; CALVETE JJ, 1991, BIOCHEM J, V274, P457, DOI 10.1042/bj2740457; CARR DJJ, 1989, IMMUNOL LETT, V20, P181, DOI 10.1016/0165-2478(89)90077-1; CLARKE NJ, 1990, NUCLEIC ACIDS RES, V18, P6703, DOI 10.1093/nar/18.22.6703; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DEWET W, 1987, J BIOL CHEM, V262, P16032; ENGHILD JJ, 1989, J BIOL CHEM, V264, P8779; FASSINA G, 1989, BIOCHEMISTRY-US, V28, P8811, DOI 10.1021/bi00448a020; FASSINA G, 1989, J BIOL CHEM, V264, P11252; FIELDS GB, 1987, J BIOL CHEM, V262, P6221; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HASTY KA, 1990, J BIOL CHEM, V265, P11421; IRVINE JW, 1990, ANAL BIOCHEM, V190, P141, DOI 10.1016/0003-2697(90)90147-2; KANG CY, 1988, SCIENCE, V240, P1034, DOI 10.1126/science.3368787; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KNUTSON VP, 1988, J BIOL CHEM, V263, P14146; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MONSON JM, 1982, MOL CELL BIOL, V2, P1362, DOI 10.1128/MCB.2.11.1362; PASQUALINI R, 1989, J BIOL CHEM, V264, P14566; PETERSEN MJ, 1987, J BIOL CHEM, V262, P835; QUINN CO, 1990, J BIOL CHEM, V265, P22342; SAUS J, 1988, J BIOL CHEM, V263, P6742; SCHOR SL, 1980, J CELL SCI, V41, P159; SCHULTZ RM, 1988, CANCER RES, V48, P5539; SHAI Y, 1987, BIOCHEMISTRY-US, V26, P669, DOI 10.1021/bi00377a002; TEMPLETON NS, 1990, CANCER RES, V50, P5431; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WU H, 1990, P NATL ACAD SCI USA, V87, P5888, DOI 10.1073/pnas.87.15.5888; YOSHIOKA H, 1987, ANAL BIOCHEM, V166, P172, DOI 10.1016/0003-2697(87)90559-8	39	66	70	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13763	13767						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320031				2022-12-27	WOS:A1992JB74600104
J	DILIBERTO, PA; GORDON, GW; YU, CL; EARP, HS; HERMAN, B				DILIBERTO, PA; GORDON, GW; YU, CL; EARP, HS; HERMAN, B			PLATELET-DERIVED GROWTH-FACTOR (PDGF)ALPHA-RECEPTOR ACTIVATION MODULATES THE CALCIUM MOBILIZING ACTIVITY OF THE PDGF BETA-RECEPTOR IN BALB/C3T3 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; INTRACELLULAR FREE CALCIUM; DIFFERENT DIMERIC FORMS; CYTOPLASMIC FREE CA-2+; SIMIAN SARCOMA-VIRUS; KINASE-C ACTIVATION; BALB/C-3T3 CELLS; A-CHAIN; TYROSINE PHOSPHORYLATION; DIFFERENT ISOFORMS	In order to determine whether distinct platelet-derived growth factor (PDGF) receptors (alpha and beta) can modulate the activity of one another, PDGF isoform (AA, BB, and AB)-stimulated changes in Ca2+i were monitored by digitized video microscopy in single cells upon sequential addition of PDGF isoforms. In Balb/c 3T3 fibroblasts, all PDGF isoforms were capable of stimulating increases in Ca2+i of 200-600% above basal levels, although with different potencies: BB greater-than-or-equal-to AB > AA. All cells were BB-PDGF-responsive, but only 74% of cells examined responded to AA-PDGF. The Ca2+i response elicited by BB-PDGF was inhibited by 60-75% in cells stimulated 10 min earlier with the AA isoform. The half-life of this inhibition was 22 min. In cells in which the alpha-receptor was down-regulated by prolonged incubation with AA-PDGF, BB-induced Ca2+i responses were not inhibited. Pretreatment of cells with phorbol ester did not inhibit BB-PDGF-induced increases in Ca2+i, yet down-regulation of PKC activity prevented the AA-PDGF inhibition of BB-PDGF-induced Ca2+i responses. An increase in Ca2+i induced by AlF4--stimulated IP3 generation did not inhibit a subsequent BB-PDGF Ca2+i response; however, attenuation of AA-PDGF-induced extracellular Ca2+ influx with EGTA prevented the inhibition of BB-PDGF-induced Ca2+i increases. Readdition of Ca2+ to the medium after removal of EGTA restored the inhibition of the BB-PDGF Ca2+i response. The inhibition of the BB-PDGF Ca2+i response by AA-PDGF was not caused by inhibition of PDGF receptor tyrosine auto-phosphorylation, which was unchanged after pretreatment with AA-PDGF. These results demonstrate: (a) that only a subpopulation of cells possess a functional alpha-receptor-mediated response as assessed by AA-PDGF-induced increases in Ca2+i, whereas all cells possess the beta-receptor-mediated responses; and (b) AA-PDGF and its associated a receptor can modulate the activity of the beta-receptor through a mechanism that is dependent upon Ca2+-influx which may be controlled in part by PKC activation.	UNIV N CAROLINA,SCH MED,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER CANC RES CTR,CANC CELL BIOL PROGRAM,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	DILIBERTO, PA (corresponding author), UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CELL BIOL LABS,CB 7090,202 TAYLOR HALL,CHAPEL HILL,NC 27599, USA.				NCI NIH HHS [2-P01-CA29589] Funding Source: Medline; NIA NIH HHS [AG07218, AG10104] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA029589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG007218, R01AG010104, R01AG007218] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANTONIADES HN, 1981, P NATL ACAD SCI-BIOL, V78, P7314, DOI 10.1073/pnas.78.12.7314; BERNACKI SH, 1990, OPTICAL MICROSCOPY FOR BIOLOGY, P307; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BLOCK LH, 1989, P NATL ACAD SCI USA, V86, P2388, DOI 10.1073/pnas.86.7.2388; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1989, ACTA ONCOL, V28, P331, DOI 10.3109/02841868909111202; DIGUISEPPI J, 1985, Biotechniques, V3, P394; DILIBERTO PA, 1990, J CELL BIOCHEM, V44, P39, DOI 10.1002/jcb.240440104; DILIBERTO PA, 1991, J BIOL CHEM, V266, P12612; DILIBERTO PA, 1991, RES COMMUN CHEM PATH, V72, P3; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DROZDOFF V, 1991, J BIOL CHEM, V266, P17165; ESCOBEDO JA, 1988, SCIENCE, V240, P1532, DOI 10.1126/science.2836953; FAIN JN, 1988, FASEB J, V2, P2569, DOI 10.1096/fasebj.2.10.2838362; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1982, J BIOL CHEM, V257, P4216; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; HELDIN CH, 1990, J CELL SCI, V96, P193; HEPLER JR, 1987, J BIOL CHEM, V262, P2951; HERMAN B, 1987, CELL MOTIL CYTOSKEL, V8, P91, DOI 10.1002/cm.970080202; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; HOPPE J, 1990, EUR J BIOCHEM, V187, P207, DOI 10.1111/j.1432-1033.1990.tb15296.x; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; JOHNSSON A, 1984, EMBO J, V3, P921, DOI 10.1002/j.1460-2075.1984.tb01908.x; KEATING MT, 1988, J BIOL CHEM, V263, P12805; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MCCUNE BK, 1989, J BIOL CHEM, V264, P15501; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NISHIMURA J, 1982, P NATL ACAD SCI-BIOL, V79, P4303, DOI 10.1073/pnas.79.14.4303; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; OLASHAW NE, 1986, P NATL ACAD SCI USA, V83, P3834, DOI 10.1073/pnas.83.11.3834; OLASHAW NE, 1991, J BIOL CHEM, V266, P10234; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; ROE MW, 1989, J CELL PHYSIOL, V139, P100, DOI 10.1002/jcp.1041390115; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SACHINIDIS A, 1990, J BIOL CHEM, V265, P10238; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SINGH JP, 1983, J CELL BIOL, V96, P1497, DOI 10.1083/jcb.96.5.1497; SJOLUND M, 1988, J CELL BIOL, V106, P403, DOI 10.1083/jcb.106.2.403; SPERTI G, 1987, FED PROC, V46, P974; STURANI E, 1986, BIOCHEM BIOPH RES CO, V137, P343, DOI 10.1016/0006-291X(86)91216-7; STURANI E, 1989, FEBS LETT, V255, P191, DOI 10.1016/0014-5793(89)81089-0; TUCKER RW, 1990, EUR J CELL BIOL, V51, P120; TUCKER RW, 1989, J CELL BIOCHEM, V39, P139, DOI 10.1002/jcb.240390206; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; VIGNE P, 1988, EUR J BIOCHEM, V176, P47, DOI 10.1111/j.1432-1033.1988.tb14249.x; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1986, P NATL ACAD SCI USA, V83, P7197, DOI 10.1073/pnas.83.19.7197; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; ZAGARI M, 1989, J CELL PHYSIOL, V139, P167, DOI 10.1002/jcp.1041390123; ZAGARI M, 1988, BIOCHEM BIOPH RES CO, V150, P1207, DOI 10.1016/0006-291X(88)90757-7	64	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11888	11897						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1318305				2022-12-27	WOS:A1992HY94700039
J	JANMEY, PA; LAMB, J; ALLEN, PG; MATSUDAIRA, PT				JANMEY, PA; LAMB, J; ALLEN, PG; MATSUDAIRA, PT			PHOSPHOINOSITIDE-BINDING PEPTIDES DERIVED FROM THE SEQUENCES OF GELSOLIN AND VILLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-FILAMENTS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PLASMA GELSOLIN; MYOSIN-I; F-ACTIN; PROTEIN; DOMAINS; POLYPHOSPHOINOSITIDES; POLYMERIZATION; IDENTIFICATION	The polyphosphoinositides phosphatidylinositol 4-monophosphate (PIP) and phosphatidylinositol 4,5-bisphosphate (PIP2) inactivate the actin filament-severing proteins villin and gelsolin and dissociate them from monomeric and polymeric actin. A potential polyphosphoinositide- (PPI) binding site of human plasma gelsolin regulating filament severing has been localized to the region between residues 150-169 and to the corresponding region in villin which occurs in the second of six homologous domains present in both proteins. Synthetic peptides based on these sequences bind tightly to both PIP and PIP2, in either micelles or bilayer vesicles, compete with gelsolin for binding to PPIs, and dissociate gelsolin-PIP2 complexes, restoring severing activity to the protein. These peptides also bind with moderate affinity to F-actin, suggesting that inactivation of the severing function of the intact proteins by PPIs results from competition between actin and PPIs for a critical binding site on gelsolin-villin. The PPI-binding peptides contain numerous basic amino acids, but their effects on PPIs are far greater than those of Arg or Lys oligomers, a highly basic peptide derived from the calmodulin-binding site of myristoylated, alanine-rich kinase C substrate protein, or the 5-kDa actin-binding protein thymosin beta-4, suggesting that specific aspects of the primary and secondary structure of these basic peptides are important for their interaction with the acidic headgroups of PPIs. In addition to elucidating the structure of PIP2-binding sites in gelsolin, the results describe a sensitive assay for phosphoinositide-binding molecules based on their ability to prevent inhibition of gelsolin function.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; MIT,WHITEHEAD INST,CAMBRIDGE,MA 02138; MIT,DEPT BIOL,CAMBRIDGE,MA 02138	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	JANMEY, PA (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV EXPTL MED,RM 302,221 LONGWOOD AVE,BOSTON,MA 02115, USA.		Matsudaira, Paul/H-1475-2012	Matsudaira, Paul/0000-0002-8399-3276	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR038910, R01AR038910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035306] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR38910] Funding Source: Medline; NIDDK NIH HHS [DK35306] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; ANDRE E, 1988, J BIOL CHEM, V263, P722; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; DASGUPTA G, 1990, BIOCHEMISTRY-US, V29, P3319, DOI 10.1021/bi00465a024; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; FUKUSHIMA K, 1989, BIOPHYS CHEM, V34, P83, DOI 10.1016/0301-4622(89)80045-6; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; JANMEY PA, 1986, J MUSCLE RES CELL M, V7, P446, DOI 10.1007/BF01753587; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KAWASAKI Y, 1976, BIOCHIM BIOPHYS ACTA, V446, P166, DOI 10.1016/0005-2795(76)90108-2; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LASSING I, 1988, J CELL BIOCHEM, V37, P255, DOI 10.1002/jcb.240370302; LASSING I, 1985, NATURE, V314, P604; MATSUDAIRA P, 1988, CELL, V54, P139, DOI 10.1016/0092-8674(88)90542-9; SAFER D, 1991, J BIOL CHEM, V266, P4029; SCHMITZ K, 1990, INTRO DYNAMIC LIGHT, P449; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; XIAN W, 1992, FASEB J, V6, pA87; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YIN HL, 1988, J CELL BIOL, V106, P805, DOI 10.1083/jcb.106.3.805; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409; YIN HL, 1990, FEBS LETT, V264, P78, DOI 10.1016/0014-5793(90)80769-F; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382	34	186	192	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11818	11823						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1318302				2022-12-27	WOS:A1992HY94700030
J	MAKI, S; TAKIGUCHI, S; MIKI, T; HORIUCHI, T				MAKI, S; TAKIGUCHI, S; MIKI, T; HORIUCHI, T			MODULATION OF DNA SUPERCOILING ACTIVITY OF ESCHERICHIA-COLI DNA GYRASE BY F-PLASMID PROTEINS - ANTAGONISTIC ACTIONS OF LETA (CCDA) AND LETD (CCDB) PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEX FACTOR-F; CELL-DIVISION; GENE-EXPRESSION; BACTERIAL CHROMOSOME; DEPENDENT INDUCTION; HOST BACTERIA; GYRB-GENE; PHAGE-MU; H-NS; TOPOISOMERASES	The letA (ccdA) and letD (ccdB) genes of F plasmid contribute to stable maintenance of the plasmid in Escherichia coli cells; a product of the latter has a lethal effect on the host cell and that of the former neutralizes functions of the letD. In cells that overproduce the LetD (CcdB) protein, the plasmid DNA is extensively relaxed. Correspondingly, DNA supercoiling activity in a cell-free extract of the overproducing strain decreases to a level of less than 1% of that seen in normal cells. However, the extract does not inhibit DNA gyrase reconstituted from purified subunits, thereby indicating that the intrinsic DNA gyrase is inactivated in the overproducing strain. Upon addition of purified LetA (CcdA) protein to the extract of LetD overproducing cells, the DNA supercoiling activity was fully restored. Using this rejuvenation as an assay, we purified the "inactivated gyrase" and obtained evidence that the LetD protein formed an isolable complex with the A subunit of DNA gyrase. Thus, the LetD and the LetA proteins constitute an opposing pair in modulating the DNA supercoiling activity of gyrase, probably by direct interaction.			MAKI, S (corresponding author), KYUSHU UNIV,FAC PHARMACEUT SCI,DEPT MICROBIOL,MAIDASHI 3-1-1,FUKUOKA 812,JAPAN.							BAILONE A, 1985, P NATL ACAD SCI USA, V82, P5973, DOI 10.1073/pnas.82.17.5973; BEX F, 1983, EMBO J, V2, P1853, DOI 10.1002/j.1460-2075.1983.tb01671.x; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDENBURGER A, 1984, J MOL BIOL, V179, P571, DOI 10.1016/0022-2836(84)90082-2; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DRI AM, 1991, J BACTERIOL, V173, P2852, DOI 10.1128/JB.173.9.2852-2863.1991; DRLICA K, 1980, P NATL ACAD SCI-BIOL, V77, P6879, DOI 10.1073/pnas.77.11.6879; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; DRLICA K, 1984, MICROBIOL REV, V48, P273, DOI 10.1128/MMBR.48.4.273-289.1984; DRLICA K, 1987, ESCHERICHIA COLI SAL, P91; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; GHELARDINI P, 1989, MOL GEN GENET, V216, P31, DOI 10.1007/BF00332227; GHELARDINI P, 1984, J BACTERIOL, V157, P665, DOI 10.1128/JB.157.2.665-668.1984; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HIGGINS CF, 1990, MOL MICROBIOL, V4, P2007, DOI 10.1111/j.1365-2958.1990.tb00559.x; HIGGINS CF, 1988, CELL, V52, P569, DOI 10.1016/0092-8674(88)90470-9; HILLYARD DR, 1990, J BACTERIOL, V172, P5402, DOI 10.1128/jb.172.9.5402-5407.1990; HIRAGA S, 1986, J BACTERIOL, V166, P100, DOI 10.1128/jb.166.1.100-104.1986; HIROTA Y, 1971, BIOMEMBRANE, V2, P13; HSIEH LS, 1991, J BACTERIOL, V173, P3914, DOI 10.1128/JB.173.12.3914-3917.1991; HULTON CSJ, 1990, CELL, V63, P631, DOI 10.1016/0092-8674(90)90458-Q; HUSSAIN K, 1987, MOL MICROBIOL, V1, P73, DOI 10.1111/j.1365-2958.1987.tb00529.x; HUSSAIN K, 1987, MOL MICROBIOL, V1, P259, DOI 10.1111/j.1365-2958.1987.tb01932.x; JAFFE A, 1985, J BACTERIOL, V163, P841; KAROUI H, 1983, EMBO J, V2, P1863, DOI 10.1002/j.1460-2075.1983.tb01672.x; KATO J, 1989, MOL GEN GENET, V217, P178, DOI 10.1007/BF00330959; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKI S, 1988, J BIOL CHEM, V263, P6547; Maniatis T., 1982, MOL CLONING; MAY G, 1990, MOL GEN GENET, V224, P81, DOI 10.1007/BF00259454; MIKI T, 1987, PROTEIN ENG, V1, P327, DOI 10.1093/protein/1.4.327; MIKI T, 1988, J MOL BIOL, V201, P327, DOI 10.1016/0022-2836(88)90141-6; MIKI T, 1978, MOL GEN GENET, V158, P217, DOI 10.1007/BF00267192; MIKI T, 1984, J MOL BIOL, V174, P627, DOI 10.1016/0022-2836(84)90087-1; MIKI T, 1984, J MOL BIOL, V174, P605, DOI 10.1016/0022-2836(84)90086-X; MIKI T, 1992, IN PRESS J MOL BIOL; MORI H, 1984, MOL GEN GENET, V196, P185, DOI 10.1007/BF00328049; MULDER E, 1990, MOL GEN GENET, V221, P87, DOI 10.1007/BF00280372; OGURA T, 1983, P NATL ACAD SCI-BIOL, V80, P4784, DOI 10.1073/pnas.80.15.4784; ORR E, 1979, MOL GEN GENET, V177, P103, DOI 10.1007/BF00267259; PAOLOZZI L, 1989, MOL GEN GENET, V218, P13, DOI 10.1007/BF00330559; PETTIGREW DW, 1988, J BIOL CHEM, V263, P135; REECE RJ, 1991, J BIOL CHEM, V266, P3540; SMITH CL, 1983, P NATL ACAD SCI-BIOL, V80, P2510, DOI 10.1073/pnas.80.9.2510; SNYDER M, 1979, J MOL BIOL, V131, P287, DOI 10.1016/0022-2836(79)90077-9; SOMMER S, 1985, MOL GEN GENET, V198, P456, DOI 10.1007/BF00332939; STAUDENBAUER WL, 1976, EUR J BIOCHEM, V62, P491, DOI 10.1111/j.1432-1033.1976.tb10183.x; STECK TR, 1984, CELL, V36, P1081, DOI 10.1016/0092-8674(84)90058-8; SUGINO A, 1980, NUCLEIC ACIDS RES, V8, P3865, DOI 10.1093/nar/8.17.3865; TAM JE, 1989, MOL GEN GENET, V219, P26, DOI 10.1007/BF00261153; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WADA M, 1988, J MOL BIOL, V204, P581, DOI 10.1016/0022-2836(88)90357-9; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; YANG Y, 1990, BACTERIAL CHROMOSOME, P211	58	69	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12244	12251						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1318314				2022-12-27	WOS:A1992HY94700089
J	PARK, K; CHUNG, M; KIM, SJ				PARK, K; CHUNG, M; KIM, SJ			INHIBITION OF MYOGENESIS BY OKADAIC ACID, AN INHIBITOR OF PROTEIN PHOSPHATASES-1 AND PHOSPHATASES-2A, CORRELATES WITH THE INDUCTION OF AP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; GENE FAMILY; TRANSCRIPTION FACTOR; COLLAGENASE GENE; TUMOR PROMOTER; GROWTH-FACTOR; ONCOGENE FOS; MYOD FAMILY; BINDING; MEMBER	Recently, we demonstrated that okadaic acid, an inhibitor of protein phosphatases 1 and 2A, inhibits myogenesis by extinguishing the expression of MyoD1 and inducing the expression of Id. Since it has been reported that transformation by c-fos also inhibits myogenesis through inhibition of MyoD1 expression, we examined the effects of okadaic acid on the activation of the c-fos and jun family of proto-oncogenes in an attempt to understand the mechanism by which okadaic acid inhibits the myogenic differentiation. Treatment of C2C12 cells in growth medium with okadaic acid increased expression of the mRNAs for the c-fos family continuously and for the jun family to a lesser extent. In contrast, in differentiation medium, the induction of c-fos, c-jun, and fos B mRNAs by okadaic acid was transient, whereas fra-1, jun D, and jun B mRNAs were induced continuously, suggesting that okadaic acid regulates the expression of the c-fos and jun family through complex regulatory mechanisms depending on the state of differentiation of the cells. Transfection of c-jun and c-fos promoter-chloramphenicol acetyltransferase constructs demonstrated that the effects of okadaic acid on the induction of c-fos and c-jun are mediated through the activation of promoter elements. These results suggest that some of the targets of protein phosphatases 1 and 2A may include transcription factors capable of forming AP1 complexes and that these factors may play an important role during myogenic differentiation.	NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FRANZA B, 1988, SCIENCE, V243, P1695; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KIM SJ, 1989, J BIOL CHEM, V264, P19373; KIM SJ, 1990, CELL REGUL, V1, P269, DOI 10.1091/mbc.1.3.269; KOURAZIDES T, 1989, NATURE, V340, P568; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SASSA T, 1989, BIOCHEM BIOPH RES CO, V159, P939, DOI 10.1016/0006-291X(89)92199-2; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TAPSCOTT SJ, 1989, SCIENCE, V245, P532, DOI 10.1126/science.2547249; THEVENIN C, 1990, New Biologist, V2, P793; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	46	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10810	10815						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1316910				2022-12-27	WOS:A1992HV09000091
J	YOSHIKAWA, S; CAUGHEY, WS				YOSHIKAWA, S; CAUGHEY, WS			INFRARED EVIDENCE OF AZIDE BINDING TO IRON, COPPER, AND NONMETAL SITES IN HEART CYTOCHROME-C-OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM SPECTROSCOPY; RESONANCE RAMAN; STATE; COMPLEXES; CYANIDE; DERIVATIVES; HEMOGLOBIN; REDUCTION; MEMBRANE; HAEM-A3	Interactions of azide ion with bovine heart cytochrome c oxidase (CcO) at five redox levels (IV) to (0), obtained by zero to four electron reduction of fully oxidized enzyme CcO(IV), were monitored by infrared and visible/Soret spectra. Partially reduced CcO gave three azide asymmetric stretch bands at 2040, 2016, and 2004 cm-1 for CcO(III)N3 and two at 2040 and 2016 cm-1 for both Cco(II)Ns and CeO(I)N3. Resting CcO(IV) reacts with N3- to give one band at 2041 cm-1 assigned to Cu(B)2+N3 and another at 2051 cm-1 to N3- that is associated with protein but is not bound to a metal ion. At high azide concentrations the weak association of many azide molecules with non-metal protein sites was observed at all redox levels. These findings provide direct evidence for 1) N3- binding to Cu(B) as well as Fe(a3) in partially reduced enzyme, but no binding to Fe(a3) in fully oxidized enzyme and no binding to either metal in fully reduced enzyme; 2) a long range effect of the oxidation state of Fe(a) or Cu(A) on ligand binding at heme a3, but not at CU(B); and 3) an insensitivity of either Fe(a3), or Cu(B) ligand site to changes in ligand or oxidation state at the other site. The observed independence of the Fe(a3) and Cu(B) sites provides further support for Fe(a3)3+ OOH, rather than Fe(a3)3+ OOCu(B)2+, as an intermediate in the reduction of O2 to water by the oxidase.	COLORADO STATE UNIV,DEPT BIOCHEM,FT COLLINS,CO 80523; HIMEJI INST TECHNOL,DEPT LIFE SCI,1479 KAMIGOHRI,AKOH,HYOGO 67812,JAPAN	Colorado State University; University of Hyogo					NHLBI NIH HHS [HL-15980] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL015980] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGRELL I, 1971, ACTA CHEM SCAND, V25, P2965, DOI 10.3891/acta.chem.scand.25-2965; ALBEN JO, 1972, BIOCHEMISTRY-US, V11, P842, DOI 10.1021/bi00755a025; BAKER GM, 1987, J BIOL CHEM, V262, P595; BOELENS R, 1984, BIOCHIM BIOPHYS ACTA, V765, P196, DOI 10.1016/0005-2728(84)90014-8; BOGUCKA K, 1966, BIOCHIM BIOPHYS ACTA, V122, P381, DOI 10.1016/0926-6593(66)90031-2; BRUNORI M, 1979, J BIOL CHEM, V254, P769; Caughey W. S., 1980, METHODS DETERMINING, P95; CAUGHEY WS, 1966, BIOCHEMISTRY-US, V5, P3830, DOI 10.1021/bi00876a014; CAUGHEY WS, 1975, J BIOL CHEM, V250, P7602; CAUGHEY WS, 1973, ANN NY ACAD SCI, V206, P296, DOI 10.1111/j.1749-6632.1973.tb43218.x; CAUGHEY WS, 1977, METAL LIGAND INTER 2, P131; CAUGHEY WS, 1976, ENZYMES, V13, P299; DORI Z, 1973, CHEM REV, V73, P247, DOI 10.1021/cr60283a003; EDWARDS JO, 1954, J AM CHEM SOC, V76, P1540, DOI 10.1021/ja01635a021; EINARSDOTTIR O, 1984, BIOCHEM BIOPH RES CO, V124, P836, DOI 10.1016/0006-291X(84)91033-7; EINARSDOTTIR O, 1988, J BIOL CHEM, V263, P13641; EINARSDOTTIR O, 1985, BIOCHEM BIOPH RES CO, V129, P840, DOI 10.1016/0006-291X(85)91968-0; FABIAN M, 1989, BIOCHIM BIOPHYS ACTA, V973, P414, DOI 10.1016/S0005-2728(89)80383-4; GILMOUR MV, 1967, BIOCHIM BIOPHYS ACTA, V143, P487, DOI 10.1016/0005-2728(67)90054-0; GOHER MAS, 1987, B SOC CHIM FR, V1, P49; GOODMAN G, 1984, J BIOL CHEM, V259, P5094; GOODMAN G, 1987, BIOCHIM BIOPHYS ACTA, V890, P360, DOI 10.1016/0005-2728(87)90164-2; HARRIS DA, 1989, BIOCHIM BIOPHYS ACTA, V974, P156, DOI 10.1016/S0005-2728(89)80368-8; HARTZELL CR, 1988, FEBS LETT, V236, P1, DOI 10.1016/0014-5793(88)80273-4; KEILIN D, 1939, P R SOC LOND B, V127, P176; KOBAYASHI H, 1977, J BIOCHEM-TOKYO, V81, P1071, DOI 10.1093/oxfordjournals.jbchem.a131530; KURTZ DM, 1976, J AM CHEM SOC, V98, P5033, DOI 10.1021/ja00432a064; LINDSAY JG, 1987, BIOELECTROCH BIOENER, V17, P369, DOI 10.1016/0302-4598(87)80047-8; LINDSAY JG, 1987, BIOELECTROCH BIOENER, V17, P383, DOI 10.1016/0302-4598(87)80048-X; MALMSTROM BG, 1990, CHEM REV, V90, P1247, DOI 10.1021/cr00105a008; MCCOY S, 1970, BIOCHEMISTRY-US, V9, P2387, DOI 10.1021/bi00814a001; NAKAO Y, 1986, B CHEM SOC JPN, V59, P2755, DOI 10.1246/bcsj.59.2755; NEYA S, 1985, BIOCHIM BIOPHYS ACTA, V827, P157, DOI 10.1016/0167-4838(85)90085-8; OGURA T, 1991, B CHEM SOC JPN, V64, P2901, DOI 10.1246/bcsj.64.2901; OHNISHI T, 1982, J BIOL CHEM, V257, P4821; OLIVEBERG M, 1991, BIOCHEMISTRY-US, V30, P7053, DOI 10.1021/bi00243a003; ORII Y, 1963, J BIOCHEM-TOKYO, V53, P489, DOI 10.1093/oxfordjournals.jbchem.a127728; ORII Y, 1964, J BIOCHEM-TOKYO, V55, P37, DOI 10.1093/oxfordjournals.jbchem.a127838; PATE JE, 1986, SPECTROCHIM ACTA A, V42, P313, DOI 10.1016/0584-8539(86)80194-5; POTTER WT, 1986, THESIS COLORADO STAT; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; SCOTT RA, 1989, ANNU REV BIOPHYS BIO, V18, P137, DOI 10.1146/annurev.bb.18.060189.001033; SHERMAN D, 1991, P NATL ACAD SCI USA, V88, P4265, DOI 10.1073/pnas.88.10.4265; THOMAS JM, 1976, THESIS COLORADO STAT; THOMSON AJ, 1982, BIOCHEM J, V207, P167, DOI 10.1042/bj2070167; THOMSON AJ, 1981, BIOCHEM J, V193, P687, DOI 10.1042/bj1930687; THOMSON AJ, 1985, J INORG BIOCHEM, V23, P187, DOI 10.1016/0162-0134(85)85025-X; VANBUUREN KJ, 1972, BIOCHIM BIOPHYS ACTA, V256, P258, DOI 10.1016/0005-2728(72)90057-6; VANGELDE.BF, 1969, BIOCHIM BIOPHYS ACTA, V189, P1, DOI 10.1016/0005-2728(69)90219-9; VANNESTE WH, 1966, BIOCHEMISTRY-US, V5, P838, DOI 10.1021/bi00867a005; WEVER R, 1973, BIOCHIM BIOPHYS ACTA, V325, P1, DOI 10.1016/0005-2728(73)90144-8; WILSON DF, 1967, BIOCHIM BIOPHYS ACTA, V143, P52, DOI 10.1016/0005-2728(67)90108-9; YORK JL, 1970, BIOCHEMISTRY-US, V9, P4549, DOI 10.1021/bi00825a014; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480; YOSHIKAWA S, 1985, J BIOL CHEM, V260, P3518; YOSHIKAWA S, 1982, J BIOL CHEM, V257, P412; YOSHIKAWA S, 1977, J BIOL CHEM, V252, P5498; YOSHIKAWA S, 1988, P NATL ACAD SCI USA, V85, P1354, DOI 10.1073/pnas.85.5.1354; YOSHIKAWA S, 1990, J BIOL CHEM, V265, P7945; YOSHIKAWA S, 1973, J BIOCHEM, V73, P637, DOI 10.1093/oxfordjournals.jbchem.a130122	60	47	47	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9757	9766						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315769				2022-12-27	WOS:A1992HT96500050
J	ZUBER, C; LACKIE, PM; CATTERALL, WA; ROTH, J				ZUBER, C; LACKIE, PM; CATTERALL, WA; ROTH, J			POLYSIALIC ACID IS ASSOCIATED WITH SODIUM-CHANNELS AND THE NEURAL CELL-ADHESION MOLECULE N-CAM IN ADULT-RAT BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG OLIGOSACCHARIDE SEGMENT; MONOCLONAL-ANTIBODY; SIALIC-ACID; ESCHERICHIA-COLI; NEURAMINIC ACID; BINDING; LOCALIZATION; UNITS; NCAM; SIALYLTRANSFERASE	We have studied alpha-2,8-linked polysialic acid (polySia) and the neural cell adhesion molecule (N-CAM in the adult rat brain by immunohistochemistry and Western blot analysis. Both molecules were widely distributed but not ubiquitous. Various brain regions showed colocalization of polySia and. N-CAM. Strong immunoreactivity for polySia was seen in regions which were negative for N-CAM, such as the main and accessory olfactory bulbs. Immunohistochemical evidence for the heterogeneity of polySia expression in different brain regions was confirmed by immunoblotting. We present evidence that N-CAM is not the only polySia bearing protein in adult rat brain. Specifically, immunoprecipitation using the polysia-specific monoclonal antibody mAb 735 precipitated not only N-CAM isoforms carrying polySia, but also the sodium channel alpha-subunit. Immunoblotting using sodium channel alpha-subunit antibody (SP20) revealed a smear from 250 kDa upwards. PolySia removal using an endoneuraminidase specific for alpha-2,8-linked polysialic acid of 8 or more residues long, reduced this smear to a single band at 250 kDa. Thus both N-CAM and sodium channels carry homopolymers of alpha-2,8-linked polysialic acid in adult rat brain.	UNIV ZURICH,DEPT PATHOL,DIV CELL & MOLEC PATHOL,SCHMELZBERGSTR 12,CH-8091 ZURICH,SWITZERLAND; UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	University of Zurich; University of Washington; University of Washington Seattle			Lackie, Peter M/I-3136-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015751, R01NS025704] Funding Source: NIH RePORTER; NINDS NIH HHS [NS25704, NS15751] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; BREEN KC, 1988, DEVELOPMENT, V104, P147; CATTERALL WA, 1979, J BIOL CHEM, V254, P1379; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; EDELMAN GM, 1983, SCIENCE, V219, P450, DOI 10.1126/science.6823544; FINNE J, 1985, J BIOL CHEM, V260, P1265; FINNE J, 1982, J BIOL CHEM, V257, P1966; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; GRIFFITHS G, 1983, METHOD ENZYMOL, V96, P466; HALL AK, 1990, J CELL BIOL, V110, P817, DOI 10.1083/jcb.110.3.817; HAYRINEN J, 1989, MOL IMMUNOL, V26, P523, DOI 10.1016/0161-5890(89)90003-5; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HOFFMAN S, 1982, J BIOL CHEM, V257, P7720; HUSMANN M, 1990, J HISTOCHEM CYTOCHEM, V38, P209, DOI 10.1177/38.2.1688896; IWASAKI M, 1990, J BIOL CHEM, V265, P2596; JAMES WM, 1987, BIOCHEM BIOPH RES CO, V148, P817, DOI 10.1016/0006-291X(87)90949-1; JAMES WM, 1989, BIOCHEMISTRY-US, V28, P6001, DOI 10.1021/bi00440a042; KADMON G, 1990, J CELL BIOL, V110, P209, DOI 10.1083/jcb.110.1.209; LACKIE PM, 1990, DEVELOPMENT, V110, P933; MCCOY RD, 1985, J BIOL CHEM, V260, P2695; NADANO D, 1986, J BIOL CHEM, V261, P1550; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PELKONEN S, 1989, J VIROL, V63, P4409, DOI 10.1128/JVI.63.10.4409-4416.1989; RECIOPINTO E, 1987, SOC NEUR ABSTR, V17, P92; RIEGER F, 1985, J CELL BIOL, V101, P285, DOI 10.1083/jcb.101.1.285; ROTH J, 1988, AM J PATHOL, V133, P227; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROTH J, 1987, P NATL ACAD SCI USA, V84, P1969, DOI 10.1073/pnas.84.7.1969; ROTHBARD JB, 1982, J BIOL CHEM, V257, P1064; ROUGON G, 1986, J CELL BIOL, V103, P2429, DOI 10.1083/jcb.103.6.2429; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SADOUL RV, 1985, NATURE, V304, P347; SCHEUER T, 1988, BIOPHYS J, V53, pA541; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; THEODOSIS DT, 1991, P NATL ACAD SCI USA, V88, P5494, DOI 10.1073/pnas.88.13.5494; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; TOMLINSON S, 1985, J VIROL, V55, P374, DOI 10.1128/JVI.55.2.374-378.1985; TROY FA, 1979, J BIOL CHEM, V254, P7377; VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971; WESTENBROEK RE, 1989, NEURON, V3, P695, DOI 10.1016/0896-6273(89)90238-9	44	208	209	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9965	9971						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315775				2022-12-27	WOS:A1992HT96500079
J	JANETZKY, B; LEHLE, L				JANETZKY, B; LEHLE, L			TY4, A NEW RETROTRANSPOSON FROM SACCHAROMYCES-CEREVISIAE, FLANKED BY TAU-ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-LIKE PARTICLES; AMINO-ACID-SEQUENCE; TRANSCRIPTION TERMINATION; REVERSE TRANSCRIPTION; NUCLEOTIDE-SEQUENCE; YEAST; RNA; PROTEINS; TRANSPOSON; GENES	We have isolated and sequenced a genomic clone from Saccharomyces cerevisiae that shows structural features of a novel retrotransposon, designated Ty4. The element is 6.2 kilobases in length, and its genetic organization of the deduced functional domains is similar to Ty1 and Ty2 and thus different from Ty3. In contrast to hitherto known Ty elements from yeast, Ty4 is flanked by long terminal tau-element repeats instead of delta or sigma sequences. Ty4 contains two overlapping open reading frames. The first open reading frame, TYA4, is 1230 base pairs long and encodes a protein with a motif found in the nucleic acid-binding gag-protein of retroviruses. The second 4395-base pair open reading frame, TYB4, encodes a polyprotein that has domains with significant homology to retroviral protease, integrase, reverse transcriptase, and RNase H, structurally arranged in that order. The deduced amino acid sequence shows the greatest similarity with Ty2 and Ty1. The overall identity of the deduced functional protein domains is 28% with Ty2, 25% with Ty1, 19% with copia from Drosophila, and 18% with Ty3. Examination of genomic DNA from several laboratory strains indicates that Ty4 is present in two to four copies. Ty4 mRNA is of low abundance as compared to other Ty retrotransposons. At the 3' end of Ty4, two "solo" delta-elements, a full length and an overlapping, truncated one, are associated.			JANETZKY, B (corresponding author), UNIV REGENSBURG,INST ZELLBIOL,W-8400 REGENSBURG,GERMANY.							ADAMS SE, 1987, CELL, V49, P111, DOI 10.1016/0092-8674(87)90761-6; BELCOURT MF, 1990, CELL, V62, P339, DOI 10.1016/0092-8674(90)90371-K; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; BOEKE JD, 1989, ANNU REV MICROBIOL, V43, P403, DOI 10.1146/annurev.micro.43.1.403; BOEKE JD, 1989, MOBILE DNA, P335; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CLARE J, 1985, P NATL ACAD SCI USA, V82, P2828; CLARK DJ, 1988, J BIOL CHEM, V263, P1413; COPELAND TD, 1984, VIROLOGY, V133, P137, DOI 10.1016/0042-6822(84)90432-X; COVEY SN, 1986, NUCLEIC ACIDS RES, V14, P623, DOI 10.1093/nar/14.2.623; DOBSON MJ, 1982, NUCLEIC ACIDS RES, V10, P2625, DOI 10.1093/nar/10.8.2625; DOMDEY H, 1984, CELL, V39, P611, DOI 10.1016/0092-8674(84)90468-9; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; ELDER RT, 1980, COLD SPRING HARB SYM, V45, P581; ELDER RT, 1983, P NATL ACAD SCI-BIOL, V80, P2432, DOI 10.1073/pnas.80.9.2432; FARABAUGH PJ, 1980, NATURE, V286, P352, DOI 10.1038/286352a0; FINK GR, 1986, TRENDS GENET, V2, P118, DOI 10.1016/0168-9525(86)90200-3; GAFNER J, 1980, NATURE, V286, P414, DOI 10.1038/286414a0; GARFINKEL DJ, 1985, CELL, V42, P507, DOI 10.1016/0092-8674(85)90108-4; GENBAUFFE FS, 1984, J BIOL CHEM, V259, P518; GRANDBASTIEN MA, 1992, TRENDS GENET, V8, P103, DOI 10.1016/0168-9525(92)90198-D; GUNTHER R, 1991, J BIOL CHEM, V266, P24557; HANSEN LJ, 1988, MOL CELL BIOL, V8, P5245, DOI 10.1128/MCB.8.12.5245; HAUBER J, 1985, NUCLEIC ACIDS RES, V13, P2745, DOI 10.1093/nar/13.8.2745; HENIKOFF S, 1984, MOL CELL BIOL, V4, P1515, DOI 10.1128/MCB.4.8.1515; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KINGSMAN AJ, 1988, CELL, V53, P333, DOI 10.1016/0092-8674(88)90151-1; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LIAO XB, 1987, P NATL ACAD SCI USA, V84, P8520, DOI 10.1073/pnas.84.23.8520; MCCLUSKEY K, 1990, CURR GENET, V18, P385, DOI 10.1007/BF00318221; MELLOR J, 1985, NATURE, V318, P583, DOI 10.1038/318583a0; MELLOR J, 1985, NUCLEIC ACIDS RES, V13, P6249, DOI 10.1093/nar/13.17.6249; MELLOR J, 1985, NATURE, V313, P243, DOI 10.1038/313243a0; MULLER F, 1987, MOL GEN GENET, V207, P421, DOI 10.1007/BF00331610; MULLER F, 1991, MOL GEN GENET, V226, P145, DOI 10.1007/BF00273598; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; Sambrook J, 1989, MOL CLONING LABORATO; SENGSTAG C, 1987, NUCLEIC ACIDS RES, V15, P233, DOI 10.1093/nar/15.1.233; Sherman F., 1986, METHODS YEAST GENETI; STUCKA R, 1986, CURR GENET, V11, P193, DOI 10.1007/BF00420606; VARMUS HE, 1977, P NATL ACAD SCI USA, V74, P911; WARMINGTON JR, 1985, NUCLEIC ACIDS RES, V13, P6679, DOI 10.1093/nar/13.18.6679; YOSHINAKA Y, 1977, CELL, V12, P709, DOI 10.1016/0092-8674(77)90271-9; YOUNGREN SD, 1988, MOL CELL BIOL, V8, P1421, DOI 10.1128/MCB.8.4.1421; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	46	17	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19798	19805						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328182				2022-12-27	WOS:A1992JR85800010
J	HORI, H; MASUYA, F; TSUBAKI, M; YOSHIKAWA, S; ICHIKAWA, Y				HORI, H; MASUYA, F; TSUBAKI, M; YOSHIKAWA, S; ICHIKAWA, Y			ELECTRONIC AND STEREOCHEMICAL CHARACTERIZATIONS OF INTERMEDIATES IN THE PHOTOLYSIS OF FERRIC CYTOCHROME P450SCC NITROSYL COMPLEXES - EFFECTS OF CHOLESTEROL AND ITS ANALOGS ON LIGAND-BINDING STRUCTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PUTIDA CYTOCHROME-P-450; PARAMAGNETIC RESONANCE; CRYSTAL-STRUCTURE; ELECTROMAGNETIC PROPERTIES; C OXIDASE; HEMOPROTEINS; PREGNENOLONE; CONVERSION; MYOGLOBIN; RAMAN	Low temperature photolysis of nitric oxide from the nitrosyl complexes of ferric cytochrome P450scc was examined by EPR spectroscopy to elucidate the stereochemical interaction between heme-bound ligand and side-chain of cholesterol or its hydroxylated analogues at the substrate-binding site. The photoproducts of the NO complexes trapped at 5 K exhibited new EPR absorptions providing information on the steric crowding of the distal heme moiety. Without substrate, the photoproduct exhibited a broad EPR absorption at g approximately 8 due to magnetic dipole-dipole interaction between the photodissociated NO (S = 1/2) and the ferric iron (S = 5/2). This indicates that the photo-dissociated NO can move far away from the heme iron in the less restricted distal heme moiety of the substrate-free cytochrome P450scc. In the presence of substrates, such as cholesterol, 20(S)-hydroxycholesterol, 22(S)-hydroxycholesterol, 22(R)-hydroxycholesterol, and 25-hydroxycholesterol, the EPR spectra of the photoproducts exhibited many variations having broad g approximately 8 absorptions and/or the widespread signals together with zero-field absorption. Among the steroid complexes used, 20(S)-hydroxycholesterol complex exhibited a conspicuously widespread EPR signal with a distinct zero-field absorption due to a spin-coupled interaction between the ferric iron (S = 5/2) and the photolyzed NO (S = 1/2). These results indicate that the 20(S)-hydroxycholesterol complex has restricted substrate-binding structure and that the hydroxylation of the cholesterol side-chain at the 22R position is necessary to proceed the side-chain cleavage reaction properly in cytochrome P450scc.	HIMEJI INST TECHNOL,FAC SCI,DEPT LIFE SCI,KAMIGORI,HYOGO 67812,JAPAN; KAGAWA MED SCH,DEPT BIOCHEM,MIKI,KAGAWA 76107,JAPAN	University of Hyogo; Kagawa University	HORI, H (corresponding author), OSAKA UNIV,FAC ENGN SCI,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN.							BENKO B, 1983, P NATL ACAD SCI USA, V80, P7042, DOI 10.1073/pnas.80.22.7042; BURSTEIN S, 1976, STEROIDS, V28, P115, DOI 10.1016/0039-128X(76)90131-8; BURSTEIN S, 1975, J BIOL CHEM, V250, P9028; COOPER CE, 1992, J BIOL CHEM, V267, P280; DUNHAM WR, 1983, BIOCHIM BIOPHYS ACTA, V748, P73, DOI 10.1016/0167-4838(83)90029-8; ENEMARK JH, 1974, COORDIN CHEM REV, V13, P339, DOI 10.1016/S0010-8545(00)80259-3; HAGEN WR, 1982, BIOCHIM BIOPHYS ACTA, V708, P82, DOI 10.1016/0167-4838(82)90206-0; HENDRICH MP, 1989, BIOPHYS J, V56, P489, DOI 10.1016/S0006-3495(89)82696-7; HOFFMAN BM, 1978, P NATL ACAD SCI USA, V75, P21, DOI 10.1073/pnas.75.1.21; HORI H, 1981, J BIOL CHEM, V256, P7849; HORI H, 1990, J BIOL CHEM, V265, P15028; HORI H, 1982, BIOCHEMISTRY-US, V21, P1431, DOI 10.1021/bi00535a050; HORI H, 1980, NATURE, V288, P501, DOI 10.1038/288501a0; HU SZ, 1991, J AM CHEM SOC, V113, P2843, DOI 10.1021/ja00008a007; HUME R, 1984, EUR J BIOCHEM, V140, P583, DOI 10.1111/j.1432-1033.1984.tb08142.x; IKEDASAITO M, 1991, J BIOL CHEM, V266, P23641; KOBAYASHI K, 1980, J BIOL CHEM, V255, P2239; MORISAKI M, 1976, FEBS LETT, V72, P337, DOI 10.1016/0014-5793(76)80999-4; ORMEJOHNSON NR, 1979, J BIOL CHEM, V254, P2103; PICIULO PL, 1974, J AM CHEM SOC, V96, P5293, DOI 10.1021/ja00823a067; POULOS TL, 1985, J BIOL CHEM, V260, P6122; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; POULOS TL, 1987, J MOL BIOL, V195, P678; RAAG R, 1989, BIOCHEMISTRY-US, V28, P917, DOI 10.1021/bi00428a077; RAAG R, 1989, BIOCHEMISTRY-US, V28, P7586, DOI 10.1021/bi00445a013; SCHEIDT WR, 1984, J AM CHEM SOC, V106, P3191, DOI 10.1021/ja00323a022; TSUBAKI M, 1986, BIOCHIM BIOPHYS ACTA, V870, P564, DOI 10.1016/0167-4838(86)90266-9; TSUBAKI M, 1986, BIOCHEMISTRY-US, V25, P3563, DOI 10.1021/bi00360a014; TSUBAKI M, 1987, BIOCHEMISTRY-US, V26, P4527, DOI 10.1021/bi00388a054; YONETANI T, 1972, J BIOL CHEM, V247, P2447	30	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18377	18381						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326522				2022-12-27	WOS:A1992JN50200024
J	HAYASHI, Y; CHAN, J; NAKABAYASHI, H; HASHIMOTO, T; TAMAOKI, T				HAYASHI, Y; CHAN, J; NAKABAYASHI, H; HASHIMOTO, T; TAMAOKI, T			IDENTIFICATION AND CHARACTERIZATION OF 2 ENHANCERS OF THE HUMAN ALBUMIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FETOPROTEIN GENE; TISSUE-SPECIFIC EXPRESSION; LIVER-SPECIFIC FACTOR; NUCLEAR FACTOR; TRANSCRIPTIONAL ACTIVATORS; PROMOTER REGIONS; MOUSE; UPSTREAM; DNA; ELEMENTS	A 12.5-kilobase pair (kb) segment upstream of the human albumin gene was analyzed for transcription enhancing activity using transient transfection analysis, gel mobility shift assays, DNase I footprinting, and site-specific mutagenesis. Two enhancer regions were identified, one 1.7 kb upstream of the transcription initiation site (E1.7) and the other 6 kb upstream (E6). In E1.7, a nuclear protein from HuH-7 hepatoma cells binds to an AT-rich sequence, GTTACTAATTGAC. Competition gel mobility shift assays suggested that this protein is HNF-1, which regulates the promoter of the albumin gene and several other liver-specific genes. A 60-base pair E1.7 fragment carrying the AT-rich sequence stimulates a heterologous (alpha-fetoprotein) promoter in a dose-dependent manner. In E6, a HuH-7 nuclear protein binds to a GT-rich sequence, TGTTTGGC. A 27-base pair E6 fragment carrying this sequence is able to stimulate the SV40 promoter in an orientation-independent manner. An alteration of this sequence by site-specific mutagenesis resulted in the loss of transcriptional activity as well as binding to the HuH-7 nuclear protein. Competition gel mobility shift assays showed that homologous elements exist in the albumin promoter. These results show that the promoter and enhancer of the human albumin gene are regulated by two common transcription factors through two shared cis-acting elements, one AT-rich and the other GT-rich.	UNIV CALGARY,DEPT MED BIOCHEM,CALGARY T2N 4N1,ALBERTA,CANADA	University of Calgary			Chan, Jeannie/B-5060-2013					BABISS LE, 1987, GENE DEV, V1, P256, DOI 10.1101/gad.1.3.256; BACH I, 1990, GENOMICS, V8, P155, DOI 10.1016/0888-7543(90)90238-P; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; FRAIN M, 1990, MOL CELL BIOL, V10, P991, DOI 10.1128/MCB.10.3.991; GODBOUT R, 1988, MOL CELL BIOL, V8, P1169, DOI 10.1128/MCB.8.3.1169; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HEARD JM, 1987, MOL CELL BIOL, V7, P2425, DOI 10.1128/MCB.7.7.2425; HERBST RS, 1989, P NATL ACAD SCI USA, V86, P1553, DOI 10.1073/pnas.86.5.1553; IZBAN MG, 1989, J BIOL CHEM, V264, P9171; JOHNSON PF, 1990, CELL GROWTH DIFFER, V1, P47; JOSEESTANYOL M, 1988, J BIOL CHEM, V263, P10865; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; NAKABAYASHI H, 1989, J BIOL CHEM, V264, P266; NAKABAYASHI H, 1984, JPN J CANCER RES, V75, P151; OTT MO, 1984, EMBO J, V3, P2505, DOI 10.1002/j.1460-2075.1984.tb02164.x; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; SAWADAISHI K, 1988, MOL CELL BIOL, V8, P5179, DOI 10.1128/MCB.8.12.5179; SHAUL Y, 1987, EMBO J, V6, P1913, DOI 10.1002/j.1460-2075.1987.tb02451.x; TRONCHE F, 1990, MOL BIOL MED, V7, P173; URANO Y, 1986, J BIOL CHEM, V261, P3244; WATANABE K, 1987, J BIOL CHEM, V262, P4812; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; ZHANG DE, 1990, J BIOL CHEM, V265, P3382	36	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14580	14585						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321810				2022-12-27	WOS:A1992JF08800016
J	MAKINEN, KK; MAKINEN, PL; SYED, SA				MAKINEN, KK; MAKINEN, PL; SYED, SA			PURIFICATION AND SUBSTRATE-SPECIFICITY OF AN ENDOPEPTIDASE FROM THE HUMAN ORAL SPIROCHETE TREPONEMA-DENTICOLA ATCC-35405, ACTIVE ON FURYLACRYLOYL-LEU-GLY-PRO-ALA AND BRADYKININ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHYMOTRYPSINLIKE PROTEASE; PERIODONTAL-DISEASE; SUBGINGIVAL PLAQUE; BASEMENT-MEMBRANE; RAT-BRAIN; ENZYME; METALLOENDOPEPTIDASE; COLLAGENASES; INHIBITION; THERMOLYSIN	An endopeptidase was purified to homogeneity from the cell extracts of Treponema denticola ATCC 35405 (a human oral spirochete) by a procedure that comprised dialysis, anion exchange fast protein liquid chromatography (FPLC), hydroxylapatite FPLC, immobilized metal affinity FPLC, FPLC chromatofocusing, and two consecutive gel permeation FPLC steps. The enzyme is a 62-kDa protein with an isoelectric point of 6.5-7.0. Experiments with enzyme inhibitors suggest that this enzyme is a metallopeptidase and that its activity is not dependent on sulfhydryl or serine residues. The enzyme is active on furylacryloyl-Leu-Gly-Pro-Ala (FALGPA; pH optimum near 6.25), bradykinin (Bk), and several Bk-related peptides. In FALGPA, the cleavage site is the Leu-Gly bond. An imino acid is absolutely necessary in position P'2. The shortest hydrolyzed peptide was FALGPA, the hydrolysis of which is strongly and competitively inhibited by Bk (K(i) = 5.0-mu-M). The pyrophosphate ion and phosphoramidon also inhibited the hydrolysis of FALGPA. The enzyme does not hydrolyze all typical synthetic collagenase substrates, Azocoll, Azocasein, or Type I and Type IV collagens, or any other proteins tested. In Bk-related peptides, the hydrolyzed bond was Phe5-Ser6. Since a Bk antagonist and a Bk-potentiating pentapeptide also were good substrates, it is possible that the enzyme hydrolyzes Bks and related peptides only because of the coincidental, specific amino acid sequence of those substrates. A proposal is made that since a substantial portion of the amino acid sequence of FALGPA is present in collagen (and additionally acknowledging that the furylacryloyl residue structurally resembles that of proline), the natural substrates of this enzyme may be small, soluble collagen fragments produced by other enzymes from periodontal connective tissue, and that such peptides are important for the nutrition and pathogenicity of T. denticola.			MAKINEN, KK (corresponding author), UNIV MICHIGAN,SCH DENT,DEPT BIOL & MAT SCI,ANN ARBOR,MI 48109, USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008664] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE08664-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BARRETT AJ, 1991, BIOCHEM SOC T, V19, P707, DOI 10.1042/bst0190707; BOEHRINGER H, 1984, INFECT IMMUN, V45, P155, DOI 10.1128/IAI.45.1.155-159.1984; BOND MD, 1984, BIOCHEMISTRY-US, V23, P3077, DOI 10.1021/bi00308a035; BREDDAM K, 1979, BIOCHEMISTRY-US, V18, P1563, DOI 10.1021/bi00575a028; CANALEPAROLA E, 1977, BACTERIOL REV, V41, P181, DOI 10.1128/MMBR.41.1.181-204.1977; CHAVIRA R, 1984, ANAL BIOCHEM, V136, P446, DOI 10.1016/0003-2697(84)90242-2; CHENG SL, 1983, J PERIODONTAL RES, V18, P362, DOI 10.1111/j.1600-0765.1983.tb00371.x; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; DOI E, 1981, ANAL BIOCHEM, V118, P173, DOI 10.1016/0003-2697(81)90175-5; Erdos E., 1979, HDB EXPT PHARM S, VXXV, P427; ERLANGER BF, 1961, ARCH BIOCHEM BIOPHYS, V95, P271, DOI 10.1016/0003-9861(61)90145-X; FELBER JP, 1962, BIOCHEMISTRY-US, V1, P231, DOI 10.1021/bi00908a006; FOURNIEZALUSKI MC, 1963, J MED CHEM, V26, P60; GRENIER D, 1990, INFECT IMMUN, V58, P347, DOI 10.1128/IAI.58.2.347-351.1990; HARRIS DL, 1972, VET MED SM ANIM CLIN, V67, P61; HARWOOD CS, 1984, ANNU REV MICROBIOL, V38, P161, DOI 10.1146/annurev.mi.38.100184.001113; HOLMQUIST B, 1974, J BIOL CHEM, V249, P4601; HOLT S C, 1991, Critical Reviews in Oral Biology and Medicine, V2, P177; KAM CM, 1979, BIOCHEMISTRY-US, V18, P3032, DOI 10.1021/bi00581a019; KIKUCHI M, 1988, BIOCHIM BIOPHYS ACTA, V965, P176, DOI 10.1016/0304-4165(88)90054-2; LISTGARTEN MA, 1978, J CLIN PERIODONTOL, V5, P115, DOI 10.1111/j.1600-051X.1978.tb01913.x; Loesche W. J., 1982, HOST PARASITE INTERA, P62; LOESCHE WJ, 1987, J PERIODONTOL, V58, P266, DOI 10.1902/jop.1987.58.4.266; LOESCHE WJ, 1985, J PERIODONTOL, V56, P447, DOI 10.1902/jop.1985.56.8.447; MAKINEN KK, 1987, CURR MICROBIOL, V14, P341; MAKINEN KK, 1978, BIOCHEM J, V175, P1051; MAKINEN KK, 1990, MOL MICROBIOL, V4, P1413, DOI 10.1111/j.1365-2958.1990.tb00721.x; MAKINEN KK, 1990, CURR MICROBIOL, V20, P69, DOI 10.1007/BF02094028; MAKINEN KK, 1988, ORAL MICROBIOL IMMUN, V3, P121, DOI 10.1111/j.1399-302X.1988.tb00096.x; MAKINEN PL, 1989, J BIOL CHEM, V264, P3325; MALKINEN KK, 1987, J BIOL CHEM, V262, P12488; MCDERMOTT JR, 1987, BIOCHEM BIOPH RES CO, V146, P154, DOI 10.1016/0006-291X(87)90704-2; MOORE WEC, 1985, INFECT IMMUN, V48, P507, DOI 10.1128/IAI.48.2.507-519.1985; MOORE WM, 1986, BIOCHEMISTRY-US, V25, P5189, DOI 10.1021/bi00366a031; NITZAN D, 1978, ARCH ORAL BIOL, V23, P465, DOI 10.1016/0003-9969(78)90078-X; OHTA K, 1986, INFECT IMMUN, V53, P213, DOI 10.1128/IAI.53.1.213-220.1986; OLSEN I, 1984, SCAND J DENT RES, V92, P55; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; ORLOWSKI M, 1981, BIOCHEMISTRY-US, V20, P4942, DOI 10.1021/bi00520a021; PASTER BJ, 1982, APPL ENVIRON MICROB, V43, P686, DOI 10.1128/AEM.43.3.686-693.1982; PASTER BJ, 1985, APPL ENVIRON MICROB, V50, P212, DOI 10.1128/AEM.50.2.212-219.1985; QUE XC, 1990, INFECT IMMUN, V58, P4099, DOI 10.1128/IAI.58.12.4099-4105.1990; REGOLI D, 1990, TRENDS PHARMACOL SCI, V11, P156, DOI 10.1016/0165-6147(90)90067-I; RUDOLPH AH, 1988, J AM ACAD DERMATOL, V18, P1121, DOI 10.1016/S0190-9622(88)80015-X; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SEPPA HEJ, 1978, J INVEST DERMATOL, V70, P84, DOI 10.1111/1523-1747.ep12541221; SIMONSON LG, 1988, INFECT IMMUN, V56, P726, DOI 10.1128/IAI.56.4.726-728.1988; STEWART JM, 1971, BIOCHEM PHARMACOL, V20, P1557, DOI 10.1016/0006-2952(71)90284-X; THOMAS DD, 1988, P NATL ACAD SCI USA, V85, P3608, DOI 10.1073/pnas.85.10.3608; UITTO VJ, 1988, ORAL MICROBIOL IMMUN, V3, P97, DOI 10.1111/j.1399-302X.1988.tb00092.x; UMEZAWA S, 1972, Tetrahedron Letters, V1, P97; VANWART HE, 1981, ANAL BIOCHEM, V113, P356, DOI 10.1016/0003-2697(81)90089-0; WEINBERG A, 1990, INFECT IMMUN, V58, P1720, DOI 10.1128/IAI.58.6.1720-1729.1990; WOLZ RL, 1990, ANAL BIOCHEM, V191, P314; WUNSCH E, 1963, H-S Z PHYSIOL CHEM, V333, P149, DOI 10.1515/bchm2.1963.333.1.149; ZOLFAGHARI R, 1986, ENZYME, V36, P165, DOI 10.1159/000469289; ZOLLNER H, 1989, HDB ENZYME INHIBITOR, P334	57	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14285	14293						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321141				2022-12-27	WOS:A1992JD32500077
J	PICKART, CM; HALDEMAN, MT; KASPEREK, EM; CHEN, ZJ				PICKART, CM; HALDEMAN, MT; KASPEREK, EM; CHEN, ZJ			IODINATION OF TYROSINE-59 OF UBIQUITIN SELECTIVELY BLOCKS UBIQUITINS ACCEPTOR ACTIVITY IN DIUBIQUITIN SYNTHESIS CATALYZED BY E2(25K)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER PROTEINS; MULTIUBIQUITIN CHAIN; CONJUGATING ENZYMES; DEGRADATION; E2; PROTEOLYSIS; SPECIFICITY; DERIVATIVES; SUBSTRATE; MECHANISM	Covalent ligation of multiubiquitin chains targets eukaryotic proteins for degradation. Ubiquitin-conjugating enzyme E2(25K) utilizes isolated ubiquitin as the substrate for synthesis of such chains, in which successive ubiquitin units are linked by isopeptide bonds involving the side chain of Lys-48 of one ubiquitin and the COOH group of Gly-76 of the next. During continuous synthesis of multiubiquitin chains in the presence of purified ubiquitin-activating enzyme and E2(25K), there was a slight discrimination against radioiodinated ubiquitin (2.3-fold reduction in specific radioactivity of diubiquitin relative to value expected for no discrimination). Single-turnover experiments employing stoichiometrically iodinated ubiquitin derivatives indicated that E2(25K) discriminates extremely strongly (>20-fold reduction in k(cat)/K(m) for diubiquitin synthesis) against ubiquitin that is monoiodinated at Tyr-59. The modest overall selection effect observed in continuous reactions is in part due to the occurrence of discrimination only when iodotyrosylubiquitin is the acceptor (Lys-48 donor) in diubiquitin synthesis; iodotyrosylubiquitin is kinetically competent when it is the species being transferred to native ubiquitin. The competence as acceptor of a site-directed mutant form of ubiquitin bearing a Tyr to Phe substitution at position 59 indicated that discrimination against iodotyrosylubiquitin by E2(25K) is not due to loss of the hydrogen-bonding interactions of Tyr-59. Rather, iodotyrosylubiquitin may be unable to react with the ubiquitin adduct of E2(25K) for steric reasons. Discrimination against iodotyrosylubiquitin as acceptor is unique to E2(25K) among three enzymes surveyed: iodotyrosylubiquitin is a fully competent acceptor in diubiquitin synthesis catalyzed by E2(35K) and is also utilized for multiubiquitin chain synthesis by E2(14K) and ubiquitin-protein ligase. These findings should assist in the design of future studies concerning E2(25K) structure and function.			PICKART, CM (corresponding author), SUNY BUFFALO,SCH MED & BIOMED SCI,DEPT BIOCHEM,BUFFALO,NY 14214, USA.		Chen, Zhijian/C-6039-2012	Chen, Zhijian/0000-0002-8475-8251				BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BERLETH ES, 1990, BIOCHEM BIOPH RES CO, V171, P705, DOI 10.1016/0006-291X(90)91203-5; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; COX MJ, 1986, ANAL BIOCHEM, V154, P345, DOI 10.1016/0003-2697(86)90535-X; COX MJ, 1986, ARCH BIOCHEM BIOPHYS, V250, P400, DOI 10.1016/0003-9861(86)90742-3; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HAAS A, 1990, J BIOL CHEM, V265, P21664; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1991, J BIOL CHEM, V266, P5104; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; Kumar V.-S., 1987, J MOL BIOL, V194, P531; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MONIA BP, 1990, BIO-TECHNOL, V8, P209, DOI 10.1038/nbt0390-209; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1985, J BIOL CHEM, V260, P7903; PICKART CM, 1988, J BIOL CHEM, V263, P15076; PICKART CM, 1988, J BIOL CHEM, V263, P12028; PICKART CM, 1988, UBIQUITIN, P77; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SUNG P, 1991, EMBO J, V10, P2187, DOI 10.1002/j.1460-2075.1991.tb07754.x	28	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14418	14423						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321147				2022-12-27	WOS:A1992JD32500095
J	RABBANI, SA; MAZAR, AP; BERNIER, SM; HAQ, M; BOLIVAR, I; HENKIN, J; GOLTZMAN, D				RABBANI, SA; MAZAR, AP; BERNIER, SM; HAQ, M; BOLIVAR, I; HENKIN, J; GOLTZMAN, D			STRUCTURAL REQUIREMENTS FOR THE GROWTH-FACTOR ACTIVITY OF THE AMINO-TERMINAL DOMAIN OF UROKINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; PRO-UROKINASE; CELL-SURFACE; ENDOTHELIAL-CELLS; RIBONUCLEIC-ACID; RECEPTOR; DEGRADATION; EXPRESSION; MECHANISM; MONOCYTES	High molecular weight urokinase-type plasminogen activator (uPA) in which proteolytic activity was inactivated (diisopropyl fluorophosphate (DFP)-uPA), its amino-terminal fragment (ATF, amino acids (aa) 1143), and fucosylated and defucosylated growth factor domains (GFD, aa 4-43) were tested for growth-promoting effects and binding in human SaOS-2 osteosarcoma cells and U-937 lymphoma cells. DFP-uPA, ATF, and both the fucosylated and defucosylated GFD were capable of competing with I-125-ATF for binding to both SaOS-2 and U-937 cells. DFP-uPA, ATF, and fucosylated GFD were also mitogenic in SaOS-2 cells and increased cell numbers. However, defucosylated GFD was nonmitogenic in SaOS-2 cells and did not stimulate cell proliferation, even though it bound to these cells in a manner equivalent to the fucosylated GFD. A nonglycosylated high molecular weight uPA expressed and purified from Escherichia coli inhibited I-125-ATF binding to SaOS-2 cells but was also nonmitogenic. No mitogenic activity was observed in U-937 cells treated with the uPA forms capable of eliciting a mitogenic response in SaOS-2 cells. Proteolytically prepared kringle domain (aa 47-135) and low molecular weight uPA (aa 144-411) did not compete for I-125-ATF binding and did not elicit any mitogenic response in either of the cell lines tested. In addition, tissue plasminogen activator (tPA), which has been shown to be homologous to uPA in its growth factor domain and is also fucosylated, did not inhibit I-125-ATF binding nor elicit any mitogenic response. These results demonstrate that the GFD, implicated in binding to the uPA receptor, is also responsible for growth factor like activity in SaOS-2 cells and that the fucosylation at Thr18 within this domain may serve as a molecular trigger in eliciting this response.	ABBOTT LABS,DIV PHARMACEUT PROD,THROMBOLYT VENTURE,ABBOTT PK,IL 60064; MCGILL UNIV,ROYAL VICTORIA HOSP,DEPT MED,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,ROYAL VICTORIA HOSP,DEPT PHYSIOL,MONTREAL H3A 1A1,QUEBEC,CANADA	Abbott Laboratories; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital				rabbani, shafaat/0000-0001-5594-3899	NCI NIH HHS [R01 CA37126] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037126] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPELLA E, 1987, J BIOL CHEM, V262, P4437; BLASI F, 1990, CELL DIFFER DEV, V32, P247, DOI 10.1016/0922-3371(90)90037-W; BOYD D, 1988, CANCER RES, V48, P3112; BUKO AM, 1991, P NATL ACAD SCI USA, V88, P3992, DOI 10.1073/pnas.88.9.3992; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FIBBI G, 1988, EXP CELL RES, V179, P385, DOI 10.1016/0014-4827(88)90277-7; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GUDEWICZ PW, 1987, BIOCHEM BIOPH RES CO, V147, P1176, DOI 10.1016/S0006-291X(87)80193-6; GUREWICH V, 1984, J CLIN INVEST, V73, P1731, DOI 10.1172/JCI111381; HARRIS RJ, 1991, BIOCHEMISTRY-US, V30, P2311, DOI 10.1021/bi00223a004; HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665; HE CJ, 1991, BIOCHEM BIOPH RES CO, V176, P1408, DOI 10.1016/0006-291X(91)90443-B; HEARING VJ, 1988, CANCER RES, V48, P1270; KENTZER EJ, 1990, BIOCHEM BIOPH RES CO, V171, P401, DOI 10.1016/0006-291X(90)91407-J; KIRCHHEIMER J, 1984, BIOCHIM BIOPHYS ACTA, V797, P256, DOI 10.1016/0304-4165(84)90129-6; KIRCHHEIMER JC, 1989, P NATL ACAD SCI USA, V86, P5424, DOI 10.1073/pnas.86.14.5424; KOUTSILIERIS M, 1987, J ENDOCRINOL, V115, P447, DOI 10.1677/joe.0.1150447; LO KM, 1991, BIOCHIM BIOPHYS ACTA, V1088, P217; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MARCOTTE PA, 1992, FIBRINOLYSIS, V6, P57, DOI 10.1016/0268-9499(92)90095-Y; MAZAR AP, 1992, FIBRINOLYSIS, V6, P49, DOI 10.1016/0268-9499(92)90094-X; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; NOVOKHATNY V, 1992, IN PRESS J BIOL CHEM, V267; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; PANNELL R, 1986, BLOOD, V67, P1215; PLOUG M, 1991, J BIOL CHEM, V266, P1926; RABBANI SA, 1990, BIOCHEM BIOPH RES CO, V173, P1058, DOI 10.1016/S0006-291X(05)80893-9; ROBBIATI F, 1990, FIBRINOLYSIS, V4, P53, DOI 10.1016/S0268-9499(05)80041-4; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3574, DOI 10.1021/bi00875a028; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STUMP DC, 1986, J BIOL CHEM, V261, P7120; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; ULRICH A, 1984, EMBO J, V3, P361; ZAMARRON C, 1984, THROMB HAEMOSTASIS, V52, P27	40	233	242	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14151	14156						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321137				2022-12-27	WOS:A1992JD32500058
J	LASCU, I; CHAFFOTTE, A; LIMBOURGBOUCHON, B; VERON, M				LASCU, I; CHAFFOTTE, A; LIMBOURGBOUCHON, B; VERON, M			A PRO/SER SUBSTITUTION IN NUCLEOSIDE DIPHOSPHATE KINASE OF DROSOPHILA-MELANOGASTER (MUTATION KILLER-OF-PRUNE) AFFECTS STABILITY BUT NOT CATALYTIC EFFICIENCY OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-METASTASIS; PROTEIN ACTIVATION; ADENYLATE KINASE; BINDING PROTEINS; PURIFICATION; GENE; RAT; DIPHOSPHOKINASE; PHOSPHORYLATION; FLUORESCENCE	Nucleoside diphosphate kinase of Drosophila, recently identified as the product of the awd gene, is essential for larval development. The conditional lethal mutation Killer of prune maps to the same gene. We purified the nucleoside diphosphate kinases from wild-type and mutant larvae by a simple procedure involving affinity chromatography on blue Sepharose. Both proteins are purified as hexamers in their native state. The mutant protein, which carries a serine instead of proline at position 97, has structural properties and catalytic efficiency that are very similar to the wild-type protein. However, the mutant protein has a much lower stability to denaturation by heat and urea. Following dilution of urea with buffer the urea-denaturated mutant nucleoside diphosphate kinase accumulates as folded monomers and cannot recover its quaternary structure and enzymatic activity. In contrast, the wild-type enzyme recovers hexameric structure and activity. This suggests that the mutation affects the folding/assembly pathway without affecting the function of the mature protein once folded and assembled into the mature hexameric structure.	INST PASTEUR, UNITE BIOCHIM CELLULAIRE, URA 1129, F-75724 PARIS 15, FRANCE; CNRS, CTR GENET MOLEC, F-91198 GIF SUR YVETTE, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								Agarwal R P, 1978, Methods Enzymol, V51, P376; ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG YC, 1973, BIOCHEMISTRY-US, V12, P5, DOI 10.1021/bi00725a002; DAVIES JR, 1981, ANAL BIOCHEM, V114, P19, DOI 10.1016/0003-2697(81)90444-9; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; DOBELN UV, 1976, BIOCHEM BIOPH RES CO, V72, P1160, DOI 10.1016/S0006-291X(76)80253-7; DUMAS C, 1991, J MOL BIOL, V217, P239, DOI 10.1016/0022-2836(91)90537-G; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; FANE B, 1991, J BIOL CHEM, V266, P11640; GARCES E, 1969, BIOCHEMISTRY-US, V8, P633, DOI 10.1021/bi00830a026; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GILLES AM, 1986, P NATL ACAD SCI USA, V83, P5798, DOI 10.1073/pnas.83.16.5798; GUISO N, 1984, J BIOL CHEM, V259, P8713; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HUITOREL P, 1984, EUR J BIOCHEM, V144, P233, DOI 10.1111/j.1432-1033.1984.tb08455.x; KEZDI M, 1976, ANAL BIOCHEM, V76, P361, DOI 10.1016/0003-2697(76)90295-5; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIKKAWA S, 1991, J BIOL CHEM, V266, P12795; KIMURA N, 1988, BIOCHEM BIOPH RES CO, V151, P248, DOI 10.1016/0006-291X(88)90586-4; KIMURA N, 1990, J BIOL CHEM, V265, P15744; KOSHY TI, 1990, P NATL ACAD SCI USA, V87, P8697, DOI 10.1073/pnas.87.22.8697; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LASCU I, 1981, ANAL BIOCHEM, V113, P207, DOI 10.1016/0003-2697(81)90068-3; LASCU I, 1983, EUR J BIOCHEM, V135, P497, DOI 10.1111/j.1432-1033.1983.tb07679.x; LASCU I, 1979, BIOCHEMISTRY-US, V18, P4818, DOI 10.1021/bi00589a009; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; MESSMER CH, 1985, BIOCHEMISTRY-US, V24, P7172, DOI 10.1021/bi00346a023; MILLER LK, 1971, P NATL ACAD SCI USA, V68, P2298, DOI 10.1073/pnas.68.9.2298; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; NICKERSON JA, 1984, J BIOL CHEM, V259, P1297; OHTSUKI K, 1986, BIOCHIM BIOPHYS ACTA, V882, P322, DOI 10.1016/0304-4165(86)90254-0; OREVI N, 1975, MUTAT RES, V33, P193, DOI 10.1016/0027-5107(75)90195-5; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; PALMIERI R, 1973, J BIOL CHEM, V248, P4486; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; PRAKASH V, 1981, ARCH BIOCHEM BIOPHYS, V210, P455, DOI 10.1016/0003-9861(81)90209-5; PRESECAN E, 1989, FEBS LETT, V250, P629, DOI 10.1016/0014-5793(89)80811-7; RANDAZZO PA, 1991, SCIENCE, V254, P850, DOI 10.1126/science.1658935; RICHARD JM, 1975, BIOCHIMIE, V57, P991, DOI 10.1016/S0300-9084(75)80225-2; ROBINSON JB, 1981, J BIOL CHEM, V256, P769; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; RUGGIERI R, 1991, NATURE, V353, P390, DOI 10.1038/353390a0; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STURTEVANT AH, 1956, GENETICS, V41, P118; TENG DHF, 1991, GENETICS, V128, P373; TENG DHF, 1991, NATURE, V353, P437, DOI 10.1038/353437a0; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; WIELAND T, 1991, EUR J BIOCHEM, V196, P707, DOI 10.1111/j.1432-1033.1991.tb15869.x; WIELAND T, 1989, FEBS LETT, V245, P189, DOI 10.1016/0014-5793(89)80219-4	55	124	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12775	12781						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1320004				2022-12-27	WOS:A1992HZ48300060
J	MCKNIGHT, GL; REASONER, J; GILBERT, T; SUNDQUIST, KO; HOKLAND, B; MCKERNAN, PA; CHAMPAGNE, J; JOHNSON, CJ; BAILEY, MC; HOLLY, R; OHARA, PJ; ORAM, JF				MCKNIGHT, GL; REASONER, J; GILBERT, T; SUNDQUIST, KO; HOKLAND, B; MCKERNAN, PA; CHAMPAGNE, J; JOHNSON, CJ; BAILEY, MC; HOLLY, R; OHARA, PJ; ORAM, JF			CLONING AND EXPRESSION OF A CELLULAR HIGH-DENSITY LIPOPROTEIN-BINDING PROTEIN THAT IS UP-REGULATED BY CHOLESTEROL LOADING OF CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-IV; AORTIC ENDOTHELIAL-CELLS; SMOOTH-MUSCLE CELLS; RECEPTOR ACTIVITY; PLASMA-MEMBRANE; RAT-LIVER; INTRACELLULAR MEMBRANES; RADIATION INACTIVATION; CULTURED FIBROBLASTS; ADIPOSE-CELLS	Plasma membranes of cultured cells contain high affinity receptors for high density lipoprotein (HDL) that appear to mediate removal of excess intracellular cholesterol. Recent studies using ligand blot analysis have identified a 110-kDa membrane protein which has features predicted for an HDL receptor, in that it preferentially binds HDL apolipoproteins and undergoes up-regulation in response to cholesterol loading of cells. In this study, we isolated a cDNA clone from an expression library using an antibody raised against partially purified 110-kDa HDL-binding protein. This clone encodes a novel cell protein, designated HBP, comprised mostly of 14 imperfect tandem repeats of approximately 70 amino acids in length. Each repeat appears to contain two amphipathic helices. Expression of HBP in cultured cells was increased severalfold when cells were loaded with cholesterol, as evident by increases in both HBP mRNA and membrane-associated protein. Overexpression of HBP in mammalian cell transfectants was associated with higher HDL binding to isolated cell protein and with modest increases in HDL binding to the cell surface. Proteins identified by ligand blot analysis had lower apparent M(r) than the primary HBP gene product and varied in M(r) and in HDL binding activity between cell types, suggesting that HBP undergoes cell-specific processing. These results provide preliminary evidence that HBP is a component of a cellular pathway that facilitates removal of excess cholesterol from cells, perhaps through its interaction with HDL. However, the predicted structure of HBP does not conform to that of any known receptor, suggesting that it does not function as a classic plasma membrane receptor.	UNIV WASHINGTON,DEPT MED,RG-26,SEATTLE,WA 98195; ZYMOGENET INC,SEATTLE,WA 98105	University of Washington; University of Washington Seattle; Zymogenet Inc.					NHLBI NIH HHS [HL31194] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031194] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALT FW, 1978, J BIOL CHEM, V253, P1357; AVIRAM M, 1989, J LIPID RES, V30, P65; BARBARAS R, 1990, BIOCHEM J, V269, P767, DOI 10.1042/bj2690767; BIESBROECK RC, 1983, J CLIN INVEST, V61, P525; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BIRD P, 1990, J BIOL CHEM, V265, P8420; BRINTON EA, 1985, ARTERIOSCLEROSIS, V5, P329, DOI 10.1161/01.ATV.5.4.329; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DELAHODDE A, 1986, NUCLEIC ACIDS RES, V14, P9213, DOI 10.1093/nar/14.22.9213; DELISI C, 1985, P NATL ACAD SCI USA, V82, P7048, DOI 10.1073/pnas.82.20.7048; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FERRERI K, 1990, ENDOCRINOLOGY, V126, P2137, DOI 10.1210/endo-126-4-2137; FIDGE NH, 1985, J BIOL CHEM, V260, P3570; FIDGE NH, 1986, FEBS LETT, V199, P265, DOI 10.1016/0014-5793(86)80492-6; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GHISELLI G, 1990, BIOCHIM BIOPHYS ACTA, V1044, P173, DOI 10.1016/0005-2760(90)90234-O; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GRAHAM DL, 1987, J BIOL CHEM, V262, P7439; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KITCHER SA, 1978, ANAL BIOCHEM, V88, P29, DOI 10.1016/0003-2697(78)90395-0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE Y, 1985, J BIOL CHEM, V260, P5592; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUO CC, 1986, J MOL BIOL, V187, P325, DOI 10.1016/0022-2836(86)90436-5; MENDEL CM, 1988, BIOCHIM BIOPHYS ACTA, V961, P188, DOI 10.1016/0005-2760(88)90113-0; MENDEL CM, 1988, J BIOL CHEM, V263, P1314; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MONACO L, 1987, EMBO J, V6, P3253, DOI 10.1002/j.1460-2075.1987.tb02643.x; MOSS DW, 1974, METHOD ENZYMAT AN, P92; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OJCIUS DM, 1991, TRENDS BIOCHEM SCI, V16, P225, DOI 10.1016/0968-0004(91)90090-I; OLIVER C, 1989, J HISTOCHEM CYTOCHEM, V37, P1645, DOI 10.1177/37.11.2553801; OPPENHEIMER MJ, 1988, J BIOL CHEM, V263, P19318; OPPENHEIMER MJ, 1987, ARTERIOSCLEROSIS, V7, P325, DOI 10.1161/01.ATV.7.4.325; Oram J F, 1986, Methods Enzymol, V129, P645; ORAM JF, 1987, J BIOL CHEM, V262, P2405; ORAM JF, 1983, J CLIN INVEST, V72, P1611, DOI 10.1172/JCI111120; ORAM JF, 1983, ARTERIOSCLEROSIS, V3, P420, DOI 10.1161/01.ATV.3.5.420; ORAM JF, 1991, ARTERIOSCLER THROMB, V11, P403, DOI 10.1161/01.ATV.11.2.403; PAYASTRE B, 1988, BIOCHIM BIOPHYS ACTA, V939, P355; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Reichlin M, 1980, Methods Enzymol, V70, P159; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVION N, 1988, ARTERIOSCLEROSIS, V8, P178, DOI 10.1161/01.ATV.8.2.178; SCHMITZ G, 1985, EMBO J, V4, P2773, DOI 10.1002/j.1460-2075.1985.tb04003.x; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SELDEN RF, 1987, CURRENT PROTOCOLS MO; SLOOP CH, 1987, J LIPID RES, V28, P225; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; STEIN O, 1986, BIOCHIM BIOPHYS ACTA, V878, P7, DOI 10.1016/0005-2760(86)90337-1; STEINMETZ A, 1990, J BIOL CHEM, V265, P7859; THERET N, 1990, BIOCHEM BIOPH RES CO, V173, P1361, DOI 10.1016/S0006-291X(05)80938-6; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOZUKA M, 1989, BIOCHEM J, V261, P239, DOI 10.1042/bj2610239; VIA DP, 1985, BIOCHIM BIOPHYS ACTA, V833, P417, DOI 10.1016/0005-2760(85)90099-2; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	67	150	154	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12131	12141						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1318310				2022-12-27	WOS:A1992HY94700073
J	ANDERSSON, M; OSTMAN, A; BACKSTROM, G; HELLMAN, U; GEORGENASCIMENTO, C; WESTERMARK, B; HELDIN, CH				ANDERSSON, M; OSTMAN, A; BACKSTROM, G; HELLMAN, U; GEORGENASCIMENTO, C; WESTERMARK, B; HELDIN, CH			ASSIGNMENT OF INTERCHAIN DISULFIDE BONDS IN PLATELET-DERIVED GROWTH-FACTOR (PDGF) AND EVIDENCE FOR AGONIST ACTIVITY OF MONOMERIC PDGF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-TYPE RECEPTOR; TYROSINE KINASE; A-CHAIN; IDENTIFICATION; CDNA; LOCALIZATION; PROTEIN; DIMERIZATION; ESTABLISHES; EXPRESSION	Platelet-derived growth factor (PDGF) is a dimeric factor stabilized by disulfide bonds. Using an approach involving partial reduction of PDGF, we have identified the 2nd and 4th cysteine residues in the PDGF chains as the cysteine residues forming interchain disulfide bonds. Analysis of PDGF mutants in which the 2nd and 4th cysteine residues were mutated to serine residues revealed that the disulfide bonds are arranged in a cross-wise manner, with the 2nd cysteine residue in one chain being linked to the 4th cysteine residue in the other. A PDGF B-chain mutant, in which both the 2nd and 4th cysteine residues were substituted with serine residues, migrated as a monomer in sodium dodecyl sulfate gel electrophoresis and retained receptor binding activity. When analyzed in receptor dimerization and autophosphorylation assays, this mutant showed agonistic activity. Thus, structural information has been obtained that will allow the large scale production of properly folded monomeric PDGF, as well as design of specific PDGF heterodimers.	UNIV HOSP UPPSALA,DEPT PATHOL,S-75185 UPPSALA,SWEDEN; CHIRON CORP,EMERYVILLE,CA 94608	Uppsala University; Uppsala University Hospital; Novartis	ANDERSSON, M (corresponding author), BIOMED CTR,LUDWIG INST CANC RES,BOX 595,S-75124 UPPSALA,SWEDEN.							ARAKAWA T, 1991, J BIOL CHEM, V266, P18942; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; CLEMENTS JM, 1991, EMBO J, V10, P4113, DOI 10.1002/j.1460-2075.1991.tb04988.x; EK B, 1984, J BIOL CHEM, V259, P1145; Eriksson A, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008867; GIESE N, 1990, MOL CELL BIOL, V10, P5496, DOI 10.1128/MCB.10.10.5496; GIESE NA, 1987, SCIENCE, V236, P1315, DOI 10.1126/science.3035718; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; JAUMANN M, 1991, BIOCHEMISTRY-US, V30, P3303, DOI 10.1021/bi00227a019; JOHNSSON A, 1984, EMBO J, V3, P921, DOI 10.1002/j.1460-2075.1984.tb01908.x; JOSEPHS SF, 1984, SCIENCE, V225, P636, DOI 10.1126/science.6740330; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; OSTMAN A, 1991, J BIOL CHEM, V266, P10073; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; SAUER MK, 1988, MOL CELL BIOL, V8, P1011, DOI 10.1128/MCB.8.3.1011; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; THYBERG J, 1990, J CELL SCI, V97, P219; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	37	51	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11260	11266						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317862				2022-12-27	WOS:A1992HX16900053
J	DEJONGE, BLM; CHANG, YS; GAGE, D; TOMASZ, A				DEJONGE, BLM; CHANG, YS; GAGE, D; TOMASZ, A			PEPTIDOGLYCAN COMPOSITION IN HETEROGENEOUS TN551 MUTANTS OF A METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS STRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSERTIONAL INACTIVATION; LEVEL	It was shown that Tn551 inactivation of two chromosomal (so-called auxiliary) loci other than the mec gene result in a dramatic reduction of methicillin resistance and decreased cell wall turnover and autolytic capacity in a methicillin-resistant Staphylococcus aureus strain (de Jonge, B. L. M., de Lencastre, H., and Tomasz, A. (1990) J. Bacteriol. 173, 1105-1110). To understand the mechanistic basis of these phenomena we have examined the status of the autolytic enzymes and the muropeptide composition of peptidoglycan using reversed-phase high-performance liquid chromatography and mass spectral analyses. While no differences could be detected in the number of autolytic hydrolases, the mutants showed major changes in peptidoglycan composition. Nine prominent muropeptides of the parental strain each carrying a pentaglycyl substituent were missing from the cell wall of one group of mutants. The second mutant lacked four parental muropeptides which were composed of the unsubstituted disaccharide pentapeptide and its alanyl-tetraglycine derivative. The auxiliary genes are genetic determinants involved with the biosynthesis of peptidoglycan precursors, the presence of which in the cell wall may be needed for optimal cell wall turnover.	ROCKEFELLER UNIV, MICROBIOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA; MICHIGAN STATE UNIV, DEPT BIOCHEM, MICHIGAN STATE UNIV NIH MASS SPECTROMETRY FACIL, E LANSING, MI 48824 USA	Rockefeller University; Michigan State University			DeJonge, Boudewijn/AAR-6717-2020	Chang, Yoon-Seok/0000-0002-0623-2932; Tomasz, Alexander/0000-0003-1520-1983	NCRR NIH HHS [RR-00480] Funding Source: Medline; NIAID NIH HHS [R01-AI16794] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000480] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BERGERBACHI B, 1983, FEMS MICROBIOL LETT, V20, P305; BUMSTED RM, 1968, J BIOL CHEM, V243, P779; DEJONGE BLM, 1991, J BACTERIOL, V173, P1105, DOI 10.1128/jb.173.3.1105-1110.1991; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; DELENCASTRE H, 1991, ANTIMICROB AGENTS CH, V35, P632, DOI 10.1128/AAC.35.4.632; KAMIRYO T, 1972, J BIOL CHEM, V247, P6306; KORNBLUM J, 1986, EUR J CLIN MICROBIOL, V5, P714, DOI 10.1007/BF02013311; MAIDHOF H, 1991, J BACTERIOL, V173, P3507, DOI 10.1128/jb.173.11.3507-3513.1991; MATSUHAS.M, 1967, J BIOL CHEM, V242, P3191; MATTHEWS P, 1990, ANTIMICROB AGENTS CH, V34, P1777, DOI 10.1128/AAC.34.9.1777; MURAKAMI K, 1989, J BACTERIOL, V171, P874, DOI 10.1128/jb.171.2.874-879.1989; SUGAI M, 1990, J BACTERIOL, V172, P6494, DOI 10.1128/jb.172.11.6494-6498.1990; THORNDIK.J, 1969, BIOCHEM BIOPH RES CO, V35, P642, DOI 10.1016/0006-291X(69)90452-5; TOMASZ A, 1991, ANTIMICROB AGENTS CH, V35, P124, DOI 10.1128/AAC.35.1.124; TOMASZ A, 1991, MOL BIOL STAPHYLOCOC, P565; WILLIAMSON R, 1980, ANTIMICROB AGENTS CH, V18, P629, DOI 10.1128/AAC.18.4.629	16	76	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11255	11259						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317861				2022-12-27	WOS:A1992HX16900052
J	KUSANO, T; TAKESHIMA, T; SUGAWARA, K; INOUE, C; SHIRATORI, T; YANO, T; FUKUMORI, Y; YAMANAKA, T				KUSANO, T; TAKESHIMA, T; SUGAWARA, K; INOUE, C; SHIRATORI, T; YANO, T; FUKUMORI, Y; YAMANAKA, T			MOLECULAR-CLONING OF THE GENE ENCODING THIOBACILLUS-FERROOXIDANS FE(II) OXIDASE - HIGH HOMOLOGY OF THE GENE-PRODUCT WITH HIPIP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURPLE PHOTOTROPHIC BACTERIUM; SODIUM DODECYL-SULFATE; POLYACRYLAMIDE-GEL ELECTROPHORESIS; REDOX-POTENTIAL FERREDOXIN; AMINO-ACID SEQUENCE; TRANSFER-RNA GENES; NUCLEOTIDE-SEQUENCE; ECTOTHIORHODOSPIRA-HALOPHILA; ESCHERICHIA-COLI; PROTEINS	The amino-terminal sequence of Thiobacillus ferrooxidans Fe(II) oxidase (linked to cytochrome c552) was determined, and the iro gene that encodes this enzyme was cloned using degenerate oligonucleotides as a probe. The DNA sequence of a region (856 base pairs) which encompasses the iro gene revealed that the enzyme was encoded by a 273-base pair open reading frame and consists of 90 amino acids, including a possible 37-residue signal sequence. The iro gene seems to be transcribed independently of any other gene because the transcriptional products are 0.45 and 0.6 kilobases in size. Current protein databases revealed that the iro gene product is a new member of the high redox potential iron sulfur proteins, which generally function in electron transport but do not show enzymatic activity.	DOWA MIN CO LTD,CENT RES LAB,HACHIOJI,TOKYO 192,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT LIFE SCI,YOKOHAMA,KANAGAWA 227,JAPAN	Tokyo Institute of Technology	KUSANO, T (corresponding author), AKITA PREFECTURAL COLL AGR,INST BIOTECHNOL,PLANT GENET ENGN LAB,OHGATA,AKITA 01004,JAPAN.		Inoue, Chihiro/N-2974-2019; Inoue, Chihiro/B-7469-2014; Fukumori, Yoshihiro/J-2483-2014	Inoue, Chihiro/0000-0002-2270-8988				Bartsch R G, 1978, Methods Enzymol, V53, P329; BOESTEN B, 1987, GENE, V55, P153, DOI 10.1016/0378-1119(87)90259-9; BOSSI L, 1983, MOL GEN GENET, V192, P163, DOI 10.1007/BF00327662; BREITER DR, 1991, J BIOL CHEM, V266, P18660; CHATTORAJ DK, 1985, P NATL ACAD SCI USA, V82, P2588, DOI 10.1073/pnas.82.9.2588; COX JC, 1978, BIOCHEM J, V174, P497, DOI 10.1042/bj1740497; DUBY A, 1987, CURRENT PROTOCOLS MO; FRY IV, 1986, ARCH BIOCHEM BIOPHYS, V246, P650, DOI 10.1016/0003-9861(86)90321-8; FUKUMORI Y, 1988, FEMS MICROBIOL LETT, V50, P169; GREEN CJ, 1983, NUCLEIC ACIDS RES, V11, P5763, DOI 10.1093/nar/11.16.5763; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HUGHES MN, 1989, METALS MICROORGANISM, P198; INGLEDEW WJ, 1982, BIOCHIM BIOPHYS ACTA, V683, P89, DOI 10.1016/0304-4173(82)90007-6; INOUE C, 1989, GENE, V84, P47, DOI 10.1016/0378-1119(89)90138-8; Jessee J., 1986, FOCUS, V8, P9; KAI M, 1989, BIOCHEM BIOPH RES CO, V160, P839, DOI 10.1016/0006-291X(89)92510-2; KRISHNAMOORTHI R, 1986, BIOCHEMISTRY-US, V25, P60, DOI 10.1021/bi00349a010; KUSANO T, 1991, CURR MICROBIOL, V22, P35, DOI 10.1007/BF02106210; KUSANO T, 1991, J BACTERIOL, V173, P7313, DOI 10.1128/jb.173.22.7313-7323.1991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARUE B, 1981, J BIOL CHEM, V256, P1539; LEWIN B, 1990, GENES; MEYER TE, 1983, P NATL ACAD SCI-BIOL, V80, P6740, DOI 10.1073/pnas.80.22.6740; MEYER TE, 1990, BIOCHIM BIOPHYS ACTA, V1017, P118, DOI 10.1016/0005-2728(90)90142-Q; MEYER TE, 1982, ADV PROTEIN CHEM, V35, P105, DOI 10.1016/S0065-3233(08)60469-6; MICHAELIS S, 1982, ANNU REV MICROBIOL, V36, P435, DOI 10.1146/annurev.mi.36.100182.002251; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; NAKAJIMA N, 1982, J BIOL CHEM, V257, P1113; NARHI LO, 1988, ARCH BIOCHEM BIOPHYS, V261, P161, DOI 10.1016/0003-9861(88)90114-2; NORDLING M, 1990, FEBS LETT, V276, P98, DOI 10.1016/0014-5793(90)80517-M; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; PRETORIUS IM, 1987, J BACTERIOL, V169, P367, DOI 10.1128/jb.169.1.367-370.1987; RAWLINGS DE, 1987, GENE, V53, P211, DOI 10.1016/0378-1119(87)90009-6; RAWLINGS DE, 1991, ADV GENE TECHNOL, V2, P215; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SILVERMAN MP, 1959, J BACTERIOL, V77, P642, DOI 10.1128/JB.77.5.642-647.1959; TEDRO SM, 1981, J BIOL CHEM, V256, P731; TEDRO SM, 1985, ARCH BIOCHEM BIOPHYS, V241, P656, DOI 10.1016/0003-9861(85)90592-2; TEDRO SM, 1985, ARCH BIOCHEM BIOPHYS, V239, P94, DOI 10.1016/0003-9861(85)90815-X; VENEGAS A, 1988, NUCLEIC ACIDS RES, V16, P8179, DOI 10.1093/nar/16.16.8179; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WAKAO N, 1991, J GEN APPL MICROBIOL, V37, P35, DOI 10.2323/jgam.37.35; WAKAO N, 1982, J GEN APPL MICROBIOL, V28, P331, DOI 10.2323/jgam.28.331; WOLFE SA, 1988, J BIOL CHEM, V263, P19147; YAMANAKA T, 1991, NEW ERA BIOENERGETIC, P223	47	68	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11242	11247						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317860				2022-12-27	WOS:A1992HX16900050
J	SHAH, S; LANCE, P; SMITH, TJ; BERENSON, CS; COHEN, SA; HORVATH, PJ; LAU, JTY; BAUMANN, H				SHAH, S; LANCE, P; SMITH, TJ; BERENSON, CS; COHEN, SA; HORVATH, PJ; LAU, JTY; BAUMANN, H			NORMAL-BUTYRATE REDUCES THE EXPRESSION OF BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE IN HEP-G2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRIEND-ERYTHROLEUKEMIA CELLS; TISSUE-SPECIFIC EXPRESSION; MIXED LYMPHOCYTE-REACTION; VOLATILE FATTY-ACIDS; SODIUM-BUTYRATE; RIBONUCLEIC-ACID; ALPHA-2->6 SIALYLTRANSFERASE; GANGLIOSIDE EXPRESSION; HISTONE MODIFICATION; MOUSE FIBROBLASTS	n-Butyrate, a short chain fatty acid that is produced by colonic bacterial fermentation, is detectable in portal blood and induces differentiation in various human neoplastic cell lines. Earlier reports indicated approximately 20-fold induction in vitro by n-butyrate of the sialyltransferase that catalyzes terminal glycosylation of G(M3) ganglioside in HeLa and colon cancer cells. We previously isolated a 1.3-kilobase cDNA for a human beta-galactoside alpha-2,6-sialyltransferase, for which N-linked glycoproteins are the acceptors. We report here that treatment of Hep G2 cells with 5 mm n-butyrate for 24 h reduced beta-galactoside alpha-2,6-sialyltransferase mRNA levels by approximately 90%. Reductions in mRNA level were followed by approximately 75 and approximately 90% reductions, respectively, in specific beta-galactoside alpha-2,6-sialyltransferase enzyme activity after treatment for 24 and 36 h with 5 mm n-butyrate. However, in contrast with earlier reports of enhanced ganglioside synthesis in response to n-butyrate treatment, incubation of Hep G2 cells with n-butyrate did not alter the ganglioside pattern as assessed by thin layer chromatography of lipids extracted from treated cells. Nuclear run-on reactions indicated that the rate of transcription of beta-galactoside, alpha-2,6-sialyltransferase was not altered by treatment with 5 mm n-butyrate for 24 h, but the effects of this treatment on cytoplasmic levels of beta-galactoside alpha-2,6-sialyltransferase mRNA were largely negated by co-treatment with actinomycin D or cycloheximide. Therefore, our results show that n-butyrate reduces expression of mature beta-galactoside alpha-2,6-sialyltransferase mRNA by post-transcriptional mechanisms.	DEPT VET AFFAIRS MED CTR, DEPT MED, GASTROINTESTINAL UNIT 111G, 3495 BAILEY AVE, BUFFALO, NY 14215 USA; SUNY BUFFALO, NUTR PROGRAM, BUFFALO, NY 14215 USA; ROSWELL PK CANC INST, DEPT MOLEC & CELLULAR BIOL, BUFFALO, NY 14263 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Roswell Park Cancer Institute			Smith, Terry/ABG-1360-2020; Lance, Peter/I-2196-2014	Lance, Peter/0000-0003-2944-1881; Smith, Terry/0000-0002-6279-9685	NCI NIH HHS [CA28835] Funding Source: Medline; NIDDK NIH HHS [DK43649] Funding Source: Medline; NIGMS NIH HHS [GM38195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BERENSON CS, 1991, J LEUKOCYTE BIOL, V50, P393, DOI 10.1002/jlb.50.4.393; BERENSON CS, 1989, J LEUKOCYTE BIOL, V45, P221, DOI 10.1002/jlb.45.3.221; BLOOM EJ, 1989, PANCREAS, V4, P59, DOI 10.1097/00006676-198902000-00009; BOFFA LC, 1981, J BIOL CHEM, V256, P9612; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESALIER RS, 1990, CANCER RES, V50, P1299; BROCKHAUSEN I, 1991, CANCER RES, V51, P3136; BURNS LJ, 1988, BLOOD, V72, P1536; CHAN YL, 1983, NUCLEIC ACIDS RES, V11, P7819, DOI 10.1093/nar/11.22.7819; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTMAN JK, 1980, J CELL BIOL, V86, P366, DOI 10.1083/jcb.86.2.366; CUMMINGS JH, 1987, GUT, V28, P1221, DOI 10.1136/gut.28.10.1221; DANKERT J, 1981, CLIN CHIM ACTA, V110, P301, DOI 10.1016/0009-8981(81)90359-4; DANNA JA, 1980, BIOCHEMISTRY-US, V19, P4331, DOI 10.1021/bi00559a029; ERNST LK, 1989, J BIOL CHEM, V264, P3436; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHMAN PH, 1976, ARCH BIOCHEM BIOPHYS, V172, P618, DOI 10.1016/0003-9861(76)90116-8; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; JOZIASSE DH, 1985, J BIOL CHEM, V260, P4941; KIM YS, 1980, CANCER-AM CANCER SOC, V45, P1185, DOI 10.1002/1097-0142(19800315)45:5+<1185::AID-CNCR2820451324>3.0.CO;2-W; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LANCE P, 1989, BIOCHEM BIOPH RES CO, V164, P225, DOI 10.1016/0006-291X(89)91706-3; LEDER A, 1975, CELL, V5, P319, DOI 10.1016/0092-8674(75)90107-5; MELKERSONWATSON LJ, 1991, J BIOL CHEM, V266, P4448; NAKAGAWA T, 1985, BRIT J CANCER, V51, P357, DOI 10.1038/bjc.1985.47; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHANLON TP, 1989, J BIOL CHEM, V264, P17389; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PILLER F, 1988, J BIOL CHEM, V263, P15146; POWELL LD, 1985, J IMMUNOL, V135, P714; POWELL LD, 1987, J IMMUNOL, V139, P262; RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0; ROEDIGER WEW, 1980, GUT, V21, P793, DOI 10.1136/gut.21.9.793; SADLER JE, 1979, J BIOL CHEM, V254, P4434; SAITO H, 1991, INT J CANCER, V48, P291, DOI 10.1002/ijc.2910480223; SAMUELS HH, 1980, J BIOL CHEM, V255, P2499; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; Seber G., 1989, NONLINEAR REGRESSION; SMETS LA, 1983, BIOCHIM BIOPHYS ACTA, V738, P237, DOI 10.1016/0304-419X(83)90006-9; SMITH TJ, 1987, J CLIN INVEST, V79, P1493, DOI 10.1172/JCI112979; STAECKER JL, 1987, BIOCHEM BIOPH RES CO, V147, P78, DOI 10.1016/S0006-291X(87)80089-X; STANLEY F, 1984, J BIOL CHEM, V259, P9768; STERNER R, 1981, J BIOL CHEM, V256, P8892; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; TORIBARA NW, 1989, CANCER RES, V49, P3321; VERNAY M, 1984, BRIT J NUTR, V52, P419, DOI 10.1079/BJN19840107; VIDALI G, 1978, P NATL ACAD SCI USA, V75, P2239, DOI 10.1073/pnas.75.5.2239; WANG XC, 1989, J BIOL CHEM, V264, P1854; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WINTERSBERGER E, 1983, J CELL BIOCHEM, V21, P239, DOI 10.1002/jcb.240210306; YOHE HC, 1991, J IMMUNOL, V146, P1900; YOHE HC, 1986, J IMMUNOL, V137, P3921	60	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10652	10658						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1316908				2022-12-27	WOS:A1992HV09000067
J	BASSELDUBY, R; JIANG, NY; BITTICK, T; MADISON, E; MCGOOKEY, D; ORTH, K; SHOHET, R; SAMBROOK, J; GETHING, MJ				BASSELDUBY, R; JIANG, NY; BITTICK, T; MADISON, E; MCGOOKEY, D; ORTH, K; SHOHET, R; SAMBROOK, J; GETHING, MJ			TYROSINE-67 IN THE EPIDERMAL GROWTH FACTOR-LIKE DOMAIN OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR IS IMPORTANT FOR CLEARANCE BY A SPECIFIC HEPATIC RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL LINE HEP-G2; SIDE-CHAIN; T-PA; FIBRINOLYTIC-ACTIVITY; DIRECTED MUTAGENESIS; PROLONGED CLEARANCE; STRUCTURAL DOMAINS; ESCHERICHIA-COLI; INHIBITOR TYPE-1; BINDING	Human tissue-type plasminogen activator (t-PA) is cleared rapidly from the circulation by hepatic receptors, one of which recognizes a site in the epidermal growth factor-like domain of the molecule. To define this site more precisely, we have used oligonucleotide-mediated mutagenesis to introduce amino acid substitutions at specific positions located in turns that connect antiparallel beta-sheets in the epidermal growth factor-like domain. Mutated t-PA proteins with amino acid substitutions of the tyrosine residue at position 67 showed markedly lower rates of endocytosis and degradation by cultured cells of the rat hepatoma (H4) line that express a specific receptor for t-PA, and their half-life in the circulation of rats was extended significantly because of a reduction in the rate of the rapid alpha-phase of clearance. The enzymatic properties and fibrinolytic activity of these mutants in vitro were not significantly different from those of wild-type t-PA. We conclude that tyrosine 67 comprises a key determinant in the clearance of t-PA by a specific hepatic receptor.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT MED, DALLAS, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Shohet, ralph V/A-1731-2011; Orth, Kim/AAV-4421-2021	Orth, Kim/0000-0002-0678-7620				AHERN TJ, 1990, J BIOL CHEM, V265, P5540; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; APPELLA E, 1987, J BIOL CHEM, V262, P4437; BANYAI L, 1983, FEBS LETT, V163, P37, DOI 10.1016/0014-5793(83)81157-0; BOOSE JA, 1989, BIOCHEMISTRY-US, V28, P635, DOI 10.1021/bi00428a033; BROMMER EJP, 1988, THROMB HAEMOSTASIS, V59, P404; BROWNE MJ, 1990, THROMB RES, V59, P687, DOI 10.1016/0049-3848(90)90429-G; BROWNE MJ, 1988, J BIOL CHEM, V263, P1599; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; COLLEN D, 1988, BLOOD, V71, P216; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; GALLAGHER P, 1988, J CELL BIOL, V107, P2059, DOI 10.1083/jcb.107.6.2059; GETHING MJ, 1988, EMBO J, V7, P2731, DOI 10.1002/j.1460-2075.1988.tb03127.x; GETHING MJ, 1989, THROMB HAEMOSTASIS, V62, P338; GETHING MJ, 1989, 2ND INT WORKSH MOL C; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HEATH WF, 1986, P NATL ACAD SCI USA, V83, P6367, DOI 10.1073/pnas.83.17.6367; HEUSSEN C, 1984, J BIOL CHEM, V259, P1635; HOLLAND SK, 1987, EMBO J, V6, P1875, DOI 10.1002/j.1460-2075.1987.tb02446.x; HOLMES WE, 1985, BIO-TECHNOL, V3, P923, DOI 10.1038/nbt1085-923; HOTCHKISS A, 1988, THROMB HAEMOSTASIS, V60, P255; JOHANNESSEN M, 1990, THROMB HAEMOSTASIS, V63, P54; KALYAN NK, 1988, J BIOL CHEM, V263, P3971; KAUFMAN RJ, 1985, MOL CELL BIOL, V5, P1750, DOI 10.1128/MCB.5.7.1750; KOHDA D, 1988, J BIOCHEM-TOKYO, V103, P741, DOI 10.1093/oxfordjournals.jbchem.a122338; KOMORIYA A, 1984, P NATL ACAD SCI-BIOL, V81, P1351, DOI 10.1073/pnas.81.5.1351; KORINGER C, 1981, THROMB HAEMOSTASIS, V46, P658; KRAUSE J, 1988, Fibrinolysis, V2, P133, DOI 10.1016/0268-9499(88)90026-4; KRUITHOF EKO, 1984, BLOOD, V64, P907; LARSEN GR, 1989, BLOOD, V73, P1842, DOI 10.1182/blood.V73.7.1842.1842; LARSEN GR, 1988, J BIOL CHEM, V263, P1023; LAZAR E, 1989, MOL CELL BIOL, V9, P860, DOI 10.1128/MCB.9.2.860; LIJNEN HR, 1984, THROMB HAEMOSTASIS, V52, P308; LIJNEN HR, 1991, THROMB HAEMOSTASIS, V66, P88; LUCORE CL, 1988, CIRCULATION, V77, P906, DOI 10.1161/01.CIR.77.4.906; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MONTELIONE GT, 1987, P NATL ACAD SCI USA, V84, P5226, DOI 10.1073/pnas.84.15.5226; MORTON PA, 1990, J BIOL CHEM, V265, P14093; MORTON PA, 1989, J BIOL CHEM, V264, P7228; NILSSON S, 1985, THROMB RES, V39, P511, DOI 10.1016/0049-3848(85)90174-4; NILSSON T, 1984, SCAND J HAEMATOL, V33, P49; NY T, 1984, P NATL ACAD SCI-BIOL, V81, P5355, DOI 10.1073/pnas.81.17.5355; OLSSON G, 1982, FEBS LETT, V145, P317, DOI 10.1016/0014-5793(82)80191-9; ORD JM, 1990, FIBRINOLYSIS, V4, P203, DOI 10.1016/0268-9499(90)90015-C; OWENSBY DA, 1988, J BIOL CHEM, V263, P10587; PARK CH, 1986, BIOCHEMISTRY-US, V25, P3977, DOI 10.1021/bi00362a001; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; POHL G, 1984, BIOCHEMISTRY-US, V23, P3701, DOI 10.1021/bi00311a020; RANBY M, 1982, FEBS LETT, V146, P289, DOI 10.1016/0014-5793(82)80936-8; REINSCH CH, 1967, NUMER MATH, V10, P177, DOI 10.1007/BF02162161; RIJKEN DC, 1990, THROMB RES, P63; RIJKEN DC, 1981, J BIOL CHEM, V256, P7035; RIJKEN DC, 1986, BIOCHEM J, V238, P643, DOI 10.1042/bj2380643; SAMBROOK J, 1986, MOL BIOL MED, V3, P459; Sambrook J, 1989, MOL CLONING LABORATO; SKEHEL JJ, 1984, P NATL ACAD SCI-BIOL, V81, P1779, DOI 10.1073/pnas.81.6.1779; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VERSTRAETE M, 1985, J PHARMACOL EXP THER, V235, P506; WALLEN P, 1982, BIOCHIM BIOPHYS ACTA, V719, P318, DOI 10.1016/0304-4165(82)90105-2; WAYNFORTH HB, 1980, EXPT SURGICAL TECHNI; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	67	40	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9668	9677						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315765				2022-12-27	WOS:A1992HT96500035
J	GRINDE, B; CAMERON, CE; LEIS, J; WEBER, IT; WLODAWER, A; BURSTEIN, H; SKALKA, AM				GRINDE, B; CAMERON, CE; LEIS, J; WEBER, IT; WLODAWER, A; BURSTEIN, H; SKALKA, AM			ANALYSIS OF SUBSTRATE INTERACTIONS OF THE ROUS-SARCOMA VIRUS WILD-TYPE AND MUTANT PROTEASES AND HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE USING A SET OF SYSTEMATICALLY ALTERED PEPTIDE-SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC HIV-1 PROTEASE; CRYSTAL-STRUCTURE; RETROVIRAL PROTEASE; ASPARTIC PROTEASE; RESOLUTION; INHIBITOR; COMPLEX	In the preceding study, mutant Rous sarcoma virus (RSV) proteases are described in which three amino acids found in the human immunodeficiency virus-1 (HIV-1) protease (PR) were substituted into structurally comparable positions (Grinde, B., Cameron, C. E., Leis, J., Weber, I., Wlodawer, A., Burstein, H., Bizub, D., and Skalka, A. M. (1992) J. Biol. Chem. 267, 9481-9490). In this report, the activity of the wild type and these mutant PRs are compared using a set of RSV NC-PR peptide substrates with single amino acid substitutions in each of the P4 to P3' positions. With most substrates, the relative activities of the two active mutants followed that of the RSV PR. Substitutions in the P1 and P1' positions were an exception; in this case, the mutants behaved more like the HIV-1 PR. These results confirm predictions from structural analyses which indicate that residues 105 and 106 of the RSV PR are important in forming the S1 and S1' binding subsites. These results, further analyzed with the aid of computer modeling of the RSV PR with different substrates, provide an explanation for why only partial HIV-1 PR-like behavior was introduced into the above RSV PR mutants.	CASE WESTERN RESERVE UNIV, SCH MED, CLEVELAND, OH 44106 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA; FOX CHASE CANC INST, INST CANC RES, PHILADELPHIA, PA 19111 USA	Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Fox Chase Cancer Center					NATIONAL CANCER INSTITUTE [R35CA047486, R01CA038046, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA38046, CA47486, CA06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER F, 1987, J VIROL, V61, P534, DOI 10.1128/JVI.61.2.534-542.1987; BIZUB D, 1991, J BIOL CHEM, V266, P4951; DARKE PL, 1988, BIOCHEM BIOPH RES CO, V156, P297, DOI 10.1016/S0006-291X(88)80839-8; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; GIAM CZ, 1988, J BIOL CHEM, V263, P14617; GRINDE B, 1982, J BIOL CHEM, V267, P9481; GUSTCHINA A, 1991, PROTEINS, V10, P325, DOI 10.1002/prot.340100406; JASKOLSKI M, 1990, BIOCHEMISTRY-US, V29, P5889, DOI 10.1021/bi00477a002; JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KOTLER M, 1989, J BIOL CHEM, V264, P3428; LAPATTO P, 1989, NATURE, V342, P299; LEIS J, 1989, CURRENT COMMUNICATIO, P235; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805; TOZSER J, 1991, FEBS LETT, V279, P356, DOI 10.1016/0014-5793(91)80186-7; WEBER IT, 1990, J BIOL CHEM, V265, P10492; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; WLODAWER A, 1991, ADV LIF SCI, P215	22	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9491	9498						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315756				2022-12-27	WOS:A1992HT96500010
J	SHIBAGAKI, Y; ITOH, N; YAMADA, H; NAGATA, S; MIZUMOTO, K				SHIBAGAKI, Y; ITOH, N; YAMADA, H; NAGATA, S; MIZUMOTO, K			MESSENGER-RNA CAPPING ENZYME - ISOLATION AND CHARACTERIZATION OF THE GENE ENCODING MESSENGER-RNA GUANYLYLTRANSFERASE SUBUNIT FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACCINIA VIRUS GUANYLYLTRANSFERASE; ELECTROPHORETIC TRANSFER; GUANYLATE INTERMEDIATE; POLYACRYLAMIDE GELS; NUCLEOTIDE-SEQUENCE; ANTIBODY PROBES; CAP STRUCTURE; 5' TERMINUS; HELA-CELLS; YEAST	The highly purified yeast mRNA capping enzyme is composed of two separate chains of 52 (alpha) and 80 kDa (beta), responsible for the activities of mRNA guanylyltransferase and RNA 5'-triphosphatase, respectively (Itoh, N., Yamada, H., Kaziro, Y., and Mizumoto, K. (1987) J. Biol. Chem. 262, 1989-1995). The gene encoding the mRNA guanylyltransferase subunit (alpha-subunit), CEG1, has been isolated by immunological screening of a yeast genomic expression library in lambda-gt11 with polyclonal antibodies directed against purified yeast capping enzyme. The identity of CEG1 was confirmed by epitope selection and by expressing the gene in Escherichia coli to give a catalytically active mRNA guanylyltransferase. The gene is present in one copy per haploid genome, and encodes a polypeptide of 459 amino acid residues. From its primary structure as well as its mRNA size, it was concluded that the alpha and the beta-subunits of yeast mRNA capping enzyme are encoded by two separate genes, not as a fused protein. CEG1 is located on the chromosome VII by a pulse-field gel electrophoresis. Gene disruption experiment indicated that CEG1 is essential for the growth of yeast. We have also found another open reading frame (ORF2) which lies in close proximity to CEG1 in our clones and encodes a 450 amino acid-polypeptide of yet unknown function.	UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN	University of Tokyo			Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				BANERJEE AK, 1980, MICROBIOL REV, V44, P175, DOI 10.1128/MMBR.44.2.175-205.1980; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARLE GF, 1987, METHOD ENZYMOL, V155, P468; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; CLEVELAND DR, 1986, J VIROL, V60, P307, DOI 10.1128/JVI.60.1.307-311.1986; COPPOLA JA, 1983, P NATL ACAD SCI-BIOL, V80, P1251, DOI 10.1073/pnas.80.5.1251; EDERY I, 1985, P NATL ACAD SCI USA, V82, P7590, DOI 10.1073/pnas.82.22.7590; ENSINGER MJ, 1975, P NATL ACAD SCI USA, V72, P2525, DOI 10.1073/pnas.72.7.2525; ENSINGER MJ, 1976, J BIOL CHEM, V251, P5283; FAUSNAUGH J, 1990, J BIOL CHEM, V265, P7669; FILIPOWICZ W, 1978, FEBS LETT, V96, P1, DOI 10.1016/0014-5793(78)81049-7; FURUICHI Y, 1976, J BIOL CHEM, V251, P5043; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; FURUICHI Y, 1975, NATURE, V253, P374, DOI 10.1038/253374a0; Furuichi Y, 1976, Prog Nucleic Acid Res Mol Biol, V19, P3; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HANAHAN D, 1983, METHOD ENZYMOL, V100, P333; ITOH N, 1987, J BIOL CHEM, V262, P1989; ITOH N, 1984, J BIOL CHEM, V259, P3923; ITOH N, 1983, FEBS LETT, V155, P161, DOI 10.1016/0014-5793(83)80231-2; JOVE R, 1984, J BIOL CHEM, V259, P8513; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LANGBERG SR, 1981, J BIOL CHEM, V256, P54; LOCKARD RE, 1978, NUCLEIC ACIDS RES, V5, P3237, DOI 10.1093/nar/5.9.3237; Maniatis T., 1982, MOL CLONING; MANLEY JL, 1979, P NATL ACAD SCI USA, V76, P160, DOI 10.1073/pnas.76.1.160; MARTIN SA, 1975, J BIOL CHEM, V250, P9330; MARTIN SA, 1976, J BIOL CHEM, V251, P7313; MARTIN SA, 1975, J BIOL CHEM, V250, P9322; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MIZUMOTO K, 1979, P NATL ACAD SCI USA, V76, P4961, DOI 10.1073/pnas.76.10.4961; MIZUMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P1693, DOI 10.1073/pnas.79.6.1693; MIZUMOTO K, 1987, PROG NUCLEIC ACID RE, V34, P1, DOI 10.1016/S0079-6603(08)60491-2; MONROY G, 1978, J BIOL CHEM, V253, P4490; MORGAN JR, 1984, J VIROL, V52, P206, DOI 10.1128/JVI.52.1.206-214.1984; Moss B, 1976, Prog Nucleic Acid Res Mol Biol, V19, P63; NILES EG, 1986, VIROLOGY, V153, P96, DOI 10.1016/0042-6822(86)90011-5; ROTH MJ, 1984, J BIOL CHEM, V259, P3488; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUGGIERI R, 1989, P NATL ACAD SCI USA, V86, P8778, DOI 10.1073/pnas.86.22.8778; SALDITTGEORGIEFF M, 1980, CELL, V19, P69, DOI 10.1016/0092-8674(80)90389-X; SANDMEYER SB, 1982, P NATL ACAD SCI-BIOL, V79, P7674, DOI 10.1073/pnas.79.24.7674; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELIGER LS, 1987, J BIOL CHEM, V262, P16289; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SHERMAN F, 1973, APPL MICROBIOL, V26, P829, DOI 10.1128/AEM.26.5.829-829.1973; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; TONG SW, 1983, J BIOL CHEM, V258, P3100; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYAMA R, 1983, EMBO J, V2, P2195, DOI 10.1002/j.1460-2075.1983.tb01723.x; VENKATESAN S, 1980, J BIOL CHEM, V255, P903; VENKATESAN S, 1980, J BIOL CHEM, V255, P2829; WANG D, 1982, MOL CELL BIOL, V2, P993, DOI 10.1128/MCB.2.8.993; WEINBERGER C, 1985, SCIENCE, V228, P740, DOI 10.1126/science.2581314; YAGI Y, 1984, J BIOL CHEM, V259, P4695; YAGI Y, 1983, EMBO J, V2, P611, DOI 10.1002/j.1460-2075.1983.tb01471.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	62	104	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9521	9528						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315757				2022-12-27	WOS:A1992HT96500015
J	VANBEILEN, JB; PENNINGA, D; WITHOLT, B				VANBEILEN, JB; PENNINGA, D; WITHOLT, B			TOPOLOGY OF THE MEMBRANE-BOUND ALKANE HYDROXYLASE OF PSEUDOMONAS-OLEOVORANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ALKALINE-PHOSPHATASE; RUBREDOXIN REDUCTASE; BETA-GALACTOSIDASE; PROTEIN TOPOLOGY; ALKBAC OPERON; PLASMID; EXPRESSION; FUSIONS; GENE	The Pseudomonas oleovorans alkane hydroxylase is an integral cytoplasmic membrane protein that is expressed and active in both Escherichia coli and P. oleovorans. Its primary sequence contains eight hydrophobic stretches that could span the membrane as alpha-helices. The topology of alkane hydroxylase was studied in E. coli using protein fusions linking different amino-terminal fragments of the alkane hydroxylase (AlkB) to alkaline phosphatase (PhoA) and to beta-galactosidase (LacZ). Four AlkB-PhoA fusions were constructed using transposon TnphoA. Site-directed mutagenesis was used to create PstI sites at 12 positions in AlkB. These sites were used to create AlkB-PhoA and AlkB-LacZ fusions. With respect to alkaline phosphatase and beta-galactosidase activity each set of AlkB-PhoA and AlkB-LacZ fusions revealed the expected complementary activities. At three positions, PhoA fusions were highly active, whereas the corresponding LacZ fusions were the least active. At all other positions the PhoA fusions were almost completely inactive, but the corresponding LacZ fusions were highly active. These data predict a model for alkane hydroxylase containing six transmembrane segments. In this model the amino terminus, two hydrophilic loops, and a large carboxyl-terminal domain are located in the cytoplasm. Only three very short loops near amino acid positions 52, 112, and 251 are exposed to the periplasm.	UNIV GRONINGEN,GRONINGEN BIOTECHNOL CTR,DEPT BIOCHEM,NIJENBORGH 16,9747 AG GRONINGEN,NETHERLANDS	University of Groningen			Witholt, Bernard/A-7340-2012					ARNOLD FH, 1991, SCIENCE, V252, P1796, DOI 10.1126/science.1648261; BASSFORD PJ, 1979, J BACTERIOL, V139, P19, DOI 10.1128/JB.139.1.19-31.1979; BENSON S, 1977, J BACTERIOL, V132, P614, DOI 10.1128/JB.132.2.614-621.1977; BENSON S, 1979, J BACTERIOL, V140, P754, DOI 10.1128/JB.140.3.754-762.1979; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHAKRABARTY AM, 1973, P NATL ACAD SCI USA, V70, P1137, DOI 10.1073/pnas.70.4.1137; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; EGGINK G, 1987, J BIOL CHEM, V262, P17712; EGGINK G, 1988, J BIOL CHEM, V263, P13400; EGGINK G, 1987, J BIOL CHEM, V262, P6400; FENNEWALD M, 1977, J BACTERIOL, V132, P622, DOI 10.1128/JB.132.2.622-627.1977; FENNEWALD M, 1979, J BACTERIOL, V139, P940, DOI 10.1128/JB.139.3.940-952.1979; FROSHAUER S, 1988, J MOL BIOL, V200, P500; GAREN A, 1960, BIOCHIM BIOPHYS ACTA, V38, P470, DOI 10.1016/0006-3002(60)91282-8; GUTIERREZ C, 1987, J MOL BIOL, V195, P289, DOI 10.1016/0022-2836(87)90650-4; HARLOW E, 1988, ANTIBODIES LAB MANUA, P495; HOFFMAN CS, 1985, P NATL ACAD SCI USA, V82, P5107, DOI 10.1073/pnas.82.15.5107; KAHN PL, 1968, J BACTERIOL, V96, P205; KOK M, 1989, J BIOL CHEM, V264, P5442; KOK M, 1989, J BIOL CHEM, V264, P5435; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGEVEEN R, 1986, THESIS U GRONINGEN; Maniatis T., 1982, MOL CLONING; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; Miller J. H, 1972, EXPT MOL GENETICS; PAUL C, 1985, EMBO J, V4, P1593, DOI 10.1002/j.1460-2075.1985.tb03822.x; PETERSON JA, 1966, J BIOL CHEM, V241, P5162; RUETTINGER RT, 1974, BIOCHEM BIOPH RES CO, V57, P1011, DOI 10.1016/0006-291X(74)90797-9; SANMILLAN JL, 1989, J BACTERIOL, V171, P5536, DOI 10.1128/jb.171.10.5536-5541.1989; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; SUZUKI M, 1991, J BACTERIOL, V173, P1690, DOI 10.1128/jb.173.5.1690-1695.1991; UEDA T, 1972, J BIOL CHEM, V247, P2109; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; YAMANE K, 1990, J BIOL CHEM, V265, P21166; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	44	93	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9194	9201						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1315749				2022-12-27	WOS:A1992HR85400075
J	LIU, HL; CHAO, W; OLSON, MS				LIU, HL; CHAO, W; OLSON, MS			REGULATION OF THE SURFACE EXPRESSION OF THE PLATELET-ACTIVATING-FACTOR RECEPTOR IN IC-21 PERITONEAL-MACROPHAGES - EFFECTS OF LIPOPOLYSACCHARIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT KUPFFER CELLS; PROTEIN-KINASE-C; GLYCERYL ETHER PHOSPHORYLCHOLINE; COLONY-STIMULATING FACTOR; ACUTE PHASE REACTANT; BACTERIAL LIPOPOLYSACCHARIDE; HUMAN-NEUTROPHILS; BINDING-PROTEIN; RABBIT PLATELETS; GENE-EXPRESSION	The effect of bacterial lipopolysaccharide (LPS) on the expression of the receptor for platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine; AGEPC) was examined in cultured IC-21 peritoneal macrophages. AGEPC binding to its receptors reached saturation within 20 min at 25-degree-C and was reversible. Scatchard analysis revealed a single class of AGEPC receptors with a B(max) of approximately 170 fmol/mg cellular protein and a K(d) of 0.25 nM. Preincubation of IC-21 cells with LPS (0.01-1,000 ng/ml) induced an increase in the surface expression of AGEPC receptors in a time- and concentration-dependent fashion. The maximal effect of LPS on the AGEPC receptor was observed between 5 and 8 h, with a typical increase between 150 and 200%. Scatchard analysis indicated that LPS treatment of IC-21 cells increased the number of AGEPC receptors on the cell surface without any apparent change in the affinity of the receptor for the ligand. The effect of LPS on the surface expression of the AGEPC receptor was nearly abolished by cycloheximide (0.1 mM) and by actinomycin D (3 muM), suggesting the involvement of enhanced receptor protein synthesis and mRNA production in this event. Moreover, LPS treatment increased the capability of the IC-21 cell to respond to AGEPC addition by elevating intracellular free Ca2+ without causing an increase in the basal level of intracellular Ca2+. The present study demonstrates that IC-21 peritoneal macrophages possess high affinity AGEPC receptors and provides the evidence that the number of functional AGEPC receptors on a cell can be increased significantly upon exposure to LPS.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio				Chao, Wei/0000-0002-2505-1360	NIADDK NIH HHS [AM-33538] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM033538] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADEREM AA, 1986, J EXP MED, V164, P165, DOI 10.1084/jem.164.1.165; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; AMANO F, 1985, FEBS LETT, V82, P263; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Braquet P, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17B, P822; CHAO W, 1989, J BIOL CHEM, V264, P13591; CHAO W, 1990, ARCH BIOCHEM BIOPHYS, V282, P188, DOI 10.1016/0003-9861(90)90103-6; CHAO W, 1989, J BIOL CHEM, V264, P20448; CHEN BDM, 1983, J IMMUNOL, V130, P2256; DING AH, 1989, J BIOL CHEM, V264, P3924; FOREHAND JR, 1989, J CLIN INVEST, V83, P74, DOI 10.1172/JCI113887; GLASER KB, 1990, J BIOL CHEM, V265, P8658; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUILBERT LJ, 1984, J IMMUNOL METHODS, V73, P17, DOI 10.1016/0022-1759(84)90027-9; HANAHAN DJ, 1980, J BIOL CHEM, V255, P5514; HOLTER W, 1987, J IMMUNOL, V138, P2917; HOMMA H, 1987, J BIOL CHEM, V262, P10582; HWANG SB, 1983, BIOCHEMISTRY-US, V22, P4756, DOI 10.1021/bi00289a022; KLOPROGGE E, 1984, BIOCHEM J, V223, P901, DOI 10.1042/bj2230901; MCMANUS LM, 1981, J CLIN INVEST, V67, P903, DOI 10.1172/JCI110108; NISHIJIMA M, 1985, P NATL ACAD SCI USA, V82, P282, DOI 10.1073/pnas.82.2.282; OFLAHERTY JT, 1986, J CLIN INVEST, V78, P381, DOI 10.1172/JCI112588; OFLAHERTY JT, 1981, AM J PATHOL, V103, P70; OFLAHERTY JT, 1989, J BIOL CHEM, V264, P6836; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; PRPIC V, 1988, J CELL BIOL, V107, P363, DOI 10.1083/jcb.107.1.363; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; REATZ CRH, 1990, ANNU REV BIOCHEM, V59, P129; SASAKI M, 1987, TRENDS PHARM RES PLA, P108; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SHERRY B, 1988, J CELL BIOL, V107, P1269, DOI 10.1083/jcb.107.4.1269; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TANNENBAUM CS, 1988, J IMMUNOL, V140, P3640; TERASHITA Z, 1985, EUR J PHARMACOL, V109, P257, DOI 10.1016/0014-2999(85)90427-3; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; TSIEN RY, 1985, CELL CALCIUM, V6, P145, DOI 10.1016/0143-4160(85)90041-7; VALONE FH, 1982, J IMMUNOL, V129, P1637; VALONE FH, 1988, J IMMUNOL, V140, P2389; VALONE FH, 1983, IMMUNOLOGY, V48, P141; VOSBECK K, 1990, J LEUKOCYTE BIOL, V47, P97, DOI 10.1002/jlb.47.2.97; WAHL SM, 1987, J IMMUNOL, V139, P1342; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YAMAZAKI M, 1989, P NATL ACAD SCI USA, V86, P5791, DOI 10.1073/pnas.86.15.5791	45	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20811	20819						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328211				2022-12-27	WOS:A1992JT97800048
J	MUALLEM, S; ZHANG, BX; LOESSBERG, PA; STAR, RA				MUALLEM, S; ZHANG, BX; LOESSBERG, PA; STAR, RA			SIMULTANEOUS RECORDING OF CELL-VOLUME CHANGES AND INTRACELLULAR PH OR CA2+ CONCENTRATION IN SINGLE OSTEOSARCOMA CELLS UMR-106-01	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECTURUS GALLBLADDER EPITHELIUM; PANCREATIC ACINAR-CELLS; ASCITES TUMOR-CELLS; REGULATORY MECHANISMS; HCO3 TRANSPORTERS; NA+/H+ EXCHANGER; LINE UMR-106-01; KIDNEY-CELLS; MEMBRANE; OSTEOBLASTS	We present a new technique for the simultaneous measurement of cell volume changes and intracellular ionic activities in single cells. The technique uses measurement of changes in the concentration of intracellularly trapped fluorescent dyes to report relative cell volume. By using pH- or Ca2+-sensitive dyes and recording at the ion-sensitive and -insensitive (isosbestic) wavelengths, the method can measure both cell volume changes and intracellular ionic activities. The technique was used to study the mechanisms of regulatory volume decrease (RVD) in the osteosarcoma cell line UMR-106-01 grown on cover slips. Swelling cells in 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid (HEPES)-buffered hypotonic medium was followed by stable cytosolic acidification and a decrease in cell volume back toward normal. The recovery of cell volume could be blocked by depolarization, treatment with ouabain, or depletion of cell Cl-. These suggest the conductive efflux of K+ and Cl- during RVD. The cytosolic acidification that accompanied cell swelling was not blocked by amiloride, bafilomycin A, or removal of Cl- and could not be reproduced by depletion of cellular ATP. These findings exclude Na+/H+ and Cl-/HCO3- exchange, intracellularly generated acid, or increased metabolism, respectively, as the cause of the acidification. The cell swelling-induced acidification was inhibited by depolarization, suggesting the involvement of an electrogenic pathway. The acidification, as well as RVD, was inhibited by short incubation with deoxyglucose, and these effects could not be reversed by valinomycin. Thus, the anionic pathway(s) participating in RVD and the acidification are sensitive to the cellular level of ATP. Together, these studies indicate that RVD in UMR-106-01 cells in HEPES-buffered medium is mediated by the conductive efflux of K+, Cl-, and OH-.	UNIV TEXAS,SW MED CTR,DEPT MED,DIV NEPHROL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	MUALLEM, S (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39245] Funding Source: Medline; NIDDK NIH HHS [DK38938] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; COTTON CU, 1991, J GEN PHYSIOL, V97, P667, DOI 10.1085/jgp.97.4.667; EVELOFF JL, 1987, AM J PHYSIOL, V252, pF1, DOI 10.1152/ajprenal.1987.252.1.F1; FOSKETT JK, 1989, SCIENCE, V244, P1582, DOI 10.1126/science.2500708; FURLONG TJ, 1990, AM J PHYSIOL, V258, pC1016; GLUCK S, 1982, P NATL ACAD SCI-BIOL, V79, P4327, DOI 10.1073/pnas.79.14.4327; GREEN J, 1988, J GEN PHYSIOL, V92, P239, DOI 10.1085/jgp.92.2.239; GREEN J, 1988, J BIOL CHEM, V263, P5012; GREEN J, 1990, J GEN PHYSIOL, V95, P121, DOI 10.1085/jgp.95.1.121; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; GRONOWICZ G, 1986, J BONE MINER RES, V1, P441; HOFFMANN EK, 1986, J MEMBRANE BIOL, V91, P227, DOI 10.1007/BF01868816; KAJI D, 1986, J GEN PHYSIOL, V88, P719, DOI 10.1085/jgp.88.6.719; KHADEMAZAD M, 1991, AM J PHYSIOL, V261, pC441, DOI 10.1152/ajpcell.1991.261.3.C441; LEWIS SA, 1990, NEWS PHYSIOL SCI, V5, P112; LOPES AG, 1988, P NATL ACAD SCI USA, V85, P2873, DOI 10.1073/pnas.85.8.2873; MCCARTY NA, 1990, AM J PHYSIOL, V259, pF950, DOI 10.1152/ajprenal.1990.259.6.F950; MONTROSERAFIZADEH C, 1990, ANNU REV PHYSIOL, V52, P761; MUALLEM S, 1990, J BIOL CHEM, V265, P12813; MUALLEM S, 1990, J BIOL CHEM, V265, P12806; MUALLEM S, 1985, J BIOL CHEM, V260, P6641; PIERCE SK, 1990, ANNU REV PHYSIOL, V52, P27, DOI 10.1146/annurev.ph.52.030190.000331; REDHEAD CR, 1988, J PHYSIOL-LONDON, V401, P455, DOI 10.1113/jphysiol.1988.sp017172; REUSS L, 1985, P NATL ACAD SCI USA, V82, P6014, DOI 10.1073/pnas.82.17.6014; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; ROY G, 1987, J MEMBRANE BIOL, V100, P83, DOI 10.1007/BF02209143; STAR RA, 1990, J CLIN INVEST, V86, P1172, DOI 10.1172/JCI114823; STAR RA, 1992, J BIOL CHEM, V267, P17665; STONE DK, SEMIN NEPHROL, V10, P159; TANIGUCHI J, 1989, AM J PHYSIOL, V257, pF347, DOI 10.1152/ajprenal.1989.257.3.F347; TAUC M, 1990, BIOCHIM BIOPHYS ACTA, V1052, P278, DOI 10.1016/0167-4889(90)90222-Y; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; UBL J, 1988, PFLUG ARCH EUR J PHY, V412, P551, DOI 10.1007/BF00582547; WALL SM, 1988, AM J PHYSIOL, V255, pF331, DOI 10.1152/ajprenal.1988.255.2.F331; XIE XS, 1989, J BIOL CHEM, V264, P18870; YAMAGUCHI DT, 1989, J BIOL CHEM, V264, P4383	38	73	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17658	17664						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325444				2022-12-27	WOS:A1992JM22300030
J	TOKUNAGA, M; KAWAMURA, A; KOHNO, K				TOKUNAGA, M; KAWAMURA, A; KOHNO, K			PURIFICATION AND CHARACTERIZATION OF BIP KAR2 PROTEIN FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA PLASMID PGKL1; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; ESCHERICHIA-COLI; ESSENTIAL COMPONENT; PRECURSOR PROTEINS; UNCOATING PROTEIN; YEAST; TRANSLOCATION; BINDING	Using specific anti-BiP/Kar2 antibody as the probe, we have developed an efficient purification method of BiP/Kar2 protein from the total cell extract of Saccharomyces cerevisiae. Overproduction of BiP/Kar2 protein was achieved by the cloning of the KAR2 gene on multicopy plasmids and the treatment of cells harboring the cloned KAR2 gene with tunicamycin. Freeze-thaw treatment, hydroxyapatite high pressure liquid chromatography, and ATP-agarose column chromatography of crude extract yielded homogeneous BiP/Kar2 protein (including less than 0.2% of degradative derivative) with a 430-fold purification and 28% recovery. Edman degradation of purified BiP/Kar2 suggests that the mature protein corresponds to a processed product with the removal of a 42-amino acid presequence. It is active as a homodimer and exhibits ATPase activity with a specific activity of 2 pmol/min/mu-g of protein. Protease susceptibility indicated that the ADP form of BiP/Kar2 is more resistant than the ATP form to the chymotrypsin digestion and that BiP/Kar2 required the presence of ATP to avoid the irreversible denaturation. Synthesis of BiP/Kar2 was induced by the inducible expression of an aberrant heterologous protein, yeast killer prepro-signal mouse alpha-amylase fusion protein.	OSAKA UNIV, DEPT MOLEC & CELLULAR BIOL, SUITA, OSAKA 565, JAPAN	Osaka University	TOKUNAGA, M (corresponding author), MITSUBISHI KASEI INST LIFE SCI, MOLEC GENET LAB, 11 MINAMIOOYA, MACHIDA, TOKYO 194, JAPAN.		Kohno, Kenji/AAZ-6573-2020	Kohno, Kenji/0000-0002-3503-6551				AKITA M, 1991, BIOCHEM BIOPH RES CO, V174, P211, DOI 10.1016/0006-291X(91)90507-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAJNIK MF, 1991, IMMUNOGENETICS, V33, P295, DOI 10.1007/BF00216688; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HIGGINS RC, 1979, ANAL BIOCHEM, V93, P257, DOI 10.1016/S0003-2697(79)80077-9; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NICHOLSON RC, 1990, P NATL ACAD SCI USA, V87, P1159, DOI 10.1073/pnas.87.3.1159; NICOLET CM, 1991, METHOD ENZYMOL, V194, P710; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OMORI A, 1990, Journal of Protein Chemistry, V9, P250; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT J, 1989, METHOD CELL BIOL, V32, P3; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; SCHEKMAN R, 1982, TRENDS BIOCHEM SCI, V7, P243, DOI 10.1016/0968-0004(82)90034-2; SCHEKMAN R, 1985, ANNU REV CELL BIOL, V1, P115, DOI 10.1146/annurev.cellbio.1.1.115; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SHARMA S, 1985, EMBO J, V4, P1479, DOI 10.1002/j.1460-2075.1985.tb03806.x; SHIU RPC, 1979, BIOCHIM BIOPHYS ACTA, V576, P141, DOI 10.1016/0005-2795(79)90493-8; TAJIMA M, 1986, MOL CELL BIOL, V6, P246, DOI 10.1128/MCB.6.1.246; TOKUNAGA M, 1990, J BIOL CHEM, V265, P17274; TOKUNAGA M, 1988, NUCLEIC ACIDS RES, V16, P7499, DOI 10.1093/nar/16.15.7499; TOKUNAGA M, 1989, NUCLEIC ACIDS RES, V17, P3435, DOI 10.1093/nar/17.9.3435; TOKUNAGA M, 1987, BIOCHEM BIOPH RES CO, V144, P613, DOI 10.1016/S0006-291X(87)80010-4; TOKUNAGA M, 1992, EUR J BIOCHEM, V203, P415, DOI 10.1111/j.1432-1033.1992.tb16565.x; UNGEWICKELL E, 1985, EMBO J, V4, P3385, DOI 10.1002/j.1460-2075.1985.tb04094.x; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885	50	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17553	17559						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325440				2022-12-27	WOS:A1992JM22300015
J	ZHONG, CZ; HAYZER, DJ; CORSON, MA; RUNGE, MS				ZHONG, CZ; HAYZER, DJ; CORSON, MA; RUNGE, MS			MOLECULAR-CLONING OF THE RAT VASCULAR SMOOTH-MUSCLE THROMBIN RECEPTOR - EVIDENCE FOR INVITRO REGULATION BY BASIC FIBROBLAST GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL CELLS; EXTRACELLULAR-MATRIX; VONWILLEBRAND-FACTOR; MITOGENIC ACTIVITY; PROLIFERATION; INJURY; ATHEROSCLEROSIS; BINDING; ACETYLCHOLINE; REACTIVITY	To study thrombin's receptor-mediated effects on vascular cells, we cloned and characterized a cDNA encoding a rat smooth muscle cell thrombin receptor. A rat aortic smooth muscle (RASM) cell cDNA library was screened with a 500-base pair (bp) sequence from the human thrombin receptor, obtained by polymerase chain reaction (PCR) amplification of cDNA synthesized from human erythropoietic leukemia (HEL) cell mRNA with PCR primers based on the published human thrombin receptor sequence. Clone pRTHR17 contains a 3418-bp insert that includes 50 bp of the 5'-untranslated region and the entire coding and 3'-untranslated regions of the RASM cell thrombin receptor. The sequence of pRTHR17 is 85% similar, at the nucleotide level, and 78% similar, at the deduced amino acid level, to the human thrombin receptor. Although the putative thrombin cleavage and binding sites are present, there are significant differences between the rat and human receptors in their amino-terminal sequences. Detectable signals (consisting of a single band of 3.45 kb) are present by Northern analysis of mRNA from RASM cells, and rat lung, kidney, and testes, but not in aorta or other tissues probed. The results of Southern analysis of rat genomic DNA are consistent with the existence of a single copy of the gene encoding this receptor. The steady state thrombin receptor mRNA level is low in cultured growth-arrested RASM cells and not detectable in rat aorta. To determine whether regulation of the RASM cell thrombin receptor occurs under growth-stimulating conditions, growth-arrested RASM cells were treated with basic fibroblast growth factor (bFGF, recently proposed to be a major mitogen controlling vascular smooth muscle cell growth following injury (Lindner, V., and Reidy, M. A. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 3739-3743)). There was a significant increase in thrombin receptor mRNA following the addition of bFGF. These data demonstrate that: 1) mRNA for a thrombin receptor similar to that reported from human megakaryocyte and hamster fibroblast cell lines is present in proliferating primary culture rat smooth muscle cells, 2) the most significant sequence differences are present in the amino-terminal tail of the thrombin receptor, and 3) the mRNA level for this receptor is regulated under growth-stimulating conditions in vitro.	EMORY UNIV,SCH MED,DIV CARDIOL,DRAWER LL,ATLANTA,GA 30322	Emory University								BARSHAVIT R, 1990, CELL REGUL, V1, P453, DOI 10.1091/mbc.1.6.453; BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; BARSHAVIT R, 1989, J CLIN INVEST, V84, P1096, DOI 10.1172/JCI114272; BARSHAVIT R, 1991, J CELL BIOL, V112, P335, DOI 10.1083/jcb.112.2.335; BERK BC, 1990, J BIOL CHEM, V265, P17334; BERK BC, 1991, BIOCHEM J, V274, P799, DOI 10.1042/bj2740799; BJORKERUD S, 1971, ATHEROSCLEROSIS, V14, P259, DOI 10.1016/0021-9150(71)90055-4; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOHISY DR, 1990, J BIOL CHEM, V265, P7729; CLOWES AW, 1986, LAB INVEST, V54, P295; EIDT JF, 1989, J CLIN INVEST, V84, P18, DOI 10.1172/JCI114138; FILES JC, 1981, BLOOD, V58, P607; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FREIMAN PC, 1986, CIRC RES, V58, P783, DOI 10.1161/01.RES.58.6.783; GELEHRTER TD, 1986, J CLIN INVEST, V77, P165, DOI 10.1172/JCI112271; GLENN KC, 1980, J BIOL CHEM, V255, P6609; GRAHAM DJ, 1990, J VASC SURG, V11, P307, DOI 10.1067/mva.1990.17098; GROVES HM, 1979, LAB INVEST, V40, P194; HANSON SR, 1988, P NATL ACAD SCI USA, V85, P3184, DOI 10.1073/pnas.85.9.3184; HARKER LA, 1991, CIRCULATION, V83, P41; HATTORI R, 1989, J BIOL CHEM, V264, P7768; KNOLLER S, 1991, EUR J BIOCHEM, V195, P801, DOI 10.1111/j.1432-1033.1991.tb15769.x; KU DD, 1982, SCIENCE, V218, P576, DOI 10.1126/science.7123259; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; LYALL RM, 1989, J BIOL CHEM, V264, P14503; Maniatis T., 1982, MOL CLONING; MELZIG M, 1986, BIOMED BIOCHIM ACTA, V45, P1199; MOSCAT J, 1987, BIOCHEM BIOPH RES CO, V145, P1302, DOI 10.1016/0006-291X(87)91579-8; OKAZAKI H, 1992, IN PRESS CIRC RES; POUYSSEGUR J, 1988, PHILOS T ROY SOC B, V320, P427, DOI 10.1098/rstb.1988.0086; PRESCOTT SM, 1984, P NATL ACAD SCI USA, V81, P534; QUILLEN JE, 1991, ARTERIOSCLER THROMB, V11, P639, DOI 10.1161/01.ATV.11.3.639; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SHULTZ PJ, 1989, AM J PHYSIOL, V257, pF366, DOI 10.1152/ajprenal.1989.257.3.F366; SPORN LA, 1987, BLOOD, V69, P1531; TRAVO P, 1980, BLOOD VESSELS, V17, P110; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; ZIMMERMAN GA, 1985, CIRCULATION, V72, P718, DOI 10.1161/01.CIR.72.4.718; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	43	181	189	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16975	16979						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324917				2022-12-27	WOS:A1992JL05300040
J	GUNASEKERA, A; EBRIGHT, YW; EBRIGHT, RH				GUNASEKERA, A; EBRIGHT, YW; EBRIGHT, RH			DNA-SEQUENCE DETERMINANTS FOR BINDING OF THE ESCHERICHIA-COLI CATABOLITE GENE ACTIVATOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RECEPTOR PROTEIN; RECOGNITION SEQUENCE; NUCLEIC-ACIDS; OPERATOR DNA; CAP; SITE; SPECIFICITY; REPRESSOR; RESOLUTION; COMPLEX	The consensus DNA site for binding of the Escherichia coli catabolite gene activator protein (CAP) is 22 base pairs in length and is 2-fold symmetric: 5'-AAATGTGATCTAGATCACATTT-3'. Positions 4 to 8 of each half of the consensus DNA half-site are the most strongly conserved. In this report, we analyze the effects of substitution of DNA base pairs at positions 4 to 8, the effects of substitution of thymine by uracil and by 5-methylcytosine at positions 4, 6, and 8, and the effect of dam methylation of the 5'-GATC-3' sequence at positions 7 to 10. All DNA sites having substitutions of DNA base pairs at positions 4 to 8 exhibit lower affinities for CAP than does the consensus DNA site, consistent with the proposal that the consensus DNA site is the ideal DNA site for CAP. Specificity for T:A at position 4 appears to be determined solely by the thymine 5-methyl group. Specificity for T:A at position 6 and specificity for A:T at position 8 appear to be determined in part, but not solely, by the thymine 5-methyl group. dam methylation has little effect on CAP . DNA complex formation. The thermodynamically defined consensus DNA site spans 28 base pairs. All, or nearly all, DNA determinants required for maximal affinity for CAP and for maximal thermodynamically defined CAP-DNA ion pair formation are contained within a 28-base pair DNA fragment that has the 22-base pair consensus DNA site at its center. The quantitative data in this report provide base-line thermodynamic data required for detailed investigations of amino acid-base pair and amino acid-phosphate contacts in this protein-DNA complex.	RUTGERS STATE UNIV,WAKSMAN INST,NEW BRUNSWICK,NJ 08855; RUTGERS STATE UNIV,DEPT CHEM,NEW BRUNSWICK,NJ 08855	Rutgers State University New Brunswick; Rutgers State University New Brunswick			Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041376] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41376] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; AIBA H, 1989, GENE, V85, P91; BARBER AM, 1990, J BIOMOL STRUCT DYN, V8, P213, DOI 10.1080/07391102.1990.10507803; BARRAS F, 1989, TRENDS GENET, V5, P139, DOI 10.1016/0168-9525(89)90054-1; BERG OG, 1988, J MOL BIOL, V200, P709, DOI 10.1016/0022-2836(88)90482-2; CHEUNG S, 1984, P NATL ACAD SCI-BIOL, V81, P3665, DOI 10.1073/pnas.81.12.3665; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7; EBRIGHT RH, 1990, NUCLEIC ACIDS RES, V18, P1457, DOI 10.1093/nar/18.6.1457; EBRIGHT RH, 1989, NUCLEIC ACIDS RES, V17, P10295, DOI 10.1093/nar/17.24.10295; EBRIGHT RH, 1984, NATURE, V311, P232, DOI 10.1038/311232a0; EBRIGHT RH, 1987, P NATL ACAD SCI USA, V84, P6083, DOI 10.1073/pnas.84.17.6083; EBRIGHT RH, 1984, P NATL ACAD SCI-BIOL, V81, P7274, DOI 10.1073/pnas.81.23.7274; EBRIGHT RH, 1986, PROTEIN STRUCTURE FO, P207; EBRIGHT RH, 1986, THESIS HARVARD U; EILEN E, 1978, BIOCHEMISTRY-US, V17, P2469, DOI 10.1021/bi00606a001; FELSENFELD GARY, 1965, J MOL BIOL, V13, P407; FISHER EF, 1979, NUCLEIC ACIDS RES, V7, P401, DOI 10.1093/nar/7.2.401; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; GEIER GE, 1979, J BIOL CHEM, V254, P1408; GUNASEKERA A, 1990, NUCLEIC ACIDS RES, V18, P6853, DOI 10.1093/nar/18.23.6853; JANSEN C, 1987, BIOCHEM J, V246, P227, DOI 10.1042/bj2460227; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCLELLAND M, 1988, GENE, V74, P291, DOI 10.1016/0378-1119(88)90305-8; MCNAMARA PT, 1990, J BIOMOL STRUCT DYN, V8, P529, DOI 10.1080/07391102.1990.10507827; MORITA T, 1988, NUCLEIC ACIDS RES, V16, P7315, DOI 10.1093/nar/16.15.7315; OLMSTED MC, 1989, P NATL ACAD SCI USA, V86, P7766, DOI 10.1073/pnas.86.20.7766; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PASTAN I, 1976, BACTERIOL REV, V40, P527, DOI 10.1128/MMBR.40.3.527-551.1976; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RECORD MT, 1978, BIOPOLYMERS, V17, P159, DOI 10.1002/bip.1978.360170112; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; ROSENBERG JM, 1982, DNA-J MOLEC CELL BIO, V1, P117, DOI 10.1089/dna.1.1982.1.117; SAENGER W, 1986, NATURE, V324, P385, DOI 10.1038/324385a0; SARAI A, 1989, P NATL ACAD SCI USA, V86, P6513, DOI 10.1073/pnas.86.17.6513; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STORMO GD, 1989, P NATL ACAD SCI USA, V86, P1183, DOI 10.1073/pnas.86.4.1183; TAKAHASHI M, 1983, J MOL BIOL, V167, P895, DOI 10.1016/S0022-2836(83)80118-1; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P439, DOI 10.1073/pnas.86.2.439; TAKEDA Y, 1983, SCIENCE, V221, P1020, DOI 10.1126/science.6308768; TUNIS MJB, 1968, BIOPOLYMERS, V6, P1345, DOI 10.1002/bip.1968.360060909; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WHARTON RP, 1987, NATURE, V326, P888, DOI 10.1038/326888a0; ZHANG XP, 1990, P NATL ACAD SCI USA, V87, P4717, DOI 10.1073/pnas.87.12.4717	49	112	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14713	14720						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321815				2022-12-27	WOS:A1992JF08800035
J	WANG, YB; DEMAYO, JL; HAHN, TM; FINEGOLD, MJ; KONECKI, DS; LICHTERKONECKI, U; WOO, SLC				WANG, YB; DEMAYO, JL; HAHN, TM; FINEGOLD, MJ; KONECKI, DS; LICHTERKONECKI, U; WOO, SLC			TISSUE-SPECIFIC AND DEVELOPMENT-SPECIFIC EXPRESSION OF THE HUMAN PHENYLALANINE-HYDROXYLASE CHLORAMPHENICOL ACETYLTRANSFERASE FUSION GENE IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-1-ANTITRYPSIN GENE; ACTING PROMOTER ELEMENTS; ALBUMIN GENE; NUCLEOTIDE-SEQUENCE; BINDING-PROTEINS; NUCLEAR FACTOR; MESSENGER-RNA; HUMAN LIVER; TRANSCRIPTION; PHENYLKETONURIA	Human phenylalanine hydroxylase (PAH) catalyzes the conversion Of L-phenylalanine to L-tyrosine. Deficiency of this enzyme results in phenylketonuria, a common genetic disorder of amino acid metabolism that causes severe mental retardation. In primates, PAH is expressed specifically in the liver, while in rodents PAH activity is also present in kidney, although at a much lower level. A 9-kilobase genomic DNA fragment at the 5' end of the hPAH gene (hPAH) was fused to the bacterial chloramphenicol acetyltransferase (CAT) gene. The hPAH/CAT minigene was used to generate multiple transgenic mouse lines. In all expressing lines, CAT activity was detected predominantly in the liver and at much lower levels in the kidney. By immunohistochemical staining, CAT expression was localized to hepatocytes and renal epithelial cells, both of which also express the endogenous mouse PAH enzyme. Furthermore, both the transgene and the endogenous mouse PAH were activated at about the same stage of embryonic development in the mouse liver. These results suggest that the 9-kilobase DNA fragment flanking the 5' end of the human PAH gene contains all the necessary cis-acting elements to direct tissue- and developmental-specific expression in vivo.	BAYLOR COLL MED,DEPT CELL BIOL,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; UNIV HEIDELBERG,KINDERKLIN,W-6900 HEIDELBERG,GERMANY	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Ruprecht Karls University Heidelberg				Wang, Yibin/0000-0003-0852-0767	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017711, R37HD017711] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-17711] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTON NK, 1979, NATURE, V282, P864, DOI 10.1038/282864a0; BANERJI J, 1983, NATURE, V323, P731; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRINSTER RL, 1983, NATURE, V306, P332, DOI 10.1038/306332a0; CARLSON JA, 1988, J CLIN INVEST, V82, P26, DOI 10.1172/JCI113580; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI OR, 1986, NATURE, V323, P731, DOI 10.1038/323731a0; COSTA RH, 1990, P NATL ACAD SCI USA, V87, P6589, DOI 10.1073/pnas.87.17.6589; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; DILELLA AG, 1988, LANCET, V1, P497; DILELLA AG, 1986, BIOCHEMISTRY-US, V25, P743, DOI 10.1021/bi00352a001; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EISENSMITH RC, 1992, IN PRESS HUM MUT, V1; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GILHAM PT, 1964, J AM CHEM SOC, V86, P4982, DOI 10.1021/ja01076a049; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAYSON DR, 1988, SCIENCE, V239, P786, DOI 10.1126/science.3257586; GREENGARD O, 1977, PEDIATR RES, V11, P669, DOI 10.1203/00006450-197705000-00009; HSIEH MC, 1979, J EXP ZOOL, V208, P161, DOI 10.1002/jez.1402080204; Kaufman S., 1976, ADV NEUROCHEM, P1; KELLY JH, 1989, IN VITRO CELL DEV B, V25, P217; KWOK SCM, 1985, BIOCHEMISTRY-US, V24, P556, DOI 10.1021/bi00324a002; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEDLEY FD, 1985, SCIENCE, V228, P77, DOI 10.1126/science.3856322; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIDSKY AS, 1985, P NATL ACAD SCI USA, V82, P6221, DOI 10.1073/pnas.82.18.6221; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MCGEE MM, 1972, BIOCHEM J, V127, P669, DOI 10.1042/bj1270669; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; RAIHA NCR, 1973, PEDIATR RES, V7, P1; RAO DN, 1986, J BIOL CHEM, V261, P8866; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; ROBSON KJH, 1982, P NATL ACAD SCI-BIOL, V79, P4701, DOI 10.1073/pnas.79.15.4701; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SCRIVER CR, 1980, ANNU REV GENET, V14, P179, DOI 10.1146/annurev.ge.14.120180.001143; SHEN RF, 1987, NUCLEIC ACIDS RES, V15, P8399, DOI 10.1093/nar/15.20.8399; SIFERS RN, 1987, NUCLEIC ACIDS RES, V15, P1459, DOI 10.1093/nar/15.4.1459; SIMONE VD, 1987, EMBO J, V6, P2759; STALLCUP MR, 1983, J BIOL CHEM, V258, P2802; TOURIAN A, 1969, J CELL PHYSIOL, V73, P159, DOI 10.1002/jcp.1040730210; TRONCHE F, 1990, MOL BIOL MED, V7, P173; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; YEOH GCT, 1988, DIFFERENTIATION, V38, P42, DOI 10.1111/j.1432-0436.1988.tb00590.x	48	29	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15105	15110						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321825				2022-12-27	WOS:A1992JF08800088
J	CROWSON, MS; SHULL, GE				CROWSON, MS; SHULL, GE			ISOLATION AND CHARACTERIZATION OF A CDNA-ENCODING THE PUTATIVE DISTAL COLON H+,K+-ATPASE - SIMILARITY OF DEDUCED AMINO-ACID-SEQUENCE TO GASTRIC H+,K+-ATPASE AND NA+,K+-ATPASE AND MESSENGER-RNA EXPRESSION IN DISTAL COLON, KIDNEY, AND UTERUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT DESCENDING COLON; MEMBRANE CA-2+-TRANSPORTING ATPASE; ACTIVE POTASSIUM ABSORPTION; GUINEA-PIG COLON; MOLECULAR-CLONING; ALPHA-SUBUNIT; FUNCTIONAL DOMAINS; CA-2+ PUMP; ADENOSINE-TRIPHOSPHATASE; TISSUE DISTRIBUTION	A series of Northern blot hybridization experiments using probes derived from the rat gastric H+,K+-ATPase cDNA and the human ATP1AL1 gene revealed the presence of a 4.3-kilobase mRNA in colon that seemed likely to encode the distal colon H+,K+-ATPase, the enzyme responsible for K+ absorption in mammalian colon. A rat colon library was then screened using a probe from the ATP1AL1 gene, and cDNAs containing the entire coding sequence of a new P-type ATPase were isolated and characterized. The deduced polypeptide is 1036 amino acids in length and has an M(r) of 114,842. The protein exhibits 63% amino acid identity to the gastric H+,K+-ATPase alpha-subunit and 63% identity to the three Na+,K+-ATPase alpha-subunit isoforms, consistent with the possibility that it is a K+-transporting ATPase. Northern blot analyses show that the 4.3-kilobase mRNA is expressed at high levels in distal colon; at much lower levels in proximal colon, kidney, and uterus; and at trace levels in heart and forestomach. The high mRNA levels in distal colon and the similarity of the colon pump to both gastric H+,K+- and Na+,K+-ATPases suggest that it is the distal colon H+,K+-ATPase. Furthermore, expression of its mRNA in kidney raises the possibility that the enzyme also corresponds to the H+,K+-ATPase that seems to play a role in K+ absorption and H+ secretion in the distal nephron.			CROWSON, MS (corresponding author), UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039626] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39626] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASTIDE F, 1973, Journal of Biological Chemistry, V248, P8385; BURK SE, 1989, J BIOL CHEM, V264, P18561; CHEVAL L, 1991, AM J PHYSIOL, V260, pF800, DOI 10.1152/ajprenal.1991.260.6.F800; DELCASTILLO JR, 1991, AM J PHYSIOL, V261, pG1005, DOI 10.1152/ajpgi.1991.261.6.G1005; DOUCET A, 1987, AM J PHYSIOL, V253, pF418, DOI 10.1152/ajprenal.1987.253.3.F418; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; FOSTER ES, 1983, AM J PHYSIOL, V245, pG668, DOI 10.1152/ajpgi.1983.245.5.G668; FOSTER ES, 1984, AM J PHYSIOL, V246, pG611, DOI 10.1152/ajpgi.1984.246.5.G611; FOSTER ES, 1986, AM J PHYSIOL, V251, pG619, DOI 10.1152/ajpgi.1986.251.5.G619; GARG LC, 1989, RENAL PHYSIOL BIOCH, V12, P295; GARG LC, 1988, J CLIN INVEST, V81, P1204, DOI 10.1172/JCI113436; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; GIFFORD J D, 1991, Journal of the American Society of Nephrology, V2, P700; GIFFORD JD, 1992, IN PRESS AM J PHYSL; GREEB J, 1989, J BIOL CHEM, V264, P18569; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; GUSTIN MC, 1981, J BIOL CHEM, V256, P651; GUSTIN MC, 1982, J BIOL CHEM, V257, P9629; HAYSLETT JP, 1982, AM J PHYSIOL, V242, pG209, DOI 10.1152/ajpgi.1982.242.3.G209; HINZ HR, 1990, J BIOL CHEM, V265, P10260; JORGENSEN PL, 1982, ANN NY ACAD SCI, V402, P207, DOI 10.1111/j.1749-6632.1982.tb25743.x; KAUNITZ JD, 1986, J BIOL CHEM, V261, P14005; KAWAKAMI K, 1986, J BIOCHEM-TOKYO, V100, P389, DOI 10.1093/oxfordjournals.jbchem.a121726; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KIRLEY TL, 1984, BIOCHEM BIOPH RES CO, V125, P767, DOI 10.1016/0006-291X(84)90605-3; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBOVITZ RM, 1989, EMBO J, V8, P193, DOI 10.1002/j.1460-2075.1989.tb03364.x; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MARXER A, 1989, J CELL BIOL, V109, P1057, DOI 10.1083/jcb.109.3.1057; MCCABE RD, 1984, AM J PHYSIOL, V246, pG594, DOI 10.1152/ajpgi.1984.246.5.G594; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P111, DOI 10.1016/0014-5793(87)81253-X; OVCHINNIKOV YA, 1988, FEBS LETT, V233, P87, DOI 10.1016/0014-5793(88)81361-9; PERRONE RD, 1988, AM J PHYSIOL, V254, pG898, DOI 10.1152/ajpgi.1988.254.6.G898; PLANELLES G, 1991, AM J PHYSIOL, V260, pF806, DOI 10.1152/ajprenal.1991.260.6.F806; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SHULL GE, 1990, J BIOL CHEM, V265, P12123; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SHULL MM, 1989, J BIOL CHEM, V264, P17532; SHULL MM, 1987, P NATL ACAD SCI USA, V84, P4039, DOI 10.1073/pnas.84.12.4039; SUZUKI Y, 1989, AM J PHYSIOL, V256, pG979, DOI 10.1152/ajpgi.1989.256.6.G979; SUZUKI Y, 1987, AM J PHYSIOL, V253, pG155, DOI 10.1152/ajpgi.1987.253.2.G155; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; TRAN CM, 1988, BIOPHYS J, V53, pA344; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WATANABE T, 1990, AM J PHYSIOL, V258, pG506, DOI 10.1152/ajpgi.1990.258.4.G506; WERNKE G R, 1989, Biophysical Journal, V55, p390A; WILLS NK, 1982, J MEMBRANE BIOL, V64, P195, DOI 10.1007/BF01870886; WINGO CS, 1989, J CLIN INVEST, V84, P361, DOI 10.1172/JCI114165; WINGO CS, 1987, AM J PHYSIOL, V253, pF1136; YANG-FENG T L, 1988, Genomics, V2, P128, DOI 10.1016/0888-7543(88)90094-8	59	211	213	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13740	13748						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320029				2022-12-27	WOS:A1992JB74600101
J	SEVERINOV, K; MUSTAEV, A; KASHLEV, M; BORUKHOV, S; NIKIFOROV, V; GOLDFARB, A				SEVERINOV, K; MUSTAEV, A; KASHLEV, M; BORUKHOV, S; NIKIFOROV, V; GOLDFARB, A			DISSECTION OF THE BETA-SUBUNIT IN THE ESCHERICHIA-COLI RNA-POLYMERASE INTO DOMAINS BY PROTEOLYTIC CLEAVAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; FUNCTIONAL TOPOGRAPHY; RIFAMPICIN RESISTANCE; GENE ORGANIZATION; CORE SUBUNITS; RPOB GENE; TRANSCRIPTION; DNA; LOCALIZATION; INITIATION	The 1342 amino acid long beta-subunit of Escherichia coli RNA polymerase includes a dispensable region (residues 940-1040) that is absent in homologous RNA polymerase subunits from chloroplasts, eukaryotes, and archaebacteria (Borukhov, S., Severinov, K., Kashlev, M., Lebedev, A., Bass, I., Rowland, G. C., Lim, P.-P., Glass, R. E., Nikiforov, V., and Goldfarb, A. (1991) J. Biol. Chem. 266, 23921-23926). Genetic disruption of this region by in-frame deletion or insertion sensitizes the beta-subunit in assembled RNA polymerase molecules to attack by trypsin. We demonstrate that RNA polymerase with the beta-polypeptide cleaved in the dispensable region retains normal in vitro activity. Moreover, the RNA polymerase activity is completely restored after denaturation and reconstitution of the enzyme carrying cleaved beta-subunit indicating that its carboxyl- and amino-terminal parts fold and assemble into RNA polymerase as separate entities.	ACAD SCI USSR,INST MOLEC GENET,MOSCOW 123182,USSR; COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032	Russian Academy of Sciences; Columbia University			Severinov, Konstantin/C-8545-2016; Borukhov, Sergei/AAF-3195-2019	Borukhov, Sergei/0000-0002-3517-3003				ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BERGHOFER B, 1988, NUCLEIC ACIDS RES, V16, P8113, DOI 10.1093/nar/16.16.8113; BIGGS J, 1985, CELL, V42, P611, DOI 10.1016/0092-8674(85)90118-7; BORODIN AM, 1988, DOKL AKAD NAUK SSSR+, V302, P1261; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; BORUKHOV S, 1991, J BIOL CHEM, V266, P23932; Burgess R.R., 1987, RNA POLYM REGULATION, P3; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; FALKENBURG D, 1987, J MOL BIOL, V195, P929, DOI 10.1016/0022-2836(87)90496-7; GLASS RE, 1988, EUR J BIOCHEM, V176, P403, DOI 10.1111/j.1432-1033.1988.tb14296.x; GLASS RE, 1986, MOL GEN GENET, V203, P487, DOI 10.1007/BF00422074; GRACHEV MA, 1987, EUR J BIOCHEM, V163, P113, DOI 10.1111/j.1432-1033.1987.tb10743.x; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; GRACHEV MA, 1982, FEBS LETT, V137, P89, DOI 10.1016/0014-5793(82)80321-9; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HUDSON GS, 1988, J MOL BIOL, V200, P639, DOI 10.1016/0022-2836(88)90477-9; Ishihama A, 1981, Adv Biophys, V14, P1; IWABE N, 1991, J MOL EVOL, V32, P70, DOI 10.1007/BF02099931; JAMES S, 1991, J BIOL CHEM, V266, P5616; JIN DJ, 1991, J BIOL CHEM, V266, P14478; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KASHLEV MV, 1989, GENETIKA+, V25, P396; KING AMQ, 1974, BIOCHEM BIOPH RES CO, V59, P38, DOI 10.1016/S0006-291X(74)80170-1; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6018, DOI 10.1073/pnas.88.14.6018; LEE JY, 1991, CELL, V66, P793, DOI 10.1016/0092-8674(91)90122-F; LEFFERS H, 1989, J MOL BIOL, V206, P1, DOI 10.1016/0022-2836(89)90519-6; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; NIKIFOROV VG, 1985, FEBS LETT, V191, P72, DOI 10.1016/0014-5793(85)80996-0; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; OVCHINNIKOV YA, 1981, EUR J BIOCHEM, V116, P621, DOI 10.1111/j.1432-1033.1981.tb05381.x; OVCHINNIKOV YA, 1983, MOL GEN GENET, V190, P344, DOI 10.1007/BF00330662; PUHLER G, 1989, NUCLEIC ACIDS RES, V17, P4517, DOI 10.1093/nar/17.12.4517; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; TEISSERE M, 1990, EUR J BIOCHEM, V193, P913, DOI 10.1111/j.1432-1033.1990.tb19417.x; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2; ZILLIG W, 1976, RNA POLYMERASE, P101	43	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12813	12819						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1320005				2022-12-27	WOS:A1992HZ48300065
J	LANINI, L; BACHS, O; CARAFOLI, E				LANINI, L; BACHS, O; CARAFOLI, E			THE CALCIUM-PUMP OF THE LIVER NUCLEAR-MEMBRANE IS IDENTICAL TO THAT OF ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ION MOTIVE ATPASES; INTRACELLULAR CALCIUM; PLASMA-MEMBRANE; CALMODULIN; PROTEINS; ACTIVATION; QUIESCENT; RECEPTOR; CYCLE	The envelope membrane of rat liver nuclei contains a P-type Ca2+-transporting pump, revealed by the presence of a Ca2+-stimulated phosphoenzyme. The level of the nuclear phosphoenzyme in autoradiographed polyacrylamide gels was decreased by lanthanum, as typically observed in the endoplasmic reticulum Ca2+ pump. It was also decreased by thapsigargin and 2,5-di-(tert-butyl)-1,4-benzohydroquinone, two accepted inhibitors of the endoplasmic reticulum Ca2+-ATPase. Comparative proteolysis of the phosphorylated enzyme of liver microsomes (endoplasmic reticulum) and nuclear membranes revealed an identical cleavage pattern. In addition, antibodies raised against the endoplasmic reticulum Ca2+ pump cross-reacted with the pump in the nuclear membranes. The findings show that nuclear membranes contain a Ca2+-transporting pump closely related to that of the endoplasmic reticulum, if not identical to it. The pump is likely to be involved in the control of nuclear free calcium.	SWISS FED INST TECHNOL,INST BIOCHEM,UNIV STR 16,CH-8092 ZURICH,SWITZERLAND; UNIV BARCELONA,DEPT BIOL CELULAR,E-08036 BARCELONA,SPAIN	ETH Zurich; University of Barcelona			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				AMORY A, 1975, NATURE, V256, P597; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; BACHS O, 1990, J BIOL CHEM, V265, P18595; Bartfai T, 1979, Adv Cyclic Nucleotide Res, V10, P219; BURGOYNE RD, 1989, NATURE, V342, P72, DOI 10.1038/342072a0; CHAFOULEAS JG, 1982, CELL, V28, P41, DOI 10.1016/0092-8674(82)90373-7; CHAFOULEAS JG, 1984, CELL, V36, P73, DOI 10.1016/0092-8674(84)90075-8; CHAFOULEAS JG, 1981, J SUPRAMOL STRUCT S, V5, P233; CHAFOULEAS JG, 1984, CALCIUM CELL FUNCTIO, V5, P101; CHANDRA S, 1989, P NATL ACAD SCI USA, V86, P1870, DOI 10.1073/pnas.86.6.1870; CHARP PA, 1985, BIOCHIM BIOPHYS ACTA, V824, P34, DOI 10.1016/0167-4781(85)90026-0; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; HAZELTON B, 1979, J CELL BIOL, V83, P487, DOI 10.1083/jcb.83.2.487; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; KESSLER F, 1990, J BIOL CHEM, V265, P16012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG I, 1986, J CELL BIOL, V102, P1183, DOI 10.1083/jcb.102.4.1183; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; NEYLON CB, 1990, AM J PHYSIOL, V259, pC675, DOI 10.1152/ajpcell.1990.259.4.C675; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PUJOL MJ, 1989, J BIOL CHEM, V264, P18863; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; Schatzmann H J, 1978, Ann N Y Acad Sci, V307, P125, DOI 10.1111/j.1749-6632.1978.tb41939.x; SERRATOSA J, 1988, BIOCHEM BIOPH RES CO, V150, P1162, DOI 10.1016/0006-291X(88)90751-6; SWANSON MA, 1955, METHOD ENZYMOL, V2, P541, DOI 10.1016/S0076-6879(55)02247-7; SZASZ I, 1978, BIOCHIM BIOPHYS ACTA, V512, P331, DOI 10.1016/0005-2736(78)90257-2; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAYBILL MM, 1991, AM J PHYSIOL, V261, pE49, DOI 10.1152/ajpendo.1991.261.1.E49; Wharton DC., 1967, METHOD ENZYMOL, P245; WHITE BA, 1985, J BIOL CHEM, V260, P1213; WHITE FL, 1987, J FUTURES MARKETS, V7, P109, DOI 10.1002/fut.3990070111; WHITFIELD JF, 1976, IN VITRO CELL DEV B, V12, P1; WHITFIELD JF, 1987, CANCER METAST REV, V5, P205, DOI 10.1007/BF00046999; WHITFIELD JF, 1990, CALCIUM CELL CYCLES, P53; WILLIAMS DA, 1987, SCIENCE, V235, P1644, DOI 10.1126/science.3103219; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0; WUYTACK F, 1987, ROLE CALCIUM BIOL SY, V4, P115	45	135	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11548	11552						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317870				2022-12-27	WOS:A1992HX16900093
J	PRATT, CW; CHURCH, FC				PRATT, CW; CHURCH, FC			HEPARIN BINDING TO PROTEIN-C INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COFACTOR-II; ANTITHROMBIN-III; DERMATAN SULFATE; ANTI-THROMBIN; MECHANISM; KINETICS; PLASMA; PURIFICATION; INACTIVATION; DEFICIENCY	Protein C inhibitor is a plasma protein whose ability to inhibit activated protein C, thrombin, and other enzymes is stimulated by heparin. These studies were undertaken to further understand how heparin binds to protein C inhibitor and how it accelerates proteinase inhibition. The region of protein C inhibitor from residues 264-283 was identified as the heparin-binding site. This differs from the putative heparin-binding site in the related proteins antithrombin and heparin cofactor. The glycosaminoglycan specificity of protein C inhibitor was relatively broad, including heparin and heparan sulfate, but not dermatan sulfate. Non-sulfated and non-carboxylated polyanions also enhanced proteinase inhibition by protein C inhibitor. Heparin accelerated inhibition of alpha-thrombin, gamma(T)-thrombin, activated protein C, factor Xa, urokinase, and chymotrypsin, but not plasma kallikrein. The ability of glycosaminoglycans to accelerate proteinase inhibition appeared to depend on the formation of a ternary complex of inhibitor, proteinase, and glycosaminoglycan. The optimum heparin concentration for maximal rate stimulation varied from 10 to 100-mu-g/ml and was related to the apparent affinity of the proteinase for heparin. There was no obvious relationship between heparin affinity and maximum inhibition rate or degree of rate enhancement. The affinity of the resultant protein C inhibitor-proteinase complex was also not related to inhibition rate enhancement, and the results showed that decreased heparin affinity of the complex is not an important part of the catalytic mechanism of heparin. The importance of protein C inhibitor as a regulator of the protein C system may depend on the relatively large increase in heparin-enhanced inhibition rate for activated protein C compared to other proteinases.	UNIV N CAROLINA,SCH MED,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill					NHLBI NIH HHS [HL-06350] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUER KA, 1991, SEMIN HEMATOL, V28, P10; BJORK I, 1986, PROTEINASE INHIBITOR, P489; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CARLSTROM AS, 1977, THROMB RES, V11, P785, DOI 10.1016/0049-3848(77)90107-4; CHURCH FC, 1986, ANAL BIOCHEM, V157, P77, DOI 10.1016/0003-2697(86)90198-3; CHURCH FC, 1989, J BIOL CHEM, V264, P3618; CHURCH FC, 1987, BIOCHEM BIOPH RES CO, V148, P362, DOI 10.1016/0006-291X(87)91119-3; CHURCH FC, 1988, FEBS LETT, V237, P26, DOI 10.1016/0014-5793(88)80164-9; ENGESSER L, 1987, ANN INTERN MED, V106, P677, DOI 10.7326/0003-4819-106-5-677; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESPANA F, 1989, THROMB RES, V56, P751, DOI 10.1016/0049-3848(89)90292-2; GEIGER M, 1991, J BIOL CHEM, V266, P11851; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; GRIFFITH MJ, 1983, P NATL ACAD SCI-BIOL, V80, P5460, DOI 10.1073/pnas.80.18.5460; GRIFFITH MJ, 1985, J CLIN INVEST, V75, P4, DOI 10.1172/JCI111694; HEEB MJ, 1987, J BIOL CHEM, V262, P15813; HEEB MJ, 1988, J BIOL CHEM, V266, P17606; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KAZAMA Y, 1987, THROMB RES, V48, P179, DOI 10.1016/0049-3848(87)90414-2; KAZAMA Y, 1989, THROMB RES, V54, P499, DOI 10.1016/0049-3848(89)90220-X; KUHN LA, 1990, P NATL ACAD SCI USA, V87, P8506, DOI 10.1073/pnas.87.21.8506; LAURELL M, 1989, THROMB HAEMOSTASIS, V62, P885; NESHEIM ME, 1983, J BIOL CHEM, V258, P4708; OLSON ST, 1988, J BIOL CHEM, V263, P1698; PETERSON CB, 1987, J BIOL CHEM, V262, P7559; PRATT CW, 1992, J BIOL CHEM, V267, P8795; PRATT CW, 1989, THROMB RES, V53, P595, DOI 10.1016/0049-3848(89)90149-7; PRATT CW, 1991, FASEB J, V5, pA1540; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; SUZUKI K, 1987, J BIOL CHEM, V262, P611; SUZUKI K, 1984, J BIOCHEM, V95, P187, DOI 10.1093/oxfordjournals.jbchem.a134583; TEIEN AN, 1976, THROMB RES, V8, P859, DOI 10.1016/0049-3848(76)90014-1; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713	36	104	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8789	8794						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1315738				2022-12-27	WOS:A1992HR85400016
J	TAMURA, JK; BATES, AD; GELLERT, M				TAMURA, JK; BATES, AD; GELLERT, M			SLOW INTERACTION OF 5'-ADENYLYL-BETA,GAMMA-IMIDODIPHOSPHATE WITH ESCHERICHIA-COLI DNA GYRASE - EVIDENCE FOR COOPERATIVITY IN NUCLEOTIDE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-N-P; ADENOSINE-TRIPHOSPHATE; ATPASE ACTIVITY; NALIDIXIC-ACID; FREE-ENERGY; BASE-PAIRS; A-PROTEIN; TOPOISOMERASES; SUBUNIT; SITE	We have examined the kinetics of interaction between Escherichia coli DNA gyrase and the nonhydrolyzable ATP analog 5'-adenylyl-beta, gamma-imidodiphosphate (ADPNP) in the presence and absence of ATP. In the absence of ATP, [alpha-P-32]ADPNP binds extremely slowly to gyrase, with an apparent second-order rate constant (k1) of 120 M-1 min-1. Similarly, the limited negative supercoiling of closed-circular DNA caused by ADPNP binding is slow, requiring at least 2 h to reach completion in the presence of 100-mu-M ADPNP. A very slow but detectable rate of dissociation of ADPNP from gyrase was measured, with a rate constant of 3.5 x 10(-4) min-1. The calculated dissociation constant for ADPNP is thus 2.9-mu-M. ADPNP is a potent competitive inhibitor of ATP-dependent DNA supercoiling. Inhibition is established much more rapidly than can be accounted for by the slow rate of ADPNP binding in the absence of ATP. We have found that ATP can accelerate the rate of [P-32]ADPNP binding by more than 15-fold (k1 = 1,850 M-1 min-1). The ATP-promoted rate enhancement requires the presence of DNA; in the absence of DNA, ATP has no effect on the rate of binding. Relaxed closed-circular, nicked-circular, and linear pBR322 DNA are all equally effective cofactors for ATP-stimulated binding of ADPNP. After a short lag, the presence of ATP also greatly speeds up ADPNP dissociation from gyrase bound initially to closed-circular DNA, with the restoration of DNA supercoiling activity. This effect is not observed in the presence of nicked-circular or linear DNA, suggesting that ADPNP dissociates more rapidly from gyrase bound to supercoiled DNA. The results of ADPNP binding provide evidence for cooperative interactions between the nucleotide binding sites. To account for these data, a model is proposed for the interaction of nucleotides at the two ATP binding sites on DNA gyrase.			TAMURA, JK (corresponding author), NIDDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA.							ADACHI T, 1987, NUCLEIC ACIDS RES, V15, P771, DOI 10.1093/nar/15.2.771; BAGSHAW CR, 1973, BIOCHEM J, V133, P323, DOI 10.1042/bj1330323; BATES AD, 1989, EMBO J, V8, P1861, DOI 10.1002/j.1460-2075.1989.tb03582.x; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CROSS RL, 1982, J BIOL CHEM, V257, P2874; CROSS RL, 1984, CURR TOP CELL REGUL, V24, P335; FISHER LM, 1981, P NATL ACAD SCI-BIOL, V78, P4165, DOI 10.1073/pnas.78.7.4165; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; HILL TL, 1969, P NATL ACAD SCI USA, V64, P267, DOI 10.1073/pnas.64.1.267; HOROWITZ DS, 1987, J BIOL CHEM, V262, P5339; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; INOUEYOKOSAWA N, 1974, J BIOL CHEM, V249, P4321; Jencks W P, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P75; KIRKEGAARD K, 1981, CELL, V23, P721, DOI 10.1016/0092-8674(81)90435-9; KLEVAN L, 1980, BIOCHEMISTRY-US, V19, P5229, DOI 10.1021/bi00564a012; KRUEGER S, 1990, J MOL BIOL, V211, P211, DOI 10.1016/0022-2836(90)90021-D; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MAXWELL A, 1984, J BIOL CHEM, V259, P4472; MAXWELL A, 1986, 4TH P CONV BIOM STER, V3, P137; MIZUUCHI K, 1978, P NATL ACAD SCI USA, V75, P5960, DOI 10.1073/pnas.75.12.5960; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; MORRISON A, 1981, P NATL ACAD SCI-BIOL, V78, P1416, DOI 10.1073/pnas.78.3.1416; PEEBLES CL, 1979, COLD SPRING HARB SYM, V43, P41, DOI 10.1101/SQB.1979.043.01.008; RAU DC, 1987, J MOL BIOL, V193, P555, DOI 10.1016/0022-2836(87)90266-X; REECE RJ, 1989, J BIOL CHEM, V264, P19648; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; SIMMONS RM, 1976, NATURE, V263, P615, DOI 10.1038/263615b0; STAUDENBAUER WL, 1981, NUCLEIC ACIDS RES, V9, P3589, DOI 10.1093/nar/9.15.3589; SUGINO A, 1980, NUCLEIC ACIDS RES, V8, P3865, DOI 10.1093/nar/8.17.3865; SUGINO A, 1980, J BIOL CHEM, V255, P6299; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; SWANBERG SL, 1987, J MOL BIOL, V197, P729, DOI 10.1016/0022-2836(87)90479-7; TAMURA JK, 1990, J BIOL CHEM, V265, P21342; TAYLOR JS, 1981, J BIOL CHEM, V256, P9793; TOMASZEK TA, 1986, J BIOL CHEM, V261, P2264; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6; WANG JC, 1974, J MOL BIOL, V87, P797, DOI 10.1016/0022-2836(74)90085-0; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JH, 1983, ANNU REV BIOPHYS BIO, V12, P21, DOI 10.1146/annurev.bb.12.060183.000321; WESTERHOFF HV, 1988, CELL BIOPHYS, V12, P157, DOI 10.1007/BF02918357; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; YAMAGISHI J, 1986, MOL GEN GENET, V204, P367, DOI 10.1007/BF00331012; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2484, DOI 10.1021/bi00789a009; YOUNT RG, 1975, ADV ENZYMOL RAMB, V43, P1; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2490, DOI 10.1021/bi00789a010	47	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9214	9222						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1315750				2022-12-27	WOS:A1992HR85400078
J	ROSEN, ED; ODONNELL, AL; KOENIG, RJ				ROSEN, ED; ODONNELL, AL; KOENIG, RJ			LIGAND-DEPENDENT SYNERGY OF THYROID-HORMONE AND RETINOID X-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RESPONSE ELEMENT; GROWTH-HORMONE; NUCLEAR-PROTEIN; GENE-EXPRESSION; BETA GENE; BINDING; MUTATIONS; ACID; IDENTIFICATION; SUPERFAMILY	The binding of thyroid hormone receptors to DNA is enhanced by heterodimerization with nuclear proteins. One such heterodimerization partner has recently been characterized as the retinoid X receptor. 9-cis-Retinoic acid has been identified as a natural ligand for retinoid X receptors, suggesting a potential receptor-mediated interaction between thyroid hormone and 9-cis-retinoic acid in the regulation of thyroid hormone-responsive genes. A transient cotransfection assay was used to test for such an interaction. When a complex thyroid hormone response element composed of both direct and inverted repeat hexamers was tested, these two ligands activated gene expression synergistically. In contrast, when the response element consisted only of directly repeated hexamers, unliganded retinoid X receptors enhanced thyroid hormone responsiveness, but 9-cis-retinoic acid induced no additional activation. The results suggest a unique mechanism to achieve differential thyroid hormone sensitivity of thyroid hormone-responsive genes within a cell. Genes with appropriate response elements will show amplification of the thyroid hormone response by 9-cis-retinoic acid in the presence of retinoid X receptors; other thyroid hormone-responsive genes will be influenced by retinoid X receptors, but not 9-cis-retinoic acid.	UNIV MICHIGAN,MED CTR,DIV ENDOCRINOL,1150 W MED CTR DR,5560 MSRB2,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIDDK NIH HHS [DK44195] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; DOZIN B, 1985, BIOCHEMISTRY-US, V24, P5581, DOI 10.1021/bi00341a044; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LEE YP, 1965, J BIOL CHEM, V240, P1427; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; ODONNELL AL, 1990, MOL ENDOCRINOL, V4, P715, DOI 10.1210/mend-4-5-715; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; TAKEDA K, 1991, J CLIN INVEST, V87, P496, DOI 10.1172/JCI115023; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WILLIAMS GR, 1991, J BIOL CHEM, V266, P19636; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	32	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22010	22013						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331043				2022-12-27	WOS:A1992JW71900007
J	BOYLAN, JF; GUDAS, LJ				BOYLAN, JF; GUDAS, LJ			THE LEVEL OF CRABP-I EXPRESSION INFLUENCES THE AMOUNTS AND TYPES OF ALL-TRANS-RETINOIC ACID METABOLITES IN F9 TERATOCARCINOMA STEM-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; BINDING-PROTEIN CRABP; MOLECULAR-CLONING; DIFFERENTIATION; MOUSE; MALFORMATIONS; EMBRYOGENESIS; PREVENTION; RECEPTORS; RATS	The CRABP-I and CRABP-II proteins are high affinity cytoplasmic retinoic acid-binding proteins. In undifferentiated F9 teratocarcinoma stem cells, only the CRABP-I protein is expressed at detectable levels. We have previously shown that overexpression of the CRABP-I protein in stably transfected F9 stem cell lines results in a lower sensitivity to a given external concentration of retinoic acid relative to that of untransfected F9 cells; in contrast, reduced CRABP-I expression in CRABP-I cDNA anti-sense transfected lines is associated with increased sensitivity of these lines to retinoic acid. These three types of cell lines were cultured in the presence of 50 nM [H-3]retinoic acid, and the metabolism of retinoic acid was followed over the next 24 h. The results demonstrate that CRABP-I has the ability to alter both the levels and types of RA metabolites produced in the cytoplasm of differentiating embryonic stem cells. Moreover, the level of CRABP-I determines the rate of RA metabolism to 4-oxo-RA such that the higher the CRABP-I level, the faster the metabolism of [H-3]retinoic acid. This is the first reported connection between the level of CRABP-I expression and intracellular RA metabolism.	CORNELL UNIV,MED CTR,COLL MED,DEPT PHARMACOL,RM 409-E,1300 YORK AVE,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Cornell University; Cornell University					NATIONAL CANCER INSTITUTE [F32CA009251, R01CA043796] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010389] Funding Source: NIH RePORTER; NCI NIH HHS [1F32 CA09251-01, CA43796] Funding Source: Medline; NIDCR NIH HHS [DE10389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; DE LUCA LM, 1991, FASEB J, V5, P2924; DENCKER L, 1990, DEVELOPMENT, V110, P343; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; FROLIK CA, 1979, BIOCHEMISTRY-US, V18, P2092, DOI 10.1021/bi00577a039; FROLIK CA, 1984, RETINOIDS, V2, P177; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GUBLER ML, 1985, J BIOL CHEM, V260, P9552; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; MADEN M, 1990, DEVELOPMENT, V109, P75; MOON RC, 1990, BASIC LIFE SCI, V52, P213; MORRISSKAY G, 1991, SEMINARS DEV BIOL, V2, P211; NEBERT DW, 1991, MOL ENDOCRINOL, V5, P1203, DOI 10.1210/mend-5-9-1203; PEREZCASTRO AV, 1989, P NATL ACAD SCI USA, V86, P8813, DOI 10.1073/pnas.86.22.8813; POLLARD M, 1991, CANCER RES, V51, P3610; ROBERTS ES, 1992, MOL PHARMACOL, V41, P427; SHENEFELT RE, 1972, TERATOLOGY, V5, P103, DOI 10.1002/tera.1420050115; SHUBEITA HE, 1987, P NATL ACAD SCI USA, V84, P5645, DOI 10.1073/pnas.84.16.5645; STONER CM, 1989, CANCER RES, V49, P1497; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; SUNDELIN J, 1985, J BIOL CHEM, V260, P6494; VAESSEN MJ, 1990, DEVELOPMENT, V110, P371; VANWAUWE JP, 1990, J PHARMACOL EXP THER, V252, P365; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WILLIAMS JB, 1985, P NATL ACAD SCI USA, V82, P4658, DOI 10.1073/pnas.82.14.4658	28	246	254	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21486	21491						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328234				2022-12-27	WOS:A1992JV01100036
J	NEMOTO, Y; NAMBA, T; TERUUCHI, T; USHIKUBI, F; MORII, N; NARUMIYA, S				NEMOTO, Y; NAMBA, T; TERUUCHI, T; USHIKUBI, F; MORII, N; NARUMIYA, S			A RHO GENE-PRODUCT IN HUMAN BLOOD-PLATELETS .1. IDENTIFICATION OF THE PLATELET SUBSTRATE FOR BOTULINUM C3 ADP-RIBOSYLTRANSFERASE AS RHOA PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; BOVINE BRAIN MEMBRANES; CLOSTRIDIUM-BOTULINUM; MOLECULAR-CLONING; TOXIN TYPE-C1; HUMAN HOMOLOG; PURIFICATION; MR; RIBOSYLATION; SEQUENCE	A substrate protein for botulinum C3 ADP-ribosyl-transferase (C3 exoenzyme) in human platelets was purified to apparent homogeneity from the cytosol by ammonium sulfate fractionation and successive chromatography on columns of DEAE-Sepharose, hydroxylapatite, phenyl-Sepharose, and TSK phenyl-5PW. The purified protein yielded an amino acid sequence identical to that of rhoA protein. When platelet cytosol and membranes were incubated with C3 exoenzyme and [P-32]NAD and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and isoelectric focusing, they gave only one [P-32]ADP-ribosylated band on each electrophoresis that showed an M(r) of 22,000 and a pI of 6.0. The radioactive bands from the two fractions co-migrated with each other and with the [P-32]ADP-ribosylated purified protein. When these radioactive products were partially digested with either alpha-chymotrypsin or trypsin and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the same digestion pattern was found in the three samples. These results suggest that the ADP-ribosylation substrate for C3 exoenzyme in the platelet cytosol and membrane is rhoA protein and that it is the sole substrate detectable in human platelets.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,SAKYO KU,KYOTO 606,JAPAN	Kyoto University			Watanabe, Mamoru/AHE-0489-2022					AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; EVANS T, 1986, J BIOL CHEM, V261, P7052; HART MJ, 1991, J BIOL CHEM, V266, P20840; HOSHIJIMA M, 1990, MOL BRAIN RES, V7, P9, DOI 10.1016/0169-328X(90)90067-N; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORII N, 1992, J BIOL CHEM, V267, P20921; MORII N, 1990, J BIOCHEM-TOKYO, V107, P769, DOI 10.1093/oxfordjournals.jbchem.a123123; MORII N, 1988, J BIOL CHEM, V263, P12420; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; NAGATA K, 1989, J BIOL CHEM, V264, P17000; NARUMIYA S, 1988, BIOCHEM BIOPH RES CO, V150, P1122, DOI 10.1016/0006-291X(88)90745-0; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OGOROCHI T, 1989, BIOCHEM BIOPH RES CO, V163, P1175, DOI 10.1016/0006-291X(89)92344-9; OHASHI Y, 1987, BIOCHEM BIOPH RES CO, V142, P1032, DOI 10.1016/0006-291X(87)91518-X; OHASHI Y, 1987, J BIOL CHEM, V262, P1430; OHMORI T, 1988, BIOCHEM BIOPH RES CO, V157, P670, DOI 10.1016/S0006-291X(88)80302-4; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; POLAKIS PG, 1989, BIOCHEM BIOPH RES CO, V160, P25, DOI 10.1016/0006-291X(89)91615-X; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SEISS W, 1990, BIOCHEM BIOPH RES CO, V170, P944; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; WHITE JG, 1990, PLATELET 1990 PLATEL, P1; YAMAMOTO K, 1988, J BIOL CHEM, V263, P9926; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	37	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20916	20920						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328215				2022-12-27	WOS:A1992JT97800064
J	PORRAS, A; NEBREDA, AR; BENITO, M; SANTOS, E				PORRAS, A; NEBREDA, AR; BENITO, M; SANTOS, E			ACTIVATION OF RAS BY INSULIN IN 3T3-L1 CELLS DOES NOT INVOLVE GTPASE-ACTIVATING PROTEIN-PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TRK PROTOONCOGENE PRODUCT; SERINE THREONINE KINASES; SIGNAL-TRANSDUCTION; TYROSINE KINASE; PC12 CELLS; P21RAS ACTIVATION; GENE-EXPRESSION; XENOPUS OOCYTES; MAP KINASES	Insulin-induced differentiation of 3T3 L1 cells to adipocytes can be mimicked by the expression of transfected ras oncogenes but not of the tyrosine-kinase oncogenes src and trk. Expression of two different transfected, dominant inhibitory ras mutants resulted in significant inhibition of insulin-induced differentiation, suggesting that endogenous Ras proteins are mediators of insulin signaling in these cells. Exposure of untransfected 3T3 L1 cells to insulin resulted in significant formation of the active Ras.GTP complex, at levels comparable with those resulting from exposure to platelet-derived growth factor. However, whereas exposure of the same cells to platelet-derived growth factor resulted in significant tyrosine phosphorylation of the p21ras GTPase-activating protein (GAP), insulin-treated cells did not show any detectable levels of de novo GAP tyrosine phosphorylation. Interestingly, insulin caused tyrosine phosphorylation of the p62 polypeptide coprecipitated with GAP by anti-GAP antibodies. Insulin-induced activation of cytosolic MAP kinase activity in untransfected 3T3 L1 cells was also mimicked by Ras expression (in the absence of insulin) in the same cells transfected with an inducible ras construct. These results confirm that Ras proteins participate in insulin signaling pathways in these mammalian cells and indicate that activation of cytosolic MAP kinases is an early event occurring downstream from Ras activation. However, tyrosine phosphorylation of GAP appears not to be a significant upstream regulatory event in the activation of Ras by insulin.	NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,RM 1D28,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Porras, Almudena/N-2121-2015; Nebreda, Angel Rodriguez/R-9594-2019; Benito, Manuel/J-5637-2014	Porras, Almudena/0000-0002-6495-3308; Benito, Manuel/0000-0002-7218-406X				AHN NG, 1990, J BIOL CHEM, V265, P11487; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COOK JS, 1988, P NATL ACAD SCI USA, V85, P2949, DOI 10.1073/pnas.85.9.2949; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ERIKSON AK, 1990, J BIOL CHEM, V265, P19728; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HEIDARAN MA, 1992, ONCOGENE, V7, P147; HRESKO RC, 1988, P NATL ACAD SCI USA, V85, P8835, DOI 10.1073/pnas.85.23.8835; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIN X, 1991, MOL CELL BIOL, V11, P2511; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; PEARSE AG, 1968, HISTOCHEMISTRY; RAPP UR, 1991, ONCOGENE, V6, P495; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; SCHMIDT W, 1990, J BIOL CHEM, V265, P15489; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	66	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21124	21131						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328223				2022-12-27	WOS:A1992JT97800095
J	TROLL, H; MALCHOW, D; MULLERTAUBENBERGER, A; HUMBEL, B; LOTTSPEICH, F; ECKE, M; GERISCH, G; SCHMID, A; BENZ, R				TROLL, H; MALCHOW, D; MULLERTAUBENBERGER, A; HUMBEL, B; LOTTSPEICH, F; ECKE, M; GERISCH, G; SCHMID, A; BENZ, R			PURIFICATION, FUNCTIONAL-CHARACTERIZATION, AND CDNA SEQUENCING OF MITOCHONDRIAL PORIN FROM DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX PROTEIN PORIN; OUTER-MEMBRANE; NEUROSPORA-CRASSA; PARAMECIUM MITOCHONDRIA; ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; FORMING PROTEIN; LIPID BILAYERS; CHANNELS; SELECTIVITY	Porin of Dictyostelium discoideum was extracted from mitochondria with Genapol X-80 and was purified by hydroxyapatite and CM-cellulose chromatography. The purified protein displayed a single band of 30 kDa in SDS-polyacrylamide gel electrophoresis. The formation of channels in artificial lipid bilayer membranes defined its function as a channel-forming component. Its average single-channel conductance was 3.9 nanosiemens in 1 M KCl, which suggested that the effective diameter of the channel is approximately 1.7 nm at small transmembrane potentials. The channel displayed a characteristic voltage dependence for potentials higher than 20 mV. It switched to substates of smaller conductance and a selectivity different to that of the open state. The closed state was stabilized at low ionic strength. The cDNA sequence of mitochondrial porin from D. discoideum was determined. It showed little sequence similarities to other known mitochondrial porins. The functional similarity, however, was striking. Localization of the porin in the mitochondrial outer membrane was confirmed by immunogold labeling of cryosections of fixed cells.	MAX PLANCK INST BIOCHEM, W-8033 MARTINSRIED, GERMANY; UNIV WURZBURG, BIOZENTRUM, LEHRSTUHL BIOTECHNOL, W-8700 WURZBURG, GERMANY	Max Planck Society; University of Wurzburg	TROLL, H (corresponding author), UNIV CONSTANCE, FAK BIOL, W-7750 CONSTANCE, GERMANY.		Müller-Taubenberger, Annette/AAG-8538-2020; Müller-Taubenberger, Annette/AAM-3671-2021	Müller-Taubenberger, Annette/0000-0003-1163-9232; Benz, Roland/0000-0002-9510-9265				BENZ R, 1990, BIOCHIM BIOPHYS ACTA, V1022, P311, DOI 10.1016/0005-2736(90)90279-W; BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1992, J BIOENERG BIOMEMBR, V24, P33, DOI 10.1007/BF00769528; BENZ R, 1985, CRC CR REV BIOCH MOL, V19, P145, DOI 10.3109/10409238509082542; BIRRELL GB, 1987, J HISTOCHEM CYTOCHEM, V35, P843, DOI 10.1177/35.8.2439584; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BRDICZKA D, 1989, ANION CARRIERS OF MITOCHONDRIAL MEMBRANES, P361; CASTELLAN GW, 1983, PHYSICAL CHEM, P769; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; COLOMBINI M, 1980, J MEMBRANE BIOL, V53, P79, DOI 10.1007/BF01870576; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P1, DOI 10.1007/BF00592566; DEPINTO V, 1989, EUR J BIOCHEM, V183, P179; DEPINTO V, 1990, FEBS LETT, V274, P122, DOI 10.1016/0014-5793(90)81345-O; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V894, P109, DOI 10.1016/0005-2728(87)90180-0; DEPINTO V, 1991, BIOCHEMISTRY-US, V30, P10191, DOI 10.1021/bi00106a017; DEPINTO V, 1989, ION CARRIERS MITOCHO, P237; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORING C, 1985, J MEMBRANE BIOL, V83, P87, DOI 10.1007/BF01868741; ENHENEGOUWEN PMP, 1986, HISTOCHEMISTRY, V85, P81; FREITAG H, 1982, EUR J BIOCHEM, V123, P629; KAYSER H, 1989, BIOL CHEM H-S, V370, P1265; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; KOTTKE M, 1988, BIOCHIM BIOPHYS ACTA, V935, P87, DOI 10.1016/0005-2728(88)90111-9; KRAUSE J, 1986, BIOCHIM BIOPHYS ACTA, V860, P690, DOI 10.1016/0005-2736(86)90568-7; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LINDEN M, 1989, J BIOENERG BIOMEMBR, V21, P507, DOI 10.1007/BF00762522; LINDEN M, 1982, BIOCHEM J, V208, P77, DOI 10.1042/bj2080077; LUDWIG O, 1986, BIOCHIM BIOPHYS ACTA, V860, P268, DOI 10.1016/0005-2736(86)90523-7; LUDWIG O, 1989, BIOCHIM BIOPHYS ACTA, V978, P319, DOI 10.1016/0005-2736(89)90131-4; LUDWIG O, 1988, EUR BIOPHYS J BIOPHY, V15, P269, DOI 10.1007/BF00256477; MANNELLA CA, 1984, BIOPHYS J, V45, P139, DOI 10.1016/S0006-3495(84)84140-5; MANNELLA CA, 1984, ULTRAMICROSCOPY, V13, P93, DOI 10.1016/0304-3991(84)90060-3; MANNELLA CA, 1992, J BIOENERG BIOMEMBR, V24, P7, DOI 10.1007/BF00769525; MIHARA K, 1985, EMBO J, V4, P769, DOI 10.1002/j.1460-2075.1985.tb03695.x; MIHARA K, 1982, P NATL ACAD SCI-BIOL, V79, P7102, DOI 10.1073/pnas.79.23.7102; NAKAE T, 1976, J BIOL CHEM, V251, P2176; OIKI S, 1988, P NATL ACAD SCI USA, V85, P2393, DOI 10.1073/pnas.85.7.2393; PFALLER R, 1985, J BIOL CHEM, V260, P8188; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; ROOS N, 1982, BIOCHIM BIOPHYS ACTA, V686, P204, DOI 10.1016/0005-2736(82)90114-6; SAMESHIMA M, 1991, CELL MOTIL CYTOSKEL, V18, P293, DOI 10.1002/cm.970180406; SANDERMANN H, 1972, J BIOL CHEM, V247, P5123; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; SCHWARZ H, 1989, SCANNING MICROSCOPY, P57; STEFANINI M, 1967, NATURE, V216, P173, DOI 10.1038/216173a0; STIERHOF YD, 1991, J ELECTRON MICR TECH, V17, P336, DOI 10.1002/jemt.1060170307; THINNES FP, 1984, BIOL CHEM HOPPESEYLE, V370, P1265; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; ZALMAN LS, 1980, J BIOL CHEM, V255, P1771	55	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21072	21079						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328220				2022-12-27	WOS:A1992JT97800088
J	LEBONNIEC, BF; GUINTO, ER; ESMON, CT				LEBONNIEC, BF; GUINTO, ER; ESMON, CT			INTERACTION OF THROMBIN DES-ETW WITH ANTITHROMBIN-III, THE KUNITZ INHIBITORS, THROMBOMODULIN AND PROTEIN-C - STRUCTURAL LINK BETWEEN THE AUTOLYSIS LOOP AND THE TYR-PRO-PRO-TRP INSERTION OF THROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; BLOOD-COAGULATION; CRYSTAL-STRUCTURE; BINDING-SITE; ACTIVE-SITE; HUMAN-PROTHROMBIN; CLOTTING ACTIVITY; HIRUDIN COMPLEX; ACTIVATION; RESIDUES	X-ray diffraction studies of human thrombin revealed that compared with trypsin, two insertions (B and C) potentially limit access to the active site groove. When amino acids Glu146, Thr147, and Trp148, adjacent to the C-insertion (autolysis loop), are deleted the resulting thrombin (des-ETW) has dramatically altered interaction with serine protease inhibitors. Whereas des-ETW resists antithrombin III inactivation with a rate constant (K(on)) almost-equal-to 350-fold slower than for thrombin, des-ETW is remarkably sensitive to the Kunitz inhibitors, with inhibition constants (K(i)) decreased from 2.6 muM to 34 nM for the soybean trypsin inhibitor and from 52 muM to 1.8 muM for the bovine pancreatic trypsin inhibitor. The affinity for hirudin (K(i) = 5.6 pm) is weakened at least 30-fold compared with recombinant thrombin. The mutation affects the charge stabilizing system and the primary binding pocket of thrombin as depicted by a decrease in K(on) for diisopropylfluorophosphate (9.5-fold) and for N(alpha)-p-tosyl-L-lysine-chloromethyl ketone (51-fold) and a 39-fold increase in the K(i) for benzamidine. With peptidyl p-nitroanilide substrates, the des-ETW deletion results in changes in the Michaelis (K(m)) and/or catalytic (k(cat)) constants, worsened as much as 85-fold (K(m)) or 100-fold (k(cat)). The specific clotting activity of des-ETW is less than 5% that of thrombin and the k(cat)/K(m) for protein C activation in the absence of cofactor less than 2%. Thrombomodulin binds to des-ETW with a dissociation constant of almost-equal-to 2.5 nM and partially restores its ability to activate protein C since, in the presence of the cofactor, k(cat)/K(m) rises to 6.5% that of thrombin. This study suggests that the ETW motif of thrombin prevents (directly or indirectly) its interaction with the two Kunitz inhibitors and is not essential for the thrombomodulin-mediated enhancement of protein C activation.	OKLAHOMA MED RES FDN, CARDIOVASC BIOL RES PROGRAM, 825 NE 13TH ST, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT PATHOL, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HOWARD HUGHES MED INST, OKLAHOMA CITY, OK 73104 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center			Le Bonniec, Bernard/ABA-1366-2020; Le Bonniec, Bernard/S-5756-2016	Le Bonniec, Bernard/0000-0002-8432-7363; Le Bonniec, Bernard/0000-0002-8432-7363	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030340, R01HL029807] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL29807, R37-HL30340] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; ASCENZI P, 1988, BIOCHIM BIOPHYS ACTA, V956, P156, DOI 10.1016/0167-4838(88)90262-2; BANNER DW, 1991, J BIOL CHEM, V266, P20085; BERLINER LJ, 1986, ANN NY ACAD SCI, V485, P80, DOI 10.1111/j.1749-6632.1986.tb34570.x; BETZ A, 1991, BIOCHEMISTRY-US, V30, P9848, DOI 10.1021/bi00105a006; BEZEAUD A, 1988, J BIOL CHEM, V263, P3576; BEZEAUD A, 1985, EUR J BIOCHEM, V153, P491, DOI 10.1111/j.1432-1033.1985.tb09328.x; BING DH, 1977, J BIOL CHEM, V252, P8027; BLOW DM, 1974, NATURE, V249, P55, DOI 10.1038/249054a0; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BOISSEL JP, 1984, J BIOL CHEM, V259, P5691; BRAUN PJ, 1988, BIOCHEMISTRY-US, V27, P6517, DOI 10.1021/bi00417a048; BREZNIAK DV, 1990, BIOCHEMISTRY-US, V29, P3536, DOI 10.1021/bi00466a017; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CHANG JY, 1986, BIOCHEM J, V240, P797, DOI 10.1042/bj2400797; CHANG JY, 1989, J BIOL CHEM, V264, P7141; CHASE T, 1970, METHOD ENZYMOL, V19, P21; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; ESMON CT, 1982, J BIOL CHEM, V257, P7944; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P3634, DOI 10.1021/bi00410a017; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; IRWIN DM, 1986, THESIS U BRIT COLUMB; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KAWABATA S, 1985, J BIOCHEM, V97, P325, DOI 10.1093/oxfordjournals.jbchem.a135057; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAZAR JB, 1991, J BIOL CHEM, V266, P685; LEATHERBARROW RJ, 1987, ENZFITTER PROGRAM NO; LEBONNIEC B, 1988, ANAL BIOCHEM, V174, P280, DOI 10.1016/0003-2697(88)90547-7; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; LONGSTAFF C, 1990, BIOCHEMISTRY-US, V29, P7339, DOI 10.1021/bi00483a025; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MAO SJT, 1988, BIOCHEMISTRY-US, V27, P8170, DOI 10.1021/bi00421a027; Markwardt F., 1970, METHOD ENZYMOL, V19, P924, DOI [10.1016/0076-6879(70)19082-3, DOI 10.1016/0076-6879(70)19082-3]; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; NOE G, 1988, J BIOL CHEM, V263, P11729; OLSON ST, 1982, J BIOL CHEM, V257, P4891; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; STONE SR, 1991, BIOCHEMISTRY-US, V30, P3950, DOI 10.1021/bi00230a021; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; SUZUKI K, 1990, J BIOL CHEM, V265, P13263; SWEET RM, 1974, BIOCHEMISTRY-US, V13, P4212, DOI 10.1021/bi00717a024; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WALLIS RB, 1988, TRENDS PHARMACOL SCI, V9, P425, DOI 10.1016/0165-6147(88)90124-1; WALZ DA, 1986, ANN NY ACAD SCI, V485, P323, DOI 10.1111/j.1749-6632.1986.tb34594.x; Williams J W, 1979, Methods Enzymol, V63, P437; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775	67	76	76	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19341	19348						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326550				2022-12-27	WOS:A1992JP59300050
J	BRAWLEY, RM; HOSEY, MM				BRAWLEY, RM; HOSEY, MM			IDENTIFICATION OF 2 DISTINCT PROTEINS THAT ARE IMMUNOLOGICALLY RELATED TO THE ALPHA-1-SUBUNIT OF THE SKELETAL-MUSCLE DIHYDROPYRIDINE-SENSITIVE CALCIUM-CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CA-2+ CHANNEL; POLARIZED PLANAR BILAYERS; 1,4-DIHYDROPYRIDINE RECEPTOR; TRANSVERSE TUBULES; CA CHANNELS; KINASE-C; PHOSPHORYLATION; SUBUNITS; PURIFICATION; BINDING	The alpha-1 subunit of the dihydropyridine-sensitive calcium channel is a protein which is critical for excitation-contraction coupling and L-type calcium current in skeletal muscle. Using antibodies generated against peptides from three regions of the deduced amino acid sequence of the alpha-1 subunit, we have identified two distinct proteins in rabbit skeletal muscle. Both proteins appeared to be recognized by antibodies against the amino (N) terminus of the alpha-1 subunit sequence. One protein was also recognized by antibodies against an internal (I) region of the predicted sequence but not by antibodies against the carboxyl (C) terminus. In contrast, the other protein was recognized by antibodies against the carboxyl terminus but not by the antibodies against the internal region. We have designated these proteins pNI and pNC based on their patterns of antibody recognition. No protein was detected which was recognized by all three antibodies. pNI is the protein commonly identified as the alpha-1 subunit of the dihydropyridine-sensitive calcium channel. Of note is that pNI, which apparently lacks sequences from the predicted carboxyl tail, is the protein present in preparations which we have previously demonstrated contain dihydropyridine-sensitive calcium channel activity. pNC is herein identified as a skeletal muscle protein that is immunologically related to the alpha-1 subunit of the dihydropyridine-sensitive calcium channel. Its function is unknown. In addition to their distinct patterns of antibody recognition, pNI and pNC were also distinguishable by several other properties. pNC migrated as a protein of approximately 160 kDa in 5% sodium dodecyl sulfate-polyacrylamide gels versus approximately 165 kDa for pNI. pNI was enriched in transverse tubule membranes, whereas pNC was found to be enriched in triad and junctional sarcoplasmic reticulum membrane fractions and was not found in transverse tubule membranes. Under conditions in which pNI bound to wheat germ agglutinin-Sepharose, pNC did not bind. The results demonstrate that there are two proteins in skeletal muscle which are immunologically related to the alpha-1 subunit of the dihydropyridine-sensitive calcium channel but which are distinguishable by several biochemical and immunological characteristics.	NORTHWESTERN UNIV,SCH MED,DEPT PHARMACOL,303 E CHICAGO AVE,CHICAGO,IL 60611	Northwestern University					NHLBI NIH HHS [HL-23306] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023306, R37HL023306] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BORSOTTO M, 1985, J BIOL CHEM, V260, P4255; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHANG CF, 1991, J BIOL CHEM, V266, P16395; CURTIS BM, 1984, BIOCHEMISTRY-US, V23, P2113, DOI 10.1021/bi00305a001; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FOSSET M, 1983, J BIOL CHEM, V258, P6086; GALIZZI JP, 1984, EUR J BIOCHEM, V144, P211, DOI 10.1111/j.1432-1033.1984.tb08451.x; GUTIERREZ LM, 1991, J BIOL CHEM, V266, P16387; HOSEY MM, 1988, J MEMBRANE BIOL, V104, P81, DOI 10.1007/BF01870922; HOSEY MM, 1987, BIOCHEM BIOPH RES CO, V147, P1137; IMAGAWA T, 1987, J BIOL CHEM, V262, P8333; JAHN H, 1988, EUR J BIOCHEM, V178, P535, DOI 10.1111/j.1432-1033.1988.tb14480.x; KIM HS, 1990, J BIOL CHEM, V265, P11858; KRANER S, 1989, J BIOL CHEM, V264, P13273; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; MA JJ, 1991, BIOPHYS J, V60, P890, DOI 10.1016/S0006-3495(91)82123-3; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MITCHELL RD, 1983, J CELL BIOL, V96, P1008, DOI 10.1083/jcb.96.4.1008; MOCZYDLOWSKI EG, 1983, BIOCHIM BIOPHYS ACTA, V732, P412, DOI 10.1016/0005-2736(83)90058-5; MUNDINAWEILENMANN C, 1991, BIOPHYS J, V60, P902, DOI 10.1016/S0006-3495(91)82124-5; OCALLAHAN CM, 1988, J BIOL CHEM, V263, P17342; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; SHARP AH, 1987, J BIOL CHEM, V262, P12309; SHULMAN D, 1992, FASEB J, V6, P21; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0	28	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18218	18223						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325462				2022-12-27	WOS:A1992JM22300112
J	ROTH, EJ; KURZ, B; LIANG, LM; HANSEN, CL; DAMERON, CT; WINGE, DR; SMOTKIN, D				ROTH, EJ; KURZ, B; LIANG, LM; HANSEN, CL; DAMERON, CT; WINGE, DR; SMOTKIN, D			METAL THIOLATE COORDINATION IN THE E7 PROTEINS OF HUMAN PAPILLOMA VIRUS-16 AND COTTONTAIL RABBIT PAPILLOMA-VIRUS AS EXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; COPPER METALLOTHIONEIN; CERVICAL-CARCINOMA; DNA-SEQUENCE; TYPE-16; CELLS; IDENTIFICATION; TRANSCRIPTION; COMPLEXES; PHOTOLUMINESCENCE	The oncogenic E7 proteins of human papilloma virus (HPV 16) and of cottontail rabbit papilloma virus (CRPV) have been purified from an expression system in Escherichia coli. The proteins as purified from E. coli contain one tightly bound Zn(II) ion per molecule. The metal site shows facile exchange with either Cd(II) or Cu(I). The HPV 16 E7 maximally bound one Cd(II) or two Cu(I) ions, while the CRPV E7 bound two Cd(II) or three Cu(I) ions. The Cd(II) and Cu(I) E7 molecules exhibited optical transitions in the ultraviolet suggestive of metal:thiolate coordination. E7 proteins from HPV 16 and CRPV contain 7 and 8 cysteines/molecule, respectively. Reaction of the E7 proteins with the sulfhydryl reagent, dithiodipyridine, revealed that all the cysteinyl sulfurs are present in the reduced thiol state. Cu(I)-E7 molecules are luminescent with maximal emission at 570 nm. The observed emission at room temperature is indicative of metal coordination within a compact protein environment shielded from solvent interactions. The emission maxima occurs at the same wavelength (570 nm) as Cu(I)-cysteinyl sulfur clusters in Cu(I)-metallothioneins. The single Zn(II) atom in each protein can be removed from E7 in the presence of EDTA. The resulting apoE7 molecules remain soluble and can be partially reconstituted with Cd(II) to regain the ultraviolet charge transfer transitions.	UNIV UTAH, DEPT OBSTET & GYNECOL, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, DEPT BIOCHEM, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NATIONAL CANCER INSTITUTE [P30CA042014, R29CA047127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES003817, R01ES003817] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA42014, CA47127] Funding Source: Medline; NIEHS NIH HHS [ES03817] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADMAN E, 1975, P NATL ACAD SCI USA, V72, P4854, DOI 10.1073/pnas.72.12.4854; BARBOSA MS, 1988, VIROLOGY, V165, P134, DOI 10.1016/0042-6822(88)90666-6; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BAUMGARTNER MR, 1990, THESIS U ZURICH; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; BELTRAMINI M, 1989, BIOCHEM J, V260, P189, DOI 10.1042/bj2600189; BUTT TR, 1989, P NATL ACAD SCI USA, V86, P2540, DOI 10.1073/pnas.86.8.2540; BYRD J, 1988, J BIOL CHEM, V263, P6688; CULP JS, 1988, P NATL ACAD SCI USA, V85, P6450, DOI 10.1073/pnas.85.17.6450; Dalgarno D C, 1984, Adv Inorg Biochem, V6, P113; DAMERON CT, 1991, P NATL ACAD SCI USA, V88, P6127, DOI 10.1073/pnas.88.14.6127; DANOS O, 1982, EMBO J, V1, P231, DOI 10.1002/j.1460-2075.1982.tb01152.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ECKER DJ, 1987, J BIOL CHEM, V262, P14213; GEORGE GN, 1988, J BIOL CHEM, V263, P8199; GIRI I, 1985, P NATL ACAD SCI USA, V82, P1580, DOI 10.1073/pnas.82.6.1580; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HENARY M, 1989, J AM CHEM SOC, V111, P7407, DOI 10.1021/ja00201a020; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; LYTLE FE, 1970, APPL SPECTROSC, V24, P319, DOI 10.1366/000370270774371651; MCMILLIN DR, 1985, COORDIN CHEM REV, V64, P83, DOI 10.1016/0010-8545(85)80043-6; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MUNGER K, 1989, J VIROL, V63, P4417; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NASSERI M, 1984, J VIROL, V51, P706, DOI 10.1128/JVI.51.3.706-712.1984; NASSERI M, 1989, VIROLOGY, V170, P321, DOI 10.1016/0042-6822(89)90388-7; ROBBINS AH, 1991, J MOL BIOL, V221, P1269, DOI 10.1016/0022-2836(91)90933-W; SCHNEIDER G, 1983, P NATL ACAD SCI-BIOL, V80, P5289, DOI 10.1073/pnas.80.17.5289; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SOUTH TL, 1990, METAL ION INDUCED RE, V8, P199; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VOGLER A, 1986, J AM CHEM SOC, V108, P7211, DOI 10.1021/ja00283a012; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	41	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16390	16395						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322900				2022-12-27	WOS:A1992JJ45800064
J	BU, GJ; MORTON, PA; SCHWARTZ, AL				BU, GJ; MORTON, PA; SCHWARTZ, AL			IDENTIFICATION AND PARTIAL CHARACTERIZATION BY CHEMICAL CROSS-LINKING OF A BINDING-PROTEIN FOR TISSUE-TYPE PLASMINOGEN-ACTIVATOR (T-PA) ON RAT HEPATOMA-CELLS - A PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1-INDEPENDENT T-PA RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY THROMBOLYSIS; MEDIATED ENDOCYTOSIS; EXTRACELLULAR-MATRIX; LIPOPROTEIN RECEPTOR; HIGH-AFFINITY; LINE HEP-G2; CATABOLISM; UROKINASE; PURIFICATION; HEPATOCYTES	Plasma tissue-type plasminogen activator (t-PA) is cleared rapidly in vivo by the liver. Previous studies with the human hepatoma cell line HepG2 have identified a clearance system for t-PA modulated by plasminogen activator inhibitor type 1 (PAI-1). In the present study, a rat hepatoma cell line MH1C1 is shown to contain a PAI-1-independent t-PA clearance system. At 4-degrees-C, binding of I-125-t-PA to MH1C1 cells was rapid, specific, and saturable. Scatchard analysis of the binding data yielded a mean estimate of 105,000 high affinity binding sites per cell (K(d) = 4.1 nM). When the bound ligand was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the majority (about 90%) of the specific binding was in the form of uncomplexed I-125-t-PA. This is in contrast to HepG2 cells in which specific binding was mainly in the form of a sodium dodecyl sulfate-stable I-125-PA.PAI-1 complex. When availability of matrix-associated PAI-1 was blocked by preincubation with anti-PAI-1 antibody or removed by elastase treatment, specific I-125-t-PA binding to MH1C1 cells was unaffected, whereas most of the specific I-125-t-PA binding to HepG2 cells was abolished. Furthermore, when the active site of t-PA was inactivated with diisopropyl fluorophosphate, the diisopropyl fluorophosphate-t-PA specifically competed for binding of I-125-t-PA to MH1C1 cells, but failed to block specific I-125-t-PA binding to HepG2 cells. At 37-degrees-C, PAI-1-independent t-PA binding to MH1C1 cells was followed by ligand uptake and degradation with kinetics similar to that seen in HepG2 cells. Chemical cross-linking of t-PA to MH1C1 cells revealed a specific t-PA binding protein with a molecular mass of about 500,000 daltons. Ligand-receptor complexes generated by chemical cross-linking were immunoprecipitable by anti-t-PA antibody but not by anti-PAI-1 antibody, further supporting the finding that binding of t-PA to MH1C1 cells is PAI-1-independent.	WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; ST LOUIS CHILDRENS HOSP,DIV PEDIAT HEMATOL ONCOL,ST LOUIS,MO 63178	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL017646, P50HL017646] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL17646] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKHIT C, 1987, J BIOL CHEM, V262, P8716; BEEBE DP, 1986, THROMB RES, V43, P663, DOI 10.1016/0049-3848(86)90103-9; BERGMANN SR, 1983, SCIENCE, V220, P1181; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BOUNAMEAUX H, 1985, THROMBOLYSIS BIOL TH, P85; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEVRIES S R, 1987, Fibrinolysis, V1, P17, DOI 10.1016/0268-9499(87)90027-0; EMEIS JJ, 1985, THROMB HAEMOSTASIS, V54, P661; FUCHS HE, 1985, BLOOD, V65, P539; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HAJJAR KA, 1990, J BIOL CHEM, V265, P2908; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; KORNINGER C, 1981, THROMB HAEMOSTASIS, V46, P658; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORTON PA, 1990, J BIOL CHEM, V265, P14093; MORTON PA, 1989, J BIOL CHEM, V264, P7228; OWENSBY DA, 1988, J BIOL CHEM, V263, P10587; OWENSBY DA, 1989, J BIOL CHEM, V264, P18180; OWENSBY DA, 1991, J BIOL CHEM, V266, P4334; PLOUG M, 1991, J BIOL CHEM, V266, P1926; RIJKEN DC, 1981, J BIOL CHEM, V256, P7035; RIJKEN DC, 1986, BIOCHEM J, V238, P643, DOI 10.1042/bj2380643; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWARTZ AL, 1981, J BIOL CHEM, V256, P8878; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANDEWERF F, 1984, NEW ENGL J MED, V310, P609; VERSTRAETE M, 1985, J PHARMACOL EXP THER, V235, P506; WING LR, 1991, FEBS LETT, V278, P95, DOI 10.1016/0014-5793(91)80092-H; WUN TC, 1989, J BIOL CHEM, V264, P7862; 1985, NEW ENGL J MED, V310, P609	32	65	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15595	15602						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322401				2022-12-27	WOS:A1992JG11300055
J	VASSBOTN, FS; OSTMAN, A; SIEGBAHN, A; HOLMSEN, H; HELDIN, CH				VASSBOTN, FS; OSTMAN, A; SIEGBAHN, A; HOLMSEN, H; HELDIN, CH			NEOMYCIN IS A PLATELET-DERIVED GROWTH-FACTOR (PDGF) ANTAGONIST THAT ALLOWS DISCRIMINATION OF PDGF ALPHA-RECEPTOR AND BETA-RECEPTOR SIGNALS IN CELLS EXPRESSING BOTH RECEPTOR TYPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN SARCOMA-VIRUS; B-TYPE RECEPTOR; HUMAN-FIBROBLASTS; MONOCLONAL-ANTIBODY; DIFFERENT ISOFORMS; KINASE ACTIVATION; DNA-SYNTHESIS; A-CHAIN; BINDING; IDENTIFICATION	The aminoglycoside neomycin has recently been found to affect certain platelet-derived growth factor (PDGF) responses in C3H/10T1/2 C18 fibroblasts. Using porcine aortic endothelial cells transfected with PDGF alpha- or beta-receptors, we explored the possibility that neomycin interferes with the interaction between the different PDGF isoforms and their receptors. We found that neomycin (5 mM) inhibited the binding of I-125-PDGF-BB to the alpha-receptor with only partial effect on the binding of I-125-PDGF-AA; in contrast, the binding of I-125-PDGF-BB to the beta-receptor was not affected by the aminoglycoside. Scatchard analyses showed that neomycin (5 mM) decreased the number of binding sites for PDGF-BB on alpha-receptor-expressing cells by 87%. Together with cross-competition studies with I-125-labeled PDGF homodimers, the effect of neomycin indicates that PDGF-AA and PDGF-BB bind to both common and unique structures on the PDGF alpha-receptor. Neomycin specifically inhibited the autophosphorylation of the alpha-receptor by PDGF-BB, with less effect on the phosphorylation induced by PDGF-AA and no effect on the phosphorylation of the beta-receptor by PDGF-BB. Thus, neomycin is a PDGF isoform- and receptor-specific antagonist that provides a possibility to compare the signal transduction pathways of alpha- and beta-receptors in cells expressing both receptor types. This approach was used to show that activation of PDGF beta-receptors by PDGF-BB mediated a chemotactic response in human fibroblasts, whereas activation of alpha-receptors by the same ligand inhibited chemotaxis.	LUDWIG INST CANC RES,CTR BIOMED,BOX 595,S-75124 UPPSALA,SWEDEN; UNIV BERGEN,DEPT BIOCHEM,N-5009 BERGEN,NORWAY; UNIV HOSP UPPSALA,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research; University of Bergen; Uppsala University; Uppsala University Hospital								BAR RS, 1989, ENDOCRINOLOGY, V124, P1841, DOI 10.1210/endo-124-4-1841; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; CARNEY DH, 1985, CELL, V42, P479, DOI 10.1016/0092-8674(85)90105-9; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DUAN DSR, 1991, J BIOL CHEM, V266, P413; EK B, 1984, J BIOL CHEM, V259, P1145; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; ERIKSSON A, 1991, J BIOL CHEM, V266, P21138; Eriksson A, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008867; Ferns GAA, 1990, GROWTH FACTORS, V3, P315, DOI 10.3109/08977199009003674; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1982, J BIOL CHEM, V257, P4216; HELDIN CH, 1981, EXP CELL RES, V136, P255, DOI 10.1016/0014-4827(81)90003-3; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; HOSANG M, 1985, J CELL BIOCHEM, V29, P265, DOI 10.1002/jcb.240290310; JOHNSSON A, 1984, EMBO J, V3, P921, DOI 10.1002/j.1460-2075.1984.tb01908.x; JOSEPHS SF, 1984, SCIENCE, V223, P487, DOI 10.1126/science.6318322; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; LANGELAND N, 1987, J VIROL, V61, P3388, DOI 10.1128/JVI.61.11.3388-3393.1987; LAROCHELLE WJ, 1989, MOL CELL BIOL, V9, P3538, DOI 10.1128/MCB.9.8.3538; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; NISTER M, 1988, CANCER RES, V48, P3910; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; PRINGLE N, 1989, EMBO J, V8, P1049, DOI 10.1002/j.1460-2075.1989.tb03472.x; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; SMITS A, 1991, P NATL ACAD SCI USA, V88, P8159, DOI 10.1073/pnas.88.18.8159; Smits A, 1989, GROWTH FACTORS, V2, P1, DOI 10.3109/08977198909069076; STROOBANT P, 1984, EMBO J, V3, P2963, DOI 10.1002/j.1460-2075.1984.tb02241.x; TYSNES OB, 1991, BIOCHEM J, V273, P241, DOI 10.1042/bj2730241; VASSBOTN FS, 1990, BIOCHIM BIOPHYS ACTA, V1054, P207, DOI 10.1016/0167-4889(90)90242-6; VASSBOTN FS, 1990, BIOCHIM BIOPHYS ACTA, V1054, P246, DOI 10.1016/0167-4889(90)90248-C; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WESTERMARK B, 1986, P NATL ACAD SCI USA, V83, P7197, DOI 10.1073/pnas.83.19.7197; WILKINSON PC, 1982, CHEMOTAXIS INFLAMMAT, P35; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	54	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15635	15641						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322402				2022-12-27	WOS:A1992JG11300060
J	HIRAISHI, H; TERANO, A; RAZANDI, M; SUGIMOTO, T; HARADA, T; IVEY, KJ				HIRAISHI, H; TERANO, A; RAZANDI, M; SUGIMOTO, T; HARADA, T; IVEY, KJ			ROLE OF CELLULAR SUPEROXIDE-DISMUTASE AGAINST REACTIVE OXYGEN METABOLITE INJURY IN CULTURED BOVINE AORTIC ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE REDOX CYCLE; GASTRIC-MUCOSAL INJURY; HYDROGEN-PEROXIDE; FREE-RADICALS; HYDROXYL RADICALS; CYTO-TOXICITY; XANTHINE DEHYDROGENASE; HEMORRHAGIC-SHOCK; REDUCING AGENTS; RAT	We examined the protective effect of cellular superoxide dismutase against extracellular hydrogen-peroxide in cultured bovine aortic endothelial cells. Cr-51-labeled cells were exposed to hydrogen peroxide generated by glucose oxidase/glucose. Glucose oxidase caused a dose-dependent increase of Cr-51 release. Pretreatment with diethyldithiocarbamate enhanced injury induced by glucose oxidase, corresponding with the degree of inhibition of endogenous superoxide dismutase activity. Inhibition of cellular superoxide dismutase by diethyldithiocarbamate was not associated either with alteration of other antioxidant defenses or with potentiation of nonoxidant injury. Enhanced glucose oxidase damage by diethyldithiocarbamate was prevented by chelating cellular iron. Inhibition of cellular xanthine oxidase neither prevented lysis by hydrogen peroxide nor diminished enhanced susceptibility by diethyldithiocarbamate. These results suggest that, in cultured endothelial cells: 1) cellular superoxide is involved in mediating hydrogen peroxide-induced damage; 2) superoxide, which would be generated upon exposure to excess hydrogen peroxide independently of cellular xanthine oxidase, promotes the Haber-Weiss reaction by initiating reduction of stored iron (Fe3+) to Fe2+; 3) cellular iron catalyzes the production of a more toxic species from these two oxygen metabolites; 4) cellular superoxide dismutase plays a critical role in preventing hydrogen peroxide damage by scavenging superoxide and consequently by inhibiting the generation of the toxic species.	VET AFFAIRS MED CTR, DEPT MED, LONG BEACH, CA 90822 USA; UNIV CALIF IRVINE, DEPT CHEM, IRVINE, CA 92717 USA; UNIV TOKYO, FAC MED, DEPT INTERNAL MED 2, TOKYO 113, JAPAN; DOKKYO UNIV, SCH MED, MIBU, TOCHIGI 32102, JAPAN	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of Tokyo; Dokkyo Medical University								BACON BR, 1984, SEMIN LIVER DIS, V4, P181, DOI 10.1055/s-2008-1041769; BAUGHMAN RP, 1986, J LAB CLIN MED, V107, P233; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; Beutler E., 1975, RED CELL METABOLISM, P69; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN CHB, 1986, P NATL ACAD SCI USA, V83, P7147, DOI 10.1073/pnas.83.19.7147; CHOPRA J, 1987, LAB INVEST, V57, P578; CUNNINGHAM SK, 1977, IRISH J MED SCI, V146, P136, DOI 10.1007/BF03030948; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; FREEMAN BA, 1983, J BIOL CHEM, V258, P2534; FREEMAN BA, 1982, LAB INVEST, V47, P412; FUCHS HJR, 1983, BIOCHEM BIOPH RES CO, V116, P1107, DOI 10.1016/S0006-291X(83)80256-3; GARDNER TJ, 1983, SURGERY, V94, P423; GRANGER DN, 1986, ACTA PHYSIOL SCAND, V126, P47; GRANGER DN, 1981, GASTROENTEROLOGY, V81, P22; Grisham MB, 1986, PHYSL OXYGEN RADICAL, P01; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/RSPA.1934.0221, DOI 10.1098/rspa.1934.0221]; HALLIWELL B, 1985, MOL ASPECTS MED, V8, P89, DOI 10.1016/0098-2997(85)90001-9; HALLIWELL B, 1989, FREE RADICAL BIO MED, V7, P645, DOI 10.1016/0891-5849(89)90145-7; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HALLIWELL B, 1982, BIOCHEM J, V205, P461, DOI 10.1042/bj2050461; HARLAN JM, 1984, J CLIN INVEST, V73, P706, DOI 10.1172/JCI111263; HASSAN HM, 1988, FREE RADICAL BIO MED, V5, P377, DOI 10.1016/0891-5849(88)90111-6; Heikkila R.E., 1985, HDB METHODS OXYGEN R, P387; HEIKKILA RE, 1976, J BIOL CHEM, V251, P2182; HIRAISHI H, 1987, AM J PHYSIOL, V253, pG40, DOI 10.1152/ajpgi.1987.253.1.G40; HOMANMULLER JWT, 1975, J LAB CLIN MED, V85, P198; ITOH T, 1986, STROKE, V17, P1284, DOI 10.1161/01.STR.17.6.1284; JONES CE, 1968, AM J PHYSIOL, V214, P1374, DOI 10.1152/ajplegacy.1968.214.6.1374; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KEBERLE H, 1964, ANN NY ACAD SCI, V119, P758; KELNER MJ, 1986, J BIOL CHEM, V261, P1636; KELNER MJ, 1989, FREE RADICAL BIO MED, V6, P355, DOI 10.1016/0891-5849(89)90079-8; Korthuis R., 1986, PHYSL OXYGEN RADICAL, P217; Kosower N S, 1978, Int Rev Cytol, V54, P109, DOI 10.1016/S0074-7696(08)60166-7; KYLE ME, 1988, J BIOL CHEM, V263, P3784; MARGOLIASH E, 1958, BIOCHEM J, V68, P468, DOI 10.1042/bj0680468; MARKEY BA, 1990, FREE RADICAL BIO MED, V9, P307, DOI 10.1016/0891-5849(90)90005-4; MARUBAYASHI S, 1986, SURGERY, V99, P184; MCCORD JM, 1982, CAN J PHYSIOL PHARM, V60, P1346, DOI 10.1139/y82-201; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MICHIELS C, 1990, J CELL PHYSIOL, V144, P295, DOI 10.1002/jcp.1041440216; MOLDOW CF, 1984, METHOD ENZYMOL, V105, P378; ODY C, 1985, P SOC EXP BIOL MED, V180, P103; PALLER MS, 1986, AM J PHYSIOL, V251, pF839, DOI 10.1152/ajprenal.1986.251.5.F839; PARKS DA, 1988, AM J PHYSIOL, V254, pG768, DOI 10.1152/ajpgi.1988.254.5.G768; PARKS DA, 1986, ACTA PHYSIOL SCAND, V126, P87; Roy R.S., 1983, CELLULAR MED ASPECTS, VII, P145; SCHWARTZ SM, 1978, IN VITRO CELL DEV B, V14, P966, DOI 10.1007/BF02616210; SCOTT MD, 1989, J BIOL CHEM, V264, P2498; SCOTT MD, 1987, J BIOL CHEM, V262, P3640; SMITH SM, 1987, GASTROENTEROLOGY, V93, P466, DOI 10.1016/0016-5085(87)90907-3; SMITH SM, 1987, GASTROENTEROLOGY, V92, P950, DOI 10.1016/0016-5085(87)90969-3; STARKE PE, 1985, J BIOL CHEM, V260, P99; SUTTORP N, 1986, AM J PHYSIOL, V251, pC671, DOI 10.1152/ajpcell.1986.251.5.C671; TAKAHASHI MA, 1983, ARCH BIOCHEM BIOPHYS, V226, P558, DOI 10.1016/0003-9861(83)90325-9; Taylor A E, 1983, Physiologist, V26, P152; TROMBETTA LD, 1988, TOXICOL APPL PHARM, V93, P154, DOI 10.1016/0041-008X(88)90035-X; VANSTEVENINCK J, 1985, BIOCHEM J, V232, P309, DOI 10.1042/bj2320309; VERCELLOTTI GM, 1988, P SOC EXP BIOL MED, V187, P181; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P365, DOI 10.1016/0003-9861(76)90088-6; WINTERBOURN CC, 1979, BIOCHEM J, V182, P625, DOI 10.1042/bj1820625; YOKOYAMA Y, 1988, GASTROENTEROLOGY, V94, pA607	65	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14812	14817						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321816				2022-12-27	WOS:A1992JF08800048
J	ALSNER, J; SVEJSTRUP, JQ; KJELDSEN, E; SORENSEN, BS; WESTERGAARD, O				ALSNER, J; SVEJSTRUP, JQ; KJELDSEN, E; SORENSEN, BS; WESTERGAARD, O			IDENTIFICATION OF AN N-TERMINAL DOMAIN OF EUKARYOTIC DNA TOPOISOMERASE-I DISPENSABLE FOR CATALYTIC ACTIVITY BUT ESSENTIAL FOR INVIVO FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SACCHAROMYCES-CEREVISIAE; REQUIREMENTS; CAMPTOTHECIN	We have found that deletion of a 70-amino acid domain, spanning from position 141 to 210 in the N-terminal part of human topoisomerase I, has no effect on the catalytic activity of the enzyme in vitro but suppresses the lethal consequence of overexpressing human topoisomerase I in a rad52 top1 Saccharomyces cerevisiae strain. By immunostaining, the 70-amino acid domain is shown to be necessary for nuclear location of topoisomerase I. We demonstrate that the nuclear localization signal from the SV40 large T antigen can substitute for the 70-amino acid domain, restoring both the lethal effect of overexpression and the correct subcellular localization of topoisomerase I. Thus, we have identified a domain in the N-terminal part of human topoisomerase I, nonessential for catalytic activity in vitro but serving an in vivo function by directing the enzyme to the nucleus. Based on sequence comparisons, we suggest that this domain is a conserved element in the apparently non-homologous N-terminal parts of yeast and human topoisomerase I.	AARHUS UNIV,DEPT MOLEC BIOL,CF MOLLERS ALLE,BLDG 130,DK-8000 AARHUS,DENMARK; AARHUS UNIV,DEPT HUMAN GENET,DK-8000 AARHUS,DENMARK	Aarhus University; Aarhus University			Alsner, Jan/A-3056-2009	Alsner, Jan/0000-0002-5395-3193; Sorensen, Boe/0000-0002-9472-8099; Svejstrup, Jesper/0000-0003-4964-6147				ANDERSEN AH, 1991, J BIOL CHEM, V266, P9203; BENTON BM, 1990, MOL CELL BIOL, V10, P353, DOI 10.1128/MCB.10.1.353; BJORNSTI MA, 1987, P NATL ACAD SCI USA, V84, P8971, DOI 10.1073/pnas.84.24.8971; BJORNSTI MA, 1989, CANCER RES, V49, P6318; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ENG WK, 1988, MOL PHARMACOL, V34, P755; Hsieh T, 1990, CURR OPIN CELL BIOL, V2, P461, DOI 10.1016/0955-0674(90)90128-2; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KIKUCHI A, 1991, 1991 INT S DNA TOP C; KROGH S, 1991, NUCLEIC ACIDS RES, V19, P1235, DOI 10.1093/nar/19.6.1235; LEE MP, 1989, J BIOL CHEM, V264, P21779; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MULLER MT, 1985, EMBO J, V4, P1237, DOI 10.1002/j.1460-2075.1985.tb03766.x; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; RENTROP M, 1986, HISTOCHEM J, V18, P271, DOI 10.1007/BF01676237; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Sherman F., 1982, METHODS YEAST GENETI; SHERO JH, 1987, J RHEUMATOL, V14, P138; SIKORSKI RS, 1989, GENETICS, V122, P19; Sternglanz R, 1989, CURR OPIN CELL BIOL, V1, P533, DOI 10.1016/0955-0674(89)90016-1; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; SVEJSTRUP JQ, 1990, J BIOL CHEM, V265, P12529; THOMSEN B, 1990, J MOL BIOL, V215, P237, DOI 10.1016/S0022-2836(05)80342-0; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19	26	86	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12408	12411						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1319995				2022-12-27	WOS:A1992HZ48300005
J	MARTINEZAZORIN, F; TERUEL, JA; FERNANDEZBELDA, F; GOMEZFERNANDEZ, JC				MARTINEZAZORIN, F; TERUEL, JA; FERNANDEZBELDA, F; GOMEZFERNANDEZ, JC			EFFECT OF DIETHYLSTILBESTROL AND RELATED-COMPOUNDS ON THE CA2+-TRANSPORTING ATPASE OF SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITION; CA-2+-ATPASE; ACTIVATION; MEMBRANES; LOCATION; FLUORESCENCE; HYDROLYSIS; MECHANISM; MICELLES; PROBE	Diethylstilbestrol is a potent inhibitory agent of the Ca2+-ATPase activity of sarcoplasmic reticulum membranes. Other structurally related molecules, such as dienestrol or hexestrol having hydroxyl groups at para positions of the two benzene rings produce similar effects. The absence or derivatization of the hydroxyl groups as occurs with trans-stilbene or diethylstilbestrol dipropionate converts the structure in an activating agent of the enzyme. The Ca2+ transport profiles in the presence of the referred drugs reproduces the same behavior observed for the hydrolytic activity. There is also a clear indication of a membrane-mediated mechanism of these drugs. Ligand binding experiments at equilibrium indicate that diethylstilbestrol decreases the affinity for Ca2+ of the high affinity Ca2+ sites. Functional studies reveal that the activation/inhibition induced by these drugs is correlated with decreased levels of phosphoenzyme at steady state, and these levels are sensitive to the Ca2+ concentration. Chase experiments of [P-32]phosphoenzyme and Ca-45(2+) indicate a slight activation effect of diethylstilbestrol dipropionate on Ca2+ dissociation during the enzyme turnover. The use of different anthroyloxy derivatives of stearic acid as a fluorescent probe suggest that diethylstilbestrol and other inhibitory agents could be located close to the polar region of the lipid bilayer, which interferes with the Ca2+-binding sites, whereas the activators trans-stilbene and diethylstilbestrol dipropionate may have a deeper position into the membrane, which accelerates the Ca2+ translocation process.	UNIV MURCIA, FAC VET, DEPT BIOQUIM & BIOL MOLEC, E-30071 ESPINARDO, SPAIN	University of Murcia			Gomez-Fernandez, Juan C/K-6758-2014; Puche, José Antonio Teruel/R-4137-2018	Gomez-Fernandez, Juan C/0000-0002-5331-9029; Puche, José Antonio Teruel/0000-0003-2256-3368; Martinez-Azorin, Francisco/0000-0001-6250-7745				BLATT E, 1985, BIOCHIM BIOPHYS ACTA, V822, P43, DOI 10.1016/0304-4157(85)90003-6; BLATT E, 1984, PHOTOCHEM PHOTOBIOL, V39, P477; BLINKS JR, 1982, PROG BIOPHYS MOL BIO, V40, P1, DOI 10.1016/0079-6107(82)90011-6; CADENHEAD DA, 1977, BIOCHEMISTRY-US, V16, P5386, DOI 10.1021/bi00643a034; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Dodds EC, 1938, NATURE, V141, P247, DOI 10.1038/141247b0; DUPONT Y, 1976, BIOCHEM BIOPH RES CO, V71, P544, DOI 10.1016/0006-291X(76)90821-4; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FERNANDEZBELDA F, 1984, J BIOL CHEM, V259, P9687; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GRONBERG M, 1988, FEBS LETT, V229, P40, DOI 10.1016/0014-5793(88)80793-2; HARA H, 1986, J BIOL CHEM, V261, P6584; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; HO MM, 1983, BIOCHIM BIOPHYS ACTA, V730, P64, DOI 10.1016/0005-2736(83)90317-6; INESI G, 1982, Z NATURFORSCH C, V37, P685; INESI G, 1980, J BIOL CHEM, V255, P3025; KAWASHIMA T, 1990, J BIOL CHEM, V265, P10993; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; LIN TI, 1977, ANAL BIOCHEM, V77, P10, DOI 10.1016/0003-2697(77)90284-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCENERY MW, 1986, J BIOL CHEM, V261, P1745; MCENERY MW, 1989, J BIOL CHEM, V264, P12029; MCMARTIN KE, 1978, J ENVIRON PATHOL TOX, V1, P279; MICHELANGELI F, 1990, BIOCHEMISTRY-US, V29, P3091, DOI 10.1021/bi00464a028; NOLLER KL, 1974, MED CLIN N AM, V58, P793, DOI 10.1016/S0025-7125(16)32122-8; OGILVIE ML, 1960, J ANIM SCI, V19, P991, DOI 10.2527/jas1960.194991x; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PETRETSKI JH, 1989, J BIOL CHEM, V264, P20339; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SCHWARZENBACH G, 1957, HELV CHIM ACTA, V40, P1886, DOI 10.1002/hlca.19570400640; SHOSHAN V, 1981, J BIOL CHEM, V256, P887; SOKOLOVE PM, 1986, FEBS LETT, V203, P121, DOI 10.1016/0014-5793(86)80726-8; SOLER F, 1988, BIOCHEM BIOPH RES CO, V151, P1093, DOI 10.1016/S0006-291X(88)80478-9; SUMBILLA C, 1991, J BIOL CHEM, V266, P12682; WAKABAYASHI S, 1988, J BIOL CHEM, V263, P15304	37	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11923	11929						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1318306				2022-12-27	WOS:A1992HY94700043
J	VOGEL, PD; NETT, JH; SAUER, HE; SCHMADEL, K; CROSS, RL; TROMMER, WE				VOGEL, PD; NETT, JH; SAUER, HE; SCHMADEL, K; CROSS, RL; TROMMER, WE			NUCLEOTIDE BINDING-SITES ON MITOCHONDRIAL F1-ATPASE - ELECTRON-SPIN-RESONANCE SPECTROSCOPY AND PHOTOLABELING BY AZIDO-SPIN-LABELED ADENINE-NUCLEOTIDES SUPPORT AN ADENYLATE KINASE-LIKE ORIENTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEEF-HEART F1-ATPASE; ESCHERICHIA-COLI; ADENOSINE-TRIPHOSPHATASE; BETA-SUBUNIT; NONCATALYTIC SITES; PARAMAGNETIC-RES; ATP-BINDING; F1 ATPASE; 2-AZIDO-ATP; MECHANISM	A spin-labeled photoaffinity ATP analog, 2-N3-2',3'-SL-ATP (2-N3-SL-ATP) was specifically loaded at catalytic (exchangeable) or noncatalytic (nonexchangeable) nucleotide-binding sites on nucleotide-depleted mitochondrial F1-ATPase. Photolysis of the enzyme complexes resulted in the specific modification of beta-Tyr-345 when the catalytic sites were occupied and beta-Tyr-368 when noncatalytic sites were filled. These are the same amino acid assignments that were made previously using 2-N3ATP. The results demonstrate that the attachment of a spin label moiety to the ribose ring does not prevent proper binding of the analog at both types of nucleotide sites on F1-ATPase and suggest that the probe can be used for investigations of the nucleotide-binding sites using ESR spectroscopy. Enzyme that is in complex with the 2-N3-SL-ATP exhibits an ESR spectrum that is typical for highly immobilized nitroxyl radicals both in the dark or after photolysis. Additional peaks in the high- and low-field regions arise due to dipolar spin interactions most likely involving a pair of catalytic and noncatalytic sites. The two sites are calculated to be approximately 15 angstrom apart. This distance, obtained through ESR spectroscopy, combined with the finding that the 2 labeled amino acids are only 23 residues apart from each other, further supports an adenylate kinase-like arrangement of nucleotide binding sites on F1-ATPase where catalytic and noncatalytic sites are in close proximity (Vogel, P. D., and Cross, R. L. (1991) J. Biol. Chem. 266,6101-6105).	SUNY HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, SYRACUSE, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	VOGEL, PD (corresponding author), UNIV KAISERSLAUTERN, FACHBEREICH CHEM, W-6750 KAISERSLAUTERN, GERMANY.			Vogel, Pia/0000-0002-8135-4649	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023152, R01GM023152] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 23152] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BETH AH, 1984, J BIOL CHEM, V259, P9717; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; CROSS RL, 1982, J BIOL CHEM, V257, P2874; CZARNECKI JJ, 1984, BIOCHIM BIOPHYS ACTA, V800, P41, DOI 10.1016/0304-4165(84)90092-8; DIPIETRO A, 1980, BIOCHEMISTRY-US, V19, P5671, DOI 10.1021/bi00566a002; DUNCAN TM, 1986, FEBS LETT, V208, P1, DOI 10.1016/0014-5793(86)81519-8; EATON SS, 1983, J MAGN RESON, V52, P435, DOI 10.1016/0022-2364(83)90169-5; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GARRETT NE, 1975, J BIOL CHEM, V250, P6640; GUERRERO KJ, 1989, BIOCHEM BIOPH RES CO, V54, P854; JAKOBS P, 1989, FEBS LETT, V254, P8, DOI 10.1016/0014-5793(89)80998-6; KIRONDE FAS, 1987, J BIOL CHEM, V262, P3488; MELESE T, 1985, J BIOL CHEM, V260, P5398; MILGROM YM, 1990, J BIOL CHEM, V265, P18725; PARK JH, 1989, BIOL MAGN RESON, V8, P547; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; STRECKENBACH B, 1980, BIOCHIM BIOPHYS ACTA, V601, P34, DOI 10.1016/0005-2736(80)90511-8; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TIEDGE H, 1982, EUR J BIOCHEM, V127, P291, DOI 10.1111/j.1432-1033.1982.tb06869.x; TROMMER WE, 1987, PYRIDINE NUCLEOTID A, V2, P613; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; VOGEL PD, 1991, J BIOL CHEM, V266, P6101; VOGELCLAUDE P, 1988, FEBS LETT, V227, P107, DOI 10.1016/0014-5793(88)80878-0; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WILDER RT, 1989, BIOCHIM BIOPHYS ACTA, V997, P65, DOI 10.1016/0167-4838(89)90136-2; WISE JG, 1987, FEBS LETT, V223, P395, DOI 10.1016/0014-5793(87)80326-5; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343; WISE JG, 1985, BIOCHEMISTRY-US, V24, P6949, DOI 10.1021/bi00345a030; XUE ZX, 1987, FEBS LETT, V223, P391, DOI 10.1016/0014-5793(87)80325-3; [No title captured]	31	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11982	11986						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1318307				2022-12-27	WOS:A1992HY94700052
J	GEORGALIS, Y; ZOUNI, A; ZIELENKIEWICZ, P; HOLZWARTH, JF; CLARKE, R; HAHN, U; SAENGER, W				GEORGALIS, Y; ZOUNI, A; ZIELENKIEWICZ, P; HOLZWARTH, JF; CLARKE, R; HAHN, U; SAENGER, W			MODES OF MONONUCLEOTIDE BINDING TO RIBONUCLEASE-T1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; ESCHERICHIA-COLI; TEMPERATURE-JUMP; ACID COMPLEX; PANCREATIC RIBONUCLEASE; 3-DIMENSIONAL STRUCTURE; 1.9-A RESOLUTION; IODINE LASER; X-RAY; PURIFICATION	The binding of the mononucleotide inhibitors 2'-GMP, 3'-GMP, and 5'-GMP to genetically engineered ribonuclease T1 has been investigated by conventional inhibition kinetics, fluorimetric titrations, molecular modeling, and fast relaxation techniques. The fluorimetric titrations in conjunction with molecular modeling revealed that apart from the already known primary binding site, three to four additional sites are present on the enzyme's surface. The association constants obtained from the fluorimetric titrations and the temperature jump experiments range between 3.1 x 10(6) M-1 and 4.3 x 10(6) M-1, indicating that the binding of the mononucleotides to the specific binding site of ribonuclease T1 is at least one order of magnitude tighter than has been anticipated so far. The kinetics of binding are nearly diffusion controlled with a k(on) determined for 2'-GMP and 3'-GMP, as (5.0 +/- 0.5 x 10(9) and 6.1 +/- 0.5 x 10(9) M-1, s-1 and k(off) as 1.2 +/- 0.2 x 10(3) and 2.0 +/- 0.3 x 10(3) s-1, respectively. Molecular modeling studies indicate that all three nucleotides are able to bind via their phosphate group to a positively charged array of surface amino acids including His27, His40, Lys41, and most probably Lys25 without obvious stereochemical hindrance. We propose that RNA wraps around RNase T1 in a similar fashion via phosphate binding when enzymatic hydrolysis occurs.	MAX PLANCK GESELL,FRITZ HABER INST,W-1000 BERLIN 33,GERMANY	Max Planck Society; Fritz Haber Institute of the Max Planck Society	GEORGALIS, Y (corresponding author), FREE UNIV BERLIN,INST KRISTALLOG,TAKUSTR 6,W-1000 BERLIN 33,GERMANY.		Clarke, Ronald J/L-5259-2016; Hahn, Ulrich/E-8069-2010	Clarke, Ronald J/0000-0002-0950-8017; Hahn, Ulrich/0000-0002-6526-0693; Zielenkiewicz, Piotr/0000-0001-8151-6874				ARATA Y, 1979, BIOCHEMISTRY-US, V18, P18, DOI 10.1021/bi00568a003; ARNI R, 1988, J BIOL CHEM, V263, P15358; Bagshaw C. R., 1987, SPECTROPHOTOMETRY SP, P91; BANNISTER JJ, 1984, CHEM BRIT, V20, P227; Bevington P. R, 1969, DATA REDUCTION ERROR; BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P8149; DAWSON A, 1981, J CHEM SOC CHEM COMM, P386, DOI 10.1039/c39810000386; DING JP, 1991, J BIOL CHEM, V266, P15128; Dixon M, 1964, ENZYMES, P116; FULLING R, 1978, FEBS LETT, V88, P279, DOI 10.1016/0014-5793(78)80193-8; GEORGALIS Y, 1991, BIOCHIM BIOPHYS ACTA, V1118, P1, DOI 10.1016/0167-4838(91)90434-2; GEORGALIS Y, 1989, J MOL BIOL, V209, P315, DOI 10.1016/0022-2836(89)90279-9; GRUNERT HP, 1991, EUR J BIOCHEM, V197, P203, DOI 10.1111/j.1432-1033.1991.tb15900.x; HAGLER AT, 1979, J AM CHEM SOC, V101, P5122, DOI 10.1021/ja00512a002; HALFMAN CJ, 1972, BIOCHEMISTRY-US, V11, P3493, DOI 10.1021/bi00768a025; HEINEMANN U, 1982, NATURE, V299, P27, DOI 10.1038/299027a0; HOLZWARTH JF, 1988, BIOCHEMISTRY-US, V27, P6628, DOI 10.1021/bi00417a062; HOLZWARTH JF, 1979, TECHNIQUES APPLICATI, P47; IKEHARA M, 1986, P NATL ACAD SCI USA, V83, P4695, DOI 10.1073/pnas.83.13.4695; INAGAKI F, 1985, BIOCHEMISTRY-US, V24, P1013, DOI 10.1021/bi00325a031; JENSEN DE, 1976, J BIOL CHEM, V251, P7198; KAWATA Y, 1990, EUR J BIOCHEM, V187, P255, DOI 10.1111/j.1432-1033.1990.tb15303.x; KLOTZ IM, 1989, PROTEIN FUNCTION PRA, P25; KOPKLE J, 1989, J MOL BIOL, V206, P475; LENZ A, 1991, ACTA CRYSTALLOGR B, V47, P521, DOI 10.1107/S0108768191001684; MACKERELL AD, 1991, BIOCHIM BIOPHYS ACTA, V1073, P357, DOI 10.1016/0304-4165(91)90143-5; MACKERELL DA, 1987, STRUCTURE DYNAMICS F, P260; MARCANDALLI B, 1984, BER BUNSEN PHYS CHEM, V88, P368, DOI 10.1002/bbpc.19840880411; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MARTINEZOYANEDEL J, 1991, J MOL BIOL, V222, P335, DOI 10.1016/0022-2836(91)90215-R; MCPHERSON A, 1986, SCIENCE, V232, P765, DOI 10.1126/science.3961503; MCPHERSON A, 1984, J MOL BIOL, V189, P305; McPherson A., 1987, CRYSTALLOGR REV, V1, P191; QUAAS R, 1988, EUR J BIOCHEM, V173, P617, DOI 10.1111/j.1432-1033.1988.tb14043.x; QUAAS R, 1988, NUCLEOS NUCLEOT, V7, P619, DOI 10.1080/07328318808056297; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; RENUGOPALAKRISHNAN V, 1971, BIOPOLYMERS, V10, P1159, DOI 10.1002/bip.360100707; SHIRLEY BA, 1990, J BIOCHEM BIOPH METH, V20, P181, DOI 10.1016/0165-022X(90)90076-O; SUGIO S, 1985, FEBS LETT, V183, P115, DOI 10.1016/0014-5793(85)80966-2; SUGIO S, 1988, J BIOCHEM-TOKYO, V103, P354, DOI 10.1093/oxfordjournals.jbchem.a122274; TAKAHASHI K, 1985, J BIOCHEM-TOKYO, V98, P815, DOI 10.1093/oxfordjournals.jbchem.a135339; Takahashi K., 1982, ENZYMES, V15, p435 468; Tanford C, 1961, PHYSICAL CHEM MACROM, P526; WALZ FG, 1973, BIOCHEMISTRY-US, V12, P4846, DOI 10.1021/bi00748a006; WALZ FG, 1976, BIOCHEMISTRY-US, V15, P2837, DOI 10.1021/bi00658a021; WALZ FG, 1977, BIOCHEMISTRY-US, V16, P5509, DOI 10.1021/bi00644a018	48	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10323	10330						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1316897				2022-12-27	WOS:A1992HV09000021
J	PAGES, F; DETERRE, P; PFISTER, C				PAGES, F; DETERRE, P; PFISTER, C			ENHANCED GTPASE ACTIVITY OF TRANSDUCIN WHEN BOUND TO CGMP PHOSPHODIESTERASE IN BOVINE RETINAL RODS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							OUTER SEGMENTS; INTRINSIC FLUORESCENCE; MOLECULAR MECHANISM; GUANYLATE-CYCLASE; ALPHA-SUBUNIT; G-PROTEIN; DEACTIVATION; ACTIVATION; HYDROLYSIS; LIGHT	The generation of the physiological response of a retinal rod cell to an incident photon involves activation of a cGMP phosphodiesterase (PDE) by a GTP-binding protein, transducin (T). This activation has been shown to occur by formation of a membrane-bound Talpha(GTP)-PDE complex (Clerc, A., and Bennett, N. (1992) J. Biol. Chem. 267,6620-6627; Catty, P., Pfister, C., Bruckert, F., and Deterre, P. (1992) J. Biol. Chem 267, 19489-19493). The recovery of the response involves turning-off of T by its intrinsic GTPase activity. We show here that the formation of the membrane-bound Talpha(GTP)-PDE complex correlates with an enhanced rate of GTP hydrolysis. In vivo, this would provide an appropriate mechanism for fast turn-off of cGMP hydrolysis.	CEN,BIOPHYS MOLEC & CELLULAIRE LAB,DEPT BIOL MOLEC & STRUCT,BP 85-X,F-38041 GRENOBLE,FRANCE				Deterre, Philippe/O-8984-2017	Deterre, Philippe/0000-0001-9303-0791				ARCHAVSKY VY, 1989, FEBS LETT, V250, P353; ARCHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARCHAVSKY VY, 1992, NATURE, V357, P416; BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; BRUCKERT F, 1992, IN PRESS BIOPHYS J; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; CATTY P, 1992, J BIOL CHEM, V267, P19489; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHABRE M, 1990, ACTIVATION DESENSI H, V44, P215; CLERC A, 1992, J BIOL CHEM, V267, P6620; COMPTON SJ, 1985, ANAL BIOCHEM, V151, P369, DOI 10.1016/0003-2697(85)90190-3; DETERRE P, 1984, FEBS LETT, V178, P228, DOI 10.1016/0014-5793(84)80606-7; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GUY PM, 1990, BIOCHEMISTRY-US, V29, P6954, DOI 10.1021/bi00482a003; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KUHN H, 1981, CURR TOP MEMBR TRANS, V15, P171; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; PEPE IM, 1986, FEBS LETT, V203, P73, DOI 10.1016/0014-5793(86)81439-9; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P651, DOI 10.1021/bi00351a021; SITARAMAYYA A, 1988, BIOCHEMISTRY-US, V27, P4880, DOI 10.1021/bi00413a044; STRYER L, 1991, J BIOL CHEM, V266, P10711; TING TD, 1991, BIOCHEMISTRY-US, V30, P8996, DOI 10.1021/bi00101a013; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VUONG TM, 1990, NATURE, V346, P71, DOI 10.1038/346071a0; VUONG TM, 1984, NATURE, V311, P659, DOI 10.1038/311659a0; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039	31	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22018	22021						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331045				2022-12-27	WOS:A1992JW71900009
J	HOMMA, Y; TAKENAWA, T				HOMMA, Y; TAKENAWA, T			INHIBITORY EFFECT OF SRC HOMOLOGY (SH) 2/SH3 FRAGMENTS OF PHOSPHOLIPASE C-GAMMA ON THE CATALYTIC ACTIVITY OF PHOSPHOLIPASE-C ISOFORMS - IDENTIFICATION OF A NOVEL PHOSPHOLIPASE-C INHIBITOR REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; PHOSPHORYLATION; PROTEIN; ASSOCIATION; SEQUENCE; BINDING; CELLS; PURIFICATION; HYDROLYSIS; PI3-KINASE	In order to study the regulatory mechanisms of phospholipase C-gamma (PLC-gamma) via the intrinsic SH2/SH3 region (Z region), two recombinant Z proteins, rP45Z and rP38Z, derived from rat PLC-gamma1 and PLC-gamma2, respectively, were purified from the inclusion bodies of Escherichia coli. We examined their direct effects on phosphoinositide hydrolysis induced by four different PLC isoforms purified from bovine brain and thymus, and found that both of these Z proteins suppress the enzyme activity of all four PLC isoforms in a dose-dependent manner. This suppressive effect is very potent and stoichiometric. The kinetics studies indicate that the suppression is non-competitive. This suppression is eliminated by treatment with proteases but is not affected by heat treatment at 95-degrees-C for 15 min, indicating that the primary structure might be important for the action of Z proteins. Comparative studies suggested that two Z proteins but not Src and phosphatidylinositol 3-kinase possess, adjacent to their SH2 and SH3 motifs, a phospholipase C inhibitor (PCI) region that strongly suppresses their phosphatidylinositol 4,5-bisphosphate (PIP2)-hydrolyzing activity. A series of synthetic peptides identical with the sequence of the proposed PCI region, including an octamer, YRKMRLRY, inhibited PIP2 hydrolysis induced by four different phospholipase C isoforms. These results demonstrate that both types of phospholipase C-gamma contain the PCI sequence which is responsible for the inhibition of PIP2 hydrolysis, indicating that phospholipase C-gamma is a self-regulating enzyme.	UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN	University of Tokyo	HOMMA, Y (corresponding author), TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,35-2 SAKAE,TOKYO 173,JAPAN.							BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; EMORI Y, 1989, J BIOL CHEM, V264, P21885; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HOMMA Y, 1992, BIOCHEM BIOPH RES CO, V182, P1402, DOI 10.1016/0006-291X(92)91889-X; HOMMA Y, 1990, BIOCHEM J, V269, P13, DOI 10.1042/bj2690013; HOMMA Y, 1992, J BIOL CHEM, V267, P3778; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM UH, 1991, J BIOL CHEM, V266, P1359; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P47; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RYU SH, 1987, J BIOL CHEM, V262, P12511; Sambrook J, 1989, MOL CLONING LABORATO; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218	30	59	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21844	21849						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328245				2022-12-27	WOS:A1992JV01100090
J	LI, L; LIN, K; PILKIS, J; CORREIA, JJ; PILKIS, SJ				LI, L; LIN, K; PILKIS, J; CORREIA, JJ; PILKIS, SJ			HEPATIC 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE - THE ROLE OF SURFACE LOOP BASIC RESIDUES IN SUBSTRATE BINDING TO THE FRUCTOSE-2,6-BISPHOSPHATASE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; FRUCTOSE-6-PHOSPHATE 2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; RAT TESTES FRUCTOSE-6-PHOSPHATE; 5' FLANKING SEQUENCE; FRUCTOSE 2,6-BISPHOSPHATASE; PHOSPHORYLATION SITES; MOLECULAR-CLONING; LIVER; DNA; GLUCONEOGENESIS	Lys-356 has been implicated as a critical residue for binding the C-6 phospho group of fructose 2,6-bisphosphate to the fructose-2,6-bisphosphatase domain of rat liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (Li, L., Lin, K., Correia, J., and Pilkis, S. J. (1992) J. Biol. Chem. 267, 16669-16675). To ascertain whether the three other basic residues (Arg-352, Arg-358, and Arg-360), which are located in a surface loop (residues 331-362) which contains Lys-356, are important in substrate binding, these arginyl residues were mutated to Ala, and each arginyl mutant was expressed in Escherichia coli and purified to homogeneity. The far UV circular dichroism spectra of the mutants were identical to that of the wild-type enzyme. The kinetic parameters of 6-phosphofructo-2-kinase of the mutants revealed only small changes. However, the K(m) for fructose 2,6-bisphosphate, K(i) for fructose 6-phosphate, and K(a) for inorganic phosphate of fructose-2,6-bisphosphatase for Arg352Ala were, respectively, 2,800-, 4,500-, and 1,500-fold higher than those for the wild-type enzyme, whereas there was no change in the maximal velocity or the K(i) for inorganic phosphate. The K(m) for fructose 2,6-bisphosphate and K(i) for inorganic phosphate of Arg360Ala were 10- and 12-fold higher, respectively, than those of the wild-type enzyme, whereas the maximal velocity and K(i) for fructose 6-phosphate were unchanged. In addition, substrate inhibition was not observed with Arg352Ala and greatly reduced with Arg360Ala. The properties of the Arg358Ala mutant were identical to those of the wild-type enzyme. The results demonstrate that in addition to Lys-356, Arg-352 is another critical residue in fructose-2,6-bisphosphatase for binding the C-6 phospho group of fructose 2,6-bisphosphate and that Arg-360 binds the C-2 phospho group of fructose 2,6-bisphosphate in the phosphoenzyme.fructose 2,6-bis-phosphate complex. The results also provide support for Arg-352, Lys-356, and Arg-360 constituting a specificity pocket for fructose-2,6-bisphosphatase.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794; UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,JACKSON,MS 39216	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Mississippi; University of Mississippi Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038354, R37DK038354] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38354] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; CLAUS TH, 1984, CURR TOP CELL REGUL, V23, P57; COLOSIA AD, 1988, J BIOL CHEM, V263, P18669; COLOSIA AD, 1987, BIOCHEM BIOPH RES CO, V143, P1092, DOI 10.1016/0006-291X(87)90364-0; DARVILLE MI, 1989, P NATL ACAD SCI USA, V86, P6543, DOI 10.1073/pnas.86.17.6543; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; ELMAGHRABI MR, 1982, BIOCHEM BIOPH RES CO, V106, P794, DOI 10.1016/0006-291X(82)91780-6; ELMAGHRABI MR, 1984, J BIOL CHEM, V259, P3096; HERS HG, 1982, BIOCHEM J, V206, P1; KITAJIMA S, 1984, J BIOL CHEM, V259, P6896; KRETSCHMER M, 1991, BIOCHEMISTRY-US, V30, P10663, DOI 10.1021/bi00108a009; LANGE AJ, 1991, ARCH BIOCHEM BIOPHYS, V290, P258, DOI 10.1016/0003-9861(91)90617-R; LANGE AJ, 1990, NUCLEIC ACIDS RES, V18, P3652, DOI 10.1093/nar/18.12.3652; LI L, 1992, J BIOL CHEM, V267, P4386; LI L, 1992, J BIOL CHEM, V267, P16669; LIN K, 1992, J BIOL CHEM, V267, P6556; Lin K, 1990, Protein Expr Purif, V1, P169, DOI 10.1016/1046-5928(90)90012-N; LIVELY MO, 1988, J BIOL CHEM, V263, P839; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PILKIS SJ, 1983, J BIOL CHEM, V258, P6135; PILKIS SJ, 1984, J BIOL CHEM, V259, P949; PILKIS SJ, 1982, MOL CELL ENDOCRINOL, V25, P245, DOI 10.1016/0303-7207(82)90082-X; PILKIS SJ, 1991, ANNU REV NUTR, V11, P465, DOI 10.1146/annurev.nu.11.070191.002341; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PILKIS SJ, 1990, DIABETES CARE, V13, P582, DOI 10.2337/diacare.13.6.582; PILKIS SJ, 1987, J BIOL CHEM, V262, P12672; PILKIS SJ, 1990, FRUCTOSE 2 6 BISPHOS; SAKATA J, 1991, J BIOL CHEM, V266, P15764; SAKATA J, 1990, P NATL ACAD SCI USA, V87, P4951, DOI 10.1073/pnas.87.13.4951; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEWART HB, 1985, J BIOL CHEM, V260, P2935; STEWART HB, 1986, J BIOL CHEM, V261, P8793; STRICKLAND EH, 1987, CRC HDB BIOCH MOL BI, V3, P141; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAULER A, 1990, J BIOL CHEM, V265, P15617; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V124, P143; VENTURA F, 1992, J BIOL CHEM, V267, P17939	38	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21588	21594						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328239				2022-12-27	WOS:A1992JV01100052
J	RAMARAO, CS; DENKER, JMK; PEREZ, DM; GAIVIN, RJ; RIEK, RP; GRAHAM, RM				RAMARAO, CS; DENKER, JMK; PEREZ, DM; GAIVIN, RJ; RIEK, RP; GRAHAM, RM			GENOMIC ORGANIZATION AND EXPRESSION OF THE HUMAN ALPHA-1B-ADRENERGIC RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-P RECEPTOR; RNA POLYMERASE-II; MOLECULAR-CLONING; MESSENGER-RNAS; ALPHA-2-ADRENERGIC RECEPTOR; CHROMOSOME LOCALIZATION; ADRENERGIC-RECEPTOR; GENE; TRANSCRIPTION; CDNA	Alpha1-adrenergic receptors (ARs) are members of the guanine nucleotide-binding protein-coupled receptor superfamily. The genes for all ARs described thus far are intronless. We report here the cloning and the nucleotide sequence of the gene for the human alpha1B-AR. It consists of two exons and a single large intron of at least 20 kilobases which interrupts the coding region at the end of the putative sixth transmembrane domain. The deduced amino acid sequence of the encoded receptor has a high degree of homology to the cloned hamster, rat, and dog alpha1B-ARs. To characterize the encoded protein, a fusion gene constructed by splicing together exon 1 and exon 2 was expressed transiently in COS-1 cells. The transfected gene fusion product resulted in the production of an alpha1B-AR with ligand binding characteristics indistinguishable from those of the expressed hamster alpha1B cDNA. Evidence that the human alpha1B-AR gene we have isolated is indeed transcribed is the finding of similar sized (2.8-kilobase) transcripts in human heart and other tissues by Northern blot analysis when either exon 1 or exon 2 is used as a probe. Moreover, using primers designed to span the exon 1/exon 2 boundary, a polymerase chain reaction product generated from single-stranded DNA prepared from human heart mRNA had the exact size and nucleotide sequence predicted for a transcript in which exon 1 is spliced to exon 2. The 5'-flanking region (924 base pairs (bp)) of exon 1 contains neither a TATA box nor a CAAT box but is high in GC content (70%) and contains several Sp1 binding sites (GC boxes), consistent with promoters described for housekeeping genes. The 5'-untranslated region also contains a putative cyclic AMP response element. Primer extension studies and RNase protection assays suggested that there are several potential transcription start sites in most tissues with a predominant site located 173 bp upstream from the translation start site. The 3'-flanking region contains a putative polyadenylation signal (ATTAAA) 492 bp downstream from the stop codon. The genomic organization of the human alpha1B-AR with a single large intron interrupting its coding region differs from those of other ARs as well as muscarinic and 5-hydroxy-tryptamine receptors, which are intronless. The location of the intron in the human alpha1B-AR gene is also unique among those members of the G-protein-coupled receptor family that do possess introns. Availability of this gene will now allow further studies on the transcriptional control of human alpha1B-AR expression.	CLEVELAND CLIN FDN, RES INST,DEPT HEART & HYPERTENS RES,FF3-20, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation					NIGMS NIH HHS [GM45985] Funding Source: Medline; NINDS NIH HHS [NS19583, NS09056] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019583, F32NS009056] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLQUIST RP, 1948, AM J PHYSIOL, V153, P586, DOI 10.1152/ajplegacy.1948.153.3.586; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; COLLINS J, 1980, COLD SPRING HARB SYM, V45, P409, DOI 10.1101/SQB.1981.045.01.055; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DOMINSKI Z, 1991, MOL CELL BIOL, V11, P6075, DOI 10.1128/MCB.11.12.6075; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; GERARD NP, 1991, BIOCHEMISTRY-US, V30, P10640, DOI 10.1021/bi00108a006; GERARD NP, 1990, J BIOL CHEM, V265, P20455; HAGENBUCHLE O, 1980, CELL, V21, P179, DOI 10.1016/0092-8674(80)90125-7; HARRISON JK, 1991, TRENDS PHARMACOL SCI, V12, P62, DOI 10.1016/0165-6147(91)90499-I; HERSHEY AD, 1991, J BIOL CHEM, V266, P4366; JOB D, 1991, EUR J BIOCHEM, V195, P831, DOI 10.1111/j.1432-1033.1991.tb15772.x; JUNG A, 1980, P NATL ACAD SCI-BIOL, V77, P5759, DOI 10.1073/pnas.77.10.5759; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; MINOWA MT, 1992, P NATL ACAD SCI USA, V89, P3045, DOI 10.1073/pnas.89.7.3045; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; PONCE MR, 1992, NUCLEIC ACIDS RES, V20, P623, DOI 10.1093/nar/20.3.623; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; RAYMOND JR, 1990, HYPERTENSION, V15, P119, DOI 10.1161/01.HYP.15.2.119; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROGERS J, 1985, NATURE, V315, P458, DOI 10.1038/315458a0; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STALKER DM, 1981, ICN UCLA S MOL CELL, V22, P113; TOSO RD, 1989, EMBO J, V8, P4025; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; VOIGT MM, 1990, NUCLEIC ACIDS RES, V18, P1053, DOI 10.1093/nar/18.4.1053; WEINSHANK RL, 1990, MOL PHARMACOL, V38, P681; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILLIAMS WL, 1987, J MOL BIOL, V196, P743	46	158	171	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21936	21945						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328250				2022-12-27	WOS:A1992JV01100104
J	FEDOROV, S; UYEDA, K				FEDOROV, S; UYEDA, K			OSCILLATION IN FRUCTOSE 2,6-BISPHOSPHATE LEVELS AND IN THE PHOSPHORYLATION STATES OF FRUCTOSE 6-PHOSPHATE,2-KINASE-FRUCTOSE-2,6-BISPHOSPHATASE IN ISCHEMIC RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURINE NUCLEOTIDE CYCLE; CATALYZES HYDROLYSIS; INSULIN-SECRETION; MUSCLE EXTRACTS; ENZYME; GLYCOLYSIS; FORMS; AMP; FRUCTOSE-2,6-BISPHOSPHATE; PHOSPHOFRUCTOKINASE-2	In order to determine the role of fructose (Fru) 2,6-P2 in stimulation of phosphofructokinase in ischemic liver, tissue contents of Fru-2,6-P2, hexose-Ps, adenine nucleotides, and Fru-6-P,2-kinase:Fru-2,6-bisphosphatase were investigated during the first few minutes of ischemia. The Fru-2,6-P2 concentration in the liver changed in an oscillatory manner. Within 7 s after the initiation of ischemia, Fru-2,6-P2 increased from 6 to 21 nmol/g liver and decreased to 5 nmol/g liver within 30 s. Subsequently, it reached the maximum value at 50, 80, and 100 s and decreased to the basal concentration at 60, 90, and 120 s. Oscillatory patterns were also observed with Glc-6-P and Fru-6-P, but the ATP/ADP ratio decreased monotonically. Determination of Fru-6-P,2-kinase activity and the phosphorylation states of Fru-6-P,2-kinase:Fru-2,6-bisphosphatase demonstrated that at 7 and 50 s, where Fru-2,6-P2 was the highest, the enzyme was activated and mostly in a dephosphorylated form. On the other hand, at 0, 30, and 300 s, the enzyme was predominantly in the phosphorylated form. The concentration of cAMP in the liver also changed in an oscillatory manner between 0.5 to 1.3 nmol/g with varying frequency of 10 to 40 s. These results indicated that: (a) Fru-2,6-P2 was important in rapid activation of phosphofructokinase in the first few seconds and up to 2-3 min, and (b) the oscillation of Fru-2,6-P2 concentration was the result of activation and inhibition of Fru-6-P,2-kinase:Fru-2,6-bisphosphatase, which was caused by changes in the phosphorylation state of the enzyme.	DEPT VET AFFAIRS MED CTR,PRECLIN SCI UNIT,4500 S LANCASTER RD,DALLAS,TX 75216; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75216	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016194] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK16194] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGSTROM RW, 1989, AM J PHYSIOL, V257, pE479, DOI 10.1152/ajpendo.1989.257.4.E479; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BETZ A, 1965, ARCH BIOCHEM BIOPHYS, V109, P585, DOI 10.1016/0003-9861(65)90404-2; BRADFORD MM, 1976, ANAL BIOCHEM, V28, P216; CHANCE B, 1965, J BIOL CHEM, V240, P3170; CHOU HF, 1990, DIABETES, V39, P112, DOI 10.2337/diabetes.39.1.112; CONGO EA, 1991, J BIOL CHEM, V266, P9314; Corbin J D, 1974, Methods Enzymol, V38, P287; ELMAGHRABI MR, 1982, J BIOL CHEM, V257, P7603; ELMAGHRABI MR, 1981, BIOCHEM BIOPH RES CO, V101, P1071, DOI 10.1016/0006-291X(81)91858-1; ELMAGHRABI MR, 1982, P NATL ACAD SCI-BIOL, V79, P315, DOI 10.1073/pnas.79.2.315; FRENKEL R, 1968, ARCH BIOCHEM BIOPHYS, V125, P157, DOI 10.1016/0003-9861(68)90650-4; FURUYA E, 1982, BIOCHEM BIOPH RES CO, V105, P264, DOI 10.1016/S0006-291X(82)80040-5; FURUYA E, 1982, P NATL ACAD SCI-BIOL, V79, P325, DOI 10.1073/pnas.79.2.325; FURUYA E, 1981, J BIOL CHEM, V256, P7109; HESS B, 1971, ANNU REV BIOCHEM, V40, P237, DOI 10.1146/annurev.bi.40.070171.001321; HUE L, 1982, BIOCHEM J, V206, P359, DOI 10.1042/bj2060359; KITAJIMA S, 1984, J BIOL CHEM, V259, P6896; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lowry O. H., 1972, FLEXIBLE SYSTEM ENZY, P146; LOWRY OH, 1964, J BIOL CHEM, V239, P18; OGUSHI S, 1990, J BIOL CHEM, V265, P10943; RAPP PE, 1987, PROG NEUROBIOL, V29, P261, DOI 10.1016/0301-0082(87)90023-2; SAKAKIBARA R, 1984, J BIOL CHEM, V259, P41; STALMANS W, 1975, EUR J BIOCHEM, V54, P341, DOI 10.1111/j.1432-1033.1975.tb04144.x; THOMAS H, 1986, ANAL BIOCHEM, V154, P50, DOI 10.1016/0003-2697(86)90494-X; THOMAS H, 1986, FED PROC, V45, P1013; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TORNHEIM K, 1979, J THEOR BIOL, V79, P491, DOI 10.1016/0022-5193(79)90240-6; TORNHEIM K, 1988, J BIOL CHEM, V263, P2619; TORNHEIM K, 1973, J BIOL CHEM, V248, P2670; UYEDA K, 1982, MOL CELL BIOCHEM, V48, P97; UYEDA K, 1978, J BIOL CHEM, V253, P8319; VANSCHAFTINGEN E, 1981, BIOCHEM BIOPH RES CO, V103, P362, DOI 10.1016/0006-291X(81)91701-0; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V124, P143; VANSCHAFTINGEN E, 1981, BIOCHEM BIOPH RES CO, V101, P1078; VEECH RL, 1973, J NEUROCHEM, V20, P183, DOI 10.1111/j.1471-4159.1973.tb12115.x	37	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20826	20830						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328212				2022-12-27	WOS:A1992JT97800050
J	FRATTALI, AL; TREADWAY, JL; PESSIN, JE				FRATTALI, AL; TREADWAY, JL; PESSIN, JE			TRANSMEMBRANE SIGNALING BY THE HUMAN INSULIN-RECEPTOR KINASE - RELATIONSHIP BETWEEN INTRAMOLECULAR BETA-SUBUNIT TRANS-AUTOPHOSPHORYLATION AND CIS-AUTOPHOSPHORYLATION AND SUBSTRATE KINASE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; COOH-TERMINAL TRUNCATION; EXPRESSION SYSTEM; TYROSINE KINASE; PROTEIN-KINASE; DEPENDENT COVALENT; CYTOPLASMIC DOMAIN; POSSIBLE MECHANISM; TRANSFECTED CELLS; HYBRID RECEPTORS	To examine the role of intramolecular beta subunit trans- and cis-autophosphorylation in signal transduction, the vaccinia virus/bacteriophage T7 expression system was used to generate insulin holoreceptors composed of a kinase-defective half-receptor precursor (alphabeta(A/K) or alphabeta(A/K.DELTACT)) and a kinase-active half-receptor precursor (alphabeta(DELTACT) or alphabeta(WT)). In the alphabeta(A/K-alphabeta(DELTACT) hybrid insulin receptor, insulin stimulated a 20-fold increase in intramolecular beta subunit trans-phosphorylation, whereas cis-phosphorylation increased only 3-fold over the basal state. Similarly, in the alphabeta(WT)-alphabeta(A/K.DELTACT) hybrid insulin receptor, insulin stimulated trans-phosphorylation approximately 30-fold and cis-phosphorylation only 3-fold over the basal state. Although cis-phosphorylation of the kinase-functional alphabeta half-receptor was observed within these hybrid receptor species, this was not sufficient to stimulate exogenous substrate kinase activity. These data demonstrate that insulin primarily activates an intramolecular beta subunit trans-phosphorylation reaction within the insulin holoreceptor and suggest that this reaction is necessary for activation of the holoreceptor. Furthermore, our results suggest a molecular basis for the dominant-negative phenotype observed in insulin-resistant patients possessing one kinase-defective insulin receptor allele.			FRATTALI, AL (corresponding author), UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242, USA.				NIDDK NIH HHS [DK01822, DK33823, DK25295] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033823, R37DK033823, K04DK001822, P30DK025295] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACCILI D, 1991, J BIOL CHEM, V266, P434; ALEXANDRIDES TK, 1989, J BIOL CHEM, V264, P12922; BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BONISCHNETZLER M, 1986, J BIOL CHEM, V261, P5281; BONISCHNETZLER M, 1988, J BIOL CHEM, V263, P6822; BOYLE TR, 1985, J BIOL CHEM, V260, P8593; CHIN JE, 1991, J BIOL CHEM, V266, P15587; COBB MH, 1989, J BIOL CHEM, V264, P18701; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; FRATTALI AL, 1992, J CELL BIOCHEM, V48, P43, DOI 10.1002/jcb.240480108; FRATTALI AL, 1991, J BIOL CHEM, V266, P9829; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; HAYES GR, 1991, DIABETES, V40, P300, DOI 10.2337/diabetes.40.2.300; HERRERA R, 1988, J BIOL CHEM, V263, P5560; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MORRISON BD, 1988, J BIOL CHEM, V263, P7806; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; OHARE T, 1988, BIOCHEMISTRY-US, V27, P5693, DOI 10.1021/bi00415a045; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; PETRUZZELLI L, 1984, P NATL ACAD SCI-BIOL, V81, P3327, DOI 10.1073/pnas.81.11.3327; SHIA MA, 1983, J BIOL CHEM, V258, P4450; SHOELSON SE, 1991, BIOCHEMISTRY-US, V30, P7740, DOI 10.1021/bi00245a010; SOOS MA, 1989, BIOCHEM J, V263, P553, DOI 10.1042/bj2630553; SOOS MA, 1990, BIOCHEM J, V270, P383, DOI 10.1042/bj2700383; SWEET LJ, 1987, J BIOL CHEM, V262, P16730; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; TREADWAY JL, 1989, J BIOL CHEM, V264, P15136; VANOBBERGHENSCHILLING EE, 1981, J CLIN INVEST, V68, P1356, DOI 10.1172/JCI110383; VILLALBA M, 1989, P NATL ACAD SCI USA, V86, P7848, DOI 10.1073/pnas.86.20.7848; WHITE MF, 1984, J BIOL CHEM, V259, P255; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1989, BIOCHEMISTRY-US, V28, P785, DOI 10.1021/bi00428a056; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858	44	80	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19521	19528						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326556				2022-12-27	WOS:A1992JP59300076
J	GHALAYINI, AJ; ANDERSON, RE				GHALAYINI, AJ; ANDERSON, RE			ACTIVATION OF BOVINE ROD OUTER SEGMENT PHOSPHOLIPASE-C BY ARRESTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LIGHT-MEDIATED BREAKDOWN; 48-KDA PROTEIN; S-ANTIGEN; IMMUNOCYTOCHEMICAL EVIDENCE; PHOTOEXCITED RHODOPSIN; GUANYLATE-CYCLASE; RETINAL RODS; BINDING; CALCIUM	Phospholipase C (PLC) enzyme activity in rod outer segment (ROS) membranes bleached in the presence of ATP and GTP was assayed using exogenously added [H-3]phosphatidylinositol 4,5-bisphosphate vesicles as substrate. The addition of the soluble ROS protein arrestin (also known as S-antigen or 48K protein) to ROS membranes activated PLC 2-3.4-fold. This activation was dose-dependent, and maximal activation was observed at an arrestin concentration of congruent-to 110-220 nM. PLC activation by arrestin was dependent on ROS protein concentration and free Ca2+. Soluble PLC (s-PLC) enzyme activity present in hypotonic extracts of bleached ROS was also activated 2-4-fold by arrestin. Maximum activation of s-PLC by arrestin was observed at free Ca2+ of 80 nM. Arrestin activation of s-PLC was not affected by urea-treated and extensively washed ROS membranes, suggesting that rhodopsin was not required for the observed effect of arrestin on s-PLC. The results are indicative of a direct interaction of arrestin with s-PLC, resulting in the activation of the latter. Based on these results and the documented binding of arrestin to bleached and phosphorylated rhodopsin, a model for the light activation of PLC in ROS is proposed.			GHALAYINI, AJ (corresponding author), BAYLOR COLL MED,CULLEN EYE INST,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NATIONAL EYE INSTITUTE [P30EY002520, R01EY004149, R01EY000871] Funding Source: NIH RePORTER; NEI NIH HHS [EY04149, EY00871, EY02520] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GEHM BD, 1990, BIOCHEMISTRY-US, V29, P5447, DOI 10.1021/bi00475a006; GEHM BD, 1991, BIOCHEMISTRY-US, V30, P11302, DOI 10.1021/bi00111a016; GHALAYINI A, 1984, BIOCHEM BIOPH RES CO, V124, P503, DOI 10.1016/0006-291X(84)91582-1; GHALAYINI AJ, 1991, J NEUROCHEM, V57, P1405, DOI 10.1111/j.1471-4159.1991.tb08307.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLITSCHER W, 1989, FEBS LETT, V256, P101, DOI 10.1016/0014-5793(89)81726-0; GLITSCHER W, 1991, FEBS LETT, V282, P431, DOI 10.1016/0014-5793(91)80530-G; HAYASHI F, 1985, BIOCHEM BIOPH RES CO, V128, P954, DOI 10.1016/0006-291X(85)90139-1; HUPPERTZ B, 1990, J BIOL CHEM, V265, P9470; JEANSONNE NE, 1991, J BIOL CHEM, V266, P14675; KAPOOR CL, 1987, EXP EYE RES, V45, P545, DOI 10.1016/S0014-4835(87)80065-9; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KELLEHER DJ, 1985, J CYCLIC NUCL PROT, V10, P579; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KORF H, 1987, CANCER, V60, P1763, DOI 10.1002/1097-0142(19871015)60:8<1763::AID-CNCR2820600815>3.0.CO;2-3; Kuhn H., 1980, Neurochemistry International, V1, P269, DOI 10.1016/0197-0186(80)90066-2; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITOSCH I, 1991, J BIOL CHEM, V266, P4764; MATHEWS HR, 1988, NATURE, V3334, P67; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; MILLAR FA, 1988, BIOCHIM BIOPHYS ACTA, V970, P205, DOI 10.1016/0167-4889(88)90180-2; MIRSHAHI M, 1989, FEBS LETT, V258, P240, DOI 10.1016/0014-5793(89)81663-1; MIRSHAHI M, 1991, C R ACD SCI PARIS, V312, P1441; MORRIS AJ, 1990, G PROTEINS SIGNAL TR, V81, P61; NAKAMURA S, 1990, P NATL ACAD SCI USA, V87, P6413, DOI 10.1073/pnas.87.16.6413; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; OLIVER J, 1987, CR ACAD SCI III-VIE, V305, P485; PANFOLI I, 1990, BIOCHEM BIOPH RES CO, V173, P283, DOI 10.1016/S0006-291X(05)81054-X; REBECCHI MJ, 1987, J BIOL CHEM, V262, P12526; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SAGIEISENBERG R, 1989, CELL SIGNAL, V1, P519, DOI 10.1016/0898-6568(89)90036-3; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SHINOHARA T, 1988, PROGR RETINAL RES, V8, P51; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRYER L, 1991, J BIOL CHEM, V266, P10711; TARVER AP, 1988, EXP EYE RES, V46, P29, DOI 10.1016/S0014-4835(88)80090-3; TAYLOR SJ, 1991, NATURE, V350, P512; USUDA N, 1991, J CELL BIOL, V112, P1241, DOI 10.1083/jcb.112.6.1241; WACKER WB, 1977, J IMMUNOL, V119, P1949; WANG P, 1987, J BIOCHEM-TOKYO, V102, P1275, DOI 10.1093/oxfordjournals.jbchem.a122166; WEYAND I, 1990, EUR J BIOCHEM, V193, P459, DOI 10.1111/j.1432-1033.1990.tb19360.x; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1986, FEBS LETT, V207, P292, DOI 10.1016/0014-5793(86)81507-1; WISTOW GJ, 1986, FEBS LETT, V196, P23, DOI 10.1016/0014-5793(86)80207-1	48	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17977	17982						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325454				2022-12-27	WOS:A1992JM22300076
J	FILATOV, D; INGEMARSON, R; GRASLUND, A; THELANDER, L				FILATOV, D; INGEMARSON, R; GRASLUND, A; THELANDER, L			THE ROLE OF HERPES-SIMPLEX VIRUS RIBONUCLEOTIDE REDUCTASE SMALL SUBUNIT CARBOXYL TERMINUS IN SUBUNIT INTERACTION AND FORMATION OF IRON-TYROSYL CENTER STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SYNTHETIC PEPTIDES; R2 SUBUNIT; TYPE-1; INHIBITION; PURIFICATION; PROTEIN; DNA; TRANSFORMATION; EXPRESSION	Herpes simplex virus ribonucleotide reductase consists of two nonidentical subunits, proteins R1 and R2, which are required together for activity. Active R2 protein contains a tyrosyl free radical and a binuclear iron center. A truncated form of the R2 subunit, lacking 7 amino acid residues in the carboxyl terminus, was constructed, overexpressed in Escherichia coli and purified to homogeneity. In the presence of ferrous iron and oxygen, the truncated protein readily generated similar amounts of tyrosyl free radical as the intact protein. However, the radical showed differences in EPR characteristics in the truncated protein compared with the normal one, indicating an altered structural arrangement of the radical relative to the iron center. The truncated R2* protein was completely devoid of binding affinity to the R1 protein, demonstrating that the subunit interaction is totally dependent on the 7 outermost carboxyl-terminal amino acids of protein R2.	UMEA UNIV,DEPT MED BIOCHEM & BIOPHYS,S-90187 UMEA,SWEDEN	Umea University								AVERETT DR, 1983, J BIOL CHEM, V258, P9831; BACCHETTI S, 1986, J VIROL, V57, P1177, DOI 10.1128/JVI.57.3.1177-1181.1986; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; CLIMENT I, 1992, IN PRESS BIOCHEMISTR; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; COSENTINO G, 1991, BIOCHEM CELL BIOL, V69, P79, DOI 10.1139/o91-011; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FRAME MC, 1985, J GEN VIROL, V66, P1581, DOI 10.1099/0022-1317-66-7-1581; FURLONG J, 1991, VIROLOGY, V182, P846, DOI 10.1016/0042-6822(91)90627-N; GAUDREAU P, 1987, J BIOL CHEM, V262, P12413; GAUDREAU P, 1990, J MED CHEM, V33, P723, DOI 10.1021/jm00164a040; GOLDIN AL, 1981, J VIROL, V38, P50, DOI 10.1128/JVI.38.1.50-58.1981; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; INGEMARSON R, 1989, J VIROL, V63, P3769, DOI 10.1128/JVI.63.9.3769-3776.1989; INGEMARSON R, 1987, VIROLOGY, V156, P417, DOI 10.1016/0042-6822(87)90422-3; INGEMARSON R, 1989, UMEA U MED DISSERTAT, V4, P1; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LANKINEN H, 1982, J VIROL, V41, P893, DOI 10.1128/JVI.41.3.893-900.1982; LYNCH JB, 1989, J BIOL CHEM, V264, P8091; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MCLAUCHLAN J, 1983, J GEN VIROL, V64, P997, DOI 10.1099/0022-1317-64-5-997; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; PARADIS H, 1991, J BIOL CHEM, V266, P9647; PARADIS H, 1988, J BIOL CHEM, V263, P16045; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5542; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SJOBERG BM, 1987, J BIOL CHEM, V262, P9736; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; YANG FD, 1990, FEBS LETT, V272, P61, DOI 10.1016/0014-5793(90)80449-S	36	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15816	15822						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322407				2022-12-27	WOS:A1992JG11300085
J	SEOK, JH; XU, L; KRAMARCY, NR; SEALOCK, R; MEISSNER, G				SEOK, JH; XU, L; KRAMARCY, NR; SEALOCK, R; MEISSNER, G			THE 30-S LOBSTER SKELETAL-MUSCLE CA2+ RELEASE CHANNEL (RYANODINE RECEPTOR) HAS FUNCTIONAL-PROPERTIES DISTINCT FROM THE MAMMALIAN CHANNEL PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE; CA-2+ RELEASE; COMPLEMENTARY-DNA; MOLECULAR-CLONING; CONTRACTION; CDNA; ACTIVATION; FIBERS; PURIFICATION	The 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (Chaps)-solubilized ryanodine receptor (RyR) of lobster skeletal muscle has been isolated by rate density centrifugation as a 30 S protein complex. Sodium dodecyl sulfate-polyacrylamide gel electrophoretic analysis of the purified 30 S receptor revealed a single high molecular weight protein band with a mobility intermediate between those of the mammalian skeletal and cardiac M(r) 565,000 RyR polypeptides. Immunoblot analysis showed no or only minimal cross-reactivity with the rabbit skeletal and canine cardiac RyR polypeptides. By immunofluorescence the lobster RyR was localized to the junctions of the A-I bands. Following planar lipid bilayer reconstitution of the purified 30 S lobster RyR, single channel K+ and Ca2+ currents were observed which were modified by ryanodine and optimally activated by millimolar concentrations of cis (cytoplasmic) Ca2+. Vesicle-Ca-45(2+) flux measurements also indicated an optimal activation of the lobster Ca2+ channel by millimolar Ca2+, whereas Ca-45(2+) efflux from mammalian skeletal and cardiac muscle sarcoplasmic reticulum (SR) vesicles is optimally activated by micromolar Ca2+. Further, mammalian muscle SR Ca2+ release activity is modulated by Mg2+ and ATP, whereas neither ligand appreciably affected Ca-45(2+) efflux from lobster SR vesicles. These results suggested that lobster and mammalian muscle express immunologically and functionally distinct SR Ca2+ release channel protein complexes.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CB 7260,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHYSIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018687, R01AR018687] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 18687] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON K, 1989, J BIOL CHEM, V264, P1329; ARISPE N, 1992, Biophysical Journal, V61, pA24; ASHLEY CC, 1978, J PHYSIOL-LONDON, V282, P307, DOI 10.1113/jphysiol.1978.sp012465; ATWATER I, 1974, J PHYSIOL-LONDON, V243, P523, DOI 10.1113/jphysiol.1974.sp010765; BASKIN RJ, 1971, J CELL BIOL, V48, P49, DOI 10.1083/jcb.48.1.49; BEZANILLA F, 1973, ACTA PHYSIOL LAT AM, V23, P497; Bourne GH, 1972, STRUCTURE FUNCTION M, V1, P421; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; CROWE LM, 1981, TISSUE CELL, V13, P153, DOI 10.1016/0040-8166(81)90045-8; DUPONT Y, 1987, METHOD ENZYMOL, V148, P675; EBASHI S, 1976, ANNU REV PHYSIOL, V38, P293, DOI 10.1146/annurev.ph.38.030176.001453; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FORMELOVA J, 1990, GEN PHYSIOL BIOPHYS, V9, P445; FRANZINI.C, 1970, J CELL BIOL, V47, P488, DOI 10.1083/jcb.47.2.488; GAINER H, 1968, J GEN PHYSIOL, V52, P88, DOI 10.1085/jgp.52.1.88; GYORKE S, 1991, PHYSIOLOGIST, V34, P110; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; JAHROMI SS, 1969, J EXP ZOOL, V171, P25, DOI 10.1002/jez.1401710105; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEA TJ, 1989, PFLUG ARCH EUR J PHY, V413, P401, DOI 10.1007/BF00584490; LILLIE SH, 1987, YEAST, V3, P63, DOI 10.1002/yea.320030202; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MALAN NT, 1975, FEBS LETT, V60, P122, DOI 10.1016/0014-5793(75)80432-7; MEISSNER G, 1989, J BIOL CHEM, V264, P1715; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MILLER C, 1978, J MEMBRANE BIOL, V40, P1, DOI 10.1007/BF01909736; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; OLIVARES E, 1992, Biophysical Journal, V61, pA23; OLIVARES EB, 1991, BIOPHYS J, V59, P1153, DOI 10.1016/S0006-3495(91)82331-1; OTSU K, 1990, J BIOL CHEM, V265, P13472; REUBEN JP, 1967, AM ZOOL, V7, P623; RIOS E, 1988, NEWS PHYSIOL SCI, V3, P223, DOI 10.1152/physiologyonline.1988.3.6.223; ROJAS E, 1987, CAN J PHYSIOL PHARM, V65, P672, DOI 10.1139/y87-111; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; SCHNEIDER MF, 1981, ANNU REV PHYSIOL, V43, P507, DOI 10.1146/annurev.ph.43.030181.002451; SEALOCK R, 1991, J CELL BIOL, V113, P1133, DOI 10.1083/jcb.113.5.1133; SEOK J H, 1992, Biophysical Journal, V61, pA23; SMITH JS, 1989, CIRC RES, V64, P352, DOI 10.1161/01.RES.64.2.352; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SUAREZISLA BA, 1988, BIOPHYS J, V54, P737, DOI 10.1016/S0006-3495(88)83009-1; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	52	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15893	15901						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322408				2022-12-27	WOS:A1992JG11300095
J	ODENWALLER, R; MADDIPATI, KR; MARNETT, LJ				ODENWALLER, R; MADDIPATI, KR; MARNETT, LJ			DETECTION OF A HIGHER OXIDATION-STATE OF MANGANESE-PROSTAGLANDIN ENDOPEROXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR GLAND MICROSOMES; ELECTRON-PARAMAGNETIC-RES; H SYNTHASE; PEROXIDASE-ACTIVITIES; CYCLOOXYGENASE; BIOSYNTHESIS; PURIFICATION; SYNTHETASE; HEME; HYDROPEROXIDE	Addition of arachidonic acid or 5-phenyl-4-pentenylhydroperoxide to manganese-prostaglandin endoperoxide synthase (Mn-PGH synthase) produced a species with an absorbance maximum at 418 nm. This maximum is distinct from those of resting enzyme (3 7 2 and 468 nm) or reduced enzyme (434 nm). The formation of the 418 nm-absorbing species was observed immediately after the addition of hydroperoxide to enzyme but only after a 10-s lag period following addition of arachidonate. Mn-PGH synthase exhibited a peroxidase activity that was 0.8% that of Fe-PGH synthase. Addition of peroxidase reducing substrates to the oxidized form of Mn-PGH synthase diminished the absorbance at 418 nm. In the case of N,N,N',N'-tetramethylphenylenediamine, reduction of the 418 nm-absorbing species was accompanied by an increase in absorbance at 610 nm due to the oxidized form of the amine. Thus, the spectral and chemical properties of the 418 nm-absorbing species are consistent with its existence as a higher oxidation state of Mn-PGH synthase. Kinetic analysis indicated that formation of the higher oxidation state preceded or was coincident with oxygenation of the fatty acid substrate, eicosa-11, 14-dienoic acid. The cyclooxygenase activity of Mn-PGH synthase was inhibited by the combination of glutathione and human plasma glutathione peroxidase at a glutathione peroxidase concentration 227-fold lower than the concentration that inhibited Fe-PGH synthase. The results suggest that Mn-PGH synthase forms a higher oxidation state following reaction with hydroperoxides added exogenously or generated endogenously from polyunsaturated fatty acid substrates. This higher oxidation state functions in the peroxidase catalytic cycle of Mn-PGH synthase, and its formation appears to be essential for activation of the cyclooxygenase catalytic cycle.	VANDERBILT UNIV, MED CTR,SCH MED,DEPT BIOCHEM, AB HANCOCK JR MEM LAB CANC RES,CTR MOLEC TOXICOL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT CHEM, NASHVILLE, TN 37232 USA	Vanderbilt University; Vanderbilt University			Maddipati, Krishna Rao/H-3569-2019	Maddipati, Krishna Rao/0000-0003-1445-791X	NCI NIH HHS [CA-47479] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; GRAFF G, 1990, ANAL BIOCHEM, V188, P38, DOI 10.1016/0003-2697(90)90525-E; HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HAZZARD JT, 1991, J AM CHEM SOC, V113, P8956, DOI 10.1021/ja00023a059; HEMLER ME, 1978, BIOCHEMISTRY-US, V17, P1772, DOI 10.1021/bi00602a031; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; HEMLER ME, 1978, BIOCHEM BIOPH RES CO, V85, P1325, DOI 10.1016/0006-291X(78)91148-8; HORI H, 1987, BIOCHIM BIOPHYS ACTA, V912, P74, DOI 10.1016/0167-4838(87)90249-4; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1985, BIOCHEM BIOPH RES CO, V130, P918, DOI 10.1016/0006-291X(85)90504-2; KULMACZ RJ, 1987, J BIOL CHEM, V262, P10524; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; KULMACZ RJ, 1991, DEV ONCOL, V67, P205; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LANDS W, 1971, ANN NY ACAD SCI, V180, P107, DOI 10.1111/j.1749-6632.1971.tb53190.x; Lands WE, 1984, FREE RADICAL BIO MED, P39; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; MADDIPATI KR, 1987, J BIOL CHEM, V262, P17398; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; Marnett L. J., 1991, PEROXIDASES CHEM BIO, V1, P293; MARNETT LJ, 1988, J BIOL CHEM, V263, P16532; MARNETT LJ, 1984, MOL PHARMACOL, V26, P328; MARSHALL PJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P162, DOI 10.1016/0003-9861(88)90246-9; MILLER DM, 1990, FREE RADICAL BIO MED, V8, P95, DOI 10.1016/0891-5849(90)90148-C; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; NUGTEREN DH, 1973, BIOCHIM BIOPHYS ACTA, V326, P448, DOI 10.1016/0005-2760(73)90145-8; O'Brien P J, 1980, Adv Prostaglandin Thromboxane Res, V6, P145; ODENWALLER R, 1990, METHOD ENZYMOL, V187, P479; OGINO N, 1978, J BIOL CHEM, V253, P5061; PORTER NA, 1986, ACCOUNTS CHEM RES, V19, P262, DOI 10.1021/ar00129a001; RAZ A, 1990, BIOCHEM J, V269, P603, DOI 10.1042/bj2690603; ROTH GJ, 1981, J BIOL CHEM, V256, P18; RUF HH, 1984, FEBS LETT, V165, P293, DOI 10.1016/0014-5793(84)80189-1; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SMITH WL, 1991, ACTA LIPIDS LIPID ME, V1083, P1; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WELLER PE, 1985, ARCH BIOCHEM BIOPHYS, V243, P633, DOI 10.1016/0003-9861(85)90541-7; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YONETANI T, 1969, J BIOL CHEM, V244, P4580; YONETANI T, 1968, J BIOL CHEM, V243, P3996	45	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13863	13869						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321128				2022-12-27	WOS:A1992JD32500015
J	ANDERSEN, AS; KJELDSEN, T; WIBERG, FC; VISSING, H; SCHAFFER, L; RASMUSSEN, JS; DEMEYTS, P; MOLLER, NPH				ANDERSEN, AS; KJELDSEN, T; WIBERG, FC; VISSING, H; SCHAFFER, L; RASMUSSEN, JS; DEMEYTS, P; MOLLER, NPH			IDENTIFICATION OF DETERMINANTS THAT CONFER LIGAND SPECIFICITY ON THE INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; CYSTEINE-RICH REGION; ALPHA-SUBUNIT; BINDING-SITE; LOCALIZATION; MUTATION; AFFINITY; CHAIN; GENE	We have previously shown, using truncated soluble recombinant receptors, that substituting the 62 N-terminal amino acids of the alpha-subunit from the insulin-like growth factor I receptor (IGFIR) with the corresponding 68 amino acids from the insulin receptor (IR) results in a chimeric receptor with an approximately 200-fold increase in affinity for insulin and only a 5-fold decrease in insulin-like growth factor I (IGFI) affinity (Kjeldsen, T., Andersen, A. S., Wiberg, F. C., Rasmussen, J. S., Schaffer, L., Balschmidt, P., Moller, K. B., and Moller, N. P. H. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 4404-4408). We demonstrate that these 68 N-terminal amino acids of the IR also confer insulin affinity on the intact IGFI holoreceptor both in the membrane-bound state and when solubilized by Triton X-100. Furthermore, this domain can be subdivided into two regions (amino acids 1-27 and 28-68 of the IR alpha-subunit) that, when replacing the corresponding IGFIR sequences, increases the insulin affinity of truncated soluble receptor chimeras 8- and 20-fold, respectively, with only minor effects on the IGFI affinity. Within the latter of these two regions, we found that amino acids 38-68 of the IR, representing 13 amino acid differences from IGFIR, confer the same 20-fold increase in insulin affinity on the IGFIR. Finally, the amino acids from position 42 to 50 are not responsible for this increase in insulin affinity. We thus propose that at least two determinants within the 68 N-terminal amino acids of the insulin receptor are involved in defining the ligand specificity of the insulin receptor, and that one or a combination of the remaining seven amino acid differences between position 38 and 68 are involved in conferring insulin affinity on the insulin receptor.	NOVO NORDISK AS,CORP RES,DK-2880 BAGSVAERD,DENMARK; HAGEDORN RES LAB,DK-2820 GENTOFTE,DENMARK	Novo Nordisk; Novo Nordisk; Hagedorn Research Institute	ANDERSEN, AS (corresponding author), NOVO NORDISK AS,DIABET RES,NOVO ALLE,DK-2880 BAGSVAERD,DENMARK.			Kjeldsen, Thomas/0000-0003-0094-9286; De Meyts, Pierre/0000-0001-6214-0824				ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; BRANGE J, 1990, DIABETES CARE, V13, P923, DOI 10.2337/diacare.13.9.923; CHIN JE, 1991, J BIOL CHEM, V266, P15587; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DEMEYTS P, 1990, MOL ENDOCRINOL, V4, P409, DOI 10.1210/mend-4-3-409; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HOLLENBERG MD, 1985, INSULIN ITS RECEPTOR, P57; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KADOWAKI T, 1990, J BIOL CHEM, V265, P19143; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; LEATHERBARROW RJ, 1990, GRAFIT VERSION 20; MIRMIRA RG, 1991, J BIOL CHEM, V266, P1428; MIRMIRA RG, 1989, J BIOL CHEM, V264, P6349; RAFAELOFF R, 1989, J BIOL CHEM, V264, P15900; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SOOS MA, 1990, BIOCHEM J, V270, P383, DOI 10.1042/bj2700383; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001; YIP CC, 1992, J CELL BIOCHEM, V48, P19, DOI 10.1002/jcb.240480105; YIP CC, 1988, BIOCHEM BIOPH RES CO, V157, P321, DOI 10.1016/S0006-291X(88)80050-0; YIP CC, 1991, BIOCHEMISTRY-US, V30, P695, DOI 10.1021/bi00217a016; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	27	73	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13681	13686						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320025				2022-12-27	WOS:A1992JB74600092
J	KETCHAM, CM; KORNFELD, S				KETCHAM, CM; KORNFELD, S			PURIFICATION OF UDP-N-ACETYLGLUCOSAMINE-GLYCOPROTEIN N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE FROM ACANTHAMOEBA-CASTELLANII AND IDENTIFICATION OF A SUBUNIT OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL-ENZYMES; RAT-LIVER; PHOSPHORYLATION; PHOSPHODIESTERASE; PROTEINS; ACETYLGLUCOSAMINYLPHOSPHOTRANSFERASE; OLIGOSACCHARIDES; RECOGNITION; UTEROFERRIN; BINDING	UDP-N-acetylglucosamine:glycoprotein N-acetylglucosamine-1-phosphotransferase (GlcNAc-phosphotransferase) from the soil amoeba Acanthamoeba castellanii has been purified over 100,000-fold by means of wheat germ agglutinin-Sepharose affinity chromatography, DEAE-cellulose chromatography, concanavalin A-Sepharose affinity chromatography, orange A-agarose dye chromatography, and gel filtration on Superose 6. The most purified enzyme has an estimated specific activity of at least 5-mu-mol of GlcNAc-phosphate transferred/min/mg of protein using alpha-methylmannoside as acceptor. The molecular weight of the native enzyme is approximately 250,000, as determined by gel filtration and glycerol gradients in H2O and D2O. A protein with an apparent M(r) of 97,000 in small scale preparations and its putative proteolytic fragment of 43,000 in large scale preparations co-purifies with the enzyme activity. This protein is covalently modified with GlcNAc-[P-32]phosphate when the enzyme preparation is incubated with [beta-P-32]UDP-GlcNAc in the absence of an acceptor substrate. The labeling of the 97(43)-kDa protein requires active enzyme and is completely inhibited by the addition of the acceptor substrate alpha-methylmannoside. The GlcNAc-[P-32]phosphate transferred to the protein is not bound to serine, threonine, tyrosine, or mannose residues. The 97(43)-kDa protein with covalently bound GlcNAc-P does not serve as a kinetically competent enzyme-substrate intermediate. However, preincubation of GlcNAc-phosphotransferase with UDP-GlcNAc does result in a decrease in the V(max) of the enzyme in subsequent assays. Taken together, these data are consistent with the 97(43)-kDa protein being a subunit of GlcNAc-phosphotransferase.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,660 S EUCLID AVE,BOX 8125,ST LOUIS,MO 63110	Washington University (WUSTL)					NCI NIH HHS [CA 08759] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERS GK, 1967, J BIOL CHEM, V242, P3237; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BENYOSEPH Y, 1986, BIOCHEM J, V235, P883, DOI 10.1042/bj2350883; BUHI WC, 1982, BIOCHIM BIOPHYS ACTA, V701, P32, DOI 10.1016/0167-4838(82)90308-9; CLARKE S, 1975, J BIOL CHEM, V250, P5459; COUSO R, 1986, J BIOL CHEM, V261, P6326; FULTON S, 1980, DYE LIGAND CHROMATOG; GABEL CA, 1982, J BIOL CHEM, V257, P605; KETCHAM CM, 1992, J BIOL CHEM, V267, P11654; Korn E.D., 1974, Methods Enzymol, V31, P686; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRYSTAL G, 1987, ANAL BIOCHEM, V167, P86, DOI 10.1016/0003-2697(87)90136-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG L, 1984, ANAL BIOCHEM, V140, P264, DOI 10.1016/0003-2697(84)90163-5; LANG L, 1984, J BIOL CHEM, V259, P4663; LANG L, 1986, J BIOL CHEM, V2631, P6320; LOTAN R, 1977, BIOCHEMISTRY-US, V16, P1787, DOI 10.1021/bi00628a004; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTHEWS HR, 1984, MOL CELL BIOCHEM, V59, P81; MITCHELL CA, 1990, P NATL ACAD SCI USA, V87, P9396, DOI 10.1073/pnas.87.23.9396; REITMAN ML, 1981, J BIOL CHEM, V256, P4275; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; REITMAN ML, 1984, METHOD ENZYMOL, V107, P163; RUDINGER J, 1973, BIOCHEM J, V133, P538, DOI 10.1042/bj1330538; SADLER JE, 1979, J BIOL CHEM, V254, P4434; SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X; Steele J C Jr, 1978, Methods Enzymol, V48, P11; VARKI A, 1981, J BIOL CHEM, V256, P9937; WAHEED A, 1982, J BIOL CHEM, V257, P2322; WAHEED A, 1981, J BIOL CHEM, V256, P5717; WALKER DH, 1988, BIOCHEMISTRY-US, V27, P6504, DOI 10.1021/bi00417a046	31	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11645	11653						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317873				2022-12-27	WOS:A1992HX16900108
J	KUNITOMO, R; MIYAUCHI, Y; INOUE, M				KUNITOMO, R; MIYAUCHI, Y; INOUE, M			SYNTHESIS OF A CYTOCHROME-C DERIVATIVE WITH PROLONGED INVIVO HALF-LIFE AND DETERMINATION OF ASCORBYL RADICALS IN THE CIRCULATION OF THE RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; VITAMIN-E; INHIBITION; ALBUMIN; CERULOPLASMIN; LEUKOCYTES; GENERATION; MECHANISM; BINDING; INJURY	Since cytochrome c and acetylated cytochrome c disappear from the circulation with a half-life of 4 min, these proteins cannot be used for in vivo detection of superoxide radicals and related metabolites. To determine superoxide and other radicals in vivo, a cytochrome c derivative (SMAC) was synthesized by linking 1 mol of poly(styrene-co-maleic acid) butyl ester (SM) to cytochrome c, followed by acetylation of its lysyl amino groups. SMAC retained 8 and 80% of cytochrome c activity to react with ascorbyl and superoxide radicals, respectively. However, SMAC did not serve as a substrate for cytochrome c reductase and cytochrome c oxidase. When injected intravenously to the rat, SMAC circulated bound to albumin with a half-life of 130 min. SMAC was rapidly reduced in the circulation of intact animals. Treatment of animals with paraquat markedly enhanced the reduction of the circulating SMAC. We have synthesized an SM-conjugated superoxide dismutase (SOD) derivative (SM-SOD) that circulates bound to albumin with a half-life of 6 h. Kinetic analysis revealed that SM-SOD effectively inhibited the superoxide-dependent reduction of SMAC either in the presence or absence of 0.5 mm albumin. However, the reduction of the circulating SMAC was not inhibited by SM-SOD both in normal and paraquat-treated animals. Plasma samples from both animal groups also reduced cytochrome c and SMAC by an SOD-insensitive mechanism. However, after treatment with ascorbate oxidase, both plasma samples lost their activity to reduce cytochrome c and SMAC. These and other results suggest that ascorbyl radical might principally be responsible for the reduction of circulating SMAC and that plasma levels of ascorbyl radical might increase in paraquat-treated animals.	KUMAMOTO UNIV, SCH MED, DEPT BIOCHEM, 2-2-1 HONJO, KUMAMOTO 860, JAPAN; KUMAMOTO UNIV, SCH MED, DEPT SURG, KUMAMOTO 860, JAPAN	Kumamoto University; Kumamoto University								ANDO Y, 1989, BRAIN RES, V477, P286, DOI 10.1016/0006-8993(89)91416-9; AZZI A, 1975, BIOCHEM BIOPH RES CO, V65, P597, DOI 10.1016/S0006-291X(75)80188-4; Balentine J.D., 1982, PATHOLOGY OXYGEN TOX; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BRITIGAN BE, 1986, J BIOL CHEM, V261, P4426; CABELLI DE, 1983, J PHYS CHEM-US, V87, P1809, DOI 10.1021/j100233a031; DEDRICK RL, 1973, J PHARM SCI, V62, P882, DOI 10.1002/jps.2600620603; EMERIT I, 1990, ANTIOXIDANTS THERAPY; Fields R, 1972, Methods Enzymol, V25, P464, DOI 10.1016/S0076-6879(72)25042-X; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; GOLDSTEIN IM, 1979, J BIOL CHEM, V254, P4040; GOLDSTEIN IM, 1982, ANN NY ACAD SCI, V389, P368, DOI 10.1111/j.1749-6632.1982.tb22150.x; GREENLEE L, 1964, J BIOL CHEM, V239, P1090; HAGIHARA B, 1959, NATURE, V178, P631; HEIKKILA RE, 1976, J BIOL CHEM, V251, P2182; HIROTA M, 1990, ARCH BIOCHEM BIOPHYS, V280, P269, DOI 10.1016/0003-9861(90)90329-W; INOUE M, 1990, ADV EXP MED BIOL, V264, P5; INOUE M, 1987, KIDNEY INT, V32, P198, DOI 10.1038/ki.1987.192; INOUE M, 1991, FREE RADICAL RES COM, V12-3, P391, DOI 10.3109/10715769109145809; INOUE M, 1991, J BIOL CHEM, V266, P16409; INOUE M, 1989, BIOCHEMISTRY-US, V28, P6619, DOI 10.1021/bi00442a013; INOUE M, 1990, FEBS LETT, V269, P89, DOI 10.1016/0014-5793(90)81126-9; JOESTER KE, 1972, FEBS LETT, V25, P25, DOI 10.1016/0014-5793(72)80445-9; KAWAMOTO S, 1990, ARCH BIOCHEM BIOPHYS, V277, P160, DOI 10.1016/0003-9861(90)90565-G; MCCAY PB, 1985, ANNU REV NUTR, V5, P323, DOI 10.1146/annurev.nu.05.070185.001543; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MINAKAMI S, 1958, J BIOCHEM-TOKYO, V45, P341, DOI 10.1093/oxfordjournals.jbchem.a126874; NAGANO T, 1989, J BIOL CHEM, V264, P9243; NAKAZONO K, 1991, P NATL ACAD SCI USA, V88, P10045, DOI 10.1073/pnas.88.22.10045; NJUS D, 1983, J BIOL CHEM, V258, P27; OGINO T, 1988, INT J PEPT PROT RES, V32, P153; PACKER JE, 1979, NATURE, V278, P737, DOI 10.1038/278737a0; PACKER L, 1989, ANN NY ACAD SCI, V570, P1; PYATAK PS, 1980, RES COMMUN CHEM PATH, V29, P113; ROSEN H, 1976, J CLIN INVEST, V58, P50, DOI 10.1172/JCI108458; Sies H., 1985, OXIDATIVE STRESS; SUEMATSU M, 1987, J CLIN LAB IMMUNOL, V24, P125; TAKAHASHI A, 1990, FEBS LETT, V261, P369, DOI 10.1016/0014-5793(90)80594-9; TOGASHI H, 1991, HEPATOLOGY, V14, P707, DOI 10.1002/hep.1840140422; WATANABE N, 1989, BIOCHEM PHARMACOL, V38, P3477; YAMAZAKI I, 1961, BIOCHIM BIOPHYS ACTA, V50, P62, DOI 10.1016/0006-3002(61)91060-5; YAMAZAKI I, 1960, J BIOL CHEM, V235, P2444	43	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8732	8738						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1315736				2022-12-27	WOS:A1992HR85400007
J	ALLAN, GF; LENG, XH; TSAI, SY; WEIGEL, NL; EDWARDS, DP; TSAI, MJ; OMALLEY, BW				ALLAN, GF; LENG, XH; TSAI, SY; WEIGEL, NL; EDWARDS, DP; TSAI, MJ; OMALLEY, BW			HORMONE AND ANTIHORMONE INDUCE DISTINCT CONFORMATIONAL-CHANGES WHICH ARE CENTRAL TO STEROID-RECEPTOR ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; HUMAN PROGESTERONE-RECEPTOR; CELL GLUCOCORTICOID RECEPTOR; DNA-BINDING STATE; ESTROGEN-RECEPTOR; DEPENDENT PHOSPHORYLATION; DEOXYRIBONUCLEIC-ACID; GENE-TRANSCRIPTION; RESPONSE ELEMENT; BREAST-CANCER	Antihormones are potent antagonists of hormone action in vivo, but the mechanism underlying this antagonism is not understood. Several steroid hormones transform (activate) their receptors from a cytosolic, non-DNA binding 8 S sedimentation form to a nuclear, DNA binding 4 S form. Transformation is accompanied by the loss of associated heat shock proteins. We have previously demonstrated that an additional hormone-dependent step, separate from heat shock protein removal, is required for activation of the human progesterone receptor. We have devised an assay in which the human progesterone receptor translated in vitro binds to its specific response element in a hormone-dependent manner. As assessed by limited proteolytic digestion, hormone treatment of the nascent receptor induces a dramatic conformational change within the protein. The conformational change occurs in the absence of DNA and renders the entire ligand binding domain resistant to digestion by proteases. A number of antiprogestins, including RU486, induce an equally dramatic, but distinct, structural alteration of the ligand binding domain. The distinction centers upon the final 30 to 40 amino acids at the carboxyl terminus. The conformational change can be induced by ligand prior to dissociation of the 8 S complex and is not induced by heat shock protein removal in the absence of hormone. Remarkably, virtually identical hormone-induced conformational changes were detected following proteolytic analysis of in vitro translated retinoic acid receptors. Our data indicate that the sole necessary event in the activation of steroid receptors is conformational modification by the ligand. Furthermore, we conclude that transcriptional inactivation of steroid receptors by antihormones involves the induction of an inappropriate structural conformation at the extreme carboxyl terminus of the ligand binding domain.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV COLORADO,HLTH SCI CTR,DEPT PATHOL,DENVER,CO 80262	Baylor College of Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BAGCHI MK, 1990, NATURE, V345, P547, DOI 10.1038/345547a0; BAGCHI MK, 1988, MOL ENDOCRINOL, V2, P1221, DOI 10.1210/mend-2-12-1221; BAGCHI MK, 1992, P NATL ACAD SCI USA, V89, P2664, DOI 10.1073/pnas.89.7.2664; BAGCHI MK, 1991, MOL CELL BIOL, V11, P4998, DOI 10.1128/MCB.11.10.4998; BAKKER GH, 1990, J STEROID BIOCHEM, V37, P789, DOI 10.1016/0960-0760(90)90421-G; Baulieu E E, 1971, Recent Prog Horm Res, V27, P351; BAULIEU EE, 1987, J CELL BIOCHEM, V35, P161, DOI 10.1002/jcb.240350209; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CARSON MA, 1987, MOL ENDOCRINOL, V1, P791, DOI 10.1210/mend-1-11-791; CHRISTENSEN K, 1991, MOL ENDOCRINOL, V5, P1755, DOI 10.1210/mend-5-11-1755; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DENIS M, 1988, NATURE, V333, P686, DOI 10.1038/333686a0; DENIS M, 1989, J BIOL CHEM, V264, P6005; DENNER LA, 1987, J STEROID BIOCHEM, V27, P235, DOI 10.1016/0022-4731(87)90315-3; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DOUGHERTY JJ, 1982, J BIOL CHEM, V257, P4226; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; ELLISTON JF, 1992, J BIOL CHEM, V267, P5193; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUIOCHONMANTEL A, 1988, NATURE, V336, P695, DOI 10.1038/336695a0; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HORWITZ KB, 1985, DNA-J MOLEC CELL BIO, V4, P451, DOI 10.1089/dna.1985.4.451; HOUSLEY PR, 1983, J BIOL CHEM, V258, P4630; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; KLEINHITPASS L, 1991, NUCLEIC ACIDS RES, V19, P1227, DOI 10.1093/nar/19.6.1227; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LOGEAT F, 1985, BIOCHEM BIOPH RES CO, V131, P421, DOI 10.1016/0006-291X(85)91819-4; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MENDEL DB, 1986, J BIOL CHEM, V261, P3758; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MIGLIACCIO A, 1986, EMBO J, V5, P2867, DOI 10.1002/j.1460-2075.1986.tb04581.x; NEEF G, 1984, STEROIDS, V44, P349, DOI 10.1016/S0039-128X(84)80027-6; NISHIGORI H, 1980, BIOCHEMISTRY-US, V19, P77, DOI 10.1021/bi00542a012; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PIKE JW, 1985, BIOCHEM BIOPH RES CO, V131, P378, DOI 10.1016/0006-291X(85)91813-3; PRATT WB, 1987, J CELL BIOCHEM, V35, P51, DOI 10.1002/jcb.240350105; PRATT WB, 1988, J BIOL CHEM, V263, P267; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; TSAI SY, 1990, J BIOL CHEM, V265, P17055; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; WATERMAN ML, 1988, MOL ENDOCRINOL, V2, P14, DOI 10.1210/mend-2-1-14; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	67	310	319	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19513	19520						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326555				2022-12-27	WOS:A1992JP59300075
J	NAKAMURA, T; SUGINO, K; KUROSAWA, N; SAWAI, M; TAKIO, K; ETO, Y; IWASHITA, S; MURAMATSU, M; TITANI, K; SUGINO, H				NAKAMURA, T; SUGINO, K; KUROSAWA, N; SAWAI, M; TAKIO, K; ETO, Y; IWASHITA, S; MURAMATSU, M; TITANI, K; SUGINO, H			ISOLATION AND CHARACTERIZATION OF ACTIVIN RECEPTOR FROM MOUSE EMBRYONAL CARCINOMA-CELLS - IDENTIFICATION OF ITS SERINE THREONINE TYROSINE PROTEIN-KINASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-DIFFERENTIATION FACTOR; FOLLICULAR GRANULOSA-CELL; FSH-RELEASING PROTEIN; BINDING PROTEIN; FACTOR EDF; INHIBIN; LEUKEMIA; MESODERM; GROWTH; BETA	The activin receptor protein was isolated from the mouse embryonal carcinoma (EC) cell line P 19 by three cycles of affinity chromatography on an activin A-immobilized column. The purified receptor had a specific and high affinity for activins A, AB, and B (K(d) = 345 pM), but not for transforming growth factor-beta. The purified activin receptor was identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and ligand blotting analysis as a single protein of 70 kDa. The amino acid sequence of the first 18 NH2-terminal residues revealed that the receptor is a member of the activin receptor family. The purified receptor phosphorylated itself and exogenous substrate proteins on serine, threonine, and tyrosine residues, indicating that the activin receptor is a transmembrane serine/threonine/tyrosine protein kinase. These results suggest that signal transduction of activin employs a novel pathway via a new class of cellular receptor in EC P19 cells.	INST PHYS & CHEM RES, FRONTIER RES PROGRAM, WAKU, SAITAMA 35101, JAPAN; AJINOMOTO CO INC, CENT RES LABS, KAWASAKI KU, KAWASAKI, KANAGAWA 210, JAPAN; MITSUBISHI KASEI INST LIFE SCI, MACHIDA, TOKYO 194, JAPAN; UNIV TOKYO, FAC MED, DEPT BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN; FUJITA HLTH UNIV, SCH MED, TOYOAKE, AICHI 47011, JAPAN	RIKEN; Ajinomoto Co Inc; University of Tokyo; Fujita Health University				Kurosawa, Nobuyuki/0000-0002-1548-4541; Iwashita, Shintaro/0000-0001-8086-9192				ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BILLESTRUP N, 1990, MOL ENDOCRINOL, V4, P356, DOI 10.1210/mend-4-2-356; BROXMEYER HE, 1988, P NATL ACAD SCI USA, V85, P9052, DOI 10.1073/pnas.85.23.9052; BURGER HG, 1988, ENDOCRINOLOGY, V122, P1701; CAMPEN CA, 1988, BIOCHEM BIOPH RES CO, V157, P844, DOI 10.1016/S0006-291X(88)80326-7; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HASEGAWA Y, 1986, ENDOCRINOL JAPON, V33, P645; HASHIMOTO M, 1992, J BIOL CHEM, V267, P7203; HASHIMOTO M, 1990, BIOCHEM BIOPH RES CO, V173, P193, DOI 10.1016/S0006-291X(05)81040-X; HINO M, 1989, J BIOL CHEM, V264, P10309; HSUEH AJW, 1987, P NATL ACAD SCI USA, V84, P5082, DOI 10.1073/pnas.84.14.5082; HUTCHINSON LA, 1987, BIOCHEM BIOPH RES CO, V146, P1405, DOI 10.1016/0006-291X(87)90806-0; KITAOKA M, 1988, BIOCHEM BIOPH RES CO, V157, P48, DOI 10.1016/S0006-291X(88)80009-3; KONDO S, 1989, BIOCHEM BIOPH RES CO, V161, P1267, DOI 10.1016/0006-291X(89)91379-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MIYAMOTO K, 1985, BIOCHEM BIOPH RES CO, V129, P396, DOI 10.1016/0006-291X(85)90164-0; MURATA M, 1988, BIOCHEM BIOPH RES CO, V151, P230, DOI 10.1016/0006-291X(88)90583-9; NAKAMURA T, 1992, J BIOL CHEM, V267, P16385; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; SUGINO H, 1988, BIOCHEM BIOPH RES CO, V153, P281, DOI 10.1016/S0006-291X(88)81219-1; SUGINO H, 1988, J BIOL CHEM, V263, P15249; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VALE W, 1988, RECENT PROG HORM RES, V44, P1; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Vale W., 1990, HDB EXPT PHARM, P211; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0	42	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18924	18928						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326537				2022-12-27	WOS:A1992JN50200101
J	MITSUI, T; INAGAKI, M; IKEBE, M				MITSUI, T; INAGAKI, M; IKEBE, M			PURIFICATION AND CHARACTERIZATION OF SMOOTH-MUSCLE MYOSIN-ASSOCIATED PHOSPHATASE FROM CHICKEN GIZZARDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; DEPENDENT PROTEIN-KINASE; LIGHT CHAIN KINASE; CELLULAR-REGULATION; OKADAIC ACID; PHOSPHORYLATION SITES; CALMODULIN BINDING; MAMMALIAN-TISSUES; CATALYTIC SUBUNIT; CALDESMON	Myosin light chain phosphatase associated with smooth muscle myosin (MAPP) was isolated from chicken gizzard. The MAPP was tightly associated with myosin and was not dissociated from myosin under the physiological ionic conditions. The phosphatase was dissociated from myosin in the presence of high MgCl2, i.e. 80 mM MgCl2. The binding site of the enzyme on the myosin molecule was the subfragment-2 region, since the enzyme did bind to the myosin rod and heavy meromyosin but not to the subfragment-1 affinity column. MAPP was purified with a heparin-Sepharose 6B column, and two activity peaks were obtained, i.e. MAPP I and MAPP II. The major activity peak, MAPP I, was further purified to homogeneity by thiophosphorylated myosin light chain-Sepharose 4B column chromatography. MAPP I was a tetramer composed of four 34-kDa subunits. The enzyme preferentially dephosphorylated the beta-subunit of phosphorylase kinase and was strongly inhibited by the heat- and acid-stable protein phosphatase inhibitor-1, whereas it was partially inhibited by the inhibitor-2. The IC50 (concentration of inhibitor giving 50% inhibition) value for the inhibition of the enzyme by okadaic acid was 70 nM which was about eight times higher than skeletal muscle type-1 and 390 times higher than type-2 protein phosphatase. These results demonstrate that the MAPP I is a type-1-like protein phosphatase, although the properties are not the same as type-I phosphatase. The properties of the myosin-associated phosphatase were distinct from the phosphatases reported previously, although some properties were similar to smooth muscle phosphatase-IV. Therefore, it is concluded that MAPP I is a novel smooth muscle protein phosphatase. Since it strongly associated with smooth muscle myosin, it is likely that MAPP I is responsible for the dephosphorylation of smooth muscle myosin in situ.	CASE WESTERN RESERVE UNIV, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA	Case Western Reserve University			Inagaki, Masaki/B-9920-2016; Mitsui, Toshiaki/N-9773-2017	Mitsui, Toshiaki/0000-0002-9165-8830				BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; CHISHOLM AAK, 1988, BIOCHIM BIOPHYS ACTA, V971, P163, DOI 10.1016/0167-4889(88)90188-7; CHISHOLM AAK, 1988, BIOCHIM BIOPHYS ACTA, V968, P392, DOI 10.1016/0167-4889(88)90032-8; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, METHOD ENZYMOL, V159, P427; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1983, METHOD ENZYMOL, V99, P243; COHEN P, 1988, METHOD ENZYMOL, V159, P390; CONTI MA, 1981, J BIOL CHEM, V256, P3178; COOKE R, 1981, CELL MUSCLE MOTILITY, V1, P99; DISALVO J, 1988, ADV PROTEIN PHOSPHAT, V1, P327; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P432; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; HUBBARD MJ, 1989, EUR J BIOCHEM, V180, P457, DOI 10.1111/j.1432-1033.1989.tb14668.x; IKEBE M, 1990, BIOCHEMISTRY-US, V29, P11242, DOI 10.1021/bi00503a013; IKEBE M, 1988, J BIOL CHEM, V263, P10698; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1990, BIOCHEMISTRY-US, V29, P2713, DOI 10.1021/bi00463a014; IKEBE M, 1991, ARCH BIOCHEM BIOPHYS, V288, P538, DOI 10.1016/0003-9861(91)90232-8; IKEBE M, 1987, J BIOL CHEM, V262, P13828; IKEBE M, 1988, J BIOL CHEM, V263, P6432; IKEBE M, 1990, J BIOL CHEM, V265, P17607; INAGAKI M, 1990, BIOPHYS J, V57, pA145; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; ISHIHARA H, 1989, BIOPHYS J, V55, pA475; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MARGOSSIAN SS, 1973, J MOL BIOL, V74, P301, DOI 10.1016/0022-2836(73)90375-6; ONISHI H, 1982, J BIOCHEM, V91, P265, DOI 10.1093/oxfordjournals.jbchem.a133684; ONISHI H, 1979, J BIOCHEM, V85, P457, DOI 10.1093/oxfordjournals.jbchem.a132352; PATO MD, 1985, J BIOL CHEM, V260, P2359; PATO MD, 1990, ARCH BIOCHEM BIOPHYS, V276, P116, DOI 10.1016/0003-9861(90)90017-S; PATO MD, 1983, EUR J BIOCHEM, V132, P283, DOI 10.1111/j.1432-1033.1983.tb07360.x; PATO MD, 1983, J BIOL CHEM, V258, P7047; PATO MD, 1983, J BIOL CHEM, V258, P7055; PATO MD, 1988, BIOCHEM J, V256, P283; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; SPECTOR T, 1978, ANAL BIOCHEM, V86, P142, DOI 10.1016/0003-2697(78)90327-5; STEWART AA, 1981, EUR J BIOCHEM, V115, P197; TAKAI A, 1989, BIOCHEM J, V262, P617, DOI 10.1042/bj2620617; TULLOCH AG, 1991, J BIOL CHEM, V266, P20168; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; WERTH DK, 1982, J BIOL CHEM, V257, P7036; YOSHIDA M, 1988, J BIOCHEM-TOKYO, V103, P380, DOI 10.1093/oxfordjournals.jbchem.a122278	47	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16727	16735						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322916				2022-12-27	WOS:A1992JJ45800111
J	ZHANG, BX; ZHAO, H; LOESSBERG, P; MUALLEM, S				ZHANG, BX; ZHAO, H; LOESSBERG, P; MUALLEM, S			ACTIVATION OF THE PLASMA-MEMBRANE CA2+ PUMP DURING AGONIST STIMULATION OF PANCREATIC ACINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM POOL; DEPENDENT PROTEIN-KINASE; VASCULAR SMOOTH-MUSCLE; CA-2+ PUMP; CYTOSOLIC CALCIUM; ENDOPLASMIC-RETICULUM; INTRACELLULAR CALCIUM; INOSITOL PHOSPHATES; MOBILIZING HORMONES; RAT HEPATOCYTES	The role of internal stores and plasma membrane Ca2+ pumps in controlling [Ca2+]i during agonist stimulation and their regulation by agonists are not well understood. We report here measurements of intracellular ([Ca2+]i) and extracellular ([Ca2+]o) Ca2+ concentrations in agonist-stimulated pancreatic acini in an effort to directly address these questions. Stimulation of acini suspended in Ca2+-free or Ca2+-containing medium with Ca2+ mobilizing agonists resulted in a typical transient increase in [Ca2+]i. Thapsigargin, a specific inhibitor of internal Ca2+ pumps, inhibited the rate of [Ca2+]i reduction after agonist stimulation by approximately 40%. Under the same conditions, thapsigargin had no effect on the rate of the unidirectional Ca2+ efflux across the plasma membrane as revealed by measurements of [Ca2+]o. These findings suggest that internal Ca2+ pumps actively remove Ca2+ from the cytosol during continued agonist stimulation. The correlation between the reduction in [Ca2+]i and the increase in [Ca2+]o showed that Ca2+ efflux from cells stimulated with agonist and thapsigargin represent Ca2+ efflux across the plasma membrane. Inhibition of cells exposed to agonist and thapsigargin with a specific antagonist sharply reduced the rates of the [Ca2+]i decrease and the accompanied [Ca2+]o increase. Hence, at comparable [Ca2+]i, Ca2+ efflux from stimulated cells was about 3-fold faster than that from resting cells, indicating that agonists directly activate the plasma membrane Ca2+ pump. To study the role of [Ca2+]i increase in plasma membrane Ca2+ pump activation the acini were loaded with 1,2-bis-(2-aminophenoxyethane-N,N',N')-tetraacetic acid (BAPTA), and [Ca2+]o Was measured during agonist stimulation. Surprisingly, although BAPTA completely prevented the increase in [Ca2+]i, Ca2+ efflux rate was reduced by only 34%. These findings provide the first evidence for Ca2+-independent activation of the plasma membrane Ca2+ pump by Ca2+ mobilizing agonists.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK38938] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANSAH TA, 1984, J BIOL CHEM, V259, P3442; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLOINK JL, 1991, J BIOL CHEM, V266, P18206; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; CHEEK TR, 1989, CELL CALCIUM, V10, P213, DOI 10.1016/0143-4160(89)90004-3; DUDDY SK, 1989, J BIOL CHEM, V264, P20863; ELY JA, 1991, J BIOL CHEM, V266, P18635; FODER B, 1981, BIOCHIM BIOPHYS ACTA, V649, P367, DOI 10.1016/0005-2736(81)90426-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAROOTUNIAN AT, 1988, COLD SPRING HARB SYM, V53, P935, DOI 10.1101/SQB.1988.053.01.108; HEILMANN C, 1989, CELL CALCIUM, V10, P275, DOI 10.1016/0143-4160(89)90054-7; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; KURTZ A, 1989, P NATL ACAD SCI USA, V86, P3423, DOI 10.1073/pnas.86.9.3423; LEW VL, 1982, NATURE, V298, P478, DOI 10.1038/298478a0; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MENNITI FS, 1991, J BIOL CHEM, V266, P13646; MINTA A, 1989, J BIOL CHEM, V264, P8171; MUALLEM S, 1989, AM J PHYSIOL, V257, pG917, DOI 10.1152/ajpgi.1989.257.6.G917; MUALLEM S, 1988, BIOCHEM J, V255, P301; MUALLEM S, 1988, AM J PHYSIOL, V255, pG229, DOI 10.1152/ajpgi.1988.255.2.G229; MUALLEM S, 1989, BIOCHEM J, V263, P333, DOI 10.1042/bj2630333; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; MUALLEM S, 1987, BIOCHEM BIOPH RES CO, V149, P213, DOI 10.1016/0006-291X(87)91626-3; MUALLEM S, 1988, J MEMBRANE BIOL, V102, P153, DOI 10.1007/BF01870453; MUALLEM S, 1988, J MEMBRANE BIOL, V106, P57, DOI 10.1007/BF01871767; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; MUALLEM S, 1988, AM J PHYSIOL, V255, pG221, DOI 10.1152/ajpgi.1988.255.2.G221; MUALLEM S, 1981, BIOCHIM BIOPHYS ACTA, V647, P73, DOI 10.1016/0005-2736(81)90296-0; NEYSES L, 1985, J BIOL CHEM, V260, P283; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PANDOL SJ, 1990, CELL CALCIUM, V11, P477, DOI 10.1016/0143-4160(90)90080-E; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; PETERSEN OH, 1990, INTRACELLULAR CALCIU, P77; POLLOCK WK, 1987, FEBS LETT, V210, P132, DOI 10.1016/0014-5793(87)81322-4; PONAPPA BC, 1981, LIFE SCI, V28, P2395; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; REEVES JP, 1990, INTRACELLULAR CALCIU, P305; RICHARDSON AE, 1984, BIOCHEM J, V219, P679, DOI 10.1042/bj2190679; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SATO K, 1988, J PHARMACOL EXP THER, V246, P294; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STUENKEL EL, 1990, AM J PHYSIOL, V258, pC289, DOI 10.1152/ajpcell.1990.258.2.C289; TAKEMURA H, 1990, CELL CALCIUM, V11, P11, DOI 10.1016/0143-4160(90)90044-U; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; THASTRUP O, 1987, BIOCHEM BIOPH RES CO, V142, P654, DOI 10.1016/0006-291X(87)91464-1; THERENOD F, 1989, J MEMBRANE BIOL, V109, P173; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WANG KKW, 1991, J BIOL CHEM, V266, P9078; WILLIAMS JA, 1980, CELL TISSUE RES, V210, P295; WOODS NM, 1987, CELL CALCIUM, V8, P79, DOI 10.1016/0143-4160(87)90038-8; YOSHIDA Y, 1991, J BIOL CHEM, V266, P19819; YOSKIDA K, 1987, J BIOL CHEM, V262, P16048; ZHAO H, 1990, J BIOL CHEM, V265, P20856	59	77	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15419	15425						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322397				2022-12-27	WOS:A1992JG11300027
J	RANDALL, SK; KELLY, TJ				RANDALL, SK; KELLY, TJ			THE FATE OF PARENTAL NUCLEOSOMES DURING SV40 DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; CHROMATIN ASSEMBLY INVITRO; NEWLY SYNTHESIZED HISTONES; NUCLEAR FACTOR-I; HYPERSENSITIVE SITES; GEL-ELECTROPHORESIS; CELL-EXTRACTS; SEGREGATION; PURIFICATION; INITIATION	The fate of parental nucleosomes during the replication of chromatin templates was studied using a modification of the cell-free SV40 DNA replication system. Plasmid DNA molecules containing the SV40 origin were assembled into chromatin with purified core histones and fractionated assembly factors derived from HeLa cells. When these templates were replicated in vitro, the resulting progeny retained a nucleosomal organization. To determine whether the nucleosomes associated with the progeny molecules resulted from displacement of parental histones during replication followed by reassembly, the replication reactions were performed in the presence of control templates. It was observed that the progeny genomes resulting from the replication of chromatin templates retained a nucleosomal structure, whereas the progeny of the control DNA molecules were not assembled into chromatin. Additional experiments, involving direct addition of histones to the replication reaction mixtures, confirmed that the control templates were not sequestered in some form which made them unavailable for nucleosome assembly. Thus, our data demonstrate that parental nucleosomes remain associated with the replicating molecules and are transferred to the progeny molecules without displacement into solution. We propose a simple model in which nucleosomes ahead of the fork are transferred intact to the newly synthesized daughter duplexes.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,PCTB RM 605,725 N WOLFE ST,BALTIMORE,MD 21205	Johns Hopkins University					NCI NIH HHS [CA09139, CA40414] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040414, R01CA040414, T32CA009139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMOUZNI G, 1988, EMBO J, V7, P4355, DOI 10.1002/j.1460-2075.1988.tb03334.x; ANNUNZIATO AT, 1984, NUCLEIC ACIDS RES, V12, P6179, DOI 10.1093/nar/12.15.6179; BANERJEE S, 1990, MOL CELL BIOL, V10, P2863, DOI 10.1128/MCB.10.6.2863; BONNEANDREA C, 1990, NATURE, V343, P719, DOI 10.1038/343719a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CHENG LZ, 1992, P NATL ACAD SCI USA, V89, P589, DOI 10.1073/pnas.89.2.589; CLARK DJ, 1991, EMBO J, V10, P387, DOI 10.1002/j.1460-2075.1991.tb07960.x; COTTEN M, 1985, NUCLEIC ACIDS RES, V13, P401, DOI 10.1093/nar/13.2.401; CUSICK ME, 1981, BIOCHEMISTRY-US, V20, P6648, DOI 10.1021/bi00526a020; CUSICK ME, 1984, J MOL BIOL, V178, P249, DOI 10.1016/0022-2836(84)90143-8; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DILWORTH SM, 1988, BIOESSAYS, V9, P44, DOI 10.1002/bies.950090203; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; EARNSHAW WC, 1980, CELL, V21, P373, DOI 10.1016/0092-8674(80)90474-2; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOTEDAR R, 1989, P NATL ACAD SCI USA, V86, P6459, DOI 10.1073/pnas.86.17.6459; FOWLER E, 1982, NUCLEIC ACIDS RES, V10, P735, DOI 10.1093/nar/10.2.735; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GRUSS C, 1990, EMBO J, V9, P2911, DOI 10.1002/j.1460-2075.1990.tb07482.x; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; JACKSON V, 1988, BIOCHEMISTRY-US, V27, P2109, DOI 10.1021/bi00406a044; JACKSON V, 1987, BIOCHEMISTRY-US, V26, P2315, DOI 10.1021/bi00382a037; JACKSON V, 1985, BIOCHEMISTRY-US, V24, P6930, DOI 10.1021/bi00345a027; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; KLEINSCHMIDT JA, 1982, CELL, V29, P799, DOI 10.1016/0092-8674(82)90442-1; KRUDE T, 1991, MOL CELL BIOL, V11, P6257, DOI 10.1128/MCB.11.12.6257; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LEFFAK IM, 1977, CELL, V12, P837, DOI 10.1016/0092-8674(77)90282-3; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MCKNIGHT SL, 1977, CELL, V12, P795, DOI 10.1016/0092-8674(77)90278-1; MULLER U, 1978, SCIENCE, V201, P406, DOI 10.1126/science.208155; PALTER KB, 1979, J BIOL CHEM, V254, P1160; POSPELOV V, 1982, J MOL BIOL, V156, P79, DOI 10.1016/0022-2836(82)90460-0; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SEALE RL, 1976, CELL, V9, P423, DOI 10.1016/0092-8674(76)90087-8; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; TACK LC, 1981, J BIOL CHEM, V256, P8821; TOOZE J, 1980, DNA TUMOR VIRUSES, P801; TSURIMOTO T, 1990, NATURE, V346, P1023; van Holde K. E., 1989, CHROMATIN, P1; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WEINTRAUB H, 1976, CELL, V9, P419, DOI 10.1016/0092-8674(76)90086-6; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	58	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14259	14265						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321140				2022-12-27	WOS:A1992JD32500073
J	SANDERS, SL; SCHEKMAN, R				SANDERS, SL; SCHEKMAN, R			POLYPEPTIDE TRANSLOCATION ACROSS THE ENDOPLASMIC-RETICULUM MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MICROSOMAL SIGNAL PEPTIDASE; CHAIN BINDING-PROTEIN; ESCHERICHIA-COLI; SECRETORY PROTEINS; YEAST; GLYCOPROTEIN; COMPONENT; BIP/GRP78; COMPLEX; GENE				SANDERS, SL (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.							ADAMS AEM, 1989, SCIENCE, V243, P231, DOI 10.1126/science.2643162; AMAYA Y, 1991, FEBS LETT, V283, P325, DOI 10.1016/0014-5793(91)80619-E; BAKER RK, 1987, BIOCHEMISTRY-US, V26, P8561, DOI 10.1021/bi00400a010; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; COLLINS PG, 1991, J CELL BIOL, V114, P639, DOI 10.1083/jcb.114.4.639; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1989, TRENDS GENET, V5, P87, DOI 10.1016/0168-9525(89)90032-2; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HANN BC, 1992, NATURE, V356, P532, DOI 10.1038/356532a0; HARTMANN E, 1989, EMBO J, V8, P2225, DOI 10.1002/j.1460-2075.1989.tb08346.x; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; MIGLIACCIO G, 1992, J CELL BIOL, V117, P15, DOI 10.1083/jcb.117.1.15; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; NUNNARI JM, 1991, NATURE, V352, P638, DOI 10.1038/352638a0; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; POUYSSEGUR J, 1977, CELL, V11, P941, DOI 10.1016/0092-8674(77)90305-1; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SAVITZ AJ, 1990, NATURE, V346, P540, DOI 10.1038/346540a0; SHELNESS GS, 1988, J BIOL CHEM, V263, P17063; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STIRLING CJ, 1992, NATURE, V356, P534, DOI 10.1038/356534a0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TAZAWA S, 1991, J BIOCHEM-TOKYO, V109, P89; TOYN J, 1988, EMBO J, V7, P4347, DOI 10.1002/j.1460-2075.1988.tb03333.x; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2; WOLFE PB, 1982, J BIOL CHEM, V257, P7898; YADEAU JT, 1991, P NATL ACAD SCI USA, V88, P517, DOI 10.1073/pnas.88.2.517; YU Y, 1990, J CELL BIOL, V111, P1335, DOI 10.1083/jcb.111.4.1335	59	72	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13791	13794						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321124				2022-12-27	WOS:A1992JD32500001
J	WEI, L; CLAUSER, E; ALHENCGELAS, F; CORVOL, P				WEI, L; CLAUSER, E; ALHENCGELAS, F; CORVOL, P			THE 2 HOMOLOGOUS DOMAINS OF HUMAN ANGIOTENSIN-I-CONVERTING ENZYME INTERACT DIFFERENTLY WITH COMPETITIVE INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL CARBOXYPEPTIDASE; CATALYTIC PROPERTIES; MOLECULAR-CLONING; DEPENDENCE; MECHANISM; CHLORIDE; BINDING; ISOZYME	The endothelial angiotensin 1-converting enzyme (ACE; EC 3.4.15. 1) has recently been shown to contain two large homologous domains (called here the N and C domains), each being a zinc-dependent dipeptidyl carboxypeptidase. To further characterize the two active sites of ACE, we have investigated their interaction with four competitive ACE inhibitors, which are all potent antihypertensive drugs. The binding of [H-3] trandolaprilat to the two active sites was examined using the wild-type ACE and four ACE mutants each containing only one intact domain, the other domain being either deleted or inactivated by point mutation of the zinc-coordinating histidines. In contrast with all the previous studies, which suggested the presence of a single high affinity inhibitor binding site in ACE, the present study shows that both the N and C domains of ACE contain a high affinity inhibitor binding site (K(D) = 3 and 1 x 10(-10) M, respectively, at pH 7.5, 4-degrees-C, and 100 mM NaCl). Chloride stabilizes the enzyme-inhibitor complex for each domain primarily by slowing its dissociation rate, as the k-1 values of the N and C domains are markedly decreased (about 30- and 1100-fold, respectively) by 300 mM NaCl. At high chloride concentrations, the chloride effect is much greater for the C domain than for the N domain resulting in a higher affinity of this inhibitor for the C domain. In addition, the inhibitory potency of captopril (C), enalaprilat (E), and lisinopril (L) for each domain was assayed by hydrolysis of Hip-His-Leu. Their K(i) values for the two domains are all within the nanomolar range, indicating that they are all highly potent inhibitors for both domains. However, their relative potencies are different for the C domain (L > E > C) and the N domain (C > E > L). The different inhibitor binding properties of the two domains observed in the present study provide strong evidence for the presence of structural differences between the two active sites of ACE.			WEI, L (corresponding author), INSERM,U36,3 RUE ULM,F-75005 PARIS,FRANCE.		Alhenc-Gelas, Francois/F-9511-2017					BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; BROWN NL, 1988, EUR J PHARMACOL, V148, P79, DOI 10.1016/0014-2999(88)90456-6; BULL HG, 1985, J BIOL CHEM, V260, P2952; BUNNING P, 1985, J INORG BIOCHEM, V24, P183, DOI 10.1016/0162-0134(85)85002-9; CALDWELL PRB, 1976, SCIENCE, V191, P1050, DOI 10.1126/science.175444; CLAIRE M, 1978, FEBS LETT, V88, P295, DOI 10.1016/0014-5793(78)80197-5; CUMIN F, 1989, BIOCHEM BIOPH RES CO, V163, P718, DOI 10.1016/0006-291X(89)92282-1; DAS M, 1975, J BIOL CHEM, V250, P6762; DEFENDINI R, 1983, NEUROENDOCRINOLOGY, V37, P32, DOI 10.1159/000123512; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P7118, DOI 10.1021/bi00243a012; EHLERS MRW, 1989, P NATL ACAD SCI USA, V86, P7741, DOI 10.1073/pnas.86.20.7741; ELDORRY HA, 1982, J BIOL CHEM, V257, P4128; ERDOS EG, 1987, LAB INVEST, V56, P345; GAVRAS H, 1974, NEW ENGL J MED, V291, P817, DOI 10.1056/NEJM197410172911603; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LATTION AL, 1989, FEBS LETT, V252, P99, DOI 10.1016/0014-5793(89)80897-X; NAQUI A, 1983, BIOCHEM J, V215, P429, DOI 10.1042/bj2150429; ONDETTI MA, 1977, SCIENCE, V196, P441, DOI 10.1126/science.191908; PATCHETT AA, 1980, NATURE, V288, P280, DOI 10.1038/288280a0; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHAPIRO R, 1984, BIOCHEMISTRY-US, V23, P5234, DOI 10.1021/bi00317a022; SHAPIRO R, 1984, BIOCHEMISTRY-US, V23, P5225, DOI 10.1021/bi00317a021; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; STRITTMATTER SM, 1986, ENDOCRINOLOGY, V118, P1690, DOI 10.1210/endo-118-4-1690; Waeber BNJ, 1990, HYPERTENSION PATHOPH, P2209; WEI L, 1991, J BIOL CHEM, V266, P9002; WEI L, 1991, J BIOL CHEM, V266, P5540; WEILAND GA, 1981, LIFE SCI, V29, P313, DOI 10.1016/0024-3205(81)90324-6; YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6	30	236	243	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13398	13405						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320019				2022-12-27	WOS:A1992JB74600049
J	ITOH, M; STREULI, M; KRUEGER, NX; SAITO, H				ITOH, M; STREULI, M; KRUEGER, NX; SAITO, H			PURIFICATION AND CHARACTERIZATION OF THE CATALYTIC DOMAINS OF THE HUMAN RECEPTOR-LINKED PROTEIN TYROSINE PHOSPHATASES HPTP-BETA, LEUKOCYTE COMMON ANTIGEN (LCA), AND LEUKOCYTE COMMON ANTIGEN-RELATED MOLECULE (LAR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; PHOSPHOTYROSINE PHOSPHATASES; HUMAN-PLACENTA; FAMILY; CLONING; EXPRESSION; VANADATE; MEMBER; KINASE; ENZYME	Human HPTP-beta, leukocyte common antigen (LCA), and leukocyte common antigen-related molecule (LAR) are transmembrane receptor-like proteins whose cytoplasmic regions contain either one (HPTP-beta) or two (LCA and LAR) domains that are homologous to protein tyrosine phosphatases (PTPases). Whereas the membrane-proximal domain 1 has enzymatic activity, the membrane-distal domain 2 of both LCA and LAR has no detectable catalytic activity. The cytoplasmic regions of HPTP-beta, LCA, and LAR were expressed in Escherichia coli and purified to greater than 90% purity. Modulatory effects of various low molecular weight compounds and homo- and copolymers of amino acids were examined. Several polypeptides that contain a high proportion of tyrosine were strongly inhibitory to these PTPases. To determine a possible role for the LAR domain 2, the properties of recombinant LAR PTPases containing both domains 1 and 2 (LAR-D1D2) or only domain 1 (LAR-D1) were compared. In nearly all aspects examined, LAR-D1 and LAR-D1D2 were indistinguishable. However, polycationic polypeptides strongly stimulated the PTPase activity of LAR-D1D2, but not LAR-D1, using the peptide substrate Raytide. Thus, basic polypeptides seem to indirectly alter the catalytic activity of domain 1 by interacting with domain 2. This result suggests that domain 2 has a regulatory function.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Saito, Haruo/AAF-6113-2019	Saito, Haruo/0000-0001-7891-1689	NATIONAL CANCER INSTITUTE [R01CA051132] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026598] Funding Source: NIH RePORTER; NCI NIH HHS [CA-51132] Funding Source: Medline; NIAID NIH HHS [AI-26598] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM, 1988, MOL REPROD DEV; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN DJ, 1984, J BIOL CHEM, V259, P9580; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CHO HJ, 1991, BIOCHEMISTRY-US, V30, P6210, DOI 10.1021/bi00239a019; CHO HJ, 1992, BIOCHEMISTRY-US, V31, P133, DOI 10.1021/bi00116a019; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; DAUM G, 1991, J BIOL CHEM, V266, P12211; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GALLIS B, 1981, P NATL ACAD SCI-BIOL, V78, P6689, DOI 10.1073/pnas.78.11.6689; GIBBINK MFB, 1991, FEBS LETT, V290, P123; GRUPPUSO PA, 1990, J CLIN INVEST, V85, P1754, DOI 10.1172/JCI114632; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; JONES SW, 1989, J BIOL CHEM, V264, P7747; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MONTESANO R, 1988, J CELL PHYSIOL, V134, P460, DOI 10.1002/jcp.1041340318; OTTILIE S, 1991, P NATL ACAD SCI USA, V88, P3455, DOI 10.1073/pnas.88.8.3455; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; RAMER SE, 1991, P NATL ACAD SCI USA, V88, P6254, DOI 10.1073/pnas.88.14.6254; SAITO H, 1991, CELL GROWTH DIFFER, V2, P59; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHRINER CL, 1984, J BIOL CHEM, V259, P1383; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; SWARUP G, 1989, J BIOL CHEM, V264, P7801; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TSAI AYM, 1991, J BIOL CHEM, V266, P10534; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	46	41	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12356	12363						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1318316				2022-12-27	WOS:A1992HY94700105
J	JERZMANOWSKI, A; COLE, RD				JERZMANOWSKI, A; COLE, RD			PARTIAL DISPLACEMENT OF HISTONE H1 FROM CHROMATIN IS REQUIRED BEFORE IT CAN BE PHOSPHORYLATED BY MITOTIC H1 KINASE INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDC2 PROTEIN; CHROMOSOME CONDENSATION; CELL-CYCLE; MITOSIS; AGGREGATION; ACTIVATION; COMPONENT; SUBUNIT; PHASE; MPF	The massive nonselective and reversible phosphorylation of histone H1 during mitosis is a universal phenomenon among eukaryotes. The growth-associated kinase responsible for this phosphorylation is identical to the maturation promoting factor, a key regulator of the cell cycle. Here we showed that growth-associated kinase, isolated from mitotic HeLa cells which were capable of phosphorylating HeLa H1 in vitro with high activity and mostly at the same sites phosphorylated during mitosis in vivo (assayed by two-dimensional analysis of tryptic phosphopeptides), did not significantly phosphorylate chromatin-bound or nuclear H1 in vitro. Its inability to phosphorylate chromatin-bound H1 did not change when the amount of kinase was increased or the incubation was prolonged. The resistance of chromatin-bound H1 to phosphorylation did not result from chromatin aggregation. Rapid phosphorylation of H1 in vitro, as well as in a nuclear system, was restored when NaCl concentrations were raised above 200 mM where H1:DNA interactions are weakened. At 300 mM NaCl, chromatin-bound H1 was phosphorylated in a subset of the sites observed for free H1 phosphorylated in vitro. These results suggest that active displacement of H1 from chromatin DNA may take place before H1 can be fully phosphorylated during mitosis.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,MCB,BERKELEY,CA 94720	University of California System; University of California Berkeley					NIEHS NIH HHS [ES-01896] Funding Source: Medline; NIGMS NIH HHS [GM20338] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020338] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BOHM J, 1977, EUR J BIOCHEM, V78, P251, DOI 10.1111/j.1432-1033.1977.tb11736.x; BRADBURY EM, 1974, NATURE, V247, P257, DOI 10.1038/247257a0; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; CHAMBERS TC, 1990, J BIOL CHEM, V265, P16940; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; FREEMAN RS, 1991, BIOCHEMISTRY-US, V30, P2293, DOI 10.1021/bi00223a001; GUO XW, 1989, J BIOL CHEM, V264, P11653; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; HALL JM, 1986, J BIOL CHEM, V261, P5168; HUANG HC, 1984, J BIOL CHEM, V259, P4237; JERZMANOWSKI A, 1990, J BIOL CHEM, V265, P10726; JERZMANOWSKI A, 1985, BIOCHEMISTRY-US, V24, P2360, DOI 10.1021/bi00330a035; JIN YJ, 1986, J BIOL CHEM, V261, P5805; KINKADE JM, 1966, J BIOL CHEM, V241, P5790; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LANGAN TA, 1982, J BIOL CHEM, V257, P4835; LANGAN TA, 1978, METHOD CELL BIOL, V19, P147; LASKEY RA, 1980, NATURE, V286, P763, DOI 10.1038/286763a0; LENNOX RW, 1988, CHROMOSOMES CHROMATI, P33; LEVIN B, 1990, CELL, V61, P743; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; ROBERGE M, 1990, J CELL BIOL, V111, P1753, DOI 10.1083/jcb.111.5.1753; WU LH, 1986, J CELL BIOL, V103, P465, DOI 10.1083/jcb.103.2.465; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0	30	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8514	8520						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314829				2022-12-27	WOS:A1992HQ18500085
J	CHANG, CN; SKALSKI, V; ZHOU, JH; CHENG, YC				CHANG, CN; SKALSKI, V; ZHOU, JH; CHENG, YC			BIOCHEMICAL PHARMACOLOGY OF (+)-2',3'-DIDEOXY-3'-THIACYTIDINE AND (-)-2',3'-DIDEOXY-3'-THIACYTIDINE AS ANTIHEPATITIS B-VIRUS AGENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCELLULAR-CARCINOMA; INVITRO; CELLS; REPLICATION; 2',3'-DIDEOXYCYTIDINE; INHIBITION; DNA	2',3'-Dideoxy-3'-thiacytidine (cis-(+/-)-SddC) was found to have potent activity against hepatitis B virus and human immunodeficiency viruses in culture. Recent studies by us identified (-)-SddC as the stereoisomer responsible for the antiviral effect and showed that the cytotoxicity was mainly caused by (+)-SddC. Metabolism studies showed that these drugs were converted to their monophosphates, diphosphates, and triphosphates. The enzyme responsible for the formation of monophosphates was identified to be cytoplasmic deoxycytidine kinase in CEM cells. Uptake studies showed that the intracellular concentration of (-)SddC and its metabolites was approximately 5-fold higher than that of (+)-SddC metabolites. (-)-SddCTP was more potent than (+)-SddCTP in inhibiting hepatitis B virus replication; (+)- and (-)-SddCTP exhibited minimal inhibition on polymerases alpha and delta, more inhibition on beta, and strong inhibition on gamma. In all cases, (+)SddCTP was found to be more inhibitory than (-)SddCTP to all four polymerases. (+)-SddCMP competed with dCTP for incorporation into DNA by DNA polymerase gamma and beta and served as a chain terminator; however, similar incorporation was not detected using other polymerases. The selective inhibition of DNA synthesis in isolated mitochondria by (+)- and (-)SddCTP suggests a stereospecificity on the mitochondrial uptake of deoxynucleoside triphosphates.	YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	Yale University					NATIONAL CANCER INSTITUTE [R35CA044358] Funding Source: NIH RePORTER; NCI NIH HHS [CA44358] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKISEI S, 1991, J INFECT DIS, V164, P843, DOI 10.1093/infdis/164.5.843; Ayoola E.A., 1988, B WORLD HEALTH ORGAN, V66, P443; BEACH JW, 1992, J ORG CHEM, V57, P2217, DOI 10.1021/jo00034a006; BEASLEY RP, 1981, LANCET, V2, P1129; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; CHANG CN, 1992, J BIOL CHEM, V267, P13938; CHEN CH, 1989, J BIOL CHEM, V264, P11934; CHEN CH, 1992, J BIOL CHEM, V267, P2856; CHENG YC, 1977, BIOCHIM BIOPHYS ACTA, V481, P481, DOI 10.1016/0005-2744(77)90281-9; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P733, DOI 10.1128/AAC.36.4.733; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P202, DOI 10.1128/AAC.36.1.202; DIBISCEGLIE AM, 1988, ANN INTERN MED, V108, P390, DOI 10.7326/0003-4819-108-3-390; DOONG SL, 1991, P NATL ACAD SCI USA, V88, P8495, DOI 10.1073/pnas.88.19.8495; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; MILLER RH, 1986, P NATL ACAD SCI USA, V83, P2531, DOI 10.1073/pnas.83.8.2531; SCHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P672, DOI 10.1128/AAC.36.3.672; STARNES MC, 1987, J BIOL CHEM, V262, P988; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330	19	198	214	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22414	22420						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331054				2022-12-27	WOS:A1992JW71900067
J	DEVARAJAN, P; GILMOREHEBERT, M; BENZ, EJ				DEVARAJAN, P; GILMOREHEBERT, M; BENZ, EJ			DIFFERENTIAL TRANSLATION OF THE NA,K-ATPASE SUBUNIT MESSENGER-RNAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; ALPHA-SUBUNIT; RAT-BRAIN; 5'-UNTRANSLATED REGION; EUKARYOTIC RIBOSOMES; MOLECULAR-CLONING; BETA-SUBUNIT; AMINO-ACID; EXPRESSION; NA+	Expression of the Na,K-ATPase alpha and beta subunit genes is influenced by a complex series of regulatory pathways. For example, unequal amounts of subunit mRNAs are detected in several tissues, both at rest and upon mRNA induction, even though equal quantities of subunit proteins exist. We therefore studied mRNA stability and translational efficiency of wild type, deletion mutant, and chimeric subunit mRNAs in a cell-free translation system, to examine the possible role of post-transcriptional events in regulating subunit expression. Alpha1 mRNA translated less efficiently than beta1 mRNA and competed less efficiently for rate-limiting translation factors. Deletion of the 5'-untranslated region of alpha1 mRNA significantly increased its translation efficiency. Conversely, the alpha1 5'-untranslated region impaired translation of beta1 mRNA when attached upstream of the beta1 coding sequence. This region is G/C-rich, and has a complex mRNA secondary structure. We propose that differential translational efficiency may contribute to the equal biosynthesis of subunit proteins in those tissues in which subunit mRNAs either exist in unequal amounts or are differentially induced.	YALE UNIV, DEPT PEDIAT, NEW HAVEN, CT 06510 USA; YALE UNIV, DEPT THERAPEUT RADIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, DEPT INTERNAL MED, NEW HAVEN, CT 06510 USA; YALE UNIV, DEPT GENET, NEW HAVEN, CT 06510 USA	Yale University; Yale University; Yale University; Yale University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044430, R01HL024385] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-44430, HL-24385] Funding Source: Medline; NICHD NIH HHS [HD-22297] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; CAYANIS E, 1990, J BIOL CHEM, V265, P10829; CHAMBERS SK, 1992, IN PRESS BLOOD; GICK GG, 1988, J BIOL CHEM, V263, P16610; GICK GG, 1988, NAPLUS KPLUS PUMP B, P277; GILMOREHEBERT M, 1989, J CLIN INVEST, V84, P347, DOI 10.1172/JCI114161; GILMOREHEBERT M, 1988, NA K PUMP B, P71; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HORIUCHI T, 1990, J BIOL CHEM, V265, P6521; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ISMAILBEIGI F, 1971, J GEN PHYSIOL, V57, P710, DOI 10.1085/jgp.57.6.710; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; KOZAK M, 1988, MOL CELL BIOL, V8, P2737, DOI 10.1128/MCB.8.7.2737; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAZ T, 1987, TRANSLATIONAL REGULA, P413; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; MACKNIGHT ADC, 1977, PHYSIOL REV, V57, P510, DOI 10.1152/physrev.1977.57.3.510; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MERCER RW, 1986, MOL CELL BIOL, V6, P3884, DOI 10.1128/MCB.6.11.3884; MERCER RW, 1988, NA K PUMP, P119; NOGUCHI S, 1990, J BIOL CHEM, V265, P15991; ORLOWSKI J, 1988, J BIOL CHEM, V263, P17817; OZAWA K, 1988, J BIOL CHEM, V263, P10922; PAVLAKIS GN, 1980, CELL, V19, P91, DOI 10.1016/0092-8674(80)90391-8; PELLETIER J, 1987, BIOCHEM CELL BIOL, V65, P576, DOI 10.1139/o87-074; PHILIPSON KD, 1985, ANNU REV PHYSIOL, V47, P561; PRESSLEY TA, 1988, AM J PHYSIOL, V255, pC252, DOI 10.1152/ajpcell.1988.255.2.C252; SCHNEIDER JW, 1985, P NATL ACAD SCI USA, V82, P6357, DOI 10.1073/pnas.82.18.6357; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SWEADNER KJ, 1985, J BIOL CHEM, V260, P9016; TAMKUN MM, 1986, J BIOL CHEM, V261, P1009; THOMAS RC, 1972, PHYSIOL REV, V52, P563, DOI 10.1152/physrev.1972.52.3.563; ULLRICH KJ, 1979, ANNU REV PHYSIOL, V41, P181, DOI 10.1146/annurev.ph.41.030179.001145; YOUNG RM, 1987, BIOCHEM BIOPH RES CO, V145, P52, DOI 10.1016/0006-291X(87)91286-1; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	42	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22435	22439						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331056				2022-12-27	WOS:A1992JW71900070
J	BRITTEN, CJ; ZHEN, RG; KIM, EJ; REA, PA				BRITTEN, CJ; ZHEN, RG; KIM, EJ; REA, PA			RECONSTITUTION OF TRANSPORT FUNCTION OF VACUOLAR H+-TRANSLOCATING INORGANIC PYROPHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-PLANT TONOPLAST; RED BEET; ATPASE; PURIFICATION; RESOLUTION; MEMBRANE; PROTEINS; SUBUNIT; VESICLES; CELL	A procedure for reconstitution of the transport function of the vacuolar H+-translocating inorganic pyrophosphatase H+-PPase; EC 3.6.1.1) prepared from etiolated hypocotyls of Vigna radiata (mung bean) is described. The method entails sequential extraction of isolated vacuolar membrane (tonoplast) vesicles with deoxycholate and CHAPS (3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate), combination of CHAPS-solubilized protein with phospholipid-cholesterol mixtures, diaLysis, and glycerol density gradient centrifugation. The final proteoliposome preparation is 9-fold enriched for PPase activity and active in pyrophosphate (PP(i))-energized electrogenic H+-translocation. Since both PP(i) hydrolysis and PP(i)-dependent H+-translocation by the proteoliposomes are indistinguishable from the corresponding activities of native tonoplast vesicles, the functional integrity of the H+-PPase appears to be conserved during solubilization and reconstitution. The high transport capacity and amenability of the reconstituted enzyme to both radiometric membrane filtration and fluorimetric H+-translocation assays, on the other hand, demonstrate its applicability to a broad range of transport studies. SDS-polyacrylamide gel electrophoresis of the proteoliposomes reveals selective enrichment of the M(r) 66,000, substrate-binding subunit of the H+-PPase and two additional polypeptides of M(r) 21,000 and 20,000. Although the M(r) 21,000 and 20,000 polypeptides have not been described previously, all attempts to reconstitute H+-PPase lacking these components were unsuccessful. It is therefore tentatively proposed that the M(r) 21,000 and 20,000 polypeptides, as well as the M(r) 66,000 subunit, are required for the productive reconstitution of PP(i)-dependent H+-translocation.	UNIV PENN,DEPT BIOL,INST PLANT SCI,PHILADELPHIA,PA 19104	University of Pennsylvania								Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BRITTEN CJ, 1989, FEBS LETT, V256, P200, DOI 10.1016/0014-5793(89)81748-X; DAVIES JM, 1991, FEBS LETT, V278, P66, DOI 10.1016/0014-5793(91)80085-H; DZANDU JK, 1984, P NATL ACAD SCI-BIOL, V81, P1733, DOI 10.1073/pnas.81.6.1733; KAESTNER KH, 1987, PLANT PHYSIOL, V83, P483, DOI 10.1104/pp.83.3.483; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KURKDJIAN A, 1988, EMBO J, V7, P3661; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI S, 1991, J BIOL CHEM, V266, P16078; LAI SP, 1988, J BIOL CHEM, V263, P16731; MAESHIMA M, 1989, J BIOL CHEM, V264, P20068; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Rea P.A., 1990, METHODS PLANT BIOCH, V3, P385, DOI DOI 10.1016/B978-0-12-461013-2.50035-6; REA PA, 1987, J BIOL CHEM, V262, P14745; REA PA, 1987, PHYSIOL PLANTARUM, V71, P131, DOI 10.1111/j.1399-3054.1987.tb04630.x; REA PA, 1992, TRENDS BIOCHEM SCI, V17, P348, DOI 10.1016/0968-0004(92)90313-X; REA PA, 1987, BIOCHIM BIOPHYS ACTA, V904, P1, DOI 10.1016/0005-2736(87)90080-0; REA PA, 1986, PLANT PHYSIOL, V81, P126, DOI 10.1104/pp.81.1.126; REA PA, 1985, PLANT PHYSIOL, V77, P46, DOI 10.1104/pp.77.1.46; REA PA, 1992, TRANSPORT AND RECEPTOR PROTEINS OF PLANT MEMBRANES, P25; REA PA, 1992, IN PRESS PLANT PHYSL, V100; SARAFIAN V, 1989, PLANT PHYSIOL, V91, P34, DOI 10.1104/pp.91.1.34; SARAFIAN V, 1992, P NATL ACAD SCI USA, V89, P1775, DOI 10.1073/pnas.89.5.1775; SHIMMEN T, 1987, PROTOPLASMA, V136, P205, DOI 10.1007/BF01276370; WARD JM, 1992, IN PRESS PLANT PHYSL, V100	29	30	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21850	21855						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328246				2022-12-27	WOS:A1992JV01100091
J	MCCARTHY, SA; BICKNELL, R				MCCARTHY, SA; BICKNELL, R			RESPONSES OF PERTUSSIS TOXIN-TREATED MICROVASCULAR ENDOTHELIAL-CELLS TO TRANSFORMING GROWTH FACTOR-BETA-1 - NO EVIDENCE FOR PERTUSSIS-SENSITIVE G-PROTEIN INVOLVEMENT IN TGF-BETA SIGNAL TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; AKR-2B CELLS; INHIBITION; PROLIFERATION; RECEPTOR; ACTIVATION; BINDING; PROMOTER; PATHWAYS; PHOSPHORYLATION	Responses of bovine adrenal capillary endothelial cells (BACE) on treatment with transforming growth factor beta1 (TGF-beta1) have been characterized and tested for sensitivity to inactivation of pertussis toxin-sensitive G-proteins. TGF-beta1 elicited growth inhibition, monolayer remodeling, elevation of steady state mRNA levels for collagen type 1 (alpha1(1) and alpha2(1)) and TGF-beta1, and inhibition of p34cdc2 histone H1 kinase activity in BACE cells. Pertussis toxin treatment enhanced both inhibition of BACE cell [H-3]methylthymidine uptake and remodeling of BACE monolayers by TGF-beta1. These findings contrast with studies of mink lung epithelial cells, in which TGF-beta1 growth inhibition has been shown to be pertussis-sensitive. Further investigation revealed that pertussis toxin treatment of BACE cells had no effect on TGF-beta1-stimulated elevation of steady state mRNA levels for collagen type 1 (alpha1(1) or alpha2(1)) or for TGF-beta1. Analysis of p34cdc2 activity in BACE cells revealed potent inhibition of p34cdc2 histone H1 kinase activity by TGF-beta1. Pertussis toxin treatment also abolished the increase in p34cdc2 activity, however, precluding the determination of the pertussis toxin sensitivity of this response to TGF-beta1. Consistent with suppression of p34cdc2 activation, pertussis toxin also caused substantial inhibition of mitogen-stimulated BACE cell [H-3]methylthymidine uptake. It is concluded that TGF-beta1 signal transduction in this cell type does not involve G-proteins of the pertussis toxin-sensitive class and that, in view of its potent effects on DNA synthesis and p34cdc2 activation, the use of pertussis toxin to determine G-protein involvement in cytokine signalling pathways should be approached with caution.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND	Cancer Research UK; University of Oxford			McCarthy, Sarah/HCI-8963-2022	Bicknell, Roy/0000-0002-0941-8919				BAIRD A, 1986, BIOCHEM BIOPH RES CO, V138, P476, DOI 10.1016/0006-291X(86)90305-0; BIRNBAUMER L, 1990, ADP RIBOSYLATING TOX, P225; BIRNBAUMER L, 1990, FASEB J, V4, P3068; BOYD FT, 1989, J BIOL CHEM, V264, P2272; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; FAWCETT J, 1991, BIOCHEM BIOPH RES CO, V174, P903, DOI 10.1016/0006-291X(91)91503-5; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HEIMARK RL, 1986, SCIENCE, V233, P1078, DOI 10.1126/science.3461562; HOWE PH, 1990, J CELL PHYSIOL, V142, P39, DOI 10.1002/jcp.1041420106; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HOWE PH, 1989, BIOCHEM J, V261, P879, DOI 10.1042/bj2610879; HOWE PH, 1990, BIOCHEM J, V266, P537, DOI 10.1042/bj2660537; HOWE PH, 1989, CANCER RES, V49, P6024; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; KIM SJ, 1989, J BIOL CHEM, V264, P7041; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KUZU I, 1992, J CLIN PATHOL, V45, P143, DOI 10.1136/jcp.45.2.143; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; MULLER G, 1987, P NATL ACAD SCI USA, V84, P5600, DOI 10.1073/pnas.84.16.5600; MURTHY US, 1988, BIOCHEM BIOPH RES CO, V152, P1228, DOI 10.1016/S0006-291X(88)80416-9; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; RAYCHAUDHURY A, 1991, J CELL BIOCHEM, V47, P224, DOI 10.1002/jcb.240470307; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1991, PEPTIDE GROWTH FACTO, P421; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; TAKEHARA K, 1987, CELL, V49, P415, DOI 10.1016/0092-8674(87)90294-7; UI M, 1990, ADP RIBOSYLATING TOX, P45; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; WANG XF, 1991, CELL, V67, P796; YANG LJ, 1991, J BIOL CHEM, V266, P22451	43	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21617	21622						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328241				2022-12-27	WOS:A1992JV01100057
J	RAUFMAN, JP; SINGH, L; SINGH, G; ENG, J				RAUFMAN, JP; SINGH, L; SINGH, G; ENG, J			TRUNCATED GLUCAGON-LIKE PEPTIDE-1 INTERACTS WITH EXENDIN RECEPTORS ON DISPERSED ACINI FROM GUINEA-PIG PANCREAS - IDENTIFICATION OF A MAMMALIAN ANALOG OF THE REPTILIAN PEPTIDE EXENDIN-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING POLYPEPTIDE; VASOACTIVE-INTESTINAL-PEPTIDE; HELODERMA-HORRIDUM VENOM; PERFUSED RAT PANCREAS; ADENYLATE-CYCLASE; BINDING-SITES; CELL-LINE; HYPOTHALAMIC POLYPEPTIDE; PREPROGLUCAGON CONTAINS; AMYLASE RELEASE	To find mammalian analogues of exendin-4, a peptide from Helodermatidae venoms that interacts with newly discovered exendin receptors on dispersed acini from guinea pig pancreas, we examined the actions of recent additions to the vasoactive intestinal peptide/secretin/glucagon family of regulatory peptides. In every respect tested, the truncated form of glucagon-like peptide-1, GLP-1(7-36)NH2, mimicked the actions of exendin-4. Like exendin-4, GLP-1(7-36)NH2 caused an increase in acinar cAMP without stimulating amylase release. GLP-1(7-36)NH2-induced increases in cAMP were inhibited progressively by increasing concentrations of the specific exendin-receptor antagonist, exendin(9-39)NH2. In dispersed acini from guinea pig and rat pancreas, concentrations of GLP-1(7-36)NH2 that stimulated increases in cAMP caused potentiation of cholecystokinin-induced amylase release. Binding of I-125-[Y39]exendin-4 or I-125-GLP-1(7-36)NH2 to dispersed acini from guinea pig pancreas was inhibited by adding increasing concentrations of unlabeled exendin-4 or GLP-1(7-36)NH2. We conclude that the mammalian peptide GLP-1(7-36)NH2 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Exendin(9-39)NH2, a competitive antagonist of the actions of GLP-1(7-36)NH2 in pancreatic acini, may be a useful tool for examining the physiological actions of this peptide.	VET AFFAIRS MED CTR, SOLOMON A BERSON RES LAB, BRONX, NY 10468 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	RAUFMAN, JP (corresponding author), SUNY HLTH SCI CTR, DEPT MED, DIV DIGEST DIS, 450 CLARKSON AVE, BOX 1196, BROOKLYN, NY 11203 USA.							BELL GI, 1983, NATURE, V302, P716, DOI 10.1038/302716a0; BELL GI, 1983, NATURE, V304, P368, DOI 10.1038/304368a0; BUSCAIL L, 1990, FEBS LETT, V262, P77, DOI 10.1016/0014-5793(90)80158-F; CAUVIN A, 1990, PEPTIDES, V11, P773, DOI 10.1016/0196-9781(90)90194-A; CESKA M, 1969, CLIN CHIM ACTA, V26, P437, DOI 10.1016/0009-8981(69)90071-0; CHRISTOPHE JP, 1976, J BIOL CHEM, V251, P4629; COLLEN MJ, 1982, AM J PHYSIOL, V242, pG423, DOI 10.1152/ajpgi.1982.242.4.G423; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; ENG J, 1990, J BIOL CHEM, V265, P20259; ENG J, 1992, J BIOL CHEM, V267, P7402; FEHMANN HC, 1991, BIOCHIM BIOPHYS ACTA, V1091, P356, DOI 10.1016/0167-4889(91)90200-H; FEHMANN HC, 1990, PANCREAS, V5, P361, DOI 10.1097/00006676-199005000-00019; GARDNER JD, 1982, AM J PHYSIOL, V242, pG547, DOI 10.1152/ajpgi.1982.242.6.G547; GARDNER JD, 1979, BIOCHIM BIOPHYS ACTA, V583, P491, DOI 10.1016/0304-4165(79)90066-7; GARDNER JD, 1981, PHYSL GASTROINTESTIN, P831; GOKE R, 1991, EUR J CLIN INVEST, V21, P135, DOI 10.1111/j.1365-2362.1991.tb01802.x; GOTTSCHALL PE, 1990, ENDOCRINOLOGY, V127, P272, DOI 10.1210/endo-127-1-272; HEINRICH G, 1984, J BIOL CHEM, V259, P4082; HOLST JJ, 1987, FEBS LETT, V211, P169, DOI 10.1016/0014-5793(87)81430-8; HOOSEIN NM, 1984, FEBS LETT, V178, P83, DOI 10.1016/0014-5793(84)81245-4; KOMATSU R, 1989, DIABETES, V38, P902, DOI 10.2337/diabetes.38.7.902; KREYMANN B, 1988, FEBS LETT, V242, P167, DOI 10.1016/0014-5793(88)81008-1; KREYMANN B, 1987, LANCET, V2, P1300; LEMEUTH V, 1991, AM J PHYSIOL, V260, pG265, DOI 10.1152/ajpgi.1991.260.2.G265; LOPEZ LC, 1983, P NATL ACAD SCI-BIOL, V80, P5485, DOI 10.1073/pnas.80.18.5485; MALHOTRA R, 1991, Gastroenterology, V100, pA653; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MOJSOV S, 1990, J BIOL CHEM, V265, P8001; MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172/JCI112855; OHTAKI T, 1990, BIOCHEM BIOPH RES CO, V171, P838, DOI 10.1016/0006-291X(90)91222-E; ORSKOV C, 1988, ENDOCRINOLOGY, V123, P2009, DOI 10.1210/endo-123-4-2009; ORSKOV C, 1986, ENDOCRINOLOGY, V119, P1467, DOI 10.1210/endo-119-4-1467; PATZELT C, 1984, P NATL ACAD SCI-BIOL, V81, P5007, DOI 10.1073/pnas.81.16.5007; PEIKIN SR, 1978, AM J PHYSIOL, V235, pE743, DOI 10.1152/ajpendo.1978.235.6.E743; RAUFMAN JP, 1991, J BIOL CHEM, V266, P2897; RAUFMAN JP, 1991, REGUL PEPTIDES, V36, P121, DOI 10.1016/0167-0115(91)90200-Z; RAUFMAN JP, 1986, REGUL PEPTIDES, V14, P93, DOI 10.1016/0167-0115(86)90208-9; ROBBERECHT P, 1991, AM J PHYSIOL, V260, pG97, DOI 10.1152/ajpgi.1991.260.1.G97; SCHJOLDAGER BTG, 1989, DIGEST DIS SCI, V34, P703, DOI 10.1007/BF01540341; SCHMIDT WE, 1985, DIABETOLOGIA, V28, P704, DOI 10.1007/BF00291980; SCHMIDTLER J, 1991, AM J PHYSIOL, V260, pG940, DOI 10.1152/ajpgi.1991.260.6.G940; SHIMIZU I, 1987, ENDOCRINOLOGY, V121, P1076, DOI 10.1210/endo-121-3-1076; TATSUNO I, 1990, BIOCHEM BIOPH RES CO, V168, P1027, DOI 10.1016/0006-291X(90)91132-C	43	102	135	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21432	21437						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328231				2022-12-27	WOS:A1992JV01100029
J	REINHART, J; MERTZ, LM; CATT, KJ				REINHART, J; MERTZ, LM; CATT, KJ			MOLECULAR-CLONING AND EXPRESSION OF CDNA-ENCODING THE MURINE GONADOTROPIN-RELEASING-HORMONE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LUTEINIZING-HORMONE; PITUITARY GONADOTROPHS; CELL-LINES; PROTEIN; MEMBRANE; BINDING; SITES; LOCALIZATION; METABOLISM; RESPONSES	The primary structure of the gonadotropin-releasing hormone (GnRH) receptor was determined by sequencing a functional receptor cDNA isolated by expression cloning from an immortalized murine gonadotroph (alphaT3) cell line. Positive clone pools from a cDNA library were detected by screening expressed RNA in aequorin-injected Xenopus laevis oocytes, in which receptor-mediated calcium responses were monitored as light emission during stimulation by GnRH. The isolated receptor cDNA encodes a 327-amino acid protein that has seven putative transmembrane regions and is unique among G protein-coupled receptors in that the predicted sequence lacks a carboxyl-terminal cytoplasmic domain. COS-7 cells transfected with the receptor cDNA expressed high affinity binding sites for GnRH and its agonist and antagonist analogs and exhibited calcium responses to GnRH stimulation. These, and the prominent calcium responses of Xenopus oocytes injected with receptor RNA, were inhibited by GnRH antagonists. Northern blot analysis revealed two mRNAs (1.6 and 3.5 kilobases) in alphaT3 cells and in the mouse pituitary gland, and both transcripts were shown to encode functional GnRH receptors when expressed in Xenopus oocytes. In contrast, a single 4.6-kilobase receptor mRNA was present in rat anterior pituitary gland, ovary, and Leydig cells. The absence of a carboxyl-terminal cytoplasmic domain indicates the importance of other regions of the GnRH receptor in agonist-induced signal transduction, and possibly in receptor desensitization and sequestration.	NICHHD, ENDOCRINOL & REPROD RES BRANCH, BLDG 10, RM B1-L400, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BURGUS R, 1972, P NATL ACAD SCI USA, V69, P278, DOI 10.1073/pnas.69.1.278; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; CHANG JP, 1986, J BIOL CHEM, V261, P9105; CHANG JP, 1988, J BIOL CHEM, V263, P18614; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; CLAYTON RN, 1979, NATURE, V282, P90, DOI 10.1038/282090a0; CLAYTON RN, 1980, P NATL ACAD SCI-BIOL, V77, P4459, DOI 10.1073/pnas.77.8.4459; CLAYTON RN, 1981, ENDOCR REV, V2, P186, DOI 10.1210/edrv-2-2-186; CLAYTON RN, 1989, J ENDOCRINOL, V120, P11, DOI 10.1677/joe.0.1200011; CURRIE AJ, 1981, BIOCHEM BIOPH RES CO, V99, P332, DOI 10.1016/0006-291X(81)91749-6; EIDNE KA, 1987, J CLIN ENDOCR METAB, V64, P425, DOI 10.1210/jcem-64-3-425; EIDNE KA, 1988, J MOL ENDOCRINOL, V1, pR9; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUARDABASSO V, 1987, AM J PHYSIOL, V252, pE357, DOI 10.1152/ajpendo.1987.252.3.E357; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAZUM E, 1981, ENDOCRINOLOGY, V109, P1281, DOI 10.1210/endo-109-4-1281; HIROTA K, 1985, J BIOL CHEM, V260, P3243; HORN F, 1991, MOL ENDOCRINOL, V5, P347, DOI 10.1210/mend-5-3-347; IWASHITA M, 1988, J MOL ENDOCRINOL, V1, P187, DOI 10.1677/jme.0.0010187; IWASHITA M, 1986, J CLIN ENDOCR METAB, V62, P127, DOI 10.1210/jcem-62-1-127; IWASHITA M, 1985, ENDOCRINOLOGY, V117, P738, DOI 10.1210/endo-117-2-738; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOUMAYE E, 1984, J BIOL CHEM, V259, P2663; LOUMAYE E, 1982, SCIENCE, V215, P983, DOI 10.1126/science.6296998; LOUMAYE E, 1982, SCIENCE, V218, P1323, DOI 10.1126/science.6293058; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MERELLI F, 1992, ENDOCRINOLOGY, V131, P925, DOI 10.1210/en.131.2.925; Millan M, 1986, Methods Enzymol, V124, P590; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MORGAN RO, 1987, J BIOL CHEM, V262, P1166; NUSSENZVEIG DR, 1992, 74TH END SOC M; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PAHWA GS, 1989, BIOCHEM BIOPH RES CO, V161, P1086, DOI 10.1016/0006-291X(89)91354-5; PERRIN MH, 1989, ENDOCRINOLOGY, V124, P798, DOI 10.1210/endo-124-2-798; Sambrook J, 1989, MOL CLONING LABORATO, P1881; SANDBERG K, 1988, FEBS LETT, V241, P177, DOI 10.1016/0014-5793(88)81055-X; SANDBERG K, 1992, J BIOL CHEM, V267, P9455; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALLY AV, 1971, J BIOL CHEM, V246, P7230; SEALFON SC, 1990, MOL ENDOCRINOL, V4, P119, DOI 10.1210/mend-4-1-119; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEGERSON TP, 1992, 74TH END SOC M SAN A; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; THOMAS KM, 1990, J BIOL CHEM, V265, P20061; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597	50	230	233	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21281	21284						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328228				2022-12-27	WOS:A1992JV01100003
J	SUH, K; GABEL, CA; BERGMANN, JE				SUH, K; GABEL, CA; BERGMANN, JE			IDENTIFICATION OF A NOVEL MECHANISM FOR THE REMOVAL OF GLUCOSE RESIDUES FROM HIGH MANNOSE-TYPE OLIGOSACCHARIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; VIRUS-G-PROTEIN; ROUGH ENDOPLASMIC-RETICULUM; ALPHA-D-MANNOSIDASE; SECRETORY GLYCOPROTEINS; VIRAL GLYCOPROTEIN; PROCESSING ENZYME; GOLGI-COMPLEX; RAT-LIVER; 1-DEOXYNOJIRIMYCIN	The role of glucosylated oligosaccharides in the biogenesis of the glycoprotein (G protein) of vesicular stomatitis virus was studied in PhaR2.7, a mouse lymphoma cell line deficient in glucosidase II activity. As expected, the great majority of cell-associated G protein remained glucosylated in PhaR2.7, and the G protein was rapidly deglucosylated in BW5147, the parental cell line. Despite these differences in glucosylation, the rates of G protein trimerization and transport to the cell surface were as rapid and efficient in the PhaR2.7 mutant as in BW5147. Surprisingly, greater than 73% of the oligosaccharides on G proteins recovered from released virions were complex-type units. The efficient processing of the G protein oligosaccharides coincided with the efficient removal of glucose residues from its oligosaccharides. After treatment with deoxynojirimycin, an inhibitor of endoplasmic reticulum (ER) glucosidases I and II, the total percentage of G protein-associated high mannose-type oligosaccharides increased more in the parental cells than in the mutant cells. Furthermore, when the G protein was retained in the ER of PhaR2.7 cells by depletion of the cellular ATP pools with carbonyl cyanide m-chlorophenylhydrazone, its oligosaccharides remained glucosylated. Under identical conditions, BW5147 cells removed the glucose residues from > 90% of the retained G protein's oligosaccharides. Thus, PhaR2.7 cells efficiently remove glucose residues from high mannose-type oligosaccharides of selected proteins using a deoxynojirimycin-insensitive enzyme located in a post-ER compartment. The existence of a second mechanism for the deglucosylation of N-linked oligosaccharides provides evidence for the important role of glucose removal in glycoprotein maturation.	COLUMBIA UNIV COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032	Columbia University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032617, R01GM033342] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33342, GM32617] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON PH, 1984, J CELL BIOL, V98, P2245, DOI 10.1083/jcb.98.6.2245; BRANDS R, 1985, J CELL BIOL, V101, P1724, DOI 10.1083/jcb.101.5.1724; DATEMA R, 1981, J BIOL CHEM, V256, P1191; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; GABEL CA, 1985, J CELL BIOL, V101, P460, DOI 10.1083/jcb.101.2.460; HETTKAMP H, 1982, BIOSCIENCE REP, V2, P899, DOI 10.1007/BF01114896; HICKMAN S, 1984, J CELL BIOL, V98, P407, DOI 10.1083/jcb.98.2.407; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HUBBARD SC, 1979, J BIOL CHEM, V254, P4568; KABCENELL AK, 1985, J CELL BIOL, V101, P1270, DOI 10.1083/jcb.101.4.1270; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMANSKY P, 1984, J BIOL CHEM, V259, P13129; LI E, 1978, J BIOL CHEM, V253, P7762; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; MCELDUFF A, 1986, BIOCHEM J, V239, P679, DOI 10.1042/bj2390679; MICHAEL JM, 1980, ARCH BIOCHEM BIOPHYS, V199, P249, DOI 10.1016/0003-9861(80)90278-7; PARENT JB, 1986, MOL CELL BIOCHEM, V72, P21; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; REITMAN ML, 1982, J BIOL CHEM, V257, P357; ROSENFELD MG, 1984, J CELL BIOL, V99, P1076, DOI 10.1083/jcb.99.3.1076; SAUNIER B, 1982, J BIOL CHEM, V257, P4155; SCHLESINGER S, 1984, J BIOL CHEM, V259, P7597; SPIRO MJ, 1979, J BIOL CHEM, V254, P7668; STANELONI RJ, 1980, EUR J BIOCHEM, V105, P275, DOI 10.1111/j.1432-1033.1980.tb04498.x; STRUCK DK, 1980, BIOCH GLYCOPROTEINS, P35; SUH KS, 1989, J CELL BIOL, V108, P811, DOI 10.1083/jcb.108.3.811; TARTAKOFF AM, 1977, J EXP MED, V146, P1332, DOI 10.1084/jem.146.5.1332; TRIMBLE RB, 1980, J BIOL CHEM, V255, P1892; TROMBETTA SE, 1989, BIOCHEMISTRY-US, V28, P8108, DOI 10.1021/bi00446a022; TURCO SJ, 1977, P NATL ACAD SCI USA, V74, P4411, DOI 10.1073/pnas.74.10.4411	35	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21671	21677						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328242				2022-12-27	WOS:A1992JV01100065
J	ROESLER, WJ; MCFIE, PJ; DAUVIN, C				ROESLER, WJ; MCFIE, PJ; DAUVIN, C			THE LIVER-ENRICHED TRANSCRIPTION FACTOR D-SITE-BINDING PROTEIN ACTIVATES THE PROMOTER OF THE PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE IN HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; RAT-LIVER; REGULATORY REGION; GTP GENE; C/EBP; CAMP; IDENTIFICATION; ELEMENTS; DBP; PHOSPHORYLATION	It has been previously demonstrated that the CCAAT/enhancer-binding protein (C/EBP) trans-activates the gene coding for the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) (EC 4.1.1.32) (PEPCK) and binds to several sites along the promoter. The additional observations that C/EBP is expressed in liver and follows the same developmental profile as PEPCK suggests that C/EBP plays an important role in the regulation of PEPCK gene expression. However, since C/EBP is expressed at high levels in lung, a tissue in which PEPCK is not expressed, it appears that other mechanisms are involved to provide PEPCK with high level expression in liver. We now show that the albumin promoter D-site-binding protein (DBP), a transcription factor whose expression is limited to the liver, is also able to trans-activate the PEPCK promoter through sequence-specific binding. Both recombinant DBP and C/EBP bind with highest affinity to regions located at positions -85 and -245 in the promoter, but display differences in their binding properties at other sites. Using eukaryotic expression vectors for both C/EBP and DBP, we found that with 5'-deletion mutants of the PEPCK promoter, both C/EBP and DBP exerted their effects through similar regions of the promoter. However, the use of internal deletion mutants of the promoter identified distinct differences in the mechanism of activation by C/EBP and DBP. In particular, a region of the promoter between positions -86 and -117 significantly attenuated the level of trans-activation by DBP, but not by C/EBP. Evidence presented also supports a model whereby the relative ratios of C/EBP and DBP in the cell fine-tune the expression of the PEPCK gene. These results demonstrate that DBP and C/EBP, while having similar DNA binding specificities, have distinct functional differences in the context of the PEPCK promoter. These differences, along with the developmental profiles of C/EBP and DBP, may provide a mechanistic explanation for the liver-specific as well as the developmental profile of PEPCK gene expression.			ROESLER, WJ (corresponding author), UNIV SASKATCHEWAN,COLL MED,DEPT BIOCHEM,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA.							BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; IP YT, 1990, MOL CELL BIOL, V10, P3770, DOI 10.1128/MCB.10.7.3770; IYER SV, 1991, MOL CELL BIOL, V11, P4863, DOI 10.1128/MCB.11.10.4863; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU JS, 1990, BIOTECHNIQUES, V9, P738; LOOSE DS, 1985, BIOCHEMISTRY-US, V24, P4509, DOI 10.1021/bi00338a004; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MIRKOVITCH J, 1991, GENE DEV, V5, P83, DOI 10.1101/gad.5.1.83; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; RUIZ J P G, 1978, Proceedings of the National Academy of Sciences of the United States of America, V75, P4189, DOI 10.1073/pnas.75.9.4189; Sambrook J, 1989, MOL CLONING LABORATO; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SHORT JM, 1986, J BIOL CHEM, V261, P9721; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	35	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21235	21243						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328227				2022-12-27	WOS:A1992JT97800112
J	ROUXEL, FP; HILLY, M; MAUGER, JP				ROUXEL, FP; HILLY, M; MAUGER, JP			CHARACTERIZATION OF A RAPIDLY DISSOCIATING INOSITOL 1,4,5-TRISPHOSPHATE-BINDING SITE IN LIVER MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM RELEASE; RAT-LIVER; CA-2+ RELEASE; TRISPHOSPHATE RECEPTOR; BINDING; HEPATOCYTES; PHOSPHATES; INHIBITION; MECHANISM; VESICLES	The binding of inositol 1,4,5-trisphosphate (InsP3) to a specific receptor induces the release of Ca2+ from an intracellular store. In the liver, the K(D) of a low affinity state of the receptor (R(L)) found at low Ca2+ concentration ([Ca2+]) is in close agreement with the EC50 of the InsP3-induced Ca2+ release. We have developed an experimental procedure for measuring the rate of dissociation of this low affinity [P-32]InsP3-receptor complex in less than 1 s. When the receptor was in the R(L) state, two kinetic components, R(L1) and R(L2), were identified with respective rate constants (k(off)) of 1-2 s-1 and 0.03-0.06 s-1. Increasing the [Ca2+] up to 1-muM transformed the receptor into the high affinity state (R(H)) and decreased the dissociation rate constant to 2.10(-2) min-1. We also investigated the time course of the transformation of the receptor from the high affinity (R(H)) to the low affinity state (R(L)) after decreasing the [Ca2+] to less than 10 nM. This reversion was dramatically dependent on temperature: at 4-degrees-C, the receptor was locked in the R(H) state, whereas at 37-degrees-C the receptor reverted to the R(L) state with a half-time of less than 1 s. The reversion from the R(H) state to the R(L) one is associated to a recovery of InSP3-induced Ca-45(2+) release on permeabilized hepatocytes. The rapid and reversible transformation of the InsP3 receptor from an active to an inactive state may be a key event in the Ca2+ release process in intact cells.	UNIV PARIS 11,INSERM,U274,BATIMENT 443,F-91405 ORSAY,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay								BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; CHILVERS ER, 1990, BRIT J PHARMACOL, V99, P297, DOI 10.1111/j.1476-5381.1990.tb14698.x; CULLEN PJ, 1988, FEBS LETT, V228, P57, DOI 10.1016/0014-5793(88)80584-2; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GUILLEMETTE G, 1988, J BIOL CHEM, V263, P4541; HINGORANI SR, 1991, ANAL BIOCHEM, V194, P204, DOI 10.1016/0003-2697(91)90169-T; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JOSEPH SK, 1986, J BIOL CHEM, V261, P4658; MAUGER JP, 1989, J BIOL CHEM, V264, P8821; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NILSSON T, 1988, FEBS LETT, V229, P211, DOI 10.1016/0014-5793(88)80829-9; NUNN DL, 1990, BIOCHEM J, V265, P393, DOI 10.1042/bj2650393; NUNN DL, 1990, BIOCHEM J, V270, P227, DOI 10.1042/bj2700227; PAYNE R, 1990, NEURON, V4, P547, DOI 10.1016/0896-6273(90)90112-S; PIETRI F, 1990, CELL SIGNAL, V2, P253, DOI 10.1016/0898-6568(90)90053-D; PIETRI F, 1990, J BIOL CHEM, V265, P17478; PRPIC V, 1984, J BIOL CHEM, V259, P1382; SPAT A, 1986, BIOCHEM J, V233, P929; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; VARNEY MA, 1990, BIOCHEM J, V269, P211, DOI 10.1042/bj2690211; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	30	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20017	20023						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328191				2022-12-27	WOS:A1992JR85800044
J	PARYS, JB; SERNETT, SW; DELISLE, S; SNYDER, PM; WELSH, MJ; CAMPBELL, KP				PARYS, JB; SERNETT, SW; DELISLE, S; SNYDER, PM; WELSH, MJ; CAMPBELL, KP			ISOLATION, CHARACTERIZATION, AND LOCALIZATION OF THE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR PROTEIN IN XENOPUS-LAEVIS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM RELEASE CHANNEL; SKELETAL-MUSCLE; TRISPHOSPHATE RECEPTOR; ENDOPLASMIC-RETICULUM; RYANODINE RECEPTOR; SMOOTH-MUSCLE; FUNCTIONAL-CHARACTERIZATION; MOUSE CEREBELLUM; SEA-URCHIN	Inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) induces Ca2+ oscillations and waves in Xenopus laevis oocytes. Microsomes from oocytes exhibit high-affinity binding for Ins(1,4,5)P3, and demonstrate Ins(1,4,5)P3-induced Ca2+ release. The Ins(1,4,5)P3 receptor (InsP3R) was purified from oocyte microsomes as a large tetrameric complex and shown to have a monomer molecular mass of 256 kDa, compared with 273 kDa for the brain InSP3R. Binding to the oocyte receptor is highly specific for Ins(1,4,5)P3 and is inhibited by heparin (IC50, 2-mu-g/ml). Immunoblot analysis revealed that an antibody against the C-terminal sequence of the brain receptor recognized the oocyte receptor. These results, in addition to the difference in pattern obtained after limited proteolysis, suggest that the oocyte InsP3R is a new shorter isoform of the mammalian brain type I InsP3R. Immunofluorescence experiments indicated the presence of the InsP3R in the cortical layer and the perinuclear endoplasmic reticulum of the oocyte. However, immunological and biochemical experiments did not reveal the presence of the ryanodine receptor. The presence of an InsP3R and the absence of a ryanodine receptor support the importance of Ins(1,4,5)P3 in Ca2+ handling by oocytes and particularly in the induction of Ca2+ oscillations and waves.	UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, 400 ECKSTEIN MED RES BLDG, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa				Parys, Jan/0000-0002-3591-4967; Welsh, Michael/0000-0002-1646-6206; Campbell, Kevin/0000-0003-2066-5889				ANDERSON K, 1989, J BIOL CHEM, V264, P1329; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; BUSA WB, 1990, J REPROD FERTIL, P155; BUSA WB, 1985, J CELL BIOL, V101, P677, DOI 10.1083/jcb.101.2.677; CAMPBELL KP, 1980, BIOCHIM BIOPHYS ACTA, V602, P97, DOI 10.1016/0005-2736(80)90293-X; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DELISLE S, 1991, CELL CALCIUM, V12, P217, DOI 10.1016/0143-4160(91)90022-7; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DELISLE S, 1990, J BIOL CHEM, V265, P11726; DELISLE S, 1992, AM J PHYSIOL, V262, pC1456, DOI 10.1152/ajpcell.1992.262.6.C1456; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FERGUSON JE, 1991, EXP CELL RES, V192, P352, DOI 10.1016/0014-4827(91)90052-V; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HAN JK, 1990, J CELL BIOL, V110, P1103, DOI 10.1083/jcb.110.4.1103; HENSON JH, 1989, J CELL BIOL, V109, P149, DOI 10.1083/jcb.109.1.149; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; JAFFE LF, 1983, DEV BIOL, V99, P265, DOI 10.1016/0012-1606(83)90276-2; JORGENSEN AO, 1984, J CELL BIOL, V98, P1597, DOI 10.1083/jcb.98.4.1597; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MCPHERSON PS, 1990, J BIOL CHEM, V265, P18454; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MILNER RE, 1991, J BIOL CHEM, V266, P7155; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OLIVARES EB, 1991, BIOPHYS J, V59, P1153, DOI 10.1016/S0006-3495(91)82331-1; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1991, J PHYSIOL-LONDON, V433, P207, DOI 10.1113/jphysiol.1991.sp018422; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SHARP AH, 1987, J BIOL CHEM, V262, P12309; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	55	245	247	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18776	18782						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326534				2022-12-27	WOS:A1992JN50200080
J	WIEGMANN, K; SCHUTZE, S; KAMPEN, E; HIMMLER, A; MACHLEIDT, T; KRONKE, M				WIEGMANN, K; SCHUTZE, S; KAMPEN, E; HIMMLER, A; MACHLEIDT, T; KRONKE, M			HUMAN 55-KDA RECEPTOR FOR TUMOR-NECROSIS-FACTOR COUPLED TO SIGNAL TRANSDUCTION CASCADES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TNF RECEPTOR; PROTEIN-KINASE-C; CELL-SURFACE RECEPTORS; NATURAL-KILLER-CELLS; MOLECULAR-CLONING; FACTOR-ALPHA; MONOCLONAL-ANTIBODIES; BINDING PROTEIN; DOWN-REGULATION; SOLUBLE FORM	The numerous biological activities of tumor necrosis factor (TNF) appear mediated by two types of receptors of 55 kDa (TR55) and 75 kDa (TR75) molecular mass. To test TR55 for its individual role in signaling across the membrane, a cDNA coding for the human TR55 was stably expressed in murine 70Z/3 pre-B cells, which lack binding sites for, and proved nonresponsive to human TNF. The transfected TR55 showed high affinity ligand binding and active internalization. It is demonstrated that the TNF signaling cascade, i.e. stimulation of protein kinase C, sphingomyelinase, and phospholipase A2, production of the second messengers diacylglycerol and ceramide, can occur completely through exclusive binding of TNF to TR55. The p55 TNF-binding site functions as an autonomous TNF receptor that mediates key signal transduction pathways, which may control the majority of TNF actions.	TECH UNIV MUNICH,INST MED MIKROBIOL & HYG,TROGERSTR 4A,W-8000 MUNICH 80,GERMANY; BENDER & CO GMBH,ERNST BOEHRINGER INST,A-1121 VIENNA,AUSTRIA	Technical University of Munich			Schütze, Stefan/C-8596-2011					AGGARWAL BB, 1987, J BIOL CHEM, V262, P16450; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GRAY PW, 1990, P NATL ACAD SCI USA, V87, P7380, DOI 10.1073/pnas.87.19.7380; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HIMMLER A, 1990, DNA CELL BIOL, V9, P705, DOI 10.1089/dna.1990.9.705; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KEHRL JH, 1988, J CLIN INVEST, V81, P200, DOI 10.1172/JCI113295; KIM MY, 1991, J BIOL CHEM, V266, P484; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KRONKE M, 1992, TUMOR NECROSIS FACTO, P189; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LE TBT, 1986, J IMMUNOL, V139, P1550; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LIN JX, 1987, J BIOL CHEM, V262, P11908; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; NAUME B, 1991, J IMMUNOL, V146, P3045; NEALE ML, 1988, IMMUNOLOGY, V64, P81; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; RALPH P, 1984, J IMMUNOL, V133, P2442; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SCHUTZE S, 1988, J IMMUNOL, V140, P3000; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; TSUDO M, 1987, P NATL ACAD SCI USA, V84, P5394, DOI 10.1073/pnas.84.15.5394; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; UNGLAUB R, 1987, J EXP MED, V166, P1788, DOI 10.1084/jem.166.6.1788; YOSHIE O, 1986, J BIOCHEM-TOKYO, V100, P531, DOI 10.1093/oxfordjournals.jbchem.a121744; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	43	194	205	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17997	18001						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325455				2022-12-27	WOS:A1992JM22300079
J	FARRANCE, IKG; MAR, JH; ORDAHL, CP				FARRANCE, IKG; MAR, JH; ORDAHL, CP			M-CAT BINDING-FACTOR IS RELATED TO THE SV40 ENHANCER BINDING-FACTOR, TEF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC TRANSCRIPTION; MYOGENIC CELL-LINE; CARDIAC ACTIN GENE; TROPONIN-T-GENE; UPSTREAM REGIONS; EXPRESSION; SEQUENCE; SKELETAL; PROMOTER; MOTIF	M-CAT binding factor (MCBF) governs the activity of the cardiac troponin T gene promoter. M-CAT motifs have also been implicated recently in the regulation of other contractile protein genes which, like cardiac troponin T, do not require direct interaction with MyoD1 or related factors for activity. Mutational analysis of the M-CAT motif revealed that it can be functionally replaced by a regulatory motif of the SV40 enhancer which binds human transcription factor TEF-1. Biochemical analyses show that MCBF from muscle nuclei is indistinguishable from TEF-1 in terms of specificity of binding site recognition, fractionation on DNA-agarose, and apparent molecular weight. In addition, antibodies raised against amino- and carboxyl-terminal regions of human TEF-1 also bind to MCBF from chicken muscle. We conclude, therefore, that MCBF is closely related to TEF-1. Finally, MCBF/TEF-1 is highly enriched in the nuclei of striated muscle, as compared with other tissues, consistent with a role in muscle-specific promoter regulation.	UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ADRIANOPOULOS A, 1991, PLANT CELL, V3, P747, DOI 10.1105/tpc.3.8.747; ANTIN PB, 1991, DEV BIOL, V143, P122, DOI 10.1016/0012-1606(91)90059-C; ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRICHNIK JM, 1986, NUCLEIC ACIDS RES, V14, P1683, DOI 10.1093/nar/14.4.1683; HERRERA VLM, 1990, J BIOL CHEM, V265, P9555; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LALOUX I, 1990, MOL CELL BIOL, V10, P3541, DOI 10.1128/MCB.10.7.3541; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MIRABITO PM, 1989, CELL, V57, P859, DOI 10.1016/0092-8674(89)90800-3; MOHUN TJ, 1989, EMBO J, V8, P1153, DOI 10.1002/j.1460-2075.1989.tb03486.x; NER SS, 1988, DNA-J MOLEC CELL BIO, V7, P127, DOI 10.1089/dna.1988.7.127; NIKOVITS W, 1986, NUCLEIC ACIDS RES, V14, P3377, DOI 10.1093/nar/14.8.3377; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; ORDAHL CP, 1992, CURR TOP DEV BIOL, V26, P145, DOI 10.1016/S0070-2153(08)60444-5; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; Sambrook J, 1989, MOL CLONING LABORATO; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SHIMIZU N, 1992, MOL CELL BIOL, V12, P619, DOI 10.1128/MCB.12.2.619; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; UETSUKI T, 1990, MOL CELL BIOL, V10, P2562, DOI 10.1128/MCB.10.6.2562; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G	34	147	148	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17234	17240						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324927				2022-12-27	WOS:A1992JL05300077
J	NICKELS, JT; BUXEDA, RJ; CARMAN, GM				NICKELS, JT; BUXEDA, RJ; CARMAN, GM			PURIFICATION, CHARACTERIZATION, AND KINETIC-ANALYSIS OF A 55-KDA FORM OF PHOSPHATIDYLINOSITOL 4-KINASE FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; MIXED MICELLES; GEL-ELECTROPHORESIS; CELL-PROLIFERATION; TRITON X-100; PHOSPHATIDATE PHOSPHATASE; MEMBRANE-PROTEINS; ESCHERICHIA-COLI; KINASE; PHOSPHOLIPASE-A2	A 55-kDa form of membrane-associated phosphatidylinositol 4-kinase (ATP:phosphatidylinositol 4-phosphotransferase, EC 2.7.1.67) was purified 10,166-fold from Saccharomyces cerevisiae. The purification procedure included solubilization of microsome membranes with 1% Triton X-100 followed by chromatography with DE52, hydroxylapatite I, Q-Sepharose, Mono Q, and hydroxylapatite II. The procedure resulted in a nearly homogeneous 55-kDa phosphatidylinositol 4-kinase preparation. The 55-kDa phosphatidylinositol 4-kinase and the previously purified 45-kDa phosphatidylinositol 4-kinase differed with respect to their amino acid composition, isoelectric points, and peptide maps. Furthermore, the two forms of phosphatidylinositol 4-kinase did not show an immunological relationship. Maximum 55-kDa phosphatidylinositol 4-kinase activity was dependent on magnesium (10 mM) or manganese (0.5 mM) ions and Triton X-100 at the pH optimum of 7.0. The activation energy for the reaction was 12 kcal/mol, and the enzyme was labile above 30-degrees-C. The enzyme was inhibited by thioreactive agents, MgADP, and calcium ions. A detailed kinetic analysis of the purified enzyme was performed using Triton X-100/phosphatidylinositol-mixed micelles. 55-kDa phosphatidylinositol 4-kinase activity followed saturation kinetics with respect to the bulk and surface concentrations of phosphatidylinositol and followed surface dilution kinetics. The interfacial Michaelis constant (K(m)) and the dissociation constant (K(s)) for phosphatidylinositol in the Triton X-100 micelle surface were 1.3 mol % and 0.035 mM, respectively. The K(m) for MgATP was 0.36 mM. 55-kDa phosphatidylinositol 4-kinase catalyzed a sequential reaction mechanism as indicated by the results of kinetic and isotopic exchange reactions. The enzyme bound to phosphatidylinositol before ATP and released phosphatidylinositol 4-phosphate before ADP. The enzymological and kinetic properties of the 55-kDa phosphatidylinositol 4-kinase differed significantly from those of the 45-kDa phosphatidylinositol 4-kinase. This may suggest that the two forms of phosphatidylinositol 4-kinase from S. cerevisiae are regulated differentially in vivo.	RUTGERS STATE UNIV, COOK COLL, NEW JERSEY AGR EXPT STN, DEPT FOOD SCI, NEW BRUNSWICK, NJ 08903 USA	Rutgers State University New Brunswick					NIGMS NIH HHS [GM-35655] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035655] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES GFL, 1976, BIOCHEMISTRY-US, V15, P616, DOI 10.1021/bi00648a026; BELUNIS CJ, 1988, J BIOL CHEM, V263, P18897; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; CARMAN GM, 1979, J BIOL CHEM, V254, P8391; Cleland W. W, 1970, ENZYMES, V2, P1; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLODZIN M, 1965, J BIOL CHEM, V240, P3771; DAHL C, 1987, P NATL ACAD SCI USA, V84, P4012, DOI 10.1073/pnas.84.12.4012; DAHL JS, 1985, BIOCHEM BIOPH RES CO, V133, P844, DOI 10.1016/0006-291X(85)91211-2; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; Dennis EA, 1983, ENZYMES, P307; DOWHAN W, 1974, J BIOL CHEM, V249, P3079; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; DUBOIS EL, 1978, MOL GEN GENET, V164, P275, DOI 10.1007/BF00333157; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; GREENBERG ML, 1983, J BACTERIOL, V153, P791, DOI 10.1128/JB.153.2.791-799.1983; HAID A, 1983, METHOD ENZYMOL, V96, P192; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5740; HOLLAND KM, 1988, J BACTERIOL, V170, P828, DOI 10.1128/jb.170.2.828-833.1988; JENKINS GH, 1991, BIOCHIM BIOPHYS ACTA, V1080, P11, DOI 10.1016/0167-4838(91)90105-9; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KATO H, 1989, J BIOL CHEM, V264, P3116; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KUCERA GL, 1988, J BIOL CHEM, V263, P12964; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P49; LESTER RL, 1968, J BIOL CHEM, V243, P4889; LIN YP, 1990, J BIOL CHEM, V265, P166; MCKENZIE MA, 1983, J BACTERIOL, V156, P421, DOI 10.1128/JB.156.1.421-423.1983; MCKENZIE MA, 1982, J FOOD BIOCHEM, V6, P77, DOI 10.1111/j.1745-4514.1982.tb00297.x; MCKENZIE MA, 1982, PARTIAL PURIFICATION; MERRIL CR, 1981, ANAL BIOCHEM, V110, P201, DOI 10.1016/0003-2697(81)90136-6; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; PATTON JL, 1992, ARCH BIOCHEM BIOPHYS, V292, P70, DOI 10.1016/0003-9861(92)90052-X; POOLE MA, 1985, J BACTERIOL, V161, P772, DOI 10.1128/JB.161.2.772-774.1985; PORTER FD, 1988, J BIOL CHEM, V263, P8989; ROBERTS MF, 1977, P NATL ACAD SCI USA, V74, P1950, DOI 10.1073/pnas.74.5.1950; SALTIEL AR, 1987, BIOCHEM J, V241, P759, DOI 10.1042/bj2410759; SCHOLZ G, 1991, EUR J BIOCHEM, V201, P249, DOI 10.1111/j.1432-1033.1991.tb16281.x; STEINER S, 1972, J BACTERIOL, V109, P81, DOI 10.1128/JB.109.1.81-88.1972; TALWALKAR RT, 1974, BIOCHIM BIOPHYS ACTA, V360, P306, DOI 10.1016/0005-2760(74)90060-5; UNO I, 1988, NATURE, V333, P188, DOI 10.1038/333188a0; WALKER DH, 1988, BIOCHEMISTRY-US, V27, P6504, DOI 10.1021/bi00417a046; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WETZKER R, 1991, EUR J BIOCHEM, V200, P179, DOI 10.1111/j.1432-1033.1991.tb21065.x; YAMAKAWA A, 1988, J BIOL CHEM, V263, P17555	52	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16297	16304						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322897				2022-12-27	WOS:A1992JJ45800049
J	VOZNESENSKY, AI; SCHENKMAN, JB				VOZNESENSKY, AI; SCHENKMAN, JB			THE CYTOCHROME-P450 2B4-NADPH CYTOCHROME-P450 REDUCTASE ELECTRON-TRANSFER COMPLEX IS NOT FORMED BY CHARGE-PAIRING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; WATER-SOLUBLE CARBODIIMIDE; P-450 REDUCTASE; NADPH-CYTOCHROME-P-450 REDUCTASE; RAT-LIVER; CHEMICAL MODIFICATION; IONIC-STRENGTH; B5; MECHANISM; MEMBRANE	Attempts to covalently link NADPH-cytochrome P450 reductase to cytochrome P450 2B4 using a water-soluble carbodiimide, 1-ethyl-3-(3-dimethylisopropyl)carbodiimide, were unsuccessful, despite the fact that under the same conditions about 30% of P450 2B4 could be covalently linked with cytochrome b5 in a functionally active complex (Tamburini, P. P., and Schenkman, J. B. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 11-15). This suggested that the functional electron transfer complex between P450 2B4 and reductase is not stabilized by electrostatic forces. Raising the ionic strength of the medium is disruptive to salt bridges and was used to further test whether P450 2B4 and the reductase form charge-pairing complexes. Instead of inhibiting electron transfer, high ionic strength increased the apparent fast phase rate constant and the fraction of P450 2B4 reduced in the fast phase. The possibility that electron transfer between NADPH-cytochrome P450 reductase and P450 2B4 is diminished by charge repulsion was examined. Consistent with this hypothesis, the K(m) of P450 2B4 for reductase was decreased 26-fold by increasing the ionic strength from 10 to 100 mM sodium phosphate without affecting the V(max). The rate of benzphetamine N-demethylation also was increased by elevation of the ionic strength. Electron transfer from the reductase to other charged redox acceptors, e.g. cytochrome c and ferricyanide, was also stimulated by increased ionic strength. However, no similar stimulation was observed with the uncharged acceptor 1,4-benzoquinone. Polylysine, a polypeptide that binds to anionic sites, enhanced electron transfer from NADPH to ferricyanide and the apparent fast phase of reduction of cytochrome P450. The results are consistent with the hypothesis that charges on NADPH-cytochrome P450 reductase and cytochrome P450 decrease the stability of the electron transfer complex.	UNIV CONNECTICUT,CTR HLTH,DEPT PHARMACOL,FARMINGTON,CT 06030	University of Connecticut					NIGMS NIH HHS [GM26114] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026114] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKES WL, 1989, J BIOL CHEM, V264, P6252; BACKES WL, 1992, ARCH BIOCHEM BIOPHYS, V293, P231; BERNHARDT R, 1983, BIOCHIM BIOPHYS ACTA, V745, P140, DOI 10.1016/0167-4838(83)90042-0; BERNHARDT R, 1988, BIOMED BIOCHIM ACTA, V47, P581; BILIMORIA MH, 1973, ANN NY ACAD SCI, V212, P428, DOI 10.1111/j.1749-6632.1973.tb47612.x; BLACK SD, 1979, BIOCHEM BIOPH RES CO, V91, P1528, DOI 10.1016/0006-291X(79)91238-5; BLACK SD, 1982, FLAVINS FLAVOPROTEIN, P710; BOSTERLING B, 1982, J BIOL CHEM, V257, P4783; CHEDDAR G, 1990, ARCH BIOCHEM BIOPHYS, V278, P264; DIGNAM JD, 1975, BIOCHEM BIOPH RES CO, V63, P845, DOI 10.1016/0006-291X(75)90644-0; ENOCH HG, 1979, J BIOL CHEM, V254, P8976; FRENCH JS, 1980, J BIOL CHEM, V255, P4112; GEMZIK B, 1990, J STEROID BIOCHEM, V35, P429, DOI 10.1016/0022-4731(90)90251-M; GUM J R, 1979, Journal of Biological Chemistry, V254, P4177; HACKETT CS, 1984, J BIOL CHEM, V259, P3275; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; HAZZARD JT, 1988, BIOCHEMISTRY-US, V27, P2002, DOI 10.1021/bi00406a029; JANSSON I, 1975, MOL PHARMACOL, V11, P450; JANSSON I, 1985, DRUG METAB DISPOS, V13, P453; KOPPENOL WH, 1980, BIOPHYS J, V29, P493, DOI 10.1016/S0006-3495(80)85148-4; KUNZ BC, 1991, BIOCHIM BIOPHYS ACTA, V1063, P226, DOI 10.1016/0005-2736(91)90375-I; KUNZ BC, 1983, FEBS LETT, V161, P311, DOI 10.1016/0014-5793(83)81031-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE R, 1980, EUR J BIOCHEM, V107, P441; MAUK MR, 1989, EUR J BIOCHEM, V186, P473, DOI 10.1111/j.1432-1033.1989.tb15231.x; MEANS GE, 1971, CHEM MODIFICATION PR, P144; NADLER SG, 1988, ARCH BIOCHEM BIOPHYS, V261, P418, DOI 10.1016/0003-9861(88)90358-X; NISIMOTO Y, 1985, ARCH BIOCHEM BIOPHYS, V241, P386, DOI 10.1016/0003-9861(85)90561-2; OMURA T, 1964, J BIOL CHEM, V239, P2379; PHILLIPS AH, 1962, J BIOL CHEM, V237, P2652; RAW I, 1959, J BIOL CHEM, V234, P1867; SCHELLENBERG KA, 1958, J BIOL CHEM, V231, P547; SHIMIZU T, 1991, J BIOL CHEM, V266, P3372; STROBEL HW, 1989, DRUG METAB REV, V20, P519, DOI 10.3109/03602538909103558; TAMBURINI PP, 1986, ARCH BIOCHEM BIOPHYS, V245, P512, DOI 10.1016/0003-9861(86)90244-4; TAMBURINI PP, 1986, MOL PHARMACOL, V30, P178; TAMBURINI PP, 1987, P NATL ACAD SCI USA, V84, P11, DOI 10.1073/pnas.84.1.11; TAMBURINI PP, 1985, J BIOL CHEM, V260, P4007; TAMBURINI PP, 1986, BIOCHEM BIOPH RES CO, V134, P519, DOI 10.1016/S0006-291X(86)80451-X; TAMBURINI PP, 1984, BIOCHEMISTRY-US, V23, P4526, DOI 10.1021/bi00315a004; VERMILION JL, 1978, J BIOL CHEM, V253, P2694	41	66	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14669	14676						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321814				2022-12-27	WOS:A1992JF08800029
J	HAZUDA, DJ; PERRY, HC; MCCLEMENTS, WL				HAZUDA, DJ; PERRY, HC; MCCLEMENTS, WL			COOPERATIVE INTERACTIONS BETWEEN REPLICATION ORIGIN-BOUND MOLECULES OF HERPES-SIMPLEX VIRUS ORIGIN-BINDING PROTEIN ARE MEDIATED VIA THE AMINO TERMINUS OF THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTANTS; VIRAL-DNA REPLICATION; HELICASE-PRIMASE; GENE-PRODUCTS; TYPE-1 ORIGIN; IDENTIFICATION; COMPLEMENTATION; OVEREXPRESSION; SEQUENCE; HSV-1	The virally encoded origin binding protein (OBP) of herpes simplex virus (HSV) is required for viral DNA synthesis. OBP binds at the replication origin to initi-multienzyme replication complex (Challberg, M. D., and Kelly, T. J. (1989) Annu Rev. Biochem. 58, 671-717). OBP binds to two sites at the replication origin. The sequence-specific interaction of OBP with each binding site is localized to the major groove, and in both HSV origins the two interaction surfaces are in phase, aligned on the same face of the helix (Hazuda, D.J., Perry, H. C., Naylor, A. M., and McClements, W. L. (1991) J. Biol. Chem. 261, 24621-24625). Using native gel electrophoresis, we now demonstrate that OBP binding to the origin is highly cooperative and that cooperativity requires the putative NH2-terminal leucine zipper. Neither the phase nor orientation of the binding sites affect cooperativity, suggesting that the interaction promotes wrapping of origin DNA around the OBP multimer. A comparison of OBP DNase I footprints with the DNase I footprints of a truncated protein defective in cooperativity demonstrates that the interaction between OBPs bound at sites I and II affects the conformation of the intervening DNA, particularly when the phase or orientation of the two sites is different from wild type. OBP may elicit a unique nucleoprotein structure which facilitates unwinding of the origin and/or assembly of the replication complex. We also demonstrate that OBP can exchange binding sites, forming interduplex complexes. This property may be important for reinitiation of DNA replication.			HAZUDA, DJ (corresponding author), MERCK SHARP & DOHME LTD,DEPT VIRUS & CELL BIOL,W POINT,PA 19486, USA.							BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; CHALLBERG MD, 1986, P NATL ACAD SCI USA, V83, P9094, DOI 10.1073/pnas.83.23.9094; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DABROWSKI CE, 1991, J VIROL, V65, P3140, DOI 10.1128/JVI.65.6.3140-3150.1991; DEB S, 1989, NUCLEIC ACIDS RES, V17, P2733, DOI 10.1093/nar/17.7.2733; DEB S, 1991, J VIROL, V65, P4359; DODSON MS, 1989, J BIOL CHEM, V264, P20835; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; ELIAS P, 1986, P NATL ACAD SCI USA, V83, P6322, DOI 10.1073/pnas.83.17.6322; ELIAS P, 1990, J BIOL CHEM, V265, P17167; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; HAZUDA DJ, 1991, J BIOL CHEM, V261, P24621; Hochschild A., 1990, DNA TOPOLOGY ITS BIO, P107; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KOFF A, 1988, J VIROL, V62, P4096, DOI 10.1128/JVI.62.11.4096-4103.1988; KOFF A, 1991, J VIROL, V65, P3284, DOI 10.1128/JVI.65.6.3284-3292.1991; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LOCKSHON D, 1988, MOL CELL BIOL, V8, P4018, DOI 10.1128/MCB.8.10.4018; MARCHETTI ME, 1988, J VIROL, V62, P715, DOI 10.1128/JVI.62.3.715-721.1988; MARTIN DW, 1991, J VIROL, V65, P4359, DOI 10.1128/JVI.65.8.4359-4369.1991; MCGEOCH DJ, 1988, J VIROL, V62, P444, DOI 10.1128/JVI.62.2.444-453.1988; OLIVO PD, 1989, J VIROL, V63, P196, DOI 10.1128/JVI.63.1.196-204.1989; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; RHODES D, 1989, PROTEIN FUNCTION PRA, P177; SCHAFFER PA, 1973, VIROLOGY, V52, P57, DOI 10.1016/0042-6822(73)90398-X; STOW ND, 1982, EMBO J, V1, P863, DOI 10.1002/j.1460-2075.1982.tb01261.x; STOW ND, 1985, J GEN VIROL, V66, P31, DOI 10.1099/0022-1317-66-1-31; STOW ND, 1983, VIROLOGY, V130, P427, DOI 10.1016/0042-6822(83)90097-1; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WEIR HM, 1989, NUCLEIC ACIDS RES, V17, P1409, DOI 10.1093/nar/17.4.1409; WEIR HM, 1990, J GEN VIROL, V71, P1379, DOI 10.1099/0022-1317-71-6-1379; WELLER SK, 1985, MOL CELL BIOL, V5, P930, DOI 10.1128/MCB.5.5.930; WELLER SK, 1983, VIROLOGY, V130, P290, DOI 10.1016/0042-6822(83)90084-3; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988	40	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14309	14315						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321142				2022-12-27	WOS:A1992JD32500080
J	SEABRA, MC; GOLDSTEIN, JL; SUDHOF, TC; BROWN, MS				SEABRA, MC; GOLDSTEIN, JL; SUDHOF, TC; BROWN, MS			RAB GERANYLGERANYL TRANSFERASE - A MULTISUBUNIT ENZYME THAT PRENYLATES GTP-BINDING PROTEINS TERMINATING IN CYS-X-CYS OR CYS-CYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SUBUNITS CONTAIN; FARNESYL	Rab proteins are membrane-bound prenylated GTP-binding proteins required for the targeted movement of membrane vesicles from one organelle to another. In the current paper we have characterized and purified an enzyme that attaches geranylgeranyl residues to Rab proteins that bear the COOH-terminal sequence Cys-X-Cys (such as Rab3A) and Cys-Cys (such as Rab1A). This enzyme is designated Rab geranylgeranyl transferase (Rab GG transferase). At high salt concentrations, Rab GG transferase from rat brain cytosol separates into two components, designated A and B, both of which are required for activity. We purified Component B to apparent homogeneity and found that it contains two peptides of 60 and 38 kDa. The purified Rab GG transferase did not attach geranylgeranyl to p21H-ras-CVLL, which is prenylated by a GG transferase of the CAAX type that resembles the CAAX farnesyltransferase. Rab GG transferase was strongly inhibited by Zn2+, a cation that is absolutely required by farnesyltransferase. The Rab GG transferase was also inhibited by NaCl concentrations in excess of 100 mM. Together with previous data, the current findings indicate that mammalian cells possess at least three protein prenyltransferases (CAAX farnesyltransferase, CAAX GG transferase, and Rab GG transferase) that are specific for different classes of low molecular weight GTP-binding proteins and other proteins.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	SEABRA, MC (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.		Seabra, Miguel C/M-3280-2013; Seabra, Miguel/AAC-3099-2019	Seabra, Miguel C/0000-0002-6404-4892; 	NHLBI NIH HHS [HL 20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; GIANNAKOURS TO, 1992, IN PRESS LIPID MODIF; HAUBRUCK H, 1989, EMBO J, V8, P1427, DOI 10.1002/j.1460-2075.1989.tb03524.x; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; JOHNSTON PA, 1991, NEURON, V7, P101, DOI 10.1016/0896-6273(91)90078-E; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KOHL NE, 1991, J BIOL CHEM, V266, P18884; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	26	299	304	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14497	14503						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321151				2022-12-27	WOS:A1992JD32500107
J	URUSHIHARA, H; TOHDA, M; NOMURA, Y				URUSHIHARA, H; TOHDA, M; NOMURA, Y			SELECTIVE POTENTIATION OF N-METHYL-D-ASPARTATE-INDUCED CURRENT BY PROTEIN-KINASE-C IN XENOPUS OOCYTES INJECTED WITH RAT-BRAIN RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LONG-TERM POTENTIATION; AMINO-ACID RECEPTORS; NMDA-RECEPTORS; MESSENGER-RNA; SYNAPTIC TRANSMISSION; CHLORIDE CURRENT; HIPPOCAMPUS; RESPONSES; GLUTAMATE; BINDING	Glutamate receptors and protein kinase C (PKC) may play significant roles in long-term potentiation in hippocampus. To clarify the regulatory involvement of PKC in the functions of glutamate receptors, we examined the effects of PKC activation on current response induced by the activation of each subtype of glutamate receptor in Xenopus oocytes injected with rat brain RNA. Treatment with the PKC activator, 12-O-tetradecanoylphorbol-13-acetate (TPA), potentiated N-methyl-D-aspartate (NMDA)-induced current by about 2.5-fold, although it did not affect kainate-induced current at all. Quisqualate-mediated oscillatory current was almost abolished by this treatment. The TPA-induced potentiation of NMDA current was suppressed by staurosporine, an inhibitor of protein kinases. Pretreatment with 4-O-methyl-TPA, an inactive phorbol ester, had no effect on NMDA current. Current response mediated by NMDA receptors would thus appear to be modulated by PKC.			URUSHIHARA, H (corresponding author), HOKKAIDO UNIV,FAC PHARMACEUT SCI,DEPT PHARMACOL,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN.			Urushihara, Hisashi/0000-0001-6913-9930				AIZENMAN E, 1990, NEURON, V5, P841, DOI 10.1016/0896-6273(90)90343-E; AIZENMAN E, 1989, NEURON, V2, P1257, DOI 10.1016/0896-6273(89)90310-3; AKERS RF, 1986, SCIENCE, V231, P587, DOI 10.1126/science.3003904; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KANEKO S, 1990, CELL CALCIUM, V11, P309, DOI 10.1016/0143-4160(90)90008-I; KITAMURA Y, 1991, Japanese Journal of Pharmacology, V55, p288P; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; LEONARD JP, 1990, NEURON, V4, P53, DOI 10.1016/0896-6273(90)90443-J; LEONARD JP, 1989, SOC NEUR ABSTR; MACDONALD JF, 1989, J PHYSIOL-LONDON, V414, P17, DOI 10.1113/jphysiol.1989.sp017674; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; MALENKA RC, 1989, TRENDS NEUROSCI, V12, P444, DOI 10.1016/0166-2236(89)90094-5; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MULLER D, 1988, P NATL ACAD SCI USA, V85, P9346, DOI 10.1073/pnas.85.23.9346; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; MULLER D, 1990, P NATL ACAD SCI USA, V87, P4073, DOI 10.1073/pnas.87.11.4073; NOMURA Y, 1987, MOL BRAIN RES, V2, P113, DOI 10.1016/0169-328X(87)90004-0; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; Sambrook J, 1989, MOL CLONING LABORATO; SEUBERT P, 1988, BRAIN RES, V460, P189, DOI 10.1016/0006-8993(88)91222-X; SIMAN R, 1985, NATURE, V313, P225, DOI 10.1038/313225a0; SNUTCH TP, 1988, TRENDS NEUROSCI, V11, P250, DOI 10.1016/0166-2236(88)90102-6; TOHDA M, 1989, EUR J PHARMACOL, V166, P57, DOI 10.1016/0014-2999(89)90683-3; TSUJINO T, 1990, J NEUROSCI, V10, P870; VERDOORN TA, 1988, MOL PHARMACOL, V34, P298; WILLIAMS K, 1990, NEURON, V5, P199, DOI 10.1016/0896-6273(90)90309-4	32	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11697	11700						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1318298				2022-12-27	WOS:A1992HY94700010
J	JADOT, M; CANFIELD, WM; GREGORY, W; KORNFELD, S				JADOT, M; CANFIELD, WM; GREGORY, W; KORNFELD, S			CHARACTERIZATION OF THE SIGNAL FOR RAPID INTERNALIZATION OF THE BOVINE MANNOSE 6-PHOSPHATE INSULIN-LIKE GROWTH FACTOR-II RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LYSOSOMAL MEMBRANE GLYCOPROTEIN; CYTOPLASMIC DOMAIN; CELL-SURFACE; ENDOCYTOSIS; IDENTIFICATION; SEQUENCE; PROTEIN; ENZYME; OLIGOSACCHARIDES	The signal for rapid internalization of the mannose 6-phosphate/insulin-like growth factor II receptor has been localized to the sequence Tyr-Lys-Tyr-Ser-Lys-Val in positions 24-29 of its 163-residue cytoplasmic tail. Most of the activity of this signal is mediated by the carboxyl 4 amino acids, especially Tyr26 and Val29 (Canfield, W. M., Johnson, K. F., Ye, R. D., Gregory, W. and Kornfeld, S. (1991) J. Biol. Chem. 266, 5682-5688). In this study, we have tested the effect of a series of mutations on the internalization rate of a mutant receptor that contains a 29-amino acid cytoplasmic tail terminating with the 4-amino acid internalization sequence Tyr-Ser-Lys-Val. Replacement of Tyr26 with Phe or Trp gave rise to mutant receptors that were internalized at 10% the wild-type rate, while receptors with Ala, Leu, Ile, Val, or Asn at this position were totally inactive. Val29 could be replaced by other large hydrophobic residues (Phe, Leu, Ile, or Met) with no loss of activity, but the presence of Ala, Gly, Arg, Gln, or Tyr in this position inactivated the signal. Ser27 could be effectively replaced by many different amino acids, but not by Pro or Gly. However, Gly27 could be tolerated if the residues at positions 28 and 29 were also changed. A change in the 2-residue spacing between Tyr26 and Val29 destroyed the signal. These data show that the essential elements of this signal are an aromatic residue, especially a Tyr in the first position, separated from a large hydrophobic residue in the last position by 2 amino acids. The residues in positions 2 and 3 of the signal may have a modulating effect on its activity. The Tyr-Ser-Lys-Val signal could be moved to a more proximal region of the cytoplasmic tail with only a modest loss of activity. In addition, the signal could be effectively replaced by the putative 4-residue signals of seven other receptors and membrane proteins known to undergo rapid endocytosis, including the Tyr-Thr-Arg-Phe sequence of the transferrin receptor, a Type II membrane protein. These results are compatible with the 4-residue signals of this type being interchangeable, even among Type I and Type II membrane proteins.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,660 S EUCLID AVE,BOX 8125,ST LOUIS,MO 63110	Washington University (WUSTL)					NCI NIH HHS [CA08759] Funding Source: Medline; NHLBI NIH HHS [T32-HLO7088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GIRONES N, 1991, J BIOL CHEM, V266, P19006; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GRANGER BL, 1990, J BIOL CHEM, V265, P12036; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HOFLACK B, 1987, J BIOL CHEM, V262, P123; HOWE CL, 1988, P NATL ACAD SCI USA, V85, P7577, DOI 10.1073/pnas.85.20.7577; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KORNFELD S, 1992, IN PRESS ANN REV BIO; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; PEARSE BMF, 1985, EMBO J, V4, P2457, DOI 10.1002/j.1460-2075.1985.tb03956.x; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAIT JF, 1981, J BIOL CHEM, V256, P1086; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WILLINGHAM MC, 1981, P NATL ACAD SCI-BIOL, V78, P6967, DOI 10.1073/pnas.78.11.6967	30	126	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11069	11077						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317852				2022-12-27	WOS:A1992HX16900024
J	KETCHAM, CM; KORNFELD, S				KETCHAM, CM; KORNFELD, S			CHARACTERIZATION OF UDP-N-ACETYLGLUCOSAMINE-GLYCOPROTEIN N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE FROM ACANTHAMOEBA-CASTELLANII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; DICTYOSTELIUM-DISCOIDEUM; CARBOHYDRATE STRUCTURE; MANNOSE 6-PHOSPHATE; CATHEPSIN-D; PHOSPHORYLATION; UTEROFERRIN; OLIGOSACCHARIDES; PROTEIN; PORCINE	The kinetic properties of UDP-N-acetylglucosamine:glycoprotein N-acetylglucosamine-1-phosphotransferase (GlcNAc-phosphotransferase) partially purified from the soil amoeba Acanthamoeba castellanii have been studied. The transferase phosphorylated the lysosomal enzymes uteroferrin and cathepsin D 3-90-fold better than nonlysosomal glycoproteins and 16-83-fold better than a Man9GlcNAc oligosaccharide. Deglycosylated uteroferrin was a potent competitive inhibitor of the phosphorylation of intact uteroferrin (K(i) of 48-mu-M) but did not inhibit the phosphorylation of RNase B or the simple sugar alpha-methylmannoside. Deglycosylated RNase (RNase A) did not inhibit the phosphorylation of RNase B or uteroferrin. These results indicate that purified amoeba GlcNAc-phosphotransferase recognizes a protein domain present on lysosomal enzymes but absent in most nonlysosomal glycoproteins. The transferase also exhibited a marked preference for oligosaccharides containing mannose alpha-1,2-mannose sequences, but this cannot account for the high affinity binding to lysosomal enzymes. A. castellanii extracts do not contain detectable levels of N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase, the second enzyme in the biosynthetic pathway for the mannose 6-phosphate recognition marker. We conclude that A. castellanii does not utilize the phosphomannosyl sorting pathway despite expression of very high levels of GlcNAc-phosphotransferase.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,660 S EUCLID AVE,BOX 8125,ST LOUIS,MO 63110	Washington University (WUSTL)					NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NCI NIH HHS [CA 08759] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BAUMBACH GA, 1984, P NATL ACAD SCI-BIOL, V81, P2985, DOI 10.1073/pnas.81.10.2985; COUSO R, 1986, J BIOL CHEM, V261, P6326; DORLAND L, 1981, J BIOL CHEM, V256, P7708; GORDON JA, 1972, METHOD ENZYMOL, V28, P365; KETCHAM CM, 1992, J BIOL CHEM, V267, P11645; LANG L, 1986, J BIOL CHEM, V261, P6320; LANG L, 1984, J BIOL CHEM, V259, P4663; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADIYALAKAN R, 1986, CARBOHYD RES, V152, P183, DOI 10.1016/S0008-6215(00)90298-2; ROBERTS RM, 1984, BIOESSAYS, V1, P8, DOI 10.1002/bies.950010106; SAUNDERS PTK, 1985, J BIOL CHEM, V260, P3658; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SHARKEY DJ, 1989, J BIOL CHEM, V264, P10411; TAKAHASHI T, 1981, METHOD ENZYMOL, V80, P565; TAKAHASHI T, 1983, J BIOL CHEM, V258, P2819; TONG PY, 1989, J BIOL CHEM, V264, P7962; VARKI A, 1981, J BIOL CHEM, V256, P9937	18	18	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11654	11659						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317874				2022-12-27	WOS:A1992HX16900109
J	KANAYA, S; ITAYA, M				KANAYA, S; ITAYA, M			EXPRESSION, PURIFICATION, AND CHARACTERIZATION OF A RECOMBINANT RIBONUCLEASE-H FROM THERMUS-THERMOPHILUS HB8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCED PROTEIN THERMOSTABILITY; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; SECONDARY STRUCTURE; ENZYMATIC CLEAVAGE; CYTOCHROME C-552; GENE; RNA; STABILITY; RESIDUES	Thermus thermophilus ribonuclease H was overexpressed and purified from Escherichia coli. The determination of the complete amino acid sequence allowed modification of that predicted from the DNA sequence, and the enzyme was shown to be composed of 166 amino acid residues with a molecular weight of 18,279. The isoelectric point of the enzyme was 10.5, and the specific absorption coefficient A280(0.1%) was 1.69. The enzymatic and physicochemical properties as well as the thermal and conformational stabilities of the enzyme were compared with those of E. coli RNase HI, which shows 52% amino acid sequence identity. Comparison of the far and near UV circular dichroism spectra suggests that the two enzymes are similar in the main chain folding but different in the spatial environments of tyrosine and tryptophan residues. The enzymatic activities of T. thermophilus RNase H at 37 and 70-degrees-C for the hydrolysis of either an M13 DNA/RNA hybrid or a nonanucleotide duplex were approximately 5-fold lower and 3-fold higher, respectively, as compared with E. coli RNase HI at 37-degrees-C. The melting temperature, T(m), of T. thermophilus RNase H was 82.1-degrees-C in the presence of 1.2 M guanidine hydrochloride, which was 33.9-degrees-C higher than that observed for E. coli RNase HI. The free energy changes of unfolding in the absence of denaturant, DELTA-G[H2O], of T. thermophilus RNase H increased by 11.79 kcal/mol at 25-degrees-C and 14.07 kcal/mol at 50-degrees-C, as compared with E. coli RNase HI.	MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN		KANAYA, S (corresponding author), PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN.							ARAI H, 1990, FEBS LETT, V261, P196, DOI 10.1016/0014-5793(90)80669-A; ARGOS P, 1979, BIOCHEMISTRY-US, V18, P5698, DOI 10.1021/bi00592a028; ATABEKOV KJ, 1988, FEBS LETT, V232, P96, DOI 10.1016/0014-5793(88)80393-4; BIRO J, 1990, FEBS LETT, V275, P130, DOI 10.1016/0014-5793(90)81456-X; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P863; CARUTHERS MH, 1985, SCIENCE, V230, P281, DOI 10.1126/science.3863253; CROUCH R J, 1990, New Biologist, V2, P771; Crouch R. J., 1982, NUCLEASES, P211; CROUCH RJ, 1981, GENE AMPLIFICATION A, V2, P218; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P7142, DOI 10.1021/bi00243a015; DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAYASE Y, 1990, BIOCHEMISTRY-US, V29, P8793, DOI 10.1021/bi00489a041; ITAYA M, 1991, NUCLEIC ACIDS RES, V19, P4443, DOI 10.1093/nar/19.16.4443; ITAYA M, 1991, MOL GEN GENET, V227, P438, DOI 10.1007/BF00273935; ITAYA M, 1990, P NATL ACAD SCI USA, V87, P8587, DOI 10.1073/pnas.87.21.8587; ITAYA M, 1991, MOL GEN GENET, V227, P424, DOI 10.1007/BF00273933; ITAYA M, 1991, MOL GEN GENET, V227, P433, DOI 10.1007/BF00273934; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KANAYA S, 1989, J BIOL CHEM, V264, P11546; KANAYA S, 1983, J BIOL CHEM, V258, P1276; KANAYA S, 1991, J BIOL CHEM, V266, P6038; KANAYA S, 1991, EUR J BIOCHEM, V198, P437, DOI 10.1111/j.1432-1033.1991.tb16033.x; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KATAYANAGI K, 1982, IN PRESS J MOL BIOL; KNAPP JA, 1974, BIOCHEMISTRY-US, V13, P1289, DOI 10.1021/bi00703a036; KUROKI R, 1989, P NATL ACAD SCI USA, V86, P6903, DOI 10.1073/pnas.86.18.6903; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MENDENDEZARIAS L, 1989, J MOL BIOL, V206, P397; Miller J. H., 1972, EXPT MOL GENETICS, P433; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; NICHOLSON H, 1988, NATURE, V336, P651, DOI 10.1038/336651a0; NOJIMA H, 1978, J MOL BIOL, V122, P33, DOI 10.1016/0022-2836(78)90106-7; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; OSHIMA T, 1986, PROTEIN ENG APPLICAT, P81; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; PAKULA AA, 1990, NATURE, V344, P363, DOI 10.1038/344363a0; PERRY LJ, 1984, SCIENCE, V226, P555, DOI 10.1126/science.6387910; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; SANBONGI Y, 1989, BIOCHEMISTRY-US, V28, P9574, DOI 10.1021/bi00451a004; SANBONGI Y, 1991, EUR J BIOCHEM, V198, P7, DOI 10.1111/j.1432-1033.1991.tb15979.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SHIBAHARA S, 1987, NUCLEIC ACIDS RES, V15, P4403, DOI 10.1093/nar/15.11.4403; SUZUKI Y, 1989, J BIOL CHEM, V264, P18933; Vesterberg O., 1971, METHODS ENZYMOLOGY, V22, P389; YAMAZAKI T, 1991, BIOCHEMISTRY-US, V30, P6036, DOI 10.1021/bi00238a030; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; YUTANI K, 1987, P NATL ACAD SCI USA, V84, P4441, DOI 10.1073/pnas.84.13.4441; ZULLI F, 1990, BIOL CHEM H-S, V371, P655, DOI 10.1515/bchm3.1990.371.2.655; ZULLI F, 1991, BIOL CHEM H-S, V372, P363, DOI 10.1515/bchm3.1991.372.1.363	58	72	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10184	10192						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315754				2022-12-27	WOS:A1992HT96500110
J	ROTIN, D; HONEGGER, AM; MARGOLIS, BL; ULLRICH, A; SCHLESSINGER, J				ROTIN, D; HONEGGER, AM; MARGOLIS, BL; ULLRICH, A; SCHLESSINGER, J			PRESENCE OF SH2 DOMAINS OF PHOSPHOLIPASE-C-GAMMA-1 ENHANCES SUBSTRATE PHOSPHORYLATION BY INCREASING THE AFFINITY TOWARD THE EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; C-GAMMA; SELF-PHOSPHORYLATION; SIGNAL TRANSDUCTION; BINDING; CLONING; GAP; SRC; AUTOPHOSPHORYLATION; SIMILARITY	src homology region 2 and 3 (SH2 and SH3) domains are conserved noncatalytic regions originally described in cytoplasmic tyrosine kinases and subsequently identified in phospholipase C(gamma-1) (PLC(gamma-1)), GTPase-activating protein of ras, and other signaling proteins. Although numerous studies indicate that SH2 domains promote protein-protein interactions by specific binding to tyrosine phosphorylated proteins, the function of SH3 domains is not known. The SH2 domain of PLC(gamma-1) binds to certain tyrosine-phosphorylated growth factor receptors, and following phosphorylation on Tyr783 the enzymatic activity of PLC(gamma-1) is enhanced, leading to phosphatidylinositol hydrolysis. To determine the functional role of the SH2 domain(s) on substrate phosphorylation in quantitative terms, we have expressed in Escherichia coli PLC(gamma-1) constructs encoding the region containing Tyr783 and Tyr771, their two flanking SH2 domains and the SH3 domain, and five different deletion mutants of this region. These six proteins were purified and subjected to quantitative phosphorylation by the epidermal growth factor receptor (EGFR). Analysis of the kinetics of substrate phosphorylation revealed similar V(max) for the phosphorylation of the various mutant proteins. However, the affinity was enhanced for substrates containing SH2 domains: from S0.5 (average apparent K(m)) of 110-mu-M to S0.5 of 20-mu-M with the addition of a single SH2 domain and S0.5 of 3-4-mu-M for mutants containing two SH2 domains. The presence of the SH3 domain did not influence the apparent K(m) of substrate phosphorylation. These results demonstrate that the presence of the SH2 domain in PLC(gamma-1) lowers the apparent K(m) (increases the affinity) of substrate phosphorylation by the EGFR, thereby facilitating PLC(gamma-1) phosphorylation and activation.	NYU MED CTR,DEPT PHARMACOL,550 1ST AVE,NEW YORK,NY 10016; MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,W-8033 MARTINSRIED,GERMANY	New York University; Max Planck Society				Honegger, Annemarie/0000-0002-3378-3967				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1990, J BIOL CHEM, V265, P3940; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEINSENHELDER J, 1989, CELL, V57, P1109; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WALTON GM, 1990, J BIOL CHEM, V265, P1750	34	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9678	9683						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315766				2022-12-27	WOS:A1992HT96500036
J	UHLER, MD; ABOUCHEBL, A				UHLER, MD; ABOUCHEBL, A			CELLULAR CONCENTRATIONS OF PROTEIN KINASE-A MODULATE PROSTAGLANDIN AND CAMP INDUCTION OF ALKALINE-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE L-CELLS; I REGULATORY SUBUNIT; CATALYTIC SUBUNIT; MEDIATED INDUCTION; GENE; LIVER; EXPRESSION; ISOFORMS; ENZYMES; KIDNEY	The relationship between the concentration of cAMP-dependent protein kinase (PKA) activity and the induction of alkaline phosphatase (AP) was examined in transfected L cell lines with altered PKA levels. C-alpha-12 cells were generated by transfecting mouse L cells with an expression vector coding for the mouse C-alpha-catalytic subunit of PKA and were shown to contain 2.5-fold more PKA activity than L cells. RAB10 cells were generated by transfection with an expression vector for a mutant regulatory subunit and had 10-fold lower levels of PKA activity than L cells. AP induction by 8-chlorophenylthio-cAMP (CPT-cAMP) was found to be 2-fold greater in C-alpha-12 cells than in L cells, while RAB10 cells lacked any induction of AP in response to CPT-cAMP. Northern blot and solution hybridization analyses of AP mRNA showed that induced AP mRNA levels were comparable in C-alpha-12 and in L cells. Western blot analysis demonstrated that AP protein levels were greater in C-alpha-12 cells and suggested that the increased AP protein level resulted from either increased stability of the AP protein or increased rate of translation of the AP mRNA. In contrast, Northern blot analysis of the RAB10 cells failed to detect AP mRNA after CPT-cAMP treatment and suggested that PKA is required for induction of AP mRNA. Stimulation of endogenous cAMP levels by treatment with prostaglandin E1 gave similar effects on AP activity as those seen with CPT-cAMP. These results indicate that cellular levels of PKA can determine the magnitude of cellular response to hormonal stimulation and also suggest that PKA can regulate AP gene expression at both the level of the AP mRNA and AP protein.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	UHLER, MD (corresponding author), UNIV MICHIGAN,MENTAL HLTH RES INST,205 ZINA PITCHER PL,ANN ARBOR,MI 48109, USA.				NIGMS NIH HHS [GM-38788] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038788, R01GM038788] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEEBE SJ, 1986, ENZYMES, V17, P44; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; Brown DA, 1990, CURR OPIN CELL BIOL, V2, P221, DOI 10.1016/0955-0674(90)90010-C; BROWN NA, 1990, J BIOL CHEM, V265, P13181; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; DAIRIKI K, 1989, IMMUNOGENETICS, V29, P235, DOI 10.1007/BF00717907; EHRLICHMAN J, 1984, J BIOL CHEM, V259, P10289; FIRESTONE GL, 1981, J BIOL CHEM, V256, P1404; FIRESTONE GL, 1981, J BIOL CHEM, V256, P1396; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GREEN WN, 1991, P NATL ACAD SCI USA, V88, P854, DOI 10.1073/pnas.88.3.854; GUM JR, 1983, P NATL ACAD SCI-BIOL, V80, P3918, DOI 10.1073/pnas.80.13.3918; HAWRYLAK K, 1987, FEBS LETT, V212, P289, DOI 10.1016/0014-5793(87)81362-5; HOFMANN F, 1977, J BIOL CHEM, V252, P1441; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; KOYAMA H, 1972, BIOCHEM BIOPH RES CO, V46, P305, DOI 10.1016/0006-291X(72)90663-8; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGANIELLO V, 1972, P NATL ACAD SCI USA, V69, P269, DOI 10.1073/pnas.69.1.269; MCKNIGHT GS, 1988, METHOD ENZYMOL, V159, P299; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; MUALLEM S, 1989, BIOCHEM J, V263, P769, DOI 10.1042/bj2630769; NEBES VL, 1988, BIOCHEM J, V255, P741; NODA M, 1990, ENDOCRINOLOGY, V127, P185, DOI 10.1210/endo-127-1-185; NOSE K, 1974, EXP CELL RES, V87, P8, DOI 10.1016/0014-4827(74)90520-5; OLSEN SR, 1989, J BIOL CHEM, V264, P18662; OLSEN SR, 1991, J BIOL CHEM, V266, P11158; SCHECTERSON LC, 1991, MOL ENDOCRINOL, V5, P170, DOI 10.1210/mend-5-2-170; TAYLOR SS, 1988, FASEB J, V2, P2677, DOI 10.1096/fasebj.2.11.3294077; TOH Y, 1989, EUR J BIOCHEM, V182, P231, DOI 10.1111/j.1432-1033.1989.tb14822.x; UHLER MD, 1986, J BIOL CHEM, V261, P5360; UHLER MD, 1987, J BIOL CHEM, V262, P15202; WANG HY, 1990, MOL ENDOCRINOL, V4, P80, DOI 10.1210/mend-4-1-80; YEE GM, 1991, BIOL REPROD, V45, P163, DOI 10.1095/biolreprod45.1.163	37	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8658	8665						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314834				2022-12-27	WOS:A1992HQ18500104
J	THEODOROU, ME; CORNEL, FA; DUFF, SMG; PLAXTON, WC				THEODOROU, ME; CORNEL, FA; DUFF, SMG; PLAXTON, WC			PHOSPHATE STARVATION-INDUCIBLE SYNTHESIS OF THE ALPHA-SUBUNIT OF THE PYROPHOSPHATE-DEPENDENT PHOSPHOFRUCTOKINASE IN BLACK MUSTARD SUSPENSION CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUCTOSE-6-PHOSPHATE PHOSPHOTRANSFERASE; FRUCTOSE 2,6-BISPHOSPHATE; PYROPHOSPHATE-FRUCTOSE-6-PHOSPHATE PHOSPHOTRANSFERASE; CHENOPODIUM-RUBRUM; GLYCOLYTIC ENZYME; POTATO-TUBERS; 1-PHOSPHOTRANSFERASE; TISSUES; FRUCTOSE-2,6-BISPHOSPHATE; PURIFICATION	PP(i)-dependent phosphofructokinase (PFP) activity, measured in the forward direction, increased approximately 19-fold when suspension cell cultures of black mustard (Brassica nigra) were subjected to 18 days of P(i) deprivation. Fructose 2,6-bisphosphate (2 muM) elicited a 10-fold activation of PFP from P(i)-deficient cells, compared to only a 2-fold activation of the enzyme from nutrient-sufficient cells. Also, PFP from P(i)-starved cells exhibited a greater affinity for the activator (K(a) = 0.09 muM) than the enzyme from nutrient-sufficient cells (K(a) = 0.32 muM). Western blots of extracts from P(i)-deficient cells were probed with rabbit anti-(potato tuber PFP) immune serum and revealed equal intensity staining immunoreactive polypeptides of M(r) 66,000 (alpha-subunit) and 60,000 (beta-subunit) that co-migrated with the alpha- and beta-subunits of homogeneous potato tuber PFP. By contrast, only the M(r) 60,000 beta-subunit was observed on immunoblots of extracts prepared from nutrient-sufficient cells. Quantification of immunoblots indicated that in black mustard cells experiencing transition from P(i) sufficiency to deficiency or vice versa, the relative amount of immunoreactive alpha-subunit correlated with the degree of activation of PFP by fructose 2,6-bisphosphate. These observations provide additional evidence that (i) plant PFP is an adaptive enzyme that may function in glycolysis during P(i) deprivation, and (ii) the alpha-subunit acts as a regulatory protein in controlling the catalytic activity of the beta-subunit and its regulation by fructose 2,6-bisphosphate.	QUEENS UNIV,DEPT BIOL,KINGSTON K7L 3N6,ONTARIO,CANADA; QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA	Queens University - Canada; Queens University - Canada			Plaxton, William C/O-3353-2013	Plaxton, William C/0000-0002-8447-7249				APREES T, 1985, BIOCHEM J, V227, P299, DOI 10.1042/bj2270299; APREES T, 1985, CARBOHYDRATE PARTITI, P129; BLACK CC, 1987, PHYSIOL PLANTARUM, V69, P387, DOI 10.1111/j.1399-3054.1987.tb04305.x; BOTHA AM, 1990, PLANT PHYSIOL, V93, P683, DOI 10.1104/pp.93.2.683; BOTHA AM, 1991, PLANT CELL PHYSIOL, V32, P1299; BOTHA AM, 1991, PLANT PHYSIOL, V96, P1185, DOI 10.1104/pp.96.4.1185; BOTHA FC, 1988, PLANT CELL PHYSIOL, V29, P223; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLISLE SM, 1990, J BIOL CHEM, V265, P18366; CHENG HF, 1990, J BIOL CHEM, V265, P2173; DANCER JE, 1989, J PLANT PHYSIOL, V135, P197, DOI 10.1016/S0176-1617(89)80177-4; DOUCET JP, 1988, ANAL BIOCHEM, V168, P265, DOI 10.1016/0003-2697(88)90317-X; DUFF SMG, 1991, P NATL ACAD SCI USA, V88, P9538, DOI 10.1073/pnas.88.21.9538; DUFF SMG, 1989, PLANT PHYSIOL, V90, P734, DOI 10.1104/pp.90.2.734; DUFF SMG, 1989, PLANT PHYSIOL, V90, P1275, DOI 10.1104/pp.90.4.1275; EDWARDS J, 1986, PHYTOCHEMISTRY, V25, P2033, DOI 10.1016/0031-9422(86)80062-0; FAHRENDORF T, 1987, PLANT PHYSIOL, V84, P182, DOI 10.1104/pp.84.1.182; GOLDSTEIN AH, 1989, PLANT MOL BIOL REP, V7, P7; HAJIREZAEI M, 1991, PLANT SCI, V77, P177, DOI 10.1016/0168-9452(91)90086-N; HATZFELD WD, 1990, PLANTA, V180, P198, DOI 10.1007/BF00193996; HATZFELD WD, 1990, PLANTA, V180, P205, DOI 10.1007/BF00193997; HATZFELD WD, 1989, FEBS LETT, V254, P215, DOI 10.1016/0014-5793(89)81042-7; HUBER SC, 1986, PLANT PHYSIOL, V81, P1008, DOI 10.1104/pp.81.4.1008; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; KRUGER NJ, 1987, ARCH BIOCHEM BIOPHYS, V256, P273, DOI 10.1016/0003-9861(87)90446-2; LEFEBVRE DD, 1990, PLANT PHYSL BETHESDA, V93, P505; MAHAJAN R, 1989, PLANT PHYSIOL, V91, P421, DOI 10.1104/pp.91.1.421; MERTENS E, 1991, FEBS LETT, V285, P1, DOI 10.1016/0014-5793(91)80711-B; Moorhead G B, 1991, Protein Expr Purif, V2, P29, DOI 10.1016/1046-5928(91)90005-4; MOORHEAD GBG, 1990, BIOCHEM J, V269, P133, DOI 10.1042/bj2690133; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; PILKIS SJ, 1990, DIABETES CARE, V13, P582, DOI 10.2337/diacare.13.6.582; STITT M, 1989, PLANT PHYSIOL, V89, P628, DOI 10.1104/pp.89.2.628; STITT M, 1990, ANNU REV PLANT PHYS, V41, P153, DOI 10.1146/annurev.pp.41.060190.001101; VANSCHAFTINGEN E, 1987, ADV ENZYMOL RAMB, V59, P315; WEINER H, 1987, BIOCHIM BIOPHYS ACTA, V893, P13, DOI 10.1016/0005-2728(87)90143-5; WONG JH, 1990, PLANT PHYSIOL, V94, P499, DOI 10.1104/pp.94.2.499; WU FS, 1984, ANAL BIOCHEM, V139, P100, DOI 10.1016/0003-2697(84)90394-4; XU DP, 1989, PLANT PHYSIOL, V90, P635, DOI 10.1104/pp.90.2.635; YAN TFJ, 1984, J BIOL CHEM, V259, P5087	40	67	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21901	21905						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328248				2022-12-27	WOS:A1992JV01100098
J	HUNG, DT; WONG, YH; VU, TKH; COUGHLIN, SR				HUNG, DT; WONG, YH; VU, TKH; COUGHLIN, SR			THE CLONED PLATELET THROMBIN RECEPTOR COUPLES TO AT LEAST 2 DISTINCT EFFECTORS TO STIMULATE PHOSPHOINOSITIDE HYDROLYSIS AND INHIBIT ADENYLYL CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; HAMSTER FIBROBLASTS; BINDING PROTEIN; ACTIVATION; MOBILIZATION; ACCUMULATION; CLONING; CELLS; GI	Thrombin both stimulates phosphoinositide hydrolysis and inhibits adenylyl cyclase in a variety of cell types. Whether the cloned human platelet thrombin receptor accounts for both of these signaling events is unknown. We report that thrombin receptor agonist peptide causes both phosphoinositide hydrolysis and inhibition of adenylyl cyclase in naturally thrombin-responsive CCL-39 cells. To exclude the possibility that the agonist peptide or thrombin itself may activate these pathways via distinct receptors and to circumvent a lack of suitable thrombin receptor-null cells, we utilized a designed "enterokinase receptor," a thrombin receptor with its thrombin cleavage recognition sequence LDPR replaced by DDDDK, the enterokinase cleavage recognition sequence. Transfection of enterokinase-unresponsive cells with this construct conferred both enterokinase-sensitive phosphoinositide hydrolysis and inhibition of adenylyl cyclase. The phosphoinositide hydrolysis response was largely insensitive to pertussis toxin, whereas the adenylyl cyclase response was completely blocked by pertussis toxin. These data show that the cloned thrombin receptor can effect both phosphoinositide hydrolysis and inhibition of adenylyl cyclase via at least two distinct effectors, most likely G(q)-like and G(i)-like G-proteins.	UNIV CALIF SAN FRANCISCO, DEPT LAB MED, BOX 0524, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL44907, HL0248-01] Funding Source: Medline; NIGMS NIH HHS [GM27800] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027800, R01GM027800] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BRASS LF, 1991, J BIOL CHEM, V266, P958; BRASS LF, 1986, J BIOL CHEM, V261, P6838; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; CROUCH MF, 1988, J BIOL CHEM, V263, P3363; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; HUANG RS, 1991, J BIOL CHEM, V266, P18435; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; JONES LG, 1989, MOL PHARMACOL, V36, P142; KROLL MH, 1989, BLOOD, V74, P1181; LIU LW, 1991, J BIOL CHEM, V266, P16977; MAGNALDO I, 1988, BIOCHEM J, V253, P711, DOI 10.1042/bj2530711; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	22	247	254	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20831	20834						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328213				2022-12-27	WOS:A1992JT97800051
J	AMLAIKY, N; RAMBOZ, S; BOSCHERT, U; PLASSAT, JL; HEN, R				AMLAIKY, N; RAMBOZ, S; BOSCHERT, U; PLASSAT, JL; HEN, R			ISOLATION OF A MOUSE 5HT1E-LIKE SEROTONIN RECEPTOR EXPRESSED PREDOMINANTLY IN HIPPOCAMPUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITES; NEURONS; PROTEIN; BRAIN	Using a strategy based on amino acid sequence homology between 5-hydroxytryptamine (5-HT) receptors that interact with G proteins, we have isolated from a mouse brain library a cDNA encoding a new serotonin receptor, the 5HT1Ebeta receptor. Amino acid sequence comparisons revealed that its closest relatives were the recently characterized 5HT1E receptor (S31) and the 5HT1B and 5HT1D receptors. When expressed transiently in Cos-7 cells, the 5HT1Ebeta receptor displayed a high affinity for the nonspecific serotonergic radioligand 2-[I-125]iodolysergic acid diethylamide (K(d) = 980 pM). The pharmacological profile of the 5HT1Ebeta receptor resembled that of previously reported 5HT1E sites that have a low affinity for 5-carboxamidotryptamine and that have been found in human and rat brain. When stably expressed in NIH-3T3 cells, the 5HT1Ebeta receptor was negatively coupled to adenylate cyclase. In situ hybridization experiments revealed that the 5HT1Ebeta transcripts were detected only in the CA1, CA2, and CA3 layers of the hippocampus. Our results therefore demonstrate that the 5HT1E receptors constitute a heterogeneous family of receptors.	FAC MED STRASBOURG,GENET MOLEC EUCARYOTES LAB,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ASARCH KB, 1985, LIFE SCI, V36, P1265, DOI 10.1016/0024-3205(85)90271-1; BEER MS, 1992, EUR J PHARMACOL, V213, P193, DOI 10.1016/0014-2999(92)90681-S; COLINO A, 1987, NATURE, V328, P73, DOI 10.1038/328073a0; CONN PJ, 1985, J PHARMACOL EXP THER, V234, P15; DELEAN A, 1982, MOL PHARMACOL, V22, P290; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAFEN E, 1983, EMBO J, V2, P617, DOI 10.1002/j.1460-2075.1983.tb01472.x; HAMBLIN MW, 1991, MOL PHARMACOL, V40, P143; HARTIG PR, 1992, TRENDS PHARMACOL SCI, V13, P152, DOI 10.1016/0165-6147(92)90053-9; HEN R, 1992, TRENDS PHARMACOL SCI, V13, P160, DOI 10.1016/0165-6147(92)90054-A; HEURING RE, 1986, EUR J PHARMACOL, V122, P279, DOI 10.1016/0014-2999(86)90114-7; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; JULIUS D, 1991, ANNU REV NEUROSCI, V14, P335, DOI 10.1146/annurev.neuro.14.1.335; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; LEONHARDT S, 1989, J NEUROCHEM, V53, P465, DOI 10.1111/j.1471-4159.1989.tb07357.x; LEVY FO, 1992, FEBS LETT, V296, P201, DOI 10.1016/0014-5793(92)80379-U; MAHLE CD, 1991, EUR J PHARMACOL, V205, P323, DOI 10.1016/0014-2999(91)90919-H; MAROTEAUX L, 1992, P NATL ACAD SCI USA, V89, P3020, DOI 10.1073/pnas.89.7.3020; MCALLISTER G, 1992, P NATL ACAD SCI USA, V89, P5517, DOI 10.1073/pnas.89.12.5517; MILLER KJ, 1992, NEUROSCI LETT, V136, P223, DOI 10.1016/0304-3940(92)90054-B; Peroutka S. J., 1991, SEROTONIN RECEPTOR S, P65; PEROUTKA SJ, 1991, BRAIN RES, V553, P206, DOI 10.1016/0006-8993(91)90826-H; PRITCHETT DB, 1988, EMBO J, V7, P4135, DOI 10.1002/j.1460-2075.1988.tb03308.x; SAUDOU F, 1992, EMBO J, V11, P7, DOI 10.1002/j.1460-2075.1992.tb05021.x; SUMNER MJ, 1989, BRIT J PHARMACOL, V98, P29, DOI 10.1111/j.1476-5381.1989.tb16856.x; WAEBER C, 1990, NEUROCHEM RES, V15, P567, DOI 10.1007/BF00973745; WEISBERG E, 1992, DRUG DEVELOP RES, V26, P225, DOI 10.1002/ddr.430260303; Wilkinson LO, 1991, SEROTONIN RECEPTOR S, P147; YAKEL JL, 1988, J NEUROSCI, V8, P1273	30	88	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19761	19764						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328180				2022-12-27	WOS:A1992JR85800003
J	DESBARATS, L; LAM, TY; WONG, LM; SIU, CH				DESBARATS, L; LAM, TY; WONG, LM; SIU, CH			IDENTIFICATION OF A UNIQUE CAMP-RESPONSE ELEMENT IN THE GENE ENCODING THE CELL-ADHESION MOLECULE GP80 IN DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION PATHWAYS; ALPHA PROTEIN SUBUNITS; SITE-A GLYCOPROTEIN; CYCLIC-AMP; MULTICELLULAR DEVELOPMENT; MONOCLONAL-ANTIBODIES; AGGREGATION STAGE; SEQUENCE ELEMENT; INDUCIBLE GENE; ACTIN GENE	Extracellular cAMP serves as a chemoattractant as well as a signal which regulates gene expression during development of Dictyostelium discoideum. The cell adhesion molecule gp80 is expressed at the aggregation stage, between 6 and 10 h of development, and is known to be under cAMP regulation. Transcription of the gp80 gene is first turned on at a low, basal level at the preaggregation stage and is then greatly augmented by pulses of low levels of cAMP at the aggregation stage. Using cloned cDNA sequences, we have isolated genomic DNA fragments encompassing the gp80 gene. The gp80 gene has a single open reading frame, with multiple transcription start sites located downstream from a putative TATA box. Several short, repeated sequences in the upstream sequence have also been identified. The cloned 1.3-kilobase upstream DNA was sufficient to confer proper temporal and cAMP regulation on a gp80 minigene reporter in Dictyostelium cells. Deletional analysis of this 5'-flanking DNA led to the mapping of a cAMP-response element (CRE) in the gp80 gene to sequences between -306 and -289 base pairs upstream of the translational start site. Present within this region is a sequence we refer to as box 1 (TGGTGTG). The gp80 box 1-CRE binds specifically to a protein present in nuclear extracts, but binding is abolished when mutations are introduced in the box 1 sequence. The gp80 box 1-CRE shows little sequence homology to CREs of late developmental genes and the expression of gp80 may involve a distinct signal transduction pathway.	UNIV TORONTO,CHARLES H BEST INST,DEPT BIOCHEM,112 COLL ST,TORONTO M5G 1L6,ONTARIO,CANADA; UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto; University of Toronto								BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRODIE C, 1983, CELL, V32, P1115, DOI 10.1016/0092-8674(83)90295-7; CHOI AHC, 1987, J CELL BIOL, V104, P1375, DOI 10.1083/jcb.104.5.1375; COCUCCI SM, 1970, J CELL BIOL, V45, P399, DOI 10.1083/jcb.45.2.399; COFFMAN DS, 1982, DEV BIOL, V93, P422, DOI 10.1016/0012-1606(82)90129-4; COHEN SM, 1986, EMBO J, V5, P3361, DOI 10.1002/j.1460-2075.1986.tb04651.x; DATTA S, 1987, MOL CELL BIOL, V7, P149, DOI 10.1128/MCB.7.1.149; DRISCOLL DM, 1988, DEV GENET, V9, P455, DOI 10.1002/dvg.1020090423; EARLY AE, 1987, GENE, V59, P99, DOI 10.1016/0378-1119(87)90270-8; EARLY AE, 1989, NUCLEIC ACIDS RES, V17, P6473; FIRTEL RA, 1991, TRENDS GENET, V7, P381, DOI 10.1016/0168-9525(91)90260-W; FIRTEL RA, 1989, CELL, V58, P235, DOI 10.1016/0092-8674(89)90837-4; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P3047; HADWIGER JA, 1991, P NATL ACAD SCI USA, V88, P8213, DOI 10.1073/pnas.88.18.8213; HARIBABU B, 1986, MOL CELL BIOL, V6, P2402, DOI 10.1128/MCB.6.7.2402; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HJORTH A, 1988, DEV GENET, V9, P435, DOI 10.1002/dvg.1020090422; HJORTH AL, 1989, GENE DEV, V3, P747, DOI 10.1101/gad.3.6.747; HJORTH AL, 1990, GENE DEV, V4, P419, DOI 10.1101/gad.4.3.419; KAMBOJ RK, 1988, BIOCHIM BIOPHYS ACTA, V951, P78, DOI 10.1016/0167-4781(88)90027-9; KAMBOJ RK, 1988, J CELL BIOL, V107, P1835, DOI 10.1083/jcb.107.5.1835; KIMMEL AR, 1983, NUCLEIC ACIDS RES, V11, P541, DOI 10.1093/nar/11.2.541; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; LAM TY, 1981, DEV BIOL, V83, P127, DOI 10.1016/S0012-1606(81)80015-2; Loomis WF., 1975, DICTYOSTELIUM DISCOI; MA PCC, 1990, MOL CELL BIOL, V10, P3297, DOI 10.1128/MCB.10.7.3297; Maniatis T., 1982, MOL CLONING; MANN SKO, 1989, P NATL ACAD SCI USA, V86, P1924, DOI 10.1073/pnas.86.6.1924; MANN SKO, 1988, DEV BIOL, V130, P294, DOI 10.1016/0012-1606(88)90435-6; MAY T, 1989, MOL CELL BIOL, V9, P4653, DOI 10.1128/MCB.9.11.4653; MAY T, 1991, MECH DEVELOP, V33, P147, DOI 10.1016/0925-4773(91)90081-G; MCNEIL JB, 1986, J MOL BIOL, V187, P363, DOI 10.1016/0022-2836(86)90439-0; MULLER K, 1978, NATURE, V274, P445, DOI 10.1038/274445a0; MURRAY BA, 1981, J SUPRAMOL STR CELL, V17, P197, DOI 10.1002/jsscb.380170302; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; NELLEN W, 1986, EMBO J, V5, P3367, DOI 10.1002/j.1460-2075.1986.tb04652.x; NOEGEL A, 1986, EMBO J, V5, P1473, DOI 10.1002/j.1460-2075.1986.tb04384.x; OYAMA M, 1986, P NATL ACAD SCI USA, V83, P4819, DOI 10.1073/pnas.83.13.4819; PAVLOVIC J, 1989, MOL CELL BIOL, V9, P4660, DOI 10.1128/MCB.9.11.4660; PEARS CJ, 1988, NUCLEIC ACIDS RES, V16, P8467, DOI 10.1093/nar/16.17.8467; PEARS CJ, 1987, EMBO J, V6, P195, DOI 10.1002/j.1460-2075.1987.tb04738.x; POOLE SJ, 1984, J MOL BIOL, V172, P203, DOI 10.1016/S0022-2836(84)80038-8; PUPILLO M, 1989, P NATL ACAD SCI USA, V86, P4892, DOI 10.1073/pnas.86.13.4892; SACE CL, 1991, DEV GENET, V12, P6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAXE CL, 1991, GENE DEV, V5, P1, DOI 10.1101/gad.5.1.1; SCHAAP P, 1985, EXP CELL RES, V159, P388, DOI 10.1016/S0014-4827(85)80012-4; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SIU CH, 1988, BIOCHIM BIOPHYS ACTA, V968, P283, DOI 10.1016/0167-4889(88)90019-5; SIU CH, 1987, J CELL BIOL, V105, P2523, DOI 10.1083/jcb.105.6.2523; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; VAUTI F, 1990, MOL CELL BIOL, V10, P4080, DOI 10.1128/MCB.10.8.4080; WONG LM, 1986, P NATL ACAD SCI USA, V83, P4248, DOI 10.1073/pnas.83.12.4248; WONG LM, 1988, THESIS U TORONTO	57	18	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19655	19664						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326559				2022-12-27	WOS:A1992JP59300095
J	KUKOLJ, G; DUBOW, MS				KUKOLJ, G; DUBOW, MS			INTEGRATION HOST FACTOR ACTIVATES THE NER-REPRESSED EARLY PROMOTER OF TRANSPOSABLE MU-LIKE PHAGE-D108	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA BENDING PROTEIN; ESCHERICHIA-COLI; BACTERIOPHAGE-MU; GENE-EXPRESSION; STRAND TRANSFER; BINDING; TRANSCRIPTION; SITE; TRANSPOSITION; SEQUENCES	The lytic-lysogenic switch in transposable, Mu-like bacteriophage D108 is governed by two divergent and slightly overlapping transcription units originating from the Pe and Pc promoters. DNase I footprinting and in vivo mutational analysis suggest that lysogeny is maintained by c-repressor occupancy of the O2 operator, which precludes RNA polymerase from binding to Pe. Lytic development is controlled by the Ner repressor, which binds to a site symmetrically situated between the converging promoters and, in the absence of other factors, prevents RNA polymerase from binding to either Pc or Pe. DNase I protection and potassium permanganate hypersensitivity in the presence of integration host factor (IHF), which binds and alters the DNA structure upstream of Pe, revealed that RNA polymerase was able to bind Pe irrespective of the Ner.DNA-bound complex, and partially unwind the Pe "-10 region." Ner repression of Pe transcription in vitro was significantly more effective in the absence of IHF. Using a cloned D108 early region-lacZ fusion in IHF-deficient and -proficient backgrounds, we also demonstrate this host factor's affect on ner-repressed Pe in vivo, and generate a system for isolating mutants in the regulatory genes and sites controlling this genetic switch. D108 lytic growth is proposed to occur through IHF-mediated activation of the phage Ner-repressed early operon.	MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL H3A 2B4,QUEBEC,CANADA	McGill University								ADHYA S, 1990, J BIOL CHEM, V265, P10797; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BECK CF, 1988, MICROBIOL REV, V52, P318, DOI 10.1128/MMBR.52.3.318-326.1988; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; DEVARGAS LM, 1989, SCIENCE, V244, P1457; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FIEDLER S, 1988, ANAL BIOCHEM, V170, P38, DOI 10.1016/0003-2697(88)90086-3; FLAMM EL, 1985, J MOL BIOL, V183, P117, DOI 10.1016/0022-2836(85)90206-2; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; GILADI H, 1990, J MOL BIOL, V213, P109, DOI 10.1016/S0022-2836(05)80124-X; GIPHARTGASSLER M, 1979, COLD SPRING HARB SYM, V43, P1179, DOI 10.1101/SQB.1979.043.01.133; GOBER JW, 1990, GENE DEV, V4, P1494, DOI 10.1101/gad.4.9.1494; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GOOSEN N, 1984, GENE, V30, P41, DOI 10.1016/0378-1119(84)90103-3; GOOSEN N, 1986, J BACTERIOL, V167, P503, DOI 10.1128/jb.167.2.503-507.1986; GOOSEN N, 1984, GENE, V32, P419, DOI 10.1016/0378-1119(84)90017-9; GRIFFO G, 1989, J MOL BIOL, V209, P55, DOI 10.1016/0022-2836(89)90169-1; HIGGINS NP, 1989, J BIOL CHEM, V264, P3035; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; HUANG L, 1990, J BACTERIOL, V172, P5293, DOI 10.1128/jb.172.9.5293-5298.1990; HULL RA, 1978, J VIROL, V27, P513, DOI 10.1128/JVI.27.3.513-518.1978; KINCADE JM, 1991, GENE, V97, P7, DOI 10.1016/0378-1119(91)90003-T; KONIG U, 1988, VIROLOGY, V164, P75, DOI 10.1016/0042-6822(88)90621-6; KOSTURKO LD, 1989, NUCLEIC ACIDS RES, V17, P317, DOI 10.1093/nar/17.1.317; KRAUSE HM, 1983, NUCLEIC ACIDS RES, V11, P5483, DOI 10.1093/nar/11.16.5483; KRAUSE HM, 1986, J BIOL CHEM, V261, P3744; KUKOLJ G, 1991, NUCLEIC ACIDS RES, V19, P5949, DOI 10.1093/nar/19.21.5949; KUKOLJ G, 1989, EMBO J, V8, P3141, DOI 10.1002/j.1460-2075.1989.tb08467.x; LEE JY, 1991, CELL, V66, P793, DOI 10.1016/0092-8674(91)90122-F; LEVIN DB, 1989, MOL GEN GENET, V217, P392, DOI 10.1007/BF02464909; LEVIN DB, 1987, FEBS LETT, V222, P199, DOI 10.1016/0014-5793(87)80219-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCARTHY JG, 1990, BIOCHEMISTRY-US, V29, P6071, DOI 10.1021/bi00477a027; MILLER HI, 1984, COLD SPRING HARB SYM, V49, P691, DOI 10.1101/SQB.1984.049.01.078; MILLER HI, 1977, DNA INSERTION ELEMEN, P349; Miller J.H., 1972, EXPT MOL GENETICS; MIZUUCHI M, 1986, NUCLEIC ACIDS RES, V14, P3813, DOI 10.1093/nar/14.9.3813; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; PATO ML, 1984, CELL, V36, P197, DOI 10.1016/0092-8674(84)90089-8; PEREIRA RF, 1988, NUCLEIC ACIDS RES, V16, P5973, DOI 10.1093/nar/16.13.5973; Ptashne M., 1986, A GENETIC SWITCH; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STENZEL TT, 1991, GENE DEV, V5, P1453, DOI 10.1101/gad.5.8.1453; STENZEL TT, 1987, CELL, V49, P709, DOI 10.1016/0092-8674(87)90547-2; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; Symonds N., 1987, PHAGE MU; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TOLIAS PP, 1986, VIROLOGY, V148, P298, DOI 10.1016/0042-6822(86)90327-2; TOLIAS PP, 1985, EMBO J, V4, P3031, DOI 10.1002/j.1460-2075.1985.tb04040.x; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; TSUI P, 1991, J BACTERIOL, V173, P5800, DOI 10.1128/jb.173.18.5800-5807.1991; VANRIJN PA, 1988, NUCLEIC ACIDS RES, V16, P4595, DOI 10.1093/nar/16.10.4595; VOGEL JL, 1991, J BACTERIOL, V173, P6568, DOI 10.1128/jb.173.20.6568-6577.1991; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	65	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17827	17835						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325451				2022-12-27	WOS:A1992JM22300055
J	BRAULKE, T; MIESKES, G				BRAULKE, T; MIESKES, G			ROLE OF PROTEIN PHOSPHATASES IN INSULIN-LIKE GROWTH FACTOR-II (IGF-II)-STIMULATED MANNOSE 6-PHOSPHATE/IGF-II RECEPTOR REDISTRIBUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; LIGHT CHAIN KINASE; OKADAIC ACID; TRANSFERRIN RECEPTOR; CYTOPLASMIC DOMAIN; LYSOSOMAL-ENZYMES; GLUCOSE-TRANSPORT; CELL-SURFACE; 6-PHOSPHATE-SPECIFIC RECEPTOR; INTRACELLULAR MOVEMENT	The regulated expression of mannose 6-phosphate/insulin-like growth factor II (M6P/IGF II) receptors in plasma membranes has previously been shown to be accompanied by marked changes in the phosphorylation state of the receptors (Corvera, S., Folander, K., Clairmont, K. B., and Czech, M. P. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 7567-7571). In the present study we show that protein phosphatase 2A dephosphorylates the human M6P/IGF II receptor in vitro. Incubation of human fibroblasts with okadaic acid, a specific inhibitor of this phosphatase, resulted in a depletion of M6P/IGF II receptors at the cell surface without affecting their internalization kinetics. The phosphorylation state of the remaining cell surface receptors was 3-fold increased. Thus, the endocytosis rate of M6P/IGF II receptors appears to be unaltered by increased phosphorylation. While the decreased cell surface expression of receptors was reversible upon removal of okadaic acid the IGF II-induced redistribution of M6P/IGF II receptors to the plasma membrane (Braulke, T., Tippmer, S., Neher, E., and von Figura, K. (1989) EMBO J. 8,681-686) was irreversibly inhibited by the phosphatase inhibitor. Receptor redistribution in response to protein kinase C activation was not affected by okadaic acid. These results suggest that the cell surface expression of M6P/IGF II receptor can be regulated by phosphatase-dependent and -independent pathways. In addition, the phosphorylation state and the steady-state cell surface number of transferrin receptors were not affected by okadaic acid, whereas it impaired the IGF II-stimulated receptor redistribution similarly as for M6P/IGF II receptors. The data indicate that okadaic acid-sensitive protein phosphatases may play a general role in terms of IGF II-modulated receptor recycling.	UNIV GOTTINGEN,DEPT CLIN BIOCHEM,W-3400 GOTTINGEN,GERMANY	University of Gottingen	BRAULKE, T (corresponding author), UNIV GOTTINGEN,INST BIOCHEM 2,GOSSLERSTR 12D,W-3400 GOTTINGEN,GERMANY.		Braulke, Thomas/AAV-9121-2020	Braulke, Thomas/0000-0002-2336-8532				BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BRAULKE T, 1992, BIOCHIM BIOPHYS ACTA, V1138, P334, DOI 10.1016/0925-4439(92)90012-C; BRAULKE T, 1987, J CELL BIOL, V104, P1735, DOI 10.1083/jcb.104.6.1735; BRAULKE T, 1990, EUR J BIOCHEM, V189, P609, DOI 10.1111/j.1432-1033.1990.tb15529.x; BRAULKE T, 1989, EMBO J, V8, P681, DOI 10.1002/j.1460-2075.1989.tb03426.x; BRAULKE T, 1990, J BIOL CHEM, V265, P6650; BRAULKE T, 1991, BIOCHEM BIOPH RES CO, V179, P108, DOI 10.1016/0006-291X(91)91341-9; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CORVERA S, 1985, P NATL ACAD SCI USA, V82, P7314, DOI 10.1073/pnas.82.21.7314; CORVERA S, 1988, P NATL ACAD SCI USA, V85, P7567, DOI 10.1073/pnas.85.20.7567; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAMKE H, 1992, BIOCHEM J, V281, P225, DOI 10.1042/bj2810225; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HERNANDEZSOTOMAYOR SMT, 1991, J BIOL CHEM, V266, P21281; HU KQ, 1990, J BIOL CHEM, V265, P13864; HUBBARD AL, 1972, J CELL BIOL, V55, P390, DOI 10.1083/jcb.55.2.390; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LEE EYC, 1981, COLD SPRING HARBOR C, V8, P425; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGOWAN CH, 1987, EUR J BIOCHEM, V166, P713, DOI 10.1111/j.1432-1033.1987.tb13570.x; MERESSE S, 1990, J BIOL CHEM, V265, P18833; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; OKAMOTO T, 1991, J BIOL CHEM, V266, P1085; OPPENHEIMER CL, 1983, J BIOL CHEM, V258, P4824; PETERS KA, 1977, BIOCHEMISTRY-US, V16, P5691, DOI 10.1021/bi00645a007; ROGERS SA, 1989, J BIOL CHEM, V264, P4273; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; SAHAGIAN GG, 1983, J BIOL CHEM, V258, P7121; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SNIDER MD, 1985, J CELL BIOL, V100, P826, DOI 10.1083/jcb.100.3.826; TAKIO K, 1985, BIOCHEMISTRY-US, V24, P6028, DOI 10.1021/bi00343a002; TALLANT EA, 1983, METHOD ENZYMOL, V102, P244; TANTI JF, 1991, J BIOL CHEM, V266, P2099; TUNG HYL, 1984, EUR J BIOCHEM, V138, P635, DOI 10.1111/j.1432-1033.1984.tb07962.x; VONFIGURA K, 1985, BIOCHEM J, V225, P543, DOI 10.1042/bj2250543	44	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17347	17353						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324932				2022-12-27	WOS:A1992JL05300092
J	MUSVETEAU, I; DOLLA, A; GUERLESQUIN, F; PAYAN, F; CZJZEK, M; HASER, R; BIANCO, P; HALADJIAN, J; RAPPGILES, BJ; WALL, JD; VOORDOUW, G; BRUSCHI, M				MUSVETEAU, I; DOLLA, A; GUERLESQUIN, F; PAYAN, F; CZJZEK, M; HASER, R; BIANCO, P; HALADJIAN, J; RAPPGILES, BJ; WALL, JD; VOORDOUW, G; BRUSCHI, M			SITE-DIRECTED MUTAGENESIS OF TETRAHEME CYTOCHROME C3 - MODIFICATION OF OXIDOREDUCTION POTENTIALS AFTER HEME AXIAL LIGAND REPLACEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-DESULFURICANS NORWAY; REDOX POTENTIALS; VULGARIS HILDENBOROUGH; DIFFERENT CHIRALITY; ELECTRON-EXCHANGE; X-RAY; COMPLEX; STRAIN; FERREDOXIN; CONFORMATION	The nature of the axial ligands of a heme group is an important factor in maintaining the oxidation-reduction potential of a c-type cytochrome. Cytochrome c3 from Desulfovibrio vulgaris Hildenborough contains four bis-histidinyl coordinated hemes with low oxidation-reduction potentials. Site-directed mutagenesis was used to generate a mutant in which histidine 70, the sixth axial ligand of heme 4, has been replaced by a methionine. The mutant protein was expressed in Desulfovibrio desulfuricans G200 at a level similar to the wild type cytochrome. A model for the three-dimensional structure of D. vulgaris Hildenborough cytochrome c3 was generated on the basis of the crystal structure of D. vulgaris Miyazaki cytochrome c3 in order to investigate the effects of the H70M mutation. The model, together with NMR data, suggested that methionine 70 has effectively replaced histidine 70 as the sixth axial ligand of heme 4 without significant alteration of the structure. A large increase of at least 200 mV of one of the four oxidation-reduction potentials was observed by electrochemistry and is interpreted in terms of structure/potential relationships.	CNRS, CHIM BACTERIENNE LAB, BP71, F-13277 MARSEILLE 9, FRANCE; UNIV CALGARY, DEPT BIOL SCI, CALGARY T2N 1N4, ALBERTA, CANADA; UNIV AIX MARSEILLE 2, FAC MED, CRISTALLOG CRISTALLISAT & MACROMOLEC BIOL LAB,CNRS, URA 1296, F-13326 MARSEILLE 15, FRANCE; UNIV AIX MARSEILLE 1, CHIM BACTERIENNE LAB, CHIM & ELECTROCHIM COMPLEXES LAB, F-13331 MARSEILLE 3, FRANCE; UNIV MISSOURI, DEPT BIOCHEM, COLUMBIA, MO 65211 USA	Centre National de la Recherche Scientifique (CNRS); University of Calgary; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; University of Missouri System; University of Missouri Columbia			Mus-veteau, Isabelle/M-8875-2016; Voordouw, Gerrit/F-5327-2013	Mus-veteau, Isabelle/0000-0001-5739-7684; 				ARMSTRONG FA, 1990, STRUCT BOND, V72, P137; BIANCO P, 1982, J ELECTROANAL CHEM, V137, P367, DOI 10.1016/0022-0728(82)80050-8; BIANCO P, 1982, J ELECTROANAL CHEM, V136, P291, DOI 10.1016/0022-0728(82)85050-X; BIANCO P, 1983, BIOCHEM BIOPH RES CO, V113, P526, DOI 10.1016/0006-291X(83)91757-6; BRUSCHI M, 1984, BIOCHEM BIOPH RES CO, V120, P384, DOI 10.1016/0006-291X(84)91265-8; BRUSCHI M, 1981, BIOCHIM BIOPHYS ACTA, V671, P219, DOI 10.1016/0005-2795(81)90137-9; BRUSCHI M, 1991, IN PRESS BIOCHEMISTR; CAFFREY MS, 1991, BIOCHEMISTRY-US, V30, P4119, DOI 10.1021/bi00231a002; CAMBILLAU C, 1988, PROTEINS, V4, P63, DOI 10.1002/prot.340040109; CAPEILLEREBLANDIN C, 1986, BIOCHIM BIOPHYS ACTA, V848, P279, DOI 10.1016/0005-2728(86)90202-1; Dickerson R., 1975, ENZYMES, V11, P397; DOLLA A, 1987, BIOCHEM BIOPH RES CO, V147, P818, DOI 10.1016/0006-291X(87)91003-5; DOLLA A, 1989, BIOCHIM BIOPHYS ACTA, V975, P395, DOI 10.1016/S0005-2728(89)80348-2; DOLLA A, 1991, BIOCHIM BIOPHYS ACTA, V1058, P171, DOI 10.1016/S0005-2728(05)80234-8; Dolla A, 1991, J Mol Recognit, V4, P27, DOI 10.1002/jmr.300040105; FAN K, 1990, BIOCHEMISTRY-US, V29, P2257, DOI 10.1021/bi00461a008; GAYDA JP, 1988, EUR J BIOCHEM, V177, P199, DOI 10.1111/j.1432-1033.1988.tb14362.x; GUERLESQUIN F, 1987, BIOCHEMISTRY-US, V26, P7438, DOI 10.1021/bi00397a036; GUIGLIARELLI B, 1990, J MOL BIOL, V216, P161, DOI 10.1016/S0022-2836(05)80067-1; HAMPSEY DM, 1986, J BIOL CHEM, V261, P3259; HIGUCHI Y, 1984, J MOL BIOL, V172, P109, DOI 10.1016/0022-2836(84)90417-0; KASSNER RJ, 1973, J AM CHEM SOC, V95, P2674, DOI 10.1021/ja00789a044; KOSHY TI, 1990, P NATL ACAD SCI USA, V87, P8697, DOI 10.1073/pnas.87.22.8697; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPPIN AG, 1985, INORG CHEM, V24, P1446, DOI 10.1021/ic00204a008; LeGall J, 1988, DISSIMILATORY REDUCT, P587; Maniatis T., 1982, MOL CLONING; MATHEWS FS, 1985, PROG BIOPHYS MOL BIO, V45, P1, DOI 10.1016/0079-6107(85)90004-5; MAUK AG, 1991, STRUCT BOND, V75, P131; MOORE GR, 1977, FEBS LETT, V79, P229, DOI 10.1016/0014-5793(77)80793-X; MORIMOTO Y, 1991, J BIOCHEM-TOKYO, V110, P532, DOI 10.1093/oxfordjournals.jbchem.a123615; NAKAI M, 1990, J BIOCHEM-TOKYO, V108, P798, DOI 10.1093/oxfordjournals.jbchem.a123283; PIERROT M, 1982, J BIOL CHEM, V257, P4341; Postgate JR, 1984, SULPHATE REDUCING BA, V2nd; RAPHAEL AL, 1991, J AM CHEM SOC, V113, P1038, DOI 10.1021/ja00003a045; RIKFIN SC, 1976, ANAL CHEM, V48, P2172; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SALEMME FR, 1973, J BIOL CHEM, V248, P7701; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENN H, 1980, BIOCHEM BIOPH RES CO, V92, P1362, DOI 10.1016/0006-291X(80)90436-2; SENN H, 1983, BIOCHIM BIOPHYS ACTA, V748, P194, DOI 10.1016/0167-4838(83)90295-9; SENN H, 1985, Q REV BIOPHYS, V18, P111, DOI 10.1017/S0033583500005151; SOKOL WF, 1980, J ELECTROANAL CHEM, V108, P107, DOI 10.1016/S0022-0728(80)80097-0; SORRELL TN, 1989, J AM CHEM SOC, V111, P766, DOI 10.1021/ja00184a074; STELLWAGEN E, 1978, NATURE, V275, P73, DOI 10.1038/275073a0; STEWART DE, 1988, BIOCHEMISTRY-US, V27, P2444, DOI 10.1021/bi00407a030; TAKANO T, 1981, J MOL BIOL, V153, P95, DOI 10.1016/0022-2836(81)90529-5; THURGOOD AGP, 1991, FEBS LETT, V284, P173, DOI 10.1016/0014-5793(91)80678-V; VOORDOUW G, 1990, J BACTERIOL, V172, P6122, DOI 10.1128/jb.172.10.6122-6126.1990; VOORDOUW G, 1986, EUR J BIOCHEM, V159, P347, DOI 10.1111/j.1432-1033.1986.tb09874.x; WUTHRICH K, 1969, P NATL ACAD SCI USA, V63, P1071, DOI 10.1073/pnas.63.4.1071	52	49	49	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16851	16858						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324913				2022-12-27	WOS:A1992JL05300022
J	PATEL, SS; ROSENBERG, AH; STUDIER, FW; JOHNSON, KA				PATEL, SS; ROSENBERG, AH; STUDIER, FW; JOHNSON, KA			LARGE-SCALE PURIFICATION AND BIOCHEMICAL-CHARACTERIZATION OF T7-PRIMASE HELICASE PROTEINS - EVIDENCE FOR HOMODIMER AND HETERODIMER FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 DEOXYRIBONUCLEIC-ACID; NUCLEOSIDE 5'-TRIPHOSPHATASE ACTIVITY; LAGGING STRAND SYNTHESIS; PRIMED DNA-SYNTHESIS; GENE-4 PROTEIN; ESCHERICHIA-COLI; REPLICATION INVITRO; ADENOSINE-TRIPHOSPHATASE; PRIMASE-HELICASE; ATP HYDROLYSIS	A rapid purification procedure produces milligram amounts of the T7 gene 4A' primase/helicase, 4B helicase, and the wild-type 4AB proteins expressed from the clones described in the accompanying paper (Rosenberg, A. H., Patel, S. S., Johnson, K. A., and Studier, F. W. (1992) J. Biol. Chem. 267, 15005-15012). Purified 4A' protein (in which the wild-type methionine at amino acid 64 has been replaced by leucine to eliminate the 4B initiation codon) appears to be equivalent to the wild-type 4A protein in primase, helicase, and NTPase activities. Gel filtration chromatography and polyacrylamide gel electrophoresis of native proteins indicate that the 4A' and 4B proteins form homodimers and heterodimers in solution. Heterodimer formation presumably accounts for an observed 3-fold increase in the primase activity of 4A' upon addition of 4B that lacks primase activity of its own. Steady-state k(cat) and K(m) values for hydrolysis of the nucleoside triphosphates ATP, dATP, dTTP, and dGTP were measured for 4A', 4B, 4A'B (1:1), and wild-type 4AB (1:2) proteins. The dependence of the dNTPase activities on the concentration was hyperbolic, suggesting single or noncooperative binding sites, whereas ATPase activity was sigmoidal, suggesting more than one ATP binding site. The k(cat)/K(m) ratios for hydrolysis of the dNTPs by the four protein preparations were within a factor of 6 of each other. The 1:1 mixture of 4A'B had the highest k(cat)/K(m) ratios, with a preference for dATP and dTTP.	PENN STATE UNIV,DEPT MOLEC & CELL BIOL,UNIV PK,PA 16802; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; United States Department of Energy (DOE); Brookhaven National Laboratory					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044613, F32GM013135, R01GM021872] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM13135, GM44613, GM21872] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1981, J BIOL CHEM, V256, P5247; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; CAMPBELL JL, 1986, ANNU REV BIOCHEM, V55, P733, DOI 10.1146/annurev.bi.55.070186.003505; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; DUNN JJ, 1984, J MOL BIOL, V175, P111; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; FISCHER H, 1980, J BIOL CHEM, V255, P7956; GOETZ GS, 1988, J BIOL CHEM, V263, P383; HINKLE DC, 1975, J BIOL CHEM, V250, P5523; KOLODNER R, 1977, P NATL ACAD SCI USA, V74, P1525, DOI 10.1073/pnas.74.4.1525; KORNBERG A, 1991, DNA REPLIATION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LIU CC, 1981, J BIOL CHEM, V256, P2813; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MILLER H, 1987, METHOD ENZYMOL, V152, P145; NAKAI H, 1986, J BIOL CHEM, V261, P5217; NAKAI H, 1986, J BIOL CHEM, V261, P5208; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NOSSAL NG, 1987, J BIOL CHEM, V262, P10879; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; RICHARDSON CC, 1983, REPLICATION VIRAL CE, P163; RICHARDSON CC, 1987, UCLA S MOL CELL BIOL, V47, P151; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; ROMANO LJ, 1979, J BIOL CHEM, V254, P476; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; SCHERZINGER E, 1977, NUCLEIC ACIDS RES, V4, P4151, DOI 10.1093/nar/4.12.4151; SEKI M, 1986, BIOCHEMISTRY-US, V25, P3239, DOI 10.1021/bi00359a024; VENKATESAN M, 1982, J BIOL CHEM, V257, P124; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; YARRANTON GT, 1979, J BIOL CHEM, V254, P1997	43	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15013	15021						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321824				2022-12-27	WOS:A1992JF08800076
J	AMEMIYA, K; TRAUB, R; DURHAM, L; MAJOR, EO				AMEMIYA, K; TRAUB, R; DURHAM, L; MAJOR, EO			ADJACENT NUCLEAR FACTOR-I AND ACTIVATOR PROTEIN-BINDING SITES IN THE ENHANCER OF THE NEUROTROPIC JC VIRUS - A COMMON CHARACTERISTIC OF MANY BRAIN-SPECIFIC GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOMEGALO-VIRUS; RNA POLYMERASE-II; POLYOMAVIRUS-JC; DNA-BINDING; GLUCOCORTICOID RECEPTOR; OSTEOCALCIN GENE; NERVOUS-SYSTEM; CYCLIC-AMP; BK VIRUS; C-JUN	JC virus is a neurotropic virus that causes the demyelinating disease progressive multifocal leukoencephalopathy in humans. In order to understand the neurotropic nature of this virus, we examined the binding of nuclear proteins to the viral regulatory region. A close association of nuclear factor-1 (NF-1) and Jun protein binding sites was found. These binding sites were either adjacent or overlapped each other. Depending on the order of binding, there was some interference of binding of the NF-1 protein by Jun even at a non-Jun binding site. This suggests that there may be a direct interaction between these proteins. Examination of the regulatory region of a number of genes expressed in the central and peripheral nervous systems revealed that many of these genes apparently have adjacent NF-1 and activator protein binding sites immediately upstream from the the mRNA start site. Since it had been demonstrated that nuclear proteins from brain and non-brain cells could interact with these sites, it is probable that the NF-1- and Jun-related proteins which interact at these sites are involved in the basal activity of these genes. It appears that adjacent binding sites for NF-1 and Jun immediately upstream from the mRNA start site may be a characteristic of many genes expressed in the nervous system.	IGEN INC,ROCKVILLE,MD 20852		AMEMIYA, K (corresponding author), NINCDS,VIRAL & MOLEC PATHOGENESIS LAB,MOLEC VIROL & GENET SECT,BLDG 36,BETHESDA,MD 20892, USA.							ALLORE RJ, 1990, J BIOL CHEM, V265, P15537; AMEMIYA K, 1989, J BIOL CHEM, V264, P7025; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BESNARD F, 1991, J BIOL CHEM, V266, P18877; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COMB M, 1988, EMBO J, V7, P3797; CORALLINI A, 1987, INT J CANCER, V39, P60, DOI 10.1002/ijc.2910390111; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DORRIES K, 1987, VIROLOGY, V160, P268, DOI 10.1016/0042-6822(87)90071-7; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; DYNAN WS, 1987, GENETIC ENG PRINCIPL, V9, P75; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HENNIGHAUSEN L, 1986, EMBO J, V5, P1367, DOI 10.1002/j.1460-2075.1986.tb04368.x; JEANG KT, 1987, J VIROL, V61, P1559, DOI 10.1128/JVI.61.5.1559-1570.1987; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JONT C, 1990, CELL, V62, P1189; KAMHOLZ J, 1988, J NEUROSCI RES, V21, P62, DOI 10.1002/jnr.490210110; KENNEY S, 1984, SCIENCE, V226, P1337, DOI 10.1126/science.6095453; KERR D, 1991, J BIOL CHEM, V266, P15876; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; MAJOR EO, 1985, P NATL ACAD SCI USA, V82, P1257, DOI 10.1073/pnas.82.4.1257; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MARKOWITZ RB, 1991, J VIROL, V65, P4515, DOI 10.1128/JVI.65.8.4515-4519.1991; Maxam A M, 1980, Methods Enzymol, V65, P499; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORGELLO S, 1987, HUM PATHOL, V18, P289, DOI 10.1016/S0046-8177(87)80012-6; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAKAHIRA K, 1990, J BIOL CHEM, V265, P19786; NAVE KA, 1991, J NEUROSCI, V11, P3060; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; PADGETT BL, 1977, INFECT IMMUN, V15, P656, DOI 10.1128/IAI.15.2.656-662.1977; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SALZMAN NP, 1986, PAPOVAVIRIDAE, V1, P27; SAMBUCETTI LC, 1989, EMBO J, V8, P4251, DOI 10.1002/j.1460-2075.1989.tb08610.x; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; STAMMINGER T, 1990, J GEN VIROL, V71, P105, DOI 10.1099/0022-1317-71-1-105; SUNDSFJORD A, 1990, J VIROL, V64, P3864, DOI 10.1128/JVI.64.8.3864-3871.1990; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; TAMURA T, 1988, NUCLEIC ACIDS RES, V16, P11441, DOI 10.1093/nar/16.24.11441; VINTERS HV, 1989, BRAIN, V112, P245, DOI 10.1093/brain/112.1.245; WILEY CA, 1986, J NEUROPATH EXP NEUR, V45, P127, DOI 10.1097/00005072-198603000-00003; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	59	99	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14204	14211						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321139				2022-12-27	WOS:A1992JD32500065
J	DEREMER, MF; SAELI, RJ; EDELMAN, AM				DEREMER, MF; SAELI, RJ; EDELMAN, AM			CA2+-CALMODULIN-DEPENDENT PROTEIN KINASE-IA AND KINASE-IB FROM RAT-BRAIN .1. IDENTIFICATION, PURIFICATION, AND STRUCTURAL COMPARISONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION SITES; MUSCLE MYOSIN; SYNAPSIN-I; CALMODULIN; CALCIUM	Two Ca2+-calmodulin (CaM)-dependent protein kinases were purified from rat brain using as substrate a synthetic peptide based on site 1 (site 1 peptide) of the synaptic vesicle-associated protein, synapsin I. One of the purified enzymes was an approximately 89% pure protein of M(r) = 43,000 which bound CaM in a Ca2+-dependent fashion. The other purified enzyme was an apparently homogenous protein of M(r) = 39,000 accompanied by a small amount of a M(r) = 37,000 form which may represent a proteolytic product of the 39-kDa enzyme. The 39-kDa protein bound CaM in a Ca2+-dependent fashion. Gel filtration analysis indicated that both enzymes are monomers. The 43- and 39-kDa enzymes are named Ca2+-CaM-dependent protein kinases Ia and Ib (CaM kinases Ia, Ib), respectively. The specific activities of CaM kinases Ia and Ib were similar (5-8-mu-mol/min/mg protein). CaM kinase Ia (but not CaM kinase Ib) activity was enhanced by addition of a CaM-Sepharose column wash (non-binding) fraction suggesting the existence of an "activator" of CaM kinase la. Both kinases phosphorylated exogenous substrates (site 1 peptide and synapsin I) in a Ca2+-CaM-dependent fashion and both kinases underwent autophosphorylation. CaM kinase Ia autophosphorylation was Ca2+-CaM-dependent and occurred exclusively on threonine while CaM kinase Ib autophosphorylation showed Ca2+-CaM independence and occurred on both serine and threonine. Proteolytic digestion of autophosphorylated CaM kinases Ia and Ib yielded phosphopeptides of differing M(r). These characteristics, as well as enzymatic and regulatory properties (DeRemer, M. F., Saeli, R. J. Brautigen, D. L., and Edelman, A. M. (1992) J. Biol. Chem. 267, 13466-13471), indicate that CaM kinases Ia and Ib are distinct and possibly previously unrecognized enzymes.	SUNY BUFFALO, DEPT PHARMACOL & THERAPEUT, 102 FARBER HALL, BUFFALO, NY 14260 USA; SUNY BUFFALO, DEPT BIOL SCI, BUFFALO, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS024738, R01NS024738] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24738] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BENNETT V, 1986, METHOD ENZYMOL, V134, P55; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DEREMER MF, 1992, J BIOL CHEM, V267, P13466; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EDELMAN AM, 1990, MOL CELL BIOCHEM, V97, P87; EDELMAN AM, 1985, J BIOL CHEM, V260, P1275; HUTTNER WB, 1979, P NATL ACAD SCI USA, V76, P5402, DOI 10.1073/pnas.76.10.5402; KENNEDY MB, 1981, P NATL ACAD SCI-BIOL, V78, P1293, DOI 10.1073/pnas.78.2.1293; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANALAN AS, 1984, ADV CYCLIC NUCL PROT, V18, P227; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RUBIN RP, 1970, PHARMACOL REV, V22, P389; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; WALAAS SI, 1991, PHARMACOL REV, V43, P299; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	19	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13460	13465						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320021				2022-12-27	WOS:A1992JB74600059
J	ELSEA, SH; OSHEROFF, N; NITISS, JL				ELSEA, SH; OSHEROFF, N; NITISS, JL			CYTOTOXICITY OF QUINOLONES TOWARD EUKARYOTIC CELLS - IDENTIFICATION OF TOPOISOMERASE-II AS THE PRIMARY CELLULAR TARGET FOR THE QUINOLONE CP-115,953 IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DNA GYRASE INHIBITORS; HAMSTER OVARY CELLS; SACCHAROMYCES-CEREVISIAE; MAMMALIAN MITOCHONDRIA; ANTIBACTERIAL AGENTS; ANTITUMOR DRUGS; CLEAVAGE; RESISTANT; RELIGATION; ACID	The quinolone CP-115,953 (6,8-difluoro-7-(4-hydroxyphenyl)-1-cyclopropyl-4-quinolone-3-carboxylic acid) represents a novel mechanistic class of drugs with potent activity against eukaryotic topoisomerase II in vitro (Robinson, M. J., Martin, B. A., Gootz, T. D., McGuirk, P. R., Moynihan, M., Sutcliffe, J. A., and Osheroff, N. (1991) J. Biol. Chem. 266, 14585-14592). Although the quinolone is highly toxic to mammalian cells in culture, its mechanism of cytotoxic action is not known. Therefore, yeast was used as a model system to determine whether topoisomerase II is the primary target responsible for the in vivo effects of CP- 1 15,953. The quinolone was equipotent to etoposide at enhancing DNA breakage mediated by the Saccharomyces cerevisiae type 11 enzyme. Moreover, at concentrations as low as 5-mu-M, CP-115,953 was cytotoxic to yeast cells that carried wild type topoisomerase II (TOP2+). By utilizing a yeast strain that expressed the top2-1 temperature-sensitive mutant, the effect of topoisomerase II activity on quinolone cytotoxicity was determined. At the permissive temperature of 25-degrees-C, cells were highly sensitive to CP-115,953. However, at the semipermissive temperature of 30-degrees-C (where in vivo enzyme activity is present but is greatly diminished), cells displayed only marginal sensitivity to the quinolone at concentrations as high as 50-mu-M. These results strongly suggest that topoisomerase II is the primary physiological target responsible for quinolone cytotoxicity and that CP-115,953 kills cells by converting the type II enzyme into a cellular poison.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,621 LIGHT HALL,NASHVILLE,TN 37232; CHILDRENS HOSP LOS ANGELES,DEPT PEDIAT,DIV HEMATOL ONCOL,LOS ANGELES,CA 90027; CHILDRENS HOSP LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90027	Vanderbilt University; Children's Hospital Los Angeles; Children's Hospital Los Angeles			Nitiss, John/E-9974-2010	Elsea, Sarah/0000-0002-1400-8519; Nitiss, John/0000-0002-1013-4972	NCI NIH HHS [5 T32 CA09582, CA52814] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009582, R01CA052814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRETT JF, 1989, ANTIMICROB AGENTS CH, V33, P1697, DOI 10.1128/AAC.33.10.1697; CASTORA FJ, 1979, J BIOL CHEM, V254, P1193; CASTORA FJ, 1983, BIOCHIM BIOPHYS ACTA, V740, P417, DOI 10.1016/0167-4781(83)90090-8; CHARCOSSET JY, 1988, BIOCHEM PHARMACOL, V37, P2145, DOI 10.1016/0006-2952(88)90573-4; CHU DTW, 1989, ANTIMICROB AGENTS CH, V33, P131, DOI 10.1128/AAC.33.2.131; DAVIES SM, 1988, J BIOL CHEM, V263, P17724; DEFFIE AM, 1989, CANCER RES, V49, P58; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; FRICHE E, 1991, CANCER RES, V51, P4213; FRY AM, 1991, CANCER RES, V51, P6592; GALE KC, 1990, BIOCHEMISTRY-US, V29, P9538, DOI 10.1021/bi00493a007; GALLAGHER M, 1986, J BIOL CHEM, V261, P8604; GILLIGAN PJ, 1986, Patent No. 4623650; GOOTZ TD, 1990, ANTIMICROB AGENTS CH, V34, P8, DOI 10.1128/AAC.34.1.8; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; GUPTA RS, 1983, CANCER RES, V43, P1568; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOOPER DC, 1991, NEW ENGL J MED, V324, P384, DOI 10.1056/NEJM199102073240606; JEFSON MR, 1989, 29TH ICAAC, P1190; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; POTMESIL M, 1988, CANCER RES, V48, P3537; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; ROBINSON MJ, 1992, ANTIMICROB AGENTS CH, V36, P751, DOI 10.1128/AAC.36.4.751; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROBINSON MJ, 1990, BIOCHEMISTRY-US, V29, P2511, DOI 10.1021/bi00462a012; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; Schneider E, 1990, Adv Pharmacol, V21, P149, DOI 10.1016/S1054-3589(08)60342-7; SULLIVAN DM, 1989, BIOCHEMISTRY-US, V28, P5680, DOI 10.1021/bi00439a051; SULLIVAN DM, 1987, CANCER RES, V47, P3973; SUTCLIFFE JA, 1989, ANTIMICROB AGENTS CH, V33, P2027, DOI 10.1128/AAC.33.12.2027; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WEBB CD, 1991, CANCER RES, V51, P6543; WENTLAND M P, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P336; Wentland M. P., 1990, NEW GENERATION QUINO, P1; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	41	112	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13150	13153						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320012				2022-12-27	WOS:A1992JB74600010
J	GILLILAND, LK; SCHIEVEN, GL; NORRIS, NA; KANNER, SB; ARUFFO, A; LEDBETTER, JA				GILLILAND, LK; SCHIEVEN, GL; NORRIS, NA; KANNER, SB; ARUFFO, A; LEDBETTER, JA			LYMPHOCYTE LINEAGE-RESTRICTED TYROSINE-PHOSPHORYLATED PROTEINS THAT BIND PLC-GAMMA-1 SH2 DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; T-CELL RECEPTOR; SIGNAL TRANSDUCTION; PDGF RECEPTOR; KINASE P56LCK; V-SRC; PHYSICAL ASSOCIATION; COMPLEMENTARY-DNA; MOLECULAR-CLONING; ANTIGEN RECEPTOR	Epidermal growth factor (EGF) or platelet-derived growth factor binding to their receptors on fibroblasts induces tyrosine phosphorylation of PLC-gamma-1 and stable association of PLC-gamma-1 with the receptor protein tyrosine kinase. Similarly in lymphocytes, cross-linking of antigen receptors induces the formation of molecular complexes incorporating PLC-gamma-1; however, associated kinase activity is thought to be mediated through cytoplasmic protein tyrosine kinase(s). In this report, we generated a fusion protein containing the SH2 domains of human PLC-gamma-1 and human IgG1 heavy chain constant region to identify lymphocyte phosphoprotein-binding PLC-gamma-1 SH2 domains following cellular activation. As in EGF- or platelet-derived growth factor-stimulated fibroblasts, PLC-gamma-1 is coprecipitated in activated lymphocytes, complexed with associated tyrosine-phosphorylated proteins. One of these, a 35/36-kDa protein found prominently in T cells and at lower levels in B cells, bound to the fusion protein in immunoprecipitation experiments. The fusion protein showed lineage restricted association with a 74-kDa phosphoprotein in T cells and a 93-kDa phosphoprotein in B cells. It bound to activated EGF receptor in fibroblasts as expected, and protein tyrosine kinase activity was precipitated from EGF-stimulated cells. However, PLC-gamma-1-associated protein tyrosine kinase activity was not detected in activated lymphocytes. These data suggest that lymphocyte PLC-gamma-1 SH2-binding proteins are cell lineage specific and may be transiently associated with activated PLC-gamma-1.			GILLILAND, LK (corresponding author), BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,3005 1ST AVE,SEATTLE,WA 98121, USA.							ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; EMORI Y, 1989, J BIOL CHEM, V264, P21885; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HELLSTROM I, 1986, CANCER RES, V46, P3917; JONES NH, 1986, NATURE, V323, P346, DOI 10.1038/323346a0; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAMLE NK, 1992, J IMMUNOL, V148, P665; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KANNER SB, 1992, IMMUNOLOGY, V75, P441; KANNER SB, 1992, BIOCHEM SOC T, V20, P178, DOI 10.1042/bst0200178; KATAGIRI T, 1989, MOL CELL BIOL, V9, P4914, DOI 10.1128/MCB.9.11.4914; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; LANZAVECCHIA A, 1987, EUR J IMMUNOL, V17, P105, DOI 10.1002/eji.1830170118; Ledbetter J A, 1990, Semin Immunol, V2, P99; LEDBETTER JA, 1989, MOL IMMUNOL, V26, P137, DOI 10.1016/0161-5890(89)90095-3; LEDBETTER JA, 1985, J IMMUNOL, V135, P2331; LEDBETTER JA, 1988, EUR J IMMUNOL, V18, P525, DOI 10.1002/eji.1830180406; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OHTA S, 1988, FEBS LETT, V242, P31, DOI 10.1016/0014-5793(88)80979-7; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PAWSON T, 1988, ONCOGENE, V3, P491; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, NATURE, V324, P6956; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TAKADA S, 1987, J IMMUNOL, V139, P3231; TAKAGI S, 1991, J EXP MED, V174, P381, DOI 10.1084/jem.174.2.381; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEYAND CM, 1987, J IMMUNOL, V138, P1351	70	74	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13610	13616						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320023				2022-12-27	WOS:A1992JB74600081
J	WALSH, K; GUALBERTO, A				WALSH, K; GUALBERTO, A			MYOD BINDS TO THE GUANINE TETRAD NUCLEIC-ACID STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TELOMERIC DNA; CONFORMATION; PROTEIN; MODEL	A high affinity interaction between a protein and the guanine tetrad nucleic acid structure is described. Recombinant MyoD, a transcription factor that can initiate myogenesis, specifically bound to helical structures formed by stacks of guanine residues in square planar arrays. The N-7 methylation of a set of consecutive dG residues in a single-stranded probe of the creatine kinase enhancer interfered with the formation of this nucleic acid structure and prevented protein binding. Recombinant MyoD also bound to a guanine tetrad formed with a telomeric DNA probe, and it had a higher affinity for the four-stranded structure than for the double-stranded E-box-binding site. These data are the first report of a direct interaction between a protein and this nucleic acid conformation. The potential biological significance of this finding is discussed.			WALSH, K (corresponding author), CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,2109 ADELBERT RD,CLEVELAND,OH 44106, USA.			Gualberto, Antonio/0000-0002-6590-839X	NHLBI NIH HHS [HL 45345] Funding Source: Medline; NIAMS NIH HHS [AR 40197] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; HENDERSON ER, 1990, BIOCHEMISTRY-US, V29, P732, DOI 10.1021/bi00455a020; JIN R, 1990, SCIENCE, V250, P543, DOI 10.1126/science.2237404; KIM J, 1991, NATURE, V351, P331, DOI 10.1038/351331a0; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; NICKOL JM, 1983, CELL, V35, P467, DOI 10.1016/0092-8674(83)90180-0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PANYUTIN IG, 1990, P NATL ACAD SCI USA, V87, P867, DOI 10.1073/pnas.87.3.867; RAGHURAMAN MK, 1990, NUCLEIC ACIDS RES, V18, P4543, DOI 10.1093/nar/18.15.4543; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SMITH SS, 1989, BIOCHEM BIOPH RES CO, V160, P1397, DOI 10.1016/S0006-291X(89)80159-7; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, CELL, V66, P423, DOI 10.1016/0092-8674(81)90003-9; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; USDIN K, 1988, P NATL ACAD SCI USA, V85, P4416, DOI 10.1073/pnas.85.12.4416; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; ZIMMERMAN SB, 1975, J MOL BIOL, V92, P181, DOI 10.1016/0022-2836(75)90222-3	23	76	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13714	13718						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320026				2022-12-27	WOS:A1992JB74600097
J	KOHAN, DE; HUGHES, AK; PERKINS, SL				KOHAN, DE; HUGHES, AK; PERKINS, SL			CHARACTERIZATION OF ENDOTHELIN RECEPTORS IN THE INNER MEDULLARY COLLECTING DUCT OF THE RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; BINDING-SITES; KIDNEY	Endothelins may be important regulators of renal inner medullary collecting duct (IMCD) function. These peptides are secreted in large amounts by IMCD cells and can, in turn, potently inhibit sodium and water transport systems in the IMCD. This study characterized endothelin (ET) receptors in the IMCD in order to gain insight into this unique renal autocrine system. Radioligand binding studies with I-125-ET-1 yielded a B(max) of 205.7 fmol/mg and a K(D) of 218 pm for ET-1. Similar studies with I-125-ET-3 yielded two populations of receptors for ET-3, one with a K(D) of 50 pm and one with a K(D) of 920 pM. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of IMCD cells covalently labeling with I-125-ET-1 yielded two bands, one at 97 kDa with affinities of ET-1 greater-than-or-equal-to ET-2 >> ET-3 and one at 47 kDa with affinities ET-1 greater-than-or-equal-to ET-2 = ET-3. Reverse transcription and polymerase chain reaction revealed the presence of both endothelin receptor types A and B. These data indicate that IMCD cells have high affinity, high density receptors for endothelin and express both known types of endothelin receptor.	UNIV UTAH,SCH MED,SALT LAKE CITY,UT 84112; VET ADM MED CTR,SALT LAKE CITY,UT 84148	Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA)								BALDI E, 1991, J PHARMACOL EXP THER, V256, P581; BOUSSOMITTLER D, 1991, BIOCHEM BIOPH RES CO, V178, P921, DOI 10.1016/0006-291X(91)90979-H; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEGOUVILLE ACL, 1989, LIFE SCI, V45, P1499, DOI 10.1016/0024-3205(89)90415-3; HARPER PA, 1984, KIDNEY INT, V26, P91; KITAMURA K, 1989, BIOCHEM BIOPH RES CO, V161, P348, DOI 10.1016/0006-291X(89)91603-3; KOHAN DE, 1991, J AM SOC NEPHROL, V2, P150; KOHAN DE, 1991, AM J PHYSIOL, V261, pF221, DOI 10.1152/ajprenal.1991.261.2.F221; KOZUKA M, 1991, J BIOL CHEM, V266, P16892; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; MARTIN ER, 1989, BIOCHEM BIOPH RES CO, V162, P130, DOI 10.1016/0006-291X(89)91972-4; MARTIN ER, 1990, J BIOL CHEM, V265, P14044; NADLER S P, 1991, Journal of the American Society of Nephrology, V2, P410; NEUSER D, 1990, EUR J PHARMACOL, V176, P241, DOI 10.1016/0014-2999(90)90536-F; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SCHNERMANN J, 1991, Journal of the American Society of Nephrology, V2, P416; SOKOLOVSKY M, 1991, TRENDS BIOCHEM SCI, V16, P212; TAKAYANAGI R, 1991, REGUL PEPTIDES, V32, P23, DOI 10.1016/0167-0115(91)90004-Z; TERADA Y, 1991, Journal of the American Society of Nephrology, V2, P418; WAEBER C, 1990, EUR J PHARMACOL, V176, P233, DOI 10.1016/0014-2999(90)90534-D; WILLIAMS DL, 1991, BIOCHEM BIOPH RES CO, V175, P556, DOI 10.1016/0006-291X(91)91601-8; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZEIDEL ML, 1989, AM J PHYSIOL, V257, pC1101, DOI 10.1152/ajpcell.1989.257.6.C1101	23	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12336	12340						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1318315				2022-12-27	WOS:A1992HY94700102
J	MOUILLAC, B; CARON, M; BONIN, H; DENNIS, M; BOUVIER, M				MOUILLAC, B; CARON, M; BONIN, H; DENNIS, M; BOUVIER, M			AGONIST-MODULATED PALMITOYLATION OF BETA-2-ADRENERGIC RECEPTOR IN SF9 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; INFECTED INSECT CELLS; PHOSPHORYLATION SITES; TRANSFERRIN RECEPTOR; EXPRESSION VECTORS; C-MYC; PROTEIN; DESENSITIZATION; PALMITYLATION; BINDING	The palmitoylation of the human beta2-adrenergic receptor (beta2-AR) was studied in recombinant baculo-virus-infected insect Sf9 cells. At 48 h post-infection, a high level expression of an epitope-tagged beta2-AR (10-25 pmol/mg protein) was detected by [I-125]iodocyanopindolol ([I-125]CYP) binding assays. The identity of the receptor was confirmed both by photoaffinity labeling and immunoblotting. The fusion receptor displayed typical beta2-AR pharmacological properties and conferred a beta-adrenergic sensitive adenylyl cyclase activity to the Sf9 cells. Moreover, exposure of the Sf9 cells to the beta-adrenergic agonist isoproterenol induced a rapid desensitization of the receptor-stimulated adenylyl cyclase activity. Purification of the epitope-tagged beta2-AR by immunoprecipitation as well as by alprenolol-Sepharose affinity chromatography revealed that the receptor is covalently modified with palmitic acid in the insect cells as is observed in mammalian cells. In addition, short-term incubation of the cells with isoproterenol led to a specific increase in the incorporation of [H-3]palmitate in the receptor, consistent with a rapid agonist-modulated turnover of the beta2-AR-attached palmitic acid. These results suggest that agonist-mediated regulation of beta2-AR post-translational palmitoylation could represent an other regulatory process for G protein-coupled receptors.	UNIV MONTREAL,DEPT BIOCHEM,POB 6128,STN A,MONTREAL H3C 3J7,QUEBEC,CANADA; BIOTECHNOL RES INST,MONTREAL H4P 2R2,QUEBEC,CANADA	Universite de Montreal; National Research Council Canada			MOUILLAC, Bernard/M-3896-2014; Bouvier, Michel/H-2758-2014	MOUILLAC, Bernard/0000-0002-3906-8673; Bouvier, Michel/0000-0003-1128-0100				ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; BONATTI S, 1989, J BIOL CHEM, V264, P12590; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BOUVIER M, 1987, MOL PHARMACOL, V33, P133; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; CIERNIEWSKI CS, 1989, J BIOL CHEM, V264, P12158; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GEORGE ST, 1989, BIOCHEM BIOPH RES CO, V163, P1265, DOI 10.1016/0006-291X(89)91114-5; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; KING K, 1990, SCIENCE, V250, P121, DOI 10.1126/science.2171146; KOBILKA BK, 1987, J BIOL CHEM, V262, P15796; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MORRISON DF, 1991, J BIOL CHEM, V266, P20118; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OMARY MB, 1981, J BIOL CHEM, V256, P2888; PARKER EM, 1991, J BIOL CHEM, V266, P519; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; RANDS E, 1990, J BIOL CHEM, V265, P10759; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SKANE JHP, 1989, J CELL BIOL, V108, P613; STAUFENBIEL M, 1988, J BIOL CHEM, V263, P13615; SUMMERS MD, 1987, B TEXAS AGR EXPT STA, V1555, P10; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; WONG SKF, 1990, J BIOL CHEM, V265, P6219	32	178	181	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21733	21737						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328244				2022-12-27	WOS:A1992JV01100074
J	HOU, JZ; KAN, M; WANG, F; XU, JM; NAKAHARA, M; MCBRIDE, G; MCKEEHAN, K; MCKEEHAN, WL				HOU, JZ; KAN, M; WANG, F; XU, JM; NAKAHARA, M; MCBRIDE, G; MCKEEHAN, K; MCKEEHAN, WL			SUBSTITUTION OF PUTATIVE HALF-CYSTINE RESIDUES IN HEPARIN-BINDING FIBROBLAST GROWTH-FACTOR RECEPTORS - LOSS OF BINDING-ACTIVITY IN BOTH 2-LOOP AND 3-LOOP ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; PROTEINS; CLONING; FAMILY; COMMON; CELL	Alternate use of an exon coding for an 89-residue NH2 terminal immunoglobulin-like disulfide loop results in isoforms of the heparin-binding fibroblast growth factor receptor (FGF-R) with three (FGF-R-alpha) and two (FGF-R-beta) Ig-like loops in the extracellular domain. Both FGF-R-alpha and FGF-R-beta isoforms exhibit qualitatively similar ligand-binding activities. In this report, we show by site-directed mutagenesis and analysis of ligand-binding activity in transfected cells that substitution of a cysteine that potentially forms an intra-loop disulfide in either juxtamembrane Loop II or III disrupted maturation and formation of the ligand-binding site in both FGF-R-alpha and FGF-R-beta isoforms. Neither three loop FGF-R-alpha constructions coding for intact Loops I and II adjacent to defective Loop III nor intact Loops I and III separated by defective Loop II exhibited ligand-binding activity. In addition, a two-loop molecule of tandem Loops I and III was inactive. The results suggest that single Loops I, II, or III of FGF-R are insufficient to form a ligand-binding site. Loop I does not form an independent ligand-binding site with either Loop II or III, but interacts with a common ligand-binding site formed by Loops II and III (Xu, J., Nakahara, M., Crabb, J. W., Shi, E., Matuo, Y., Fraser, M., Kan, M., Hou, J., and McKeehan, W. L. (1992) J. Biol. Chem. 267, 17792-17803, 1992).	W ALTON JONES CELL SCI CTR, 10 OLD BARN RD, LAKE PLACID, NY 12946 USA						NCI NIH HHS [CA37589] Funding Source: Medline; NIDDK NIH HHS [DK40739, DK35310] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA037589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040739, R01DK035310] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAN M, 1988, J BIOL CHEM, V263, P11306; KAN M, 1991, METHOD ENZYMOL, V198, P158; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PINNA LA, 1990, PEPT PROT PHOSPH, P145; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUDIKOFF S, 1986, P NATL ACAD SCI USA, V83, P7875, DOI 10.1073/pnas.83.20.7875; SHI E, 1991, J BIOL CHEM, V266, P5774; SHI E, 1991, Journal of Cell Biology, V115, p416A; SHI E, 1991, Journal of Cell Biology, V115, p417A; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; XU JM, 1992, J BIOL CHEM, V267, P17792	20	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17804	17808						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325450				2022-12-27	WOS:A1992JM22300052
J	KATO, A; GORES, GJ; LARUSSO, NF				KATO, A; GORES, GJ; LARUSSO, NF			SECRETIN STIMULATES EXOCYTOSIS IN ISOLATED BILE-DUCT EPITHELIAL-CELLS BY A CYCLIC AMP-MEDIATED MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMAL RAT-LIVER; INTRACELLULAR PH; PLASMA-MEMBRANE; ENDOCYTOSIS; VESICLES; FLUORESCENCE; MICROTUBULES; HEPATOCYTES; ACIDOSIS; CULTURE	Intrahepatic bile duct epithelial cells, or cholangiocytes, contribute to bile secretion in response to hormones, including secretin. However, the mechanism by which secretin stimulates ductular bile flow is unknown. Since recent data in nonhepatic epithelia have suggested a role for exocytosis in fluid secretion, we tested the hypothesis that secretin stimulates exocytosis by isolated cholangiocytes. Cholangiocytes were isolated from normal rat liver by a newly described method employing enzymatic digestion and mechanical disruption followed by immunomagnetic separation using specific monoclonal antibodies, and exocytosis was measured using a fluorescence unquenching assay employing acridine orange. Secretin caused a dose-dependent (10(-12)-10(-7) M) increase in acridine orange fluorescence by acridine orange-loaded cholangiocytes with a peak response at 10 min; the half-maximal concentration of secretin was 7 x 10(-9) M. The secretin effect was inhibited by preincubation of cholangiocytes with colchicine (30% inhibition, p < 0.05) or trypsin (90% inhibition, p < 0.001); no inhibition was seen with lumicolchicine and heat-inactivated trypsin. Cholecystokinin, insulin, and somatostatin had no effect on fluorescence of acridine orange-loaded cholangiocytes; secretin had no effect on fluorescence of acridine orange-loaded hepatocytes or hepatic endothelial cells. Exposure of isolated cholangiocytes to secretin at doses that stimulated exocytosis caused a dose-dependent increase in cyclic AMP levels (218% maximal increase, p < 0.05); moreover, an analogue of cyclic AMP stimulated exocytosis by cholangiocytes. Secretin had no effect on intracellular calcium concentration using Fura-2-loaded cholangiocytes assessed by digitized video microscopy. Our results demonstrate, for the first time, that secretin stimulates exocytosis by rat cholangiocytes. The effect is cell- and hormone-specific, dependent on intact microtubules, on a protein(s) on the external surface of cholangiocytes, and on changes in cellular levels of cyclic AMP. The results are consistent with the hypothesis that secretin-induced changes in bile flow may involve an exocytic process.	MAYO MED SCH CLIN & FDN,CTR BASIC RES DIGEST DIS,DEPT INTERNAL MED,ROCHESTER,MN 55905; MAYO MED SCH CLIN & FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK024031, R37DK024031] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-24031, DK-45331] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPINI G, 1988, J CLIN INVEST, V81, P569, DOI 10.1172/JCI113355; ALVARO D, 1991, HEPATOLOGY, V14, pA152; ARGENT BE, 1986, Q J EXP PHYSIOL CMS, V71, P633, DOI 10.1113/expphysiol.1986.sp003023; BAFFER BM, 1990, GASTROENTEROLOGY, V98, pA218; BJERKNES R, 1984, SCAND J HAEMATOL, V33, P197; BROWN D, 1989, AM J PHYSIOL, V256, pF1, DOI 10.1152/ajprenal.1989.256.1.F1; BUANES T, 1987, ACTA PHYSIOL SCAND, V131, P55, DOI 10.1111/j.1748-1716.1987.tb08205.x; BUANES T, 1988, GASTROENTEROLOGY, V95, P417, DOI 10.1016/0016-5085(88)90499-4; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CASE RM, 1986, EXOCRINE PANCREAS BI, P213; ERLINGER S, 1988, LIVER BIOL PATHOBIOL, P643; FAROUK M, 1990, HEPATOLOGY, V12, P917; FORKER EL, 1967, J CLIN INVEST, V46, P1189, DOI 10.1172/JCI105612; FORTE JG, 1989, HDB PHYSL, V3, P207; GOLDFARB S, 1963, J LAB CLIN MED, V62, P608; GORES GJ, 1989, J CLIN INVEST, V83, P386, DOI 10.1172/JCI113896; GORES GJ, 1986, HEPATOLOGY, V6, P511, DOI 10.1002/hep.1840060331; GORES GJ, 1988, AM J PHYSIOL, V255, pC315, DOI 10.1152/ajpcell.1988.255.3.C315; GRAY EG, 1975, PROC R SOC SER B-BIO, V190, P369, DOI 10.1098/rspb.1975.0100; GRAY MA, 1988, J MEMBRANE BIOL, V105, P131, DOI 10.1007/BF02009166; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HENDERSO.PJ, 1969, BIOCHEM J, V111, P521, DOI 10.1042/bj1110521; HUBEL KA, 1972, GASTROENTEROLOGY, V62, P318; ISHII M, 1990, J HISTOCHEM CYTOCHEM, V38, P515, DOI 10.1177/38.4.2319122; ISHII M, 1989, GASTROENTEROLOGY, V97, P1236, DOI 10.1016/0016-5085(89)91695-8; ISHII M, 1990, GASTROENTEROLOGY, V98, P1284, DOI 10.1016/0016-5085(90)90346-3; JONES AL, 1990, HEPATOLOGY TXB LIVER, P3; KEMPSON SA, 1989, J BIOL CHEM, V264, P18451; KUIJPERS GAJ, 1989, J BIOL CHEM, V264, P698; LACY PE, 1975, LAB INVEST, V33, P570; LENZEN R, 1990, HEPATOLOGY, V12, P810; LUKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P258; NORTHRUP TE, 1979, AM J PHYSIOL, V236, pE649, DOI 10.1152/ajpendo.1979.236.6.E649; OHKUMA S, 1982, P NATL ACAD SCI-BIOL, V79, P2758, DOI 10.1073/pnas.79.9.2758; OLSSON GM, 1990, ANAL CELL PATHOL, V2, P179; PARCZYK K, 1989, J BIOL CHEM, V264, P16837; PLATTNER H, 1982, J CELL BIOL, V92, P368, DOI 10.1083/jcb.92.2.368; STUENKEL EL, 1990, PFLUG ARCH EUR J PHY, V416, P652, DOI 10.1007/BF00370610; TAVOLONI N, 1987, SEMIN LIVER DIS, V7, P280, DOI 10.1055/s-2008-1040583; TIETZ P S, 1992, Gastroenterology, V102, pA901; TOMODA H, 1989, J BIOL CHEM, V264, P15445; TRIMBLE ER, 1987, P NATL ACAD SCI USA, V84, P3146, DOI 10.1073/pnas.84.10.3146; VEEL T, 1990, ACTA PHYSIOL SCAND, V139, P603, DOI 10.1111/j.1748-1716.1990.tb08965.x; VERKMAN AS, 1989, AM J PHYSIOL, V257, pC837, DOI 10.1152/ajpcell.1989.257.5.C837; WARNOCK DG, 1982, AM J PHYSIOL, V242, pF733, DOI 10.1152/ajprenal.1982.242.6.F733; WHEELER HO, 1966, AM J PHYSIOL, V210, P1153, DOI 10.1152/ajplegacy.1966.210.5.1153; WILSON L, 1986, BIOCHEMISTRY-US, V5, P2463	47	151	153	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15523	15529						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322400				2022-12-27	WOS:A1992JG11300043
J	KIM, SJ; KIM, KY; TAPSCOTT, SJ; WINOKUR, TS; PARK, K; FUJIKI, H; WEINTRAUB, H; ROBERTS, AB				KIM, SJ; KIM, KY; TAPSCOTT, SJ; WINOKUR, TS; PARK, K; FUJIKI, H; WEINTRAUB, H; ROBERTS, AB			INHIBITION OF PROTEIN PHOSPHATASES BLOCKS MYOGENESIS BY 1ST ALTERING MYOD BINDING-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH-FACTOR; OKADAIC ACID; TUMOR-PROMOTER; MUSCLE DIFFERENTIATION; NUCLEAR FACTOR; GENE FAMILY; PHOSPHORYLATION; CELLS; ACTIVATION; EXPRESSION	To examine the role of protein phosphatases in skeletal muscle differentiation, C2C12 myoblasts were treated with okadaic acid, a potent in vitro inhibitor of protein phosphatases 1 and 2A which regulate various cellular events in intact cells. We now show that okadaic acid treatment of the mouse myoblast C2C12 cell line reversibly altered the morphology of the cells and blocked differentiation. At a molecular level, it extinguished expression of the myogenic determination genes, MyoD1 and myogenin, but induced the expression of an inhibitor of differentiation, Id. Analysis of the MyoD1 promoter showed that inhibition of MyoD1 expression by okadaic acid occurs at the transcriptional level. These changes occur 10-20 h after okadaic acid treatment. However, within 1 h of treatment the ability of muscle extracts to support a specific MyoD-dependent gel mobility shift using a MyoD DNA binding site is lost. These data suggest that protein phosphatases play an important role during myogenic differentiation.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; NATL CANC CTR,RES INST,TOKYO 104,JAPAN	Fred Hutchinson Cancer Center; National Cancer Center - Japan	KIM, SJ (corresponding author), NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892, USA.			Winokur, Thomas/0000-0002-6785-2991				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BIALOJAN C, 1988, BIOCHEM J, V256, P248; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ERDODI F, 1988, BIOCHEM BIOPH RES CO, V153, P156, DOI 10.1016/S0006-291X(88)81202-6; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; ISSINGER OG, 1988, EMBO J, V7, P1621, DOI 10.1002/j.1460-2075.1988.tb02988.x; KIM SJ, 1990, CELL REGUL, V1, P269, DOI 10.1091/mbc.1.3.269; KONDO K, 1989, J CELL BIOL, V109, P285, DOI 10.1083/jcb.109.1.285; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PARK K, 1992, J BIOL CHEM, V267, P10810; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SASSA T, 1989, BIOCHEM BIOPH RES CO, V159, P939, DOI 10.1016/0006-291X(89)92199-2; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TAPSCOTT SJ, 1989, SCIENCE, V245, P532, DOI 10.1126/science.2547249; THEVENIN C, 1990, New Biologist, V2, P793; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WICE B, 1987, J BIOL CHEM, V262, P1810; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	43	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15140	15145						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321827				2022-12-27	WOS:A1992JF08800093
J	CHANG, CN; DOONG, SL; ZHOU, JH; BEACH, JW; JEONG, LS; CHU, CK; TSAI, CH; CHENG, YC				CHANG, CN; DOONG, SL; ZHOU, JH; BEACH, JW; JEONG, LS; CHU, CK; TSAI, CH; CHENG, YC			DEOXYCYTIDINE DEAMINASE-RESISTANT STEREOISOMER IS THE ACTIVE FORM OF (+-)-2',3'-DIDEOXY-3'-THIACYTIDINE IN THE INHIBITION OF HEPATITIS-B VIRUS-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCELLULAR-CARCINOMA; NUCLEOSIDE ANALOGS; INVITRO; DNA; 2',3'-DIDEOXYNUCLEOSIDES; POLYMERASE; PURINE	2',3'-Dideoxy-3'-thiacytidine ((+/-)-SddC) was found to have potent activity against human hepatitis B virus as well as human immunodeficiency viruses in culture. The (-)form ((-)-SddC) which is resistant to deoxycytidine deaminase was found to be the more active antiviral stereoisomer than the (+)-form ((+)-SddC). The (+)-SddC is susceptible to deamination by deoxycytidine deaminase and is 25- and 12-fold more toxic than (-)-SddC in CEM cells in terms of anti-cell growth and anti-mitochondrial DNA synthesis, respectively. Similar results were obtained using a mixture of their 5-fluoro analogs ((+/-)-FSddC). Unlike 2',3'-dideoxycytidine, which is a potent inhibitor of mitochondrial DNA synthesis and results in such delayed toxicity as peripheral neuropathy with long term usage, (-)-SddC does not affect mitochondrial DNA synthesis. The (-)form is phosphorylated to (-)-SddCMP and is subsequently converted to (-)-SddCDP and (-)-SddCTP. One additional major metabolite which has been tentatively assigned the name "(-)-SddCMP sialate" was also identified. No significant difference in terms of the profiles of the metabolites was found between 4 and 24 h. There is an appreciable amount of (-)-SddCTP detectable 24 h after removal of the drug. (-)-SddCTP was also found to be approximately 3-fold more potent than (+)-SddCTP in inhibiting human hepatitis B virus DNA polymerase. This is the first nucleoside analog with the unnatural sugar configuration demonstrated to have antiviral activity.	YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; UNIV GEORGIA,COLL PHARM,DEPT MED CHEM,ATHENS,GA 30602	Yale University; University System of Georgia; University of Georgia				DOONG, SHIN-LIAN/0000-0002-0936-3858	NCI NIH HHS [CA44358] Funding Source: Medline; NIAID NIH HHS [AI25899] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044358] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI025899, R01AI025899] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ayoola E.A., 1988, B WORLD HEALTH ORGAN, V66, P443; BEASLEY RP, 1981, LANCET, V2, P1129; CHANG LJ, 1990, J VIROL, V64, P5553, DOI 10.1128/JVI.64.11.5553-5558.1990; CHENG YC, 1983, BIOCHEM PHARMACOL, V32, P726, DOI 10.1016/0006-2952(83)90503-8; DIBISCEGLIE AM, 1988, ANN INTERN MED, V108, P390, DOI 10.7326/0003-4819-108-3-390; DOONG SL, 1991, P NATL ACAD SCI USA, V88, P8495, DOI 10.1073/pnas.88.19.8495; GREENBERG ML, 1990, ANN NY ACAD SCI, V616, P517; HIRSCHMAN SZ, 1978, J MED VIROL, V2, P61, DOI 10.1002/jmv.1890020109; LEE B, 1989, ANTIMICROB AGENTS CH, V33, P336, DOI 10.1128/AAC.33.3.336; MANIATIS T, 1982, MOL CLONING LABORATO, P468; MATTHES E, 1990, ANTIMICROB AGENTS CH, V34, P1986, DOI 10.1128/AAC.34.10.1986; MATTHES E, 1991, ANTIMICROB AGENTS CH, V35, P1254, DOI 10.1128/AAC.35.6.1254; MEISEL H, 1990, J MED VIROL, V30, P137, DOI 10.1002/jmv.1890300211; PRICE PM, 1989, P NATL ACAD SCI USA, V86, P8541, DOI 10.1073/pnas.86.21.8541; RUTH JL, 1981, MOL PHARMACOL, V20, P415; SOUDEYNS H, 1991, ANTIMICROB AGENTS CH, V35, P1386, DOI 10.1128/AAC.35.7.1386; SUZUKI S, 1988, BIOCHEM BIOPH RES CO, V156, P1144, DOI 10.1016/S0006-291X(88)80752-6; TOWNSEND A, 1985, CANCER RES, V45, P3522; WAINBERG MA, 1990, ANN NY ACAD SCI, V616, P346; YOKOTA T, 1990, ANTIMICROB AGENTS CH, V34, P1326, DOI 10.1128/AAC.34.7.1326	20	219	247	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13938	13942						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321132				2022-12-27	WOS:A1992JD32500027
J	HASHIMOTO, N; FEENER, EP; ZHANG, WR; GOLDSTEIN, BJ				HASHIMOTO, N; FEENER, EP; ZHANG, WR; GOLDSTEIN, BJ			INSULIN-RECEPTOR PROTEIN-TYROSINE PHOSPHATASES - LEUKOCYTE COMMON ANTIGEN-RELATED PHOSPHATASE RAPIDLY DEACTIVATES THE INSULIN-RECEPTOR KINASE BY PREFERENTIAL DEPHOSPHORYLATION OF THE RECEPTOR REGULATORY DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-PLACENTA; BETA-SUBUNIT; CLONING; AUTOPHOSPHORYLATION; FAMILY; PHOSPHORYLATION; IDENTIFICATION; EXPRESSION; MEMBER; SITES	A number of protein-tyrosine phosphatase(s) (PTPases) have been shown to dephosphorylate the insulin receptor in vitro; however, it is not known whether any individual PTPase has specificity for certain phosphotyrosine residues of the receptor that regulate its intrinsic tyrosine kinase activity. We evaluated the deactivation of the insulin receptor kinase by three candidate enzymes that are expressed in insulin-sensitive rat tissues, including the receptor-like PTPases LAR and LRP, and the intracellular enzyme, PTPase1B. Purified insulin receptors were activated by insulin and receptor dephosphorylation, and kinase activity was quantitated after incubation with recombinant PTPases from an Escherichia coli expression system. When related to the level of overall receptor dephosphorylation, LAR deactivated the receptor kinase 3.1 and 2.1 times more rapidly than either PTPase1B or LRP, respectively (p < 0.03). To assess whether these effects were associated with preferential dephosphorylation of the regulatory (Tyr-1150) domain of the receptor beta-subunit, we performed tryptic mapping of the insulin receptor beta-subunit after dephosphorylation by PTPases. Relative to the rate of initial loss of P-32 from receptor C-terminal sites, LAR dephosphorylated the Tris-phosphorylated Tyr-1150 domain 3.5 and 3.7 times more rapidly than either PTPase1B or LRP, respectively (p < 0.01). The accelerated deactivation of the insulin receptor kinase by LAR and its relative preference for regulatory phosphotyrosine residues further support a potential role for this transmembrane PTPase in the physiological regulation of insulin receptors in intact cells.	BRIGHAM & WOMENS HOSP,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK043396] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36836, DK43396] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVRUCH J, 1990, HDB EXPT PHARM, V92, P313; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATTERJEE S, 1992, PEPTIDES CHEM BIOL, P553; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CHO HJ, 1991, BIOCHEMISTRY-US, V30, P6210, DOI 10.1021/bi00239a019; CHO HJ, 1992, BIOCHEMISTRY-US, V31, P133, DOI 10.1021/bi00116a019; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GOLDSTEIN BJ, 1992, J CELL BIOCHEM, V48, P33, DOI 10.1002/jcb.240480107; GOLDSTEIN BJ, 1992, MOL CELL BIOCHEM, V109, P107; GOLDSTEIN BJ, 1991, ADV PROTEIN PHOSPHAT, V6, P1; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HASHIMOTO N, 1992, IN PRESS BIOCH J, V284; JIRIK FR, 1990, FEBS LETT, V273, P239, DOI 10.1016/0014-5793(90)81094-5; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KASUGA M, 1985, METHOD ENZYMOL, V109, P609; KING MJ, 1991, BIOCHEM J, V275, P413, DOI 10.1042/bj2750413; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MYERS MG, 1991, J BIOL CHEM, V266, P10616; PALLEN CJ, 1991, BIOCHEM J, V276, P315, DOI 10.1042/bj2760315; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SALE GJ, 1991, ADV PROTEIN PHOSPHAT, V6, P159; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TAPPIA PS, 1991, BIOCHEM J, V278, P69, DOI 10.1042/bj2780069; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WOODFORD TA, 1991, ADV PROTEIN PHOSPHAT, V6, P503; ZHANG WR, 1991, BIOCHEM BIOPH RES CO, V178, P1291, DOI 10.1016/0006-291X(91)91034-A	42	100	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13811	13814						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321126				2022-12-27	WOS:A1992JD32500006
J	LIEBL, U; PEZENNEC, S; RIEDEL, A; KELLNER, E; NITSCHKE, W				LIEBL, U; PEZENNEC, S; RIEDEL, A; KELLNER, E; NITSCHKE, W			THE RIESKE FES CENTER FROM THE GRAM-POSITIVE BACTERIUM PS3 AND ITS INTERACTION WITH THE MENAQUINONE POOL STUDIED BY EPR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIOBACTERIUM-CHLORUM; ISOPRENOID QUINONE; ELECTRON-TRANSPORT; MEMBRANE; STIGMATELLIN; OXIDATION; BINDING; CYTOCHROMES; INHIBITION; RESONANCE	The Rieske 2Fe2S center from Bacillus PS3, a Gram-positive thermophilic eubacterium, has been studied by EPR spectroscopy. Its redox midpoint potential at pH 7.0 was determined to be +165 +/- 10 mV and was found to decrease with an apparent slope of -80 mV/pH unit above pH 7.9. The Q(o)-site inhibitor stigmatellin induced spectral changes analogous to those reported for Rieske centers from mitochondria and chloroplasts. The redox midpoint potential of the PS3 Rieske cluster was not affected by stigmatellin. The orientation of the g tensor was similar to other Rieske centers (g(z) and g(y) are oriented parallel, g(x) is oriented perpendicular to the membrane plane). The shape of the EPR spectrum of the Rieske cluster from PS3 changed as a function of the redox state of the menaquinone (MK) pool. This permitted the redox midpoint potential of the MK pool to be determined in the membrane. Values of -60 +/- 20 mV at pH 7.0 and of -130 +/- 20 mV at pH 8.0 were obtained. The results are compared with already published data from other Rieske centers. It is proposed that all Rieske centers that function in electron transport chains using MK as pool quinone show common features that distinguish them from Rieske centers operating in ubiquinone- or plastoquinone-based electron transfer chains.	INST BIOL PHYSICO CHIM,13 RUE PIERRE & MARIE CURIE,F-75005 PARIS,FRANCE; CENS,DEPT BIOL CELLULAIRE & MOLEC,CNRS,URA 1290,BIOENERGET SECT,F-91191 GIF SUR YVETTE,FRANCE; UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,W-8400 REGENSBURG,GERMANY	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Regensburg			Nitschke, Wolfgang/C-4812-2012	Nitschke, Wolfgang/0000-0003-2084-3032; LIEBL, Ursula/0000-0003-0869-4388; Pezennec, Stephane/0000-0003-1265-8048				BLASIE JK, 1978, BIOCHIM BIOPHYS ACTA, V501, P33, DOI 10.1016/0005-2728(78)90093-2; BRANDT U, 1988, EUR J BIOCHEM, V173, P499, DOI 10.1111/j.1432-1033.1988.tb14026.x; BRITT RD, 1991, BIOCHEMISTRY-US, V30, P1892, DOI 10.1021/bi00221a023; COLLINS MD, 1981, MICROBIOL REV, V45, P316, DOI 10.1128/MMBR.45.2.316-354.1981; DEVRIES S, 1979, BIOCHIM BIOPHYS ACTA, V546, P316, DOI 10.1016/0005-2728(79)90049-5; DUTTON PL, 1971, BIOCHIM BIOPHYS ACTA, V226, P63, DOI 10.1016/0005-2728(71)90178-2; GURBIEL RJ, 1989, BIOCHEMISTRY-US, V28, P4861, DOI 10.1021/bi00437a051; GURBIEL RJ, 1991, BIOCHEMISTRY-US, V30, P11579, DOI 10.1021/bi00113a013; HAUSKA G, 1988, J BIOENERG BIOMEMBR, V20, P211, DOI 10.1007/BF00768395; HIRAISHI A, 1989, ARCH MICROBIOL, V151, P378, DOI 10.1007/BF00406568; HURT EC, 1984, FEBS LETT, V168, P149, DOI 10.1016/0014-5793(84)80225-2; Kagawa Y, 1979, Methods Enzymol, V55, P781; KNAFF DB, 1976, BIOCHIM BIOPHYS ACTA, V430, P24; Kroger A., 1985, COENZYME Q, P285; KUILA D, 1986, J BIOL CHEM, V261, P2768; KUTOH E, 1988, J BIOL CHEM, V263, P9020; LEWIS RJ, 1981, J BIOL CHEM, V256, P543; LIEBL U, 1990, FEBS LETT, V261, P427, DOI 10.1016/0014-5793(90)80608-L; MATSUURA K, 1983, J BIOL CHEM, V258, P1571; NITSCHKE W, 1989, BIOCHIM BIOPHYS ACTA, V974, P223, DOI 10.1016/S0005-2728(89)80376-7; OETTMEIER W, 1985, BIOCHIM BIOPHYS ACTA, V807, P216, DOI 10.1016/0005-2728(85)90125-2; PRINCE RC, 1976, FEBS LETT, V65, P117, DOI 10.1016/0014-5793(76)80634-5; REDFEARN ER, 1968, BIOCHEM J, V106, P50; RIEDEL A, 1991, J BIOL CHEM, V266, P17838; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; VENTUROLI G, 1990, HIGHLIGHTS IN UBIQUINONE RESEARCH, P116; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; ZANNONI D, 1985, FEBS LETT, V193, P93, DOI 10.1016/0014-5793(85)80086-7	28	62	62	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14068	14072						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321134				2022-12-27	WOS:A1992JD32500046
J	LICHTNER, RB; WIEDEMUTH, M; KITTMANN, A; ULLRICH, A; SCHIRRMACHER, V; KHAZAIE, K				LICHTNER, RB; WIEDEMUTH, M; KITTMANN, A; ULLRICH, A; SCHIRRMACHER, V; KHAZAIE, K			LIGAND-INDUCED ACTIVATION OF EPIDERMAL GROWTH-FACTOR RECEPTOR IN INTACT RAT MAMMARY ADENOCARCINOMA CELLS WITHOUT DETECTABLE RECEPTOR PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; ALTERED AUTOPHOSPHORYLATION SITES; SERINE-THREONINE KINASE; ATP-BINDING-SITE; EGF-RECEPTOR; SIGNAL TRANSDUCTION; CARCINOMA-CELLS; RAPID PHOSPHORYLATION; MORPHOLOGICAL-CHANGES; SELF-PHOSPHORYLATION	Expression and function of epidermal growth factor receptor (EGFR) was investigated in a metastatic cell clone (MTLn3) derived from the 13762NF rat mammary adenocarcinoma. No receptor phosphorylation could be identified in intact cells or in membrane preparations, while EGF-dependent phosphorylation of substrates occurred in intact cells. Indications for active suppression of receptor phosphorylation came from the fact that EGFRs bound in immunocomplexes or associated with the cytoskeleton of detergent treated cells were able to undergo basal and EGF-induced phosphorylation in vitro. Cross-linking experiments with I-125-EGF, as well as [S-35]methionine labeling followed by immunoprecipitation with receptor specific antibodies readily detected in MTLn3 cells the expected 170-kDa EGFR protein. In addition, two proteins with molecular masses of 420-480 and 95 kDa specifically bound I-125-EGF on intact MTLn3 and sparse cultures of A431 cells. Phosphorylation of the 420-480 kDa molecule could be identified in immunocomplexes of EGFRs isolated from MTLn3 and sparse A431 cells, but the 95-kDa receptor molecule was never phosphorylated. While the presence of alternative forms of EGFR in the highly metastatic cell clone MTLn3 was unexpected, our observations of inefficient receptor autophosphorylation are in agreement with other recent reports and suggest that in MTLn3 cells EGFR-mediated signal transduction can be an event independent from receptor autophosphorylation.	GERMAN CANC RES CTR, DEPT IMMUNOL & GENET, W-6900 HEIDELBERG 1, GERMANY; MAX PLANCK INST BIOCHEM, W-8033 MARTINSRIED, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Max Planck Society								AKIYAMA T, 1986, J BIOL CHEM, V261, P4797; BACCARINI M, 1991, J BIOL CHEM, V266, P10941; BARON V, 1989, BIOCHEM J, V260, P749, DOI 10.1042/bj2600749; BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BISHOP R, 1983, BIOCHEM BIOPH RES CO, V115, P536, DOI 10.1016/S0006-291X(83)80178-8; BLAY J, 1985, J CELL PHYSIOL, V124, P107, DOI 10.1002/jcp.1041240117; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BREMER EG, 1986, J BIOL CHEM, V261, P2434; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHINKERS M, 1981, J CELL BIOL, V88, P422, DOI 10.1083/jcb.88.2.422; CHINKERS M, 1979, J CELL BIOL, V83, P260, DOI 10.1083/jcb.83.1.260; CONDORELLI G, 1989, J BIOL CHEM, V264, P12633; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; DEFIZE LHK, 1989, J CELL BIOL, V109, P2495, DOI 10.1083/jcb.109.5.2495; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FAVA RA, 1984, J BIOL CHEM, V259, P2636; FRACKELTON AR, 1983, MOL CELL BIOL, V3, P1343, DOI 10.1128/MCB.3.8.1343; GAMOU S, 1988, CELL STRUCT FUNCT, V13, P25, DOI 10.1247/csf.13.25; GILL GN, 1987, J CELL PHYSIOL, P35; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HENEGOUWEN PMP, 1989, J CELL BIOCHEM, V39, P455; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092-8674(81)90100-8; IGARASHI Y, 1990, BIOCHEM BIOPH RES CO, V172, P77, DOI 10.1016/S0006-291X(05)80175-5; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KING AC, 1982, J BIOL CHEM, V257, P3053; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LEE BA, 1991, J CELL BIOL, V113, P361, DOI 10.1083/jcb.113.2.361; LICHTNER RB, 1990, J CELL PHYSIOL, V144, P303, DOI 10.1002/jcp.1041440217; LICHTNER RB, 1987, CLIN EXP METASTAS, V5, P219, DOI 10.1007/BF00124304; LICHTNER RB, 1988, J CELL PHYSIOL, V137, P285, DOI 10.1002/jcp.1041370211; LICHTNER RB, 1987, CANCER RES, V47, P1870; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; NERI A, 1982, J NATL CANCER I, V68, P507; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PONZIO G, 1988, EMBO J, V7, P4111, DOI 10.1002/j.1460-2075.1988.tb03305.x; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROY LM, 1989, J CELL PHYSIOL, V140, P295, DOI 10.1002/jcp.1041400215; RUBIN RA, 1983, J BIOL CHEM, V258, P5177; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SHAW JP, 1988, J BIOL CHEM, V263, P1459; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SONG WX, 1991, J BIOL CHEM, V266, P10174; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANBELZEN N, 1990, J CELL PHYSIOL, V145, P365, DOI 10.1002/jcp.1041450223; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WIEGANT FAC, 1986, J CELL BIOL, V103, P87, DOI 10.1083/jcb.103.1.87; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	70	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11872	11880						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1318304				2022-12-27	WOS:A1992HY94700037
J	PETER, F; VAN, PN; SOLING, HD				PETER, F; VAN, PN; SOLING, HD			DIFFERENT SORTING OF LYS-ASP-GLU-LEU PROTEINS IN RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUMINAL ER PROTEINS; GOLGI-APPARATUS; ENDOPLASMIC-RETICULUM; LYSOSOMAL-ENZYMES; DISULFIDE-ISOMERASE; RECOGNITION MARKER; RETENTION SIGNAL; CIS; OLIGOSACCHARIDES; SUBFRACTIONATION	Most of the resident soluble proteins of the endoplasmic reticulum (ER) seem to be sorted into this compartment via their COOH-terminal tetrapeptide Lys-Asp-Glu-Leu (KDEL). This sorting is supposed to occur in a post-ER compartment. Three resident soluble ER glycoproteins belonging to the KDEL family are CaBP1, CaBP2, CaBP3 (= calreticulin), and CaBP4 (= grp94) (Nguyen Van, P., Peter, F., and Soling, H.-D. (1989) J. Biol. Chem. 264, 17494-17501). In rat liver, calreticulin possesses a carbohydrate moiety of the complex hybrid type with terminal galactoses (Nguyen Van, P., Peter, F., and Soling, H.-D. (1989) J. Biol. Chem. 264, 17494-17501). We can show now that practically all calreticulin molecules (and not only a fraction) possess terminal galactoses as well as the COOH-terminal KDEL sequence. This as well as pulse-chase experiments performed at 37 and 15-degrees-C indicate that calreticulin must have passed through the trans-Golgi. Subcellular fractionations of post-mitochondrial supernatants from isolated rat hepatocytes by sucrose-Nycodenz gradient centrifugation revealed that calreticulin is confined mainly to the rough ER, grp94 mainly to the smooth ER. CaBP1, a member of the thioredoxin family, was recovered in fractions which most likely represent the intermediate compartment. This indicates that KDEL is a sorting signal which leads to the retention of these proteins in the pre-Golgi compartments. However, additional factors, most likely residing within the specific KDEL protein itself, determine the final location of the protein within the pre-Golgi compartments. This is underlined by experiments in which the density dependent distribution of total KDEL proteins was studied using a COOH-terminal KDEL-specific antibody.	UNIV GOTTINGEN,ZENTRUM INNERE MED,KLIN BIOCHEM ABT,ROBERT KOCH STR 40,W-3400 GOTTINGEN,GERMANY	University of Gottingen								AROUSON NN, 1974, METHOD ENZYMOL, V31, P90; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V3, P150; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHU FK, 1986, J BIOL CHEM, V261, P172; DEUTSCHER SL, 1983, P NATL ACAD SCI-BIOL, V80, P3938, DOI 10.1073/pnas.80.13.3938; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HASELBECK A, 1990, GLYCOCONJUGATE J, V7, P63, DOI 10.1007/BF01050403; HORTIN GL, 1990, ANAL BIOCHEM, V188, P271, DOI 10.1016/0003-2697(90)90605-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; MCMENAMY RH, 1981, ANAL BIOCHEM, V112, P117, DOI 10.1016/0003-2697(81)90268-2; MINNIFIELD N, 1986, EUR J CELL BIOL, V42, P92; MORRE DJ, 1983, EUR J CELL BIOL, V31, P263; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; MURTHY KK, 1990, NUCLEIC ACIDS RES, V18, P4933, DOI 10.1093/nar/18.16.4933; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PELHAM HRB, 1989, ANN REV CELL BIOL, P1; POHLMANN R, 1982, J BIOL CHEM, V257, P5323; ROTH J, 1982, J CELL BIOL, V92, P223; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; VAN PN, 1989, J BIOL CHEM, V264, P17494; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VERDON B, 1983, METHOD ENZYMAT AN, V3, P374; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984	31	78	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10631	10637						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1316906				2022-12-27	WOS:A1992HV09000064
J	LUO, JH; AURELIAN, L				LUO, JH; AURELIAN, L			THE TRANSMEMBRANE HELICAL SEGMENT BUT NOT THE INVARIANT LYSINE IS REQUIRED FOR THE KINASE-ACTIVITY OF THE LARGE SUBUNIT OF HERPES-SIMPLEX VIRUS TYPE-2 RIBONUCLEOTIDE REDUCTASE (ICP10)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; ATP-BINDING SITE; INSULIN-RECEPTOR; TYROSINE KINASES; CELL-SURFACE; TRANSFORMATION; GENE; IDENTIFICATION; PROMOTER; ELEMENTS	The large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is a chimera consisting, at the amino terminus, of a Ser/Thr protein kinase (PK) with features of a signal peptide and a transmembrane (TM) helical segment, and at the carboxy-terminus, of the ribonucleotide reductase (Chung et al., 1989, 1990). Membrane immunofluorescence of ICP10 transformed cells with antibodies to synthetic peptides located upstream or downstream of the TM indicates that ICP10 is a membrane-spanning protein. Site-directed and deletion mutants were used to further characterize ICP10-PK. Mutation of Gly106 in catalytic motif I or of the invariant Lys in catalytic motif II, and deletion of both motifs (amino acids 106-178) did not eliminate kinase activity. PK activity was retained by the invariant Lys mutant expressed in bacteria and following protein separation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transfer to membrane filters. Both ICP10 and the invariant Lys mutant bound C-14-labeled rho-fluorosulfonylbenzoyl 5'-adenosine, an ATP affinity analog. The deletion mutant had 4-fold lower kinase activity than ICP10-PK, and it was insensitive to Mn2+, suggesting that these motifs are involved in Mn2+ activation of kinase activity. PK activity was lost by deletion of the TM segment (amino acid residues 85-106).	UNIV MARYLAND, SCH MED,DEPT PHARMACOL & EXPTL THERAPEUT, VIROL IMMUNOL LABS,10 S PINE ST, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT MICROBIOL, BALTIMORE, MD 21201 USA; JOHNS HOPKINS UNIV, SCH PUBL HLTH, DEPT BIOCHEM, BALTIMORE, MD 21205 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University					NATIONAL CANCER INSTITUTE [R01CA039691] Funding Source: NIH RePORTER; NCI NIH HHS [CA39691] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1989, ANN NY ACAD SCI, V567, P122, DOI 10.1111/j.1749-6632.1989.tb16464.x; AURELIAN L, 1989, CANCER CEL, V7, P187; BASU M, 1984, NATURE, V311, P477, DOI 10.1038/311477a0; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; CHUNG TD, 1990, VIROLOGY, V179, P168, DOI 10.1016/0042-6822(90)90286-Z; CHUNG TD, 1991, J GEN VIROL, V72, P1139, DOI 10.1099/0022-1317-72-5-1139; CHUNG TD, 1989, J VIROL, V63, P3389, DOI 10.1128/JVI.63.8.3389-3398.1989; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; ESCH FS, 1978, J BIOL CHEM, V253, P6100; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HAYASHI Y, 1985, P NATL ACAD SCI USA, V82, P8493, DOI 10.1073/pnas.82.24.8493; HEDO JA, 1987, J BIOL CHEM, V262, P954; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; INGEMARSON R, 1987, VIROLOGY, V156, P417, DOI 10.1016/0042-6822(87)90422-3; IWASAKA T, 1985, JPN J CANCER RES, V76, P946; JARIWALLA RJ, 1980, P NATL ACAD SCI-BIOL, V77, P2279, DOI 10.1073/pnas.77.4.2279; JONG SMJ, 1991, J VIROL, V65, P180, DOI 10.1128/JVI.65.1.180-189.1991; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KRUEGER JG, 1982, CELL, V28, P889, DOI 10.1016/0092-8674(82)90068-X; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LUO JH, 1991, J BIOL CHEM, V266, P20976; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MILMAN G, 1985, P NATL ACAD SCI USA, V82, P6300, DOI 10.1073/pnas.82.18.6300; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MORRISON BD, 1989, J BIOL CHEM, V264, P9994; ODA Y, 1991, J BIOL CHEM, V266, P16791; PARADIS H, 1991, J BIOL CHEM, V266, P9647; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; SELBY MJ, 1984, J BIOL CHEM, V259, P3131; SMITH CC, 1991, VIRUS GENES, V5, P215, DOI 10.1007/BF00568971; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TOGASHI CT, 1982, J BIOL CHEM, V257, P112; WENTE SR, 1990, P NATL ACAD SCI USA, V87, P2805, DOI 10.1073/pnas.87.7.2805; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; WYMER JP, 1989, J VIROL, V63, P2773, DOI 10.1128/JVI.63.6.2773-2784.1989; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1990, MOL IMMUNOL, V27, P1319, DOI 10.1016/0161-5890(90)90037-Z; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837	48	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9645	9653						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315764				2022-12-27	WOS:A1992HT96500032
J	SORKIN, A; HELIN, K; WATERS, CM; CARPENTER, G; BEGUINOT, L				SORKIN, A; HELIN, K; WATERS, CM; CARPENTER, G; BEGUINOT, L			MULTIPLE AUTOPHOSPHORYLATION SITES OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR ARE ESSENTIAL FOR RECEPTOR KINASE-ACTIVITY AND INTERNALIZATION - CONTRASTING SIGNIFICANCE OF TYROSINE-992 IN THE NATIVE AND TRUNCATED RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-II; EGF RECEPTOR; SIGNAL TRANSDUCTION; CYTOPLASMIC DOMAIN; HUMAN-FIBROBLASTS; LIGAND; DNA; PHOSPHORYLATION; DEGRADATION; BINDING	The role of epidermal growth factor (EGF) receptor autophosphorylation sites in the regulation of receptor functions has been studied using cells transfected with mutant EGF receptors. Simultaneous point mutation of 4 tyrosines (Y1068, Y1086, Y1148, Y1173) to phenylalanine, as well as removal of these sites by truncation of the carboxyl-terminal 123 amino acid residues, resulted in reduced receptor phosphorylation of an in vivo specific substrate phospholipase C-gamma-1 to less than 50% compared to the wild-type receptor. The internalization rate constant K(e) was also significantly lower in these mutants (0.15/min) compared to cells transfected with wild-type receptor (0.27/min). Additional mutation of tyrosine 992 to phenylalanine in the truncated receptor mutant (Dc-123F) further decreased the receptor internalization rate to a minimal level (k(e) = 0.07-0.10/min), equivalent to the k(e) measured for cells expressing kinase-negative receptor (A721). Moreover, tyrosine kinase activity of the Dc-123F receptor toward phospholipase C-gamma-1, compared to wild-type receptor, was reduced by 90%. Taken together, these results show that EGF receptor lacking five autophosphorylation sites functions similar to a kinase-negative receptor. Mutation of tyrosine residue Y992 alone in the context of full length EGF receptor, however, did not affect receptor internalization or kinase activity toward phospholipase C-gamma-1. These data indicate that tyrosine 992 is critical for substrate phosphorylation and internalization only in the context of the truncated receptor, and that minor autophosphorylation sites, such as Y992, may act as compensatory regulatory sties in the absence of the major EGF receptor autophosphorylation sites.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOMED ENGN, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; UNIV COPENHAGEN, INST MICROBIOL, DK-1353 COPENHAGEN, DENMARK	Vanderbilt University; Vanderbilt University; University of Copenhagen	SORKIN, A (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA.		Waters, Christopher/V-2759-2019; Helin, Kristian/K-2526-2019; Helin, Kristian/HDM-8306-2022	Helin, Kristian/0000-0003-1975-6097; Sorkin, Alexander/0000-0002-4446-1920	NCI NIH HHS [CA24071] Funding Source: Medline; NHLBI NIH HHS [HL07411] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA024071] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; FAVA RA, 1984, J BIOL CHEM, V259, P2636; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; GIRONES N, 1991, J BIOL CHEM, V266, P19006; GLADHAUG IP, 1987, EUR J BIOCHEM, V164, P267, DOI 10.1111/j.1432-1033.1987.tb11054.x; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HELIN K, 1991, ONCOGENE, V6, P825; HELIN K, 1991, J BIOL CHEM, V266, P8363; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SORKIN A, 1991, J BIOL CHEM, V266, P23453; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; SORKIN A, 1991, J CELL BIOL, V112, P55, DOI 10.1083/jcb.112.1.55; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; STOSCHECK CM, 1983, ARCH BIOCHEM BIOPHYS, V227, P457, DOI 10.1016/0003-9861(83)90476-9; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WATERS CM, 1990, BIOCHEMISTRY-US, V29, P3563, DOI 10.1021/bi00466a020; WILEY HS, 1991, J BIOL CHEM, V266, P11083	44	146	147	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8672	8678						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314835				2022-12-27	WOS:A1992HQ18500106
J	CLERC, A; CATTY, P; BENNETT, N				CLERC, A; CATTY, P; BENNETT, N			INTERACTION BETWEEN CGMP-PHOSPHODIESTERASE AND TRANSDUCIN ALPHA-SUBUNIT IN RETINAL RODS - A CROSS-LINKING STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; GTP-BINDING PROTEIN; OUTER SEGMENTS; ACTIVATION MECHANISM; LIMITED PROTEOLYSIS; INHIBITORY SUBUNIT; GAMMA-SUBUNIT; BETA-SUBUNIT; MEMBRANES; PHOTORECEPTORS	Cross-linking of the different subunits of the retinal cGMP-phosphodiesterase (PDE) with its activator GalphaGTPgammaS (alpha subunit of the retinal G-protein transducin with GTPgammaS (guanosine 5'-O-(3-thiotriphosphate) bound) has been investigated using purified proteins, with a N-hydroxysuccinimide homobifunctional cross-linker, bis(sulfosuccinimidyl)suberate (BS3) and its cleavable analog 3,3'-dithiobis(sulfosuccinimidylpropionate) (DTSSP). Interaction of purified G-protein and PDE is achieved in the presence of lecithin vesicles, at protein concentrations sufficient for full PDE activation. Protein subunits linked with DTSSP are separated by cleavage of the disulfide bridge and identified by electrophoresis. Complexes of PDEalpha (PDEbeta) with 1 and 2 molecules of activator GalphaGTPgammaS are observed, providing direct evidence for an interaction or at least a close proximity between 2 molecules of activator Galpha and each of the catalytic PDE subunits in the activated state of PDE. The results also reveal symmetrical roles of PDEalpha and PDEbeta, with the existence of one site for PDEgamma and one site for Galpha on each catalytic subunit.	CEN,DBMS,BMC,BIOPHYS MOLEC & CELLULAIRE LAB,CNRS,UA 520,BP 85X,F-38041 GRENOBLE,FRANCE	Centre National de la Recherche Scientifique (CNRS)								BAEHR W, 1979, J BIOL CHEM, V254, P1669; BAEHR W, 1982, J BIOL CHEM, V257, P6452; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; BENNETT N, 1985, J BIOL CHEM, V260, P4156; BHOWN AS, 1980, ANAL BIOCHEM, V103, P184, DOI 10.1016/0003-2697(80)90254-7; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUBIS J, 1990, J BIOL CHEM, V265, P12995; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; CLERC A, 1992, J BIOL CHEM, V267, P6620; COMPTON SJ, 1985, ANAL BIOCHEM, V151, P369, DOI 10.1016/0003-2697(85)90190-3; DAEMEN FJM, 1973, BIOCHIM BIOPHYS ACTA, V300, P255, DOI 10.1016/0304-4157(73)90006-3; DETERRE P, 1984, FEBS LETT, V178, P228, DOI 10.1016/0014-5793(84)80606-7; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; FUNG BKK, 1983, J BIOL CHEM, V258, P503; HINGORANI VN, 1988, J BIOL CHEM, V263, P6916; KROLL S, 1989, J BIOL CHEM, V264, P4490; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; MURADOV KG, 1990, BIOL MEMBRANY, V7, P565; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; SCHLEGEL W, 1979, J BIOL CHEM, V254, P5168; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P651, DOI 10.1021/bi00351a021; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; TSUI FC, 1990, BIOPHYS J, V57, P85, DOI 10.1016/S0006-3495(90)82509-1; VAILLANCOURT RR, 1990, P NATL ACAD SCI USA, V87, P3645, DOI 10.1073/pnas.87.10.3645; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539	37	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19948	19953						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328188				2022-12-27	WOS:A1992JR85800035
J	CATTY, P; PFISTER, C; BRUCKERT, F; DETERRE, P				CATTY, P; PFISTER, C; BRUCKERT, F; DETERRE, P			THE CGMP PHOSPHODIESTERASE-TRANSDUCIN COMPLEX OF RETINAL RODS - MEMBRANE-BINDING AND SUBUNITS INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; OUTER SEGMENTS; ALPHA-SUBUNIT; G-PROTEIN; INHIBITORY SUBUNIT; MONOCLONAL-ANTIBODIES; ACTIVATION MECHANISM; LIMITED PROTEOLYSIS; ADENYLATE-CYCLASE; LIGHT-SCATTERING	cGMP-specific phosphodiesterase (PDE) of vertebrate retinal rod outer segments (ROS) is composed of two catalytic subunits (PDEalpha and PDEbeta) and two identical inhibitory subunits (PDEgamma). Native PDEalphabetagamma2 is peripherally bound to the membranes of ROS discs. We studied quantitatively its partition between soluble and membrane-bound fractions in ROS homogenates. In the presence of its activator, the alpha-subunit of transducin loaded with a triphosphate guanine nucleotide (Talpha*), PDE displayed a greatly enhanced membrane binding. Neither the purified PDEgamma.Talpha* complex, nor the PDEalphabeta and PDEalphabetagamma forms of active PDE, showed a membrane binding comparable to that of PDEalphabetagamma2 in the presence of Talpha*. The Talpha*-activated PDE is therefore an undissociated complex tightly bound to the ROS membranes. Using limited proteolysis, we showed that the membrane anchoring of the whole complex implies not only PDE (mainly by the C terminus of PDEbeta) but also both termini of Talpha*. The membrane binding of the purified PDEalphabeta species was also enhanced in the presence of Talpha*; a direct link would therefore exist between the activator and the catalytic subunits. From this work emerges a plausible structural model of the Talpha*-activated PDE, with its internal interactions and its sites of anchoring into the ROS membrane.	CEN, BIOPHYS MOLEC & CELLULAIRE LAB, CNRS, UA 520, F-38041 GRENOBLE, FRANCE	Centre National de la Recherche Scientifique (CNRS)			Deterre, Philippe/O-8984-2017	Deterre, Philippe/0000-0001-9303-0791				ANANT JS, 1992, J BIOL CHEM, V267, P687; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; BRUCKERT F, 1988, EUR BIOPHYS J BIOPHY, V16, P207; CARETTA A, 1986, BIOCHEMISTRY-US, V25, P2335, DOI 10.1021/bi00357a006; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CLERC A, 1992, J BIOL CHEM, V267, P6620; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; GRAYKELLER MP, 1990, J BIOL CHEM, V265, P15323; HAMM HE, 1987, J BIOL CHEM, V262, P10831; HINGORANI VN, 1990, J BIOL CHEM, V265, P19923; HINGORANI VN, 1987, FEBS LETT, V220, P15, DOI 10.1016/0014-5793(87)80867-0; HINGORANI VN, 1988, J BIOL CHEM, V263, P6916; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; JOURNOT L, 1991, P NATL ACAD SCI USA, V88, P10054, DOI 10.1073/pnas.88.22.10054; KUHN H, 1981, CURR TOP MEMBR TRANS, V15, P171; LIEBMAN PA, 1984, ADV CYCLIC NUCL PROT, V17, P215; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MAZZONI MR, 1989, BIOCHEMISTRY-US, V28, P9873, DOI 10.1021/bi00451a047; MORRIS D, 1990, BIOCHEMISTRY-US, V29, P9079, DOI 10.1021/bi00490a027; NAVON SE, 1988, J BIOL CHEM, V263, P489; NAVON SE, 1987, J BIOL CHEM, V262, P15746; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PFEUFFER T, 1977, J BIOL CHEM, V252, P7224; PHILLIPS WJ, 1989, J BIOL CHEM, V264, P16679; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P651, DOI 10.1021/bi00351a021; STRYER L, 1991, J BIOL CHEM, V266, P10711; TYMINSKI PN, 1984, BIOCHEMISTRY-US, V23, P3986, DOI 10.1021/bi00312a028; VANDOP C, 1984, J BIOL CHEM, V259, P23; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WEST RE, 1985, J BIOL CHEM, V260, P4428; WHALEN MM, 1989, BIOCHEM J, V259, P13, DOI 10.1042/bj2590013; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539	48	59	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19489	19493						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326553				2022-12-27	WOS:A1992JP59300072
J	DRAYER, AL; VANHAASTERT, PJM				DRAYER, AL; VANHAASTERT, PJM			MOLECULAR-CLONING AND EXPRESSION OF A PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE-C OF DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE; SIGNAL TRANSDUCTION; TYROSINE KINASE; COMPLETE CDNA; SEQUENCE; GENE; CHEMOATTRACTANT; DROSOPHILA; GROWTH; CELLS	A number of phosphoinositide-specific phospholipases C (PLC) of different species have recently been cloned. The predicted amino acid sequences of these isoforms contain two highly conserved domains. Here we report the identification of a PLC gene of Dictyostelium by using the polymerase chain reaction. Primers were designed coding for highly conserved amino acid regions located within one of the conserved domains of PLCs. Cloning and sequencing of the polymerase chain reaction product revealed one unique PLC-like sequence. This sequence was used to screen a library and isolate several overlapping cDNA clones. The complete cDNA was expressed in Dictyostelium cells resulting in increased basal levels of inositol 1,4,5-trisphosphate and enhanced PLC activity. The identified Dictyostelium PLC, DdPLC, encodes a protein with a calculated molecular mass of 91 kDa. The deduced amino acid sequence contains the two conserved domains found in other PLC isoforms, separated by a short variable region. The C-terminal part of the protein shows strong homology with the mammalian PLC-delta isoform. DdPLC is expressed at all stages of development, with an increase in transcription during starvation and in the culminating fruiting body.			DRAYER, AL (corresponding author), UNIV GRONINGEN,DEPT BIOCHEM,NIJENBORGH 4,9747 AG GRONINGEN,NETHERLANDS.							ALBERTS B, 1989, MOL BIOL CELL, P681; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BOMINAAR AA, 1991, J CELL SCI, V100, P825; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; EMORI Y, 1989, J BIOL CHEM, V264, P21885; EUROPEFINNER GN, 1987, J CELL SCI, V87, P513; GERISCH G, 1987, ANNU REV BIOCHEM, V56, P853, DOI 10.1146/annurev.biochem.56.1.853; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; JANSSENS PMW, 1987, MICROBIOL REV, V51, P396, DOI 10.1128/MMBR.51.4.396-418.1987; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; OHTA S, 1988, FEBS LETT, V242, P31, DOI 10.1016/0014-5793(88)80979-7; PETERS DJM, 1991, DEV GENET, V12, P25, DOI 10.1002/dvg.1020120107; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TAKENAWA T, 1981, J BIOL CHEM, V256, P6769; TOMPKINS TA, 1991, J BIOL CHEM, V266, P4228; VANHAASTERT PJM, 1991, EUR J BIOCHEM, V195, P289; VANHAASTERT PJM, 1989, ANAL BIOCHEM, V177, P115, DOI 10.1016/0003-2697(89)90024-9; VANHAASTERT PJM, 1989, BIOCHEM J, V258, P577, DOI 10.1042/bj2580577; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171	35	73	74	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18387	18392						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326523				2022-12-27	WOS:A1992JN50200026
J	MA, ZM; GRUBB, JH; SLY, WS				MA, ZM; GRUBB, JH; SLY, WS			DIVALENT CATION-DEPENDENT STIMULATION OF LIGAND-BINDING TO THE 46-KDA MANNOSE 6-PHOSPHATE RECEPTOR CORRELATES WITH DIVALENT CATION-DEPENDENT TETRAMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL-ENZYMES; BETA-GLUCURONIDASE; EQUILIBRIUM; CLONING; FORMS	The quaternary structure and binding activity of the murine 46-kDa mannose 6-phosphate receptor (46MPR) were studied in semi-intact murine cells that overexpress the murine receptor. Chemical cross-linking studies showed that the murine 46MPR exists in monomer, dimer, and tetramer forms in membranes of overexpressing murine cells. Treatment of permeabilized cells with Mn2+ increased the tetramer form of 46MPR, and this tetramerization was reversed by removal of Mn2+. Thus, the divalent cations affected the distribution of receptor among the three forms, favoring tetramerization at the expense of dimer and monomer. Low temperature (4-degrees-C) also increases the fraction present as tetramer. The binding assay results show that Mn2+ is required for the 46MPR to achieve and retain the ability to bind ligand at 37-degrees-C but not at 4-degrees-C. Preincubation with Mn2+ produced a 3-fold increase in Man-6-P-specific binding of beta-glucuronidase which paralleled the 3-fold increase in tetramer seen during preincubation with Mn2+. The similarity of the effects of addition and removal of Mn2+ on enzyme binding to the effects of Mn2+ on favoring tetramer formation suggests that divalent cation-dependent tetramerization of the 46MPR contributes to the stimulation of ligand binding to the 46MPR by divalent cations.	ST LOUIS UNIV,SCH MED,EDWARD A DOISY DEPT BIOCHEM & MOLEC BIOL,1402 S GRAND BLVD,ST LOUIS,MO 63104	Saint Louis University					NIDDK NIH HHS [DK40163] Funding Source: Medline; NIGMS NIH HHS [GM34182] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034182, R37GM034182] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DAHMS NM, 1989, J BIOL CHEM, V264, P11458; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; FISCHER HD, 1980, J BIOL CHEM, V255, P5069; HILLE A, 1990, J CELL BIOL, V110, P963, DOI 10.1083/jcb.110.4.963; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; LI M, 1990, ARCH BIOCHEM BIOPHYS, V283, P150, DOI 10.1016/0003-9861(90)90625-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA ZM, 1991, J BIOL CHEM, V266, P10589; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; TONG PY, 1989, J BIOL CHEM, V264, P7970; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1990, BIOCHEMISTRY-US, V29, P2449, DOI 10.1021/bi00462a003; WAHEED A, 1990, EUR J BIOCHEM, V193, P47, DOI 10.1111/j.1432-1033.1990.tb19302.x; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036	16	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					19017	19022						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326539				2022-12-27	WOS:A1992JN50200114
J	LECONTE, I; AUZAN, C; DEBANT, A; ROSSI, B; CLAUSER, E				LECONTE, I; AUZAN, C; DEBANT, A; ROSSI, B; CLAUSER, E			N-LINKED OLIGOSACCHARIDE CHAINS OF THE INSULIN RECEPTOR-BETA SUBUNIT ARE ESSENTIAL FOR TRANSMEMBRANE SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; ACETYLCHOLINE-RECEPTOR; GLYCOSYLATION MUTANTS; BINDING-ACTIVITY; CELLS; CARBOHYDRATE; BIOSYNTHESIS; REPLACEMENT; HYBRID	Insulin receptor (IR) is a glycoprotein possessing N-linked oligosaccharide side chains on both alpha and beta-subunits. The present study focusses for the first time on the potential contribution of N-linked oligosaccharides of the beta-subunit in the processing, structure, and function of the insulin receptor. To investigate this point, a receptor mutant (IR beta-N1234) was obtained by stable transfection into Chinese hamster ovary cells of an IR cDNA modified by site-directed mutagenesis on the four potential N-glycosylation sites (Asn-X-Ser/Thr) of the beta-subunit. The mutated receptor presents an alpha-subunit of 135 kDa, indistinguishable from the wild type alpha-subunit, but the beta-subunit has a reduced molecular mass (80 kDa instead of 95 kDa) most likely due to the absence of N-glycosylation. Metabolic labeling experiments indicate a normal processing and maturation of this mutated receptor which is normally expressed at the surface of the cells as demonstrated by indirect immunofluorescence. The affinity of the mutant for insulin (K(d) = 0.12 nM) is similar to that of the wild type receptor (K(d) = 0.12 nM). However, a major defect of the mutated IR tyrosine kinase was assessed both in vitro and in vivo by (i) the absence of insulin-stimulated phosphorylation of the poly(Glu-Tyr) substrate in vitro; (ii) the reduction of the insulin maximal stimulation of the mutated IR autophosphorylation in vitro (2-fold stimulation for the mutant receptor as compared to a 7-fold stimulation for the wild type); and (iii) a more complex alteration of the mutated receptor tyrosine autophosphorylation in vivo (3-fold increase of the basal phosphorylation and a 4-fold simulation of this phosphorylation as compared to the wild type receptor, the phosphorylation of which is stimulated 14-fold by insulin). The physiological consequences of this defect were tested on three classical insulin cellular actions; in Chinese hamster ovary IR beta-N1234, glucose transport, glycogen synthesis, and DNA synthesis were all unable to be stimulated by insulin indicating the absence of insulin transduction through this mutated receptor. These data provide the first direct evidence for a critical role of oligosaccharide side chains of the beta-subunit in the molecular events responsible for the IR enzymatic activation and signal transduction.	COLL FRANCE,CHAIRE MED EXPTL,INSERM,U36,3 RUE ULM,F-75005 PARIS,FRANCE; FAC MED PASTEUR,INSERM,U210,NICE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur								ARAKAKI RF, 1987, J BIOL CHEM, V262, P11886; BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BREITFELD PP, 1984, J BIOL CHEM, V259, P414; CAPEAU J, 1980, FEBS LETT, V118, P25, DOI 10.1016/0014-5793(80)81210-5; CHERQUI G, 1983, BIOCHEM J, V214, P111, DOI 10.1042/bj2140111; CHERQUI G, 1990, J BIOL CHEM, V265, P21254; CHIN JE, 1991, J BIOL CHEM, V266, P15587; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COLLIER E, 1991, DIABETES, V40, P197, DOI 10.2337/diabetes.40.2.197; CUATRECASAS P, 1973, P NATL ACAD SCI USA, V70, P485, DOI 10.1073/pnas.70.2.485; CUATRECASAS P, 1972, INSULIN ACTION, P137; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DEBANT A, 1989, BIOCHEMISTRY-US, V28, P14, DOI 10.1021/bi00427a003; DURONIO V, 1988, J BIOL CHEM, V263, P5436; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; EDGE ASB, 1990, ENDOCRINOLOGY, V127, P1887, DOI 10.1210/endo-127-4-1887; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ELLIS L, 1987, P NATL ACAD SCI USA, V84, P5101, DOI 10.1073/pnas.84.15.5101; FILIPOVIC I, 1989, J BIOL CHEM, V264, P8815; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; HAYES GR, 1991, BIOCHEM BIOPH RES CO, V174, P735, DOI 10.1016/0006-291X(91)91479-V; HEDO JA, 1981, P NATL ACAD SCI-BIOL, V78, P4791, DOI 10.1073/pnas.78.8.4791; HEIDENREICH KA, 1983, J BIOL CHEM, V258, P8527; HERZBERG VL, 1985, BIOCHEM BIOPH RES CO, V129, P789, DOI 10.1016/0006-291X(85)91961-8; KAHN CR, 1978, P NATL ACAD SCI USA, V75, P4209, DOI 10.1073/pnas.75.9.4209; KEATING MT, 1989, J BIOL CHEM, V264, P9129; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PANZIO G, 1988, EMBO J, V6, P4111; PODSKALNY J, 1984, BIOCHEM BIOPH RES CO, V125, P70, DOI 10.1016/S0006-291X(84)80335-6; PONZIO G, 1987, EMBO J, V6, P333, DOI 10.1002/j.1460-2075.1987.tb04759.x; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; PRIVES J, 1983, J BIOL CHEM, V258, P1775; RANDS E, 1990, J BIOL CHEM, V265, P10759; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; RONNETT GV, 1984, J BIOL CHEM, V259, P4566; RONNETT GV, 1981, J BIOL CHEM, V256, P4704; ROUILLER DG, 1986, ENDOCRINOLOGY, V118, P1159, DOI 10.1210/endo-118-3-1159; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SLIEKER LJ, 1988, BIOCHEM BIOPH RES CO, V153, P96, DOI 10.1016/S0006-291X(88)81194-X; SLIEKER LJ, 1986, J BIOL CHEM, V261, P5233; SODORA DL, 1989, J VIROL, V63, P5184, DOI 10.1128/JVI.63.12.5184-5193.1989; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; ZICK Y, 1989, CRIT REV BIOCHEM MOL, V24, P217, DOI 10.3109/10409238909082554	50	72	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17415	17423						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324936				2022-12-27	WOS:A1992JL05300102
J	DEAN, FB; BOROWIEC, JA; EKI, T; HURWITZ, J				DEAN, FB; BOROWIEC, JA; EKI, T; HURWITZ, J			THE SIMIAN VIRUS-40 T-ANTIGEN DOUBLE HEXAMER ASSEMBLES AROUND THE DNA AT THE REPLICATION ORIGIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-TUMOR-ANTIGEN; SV40 ORIGIN; HELICASE ACTIVITY; BINDING ACTIVITY; ATPASE ACTIVITY; DUPLEX DNA; SITE-II; OLIGOMERIZATION; INITIATION; PHOSPHORYLATION	An initial step in the replication of simian virus (SV40) DNA is the ATP-dependent formation of a double hexamer of the SV40 large tumor (T) antigen at the SV40 DNA replication origin. In the absence of DNA, T antigen assembled into hexamers in the presence of magnesium and ATP. Hexameric T antigen was stable and could be isolated by glycerol gradient centrifugation. The ATPase activities of hexameric and monomeric T antigen isolated from parallel glycerol gradients were identical. However, while monomeric T antigen was active in the ATP-dependent binding, untwisting, unwinding, and replication of SV40 origin-containing DNA, hexameric T antigen was inactive in these reactions. Isolated hexamers incubated at 37-degrees-C in the presence of ATP remained intact, but dissociated into monomers when incubated at 37-degrees-0 in the absence of ATP. This dissociation restored the activity of these preparations in the DNA replication reaction, indicating that hexameric T antigen is not permanently inactivated but merely assembled into a nonproductive structure. We propose that the two hexamers of T antigen at the SV40 origin assemble around the DNA from monomer T antigen in solution. This complex untwists the DNA at the origin, melting specific DNA sequences. The resulting single-stranded regions may be utilized by the T antigen helicase activity to initiate DNA unwinding bidirectionally from the origin.	NYU MED CTR, DEPT BIOCHEM, NEW YORK, NY 10016 USA; RIKEN INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, GENE BANK, TSUKUBA, IBARAKI 305, JAPAN	New York University; RIKEN	DEAN, FB (corresponding author), SLOAN KETTERING MEM CANC CTR, PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA.			Dean, Frank/0000-0002-9416-4449	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034559] Funding Source: NIH RePORTER; NIGMS NIH HHS [5R01 GM 34559] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUBORN K, 1989, J VIROL, V63, P912, DOI 10.1128/JVI.63.2.912-918.1989; BAUMANN EA, 1982, J VIROL, V44, P78, DOI 10.1128/JVI.44.1.78-87.1982; BENJAMIN HW, 1988, EMBO J, V7, P1897, DOI 10.1002/j.1460-2075.1988.tb03023.x; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOROWIEC JA, 1988, P NATL ACAD SCI USA, V85, P64, DOI 10.1073/pnas.85.1.64; BOROWIEC JA, 1991, J VIROL, V65, P1228, DOI 10.1128/JVI.65.3.1228-1235.1991; BRADLEY MK, 1987, P NATL ACAD SCI USA, V84, P4026, DOI 10.1073/pnas.84.12.4026; BRADLEY MK, 1990, J VIROL, V64, P4939, DOI 10.1128/JVI.64.10.4939-4947.1990; BRADLEY MK, 1982, CELL, V28, P125, DOI 10.1016/0092-8674(82)90382-8; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BUCHMAN AR, 1980, DNA TUMOR VIRUSES, P799; BULLOCK PA, 1989, P NATL ACAD SCI USA, V86, P3944, DOI 10.1073/pnas.86.11.3944; BURGER C, 1983, VIROLOGY, V126, P19, DOI 10.1016/0042-6822(83)90459-2; CARROLL RB, 1974, P NATL ACAD SCI USA, V71, P3754, DOI 10.1073/pnas.71.9.3754; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COLE CN, 1986, J VIROL, V57, P539, DOI 10.1128/JVI.57.2.539-546.1986; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8267, DOI 10.1073/pnas.84.23.8267; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEAN FB, 1991, J BIOL CHEM, V266, P5062; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DEB SP, 1988, BIOCHEM BIOPH RES CO, V153, P249, DOI 10.1016/S0006-291X(88)81215-4; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; DELUCIA AL, 1983, J VIROL, V46, P143, DOI 10.1128/JVI.46.1.143-150.1983; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DODSON M, 1989, J BIOL CHEM, V264, P10719; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; FANNING E, 1981, J VIROL, V37, P92, DOI 10.1128/JVI.37.1.92-102.1981; GIACHERIO D, 1979, J BIOL CHEM, V254, P8113; GIDONI D, 1982, J VIROL, V42, P456, DOI 10.1128/JVI.42.2.456-466.1982; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GREENSPAN DS, 1981, P NATL ACAD SCI-BIOL, V78, P105, DOI 10.1073/pnas.78.1.105; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; JONES KA, 1984, CELL, V36, P155, DOI 10.1016/0092-8674(84)90084-9; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KUCHINO T, 1975, J VIROL, V15, P1302, DOI 10.1128/JVI.15.6.1302-1307.1975; LOEBER G, 1989, J VIROL, V63, P94, DOI 10.1128/JVI.63.1.94-100.1989; LOEBER G, 1991, J VIROL, V65, P3167, DOI 10.1128/JVI.65.6.3167-3174.1991; MANOS MM, 1985, J VIROL, V53, P120, DOI 10.1128/JVI.53.1.120-127.1985; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MCCORMICK F, 1980, J VIROL, V34, P213, DOI 10.1128/JVI.34.1.213-224.1980; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MOHR IJ, 1989, J VIROL, V63, P4181, DOI 10.1128/JVI.63.10.4181-4188.1989; MONTENARH M, 1987, FEBS LETT, V221, P199, DOI 10.1016/0014-5793(87)80925-0; MONTENARH M, 1984, J VIROL, V49, P658, DOI 10.1128/JVI.49.3.658-664.1984; MONTENARH M, 1983, J VIROL, V45, P531, DOI 10.1128/JVI.45.2.531-538.1983; MYERS RM, 1981, J MOL BIOL, V148, P347, DOI 10.1016/0022-2836(81)90180-7; OSBORN M, 1974, COLD SPRING HARB SYM, V39, P267, DOI 10.1101/SQB.1974.039.01.035; PARSONS R, 1990, J VIROL, V64, P509, DOI 10.1128/JVI.64.2.509-518.1990; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; POTTER CW, 1969, J VIROL, V4, P574, DOI 10.1128/JVI.4.5.574-579.1969; PRIVES C, 1979, COLD SPRING HARB SYM, V44, P123, DOI 10.1101/SQB.1980.044.01.014; REYNISDOTTIR I, 1990, J VIROL, V64, P6234; ROBERTS JM, 1989, P NATL ACAD SCI USA, V86, P3939, DOI 10.1073/pnas.86.11.3939; RUNZLER R, 1987, J VIROL, V61, P2076, DOI 10.1128/JVI.61.7.2076-2083.1987; SCHEFFNER M, 1989, NUCLEIC ACIDS RES, V17, P93, DOI 10.1093/nar/17.1.93; SCHEIDTMANN KH, 1984, J VIROL, V50, P1; SCHICKEDANZ J, 1986, VIROLOGY, V148, P47, DOI 10.1016/0042-6822(86)90402-2; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SIMMONS DT, 1990, J VIROL, V64, P4858, DOI 10.1128/JVI.64.10.4858-4865.1990; SIMMONS DT, 1990, J VIROL, V64, P1973, DOI 10.1128/JVI.64.5.1973-1983.1990; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TACK LC, 1989, J VIROL, V63, P3362, DOI 10.1128/JVI.63.8.3362-3367.1989; TJIAN R, 1978, CELL, V13, P165, DOI 10.1016/0092-8674(78)90147-2; WACHTER M, 1985, J VIROL, V56, P520, DOI 10.1128/JVI.56.2.520-526.1985; WANG EH, 1991, VIROLOGY, V184, P399, DOI 10.1016/0042-6822(91)90858-9; WIEKOWSKI M, 1987, J VIROL, V61, P411, DOI 10.1128/JVI.61.2.411-418.1987; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; WUNKIM K, 1990, J VIROL, V64, P2014, DOI 10.1128/JVI.64.5.2014-2020.1990	72	141	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14129	14137						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321135				2022-12-27	WOS:A1992JD32500055
J	HOITINK, CWG; CANTERS, GW				HOITINK, CWG; CANTERS, GW			THE IMPORTANCE OF ASN(47) FOR STRUCTURE AND REACTIVITY OF AZURIN FROM ALCALIGENES-DENITRIFICANS AS STUDIED BY SITE-DIRECTED MUTAGENESIS AND SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE COPPER PROTEINS; PSEUDOMONAS-AERUGINOSA; CRYSTAL-STRUCTURE; POPLAR PLASTOCYANIN; ESCHERICHIA-COLI; CYTOCHROME-C; REDUCTION; RESOLUTION; PSEUDOAZURIN; PURIFICATION	To study the importance of a rigid copper site for the structure and function of azurin, a mutant with a reduced number of internal hydrogen bonds around the copper has been prepared and characterized. To this purpose, the previously cloned azu gene from Alcaligenes denitrificans (Hoitink, C. W. G., Woudt, L. P., Turenhout, J. C. M., Van de Kamp, M., and Canters, G. W. (1990) Gene (Amst.) 90, 15-20) was expressed in Escherichia coli and an isolation and purification procedure for the azurin was developed. The azurin obtained after heterologous expression in E. coli appears spectroscopically indistinguishable from azurin derived from A. denitrificans. The hydrogen bonding network around the copper site was altered by replacing Asn47 by a leucine by means of site-directed mutagenesis. Asn47 is a conserved residue in all blue copper proteins of which the primary structure has been reported. Characterization of the mutant protein with UV-visible, electron spin resonance, and NMR spectroscopy, and comparison with the wild type azurin revealed that the structure of the copper site as well as the overall structure of the protein have been largely retained. The redox activity as measured by the electron self-exchange rate appears not to have changed either. However, the mutant differs from the wild type azurin with respect to stability and midpoint potential. Midpoint potentials of mutant and wild type azurin amount to 396 and 286 mV, respectively. The difference is due to sizable entropic and enthalpic contributions which to a large extent cancel. Possible explanations for the outcome of these experiments are discussed.	GORLAEUS LABS,POB 9502,2300 RA LEIDEN,NETHERLANDS									ADDISON AW, 1985, COPPER COORDINATION, P109; ADMAN ET, 1985, TOPICS MOL STRUCTU 1, P1; AINSCOUGH EW, 1987, BIOCHEMISTRY-US, V26, P71, DOI 10.1021/bi00375a011; ALBER T, 1987, NATURE, V330, P41, DOI 10.1038/330041a0; AMBLER RP, 1985, BIOCHEM J, V232, P451, DOI 10.1042/bj2320451; BAKER EN, 1988, J MOL BIOL, V203, P1071, DOI 10.1016/0022-2836(88)90129-5; BASHFORD D, 1988, J MOL BIOL, V203, P507, DOI 10.1016/0022-2836(88)90016-2; BERGMAN C, 1977, BIOCHEM BIOPH RES CO, V77, P1052, DOI 10.1016/S0006-291X(77)80084-3; CANTERS GW, 1984, J MAGN RESON, V57, P1, DOI 10.1016/0022-2364(84)90230-0; CHOTHIA C, 1982, J MOL BIOL, V160, P309, DOI 10.1016/0022-2836(82)90178-4; COLLYER CA, 1990, J MOL BIOL, V211, P617, DOI 10.1016/0022-2836(90)90269-R; CUTLER RL, 1989, BIOCHEMISTRY-US, V28, P3188, DOI 10.1021/bi00434a012; DENBLAAUWEN T, 1989, J BACTERIOL, V171, P1394, DOI 10.1128/jb.171.3.1394-1401.1989; ENGESETH HR, 1986, BIOCHEMISTRY-US, V25, P2448, DOI 10.1021/bi00357a023; GILSON MK, 1986, BIOPOLYMERS, V25, P2097, DOI 10.1002/bip.360251106; GOLDBERG M, 1976, BIOCHEMISTRY-US, V15, P4197, DOI 10.1021/bi00664a011; GROENEVELD CM, 1988, J MOL BIOL, V200, P189, DOI 10.1016/0022-2836(88)90343-9; GROENEVELD CM, 1987, J INORG BIOCHEM, V31, P143, DOI 10.1016/0162-0134(87)80059-4; GROENEVELD CM, 1988, J BIOL CHEM, V263, P167; GUSS JM, 1988, SCIENCE, V241, P806, DOI 10.1126/science.3406739; GUSS JM, 1983, J MOL BIOL, V169, P521; GUSS JM, 1986, J MOL BIOL, V192, P361, DOI 10.1016/0022-2836(86)90371-2; HARVEY S, 1989, PROTEINS, V5, P68; HERMANS J, 1984, BIOPOLYMERS, V23, P1513, DOI 10.1002/bip.360230807; HILL HAO, 1985, J ELECTROANAL CHEM, V187, P315; HOITINK CWG, 1990, GENE, V90, P15, DOI 10.1016/0378-1119(90)90434-S; KARLSSON BG, 1989, FEBS LETT, V253, P99, DOI 10.1016/0014-5793(89)80938-X; KORSZUN ZR, 1987, J MOL BIOL, V196, P413, DOI 10.1016/0022-2836(87)90701-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; NAR H, 1991, J MOL BIOL, V221, P765, DOI 10.1016/0022-2836(91)80173-R; NORRIS GE, 1979, J MOL BIOL, V135, P309, DOI 10.1016/0022-2836(79)90357-7; PARR SR, 1977, BIOCHEM J, V167, P447, DOI 10.1042/bj1670447; PETRATOS K, 1988, ACTA CRYSTALLOGR B, V44, P628, DOI 10.1107/S0108768188008912; RYDEN L, 1976, NATURE, V261, P344, DOI 10.1038/261344a0; Sambrook J, 1989, MOL CLONING LABORATO; SHEPARD WEB, 1990, J AM CHEM SOC, V112, P7817, DOI 10.1021/ja00177a065; van Gunsteren W. F., 1987, GRONINGEN MOL SIMULA; VANBEEUMEN J, 1991, J BIOL CHEM, V266, P4869; VANDEKAMP M, 1990, EUR J BIOCHEM, V194, P109; VANDEKAMP M, 1990, BIOCHIM BIOPHYS ACTA, V1019, P283, DOI 10.1016/0005-2728(90)90206-J; VARADARAJAN R, 1989, SCIENCE, V243, P69, DOI 10.1126/science.2563171; WILLIAMS RJP, 1983, PURE APPL CHEM, V55, P35, DOI 10.1351/pac198355010035; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	44	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13836	13842						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321127				2022-12-27	WOS:A1992JD32500011
J	LARHAMMAR, D; BLOMQVIST, AG; YEE, F; JAZIN, E; YOO, HY; WAHLESTEDT, C				LARHAMMAR, D; BLOMQVIST, AG; YEE, F; JAZIN, E; YOO, HY; WAHLESTEDT, C			CLONING AND FUNCTIONAL EXPRESSION OF A HUMAN NEUROPEPTIDE-Y PEPTIDE-YY RECEPTOR OF THE Y1-TYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BRAIN	Neuropeptide Y (NPY) and peptide YY (PYY) are structurally related peptides that primarily function as neurotransmitter and gastrointestinal hormone, respectively. Previous functional and binding data have indicated the existence of at least three distinct receptor types, Y1, Y2, and Y3, for NPY and/or PYY in mammals. We describe here a human Y1 cDNA clone, hY1-5, isolated from a fetal brain library. The human Y1 receptor consists of 384 amino acids and has seven putative transmembrane domains like other members of the G-protein-coupled superfamily of receptors. In the region spanning the transmembrane domains, the Y1 receptor displays 29% sequence identity to human tachykinin receptors, but it only shows 21% and 23% homology with proposed bovine (LCR1) and Drosophila (PR4) NPY receptor clones, respectively. Northern blot analysis of a human neuroblastoma cell line, SK-N-MC, previously used by many investigators as a model system for studies on the Y1 receptor, revealed a single 3.5-kilobase mRNA species. Reverse transcriptase-polymerase chain reaction analysis indicated expression also in human cultured vascular smooth muscle cells, supporting the view that the Y1 receptor is associated with NPY/PYY-evoked vasoconstriction. When expressed in COS1 cells, hY1-5 conferred specific I-125-PYY binding sites with displacement patterns characteristic of the Y1 receptor, i.e. PYY greater-than-or-equal-to NPY greater-than-or-equal-to [Leu31,Pro34]NPY >> NPY2-36 > C2NPY > pancreatic polypeptide > NPY13-36 > NPY18-36. Moreover, in the Y1 receptor-transfected COS1 cells, but not in type 1 angiotensin II receptor-transfected control cells, NPY and PYY accelerated Ca-45(2+) influx and inhibited forskolin-stimulated cAMP accumulation, both phenomena being characteristic of the mammalian Y1 receptor.	CORNELL UNIV, MED CTR,COLL MED,DEPT NEUROL & NEUROSCI, DIV NEUROBIOL,411 E 69TH ST, NEW YORK, NY 10021 USA; UNIV UPPSALA, DEPT MED GENET, S-75105 UPPSALA, SWEDEN	Cornell University; Uppsala University			Wahlestedt, Claes/A-7039-2009	Jazin, Elena/0000-0002-0363-3466; /0000-0002-8250-8152	NHLBI NIH HHS [HL 18974] Funding Source: Medline; NIDA NIH HHS [DA 06805] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006805] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AICHER SA, 1991, NEUROSCI LETT, V130, P32, DOI 10.1016/0304-3940(91)90220-N; BLOMQVIST AG, 1992, IN PRESS P NATL ACAD; EVA C, 1990, FEBS LETT, V271, P81, DOI 10.1016/0014-5793(90)80377-U; FUHLENDORFF J, 1990, P NATL ACAD SCI USA, V87, P182, DOI 10.1073/pnas.87.1.182; GRUNDEMAR L, 1992, BRIT J PHARMACOL, V105, P45, DOI 10.1111/j.1476-5381.1992.tb14208.x; LI XJ, 1992, J BIOL CHEM, V267, P9; LINDEN J, 1991, TRENDS PHARMACOL SCI, V12, P326, DOI 10.1016/0165-6147(91)90589-K; MICHEL MC, 1991, TRENDS PHARMACOL SCI, V12, P389, DOI 10.1016/0165-6147(91)90610-5; OKHUBO H, 1991, ANN NY ACAD SCI, V632, P53; RIMLAND J, 1991, MOL PHARMACOL, V40, P869; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ TW, 1990, ANN NY ACAD SCI, V611, P35; SHEIKH SP, 1989, J BIOL CHEM, V264, P6648; SUNDLER F, 1986, INT REV CYTOL, V102, P243, DOI 10.1016/S0074-7696(08)61277-2; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; WAHLESTEDT C, 1992, LIFE SCI, V50, pPL7, DOI 10.1016/0024-3205(92)90342-M; WAHLESTEDT C, 1989, PROG NEURO-PSYCHOPH, V13, P31, DOI 10.1016/0278-5846(89)90003-1; WAHLESTEDT C, 1990, ANN NY ACAD SCI, V611, P7; WAHLESTEDT C, 1986, REGUL PEPTIDES, V13, P317; WALKER MW, 1988, MOL PHARMACOL, V34, P779; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251	21	409	436	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10935	10938						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317848				2022-12-27	WOS:A1992HX16900002
J	THEIBERT, AB; ESTEVEZ, VA; MOUREY, RJ; MARECEK, JF; BARROW, RK; PRESTWICH, GD; SNYDER, SH				THEIBERT, AB; ESTEVEZ, VA; MOUREY, RJ; MARECEK, JF; BARROW, RK; PRESTWICH, GD; SNYDER, SH			PHOTOAFFINITY-LABELING AND CHARACTERIZATION OF ISOLATED INOSITOL 1,3,4,5-TETRAKISPHOSPHATE-BINDING AND INOSITOL HEXAKISPHOSPHATE-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,4,5-TRISPHOSPHATE RECEPTOR; RAT-BRAIN; TRISPHOSPHATE RECEPTOR; CALCIUM RELEASE; ACINAR-CELLS; CA-2+; TETRAKISPHOSPHATE; PURIFICATION; 3-KINASE; PENTAKISPHOSPHATE	We have isolated high affinity inositol (1,3,4,5)-tetrakisphosphate (IP4)- and inositol hexakisphosphate (IP6)-binding proteins from detergent-solubilized rat brain membranes using a P1-tethered IP4 derivative linked to an Affi-Gel support. To determine the identity, binding characteristics, and distribution of the individual IP4 recognition sites, we have synthesized an IP4 photoaffinity label probe, I-125-(D,L)-1-O-[N-(4-azidosalicyloxy)-3-aminopropyl-1-phospho]-IP4 (I-125-ASA-IP4). Two apparently distinct IP4-binding proteins (IP4BP), isolated with the IP4 affinity column, display high affinity and selectivity for IP4 over inositol trisphosphate (IP3), inositol pentakisphosphate (IP5), and IP6. The first IP4-binding protein (IP4BP1) which has a K(D) for IP4 of 4 nm, is comprised of a protein at 182 kDa which is specifically photolabeled with high affinity by I-125-ASA-IP4. The second, IP4BP2, has an affinity for IP4 of 1.5 nm and contains proteins at 84 and 174 kDa, both of which are specifically photoaffinity labeled. A putative IP6-binding protein (IP6BP), also isolated with the IP4 affinity column, binds IP6 with a KD of 14 nm and comprises three proteins of 115, 105, and 50 kDa. The 115- and 105-kDa subunits, but not the 50-kDa subunit, specifically incorporate the photolabel. The IP4BP (182, 174, and 84 kDa) and IP6BP (115 and 105 kDa) proteins are specifically photolabeled in the crude membrane, partially purified, and purified fractions. These receptor-binding proteins vary in inositol phosphate specificity and in the effects of pH, Ca2+, and heparin on IP4 photoaffinity labeling. In addition, IP4BP and IP6BP are enriched in the brain but differ in their regional localizations within the brain.	JOHNS HOPKINS MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; SUNY STONY BROOK,DEPT CHEM,STONY BROOK,NY 11794	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00266, DA-00074] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BALLA T, 1989, J BIOL CHEM, V264, P9386; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BRADFORD PG, 1987, BIOCHEM BIOPH RES CO, V149, P680, DOI 10.1016/0006-291X(87)90421-9; CHADWICK CC, 1991, BIOCHEM J, V59, P525; CHANGYA L, 1989, FEBS LETT, V251, P43, DOI 10.1016/0014-5793(89)81425-5; CULLEN PJ, 1990, BIOCHEM J, V271, P549, DOI 10.1042/bj2710549; DONIE F, 1989, FEBS LETT, V254, P155, DOI 10.1016/0014-5793(89)81029-4; DONIE F, 1991, BIOCHEM J, V275, P453, DOI 10.1042/bj2750453; ELY JA, 1990, BIOCHEM J, V268, P333, DOI 10.1042/bj2680333; ENYEDI P, 1988, J BIOL CHEM, V263, P7940; ESTEVEZ VA, 1991, TETRAHEDRON LETT, V32, P1623, DOI 10.1016/S0040-4039(00)74288-2; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GAWLER DJ, 1990, BIOCHEM J, V272, P519, DOI 10.1042/bj2720519; HANSEN CA, 1986, J BIOL CHEM, V261, P8100; HAWKINS PT, 1990, BIOCHEM BIOPH RES CO, V167, P819, DOI 10.1016/0006-291X(90)92099-L; HENNE V, 1988, EUR J BIOCHEM, V174, P95, DOI 10.1111/j.1432-1033.1988.tb14067.x; HILL TD, 1988, SCIENCE, V242, P1176, DOI 10.1126/science.2847317; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; JI H, 1989, J BIOL CHEM, V264, P20185; JOHANSON RA, 1988, J BIOL CHEM, V263, P7465; JOSEPH SK, 1989, MOL PHARMACOL, V36, P391; LEE SY, 1990, J BIOL CHEM, V265, P9434; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MOLLEMAN A, 1991, J BIOL CHEM, V266, P5658; MORRIS AJ, 1988, BIOCHEM J, V251, P157, DOI 10.1042/bj2510157; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; MOUREY RJ, 1991, SOC NEUROSCI, V17, P1174; NICOLETTI F, 1990, MOL PHARMACOL, V37, P689; NICOLETTI F, 1989, J NEUROCHEM, V53, P1026, DOI 10.1111/j.1471-4159.1989.tb07390.x; PARKER I, 1992, IN PRESS J CELL BIOL; PRESTWICH GD, 1991, J AM CHEM SOC, V113, P1822, DOI 10.1021/ja00005a055; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; STEPHENS LR, 1988, BIOCHEM J, V253, P721, DOI 10.1042/bj2530721; STEPHENS LR, 1991, BIOCHEM J, V275, P485, DOI 10.1042/bj2750485; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; THEIBERT AB, 1990, BIOCHEM J, V267, P441, DOI 10.1042/bj2670441; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; THEIBERT AB, 1987, BIOCHEM BIOPH RES CO, V148, P1283, DOI 10.1016/S0006-291X(87)80272-3; VALLEJO M, 1987, NATURE, V330, P656, DOI 10.1038/330656a0; WALKER JW, 1987, NATURE, V327, P249, DOI 10.1038/327249a0; WORLEY PF, 1987, NATURE, V325, P159, DOI 10.1038/325159a0	43	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9071	9079						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1315747				2022-12-27	WOS:A1992HR85400058
J	WU, XC; YUAN, G; BRETT, CM; HUI, AC; GIACOMINI, KM				WU, XC; YUAN, G; BRETT, CM; HUI, AC; GIACOMINI, KM			SODIUM-DEPENDENT NUCLEOSIDE TRANSPORT IN CHOROID-PLEXUS FROM RABBIT - EVIDENCE FOR A SINGLE TRANSPORTER FOR PURINE AND PYRIMIDINE NUCLEOSIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; INTESTINAL EPITHELIAL-CELLS; URIDINE TRANSPORT; VESICLES; SPECIFICITY; RAT; CARRIERS	The overall goal of this study was to determine the mechanisms by which nucleosides are transported in choroid plexus. Choroid plexus tissue slices obtained from rabbit brain were depleted of ATP with 2,4-dinitrophenol. Uridine and thymidine accumulated in the slices against a concentration gradient in the presence of an inwardly directed Na+ gradient. The Na+-driven uptake of uridine and thymidine was saturable with K(m) values of 18.1 +/- 2.0 and 13.0 +/- 2.3-mu-M and V(max) values of 5.5 +/- 0.3 and 1.0 +/- 0.2 nmol/g/s, respectively. Na+-driven uridine uptake was inhibited by naturally occurring ribo- and deoxyribonucleosides (adenosine, cytidine, and thymidine) but not by synthetic nucleoside analogs (dideoxyadenosine, dideoxycytidine, cytidine arabinoside, and 3'-azidothymidine). Both purine (guanosine, inosine, formycin B) and pyrimidine nucleosides (uridine and cytidine) were potent inhibitors of Na+-thymidine transport with IC50 values ranging between 5 and 23-mu-M. Formycin B competitively inhibited Na+-thymidine uptake and thymidine trans-stimulated formycin B uptake. These data suggest that both purine and pyrimidine nucleosides are substrates of the same system. The stoichiometric coupling ratios between Na+ and the nucleosides, guanosine, uridine, and thymidine, were 1.87 +/- 0.10, 1.99 +/- 0.35, and 2.07 +/- 0.09, respectively. The system differs from Na+-nucleoside co-transport systems in other tissues which are generally selective for either purine or pyrimidine nucleosides and which have stoichiometric ratios of 1. This study represents the first direct demonstration of a unique Na+-nucleoside co-transport system in choroid plexus.	UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	WU, XC (corresponding author), UNIV CALIF SAN FRANCISCO,SCH PHARM,SAN FRANCISCO,CA 94143, USA.		Giacomini, Kathleen/AEF-2452-2022		NIGMS NIH HHS [GM 26691, GM 42230] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042230, P50GM026691] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Carter-Su C, 1979, Am J Physiol, V237, pC67, DOI 10.1152/ajpcell.1979.237.1.C64; CRAWFORD CR, 1990, J BIOL CHEM, V265, P9732; DAGNINO L, 1991, J BIOL CHEM, V266, P6312; DARNOWSKI JW, 1987, CANCER RES, V47, P2614; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; HOFER M, 1984, TRANSPORT BIOL MEMBR, P26; JAKOBS ES, 1986, BIOCHEM BIOPH RES CO, V140, P1028, DOI 10.1016/0006-291X(86)90738-2; JAKOBS ES, 1990, J BIOL CHEM, V265, P22210; JARVIS SM, 1989, BIOCHIM BIOPHYS ACTA, V979, P132, DOI 10.1016/0005-2736(89)90533-6; LEE CW, 1990, AM J PHYSIOL, V258, pF1203, DOI 10.1152/ajprenal.1990.258.5.F1203; LEE CW, 1988, BIOCHIM BIOPHYS ACTA, V942, P139, DOI 10.1016/0005-2736(88)90283-0; LEHIR M, 1990, RENAL PHYSIOL BIOCH, V13, P154; LEHIR M, 1985, PFLUG ARCH EUR J PHY, V404, P238, DOI 10.1007/BF00581245; MURPHY VA, 1989, BIOCHIM BIOPHYS ACTA, V979, P187, DOI 10.1016/0005-2736(89)90434-3; PLAGEMANN PGW, 1990, BIOCHIM BIOPHYS ACTA, V1028, P289, DOI 10.1016/0005-2736(90)90178-Q; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; PLAGEMANN PGW, 1989, BIOCHIM BIOPHYS ACTA, V981, P315, DOI 10.1016/0005-2736(89)90043-6; SEGEL IH, 1975, ENZYME KINETICS, P398; SPECTOR R, 1982, J NEUROCHEM, V39, P837, DOI 10.1111/j.1471-4159.1982.tb07968.x; SPECTOR R, 1984, J NEUROCHEM, V42, P1048, DOI 10.1111/j.1471-4159.1984.tb12709.x; SPECTOR R, 1980, ARCH BIOCHEM BIOPHYS, V205, P85, DOI 10.1016/0003-9861(80)90086-7; SPECTOR R, 1982, ARCH BIOCHEM BIOPHYS, V216, P693, DOI 10.1016/0003-9861(82)90259-4; SUZUKI H, 1987, J PHARMACOL EXP THER, V243, P1147; TURNER RJ, 1982, J MEMBRANE BIOL, V67, P73, DOI 10.1007/BF01868649; VIJAYALAKSHMI D, 1988, J BIOL CHEM, V263, P19419; WHITTICO MT, 1990, J PHARMACOL EXP THER, V255, P615	26	101	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8813	8818						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1315741				2022-12-27	WOS:A1992HR85400020
J	SURYANARAYANA, S; VONZASTROW, M; KOBILKA, BK				SURYANARAYANA, S; VONZASTROW, M; KOBILKA, BK			IDENTIFICATION OF INTRAMOLECULAR INTERACTIONS IN ADRENERGIC-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LIGAND-BINDING; PROTEIN	Adrenergic receptors are representative of a large family of plasma membrane receptors that interact with G proteins during the process of transmembrane signal transduction. G protein-coupled receptors have a primary structure that is homologous to bacteriorhodopsin and are proposed to have a similar three-dimensional structure; however, it has not yet been possible to examine this hypothesis experimentally. We have used a novel mutagenesis approach to identify intramolecular interactions. Our results indicate that specific amino acids in the seventh hydrophobic segment of alpha2 and beta2 adrenergic receptors lie adjacent to the first hydrophobic segment. These studies provide the first experimental evidence defining spatial relationships that exist in the three-dimensional structure of adrenergic receptors.	STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DIV CARDIOVASC MED,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University				Kobilka, Brian/0000-0001-5958-3990	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028471] Funding Source: NIH RePORTER; NINDS NIH HHS [5 RO1 NS28471] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		DAHL SG, 1991, P NATL ACAD SCI USA, V88, P8111, DOI 10.1073/pnas.88.18.8111; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; FINDLAY J, 1990, TRENDS PHARMACOL SCI, V11, P492, DOI 10.1016/0165-6147(90)90050-I; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; MALONEYHUSS K, 1992, J MOL BIOL, V225, P859, DOI 10.1016/0022-2836(92)90406-A; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; SURYANARAYANA S, 1991, METHODS, V3, P193; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530	15	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					21991	21994						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331041				2022-12-27	WOS:A1992JW71900002
J	CLOUGH, RC; MATTHIS, AL; BARNUM, SR; JAWORSKI, JG				CLOUGH, RC; MATTHIS, AL; BARNUM, SR; JAWORSKI, JG			PURIFICATION AND CHARACTERIZATION OF 3-KETOACYL-ACYL CARRIER PROTEIN SYNTHASE-III FROM SPINACH - A CONDENSING ENZYME UTILIZING ACETYL-COENZYME-A TO INITIATE FATTY-ACID SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; OLERACEA LEAVES; SYNTHETASE; BIOSYNTHESIS; FORMS; SEEDS	The 3-ketoacyl-acyl carrier protein (ACP) synthase III from spinach was purified to homogeneity by an eight-step procedure that included an ACP-affinity column. The size of the native enzyme was M(r) = 63,000 based on gel filtration, and its subunit size was M(r) = 40,500 based on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, suggesting that 3-ketoacyl-ACP synthase III may be a homodimer. The purified enzyme was highly specific for acetyl-CoA and malonyl-ACP. The K(m) for acetyl-CoA was 5 muM when assayed in the presence of 10 muM malonyl-CoA. Acetyl-, butyryl-, and hexanoyl-ACP would not substitute for acetyl-CoA as substrates. The specificity for acetyl-CoA suggested that the physiological function of 3-ketoacyl-ACP synthase is to catalyze the initial condensation reaction in fatty acid biosynthesis. The homogeneous 3-ketoacyl-ACP synthase was capable of catalyzing acetyl-CoA:ACP transacylation but at a rate about 90-fold slower than the condensation reaction with malonyl-ACP. The 3-ketoacyl-ACP synthase was inhibited 100% by 5 mM N-ethylmaleimide or 20 mM sodium arsenite.	MIAMI UNIV,DEPT CHEM,OXFORD,OH 45056; MIAMI UNIV,DEPT BOT,OXFORD,OH 45056	University System of Ohio; Miami University; University System of Ohio; Miami University			Jaworski, Jan/N-2255-2014	Jaworski, Jan/0000-0003-3309-4915				ALBERTS AW, 1972, J BIOL CHEM, V247, P3190; ALBERTS AW, 1969, METHOD ENZYMOL, V14, P50; BLOCH K, 1977, ANNU REV BIOCHEM, V46, P263, DOI 10.1146/annurev.bi.46.070177.001403; CLOUGH RC, 1989, ANAL BIOCHEM, V176, P82, DOI 10.1016/0003-2697(89)90276-5; CRONAN JE, 1981, P NATL ACAD SCI-BIOL, V78, P5440, DOI 10.1073/pnas.78.9.5440; DAGNOLO G, 1975, J BIOL CHEM, V250, P5289; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P412, DOI 10.1016/0003-2697(88)90208-4; JACKOWSKI S, 1989, J BIOL CHEM, V264, P7624; JACKOWSKI S, 1987, J BIOL CHEM, V262, P7927; JAWORSKI JG, 1989, PLANT PHYSIOL, V90, P41, DOI 10.1104/pp.90.1.41; KAUPPINEN S, 1988, CARLSBERG RES COMMUN, V53, P357, DOI 10.1007/BF02983311; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKINTHOMAS PL, 1986, J BIOL CHEM, V261, P4785; LOWE PN, 1988, BIOCHEM J, V250, P789, DOI 10.1042/bj2500789; MACKINTOSH RW, 1989, BIOCHIM BIOPHYS ACTA, V1002, P114, DOI 10.1016/0005-2760(89)90073-8; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; RUTKOSKI A, 1978, ANAL BIOCHEM, V91, P370, DOI 10.1016/0003-2697(78)90854-0; SHIMAKATA T, 1982, ARCH BIOCHEM BIOPHYS, V217, P144, DOI 10.1016/0003-9861(82)90488-X; SHIMAKATA T, 1983, J BIOL CHEM, V258, P3592; SHIMAKATA T, 1982, PLANT PHYSIOL, V69, P1257, DOI 10.1104/pp.69.6.1257; SHIMAKATA T, 1983, ARCH BIOCHEM BIOPHYS, V220, P39, DOI 10.1016/0003-9861(83)90384-3; SHIMAKATA T, 1982, P NATL ACAD SCI-BIOL, V79, P5808, DOI 10.1073/pnas.79.19.5808; Stumpf P. K., 1987, Biochemistry of Plants, V9, P121; TSAY JT, 1992, J BIOL CHEM, V267, P6807; VOLPE JJ, 1973, ANNU REV BIOCHEM, V42, P21, DOI 10.1146/annurev.bi.42.070173.000321; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WALSH MC, 1990, PLANT LIPID BIOCHEMISTRY, STRUCTURE AND UTILIZATION, P114; WILLIAMS.IP, 1966, J BIOL CHEM, V241, P2326	29	97	101	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20992	20998						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328217				2022-12-27	WOS:A1992JT97800076
J	HIGUCHI, M; AGGARWAL, BB				HIGUCHI, M; AGGARWAL, BB			MODULATION OF 2 FORMS OF TUMOR-NECROSIS-FACTOR RECEPTORS AND THEIR CELLULAR-RESPONSE BY SOLUBLE RECEPTORS AND THEIR MONOCLONAL-ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTO-TOXIC RESPONSE; FACTOR TNF RECEPTOR; FACTOR-ALPHA; MOLECULAR-CLONING; DOWN-REGULATION; EXPRESSION; INTERLEUKIN-1; BINDING; CELLS; INTERNALIZATION	Recently, two different receptors for human tumor necrosis factor (TNF) with molecular masses of 60 kDa (p60) and 80 kDa (p80) have been identified. In this report, we investigated the effect of the soluble forms of these receptors and monoclonal antibodies against them on ligand interaction, receptor down-regulation, and mediation of cellular response in U-937 cells. Our results indicate that p60 and p80 constitute 20-30 and 60-80% of the total TNF-binding sites on U-937 cells, respectively. However, by cross-linking, only the p80 form of the receptor could be detected. In contrast to unlabeled TNF, the anti-p60 and anti-p80 antibodies together only partially inhibited ligand binding, and this inhibition was not additive. Lack of additive inhibition of binding was found to be not due to stereochemical hindrance. TNF binding to cells can be completely displaced by soluble forms of either the p60 or p80 receptor. However, 100-fold more of the p80 than the p60 form of the soluble receptor is needed for equivalent displacement. Under optimum conditions, TNF and the anti-p80 and anti-p60 antibodies down-regulated 30, 80, and 20% of the TNF receptors, respectively. The anti-p60 and anti-p80 antibodies down-regulated not only their own receptors, but also reciprocal receptors, suggesting a cross-communication between the p60 and p80 forms of the TNF receptor. In spite of inhibiting as much as 80% of TNF binding, none of the receptor antibodies significantly inhibited the cytotoxic response to TNF in U-937 cells. Soluble forms of both receptors, however, completely abrogated the cellular response to TNF. Thus, overall, our results indicate that the antibodies against both receptors together inhibit the majority of the receptor-ligand interaction without any significant effect on the biological response to TNF.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN IMMUNOL & BIOL THERAPY,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Aggarwal, Bharat B/G-3388-2013					AGGARWAL BB, 1987, J BIOL CHEM, V262, P10000; AGGARWAL BB, 1986, J BIOL CHEM, V261, P3652; AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; AGGARWAL BB, 1987, J BIOL CHEM, V262, P16450; AIYER RA, 1987, CRC HDB CYTOLYTIC LY, V2, P105; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DING AH, 1989, J BIOL CHEM, V264, P3924; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ERIKSTEIN BK, 1991, EUR J IMMUNOL, V21, P1033, DOI 10.1002/eji.1830210426; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; GOEDDEL DV, 1989, COLD SPRING HARB SYM, V1, P597; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HIGUCHI M, 1992, ANAL BIOCHEM, V204, P53, DOI 10.1016/0003-2697(92)90138-W; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; HOLTMANN H, 1987, J IMMUNOL, V139, P1161; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KULL FC, 1981, CANCER RES, V41, P4885; KULL FC, 1988, BIOCHEM BIOPH RES CO, V153, P402, DOI 10.1016/S0006-291X(88)81238-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE JM, 1987, LAB INVEST, V56, P234; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; POUTEU F, 1990, J EXP MED, V172, P599; RUGGIERO V, 1987, J IMMUNOL, V138, P661; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SHEURICH P, 1989, J EXP MED, V170, P947; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH MR, 1990, J IMMUNOL, V144, P162; STAUBER GB, 1988, J BIOL CHEM, V263, P19098; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; TSUJIMOTO M, 1987, J BIOCHEM-TOKYO, V102, P1571, DOI 10.1093/oxfordjournals.jbchem.a122206; TSUJIMOTO M, 1986, J IMMUNOL, V137, P2272	44	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20892	20899						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328214				2022-12-27	WOS:A1992JT97800060
J	POWELL, WS; GRAVELLE, F; GRAVEL, S				POWELL, WS; GRAVELLE, F; GRAVEL, S			METABOLISM OF 5(S)-HYDROXY-6,8,11,14-EICOSATETRAENOIC ACID AND OTHER 5(S)-HYDROXYEICOSANOIDS BY A SPECIFIC DEHYDROGENASE IN HUMAN POLYMORPHONUCLEAR LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOHYDROXY-EICOSATETRAENOIC ACIDS; LEUKOTRIENE-B4 OMEGA-HYDROXYLASE; PRESSURE LIQUID-CHROMATOGRAPHY; ARACHIDONIC-ACID; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; PROSTAGLANDIN 9-KETOREDUCTASE; DIHYDRO METABOLITES; PORCINE LEUKOCYTES; FATTY-ACIDS; NEUTROPHILS	Human polymorphonuclear leukocytes (PMNL) convert 6-trans isomers of leukotriene B4 (LTB4) to dihydro metabolites (Powell, W. S., and Gravelle, F. (1988) J. Biol. Chem. 263, 2170-2177). In the present study we investigated the mechanism for the initial step in the formation of these products. We found that the 1,500 x g supernatant fraction from human PMNL converts 12-epi-6-trans-LTB4 to its 5-oxo metabolite which was identified by mass spectrometry and UV spectrophotometry. The latter compound was subsequently converted to the corresponding dihydro-oxo product, which was further metabolized to 6,11-dihydro-12-epi-6-trans-LTB4, which was the major product after longer incubation times. The 5-hydroxyeicosanoid dehydrogenase activity is localized in the microsomal fraction and requires NADP+ as a cofactor. These experiments therefore suggest that the initial step in the formation of dihydro metabolites of 6-trans isomers of LTB4 is oxidation of the 5-hydroxyl group by a microsomal dehydrogenase. Studies with a variety of substrates revealed that the microsomal dehydrogenase in human PMNL oxidizes the hydroxyl groups of a number of other eicosanoids which contain a 5(S)-hydroxyl group followed by a 6-trans double bond. There is little or no oxidation of hydroxyl groups in the 8-, 9-, 11-, 12-, or 15-positions of eicosanoids, or of the 5-hydroxyl group of LTB4, which has a 6-cis rather than a 6-trans double bond. The preferred substrate for this enzyme is 5(S)-hydroxy-6,8,11,14-eicosatetraenoic acid (5(S)-HETE) (K(m), 0.2-mu-M), which is converted to 5-oxo-6,8,11,14-eicosatetraenoic acid. Unlike 5(S)-HETE, 5(R)-HETE is a poor substrate for the 5(S)-hydroxyeicosanoid dehydrogenase, indicating that in addition to exhibiting a high degree of positional specificity, this enzyme is also highly stereospecific. In addition to 5(S)-HETE and 6-trans isomers of LTB4, 5,15-diHETE is also a good substrate for this enzyme, being converted to 5-oxo-15-hydroxy-6,8,11,13-eicosatetraenoic acid (5-oxo-15-hydroxy-ETE). The oxidation of 5(S)-HETE to 5-oxo-ETE is reversible since human PMNL microsomes stereospecifically reduce 5-oxo-ETE to the 5(S)-hydroxy compound in the presence of NADPH. 5-Oxo-ETE is formed rapidly from 5(S)-HETE by intact human PMNL, but because of the reversibility of the reaction, its concentration only reaches about 25% that of 5(S)-HETE.			POWELL, WS (corresponding author), MCGILL UNIV,RESP HLTH NETWORK CTR EXCELLENCE,DEPT MED,MEAKINS CHRISTIE LABS,3626 ST URBAIN ST,MONTREAL H2X 2P2,QUEBEC,CANADA.		Powell, William/AAE-9000-2020	Powell, William/0000-0002-8507-4038				AGINS AP, 1987, AGENTS ACTIONS, V21, P397, DOI 10.1007/BF01966527; ANGGARD E, 1966, ARK KEMI, V25, P293; BADWEY JA, 1988, J BIOL CHEM, V263, P2779; BERGHOLTE JM, 1987, ARCH BIOCHEM BIOPHYS, V257, P444, DOI 10.1016/0003-9861(87)90589-3; BOEYNAEMS JM, 1980, ANAL BIOCHEM, V104, P259, DOI 10.1016/0003-2697(80)90073-1; BORGEAT P, 1981, PROSTAG LEUKOTR ESS, V6, P557, DOI 10.1016/0161-4630(81)90117-8; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P3213, DOI 10.1073/pnas.76.7.3213; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; BORGEAT P, 1976, J BIOL CHEM, V251, P7816; CHANG DGB, 1981, BIOCHEM BIOPH RES CO, V99, P745, DOI 10.1016/0006-291X(81)91806-4; CHANG DGB, 1981, BIOCHEM BIOPH RES CO, V101, P898, DOI 10.1016/0006-291X(81)91834-9; EARLES SM, 1991, BIOCHIM BIOPHYS ACTA, V1081, P174, DOI 10.1016/0005-2760(91)90023-B; GOETZL EJ, 1980, J IMMUNOL, V125, P1789; GOETZL EJ, 1980, IMMUNOLOGY, V39, P491; JUBIZ W, 1982, J BIOL CHEM, V257, P6106; LEE SC, 1975, J BIOL CHEM, V250, P548; LEWIS RA, 1981, J EXP MED, V154, P1243, DOI 10.1084/jem.154.4.1243; LINDGREN JA, 1981, FEBS LETT, V128, P329, DOI 10.1016/0014-5793(81)80110-X; MARCUS AJ, 1984, P NATL ACAD SCI-BIOL, V81, P903, DOI 10.1073/pnas.81.3.903; MARCUS AJ, 1988, J BIOL CHEM, V263, P2223; MASS RL, 1982, J BIOL CHEM, V257, P7056; MORITA E, 1990, J IMMUNOL, V144, P1893; OFLAHERTY JT, 1988, J IMMUNOL, V140, P4323; OFLAHERTY JT, 1986, J IMMUNOL, V137, P3277; OFLAHERTY JT, 1985, J CELL PHYSIOL, V122, P229, DOI 10.1002/jcp.1041220211; POWELL WS, 1984, J BIOL CHEM, V259, P3082; POWELL WS, 1983, ANAL BIOCHEM, V128, P93, DOI 10.1016/0003-2697(83)90349-4; POWELL WS, 1988, J BIOL CHEM, V263, P2170; POWELL WS, 1990, J BIOL CHEM, V265, P9131; POWELL WS, 1990, BIOCHIM BIOPHYS ACTA, V1044, P147, DOI 10.1016/0005-2760(90)90230-U; POWELL WS, 1989, J BIOL CHEM, V264, P5364; POWELL WS, 1987, ANAL BIOCHEM, V164, P117, DOI 10.1016/0003-2697(87)90375-7; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SHAK S, 1985, J CLIN INVEST, V76, P1218, DOI 10.1172/JCI112077; SOBERMAN RJ, 1987, J BIOL CHEM, V262, P12421; SOK DE, 1988, BIOCHEM BIOPH RES CO, V156, P524; STENSON WF, 1979, J CLIN INVEST, V64, P1457, DOI 10.1172/JCI109604; SUMIMOTO H, 1988, EUR J BIOCHEM, V172, P315, DOI 10.1111/j.1432-1033.1988.tb13889.x; Tai H H, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P159; WAINWRIGHT S, 1990, BIOCHEMISTRY-US, V29, P10126, DOI 10.1021/bi00495a017; WAINWRIGHT SL, 1991, J BIOL CHEM, V266, P20899; WERMUTH B, 1981, J BIOL CHEM, V256, P1206; WONG PYK, 1984, J BIOL CHEM, V259, P2683	43	142	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19233	19241						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326548				2022-12-27	WOS:A1992JP59300036
J	STAR, RA; ZHANG, BX; LOESSBERG, PA; MUALLEM, S				STAR, RA; ZHANG, BX; LOESSBERG, PA; MUALLEM, S			REGULATORY VOLUME DECREASE IN THE PRESENCE OF HCO3- BY SINGLE OSTEOSARCOMA CELLS UMR-106-01	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+/OH-/HCO3 TRANSPORT; COUPLED ELECTROGENIC PROCESS; INTRACELLULAR PH REGULATION; PROXIMAL CONVOLUTED TUBULE; DIPHTHERIA-TOXIN ENTRY; BASOLATERAL MEMBRANE; NA+/H+ EXCHANGER; ANION TRANSPORT; LINE UMR-106-01; VERO CELLS	The technique for the simultaneous recording of cell volume changes and pH(i) in single cells was used to study the role of HCO3- in regulatory volume decrease (RVD) by the osteosarcoma cells UMR-106-01. In the presence of HCO3-, steady state pH(i) is regulated by Na+/H+ exchange, Na+(HCO3-)3 cotransport and Na+-independent Cl-/HCO3- exchange. Following swelling in hypotonic medium, pH(i) was reduced from 7.16 +/- 0.02 to 6.48 +/- 0.02 within 3.4 +/- 0.28 min. During this period of time, the cells performed RVD until cell volume was decreased by 31 +/- 5% beyond that of control cells (RVD overshoot). Subsequently, while the cells were still in hypotonic medium, pH(i) slowly increased from 6.48 +/- 0.02 to 6.75 +/- 0.02. This increase in pH(i) coincided with an increase in cell volume back to normal (recovery from RVD overshoot or hypotonic regulatory volume increase (RVI)). The same profound changes in cell volume and pH(i) after cell swelling were observed in the complete absence of Cl- or Na+, providing HCO3- was present. On the other hand, depolarizing the cells by increasing external K+ or by inhibition of K+ channels with quinidine, Ba2+ or tetraethylammonium prevented the changes in pH(i) and RVD. These findings suggest that in the presence of HCO3-, RVD in UMR-106-01 cells is largely mediated by the conductive efflux of K+ and HCO3-. Removal of external Na+ but not Cl- prevented the hypotonic RVI that occurred after the overshoot in RVD. Amiloride had no effect, whereas pretreatment with 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS) strongly inhibited hypotonic RVI. Thus, hypotonic RVI is mediated by a Na(out)+-dependent, Cl--independent and DIDS-inhibitable mechanism, which is indicative of a Na+(HCO3-)3 cotransporter. This is the first evidence for the involvement of this transporter in cell volume regulation. The present results also stress the power of the new technique used in delineating complicated cell volume regulatory mechanisms in attached single cells.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,5323 HARRY HINES,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MED,DIV NEPHROL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39245] Funding Source: Medline; NIDDK NIH HHS [DK38938] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADORANTE JS, 1990, J GEN PHYSIOL, V96, P1153, DOI 10.1085/jgp.96.6.1153; ALPERN RJ, 1985, J GEN PHYSIOL, V86, P613, DOI 10.1085/jgp.86.5.613; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; FERRIER J, 1987, J CELL PHYSIOL, V130, P344, DOI 10.1002/jcp.1041300306; GREEN J, 1988, J GEN PHYSIOL, V92, P239, DOI 10.1085/jgp.92.2.239; GREEN J, 1988, J BIOL CHEM, V263, P5012; GREEN J, 1990, J GEN PHYSIOL, V95, P121, DOI 10.1085/jgp.95.1.121; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; JENTSCH TJ, 1985, J BIOL CHEM, V260, P795; KHADEMAZAD M, 1991, AM J PHYSIOL, V261, pC441, DOI 10.1152/ajpcell.1991.261.3.C441; LOPES AG, 1987, AM J PHYSIOL, V253, pF340, DOI 10.1152/ajprenal.1987.253.2.F340; LOPES AG, 1987, J MEMBRANE BIOL, V97, P117, DOI 10.1007/BF01869418; LOPES AG, 1988, P NATL ACAD SCI USA, V85, P2873, DOI 10.1073/pnas.85.8.2873; LUDT J, 1991, J MEMBRANE BIOL, V119, P179, DOI 10.1007/BF01871417; MONTROSERAFIZADEH C, 1990, ANNU REV PHYSIOL, V52, P761; MUALLEM S, 1990, J BIOL CHEM, V265, P12806; MUALLEM S, 1992, J BIOL CHEM, V267, P17658; OLSNES S, 1986, J BIOL CHEM, V261, P1553; OLSNES S, 1986, J BIOL CHEM, V261, P1562; PARIS S, 1986, J BIOL CHEM, V261, P6177; REDHEAD CR, 1988, J PHYSIOL-LONDON, V401, P455, DOI 10.1113/jphysiol.1988.sp017172; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SOLEIMANI M, 1991, J BIOL CHEM, V266, P8706; TONNESSEN TI, 1990, AM J PHYSIOL, V258, pC1117, DOI 10.1152/ajpcell.1990.258.6.C1117; VOLKL H, 1988, PFLUG ARCH EUR J PHY, V411, P514, DOI 10.1007/BF00582372; VOLKL H, 1988, PFLUG ARCH EUR J PHY, V412, P1; WENZL E, 1989, AM J PHYSIOL, V257, pG732, DOI 10.1152/ajpgi.1989.257.5.G732; WHISENANT N, 1991, AM J PHYSIOL, V261, pC433, DOI 10.1152/ajpcell.1991.261.3.C433; YAMAGUCHI DT, 1989, J BIOL CHEM, V264, P4383; YAMAGUCHI DT, 1989, J BIOL CHEM, V264, P197; YOSHITOMI K, 1985, PFLUG ARCH EUR J PHY, V405, pS121, DOI 10.1007/BF00581792	32	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17665	17669						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325445				2022-12-27	WOS:A1992JM22300031
J	CANTLEY, LG; ZHOU, XM; CUNHA, MJ; EPSTEIN, J; CANTLEY, LC				CANTLEY, LG; ZHOU, XM; CUNHA, MJ; EPSTEIN, J; CANTLEY, LC			OUABAIN-RESISTANT TRANSFECTANTS OF THE MURINE OUABAIN RESISTANCE GENE CONTAIN MUTATIONS IN THE ALPHA-SUBUNIT OF THE NA,K-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CELL RECIPIENTS; MOUSE; DNA; SENSITIVITY; MUTANTS	A 6.5-kilobase murine genomic DNA fragment isolated by Levenson et al. (Levenson, R., Racaniello, V., Albritton, L., and Housman, D. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 1489-1493) (called the ouabain resistance gene) has been shown to produce ouabain resistance in primate cells. Preliminary sequence information has revealed no homology with the coding sequence of the Na,K-ATPase. We have introduced this murine sequence into monkey and murine cells in an attempt to characterize its mechanism of action. In our experiments, transfection of this DNA fragment is associated with the low frequency (1 in 8 x 10(5) cells) appearance of ouabain-resistant clones of CV1, COS, and NIH 3T3 cells, an event not seen in control transfections. Characterization of a new clone of ouabain-resistant CV1 cells (called OR8 cells) revealed a 5-fold increase in the IC50 for ouabain inhibition of rubidium uptake and a 10-fold increase in cell survival on ouabain. Although the murine sequence was detectable in Southern blots of ouabain-resistant cells soon after transfection, this exogenous DNA was rapidly lost despite continued exposure to ouabain. Furthermore, we were unable to detect message expression by this genomic sequence in any of the three cell types tested. Instead, we found that all three ouabain-resistant cell lines exhibited point mutations in a domain of the alpha-subunit that has been implicated in ouabain sensitivity (H1-H2). One of these mutations (Asp121-Asn121 in OR8 cells) has been previously reported to cause ouabain resistance (Price, E. M., Rice, D. A., and Lingrel, J. B. (1989) J. Biol. Chem. 264,21902-21906). Other novel mutations in the H2 transmembrane domain were also detected. We postulate that the "ouabain resistance gene" is important in the early selection process on ouabain but that the permanent ouabain-resistant phenotype is due to a stable mutation in one allele of the alpha-subunit of the Na,K-ATPase.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; TUFTS UNIV, NEW ENGLAND MED CTR, BOSTON, MA 02111 USA	Harvard University; Brigham & Women's Hospital; Tufts Medical Center; Tufts University	CANTLEY, LG (corresponding author), BETH ISRAEL HOSP, DIV NEPHROL, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653				BAKER RM, 1974, CELL, V1, P9, DOI 10.1016/0092-8674(74)90149-4; Bedryshev G D, 1974, Tsitol Genet, V8, P452; CHARIKOVA EV, 1983, BIOL NAUKI, V4, P86; EMANUEL JR, 1989, MOL CELL BIOL, V9, P3744, DOI 10.1128/MCB.9.9.3744; ENGLISH LH, 1985, J BIOL CHEM, V260, P1114; EPSTEIN JA, 1988, AM J PHYSIOL, V254, pC847, DOI 10.1152/ajpcell.1988.254.6.C847; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HORISBERGER JD, 1991, J CELL BIOL, V115, P201; LEVENSON R, 1984, P NATL ACAD SCI-BIOL, V81, P1489, DOI 10.1073/pnas.81.5.1489; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LINGREL JB, 1991, SOC GEN PHY, V46, P1; PRESSLEY TA, 1986, J BIOL CHEM, V261, P9779; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; ROBBINS AR, 1977, BIOCHEMISTRY-US, V16, P5163, DOI 10.1021/bi00642a600; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ JT, 1988, J BIOL CHEM, V263, P624; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SODERBERG K, 1983, J BIOL CHEM, V258, P2300; SWEADNER KJ, 1991, SOC GEN PHY, V46, P63; TAKEYASU K, 1990, AM J PHYSIOL, V259, pC619, DOI 10.1152/ajpcell.1990.259.4.C619	22	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17271	17278						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324928				2022-12-27	WOS:A1992JL05300082
J	ODA, K				ODA, K			CALCIUM DEPLETION BLOCKS PROTEOLYTIC CLEAVAGES OF PLASMA-PROTEIN PRECURSORS WHICH OCCUR AT THE GOLGI AND OR TRANS-GOLGI NETWORK - POSSIBLE INVOLVEMENT OF CA2+-DEPENDENT GOLGI ENDOPROTEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED RAT HEPATOCYTES; ROUGH ENDOPLASMIC-RETICULUM; I HISTOCOMPATIBILITY MOLECULES; PROPROTEIN PROCESSING ENZYME; HEPATOMA SECRETORY PROTEINS; VESICULAR STOMATITIS-VIRUS; WEAKLY BASIC AMINES; BREFELDIN-A; SERUM-ALBUMIN; CELL-SURFACE	The effects of calcium depletion on the proteolytic cleavage and secretion of plasma protein precursors were investigated in primary cultured rat hepatocytes and HepG2 cells. When the cells were incubated with A23187, the calcium-specific ionophore, in a medium lacking CaCl2, precursors of serum albumin and the third and fourth components of complement, C3 and C4, respectively, were found to be released into the medium. The addition of ionomycin or EGTA to the medium inhibited the processing of pro-C3 as well. Blocking the secretory pathway either at the mixed endoplasmic reticulum/Golgi in the presence of brefeldin A or at the endoplasmic reticulum/tubular-vesicular structure at a reduced temperature caused accumulation of pro-C3 within hepatocytes or HepG2 cells, indicating that the cleavage of the precursor occurs at a later stage of the secretory pathway. Once the blockade was released by incubating the cells either in the brefeldin A-free medium or at 37-degrees-C, the secretion of plasma proteins resumed, irrespective of the presence of A23187. However, the processing of pro-C3 was almost completely inhibited in the presence of A23187, with only the precursor being released into the medium, implying that a decline in Ca2+ levels within the cell modulates the activity of a Golgi endoprotease responsible for the cleavage of pro-C3. When incubated with isolated Golgi membranes, pro-C3 secreted from Ca2+-depleted cells was cleaved in vitro into their subunits in the presence of Ca2+ but not in its absence, pointing to the involvement of a Ca2+-dependent Golgi endoprotease in the processing of pro-C3. These results collectively suggest that calcium depletion blocks the proteolytic cleavages of plasma protein precursors presumably by exhausting a Ca2+ pool available to the Ca2+-dependent processing enzyme(s) located at the Golgi and/or trans-Golgi network.			ODA, K (corresponding author), FUKUOKA UNIV,SCH MED,DEPT BIOCHEM,45-1 7-CHOME NANAKUMA,JONAN KU,FUKUOKA 81401,JAPAN.							ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; BALCH WE, 1986, J BIOL CHEM, V261, P4681; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRENNAN SO, 1988, FEBS LETT, V229, P167, DOI 10.1016/0014-5793(88)80819-6; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CHAN AC, 1983, J CLIN INVEST, V72, P1639, DOI 10.1172/JCI111123; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GELLER DM, 1972, BIOCHEM J, V127, P865, DOI 10.1042/bj1270865; GOLDBERGER G, 1980, NATURE, V286, P514, DOI 10.1038/286514a0; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HORTIN G, 1986, BIOCHEM BIOPH RES CO, V136, P603, DOI 10.1016/0006-291X(86)90483-3; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HUTTON JC, 1987, BIOCHEM J, V244, P457, DOI 10.1042/bj2440457; IKEHARA Y, 1977, J BIOCHEM-TOKYO, V81, P1293; JOHNSON DC, 1980, VIROLOGY, V103, P407, DOI 10.1016/0042-6822(80)90200-7; JUDAH JD, 1976, TRENDS BIOCHEM SCI, V1, P107, DOI 10.1016/0968-0004(76)90017-7; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KLENK HD, 1984, EMBO J, V3, P2911, DOI 10.1002/j.1460-2075.1984.tb02231.x; KORIYAMA Y, 1989, BIOMED RES-TOKYO, V10, P341, DOI 10.2220/biomedres.10.341; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1987, J CELL BIOL, V104, P221, DOI 10.1083/jcb.104.2.221; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; MORRIS KM, 1982, SCIENCE, V215, P399, DOI 10.1126/science.7199205; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; ODA K, 1988, J BIOL CHEM, V263, P12576; ODA K, 1978, BIOCHIM BIOPHYS ACTA, V536, P97, DOI 10.1016/0005-2795(78)90055-7; ODA K, 1990, J BIOCHEM-TOKYO, V108, P549, DOI 10.1093/oxfordjournals.jbchem.a123240; ODA K, 1986, J BIOCHEM-TOKYO, V100, P1669, DOI 10.1093/oxfordjournals.jbchem.a121876; ODA K, 1988, J BIOCHEM-TOKYO, V104, P159, DOI 10.1093/oxfordjournals.jbchem.a122432; ODA K, 1986, BIOCHEM J, V240, P739, DOI 10.1042/bj2400739; ODA K, 1983, EUR J BIOCHEM, V135, P209, DOI 10.1111/j.1432-1033.1983.tb07639.x; ODA K, 1985, EUR J BIOCHEM, V152, P605, DOI 10.1111/j.1432-1033.1985.tb09238.x; ODA K, 1990, BIOCHEM J, V265, P161, DOI 10.1042/bj2650161; ODA K, 1991, BIOCHEM BIOPH RES CO, V175, P690, DOI 10.1016/0006-291X(91)91621-I; ODA K, 1979, BIOCHIM BIOPHYS ACTA, V552, P212, DOI 10.1016/0005-2736(79)90278-5; OGAWA Y, 1975, SEIKAGAKU JIKKEN KOZ, V15, P325; REDMAN CM, 1978, J CELL BIOL, V77, P400, DOI 10.1083/jcb.77.2.400; RUSSELL JH, 1975, J BIOL CHEM, V250, P3409; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHWARTZ AL, 1985, EMBO J, V4, P899, DOI 10.1002/j.1460-2075.1985.tb03716.x; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SPAETE RR, 1990, J VIROL, V64, P2922, DOI 10.1128/JVI.64.6.2922-2931.1990; TARTAKOFF AM, 1977, J EXP MED, V146, P1332, DOI 10.1084/jem.146.5.1332; TARTAKOFF AM, 1986, EMBO J, V5, P1477, DOI 10.1002/j.1460-2075.1986.tb04385.x; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; UCHIDA N, 1979, P NATL ACAD SCI USA, V76, P1868, DOI 10.1073/pnas.76.4.1868; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VIRK SS, 1985, BIOCHEM J, V226, P741, DOI 10.1042/bj2260741; WILLIAMS DB, 1988, J BIOL CHEM, V263, P4549; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378	67	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17465	17471						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324939				2022-12-27	WOS:A1992JL05300109
J	DABIRI, GA; YOUNG, CL; ROSENBLOOM, J; SOUTHWICK, FS				DABIRI, GA; YOUNG, CL; ROSENBLOOM, J; SOUTHWICK, FS			MOLECULAR-CLONING OF HUMAN MACROPHAGE CAPPING PROTEIN CDNA - A UNIQUE MEMBER OF THE GELSOLIN VILLIN FAMILY EXPRESSED PRIMARILY IN MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-SEVERING PROTEINS; PLASMA GELSOLIN; BINDING PROTEIN; SEQUENCE; CELLS; DIFFERENTIATION; CONTAIN; DOMAINS; MUSCLE; GCAP39	Macrophage capping protein (MCP) is a Ca2+-sensitive protein which reversibly blocks the barbed ends of actin filaments but does not sever preformed actin filaments. The human cDNA for MCP has been cloned and sequenced. The derived amino acid sequence predicts a polypeptide of 38.4 kDa. Human MCP expressed in Escherichia coli using a pET12a vector was functionally identical to the native protein purified from rabbit alveolar macrophages with respect to Ca2+ sensitivity and ability to block monomer exchange at the barbed end of actin filaments. Sequence comparison with other actin-binding protein sequences indicates that MCP is a member of the gelsolin/villin family of barbed end blocking proteins. Unlike gelsolin, this protein has a limited tissue distribution being detected primarily in macrophages where it was abundant, representing 0.9-1% of the total cytoplasmic protein. Northern blot analysis of U937 and HL60 cells differentiated to macrophage-like cells demonstrated that MCP message increases to 2.6 and > 7 times initial levels, respectively. Human MCP displays a 93% amino acid sequence identity with two recently described mouse proteins, gCap39 and Mbh1. Its abundance in macrophages and the corresponding increases in mRNA levels upon promyelocyte and monocyte development into macrophages indicate that MCP may play an important role in macrophage function.	UNIV FLORIDA, COLL MED, INFECT DIS SECT, BOX 100277, GAINESVILLE, FL 32610 USA; UNIV PENN, GRAD GRP CELL BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH DENT MED, DEPT ANAT & HISTOL, PHILADELPHIA, PA 19104 USA	State University System of Florida; University of Florida; University of Pennsylvania; University of Pennsylvania					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023262] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI23262, R01 AI023262] Funding Source: Medline; NIAMS NIH HHS [R01 AR20553] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMPE C, 1987, EMBO J, V6, P4149, DOI 10.1002/j.1460-2075.1987.tb02761.x; ANDRE E, 1988, J BIOL CHEM, V263, P722; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; Ausubel FM, 1988, MOL REPROD DEV; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; CALDWELL JE, 1989, J BIOL CHEM, V264, P12648; CARSON M, 1986, J CELL BIOL, V103, P2707, DOI 10.1083/jcb.103.6.2707; CASELLA JF, 1986, J BIOL CHEM, V261, P915; CHIEN P, 1988, J CLIN INVEST, V82, P1554, DOI 10.1172/JCI113765; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS SJ, 1979, J EXP MED, V149, P969, DOI 10.1084/jem.149.4.969; GUNNING P, 1983, MOL CELL BIOL, V3, P387; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HASS R, 1989, EUR J CELL BIOL, V48, P282; HOWARD TH, 1984, J CELL BIOL, V98, P1265, DOI 10.1083/jcb.98.4.1265; JOHNSTON PA, 1990, J BIOL CHEM, V265, P17946; JOHNSTON RB, 1988, NEW ENGL J MED, V318, P747, DOI 10.1056/NEJM198803243181205; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P8239; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1985, J BIOL CHEM, V260, P5232; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P13857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LIND SE, 1982, J CLIN INVEST, V69, P1384, DOI 10.1172/JCI110578; MACCLEANFLETCHE.SD, 1980, J CELL BIOL, V85, P414; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; ROBINE S, 1985, P NATL ACAD SCI USA, V82, P8488, DOI 10.1073/pnas.82.24.8488; SAKURAI T, 1990, NEUROSCIENCE, V38, P743, DOI 10.1016/0306-4522(90)90067-E; SAKURAI T, 1991, J BIOL CHEM, V266, P15979; SHALIT M, 1987, BLOOD, V70, P1921; SOUTHWICK FS, 1983, SEMIN HEMATOL, V20, P305; SOUTHWICK FS, 1986, J BIOL CHEM, V261, P14191; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALLACE PJ, 1984, J CELL BIOL, V99, P1060, DOI 10.1083/jcb.99.3.1060; WANG LL, 1981, CELL, V25, P637, DOI 10.1016/0092-8674(81)90171-9; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; YIN HL, 1981, J CELL BIOL, V91, P901, DOI 10.1083/jcb.91.3.901; YOUNG CL, 1990, BIOCHEMISTRY-US, V29, P2232, DOI 10.1021/bi00461a005; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; YU FX, 1991, J BIOL CHEM, V266, P19269	43	77	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16545	16552						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322908				2022-12-27	WOS:A1992JJ45800086
J	VERKHOVSKAYA, M; VERKHOVSKY, M; WIKSTROM, M				VERKHOVSKAYA, M; VERKHOVSKY, M; WIKSTROM, M			PH-DEPENDENCE OF PROTON TRANSLOCATION BY ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							OXIDOREDUCTASES; OXIDASE	Proton translocation in spheroplasts from Escherichia coli has been studied in two mutants, one of which expresses cytochrome o and the other cytochrome d as the terminal oxidase. Using the O2 pulse method, the H+/e- ratio of proton translocation associated with cytochrome o was confirmed to be near 2 at neutral pH, but was found to decrease considerably when the medium pH was raised above 8. At high pH there was an increase in H+/OH- permeability of the cell membrane, but this was not sufficient to explain the decline in proton ejection. The pH effect was confined to cytochrome o-linked activity. It was not present when cytochrome d generated the electrochemical proton gradient. This makes it improbable that the Na+/H+ antiporter is responsible. The most likely explanation for our finding is that there is a "slip" in the proton-pumping mechanism of cytochrome o at high pH.			VERKHOVSKAYA, M (corresponding author), UNIV HELSINKI,DEPT MED CHEM,HELSINKI BIOENERGET GRP,SILTAVUORENPENGER 10,SF-00170 HELSINKI 17,FINLAND.		Wikstrom, Marten KF/A-4403-2008	Verkhovskaya, Marina/0000-0001-8950-5256; Wikstrom, Marten/0000-0002-7527-4415				ANRAKU Y, 1988, ANNU REV BIOCHEM, V57, P101, DOI 10.1146/annurev.bi.57.070188.000533; AVETISYAN AV, 1991, BIOCHIM BIOPHYS ACTA, V1098, P95; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; GREEN GN, 1984, J BIOL CHEM, V259, P7994; KRULWICH TA, 1985, J BACTERIOL, V162, P768, DOI 10.1128/JB.162.2.768-772.1985; MACNAB RM, 1990, J BIOL CHEM, V265, P9247; MATSUSHITA K, 1987, BIOCHEMISTRY-US, V26, P7732, DOI 10.1021/bi00398a029; ODEN KL, 1990, GENE, V96, P29, DOI 10.1016/0378-1119(90)90337-Q; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; WIKSTROM M, 1982, FEBS LETT, V144, P183, DOI 10.1016/0014-5793(82)80634-0; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1; YAGI T, 1990, ARCH BIOCHEM BIOPHYS, V281, P305, DOI 10.1016/0003-9861(90)90448-8	14	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14559	14562						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321808				2022-12-27	WOS:A1992JF08800012
J	MOSS, SJ; DOHERTY, CA; HUGANIR, RL				MOSS, SJ; DOHERTY, CA; HUGANIR, RL			IDENTIFICATION OF THE CAMP-DEPENDENT PROTEIN-KINASE AND PROTEIN-KINASE-C PHOSPHORYLATION SITES WITHIN THE MAJOR INTRACELLULAR DOMAINS OF THE BETA-1-SUBUNIT, GAMMA-2S-SUBUNIT, AND GAMMA-2L-SUBUNIT OF THE GAMMA-AMINOBUTYRIC-ACID TYPE-A RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; GABAA RECEPTOR; MOLECULAR-BIOLOGY; SUBUNIT; EXPRESSION; CHANNEL; FORMS	Gamma-aminobutyric acid Type A (GABA(A)) receptors are the major sites of synaptic inhibition in the central nervous system. These receptors are thought to be pentameric complexes of homologous transmembrane glycoproteins. Molecular cloning has revealed a multiplicity of different GABA(A) receptor subunits divided into five classes, alpha, beta, gamma, delta, and rho, based on sequence homology. Within the proposed major intracellular domain of these subunits, there are numerous potential consensus sites for protein phosphorylation by a variety of protein kinases. We have used purified fusion proteins of the major intracellular domain of GABA(A) receptor subunits produced in Escherichia coli to examine the phosphorylation of these subunits by cAMP-dependent protein kinase (PKA) and protein kinase C (PKC). The purified fusion protein of the intracellular domain of the beta-1-subunit was an excellent substrate for both PKA and PKC. PKA and PKC phosphorylated the beta-1-subunit fusion protein on serine residues on a single tryptic phosphopeptide. Site-directed mutagenesis of serine 409 in the intracellular domain of the beta-1-subunit to an alanine residue eliminated the phosphorylation of the beta-1-subunit fusion protein by both protein kinases. The purified fusion proteins of the major intracellular domain of the gamma-2S and gamma-2L subunits of the GABA(A) receptor were rapidly and stoichiometrically phosphorylated by PKC but not by PKA. The phosphorylation of the gamma-2S subunit occurred on serine residues on a single tryptic phosphopeptide. Site-directed mutagenesis of serine 327 of the gamma-2S subunit fusion protein to an alanine residue eliminated the phosphorylation of the gamma-2S fusion protein by PKC. The gamma-2L subunit is an alternatively spliced form of the gamma-2S subunit that differs by the insertion of 8 amino acids (LLRMFSFK) within the major intracellular domain of the gamma-2S subunit. The PKC phosphorylation of the gamma-2L subunit occurred on serine residues on two tryptic phosphopeptides. Site-specific mutagenesis of serine 343 within the 8-amino acid insert to an alanine residue eliminated the PKC phosphorylation of the novel site in the gamma-2L subunit. No phosphorylation of a purified fusion protein of the major intracellular loop of the alpha-1-subunit was observed with either PKA or PKC. These results identify the specific amino acid residues within GABA(A) receptor subunits that are phosphorylated by PKA and PKC and suggest that protein phosphorylation of these sites may be important in regulating GABA(A) receptor function. In addition, these studies suggest that alternative splicing of the gamma-2 subunit may provide a novel mechanism for the differential regulation of GABA(A) receptors by PKC.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,725 N WOLFE ST,900 PCTB,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University								BARNARD EA, 1987, TRENDS NEUROSCI, V10, P502, DOI 10.1016/0166-2236(87)90130-5; BROWNING MD, 1990, P NATL ACAD SCI USA, V87, P1315, DOI 10.1073/pnas.87.4.1315; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; CHEN CY, 1986, DNA NY, V4, P165; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0; HUGANIR RL, 1983, P NATL ACAD SCI-BIOL, V80, P1130, DOI 10.1073/pnas.80.4.1130; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIRKNESS EF, 1989, BIOCHEM J, V259, P613, DOI 10.1042/bj2590613; KOFUJI P, 1991, J NEUROCHEM, V56, P713, DOI 10.1111/j.1471-4159.1991.tb08209.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIDENHEIMER NJ, 1991, TRENDS PHARMACOL SCI, V12, P84, DOI 10.1016/0165-6147(91)90509-Q; MILES K, 1989, NEURON, V2, P1517, DOI 10.1016/0896-6273(89)90198-0; MOSS SJ, 1990, EUR J PHARM-MOLEC PH, V189, P77, DOI 10.1016/0922-4106(90)90232-M; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; OLSEN RW, 1986, BENZODIAZEPINE GABA, V5, P36; PORTER NM, 1990, NEURON, V5, P789, DOI 10.1016/0896-6273(90)90338-G; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; Sambrook J, 1989, MOL CLONING LABORATO; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SESSLER FM, 1989, BRAIN RES, V499, P27, DOI 10.1016/0006-8993(89)91132-3; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; SIGEL E, 1991, FEBS LETT, V291, P150, DOI 10.1016/0014-5793(91)81124-Q; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEPHENSON FA, 1988, BIOCHEM J, V249, P21, DOI 10.1042/bj2490021; SWEETNAM PM, 1988, J NEUROCHEM, V51, P1274, DOI 10.1111/j.1471-4159.1988.tb03097.x; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; WAFFORD KA, 1991, NEURON, V7, P27, DOI 10.1016/0896-6273(91)90071-7; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836; YMER S, 1989, EMBO J, V8, P1865	32	176	180	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14470	14476						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321150				2022-12-27	WOS:A1992JD32500103
J	FILOTEO, AG; ENYEDI, A; PENNISTON, JT				FILOTEO, AG; ENYEDI, A; PENNISTON, JT			THE LIPID-BINDING PEPTIDE FROM THE PLASMA-MEMBRANE CA2+ PUMP BINDS CALMODULIN, AND THE PRIMARY CALMODULIN-BINDING DOMAIN INTERACTS WITH LIPID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+ PUMP; CALCIUM; PROTEOLYSIS	Peptide G25 (KKAVKVPKKEKSVLQGKLTRLAVQI) representing the putative lipid-binding region (G region) of the erythrocyte Ca2+ pump was synthesized. This peptide interacted with acidic lipids, as shown by the increase in size of phosphatidylserine liposomes in its presence. This lipid interaction is consistent with the previous evidence suggesting that the portion of the pump from which this peptide was taken is responsible for the activation of the pump by acidic lipid. G25 also bound to calmodulin, as was shown by its cause of a shift in the fluorescence of 5-dimethylamino naphthalene-1-sulfonyl- (dansyl)-calmodulin, and by its competition with Ca2+ pump for calmodulin. Its K(d) for dansyl-calmodulin was much higher (0.8-mu-M) than that of the peptides representing the primary calmodulin-binding region (C region) of the Ca2+ pump. Although the presence of the G region provided the possibility of a second calmodulin-binding site, activation of the pump by calmodulin always could be fitted by simple saturation kinetics. The calmodulin-binding peptide from the C region of the pump, C28R2, also interacted with lipid with even greater effectiveness than G25. When the C region of the pump was saturated with calmodulin, acidic lipid activation of the pump followed simple saturation kinetics. However, when calmodulin was omitted, a higher concentration of lipid was needed for saturation and the kinetics became complex. The data are consistent with the idea that calmodulin activates the pump only by interaction at the C region, but that acidic lipid activates by interaction at both of the C and G regions.	NATL INST HAEMATOL & BLOOD TRANSFUS, DEPT CELL METAB, H-1113 BUDAPEST, HUNGARY		FILOTEO, AG (corresponding author), MAYO CLIN & MAYO FDN, DEPT BIOCHEM & MOLEC BIOL, ROCHESTER, MN 55905 USA.		Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28835] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BRODIN P, 1992, IN PRESS EUR J BIOCH; CHOQUETTE D, 1984, BIOCHEM BIOPH RES CO, V125, P908, DOI 10.1016/0006-291X(84)91369-X; DANDLIKER WB, 1973, IMMUNOCHEMISTRY, V10, P219, DOI 10.1016/0019-2791(73)90198-5; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; ENYEDI A, 1987, J BIOL CHEM, V262, P6425; HOUBRE D, 1991, J BIOL CHEM, V266, P7121; JAMES P, 1988, J BIOL CHEM, V263, P2905; LI ZP, 1991, J BIOL CHEM, V266, P1014; LINDBERG O, 1956, METHODS BIOCHEMICAL, V3, P1; Penniston J T, 1980, Ann N Y Acad Sci, V356, P245, DOI 10.1111/j.1749-6632.1980.tb29615.x; PENNISTON JT, 1982, EXP EYE RES, V34, P435, DOI 10.1016/0014-4835(82)90089-6; PENNISTON JT, 1988, METHOD ENZYMOL, V157, P340; SARKADI B, 1980, BIOCHIM BIOPHYS ACTA, V598, P326, DOI 10.1016/0005-2736(80)90010-3; TANFORD C, 1961, PHYSICAL CHEM MACROM, P313; VERBIST J, 1991, BIOCHIM BIOPHYS ACTA, V1063, P1, DOI 10.1016/0005-2736(91)90345-9; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; ZURINI M, 1984, J BIOL CHEM, V259, P618; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	20	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11800	11805						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1318301				2022-12-27	WOS:A1992HY94700027
J	SANTANA, M; KUNST, F; HULLO, MF; RAPOPORT, G; DANCHIN, A; GLASER, P				SANTANA, M; KUNST, F; HULLO, MF; RAPOPORT, G; DANCHIN, A; GLASER, P			MOLECULAR-CLONING, SEQUENCING, AND PHYSIOLOGICAL CHARACTERIZATION OF THE QOX OPERON FROM BACILLUS-SUBTILIS ENCODING THE AA3-600 QUINOL OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; ESCHERICHIA-COLI; PARACOCCUS-DENITRIFICANS; NUCLEOTIDE-SEQUENCE; GENE; EXPRESSION; DNA; PROTEIN; PROKARYOTES; MECHANISM	Bacillus subtilis contains two aa3-type terminal oxidases (caa3-605 and aa3-600) catalyzing cytochrome c and quinol oxidation, respectively, with the concomitant reduction of O2 to H2O (Lauraeus, M., Haltia, T., Saraste, M., and Wikstrom, M. (1991) Eur. J. Biochem. 197, 699-705). Previous studies characterized only the structural genes of caa3-605 oxidase. We isolated the genes coding for the four subunits of a B. subtilis terminal oxidase from a genomic DNA library. These genes, named qoxA to qoxD, are organized in an operon. Examination of the deduced amino acid sequence of Qox subunits showed that this oxidase is structurally related to the large family of mitochondrial-type aa3 terminal oxidases. In particular, the amino acid sequences are very similar to those of subunits of Escherichia coli bo quinol oxidase and B. subtilis caa3-605 cytochrome c oxidase. We produced, by in vitro mutagenesis, a mutation in the qox operon. From the phenotype of the mutant strain devoid of Qox protein, the study of expression of the qox operon in different growth conditions, and the analysis of the deduced amino acid sequence of the subunits, we concluded that Qox protein and aa3-600 quinol oxidase are the same protein. Although several terminal oxidases are found in B. subtilis, Qox oxidase (aa3-600) is predominant during the vegetative growth and its absence leads to important alterations of the phenotype of B. subtilis.	INST PASTEUR,UNITE REGULAT EXPRESS GENET,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE; INST PASTEUR,UNITE BIOCHIM MICROBIENNE,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Santana, Margarida M./B-8626-2015; Glaser, Philippe/O-2641-2015	Santana, Margarida M./0000-0002-5712-3939; Glaser, Philippe/0000-0003-4156-2782; Danchin, Antoine/0000-0002-6350-5001				ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; ARROW AS, 1986, ANTIMICROB AGENTS CH, V29, P141, DOI 10.1128/AAC.29.1.141; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CASTOR LN, 1959, J BIOL CHEM, V234, P1587; CHAIX P, 1957, BIOCHIM BIOPHYS ACTA, V25, P481, DOI 10.1016/0006-3002(57)90517-6; CHAN SI, 1990, BIOCHEMISTRY-US, V29, P1, DOI 10.1021/bi00453a001; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; CHUNG CT, 1988, NUCLEIC ACIDS RES, V16, P3580, DOI 10.1093/nar/16.8.3580; DEVRIJ W, 1987, EUR J BIOCHEM, V166, P589; EPERON IC, 1986, ANAL BIOCHEM, V156, P406, DOI 10.1016/0003-2697(86)90273-3; FOUET A, 1987, P NATL ACAD SCI USA, V84, P8773, DOI 10.1073/pnas.84.24.8773; GASCUEL O, 1986, J MOL EVOL, V24, P130, DOI 10.1007/BF02099961; Gibson T.J., 1984, THESIS CAMBRIDGE U U; HALTIA T, 1991, EMBO J, V10, P2015, DOI 10.1002/j.1460-2075.1991.tb07731.x; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HORINOUCHI S, 1982, J BACTERIOL, V150, P815, DOI 10.1128/JB.150.2.815-825.1982; HORINOUCHI S, 1969, J BACTERIOL, V51, P1642; ISHIZUKA M, 1990, J BIOCHEM-TOKYO, V108, P866, DOI 10.1093/oxfordjournals.jbchem.a123294; JAMES WS, 1989, FEMS MICROBIOL LETT, V58, P277; KITE J, 1982, J MOL BIOL, V157, P105; KUNST F, 1991, RES MICROBIOL, V142, P905, DOI 10.1016/0923-2508(91)90072-I; Labbe P, 1969, Bull Soc Chim Biol (Paris), V51, P1642; LAURAEUS M, 1991, EUR J BIOCHEM, V197, P699, DOI 10.1111/j.1432-1033.1991.tb15961.x; LUDWIG B, 1987, FEMS MICROBIOL LETT, V46, P41, DOI 10.1111/j.1574-6968.1987.tb02451.x; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; MATSUSHITA K, 1984, BIOCHEMISTRY-US, V23, P4703, DOI 10.1021/bi00315a028; MESSING J, 1983, METHOD ENZYMOL, V101, P20; Miller J.H., 1972, EXPT MOL GENETICS; MILLER P, 1988, J BACTERIOL, V170, P2742, DOI 10.1128/jb.170.6.2742-2748.1988; MOSZER I, 1991, BIOCHIMIE, V73, P1361, DOI 10.1016/0300-9084(91)90166-X; MSADEK T, 1990, J BACTERIOL, V172, P824, DOI 10.1128/jb.172.2.824-834.1990; MUELLER JP, 1989, J BACTERIOL, V171, P4967, DOI 10.1128/jb.171.9.4967-4978.1989; PEREGO M, 1988, MOL MICROBIOL, V2, P698; PIGGOT PJ, 1989, REGULATION OF PROCARYOTIC DEVELOPMENT, P1; Poole RK., 1988, BACTERIAL ENERGY TRA, P231; PROCHASKA LJ, 1981, BIOCHIM BIOPHYS ACTA, V637, P360, DOI 10.1016/0005-2728(81)90175-4; RAITIO M, 1987, EMBO J, V6, P2825, DOI 10.1002/j.1460-2075.1987.tb02579.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1991, EUR J BIOCHEM, V195, P517, DOI 10.1111/j.1432-1033.1991.tb15732.x; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SAUNDERS CW, 1984, J BACTERIOL, V157, P718, DOI 10.1128/JB.157.3.718-726.1984; SCHAEFFER P, 1965, P NATL ACAD SCI USA, V54, P704, DOI 10.1073/pnas.54.3.704; Silhavy T. J., 1984, EXPT GENE FUSIONS; SONE N, 1990, FEBS LETT, V262, P249, DOI 10.1016/0014-5793(90)80202-T; STADEN R, 1980, NUCLEIC ACIDS RES, V6, P2601; STEINRUCKE P, 1987, EUR J BIOCHEM, V167, P431, DOI 10.1111/j.1432-1033.1987.tb13356.x; VANDEROOST J, 1991, MOL MICROBIOL, V5, P2063; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6	51	107	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10225	10231						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1316894				2022-12-27	WOS:A1992HV09000007
J	ZILLMANN, M; GOROVSKY, MA; PHIZICKY, EM				ZILLMANN, M; GOROVSKY, MA; PHIZICKY, EM			HELA-CELLS CONTAIN A 2'-PHOSPHATE-SPECIFIC PHOSPHOTRANSFERASE SIMILAR TO A YEAST ENZYME IMPLICATED IN TRANSFER-RNA SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SUBSTRATE RECOGNITION; ENDONUCLEASE; LIGASE; GENES; EXTRACT	We have previously shown that HeLa cells contain activities implicated in tRNA splicing in yeast, a ligase capable of joining tRNA half-molecules and an NAD-dependent activity capable of removing the 2'-phosphate created at the splice junction by the ligase (Zillmann, M., Gorovsky, M. A., and Phizicky, E. M. (1991) Mol. Cell. Biol. 11, 5410-5416). We show here that removal of the splice junction 2'-phosphate is, as in yeast, a 2'-phosphate-specific phosphotransfer reaction that produces the same, as yet unidentified, small molecule. This enzyme is highly specific for oligomeric substrates having internal 2'-phosphates. Oligomers bearing terminal 2'-phosphates are at least 50-fold less reactive and those bearing 5'- or 3'-terminal phosphates are at least 600-fold less reactive. The requirement for an internal 2'-phosphate can be satisfied by a substrate as small as a dimer.	UNIV ROCHESTER, DEPT BIOL, ROCHESTER, NY 14627 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester								BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; CULBERTSON MR, 1989, YEAST, V5, P405, DOI 10.1002/yea.320050602; DEUTSCHER MP, 1984, CRC CR REV BIOCH MOL, V17, P45, DOI 10.3109/10409238409110269; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FILIPOWICZ W, 1983, CELL, V32, P547, DOI 10.1016/0092-8674(83)90474-9; GANDINIATTARDI D, 1985, EMBO J, V4, P3289; GREEN CJ, 1990, J BIOL CHEM, V265, P12139; GREER CL, 1987, MOL CELL BIOL, V7, P76, DOI 10.1128/MCB.7.1.76; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HO CK, 1990, EMBO J, V9, P1245, DOI 10.1002/j.1460-2075.1990.tb08232.x; KILBERSTIS PA, 1985, EMBO J, V4, P817; LASKI FA, 1983, J BIOL CHEM, V258, P1974; LEE MC, 1985, J BIOL CHEM, V260, P3108; Maniatis T., 1982, MOL CLONING; MATTOCCIA E, 1988, CELL, V55, P731, DOI 10.1016/0092-8674(88)90231-0; MCCRAITH SM, 1991, J BIOL CHEM, V266, P11986; MCCRAITH SM, 1990, MOL CELL BIOL, V10, P1049, DOI 10.1128/MCB.10.3.1049; NAYLOR R, 1966, BIOCHEMISTRY-US, V5, P2722, DOI 10.1021/bi00872a032; NISHIKURA K, 1981, J MOL BIOL, V145, P405, DOI 10.1016/0022-2836(81)90212-6; OGDEN RC, 1984, NUCLEIC ACIDS RES, V12, P9367, DOI 10.1093/nar/12.24.9367; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PHIZICKY EM, 1992, J BIOL CHEM, V267, P4577; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; RAUHUT R, 1990, J BIOL CHEM, V265, P18180; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; SWERDLOW H, 1984, J BIOL CHEM, V259, P5197; SZEKELY E, 1988, J BIOL CHEM, V263, P13839; VANTOL H, 1988, NUCLEIC ACIDS RES, V16, P1951, DOI 10.1093/nar/16.5.1951	29	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10289	10294						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1316896				2022-12-27	WOS:A1992HV09000016
J	SANKAR, S; PORTER, AG				SANKAR, S; PORTER, AG			POINT MUTATIONS WHICH DRASTICALLY AFFECT THE POLYMERIZATION ACTIVITY OF ENCEPHALOMYOCARDITIS VIRUS RNA-DEPENDENT RNA-POLYMERASE CORRESPOND TO THE ACTIVE-SITE OF ESCHERICHIA-COLI DNA-POLYMERASE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHLY CONSERVED REGION; POLIOVIRUS RNA; REVERSE-TRANSCRIPTASE; SEQUENCE MOTIF; IDENTIFICATION; REPLICASE; PROTEIN; PURIFICATION; MUTAGENESIS; FRAGMENT	The inhibitor sensitivity and functional domains of recombinant encephalomyocarditis (EMC) virus RNA-dependent RNA polymerase (3D(pol)) have been extensively analyzed. The inhibitor profiles of EMC virus 3D(pol) and Escherichia coli DNA-dependent RNA polymerase are distinct, and experiments with substrate analogs indicate that EMC virus 3D(pol) lacks reverse transcriptase activity. Twenty amino acid substitutions were engineered in EMC virus 3D(pol) based on sequence alignments of viral RNA-dependent RNA polymerases that identified conserved amino acid residues within motifs. Ten out of 17 conservative substitutions within the four most conserved motifs reduced the RNA polymerase activity of the mutants to 0-6% of the activity of the wild-type enzyme, demonstrating the importance of these amino acids in the structure and/or function of EMC virus 3D(pol). Remarkably, 5 of the 10 mutations in EMC virus 3D(pol) which had the most drastic effect on its RNA polymerase activity (D240E, S293T, N302Q, G332A, and D333E) were found to correspond to active site residues in E. coli DNA-dependent DNA polymerase I (Klenow). Our results reveal that a basic structural and functional framework is conserved in the most distantly related classes of nucleic acid polymerases and demonstrate the validity of modeling the active site of an RNA-dependent RNA polymerase on the known structure of a DNA polymerase.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,PROT ENGN GRP,10 KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore								ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; AULD DS, 1975, BIOCHEM BIOPH RES CO, V62, P296, DOI 10.1016/S0006-291X(75)80137-9; BARON MH, 1982, J BIOL CHEM, V257, P2359; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BRUENN JA, 1991, NUCLEIC ACIDS RES, V19, P217, DOI 10.1093/nar/19.2.217; CALGUIRI LT, 1968, VIROLOGY, V35, P408; COUR TFM, 1985, EMBO J, V4, P2385; DASGUPTA A, 1980, CELL, V19, P423, DOI 10.1016/0092-8674(80)90516-4; DASGUPTA A, 1979, P NATL ACAD SCI USA, V76, P2679, DOI 10.1073/pnas.76.6.2679; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DMITRIEVA TM, 1991, J VIROL, V65, P2714, DOI 10.1128/JVI.65.5.2714-2717.1991; DORSKY DI, 1990, J VIROL, V64, P1394, DOI 10.1128/JVI.64.3.1394-1397.1990; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P3677, DOI 10.1073/pnas.74.9.3677; GUINEA R, 1990, EMBO J, V9, P2011, DOI 10.1002/j.1460-2075.1990.tb08329.x; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; INOKUCHI Y, 1987, J VIROL, V61, P3946, DOI 10.1128/JVI.61.12.3946-3949.1987; JABLONSKI SA, 1991, J VIROL, V65, P4565, DOI 10.1128/JVI.65.9.4565-4572.1991; JOUNG I, 1991, VIROLOGY, V184, P235, DOI 10.1016/0042-6822(91)90840-8; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; KOONIN EV, 1991, J GEN VIROL, V72, P2197, DOI 10.1099/0022-1317-72-9-2197; KORNBERG A, 1980, DNA REPLICATION, P67; KRONER P, 1989, J VIROL, V63, P5302, DOI 10.1128/JVI.63.12.5302-5309.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LUNDBLAD V, 1990, CELL, V60, P529; MARCY AI, 1990, J VIROL, V64, P5883, DOI 10.1128/JVI.64.12.5883-5890.1990; MCCORMICK F, 1985, SCIENCE, V230, P78, DOI 10.1126/science.3898366; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MODAK MJ, 1979, J BIOL CHEM, V254, P4756; MORROW CD, 1987, P NATL ACAD SCI USA, V84, P6050, DOI 10.1073/pnas.84.17.6050; NICKLIN MJH, 1986, BIO-TECHNOL, V4, P33, DOI 10.1038/nbt0186-33; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PALMENBERG AC, 1984, NUCLEIC ACIDS RES, V12, P2969, DOI 10.1093/nar/12.6.2969; PANDEY VN, 1987, BIOCHEMISTRY-US, V26, P7744, DOI 10.1021/bi00398a031; PLOTCH SJ, 1989, J VIROL, V63, P216, DOI 10.1128/JVI.63.1.216-225.1989; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; ROSENBER.H, 1972, P NATL ACAD SCI USA, V69, P3815, DOI 10.1073/pnas.69.12.3815; ROTHSTEIN MA, 1988, VIROLOGY, V164, P301, DOI 10.1016/0042-6822(88)90542-9; SANKAR S, 1991, J VIROL, V65, P2993, DOI 10.1128/JVI.65.6.2993-3000.1991; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TERSHAK DR, 1982, J VIROL, V41, P313, DOI 10.1128/JVI.41.1.313-318.1982; TRAUB A, 1976, J VIROL, V18, P375, DOI 10.1128/JVI.18.2.375-382.1976; VANDYKE TA, 1982, J BIOL CHEM, V257, P4610; WATSON HC, 1982, EMBO J, V1, P1635, DOI 10.1002/j.1460-2075.1982.tb01366.x	49	59	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10168	10176						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315753				2022-12-27	WOS:A1992HT96500108
J	GONG, MC; FUGLSANG, A; ALESSI, D; KOBAYASHI, S; COHEN, P; SOMLYO, AV; SOMLYO, AP				GONG, MC; FUGLSANG, A; ALESSI, D; KOBAYASHI, S; COHEN, P; SOMLYO, AV; SOMLYO, AP			ARACHIDONIC-ACID INHIBITS MYOSIN LIGHT CHAIN PHOSPHATASE AND SENSITIZES SMOOTH-MUSCLE TO CALCIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; GTP-BINDING PROTEINS; RECEPTOR-MEDIATED ACTIVATION; PORCINE CORONARY-ARTERY; SKELETAL-MUSCLE; CA2+ SENSITIZATION; CA-2+ SENSITIVITY; PHOSPHOLIPASE-C; PHORBOL ESTER; PHOSPHORYLATION	Arachidonic acid (AA) increased, at constant Ca2+, the levels of force and 20-kDa myosin light chain (MLC20) phosphorylation in permeabilized smooth muscle, and slowed relaxation and MLC20 dephosphorylation. The Ca2+-sensitizing effect of AA was not inhibited by inhibitors of AA metabolism (indomethacin, nordihydroguaiaretic acid, or propyl gallate), of protein kinase C (pseudopeptide) or by guanosine-5'-O-(beta-thiodiphosphate) and was abolished by oxidation of AA in air. A non-metabolizable AA analog, 5,8,11,14-eicosatetraynoic acid) also had Ca2+-sensitizing effects. Extensive treatment with saponin abolished the Ca2+-sensitizing effects of phorbol 12,13-dibutyrate and guanosine-5'-O-(gamma-thiotriphosphate), but not that of AA. A purified, oligomeric MLC20 phosphatase isolated from gizzard smooth muscle was dissociated into subunits by AA, and its activity was inhibited toward heavy meromyosin but not phosphorylase. We conclude that AA may act as a messenger-promoting protein phosphorylation through direct inhibition of the form of protein phosphatase(s) that dephosphorylate MLC20 in vivo.	UNIV VIRGINIA, SCH MED, DEPT PHYSIOL, BOX 449, JORDAN HALL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, DEPT MED, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, DEPT PATHOL, CHARLOTTESVILLE, VA 22908 USA; UNIV DUNDEE, DEPT BIOCHEM, MRC, PROT PHOSPHORYLAT UNIT, DUNDEE DD1 4HN, SCOTLAND	University of Virginia; University of Virginia; University of Virginia; University of Dundee				Alessi, Dario/0000-0002-2140-9185	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL19242] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI DR, 1992, IN PRESS EUR J BIOCH; ANDERSON KM, 1989, PROSTAG LEUKOTR ESS, V35, P231, DOI 10.1016/0952-3278(89)90006-9; AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BRADLEY AB, 1987, J PHYSIOL-LONDON, V385, P437, DOI 10.1113/jphysiol.1987.sp016500; BUCKLEY BJ, 1991, BIOCHEM J, V280, P281, DOI 10.1042/bj2800281; BURCH RM, 1989, MOL NEUROBIOL, V3, P155, DOI 10.1007/BF02935629; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; CARTER TD, 1989, BIOCHEM J, V262, P431, DOI 10.1042/bj2620431; CHATTERJEE M, 1986, AM J PHYSIOL, V251, pC356, DOI 10.1152/ajpcell.1986.251.3.C356; COHEN P, 1988, METHOD ENZYMOL, V159, P427; COHEN P, 1992, J MOL CELL CARDIOL, V24, pS31, DOI 10.1016/0022-2828(92)90935-S; COHEN P, 1991, METHOD ENZYMOL, V201, P389; DEMEY JG, 1982, CIRC RES, V51, P439, DOI 10.1161/01.RES.51.4.439; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DENT P, 1992, IN PRESS EUR J BIOCH; FUJIWARA T, 1989, J PHYSIOL-LONDON, V408, P535, DOI 10.1113/jphysiol.1989.sp017474; GONG MC, 1992, J BIOL CHEM, V267, P14662; GRILLONE LR, 1988, J BIOL CHEM, V263, P2658; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HIMPENS B, 1990, PFLUG ARCH EUR J PHY, V417, P21, DOI 10.1007/BF00370764; HIMPENS B, 1988, J GEN PHYSIOL, V92, P713, DOI 10.1085/jgp.92.6.713; HORIUTI K, 1988, J PHYSIOL-LONDON, V398, P131, DOI 10.1113/jphysiol.1988.sp017034; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; ITOH T, 1988, J PHYSIOL-LONDON, V397, P401, DOI 10.1113/jphysiol.1988.sp017008; JELSEMA CL, 1987, J BIOL CHEM, V262, P163; KHAN WA, 1992, J BIOL CHEM, V267, P3605; KIGOSHI T, 1990, BIOCHEM BIOPH RES CO, V171, P369, DOI 10.1016/0006-291X(90)91403-F; KIKKAWA U, 1988, PHILOS T ROY SOC B, V320, P313, DOI 10.1098/rstb.1988.0079; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; KITAZAWA T, 1990, BIOCHEM BIOPH RES CO, V172, P1291, DOI 10.1016/0006-291X(90)91589-K; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KOBAYASHI S, 1991, AM J PHYSIOL, V260, pC364, DOI 10.1152/ajpcell.1991.260.2.C364; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; KUBOTA Y, 1992, AM J PHYSIOL, V262, pC405, DOI 10.1152/ajpcell.1992.262.2.C405; LAYCHOCK SG, 1989, CURR TOP CELL REGUL, V30, P203; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; NAKAJIMA T, 1991, FEBS LETT, V289, P239, DOI 10.1016/0014-5793(91)81079-N; NARASIMHAN V, 1990, J BIOL CHEM, V265, P1459; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NISHIMURA J, 1990, AM J PHYSIOL, V259, pH2, DOI 10.1152/ajpheart.1990.259.1.H2; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; PARK S, 1985, P NATL ACAD SCI USA, V82, P8835, DOI 10.1073/pnas.82.24.8835; Rainsford KD, 1988, PROSTAGLANDINS BIOL, P52; RUZYCKY AL, 1989, BRIT J PHARMACOL, V97, P391, DOI 10.1111/j.1476-5381.1989.tb11966.x; SELLERS JR, 1984, J BIOL CHEM, V259, P7740; SHIMADA T, 1992, J GEN PHYSIOL, V100, P27, DOI 10.1085/jgp.100.1.27; SINGER HA, 1983, J PHARMACOL EXP THER, V226, P790; SMITH JB, 1985, BIOCHIM BIOPHYS ACTA, V835, P344, DOI 10.1016/0005-2760(85)90290-5; SOMLYO AP, 1988, PHILOS T ROY SOC B, V320, P399, DOI 10.1098/rstb.1988.0084; SOMLYO AP, 1989, ADV PROTEIN PHOSPHAT, V5, P181; SOMLYO AV, 1990, PROG CLIN BIOL RES, V327, P167; SOMLYO AV, 1968, J PHARMACOL EXP THER, V159, P129; SOMLYO AV, 1988, J GEN PHYSIOL, V91, P165, DOI 10.1085/jgp.91.2.165; SUTTON TA, 1990, J BIOL CHEM, V265, P2749; WOLF BA, 1991, BIOCHEMISTRY-US, V30, P6372, DOI 10.1021/bi00240a004	57	229	235	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21492	21498						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328235				2022-12-27	WOS:A1992JV01100037
J	OLIVER, KG; PUTNEY, JW; OBIE, JF; SHEARS, SB				OLIVER, KG; PUTNEY, JW; OBIE, JF; SHEARS, SB			THE INTERCONVERSION OF INOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE AND INOSITOL TETRAKISPHOSPHATES IN AR4-2J CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL GLOMERULOSA CELLS; LARGE INTESTINAL CANCER; MYOINOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE; 1,4,5-TRISPHOSPHATE 3-KINASE; RECEPTOR ACTIVATION; PANCREATOMA CELLS; PAROTID-GLAND; F344 RATS; METABOLISM; PENTAKISPHOSPHATE	Data from several cell types have indicated that activation of hormone receptors promotes the metabolism of inositol 1,3,4,5,6-pentakisphosphate (IP5) to inositol 3,4,5,6-tetrakisphosphate ((3,4,5,6)IP4). However, to date, metabolism of IP5 by cell-free preparations has resulted in the formation of only inositol 1,4,5,6-tetrakisphosphate ((1,4,5,6)IP4). Thus, the metabolic relationships of IP5 with various inositol tetrakisphosphate (IP4) isomers have been investigated in both intact cells and cell homogenates of the rat pancreatoma cell line, AR4-2J. The steady-state concentration of IP5 was estimated to be 65 muM, while the combined concentration of (3,4,5,6)IP4 and (1,4,5,6)IP4 was approximately 1.0 muM. AR4-2J cell homogenates converted (1,3,4,6)IP4, (3,4,5,6)IP4, and (1,4,5,6)IP4 to IP5. (1,4,5,6)IP4 previously has not been demonstrated to be a precursor of IP5. To alter steady-state levels of inositol phosphates that were maintained by phosphorylation-dephosphorylation cycles, intact cells were treated with 10 muM antimycin A which reduced ATP levels by >90% within 10 min. Following 2 h of treatment with antimycin A, there was a 6-fold increase in both (3,4,5,6)IP4 and (1,4,5,6)IP4, presumably derived from IP5. Experiments with cell-free systems determined that IP5 was dephosphorylated to (1,4,5,6)IP4 by a predominantly particulate Mg2+-independent, Li+-insensitive IP5 3-phosphatase. However, in the presence of 5 mM MgATP, IP5 also was metabolized to (3,4,5,6)IP4. Therefore, our data demonstrate novel and complex relationships between IP5, (3,4,5,6)IP4, and (1,4,5,6)IP4.	NIEHS,CELLULAR & MOLEC PHARMACOL LAB,INOSITOL LIPID SECT,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	OLIVER, KG (corresponding author), NIEHS,CELLULAR & MOLEC PHARMACOL LAB,CALCIUM REGULAT SECT,RES TRIANGLE PK,NC 27709, USA.		Putney, James W/F-7247-2019; Shears, Stephen B/C-6335-2019	Putney, James W/0000-0002-3379-4789; Shears, Stephen B/0000-0001-7309-8916				AGRANOFF BW, 1985, INOSITOL PHOSPHOINOS, pR21; BALLA T, 1989, J BIOL CHEM, V264, P9386; BALLA T, 1989, J BIOL CHEM, V264, P13605; BARKER CJ, 1988, BIOCHEM SOC T, V16, P984, DOI 10.1042/bst0160984; BARRACO RA, 1989, EUR J PHARMACOL, V173, P75, DOI 10.1016/0014-2999(89)90010-1; BIRD GS, 1990, BIOCHEM J, V273, P541; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER D, 1989, BIOCHEM SOC T, V17, P3, DOI 10.1042/bst0170003; DOWNES CP, 1986, BIOCHEM J, V238, P501, DOI 10.1042/bj2380501; EUROPEFINNER GN, 1989, J CELL SCI, V93, P585; FRENCH PJ, 1988, BIOCHEM SOC T, V16, P985, DOI 10.1042/bst0160985; HORSTMAN DA, 1988, J BIOL CHEM, V263, P15297; HUNYADY L, 1988, BIOCHEM BIOPH RES CO, V157, P1247, DOI 10.1016/S0006-291X(88)81008-8; KIRK CJ, 1991, PEPTIDE HORMONE ACTI, P151; KOPPITZ B, 1986, EUR J BIOCHEM, V161, P421, DOI 10.1111/j.1432-1033.1986.tb10462.x; Maslanski J. A., 1990, METHODS INOSITIDE RE, P113; MATTINGLY RR, 1991, J BIOL CHEM, V266, P15144; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; MORGAN RO, 1987, J BIOL CHEM, V262, P1166; NICOLETTI F, 1989, J NEUROCHEM, V53, P1026, DOI 10.1111/j.1471-4159.1989.tb07390.x; NOGIMORI K, 1991, J BIOL CHEM, V266, P16499; NOGIMORI K, 1990, BIOCHEM J, V269, P195, DOI 10.1042/bj2690195; PHILLIPPY BQ, 1988, ANAL BIOCHEM, V175, P162, DOI 10.1016/0003-2697(88)90374-0; PITTET D, 1989, J BIOL CHEM, V264, P18489; POGGIOLI J, 1983, MOL PHARMACOL, V23, P71; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; Schacht J, 1981, Methods Enzymol, V72, P626; SHAMSUDDIN AM, 1988, CARCINOGENESIS, V9, P577, DOI 10.1093/carcin/9.4.577; SHAMSUDDIN AM, 1989, CARCINOGENESIS, V10, P625, DOI 10.1093/carcin/10.3.625; SHEARS SB, 1987, BIOCHEM J, V242, P393, DOI 10.1042/bj2420393; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; SHEARS SB, 1989, J BIOL CHEM, V264, P19879; STEPHENS L, 1988, BIOCHEM J, V249, P271, DOI 10.1042/bj2490271; STEPHENS LR, 1988, BIOCHEM J, V253, P721, DOI 10.1042/bj2530721; STEPHENS LR, 1990, NATURE, V346, P580, DOI 10.1038/346580a0; STEPHENS LR, 1991, BIOCHEM J, V275, P485, DOI 10.1042/bj2750485; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; STEPHENS LR, 1988, BIOCHEM J, V249, P283, DOI 10.1042/bj2490283; STEWART SJ, 1987, BIOCHEM BIOPH RES CO, V145, P895, DOI 10.1016/0006-291X(87)91049-7; VALLEJO M, 1987, NATURE, V330, P656, DOI 10.1038/330656a0	40	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21528	21534						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328236				2022-12-27	WOS:A1992JV01100043
J	KENDALL, RL; BRADSHAW, RA				KENDALL, RL; BRADSHAW, RA			ISOLATION AND CHARACTERIZATION OF THE METHIONINE AMINOPEPTIDASE FROM PORCINE LIVER RESPONSIBLE FOR THE COTRANSLATIONAL PROCESSING OF PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL METHIONINE; AMINO-ACID SEQUENCE; SALMONELLA-TYPHIMURIUM; BETA-CHAIN; HEMOGLOBIN; PURIFICATION; INITIATION; VARIANT; YEAST	A methionine aminopeptidase that specifically removes methionine residues from peptides with amino-terminal sequences of Met-Ala-, Met-Val-, Met-Ser-, Met-Gly-, and Met-Pro- but not Met-Leu- or Met-Lys- has been isolated to homogeneity from porcine liver by a procedure involving five chromatographic steps. The enzyme, whose specificity matches that predicted for the entity responsible for the co-translational amino-terminal processing of nascent polypeptide chains, has a measured molecular mass of 70,000 Da by SDS-polyacrylamide electrophoresis and 67,000 Da by gel chromatography (under nondenaturing conditions), suggesting the native molecule is a monomer. It is activated by Co2+ and inhibited by beta-mercaptoethanol and EDTA. With octapeptide substrates related to the amino-terminal portion of the beta-chain of human hemoglobin (with a histidine in position 3), the enzyme had a pH optimum of 6.0. With a synthetic peptide devoid of histidine, it showed no pH dependence from 6.0 to 8.0. This sensitivity may be due to the propensity of peptides with histidine in the third position to bind divalent cations such as Co2+. The measured K(m) and k(cat) values were affected by residues in the second position. The peptide corresponding to the natural sequence (Met-Val-His-) gave a k(cat)/K(m) value of 260 mM-1 s-1; substitution of alanine in the second position raised the k(cat)/K(m) to 1523 mM-1 s-1, but substitution of proline lowered the value to 130. The effects are primarily on the k(cat). The substitution of proline (for histidine) in the third position, the mutation found in hemoglobin Long Island, prevents the removal of the methionine residue, as occurs with the mutant protein. The porcine liver enzyme is similar to methionine aminopeptidases isolated from Escherichia coli, Salmonella typhimurium, and yeast in that it also is stimulated by Co2+. However, it is much larger than these enzymes and differs somewhat in specificity, particularly with the yeast enzyme.	UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717	University of California System; University of California Irvine			Bradshaw, Ralph A/K-1515-2013		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032465] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32465] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARWICK RC, 1985, P NATL ACAD SCI USA, V82, P4602, DOI 10.1073/pnas.82.14.4602; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BLOUQUIT Y, 1984, FEBS LETT, V178, P315, DOI 10.1016/0014-5793(84)80624-9; BOISSEL JP, 1988, J BIOL CHEM, V263, P8443; BRADSHAW RA, 1968, J BIOL CHEM, V243, P3817; CHANG YH, 1990, J BIOL CHEM, V265, P19892; CHANG YH, 1992, J BIOL CHEM, V267, P8007; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; Delange R. J., 1971, ENZYMES, VIII, P81; EVERT RF, 1986, ANAL BIOCHEM, V154, P431; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GONDA DK, 1989, J BIOL CHEM, V264, P16700; HANSON H, 1976, METHODS ENZYMOLOGY B, V45, P504; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; JACKSON R, 1970, NATURE, V227, P672, DOI 10.1038/227672a0; KENDALL RL, 1992, THESIS U CALIFORNIA; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALFROY B, 1989, BIOCHEM BIOPH RES CO, V161, P236, DOI 10.1016/0006-291X(89)91586-6; MILLER CG, 1987, P NATL ACAD SCI USA, V84, P2718, DOI 10.1073/pnas.84.9.2718; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; SHERMAN F, 1985, BIOESSAYS, V3, P27, DOI 10.1002/bies.950030108; TERMIGNONI C, 1986, BIOCHEM J, V234, P469, DOI 10.1042/bj2340469; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; WACHSMUTH ED, 1966, BIOCHEMISTRY-US, V5, P169, DOI 10.1021/bi00865a022; WINGFIELD P, 1989, EUR J BIOCHEM, V180, P23, DOI 10.1111/j.1432-1033.1989.tb14610.x; YAMADA R, 1988, ENZYME, V40, P223, DOI 10.1159/000469167	29	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20667	20673						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328207				2022-12-27	WOS:A1992JT97800026
J	TIDBALL, JG				TIDBALL, JG			IDENTIFICATION AND DISTRIBUTION OF A NOVEL, COLLAGEN-BINDING PROTEIN IN THE DEVELOPING SUBEPICARDIUM AND ENDOMYSIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMININ-B1 CHAIN REVEALS; PLASMA FIBRONECTIN; CELL ATTACHMENT; CONNECTIVE-TISSUE; CARDIAC-MUSCLE; MESSENGER-RNAS; RAT-HEART; SEQUENCE; HYPERTENSION; LOCALIZATION	A protein doublet (M(r) = 68,000) that copurifies with chicken cardiac collagen types I and III is purified and characterized in the present study. Peptide mapping and amino terminus sequencing for both 68-kDa polypeptides show they have similar structures. This is supported by amino terminus sequencing of a 39-kDa proteolytic fragment of each polypeptide. The 68-kDa polypeptides appear at pI 6.7-6.8 in two-dimensional gels. Under nonreducing, electrophoretic conditions, the doublet appears as a large multimer or aggregate. Amino acid sequencing of the protein shows that its amino terminus contains a heptapeptide (VCLXXGK) that appears in the heparin/fibrin-binding domain of fibronectin and the collagen-binding domain of laminin. Cardiac myocytes synthesize and secrete the protein in vitro onto cell surfaces and onto the substratum. Indirect immunofluorescence shows the protein first appears in the chicken subepicardium at approximately 10 days following fertilization. As collagen accumulates in the subepicardium and the volume of the subepicardial space increases, the 68-kDa protein is found predominantly at the interface between myocardial cells and the connective tissue and between epicardial cells and the connective tissue. In adult hearts, the protein is also present at lower concentrations in endomysial connective tissue. The 68-kDa protein is also present in the skeletal muscle endomysium of embryonic chickens. Electron microscopic immunocytochemistry shows the 68-kDa protein is located at the surface of subepicardial collagen fibers. In addition, a direct interaction between the 68-kDa protein and collagen are indicated by : 1) equilibrium gel filtration of the 68-kDa protein in the presence of gelatin, 2) gelatin affinity chromatography of the 68-kDa protein, and 3) comigration of type I collagen and the 68-kDa protein during gel filtration under reducing conditions. The 68-kDa protein exhibits no collagenase activity under native conditions or in zymograms. Together, the data indicate that the 68-kDa protein is a novel collagen-associated protein appearing in late epicardial development.	UNIV CALIF LOS ANGELES, JERRY LEWIS NEUROMUSCULAR RES CTR, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	TIDBALL, JG (corresponding author), UNIV CALIF LOS ANGELES, DEPT PHYSIOL SCI, LOS ANGELES, CA 90024 USA.		Tidball, James/H-7970-2012	Tidball, James/0000-0003-1202-8038	NCRR NIH HHS [1 S10RR05554-01] Funding Source: Medline; NHLBI NIH HHS [HL-42227] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005554] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042227] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALIAN G, 1979, J BIOL CHEM, V254, P1429; BARTOSOV.D, 1969, J PHYSIOL-LONDON, V200, P285, DOI 10.1113/jphysiol.1969.sp008693; BING OHL, 1978, CIRC RES, V43, P632, DOI 10.1161/01.RES.43.4.632; BONTHRON D, 1986, NUCLEIC ACIDS RES, V14, P7125, DOI 10.1093/nar/14.17.7125; BORG TK, 1982, COLLAGEN REL RES, V2, P211; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAPASSO JM, 1986, CIRC RES, V58, P445, DOI 10.1161/01.RES.58.4.445; CHIANG TM, 1982, J BIOL CHEM, V257, P7581; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; COX JV, 1983, CELL, V35, P331, DOI 10.1016/0092-8674(83)90236-2; EGHBALI M, 1989, J MOL CELL CARDIOL, V21, P103, DOI 10.1016/0022-2828(89)91498-3; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FACTOR SM, 1990, CARDIAC MYOCYTE CONN, P130; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; GARCIAPARDO A, 1983, J BIOL CHEM, V258, P2670; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GROVE D, 1969, CIRC RES, V25, P473, DOI 10.1161/01.RES.25.4.473; HEDIN U, 1988, J CELL BIOL, V107, P307, DOI 10.1083/jcb.107.1.307; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; HORMANN H, 1980, H-S Z PHYSIOL CHEM, V361, P1449; KLEBE RJ, 1974, NATURE, V250, P248, DOI 10.1038/250248a0; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUND DD, 1979, CARDIOVASC RES, V13, P39, DOI 10.1093/cvr/13.1.39; MECHAM RP, 1991, ANNU REV CELL BIOL, V7, P71, DOI 10.1146/annurev.cb.07.110191.000443; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MONTELL DJ, 1988, CELL, V53, P463, DOI 10.1016/0092-8674(88)90166-3; NAGASE H, 1981, J BIOL CHEM, V256, P1951; NORTON PA, 1987, MOL CELL BIOL, V7, P4297, DOI 10.1128/MCB.7.12.4297; OBRIEN LJ, 1966, EXPERIENTIA, V22, P845, DOI 10.1007/BF01897456; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PEARLMAN ES, 1982, LAB INVEST, V46, P158; POLINGER IS, 1970, EXP CELL RES, V63, P78, DOI 10.1016/0014-4827(70)90333-2; PURI EC, 1978, EXP CELL RES, V115, P159, DOI 10.1016/0014-4827(78)90413-5; RAO CN, 1982, J BIOL CHEM, V257, P9740; RUOSLAHTI E, 1979, J BIOL CHEM, V254, P6054; Sage H, 1982, Methods Enzymol, V82 Pt A, P96; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; SKOSEY JL, 1972, CIRC RES, V31, P145, DOI 10.1161/01.RES.31.2.145; STRICKLIN GP, 1988, COLLAGEN, V1, P187; TIDBALL JG, 1992, ANAT EMBRYOL, V185, P155; VARTIO T, 1981, J BIOL CHEM, V256, P471; VARTIO T, 1983, EUR J BIOCHEM, V135, P203, DOI 10.1111/j.1432-1033.1983.tb07638.x; VARTIO T, 1989, FEBS LETT, V255, P285, DOI 10.1016/0014-5793(89)81107-X; VATER CA, 1978, BIOCHIM BIOPHYS ACTA, V539, P238, DOI 10.1016/0304-4165(78)90010-7; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Weber KT, 1987, CIRCULATION S1, V75, P140	49	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21211	21219						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328225				2022-12-27	WOS:A1992JT97800108
J	PARK, JW; BABIOR, BM				PARK, JW; BABIOR, BM			THE TRANSLOCATION OF RESPIRATORY BURST OXIDASE COMPONENTS FROM CYTOSOL TO PLASMA-MEMBRANE IS REGULATED BY GUANINE-NUCLEOTIDES AND DIACYLGLYCEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; PROTEIN-KINASE-C; ADENINE-DINUCLEOTIDE PHOSPHATE; CHRONIC GRANULOMATOUS-DISEASE; NEUTROPHIL NADPH OXIDASE; ARACHIDONIC-ACID; PHORBOL ESTER; ACTIVATION; GTP; DIRADYLGLYCEROL	The respiratory burst oxidase is a multimeric enzyme responsible for O2- production by stimulated neutrophils and a few other cell types. In the resting neutrophil, the oxidase is dormant, and its subunits are distributed between the cytosol, in which they appear to exist in the form of a multisubunit complex, and the plasma membrane; but, when the neutrophil is activated, the cytosolic complex translocates to the membrane to assemble the active enzyme. Using a cell-free system in which oxidase activity was elicited with SDS, we examined the effects of GTPgammaS and dioctanoylglycerol (DiC8) on both the activation of O2- production and the transfer of the cytosolic oxidase components p47phox and p67phox to the plasma membrane. GTP (added as undialyzed cytosol) and GTPgammaS augmented the transfer of the oxidase components to the plasma membrane and was essential for the acquisition of O2- producing activity by the oxidase. DiC8 also supported the SDS-mediated transfer of oxidase components to the membrane, but O2- production did not take place unless GTP or GTPgammaS was present. In the presence of these nucleotides, however, DiC8 augmented both translocation and O2- production. We interpreted these results in terms of a mechanism in which 2 membrane-binding sites are created during the activation of the cytosolic complex, one for diacylglycerol and the other for a second site on the membrane. Development of the second membrane-binding site depends upon the action of a G protein and is essential for the expression of oxidase activity. The results further suggested that the priming of the respiratory burst oxidase in intact neutrophils might be due to an increase in membrane diacylglycerol concentration that occurs in response to the priming stimulus. Because of the increased diacylglycerol content, a larger than usual amount of active respiratory burst oxidase could be assembled on the primed plasma membrane when the neutrophil is fully activated.			PARK, JW (corresponding author), Scripps Res Inst, RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028479, R37AI024227, R01AI024227] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00833] Funding Source: Medline; NIAID NIH HHS [AI-24227, AI-28479] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BABIOR BM, 1988, J BIOL CHEM, V263, P1713; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BABIOR BM, 1992, ADV ENZYMOL RELAT AR, V65, P49; BASS DA, 1988, J BIOL CHEM, V263, P19610; BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P9317, DOI 10.1021/bi00450a011; BELL RM, 1991, J BIOL CHEM, V266, P4661; BOURGOIN S, 1990, J EXP MED, V172, P767, DOI 10.1084/jem.172.3.767; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DEWALD B, 1979, J CLIN INVEST, V63, P21, DOI 10.1172/JCI109273; DOUSSIERE J, 1988, BIOCHEM BIOPH RES CO, V152, P993, DOI 10.1016/S0006-291X(88)80382-6; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; GABIG TG, 1987, J BIOL CHEM, V262, P1685; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; ISHITOYA J, 1987, BIOCHEM BIOPH RES CO, V144, P1025, DOI 10.1016/S0006-291X(87)80066-9; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LIGETI E, 1988, BIOCHEMISTRY-US, V27, P193, DOI 10.1021/bi00401a029; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MARKERT M, 1984, METHOD ENZYMOL, V105, P358; MARONEY AC, 1989, J BIOL CHEM, V264, P2537; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; OKAMURA N, 1990, J CLIN INVEST, V85, P1583, DOI 10.1172/JCI114608; PARK JW, 1992, J BIOL CHEM, V267, P17327; RANDO RR, 1989, FASEB J, V3, P2348; SCHONHARDT T, 1987, BIOCHEM BIOPH RES CO, V149, P769, DOI 10.1016/0006-291X(87)90434-7; SCHWARZ HP, 1985, BLOOD, V66, P1452; SMITH RM, 1989, J BIOL CHEM, V264, P1958; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYAGI SR, 1988, J BIOL CHEM, V263, P13191; TYAGI SR, 1992, BIOCHEMISTRY-US, V31, P2765, DOI 10.1021/bi00125a017; UMEI T, 1991, J BIOL CHEM, V266, P6019; UTAL AK, 1991, J BIOL CHEM, V266, P24084; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138	43	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19901	19906						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328185				2022-12-27	WOS:A1992JR85800027
J	PRIEST, JW; HAJDUK, SL				PRIEST, JW; HAJDUK, SL			CYTOCHROME-C REDUCTASE PURIFIED FROM CRITHIDIA-FASCICULATA CONTAINS AN ATYPICAL CYTOCHROME-C1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; AMINO-ACID SEQUENCE; EUGLENA-GRACILIS; COMPLEX-III; RESPIRATORY-CHAIN; NEUROSPORA-CRASSA; LEISHMANIA-TARENTOLAE; YEAST MITOCHONDRIA; PURIFICATION; BINDING	Cytochrome c reductase purified from the trypanosomatid Crithidia fasciculata retained antimycin A sensitivity and catalyzed the reduction of horse heart ferricytochrome c in the presence of reduced coenzyme Q10. The complex contained heme b and heme c1 in a ratio of 2:1. Nine major protein bands ranging in size from 55.3 to approximately 12.8 kDa were resolved by SDS-polyacrylamide gel electrophoresis. A 31.6-kDa protein was identified as cytochrome c1 by the presence of a covalently attached heme. A red shift in the alpha-absorbance band of the cytochrome c1 absolute absorbance spectrum, difference absorbance spectrum, and pyridine ferrohemochrome absorbance spectrum suggested that the heme prosthetic group of C. fasciculata cytochrome c1 is bound to the apoprotein through only one thioether bond. A fragment of the cytochrome c1 gene was amplified from C. fasciculata, Trypanosoma brucei, Leishmania tarentolae, and Bodo caudatus. The deduced heme binding site sequence of each of these kinetoplastid species, Phe-Ala-Pro-Cys-His, contains a phenylalanine rather that a cysteine at the first position so that only one thioether bond can be formed between heme and apoprotein. This phenylalanine substitution and the presence of a conserved proline in the sequence may represent compensatory changes that are necessary for optimal interaction of the cytochromes c1 with the atypical cytochromes c of these species.	UNIV ALABAMA,SCH MED,DEPT BIOCHEM,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NHLBI NIH HHS [HL07631] Funding Source: Medline; NIAID NIH HHS [AI21401, AI08259] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008259, R01AI021401, R21AI021401] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASFORD RE, 1957, BIOCHIM BIOPHYS ACTA, V24, P107, DOI 10.1016/0006-3002(57)90152-X; BEATTIE DS, 1979, BIOCHEMISTRY-US, V18, P2400, DOI 10.1021/bi00578a040; BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; BERRY EA, 1991, J BIOL CHEM, V266, P9064; BHAT GJ, 1991, NUCLEIC ACIDS RES, V19, P398, DOI 10.1093/nar/19.2.398; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONSTRUP U, 1989, J BIOENERG BIOMEMBR, V21, P359, DOI 10.1007/BF00762727; CARTER KR, 1981, FEBS LETT, V132, P243, DOI 10.1016/0014-5793(81)81170-2; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EHRENBERG A, 1955, ACTA CHEM SCAND, V9, P1193, DOI 10.3891/acta.chem.scand.09-1193; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FINZEL BC, 1985, J MOL BIOL, V186, P627, DOI 10.1016/0022-2836(85)90135-4; GELLERFORS P, 1981, EUR J BIOCHEM, V115, P275, DOI 10.1111/j.1432-1033.1981.tb05234.x; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; GREEN DE, 1961, ARCH BIOCHEM BIOPHYS, V92, P312, DOI 10.1016/0003-9861(61)90354-X; GROOT GSP, 1978, BIOCHIM BIOPHYS ACTA, V517, P457, DOI 10.1016/0005-2787(78)90212-5; HAMPSEY DM, 1986, J BIOL CHEM, V261, P3259; HAUSKA G, 1988, J BIOENERG BIOMEMBR, V20, P211, DOI 10.1007/BF00768395; HILL GC, 1975, EUR J BIOCHEM, V57, P265, DOI 10.1111/j.1432-1033.1975.tb02298.x; HILL GC, 1971, BIOCHIM BIOPHYS ACTA, V253, P78, DOI 10.1016/0005-2728(71)90235-0; HILL GC, 1971, BIOCHIM BIOPHYS ACTA, V243, P225, DOI 10.1016/0005-2795(71)90079-1; HILL GC, 1973, BIOCHIM BIOPHYS ACTA, V305, P590, DOI 10.1016/0005-2728(73)90078-9; HUDGIN RL, 1974, J BIOL CHEM, V249, P5536; KADENBACH B, 1983, ANAL BIOCHEM, V129, P517, DOI 10.1016/0003-2697(83)90586-9; KATAN MB, 1976, EUR J BIOCHEM, V65, P95, DOI 10.1111/j.1432-1033.1976.tb10393.x; KUSEL JP, 1973, BIOCHIM BIOPHYS ACTA, V305, P570, DOI 10.1016/0005-2728(73)90076-5; KUSEL JP, 1969, ARCH BIOCHEM BIOPHYS, V133, P293, DOI 10.1016/0003-9861(69)90457-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; LINKE P, 1986, METHOD ENZYMOL, V126, P201; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; LJUNGDAHL PO, 1985, BIOPHYS J, V47, pA196; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MARTIN E, 1979, J BIOL CHEM, V254, P2192; MENDELHARTVIG I, 1983, J BIOENERG BIOMEMBR, V15, P289, DOI 10.1007/BF00744526; MOORE GR, 1990, CYTOCHROMES C EVOLUT, P116; MUKAI K, 1989, EUR J BIOCHEM, V178, P649, DOI 10.1111/j.1432-1033.1989.tb14494.x; MUKAI K, 1989, J BIOCHEM-TOKYO, V106, P479, DOI 10.1093/oxfordjournals.jbchem.a122877; Nelson B D, 1978, Methods Enzymol, V53, P80; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; PETTIGRE.GW, 1972, FEBS LETT, V22, P64, DOI 10.1016/0014-5793(72)80220-5; PETTIGREW GW, 1973, NATURE, V241, P531, DOI 10.1038/241531a0; PETTIGREW GW, 1975, BIOCHEM J, V147, P291, DOI 10.1042/bj1470291; RASSAM MB, 1986, MOL BIOCHEM PARASIT, V21, P1, DOI 10.1016/0166-6851(86)90072-1; Rieske J. S., 1967, METHOD ENZYMOL, V10, P239; Rieske JS, 1967, METHOD ENZYMOL, V10, P488, DOI DOI 10.1016/0076-6879(67)10081-5; ROMISCH J, 1987, EUR J BIOCHEM, V164, P111, DOI 10.1111/j.1432-1033.1987.tb11000.x; SADLER I, 1984, EMBO J, V3, P2137, DOI 10.1002/j.1460-2075.1984.tb02103.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGER F, 1991, P NATL ACAD SCI USA, V19, P398; SHAW JM, 1989, EXP PARASITOL, V68, P443, DOI 10.1016/0014-4894(89)90129-X; SIDHU A, 1982, J BIOL CHEM, V257, P7879; SIEDOW JN, 1978, J BIOL CHEM, V253, P2392; SIMPSON L, 1970, J PROTOZOOL, V17, P511, DOI 10.1111/j.1550-7408.1970.tb04719.x; TANAKA Y, 1990, J BIOCHEM-TOKYO, V108, P7, DOI 10.1093/oxfordjournals.jbchem.a123165; TANAKA Y, 1988, J BIOCHEM-TOKYO, V104, P477, DOI 10.1093/oxfordjournals.jbchem.a122493; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; TORRI AF, 1988, MOL CELL BIOL, V8, P4625, DOI 10.1128/MCB.8.11.4625; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; van Gelder B F, 1978, Methods Enzymol, V53, P125; VANGELDER BF, 1962, BIOCHIM BIOPHYS ACTA, V58, P593, DOI 10.1016/0006-3002(62)90073-2; WAKABAYASHI S, 1982, J BIOL CHEM, V257, P9335; WAN YP, 1975, BIOCHEM BIOPH RES CO, V63, P11, DOI 10.1016/S0006-291X(75)80003-9; WEISS H, 1976, BIOCHIM BIOPHYS ACTA, V456, P291, DOI 10.1016/0304-4173(76)90002-1; WEISS H, 1979, EUR J BIOCHEM, V99, P139, DOI 10.1111/j.1432-1033.1979.tb13240.x; WEISS H, 1978, EUR J BIOCHEM, V88, P17, DOI 10.1111/j.1432-1033.1978.tb12418.x; WRAY W, 1981, ANAL BIOCHEM, V118, P1697; YU CA, 1974, J BIOL CHEM, V249, P4905; YUEN SW, 1989, BIOTECHNIQUES, V7, P74	71	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20188	20195						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328195				2022-12-27	WOS:A1992JR85800071
J	NAMBI, P; PULLEN, M; WU, HL; NUTHULAGANTI, P; ELSHOURBAGY, N; KUMAR, C				NAMBI, P; PULLEN, M; WU, HL; NUTHULAGANTI, P; ELSHOURBAGY, N; KUMAR, C			DEXAMETHASONE DOWN-REGULATES THE EXPRESSION OF ENDOTHELIN RECEPTORS IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES PHOSPHOLIPASE-C; MESANGIAL CELLS; CHROMOSOMAL ASSIGNMENT; GENE-EXPRESSION; BINDING-SITES; MESSENGER-RNA; UP-REGULATION; CLONING; GLUCOCORTICOIDS; AGONIST	Steroid hormones have been shown to modulate a number of physiological processes in addition to their potent antiinflammatory effects. Endothelin (ET) is a newly discovered vasoconstrictor that is synthesized and released by endothelial cells and acts on adjacent vascular smooth muscle cells by interacting with specific cell surface receptors. Proinflammatory agents such as thrombin and transforming growth factor beta have been shown to up-regulate ET gene expression in vascular endothelial cells. We wondered whether the anti-inflammatory steroids might have any regulatory effect on the ET receptors present in the vascular smooth muscle cells. Rat vascular smooth muscle cells (A-10 cell line, ATCC.CRL 1476) were used as a model system to study the effects of glucocorticoids on ET receptor expression and function. These cells display high density and high affinity ET receptors that belong to the ETA subtype. Pretreatment of these cells with dexamethasone reduced the number of ET receptors by 50-60% without changing the affinity. Of the steroids tested, dexamethasone was most effective followed by prednisolone and hydrocortisone. Aldosterone, a mineralocorticoid, was 5000-fold less potent than dexamethasone. This effect of dexamethasone was dependent on the time of pretreatment and concentration of the steroid used. This down-regulation of ET receptors was also accompanied by an attenuated response to ET-1 in dexamethasone-pretreated cells. The inhibitory effect of dexamethasone was selective for ET receptors because the vasopressin-mediated response was unaffected. In addition, dexamethasone pretreatment of these cells resulted in 50-60% reduction in the steady-state level of ETA receptor mRNA as revealed by Northern analysis. These results suggest that glucocorticoid pretreatment of smooth muscle cells resulted in the down-regulation of the ET(A) receptor at the mRNA level.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC GENET,KING OF PRUSSIA,PA 19406	GlaxoSmithKline	NAMBI, P (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT PHARMACOL,UW2521,POB 1539,KING OF PRUSSIA,PA 19406, USA.							ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; AUGUET M, 1988, BIOCHEM BIOPH RES CO, V156, P186, DOI 10.1016/S0006-291X(88)80822-2; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BADR KF, 1989, BIOCHEM BIOPH RES CO, V161, P776, DOI 10.1016/0006-291X(89)92667-3; BLOCH KD, 1989, J BIOL CHEM, V264, P10851; BLOCH KD, 1989, J BIOL CHEM, V264, P18156; BURNSTEIN KL, 1989, ANNU REV PHYSIOL, V51, P683, DOI 10.1146/annurev.ph.51.030189.003343; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS S, 1988, J BIOL CHEM, V263, P9067; ELSHOURBAGY NA, 1992, MOL PHARMACOL, V41, P465; ELSHOURBAGY NA, 1991, CIRCULATION S2, V84, P1610; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOETZ KL, 1988, AM J PHYSIOL, V255, pR1064, DOI 10.1152/ajpregu.1988.255.6.R1064; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; KNUTSON VP, 1982, P NATL ACAD SCI-BIOL, V79, P2822, DOI 10.1073/pnas.79.9.2822; KURIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P1435, DOI 10.1016/0006-291X(89)92270-5; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LIU JJ, 1989, BIOCHEM BIOPH RES CO, V164, P1220, DOI 10.1016/0006-291X(89)91799-3; LYSKO PG, 1991, NEUROPEPTIDES, V18, P83, DOI 10.1016/0143-4179(91)90005-4; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; MARSDEN PA, 1989, BIOCHEM BIOPH RES CO, V158, P86, DOI 10.1016/S0006-291X(89)80180-9; MASUDA Y, 1989, FEBS LETT, V257, P208, DOI 10.1016/0014-5793(89)81535-2; MILLER WL, 1989, J CLIN INVEST, V83, P317, DOI 10.1172/JCI113876; MULDOON LL, 1989, J BIOL CHEM, V264, P8529; NAMBI P, 1990, NEUROPEPTIDES, V16, P195, DOI 10.1016/0143-4179(90)90062-4; NAMBI P, 1989, CELL SIGNAL, V1, P241, DOI 10.1016/0898-6568(89)90041-7; NAMBI P, 1990, EUR J PHARMACOL, V187, P113, DOI 10.1016/0014-2999(90)90346-8; NAMBI P, 1989, 9TH INT WASH SPRING, P362; OHTA K, 1990, BIOCHEM BIOPH RES CO, V169, P578, DOI 10.1016/0006-291X(90)90370-3; RESINK TJ, 1988, BIOCHEM BIOPH RES CO, V157, P1360, DOI 10.1016/S0006-291X(88)81025-8; SAKAMOTO H, 1990, BIOCHEM BIOPH RES CO, V169, P462, DOI 10.1016/0006-291X(90)90354-P; SAKAUE M, 1991, J CLIN INVEST, V88, P385, DOI 10.1172/JCI115315; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SARKAR DD, 1988, GENE DEV, V2, P1144; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; TAKAYANAGI R, 1990, REGUL PEPTIDES, V27, P247, DOI 10.1016/0167-0115(90)90043-V; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; VANE JR, 1989, ENDOTHELIN J CARDI S, V13, pS1; VIGUERIE N, 1987, BIOCHEM BIOPH RES CO, V147, P942, DOI 10.1016/S0006-291X(87)80161-4; WILLIAMS DL, 1991, BIOCHEM BIOPH RES CO, V175, P556, DOI 10.1016/0006-291X(91)91601-8; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	47	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19555	19559						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326558				2022-12-27	WOS:A1992JP59300080
J	RAUCH, U; KARTHIKEYAN, L; MAUREL, P; MARGOLIS, RU; MARGOLIS, RK				RAUCH, U; KARTHIKEYAN, L; MAUREL, P; MARGOLIS, RU; MARGOLIS, RK			CLONING AND PRIMARY STRUCTURE OF NEUROCAN, A DEVELOPMENTALLY REGULATED, AGGREGATING CHONDROITIN SULFATE PROTEOGLYCAN OF BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; BOVINE CHROMOGRANIN-A; LINK PROTEIN; CARTILAGE PROTEOGLYCAN; BINDING REGION; CORE PROTEIN; IMMUNOCYTOCHEMICAL LOCALIZATION; ENDOCRINE TISSUES; NEURITE OUTGROWTH; HYALURONIC-ACID	We have obtained the complete coding sequence of neurocan, a chondroitin sulfate proteoglycan of rat brain which is developmentally regulated with respect to its molecular size, concentration, carbohydrate composition, sulfation, and immunocytochemical localization. Two degenerate oligonucleotides, based on amino acid sequence data from the proteoglycan isolated from adult brain by immunoaffinity chromatography with the 1D1 monoclonal antibody, were used as sense and antisense primers in the polymerase chain reaction with a brain cDNA library as template to generate an unambiguous cDNA probe. A second probe for the N-terminal portion of the early postnatal form of the proteoglycan was obtained by reverse transcription/polymerase chain reaction. The composite sequence of overlapping cDNA clones is 5.2-kilobases (kb) long, including 1.3 kb of 3'-untranslated sequence and 76 base pairs of 5'-untranslated sequence. An open reading frame of 1257 amino acids encodes a protein with a molecular mass of 136 kDa containing 10 peptide sequences present in the adult and/or early postnatal brain proteoglycans. The deduced amino acid sequence revealed a 22-amino acid signal peptide followed by an immunoglobulin domain, tandem repeats characteristic of the hyaluronic acid-binding region of aggregating proteoglycans, and an RGDS sequence. The C-terminal portion (amino acids 951-1215) has approximately 60% identity to regions in the C termini of the fibroblast and cartilage proteoglycans, versican and aggrecan, including two epidermal growth factor-like domains, a lectin-like domain, and a complement regulatory protein-like sequence. The central 595-amino acid portion of neurocan has no homology with other reported protein sequences. The proteoglycan contains six potential N-glycosylation sites and 25 potential threonine O-glycosylation sites. In the adult form of the proteoglycan (which represents the C-terminal half of neurocan) a single 32-kDa chondroitin 4-sulfate chain is linked at serine-944, whereas three additional potential chondroitin sulfate attachment sites (only two of which are utilized) are present in the larger proteoglycan species. A probe corresponding to a region of neurocan having no homology with versican or aggrecan hybridized with a single band at approximately 7.5 kb on Northern blots of mRNA from both 4-day and adult rat brain (but not with muscle, kidney, liver, or lung mRNA), indicating that the 1D1 proteoglycan of adult brain, containing a 68-kDa core protein, is generated by a developmentally regulated in vivo proteolytic processing of the 136-kDa species which is predominant in early postnatal brain. Neurocan aggregates with hyaluronic acid, and both core proteins are recognized by the 8A4 monoclonal antibody to rat chondrosarcoma link protein. This antibody also reacts with a 45-kDa link protein which copurifies with the proteoglycans isolated from either early postnatal or adult brain. Our data indicate that the 8A4 epitope is a Pro-Ile-Ser/Thr-Xaa-Pro sequence present in both link protein and the 1D1 proteoglycan core proteins, and we demonstrated that this antibody recognizes the synthetic peptide His-Pro-Ile-Ser-Gly-Pro-Trp in a dot-binding assay.	SUNY HLTH SCI CTR, DEPT PHARMACOL, BROOKLYN, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	RAUCH, U (corresponding author), NYU MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA.		Maurel, Patrice/E-9559-2017		NINDS NIH HHS [NS-13876, NS-09348] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013876, R01NS009348] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AQUINO DA, 1984, J CELL BIOL, V99, P1117, DOI 10.1083/jcb.99.3.1117; AQUINO DA, 1984, J CELL BIOL, V99, P1130, DOI 10.1083/jcb.99.3.1130; ARGARANA CE, 1981, J BIOL CHEM, V256, P827; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BREUER B, 1991, J BIOL CHEM, V266, P13224; BRITTIS PA, 1992, SCIENCE, V255, P733, DOI 10.1126/science.1738848; CROSSIN KL, 1989, DEV BIOL, V136, P381, DOI 10.1016/0012-1606(89)90264-9; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; FINNE J, 1979, J BIOL CHEM, V254, P295; FRYER HJL, 1992, J BIOL CHEM, V267, P9874; GOOLEY AA, 1991, BIOCHEM BIOPH RES CO, V178, P1194, DOI 10.1016/0006-291X(91)91019-9; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; HOFFMAN S, 1988, J CELL BIOL, V106, P519, DOI 10.1083/jcb.106.2.519; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAUFMANN E, 1984, FEBS LETT, V170, P81, DOI 10.1016/0014-5793(84)81373-3; KRUEGER RC, 1990, J BIOL CHEM, V265, P12075; KRUSIUS T, 1986, J BIOL CHEM, V261, P8237; KRUSIUS T, 1987, BIOCHEM J, V245, P229, DOI 10.1042/bj2450229; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH BS, 1980, BIOCHEMISTRY-US, V19, P5734, DOI 10.1021/bi00566a011; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; MARGOLIS RK, 1991, J CELL SCI, V99, P237; MARGOLIS RK, 1989, NEUROBIOLOGY GLYCOCO, P85; MCCORMICK D, 1987, P NATL ACAD SCI USA, V84, P4044, DOI 10.1073/pnas.84.12.4044; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Miller B., 1992, Society for Neuroscience Abstracts, V18, P778; MOREMEN KW, 1989, P NATL ACAD SCI USA, V86, P5276, DOI 10.1073/pnas.86.14.5276; NEAME PJ, 1986, J BIOL CHEM, V261, P3519; NEAME PJ, 1985, J BIOL CHEM, V260, P2402; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; OAKLEY RA, 1991, DEV BIOL, V147, P187, DOI 10.1016/S0012-1606(05)80017-X; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERIDES G, 1989, J BIOL CHEM, V264, P5981; PERKINS SJ, 1991, BIOCHEMISTRY-US, V30, P10708, DOI 10.1021/bi00108a015; PERRIS R, 1990, DEV BIOL, V137, P1, DOI 10.1016/0012-1606(90)90002-Z; PERRIS R, 1991, DEVELOPMENT, V111, P583; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; RAUCH U, 1991, J BIOL CHEM, V266, P14785; RIPELLINO JA, 1988, J CELL BIOL, V106, P845, DOI 10.1083/jcb.106.3.845; RIPELLINO JA, 1989, J CELL BIOL, V108, P1899, DOI 10.1083/jcb.108.5.1899; SAKURAI T, 1990, NEUROSCIENCE, V38, P743, DOI 10.1016/0306-4522(90)90067-E; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; Segrest JP, 1972, METHOD ENZYMOL, V28, P54, DOI DOI 10.1016/0076-6879(72)28007-7; SHEPPARD AM, 1991, J NEUROSCI, V11, P3928; SITHIGORNGUL P, 1991, J IMMUNOL METHODS, V141, P23, DOI 10.1016/0022-1759(91)90206-U; SNOW DM, 1990, DEV BIOL, V138, P359, DOI 10.1016/0012-1606(90)90203-U; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; SNOW DM, 1991, DEVELOPMENT, V113, P1473; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; TANAKA KM, 1991, J BIOL CHEM, V266, P12809; ZAREMBA S, 1989, NEURON, V2, P1207, DOI 10.1016/0896-6273(89)90305-X; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	64	312	321	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19536	19547						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326557				2022-12-27	WOS:A1992JP59300078
J	JOHNSON, KF; KORNFELD, S				JOHNSON, KF; KORNFELD, S			A HIS-LEU-LEU SEQUENCE NEAR THE CARBOXYL TERMINUS OF THE CYTOPLASMIC DOMAIN OF THE CATION-DEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR IS NECESSARY FOR THE LYSOSOMAL-ENZYME SORTING FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; PLASMA-MEMBRANE; CATHEPSIN-D; CLATHRIN; CELLS; GOLGI; EXPRESSION; FORMS; INTERNALIZATION; PHOSPHORYLATION	The determinants on the cytoplasmic tail of the cation-dependent mannose 6-phosphate receptor (CD-MPR) required for lysosomal enzyme sorting have been analyzed. Mouse L cells deficient in the mannose 6-phosphate/insulin-like growth factor-II receptor were transfected with normal bovine CD-MPR cDNA or cDNAs containing mutations in the 67-amino acid cytoplasmic tail and assayed for their ability to target the lysosomal enzyme cathepsin D to lysosomes. Cells expressing the wild-type bovine CD-MPR sorted 67 +/- 2% of newly synthesized cathepsin D compared with the base-line value of 47 +/- 1%. The presence of mannose 6-phosphate in the medium did not affect the efficiency of cathepsin D sorting, indicating that the routing of the ligand-receptor complex is completely intracellular. Mutant receptors with the carboxyl-terminal His-Leu-Leu-Pro-Met67 residues deleted or replaced with alanines sorted cathepsin D below the baseline value. A mutant receptor with the outermost Pro-Met residues replaced with alanines sorted cathepsin D better than the wild-type receptor, indicating that the essential residues for sorting are the His-Leu-Leu sequence. Disruption of a putative casein kinase II phosphorylation site at Ser57 had no detectable effect on sorting. The mutant receptor with the five-amino acid deletion was able to bind to a phosphopentamannose affinity column, proving that its ligand binding site was grossly intact. Resialylation experiments showed that this mutant receptor recycled from the cell surface to the Golgi at a rate similar to the normal CD-MPR, indicating that the defect in sorting is at the level of the Golgi.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,660 S EUCLID AVE,BOX 8125,ST LOUIS,MO 63110	Washington University (WUSTL)					NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NCI NIH HHS [CA08759] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BENNETT G, 1981, J CELL BIOL, V88, P1, DOI 10.1083/jcb.88.1.1; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; FAUST PL, 1987, J CELL BIOL, V105, P1937, DOI 10.1083/jcb.105.5.1937; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; JADOT M, 1992, J BIOL CHEM, V267, P11069; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KORNFELD S, 1992, IN PRESS ANN REV BIO; KYLE JW, 1988, J BIOL CHEM, V263, P16230; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDWIG T, 1991, J CELL BIOL, V115, P1561, DOI 10.1083/jcb.115.6.1561; MA ZM, 1991, J BIOL CHEM, V266, P10589; MAHIN DT, 1970, CURRENT STATUS LIQUI; Maniatis T., 1982, MOL CLONING; MAYA E, 1991, CELL, V66, P257; MERESSE S, 1990, J BIOL CHEM, V265, P18833; MESSNER DJ, 1989, J CELL BIOL, V108, P2149, DOI 10.1083/jcb.108.6.2149; NADIMPALLI SK, 1991, FEBS LETT, V280, P61, DOI 10.1016/0014-5793(91)80204-G; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; WAHEED A, 1990, BIOCHEMISTRY-US, V29, P2449, DOI 10.1021/bi00462a003; WAHEED A, 1990, EUR J BIOCHEM, V193, P47, DOI 10.1111/j.1432-1033.1990.tb19302.x; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X	37	165	168	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17110	17115						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324923				2022-12-27	WOS:A1992JL05300060
J	LEE, CH; PARK, D; WU, DQ; RHEE, SG; SIMON, MI				LEE, CH; PARK, D; WU, DQ; RHEE, SG; SIMON, MI			MEMBERS OF THE GQ-ALPHA-SUBUNIT GENE FAMILY ACTIVATE PHOSPHOLIPASE-C BETA-ISOZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADENYLYL CYCLASE; G-PROTEINS; IDENTIFICATION; PURIFICATION; HYDROLYSIS; DIVERSITY; CELLS	The relative specificities of members of the G-alpha(q) family of GTP-binding proteins were tested for their ability to activate different phosphoinositide-specific phospholipase C (PI-PLC) beta-isozymes. Cos-7 cells were transfected with cDNA corresponding to G-alpha(q), G-alpha-11, G-alpha-14, and G-alpha-16. Most of the recombinant protein was bound to the cell membrane and these membranes were washed to elute endogenous PI-PLC activity. The membrane preparation was reconstituted with purified preparations of the PI-PLC beta-isozymes and guanosine 5'-O-thiotriphosphate (GTP-gamma-S)-stimulated enzyme activity was measured. All four proteins of the G-alpha(q) family were found to stimulate PI-PLC beta-1, with G-alpha(q) and G-alpha-11 being most efficient. On the other hand, G-alpha-16 was found to most effectively activate PI-PLC beta-2, while G-alpha(q), G-alpha-11, and G-alpha-14 showed less stimulation. Specific anti-G-alpha-16 antibody blocked the stimulation of both PI-PLC beta-1 and PI-PLC beta-2 in the enriched membrane fraction. We conclude that there is specificity in the interaction of different members of the G(q) family with different PI-PLC beta-effectors. This specificity may be important in generating tissue- or receptor-specific responses in vivo.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; NHLBI, BIOCHEM LAB, BETHESDA, MD 20892 USA	California Institute of Technology; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034236, R01GM034236] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34236] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; DEVIVO M, 1990, ADP RIBOSYLATING TOX, P267; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAMM HE, 1984, J GEN PHYSIOL, V84, P265, DOI 10.1085/jgp.84.2.265; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KRIZ R, 1990, CIBA F SYMP, V150, P112; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NAKAMURA F, 1991, J BIOL CHEM, V266, P12676; PARK D, 1992, J BIOL CHEM, V267, P16048; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RYU SH, 1987, J BIOL CHEM, V262, P12511; SCHATZMANN HJ, 1973, J PHYSIOL-LONDON, V235, P551, DOI 10.1113/jphysiol.1973.sp010403; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPIEGEL AM, 1990, ADP RIBOSYLATING TOX, P267; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WU DQ, 1992, J BIOL CHEM, V267, P1811	24	270	274	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16044	16047						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322889				2022-12-27	WOS:A1992JJ45800011
J	WEINSTEIN, SL; SANGHERA, JS; LEMKE, K; DEFRANCO, AL; PELECH, SL				WEINSTEIN, SL; SANGHERA, JS; LEMKE, K; DEFRANCO, AL; PELECH, SL			BACTERIAL LIPOPOLYSACCHARIDE INDUCES TYROSINE PHOSPHORYLATION AND ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASES IN MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASES; SEA STAR OOCYTES; HERBIMYCIN-A; MAP KINASE; INHIBITION; INSULIN; INVITRO; ERKS; RECEPTOR	Bacterial lipopolysaccharide (LPS) is a potent activator of antibacterial responses by macrophages. Following LPS stimulation, the tyrosine phosphorylation of several proteins is rapidly increased in macrophages, and this event appears to mediate some responses to LPS. We now report that two of these tyrosine phosphoproteins of 41 and 44 kDa are isoforms of mitogen-activated protein (MAP) kinase. Each of these proteins was reactive with anti-MAP kinase antibodies and comigrated with MAP kinase activity in fractions eluted from a MonoQ anion-exchange column. Following LPS stimulation, column fractions containing the tyrosine phosphorylated forms of p41 and p44 exhibited increased MAP kinase activity. Inhibition of LPS-induced tyrosine phosphorylation of these proteins was accompanied by inhibition of MAP kinase activity. Additionally, induction of p41/p44 tyrosine phosphorylation and MAP kinase activity by LPS appeared to be independent of activation of protein kinase C, even though phorbol esters also induced these responses. These results demonstrate that LPS induces the tyrosine phosphorylation and activation of at least two MAP kinase isozymes. Since MAP kinases appear to modulate cellular processes in response to extracellular signals, these kinases may be important targets for LPS action in macrophages.	UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; KINET BIOTECHNOL CORP, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, BIOMED RES LAB, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER V6T 1Z3, BC, CANADA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of British Columbia; University of British Columbia					NIAID NIH HHS [AI20038] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020038, R01AI020038] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS DO, 1984, ANNU REV IMMUNOL, V2, P283, DOI 10.1146/annurev.immunol.2.1.283; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BARRIERE SL, 1991, PATIENT CARE, V25, P95; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOPER JA, 1985, MOL CELL BIOL, V5, P3304, DOI 10.1128/MCB.5.11.3304; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Morrison D C, 1979, Adv Immunol, V28, P293; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; PABST MJ, 1989, HDB INFLAMMATION, V6, P361; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SANGHERA JS, 1991, J BIOL CHEM, V266, P6700; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	33	408	414	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14955	14962						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321821				2022-12-27	WOS:A1992JF08800069
J	STEPHENSON, RC; CLARKE, S				STEPHENSON, RC; CLARKE, S			CHARACTERIZATION OF A RAT-LIVER PROTEIN CARBOXYL METHYLTRANSFERASE INVOLVED IN THE MATURATION OF PROTEINS WITH THE -CXXX C-TERMINAL SEQUENCE MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BINDING DOMAIN; LAMIN-B; SACCHAROMYCES-CEREVISIAE; METHYL ESTERIFICATION; FARNESYL; CYSTEINE; P21RAS; IDENTIFICATION; TRANSFERASE; PRODUCT	We have utilized S-farnesyl-Leu-Ala-Arg-Tyr-Lys-Cys as a methyl-accepting substrate to characterize a membrane-bound C-terminal protein methyltransferase from rat liver. We have localized the activity to the microsomal fraction and show that the bulk of the enzyme fractionates by density gradient centrifugation with glucose-6-phosphatase, a marker of the endoplasmic reticulum, and not with 5'-nucleotidase, a marker of the plasma membrane, or galactosyl:N-acetylglucosamine transferase, a marker of the Golgi apparatus. This methyltransferase appears to form an integral part of the membrane structure. Its activity is markedly affected by a variety of detergents used to solubilize membrane proteins in their native form. All activity is lost when membranes are treated with seven different detergents at a concentration of 1% (w/v). The activity is inhibited by N-ethylmaleimide, although it can be protected against inactivation with its substrate S-adenosyl-L-methionine, or its product S-adenosyl-L-homocysteine. Finally, we find that 5'-methylthioadenosine, a substrate analogue reported to be an inhibitor of this activity in other studies, is not an effective inhibitor in vitro.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIGMS NIH HHS [GM 26020, GM 07185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026020, T32GM007185, R01GM026020] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPELMANS F, 1955, BIOCHEM J, V59, P438, DOI 10.1042/bj0590438; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; ASHBY MN, 1992, IN PRESS P NATL ACAD, V89; BACKLUND PS, 1988, J BIOL CHEM, V263, P15864; Beattie D S, 1979, Methods Enzymol, V56, P17; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; BUSCH H, 1967, METHODS ENZYMOLOGY A, V12, P421; CHELSKY D, 1989, J BIOL CHEM, V264, P7637; CHELSKY D, 1987, J BIOL CHEM, V262, P4303; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DER CJ, 1991, CANCER CELL, V3, P1; DESCHENES RJ, 1989, J BIOL CHEM, V264, P11865; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HRYCYNA CA, 1992, J BIOL CHEM, V267, P10457; HRYCYNA CA, 1990, MOL CELL BIOL, V10, P5071, DOI 10.1128/MCB.10.10.5071; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; HUZOORAKBAR, 1991, J BIOL CHEM, V266, P4387; ISHIBASHI Y, 1984, BIOCHEMISTRY-US, V23, P1399, DOI 10.1021/bi00302a010; JOLY A, 1991, J BIOL CHEM, V266, P13495; KITTEN GT, 1991, J CELL BIOL, V113, P13, DOI 10.1083/jcb.113.1.13; LAW RE, 1992, MOL CELL BIOL, V12, P103, DOI 10.1128/MCB.12.1.103; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALTESE WA, 1990, J BIOL CHEM, V265, P17883; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MARCUS S, 1991, MOL CELL BIOL, V11, P3603, DOI 10.1128/MCB.11.7.3603; MORRE DJ, 1971, METHOD ENZYMOL, V22, P130; OHNISHI ST, 1978, ANAL BIOCHEM, V88, P347, DOI 10.1016/0003-2697(78)90432-3; ONG OC, 1989, P NATL ACAD SCI USA, V86, P9238, DOI 10.1073/pnas.86.23.9238; OTA IM, 1989, J BIOL CHEM, V264, P12879; PEREZSALA D, 1991, P NATL ACAD SCI USA, V88, P3043, DOI 10.1073/pnas.88.8.3043; QUELLE FW, 1988, ENDOCRINOLOGY, V123, P1642, DOI 10.1210/endo-123-3-1642; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SIMMS SA, 1985, J BIOL CHEM, V260, P161; SIMMS SA, 1987, J BIOL CHEM, V262, P8537; SINENSKY M, 1992, BIOESSAYS, V14, P25, DOI 10.1002/bies.950140106; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; TAN EW, 1991, J BIOL CHEM, V266, P10719; VOLKER C, 1991, J BIOL CHEM, V266, P21515; WOLDA SL, 1988, J BIOL CHEM, V263, P5997; YAMANE HK, 1989, J BIOL CHEM, V264, P20100; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOSHIDA Y, 1991, BIOCHEM BIOPH RES CO, V175, P720, DOI 10.1016/0006-291X(91)91625-M	49	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13314	13319						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320016				2022-12-27	WOS:A1992JB74600037
J	ACKERMANN, U; GEERING, K				ACKERMANN, U; GEERING, K			BETA-1-SUBUNITS AND BETA-3-SUBUNITS CAN ASSOCIATE WITH PRESYNTHESIZED ALPHA-SUBUNITS OF XENOPUS OOCYTE NA,K-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; (NA+ + K+)-ATPASE; BETA-SUBUNIT; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; EXPRESSION; MEMBRANE; SEQUENCE; LAEVIS; RNA	Oligomerization of newly synthesized alpha- and beta-subunits is a prerequisite for the structural and functional maturation of Na,K-ATPase. In this study, we have tested the competence of presynthesized alpha- and beta-subunits to assemble into functional enzyme complexes. Antisense oligonucleotides complementary to alpha-mRNA were used to inhibit alpha-subunit synthesis in Xenopus oocytes leaving a presynthesized trypsin-sensitive alpha-subunit pool. Beta-Subunits expressed in these oocytes from injected cRNA assembled with the preexisting alpha-subunits, rendered them trypsin-resistant, and permitted the expression of more ouabain binding sites at the plasma membrane. Similarly, presynthesized beta-1- or beta-3-subunits produced in Xenopus oocytes by injection of beta-cRNA and later of specific antisense oligonucleotides were stabilized and transported out of the endoplasmic reticulum when alpha-cRNA was injected into oocytes. These data indicate that alpha- and beta-subunits can insert into endoplasmic reticulum membranes independent of each other in an assembly-competent form and retain their ability for oligomerization after synthesis.	UNIV LAUSANNE, INST PHARMACOL & TOXICOL, RUE BUGNON 27, CH-1005 LAUSANNE, SWITZERLAND	University of Lausanne								ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; COLMAN A, 1990, J CELL SCI, V97, P399; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; GOOD PJ, 1990, P NATL ACAD SCI USA, V87, P9088, DOI 10.1073/pnas.87.23.9088; HAN Y, 1991, DEV BIOL, V145, P174, DOI 10.1016/0012-1606(91)90223-P; HIATT A, 1984, J BIOL CHEM, V259, P2629; HORISBERGER JD, 1991, P NATL ACAD SCI USA, V88, P8397, DOI 10.1073/pnas.88.19.8397; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JAUNIN P, 1992, J BIOL CHEM, V267, P577; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; MARCUSSEKURA CJ, 1988, ANAL BIOCHEM, V172, P289, DOI 10.1016/0003-2697(88)90447-2; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NOGUCHI S, 1990, BIOCHIM BIOPHYS ACTA, V1023, P247, DOI 10.1016/0005-2736(90)90420-S; NOGUCHI S, 1990, J BIOL CHEM, V265, P15991; NOGUCHI S, 1986, FEBS LETT, V196, P315, DOI 10.1016/0014-5793(86)80270-8; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SCHMALZING G, 1991, BIOCHEM J, V279, P329, DOI 10.1042/bj2790329; SHUTTLEWORTH J, 1988, EMBO J, V7, P427, DOI 10.1002/j.1460-2075.1988.tb02830.x; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; TAMKUN MM, 1986, J BIOL CHEM, V261, P1009; VERREY F, 1989, AM J PHYSIOL, V256, pF1034, DOI 10.1152/ajprenal.1989.256.6.F1034	24	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12911	12915						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1320007				2022-12-27	WOS:A1992HZ48300078
J	HIKITA, C; MIZUSHIMA, S				HIKITA, C; MIZUSHIMA, S			THE REQUIREMENT OF A POSITIVE CHARGE AT THE AMINO TERMINUS CAN BE COMPENSATED FOR BY A LONGER CENTRAL HYDROPHOBIC STRETCH IN THE FUNCTIONING OF SIGNAL PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI MEMBRANE-VESICLES; MALTOSE-BINDING-PROTEIN; PROTON MOTIVE FORCE; ESCHERICHIA-COLI; SECA PROTEIN; INVITRO TRANSLOCATION; CYTOPLASMIC MEMBRANE; SECRETORY PROTEIN; SEQUENCE; EXPORT	A variety of model presecretory proteins, proOmpF-Lpps, possessing different numbers of lysine residues (0, 2, and 4) as positively charged amino acid residues and different numbers of leucine residues (7, 8, and 9) as hydrophobic amino acid redidues in their signal peptides were constructed. The effect of positive charges on the in vitro translocation efficiency markedly differed with the number of leucine residues. Positive charges were strongly required for translocation when the hydrophobic region comprised 7 or 8 leucine residues, whereas the translocation of proOmpF-Lpps possessing 9 leucine residues took place efficiently even in the absence of positive charges and the introduction of positive charges did not significantly enhance the translocation efficiency. The translocation of all the proOmpF-Lpps, including one possessing no positive charge, was ATP-, protonmotive force-, and SecA-dependent and accompanied by signal peptide cleavage, indicating that they are translocated via the usual secretory pathway. It is likely that the requirement of positive charges can be compensated for by a longer hydrophobic stretch in the functioning of the signal peptide.	UNIV TOKYO, INST APPL MICROBIOL, 1-1-1 YAYOI, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								AKITA M, 1990, J BIOL CHEM, V265, P8164; BANKAITIS VA, 1984, CELL, V37, P243, DOI 10.1016/0092-8674(84)90320-9; BOSCH D, 1989, BIOCHIM BIOPHYS ACTA, V979, P69, DOI 10.1016/0005-2736(89)90524-5; BRIGGS MS, 1986, ADV PROTEIN CHEM, V38, P109, DOI 10.1016/S0065-3233(08)60527-6; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CHOU MM, 1990, J BIOL CHEM, V265, P2873; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DANIELS CJ, 1981, P NATL ACAD SCI-BIOL, V78, P5396, DOI 10.1073/pnas.78.9.5396; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; EMR SD, 1980, NATURE, V285, P82, DOI 10.1038/285082a0; HIKITA C, 1992, J BIOL CHEM, V267, P4882; IINO T, 1987, J BIOL CHEM, V262, P7412; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; INOUYE S, 1982, P NATL ACAD SCI-BIOL, V79, P3438, DOI 10.1073/pnas.79.11.3438; JONES JD, 1990, J BIOENERG BIOMEMBR, V22, P213, DOI 10.1007/BF00763166; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; KENDALL DA, 1988, J BIOL CHEM, V263, P7261; KENDALL DA, 1986, NATURE, V321, P706, DOI 10.1038/321706a0; LU HM, 1991, J BIOL CHEM, V266, P9977; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; OZAWA Y, 1987, J BACTERIOL, V169, P1331, DOI 10.1128/jb.169.3.1331-1334.1987; PUZISS JW, 1989, J BACTERIOL, V171, P2303, DOI 10.1128/jb.171.5.2303-2311.1989; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI S, 1990, J BIOL CHEM, V265, P4358; TAKAGI Y, 1988, J BIOCHEM-TOKYO, V104, P801, DOI 10.1093/oxfordjournals.jbchem.a122553; TIAN GL, 1989, J BACTERIOL, V171, P1987, DOI 10.1128/jb.171.4.1987-1997.1989; TOMMASSEN J, 1989, J CELL SCI, P73; VLASUK GP, 1983, J BIOL CHEM, V258, P7141; VONHEIJNE G, 1985, CURR TOP MEMBR TRANS, V24, P151; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Weber K, 1972, Methods Enzymol, V26, P3; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMAMOTO Y, 1987, BIOCHEM BIOPH RES CO, V149, P431, DOI 10.1016/0006-291X(87)90385-8; YAMANE K, 1987, J BIOL CHEM, V262, P2358; YAMANE K, 1988, J BIOL CHEM, V263, P5368	36	40	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12375	12379						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1318317				2022-12-27	WOS:A1992HY94700108
J	HIASA, H; MARIANS, KJ				HIASA, H; MARIANS, KJ			DIFFERENTIAL INHIBITION OF THE DNA TRANSLOCATION AND DNA UNWINDING ACTIVITIES OF DNA HELICASES BY THE ESCHERICHIA-COLI TUS PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXHIBIT POLAR INHIBITION; REPLICATION FACTOR-Y; TERMINUS REGION; SEQUENCE; CHROMOSOME; TERMINATION; INVITRO; FORKS; SITES; IDENTIFICATION	Binding of the Escherichia coli Tus protein to its cognate nonpalindromic binding site on duplex DNA (a Ter sequence) is sufficient to arrest the progression of replication forks in a Ter orientation-dependent manner in vivo and in vitro. In order to probe the molecular mechanism of this inhibition, we have used a strand displacement assay to investigate the effect of Tus on the DNA helicase activities of DnaB, PriA, UvrD (helicase II), and the phi-X-type primosome. When the substrate was a short oligomer hybridized to a circular single-stranded DNA, strand displacement by DnaB, PriA, and the primosome (in both directions), but not UvrD, was blocked by Tus in a polar fashion. However, no inhibition of either DnaB or UvrD was observed when the substrate carried an elongated duplex region. With this elongated substrate, PriA helicase activity was only inhibited partially (by 50%). On the other hand, both the 5' --> 3' and 3' --> 5' helicase activities of the primosome were inhibited almost completely by Tus with the elongated substrate. These results suggest that while Tus can inhibit the translocation of some proteins along single-stranded DNA in a polar fashion, this generalized effect is insufficient for the inhibition of bona fide DNA helicase activity.	CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Cornell University	HIASA, H (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [R01 GM034558, GM34558] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; BASTIA D, 1981, GENE, V41, P81; BEDROSIAN CL, 1991, P NATL ACAD SCI USA, V88, P2618, DOI 10.1073/pnas.88.7.2618; DEMASSY B, 1987, P NATL ACAD SCI USA, V84, P1759; FRANCKE B, 1971, VIROLOGY, V44, P168, DOI 10.1016/0042-6822(71)90163-2; FRANCOIS V, 1989, MOL MICROBIOL, V3, P995, DOI 10.1111/j.1365-2958.1989.tb00250.x; GREENBAUM JH, 1984, J BIOL CHEM, V259, P2594; HIDAKA M, 1988, CELL, V55, P467, DOI 10.1016/0092-8674(88)90033-5; HIDAKA M, 1991, J BACTERIOL, V173, P391, DOI 10.1128/jb.173.1.391-393.1991; HILL TM, 1987, P NATL ACAD SCI USA, V84, P1754, DOI 10.1073/pnas.84.7.1754; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; HILL TM, 1988, J BACTERIOL, V171, P5405; HORIUCHI T, 1988, CELL, V54, P515, DOI 10.1016/0092-8674(88)90073-6; KOHATRI GS, 1989, CELL, V59, P667; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LEE MS, 1989, J BIOL CHEM, V264, P14531; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; LEE MS, 1990, J BIOL CHEM, V265, P17078; MACALLISTER T, 1990, P NATL ACAD SCI USA, V87, P2828, DOI 10.1073/pnas.87.7.2828; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MODEL P, 1974, J MOL BIOL, V83, P231, DOI 10.1016/0022-2836(74)90389-1; SISTA PR, 1989, P NATL ACAD SCI USA, V86, P3026, DOI 10.1073/pnas.86.9.3026; SMITH KR, 1989, J BIOL CHEM, V264, P6119	27	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11379	11385						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317865				2022-12-27	WOS:A1992HX16900069
J	MANDON, EC; EHSES, I; ROTHER, J; VANECHTEN, G; SANDHOFF, K				MANDON, EC; EHSES, I; ROTHER, J; VANECHTEN, G; SANDHOFF, K			SUBCELLULAR-LOCALIZATION AND MEMBRANE TOPOLOGY OF SERINE PALMITOYLTRANSFERASE, 3-DEHYDROSPHINGANINE REDUCTASE, AND SPHINGANINE N-ACYLTRANSFERASE IN MOUSE-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-CHAIN BASES; RAT-LIVER; GOLGI-APPARATUS; GANGLIOSIDE BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; SPHINGOID BASES; LM CELLS; SPHINGOLIPIDS; MODULATION; TRANSPORT	Serine palmitoyltransferase, 3-dehydrosphinganine reductase and sphinganine N-acyltransferase are responsible for the first steps in sphingolipid biosynthesis forming 3-oxosphinganine, sphinganine, and dihydroceramide, respectively. We confirmed the localization of these enzymes in the endoplasmic reticulum (ER) using highly purified mouse liver ER and Golgi preparations. Mild digestion of sealed "right-side out" mouse liver ER derived vesicles with different proteolytic enzymes under conditions where latency of mannose-6-phosphatase was 90% produced approximately 60-80% inactivation of serine palmitoyltransferase, 3-dehydrosphinganine reductase, and sphinganine N-acyltransferase activities. These sphingolipid biosynthetic activities (serine palmitoyltransferase, 3-dehydrosphinganine reductase, and sphinganine N-acyltransferase) are not latent, indicating that they face the cytosolic side of the ER, so that substrates have free access to their active sites. Moreover, the membrane-impermeable compound, 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid, which binds to a large number of ER proteins, inhibits serine palmitoyltransferase and sphinganine N-acyltransferase activities by 30-70%.	UNIV BONN, INST ORGAN CHEM & BIOCHEM, GERHARD DOMAGK STR 1, W-5300 BONN, GERMANY	University of Bonn								AARONSON NN, 1974, METHOD ENZYMOL, V31, P90; ARION WJ, 1976, J BIOL CHEM, V251, P4901; BREMER EG, 1986, J BIOL CHEM, V261, P2434; BRILES EB, 1977, J BIOL CHEM, V252, P1107; CABANTCHIK ZI, 1978, BIOCHIM BIOPHYS ACTA, V515, P239; CHATTERJEE S, 1986, J BIOL CHEM, V261, P3474; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; DEPIERRE JW, 1975, BIOCHIM BIOPHYS ACTA, V415, P411, DOI 10.1016/0304-4157(75)90006-4; DEPIERRE JW, 1977, ANNU REV BIOCHEM, V46, P201, DOI 10.1146/annurev.bi.46.070177.001221; Fleischer S, 1974, Methods Enzymol, V31, P6; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HAKOMORI S, 1984, TRENDS BIOCHEM SCI, V9, P453, DOI 10.1016/0968-0004(84)90156-7; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HIRSCHBERG CB, 1970, J BIOL CHEM, V245, P3084; KARLSSON KA, 1970, CHEM PHYS LIPIDS, V5, P6, DOI 10.1016/0009-3084(70)90008-3; KISHIMOTO Y, 1983, ENZYMES, V2, P357; MANDON EC, 1991, EUR J BIOCHEM, V198, P667, DOI 10.1111/j.1432-1033.1991.tb16065.x; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MERRILL AH, 1988, BIOCHEMISTRY-US, V27, P340, DOI 10.1021/bi00401a051; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MORRELL P, 1970, J BIOL CHEM, V245, P342; POLOKOFF MA, 1978, J BIOL CHEM, V253, P7173; RADIN NS, 1984, J LIPID RES, V25, P1536; SANDBERG PO, 1980, EXP CELL RES, V130, P393, DOI 10.1016/0014-4827(80)90017-8; SCHMIDT RR, 1988, LIEBIGS ANN CHEM, P663; SCHWARZMANN G, 1978, BIOCHIM BIOPHYS ACTA, V529, P106, DOI 10.1016/0005-2760(78)90108-X; SCHWARZMANN G, 1990, BIOCHEMISTRY-US, V29, P10865, DOI 10.1021/bi00501a001; SPIRO MJ, 1985, J BIOL CHEM, V260, P5808; STOFFEL W, 1968, H-S Z PHYSIOL CHEM, V349, P1637, DOI 10.1515/bchm2.1968.349.2.1637; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; VANECHTEN G, 1990, J BIOL CHEM, V265, P9333; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P12502; VERDERY RB, 1982, J BIOL CHEM, V257, P1412; WADDELL ID, 1991, BIOCHEM J, V275, P133, DOI 10.1042/bj2750133; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; YUSUF HKM, 1983, EUR J BIOCHEM, V134, P47, DOI 10.1111/j.1432-1033.1983.tb07529.x; YUSUF HKM, 1983, P NATL ACAD SCI-BIOL, V80, P7075, DOI 10.1073/pnas.80.23.7075; ZOCCOLI MA, 1980, J BIOL CHEM, V255, P1113	39	282	289	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11144	11148						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317856				2022-12-27	WOS:A1992HX16900035
J	BOREN, J; GRAHAM, L; WETTESTEN, M; SCOTT, J; WHITE, A; OLOFSSON, SO				BOREN, J; GRAHAM, L; WETTESTEN, M; SCOTT, J; WHITE, A; OLOFSSON, SO			THE ASSEMBLY AND SECRETION OF APO-B 100-CONTAINING LIPOPROTEINS IN HEP G2 CELLS - APO-B 100 IS COTRANSLATIONALLY INTEGRATED INTO LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; APOLIPOPROTEIN-B GENE; ENDOPLASMIC-RETICULUM; PULSE-CHASE; ABETALIPOPROTEINEMIA; TRANSPORT; LIVER; HEPATOCYTES; EXPRESSION; MEMBRANE	The possibility that apoB 100 is cotranslationally translocated to the endoplasmic reticulum lumen and integrated into lipoproteins has been investigated. ApoB 100 nascent polypeptides were shown to be secreted from Pulse-labeled Hep G2 cells after treatment with puromycin and chase for 1 or 2 h in the presence of puromycin and cycloheximide. These nascent polypeptides banded during sucrose gradient ultracentrifugation between the position of the high (HDL) and the low (LDL) density lipoproteins, revealing an inverse relationship between the length of the polypeptide and the density of the fraction. ApoB 100 occurred in the position of LDL and very low density lipoproteins (VLDL). Electronmicroscopy studies of the apoB-containing particles from the gradient indicated an increase in size with increasing length of the polypeptide. Furthermore, labeling studies indicated that the triglyceride load increased with the length of the polypeptide. An inverse relationship between the size of C-terminally truncated apoB polypeptides and the density of the assembled lipoproteins was also observed in experiments with transfected minigenes coding for apoB 41, apoB 29, and apoB 23. These proteins appeared on HDL particles. Pulse-chase experiments indicated that 80-200-kDa apoB nascent polypeptides on particles with HDL density, with time, were converted into larger polypeptides on lighter particles, to be fully replaced by apoB 100 on LDL-VLDL particles. The formation of these LDL-VLDL particles could be blocked by cycloheximide. Sixty-five percent of pulse-labeled apoB nascent polypeptides present in the microsomal fraction was released by sodium carbonate treatment, and 77% of these polypeptides could be recovered on the immature particles (banding between HDL and LDL) after sucrose gradient ultracentrifugation. Pulse-chase experiments indicated that these nascent polypeptides, on the immature lipoproteins, had the capacity to be precursors for all the apoB 100-containing LDL and VLDL particles formed in the cell. The obtained results indicate that a major portion of the apoB nascent polypeptides in the cell form lipoproteins cotranslationally during the translocation to the lumen of the endoplasmic reticulum.	GOTHENBURG UNIV,DEPT MED BIOCHEM,BOX 33031,S-40033 GOTHENBURG,SWEDEN; MRC,CLIN RES CTR,DIV MOLEC MED,HARROW HA1 3UJ,MIDDX,ENGLAND	University of Gothenburg; Medical Research Council Clinical Trials Unit								ANDERSON LJ, 1989, J LIPID RES, V30, P1819; BAMBERGER MJ, 1988, J BIOL CHEM, V263, P11868; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; BOUMA ME, 1990, J LIPID RES, V31, P1; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DAVIS RA, 1982, J BIOL CHEM, V257, P2634; DULLAART RPF, 1986, J CLIN INVEST, V78, P1397, DOI 10.1172/JCI112727; ELOVSON J, 1988, J LIPID RES, V29, P1461; FAINARU M, 1977, METABOLISM, V26, P999, DOI 10.1016/0026-0495(77)90017-8; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; HUANG LS, 1990, AM J HUM GENET, V46, P1141; JANERO DR, 1983, J BIOL CHEM, V258, P4496; KHAN B, 1989, BIOCHEM J, V259, P807; LABELLE M, 1990, BIOCHIM BIOPHYS ACTA, V1046, P288, DOI 10.1016/0005-2760(90)90243-Q; LACKNER KJ, 1986, J CLIN INVEST, V78, P1707, DOI 10.1172/JCI112766; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; LODISH HF, 1987, J CELL BIOL, V104, P221, DOI 10.1083/jcb.104.2.221; PULLINGER CR, 1989, J LIPID RES, V30, P1065; SATO R, 1990, J BIOL CHEM, V265, P11880; TALMUD PJ, 1988, J CLIN INVEST, V82, P1803, DOI 10.1172/JCI113795; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; WETTESTEN M, 1985, EUR J BIOCHEM, V149, P461, DOI 10.1111/j.1432-1033.1985.tb08947.x; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YAO ZM, 1989, J BIOL CHEM, V264, P11373	32	157	158	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9858	9867						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315773				2022-12-27	WOS:A1992HT96500066
J	MOREAU, T; BRILLARDBOURDET, M; BOUHNIK, J; GAUTHIER, F				MOREAU, T; BRILLARDBOURDET, M; BOUHNIK, J; GAUTHIER, F			PROTEIN PRODUCTS OF THE RAT KALLIKREIN GENE FAMILY - SUBSTRATE SPECIFICITIES OF KALLIKREIN RK2 (TONIN) AND KALLIKREIN RK9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-SPECIFIC ANTIGEN; AMINO-ACID-SEQUENCE; SUBMAXILLARY-GLAND; SERINE-PROTEASE; MESSENGER-RNA; CDNA CLONING; T-KININOGEN; PURIFICATION; CLEAVAGE; CONFIRMATION	Two closely related kallikrein-like proteinases having little activity toward the standard synthetic amide substrates of tissue kallikreins were isolated from the rat submandibular gland. They were found to be the protein products of the rKlk2 (tonin) and the rKlk9 genes by amino acid sequence analysis (nomenclature of the genes and proteins of the kallikrein family is according to the proposal of the discussion panel from the participants of the KININ '91 meeting held Sept. 8-14, 1991, in Munich, Germany). These two proteinases of similar structure also had very similar physicochemical properties. They differed from other kallikrein-related proteinases in having high pH(i) values of 6.20 (rK2) and 6.85 (rK9). Kallikrein rK2 was purified as a single peptide chain, whereas rK9 appeared as a two-chain protein after reduction. Their enzymatic properties were also very similar and differed significantly from those of other rat kallikrein-related proteinases. Unlike the five other kallikrein-related proteinases we have purified so far, kallikrein rK9 was not inhibited by aprotinin. rK9 also differed from rK2 by its tissue localization. The prostate gland contained only rK9 where it was the major kallikrein-like component. The amino acids preferentially accommodated by the proteinase S3 to S2' subsites were identified using synthetic amide and protein substrates. Unlike other kallikrein-related proteinases, rK2 had a prevalent chymotrypsin-like specificity, whereas rK9 had both chymotrypsin-like and trypsin-like properties. Both rK2 and rK9 preferred a prolyl residue in position P2 of the substrate and did not accommodate bulky and hydrophobic residues at that position, as did most of the other kallikrein-related proteinases. This P2-proline-directed specificity is necessary for processing the precursors of several biologically active peptides. Subsites accommodating residues COOH-terminal to the scissile bond were also important in determining the overall substrate specificity of these proteinases. rK2 and rK9 both showed a preference for hydrophobic residues in P2'. Other subsites upstream of the S3 subsite were found to intervene in substrate binding and hydrolysis. The restricted specificity of rK2 and rK9 is consistent with the presence of an extended substrate binding site, and hence with a processing enzyme function. Their P1 specificities enabled both proteinases to release angiotensin II from angiotensinogen and from angiotensinogen I, but rK9 was at least 100 times less active than rK2 on both substrates. The substrate specificities of rK2 and rK9 were correlated with key amino acids defining their substrate binding site. The predicted preferential sequence(s) around the cleavage site deduced from these data may be used to identify the biological substrate(s) of these proteinases.	UNIV TOURS, FAC MED,CNRS,URA 1334,ENZYMOL & CHIM PROT LAB, 2BIS,BD TONNELLE, F-37032 TOURS, FRANCE; INSERM, U36, F-75005 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Tours; Institut National de la Sante et de la Recherche Medicale (Inserm)								ASHLEY PL, 1985, BIOCHEMISTRY-US, V24, P4512, DOI 10.1021/bi00338a005; ASHLEY PL, 1985, BIOCHEMISTRY-US, V24, P4520, DOI 10.1021/bi00338a006; BAN Y, 1984, BIOCHEM BIOPH RES CO, V123, P482, DOI 10.1016/0006-291X(84)90256-0; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BERG T, 1992, IN PRESS BIOCH J; BIETH JG, 1980, CLIN RES PROC, V16, P183; BODE W, 1983, J MOL BIOL, V164, P237, DOI 10.1016/0022-2836(83)90077-3; BOUCHER R, 1974, CIRC RES, V34, pI203; BOUHNIK J, 1981, BIOCHEMISTRY-US, V20, P7010, DOI 10.1021/bi00527a036; BRANDTZAEG P, 1976, BRIT J PHARMACOL, V56, P155, DOI 10.1111/j.1476-5381.1976.tb07438.x; CHAGAS JR, 1991, ANAL BIOCHEM, V192, P419, DOI 10.1016/0003-2697(91)90558-B; CHAO J, 1990, J BIOL CHEM, V265, P16394; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CHRETIEN M, 1980, FEBS LETT, V113, P173, DOI 10.1016/0014-5793(80)80585-0; CLEMENTS JA, 1988, J BIOL CHEM, V263, P16132; EASSON LH, 1936, P ROY SOC LONDON, V121, P141; ELMOUJAHED A, 1990, FEBS LETT, V265, P137, DOI 10.1016/0014-5793(90)80903-V; FUJINAGA M, 1987, J MOL BIOL, V195, P373, DOI 10.1016/0022-2836(87)90658-9; GAUTHIER F, 1978, BIOCHIM BIOPHYS ACTA, V526, P218, DOI 10.1016/0005-2744(78)90306-6; GERALD WL, 1986, BIOCHIM BIOPHYS ACTA, V866, P1, DOI 10.1016/0167-4781(86)90093-X; GUTMAN N, 1991, EUR J BIOCHEM, V197, P425, DOI 10.1111/j.1432-1033.1991.tb15928.x; GUTMAN N, 1988, EUR J BIOCHEM, V171, P577, DOI 10.1111/j.1432-1033.1988.tb13827.x; HAWKE D, 1987, APPLIED BIOSYSTEMS U, V28; KOGA H, 1990, J BIOCHEM-TOKYO, V108, P976, DOI 10.1093/oxfordjournals.jbchem.a123324; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZURE C, 1987, BIOCHEM CELL BIOL, V65, P321, DOI 10.1139/o87-042; LAZURE C, 1984, FEBS LETT, V175, P1, DOI 10.1016/0014-5793(84)80557-8; LUNDWALL A, 1987, FEBS LETT, V214, P317, DOI 10.1016/0014-5793(87)80078-9; MASON AJ, 1983, NATURE, V303, P300, DOI 10.1038/303300a0; MOREAU T, 1986, EUR J BIOCHEM, V159, P341, DOI 10.1111/j.1432-1033.1986.tb09873.x; NUSTAD K, 1974, BIOCHEMISTRY-US, V13, P2312, DOI 10.1021/bi00708a012; PAGES G, 1990, EUR J BIOCHEM, V190, P385, DOI 10.1111/j.1432-1033.1990.tb15587.x; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHELLENBERG F, 1987, DRUG ALCOHOL DEPEN, V19, P181, DOI 10.1016/0376-8716(87)90056-1; SCHWARTZ TW, 1986, FEBS LETT, V200, P1, DOI 10.1016/0014-5793(86)80500-2; SEGEL IH, 1975, ENZYME KINETICS, P109; SWIFT GH, 1982, P NATL ACAD SCI-BIOL, V79, P7263, DOI 10.1073/pnas.79.23.7263; WINDERICKX J, 1989, MOL CELL ENDOCRINOL, V62, P217, DOI 10.1016/0303-7207(89)90008-7; WINES DR, 1989, J BIOL CHEM, V264, P7653; WINES DR, 1991, J MOL EVOL, V32, P476, DOI 10.1007/BF02102650; XIONG W, 1990, J BIOL CHEM, V265, P2822; YAMAGUCHI T, 1991, J BIOL CHEM, V266, P5011; YOON JB, 1987, J BIOL CHEM, V262, P4284	43	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10045	10051						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315752				2022-12-27	WOS:A1992HT96500090
J	CHARLTON, LA; SANGHERA, JS; CLARKLEWIS, I; PELECH, SL				CHARLTON, LA; SANGHERA, JS; CLARKLEWIS, I; PELECH, SL			STRUCTURE-FUNCTION ANALYSIS OF CASEIN KINASE-2 WITH SYNTHETIC PEPTIDES AND ANTIPEPTIDE ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; LARGE T-ANTIGEN; II ACTIVITY; ALPHA-SUBUNIT; GROWTH-FACTOR; PROTEIN; PHOSPHORYLATION; SUBSTRATE; BINDING; BETA	Casein kinase 2 (CK2) is a ubiquitous, multifunctional protein-seryl/threonyl kinase that has been implicated in cellular regulation. Synthetic peptides were patterned after three highly conserved regions in CK2: the N terminus (CK2-NT); the lysine-rich, kinase subdomain III segment (CK2-III) (nomenclature of Hanks et al. (Hanks, S. K., Quinn, A. M., and Hunter, T. (1988) Science 241, 42-52)); and a 10-residue segment located near kinase subdomain X that is shared between CK2 and p34cdc2 (CK2/cdc2). The CK2-III and CK2/cdc2 peptides markedly stimulated the autophosphorylation of the alpha- and alpha'-subunits of purified CK2 from sea star oocytes, and they elicited up to 2-fold increases in its casein or phosvitin phosphotransferase activity. These peptides completely reversed nearly total inhibition of CK2 phosphotransferase activity toward itself, casein, and phosvitin by either heparin or poly(Glu,Tyr; 4:1), whereas CK2-NT was ineffective. Elution of CK2 from heparin-agarose with the CK2III peptide indicated that this region of CK2 might mediate heparin binding to CK2. Affinity-purified rabbit polyclonal antibodies developed against both CK2-III and CK2/cdc2, but not CK2-NT, also produced up to 1.8-fold enhancements of the casein and phosvitin phosphotransferase activities of purified CK2. All three of the antipeptide antibody preparations immunoreacted with the alpha- and alpha'-subunits of CK2 on Western blots. These studies indicate that kinase subdomains III and X are involved in the modulation of CK2 phosphotransferase activity.	UNIV BRITISH COLUMBIA, BIOMED RES CTR, 2222 HLTH SCI MALL, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT BIOCHEM, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER V6T 1Z3, BC, CANADA	University of British Columbia; University of British Columbia; University of British Columbia								ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CARROLL D, 1988, COLD SPRING HARB SYM, V53, P91, DOI 10.1101/SQB.1988.053.01.014; CHENWU JLP, 1988, MOL CELL BIOL, V8, P4981, DOI 10.1128/MCB.8.11.4981; COCHET C, 1980, ENDOCRINOLOGY, V106, P750, DOI 10.1210/endo-106-3-750; FEIGE JJ, 1980, FEBS LETT, V121, P139, DOI 10.1016/0014-5793(80)81283-X; FIRZLAFF J M, 1989, New Biologist, V1, P44; FISCHER EH, 1989, BIOCHIM BIOPHYS ACTA, V1000, P297, DOI 10.1016/S0006-3002(89)80024-1; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATHAWAY GM, 1984, J BIOL CHEM, V259, P7011; HU E, 1990, J BIOL CHEM, V265, P20609; JAKOBI R, 1989, EUR J BIOCHEM, V183, P227, DOI 10.1111/j.1432-1033.1989.tb14917.x; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN WJ, 1991, J BIOL CHEM, V266, P5664; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MARCHIORI F, 1988, BIOCHIM BIOPHYS ACTA, V971, P332; MARIDOR G, 1991, J BIOL CHEM, V266, P2362; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1991, FEBS LETT, V279, P307, DOI 10.1016/0014-5793(91)80174-2; MEGGIO F, 1989, BIOCHIM BIOPHYS ACTA, V1010, P128, DOI 10.1016/0167-4889(89)90193-6; MEGGIO F, 1988, FEBS LETT, V237, P225, DOI 10.1016/0014-5793(88)80206-0; MEGGIO F, 1984, J BIOL CHEM, V259, P4576; MEGGIO F, 1983, FEBS LETT, V160, P203, DOI 10.1016/0014-5793(83)80967-3; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PALEN E, 1991, BIOCHEMISTRY-US, V30, P5586, DOI 10.1021/bi00236a035; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PICARD A, 1990, SCIENCE, V247, P327, DOI 10.1126/science.2153316; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; SANGHERA JS, 1992, IN PRESS BIOCH J; SCHNEIDER HR, 1989, BIOCHIM BIOPHYS ACTA, V1014, P98, DOI 10.1016/0167-4889(89)90246-2; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P4851; TAKIO K, 1987, P NATL ACAD SCI USA, V84, P4851, DOI 10.1073/pnas.84.14.4851; TRAUGH JA, 1990, ADV SEC MESS PHOSPH, V24, P224; TUAZON PT, 1991, ADV 2ND MESSENGER PH, V23, P123; VILLAMORUZZI E, 1991, BIOCHEM BIOPH RES CO, V177, P1019, DOI 10.1016/0006-291X(91)90640-S	46	16	16	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8840	8845						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1315743				2022-12-27	WOS:A1992HR85400024
J	HODGINS, RRW; ELLISON, KS; ELLISON, MJ				HODGINS, RRW; ELLISON, KS; ELLISON, MJ			EXPRESSION OF A UBIQUITIN DERIVATIVE THAT CONJUGATES TO PROTEIN IRREVERSIBLY PRODUCES PHENOTYPES CONSISTENT WITH A UBIQUITIN DEFICIENCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; GENE; ENZYME; CHAIN; DEGRADATION; ENCODES; FUSION; MUTANT	Ubiquitin (Ub) exists in a dynamic equilibrium between the free form and the conjugated form. This equilibrium is maintained and regulated through the antagonistic actions of the conjugation system and a class of enzymes referred to collectively as the Ub-protein hydrolases. Using a previously described epitope-tagged Ub approach (Ellison, M., and Hochstrasser, M. (1991) J. Biol. Chem. 266, 21150-21157) we show here that a single amino acid substitution at the carboxyl terminus of Ub (Gly-76 to Ala-76) results in a derivative of Ub (UbA-76) that becomes irreversibly conjugated to protein when expressed in the yeast Saccharomyces cerevisiae, producing a profound effect on the Ub-conjugate equilibrium. The major target of UbA-76 conjugation is itself (and presumably wild-type Ub) producing unanchored chains at the expense of the free form. Unsurprisingly, the expression of UbA-76 results in yeast phenotypes that would be expected in situations of Ub deprivation. Such cells show slow growth characteristics and sensitivity to various forms of environmental stress and to ultraviolet light. In view of these findings, the expression of UbA-76 in higher organisms may represent a convenient epigenetic strategy for examining the physiological consequences of Ub deprivation or Ub-protein hydrolase disfunction in living cells without the need for gene disruption or replacement. The observation that UbA-76 couples to itself irreversibly also provides an effective tool for elucidating the role of Ub as the proteolytic signal.	UNIV ALBERTA,DEPT BIOCHEM,RM 4-74,MED SCI BLDG,EDMONTON T6G 2H7,ALBERTA,CANADA	University of Alberta								BUTT TR, 1988, J BIOL CHEM, V263, P16364; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; ECKER DJ, 1987, J BIOL CHEM, V262, P3524; ELLISON M, 1991, J BIOL CHEM, V266, P24116; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FINLEY D, 1991, IN PRESS ANN CELL BI; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HAAS AL, 1987, J BIOL CHEM, V262, P345; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Hough R. F., 1988, UBIQUITIN, P101, DOI 10.1007/978-1-4899-2049-2_5; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1990, TRENDS BIOL SCI, V15, P105; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MITA S, 1980, EXP CELL RES, V126, P407, DOI 10.1016/0014-4827(80)90280-3; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; PICKART CM, 1988, UBIQUITIN, P77; Rose I. A., 1988, UBIQUITIN, P135; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SHERMAN F, 1986, METHODS YEAST GENETI, P164	25	66	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8807	8812						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1315740				2022-12-27	WOS:A1992HR85400019
J	ROMANIC, AM; ADACHI, E; HOJIMA, Y; ENGEL, J; PROCKOP, DJ				ROMANIC, AM; ADACHI, E; HOJIMA, Y; ENGEL, J; PROCKOP, DJ			POLYMERIZATION OF PNCOLLAGEN-I AND COPOLYMERIZATION OF PNCOLLAGEN-I WITH COLLAGEN-I - A KINETIC, THERMODYNAMIC, AND MORPHOLOGIC STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO TENDONS; FIBRIL FORMATION; PC-COLLAGEN; ELECTRON-MICROSCOPY; CONNECTIVE-TISSUE; V COLLAGEN; PROCOLLAGEN; DIAMETER; PROTEINASE; CLEAVAGE	Previous observations established that pNcollagen III copolymerized with collagen I and decreased the diameter of the fibrils formed (Romanic, A. M., Adachi, E., Kadler, K. E., Hojima, Y., and Prockop, D. J. (1991) J. Biol. Chem. 266, 12703-12709). Here, procollagen I alone or mixtures of procollagen I and pCcollagen I were incubated with procollagen C-proteinase to generate pNcollagen I or mixtures of pNcollagen I and collagen I. The results confirmed previous reports that pNcollagen I assembles into sheet-like structures. They also demonstrated that polymerization of pNcollagen I exhibits a lag period and a propagation phase similar to those seen with other protein self-assembly systems. In addition, the results demonstrated that pNcollagen I formed true copolymers with collagen I in that the presence of pNcollagen I increased the lag time, decreased the propagation rate, and increased the concentration of collagen I in solution at equilibrium. Copolymerization of pNcollagen I with collagen I, however, differed in two features from copolymerization of pNcollagen III with collagen I. One was that, in confirmation of previous work, copolymerization of pNcollagen I with collagen I markedly altered the circularity of the fibrils formed. The second difference was that the copolymerization increased the concentration in solution at equilibrium of pNcollagen I whereas copolymerization with collagen I was previously shown to decrease the concentration in solution of pNcollagen III. The increase in concentration in solution of pNcollagen I was explicable either by the assembly of soluble oligomers of pNcollagen I and collagen I, or by subtle changes in the activities of pNcollagen I and collagen I in the solid-phase. Comparison with previous data with pNcollagen III indicated that although pNcollagen I and pNcollagen III copolymerize with collagen I, there are marked differences in the two kinds of copolymers.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, JEFFERSON INST MOLEC MED, DEPT BIOCHEM & MOLEC BIOL, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, JEFFERSON INST MOLEC MED, DEPT BIOCHEM & MOLEC BIOL, PHILADELPHIA, PA 19107 USA	Jefferson University; Jefferson University					NIAMS NIH HHS [AR39740, AR38188] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039740, P01AR038188] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADACHI E, 1985, COLLAGEN REL RES, V5, P225; ADACHI E, 1989, MATRIX, V9, P232, DOI 10.1016/S0934-8832(89)80055-1; ALAKOKKO L, 1989, BIOCHEM J, V260, P509, DOI 10.1042/bj2600509; BAILEY AJ, 1973, EUR J BIOCHEM, V34, P91, DOI 10.1111/j.1432-1033.1973.tb02732.x; BECKER U, 1976, BIOCHEMISTRY-US, V15, P2853, DOI 10.1021/bi00658a024; CHAPMAN JA, 1989, BIOPOLYMERS, V28, P2201, DOI 10.1002/bip.360281212; CHAPMAN JA, 1989, BIOPOLYMERS, V28, P1367, DOI 10.1002/bip.360280803; FIEDLERNAGY C, 1982, J BIOL CHEM, V257, P9181; FLEISCHMAJER R, 1983, P NATL ACAD SCI-BIOL, V80, P3354, DOI 10.1073/pnas.80.11.3354; FLEISCHMAJER R, 1981, P NATL ACAD SCI-BIOL, V78, P7360, DOI 10.1073/pnas.78.12.7360; FLEISCHMAJER R, 1988, J HISTOCHEM CYTOCHEM, V36, P1425, DOI 10.1177/36.11.3049791; FLEISCHMAJER R, 1990, MATRIX, V4, P224; GELMAN RA, 1979, J BIOL CHEM, V254, P180; HOFMANN H, 1980, J MOL BIOL, V141, P293, DOI 10.1016/0022-2836(80)90182-5; HOJIMA Y, 1989, J BIOL CHEM, V264, P11336; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HOLBROOK KA, 1982, J INVEST DERMATOL, V79, pS7, DOI 10.1111/1523-1747.ep12544609; HOLMES DF, 1991, J MOL BIOL, V220, P111, DOI 10.1016/0022-2836(91)90385-J; HULMES DJS, 1983, COLLAGEN REL RES, V3, P317; HULMES DJS, 1989, J MOL BIOL, V210, P337, DOI 10.1016/0022-2836(89)90335-5; HULMES DJS, 1989, SPRINGER SERIES BIOP, V3, P81; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KADLER KE, 1988, J BIOL CHEM, V263, P10517; KADLER KE, 1990, ANN NY ACAD SCI, V580, P214, DOI 10.1111/j.1749-6632.1990.tb17930.x; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KADLER KE, 1990, BIOCHEM J, V268, P339, DOI 10.1042/bj2680339; KEENE DR, 1987, J CELL BIOL, V105, P2393, DOI 10.1083/jcb.105.5.2393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYAHARA M, 1982, J BIOL CHEM, V257, P8442; MIYAHARA M, 1983, COLLAGEN REL RES, V3, P279; MIYAHARA M, 1984, J BIOL CHEM, V259, P9891; MOORE WJ, 1972, PHYSICAL CHEM, P259; MOULD AP, 1990, J MOL BIOL, V211, P581, DOI 10.1016/0022-2836(90)90267-P; PARRY DAD, 1979, NATURE, V282, P213, DOI 10.1038/282213a0; PELTONEN L, 1980, P NATL ACAD SCI-BIOL, V77, P162, DOI 10.1073/pnas.77.1.162; PIERARD GE, 1986, COLLAGEN REL RES, V6, P481; POTSCHKA M, 1988, BIOCHEMISTRY-US, V27, P8481, DOI 10.1021/bi00422a028; ROMANIC AM, 1991, J BIOL CHEM, V266, P12703; TIMPL R, 1981, CLIN ORTHOP RELAT R, P224; VEIS A, 1973, P NATL ACAD SCI USA, V70, P1464, DOI 10.1073/pnas.70.5.1464; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0	41	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22265	22271						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331049				2022-12-27	WOS:A1992JW71900044
J	ALLISON, RG; CHACONAS, G				ALLISON, RG; CHACONAS, G			ROLE OF THE A PROTEIN-BINDING SITES IN THE INVITRO TRANSPOSITION OF MU-DNA - A COMPLEX CIRCUIT OF INTERACTIONS INVOLVING THE MU-ENDS AND THE TRANSPOSITIONAL ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; STRAND-TRANSFER-REACTION; BACTERIOPHAGE-MU; A-PROTEIN; B-PROTEIN; PHAGE-MU; RECOMBINATION; MECHANISM; REPRESSOR; CLEAVAGE	To investigate the role of the A protein-binding sites at the Mu ends in the DNA strand transfer reaction, we constructed mutant mini-Mu molecules in which these sites were deleted (L3 or R3) or substituted (L2 or R2) to conserve the spacing arrangements at the adjacent sites. The single site mutants are poor substrates for phosphodiester bond hydrolysis at the Mu ends in Type 1 reactions in the absence of Escherichia coli integration host factor (IHF). Addition of IHF to the reaction stimulates Type 1 cleavage more than 10 times for the DELTA-R3, DELTA-L3, S-L2 mutants and more than five times in the case of the S-R2 mutant under alternate conditions. The site of IHF stimulation resides within the transpositional enhancer which implicates the end-binding sites L2, L3, R2, and R3 in interactions with the enhancer. At least two of the L2, L3, and R3 sites are required for proficient reaction in the presence of IHF. By combining the single site mutants with O1 or O2 partially deleted enhancer elements, we have tentatively localized some of the interactions to each side of the functional enhancer revealing a complex circuit of end-enhancer interactions. The R3 site is suggested to be involved in interactions only with O2 and the L3 site only with O1. The data also suggest the possibility that L2 and R2 may be involved in interactions with both O1 and O2. Finally, our working model predicts that the L3-O1 and R3-O2 interactions may be required contacts for discriminating between the Mu left and right ends in transpososome formation.			ALLISON, RG (corresponding author), UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON N6A 5C1,ONTARIO,CANADA.							CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; GROENEN MAM, 1985, P NATL ACAD SCI USA, V82, P2087, DOI 10.1073/pnas.82.7.2087; GROENEN MAM, 1986, J MOL BIOL, V189, P597, DOI 10.1016/0022-2836(86)90490-0; HAFFTER P, 1988, EMBO J, V7, P3991, DOI 10.1002/j.1460-2075.1988.tb03287.x; HARSHEY RM, 1985, P NATL ACAD SCI USA, V82, P7676, DOI 10.1073/pnas.82.22.7676; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; HEINKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIGGINS NP, 1989, J BIOL CHEM, V264, P3035; JOHNSON RC, 1987, NATURE, V329, P462, DOI 10.1038/329462a0; KANAAR R, 1989, CELL, V58, P147, DOI 10.1016/0092-8674(89)90411-X; KIM S, 1992, SCIENCE, V256, P198, DOI 10.1126/science.1533056; KLIPPEL A, 1988, EMBO J, V7, P3983, DOI 10.1002/j.1460-2075.1988.tb03286.x; KRAUSE HM, 1986, J BIOL CHEM, V261, P3744; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; MIZUUCHI K, 1984, CELL, V39, P395, DOI 10.1016/0092-8674(84)90018-7; MIZUUCHI K, 1983, CELL, V35, P785, DOI 10.1016/0092-8674(83)90111-3; MIZUUCHI K, 1992, ANN REV BIOCH, V68, P1101; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SCHUMM JW, 1981, VIROLOGY, V114, P429, DOI 10.1016/0042-6822(81)90224-5; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; SURETTE MG, 1991, J BIOL CHEM, V266, P17306; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VOGEL JL, 1991, J BACTERIOL, V173, P6568, DOI 10.1128/jb.173.20.6568-6577.1991; ZOU A, 1991, J BIOL CHEM, V266, P20476	36	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19963	19970						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328189				2022-12-27	WOS:A1992JR85800037
J	CORBETT, AH; DEVORE, RF; OSHEROFF, N				CORBETT, AH; DEVORE, RF; OSHEROFF, N			EFFECT OF CASEIN KINASE-II-MEDIATED PHOSPHORYLATION ON THE CATALYTIC CYCLE OF TOPOISOMERASE-II - REGULATION OF ENZYME-ACTIVITY BY ENHANCEMENT OF ATP HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; DNA TOPOISOMERASE; DROSOPHILA-MELANOGASTER; MITOTIC CHROMOSOMES; PHORBOL ESTER; CELL-CYCLE; CLEAVAGE; PROLIFERATION; LOCALIZATION; RECOMBINATION	The catalytic activity of topoisomerase II is stimulated approximately 2-3-fold following phosphorylation by casein kinase II (Ackerman, P., Glover, C. V. C., and Osheroff, N. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 3164-3168). In order to delineate the mechanism by which the activity of the enzyme is enhanced, the effects of casein kinase II-mediated phosphorylation on the individual steps of the catalytic cycle of Drosophila topoisomerase II were characterized. Phosphorylation did not affect reaction steps that preceded hydrolysis of the enzyme's high energy ATP cofactor. This included enzyme-DNA binding, pre-strand passage DNA cleavage/religation, the double-stranded DNA passage event, and post-strand passage DNA cleavage/religation. In contrast, the rate of topoisomerase II-mediated ATP hydrolysis was stimulated 2.7-fold following phosphorylation by casein kinase II. Since ATP hydrolysis is a prerequisite for enzyme turnover, it is concluded that phosphorylation modulates the overall catalytic activity of topoisomerase II by stimulating the enzyme's ATPase activity.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,621 LIGHT HALL,NASHVILLE,TN 37232	Vanderbilt University			Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895	NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09582] Funding Source: Medline; NIDDK NIH HHS [DK43325] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ANDERSEN AH, 1991, J BIOL CHEM, V266, P9203; BAE YS, 1988, P NATL ACAD SCI USA, V85, P5497; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BODLEY AL, 1987, NATL CANCER I MONOGR, V4, P31; CHARTRAND P, 1991, DNA TOPOISOMERASES C, P240; CHOW KC, 1987, MOL CELL BIOL, V7, P3119, DOI 10.1128/MCB.7.9.3119; CORBETT AH, 1991, J BIOL CHEM, V266, P19666; CORBETT AH, 1992, J BIOL CHEM, V267, P683; CRESPI MD, 1988, EXP CELL RES, V175, P206, DOI 10.1016/0014-4827(88)90267-4; DEVORE RF, 1992, CANCER RES, V52, P2156; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DUGET M, 1983, NUCLEIC ACIDS RES, V11, P1059; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; GALE KC, 1990, BIOCHEMISTRY-US, V29, P9538, DOI 10.1021/bi00493a007; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GENOVESE JA, 1988, LIFE SCI, V43, P2137, DOI 10.1016/0024-3205(88)90364-5; GLOVER CVC, 1983, J BIOL CHEM, V258, P3259; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HECK MMS, 1989, J BIOL CHEM, V264, P15161; HIGGINS NP, 1982, NUCLEIC ACIDS RES, V10, P6833, DOI 10.1093/nar/10.21.6833; HOLDEN JA, 1990, BIOCHEMISTRY-US, V29, P2127, DOI 10.1021/bi00460a024; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HSIANG YH, 1988, CANCER RES, V48, P3230; HSIANG YH, 1989, MOL PHARMACOL, V36, P371; ISHIMI Y, 1992, J BIOL CHEM, V267, P462; KROLL DJ, 1991, J BIOL CHEM, V266, P7957; LIU LF, 1983, J BIOL CHEM, V258, P5365; MATTHES E, 1990, ANTIVIR RES, V13, P273, DOI 10.1016/0166-3542(90)90012-V; MILLER KG, 1981, J BIOL CHEM, V256, P9334; MISKIMINS R, 1983, EXP CELL RES, V146, P53, DOI 10.1016/0014-4827(83)90323-3; NELSON WG, 1987, CANCER RES, V47, P3246; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P6402, DOI 10.1021/bi00394a015; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; OSHEROFF N, 1983, MECHANISMS DNA REPLI, P55; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1057; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SAIJO M, 1990, BIOCHEMISTRY-US, V29, P583, DOI 10.1021/bi00454a036; SAIJO M, 1992, BIOCHEMISTRY-US, V31, P359, DOI 10.1021/bi00117a007; Sambrook J, 1989, MOL CLONING LABORATO; SANDER M, 1983, J BIOL CHEM, V258, P8421; SANDER M, 1984, P NATL ACAD SCI-BIOL, V81, P6938, DOI 10.1073/pnas.81.22.6938; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; SULLIVAN DM, 1987, CANCER RES, V47, P3973; SULLIVAN DM, 1987, NATL CANCER I MONOGR, V4, P73; SUTCLIFFE JA, 1989, ANTIMICROB AGENTS CH, V33, P2027, DOI 10.1128/AAC.33.12.2027; TAUDOU G, 1984, FEBS LETT, V176, P431, DOI 10.1016/0014-5793(84)81212-0; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WYCOFF E, 1989, J MOL BIOL, V205, P1; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	68	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20513	20518						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328202				2022-12-27	WOS:A1992JR85800118
J	ROSS, TS; WANG, FP; MAJERUS, PW				ROSS, TS; WANG, FP; MAJERUS, PW			MAMMALIAN-CELLS THAT EXPRESS BACILLUS-CEREUS PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE-C HAVE INCREASED LEVELS OF INOSITOL CYCLIC 1/2-PHOSPHATE, INOSITOL 1-PHOSPHATE, AND INOSITOL 2-PHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPHOSPHATE 1-PHOSPHATASE; HUMAN-PLATELETS; PHOSPHATE; 2-INOSITOLPHOSPHOHYDROLASE; SEQUENCE; THROMBIN; ENZYMES; CLONING; BRAIN; LI+	Phosphatidylinositol-specific phospholipase C (Ptd-Ins-PLC) of Bacillus cereus catalyzes the conversion of PtdIns to inositol cyclic 1:2-phosphate and diacylglycerol. NIH 3T3, Swiss mouse 3T3, CV-1, and Cos-7 cells were transfected with a cDNA encoding this enzyme, and the metabolic and cellular consequences were investigated. Overexpression of PtdIns-PLC enzyme activity was associated with elevated levels of inositol cyclic 1:2-phosphate (2.5-70-fold), inositol 1-phosphate (2-20-fold), and inositol 2-phosphate (3-20-fold). The increases correlated with the levels of enzyme expression obtained in each cell type. The turnover of phosphatidylinositol (PtdIns) was also increased in transfected CV-1 cells by 13-fold 20 h after transfection. The levels of PtdIns, phosphatidic acid, diacylglycerol, or other inositol phosphates were not detectably altered. Expression of bacterial PtdIns-PLC decreased rapidly after 20 h implying that either the increased PtdIns turnover or the accumulation of inositol phosphates was detrimental to cells and that by some adaptive mechanism enzyme expression was suppressed.			ROSS, TS (corresponding author), WASHINGTON UNIV, DIV HEMATOL ONCOL, ST LOUIS, MO 63130 USA.		wang, fang/GYD-4295-2022	Ross, Theodora/0000-0002-9166-1802	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R37HL016634, R01HL016634] Funding Source: NIH RePORTER; NHLBI NIH HHS [HLBI 14147, HLBI 16634] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CAMILLI A, 1991, J EXP MED, V173, P751, DOI 10.1084/jem.173.3.751; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; EISENBER.F, 1967, J BIOL CHEM, V242, P1375; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GRIFFITH OH, 1991, METHOD ENZYMOL, V197, P493; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; Ikezawa H, 1981, METHODS ENZYMOLOGY C, P731, DOI [10.1016/0076-6879(81)71086-3, DOI 10.1016/0076-6879(81)71086-3]; INHORN RC, 1987, J BIOL CHEM, V262, P15946; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUPPE A, 1989, J BACTERIOL, V171, P6077, DOI 10.1128/jb.171.11.6077-6083.1989; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; Low M G, 1981, Methods Enzymol, V71 Pt C, P741; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; RAGAN CI, 1988, BIOCHEM J, V249, P143, DOI 10.1042/bj2490143; ROSS TS, 1991, J BIOL CHEM, V266, P9086; ROSS TS, 1991, J BIOL CHEM, V266, P851; ROSS TS, 1992, J BIOL CHEM, V267, P19924; ROSS TS, 1986, J BIOL CHEM, V261, P1119; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAGUCHI R, 1978, ARCH BIOCHEM BIOPHYS, V186, P196, DOI 10.1016/0003-9861(78)90480-0; WILSON DB, 1985, J BIOL CHEM, V260, P1046; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; YORK JD, 1990, P NATL ACAD SCI USA, V87, P9548, DOI 10.1073/pnas.87.24.9548	28	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19919	19923						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328186				2022-12-27	WOS:A1992JR85800030
J	SOZZANI, S; AGWU, DE; MCCALL, CE; OFLAHERTY, JT; SCHMITT, JD; KENT, JD; MCPHAIL, LC				SOZZANI, S; AGWU, DE; MCCALL, CE; OFLAHERTY, JT; SCHMITT, JD; KENT, JD; MCPHAIL, LC			PROPRANOLOL, A PHOSPHATIDATE PHOSPHOHYDROLASE INHIBITOR, ALSO INHIBITS PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL RESPIRATORY BURST; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CHRONIC GRANULOMATOUS-DISEASE; PHOSPHOLIPASE-D ACTIVATION; PHORBOL-MYRISTATE ACETATE; HUMAN-PLATELETS; NADPH OXIDASE; PHOSPHATIDYLCHOLINE HYDROLYSIS; SIGNAL TRANSDUCTION; POTENT INHIBITOR	Propranolol, a beta-adrenergic receptor antagonist, also inhibits phosphatidate phosphohydrolase, the enzyme that converts phosphatidic acid into diacylglycerol. This latter effect has prompted recent use of propranolol in studies examining the importance of diacylglycerol and phosphatidic acid in cellular signalling events. Here, we show that propranolol is also an inhibitor of protein kinase C. At concentrations greater-than-or-equal-to 20 muM, propranolol reduced [H-3]phorbol dibutyrate binding (IC50 = 200 muM) and phorbol myristate acetate-stimulated superoxide anion release (IC50 = 130 muM) in human neutrophils. Scatchard analysis showed that propranolol lowers the number of phorbol diester binding sites without significantly affecting their affinity. In vitro kinetic analysis, performed in a mixed micellar assay with protein kinase C purified from human neutrophils, suggested a competitive inhibition of propranolol with the cofactor phosphatidylserine. Complex kinetic patterns were observed with respect to diacylglycerol and ATP, approximating competitive and noncompetitive inhibition, respectively. Taken together, these results suggest that the drug interacts at the level of the regulatory domain of the enzyme. Fifty % inhibition occurred at approximately 150 muM propranolol. Similar levels of inhibition were obtained using exogenous (histone) and endogenous (p47- phox, a NADPH oxidase component) substrates. Protein kinase C-alpha and protein kinase C-beta, two protein kinase C isozymes present in human neutrophils, were inhibited by propranolol in a comparable manner. In the range of concentrations tested (30-1000 muM), neither cAMP-dependent protein kinase nor neutrophil protein tyrosine kinases were affected. The racemic form of propranolol and the (+) and the (-) stereoisomers were equally active, and other beta-adrenergic receptor antagonists (pindolol) and agonists (isoproterenol) were inactive. This suggests that the inhibitory action of propranolol on protein kinase C is related to the amphipathic nature of the drug rather than to its beta-adrenergic receptor blocking ability. Analogs of propranolol were synthesized and found to be more potent protein kinase C inhibitors, with IC50 values in the 10-20 muM range. We conclude that the ability of propranolol to inhibit both protein kinase C and PA phosphohydrolase complicates interpretation of results when this drug is used in signal transduction studies. In addition, propranolol may be a useful prototype for the synthesis of new protein kinase C inhibitors.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT BIOCHEM, MED CTR BLVD, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT MED, INFECT DIS SECT, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center			Sozzani, Silvano/C-1447-2009; McPhail, Linda C/D-9505-2013	Sozzani, Silvano/0000-0002-3144-8743; McPhail, Linda C/0000-0002-8670-306X	NHLBI NIH HHS [HL-27799] Funding Source: Medline; NIAID NIH HHS [AI-09169, R01 AI022564, AI-22564] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL027799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI009169, R01AI009169, R01AI022564] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AGWU DE, 1989, J BIOL CHEM, V264, P1405; AMBRUSO DR, 1990, J BIOL CHEM, V265, P924; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERKOW RL, 1989, BIOCHIM BIOPHYS ACTA, V997, P292, DOI 10.1016/0167-4838(89)90200-8; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BISHOP WR, 1990, BIOCHEM J, V269, P465, DOI 10.1042/bj2690465; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CABOT MC, 1988, FEBS LETT, V233, P153, DOI 10.1016/0014-5793(88)81374-7; CALDWELL SE, 1988, J CLIN INVEST, V81, P1485, DOI 10.1172/JCI113480; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; DACHARYPRIGENT J, 1979, THROMB RES, V14, P15, DOI 10.1016/0049-3848(79)90020-3; DELLABIANCA V, 1991, BIOCHEM BIOPH RES CO, V177, P948, DOI 10.1016/0006-291X(91)90630-P; ENGLISH D, 1991, BLOOD, V77, P2746; ENGLISH D, 1991, BIOCHEM BIOPH RES CO, V175, P423, DOI 10.1016/0006-291X(91)91581-V; EXTON JH, 1990, J BIOL CHEM, V265, P1; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; GAY JC, 1991, BIOCHIM BIOPHYS ACTA, V1095, P236, DOI 10.1016/0167-4889(91)90105-7; GERARD C, 1986, J CLIN INVEST, V77, P61, DOI 10.1172/JCI112302; GROBECKER H, 1973, EUR J CLIN PHARMACOL, V5, P145, DOI 10.1007/BF00564894; HANNUN YA, 1988, J BIOL CHEM, V263, P5124; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, J BIOL CHEM, V264, P9960; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HARDY SJ, 1991, EUR J BIOCHEM, V198, P801, DOI 10.1111/j.1432-1033.1991.tb16084.x; HOLMSEN H, 1990, THROMB HAEMOSTASIS, V64, P307; HUANG KP, 1986, BIOCHEM BIOPH RES CO, V139, P320, DOI 10.1016/S0006-291X(86)80116-4; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KATOH N, 1981, P NATL ACAD SCI-BIOL, V78, P4813, DOI 10.1073/pnas.78.8.4813; KOUL O, 1987, ARCH BIOCHEM BIOPHYS, V253, P453, DOI 10.1016/0003-9861(87)90199-8; KRAMER IM, 1988, J BIOL CHEM, V263, P2352; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGSLET A, 1970, EUR J PHARMACOL, V13, P6, DOI 10.1016/0014-2999(70)90174-3; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; LEE MH, 1986, J BIOL CHEM, V261, P4867; LIN PY, 1991, BIOCHEM PHARMACOL, V41, P1941, DOI 10.1016/0006-2952(91)90134-Q; LIN PY, 1991, J IMMUNOL, V146, P1609; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; LOOMIS CR, 1988, J BIOL CHEM, V263, P1682; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; MCPHAIL LC, 1983, J CLIN INVEST, V72, P192, DOI 10.1172/JCI110957; METZ SA, 1991, BIOCHEM PHARMACOL, V41, pR1, DOI 10.1016/0006-2952(91)90470-P; MORI T, 1980, J BIOL CHEM, V255, P8378; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; MURRAY KT, 1990, J CLIN INVEST, V85, P836, DOI 10.1172/JCI114510; NAKADATE T, 1988, BIOCHEM PHARMACOL, V37, P1541, DOI 10.1016/0006-2952(88)90016-0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OFLAHERTY JT, 1990, J BIOL CHEM, V265, P9146; PIRES EMV, 1977, BIOCHEM J, V167, P137, DOI 10.1042/bj1670137; PONTREMOLI S, 1990, J BIOL CHEM, V265, P706; QIAN Z, 1990, J BIOL CHEM, V265, P3607; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; SCHATZMAN RC, 1981, BIOCHEM BIOPH RES CO, V98, P669, DOI 10.1016/0006-291X(81)91166-9; SHEARMAN MS, 1989, METHOD ENZYMOL, V168, P347; SMALLWOOD JI, 1992, J LEUKOCYTE BIOL, V51, P84, DOI 10.1002/jlb.51.1.84; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; STILES GL, 1984, PHYSIOL REV, V64, P661, DOI 10.1152/physrev.1984.64.2.661; THOMPSON NT, 1991, TRENDS PHARMACOL SCI, V12, P404, DOI 10.1016/0165-6147(91)90617-2; TURNER RS, 1985, PHOSPHOLIPIDS CELLUL, V2, P75; WISE BC, 1982, J BIOL CHEM, V257, P8489; WOLFSON M, 1985, J IMMUNOL, V135, P2057; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702	72	99	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20481	20488						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328200				2022-12-27	WOS:A1992JR85800113
J	TROYER, D; PADILLA, R; SMITH, T; KREISBERG, J; GLASS, W				TROYER, D; PADILLA, R; SMITH, T; KREISBERG, J; GLASS, W			STIMULATION OF THE THROMBIN RECEPTOR OF HUMAN GLOMERULAR MESANGIAL CELLS BY SER-PHE-LEU-LEU-ARG-ASN-PRO-ASN-ASP-LYS-TYR-GLU-PRO-PHE PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION; PHOSPHOINOSITIDES; PROLIFERATION; VASOPRESSIN; METABOLISM; ELEVATION; CLONING; SHAPE	We have studied the effects of thrombin (alpha-thrombin) and Ser-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-Glu-Pro-Phe (SFLL), a peptide agonist of the platelet thrombin receptor in cultured human mesangial cells, and find that SFLL can reproduce the biochemical and morphological effects of thrombin. Treatment of mesangial cells with cAMP-elevating agents causes fragmentation of stress fibers, loss of the vitronectin receptor from sites of focal adhesion, and produces a change in shape from a flat to a more arborized configuration. These effects are prevented by both thrombin and SFLL. Thrombin and SFLL also initiate biochemical signaling events in mesangial cells by stimulating the metabolism of phospholipids. Both thrombin and SFLL stimulate release of inositol phosphates from [H-3]inositol-labeled cells, elevation of cytosolic calcium, the formation of [H-3]myristic acid-labeled diacylglycerol, an increase in the mass of diacylglycerol, P-32 incorporation into phospholipids, and release of unesterified [H-3]arachidonic acid from cells prelabeled with [H-3]arachidonic acid. When present together, the effects of SFLL and thrombin on diacylglycerol formation, arachidonic acid production, and inositol phosphate production were not additive. This suggested that SFLL and thrombin were acting on the same receptor. This was further supported by our observations that cells pretreated with SFLL and subsequently exposed to thrombin (or vice versa) did not show elevated cytosolic calcium. We also show that phospholipase D is activated by demonstrating production of radiolabeled phosphatidylethanol when cells are treated with SFLL in the presence of ethanol. These findings indicate that SFLL can be used to study the receptor-mediated effects of thrombin in mesangial cells, thereby avoiding thrombin's proteolytic actions.	UNIV TEXAS,HLTH SCI CTR,DEPT PHYSIOL,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio	TROYER, D (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.				NCRR NIH HHS [RR 04194] Funding Source: Medline; NIDDK NIH HHS [DK 29787, DK 34234] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R23DK034234, R01DK029787, R01DK034234] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CARNEY DH, 1986, SEMIN THROMB HEMOST, V12, P231, DOI 10.1055/s-2007-1003559; GLASS WF, 1988, J CLIN INVEST, V82, P1992, DOI 10.1172/JCI113819; GLASS WF, 1991, AM J PHYSIOL, V261, pF336, DOI 10.1152/ajprenal.1991.261.2.F336; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; JAFFER F, 1989, AM J PATHOL, V135, P261; KREISBERG JI, 1985, AM J PHYSIOL, V249, pF227, DOI 10.1152/ajprenal.1985.249.2.F227; KREISBERG JI, 1986, AM J PHYSIOL, V251, pC505, DOI 10.1152/ajpcell.1986.251.4.C505; MYERS PR, 1989, AM J PHYSIOL, V257, pH603, DOI 10.1152/ajpheart.1989.257.2.H603; PAI JK, 1988, J BIOL CHEM, V263, P12472; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SCHER W, 1987, LAB INVEST, V57, P607; SCHULTZ PJ, 1989, AM J PHYSIOL, V257, pF366; SEUWEN K, 1989, BLOOD CELLS ARTERIES, P217; TROYER DA, 1985, AM J PHYSIOL, V249, pF139, DOI 10.1152/ajprenal.1985.249.1.F139; TROYER DA, 1987, J BIOL CHEM, V262, P1614; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; VANDONGEN CJ, 1985, ANAL BIOCHEM, V144, P104, DOI 10.1016/0003-2697(85)90090-9; VILLAMEDIANA LM, 1990, KIDNEY INT, V38, P956, DOI 10.1038/ki.1990.297; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WALZ DA, 1985, P SOC EXP BIOL MED, V180, P518	23	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20126	20131						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328194				2022-12-27	WOS:A1992JR85800061
J	VENEPALLY, P; CHEN, D; KEMPER, B				VENEPALLY, P; CHEN, D; KEMPER, B			TRANSCRIPTIONAL REGULATORY ELEMENTS FOR BASAL EXPRESSION OF CYTOCHROME P450IIC GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOBARBITAL-INDUCIBLE CYTOCHROME-P-450; CHLORAMPHENICOL ACETYLTRANSFERASE; INVITRO TRANSCRIPTION; MAMMALIAN-CELLS; MESSENGER-RNA; RAT-LIVER; SEQUENCE; PROMOTER; DNA; SUBFAMILY	To analyze the transcriptional regulatory elements in rabbit cytochrome P450IIC genes, varying lengths of the 5'-flanking regions of CYP2C1 and CYP2C2 were fused to a luciferase reporter gene. Promoter activity was assayed by transfection into HepG2 cells, a hepatic cell line, and monkey kidney COS-1 cells, a nonhepatic cell line. Activity of the CYP2C1 promoter in HepG2 cells increased slightly with progressive 5' deletions of the 5'-flanking region from nucleotide -3600 to - 1500 relative to the transcription start site. Additional deletions to -900, -358, and -116 each reduced activity by about 50%, and deletion of the sequence from -116 to -67 reduced activity by a factor of 12. Activity of the CYP2C2 promoter increased about 3-fold with progressive 5' deletions of sequence from nucleotide -3500 to -410. In contrast, deletions of sequences from -251 to -193 and from -133 to -64 reduced promoter activity by factors of 2 and 8, respectively. In COS-1 cells, the maximum activities of the CYP2C1 and CYP2C2 promoters normalized to a Rous sarcoma viral promoter were about 10-20% of that in the HepG2 cells. The changes in activity between different constructions in COS-1 cells largely paralleled those in the HepG2 cells except for deletions of the sequences -133 to -64 and -116 to -67 for CYP2C1 and CYP2C2, respectively, which produced the largest reduction of promoter activity in HepG2 cells but had little effect in COS-1 cells. These results show that HepG2-specific regulatory elements are present in the regions between -120 and -65 in both genes. Nuclear proteins from HepG2 cells, but not from COS-1 cells, bound to sequences within these regions, and the binding was inhibited by an oligonucleotide containing a sequence conserved in rabbit P450IIC genes which has been designated the HepG2-specific P450 2C factor-1 (HPF1) motif. Mutation of this sequence eliminated the binding of nuclear proteins and reduced transcriptional activity 25-fold. The HPF1 binding sequence is conserved in CYP2A, CYP2C, and CYP2D genes and resembles the binding motif for hepatic nuclear factor-4. These results demonstrate that CYP2C1 and CYP2C2 contain several potential regulatory elements for basal expression, including one HepG2-specific sequence that may be important for liver expression.	UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,524 BURRILL HALL,407 S GOODWIN AVE,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039360] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39360] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHAN G, 1990, BIOCHEMISTRY-US, V29, P3743, DOI 10.1021/bi00467a021; CRABB DW, 1987, ANAL BIOCHEM, V163, P88, DOI 10.1016/0003-2697(87)90096-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FUJIIKURIYAMA Y, 1982, P NATL ACAD SCI USA, V79, P8122; GED C, 1991, BIOCHIM BIOPHYS ACTA, V1088, P433, DOI 10.1016/0167-4781(91)90138-C; GONZALEZ FJ, 1990, PHARMACOL THERAPEUT, V45, P1, DOI 10.1016/0163-7258(90)90006-N; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOVIND S, 1986, DNA-J MOLEC CELL BIO, V5, P371, DOI 10.1089/dna.1986.5.371; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAHN CN, 1991, J BIOL CHEM, V266, P17031; HE JS, 1991, J BIOL CHEM, V266, P7864; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JAISWAL AK, 1990, NUCLEIC ACIDS RES, V18, P4237, DOI 10.1093/nar/18.14.4237; KIM J, 1991, BIOCHEMISTRY-US, V30, P10287, DOI 10.1021/bi00106a029; KIMURA S, 1989, AM J HUM GENET, V45, P889; KOOP DR, 1990, BIOESSAYS, V12, P429, DOI 10.1002/bies.950120906; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LEIGHTON JK, 1984, J BIOL CHEM, V259, P1165; MATSUNAGA E, 1990, J MOL EVOL, V30, P155, DOI 10.1007/BF02099942; MATSUNAGA T, 1990, BIOCHEMISTRY-US, V29, P1329, DOI 10.1021/bi00457a032; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MIZUKAMI Y, 1983, P NATL ACAD SCI-BIOL, V80, P3958, DOI 10.1073/pnas.80.13.3958; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; PENDURTHI UR, 1990, J BIOL CHEM, V265, P14662; PROTTER AA, 1984, DNA-J MOLEC CELL BIO, V3, P449, DOI 10.1089/dna.1.1984.3.449; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; RANGARAJAN PN, 1989, P NATL ACAD SCI USA, V86, P3963, DOI 10.1073/pnas.86.11.3963; RAO MV, 1990, J BIOL CHEM, V265, P5617; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SIMPSON FM, 1990, GENE DEV, V70, pC25; TUKEY RH, 1985, J BIOL CHEM, V260, P3347; UENO T, 1990, MOL CELL BIOL, V10, P4495, DOI 10.1128/MCB.10.9.4495; UENO T, 1990, NUCLEIC ACIDS RES, V18, P4623, DOI 10.1093/nar/18.15.4623; UMENO M, 1988, BIOCHEMISTRY-US, V27, P9006, DOI 10.1021/bi00425a019; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; WONG G, 1989, J BIOL CHEM, V264, P2920; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YOSHIOKA H, 1990, J BIOL CHEM, V265, P14612; ZAPHIROPOULOS PG, 1990, DNA CELL BIOL, V9, P49, DOI 10.1089/dna.1990.9.49; ZHAO J, 1987, BIOCHEM BIOPH RES CO, V146, P224, DOI 10.1016/0006-291X(87)90714-5; ZHAO J, 1990, DNA CELL BIOL, V9, P37, DOI 10.1089/dna.1990.9.37	48	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17333	17338						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324931				2022-12-27	WOS:A1992JL05300090
J	HATCH, GM; JAMIL, H; UTAL, AK; VANCE, DE				HATCH, GM; JAMIL, H; UTAL, AK; VANCE, DE			ON THE MECHANISM OF THE OKADAIC ACID-INDUCED INHIBITION OF PHOSPHATIDYLCHOLINE BIOSYNTHESIS IN ISOLATED RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; HELA-CELLS; FATTY-ACIDS; PROTEIN PHOSPHATASES; PHOSPHORYLATION; LIVER; TRANSLOCATION; DIACYLGLYCEROL; CYTOSOL; CYTIDYLTRANSFERASE	The mechanism of inhibition of phosphatidylcholine biosynthesis by okadaic acid was investigated in suspension cultures of isolated rat hepatocytes. Cells were pulsed with [methyl-H-3]choline and chased in the absence or presence of 1-mu-M okadaic acid for up to 120 min. Phosphatidylcholine biosynthesis was inhibited after 15 min of chase. To see if okadaic acid altered the degree of phosphorylation of cytidylyltransferase (CT), hepatocytes were incubated with P-32(i) and chased in the absence or presence of okadaic acid. Okadaic acid caused a rapid (within 15 min) increase in the phosphorylation state of the cytosolic enzyme. Two-dimensional peptide map analysis revealed an increase in the phosphorylation of several peptides in okadaic acid-treated hepatocytes compared with controls. After 15 min of incubation of hepatocytes with okadaic acid, membrane CT activity was decreased and a corresponding increase in cytosolic CT activity was observed. In hepatocytes incubated with okadaic acid and oleate a correlation between membrane CT activity, diacylglycerol level, and phosphatidylcholine biosynthesis was observed. These data suggest that the concentration of diacylglycerol is responsible for the increase in membrane CT activity and subsequently phosphatidylcholine biosynthesis in oleate-treated cells. We postulate that the okadaic acid-induced decrease in phosphatidylcholine biosynthesis is due to an increase in the phosphorylation state of CT which promotes a translocation of CT activity from the membranes to the cytosol.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,328 HERITAGE MED RES CTR,EDMONTON T6G 2S2,ALBERTA,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 252,ALBERTA,CANADA	University of Alberta; University of Alberta								BAISTED DJ, 1988, BIOCHEM J, V253, P693, DOI 10.1042/bj2530693; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOY PC, 1979, CAN J BIOCHEM CELL B, V57, P605, DOI 10.1139/o79-076; COHEN P, 1989, J BIOL CHEM, V264, P21435; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P37, DOI 10.1016/0005-2760(87)90215-3; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5881, DOI 10.1021/bi00238a011; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5873, DOI 10.1021/bi00238a010; DAVIS RA, 1979, J BIOL CHEM, V254, P2010; GOMEZMUNOZ A, 1992, FEBS LETT, V301, P103, DOI 10.1016/0014-5793(92)80219-7; HATCH GM, 1990, BIOCHIM BIOPHYS ACTA, V1042, P374, DOI 10.1016/0005-2760(90)90167-V; HATCH GM, 1991, BIOCHIM BIOPHYS ACTA, V1081, P25, DOI 10.1016/0005-2760(91)90245-D; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; JAMIL H, 1992, J BIOL CHEM, V267, P1752; JAMIL H, 1987, J BIOL CHEM, V262, P630; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; LIM P, 1986, BIOCHEM CELL BIOL, V64, P692, DOI 10.1139/o86-095; PADDON HB, 1977, BIOCHIM BIOPHYS ACTA, V448, P181; PELECH SL, 1982, J BIOL CHEM, V257, P4198; PELECH SL, 1983, J BIOL CHEM, V258, P6782; PELECH SL, 1983, BIOCHEM J, V216, P129, DOI 10.1042/bj2160129; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; UTAL AK, 1991, J BIOL CHEM, V266, P24084; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VANCE JE, 1988, J BIOL CHEM, V263, P5898; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WEINHOLD PA, 1984, J BIOL CHEM, V259, P315; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374	30	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15751	15758						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322404				2022-12-27	WOS:A1992JG11300076
J	MORHAM, SG; SHUMAN, S				MORHAM, SG; SHUMAN, S			COVALENT AND NONCOVALENT DNA-BINDING BY MUTANTS OF VACCINIA DNA TOPOISOMERSE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICKING-CLOSING ENZYME; ACTIVE-SITE TYROSINE; ESCHERICHIA-COLI; CAMPTOTHECIN; CLEAVAGE; IDENTIFICATION; SEQUENCE; COMPLEX	Analysis of vaccinia topoisomerase mutants that are impaired in DNA relaxation has allowed the identification of amino acid residues required for the transesterification step of catalysis. Missense mutations of wild-type residues Gly-132 --> Asp and Arg-223 --> Gln rendered the protein inert in formation of the covalent enzyme-DNA complex and hence completely inactive in DNA relaxation. Mutations of Thr-147 --> Ile and Gly-132 --> Ser caused severe defects in covalent adduct formation that correlated with the extent of inhibition of relaxation. None of these point mutations had an effect on noncovalent DNA binding sufficient to account for the defect in relaxation. Deletion of amino- or carboxyl-terminal portions of the polypeptide abrogated noncovalent DNA binding. Two distinct topoisomerase-DNA complexes were resolved by native gel electrophoresis. One complex, which was unique to those proteins competent in covalent adduct formation, contained topoisomerase bound to the 5'-portion of the incised DNA strand. The 3'-segment of the cleaved strand had dissociated spontaneously. This complex was isolated and shown to catalyze transfer of the covalently bound DNA to a heterologous acceptor oligonucleotide, thereby proving that the covalent adduct between protein and duplex DNA is a true intermediate in strand breakage and reunion. The role of the active site region of eukaryotic topoisomerase in determining sensitivity or resistance to camptothecin was examined by converting the active site region of the resistant vaccinia enzyme (SKRAY274) to that of the drug-sensitive yeast enzyme (SKINY). The SKINY mutation did not alter the resistance of the vaccinia enzyme to the cleavage-enhancing effects of camptothecin.	CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Cornell University	MORHAM, SG (corresponding author), SLOAN KETTERING MEM CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046330, R37GM046330] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46330] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJORNSTI MA, 1987, P NATL ACAD SCI USA, V84, P8971, DOI 10.1073/pnas.84.24.8971; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAMPOUX JJ, 1981, J BIOL CHEM, V256, P4805; HERTZBERG RP, 1990, J BIOL CHEM, V265, P19287; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MCCONAUGHY BL, 1981, BIOCHIM BIOPHYS ACTA, V655, P1, DOI 10.1016/0005-2787(81)90059-9; MORHAM SG, 1990, GENE DEV, V4, P515, DOI 10.1101/gad.4.4.515; SHAFFER R, 1987, J BIOL CHEM, V262, P9309; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1991, P NATL ACAD SCI USA, V88, P10104, DOI 10.1073/pnas.88.22.10104; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; TAMURA H, 1991, NUCLEIC ACIDS RES, V19, P69, DOI 10.1093/nar/19.1.69	19	59	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15984	15992						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322412				2022-12-27	WOS:A1992JG11300108
J	AROETI, B; GUTMAN, O; HENIS, YI				AROETI, B; GUTMAN, O; HENIS, YI			TRANSIENT ALTERATIONS IN THE LATERAL MOBILITY OF ERYTHROCYTE-MEMBRANE COMPONENTS DURING SENDAI VIRUS-MEDIATED FUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE PHOTOBLEACHING RECOVERY; TRANSBILAYER PHOSPHOLIPID DISTRIBUTION; CELL-FUSION; PLASMA-MEMBRANE; ENVELOPED VIRUSES; MAMMALIAN-CELLS; ANIMAL-CELLS; RED-CELLS; PROTEIN; GLYCOPROTEINS	Destabilization of the target membrane structure by fusion-promoting viral glycoproteins is assumed to be an essential part of the fusion mechanism. To explore this possibility, we employed fluorescence photo-bleaching recovery to investigate changes in the lateral mobility of native membrane constituents in human red blood cells (RBCs) during the course of Sendai virus-mediated fusion. The mobile fraction of RBC membrane proteins labeled with 5-(4,6-dichloro-5-triazin-2-yl) aminofluorescein increased significantly in the course of fusion, relaxing back to the original values upon completion of the fusion process. A different effect was observed on the lateral mobility of a fluorescent lipid probe, N-(7-nitro-2,1,3-benzoxadiazol-4-yl) phosphatidylethanolamine, incorporated initially into the external monolayer. In this case, the lateral diffusion coefficient (rather than the mobile fraction) increased during fusion; this increase was permanent in the absence of Mg-ATP and transient in its presence. An active viral fusion protein was required to mediate the effects on both protein and lipid mobility. These effects, which take place on the same time scale as that of the fusion process, suggest that the organization of the RBC membrane is perturbed during fusion and that the observed changes may be related to the fusion mechanism.	TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT BIOCHEM, IL-69978 TEL AVIV, ISRAEL	Tel Aviv University				Henis, Yoav/0000-0002-1408-3877				AROETI B, 1991, J BIOL CHEM, V266, P15845; AROETI B, 1990, BIOCHEMISTRY-US, V29, P9119, DOI 10.1021/bi00491a004; AROETI B, 1988, BIOCHEMISTRY-US, V27, P5654, DOI 10.1021/bi00415a039; AROETI B, 1986, EXP CELL RES, V162, P243, DOI 10.1016/0014-4827(86)90442-8; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BASHFORD CL, 1988, STUD BIOPHYS, V127, P155; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BENTZ J, 1991, ADV MEMBRANE FLUIDIT, V5, P259; CHERRY RJ, 1976, NATURE, V263, P389, DOI 10.1038/263389a0; CHOPPIN PW, 1980, REV INFECT DIS, V2, P40; CITOVSKY V, 1987, BIOCHEMISTRY-US, V26, P3856, DOI 10.1021/bi00387a018; CITOVSKY V, 1986, EXP CELL RES, V166, P279, DOI 10.1016/0014-4827(86)90477-5; CITOVSKY V, 1985, J BIOL CHEM, V260, P2072; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; CONNOR J, 1987, BIOCHEMISTRY-US, V26, P5099, DOI 10.1021/bi00390a031; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; GITMAN AG, 1984, J BIOL CHEM, V259, P9813; GOLAN DE, 1980, P NATL ACAD SCI-BIOL, V77, P2537, DOI 10.1073/pnas.77.5.2537; HENIS YI, 1982, J BIOL CHEM, V257, P1407; HENIS YI, 1985, EXP CELL RES, V160, P514, DOI 10.1016/0014-4827(85)90198-3; HENIS YI, 1989, J BIOL CHEM, V264, P17119; HENIS YI, 1983, BIOCHIM BIOPHYS ACTA, V762, P281, DOI 10.1016/0167-4889(83)90082-4; HERRMANN A, 1990, BIOCHEMISTRY-US, V29, P4054, DOI 10.1021/bi00469a005; HOEKSTRA D, 1989, BIOSCIENCE REP, V9, P273, DOI 10.1007/BF01114682; HSU M, 1982, P NATL ACAD SCI-BIOL, V79, P5862, DOI 10.1073/pnas.79.19.5862; KIM J, 1981, EXP CELL RES, V132, P125, DOI 10.1016/0014-4827(81)90089-6; KNUTTON S, 1978, MICRON, V9, P133, DOI 10.1016/0047-7206(78)90004-3; KOPPEL DE, 1981, NATURE, V293, P159, DOI 10.1038/293159a0; KOPPEL DE, 1976, BIOPHYS J, V16, P1315, DOI 10.1016/S0006-3495(76)85776-1; LYLES DS, 1977, P NATL ACAD SCI USA, V74, P1918, DOI 10.1073/pnas.74.5.1918; LYLES DS, 1978, VIROLOGY, V88, P25, DOI 10.1016/0042-6822(78)90106-X; MAEDA T, 1979, EXP CELL RES, V123, P333, DOI 10.1016/0014-4827(79)90475-0; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MARTIN OC, 1987, J BIOL CHEM, V262, P5890; MIURA N, 1982, EXP CELL RES, V141, P409, DOI 10.1016/0014-4827(82)90229-4; MORROT G, 1986, P NATL ACAD SCI USA, V83, P6863, DOI 10.1073/pnas.83.18.6863; NAKANISHI M, 1982, EXP CELL RES, V142, P95, DOI 10.1016/0014-4827(82)90413-X; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; OZAWA M, 1979, VIROLOGY, V99, P197, DOI 10.1016/0042-6822(79)90055-2; PAGANO RE, 1985, SCIENCE, V229, P1051, DOI 10.1126/science.4035344; PERETZ H, 1974, J CELL BIOL, V63, P1, DOI 10.1083/jcb.63.1.1; PETERSEN NO, 1986, HDB EXPT IMMUNOLOGY; Poste G., 1978, CELL SURF REV, V5, P305; RIMON G, 1984, BIOCHIM BIOPHYS ACTA, V775, P283, DOI 10.1016/0005-2736(84)90182-2; ROOS DS, 1983, J CELL BIOL, V97, P909, DOI 10.1083/jcb.97.3.909; ROSENTHAL KS, 1988, BIOCHIM BIOPHYS ACTA, V942, P38, DOI 10.1016/0005-2736(88)90272-6; ROSENTHAL KS, 1984, J VIROL, V49, P980, DOI 10.1128/JVI.49.3.980-983.1984; SCHINDLER M, 1980, P NATL ACAD SCI-BIOL, V77, P1457, DOI 10.1073/pnas.77.3.1457; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; SEKIGUCHI K, 1978, P NATL ACAD SCI USA, V75, P1740, DOI 10.1073/pnas.75.4.1740; SHEETZ MP, 1980, NATURE, V285, P510, DOI 10.1038/285510a0; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; SLEIGHT RG, 1985, J BIOL CHEM, V260, P1146; Steck T L, 1974, Methods Enzymol, V31, P172; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STRUCK DK, 1980, J BIOL CHEM, V255, P5404; TANAKA KI, 1976, BIOCHIM BIOPHYS ACTA, V426, P218, DOI 10.1016/0005-2736(76)90333-3; TULLIUS EK, 1989, BIOSCIENCE REP, V9, P623, DOI 10.1007/BF01119806; VOLSKY DJ, 1978, BIOCHIM BIOPHYS ACTA, V514, P213, DOI 10.1016/0005-2736(78)90293-6; VOLSKY DJ, 1978, J CELL BIOL, V78, P465, DOI 10.1083/jcb.78.2.465; WHITE J, 1983, Q REV BIOPHYS, V16, P151, DOI 10.1017/S0033583500005072; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WOLF DE, 1980, P NATL ACAD SCI-BIOL, V77, P2043, DOI 10.1073/pnas.77.4.2043	65	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13272	13277						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320013				2022-12-27	WOS:A1992JB74600031
J	STEINBECK, MJ; KHAN, AU; KARNOVSKY, MJ				STEINBECK, MJ; KHAN, AU; KARNOVSKY, MJ			INTRACELLULAR SINGLET OXYGEN GENERATION BY PHAGOCYTOSING NEUTROPHILS IN RESPONSE TO PARTICLES COATED WITH A CHEMICAL TRAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ANTIMICROBIAL SYSTEM; BIOLOGICAL DEFENSE-MECHANISMS; EXTRACELLULAR-MATRIX PROTEINS; MOLECULAR-OXYGEN; SUPEROXIDE ANION; POLYMORPHONUCLEAR LEUKOCYTE; BACTERICIDAL ACTIVITY; RESPIRATORY BURST; CHLORINATING ACTIVITY; HUMAN MYELOPEROXIDASE	To determine if singlet oxygen (O2(1-DELTA(g))) is produced by neutrophils (PMNs) during the process of phagocytosis, glass beads were coated with a specific chemical trap for O2(1-DELTA(g)), 9,10-diphenylanthracene (DPA). Singlet oxygen, but not other reactive oxygen species, reacts rapidly with DPA at a rate of k(r) = 1.3 x 10(6) M-1 s-1 to form a stable product, DPA-endoperoxide (Corey, E. J., and Taylor, W. C. (1964) J. Am. Chem. Soc. 86, 3881-3882; Wasserman, H. H., Scheffer, J. R., and Cooper, J. L. (1972) J. Am. Chem. Soc. 94, 4991-4996; Turro, N. J., Chow, M.-F., and Rigaudy, J. (1981) J. Am. Chem. Soc. 103, 7218-7224). The production of DPA-endoperoxide was determined by ultraviolet spectroscopy as a decrease in DPA absorbance at 355 nm. The absorbance of DPA was normalized to the absorbance of perylene, which was included in the coating on the beads as a nonreactive, internal standard. In the present study, DPA- and perylene-coated beads were initially allowed to adhere to fibro-nectin-coated coverslips. PMNs were then added to the bead-coated coverslips and allowed to adhere and phagocytose the beads for 1 h at 37-degrees-C. In some experiments, 4B-phorbol-12-myristate-13-acetate (PMA) (1 ng/2.5 x 10(7) cells/ml), a known activator of the PMN NADPH-oxidase, was added as a co-stimulant. The amount of O2(1-DELTA(g)) produced by phagocytically stimulated PMNs was calculated to be 11.3 +/- 4.9 nmol of O2(1-DELTA(g)/1.25 x 10(6) cells. Low dose PMA co-stimulation increased the production Of O2(1-DELTA(g)) to 14.1 +/- 4.1 nmol/1.25 x 10(6) cells. Averaged together these amounts represent approximately 19 +/- 5.0% of the total oxygen consumed by PMNs in response to DPA- and perylenecoated beads. The specificity of the DPA reaction with O2(1-DELTA(g)) was confirmed by warming to 120-degrees-C, which releaseS O2(1-DELTA(g)) from the DPA-endoperoxide, regenerating the parent DPA compound (Wasserman et al., 1972; Turro et al., 1981) and the absorbance at 355 nm. In addition, beta-carotene, an avid quencher of O2(1-DELTA(g)) was included in the coating of some bead preparations; assays in which these beads were used showed no change in the absorbance at 355 nm. Singlet oxygen production by myeloperoxidase was also measured using the coated bead assay and the results suggest that this is a major pathway by which singlet oxygen is generated in phagocytically stimulated PMNs. The formation of O2(1-DELTA(g)) by PMNs has been suggested by others; however, previous methods for O2(1-DELTA(g)) detection have either been nonspecific, insensitive, or incapable of measuring the intracellular production Of O2(1-DELTA(g)). With the use of DPA- and perylene-coated beads, we have developed a specific and sensitive method for the intracellular detection of O2(1-DELTA(g)) and have demonstrated that O2(1-DELTA(G)) is produced during the process of phagocytosis.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University	STEINBECK, MJ (corresponding author), HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008507] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-08507] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Agner K., 1941, ACTA PHYSIOL SCAND, V2, P1; ALLEN RC, 1975, BIOCHEM BIOPH RES CO, V63, P675, DOI 10.1016/S0006-291X(75)80437-2; ALLEN RC, 1972, BIOCHEM BIOPH RES CO, V47, P679, DOI 10.1016/0006-291X(72)90545-1; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BABIOR GL, 1981, J CLIN INVEST, V67, P1724, DOI 10.1172/JCI110210; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BAINTON DF, 1968, J CELL BIOL, V39, P299, DOI 10.1083/jcb.39.2.299; BROWNE RJ, 1965, CAN J CHEMISTRY, V43, P2915, DOI 10.1139/v65-402; CECH P, 1984, BLOOD, V63, P88; CLARK RA, 1987, J BIOL CHEM, V262, P4065; COREY EJ, 1987, BIOCHEM BIOPH RES CO, V145, P842, DOI 10.1016/0006-291X(87)91041-2; COREY EJ, 1964, J AM CHEM SOC, V86, P3881, DOI 10.1021/ja01072a062; CURNUTTE JT, 1974, J CLIN INVEST, V53, P1662, DOI 10.1172/JCI107717; DEPIERRE JW, 1974, J BIOL CHEM, V249, P7111; Dewald B, 1986, Methods Enzymol, V132, P267; FOOTE CS, 1968, J AM CHEM SOC, V90, P6233, DOI 10.1021/ja01024a061; FOOTE CS, 1964, J AM CHEM SOC, V86, P3879, DOI 10.1021/ja01072a060; FOOTE CS, 1970, J AM CHEM SOC, V92, P5216, DOI 10.1021/ja00720a036; FOOTE CS, 1981, BIOLUMINESCENCE CHEM, P81; GOLDSTEIN IM, 1977, J CLIN INVEST, V59, P249, DOI 10.1172/JCI108635; GREEN TR, 1980, BIOCHEM BIOPH RES CO, V94, P262, DOI 10.1016/S0006-291X(80)80215-4; GUIRAUD HJ, 1976, J AM CHEM SOC, V98, P1984, DOI 10.1021/ja00423a066; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HARRISON JE, 1978, FEBS LETT, V92, P327, DOI 10.1016/0014-5793(78)80780-7; HELD AM, 1978, J AM CHEM SOC, V100, P5732, DOI 10.1021/ja00486a025; HERRMANN M, 1990, J CLIN INVEST, V86, P942, DOI 10.1172/JCI114796; HODGSON EK, 1974, BIOCHEMISTRY-US, V13, P3811, DOI 10.1021/bi00715a030; HOLMES B, 1967, J CLIN INVEST, V46, P1422, DOI 10.1172/JCI105634; IYER GYN, 1963, CAN J BIOCHEM PHYS, V41, P427; KANOFSKY JR, 1989, CHEM-BIOL INTERACT, V70, P1, DOI 10.1016/0009-2797(89)90059-8; KANOFSKY JR, 1984, J CLIN INVEST, V74, P1489, DOI 10.1172/JCI111562; KANOFSKY JR, 1988, J BIOL CHEM, V263, P9692; KETTLE AJ, 1989, BIOCHEM J, V263, P823, DOI 10.1042/bj2630823; KHAN AU, 1981, J AM CHEM SOC, V103, P6516, DOI 10.1021/ja00411a051; KHAN AU, 1977, J AM CHEM SOC, V99, P370, DOI 10.1021/ja00444a010; KHAN AU, 1963, J CHEM PHYS, V39, P2105, DOI 10.1063/1.1734588; KHAN AU, 1970, J AM CHEM SOC, V92, P3293, DOI 10.1021/ja00714a010; KHAN AU, 1991, INT J QUANTUM CHEM, V39, P251, DOI 10.1002/qua.560390305; KHAN AU, 1978, PHOTOCHEM PHOTOBIOL, V28, P615, DOI 10.1111/j.1751-1097.1978.tb06980.x; KHAN AU, 1979, P NATL ACAD SCI USA, V76, P6047, DOI 10.1073/pnas.76.12.6047; KHAN AU, 1970, SCIENCE, V168, P476, DOI 10.1126/science.168.3930.476; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; KOO JY, 1978, J AM CHEM SOC, V100, P4496, DOI 10.1021/ja00482a030; KRINSKY NI, 1974, SCIENCE, V186, P363, DOI 10.1126/science.186.4161.363; KULIG MJ, 1973, J ORG CHEM, V38, P3639, DOI 10.1021/jo00960a050; MAKINO R, 1986, J BIOL CHEM, V261, P1444; MATHEWSROTH MM, 1970, PHOTOCHEM PHOTOBIOL, V11, P555, DOI 10.1111/j.1751-1097.1970.tb06027.x; MERKEL PB, 1972, J AM CHEM SOC, V94, P7244, DOI 10.1021/ja00776a003; MISRA HP, 1976, ANAL BIOCHEM, V70, P632, DOI 10.1016/0003-2697(76)90492-9; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NILSSON R, 1974, J PHYS CHEM-US, V78, P1681, DOI 10.1021/j100610a001; PAUL B, 1968, BIOCHIM BIOPHYS ACTA, V156, P168, DOI 10.1016/0304-4165(68)90116-5; QUIE PG, 1967, J CLIN INVEST, V46, P668, DOI 10.1172/JCI105568; ROSEN H, 1977, J BIOL CHEM, V252, P4803; ROSEN H, 1979, J EXP MED, V149, P27, DOI 10.1084/jem.149.1.27; ROSENTHAL I, 1975, ISRAEL J CHEM, V13, P86; ROSSI F, 1964, EXPERIENTIA, V20, P21, DOI 10.1007/BF02146019; SCHENCK GO, 1957, LIEBIGS ANN CHEM, V603, P46; SEGAL AW, 1981, J CELL BIOL, V85, P42; TAKAYAMA K, 1977, BIOCH BIOCH RES COMM, V5, P1052; TAUBER AI, 1977, J CLIN INVEST, V60, P374, DOI 10.1172/JCI108786; TURRO NJ, 1981, J AM CHEM SOC, V103, P7218, DOI 10.1021/ja00414a029; VAUDAUX PE, 1984, INFECT IMMUN, V45, P768, DOI 10.1128/IAI.45.3.768-774.1984; WASSERMA.HH, 1972, J AM CHEM SOC, V94, P4991, DOI 10.1021/ja00769a034; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; Wilson T, 1970, Photophysiology, V5, P49; ZUURBIER KWM, 1990, BIOCHIM BIOPHYS ACTA, V1037, P140, DOI 10.1016/0167-4838(90)90159-D	68	238	249	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13425	13433						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320020				2022-12-27	WOS:A1992JB74600053
J	SAMUELS, DS; SHIMIZU, N				SAMUELS, DS; SHIMIZU, N			DNA TOPOISOMERASE-I PHOSPHORYLATION IN MURINE FIBROBLASTS TREATED WITH 12-O-TETRADECANOYLPHORBOL-13-ACETATE AND INVITRO BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTING PHORBOL ESTERS; SCLERODERMA PATIENTS; SIGNAL-TRANSDUCTION; GENETIC-EVIDENCE; TUMOR PROMOTERS; HEPATOMA-CELLS; NIH-3T3 CELLS; CALF THYMUS; LAMIN-B; ACTIVATION	The phosphorylation of DNA topoisomerase I in quiescent murine 3T3-L1 fibroblasts treated with the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) was characterized by in vivo labeling with [P-32] orthophosphate and immunoprecipitation with a scleroderma anti-DNA topoisomerase I autoantibody. DNA topoisomerase I phosphorylation was stimulated 4-fold by 2 h of TPA treatment (TPA at 100 ng/ml maximally enhanced phosphorylation). Purified DNA topoisomerase I was phosphorylated in vitro in a Ca2+ and phospholipid-dependent fashion by types I, II, and III protein kinase C. The phosphorylation reaction was stimulated by TPA and had an apparent K(m) of 0.4-mu-M. DNA topoisomerase I was phosphorylated in vivo and in vitro predominantly at serine. The major tryptic phosphopeptides from DNA topoisomerase I in TPA-treated fibroblasts and phosphorylated by protein kinase C comigrated in thin-layer electrophoresis. The half-life of incorporated phosphate on DNA topoisomerase I was 40 min in both TPA-treated and control cells. These results suggest that phosphorylation is a mechanism for activating DNA topoisomerase I in fibroblasts treated with TPA and that protein kinase C functions in the phosphorylation.	UNIV ARIZONA,DEPT MOLEC & CELLULAR BIOL,TUCSON,AZ 85721; KEIO UNIV,SCH MED,DEPT MOLEC BIOL,SHINJUKU KU,TOKYO 160,JAPAN	University of Arizona; Keio University			Samuels, D Scott/B-7549-2012	Samuels, D Scott/0000-0001-8352-7593	NCI NIH HHS [CA-09213] Funding Source: Medline; NIGMS NIH HHS [GM-24375] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009213] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024375] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BUTLER AP, 1986, J BIOL CHEM, V261, P9421; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CODERONI S, 1990, MOL BIOL REP, V14, P35, DOI 10.1007/BF00422713; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; DURBAN E, 1985, EMBO J, V4, P2921, DOI 10.1002/j.1460-2075.1985.tb04024.x; DURBAN E, 1983, BIOCHEM BIOPH RES CO, V111, P897, DOI 10.1016/0006-291X(83)91384-0; FERRO AM, 1983, J BIOL CHEM, V258, P6000; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; Gorsky L D, 1989, Cancer Commun, V1, P83; GULDNER HH, 1986, CHROMOSOMA, V94, P132, DOI 10.1007/BF00286991; HALSEY DL, 1987, J BIOL CHEM, V262, P2234; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HECK MMS, 1989, J BIOL CHEM, V264, P15161; HORNBECK P, 1988, P NATL ACAD SCI USA, V85, P2279, DOI 10.1073/pnas.85.7.2279; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JONGSTRABILEN J, 1983, EUR J BIOCHEM, V136, P391, DOI 10.1111/j.1432-1033.1983.tb07754.x; KAISERMAN HB, 1988, BIOCHEMISTRY-US, V27, P3216, DOI 10.1021/bi00409a014; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KORNBERG A, 1992, DNA REPLICATION, P395; KROLL DJ, 1991, J BIOL CHEM, V266, P7957; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1983, P NATL ACAD SCI-BIOL, V80, P4208, DOI 10.1073/pnas.80.14.4208; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; MACFARLANE DE, 1986, J BIOL CHEM, V261, P6947; MAUL GG, 1986, P NATL ACAD SCI USA, V83, P5145, DOI 10.1073/pnas.83.14.5145; MILLS JS, 1982, BIOCHEM BIOPH RES CO, V109, P1222, DOI 10.1016/0006-291X(82)91907-6; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PATSKAN GJ, 1985, CANCER RES, V45, P667; POMMIER Y, 1990, J BIOL CHEM, V265, P9418; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SAIJO M, 1990, BIOCHEMISTRY-US, V29, P583, DOI 10.1021/bi00454a036; SAMUELS DS, 1986, FEBS LETT, V209, P231; SAMUELS DS, 1989, FEBS LETT, V259, P57, DOI 10.1016/0014-5793(89)81493-0; SANDER M, 1984, P NATL ACAD SCI-BIOL, V81, P6938, DOI 10.1073/pnas.81.22.6938; SHERO JH, 1986, SCIENCE, V231, P737, DOI 10.1126/science.3003910; SHIMIZU Y, 1986, CANCER RES, V46, P4027; SHIMIZU Y, 1989, SOMAT CELL MOLEC GEN, V15, P321, DOI 10.1007/BF01534971; TAN EM, 1982, ADV IMMUNOL, V33, P167, DOI 10.1016/S0065-2776(08)60836-6; THOMAS TP, 1988, CANCER RES, V48, P1910; TSEDINH YC, 1984, NATURE, V312, P785, DOI 10.1038/312785a0; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6	55	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11156	11162						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317858				2022-12-27	WOS:A1992HX16900037
J	SAVARESE, TM; WANG, CD; FRASER, CM				SAVARESE, TM; WANG, CD; FRASER, CM			SITE-DIRECTED MUTAGENESIS OF THE RAT M(1) MUSCARINIC ACETYLCHOLINE-RECEPTOR - ROLE OF CONSERVED CYSTEINES IN RECEPTOR FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; AFFINITY AGONIST BINDING; LIGAND-BINDING; BETA-2-ADRENERGIC RECEPTOR; SULFHYDRYL-REAGENTS; GUANINE-NUCLEOTIDES; SELECTIVELY COUPLE; ANTAGONIST BINDING; DISULFIDE BOND; B82 CELLS	There are 9 cysteine residues in the rat m1 muscarinic acetylcholine receptor (mAChR) that are conserved among all five mammalian mAChR subtypes sequenced to date. To study the role of these cysteines in rat m1 mAChR function, site-directed mutagenesis was used to convert each Cys residue to Ser, and the mutant receptor genes were transfected into mAChR-deficient Chinese hamster ovary (CHO) cells. Substitution of Cys391 (extracellular loop III) or Cys421 and Cys435 (carboxyl terminus) produces receptors with wild type phenotype. Cells transfected with Ser98 or Ser178 (extracellular loops I and II, respectively) receptor genes display no carbachol-mediated hydrolysis of phosphoinositides (PI), and membranes prepared from these cells do not bind the muscarinic antagonist [H-3] quinuclidinyl benzilate, even though the cells express transcripts of the m1 mAChR as determined by RNA hybridization analysis. Since biochemical evidence suggests that these cysteines form a disulfide bridge (Curtis, C. A. M., Wheatley, M., Bansal, S., Birdsall, N. J. M., Eveleigh, P., Pedder, E. K., Poyner, D., and Hulme, E. C. (1989) 264, 489-495), our findings imply that this disulfide linkage may be critical for formation of the ligand binding domain or for proper protein folding. The Ser394 mAChR (extracellular loop III) exhibits a 44% decrease in efficacy for carbachol-mediated stimulation of PI hydrolysis relative to the wild type receptor, but displays normal ligand binding affinities. The Ser-407 m1 mAChR (transmembrane helix VII) displays a decreased efficacy for eliciting carbachol-mediated PI hydrolysis (39% that of CHO cells transfected with the wild type receptor) and a 4-fold shift to the right in the carbachol dose-response curve, which is consistent with the 4-fold decrease in carbachol affinity at the Ser407 m1 mAChR. In contrast, the Ser417 m1 mAChR (transmembrane helix VII) displays an increase in carbachol affinity and a shift to the left in the carbachol dose-response curve for PI hydrolysis. These findings suggest that cysteine residues in the seventh transmembrane helix of the m1 mAChR may influence agonist binding and the efficiency of receptor activation.	NIAAA,PHYSIOL & PHARMACOL STUDIES LAB,MOLEC NEUROBIOL SECT,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)				Fraser, Claire/0000-0003-1462-2428	NCI NIH HHS [CA-01241] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K04CA001241] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONSTAM RS, 1978, MOL PHARMACOL, V14, P575; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BERSTEIN G, 1988, J NEUROCHEM, V50, P1687, DOI 10.1111/j.1471-4159.1988.tb02464.x; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BUCK MA, 1990, BIOCHEM BIOPH RES CO, V173, P666, DOI 10.1016/S0006-291X(05)80087-7; CHUNG FZ, 1988, J BIOL CHEM, V263, P4052; CURTIS CAM, 1989, J BIOL CHEM, V264, P489; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; EHLERT FJ, 1980, J SUPRAMOL STR CELL, V14, P149, DOI 10.1002/jss.400140204; FONSECA MI, 1991, BIOCHEM PHARMACOL, V41, P735, DOI 10.1016/0006-2952(91)90074-F; FRASER CM, 1989, J BIOL CHEM, V264, P9266; FRASER CM, 1989, MOL PHARMACOL, V36, P840; FRASER CM, 1988, P NATL ACAD SCI USA, V85, P5478, DOI 10.1073/pnas.85.15.5478; FRASER CM, 1987, J BIOL CHEM, V262, P14843; GOCAYNE J, 1987, P NATL ACAD SCI USA, V84, P8296, DOI 10.1073/pnas.84.23.8296; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; HEDLUND B, 1978, MOL PHARMACOL, V15, P531; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HULME, 1990, ANN REV PHARM TOXICO, V30, P633; HULME EC, 1983, EUR J PHARMACOL, V94, P59, DOI 10.1016/0014-2999(83)90442-9; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KUBO T, 1986, FEBS LETT, V209, P367, DOI 10.1016/0014-5793(86)81144-9; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; LAI J, 1988, LIFE SCI, V42, P2489, DOI 10.1016/0024-3205(88)90348-7; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MEI L, 1989, J PHARMACOL EXP THER, V248, P661; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; POTTER LT, 1991, MOL PHARMACOL, V39, P211; POTTER LT, 1988, CELL MOL NEUROBIOL, V8, P181, DOI 10.1007/BF00711244; SAVARESE TM, 1992, BIOCHEM J, V283, P1; STRADER CD, 1987, J BIOL CHEM, V262, P16439; VANKOPPEN CJ, 1991, J NEUROCHEM, V57, P1873, DOI 10.1111/j.1471-4159.1991.tb06397.x; VENTER JC, 1983, J BIOL CHEM, V258, P4842; WANG CD, 1991, MOL PHARMACOL, V40, P168; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x	45	128	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11439	11448						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317867				2022-12-27	WOS:A1992HX16900077
J	HUNT, J; MASSEY, V				HUNT, J; MASSEY, V			PURIFICATION AND PROPERTIES OF MILK XANTHINE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CENTERS; ACTIVE-SITE PROBES; O-2-DEPENDENT TYPES; OXIDASE; REDUCTION; OXIDATION; FLAVIN; MOLYBDENUM; MECHANISM; REDOX	Milk xanthine oxidase (XO) has been prepared in a dehydrogenase form (XDH) by purifying the enzyme in the presence of 2.5 mM dithiothreitol. Unlike XO, which reacts rapidly only with oxygen and not with NAD, the XDH form of the enzyme reacts rapidly with NAD. XDH has a turnover number for the NAD-dependent conversion of xanthine to urate of 380 mol/min/mol at pH 7.5, 25-degrees-C, with a K(m) = less-than-or-equal-to muM for xanthine and a K(m) = 7 muM for NAD, but has very little O2-dependent activity. There is evidence that the two forms of the enzyme have different flavin environments: XDH stabilizes the neutral form of the flavin semiquinone and XO does not. Further, XDH binds the artificial flavin 8-mercapto-FAD in its neutral form, shifting the pK of this flavin by 5 pH units, while XO binds 8-mercapto-FAD in its benzoquinoid anionic form. XDH can be converted back to the XO form by the addition of three to four equivalents of the disulfide-forming reagent 4,4'-dithiodipyridine, suggesting that, in the XDH form of the enzyme, disulfide bonds are broken; this may cause a conformational change which creates a binding site for NAD and changes the protein structure near the flavin.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIGMS NIH HHS [T32-GM07767] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER MJ, 1980, ARCH BIOCHEM BIOPHYS, V201, P468, DOI 10.1016/0003-9861(80)90535-4; BARBER MJ, 1973, BIOCHEM J, V163, P279; BATTELLI MG, 1973, BIOCHEM J, V131, P191, DOI 10.1042/bj1310191; BETCHERLANGE SL, 1979, J BIOL CHEM, V254, P8825; Bray R. C., 1975, ENZYMES, P300; CLEERE WF, 1975, COMP BIOCHEM PHYSIOL, V50, P311, DOI 10.1016/0305-0491(75)90280-1; COUGHLAN MP, 1980, MOLYBDENUM MOLYBDENU, P160; FISH KM, 1990, J BIOL CHEM, V265, P19665; FISHER TL, 1973, J BIOL CHEM, V248, P4293; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; HILLE R, 1981, J BIOL CHEM, V256, P8933; JOHNSON JL, 1989, J BIOL CHEM, V264, P13440; KOMAI H, 1969, J BIOL CHEM, V244, P1692; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MASSEY V, 1979, J BIOL CHEM, V254, P9640; MASSEY V, 1989, J BIOL CHEM, V264, P10567; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MAYHEW SG, 1969, J BIOL CHEM, V244, P794; NAKAMURA M, 1982, J BIOCHEM-TOKYO, V92, P1279, DOI 10.1093/oxfordjournals.jbchem.a134046; NISHINO T, 1981, FEBS LETT, V131, P369, DOI 10.1016/0014-5793(81)80406-1; NISHINO T, 1989, J BIOL CHEM, V264, P2518; OLSON JS, 1974, J BIOL CHEM, V249, P4363; PORRAS AG, 1982, J BIOL CHEM, V257, P1617; RAJAGOPALAN KV, 1967, J BIOL CHEM, V242, P4097; SAITO T, 1987, Yokohama Medical Bulletin, V38, P151; SAITO T, 1989, J BIOL CHEM, V264, P10015; SAITO T, 1989, J BIOL CHEM, V264, P15930; SCHOPFER LM, 1988, J BIOL CHEM, V263, P13528; SWINGLE SM, 1951, BIOCHEM J, V48, P171, DOI 10.1042/bj0480171; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P365, DOI 10.1016/0003-9861(76)90088-6	32	95	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21479	21485						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328233				2022-12-27	WOS:A1992JV01100035
J	WIESE, RJ; UHLANDSMITH, A; ROSS, TK; PRAHL, JM; DELUCA, HF				WIESE, RJ; UHLANDSMITH, A; ROSS, TK; PRAHL, JM; DELUCA, HF			UP-REGULATION OF THE VITAMIN-D RECEPTOR IN RESPONSE TO 1,25-DIHYDROXYVITAMIN-D(3) RESULTS FROM LIGAND-INDUCED STABILIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; OSTEOCALCIN GENE; DEPENDENT REGULATION; RIBONUCLEIC-ACID; MESSENGER-RNA; D METABOLITES; CELLS HL-60; INVIVO; IDENTIFICATION; BINDING	Several studies have shown that the 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) receptor protein levels increase in response to 1,25-(OH)2D3. We have studied the mechanism of this regulation in both mouse fibroblasts and rat intestinal epithelial cells. Cell extracts and total RNA were prepared at varying times after addition of 1,25-(OH)2D3. The 1,25-(OH)2D3 receptor protein levels, measured using an immunoradiometric assay, rose significantly 2-3 h posttreatment and had risen 3-fold at 8 h. Concurrently, the 1,25-(OH)2D3 receptor mRNA content, measured using a ribonuclease protection assay, was not altered by 1,25-(OH)2D3 during this time. In cycloheximide-blocked cells, the administration of 1,25-(OH)2D3 markedly reduced the degradation rate of previously formed receptor. The 1,25-(OH)2D3 receptor protein half-life was determined as 4 h in the absence of 1,25-(OH)2D3 and increased to at least 8 h in the presence of 1,25-(OH)2D3. We also measured the 1,25-(OH)2D3 receptor mRNA levels in the duodena and kidney of vitamin D-deficient rats after a single 150-pmol injection of 1,25-(OH)2D3. Again, we found that 1,25-(OH)2D3 receptor mRNA levels were not changed in these tissues after 1,25-(OH)2D3 treatment. Therefore, the elevation of the 1,25-(OH)2D3 receptor protein following 1,25-(OH)2D3 administration is apparently the result of increased receptor protein lifetime and not increased transcription.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,420 HENRY MALL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK014881] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-14881] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURMESTER JK, 1988, P NATL ACAD SCI USA, V85, P9499, DOI 10.1073/pnas.85.24.9499; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COSTA EM, 1987, ENDOCRINOLOGY, V120, P1173, DOI 10.1210/endo-120-3-1173; COSTA EM, 1985, ENDOCRINOLOGY, V117, P2203, DOI 10.1210/endo-117-5-2203; COSTA EM, 1986, BIOCHEM BIOPH RES CO, V137, P742, DOI 10.1016/0006-291X(86)91141-1; DARWISH HM, 1992, P NATL ACAD SCI USA, V89, P603, DOI 10.1073/pnas.89.2.603; DeLuca H. F. J., 1990, J BONE MINER METAB, V8, P1; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; FINLAY JA, 1990, BIOCHEMISTRY-US, V29, P4914, DOI 10.1021/bi00472a023; GEHRON R, 1986, J BONE MINER RES  S1, V1, P288; HUANG YC, 1989, J BIOL CHEM, V264, P17454; KARASAWA M, 1987, P NATL ACAD SCI USA, V84, P8810, DOI 10.1073/pnas.84.24.8810; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KIZAKI M, 1991, BLOOD, V77, P1238; LEE YS, 1989, J BIOL CHEM, V264, P13701; MAHONEN A, 1991, BIOCHIM BIOPHYS ACTA, V1088, P111, DOI 10.1016/0167-4781(91)90159-J; MANGELSDORF DJ, 1987, P NATL ACAD SCI USA, V84, P354, DOI 10.1073/pnas.84.2.354; Maniatis T., 1982, MOL CLONING; MCCAIN TA, 1978, FEBS LETT, V86, P65, DOI 10.1016/0014-5793(78)80100-8; MCDONNELL DP, 1987, SCIENCE, V235, P1214, DOI 10.1126/science.3029866; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; NAVEHMANY T, 1990, J CLIN INVEST, V86, P1968, DOI 10.1172/JCI114931; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; PAN LC, 1987, J BIOL CHEM, V262, P4670; PAN P, 1991, CELL PROLIFERAT, V24, P159, DOI 10.1111/j.1365-2184.1991.tb01146.x; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; SANDGREN ME, 1990, P NATL ACAD SCI USA, V87, P4312, DOI 10.1073/pnas.87.11.4312; SANDGREN ME, 1989, ANAL BIOCHEM, V183, P57, DOI 10.1016/0003-2697(89)90171-1; SILVER J, 1985, P NATL ACAD SCI USA, V82, P4270, DOI 10.1073/pnas.82.12.4270; STROM M, 1989, P NATL ACAD SCI USA, V86, P9770, DOI 10.1073/pnas.86.24.9770; SUDA T, 1970, J NUTR, V100, P1049, DOI 10.1093/jn/100.9.1049; WASSERMA.RH, 1966, SCIENCE, V152, P791, DOI 10.1126/science.152.3723.791; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; 1991, PROMEGA PROTOCOLS AP	35	198	200	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20082	20086						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328192				2022-12-27	WOS:A1992JR85800054
J	ZHANG, L; MCSPADDEN, B; PAKRASI, HB; WHITMARSH, J				ZHANG, L; MCSPADDEN, B; PAKRASI, HB; WHITMARSH, J			COPPER-MEDIATED REGULATION OF CYTOCHROME-C553 AND PLASTOCYANIN IN THE CYANOBACTERIUM SYNECHOCYSTIS-6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYSTEM-II; CHLAMYDOMONAS-REINHARDTII; TARGETED MUTAGENESIS; RECIPROCAL FORMATION; ELECTRON-TRANSPORT; SP PCC-6803; GENE; CLONING; ALGAE; METALLOTHIONEIN	In certain cyanobacteria and algae, cytochrome C553 or plastocyanin can serve to carry electrons from the cytochrome bf complex to photosystem I. The availability of copper in the growth medium regulates which protein is present. To investigate copper induced control of gene expression we isolated these proteins from the cyanobacterium Synechocystis 6803. Using immunodetection and optical spectroscopy, the steady state levels of cytochrome c553 and plastocyanin were measured in cells grown at different copper concentrations. The results show that in cells grown in 20-30 nm copper, cytochrome c553 was present, whereas plastocyanin was not detected. The opposite behavior was observed in cells grown in the presence of 1 muM copper; plastocyanin was present, whereas cytochrome c553 could not be detected. Both proteins were present in cells grown in 0.3 muM copper. Northern analysis of total RNA, probed with a gene fragment for cytochrome c553 or the plastocyanin gene, showed that cells grown in the presence of 20-30 nm copper have message for cytochrome c553, but not for plastocyanin, whereas cells grown in 1 muM copper have message for plastocyanin, but not for cytochrome C553. These results demonstrate that copper regulates expression of both of the genes encoding cytochrome c553 and plastocyanin prior to translation in Synechocystis 6803.	UNIV ILLINOIS, DEPT PLANT BIOL, CHICAGO, IL 60680 USA; UNIV ILLINOIS, DEPT PHYSIOL & BIOPHYS, CHICAGO, IL 60680 USA; USDA ARS, PHOTOSYNTH RES UNIT, URBANA, IL 61801 USA; WASHINGTON UNIV, DEPT BIOL, ST LOUIS, MO 63130 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; United States Department of Agriculture (USDA); Washington University (WUSTL)			Gardener, Brian B McSpadden/C-9844-2009		NIGMS NIH HHS [GM 41841] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN MM, 1968, J PHYCOL, V4, P1, DOI 10.1111/j.1529-8817.1968.tb04667.x; BOHNER H, 1978, FEBS LETT, V85, P337, DOI 10.1016/0014-5793(78)80486-4; Boulter D., 1977, INT REV BIOCH PLANT, V13, P1; BRIGGS LM, 1990, PLANT MOL BIOL, V15, P633, DOI 10.1007/BF00017837; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; CRAMER WA, 1977, ANNU REV PLANT PHYS, V28, P133, DOI 10.1146/annurev.pp.28.060177.001025; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HILL KL, 1991, J BIOL CHEM, V266, P15060; HO KK, 1984, BIOCHIM BIOPHYS ACTA, V766, P310, DOI 10.1016/0005-2728(84)90246-9; HO KK, 1979, BIOCHIM BIOPHYS ACTA, V545, P236; IKEUCHI M, 1988, PLANT CELL PHYSIOL, V29, P1233; LACY MJ, 1986, J IMMUNOL METHODS, V87, P169, DOI 10.1016/0022-1759(86)90527-2; LAUDENBACH DE, 1990, PLANT CELL, V2, P913, DOI 10.1105/tpc.2.9.913; LI HH, 1992, J BIOL CHEM, V267, P9368; LIGHTBODY JJ, 1967, BIOCHIM BIOPHYS ACTA, V131, P508, DOI 10.1016/0005-2728(67)90010-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERCHANT S, 1991, EMBO J, V10, P1383, DOI 10.1002/j.1460-2075.1991.tb07658.x; MERCHANT S, 1987, J BIOL CHEM, V262, P9062; MERCHANT S, 1986, J BIOL CHEM, V261, P5850; NAKAMURA M, 1992, J BIOCHEM, V111, P219, DOI 10.1093/oxfordjournals.jbchem.a123740; PAKRASI HB, 1988, EMBO J, V7, P325, DOI 10.1002/j.1460-2075.1988.tb02816.x; PAKRASI HB, 1992, PHOTOSYSTEMS STRUCTU, P231; REDDY KJ, 1990, BIOTECHNIQUES, V8, P250; SANDMANN G, 1986, ARCH MICROBIOL, V145, P76, DOI 10.1007/BF00413030; SANDMANN G, 1983, ARCH MICROBIOL, V134, P23, DOI 10.1007/BF00429401; SANDMANN G, 1980, PLANT SCI LETT, V17, P417, DOI 10.1016/0304-4211(80)90128-5; SMART LB, 1991, EMBO J, V10, P3289, DOI 10.1002/j.1460-2075.1991.tb04893.x; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; VANDERPLAS J, 1989, MOL MICROBIOL, V3, P275; WHITMARSH J, 1979, BIOPHYS J, V26, P223, DOI 10.1016/S0006-3495(79)85246-7; WHITMARSH J, 1984, ARCH BIOCHEM BIOPHYS, V231, P378, DOI 10.1016/0003-9861(84)90401-6; Whitmarsh J., 1986, ENCY PLANT PHYSL, V19, P508; Whitton B. A., 1970, PHYKOS, V9, P116; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; YRUELA I, 1991, J BIOL CHEM, V266, P22847; Zieger R., 1965, BEITR BIOL PFLANZ, V41, P11	37	113	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19054	19059						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326543				2022-12-27	WOS:A1992JP59300009
J	ADAMCZEWSKI, M; PAOLINI, R; KINET, JP				ADAMCZEWSKI, M; PAOLINI, R; KINET, JP			EVIDENCE FOR 2 DISTINCT PHOSPHORYLATION PATHWAYS ACTIVATED BY HIGH-AFFINITY IMMUNOGLOBULIN-E RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN-TYROSINE KINASE; MEDIATED SIGNAL TRANSDUCTION; NATURAL-KILLER-CELLS; FC-GAMMA RECEPTOR; T-CELL; ZETA-CHAIN; PHOSPHOLIPASE C-GAMMA-1; PHENYLARSINE OXIDE; HISTAMINE-RELEASE	The high affinity receptor for immunoglobulin (Ig) E on mast cells, along with the antigen receptors on T and B cells and Fc receptors for IgG, belongs to a class of receptors which lack intrinsic kinase activity, but activate non-receptor tyrosine and serine/threonine kinases. Receptor engagement triggers a chain of signaling events leading from protein phosphorylation to activation of phosphatidylinositol-specific phospholipase C, an increase in intracellular calcium levels, and ultimately the activation of more specialized functions. IgE receptor disengagement leads to reversal of phosphorylation by undefined phosphatases and to inhibition of activation pathways. Here we show that phenylarsine oxide, a chemical which reacts with thiol groups and has been reported to inhibit tyrosine phosphatases, uncouples the IgE receptor-mediated phosphorylation signal from activation of phosphatidyl inositol metabolism, the increase in intracellular calcium levels, and serotonin release. Phenylarsine oxide inhibits neither the kinases (tyrosine and serine/threonine) phosphorylating the receptor and various cellular substrates nor, unexpectedly, the phosphatases responsible for the dephosphorylation following receptor disengagement. By contrast, it abolishes the receptor-mediated phosphorylation of phospholipase C-gamma-1, but not phospholipase C activity in vitro. Therefore the phosphorylation and activation of phospholipase C likely requires a phenylarsine oxide-sensitive element. Receptor aggregation thus activates at least two distinct phosphorylation pathways: a phenylarsine oxide-insensitive pathway leading to phosphorylation/dephosphorylation of the receptor and of various substrates and a sensitive pathway leading to phospholipase C-gamma-1 phosphorylation.			ADAMCZEWSKI, M (corresponding author), NIAID,MOLEC ALLERGY & IMMUNOL SECT,TWINBROOK 2 BLDG,RM 108,12441 PARKLAWN DR,ROCKVILLE,MD 20852, USA.			PAOLINI, Rossella/0000-0001-7605-1531				ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BERNIER M, 1988, J BIOL CHEM, V263, P13626; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; DEANIN GG, 1991, BIOCHEM BIOPH RES CO, V179, P551, DOI 10.1016/0006-291X(91)91406-3; EISEMAN E, 1992, NATURE, V355, P78; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; HOOK WA, 1991, J IMMUNOL, V147, P2670; HSI ED, 1989, J BIOL CHEM, V264, P10836; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; KOYASU S, 1992, J BIOL CHEM, V267, P3375; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LEVENSON RM, 1989, J BIOL CHEM, V264, P19984; LIU FT, 1980, J IMMUNOL, V124, P2728; MAYEAMA K, 1988, J IMMUNOL, V140, P3919; MAYEAMA K, 1986, J BIOL CHEM, V261, P2583; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; TREVILLYAN JM, 1990, J IMMUNOL, V145, P3223; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; WEBB JL, 1966, ENZYMES METABOL INH, V3, P595; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YOUNG JDE, 1987, P NATL ACAD SCI USA, V84, P9175, DOI 10.1073/pnas.84.24.9175; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013	53	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18126	18132						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325458				2022-12-27	WOS:A1992JM22300099
J	GURNEY, AL; PARK, EA; GIRALT, M; LIU, JS; HANSON, RW				GURNEY, AL; PARK, EA; GIRALT, M; LIU, JS; HANSON, RW			OPPOSING ACTIONS OF FOS AND JUN ON TRANSCRIPTION OF THE PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP) GENE - DOMINANT NEGATIVE REGULATION BY FOS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; DNA-BINDING DOMAINS; C-FOS; GLUCOCORTICOID RECEPTOR; HEPATOMA-CELLS; PHORBOL-ESTER; PROTEIN COMPLEXES; NERVOUS-SYSTEM; FACTOR AP-1; EXPRESSION	Jun homodimers and Fos/Jun heterodimers bind to the gene for phosphoenolpyruvate carboxykinase (GTP) (EC 4.1.1.32) (PEPCK) at three sites within the first 350 base pairs of the promoter. These include CRE-1 (-82 to -90), and P3(II) and P4 (-252 to -258 and -268 to -285, respectively). Over-expression of Jun in HepG2 cells resulted in a 10-15-fold increase in the level of transcription of a chimeric PEPCK (-490 to +73)-CAT gene, while expression of Fos decreased transcription and blocked the induction of transcription from the PEPCK promoter by Jun. The action of Fos and Jun on PEPCK gene transcription involved each of the Fos/Jun-binding sites and was modulated by additional transcriptional regulatory elements within the PEPCK promoter. The ability of Fos to inhibit PEPCK transcription was dependent upon P3(I), a region of the promoter which does not bind Fos/Jun heterodimers, but does bind members of the C/EBP family of transcription factors. Stimulation of PEPCK transcription by 8-Br-cAMP or by overexpression of the catalytic subunit of protein kinase A was inhibited by Fos expression. The inhibitory effects of phorbol esters and protein kinase C on PEPCK gene expression may be mediated through the action of Fos and Jun.			GURNEY, AL (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106, USA.		Giralt, Marta/A-4756-2013	Giralt, Marta/0000-0001-7968-4190	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021859, R01DK021859] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-21859, DK-24451] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BOSCH F, 1990, J BIOL CHEM, V265, P13677; BOSCH F, 1992, J BIOL CHEM, V267, P2888; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHAMBIER JC, 1987, NATURE, V327, P629; CHU DTW, 1986, J BIOL CHEM, V261, P6848; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; CORRAL M, 1985, EXP CELL RES, V160, P427, DOI 10.1016/0014-4827(85)90190-9; Curran T, 1988, ONCOGENE HDB, P307; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HOD Y, 1988, J BIOL CHEM, V263, P7747; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIU J, 1991, MOL CELL BIOCHEM, V104, P89; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU JS, 1990, BIOTECHNIQUES, V9, P738; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; Maniatis T., 1982, MOL CLONING; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MCGRANE MM, 1990, J BIOL CHEM, V265, P22372; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; MILLAND J, 1990, J AM PHYS SOC, pG340; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; POHJANPELTO P, 1990, MOL CELL BIOL, V10, P5814, DOI 10.1128/MCB.10.11.5814; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, GENE DEV, V2, P687; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SCHALASTA G, 1990, MOL CELL BIOL, V10, P5558, DOI 10.1128/MCB.10.10.5558; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SQUINTO SP, 1989, MOL ENDOCRINOL, V3, P433, DOI 10.1210/mend-3-3-433; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	63	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18133	18139						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325459				2022-12-27	WOS:A1992JM22300100
J	ZIEGELIN, G; PANSEGRAU, W; LURZ, R; LANKA, E				ZIEGELIN, G; PANSEGRAU, W; LURZ, R; LANKA, E			TRAK PROTEIN OF CONJUGATIVE PLASMID RP4 FORMS A SPECIALIZED NUCLEOPROTEIN COMPLEX WITH THE TRANSFER ORIGIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GEL-ELECTROPHORESIS; ENCODED PRODUCTS; DNA; SEQUENCE; BINDING; NUCLEOTIDE; EXPRESSION; REPRESSOR; CLONING	Conjugative transfer of the self-transmissible IncP Plasmid RP4 requires the product of the RP4 traK gene. By using the phage T7 expression system, the traK gene product was efficiently overproduced and purified to near homogeneity. traK encodes a basic protein (pI = 10.7) of 14.6 kDa that, as shown by DNA fragment retention assay, interacts exclusively with its cognate transfer origin. The apparent equilibrium constant K(app) for the complex of TraK and oriT-DNA was estimated to be 4 nM. Footprinting experiments using DNase I or hydroxyl radicals indicate that several TraK molecules interact specifically with an intrinsically bent region of oriT, covering a range of almost 200 base pairs. The TraK target sequence maps in the leading region adjacent to the relaxation nick site and recognition sequences involved in relaxosome formation but does not overlap them. Specific interactions between TraK and the DNA occur only on one side of the double helix. Electron microscopy of TraK-oriT complexes demonstrates that binding of TraK to its recognition region apparently shrinks the length of the target DNA, suggesting that the nucleic acid becomes wrapped around a core of TraK molecules. Formation of this structure could be favored by the presence of the sequence-directed bend in the TraK recognition region.	MAX PLANCK INST MOLEC GENET,SCHUSTER ABT,IHNESTR 73,W-1000 BERLIN 33,GERMANY	Max Planck Society								BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CARRASCOSA JL, 1976, EUR J BIOCHEM, V66, P229, DOI 10.1111/j.1432-1033.1976.tb10512.x; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; FURSTE JP, 1989, P NATL ACAD SCI USA, V86, P1771, DOI 10.1073/pnas.86.6.1771; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HALFMAN CJ, 1972, BIOCHEMISTRY-US, V11, P3493, DOI 10.1021/bi00768a025; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HATFULL GF, 1987, CELL, V49, P103, DOI 10.1016/0092-8674(87)90760-4; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; Miller J.H., 1972, EXPT MOL GENETICS; PANSEGRAU W, 1990, J BIOL CHEM, V265, P10637; PANSEGRAU W, 1988, BIOCHIM BIOPHYS ACTA, V951, P365, DOI 10.1016/0167-4781(88)90108-X; PANSEGRAU W, 1990, P NATL ACAD SCI USA, V87, P6555, DOI 10.1073/pnas.87.17.6555; PEREZMARTIN J, 1989, J BIOL CHEM, V264, P21334; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1950, J AM CHEM SOC, V72, P535, DOI 10.1021/ja01157a138; SERRANO M, 1990, SCIENCE, V248, P1012, DOI 10.1126/science.2111580; SERRANO M, 1989, EMBO J, V8, P1879, DOI 10.1002/j.1460-2075.1989.tb03584.x; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; WANG JC, 1982, CELL, V29, P724, DOI 10.1016/0092-8674(82)90433-0; WATERS VL, 1991, P NATL ACAD SCI USA, V88, P1456, DOI 10.1073/pnas.88.4.1456; WILKINS B, 1992, BACTERIAL CONJUGATIO; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIEGELIN G, 1989, J BIOL CHEM, V264, P11989; Ziegelin G, 1991, DNA Seq, V1, P303, DOI 10.3109/10425179109020786	32	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17279	17286						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324929				2022-12-27	WOS:A1992JL05300083
J	ENGSTROM, U; ENGSTROM, A; ERNLUND, A; WESTERMARK, B; HELDIN, CH				ENGSTROM, U; ENGSTROM, A; ERNLUND, A; WESTERMARK, B; HELDIN, CH			IDENTIFICATION OF A PEPTIDE ANTAGONIST FOR PLATELET-DERIVED GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDGF BETA-RECEPTOR; A-CHAIN; KINASE ACTIVATION; HUMAN-FIBROBLASTS; B-CHAIN; BINDING; PURIFICATION; DIMERIZATION; HETERODIMER; ESTABLISHES	A series of peptides derived from the primary sequence of the B-chain of platelet-derived growth factor (PDGF) was analyzed for their ability to inhibit the binding of I-125-PDGF-AA and I-125-PDGF-BB to PDGF alpha-receptors and PDGF beta-receptors, respectively. A 13-amino acid peptide (ANFLVWEIVRKKP), corresponding to amino acids 116-121 and 157-163 in PDGF B-chain, was found to compete with binding to both alpha- and beta-receptors. Modification of this peptide on the tryptophan residue increased its receptor competing activity. The peptide was found to be a receptor antagonist, since it inhibited dimerization and autophosphorylation of PDGF receptors. When analyzed on intact cells, the peptide was found to have, in addition to the specific inhibitory effect at the receptor level, a nonspecific inhibitory effect on [H-3]thymidine incorporation. Our study has identified two regions in PDGF that are of importance for receptor interaction.	LUDWIG INST CANC RES, BOX 595, S-75124 UPPSALA, SWEDEN; BIOMED CTR, DEPT IMMUNOL, S-75123 UPPSALA, SWEDEN; UNIV HOSP UPPSALA, DEPT PATHOL, S-75185 UPPSALA, SWEDEN	Ludwig Institute for Cancer Research; Uppsala University; Uppsala University Hospital								BETSHOLTZ C, 1984, J CELL PHYSIOL, V118, P203, DOI 10.1002/jcp.1041180213; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; EK B, 1984, J BIOL CHEM, V259, P1145; Eriksson A, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008867; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; HUANG JS, 1982, J BIOL CHEM, V257, P8130; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KING CR, 1985, P NATL ACAD SCI USA, V82, P5295, DOI 10.1073/pnas.82.16.5295; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MERCOLA M, 1988, SCIENCE, V241, P1223, DOI 10.1126/science.3413486; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; OSTMAN A, 1991, J BIOL CHEM, V266, P10073; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; PIERCE GF, 1989, J CELL BIOL, V109, P429, DOI 10.1083/jcb.109.1.429; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; RONNSTRAND L, 1987, J BIOL CHEM, V262, P2929; SCOFFONE E, 1968, BIOCHEMISTRY-US, V7, P971, DOI 10.1021/bi00843a014; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; SPRUGEL KH, 1987, AM J PATHOL, V129, P601; SUNDQVIST B, 1985, MASS SPECTROM REV, V4, P421, DOI 10.1002/mas.1280040403; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	32	56	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16581	16587						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322909				2022-12-27	WOS:A1992JJ45800091
J	SHIRAKABE, K; GOTOH, Y; NISHIDA, E				SHIRAKABE, K; GOTOH, Y; NISHIDA, E			A MITOGEN-ACTIVATED PROTEIN (MAP) KINASE ACTIVATING FACTOR IN MAMMALIAN MITOGEN-STIMULATED CELLS IS HOMOLOGOUS TO XENOPUS M-PHASE MAP KINASE ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; MICROTUBULE-ASSOCIATED PROTEIN-2; SERINE THREONINE KINASES; TYROSINE PHOSPHORYLATION; FIBROBLASTIC CELLS; OOCYTE MATURATION; PC12 CELLS; INVITRO; INSULIN; IDENTIFICATION	The mitogen-activated protein (MAP) kinases, a family of 40-45-kDa kinases whose activation requires both tyrosine and threonine/serine phosphorylations, are suggested to play key roles in various phosphorylation cascades. A previous study of Krebs and co-workers (Ahn, N. G., Seger, R., Bratlien, R. L., Diltz, C. D., Tonks, N. K., and Krebs, E. G. (1991) J. Biol. Chem. 266, 4220-4227) detected an activity in epidermal growth factor (EGF)-stimulated 3T3 cells that can stimulate inactive MAP kinases. We observed this activity in rat 3Y1 cells treated with various mitogenic factors and in PC12 cells treated with nerve growth factor (NGF). Its kinetics of activation and deactivation following EGF or NGF stimulation roughly paralleled that of MAP kinase. The MAP kinase activator required the presence of ATP and a divalent cation such as Mn2+ and Mg2+ and was inactivated by phosphatase 2A treatment in vitro. This activator has been isolated from EGF-stimulated 3Y1 cells by sequential chromatography and identified as a 45-kDa monomeric protein. It was able to activate mammalian and Xenopus MAP kinases in vitro and was very similar to Xenopus M phase MAP kinase activating factor, which was purified previously from mature oocytes (Matsuda, S., Kosako, H., Takenaka, K., Moriyama, K., Sakai, H., Akiyama, T., Gotoh, Y., and Nishida, E. (1992) EMBO J. 11, 973-982), in terms of its functional, immunological, and physicochemical properties. Thus, the same or a similar upstream activating factor may function in mitogen-induced and M phase-promoting factor-induced MAP kinase activation pathways.	UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, TOKYO 113, JAPAN	University of Tokyo								AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GOTOH Y, 1990, EUR J BIOCHEM, V193, P671, DOI 10.1111/j.1432-1033.1990.tb19385.x; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; KOSAKO H, 1992, IN PRESS EMBO J; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; NEL AE, 1990, J IMMUNOL, V144, P2683; PELECH SL, 1988, DEV BIOL, V130, P28, DOI 10.1016/0012-1606(88)90410-1; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; TSAO H, 1990, J BIOL CHEM, V265, P15471	29	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16685	16690						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322914				2022-12-27	WOS:A1992JJ45800105
J	PERRINO, BA; FONG, YL; BRICKEY, DA; SAITOH, Y; USHIO, Y; FUKUNAGA, K; MIYAMOTO, E; SODERLING, TR				PERRINO, BA; FONG, YL; BRICKEY, DA; SAITOH, Y; USHIO, Y; FUKUNAGA, K; MIYAMOTO, E; SODERLING, TR			CHARACTERIZATION OF THE PHOSPHATASE-ACTIVITY OF A BACULOVIRUS-EXPRESSED CALCINEURIN-A ISOFORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN PHOSPHATASE; BOVINE BRAIN CALCINEURIN; CATALYTIC SUBUNIT; CALMODULIN; BINDING; KINASE; DEPHOSPHORYLATION; CLONING; DOMAIN; PHOSPHORYLATION	Calcineurin A was purified by calmodulin-Sepharose affinity chromatography from Sf9 cells infected with recombinant baculovirus containing the cDNA of a rat calcineurin A isoform. The Sf9-expressed calcineurin A has a low basal phosphatase activity in the presence of EDTA (0.9 nmol/min/mg) which is stimulated 3-5-fold by Mn2+. Calmodulin increased the Mn2+ stimulated activity 3-5-fold. Bovine brain calcineurin B increased the A subunit activity 10-15-fold, and calmodulin further stimulated the activity of reconstituted A and B subunits 10-15-fold (644 nmol/min/mg). The K(m) of calcineurin A for P-32-R(II) pep (a peptide substrate (DLDVPIPGRFDRRVSVAAE) for CaN), was 111-mu-M with or without calmodulin, and calmodulin increased the V(max) about 4-fold. The K(m) of reconstituted calcineurin A plus B for P-32-R(II) pep was 20-mu-M, and calmodulin increased the V(max) 18-fold without affecting the K(m). CaN A467-492, a synthetic autoinhibitory peptide (ITSFEEAKGLDRINERMPPRRDAMP) from calcineurin, inhibited the Mn2+/calmodulin-stimulated activities of the reconstituted enzyme and the A subunit with IC50's of 25-mu-M and 90-mu-M, respectively. The reconstitution of the phosphatase activity of an expressed isoform of calcineurin A by purified B subunit and calmodulin may facilitate comparative studies of the regulation of calcineurin A activity by the B subunit and calmodulin.	KUMAMOTO MED SCH, DEPT PHARMACOL, KUMAMOTO 860, JAPAN	Kumamoto University	PERRINO, BA (corresponding author), OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, 3181 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA.				NIGMS NIH HHS [GM-41292] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; GUERINI D, 1991, ADV PROT PHOSPHATASE, V6, P391; GUPTA RC, 1985, FEBS LETT, V190, P104, DOI 10.1016/0014-5793(85)80437-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HIGUCHI S, 1991, J BIOL CHEM, V266, P18104; HOGER JH, 1991, NEURON, V6, P227, DOI 10.1016/0896-6273(91)90358-7; HOSEY MM, 1986, P NATL ACAD SCI USA, V83, P3733, DOI 10.1073/pnas.83.11.3733; ITO A, 1989, BIOCHEM BIOPH RES CO, V163, P1492, DOI 10.1016/0006-291X(89)91148-0; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KING MM, 1987, J BIOL CHEM, V262, P10658; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KLEE CB, 1983, METHOD ENZYMOL, V102, P227; Klee CB, 1985, ADV PROTEIN PHOSPHAT, P135; KUNO T, 1989, BIOCHEM BIOPH RES CO, V165, P1352, DOI 10.1016/0006-291X(89)92752-6; MERAT DL, 1985, J BIOL CHEM, V260, P1053; OSTERGAARD HL, 1991, J BIOL CHEM, V253, P1423; PALLEN CJ, 1983, J BIOL CHEM, V258, P8550; PERRINO BA, 1990, FASEB J, V4, pA2237; SAITOH Y, 1991, BIOMED RES-TOKYO, V12, P215, DOI 10.2220/biomedres.12.215; SILVA EFD, 1989, BIOCHIM BIOPHYS ACTA, V1009, P293, DOI 10.1016/0167-4781(89)90118-8; SUMMERS MD, 1988, TEX AGR EXP STN B, V1555; TAKAISHI T, 1991, BIOCHEM BIOPH RES CO, V174, P393, DOI 10.1016/0006-291X(91)90533-D; WRIGHT DE, 1981, P NATL ACAD SCI-BIOL, V78, P6048, DOI 10.1073/pnas.78.10.6048	32	89	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15965	15969						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322410				2022-12-27	WOS:A1992JG11300105
J	CAMPOSGONZALEZ, R; GLENNEY, JR				CAMPOSGONZALEZ, R; GLENNEY, JR			TYROSINE PHOSPHORYLATION OF MITOGEN-ACTIVATED PROTEIN-KINASE IN CELLS WITH TYROSINE KINASE-NEGATIVE EPIDERMAL GROWTH-FACTOR RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EGF RECEPTOR; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; MAP KINASE; ASSOCIATION; GEL	Epidermal growth factor (EGF) treatment of cells expressing the human EGF receptor (EGFr) results in rapid tyrosine phosphorylation of several cellular proteins including mitogen-activated protein (MAP) kinase. EGF treatment of cells expressing a tyrosine kinase-inactive EGFr failed to induce the tyrosine phosphorylation of endogenous substrates in response to EGF; however, the tyrosine phosphorylation and activation of MAP kinase did occur. This observation indicates that MAP kinase is activated in response to a signal other than the tyrosine kinase activity of the EGFr. Because EGF does not stimulate cells expressing the inactive EGFr to proliferate, phosphorylation of MAP kinase may not be sufficient for the EGF-dependent mitogenesis.	UNIV KENTUCKY,DEPT BIOCHEM,LEXINGTON,KY 40536	University of Kentucky	CAMPOSGONZALEZ, R (corresponding author), UNIV KENTUCKY,LUCILLE P MARKEY CANC CTR,COMBS BLDG,RM 227,800 ROSE ST,LEXINGTON,KY 40536, USA.							ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; Campos-Gonzalez R, 1991, GROWTH FACTORS, V4, P305, DOI 10.3109/08977199109043916; CAMPOSGONZALEZ R, 1991, CELL REGUL, V2, P663, DOI 10.1091/mbc.2.8.663; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; HAWLEY DM, 1989, J BIOL CHEM, V264, P2438; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; NORTHWOOD IC, 1990, P NATL ACAD SCI USA, V87, P6107, DOI 10.1073/pnas.87.16.6107; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUNG CK, 1989, J BIOL CHEM, V264, P18951; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D	23	68	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14535	14538						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321807				2022-12-27	WOS:A1992JF08800006
J	SCHMIDT, AM; VIANNA, M; GERLACH, M; BRETT, J; RYAN, J; KAO, J; ESPOSITO, C; HEGARTY, H; HURLEY, W; CLAUSS, M; WANG, F; PAN, YCE; TSANG, TC; STERN, D				SCHMIDT, AM; VIANNA, M; GERLACH, M; BRETT, J; RYAN, J; KAO, J; ESPOSITO, C; HEGARTY, H; HURLEY, W; CLAUSS, M; WANG, F; PAN, YCE; TSANG, TC; STERN, D			ISOLATION AND CHARACTERIZATION OF 2 BINDING-PROTEINS FOR ADVANCED GLYCOSYLATION END-PRODUCTS FROM BOVINE LUNG WHICH ARE PRESENT ON THE ENDOTHELIAL-CELL SURFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED BINDING; LOW-DENSITY LIPOPROTEIN; HUMAN LACTOFERRIN; IDENTIFICATION; ALBUMIN; MACROPHAGES; DEGRADATION; FORMS; COMPLICATIONS; MECHANISM	Nonenzymatic glycosylation of proteins, as occurs at an accelerated rate in diabetes, can lead to the formation of advanced glycosylation end products of proteins (AGEs), which can bind to endothelial cells, thereby altering cellular function in a manner which could contribute to the pathogenesis of diabetic angiopathy. In this report, we describe the isolation of two endothelial cell surface-associated proteins which mediate, at least in part, the interaction of AGEs with endothelium. Based on pilot studies demonstrating AGE binding activity with comparable characteristics in bovine endothelial cell and lung extracts, the material from lung was sequentially subjected to chromatography on hydroxylapatite, fast protein liquid chromatography Mono S, and gel filtration. Two distinct polypeptides, almost-equal-to 35 and almost-equal-to 80 kDa, were purified to homogeneity, each of which bound AGEs as demonstrated by competitive binding assays using cellular binding proteins immobilized on a plastic surface. NH2-terminal sequence analysis indicated that the almost-equal-to 35-kDa protein was novel, whereas the NH2-terminal sequence of the almost-equal-to 80-kDa protein was identical to that of lactoferrin. Immunocytologic studies using polyclonal antibody prepared to each of the purified polypeptides demonstrated the presence of immunoreactive material on the surface of bovine endothelial cells maintained under serum-free conditions. Furthermore, immunoelectron microscopic studies with antibodies to the almost-equal-to 35- and almost-equal-to 80-kDa AGE-binding proteins conjugated to different size colloidal gold particles confirmed the presence of the target antigens on the cell surface and suggested that they were closely associated. IgG purified from polyclonal antisera to either the 35- or 80-kDa AGE-binding proteins blocked the binding of I-125-AGE-albumin to the cell surface. These results indicate that endothelial cells express specific cell surface molecules which mediate AGE-endothelial interaction. These polypeptides represent a novel class of cell surface acceptor molecules for glucose-modified proteins which may promote degradation and/or transcytosis of the ligand, and modulation of cellular function.	HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT PROT BIOCHEM,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT MOLEC GENET,NUTLEY,NJ 07110; UNIV ILLINOIS,DEPT ANIM SCI,URBANA,IL 61801	Roche Holding; Roche Holding; University of Illinois System; University of Illinois Urbana-Champaign	SCHMIDT, AM (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL & CELLULAR BIOPHYS,ROVER PHYSIOL RES LAB,NEW YORK,NY 10032, USA.		esposito, ciro/AAC-8023-2020	esposito, ciro/0000-0002-7906-1097; Clauss, Matthias/0000-0001-5180-3899	NHLBI NIH HHS [HL-21006] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRETT JG, 1988, J CELL BIOL, V106, P2109, DOI 10.1083/jcb.106.6.2109; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; BUCALA R, 1984, P NATL ACAD SCI-BIOL, V81, P105, DOI 10.1073/pnas.81.1.105; BUCALA R, 1991, J CLIN INVEST, V87, P432, DOI 10.1172/JCI115014; COZZOLINO FM, 1990, CIRCULATION S, V82, P142; DAVID GS, 1974, BIOCHEMISTRY-US, V13, P1014, DOI 10.1021/bi00702a028; DAVIDSON LA, 1989, AM J PHYSIOL, V257, pG930, DOI 10.1152/ajpgi.1989.257.6.G930; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; FURMANSKI P, 1989, J EXP MED, V170, P415, DOI 10.1084/jem.170.2.415; GERLACH H, 1989, J EXP MED, V170, P913, DOI 10.1084/jem.170.3.913; GHINEA N, 1988, J CELL BIOL, V107, P231, DOI 10.1083/jcb.107.1.231; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HORIUCHI S, 1985, J BIOL CHEM, V260, P475; HORIUCHI S, 1986, J BIOL CHEM, V261, P4962; HUTCHENS TW, 1991, P NATL ACAD SCI USA, V88, P2994, DOI 10.1073/pnas.88.8.2994; Johns EW, 1982, HMG CHROMOSOMAL PROT; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KLOTZ I, 1984, J BIOL CHEM, V258, P11442; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPTON H, 1990, CIRCULATION S, V82, P81; Low M G, 1981, Methods Enzymol, V71 Pt C, P741; LOW MG, 1986, TRENDS BIOCHEM SCI, V11, P212, DOI 10.1016/0968-0004(86)90009-5; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; MORA R, 1992, FASEB J, V6, pA1593; OIMOMI M, 1988, J GERONTOL, V43, pB98, DOI 10.1093/geronj/43.4.B98; PAONESSA G, 1987, NUCLEIC ACIDS RES, V15, P9077, DOI 10.1093/nar/15.21.9077; RADOFF S, 1990, DIABETES, V39, P1510, DOI 10.2337/diabetes.39.12.1510; RADOFF S, 1988, ARCH BIOCHEM BIOPHYS, V263, P418, DOI 10.1016/0003-9861(88)90654-6; REJMAN JJ, 1989, COMP BIOCHEM PHYS B, V93, P929, DOI 10.1016/0305-0491(89)90068-0; ROCHARD E, 1989, FEBS LETT, V255, P201, DOI 10.1016/0014-5793(89)81091-9; SCHMIDT AM, 1991, CIRCULATION S, V84, P456; SCHNITZER JE, 1988, P NATL ACAD SCI USA, V85, P6773, DOI 10.1073/pnas.85.18.6773; STAHL PD, 1978, P NATL ACAD SCI USA, V75, P1399, DOI 10.1073/pnas.75.3.1399; STERN D, 1986, J CELL BIOL, V102, P1971, DOI 10.1083/jcb.102.5.1971; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; VLASSARA H, 1985, P NATL ACAD SCI USA, V82, P5588, DOI 10.1073/pnas.82.17.5588; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; YANG Z, 1991, J EXP MED, V174, P515, DOI 10.1084/jem.174.3.515	41	705	740	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14987	14997						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321822				2022-12-27	WOS:A1992JF08800073
J	WILDEN, PA; SIDDLE, K; HARING, E; BACKER, JM; WHITE, MF; KAHN, CR				WILDEN, PA; SIDDLE, K; HARING, E; BACKER, JM; WHITE, MF; KAHN, CR			THE ROLE OF INSULIN-RECEPTOR KINASE DOMAIN AUTOPHOSPHORYLATION IN RECEPTOR-MEDIATED ACTIVITIES - ANALYSIS WITH INSULIN AND ANTIRECEPTOR ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; MONOCLONAL-ANTIBODIES; BETA-SUBUNIT; PHOSPHORYLATION SITES; INTACT-CELLS; PROTEIN; ACTIVATION; REPLACEMENT; BINDING; HORMONE	The role of specific tyrosine autophosphorylation sites in the human insulin receptor kinase domain (Tyr1158, Tyr1162, and Tyr1163) was analyzed using in vitro mutagenesis to replace tyrosine residues individually or in combination. Each of the three single-Phe, the three possible double-Phe a triple-Phe and a triple-Ser mutant receptors, stably expressed in Chinese hamster ovary cells, were compared with the wild-type receptor in their ability to mediate stimulation of receptor kinase activity, glycogen synthesis, and DNA synthesis by insulin or the human-specific anti-receptor monoclonal antibody 83-14. At a concentration of 0.1 nM insulin which produced approximately half-maximal responses with wild-type receptor, DNA synthesis and glycogen synthesis mediated by the three single-Phe mutants ranged from 52 to 88% and from 32 to 79% of the wild-type receptor, respectively. The corresponding figures for the double-Phe mutants averaged 15 and 6%, whereas the triple-mutants were unresponsive in both assays. The level of biological function approximately paralleled the insulin-stimulated tyrosine kinase activity in the intact cell as estimated by tyrosine phosphorylation of the insulin receptor and its endogenous substrate pp185/IRS-1. Interestingly, all mutants showed a marked decrease in insulin-stimulated receptor internalization. Anti-receptor antibody stimulated receptor kinase activity and mimicked insulin action in these cells. In general, the impairment of the metabolic response was greater and impairment of the growth response was less when antibody was the stimulus. These experiments show that the level and specific sites of autophosphorylation are critical determinants of receptor function. The data are consistent with a requirement for the receptor tyrosine kinase either as an obligatory step or a modulator, in both metabolic and growth responses, and demonstrate the important role of the level of insulin receptor kinase domain autophosphorylation in regulating insulin sensitivity.	BRIGHAM & WOMENS HOSP,DEPT MED,JOSLIN DIABET CTR,DIV RES,1 JOSLIN PL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038712, R01DK031036, R01DK033201, R29DK038712, R55DK038712, R37DK031036] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33201, DK 38712, DK 31036] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1989, P NATL ACAD SCI USA, V86, P3209, DOI 10.1073/pnas.86.9.3209; BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; BRINDLE NPJ, 1990, BIOCHEM J, V268, P615, DOI 10.1042/bj2680615; BRUNETTI A, 1989, BIOCHEM BIOPH RES CO, V165, P212, DOI 10.1016/0006-291X(89)91056-5; CHIN JE, 1991, J BIOL CHEM, V266, P15587; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DEBANT A, 1989, BIOCHEMISTRY-US, V28, P14, DOI 10.1021/bi00427a003; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; GHERZI R, 1987, J BIOL CHEM, V262, P16900; GOTTSCHALK WK, 1991, J BIOL CHEM, V266, P8814; HARLOW E, 1988, ANTIBODIES LABORATOR; HAWLEY DM, 1989, J BIOL CHEM, V264, P2438; HERRERA R, 1986, J BIOL CHEM, V261, P1980; HOUSLAY MD, 1989, BRIT MED BULL, V45, P264, DOI 10.1093/oxfordjournals.bmb.a072316; ISAAD T, 1991, BIOCHEM J, V275, P15; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MAMOUNAS M, 1989, P NATL ACAD SCI USA, V86, P9294, DOI 10.1073/pnas.86.23.9294; MCCLAIN DA, 1991, MOL ENDOCRINOL, V5, P734, DOI 10.1210/mend-5-5-734; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; MYERS MG, 1991, J BIOL CHEM, V266, P10616; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; RAFAELOFF R, 1991, BIOCHEM BIOPH RES CO, V179, P912, DOI 10.1016/0006-291X(91)91905-R; REYNET C, 1990, MOL ENDOCRINOL, V4, P304, DOI 10.1210/mend-4-2-304; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SBRACCIA P, 1990, J BIOL CHEM, V265, P4902; SOOS MA, 1990, BIOCHEM J, V270, P383, DOI 10.1042/bj2700383; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; SOOS MA, 1989, P NATL ACAD SCI USA, V86, P5217, DOI 10.1073/pnas.86.14.5217; STEELEPERKINS G, 1990, J BIOL CHEM, V265, P9458; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUNG CK, 1989, J BIOL CHEM, V264, P18951; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TAYLOR R, 1987, BIOCHEM J, V242, P123, DOI 10.1042/bj2420123; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANOBBERGHEN E, 1981, MOL CELL ENDOCRINOL, V22, P277, DOI 10.1016/0303-7207(81)90037-X; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; YONEZAWA K, 1991, MOL ENDOCRINOL, V5, P194, DOI 10.1210/mend-5-2-194; ZHANG B, 1991, J BIOL CHEM, V266, P990; ZICK Y, 1989, CRIT REV BIOCHEM MOL, V24, P217, DOI 10.3109/10409238909082554; ZICK Y, 1984, J BIOL CHEM, V259, P4396	56	128	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13719	13727						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320027				2022-12-27	WOS:A1992JB74600098
J	KATO, Y; NAKAYAMA, Y; UMEDA, M; MIYAZAKI, K				KATO, Y; NAKAYAMA, Y; UMEDA, M; MIYAZAKI, K			INDUCTION OF 103-KDA GELATINASE TYPE-IV COLLAGENASE BY ACIDIC CULTURE CONDITIONS IN MOUSE METASTATIC MELANOMA CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; MATRIX-DEGRADING METALLOPROTEINASE; NECROSIS FACTOR-ALPHA; ROUS-SARCOMA VIRUS; TISSUE INHIBITOR; TUMOR-CELLS; GENE-EXPRESSION; TRANSIN GENE; ONCOGENE; PURIFICATION	Gelatinases/type IV collagenases have been shown to be involved in tumor invasion and metastasis. In this study, we examined the effect of culture medium pH on the secretion of the gelatinases from mouse B16 melanoma cell lines and human tumor cell lines using zymography analysis. The highly metastatic clone F10 of B16 melanoma did not secrete any gelatinase in neutral culture media (pH 7.1-7.3), whereas it secreted a high level of a 103-kDa gelatinase in an initial pH range of 5.4-6.1. The addition of an excess amount of glucose into a neutral culture medium also induced the gelatinase secretion from the cells by decreasing the medium pH during incubation. The extent of the acid-induced gelatinase secretion by the B16 melanoma cell lines was in the order of BL6 > F10 > F1 >> the parent B16 line, in good agreement with the order of their metastatic potentials. Two human cell lines (A549 and HT1080) secreted a higher level of a 90-kDa gelatinase at pH 6.8 compared with pH 7.3. The acid-induced gelatinase secretion from B16-F10 cells was blocked by cycloheximide, indicating that the enzyme induction was due to de novo synthesis. When in vitro tumor cell invasion was assayed in Boyden chambers, B16-F10 cells incubated in an acidic medium exerted a more active migration through type IV collagen gel than those in a neutral medium. These results suggest that the acidic environment formed around tumor tissues may be an important factor in invasion and metastasis of some types of tumors.	YOKOHAMA CITY UNIV,KIHARA INST BIOL RES,DIV CELL BIOL,2-120-3 NAKAMURA CHO,MINAMI KU,YOKOHAMA,KANAGAWA 232,JAPAN; KANAGAWA DENT COLL,DEPT BIOCHEM,YOKOSUKA 238,JAPAN	Yokohama City University; Kanagawa Dental College			Kato, Yasumasa/H-5312-2012	Kato, Yasumasa/0000-0003-0192-9324				ALBINI A, 1987, CANCER RES, V47, P3239; APODACA G, 1990, CANCER RES, V50, P2322; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BERNHARD EJ, 1990, CANCER RES, V50, P3872; CHIN JR, 1985, J BIOL CHEM, V260, P1367; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DAVIS GE, 1990, CANCER RES, V50, P1113; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; GARBISA S, 1987, CANCER RES, V47, P1523; Geschickter C.F., 1930, J CHEM EDUC, DOI [10.1021/ed007p179, DOI 10.1021/ED007P179]; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HATANAKA M, 1970, VIROLOGY, V41, P647, DOI 10.1016/0042-6822(70)90429-0; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; OKADA Y, 1990, BIOCHEM BIOPH RES CO, V171, P610, DOI 10.1016/0006-291X(90)91190-4; POSTE G, 1980, CANCER RES, V40, P1636; SALO T, 1983, J BIOL CHEM, V258, P3058; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; UMENISHI F, 1991, J BIOCHEM-TOKYO, V110, P189, DOI 10.1093/oxfordjournals.jbchem.a123555; UMENISHI F, 1990, J BIOCHEM-TOKYO, V108, P537, DOI 10.1093/oxfordjournals.jbchem.a123238; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; YAMAGATA S, 1989, BIOCHEM BIOPH RES CO, V158, P228, DOI 10.1016/S0006-291X(89)80202-5; YASUMITSU H, 1992, J BIOCHEM-TOKYO, V1111, P74; ZUCKER S, 1990, INT J CANCER, V45, P1137, DOI 10.1002/ijc.2910450625	35	156	165	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11424	11430						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317866				2022-12-27	WOS:A1992HX16900075
J	RABOUILLE, C; SPIRO, RG				RABOUILLE, C; SPIRO, RG			NONSELECTIVE UTILIZATION OF THE ENDOMANNOSIDASE PATHWAY FOR PROCESSING GLYCOPROTEINS BY HUMAN HEPATOMA (HEPG2) CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; ALPHA-D-MANNOSIDASE; ROUGH ENDOPLASMIC-RETICULUM; ALPHA-1-PROTEINASE INHIBITOR; SECRETORY GLYCOPROTEINS; GOLGI-COMPLEX; RAT-LIVER; CASTANOSPERMINE; PROTEINS; 1-DEOXYNOJIRIMYCIN	Endo-alpha-D-mannosidase, a Golgi-situated processing enzyme, provides a glucosidase-independent pathway for the formation of complex N-linked oligosaccharides of glycoproteins (Moore, S. E. H., and Spiro, R. G. (1990) J. Biol. Chem. 265, 13104-13112). The present report demonstrates that at least five distinct glycoproteins secreted by HepG2 cells (alpha-1-antitrypsin, transferrin, alpha-1-acid glycoprotein, alpha-1-antichymotrypsin, and alpha-fetoprotein) as well as cell surface components can effectively utilize this alternate processing route. During a castanospermine (CST)-imposed glucosidase blockade, these glycoproteins apparently were produced with their usual complement of complex carbohydrate units, and upon addition of the mannosidase I inhibitor, 1-deoxymannojirimycin (DMJ), to prevent further processing of deglucosylated N-linked oligosaccharides, Man6-8GlcNAc, but not Man9GlcNAc, were identified; the Man8GlcNAc component occurred as the characteristic isomer generated by endomannosidase cleavage. Although the endomannosidase-mediated deglucosylation pathway appeared to be nonselective, a differential inhibitory effect on the secretion of the various glycoproteins was noted in the presence of CST which was directly related to the number of their N-linked oligosaccharides, ranging from minimal in alpha-fetoprotein to substantial (approximately-65%) in alpha-1-acid glycoprotein. Addition of DMJ to CST-incubated cells did not further decrease secretion of the glycoproteins, although processing was now arrested at the polymannose stage, and a portion of the oligosaccharides were still in the glucosylated form. These latter findings indicate that complex carbohydrate units are not required for secretion of these glycoproteins and that any effect which glucose residues exert on their intracellular transit would be related to movement from the endoplasmic reticulum to the Golgi compartment.	JOSLIN DIABET CTR, ELLIOTT P JOSLIN RES LAB, 1 JOSLIN PL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MED, BOSTON, MA 02115 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK17477] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017477] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERT E, 1972, J BIOL CHEM, V247, P3792; ANUMULA KR, 1983, J BIOL CHEM, V258, P5274; CAMPION B, 1989, EUR J BIOCHEM, V184, P405, DOI 10.1111/j.1432-1033.1989.tb15032.x; DURONIO V, 1988, J BIOL CHEM, V263, P5463; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FODDY L, 1988, EUR J BIOCHEM, V175, P291, DOI 10.1111/j.1432-1033.1988.tb14196.x; GROSS V, 1983, J BIOL CHEM, V258, P2203; GROSS V, 1986, BIOCHEM J, V236, P853, DOI 10.1042/bj2360853; HODGES LC, 1982, BIOCHEMISTRY-US, V21, P2805, DOI 10.1021/bi00540a036; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAINE A, 1991, EUR J BIOCHEM, V197, P209, DOI 10.1111/j.1432-1033.1991.tb15901.x; LODISH HF, 1987, J CELL BIOL, V104, P221, DOI 10.1083/jcb.104.2.221; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; MATTER K, 1989, J BIOL CHEM, V264, P13131; MEGA T, 1980, J BIOL CHEM, V255, P4053; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; PAN YT, 1983, BIOCHEMISTRY-US, V22, P3975, DOI 10.1021/bi00285a038; PARENT JB, 1986, MOL CELL BIOCHEM, V72, P21; REITMAN ML, 1982, J BIOL CHEM, V257, P357; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; SASAK VW, 1985, BIOCHEM J, V232, P759, DOI 10.1042/bj2320759; SASAK W, 1982, BIOCHEM J, V201, P359, DOI 10.1042/bj2010359; SPIRO MJ, 1985, J BIOL CHEM, V260, P5808; SPIRO MJ, 1979, J BIOL CHEM, V254, P7668; SPIRO RG, 1982, PHILOS T ROY SOC B, V300, P117, DOI 10.1098/rstb.1982.0160; SPIRO RG, 1966, J BIOL CHEM, V241, P1271; TRAVIS J, 1978, BIOCHEMISTRY-US, V17, P5647, DOI 10.1021/bi00619a010; VARKI A, 1983, J BIOL CHEM, V258, P2808; YOSHIMA H, 1980, CANCER RES, V40, P4276; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476	35	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11573	11578						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317871				2022-12-27	WOS:A1992HX16900097
J	TA, DT; VICKERY, LE				TA, DT; VICKERY, LE			CLONING, SEQUENCING, AND OVEREXPRESSION OF A [2FE-2S] FERREDOXIN GENE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; PUTIDAREDOXIN REDUCTASE; ADRENODOXIN; IDENTIFICATION; EXPRESSION; RESOLUTION; DNA	Escherichia coli contains a soluble, [2Fe-2S] ferredoxin of unknown function (Knoell, H.-E., and Knappe, J. (1974) Eur. J. Biochem. 50, 245-252). Using antiserum to the purified protein to screen E. coli genomic expression libraries, we have cloned a gene (designated fdx) encoding this protein. The DNA sequence of the gene predicts a polypeptide of 110 residues after removal of the initiator methionine (polypeptide M(r) = 12,186, holoprotein M(r) = 12,358). The deduced amino acid sequence is strikingly similar to those of the ferredoxins found in animal mitochondria which function with cytochrome P450 enzymes and to the ferredoxin from Pseudomonas putida which functions with P450cam. The overall sequence identity is approximately 36% when compared with human mitochondrial and P. putida ferredoxins, and the identities include 4 cysteine residues proposed to coordinate the iron cluster. The protein was overproduced approximately 500-fold using an expression plasmid, and the holoprotein was assembled and accumulated in amounts exceeding 30% of the total cell protein. The overexpressed ferredoxin exhibits absorption, circular dichroism, and electron paramagnetic resonance spectra closely resembling those of the animal ferredoxins and P. putida ferredoxin.	UNIV CALIF IRVINE, DEPT PHYSIOL & BIOPHYS, IRVINE, CA 92717 USA	University of California System; University of California Irvine					NIGMS NIH HHS [GM43548] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043548] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLASCHKOWSKI HP, 1982, EUR J BIOCHEM, V123, P563; BRANDT ME, 1992, IN PRESS ARCH BIOCH, V294; BRUSCHI M, 1988, FEMS MICROBIOL LETT, V54, P155, DOI 10.1111/j.1574-6968.1988.tb02741.x; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHENG SWC, 1991, SCIENCE, V254, P1205, DOI 10.1126/science.1835546; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; COGHLAN VM, 1989, P NATL ACAD SCI USA, V86, P835, DOI 10.1073/pnas.86.3.835; COGHLAN VM, 1992, J BIOL CHEM, V267, P8932; CUPP JR, 1988, J BIOL CHEM, V263, P17418; DERVARTI.DV, 1967, BIOCHEM BIOPH RES CO, V26, P569, DOI 10.1016/0006-291X(67)90103-9; GERBER NC, 1990, BIOCHEM BIOPH RES CO, V169, P1016, DOI 10.1016/0006-291X(90)91995-5; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HENDLER RW, 1970, J CELL BIOL, V46, P114, DOI 10.1083/jcb.46.1.114; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HUANG JJ, 1973, BIOCHEMISTRY-US, V12, P406, DOI 10.1021/bi00727a007; KNOELL HE, 1974, EUR J BIOCHEM, V50, P245, DOI 10.1111/j.1432-1033.1974.tb03893.x; KOGA H, 1989, J BIOCHEM-TOKYO, V106, P831, DOI 10.1093/oxfordjournals.jbchem.a122939; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUBARA H, 1987, IRON SULFUR PROTEIN; MEYER J, 1988, TRENDS ECOL EVOL, V3, P222, DOI 10.1016/0169-5347(88)90162-0; MITTAL S, 1988, ARCH BIOCHEM BIOPHYS, V264, P383, DOI 10.1016/0003-9861(88)90303-7; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; PALMER G, 1967, BIOCHEMISTRY-US, V6, P1658, DOI 10.1021/bi00858a012; PETERSON JA, 1990, J BIOL CHEM, V265, P6066; POCHAPSKY TC, 1991, BIOCHEMISTRY-US, V30, P3850, DOI 10.1021/bi00230a007; RYPNIEWSKI WR, 1991, BIOCHEMISTRY-US, V30, P4126, DOI 10.1021/bi00231a003; Sambrook J, 1989, MOL CLONING LABORATO; SANDS RH, 1974, Q REV BIOPHYS, V7, P443, DOI 10.1017/S0033583500001517; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SHIPP WS, 1972, ARCH BIOCHEM BIOPHYS, V150, P459, DOI 10.1016/0003-9861(72)90063-X; Spiro T. G., 1982, IRON SULFUR PROTEINS; TSUKIHARA T, 1990, J MOL BIOL, V216, P399, DOI 10.1016/S0022-2836(05)80330-4; TSUKIHARA T, 1981, J BIOCHEM-TOKYO, V90, P1763, DOI 10.1093/oxfordjournals.jbchem.a133654; TULS J, 1987, J BIOL CHEM, V262, P10020; VETTER H, 1971, H-S Z PHYSIOL CHEM, V352, P433, DOI 10.1515/bchm2.1971.352.1.433; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	37	122	139	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11120	11125						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317854				2022-12-27	WOS:A1992HX16900031
J	VASSAUX, G; GAILLARD, D; AILHAUD, G; NEGREL, R				VASSAUX, G; GAILLARD, D; AILHAUD, G; NEGREL, R			PROSTACYCLIN IS A SPECIFIC EFFECTOR OF ADIPOSE CELL-DIFFERENTIATION - ITS DUAL ROLE AS A CAMP-ELEVATING AND CA2+-ELEVATING AGENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDIDYMAL FAT PAD; SERUM-FREE MEDIUM; PRECURSOR CELLS; CALCIUM-ION; GROWTH; LINE; ESTABLISHMENT; CONVERSION; ADIPOCYTES	The mitogenic-adipogenic activity of carbaprostacyclin (cPGI2), a stable analogue of prostacyclin (PGI2), has been proposed to be related to its ability to elicit cAMP production and to activate the protein kinase A cascade (Negrel, R., Gaillard, D., and Ailhaud, G. (1989) Biochem. J. 257, 399-405). In the present study, cPGI2 has been compared with other activators of the cAMP pathway, namely isoproterenol, forskolin and 8-bromo-cAMP, with respect to adipose cell differentiation. Carbaprostacyclin behaved as a much more potent and efficient effector of mouse Ob1771 preadipocyte differentiation than the latter agents. Moreover, cPGI2 also exerted a specific amplifying mitogenic-adipogenic role, as compared with isoproterenol in rat as well as human adipose precursor cells in primary culture, suggesting that the prostanoid was able to generate an additional second messenger. The fact that ionomycin was able to potentiate and amplify t he differentiation induced by 8-bromo-cAMP led us to give evidence, using preadipocytes preloaded with the fluorescent calcium chelator Indo-1, that cPGI2, besides its ability to activate adenyl cyclase, was also able to induce a transient increase in intracellular free calcium. This phenomenon was independent of cAMP production or inositol phospholipid breakdown and appeared to be mediated after binding to a single class of PGI2 receptor. The potential to generate simultaneously two synergistic intracellular signals allows us to ascribe to PGI2 a key and specific role in the differentiation of adipose precursor cells in vitro that would likely lead in vivo to the recruitment of "dormant" preadipocytes to become adipocytes.	UNIV NICE SOPHIA ANTIPOLIS,FAC SCI,CNRS,UMR 134,CTR BIOCHIM,PARC VALROSE,F-06108 NICE 2,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Vassaux, Georges/N-9724-2016	Vassaux, Georges/0000-0002-1149-7716; Ailhaud, Gerard/0000-0003-0596-2906				ADACHI M, 1989, CANCER RES, V49, P3805; AIKEN JW, 1980, PROSTAGLANDINS, V19, P629, DOI 10.1016/S0090-6980(80)80011-6; AMRI EZ, 1986, BIOCHEM BIOPH RES CO, V137, P903, DOI 10.1016/0006-291X(86)91165-4; AXELROD L, 1981, DIABETES, V30, P163, DOI 10.2337/diabetes.30.2.163; BRUNTON LL, 1976, J BIOL CHEM, V251, P3037; CATALIOTO RM, 1991, BIOCHIM BIOPHYS ACTA, V1091, P364, DOI 10.1016/0167-4889(91)90201-8; CATALIOTO RM, 1987, J CELL PHYSIOL, V130, P352, DOI 10.1002/jcp.1041300307; CATALIOTO RM, 1992, IN PRESS GROWTH FACT; DANI C, 1989, J BIOL CHEM, V264, P10119; DESLEX S, 1987, EXP CELL RES, V168, P15, DOI 10.1016/0014-4827(87)90412-5; DESLEX S, 1986, INT J OBESITY, V10, P19; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; DONI MG, 1988, BIOCHEM BIOPH RES CO, V156, P1316; DUTTAROY AK, 1987, J BIOL CHEM, V262, P12685; FOREST C, 1981, BIOCHEM BIOPH RES CO, V102, P577, DOI 10.1016/S0006-291X(81)80171-4; FOREST C, 1983, IN VITRO CELL DEV B, V19, P344; GAILLARD D, 1991, J LIPID RES, V32, P569; GAILLARD D, 1989, BIOCHEM J, V257, P389, DOI 10.1042/bj2570389; GAILLARD D, 1985, BIOCHIM BIOPHYS ACTA, V846, P185, DOI 10.1016/0167-4889(85)90125-9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAUNER H, 1989, J CLIN INVEST, V84, P1663, DOI 10.1172/JCI114345; KOJIMA I, 1985, J BIOL CHEM, V260, P4248; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LEDBETTER JA, 1987, P NATL ACAD SCI USA, V84, P1384, DOI 10.1073/pnas.84.5.1384; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDERMOT J, 1981, BIOCHEM PHARMACOL, V30, P2041, DOI 10.1016/0006-2952(81)90220-3; NEGREL R, 1978, P NATL ACAD SCI USA, V75, P6054, DOI 10.1073/pnas.75.12.6054; NEGREL R, 1989, BIOCHEM J, V257, P399, DOI 10.1042/bj2570399; NEGREL R, 1985, METHOD ENZYMOL, V109, P377; Rasmussen H, 1990, Curr Top Cell Regul, V31, P1; RICHELSEN B, 1987, BIOCHEM J, V247, P389, DOI 10.1042/bj2470389; RICHELSEN B, 1991, DAN MED BULL, V38, P228; YAMASHITA T, 1987, J BIOL CHEM, V262, P5536	33	168	174	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11092	11097						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317853				2022-12-27	WOS:A1992HX16900027
J	KAWABATA, S; DAVIE, EW				KAWABATA, S; DAVIE, EW			A MICROSOMAL ENDOPEPTIDASE FROM LIVER WITH SUBSTRATE-SPECIFICITY FOR PROCESSING PROPROTEINS SUCH AS THE VITAMIN-K-DEPENDENT PROTEINS OF PLASMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT COMPONENT; MAMMALIAN-CELLS; CDNA; CLEAVAGE; SEQUENCE; PROPEPTIDE; PRECURSOR; ARGININE; POSITION; PROTEASE	The microsomal fraction of rabbit liver contains an endopeptidase that cleaves synthetic peptides that mimic the amino acid sequences of the processing sites of many proproteins, including the vitamin K-dependent proteins. The endopeptidase (M(r) 69,000) was extracted from liver microsomes with 1% Lubrol and purified about 2,700-fold. The substrate employed for isolation and characterization of the enzyme was the decapeptide acetyl-Ala-Arg-Val-Arg-Arg-Ala-Asn-Ser-Phe-Leu (prothrombin peptide), in which hydrolysis occurred on the carboxyl side of the paired Arg-Arg residues. The purified enzyme, whose activity was enhanced 1.8-fold by 0.1 mM CoCl2, has a K(m) = 80-mu-M and V(max) = 2 1,000 nmol.min-1.mg-1 and a pH optimum of 8.7. Proteolytic cleavage of decapeptide substrates was dependent on an arginine residue at positions P1 and P4. The enzyme was completely inhibited by EDTA and 1,10-phenanthroline as well as by p-chloromercuriphenylsulfonic acid and Hg2+. Inhibitors of serine proteases and cysteine proteases had no effect. Based on the substrate preference, the endopeptidase appears to be a good candidate for the enzyme responsible for the precursor processing of the vitamin K-dependent proteins and a number of other proproteins that are synthesized via the secretory pathway in liver and other tissues.	UNIV WASHINGTON, DEPT BIOCHEM, SJ-70, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016919] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16919] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BELT KT, 1984, CELL, V36, P907; BENTLEY AK, 1986, CELL, V45, P343, DOI 10.1016/0092-8674(86)90319-3; BRENNAN SO, 1988, FEBS LETT, V229, P167, DOI 10.1016/0014-5793(88)80819-6; CATTERALL CF, 1987, BIOCHEM J, V242, P849, DOI 10.1042/bj2420849; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DIUGUID DL, 1986, P NATL ACAD SCI USA, V83, P5803, DOI 10.1073/pnas.83.16.5803; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FOSTER D, 1984, P NATL ACAD SCI-BIOL, V81, P4766, DOI 10.1073/pnas.81.15.4766; FOSTER DC, 1990, BIOCHEMISTRY-US, V29, P347, DOI 10.1021/bi00454a007; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GREEN PM, 1989, EMBO J, V8, P1067, DOI 10.1002/j.1460-2075.1989.tb03474.x; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; JORNVALL H, 1983, FEBS LETT, V156, P47, DOI 10.1016/0014-5793(83)80245-2; KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x; KAWAOKA Y, 1988, P NATL ACAD SCI USA, V85, P324, DOI 10.1073/pnas.85.2.324; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN KS, 1989, BIOCHEMISTRY-US, V28, P9620, DOI 10.1021/bi00451a012; LEYTUS SP, 1984, P NATL ACAD SCI-BIOL, V81, P3699, DOI 10.1073/pnas.81.12.3699; LIDDELL MB, 1988, BRIT J HAEMATOL, V69, P120; LUNDWALL AB, 1985, J BIOL CHEM, V260, P2108; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MILETICH JP, 1983, BLOOD, V62, P306; MIZUNO K, 1989, BIOCHEM BIOPH RES CO, V159, P305, DOI 10.1016/0006-291X(89)92438-8; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; PAN LC, 1985, P NATL ACAD SCI USA, V82, P6109, DOI 10.1073/pnas.82.18.6109; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; Riordan J F, 1972, Methods Enzymol, V25, P494, DOI 10.1016/S0076-6879(72)25045-5; SADLER JE, 1985, P NATL ACAD SCI USA, V82, P6394, DOI 10.1073/pnas.82.19.6394; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SUGIMOTO M, 1989, BRIT J HAEMATOL, V72, P216, DOI 10.1111/j.1365-2141.1989.tb07685.x; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; TOLLEFSEN DM, 1990, J BIOL CHEM, V265, P9778; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378	44	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10331	10336						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1316898				2022-12-27	WOS:A1992HV09000022
J	PRATT, CW; WHINNA, HC; CHURCH, FC				PRATT, CW; WHINNA, HC; CHURCH, FC			A COMPARISON OF 3 HEPARIN-BINDING SERINE PROTEINASE-INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COFACTOR-II; ANTITHROMBIN-III; DERMATAN SULFATE; MOLECULAR-WEIGHT; HIGH-AFFINITY; C INHIBITOR; FACTOR-XA; THROMBIN; KINETICS; SITE	The purpose of this study was to compare three heparin-binding plasma proteinase inhibitors in order to identify common and unique features of heparin binding and heparin-enhanced proteinase inhibition. Experiments with antithrombin, heparin cofactor, and protein C inhibitor were performed under identical conditions in order to facilitate comparisons. Synthetic peptides corresponding to the putative heparin binding regions of antithrombin, heparin cofactor, and protein C inhibitor bound to heparin directly and interfered in heparin-enhanced proteinase inhibition assays. All three inhibitors obeyed a ternary complex mechanism for heparin-enhanced thrombin inhibition, and the optimum heparin concentration was related to the apparent heparin affinity of the inhibitor. The maximum inhibition rate and rate enhancement due to heparin appeared to be unique properties of each inhibitor. In assays with heparin oligosaccharides of known size, only the antithrombin-thrombin reaction exhibited a sharp threshold for rate enhancement at 14-16 saccharide units. Acceleration of antithrombin inhibition of factor Xa, heparin cofactor inhibition of thrombin, and protein C inhibitor inhibition of thrombin, activated protein C, and factor Xa did not require a minimum saccharide size. The differences in heparin size dependence and rate enhancement of proteinase inhibition by these inhibitors might reflect differences in the importance of the ternary complex mechanism and other mechanisms, alterations in inhibitor reactivity, and orientation effects in heparin-enhanced proteinase inhibition.	UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CTR THROMBOSIS & HEMOSTASIS, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032656] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-06530, HL-32656] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BERESFORD CH, 1990, INT J BIOCHEM, V22, P121, DOI 10.1016/0020-711X(90)90172-Y; BERTINA RM, 1987, THROMB HAEMOSTASIS, V57, P196; BJORK I, 1986, PROTEINASE INHIBITOR, P489; BLINDER MA, 1989, J BIOL CHEM, V264, P5128; BLINDER MA, 1990, J BIOL CHEM, V265, P286; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; EVANS DL, 1991, J BIOL CHEM, V266, P22307; GANDRILLE S, 1990, J BIOL CHEM, V265, P18997; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; GRIFFITH MJ, 1985, BIOCHEMISTRY-US, V24, P6777, DOI 10.1021/bi00345a008; HATHAWAY WE, 1991, SEMIN HEMATOL, V28, P19; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KIM YS, 1989, THROMB RES, V53, P55, DOI 10.1016/0049-3848(89)90115-1; KUHN LA, 1990, P NATL ACAD SCI USA, V87, P8506, DOI 10.1073/pnas.87.21.8506; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; NESHEIM M, 1986, J BIOL CHEM, V261, P3214; NESHEIM ME, 1983, J BIOL CHEM, V258, P4708; OFOSU FA, 1989, BIOCHEM J, V257, P143, DOI 10.1042/bj2570143; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OWEN BA, 1990, BIOCHEMISTRY-US, V29, P9412, DOI 10.1021/bi00492a015; PETERSON CB, 1987, J BIOL CHEM, V262, P7559; PRATT CW, 1989, ANN NY ACAD SCI, V556, P104; PRATT CW, 1992, J BIOL CHEM, V267, P8789; PRATT CW, 1991, SEMIN HEMATOL, V28, P3; PRATT CW, 1991, THROMB HAEMOSTASIS, V65, P1209; RAGG H, 1990, J BIOL CHEM, V265, P5211; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; SIE P, 1988, BIOCHIM BIOPHYS ACTA, V966, P188, DOI 10.1016/0304-4165(88)90111-0; SIM RB, 1980, BIOCHIM BIOPHYS ACTA, V612, P433, DOI 10.1016/0005-2744(80)90126-6; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; SUN XJ, 1990, BIOCHEMISTRY-US, V29, P8957, DOI 10.1021/bi00490a011; SUN XJ, 1989, EUR J BIOCHEM, V185, P225, DOI 10.1111/j.1432-1033.1989.tb15106.x; SUZUKI K, 1987, J BIOL CHEM, V262, P611; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WALLACE A, 1989, BIOCHEM J, V257, P191, DOI 10.1042/bj2570191; WHINNA HC, 1991, J BIOL CHEM, V266, P8129	45	96	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8795	8801						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1315739				2022-12-27	WOS:A1992HR85400017
J	NAKA, D; ISHII, T; YOSHIYAMA, Y; MIYAZAWA, K; HARA, H; HISHIDA, T; KITAMURA, N				NAKA, D; ISHII, T; YOSHIYAMA, Y; MIYAZAWA, K; HARA, H; HISHIDA, T; KITAMURA, N			ACTIVATION OF HEPATOCYTE GROWTH-FACTOR BY PROTEOLYTIC CONVERSION OF A SINGLE CHAIN FORM TO A HETERODIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; HEPATOPOIETIN-A; MESSENGER-RNA; SCATTER FACTOR; PURIFICATION; IDENTIFICATION; RECEPTOR; SEQUENCE; CDNA; FIBROBLASTS	Hepatocyte growth factor (HGF) is a heterodimeric protein consisting of a heavy chain and a light chain held by a disulfide bond. These chains are produced by endoproteolytic processing from a single chain precursor. In this study, we examined whether the processing is a prerequisite for the mitogenic activity of HGF on hepatocytes in primary culture. Single chain HGF was proteolytically converted to the heterodimeric form during incubation with hepatocytes and was as mitogenic as the heterodimeric form. When the conversion was inhibited by serine-protease inhibitors, the mitogenic activity of single chain HGF was markedly reduced. Furthermore, a mutant resistant to the proteolytic processing, which was prepared by in vitro mutagenesis, completely lost the mitogenic activity. From these results, we concluded that the single chain form of HGF is endoproteolytically processed by a serine-protease and that this processing is a prerequisite for the mitogenic activity of HGF.	KANSAI MED UNIV,INST LIVER RES,MORIGUCHI,OSAKA 570,JAPAN	Kansai Medical University	NAKA, D (corresponding author), MITSUBISHI KASEI CORP,RES CTR,BIOSCI LAB,1000 KAMOSHIDA CHO,MIDORI KU,YOKOHAMA 227,JAPAN.		MIYAZAWA, KEIJI/I-9713-2014					BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HERNANDEZ J, 1992, J CELL PHYSIOL, V150, P116, DOI 10.1002/jcp.1041500116; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KOMADA M, 1992, EUR J BIOCHEM, V204, P857, DOI 10.1111/j.1432-1033.1992.tb16705.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; OHARE K, 1981, P NATL ACAD SCI-BIOL, V78, P1527, DOI 10.1073/pnas.78.3.1527; OKAJIMA A, 1990, EUR J BIOCHEM, V193, P375, DOI 10.1111/j.1432-1033.1990.tb19349.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SHIMA N, 1991, BIOCHEM BIOPH RES CO, V180, P1151, DOI 10.1016/S0006-291X(05)81187-8; SHIMOMURA T, 1992, IN PRESS CYTOTECHNOL; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRAIN AJ, 1991, J CLIN INVEST, V87, P1853, DOI 10.1172/JCI115207; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YOSHIYAMA Y, 1991, BIOCHEM BIOPH RES CO, V175, P660, DOI 10.1016/0006-291X(91)91616-K; ZARNEGAR R, 1989, BIOCHEM BIOPH RES CO, V163, P1370, DOI 10.1016/0006-291X(89)91130-3; ZARNEGAR R, 1989, CANCER RES, V49, P3314	31	207	231	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20114	20119						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328193				2022-12-27	WOS:A1992JR85800059
J	MUERHOFF, AS; GRIFFIN, KJ; JOHNSON, EF				MUERHOFF, AS; GRIFFIN, KJ; JOHNSON, EF			THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR MEDIATES THE INDUCTION OF CYP4A6, A CYTOCHROME-P450 FATTY-ACID OMEGA-HYDROXYLASE, BY CLOFIBRIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RETINOIC ACID; BETA-GENE; SUPERFAMILY; CLONING; HORMONE; EXPRESSION; SEQUENCES; BINDING; ELEMENT; MEMBER	Gene transfer experiments indicate that induction by the peroxisome proliferators, clofibric acid and WY-14,643, of luciferase expression driven by the promoter and 5'-flanking sequences of the rabbit cytochrome P450 4A6 gene (CYP4A6) is dependent on cotransfection of expression plasmids for the peroxisome proliferator-activated receptor, PPAR. Activation by PPAR is observed in the absence of the inducers. However, a mutant, PPAR-G (Glu282 --> Gly) activated luciferase expression only in the presence of peroxisome proliferators. Deletion analysis has localized a response element to a 34-base pair segment located 677 base pairs upstream of the CYP4A6 transcription start site that is similar to an element that regulates the response of the rat fatty acyl-CoA oxidase gene to peroxisome proliferators and that binds PPAR.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED,DIV BIOCHEM,NX 4, LA JOLLA, CA 92037 USA	Scripps Research Institute					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD004445] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD004445] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00833] Funding Source: Medline; NICHD NIH HHS [HD04445] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KRAUPPGRASL B, 1990, CANCER RES, V50, P3701; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MUERHOFF AS, 1992, ARCH BIOCHEM BIOPHYS, V296, P66, DOI 10.1016/0003-9861(92)90545-8; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; POLAND A, 1976, J BIOL CHEM, V251, P4936; RAO MS, 1987, CARCINOGENESIS, V8, P631; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Sambrook J, 1989, MOL CLONING LABORATO; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; YOKOTANI N, 1989, J BIOL CHEM, V264, P21665	23	309	316	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19051	19053						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326542				2022-12-27	WOS:A1992JP59300008
J	YAMAGUCHI, A; SOMEYA, Y; SAWAI, T				YAMAGUCHI, A; SOMEYA, Y; SAWAI, T			METAL-TETRACYCLINE/H+ ANTIPORTER OF ESCHERICHIA-COLI ENCODED BY TRANSPOSON TN10 - THE ROLE OF A CONSERVED SEQUENCE MOTIF, GXXXXRXGRR, IN A PUTATIVE CYTOPLASMIC LOOP BETWEEN HELICES 2 AND 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE PROTEIN; NUCLEOTIDE-SEQUENCE; GENE; DETERMINANTS; EFFLUX	The region including the conserved Ser65-Asp66 dipeptide in the tetracycline/H+ antiporter (TET) encoded by transposon Tn10 is thought to play a gating role (Yamaguchi, A., Ono, N., Akasaka, T., Noumi, T., and Sawai, T. (1990) J. Biol. Chem. 265, 15525-15530). The dipeptide is in putative interhelix loop2-3, which also includes the conserved sequence motif, GXXXXRXGRR, found in all TET proteins and sugar/H+ symporters. Through the combination of localized random and site-directed mutagenesis, each residue in loop2-3 was replaced. Among 10 residues in putative loop2-3, the important residues, of which substitution resulted in significant reduction or complete loss of the transport activity, were Gly62, Asp66, Gly69, and Arg70. The defect in the transport activity of the Gly62 and Gly69 substitution mutants corresponded to the steric hindrance by the substituents as to the putative beta-turn structure of the peptide backbone containing these glycines. Of 3 conserved Arg residues, the replacement of only Arg70 caused complete loss of the activity except for replacement with Lys, indicating the importance of a positive charge at this position, which is similar to the essentiality of a negative charge at Asp66. A "charge-neutralizing" intra-loop salt bridge between Asp66 and Arg70 was not likely because the double mutant in which Asp66 and Arg70 were replaced with asparagine and leucine, respectively, showed no transport activity. A triple mutant with only one positive charge at Arg70 in this loop showed about half the wild-type activity, indicating that the polycationic nature of the loop was not critical for the activity. Cys mutants as to the unessential residues in the loop were modifiable with N-ethylmaleimide, except for the Met64 --> Cys and Arg71 --> Cys mutants; however, the modification of only the Ser65 --> Cys mutant caused significant inhibition of the transport activity, indicating that position 65 is a unique position in the structure of loop2-3.			YAMAGUCHI, A (corresponding author), CHIBA UNIV, FAC PHARMACEUT SCI, DIV MICROBIAL CHEM, CHIBA 263, JAPAN.							CHOPRA I, 1986, J ANTIMICROB CHEMOTH, V18, P51, DOI 10.1093/jac/18.Supplement_C.51; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Creighton TE, 1983, PROTEINS STRUCTURES; ECKERT B, 1989, J BIOL CHEM, V264, P11663; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; HILLEN W, 1983, NUCLEIC ACIDS RES, V11, P525, DOI 10.1093/nar/11.2.525; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; MOYED HS, 1983, J BACTERIOL, V155, P549, DOI 10.1128/JB.155.2.549-556.1983; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; RUBIN RA, 1990, GENE, V87, P7, DOI 10.1016/0378-1119(90)90489-E; STOKER NG, 1982, GENE, V18, P335, DOI 10.1016/0378-1119(82)90172-X; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WATERS SH, 1983, NUCLEIC ACIDS RES, V11, P6089, DOI 10.1093/nar/11.17.6089; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1991, FEBS LETT, V282, P415, DOI 10.1016/0014-5793(91)80527-A; YAMAGUCHI A, 1991, J BIOL CHEM, V266, P6045; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P7490; YAMAMOTO T, 1981, J BACTERIOL, V145, P808, DOI 10.1128/JB.145.2.808-813.1981	24	96	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19155	19162						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326546				2022-12-27	WOS:A1992JP59300025
J	JIN, SLC; SWINNEN, JV; CONTI, M				JIN, SLC; SWINNEN, JV; CONTI, M			CHARACTERIZATION OF THE STRUCTURE OF A LOW KM, ROLIPRAM-SENSITIVE CAMP PHOSPHODIESTERASE - MAPPING OF THE CATALYTIC DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; DEPENDENT PROTEIN-KINASE; SITE-DIRECTED MUTAGENESIS; SERTOLI-CELL; REGULATORY SUBUNIT; MOLECULAR-CLONING; DICTYOSTELIUM-DISCOIDEUM; HORMONAL-REGULATION; ESCHERICHIA-COLI; BINDING	Considerable structural similarities are present in a region of approximately 270 amino acids in most known cyclic nucleotide phosphodiesterase (PDE) sequences, opening the possibility that this region encodes the catalytic domain of the enzyme. To test this hypothesis, the structure of a high affinity cAMP PDE (cAMP-PDE) was analyzed by deletion mutations and site-directed mutagenesis. A ratPDE3 cDNA was mutated using a strategy based on fragment amplification by polymerase chain reaction. The effect of the introduced mutations was determined by expressing wild type and mutated proteins in prokaryotic and eukaryotic cells. The level of expression of the PDE protein was monitored by immunoblot analysis using two specific cAMP-PDE polyclonal antibodies and by measuring the PDE activity. After removal of a 99-amino acid region at the carboxyl terminus flanking the conserved domain, the protein retains its catalytic activity even though its K(m) and velocity were changed. Internal deletions at the amino terminus of this PDE showed that the enzyme activity was increased when a 97-amino acid fragment (from Tyr49 to Lys145) was removed. Further deletions within the amino terminus produced inactive proteins. Within the domain that appears essential for catalysis, 1 threonine and 2 serine residues are conserved in all PDEs. Substitutions of the invariant threonine (Thr349) present in the most conserved region with alanine, proline, or serine yielded proteins of the correct size and a level of expression comparable to the wild type PDE. However, in both expression systems used, proteins were completely devoid of the ability to hydrolyze cyclic nucleotides, except when the threonine was substituted with a serine. Conversely, mutations of 2 other conserved serine residues (Ser305 and Ser398) present in the catalytic domain either had no effect or produced changes only in K(m) and V(max), but did not abolish catalytic activity. In addition, 2 histidine residues (His278 and His311) present in proximity to Thr349 appeared to be essential for the structure of the catalytic domain, since any substitution performed in these residues yielded an inactive enzyme. Mutations of a serine residue (Ser295) in the region homologous to the cAMP binding site of the regulatory subunit of the cAMP-dependent protein kinase demonstrated that this region does not have the same function in the two proteins. These data provide direct evidence that a 37-kDa domain, which in part corresponds to the region of conservation in all PDEs, contains the catalytic domain, and that threonine and histidine residues are probably involved in catalysis and/or are essential for the conformation of an active enzyme.	UNIV N CAROLINA, DEPT PEDIAT, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PHYSIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	JIN, SLC (corresponding author), GLAXO INC, DIV PHARMACOL, 5 MOORE DR, RES TRIANGLE PK, NC 27709 USA.		Swinnen, Johannes V/AAA-2214-2022	Swinnen, Johannes V/0000-0002-7720-5077	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20788] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; Bernard H U, 1979, Methods Enzymol, V68, P482; BUBIS J, 1988, J BIOL CHEM, V263, P9668; CAMPAGNE MMV, 1990, J BIOL CHEM, V265, P5847; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; Charbonneau H., 1990, CYCLIC NUCLEOTIDE PH, P267; CHARBONNEAU H, 1987, CALCIUM BINDING PROT, P505; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; CONTI M, 1986, ENDOCRINOLOGY, V118, P901, DOI 10.1210/endo-118-3-901; CONTI M, 1982, ENDOCRINOLOGY, V110, P1189, DOI 10.1210/endo-110-4-1189; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; CONTI M, 1983, ENDOCRINOLOGY, V113, P1845, DOI 10.1210/endo-113-5-1845; Conti M., 1990, Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action, P243; CROWL R, 1985, GENE, V38, P31, DOI 10.1016/0378-1119(85)90200-8; CULP JS, 1985, J BIOL CHEM, V260, P8320; EPSTEIN PM, 1982, ARCH BIOCHEM BIOPHYS, V218, P119, DOI 10.1016/0003-9861(82)90327-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KINCAID RL, 1985, J BIOL CHEM, V260, P9009; LACOMBE ML, 1986, J BIOL CHEM, V261, P6811; LETRONG H, 1990, BIOCHEMISTRY-US, V29, P10280; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; NIKAWA JI, 1987, MOL CELL BIOL, V7, P3629, DOI 10.1128/MCB.7.10.3629; OGREID D, 1988, J BIOL CHEM, V263, P17397; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SHEPARD HM, 1982, DNA-J MOLEC CELL BIO, V1, P125, DOI 10.1089/dna.1.1982.1.125; STROOP SD, 1989, J BIOL CHEM, V264, P13718; SWINNEN JV, 1991, J BIOL CHEM, V266, P18370; SWINNEN JV, 1991, J BIOL CHEM, V266, P14383; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; VANHAASTERT PJM, 1983, EUR J BIOCHEM, V131, P659; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WOODFORD TA, 1989, J BIOL CHEM, V264, P13321	43	115	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18929	18939						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326538				2022-12-27	WOS:A1992JN50200102
J	HANSON, PI; SCHULMAN, H				HANSON, PI; SCHULMAN, H			INHIBITORY AUTOPHOSPHORYLATION OF MULTIFUNCTIONAL CA2+ CALMODULIN-DEPENDENT PROTEIN-KINASE ANALYZED BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; CA-2+ CALMODULIN; BINDING DOMAIN; CA-2+-INDEPENDENT ACTIVITY; BIOTINYLATED CALMODULIN; REGULATORY INTERACTIONS; MOLECULAR-CLONING; EXPRESSION SYSTEM; AUTONOMOUS ENZYME; SENSITIVE METHOD	Initial autophosphorylation of multifunctional Ca2+/calmodulin-dependent protein kinase (CaM kinase) occurs at Thr286 (the "autonomy" site) and converts the kinase from a Ca2+-dependent to a partially Ca2+-independent or autonomous enzyme. After removal of Ca2+/calmodulin, the autonomous kinase undergoes a "burst" of inhibitory autophosphorylation at sites distinct from the autonomy site which may be masked in the presence of bound calmodulin. This burst of Ca2+-independent autophosphorylation blocks the ability of calmodulin to activate the kinase. We have used site-directed mutagenesis to replace putative inhibitory autophosphorylation sites within the calmodulin binding domain of recombinant alpha-CaM kinase with nonphosphorylatable alanines and examined the effects on autophosphorylation, kinase activity, and calmodulin binding. Although prominent Ca2+-independent autophosphorylation occurs within the calmodulin binding domain at Thr305, Thr306, and Ser314 in wild-type alpha-CaM kinase, the inhibitory effect on kinase activity and calmodulin binding is retained in mutants lacking any one of these three sites. However, when both Thr305 and Thr306 are converted to alanines the kinase does not display inhibition of either activity or calmodulin binding. Autophosphorylation at either Thr305 or Thr306 is therefore sufficient to block both binding and activation of the kinase by Ca2+/calmodulin. Thr306 is also slowly autophosphorylated in a basal reaction in the continuous absence of Ca2+/calmodulin. Autophosphorylation of Thr306 by the kinase in either its basal or autonomous state suggests that in the absence of bound calmodulin, the region of the autoregulatory domain surrounding Thr306, rather than the region near the autonomy site, lies nearest the peptide substrate binding site of the kinase.	STANFORD UNIV, MED CTR, SCH MED, DEPT PHARMACOL, STANFORD, CA 94305 USA	Stanford University			Hanson, Phyllis/E-9420-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030179, R01GM030179] Funding Source: NIH RePORTER; NCI NIH HHS [CA09302] Funding Source: Medline; NIGMS NIH HHS [GM30179] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; CONTI MA, 1981, J BIOL CHEM, V256, P3178; FONG YL, 1989, J BIOL CHEM, V264, P16759; GILBERT DG, 1989, ENZYME KINETICS; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HANLEY RM, 1988, BIOCHEM BIOPH RES CO, V152, P122, DOI 10.1016/S0006-291X(88)80688-0; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P16524; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; HASHIMOTO Y, 1988, P NATL ACAD SCI USA, V85, P7001, DOI 10.1073/pnas.85.18.7001; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P10884; KANASEKI T, 1991, J CELL BIOL, V115, P1049, DOI 10.1083/jcb.115.4.1049; KELLY PT, 1988, P NATL ACAD SCI USA, V85, P4991, DOI 10.1073/pnas.85.14.4991; KINCAID RL, 1988, METHOD ENZYMOL, V159, P605; KING MM, 1988, J BIOL CHEM, V263, P4754; LICKTEIG R, 1988, J BIOL CHEM, V263, P19232; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; LOU LL, 1989, J NEUROSCI, V9, P2020; MARTENSEN TM, 1989, BIOCHEMISTRY-US, V28, P9243, DOI 10.1021/bi00450a002; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; NISHIKAWA M, 1985, J BIOL CHEM, V260, P8978; OLWIN BB, 1983, METHOD ENZYMOL, V102, P148; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PATTON BL, 1990, J BIOL CHEM, V265, P11204; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; SAITOH T, 1985, J CELL BIOL, V100, P835, DOI 10.1083/jcb.100.3.835; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULMAN H, 1984, J CELL BIOL, V99, P11, DOI 10.1083/jcb.99.1.11; SCHULMAN H, 1978, NATURE, V271, P478, DOI 10.1038/271478a0; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SHARMA RK, 1985, P NATL ACAD SCI USA, V82, P2603, DOI 10.1073/pnas.82.9.2603; SHIELDS SM, 1984, J NEUROCHEM, V43, P1599, DOI 10.1111/j.1471-4159.1984.tb06084.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; UEDA T, 1977, J BIOL CHEM, V252, P5155; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; YAMAUCHI T, 1989, J BIOL CHEM, V264, P19108	55	172	174	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17216	17224						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324926				2022-12-27	WOS:A1992JL05300075
J	LEE, AW; NIENHUIS, AW				LEE, AW; NIENHUIS, AW			FUNCTIONAL DISSECTION OF STRUCTURAL DOMAINS IN THE RECEPTOR FOR COLONY-STIMULATING FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR-I RECEPTOR; PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; DEPENDENT PROTEIN-KINASE; GLYCOPHORIN-A; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODIES; INSULIN-RECEPTORS; TYROSINE KINASES; TRANSMEMBRANE DOMAIN	Receptor tyrosine kinases (RTKs) transduce external signals to the interior of the cell via a cytoplasmic kinase domain. We demonstrated previously that ligand-induced kinase activation of the colony-stimulating factor-1 receptor (CSF-1R) occurs via receptor oligomerization without propagation of conformational changes through the transmembrane (TM) domain (Lee, A. W., and Nienhuis, A. W. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7270-7274). We have now examined the role of the different subdomains in the metabolic and signaling properties of CSF-1R. Two types of chimeric receptors have been utilized, Glyfms A, with the extracellular and TM domains of glycophorin A (GpA) and the cytoplasmic domain of CSF-1R, and Glyfms B, where only the extracellular domain originates from GpA. Glyfms A was found to exhibit a higher basal level of in vitro kinase activity, an increased associated phosphatidylinositol (PtdIns) 3-kinase activity and to support enhanced cellular mitogenesis, compared with wild-type CSF-1R or to Glyfms B. The constitutive activation of Glyfms A is consistent with the hypothesis that the TM domain may play a role in receptor oligomerization. Cross-linking with anti-GpA antibodies activated the kinase function of Glyfms B leading to an increase in PtdIns 3-kinase association and to the transmission of a mitogenic signal. Our results indicate that an activated kinase domain contains the major determinant for coupling with PtdIns 3-kinase, independent of extracellular and TM sequences and of ligand binding. Both chimeric receptors underwent internalization in the presence of anti-GpA antibodies but were not degraded, including the tyrosine-phosphorylated and kinase-active population. These results suggest that structural determinants in the extracellular domain must be important for targeting internalized receptors for lysosomal degradation.			LEE, AW (corresponding author), NHLBI, CLIN HEMATOL BRANCH, BETHESDA, MD 20892 USA.							ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BARSOUM AL, 1989, INT J BIOCHEM, V21, P635, DOI 10.1016/0020-711X(89)90383-2; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; CALBERG K, 1991, EMBO J, V10, P877; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CD, 1991, J BIOL CHEM, V266, P5750; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHOUDHURY GG, 1991, J BIOL CHEM, V266, P8068; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRATTALI AL, 1991, J BIOL CHEM, V266, P9829; FURTHMAYR H, 1976, BIOCHEMISTRY-US, V15, P1137, DOI 10.1021/bi00650a028; GAHMBERG CG, 1979, J BIOL CHEM, V254, P7442; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GREENBERGER J, 1985, P NATL ACAD SCI USA, V80, P2931; HARI J, 1987, J BIOL CHEM, V262, P15341; HARLOW E, 1988, ANTIBODIES LABORATOR; HEFFETZ D, 1986, J BIOL CHEM, V261, P889; HUECKSTEADT T, 1986, J BIOL CHEM, V261, P8655; KAHLES O, 1988, P NATL ACAD SCI USA, V85, P8567; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LANGLOIS RG, 1985, J IMMUNOL, V134, P4009; LEE AW, 1990, P NATL ACAD SCI USA, V87, P7270, DOI 10.1073/pnas.87.18.7270; LEE AWM, 1992, CURR TOP CELL REGUL, V32, P73; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MARSHALL S, 1981, J BIOL CHEM, V256, P1464; MARSHALL S, 1985, J BIOL CHEM, V260, P4136; MELLMAN I, 1988, J CELL SCI, P45; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORROW B, 1987, J BIOL CHEM, V262, P13812; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PELCHENMATTHEWS A, 1989, EMBO J, V8, P3641, DOI 10.1002/j.1460-2075.1989.tb08538.x; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROUSSEL MF, 1990, MOL CELL BIOL, V10, P2407, DOI 10.1128/MCB.10.5.2407; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHREIBER AB, 1981, P NATL ACAD SCI-BIOL, V78, P7535, DOI 10.1073/pnas.78.12.7535; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; SHERR CJ, 1989, BLOOD, V73, P1786; SHERR CJ, 1990, BLOOD, V75, P1; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SIEBERT PD, 1986, P NATL ACAD SCI USA, V83, P1665, DOI 10.1073/pnas.83.6.1665; SILVERBERG M, 1976, BIOCHEMISTRY-US, V15, P1448, DOI 10.1021/bi00652a015; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1991, P NATL ACAD SCI USA, V11, P4698; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLIAMS GT, 1990, J EXP MED, V171, P947, DOI 10.1084/jem.171.3.947; YAMAKAWA A, 1991, J BIOL CHEM, V266, P17580	71	10	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16472	16483						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322904				2022-12-27	WOS:A1992JJ45800076
J	POMERANCE, M; SCHWEIGHOFFER, F; TOCQUE, B; PIERRE, M				POMERANCE, M; SCHWEIGHOFFER, F; TOCQUE, B; PIERRE, M			STIMULATION OF MITOGEN-ACTIVATED PROTEIN-KINASE BY ONCOGENIC RAS-P21 IN XENOPUS OOCYTES - REQUIREMENT FOR RAS-P21-GTPASE-ACTIVATING PROTEIN-INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; CYCLIC-AMP PHOSPHODIESTERASE; SERINE THREONINE KINASE; ROUS-SARCOMA VIRUS; TYROSINE PHOSPHORYLATION; RAS PROTEINS; S6 KINASE; LAEVIS OOCYTES; OKADAIC ACID; MAP KINASE	p21ras plays an important role in the control of cell proliferation. The molecular mechanisms implicated are unknown. We report that the injection of oncogenic Lys12 Ras into Xenopus laevis oocytes promoted the activation of mitogen-activated protein kinase (MAP kinase) after a lag of about 90 min. MAP kinase activity was 10-fold higher 4 h after injection of oncogenic Lys12 Ras than after injection of nononcogenic Gly12 Ras. The stimulated MAP kinase activity remained at a plateau for at least 18 h. Maximal stimulation was obtained with 5 ng of Lys12 Ras, which is similar to the amount that elicits germinal vesicle breakdown. DEAE-Sephacel chromatography of extracts from Lys12 Ras-injected oocytes showed one peak of MAP kinase. MAP kinase activation by Lys12 Ras was associated with tyrosine phosphorylation of MAP kinase (p42). As previously shown, the S6-kinase II (likely pp90rsk), which is activated in vitro by MAP kinase, was also activated by oncogenic Lys12 Ras. Lys12 Ras with an additional mutation (Glu38) in the effector region that binds GTPase-activating protein (GAP) did not promote MAP kinase or S6 kinase activations. Thus, GAP may be involved downstream to Ras in these activation processes. Our results indicate that the Ras-GAP complex promotes MAP kinase activation in oocytes. This supports the idea that Ras-GAP controls MAP kinase, a kinase implicated in the action of various stimuli.	RHONE POULENC RORER SA, CTR RECH VITRY, F-94403 VITRY, FRANCE	Sanofi-Aventis	POMERANCE, M (corresponding author), INSERM, U96, UNITE RECH GLANDE THYROIDE & REGULAT HORMONALE, 80 RUE GEN LECLERC, F-94276 LE KREMLIN BICETRE, FRANCE.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; CICIRELLI MF, 1988, FEBS LETT, V241, P195, DOI 10.1016/0014-5793(88)81060-3; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; DEHERREROS AG, 1991, J BIOL CHEM, V266, P6825; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; ELETR M, 1979, SCIENCE, V205, P1397, DOI 10.1126/science.472755; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; ERICKSON F, 1986, J BIOL CHEM, V261, P350; ERICKSON RL, 1991, J BIOL CHEM, V266, P6007; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HACCAFD O, 1991, EUR J BIOCHEM, V192, P633; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HOSHI M, 1988, J BIOL CHEM, V263, P5396; KIM R, 1990, MOL CELL BIOL, V10, P5945, DOI 10.1128/MCB.10.11.5945; MALLER JL, 1985, CELL DIFFER DEV, V16, P211, DOI 10.1016/0045-6039(85)90570-6; MARTIN TE, 1969, J MOL BIOL, V43, P151, DOI 10.1016/0022-2836(69)90085-0; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PAN BT, 1990, MOL CELL BIOL, V10, P923, DOI 10.1128/MCB.10.3.923; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; SADLER SE, 1989, J BIOL CHEM, V264, P856; SADLER SE, 1990, MOL CELL BIOL, V10, P1689, DOI 10.1128/MCB.10.4.1689; SANO M, 1990, J NEUROCHEM, V55, P427, DOI 10.1111/j.1471-4159.1990.tb04154.x; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHORDERET-SLATKINE S, 1972, Cell Differentiation, V1, P179, DOI 10.1016/0045-6039(72)90027-9; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAMATA T, 1990, MOL CELL BIOL, V10, P880; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TORUDELBAUFFE D, 1988, J NEUROCHEM, V51, P1448, DOI 10.1111/j.1471-4159.1988.tb01110.x; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VEDA T, 1991, BIOCHEMISTRY-US, V30, P909; WOLFMAN A, 1990, SCIENCE, V248, P247; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	63	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16155	16160						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322893				2022-12-27	WOS:A1992JJ45800029
J	WANG, Y; PALLEN, CJ				WANG, Y; PALLEN, CJ			EXPRESSION AND CHARACTERIZATION OF WILD-TYPE, TRUNCATED, AND MUTANT FORMS OF THE INTRACELLULAR REGION OF THE RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASE HPTP-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; IMMUNOGLOBULIN SUPERFAMILY; ADHESION MOLECULE; KINASE-ACTIVITY; HUMAN-PLACENTA; FAMILY; DOMAINS; CLONING; FIBRONECTIN; ACTIVATION	Human HPTP-beta is unique among mammalian receptor-like protein tyrosine phosphatases in that it has only a single catalytic domain. The intracellular region of HPTP-beta was expressed in bacteria, purified, and characterized. It exhibits high activity toward all substrates tested and is potently inhibited by zinc. Vanadate and polyanions also inhibited activity. The juxtamembrane segment of HPTP-beta (residues 1622-1639) potentially functions as a negative regulatory sequence since its deletion can increase HPTP-beta activity 5-fold. This segment contains up to two sites for protein kinase C phosphorylation, although in vitro phosphorylation by this kinase did not affect HPTP-beta activity. The boundaries of the catalytic domain were delineated by truncation analyses. Successive deletion of N-terminal sequence prior to residue 1684 had little effect on substrate affinity and at most reduced activity about 6-fold. Further removal of residues 1684-1686 resulted in a marked 50-500-fold drop in activity, and loss of N-terminal sequence prior to residue 1690 abolished activity. Based on these analyses a highly conserved motif was identified in all mammalian tyrosine phosphatases (E/q)(F/y)XX(L/i), corresponding to positions 1684-1688 of HPTP-beta. Mutation of residue 1684 or 1685 generally gave rise to proteins with marked temperature sensitivity. These mutant HPTP-beta were active but had reduced activity compared to the wild type enzyme. In conjunction, these results suggest that this region represents the N-terminal border of the catalytic domain and is essential for correct phosphatase folding although not directly involved in catalysis. Parallel truncation studies have defined residues 1930-1939/40 as the C-terminal border of the catalytic domain.	NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, CELL REGULAT LAB, 10 KENT RIDGE CRESCENT, SINGAPORE 0511, SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Wang, Yue/H-2107-2011	Wang, Yue/0000-0002-1211-2822; Pallen, Catherine/0000-0002-3576-5295				BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BOWEN S, 1991, J BIOL CHEM, V266, P1162; BRAUTIGAN DL, 1991, P NATL ACAD SCI USA, V88, P6696, DOI 10.1073/pnas.88.15.6696; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; COCHET C, 1984, J BIOL CHEM, V259, P2553; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAUM G, 1991, J BIOL CHEM, V266, P12211; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NORTON PA, 1990, CELL, V61, P15, DOI 10.1016/0092-8674(90)90209-W; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POT DA, 1991, J BIOL CHEM, V266, P19688; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STREULI M, 1988, J EXP MED, V168, P1553; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TSAI AYM, 1991, J BIOL CHEM, V266, P10534; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836	48	30	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16696	16702						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322915				2022-12-27	WOS:A1992JJ45800107
J	BEERS, EP; MORENO, TN; CALLIS, J				BEERS, EP; MORENO, TN; CALLIS, J			SUBCELLULAR-LOCALIZATION OF UBIQUITIN AND UBIQUITINATED PROTEINS IN ARABIDOPSIS-THALIANA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE MUTANT TS85; ABNORMAL PROTEINS; DEPENDENT PROTEOLYSIS; CONJUGATING ENZYMES; LYSOSOMAL SYSTEM; HIGHER-PLANT; HELA-CELLS; HEAT-SHOCK; DEGRADATION; YEAST	Ubiquitin is a highly conserved, 76-amino acid, eukaryotic protein. Its widely accepted role as a proteolytic cofactor depends on its unique ability to covalently ligate to other cellular proteins. While there is good evidence for the existence of such ubiquitinated proteins in the cytosolic and nuclear compartments, relatively little is known about the presence of free ubiquitin and ubiquitinated proteins in other subcellular compartments. This is especially true of higher plants, which have not previously been the subject of extensive biochemical subcellular localizations of ubiquitinated proteins. We extracted cell wall proteins and purified nuclei, vacuoles, chloroplasts, and microsomes from chlorophyllous tissues of Arabidopsis. Immunoblot analyses were used to compare the profiles of ubiquitinated proteins from purified subcellular fractions to those from unfractionated extracts. Purified nuclei contained, in addition to a complex mixture of high molecular mass ubiquitinated proteins, a strongly immunoreactive 28-kDa protein. In the apoplastic extract, we did not detect any ubiquitinated proteins enriched above the background level of those due to cytosolic contamination. Vacuoles appeared to contribute significantly to the ubiquitinated proteins present in the whole protoplast extract. At least three high molecular mass ubiquitinated proteins were unique to the vacuolar extract. Chloroplast stromal proteins did not react specifically with anti-ubiquitin antibodies. When microsomal ubiquitinated proteins were compared to those found in a whole protoplast extract, a distinct pattern was evident. Microsomal ubiquitinated proteins were not visible in the 10,000 x g supernatant used to prepare the 100,000 x g pellet, indicating that they were probably low abundance proteins in the protoplast extract.	UNIV CALIF DAVIS,DEPT BIOCHEM & BIOPHYS,DAVIS,CA 95616	University of California System; University of California Davis				Callis, Judy/0000-0002-0622-078X				ANDERSEN MW, 1981, FEBS LETT, V132, P210, DOI 10.1016/0014-5793(81)81162-3; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BALL E, 1987, CELL, V51, P221, DOI 10.1016/0092-8674(87)90149-8; BEERS EP, 1988, PLANT PHYSIOL, V87, P799, DOI 10.1104/pp.87.4.799; BOLLER T, 1979, PLANT PHYSIOL, V63, P1123, DOI 10.1104/pp.63.6.1123; BONNER WM, 1988, UBIQUITIN, P157; CARLSON N, 1987, J CELL BIOL, V104, P547, DOI 10.1083/jcb.104.3.547; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHIN DT, 1982, P NATL ACAD SCI-BIOL, V79, P5857, DOI 10.1073/pnas.79.19.5857; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; DELLAPENNA D, 1989, PLANT PHYSIOL, V90, P1372, DOI 10.1104/pp.90.4.1372; DIETZGEN RG, 1991, VIROLOGY, V184, P397, DOI 10.1016/0042-6822(91)90857-8; DOHERTY FJ, 1989, BIOCHEM J, V263, P47, DOI 10.1042/bj2630047; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FREHNER M, 1987, PLANT PHYSIOL, V84, P1296, DOI 10.1104/pp.84.4.1296; GANOTH D, 1988, J BIOL CHEM, V263, P12412; GASPAR JO, 1990, MOL PLANT MICROBE IN, V3, P182, DOI 10.1094/MPMI-3-182; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1987, J BIOL CHEM, V262, P345; HARLOW E, 1988, ANTIBODIES LABORATOR; HAZELWOOD D, 1990, VIROLOGY, V177, P352, DOI 10.1016/0042-6822(90)90490-I; HEINEMEYER W, 1991, BIOCHEM SOC T, V19, P724, DOI 10.1042/bst0190724; HERSHKO A, 1982, J BIOL CHEM, V257, P3964; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOFFMAN NE, 1991, PLANT MOL BIOL, V17, P1189, DOI 10.1007/BF00028735; HOUGH R, 1987, J BIOL CHEM, V262, P8303; Hough R. F., 1988, UBIQUITIN, P101, DOI 10.1007/978-1-4899-2049-2_5; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KLEMES Y, 1981, J BIOL CHEM, V256, P8436; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASZLO L, 1990, FEBS LETT, V261, P365, DOI 10.1016/0014-5793(90)80593-8; LUTHE DS, 1980, PLANT PHYSIOL, V65, P305, DOI 10.1104/pp.65.2.305; MAGNANI M, 1986, J BIOL CHEM, V261, P8327; MAGNANI M, 1991, J BIOL CHEM, V266, P21018; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MILLER HI, 1989, BIO-TECHNOL, V7, P698, DOI 10.1038/nbt0789-698; MURTI KG, 1988, P NATL ACAD SCI USA, V85, P3019, DOI 10.1073/pnas.85.9.3019; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PICKART CM, 1985, J BIOL CHEM, V260, P7903; RABOY B, 1986, EMBO J, V5, P863, DOI 10.1002/j.1460-2075.1986.tb04296.x; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; Rechsteiner M., 1988, UBIQUITIN; RECORD RD, 1988, PLANTA, V176, P425, DOI 10.1007/BF00397648; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARTZ AL, 1988, EMBO J, V7, P2961, DOI 10.1002/j.1460-2075.1988.tb03158.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SHAEFFER JR, 1988, J BIOL CHEM, V263, P13663; SHANKLIN J, 1987, P NATL ACAD SCI USA, V84, P359, DOI 10.1073/pnas.84.2.359; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; Somerville C.R., 1982, METHODS CHLOROPLAST, P129; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; SWERDLOW PS, 1986, ANAL BIOCHEM, V156, P147, DOI 10.1016/0003-2697(86)90166-1; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; VANDERVALK HCPM, 1988, PLANT PHYSIOL, V87, P536, DOI 10.1104/pp.87.2.536; VEIERSKOV B, 1991, PLANT PHYSIOL, V96, P4, DOI 10.1104/pp.96.1.4; VIERSTRA RD, 1985, J BIOL CHEM, V260, P2015; VIERSTRA RD, 1988, BIOCHEMISTRY-US, V27, P3290, DOI 10.1021/bi00409a025; WETTERN M, 1990, EUR J BIOCHEM, V191, P571, DOI 10.1111/j.1432-1033.1990.tb19159.x; YANG JF, 1991, PHYTOCHEMISTRY, V30, P2487, DOI 10.1016/0031-9422(91)85087-G; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZIEGLER P, 1986, PLANT PHYSIOL, V82, P119	70	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15432	15439						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322398				2022-12-27	WOS:A1992JG11300029
J	RIJNBOUTT, S; STOORVOGEL, W; GEUZE, HJ; STROUS, GJ				RIJNBOUTT, S; STOORVOGEL, W; GEUZE, HJ; STROUS, GJ			IDENTIFICATION OF SUBCELLULAR COMPARTMENTS INVOLVED IN BIOSYNTHETIC PROCESSING OF CATHEPSIN-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTORS; LYSOSOMAL-ENZYMES; MEDIATED ENDOCYTOSIS; HEPG2 CELLS; RAT-LIVER; INTRACELLULAR MOVEMENT; MACROPHAGE ENDOSOMES; BETA-HEXOSAMINIDASE; HUMAN-FIBROBLASTS; HEPATOMA-CELLS	We have assigned the biosynthetic processing steps of cathepsin D to intracellular compartments which are involved in its transport to lysosomes in HepG2 cells. Cathepsin D was synthesized as a 51-kDa proenzyme. After formation of 51-55-kDa intermediates due to processing of N-linked oligosaccharides, procathepsin D was proteolytically processed to an intermediate 44-kDa and the mature 31-kDa enzyme. The intersection of the biosynthetic pathway of cathepsin D with the endocytic pathway was labeled with horseradish peroxidase and monitored biochemically by 3,3'-diaminobenzidine cytochemistry. Horseradish peroxidase was used either as a fluid-phase marker to label the entire endocytic pathway or conjugated to transferrin (Tf) to label endosomes only. Directly after biosynthesis cathepsin D was accessible neither to horseradish peroxidase nor Tf-horseradish peroxidase. Newly synthesized 51-55-kDa species of cathepsin D present in the trans-Golgi reticulum were accessible to both horseradish peroxidase and Tf-horseradish peroxidase. The accessibility of trans-Golgi reticulum to both endocytosed horseradish peroxidase and Tf-horseradish peroxidase was monitored by colocalization with a secretory protein, alpha-1-anti-trypsin. The proteolytic processing of 51-55-kDa to 44-kDa cathepsin D occurred in compartments which were fully accessible to fluid-phase horseradish peroxidase. Tf-horseradish peroxidase had access to only 20% of 44-kDa cathepsin D while it had no access to 31-kDa cathepsin D. In contrast, the 31-kDa species was completely accessible to fluid-phase horseradish peroxidase. We conclude that proteolytic processing of 51-55-kDa to 44-kDa cathepsin D occurs in endosomes, whereas the processing of 44-31-kDa cathepsin D takes place in lysosomes.	UNIV UTRECHT, SCH MED, CELL BIOL LAB, AZU, ROOM H02314, 3584 CX UTRECHT, NETHERLANDS	Utrecht University								BACKER JM, 1990, J BIOL CHEM, V265, P14828; BLEEKEMOLEN JE, 1988, EUR J CELL BIOL, V47, P366; BOWSER R, 1990, J CELL PHYSIOL, V143, P110, DOI 10.1002/jcp.1041430115; CONNER GE, 1989, BIOCHEM J, V263, P601, DOI 10.1042/bj2630601; COURTOY PJ, 1984, J CELL BIOL, V98, P870, DOI 10.1083/jcb.98.3.870; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DIMENT S, 1985, J BIOL CHEM, V260, P5311; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; FARQUHAR MG, 1983, FED PROC, V42, P2407; FISCHER HD, 1980, J BIOL CHEM, V255, P5069; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; GEUZE HJ, 1984, EMBO J, V3, P2677, DOI 10.1002/j.1460-2075.1984.tb02193.x; GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HASILIK A, 1982, EUR J BIOCHEM, V125, P317, DOI 10.1111/j.1432-1033.1982.tb06685.x; HASILIK A, 1981, EUR J BIOCHEM, V121, P125, DOI 10.1111/j.1432-1033.1981.tb06440.x; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; JONSSON LMV, 1987, EUR J BIOCHEM, V164, P171, DOI 10.1111/j.1432-1033.1987.tb11008.x; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEIBOLD DM, 1988, J CELL PHYSIOL, V137, P411, DOI 10.1002/jcp.1041370304; LUDWIG T, 1991, J CELL BIOL, V115, P1561, DOI 10.1083/jcb.115.6.1561; NEEFJES JJ, 1988, J CELL BIOL, V107, P79, DOI 10.1083/jcb.107.1.79; PEARSE BMF, 1987, EMBO J, V6, P2507, DOI 10.1002/j.1460-2075.1987.tb02536.x; PFEFFER SR, 1987, J CELL BIOL, V105, P229, DOI 10.1083/jcb.105.1.229; REGOECZI E, 1982, P NATL ACAD SCI-BIOL, V79, P2226, DOI 10.1073/pnas.79.7.2226; RENFREW CA, 1991, J BIOL CHEM, V266, P4348; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; SNIDER MD, 1985, J CELL BIOL, V100, P826, DOI 10.1083/jcb.100.3.826; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; STOORVOGEL W, 1991, J BIOL CHEM, V266, P5438; STOORVOGEL W, 1988, J CELL BIOL, V106, P1821, DOI 10.1083/jcb.106.6.1821; VANDEURS B, 1989, INT REV CYTOL, V117, P131; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WILLINGHAM MC, 1980, CELL, V21, P67, DOI 10.1016/0092-8674(80)90115-4	47	90	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15665	15672						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322403				2022-12-27	WOS:A1992JG11300064
J	GONG, MC; COHEN, P; KITAZAWA, T; IKEBE, M; MASUO, M; SOMLYO, AP; SOMLYO, AV				GONG, MC; COHEN, P; KITAZAWA, T; IKEBE, M; MASUO, M; SOMLYO, AP; SOMLYO, AV			MYOSIN LIGHT CHAIN PHOSPHATASE-ACTIVITIES AND THE EFFECTS OF PHOSPHATASE INHIBITORS IN TONIC AND PHASIC SMOOTH-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; PIG TAENIA-COLI; OKADAIC ACID; PROTEIN PHOSPHATASE; CELLULAR-REGULATION; CATALYTIC SUBUNIT; FLASH-PHOTOLYSIS; HEAVY-MEROMYOSIN; KINASE; PHOSPHORYLATION	Phosphatase inhibitors microcystin-LR, tautomycin, and okadaic acid caused contraction and increased 20-kDa myosin light chain (MLC20) phosphorylation in Ca2+-free solutions in both phasic and tonic smooth muscle permeabilized with beta-escin, and inhibited the heavy meromyosin (HMM) phosphatase activity of smooth muscle homogenates with the same potency sequence: microcystin-LR > tautomycin > okadaic acid. The sensitivity to all three inhibitors was significantly higher, the half-times of relaxation and dephosphorylation were 4-6 times longer, and the HMM phosphatase and MLC20 kinase activity/smooth muscle cell wet weight was 2.0- and 1.9-fold lower in the tonic, femoral artery, than in the phasic, ileum or portal vein, smooth muscle. Preincubation with 0.2-mu-M inhibitor-2 decreased the HMM phosphatase activity by 35% in the ileum and by 60% in the femoral artery. The results suggest that the HMM phosphatases of smooth muscle have properties common to type 1 protein phosphatases, but are inhibited only partially by high concentrations of inhibitor-2, and that the lower HMM phosphatase activity of tonic smooth muscle may contribute to its greater sensitivity to phosphatase inhibitors and its slower rate of relaxation.	UNIV DUNDEE, DEPT BIOCHEM, MRC, PROT PHOSPHORYLAT GRP, DUNDEE DD1 4HN, SCOTLAND; UNIV VIRGINIA, SCH MED, DEPT PATHOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, DEPT MED, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, DEPT PHYSIOL, CHARLOTTESVILLE, VA 22908 USA; CASE WESTERN RESERVE UNIV, DEPT PHYSIOL, CLEVELAND, OH 44106 USA	University of Dundee; University of Virginia; University of Virginia; University of Virginia; Case Western Reserve University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038888] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL19242-14] Funding Source: Medline; NIAMS NIH HHS [AR 38888] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABIJ P, 1991, P NATL ACAD SCI USA, V88, P10676, DOI 10.1073/pnas.88.23.10676; BIALOJAN C, 1988, J PHYSIOL-LONDON, V398, P81, DOI 10.1113/jphysiol.1988.sp017030; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOLLEN M, 1988, BIOCHEM J, V250, P659, DOI 10.1042/bj2500659; CASSIDY P, 1979, J BIOL CHEM, V254, P1148; CHENG XC, 1987, J ANTIBIOT, V40, P907, DOI 10.7164/antibiotics.40.907; CHISHOLM AAK, 1988, BIOCHIM BIOPHYS ACTA, V971, P163, DOI 10.1016/0167-4889(88)90188-7; CHISHOLM AAK, 1988, BIOCHIM BIOPHYS ACTA, V968, P392, DOI 10.1016/0167-4889(88)90032-8; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN P, 1988, METHOD ENZYMOL, V159, P427; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DISALVO J, 1982, BIOCHEM BIOPH RES CO, V108, P534, DOI 10.1016/0006-291X(82)90861-0; DRISKA SP, 1989, AM J PHYSIOL, V256, pC315, DOI 10.1152/ajpcell.1989.256.2.C315; EDDINGER TJ, 1988, BIOCHEMISTRY-US, V27, P3807, DOI 10.1021/bi00410a043; EDELMAN AM, 1990, MOL CELL BIOCHEM, V97, P87; HAEBERLE JR, 1985, J BIOL CHEM, V260, P9965; HAMADA Y, 1990, BIOCHEM BIOPH RES CO, V170, P53, DOI 10.1016/0006-291X(90)91239-O; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HARTSHORNE DJ, 1989, ADV PROTEIN PHOSPHAT, V5, P219; HELPER DJ, 1988, J BIOL CHEM, V263, P15748; HIMPENS B, 1988, J GEN PHYSIOL, V92, P713, DOI 10.1085/jgp.92.6.713; HIRANO K, 1989, BRIT J PHARMACOL, V98, P1261, DOI 10.1111/j.1476-5381.1989.tb12672.x; HORI M, 1991, FEBS LETT, V285, P145, DOI 10.1016/0014-5793(91)80745-O; HORIUTI K, 1988, J PHYSIOL-LONDON, V398, P131, DOI 10.1113/jphysiol.1988.sp017034; HORIUTI K, 1989, J GEN PHYSIOL, V94, P769, DOI 10.1085/jgp.94.4.769; IKEBE M, 1987, J BIOL CHEM, V262, P9569; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; IKEBE M, 1987, J BIOL CHEM, V262, P13828; INAGAKI M, 1987, ARCH BIOCHEM BIOPHYS, V254, P136, DOI 10.1016/0003-9861(87)90089-0; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KOBAYASHI S, 1991, AM J PHYSIOL, V260, pC364, DOI 10.1152/ajpcell.1991.260.2.C364; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; MACKINTOSH C, 1990, FEBS LETT, V277, P137, DOI 10.1016/0014-5793(90)80828-7; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8808; OZAKI H, 1987, N-S ARCH PHARMACOL, V335, P356; PATO MD, 1985, J BIOL CHEM, V260, P2359; PATO MD, 1983, EUR J BIOCHEM, V132, P283, DOI 10.1111/j.1432-1033.1983.tb07360.x; PATO MD, 1983, J BIOL CHEM, V258, P7047; PATO MD, 1983, J BIOL CHEM, V258, P7055; PAUL RJ, 1983, CIRC RES, V53, P342, DOI 10.1161/01.RES.53.3.342; REMBOLD CM, 1988, CIRC RES, V63, P593, DOI 10.1161/01.RES.63.3.593; RUEGG JC, 1982, BIOCHEM BIOPH RES CO, V106, P1126, DOI 10.1016/0006-291X(82)91229-3; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SHIBATA S, 1982, J PHARMACOL EXP THER, V223, P135; SIEGMAN MJ, 1989, ADV PROTEIN PHOSPHAT, V5, P233; SOMLYO A V, 1969, Microvascular Research, V1, P354, DOI 10.1016/0026-2862(69)90014-4; SOMLYO AV, 1968, J PHARMACOL EXP THER, V159, P129; SOMLYO AV, 1988, J GEN PHYSIOL, V91, P165, DOI 10.1085/jgp.91.2.165; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; TAKAI A, 1989, BIOCHEM J, V262, P617, DOI 10.1042/bj2620617; TULLOCH AG, 1991, J BIOL CHEM, V266, P20168; WALSH MP, 1982, BIOCHEMISTRY-US, V21, P1919, DOI 10.1021/bi00537a034; WERTH DK, 1982, J BIOL CHEM, V257, P7306	59	196	196	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14662	14668						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321813				2022-12-27	WOS:A1992JF08800028
J	ARAMORI, I; NAKANISHI, S				ARAMORI, I; NAKANISHI, S			COUPLING OF 2 ENDOTHELIN RECEPTOR SUBTYPES TO DIFFERING SIGNAL TRANSDUCTION IN TRANSFECTED CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-MONOPHOSPHATE ACCUMULATION; STIMULATES PHOSPHOLIPASE-C; SMOOTH-MUSCLE CELLS; ADENYLATE-CYCLASE; PEPTIDE ENDOTHELIN; MESANGIAL CELLS; PERTUSSIS TOXIN; RAT; MITOGENESIS; EXPRESSION	We examined the intracellular signal transduction of two endothelin receptor subtypes (ET(A) and ET(B)) by transfection and stable expression of individual receptor cDNAs in Chinese hamster ovary cells. Both receptors showed a rapid and marked stimulation of phosphatidylinositol hydrolysis and arachidonic acid release in response to agonist interaction. The two receptors, however, exhibited different responses in the cyclic AMP transduction caseades. ET(A) mediated the accumulation of cyclic AMP formation, whereas ET(B) displayed an inhibitory action on the forskolin-stimulated cyclic AMP accumulation. In both receptors, the responses of phosphatidylinositol hydrolysis, arachidonic acid release, and cyclic AMP formation were induced in complete agreement with the endothelin-binding selectivity of each receptor subtype. Endothelin, added together with GTP, activated the adenylate cyclase activity in membrane preparations of ET(A)-expressing cells, indicating the direct linkage of ET(A) to the adenylate cyclase system. Pertussis toxin treatment of ET(A)-expressing cells resulted in partial inhibition of the endothelin-induced cyclic AMP accumulation, whereas the same treatment of ET(B)-expressing cells completely abolished the endothelin-induced inhibition of cyclic AMP formation. Thus, the two endothelin receptor subtypes are coupled to multiple but distinct signal transduction cascades through different G proteins.	KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN	Kyoto University								ABDELLATIF AA, 1991, INVEST OPHTH VIS SCI, V32, P2432; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; FELDER CC, 1989, J BIOL CHEM, V264, P20356; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARRIS PJ, 1991, J PHYSIOL-LONDON, V433, P25, DOI 10.1113/jphysiol.1991.sp018412; HORI S, 1992, IN PRESS ENDOCRINOLO; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISHIKAWA T, 1988, AM J PHYSIOL, V255, pH970, DOI 10.1152/ajpheart.1988.255.4.H970; ITO S, 1991, J NEUROCHEM, V56, P531, DOI 10.1111/j.1471-4159.1991.tb08182.x; IWAI M, 1991, ENDOCRINOLOGY, V129, P1909, DOI 10.1210/endo-129-4-1909; JONES SVP, 1991, MOL PHARMACOL, V40, P242; KANTERMAN RY, 1991, MOL PHARMACOL, V39, P364; KELLY RA, 1990, J CLIN INVEST, V86, P1164, DOI 10.1172/JCI114822; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; MARIN P, 1991, J NEUROCHEM, V56, P1270, DOI 10.1111/j.1471-4159.1991.tb11421.x; MARSAULT R, 1990, J NEUROCHEM, V54, P2142, DOI 10.1111/j.1471-4159.1990.tb04921.x; MARTIN ER, 1990, J BIOL CHEM, V265, P14044; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; RESINK TJ, 1988, BIOCHEM BIOPH RES CO, V157, P1360, DOI 10.1016/S0006-291X(88)81025-8; RESINK TJ, 1989, BIOCHEM BIOPH RES CO, V158, P279, DOI 10.1016/S0006-291X(89)80209-8; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAMSON WK, 1991, BRAIN RES, V539, P347, DOI 10.1016/0006-8993(91)91643-F; SIMONSON MS, 1990, J CLIN INVEST, V85, P790, DOI 10.1172/JCI114505; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; SPOKES RA, 1989, J CARDIOVASC PHARM, V13, pS191, DOI 10.1097/00005344-198900135-00053; SUGIURA M, 1989, BIOCHEM BIOPH RES CO, V158, P170, DOI 10.1016/S0006-291X(89)80193-7; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; TOMITA K, 1990, J CLIN INVEST, V85, P2014, DOI 10.1172/JCI114667; UI M, 1984, TRENDS PHARMACOL SCI, V5, P277, DOI 10.1016/0165-6147(84)90444-9; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VANE J, 1990, NATURE, V348, P673, DOI 10.1038/348673a0; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; VIGNE P, 1989, FEBS LETT, V249, P143, DOI 10.1016/0014-5793(89)80611-8; YANAGISAWA M, 1989, TRENDS PHARMACOL SCI, V10, P374; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	43	215	217	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12468	12474						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1319997				2022-12-27	WOS:A1992HZ48300017
J	KO, JL; LEE, NM; LOH, HH				KO, JL; LEE, NM; LOH, HH			CHARACTERIZATION OF BETA-I-125-ENDORPHIN CROSS-LINKED PROTEINS IN NG108-15 CELL-MEMBRANES - A 25-KILODALTON PROTEIN WITH PROPERTIES OF DELTA-OPIOID-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURO-BLASTOMA; RAT-BRAIN; OPIATE RECEPTOR; DOWN-REGULATION; BETA-ENDORPHIN; HYBRID-CELLS; MONOCLONAL-ANTIBODY; ADENYLATE-CYCLASE; MU; IDENTIFICATION	Cross-linking of beta-I-125-endorphin to NG108-15 cell membranes labeled bands with molecular masses of 55, 35, and 25 kDa on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. We applied several criteria to evaluate the relevance of these cross-linked bands to delta-opioid receptors, including selectivity, stereospecificity, affinity, G-protein coupling, down-regulation, and correlation with opioid receptor level in different well-characterized cell lines. Only the 25 kDa protein adequately fulfilled all these criteria. Thus, cross-linking to the 25-kDa band was selectively inhibited by ligands with delta-opioid affinity, but not by mu-opioid, kappa-opioid, or optically inactive opioid ligands or by non-opioid ligands. Based on inhibition of cross-linking, we calculated an affinity Of [D-Ala2,D-Leu5]enkephalin binding to the 25-kDa band (K(d) = 6 nM) that is similar to that reported for [D-Ala2,D-Leu5]enkephalin binding to NG108-15 membranes; this affinity decreased approximately 10-fold in the presence of Na+/guanyl-5'-yl imidodiphosphate. Chronic agonist treatment of NG108-15 cells reduced cross-linking to the 25-kDa band, but not to others, in a manner parallel to down-regulation of opioid receptors. Finally, the amount of the 25-kDa band was roughly proportional to the level of opioid receptors present in N18TG2, NS20Y, ST7-3, and ST8-4 cells. The 25-kDa band was absent in PC12h, NIH3T3, and C6BU1 cells as well as in liver, all of which had no detectable opioid binding.			KO, JL (corresponding author), UNIV MINNESOTA, SCH MED, DEPT PHARMACOL, 3-249 MILLARD HALL, 435 DELAWARE ST SE, MINNEAPOLIS, MN 55455 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002643, K05DA000020, R37DA002643] Funding Source: NIH RePORTER; NIDA NIH HHS [KO5-DA-00020, DA-00546, DA-02643] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ANN DK, 1992, J BIOL CHEM, V267, P7921; BERO LA, 1988, MOL PHARMACOL, V34, P614; BIDLACK JM, 1988, MOL PHARMACOL, V33, P170; CHANG KJ, 1978, MOL PHARMACOL, V14, P961; CHANG KJ, 1982, NATURE, V296, P446, DOI 10.1038/296446a0; CHERUBINI E, 1985, P NATL ACAD SCI USA, V82, P1860, DOI 10.1073/pnas.82.6.1860; CRAIN SM, 1990, TRENDS PHARMACOL SCI, V11, P77, DOI 10.1016/0165-6147(90)90322-Y; FEDYNYSHYN JP, 1989, BRAIN RES, V476, P102, DOI 10.1016/0006-8993(89)91541-2; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HOLLENBERG MD, 1991, FASEB J, V5, P178, DOI 10.1096/fasebj.5.2.1848518; HOWARD AD, 1986, BIOCHEMISTRY-US, V25, P357, DOI 10.1021/bi00350a012; HOWARD AD, 1985, J BIOL CHEM, V260, P833; ICARDLIEPKALNS C, 1988, FEBS LETT, V233, P167, DOI 10.1016/0014-5793(88)81377-2; KEREN O, 1988, BRAIN RES, V440, P280, DOI 10.1016/0006-8993(88)90996-1; KLEE WA, 1982, FEBS LETT, V150, P125, DOI 10.1016/0014-5793(82)81318-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW PY, 1982, MOL PHARMACOL, V21, P483; LAW PY, 1984, J BIOL CHEM, V259, P4096; LAW PY, 1979, J NEUROCHEM, V33, P1177, DOI 10.1111/j.1471-4159.1979.tb05262.x; LAW PY, 1983, MOL PHARMACOL, V24, P413; LAW PY, 1985, J BIOL CHEM, V260, P4818; LEFKOWITZ RJ, 1991, NATURE, V351, P353, DOI 10.1038/351353a0; LI CH, 1981, HORMONAL PROTEINS PE, V10, P22; LIUCHEN LY, 1987, MOL PHARMACOL, V32, P321; LOH HH, 1990, ANNU REV PHARMACOL, V30, P123; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANSOUR A, 1986, BRAIN RES, V399, P69, DOI 10.1016/0006-8993(86)90601-3; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; NASSAL M, 1987, J BIOL CHEM, V262, P9264; NEWMAN EL, 1984, BIOCHEMISTRY-US, V23, P5385, DOI 10.1021/bi00318a001; NORTH RA, 1983, BRIT J PHARMACOL, V80, P225, DOI 10.1111/j.1476-5381.1983.tb10023.x; OFFERMANNS S, 1991, J BIOL CHEM, V266, P3365; OTT S, 1988, J BIOL CHEM, V263, P10524; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; REYNOLDS JA, 1977, P NATL ACAD SCI USA, V74, P2803, DOI 10.1073/pnas.74.7.2803; SCHEIDELER MA, 1990, J BIOL CHEM, V265, P15176; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; TAO PL, 1988, BRAIN RES, V462, P313, DOI 10.1016/0006-8993(88)90559-8; TAO PL, 1990, BRAIN RES, V526, P270, DOI 10.1016/0006-8993(90)91231-5; TERENIUS L, 1973, ACTA PHARMACOL TOX, V32, P317; UEDA H, 1987, NEUROSCI LETT, V75, P339, DOI 10.1016/0304-3940(87)90546-5; WERZ MA, 1985, J PHARMACOL EXP THER, V234, P49; WESTPHAL M, 1984, BIOCHEM BIOPH RES CO, V122, P428, DOI 10.1016/0006-291X(84)90493-5; YEUNG CWT, 1987, ARCH BIOCHEM BIOPHYS, V254, P81, DOI 10.1016/0003-9861(87)90083-X; ZUKIN RS, 1979, P NATL ACAD SCI USA, V76, P1593, DOI 10.1073/pnas.76.4.1593	48	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12722	12727						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1320002				2022-12-27	WOS:A1992HZ48300053
J	OKUN, MM; SHIELDS, D				OKUN, MM; SHIELDS, D			TRANSLOCATION OF PREPROINSULIN ACROSS THE ENDOPLASMIC-RETICULUM MEMBRANE - THE RELATIONSHIP BETWEEN NASCENT POLYPEPTIDE SIZE AND EXTENT OF SIGNAL RECOGNITION PARTICLE-MEDIATED INHIBITION OF PROTEIN-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN MICROSOMAL-MEMBRANES; SECRETORY PROTEIN; ELONGATION ARREST; DOCKING PROTEIN; MESSENGER-RNA; SRP; TRANSLATION; SEQUENCE; RECEPTOR; GLYCOSYLATION	Signal recognition particle (SRP) induces elongation arrest of nascent presecretory proteins as the signal peptide protrudes from the large ribosomal subunit. To examine the relationship between the size of the precursor and extent of SRP mediated inhibition of polypeptide chain elongation, we performed in vitro translation experiments in the presence of SRP using a series of truncated preproinsulin mRNA molecules. These precursors possessed the same NH2 terminus as native preproinsulin followed by progressively shorter COOH termini. SRP inhibited translation of precursors as short as 64 amino acids in length, however, the extent of inhibition diminished for shorter precursors. This correlated with a reduction in the time required for ribosomes to transit through the mRNA encoding the shortened precursors. By exploiting a chimeric protein comprising the first 71 residues of preproinsulin fused to the bacterial cytoplasmic enzyme chloramphenicol acetyltransferase, we demonstrate that the largest size a nascent chain can reach and still be susceptible to SRP-mediated elongation arrest is approximately 17 kDa. Our data support the model that SRP binding to the signal peptide is a reversible process even in the absence of microsomal membranes, and that SRP can arrest polypeptide chain elongation at multiple stages during translation.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT DEV BIOL & CANC, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT ANAT & STRUCT BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NCI NIH HHS [P30-CA1330] Funding Source: Medline; NIDDK NIH HHS [DK 21860] Funding Source: Medline; NIGMS NIH HHS [GM7288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K04CA001330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021860, R37DK021860] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; ESKRIDGE EM, 1986, J CELL BIOL, V103, P2263, DOI 10.1083/jcb.103.6.2263; ESKRIDGE EM, 1983, J BIOL CHEM, V258, P1487; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GILMORE R, 1983, CELL, V262, P9463; KLAPPA P, 1991, EMBO J, V10, P2795, DOI 10.1002/j.1460-2075.1991.tb07828.x; LIPP J, 1987, J BIOL CHEM, V262, P1680; LIPP J, 1986, J CELL BIOL, V102, P2169, DOI 10.1083/jcb.102.6.2169; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; OKUN MM, 1990, J BIOL CHEM, V265, P7478; PREHN S, 1987, EMBO J, V6, P2093, DOI 10.1002/j.1460-2075.1987.tb02475.x; RAPOPORT TA, 1987, J MOL BIOL, V195, P621, DOI 10.1016/0022-2836(87)90186-0; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROTHMAN JE, 1977, NATURE, V269, P775, DOI 10.1038/269775a0; SCHLENSTEDT G, 1990, J BIOL CHEM, V265, P13960; SHIELDS D, 1977, P NATL ACAD SCI USA, V74, P2059, DOI 10.1073/pnas.74.5.2059; SHIELDS D, 1978, J BIOL CHEM, V253, P3753; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SIEGEL V, 1986, NATURE, V320, P81, DOI 10.1038/320081a0; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; WOLIN SL, 1989, J CELL BIOL, V109, P2617, DOI 10.1083/jcb.109.6.2617	35	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11476	11482						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317869				2022-12-27	WOS:A1992HX16900082
J	HILALDANDAN, R; URASAWA, K; BRUNTON, LL				HILALDANDAN, R; URASAWA, K; BRUNTON, LL			ENDOTHELIN INHIBITS ADENYLATE-CYCLASE AND STIMULATES PHOSPHOINOSITIDE HYDROLYSIS IN ADULT CARDIAC MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; VENTRICULAR MYOCYTES; PERTUSSIS TOXIN; PROTEIN-KINASE; RAT; RECEPTOR; PEPTIDE; BINDING; CELLS; CARDIOMYOCYTES	We have assessed the effects of endothelin-1 (ET-1) on transmembrane signaling in adult rat ventricular myocytes. ET-1 stimulates phosphoinositide hydrolysis with an EC50 of 0.3-0.8 nM. This stimulation is linear for up to 30 min in the presence of a protease inhibitor, is additive with the effects of other stimulators of phosphoinositide hydrolysis, is not inhibited by the Ca2+ entry blocker, nifedipine, and is insensitive to pertussis toxin. ET-1 also reduces cyclic AMP production in myocytes in response to isoproterenol and forskolin (EC50, 1 nM). This cyclic AMP-lowering effect of ET-1 is sensitive to pertussis toxin, can be demonstrated directly in assays of adenylate cyclase activity of myocyte membranes, and seems to be mediated by G(i). These data indicate that the effects of endothelin on adult cardiac myocytes involve multiple signaling pathways, including enhanced activity of the inositol phosphate pathway and a decrease in cyclic AMP-mediated responses, neither of which seems likely to account for the positive contractile effects of endothelin.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,0636,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,DIV CARDIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NHLBI NIH HHS [HL41307] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041307] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBAR I, 1990, BIOCHEMISTRY-US, V29, P6415, DOI 10.1021/bi00479a012; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BAYDOUN AR, 1989, J CARDIOVASC PHARM, V13, pS193, DOI 10.1097/00005344-198900135-00054; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; BRUNTON LL, 1979, J BIOL CHEM, V254, P9714; BUXTON ILO, 1983, J BIOL CHEM, V258, P233; BUXTON ILO, 1985, J BIOL CHEM, V260, P6733; GALRON R, 1990, BIOCHEM BIOPH RES CO, V171, P949, DOI 10.1016/0006-291X(90)90776-J; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; HILALDANDAN R, 1991, J MOL CELL CARDIOL, V23, P705, DOI 10.1016/0022-2828(91)90980-Z; KATADA T, 1986, J BIOL CHEM, V261, P8182; KELLY RA, 1990, J CLIN INVEST, V86, P1164, DOI 10.1172/JCI114822; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERMAN A, 1990, MAYO CLIN PROC, V65, P1441, DOI 10.1016/S0025-6196(12)62168-5; MASUDA Y, 1989, FEBS LETT, V257, P208, DOI 10.1016/0014-5793(89)81535-2; MOODY CJ, 1990, CIRC RES, V67, P764, DOI 10.1161/01.RES.67.3.764; MORAVEC CS, 1989, BIOCHEM BIOPH RES CO, V159, P14, DOI 10.1016/0006-291X(89)92397-8; OGAWA Y, 1991, BIOCHEM BIOPH RES CO, V178, P248, DOI 10.1016/0006-291X(91)91806-N; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONSON MS, 1991, HYPERTENSION, V17, P856, DOI 10.1161/01.HYP.17.6.856; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; SPEIZER LA, 1987, FASEB J, V46, P2065; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; TOMITA K, 1990, J CLIN INVEST, V85, P2014, DOI 10.1172/JCI114667; URASAWA K, 1991, JPN CIRC J, V55, P676, DOI 10.1253/jcj.55.676; VIGNE P, 1989, FEBS LETT, V249, P143, DOI 10.1016/0014-5793(89)80611-8; WATANABE H, 1989, BIOCHEM BIOPH RES CO, V161, P1252, DOI 10.1016/0006-291X(89)91377-6; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	34	122	122	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10620	10624						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1316904				2022-12-27	WOS:A1992HV09000062
J	WILKS, A; DEMONTELLANO, PRO				WILKS, A; DEMONTELLANO, PRO			INTRAMOLECULAR TRANSLOCATION OF THE PROTEIN RADICAL FORMED IN THE REACTION OF RECOMBINANT SPERM WHALE MYOGLOBIN WITH H2O2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDASE; DNA; OXIDASE; STYRENE; BINDING	A sperm whale myoglobin gene containing multiple unique restriction sites has been constructed in pUC 18 by sequential assembly of chemically synthesized oligonucleotide fragments. Expression of the gene in Escherichia coli DH5-alpha cells yields protein that is identical to native sperm whale myoglobin except that it retains the terminal methionine. Site-specific mutagenesis has been used to prepare all the possible tyrosine --> phenylalanine mutants of the recombinant myoglobin, including the three single mutants at Tyr- 103, -146, and -151, the three double mutants, and the triple mutant. All of the mutant proteins are stable except the Tyr-103 mutant. Introduction of a second mutation (Lys-102 --> Gln) stabilizes the Tyr-103 mutant. Absorption spectroscopy suggests that the active sites of the mutant proteins are intact. EPR and absorption spectroscopy show that all the proteins, including the triple mutant devoid of tyrosine residues, react with H2O2 to give a ferryl species and a protein radical. The presence of a protein radical in all the mutants suggests that the radical center is readily transferred from one amino acid to another. Cross-linking studies show, however, that protein dimers are only formed when Tyr-151 is present. Tyr-103, shown earlier to be the residue that primarily cross-links to Tyr-151 (Tew, D., and Ortiz de Montellano, P. R. (1988) J. Biol. Chem. 263, 17880-17886), is not essential for cross-linking. Electron transfer from Tyr-151 to the heme, which are 12 angstrom apart, occurs in the absence of the intervening tyrosines at positions 103 and 146. The present studies show that the peroxide-generated myoglobin radical readily exchanges between remote loci, including non-tyrosine residues, but protein cross-linking only occurs when radical density is located on Tyr-151.	UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CTR LIVER, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743, R01DK030297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER; NIDDK NIH HHS [5 P30 DK26743, DK30297] Funding Source: Medline; NIGMS NIH HHS [GM32488] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P7; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; DAVIES MJ, 1991, BIOCHIM BIOPHYS ACTA, V1077, P86, DOI 10.1016/0167-4838(91)90529-9; DAYHOFF MO, 1976, ATLAS PROTEIN SEQ S2, V5, P208; de Boer HA., 1986, MAXIMIZING GENE EXPR, P225; DEAN RT, 1987, FEBS LETT, V220, P278, DOI 10.1016/0014-5793(87)80829-3; DEMONTELLANO PRO, 1987, BIOCHEMISTRY-US, V26, P5310, DOI 10.1021/bi00391a014; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; DICKERSON RE, 1983, HEMOGLOBIN, P27; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; GIBSON JF, 1958, NATURE, V181, P1398, DOI 10.1038/1811398a0; GIBSON JF, 1956, NATURE, V178, P871, DOI 10.1038/178871b0; GOODIN DB, 1987, J BIOL CHEM, V262, P7719; GRISHAM MB, 1991, PEROXIDASES CHEM BIO, V1, P335; KING NK, 1967, BIOCHIM BIOPHYS ACTA, V133, P65; KING NK, 1964, BIOCHIM BIOPHYS ACTA, V88, P235; KING NK, 1963, J BIOL CHEM, V238, P1520; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTINEZ HM, 1985, SEQUENCE ANAL PROGRA; MIEYAL JJ, 1985, REV BIOCHEM TOXICOL, V7, P1; PRYOR WA, 1986, ANNU REV PHYSIOL, V48, P657, DOI 10.1146/annurev.ph.48.030186.003301; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; RICE RH, 1983, ARCH BIOCHEM BIOPHYS, V221, P417, DOI 10.1016/0003-9861(83)90160-1; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIGA T, 1975, ARCH BIOCHEM BIOPHYS, V167, P469, DOI 10.1016/0003-9861(75)90489-0; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STUBBE J, 1988, BIOCHEMISTRY-US, V27, P3893, DOI 10.1021/bi00411a001; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAKANO T, 1977, J MOL BIOL, V110, P537, DOI 10.1016/S0022-2836(77)80111-3; TEW D, 1988, J BIOL CHEM, V263, P17880; TOMODA A, 1978, BIOCHEM J, V171, P329, DOI 10.1042/bj1710329; WHITTAKER MM, 1990, J BIOL CHEM, V265, P9610; YONETANI T, 1967, J BIOL CHEM, V242, P1974	39	110	111	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8827	8833						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1315742				2022-12-27	WOS:A1992HR85400022
J	COSTELLO, LC; ORLEAN, P				COSTELLO, LC; ORLEAN, P			INOSITOL ACYLATION OF A POTENTIAL GLYCOSYL PHOSPHOINOSITOL ANCHOR PRECURSOR FROM YEAST REQUIRES ACYL COENZYME-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; PHOSPHOLIPID MEMBRANE ANCHOR; SACCHAROMYCES-CEREVISIAE; STRUCTURAL CHARACTERIZATION; PHOSPHATIDYLINOSITOL; BIOSYNTHESIS; SPHINGOLIPIDS; PROTEINS	Glycosyl phosphoinositol (GPI) anchors on proteins can be modified by palmitoylation of their inositol residue, which makes such anchors resistant to cleavage by phosphatidylinositol-specific phospholipase C (PI-PLC) (Roberts, W. L., Myher, J. J., Kuksis, A., Low, M. G., and Rosenberry, T.L. (1988) J. Biol. Chem. 263, 18766-18775). Mannosylated GPI lipids made in trypanosomal and mammalian cells can also be inositol-acylated, indicating that inositol acylation may be a normal step in GPI anchor synthesis. We find that Saccharomyces cerevisiae mutants blocked in dolichyl phosphate mannose synthesis accumulate a lipid that can be radiolabeled in vivo with [H-3]myo-inositol, [H-3]GlcN, and [H-3]palmitic acid. This lipid is resistant to PI-PLC, yet sensitive to mild alkaline hydrolysis, and has been characterized as GlcN-phosphatidylinositol (PI), fatty acylated on its inositol residue. When yeast membranes are incubated with UDP-[C-14] GlcNAc, C-14-labeled GlcNAc-PI and GlcN-PI are made. Addition of ATP and CoA, or of palmitoyl-CoA to incubations results in the synthesis of [C-14]GlcN-(acyl-inositol)PI. This lipid is also made when membranes are incubated with [1-C-14]palmitoyl-CoA and UDP-GlcNAc. We propose that acyl CoA is the donor in inositol acylation of GlcN-PI, and that GlcN-(acyl-inositol)PI is an obligatory intermediate in GPI synthesis.	UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign					NIGMS NIH HHS [GM46220-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046220] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BRENNAN P, 1968, J BIOL CHEM, V243, P2975; CONZELMANN A, 1991, CELL BIOL INT REP, V15, P863, DOI 10.1016/0309-1651(91)90038-K; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; CONZELMANN A, 1990, EMBO J, V9, P653, DOI 10.1002/j.1460-2075.1990.tb08157.x; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAHN U, 1976, ARCH MICROBIOL, V107, P143, DOI 10.1007/BF00446834; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; DOERING TL, 1989, J BIOL CHEM, V264, P11168; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIELD MC, 1991, EMBO J, V10, P2731, DOI 10.1002/j.1460-2075.1991.tb07821.x; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1991, OCT AM SOC BIOCH MOL; KRAKOW JL, 1989, MOL BIOCHEM PARASIT, V36, P263, DOI 10.1016/0166-6851(89)90174-6; LEHLE L, 1976, FEBS LETT, V71, P167, DOI 10.1016/0014-5793(76)80922-2; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; ORLEAN P, 1987, J BIOL CHEM, V262, P5732; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SINGH N, 1991, MOL CELL BIOL, V11, P391, DOI 10.1128/MCB.11.1.391; SINGH N, 1991, MOL CELL BIOL, V11, P2362, DOI 10.1128/MCB.11.5.2362; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001	34	90	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8599	8603						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314831				2022-12-27	WOS:A1992HQ18500096
J	DORSEUIL, O; VAZQUEZ, A; LANG, P; BERTOGLIO, J; GACON, G; LECA, G				DORSEUIL, O; VAZQUEZ, A; LANG, P; BERTOGLIO, J; GACON, G; LECA, G			INHIBITION OF SUPEROXIDE PRODUCTION IN LYMPHOCYTES-B BY RAC ANTISENSE OLIGONUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING-PROTEIN; CHRONIC GRANULOMATOUS-DISEASE; CELL-LINES; SURFACE IG; OXIDASE; GENE; ACTIVATION; SUPERFAMILY; GENERATION; SYSTEM	Rac1 and Rac2 gene products are small GTP-binding proteins showing 92% homology to each other. According to recent studies performed in cell-free systems, Rac1 and Rac2 proteins may be involved in the activation of NADPH-oxidase, the superoxide-generating enzymatic complex active in phagocytes. Epstein-Barr virus (EBV) transformed B lymphocytes, which express rac1 and rac2 genes, also efficiently release superoxide anions when triggered by various cell surface stimuli. To investigate the regulatory role of Rac proteins in living cells, we analyzed superoxide production in response to cross-linking of surface immunoglobulins or phorbol ester treatment in human EBV-transformed B lymphocytes pretreated with Rac sense and antisense oligonucleotides. We report here that (i) the rac protein content estimated by immunoblotting can be decreased by 60% in Rac antisense pretreated cells and (ii) a strong (50-60%), dose-dependent inhibition of superoxide production is observed in antisense pretreated cells whereas cells pretreated with sense oligonucleotide are unaffected. The data presented show, for the first time in whole cells, that superoxide production is modulated by the Rac protein content, thus demonstrating the physiological role of Rac proteins in the regulation of NADPH-oxidase.	INST COCHIN GENET MOLEC,INSERM,U257,24 RUE FBG ST JACQUES,F-75014 PARIS,FRANCE; INSERM,U131,F-92140 CLAMART,FRANCE; ASSOC CLAUDE BERNARD,RES CTR,F-92140 CLAMART,FRANCE; INST GUSTAVE ROUSSY,INSERM,U333,F-94805 VILLEJUIF,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy								ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ALLEN RC, 1986, METHOD ENZYMOL, V133, P449; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; CHEUNG RK, 1991, J BIOL CHEM, V266, P8667; COHENTANUGI L, 1991, EUR J BIOCHEM, V202, P649, DOI 10.1111/j.1432-1033.1991.tb16419.x; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JT, 1989, BIOCHEM J, V262, P373, DOI 10.1042/bj2620373; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LANG P, 1992, J BIOL CHEM, V267, P11677; LECA G, 1990, FEBS LETT, V269, P171, DOI 10.1016/0014-5793(90)81146-F; LECA G, 1991, J IMMUNOL, V146, P3542; MALY FE, 1988, J IMMUNOL, V140, P2334; MOLL J, 1991, ONCOGENE, V6, P863; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; SHIRSAT NV, 1990, ONCOGENE, V5, P769; SHRECK R, 1991, EMBO J, V10, P2247; VOLKMAN DJ, 1984, J IMMUNOL, V133, P3006	23	118	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20540	20542						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328203				2022-12-27	WOS:A1992JT97800005
J	COURVALIN, JC; SEGIL, N; BLOBEL, G; WORMAN, HJ				COURVALIN, JC; SEGIL, N; BLOBEL, G; WORMAN, HJ			THE LAMIN-B RECEPTOR OF THE INNER NUCLEAR-MEMBRANE UNDERGOES MITOSIS-SPECIFIC PHOSPHORYLATION AND IS A SUBSTRATE FOR P34CDC2-TYPE PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PRIMARY BILIARY-CIRRHOSIS; STEP PURIFICATION; MEVALONIC ACID; CELL-CYCLE; ENVELOPE; INVIVO; IDENTIFICATION; AUTOANTIBODIES; CLEAVAGE; BINDING	The lamin B receptor (LBR) is an integral protein of the inner nuclear membrane that interacts with lamin B in vitro. It contains a 204-amino acid nucleoplasmic amino-terminal domain and a hydrophobic carboxyl-terminal domain with eight putative transmembrane segments. We found cell cycle-dependent phosphorylation of LBR using phosphoamino acid analysis and phosphopeptide mapping of in vivo P-32-labeled LBR immunoprecipitated from chicken cells in interphase and arrested in mitosis. LBR was phosphorylated only on serine residues in interphase and on serine and threonine residues in mitosis. Some serine residues phosphorylated in interphase were not phosphorylated in mitosis. To identify a threonine residue specifically phosphorylated in mitosis and the responsible protein kinase, wild-type and mutant LBR nucleoplasmic domain fusion proteins were phosphorylated in vitro by p34cdc2-type protein kinase. Comparisons of phosphopeptide maps to those of in vivo P-32-labeled mitotic LBR showed that Thr188 is likely to be phosphorylated by this enzyme during mitosis. These phosphorylation/dephosphorylation events may be responsible for some of the changes in the interaction between the nuclear lamina and the inner nuclear membrane that occur during mitosis.	CUNY MT SINAI SCH MED,DEPT MED,BOX 1039,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOLEC BIOL LAB,NEW YORK,NY 10021	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Howard Hughes Medical Institute; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK001790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013752] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK01790] Funding Source: Medline; NIGMS NIH HHS [GM13752] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPELBAUM J, 1990, J BIOL CHEM, V265, P4181; ARIS JP, 1989, J CELL BIOL, V108, P2059, DOI 10.1083/jcb.108.6.2059; BECK LA, 1988, J CELL BIOL, V107, P1307, DOI 10.1083/jcb.107.4.1307; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; COURVALIN JC, 1990, J CLIN INVEST, V86, P279, DOI 10.1172/JCI114696; COURVALIN JC, 1990, J EXP MED, V172, P961, DOI 10.1084/jem.172.3.961; EARNSHAW WC, 1991, J CELL SCI, V98, P443; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROBBINS E, 1964, J CELL BIOL, V21, P429, DOI 10.1083/jcb.21.3.429; ROBERTS SB, 1991, SCIENCE, V253, P1022, DOI 10.1126/science.1887216; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WOLDA SL, 1988, J BIOL CHEM, V263, P5997; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; ZELIGS JD, 1979, J ULTRA MOL STRUCT R, V66, P53, DOI 10.1016/S0022-5320(79)80065-9	27	110	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19035	19038						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326541				2022-12-27	WOS:A1992JP59300004
J	SHUMAN, S				SHUMAN, S			2 CLASSES OF DNA END-JOINING REACTIONS CATALYZED BY VACCINIA TOPOISOMERASE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; CLEAVAGE; RECOMBINATION; SITE; SEQUENCE; INVITRO	The ability of a eukaryotic DNA topoisomerase I to catalyze DNA rearrangements was examined in vitro using defined substrates and purified enzyme. Site-specific DNA strand cleavage by vaccinia topoisomerase I across from a nick generated double-strand breaks that could be religated to a heterologous blunt-ended duplex DNA regardless of the sequence of the acceptor molecule. Topoisomerase bound covalently at internal positions could religate the bound strand to an incoming acceptor provided that DNA molecule had sequence homology to the region 3' of the scissile bond. These end-joining reactions suggest two potential modes of topoisomerase-mediated recombination that differ in their requirements for DNA homology.			SHUMAN, S (corresponding author), SLOAN KETTERING MEM CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046330, R01GM046330] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 46330] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BULLOCK P, 1985, SCIENCE, V230, P954, DOI 10.1126/science.2997924; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P3489, DOI 10.1073/pnas.86.10.3489; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1991, P NATL ACAD SCI USA, V88, P10104, DOI 10.1073/pnas.88.22.10104; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; WANG HP, 1991, J VIROL, V65, P2381, DOI 10.1128/JVI.65.5.2381-2392.1991	10	54	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16755	16758						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324909				2022-12-27	WOS:A1992JL05300003
J	DOUCET, JP; PIERCE, GN; HERTZBERG, EL; TUANA, BS				DOUCET, JP; PIERCE, GN; HERTZBERG, EL; TUANA, BS			LOW-MOLECULAR-WEIGHT GTP-BINDING PROTEINS IN CARDIAC-MUSCLE - ASSOCIATION WITH A 32-KDA COMPONENT RELATED TO CONNEXINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; GAP JUNCTION PROTEIN; ENDOPLASMIC-RETICULUM; RAS P21; ACTIVATING PROTEIN; SKELETAL-MUSCLE; INTERCELLULAR COMMUNICATION; SUBCELLULAR-FRACTIONS; SARCOLEMMAL VESICLES; POLYACRYLAMIDE GELS	Low molecular weight GTP-binding proteins and their cellular interactions were examined in cardiac muscle. Heart homogenate was separated into various subcellular fractions by differential and sucrose density gradient centrifugation. Various fractions were separated by sodium dodecyl sulfate-gel electrophoresis, blotted to nitrocellulose, and GTP-binding proteins detected by incubating with [alpha-P-32]GTP. Three polypeptides of M(r) 23,000, 26,000, and 29,000 were specifically labeled with [alpha-P-32]GTP in all the fractions examined and enriched in sarcolemmal membranes. The 23-kDa polypeptide was labeled to a higher extent with [alpha-P-32]GTP than the 26- and 29-kDa polypeptides. A polypeptide of M(r) 40,000 was weakly labeled with [alpha-P-32]GTP in the sarcolemmal membrane and tentatively identified as G(i)alpha by immunostaining with anti-G(i)alpha antibodies. Cytosolic GTP-binding proteins were labeled with [alpha-P-32]GTP and their potential sites of interaction investigated using the blot overlay approach. A polypeptide of 32 kDa present in sarcolemmal membranes, intercalated discs, and enriched in heart gap junctions was identified as a major site of interaction. The low molecular weight GTP-binding proteins associated with the 32-kDa polypeptide through a complex involving cytosolic components of M(r) 56,000, 36,000, 26,000, 23,000, and 12,000. A monoclonal antibody against connexin 32 from liver strongly recognized the 32-kDa polypeptide in heart gap junctions, whereas polyclonal antibodies only weakly reacted with this polypeptide. The low molecular weight GTP-binding proteins associated with a 32-kDa polypeptide in liver membranes that was also immunologically related to connexin 32. These results indicate the presence of a subset of low molecular weight GTP-binding proteins in a membrane-associated and a cytoplasmic pool in cardiac muscle. Their association with a 32-kDa component that is related to the connexins suggests that these polypeptides may be uniquely situated to modulate communication at the cell membrane.	UNIV OTTAWA, FAC MED, DEPT PHARMACOL, 451 SMYTH RD, OTTAWA K1H 8M5, ONTARIO, CANADA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT NEUROSCI, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT ANAT & STRUCT BIOL, BRONX, NY 10461 USA; UNIV MANITOBA, ST BONIFACE HOSP, RES CTR, DIV CARDIOVASC SCI, WINNIPEG R2H 2A6, MANITOBA, CANADA	University of Ottawa; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Manitoba; Children's Hospital Research Institute of Manitoba				Pierce, Grant/0000-0001-7674-0142	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030667] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30667] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZARNIA R, 1987, MOL CELL BIOL, V7, P946, DOI 10.1128/MCB.7.2.946; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BIELINSKI DF, 1989, J BIOL CHEM, V264, P18363; BOKOCH GM, 1988, FEBS LETT, V227, P66, DOI 10.1016/0014-5793(88)81415-7; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRANDT NR, 1990, J MEMBRANE BIOL, V113, P237, DOI 10.1007/BF01870075; BURGOYNE RD, 1989, FEBS LETT, V245, P122, DOI 10.1016/0014-5793(89)80204-2; CARLIN RK, 1981, J CELL BIOL, V89, P449, DOI 10.1083/jcb.89.3.449; DAWSON AP, 1989, CELL CALCIUM, V10, P343, DOI 10.1016/0143-4160(89)90060-2; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DOLPHIN AC, 1988, TRENDS NEUROSCI, V11, P287, DOI 10.1016/0166-2236(88)90085-9; DOUCET JP, 1991, J BIOL CHEM, V266, P17613; DOUCET JP, 1990, ANAL BIOCHEM, V190, P209, DOI 10.1016/0003-2697(90)90182-9; DOUCET JP, 1988, ANAL BIOCHEM, V168, P265, DOI 10.1016/0003-2697(88)90317-X; DOUCET JP, 1989, FEBS LETT, V247, P127, DOI 10.1016/0014-5793(89)81254-2; DROBAK BK, 1988, BIOCHEM BIOPH RES CO, V150, P899, DOI 10.1016/0006-291X(88)90713-9; EDELSTEIN NG, 1988, BIOCHEMISTRY-US, V27, P1818, DOI 10.1021/bi00406a003; EGHBALI B, 1990, P NATL ACAD SCI USA, V87, P1328, DOI 10.1073/pnas.87.4.1328; EGHBALI B, 1990, P NATL ACAD SCI USA, V111, pA153; FEDORCHAIKEN M, 1990, CELL, V61, P329, DOI 10.1016/0092-8674(90)90813-T; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; GERSHONI JM, 1983, ANAL BIOCHEM, V131, P1, DOI 10.1016/0003-2697(83)90128-8; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GREEN CR, 1983, TISSUE CELL, V15, P17, DOI 10.1016/0040-8166(83)90030-7; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HERTZBERG EL, 1984, CELL, V39, P61, DOI 10.1016/0092-8674(84)90191-0; HERTZBERG EL, 1985, GAP JUNCTIONS, P57; HUBBARD MJ, 1987, J BIOL CHEM, V262, P15062; IKEDA N, 1980, J MOL CELL CARDIOL, V12, P809, DOI 10.1016/0022-2828(80)90082-6; KANTER HL, 1992, CIRC RES, V70, P438, DOI 10.1161/01.RES.70.2.438; KAPLAN S, 1991, J BIOL CHEM, V266, P18934; KLEBER AG, 1986, CIRCULATION, V73, P189, DOI 10.1161/01.CIR.73.1.189; KUTRYK MJB, 1988, J BIOL CHEM, V263, P13167; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LANOIX J, 1989, BIOCHEM J, V262, P497, DOI 10.1042/bj2620497; MANJUNATH CK, 1984, AM J PHYSIOL, V246, pH865, DOI 10.1152/ajpheart.1984.246.6.H865; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MESNIL M, 1986, EXP CELL RES, V165, P391, DOI 10.1016/0014-4827(86)90593-8; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAGAHARA H, 1987, BIOCHEM BIOPH RES CO, V149, P686, DOI 10.1016/0006-291X(87)90422-0; NGSEE JK, 1990, J NEUROSCI, V10, P317; NICHOLSON BJ, 1985, J BIOL CHEM, V260, P6514; NICOLSON GL, 1988, P NATL ACAD SCI USA, V85, P473, DOI 10.1073/pnas.85.2.473; PAGE E, 1985, GAP JUNCTIONS, P49; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; PAUL DL, 1985, GAP JUNCTIONS, P107; PIERCE GN, 1989, J APPL PHYSIOL, V66, P1715, DOI 10.1152/jappl.1989.66.4.1715; PIERCE GN, 1985, BIOCHIM BIOPHYS ACTA, V818, P109, DOI 10.1016/0005-2736(85)90553-X; PIERCE GN, 1989, J BIOL CHEM, V264, P15344; PINES M, 1985, P NATL ACAD SCI USA, V82, P4095, DOI 10.1073/pnas.82.12.4095; ROBINSON A, 1987, FEBS LETT, V218, P63, DOI 10.1016/0014-5793(87)81019-0; SAEZ JC, 1986, P NATL ACAD SCI USA, V83, P2473, DOI 10.1073/pnas.83.8.2473; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TUANA BS, 1988, FEBS LETT, V235, P219, DOI 10.1016/0014-5793(88)81266-3; VANHAMME L, 1989, EXP CELL RES, V180, P297, DOI 10.1016/0014-4827(89)90234-6; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WARNER AE, 1984, NATURE, V311, P127, DOI 10.1038/311127a0; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WILDEY G M, 1989, Journal of Cell Biology, V109, p293A; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YAMAMOTO T, 1990, BRAIN RES, V508, P313, DOI 10.1016/0006-8993(90)90415-8; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	77	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16503	16508						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322906				2022-12-27	WOS:A1992JJ45800080
J	LIN, SX; YANG, F; JIN, JZ; BRETON, R; ZHU, DW; VAN, LT; LABRIE, F				LIN, SX; YANG, F; JIN, JZ; BRETON, R; ZHU, DW; VAN, LT; LABRIE, F			SUBUNIT IDENTITY OF THE DIMERIC 17-BETA-HYDROXYSTEROID DEHYDROGENASE FROM HUMAN PLACENTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYSTEROID DEHYDROGENASE; AFFINITY-CHROMATOGRAPHY; PURIFICATION; ESTRADIOL-17-BETA; INACTIVATION; PROTEINS	Human placental 17-beta-hydroxysteroid dehydrogenase has been purified with a new rapid procedure based on fast protein liquid chromatography, yielding quantitatively a homogeneous preparation with high specific activity catalyzing the oxidation of 7.2-mu-mol of estradiol/min/mg of enzyme protein at 23-degrees-C, pH 9.2. This preparation was shown to have a subunit mass of 34.5 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis while having a molecular mass of 68 kDa by both Superose-12 gel filtration and native pore gradient gel electrophoresis. When 17-beta-hydroxysteroid dehydrogenase was expressed in HeLa cells or overproduced in insect cells using the baculovirus expression system, both from its cDNA encoding a protein of 34 kDa, the enzyme had the same migration in native and sodium dodecyl sulfate-gel electrophoresis as the purified one from human placenta and eluted from the Superose-12 column at the same elution volume. Moreover, all the above forms of this enzyme have similar specific activity. These results clearly demonstrate the identity of the three enzyme forms. The enzyme produced from the cDNA is expressed as a dimer, and its two subunits are identical. 17-Beta-hydroxysteroid dehydrogenase subunit identity is thus proved. The NH2-terminal analysis revealed a unique sequence of Ala-Arg-Thr-Val-Val-Leu-Ile for the purified enzyme from placenta, further confirming the above conclusion.	UNIV LAVAL, QUEBEC CITY G1V 4G2, QUEBEC, CANADA	Laval University	LIN, SX (corresponding author), CHU LAVAL, RES CTR, MRC, MOLEC ENDOCRINOL GRP, 2705 LAURIER BLVD, QUEBEC CITY G1V 4G2, QUEBEC, CANADA.			Lin, Sheng-Xiang/0000-0001-9149-375X				AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, P671; BURNS DJW, 1971, BIOCHEM BIOPH RES CO, V44, P786, DOI 10.1016/0006-291X(71)90779-0; CHIN CC, 1973, STEROIDS, V22, P373; CHIN CC, 1975, J BIOL CHEM, V250, P7682; DESCOMPS B, 1968, B SOC CHIM BIOL, V50, P1681; DUMONT M, 1992, J STEROID BIOCHEM, V41, P605, DOI 10.1016/0960-0760(92)90391-U; GIEGE R, 1986, J CRYST GROWTH, V76, P554, DOI 10.1016/0022-0248(86)90172-7; GIEGE R, 1987, NATO ASI SERIES A, V126, P15; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; JARABAK J, 1971, BIOCHEMISTRY-US, V10, P3831, DOI 10.1021/bi00797a005; Jarabak J, 1969, METHOD ENZYMOL, V15, P746, DOI DOI 10.1016/S0076-6879(69)15041-7; KARAVOLAS HJ, 1970, J BIOL CHEM, V245, P4948; KINGSTONRE, 1987, CURRENT PROTOCOLS MO, P911; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER LJ, 1959, J BIOL CHEM, V234, P2609; LANGER LJ, 1958, J BIOL CHEM, V233, P583; LIN SX, 1988, BIOCHEMISTRY-US, V27, P6343, DOI 10.1021/bi00417a022; LIN SX, 1992, PROTEIN EXPRES PURIF, V3, P41; Luu The V, 1989, Mol Endocrinol, V3, P1301; LUU-THE V, 1990, Molecular Endocrinology, V4, P268; MAINATIS T, 1989, MOL CLONING LABORATO; MURDOCK GL, 1986, BIOCHEMISTRY-US, V25, P641, DOI 10.1021/bi00351a019; REED MJ, 1991, J ENDOCRINOL, V129, P163, DOI 10.1677/joe.0.1290163; REED MJ, 1991, J STEROID BIOCHEM, V39, P791, DOI 10.1016/0960-0760(91)90027-3; SIMARD J, 1991, J BIOL CHEM, V266, P14842; SUMMERS MD, 1987, B TEXAS AM U, V1555; THOMAS JL, 1983, J BIOL CHEM, V258, P1500; TOBIAS B, 1982, J BIOL CHEM, V257, P2783; WAHAWISAN R, 1980, STEROIDS, V36, P115, DOI 10.1016/0039-128X(80)90073-2; Warburg O, 1942, BIOCHEM Z, V310, P384; 1989, BCA PROTEIN ASSAY RE; 1990, MINI PROTEAN 2 DUAL; 1982, GEL FILTRATION THERY; 1986, TECHNICAL B SIGM MKR, V137	34	114	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16182	16187						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322895				2022-12-27	WOS:A1992JJ45800033
J	ADAMS, PD; PARKER, PJ				ADAMS, PD; PARKER, PJ			ACTIVATION OF MITOGEN-ACTIVATED PROTEIN (MAP) KINASE BY A MAP KINASE-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BINDING	Previously it has been shown that acute 12-O-tetradecanoylphorbol-13-acetate treatment of intact U937 cells results in activation of mitogen-activated protein (MAP) kinase and a MAP kinase activator. MAP kinase activator induces phosphorylation of MAP kinase on tyrosine and threonine residues, thereby activating MAP kinase. Here, experiments with the irreversible kinase inhibitor, 5'-p-fluorosulfonylbenzoyladenosine (FSBA), show that MAP kinase activator is in fact a MAP kinase-kinase. Treatment of MAP kinase activator with FSBA results in complete inactivation. This inactivation is prevented by a 10-fold excess of ATP. Inactivation of MAP kinase by FSBA does not affect the extent of threonine/tyrosine phosphorylation induced by MAP kinase-kinase.	IMPERIAL CANC RES FUND, POB 123, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND	Cancer Research UK			Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933; Adams, Peter/0000-0002-0684-1770				ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; WU T, 1991, P NATL ACAD SCI USA, V88, P9508; ZOLLER MJ, 1979, J BIOL CHEM, V254, P8363	23	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13135	13137						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320010				2022-12-27	WOS:A1992JB74600006
J	OMBURO, GA; KUO, JM; MULLINS, LS; RAUSHEL, FM				OMBURO, GA; KUO, JM; MULLINS, LS; RAUSHEL, FM			CHARACTERIZATION OF THE ZINC-BINDING SITE OF BACTERIAL PHOSPHOTRIESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-DIMINUTA; ESCHERICHIA-COLI; GENE	The bacterial phosphotriesterase has been found to require a divalent cation for enzymatic activity. This enzyme catalyzes the detoxification of organophosphorus insecticides and nerve agents. In an Escherichia coli expression system significantly higher concentrations of active enzyme could be produced when 1.0 mM concentrations of Mn2+, Co2+, Ni2+, and Cd2+ were included in the growth medium. The isolated enzymes contained up to 2 equivalents of the these metal ions as determined by atomic absorption spectroscopy. The catalytic activity of the various metal enzyme derivatives was lost upon incubation with EDTA, 1,10-phenanthroline, and 8-hydroxyquinoline-5-sulfonic acid. Protection against inactivation by metal chelation was afforded by the binding of competitive inhibitors, suggesting that at least one metal is at or near the active site. Apoenzyme was prepared by incubation of the phosphotriesterase with beta-mercaptoethanol and EDTA for 2 days. Full recovery of enzymatic activity could be obtained by incubation of the apoenzyme with 2 equivalents of Zn2+, Co2+, Ni2+, Cd2+, or Mn2+. The Cd-113 NMR spectrum of enzyme containing 2 equivalents of Cd-113(2+) showed two resonances at 120 and 215 ppm downfield from Cd(ClO4)2. The NMR data are consistent with nitrogen (histidine) and oxygen ligands to the metal centers.	TEXAS A&M UNIV SYST,DEPT CHEM,COLLEGE STN,TX 77843; TEXAS A&M UNIV SYST,CTR MACROMOLEC DESIGN,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station			Raushel, Frank/B-7125-2015	Raushel, Frank/0000-0002-5918-3089				BROWN KA, 1980, SOIL BIOL BIOCHEM, V12, P105, DOI 10.1016/0038-0717(80)90044-9; CALDWELL SR, 1991, BIOCHEMISTRY-US, V30, P7438, DOI 10.1021/bi00244a010; Cleland W W, 1979, Methods Enzymol, V63, P103; COLEMAN JE, 1986, PROGR INORGANIC BIOC, V1, P77; CURDEL A, 1968, Febs Letters, V1, P133, DOI 10.1016/0014-5793(68)80040-7; DONARSKI WJ, 1989, BIOCHEMISTRY-US, V28, P4650, DOI 10.1021/bi00437a021; DUMAS DP, 1989, J BIOL CHEM, V264, P19659; DUMAS DP, 1990, J BIOL CHEM, V265, P21498; LARSEN KS, 1988, FASEB J, V2, P4754; LEWIS VE, 1988, BIOCHEMISTRY-US, V27, P1591, DOI 10.1021/bi00405a030; MCDANIEL CS, 1988, J BACTERIOL, V170, P2306, DOI 10.1128/jb.170.5.2306-2311.1988; MULBRY WW, 1989, J BACTERIOL, V171, P6740, DOI 10.1128/jb.171.12.6740-6746.1989; MULBRY WW, 1989, APPL ENVIRON MICROB, V54, P2566; READ DC, 1983, AGR ECOSYST ENVIRON, V10, P37, DOI 10.1016/0167-8809(83)90068-3; ROWLAND SS, 1991, APPL ENVIRON MICROB, V57, P440, DOI 10.1128/AEM.57.2.440-444.1991; SERDAR CM, 1989, BIO-TECHNOL, V7, P1151; SPECKHARD DC, 1977, BIOCHEMISTRY-US, V16, P5228, DOI 10.1021/bi00643a011; VALLEE BL, 1954, J AM CHEM SOC, V76, P5006, DOI 10.1021/ja01648a088; Veillon C, 1978, Methods Enzymol, V54, P446	19	295	325	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13278	13283						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320014				2022-12-27	WOS:A1992JB74600032
J	RHEE, SG; CHOI, KD				RHEE, SG; CHOI, KD			REGULATION OF INOSITOL PHOSPHOLIPID-SPECIFIC PHOSPHOLIPASE-C ISOZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							EPIDERMAL GROWTH-FACTOR; PROTEIN; BETA				RHEE, SG (corresponding author), NHLBI, BIOCHEM LAB, BLDG 3, RM 122, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BRUZIK KS, 1992, IN PRESS BIOCHEMISTR; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; KATO H, 1992, J BIOL CHEM, V267, P6483; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1989, BIOCHEM BIOPH RES CO, V163, P177, DOI 10.1016/0006-291X(89)92117-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; PARK D, 1992, IN PRESS J BIOL CHEM; PARK DJ, 1992, J BIOL CHEM, V267, P1496; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, IN PRESS CELLULAR MO; ROTIN D, 1992, J BIOL CHEM, V267, P9678; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1990, J BIOL CHEM, V265, P17941; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SRIVASTAVA SP, 1991, J BIOL CHEM, V266, P20337; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WONG SKF, 1990, J BIOL CHEM, V265, P6219; WU DQ, 1992, J BIOL CHEM, V267, P1811; YAGISAWA H, 1991, J HYPERTENS, V9, P997, DOI 10.1097/00004872-199111000-00004	40	758	770	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12393	12396						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1319994				2022-12-27	WOS:A1992HZ48300001
J	GALE, KC; OSHEROFF, N				GALE, KC; OSHEROFF, N			INTRINSIC INTERMOLECULAR DNA LIGATION ACTIVITY OF EUKARYOTIC TOPOISOMERASE-II - POTENTIAL ROLES IN RECOMBINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER CHROMATID EXCHANGES; SINGLE-STRANDED-DNA; ILLEGITIMATE RECOMBINATION; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; CLEAVAGE REACTION; ESCHERICHIA-COLI; DUPLEX DNA; REPLICATION; INVITRO	Drosophila melanogaster topoisomerase II is capable of joining phi-X 174 (+) strand DNA that it has cleaved to duplex oligonucleotide acceptor molecules by an intermolecular ligation reaction (Gale, K. C. and Osheroff, N. (1990) Biochemistry 29, 9538-9545). In order to investigate potential mechanisms for topoisomerase II-mediated DNA recombination, this intrinsic enzyme activity was further characterized. Intermolecular DNA ligation proceeded in a time-dependent fashion and was concentration-dependent with respect to oligonucleotide. The covalent linkage between phi-X174 (+) strand DNA and acceptor molecules was confirmed by Southern analysis and alkaline gel electrophoresis. Topoisomerase II-mediated intermolecular DNA ligation required the oligonucleotide to contain a 3'-OH terminus. Moreover, the reaction was dependent on the presence of a divalent cation, was inhibited by salt, and was not affected by the presence of ATP. The enzyme was capable of ligating phi-X174 (+) strand DNA to double-stranded oligonucleotides that contained 5'-overhang, 3'-overhang, or blunt ends. Single-stranded, nicked, or gapped oligonucleotides also could be used as acceptor molecules. These results demonstrate that the type II enzyme has an intrinsic ability to mediate illegitimate DNA recombination in vitro and suggests possible roles for topoisomerase II in nucleic acid recombination in vivo.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,621 LIGHT HALL,NASHVILLE,TN 37232	Vanderbilt University					NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA-09582] Funding Source: Medline; NIGMS NIH HHS [GM-33944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN AH, 1991, J BIOL CHEM, V266, P9203; ANDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P6237, DOI 10.1021/bi00441a015; ANDERSSON HC, 1989, CARCINOGENESIS, V10, P123, DOI 10.1093/carcin/10.1.123; BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; BAE YS, 1991, GENE, V101, P285; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BEEN MD, 1981, P NATL ACAD SCI-BIOL, V78, P2883, DOI 10.1073/pnas.78.5.2883; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; BULLOCK P, 1985, SCIENCE, V230, P954, DOI 10.1126/science.2997924; CHARTRAND P, 1991, DNA TOPOISOMERASES C, P240; CHATTERJEE S, 1990, CANCER RES, V50, P2713; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; DEGRASSI F, 1989, MUTAT RES, V211, P125, DOI 10.1016/0027-5107(89)90112-7; DEVORE R, 1989, ANN INTERN MED, V110, P704, DOI 10.7326/0003-4819-110-9-740; DILLEHAY LE, 1989, MUTAT RES, V215, P15, DOI 10.1016/0027-5107(89)90213-3; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DOWD DR, 1990, J BIOL CHEM, V265, P3424; FRIEDBERGEC, 1985, DNA REPAIR; GALE KC, 1990, BIOCHEMISTRY-US, V29, P9538, DOI 10.1021/bi00493a007; GLIKIN GC, 1986, EMBO J, V5, P151, DOI 10.1002/j.1460-2075.1986.tb04189.x; HALLIGAN BD, 1982, J BIOL CHEM, V257, P3995; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; IKEDA H, 1986, P NATL ACAD SCI USA, V83, P922, DOI 10.1073/pnas.83.4.922; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; KIM RA, 1989, J MOL BIOL, V208, P257, DOI 10.1016/0022-2836(89)90387-2; KORNBERG A, 1988, J BIOL CHEM, V263, P1; KREUZER KN, 1984, J BIOL CHEM, V259, P5347; LEE MP, 1989, J BIOL CHEM, V264, P13510; LIM M, 1986, CELL BIOL TOXICOL, V2, P485, DOI 10.1007/BF00117850; LIU LF, 1983, J BIOL CHEM, V258, P1365; LONN U, 1989, CANCER RES, V49, P6202; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MULLER MT, 1988, BIOCHEMISTRY-US, V27, P8369, DOI 10.1021/bi00422a012; MYLES GM, 1989, CHEM RES TOXICOL, V2, P197, DOI 10.1021/tx00010a001; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P6402, DOI 10.1021/bi00394a015; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; POMMIER Y, 1985, CANCER RES, V45, P3143; RENAULT G, 1987, TOXICOL APPL PHARM, V89, P281, DOI 10.1016/0041-008X(87)90049-4; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; Sambrook J, 1989, MOL CLONING LABORATO; SANDER M, 1987, J MOL BIOL, V194, P219, DOI 10.1016/0022-2836(87)90370-6; SANDER M, 1983, J BIOL CHEM, V258, P8421; SCHAACK J, 1990, J VIROL, V64, P78, DOI 10.1128/JVI.64.1.78-85.1990; Schneider E, 1990, Adv Pharmacol, V21, P149, DOI 10.1016/S1054-3589(08)60342-7; Segel I.H., 1975, ENZYME KINETICS, P44; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P3489, DOI 10.1073/pnas.86.10.3489; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; WANG HP, 1991, J VIROL, V65, P2381, DOI 10.1128/JVI.65.5.2381-2392.1991; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WELLS RD, 1988, J BIOL CHEM, V263, P1095; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	66	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12090	12097						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1318309				2022-12-27	WOS:A1992HY94700068
J	ZHU, XY; ZENG, YC; LEHRMAN, MA				ZHU, XY; ZENG, YC; LEHRMAN, MA			EVIDENCE THAT THE HAMSTER TUNICAMYCIN RESISTANCE GENE ENCODES UDP-GLCNAC-DOLICHOL PHOSPHATE N-ACETYLGLUCOSAMINE-1-PHOSPHATE TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; N-ACETYLGLUCOSAMINE SYNTHESIS; ACETYL-D-GLUCOSAMINE; RAT LUNG MICROSOMES; OVARY CELLS; MAMMARY-GLAND; BIOSYNTHESIS; SEQUENCE; CLONING; GLYCOSYLTRANSFERASES	A cDNA clone isolated from Chinese hamster ovary cells conferred elevated GlcNAc-1-P-transferase (GPT) activity and resistance to tunicamycin in transfected cells (Zhu, X., and Lehrman, M. A. (1990) J. Biol. Chem. 265, 14250-14255). It had been assumed that this cDNA, termed TRG for tunicamycin resistance gene, encoded GPT enzyme. However, other functions were not ruled out. Thus, by one of several mechanisms, the TRG protein could have instead functioned by activation of the transfected host's endogenous GPT enzyme. To analyze the biochemical function of the TRG protein, hamster TRG cDNA was stably expressed at high levels in Chinese hamster ovary cells. In addition, several antipeptide polyclonal antibodies directed against the predicted TRG protein were obtained. With these tools in hand, experiments were performed to test the hypothesis that the TRG encodes GPT enzyme, as well as to rule out other possible functions for the TRG protein. These experiments included examination of the effects of solubilization of membranes on TRG-dependent GPT activity, the apparent binding of tunicamycin to the TRG protein, and the immunoadsorption of GPT activity with TRG protein-specific antibodies. From these results, we conclude that the hamster TRG most likely encodes GPT enzyme.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038545] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38545] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRIGHT CF, 1989, P NATL ACAD SCI USA, V86, P7366, DOI 10.1073/pnas.86.19.7366; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CRISCUOLO BA, 1982, J CELL BIOL, V94, P586, DOI 10.1083/jcb.94.3.586; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYES GR, 1983, J BIOL CHEM, V258, P5095; HEIFETZ A, 1979, BIOCHEMISTRY-US, V18, P2186, DOI 10.1021/bi00578a008; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KELLER RK, 1979, BIOCHEMISTRY-US, V18, P3946, DOI 10.1021/bi00585a016; LACHMANN PJ, 1986, CIBA F SYMP, V119, P25; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; LEHRMAN MA, 1989, J BIOL CHEM, V264, P1584; LEHRMAN MA, 1988, J BIOL CHEM, V263, P19796; MEIERDIETER U, 1990, J BIOL CHEM, V265, P13490; PLOUHAR PL, 1983, J BIOL CHEM, V258, P2988; PLOUHAR PL, 1982, J BIOL CHEM, V257, P8907; RINE J, 1983, P NATL ACAD SCI-BIOL, V80, P6750, DOI 10.1073/pnas.80.22.6750; ROSNER MR, 1982, METHOD ENZYMOL, V83, P399; RUSH J S, 1991, Glycobiology, V1, P229, DOI 10.1093/glycob/1.2.229; Sambrook J, 1989, MOL CLONING LABORATO; SCOCCA JR, 1990, J BIOL CHEM, V265, P20621; SHAILUBHAI K, 1988, J BIOL CHEM, V263, P15964; TABAS I, 1982, METHOD ENZYMOL, V83, P416; TURCO SJ, 1981, ANAL BIOCHEM, V118, P278, DOI 10.1016/0003-2697(81)90582-0; VIJAY IK, 1986, EUR J BIOCHEM, V154, P57, DOI 10.1111/j.1432-1033.1986.tb09358.x; WALDMAN BC, 1987, J CELL PHYSIOL, V131, P302, DOI 10.1002/jcp.1041310303; ZHU XY, 1990, J BIOL CHEM, V265, P14250	29	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8895	8902						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1315744				2022-12-27	WOS:A1992HR85400032
J	ATTA, M; NORDLUND, P; ABERG, A; EKLUND, H; FONTECAVE, M				ATTA, M; NORDLUND, P; ABERG, A; EKLUND, H; FONTECAVE, M			SUBSTITUTION OF MANGANESE FOR IRON IN RIBONUCLEOTIDE REDUCTASE FROM ESCHERICHIA-COLI - SPECTROSCOPIC AND CRYSTALLOGRAPHIC CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; DIMERIC SMALL SUBUNIT; SUPEROXIDE-DISMUTASE; 3-DIMENSIONAL STRUCTURE; THERMUS-THERMOPHILUS; RADICAL FORMATION; ONE TYROSINE-122; CONCANAVALIN-A; REDUCED FORMS; OXO PROTEINS	Each polypeptide chain of protein R2, the small subunit of ribonucleotide reductase from Escherichia coli, contains a stable tyrosyl radical and two antiferromagnetically coupled oxo-bridged ferric ions. A refined structure of R2 has been recently obtained. R2 can be converted into apoR2 by chelating out the metal cofactor and scavenging the radical. This study shows that apoR2 has a very strong affinity for four stable Mn2+ ions. The manganese-containing form of R2, named Mn-R2, has been studied by EPR spectroscopy and x-ray crystallography. It contains two binuclear manganese clusters in which the two manganese ions occupy the natural iron-binding sites and are only bridged by carboxylates from glutamates 115 and 238. This in turn explains why the spin-exchange interaction between the two ions is very weak and why Mn-R2 is EPR active. Mn-R2 could provide a model for the native diferrous form of protein R2, and a detailed molecular mechanism for the reduction of the iron center of protein R2 is proposed.	UNIV JOSEPH FOURIER, ETUD DYNAM & STRUCT SELECTIV,CNRS,URA 0332,BP 53X, F-38041 GRENOBLE, FRANCE; UNIV STOCKHOLM, DEPT MOLEC BIOL, S-10691 STOCKHOLM, SWEDEN; LAB MOLEC BIOPHYS, OXFORD OX1 3QU, ENGLAND; SWEDISH UNIV AGR SCI, CTR BIOMED, DEPT MOLEC BIOL, S-75124 UPPSALA, SWEDEN	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Stockholm University; University of Oxford; Swedish University of Agricultural Sciences								ANTANAITIS BC, 1987, BIOCHEMISTRY-US, V26, P7932, DOI 10.1021/bi00398a058; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BARYNIN VV, 1986, DOKL AKAD NAUK SSSR+, V288, P877; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BOROVIK AS, 1990, J AM CHEM SOC, V112, P6031, DOI 10.1021/ja00172a019; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUTTLAIRE DH, 1980, J BIOL CHEM, V255, P2164; CANESCHI A, 1989, ANGEW CHEM INT EDIT, V28, P1365, DOI 10.1002/anie.198913651; ELGREN TE, 1991, J BIOL CHEM, V266, P19265; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FONTECAVE M, 1992, ADV ENZYMOL, V65, P147; GEREZ C, 1991, ANGEW CHEM INT EDIT, V30, P1135, DOI 10.1002/anie.199111351; HARDMAN KD, 1982, J MOL BIOL, V157, P69, DOI 10.1016/0022-2836(82)90513-7; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KHANGULOV SV, 1990, J INORG BIOCHEM, V40, P279, DOI 10.1016/0162-0134(90)80062-3; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LARSSON A, 1988, J BIOL CHEM, V263, P17780; LUDWIG ML, 1991, J MOL BIOL, V219, P335, DOI 10.1016/0022-2836(91)90569-R; LYNCH JB, 1989, J BIOL CHEM, V264, P8091; MARKHAM GD, 1981, J BIOL CHEM, V256, P1903; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NORDLUND P, 1989, FEBS LETT, V258, P251, DOI 10.1016/0014-5793(89)81666-7; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; RARDIN RL, 1991, NEW J CHEM, V15, P417; REED GH, 1970, J BIOL CHEM, V245, P662; REED GH, 1972, J BIOL CHEM, V247, P3073; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SAHLIN M, 1989, BIOCHEMISTRY-US, V28, P2618, DOI 10.1021/bi00432a039; SJOBERG BM, 1982, BIOCHEMISTRY-US, V21, P96; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; STODDARD BL, 1990, BIOCHEMISTRY-US, V29, P8885, DOI 10.1021/bi00490a002; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; Thelander L, 1978, Methods Enzymol, V51, P227; THORP HH, 1991, NEW J CHEM, V15, P479; TOLMAN WB, 1991, J AM CHEM SOC, V113, P152, DOI 10.1021/ja00001a023; WAGNER UG, 1989, J MOL BIOL, V206, P787, DOI 10.1016/0022-2836(89)90586-X; WIEGHARDT K, 1988, J AM CHEM SOC, V110, P7398, DOI 10.1021/ja00230a021; WIEGHARDT K, 1989, ANGEW CHEM INT EDIT, V28, P1153, DOI 10.1002/anie.198911531; WILLING A, 1988, EUR J BIOCHEM, V170, P603, DOI 10.1111/j.1432-1033.1988.tb13740.x; YAMASHITA MM, 1989, J BIOL CHEM, V264, P17681	43	144	145	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20682	20688						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328209				2022-12-27	WOS:A1992JT97800028
J	POSNER, I; ENGEL, M; LEVITZKI, A				POSNER, I; ENGEL, M; LEVITZKI, A			KINETIC-MODEL OF THE EPIDERMAL GROWTH-FACTOR (EGF) RECEPTOR TYROSINE KINASE AND A POSSIBLE MECHANISM OF ITS ACTIVATION BY EGF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; PHOSPHORYLATION; DOMAIN	The tyrosine kinase activity of the epidermal growth factor receptor (EGFR-TK) was determined at varying poly-Glu6Ala3Tyr1 (GAT) or [Val5]-angiotensin II (AT) and constant ATP concentrations and vice versa. With GAT as substrate, double reciprocal plots intersected practically on the abscissa following EGFR-TK pre-activation with EGF, but below the abscissa without EGF pre-activation. The EGFR-TK inhibitors App(NH)p (5'-adenylyl-beta,gamma-imidodiphosphate) and ADP were competitive with ATP and noncompetitive with GAT. Four families of 1/v vs. 1/[ATP] plots, constructed at different fixed concentrations of ADP and a different constant concentration of GAT for each family, yielded Slope1/ATP replots which intersected to the left of the ordinate and below the abscissa. GAT and AT, as cosubstrates, were competitive with each other and noncompetitive with ATP; 1/v vs. 1/[GAT] or 1/[AT] plots were hyperbolic and reached horizontal asymptotes when v was expressed as the rate of common product formation. All data were subjected to computer best-fit analysis by a program written especially for this purpose. We conclude that (i) the EGFR-TK reaction follows a Sequential Bi-Bi Rapid Equilibrium Random mechanism, and (ii) EGF induces conformational changes in the EGFR-TK active center which lead to marked decreases in the apparent dissociation constants of both substrates of the kinase reaction and a concomitant increase in initial velocities and V(max)(apparent).	HEBREW UNIV JERUSALEM, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, CTR COMPUTAT, IL-91904 JERUSALEM, ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem								BRAUN S, 1984, J BIOL CHEM, V259, P2051; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CLELAND WW, 1979, METHOD ENZYMOL, V63, P108; ERNEUX C, 1983, J BIOL CHEM, V258, P4137; Fromm H J, 1979, Methods Enzymol, V63, P42; Fromm H J, 1979, Methods Enzymol, V63, P467; FROMM HJ, 1964, BIOCHIM BIOPHYS ACTA, V81, P413, DOI 10.1016/0926-6569(64)90126-9; GOLDBERG AR, 1984, ADV ENZYME REGUL, V22, P289, DOI 10.1016/0065-2571(84)90019-0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HSU CYJ, 1991, J BIOL CHEM, V266, P21105; HSU CYJ, 1991, J BIOL CHEM, V266, P603; HSU CYJ, 1990, CELL GROWTH DIFFER, V1, P191; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308; Rudolph F B, 1979, Methods Enzymol, V63, P411; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; Segel I. H., 1975, ENZYME KINETICS, P273; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALKER DH, 1987, BIOCHEMISTRY-US, V26, P1428, DOI 10.1021/bi00379a033; WONG TW, 1984, J BIOL CHEM, V259, P3127; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YUAN CJ, 1990, J BIOL CHEM, V265, P16205; ZEWE V, 1964, J BIOL CHEM, V239, P1625	25	63	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20638	20647						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328205				2022-12-27	WOS:A1992JT97800023
J	DUESCHER, RJ; ELFARRA, AA				DUESCHER, RJ; ELFARRA, AA			1,3-BUTADIENE OXIDATION BY HUMAN MYELOPEROXIDASE - ROLE OF CHLORIDE-ION IN CATALYSIS OF DIVERGENT PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHONUCLEAR LEUKOCYTES; CHLORINATING ACTIVITY; BUTADIENE MONOXIDE; EXPOSURE; RATS; CARCINOGENICITY; ACTIVATION; CHLOROPEROXIDASE; EPICHLOROHYDRIN; ENZYME	1,3-Butadiene was oxidized by human myeloperoxidase in the absence of KCl to yield butadiene monoxide (BM) and crotonaldehyde (CA), but at KCl concentrations higher than 50 mM, 1-chloro-2-hydroxy-3-butene (CHB) was the major metabolite detected; metabolite formation was dependent on incubation time, pH, KCl, 1,3-butadiene, and H2O2 concentrations. The data are best explained by 1,3-butadiene being oxidized by myeloperoxidase by two different mechanisms. First, oxygen transfer from the hemoprotein would occur to either C-1 or C-4 of 1,3-butadiene to form an intermediate which may cyclize to form BM or undergo a hydrogen shift to form 3-butenal, an unstable precursor of CA. Further evidence for this mechanism was provided by the inability to detect methyl vinyl ketone, a possible product of an oxygen transfer reaction to C-2 or C-3 of 1,3-butadiene, and by the finding that CA was not simply a decomposition product of BM under assay conditions. In the second mechanism, however, chloride ion is oxidized by myeloperoxidase to HOCl which reacts with 1,3-butadiene to yield CHB. Further evidence for this mechanism was provided by the finding that CHB was readily formed when 1,3-butadiene was added to the filtrate of a myeloperoxidase/H2O2/KCl incubation and when 1,3-butadiene was allowed to react with authentic HOCl. In addition, CHB was not detected when BM or CA was incubated with myeloperoxidase, H2O2, and KCl for up to 60 min, or when 1,3-butadiene and KCl were incubated with chloroperoxidase and H2O2 or with mouse liver microsomes and NADPH, enzyme systems which catalyze 1,3-butadiene oxidation to BM and CA, but unlike myeloperoxidase, do not catalyze chloride ion oxidation to HOCl. These results provide clear evidence for novel olefinic oxidation reactions by myeloperoxidase.	UNIV WISCONSIN,SCH VET MED,DEPT COMPARAT BIOSCI,2015 LINDEN DR W,MADISON,WI 53706; UNIV WISCONSIN,CTR ENVIRONM TOXICOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040375] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 40375] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agner K., 1972, STRUCTURE FUNCTION O, P329; BERRY CA, 1991, KIDNEY, V1, P245; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V784, P189, DOI 10.1016/0167-4838(84)90127-4; BRUNNEMANN KD, 1990, CARCINOGENESIS, V11, P1863, DOI 10.1093/carcin/11.10.1863; CHANCE B, 1955, METHOD ENZYMOL, V2, P764, DOI 10.1016/S0076-6879(55)02300-8; CITTI L, 1984, CARCINOGENESIS, V5, P47, DOI 10.1093/carcin/5.1.47; DEMONTELLANO PRO, 1987, J BIOL CHEM, V262, P11641; DEROBERTIS EDP, 1975, CELL BIOL, P472; EASTMOND DA, 1990, METHOD ENZYMOL, V186, P579; ELFARRA AA, 1991, ARCH BIOCHEM BIOPHYS, V286, P244, DOI 10.1016/0003-9861(91)90036-I; GOODROW T, 1990, CANCER RES, V50, P4818; GREENBERG HL, 1990, BRIT J IND MED, V47, P221; Hallenberg P F, 1978, Methods Enzymol, V52, P521; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; ICHIHARA S, 1986, BIOCHEM PHARMACOL, V35, P3935, DOI 10.1016/0006-2952(86)90007-9; IRONS RD, 1987, CARCINOGENESIS, V8, P1711, DOI 10.1093/carcin/8.11.1711; KADESCH RG, 1946, J AM CHEM SOC, V68, P41, DOI 10.1021/ja01205a013; KLUWE WM, 1983, TOXICOL APPL PHARM, V70, P67, DOI 10.1016/0041-008X(83)90180-1; KREILING R, 1987, ARCH TOXICOL, V61, P7, DOI 10.1007/BF00324541; LASKIN S, 1980, J NATL CANCER I, V65, P751, DOI 10.1093/jnci/65.4.751; LEIDERMAN LJ, 1986, EXP MOL PATHOL, V44, P50, DOI 10.1016/0014-4800(86)90032-8; LIBBY RD, 1992, J BIOL CHEM, V267, P1769; MALLET WG, 1991, CARCINOGENESIS, V12, P521, DOI 10.1093/carcin/12.3.521; MATANOSKI GM, 1990, ENVIRON HEALTH PERSP, V86, P107, DOI 10.2307/3430942; MELNICK RL, 1990, CANCER RES, V50, P6592; OTT MG, 1989, AM J IND MED, V16, P631; OWEN PE, 1987, AM IND HYG ASSOC J, V48, P407, DOI 10.1080/15298668791384959; PEMBER SO, 1983, BLOOD, V61, P1116; Reed C. D., 1959, J CHEM ENG DATA, V4, P294; SHARER JE, 1991, CHEM RES TOXICOL, V4, P430, DOI 10.1021/tx00022a006; SHARER JE, 1992, IN PRESS DRUG METAB; STELMASZYNSKA T, 1974, EUR J BIOCHEM, V45, P305, DOI 10.1111/j.1432-1033.1974.tb03555.x; SUMRELL G, 1964, CAN J CHEM, V42, P2896, DOI 10.1139/v64-428; UETRECHT JP, 1991, CHEM RES TOXICOL, V4, P218, DOI 10.1021/tx00020a015; ZGLICZYNSKI JM, 1971, BIOCHIM BIOPHYS ACTA, V235, P419, DOI 10.1016/0005-2744(71)90281-6; [No title captured]	37	53	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19859	19865						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328183				2022-12-27	WOS:A1992JR85800020
J	TAKEDA, S; NORTH, DL; LAKICH, MM; RUSSELL, SD; WHALEN, RG				TAKEDA, S; NORTH, DL; LAKICH, MM; RUSSELL, SD; WHALEN, RG			A POSSIBLE REGULATORY ROLE FOR CONSERVED PROMOTER MOTIFS IN AN ADULT-SPECIFIC MUSCLE MYOSIN GENE FROM MOUSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREATINE-KINASE GENE; HEAVY-CHAIN GENE; THYROID-HORMONE; SKELETAL-MUSCLE; MESSENGER-RNA; ACTIN GENE; CARDIAC ACTIN; RAT HINDLIMB; BINDING-SITE; DNA-BINDING	The mouse gene encoding a myosin heavy chain (MHC) protein expressed in type IIB fibers of adult skeletal muscle has been cloned and its promoter isolated. A number of DNA sequence motifs are found within the first 2.5 kilobases of the promoter which are similar to motifs present in the promoters of other muscle-specific genes. One sequence located at approximately-940 base pairs corresponds to the motif called MEF1 which has been shown in other muscle genes to bind the myogenic regulatory factors of which MyoD is one example. The MEF1 site of this adult IIB MHC promoter does indeed bind MyoD although this factor is normally thought to be involved in early muscle cell differentiation. The IIB MHC promoter also has several motifs located in the first 200 base pairs which are strikingly conserved between this mouse gene and several chicken skeletal MHC genes. Of these evolutionarily conserved sequences, two motifs rich in A and T residues appear to be major contributors to the muscle-specific transcriptional activity of the mouse IIB MHC promoter when transfected into quail myogenic and non-myogenic cells. These observations suggest an important functional role for these AT-rich sequence motifs in the regulation of genes of the MHC family.	INST PASTEUR,DEPT MOLEC BIOL,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								BANDMAN E, 1985, INT REV CYTOL, V97, P97, DOI 10.1016/S0074-7696(08)62349-9; BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BOUVAGNET PF, 1987, MOL CELL BIOL, V7, P4377, DOI 10.1128/MCB.7.12.4377; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; BUTLERBROWNE GS, 1987, J BIOL CHEM, V262, P15188; BUTLERBROWNE GS, 1984, DEV BIOL, V102, P324, DOI 10.1016/0012-1606(84)90197-0; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONDON K, 1990, DEV BIOL, V138, P256, DOI 10.1016/0012-1606(90)90196-P; COX RD, 1991, DEV BIOL, V143, P36, DOI 10.1016/0012-1606(91)90052-5; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAVIS HL, 1988, NERVE MUSCLE CELL TR, P101; DEPONTIZILLI L, 1988, P NATL ACAD SCI USA, V85, P1389, DOI 10.1073/pnas.85.5.1389; DUCLERT A, 1991, NEUROREPORT, V2, P25, DOI 10.1097/00001756-199101000-00006; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; EMERSON CP, 1987, ANNU REV BIOCHEM, V56, P695, DOI 10.1146/annurev.bi.56.070187.003403; ERNST H, 1991, MOL CELL BIOL, V11, P3735, DOI 10.1128/MCB.11.7.3735; FISZMAN MY, 1975, NATURE, V254, P429, DOI 10.1038/254429a0; GOBLET C, 1989, NUCLEIC ACIDS RES, V17, P2144, DOI 10.1093/nar/17.5.2144; GORMAN CM, 1982, MOL CELL BIOL, V2, P1004; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GUSTAFSON TA, 1987, P NATL ACAD SCI USA, V84, P3122, DOI 10.1073/pnas.84.10.3122; GUSTAFSON TA, 1989, MOL CELL BIOL, V9, P3269, DOI 10.1128/MCB.9.8.3269; HARRIS AJ, 1989, DEVELOPMENT, V107, P7251; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; KIRSCHBAUM BJ, 1990, J BIOL CHEM, V265, P13974; KROPP KE, 1987, J BIOL CHEM, V262, P16536; LAFRAMBOISE WA, 1991, DEV BIOL, V144, P1, DOI 10.1016/0012-1606(91)90473-G; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI ZL, 1991, J BIOL CHEM, V266, P6562; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; MAHDAVI V, 1986, MOL BIOL MUSCLE DEV, P345; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MOLINA MI, 1987, J BIOL CHEM, V262, P6478; MONTARRAS D, 1983, J BIOL CHEM, V258, P3883; MONTARRAS D, 1991, NEW BIOL, V3, P592; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MOULY V, 1990, DYNAMIC STATE OF MUSCLE FIBERS, P651; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; NARUSAWA M, 1987, J CELL BIOL, V104, P447, DOI 10.1083/jcb.104.3.447; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PHANDINHTUY F, 1988, EUR J BIOCHEM, V173, P507, DOI 10.1111/j.1432-1033.1988.tb14027.x; POUTSKA A, 1984, P NATL ACAD SCI USA, V81, P429; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUSSELL SD, 1988, J BIOL CHEM, V263, P6370; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO IM, 1991, MOL CELL BIOL, V11, P6296, DOI 10.1128/MCB.11.12.6296; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHEN RQ, 1991, MOL CELL BIOL, V11, P1676, DOI 10.1128/MCB.11.3.1676; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEDMAN HH, 1990, J BIOL CHEM, V265, P3568; TONG SW, 1983, J BIOL CHEM, V258, P3100; TSIKA RW, 1990, P NATL ACAD SCI USA, V87, P379, DOI 10.1073/pnas.87.1.379; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WEYDERT A, 1983, J BIOL CHEM, V258, P3867; WHALEN RG, 1985, J EXP BIOL, V115, P43; WHALEN RG, 1981, NATURE, V292, P805, DOI 10.1038/292805a0; WHALEN RG, 1979, P NATL ACAD SCI USA, V76, P5197, DOI 10.1073/pnas.76.10.5197; WHALEN RG, 1990, DEV BIOL, V141, P24, DOI 10.1016/0012-1606(90)90099-5; WHALEN RG, 1985, J CELL BIOL, V101, P603, DOI 10.1083/jcb.101.2.603; WIECZOREK DF, 1985, J CELL BIOL, V101, P618, DOI 10.1083/jcb.101.2.618; WITZEMANN V, 1991, FEBS LETT, V282, P259, DOI 10.1016/0014-5793(91)80490-T; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934	73	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16957	16967						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324916				2022-12-27	WOS:A1992JL05300038
J	PONGRATZ, I; MASON, GGF; POELLINGER, L				PONGRATZ, I; MASON, GGF; POELLINGER, L			DUAL ROLES OF THE 90-KDA HEAT-SHOCK PROTEIN HSP90 IN MODULATING FUNCTIONAL ACTIVITIES OF THE DIOXIN RECEPTOR - EVIDENCE THAT THE DIOXIN RECEPTOR FUNCTIONALLY BELONGS TO A SUBCLASS OF NUCLEAR RECEPTORS WHICH REQUIRE HSP90 BOTH FOR LIGAND-BINDING ACTIVITY AND REPRESSION OF INTRINSIC DNA-BINDING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOBIOTIC RESPONSIVE ELEMENTS; CELL GLUCOCORTICOID RECEPTOR; HEPATIC AH RECEPTOR; P-450C GENE; MOUSE; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; STATE; RAT; TRANSLATION; ASSOCIATION	Signal transduction by dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin) is mediated by the intracellular dioxin receptor which, in its dioxin-activated state, regulates transcription of target genes encoding drug metabolizing enzymes such as cytochrome P-450IA1 and glutathione S-transferase Ya. Upon binding of dioxin the receptor translocates from the cytoplasm to the nucleus in vivo and is converted from a latent non-DNA binding form to a species which binds to dioxin-responsive positive control elements in vitro. The latent receptor form is associated with an inhibitory protein (the 90-kDa heat shock protein, hsp90), the release of which is necessary to unmask the DNA binding activity of the receptor. Here we have established a protocol to disrupt the hsp90-receptor complex in the absence of ligand. We show that it was possible to covalently cross-link with dioxin only the hsp90-associated form of dioxin receptor. In contrast, the disrupted hsp90-free form of receptor did not form a stable complex with dioxin but bound DNA constitutively. Moreover, we could partially reconstitute the ligand binding activity of the salt-disrupted hsp90-free dioxin receptor by incubation with hsp90-containing reticulocyte lysate but not by incubation with wheat germ lysate which lacks immuno-detectable levels of hsp90. Thus, we demonstrate that the dioxin receptor loses its high affinity ligand binding activity following release of hsp90 and that it is possible to reverse this process. In conclusion, hsp90 appears to play dual roles in the modulation of functional activities of the dioxin receptor: (i) it represses the intrinsic DNA binding activity of the receptor and (ii) it appears to determine the ability of the receptor to assume and/or maintain a ligand binding conformation.	KAROLINSKA INST, HUDDINGE UNIV HOSP, DEPT MED NUTR, S-14186 HUDDINGE, SWEDEN	Karolinska Institutet					NIEHS NIH HHS [ESO 3954] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003954] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAGCHI MK, 1990, NATURE, V345, P547, DOI 10.1038/345547a0; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CAIRNS W, 1991, J BIOL CHEM, V266, P11221; CUTHILL S, 1988, BIOCHEMISTRY-US, V27, P2978, DOI 10.1021/bi00408a047; CUTHILL S, 1987, J BIOL CHEM, V262, P3477; CUTHILL S, 1991, MOL CELL BIOL, V11, P401, DOI 10.1128/MCB.11.1.401; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DALMAN FC, 1990, J BIOL CHEM, V265, P3615; DALMAN FC, 1991, BIOCHEMISTRY-US, V30, P5605, DOI 10.1021/bi00236a038; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARZO AM, 1991, P NATL ACAD SCI USA, V88, P72, DOI 10.1073/pnas.88.1.72; DENIS M, 1988, NATURE, V333, P686, DOI 10.1038/333686a0; DENIS M, 1989, J BIOL CHEM, V264, P6005; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1990, ARCH BIOCHEM BIOPHYS, V277, P382, DOI 10.1016/0003-9861(90)90594-O; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1986, J BIOL CHEM, V261, P189; DOUGHERTY JJ, 1990, J BIOL CHEM, V264, P8786; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GASIEWICZ TA, 1991, BIOCHEMISTRY-US, V30, P2909, DOI 10.1021/bi00225a026; GILLNER M, 1985, MOL PHARMACOL, V28, P357; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; HANKINSON O, 1983, SOMAT CELL GENET, V9, P497, DOI 10.1007/BF01543050; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HAPGOOD J, 1991, MOL CELL BIOL, V11, P4314, DOI 10.1128/MCB.11.9.4314; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; LANDERS JP, 1989, J BIOL CHEM, V264, P18463; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; NEMOTO T, 1990, BIOCHEMISTRY-US, V29, P1880, DOI 10.1021/bi00459a031; NEMOTO T, 1990, J BIOL CHEM, V265, P2269; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1990, BIOCHEMISTRY-US, V29, P6210, DOI 10.1021/bi00478a014; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; POELLINGER L, 1983, J BIOL CHEM, V258, P3535; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; POELLINGER L, 1991, BANB REPORT, V35, P311; POLAND A, 1986, J BIOL CHEM, V261, P6352; PONGRATZ I, 1991, J BIOL CHEM, V266, P16813; PROKIPCAK RD, 1988, ARCH BIOCHEM BIOPHYS, V261, P6352; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; WILHELMSSON A, 1986, J BIOL CHEM, V261, P3456; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	56	209	213	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13728	13734						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320028				2022-12-27	WOS:A1992JB74600099
J	CHESNUT, JD; STEPHENS, JH; DAHMUS, ME				CHESNUT, JD; STEPHENS, JH; DAHMUS, ME			THE INTERACTION OF RNA POLYMERASE-II WITH THE ADENOVIRUS-2 MAJOR LATE PROMOTER IS PRECLUDED BY PHOSPHORYLATION OF THE C-TERMINAL DOMAIN OF SUBUNIT-IIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION; DROSOPHILA-MELANOGASTER; PURIFICATION; COMPLEXES; PROTEINS; INVITRO	Mammalian RNA polymerase II contains at the C terminus of its largest subunit an unusual domain consisting of 52 tandem repeats of the consensus sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser. The phosphorylation of this domain is thought to play an important role in the transition of RNA polymerase II from a preinitiation complex to an elongating complex. The unphosphorylated form of RNA polymerase II is designated IIA, whereas the phosphorylated form is designated IIO. In an effort to determine the consequence of C-terminal domain phosphorylation on complex formation, P-32-labeled RNA polymerases IIA and IIO were prepared and examined for their ability to form a stable preinitiation complex on the adenovirus-2 major late promoter in the presence of a reconstituted HeLa cell transcription extract. Preinitiation complexes were formed in the absence of ATP and purified from free RNA polymerase II by chromatography on Sepharose CL-4B. The state of phosphorylation of the largest subunit was monitored by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and the transcriptional activity was determined by assaying specific transcript formation upon the addition of nucleotides and a competing DNA template. RNA polymerase IIA was recovered in transcriptionally active complexes in reactions in which the input enzyme was RNA polymerase IIA. In reactions with RNA polymerase IIO as the input enzyme, no IIO was recovered in excluded fractions that normally contain preinitiation complex. In reactions with equimolar amounts of RNA polymerases IIO and IIA, purified preinitiation complexes contained almost exclusively RNA polymerase IIA. These results support the idea that RNA polymerase II containing an unphosphorylated C-terminal domain preferentially associates with the adenovirus-2 major late promoter. The state of phosphorylation of the C-terminal domain can, therefore, directly influence preinitiation complex formation. We also report here the presence of an activity in HeLa cell extracts that catalyzes dephosphorylation of the C-terminal domain, thereby converting RNA polymerase IIO to IIA. This C-terminal domain phosphatase is specific in that it does not catalyze the dephosphorylation of a serine residue phosphorylated by casein kinase II. The presence of a C-terminal domain phosphatase in in vitro transcription reactions containing RNA polymerase IIO results in the formation of RNA polymerase IIA. This RNA polymerase IIA associates preferentially with preinitiation complexes.	UNIV CALIF DAVIS,DEPT BIOCHEM & BIOPHYS,DAVIS,CA 95616	University of California System; University of California Davis					NIGMS NIH HHS [GM 33300] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033300] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CAREY MF, 1986, J BIOL CHEM, V261, P4309; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DAHMUS ME, 1983, J BIOL CHEM, V258, P2303; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; KIM WY, 1989, J BIOL CHEM, V264, P3169; KIM WY, 1988, J BIOL CHEM, V263, P18880; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; WOYCHIK NA, 1990, TRENDS BIOCHEM SCI, V15, P347, DOI 10.1016/0968-0004(90)90074-L; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	29	129	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10500	10506						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1316903				2022-12-27	WOS:A1992HV09000045
J	CHATANI, Y; TANAKA, E; TOBE, K; HATTORI, A; SATO, M; TAMEMOTO, H; NISHIZAWA, N; NOMOTO, H; TAKEYA, T; KADOWAKI, T; KASUGA, M; KOHNO, M				CHATANI, Y; TANAKA, E; TOBE, K; HATTORI, A; SATO, M; TAMEMOTO, H; NISHIZAWA, N; NOMOTO, H; TAKEYA, T; KADOWAKI, T; KASUGA, M; KOHNO, M			MITOGEN-INDUCED TYROSINE-PHOSPHORYLATED 41-KDA AND 43-KDA PROTEINS ARE FAMILY MEMBERS OF EXTRACELLULAR SIGNAL-REGULATED KINASES/MICROTUBULE-ASSOCIATED PROTEIN-2 KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MICROTUBULE-ASSOCIATED PROTEIN-2; SERINE-THREONINE KINASE; SODIUM DODECYL-SULFATE; GEL-ELECTROPHORESIS; CELLULAR PROTEINS; AGENTS INDUCE; CELLS; INSULIN; PHOSPHOTYROSINE	Two antipeptide antibodies, one against the peptide corresponding to residues 307-327 (alpha-Y91) and one against the peptide corresponding to the C-terminal portion (alpha-C92) of the deduced amino acid sequence of the extracellular signal-regulated kinase 1 (ERK1), precipitated two 41-kDa and/or two 43-kDa phosphoproteins from mitogen-stimulated Swiss 3T3 cells. Electrophoretic mobilities on two-dimensional gels of the immunoprecipitated 41- and 43-kDa phosphoproteins were similar to those of the 41- and 43-kDa cytosol proteins, whose increased tyrosine phosphorylation we and others had originally identified in various mitogen-stimulated cells (Cooper, J. A., Sefton, B. M., and Hunter, T. (1984) Mol. Cell Biol. 4, 30-37; Kohno, M. (1985) J. Biol Chem. 260, 1771-1779); phosphopeptide map analysis revealed that they were respectively identical molecules. All those phosphoproteins contained phosphotyrosine, and the more acidic forms contained additional phosphothreonine. Immunoprecipitated 41- and 43-kDa phosphoproteins had serine/threonine kinase activity toward myelin basic protein (MBP) and microtuble-associated protein 2 (MAP2). With the combination of two-dimensional gel electrophoresis and the kinase assay in MBP-containing Polyacrylamide gels of the alpha-Y91 immunoprecipitates, with or without phosphatase 2A treatment, we showed that only their acidic forms were active. These results clearly indicate that 41- and 43-kDa proteins, the increased tyrosine phosphorylation of which is rapidly and commonly induced by mitogen stimulation of fibroblasts, are family members of ERKs/MAP2 kinases and that phosphorylation both on tyrosine and threonine residues is necessary for their activation.	GIFU PHARMACEUT UNIV,DEPT BIOL,5-6-1 MITAHORA HIGASHI,GIFU 502,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN; KYOTO UNIV,INST CHEM RES,UJI,KYOTO 611,JAPAN; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,KOBE 650,JAPAN	Gifu Pharmaceutical University; University of Tokyo; Kyoto University; Kobe University								AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRANDT H, 1975, J BIOL CHEM, V250, P8038; CHENG YSE, 1981, P NATL ACAD SCI-BIOL, V78, P2388, DOI 10.1073/pnas.78.4.2388; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CONTOR L, 1988, MOL CELL BIOL, V8, P2494, DOI 10.1128/MCB.8.6.2494; COOPER JA, 1982, CELL, V31, P263, DOI 10.1016/0092-8674(82)90426-3; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; HOSHI M, 1988, J BIOL CHEM, V263, P5396; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KOHNO M, 1986, BIOCHEM J, V238, P451, DOI 10.1042/bj2380451; KOHNO M, 1985, J BIOL CHEM, V260, P1771; KOHON M, 1990, BIOCHEM J, V267, P91; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; NEL AE, 1990, J IMMUNOL, V144, P2683; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; TOBE K, 1991, J BIOL CHEM, V266, P24793; TSAO H, 1990, J BIOL CHEM, V265, P15471	33	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9911	9916						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315774				2022-12-27	WOS:A1992HT96500072
J	SOMMERGRUBER, W; AHORN, H; ZOPHEL, A; MAURERFOGY, I; FESSL, F; SCHNORRENBERG, G; LIEBIG, HD; BLAAS, D; KUECHLER, E; SKERN, T				SOMMERGRUBER, W; AHORN, H; ZOPHEL, A; MAURERFOGY, I; FESSL, F; SCHNORRENBERG, G; LIEBIG, HD; BLAAS, D; KUECHLER, E; SKERN, T			CLEAVAGE SPECIFICITY ON SYNTHETIC PEPTIDE-SUBSTRATES OF HUMAN RHINOVIRUS-2 PROTEINASE-2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION FACTOR-4F; CYSTEINE PROTEASES; SERINE PROTEASES; ESCHERICHIA-COLI; RNA VIRUSES; POLIOVIRUS; IDENTIFICATION; EXPRESSION; INHIBITION; FAMILIES	Proteinase 2A of human rhinovirus serotype 2 (HRV2 2A) was expressed in Escherichia coli and partially purified; the preparation was used to study various enzymatic parameters. Using a 16-amino acid peptide representing the native cleavage region of HRV2 2A, an apparent K(m) value of 5.4 x 10(-4) mol/liter was determined. A minimum of 9 amino acids (comprising residues P8 to P1') was necessary for cleavage to occur. Proteolysis of substituted peptides was highly tolerant toward changes at P1, P2', and P3' but an absolute requirement for glycine P1' and a high preference for threonine P2 was found. Furthermore, HRV2 2A only cleaved peptide substrates derived from other rhinovirus serotypes and poliovirus that possessed P2 Thr and P1' Gly. Thus, the sequence Thr-X-Gly may form the basis of the cellular cleavage site processed by rhinoviral 2As during viral replication. Studies with various inhibitors support the hypothesis that HRV2 2A belongs to a new class of cysteine proteinases.	BOEHRINGER MANNHEIM GMBH,CTR RES,DEPT CHEM,W-6800 MANNHEIM 31,GERMANY; UNIV VIENNA,INST BIOCHEM,A-1090 VIENNA,AUSTRIA	University of Vienna	SOMMERGRUBER, W (corresponding author), ERNST BOEHRINGER INST ARZNEIMITTELFORSCH,DR BOEHRINGERGASSE 5-11,A-1120 VIENNA,AUSTRIA.		Skern, Tim/AAC-1732-2022	Skern, Tim/0000-0001-8865-5500				ARGOS P, 1984, NUCLEIC ACIDS RES, V12, P7251, DOI 10.1093/nar/12.18.7251; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; CORDINGLEY MG, 1989, J VIROL, V63, P5037, DOI 10.1128/JVI.63.12.5037-5045.1989; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; GORBALENYA AE, 1986, FEBS LETT, V194, P253, DOI 10.1016/0014-5793(86)80095-3; HANECAK R, 1982, P NATL ACAD SCI-BIOL, V79, P3973, DOI 10.1073/pnas.79.13.3973; HELLEN CUT, 1989, BIOCHEMISTRY-US, V28, P9881, DOI 10.1021/bi00452a001; HUNKAPILLER MW, 1983, SCIENCE, V219, P650, DOI 10.1126/science.6687410; IVANOFF LA, 1986, P NATL ACAD SCI USA, V83, P5392, DOI 10.1073/pnas.83.15.5392; JEWELL JE, 1990, J VIROL, V64, P1388, DOI 10.1128/JVI.64.3.1388-1393.1990; KOENIG H, 1988, J VIROL, V62, P1243; KRAUSSLICH HG, 1987, J VIROL, V61, P2711; LLOYD RE, 1987, J VIROL, V61, P2480, DOI 10.1128/JVI.61.8.2480-2488.1987; MCBRIDE LJ, 1988, BIOTECHNIQUES, V6, P362; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MORRISON JM, 1991, VIRUS INDUCED ENZYME, P391; PALLAI PV, 1989, J BIOL CHEM, V264, P9738; PALMENBERG AC, 1989, MOL ASPECTS PICORNAV, P211; RUECKERT RR, 1990, VIROLOGY, V1, P507; Sambrook J, 1989, MOL CLONING LABORATO; SKERN T, 1991, VIROLOGY, V181, P46, DOI 10.1016/0042-6822(91)90468-Q; SOMMERGRUBER W, 1989, VIROLOGY, V169, P68, DOI 10.1016/0042-6822(89)90042-1; TOYODA H, 1986, CELL, V45, P761, DOI 10.1016/0092-8674(86)90790-7; WIMMER E, 1989, VIRAL PROTEINASES TA; WYCKOFF EE, 1990, P NATL ACAD SCI USA, V87, P9529, DOI 10.1073/pnas.87.24.9529; YPMAWONG MF, 1988, VIROLOGY, V166, P265, DOI 10.1016/0042-6822(88)90172-9; YU SF, 1991, VIROLOGY, V182, P615, DOI 10.1016/0042-6822(91)90602-8	27	71	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22639	22644						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331062				2022-12-27	WOS:A1992JW71900100
J	BARBER, DL; GANZ, MB				BARBER, DL; GANZ, MB			GUANINE-NUCLEOTIDES REGULATE BETA-ADRENERGIC ACTIVATION OF NA-H EXCHANGE INDEPENDENTLY OF RECEPTOR COUPLING TO G(S)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE ADENYLATE-CYCLASE; NA+/H+ EXCHANGE; PERTUSSIS TOXIN; PHOSPHOLIPASE-C; PROTEIN-KINASE; GROWTH-FACTOR; HAMSTER FIBROBLASTS; PARATHYROID-HORMONE; PH REGULATION; CELLS	We have previously shown that the beta-adrenergic receptor (beta-AR) stimulates activity of the ubiquitous Na-H exchanger (NHE-1) independently of changes in cAMP accumulation and independently of a cholera toxin-sensitive stimulatory GTP-binding protein (G(s)). To further investigate the potential role of a GTP-binding protein in coupling the beta-AR to NHE-1, we have used a recently available nonhydrolyzable GTP analog, "caged" guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS), to study time-dependent effects of GTP on NHE-1 in intact cells. By monitoring intracellular pH (pH(i)) in cells loaded with the fluorescent pH-sensitive dye, 2,7-biscarboxyethyl-5(6)-carboxyfluorescein, we determined NHE-1 activity in primary cultures of canine enteric endocrine cells, which express an endogenous beta-AR, and in mouse L cells stably transfected with either the wild type hamster beta2-AR or a mutant construct of the hamster beta2-AR containing a deletion in amino acid residues 222-229. This D(222-229)beta2-AR is functionally uncoupled from G(s) and adenylylcyclase. In all three cell types, NaF and GTPgammaS induced an increase in activity of the exchanger, determined by assessing the rate of pH(i) recovery from an acute intracellular acid load (dpH(i)/dt). This increase in pH(i) recovery was dependent on extracellular Na+ and sensitive to the amiloride analog ethylisopropylamiloride. GTPgammaS, but not NaF, also increased beta-adrenergic stimulation of resting NHE-1 activity. The alkalinization in response to isoproterenol was reversed by propranolol in the absence, but not the presence, of GTPgammaS and was completely blocked by GDPbetaS. The ability of guanine nucleotides to regulate beta-adrenergic activation of NHE-1 in cells expressing the mutant D(222-229)beta2-AR suggests that functional coupling of the beta-AR to NHE-1 may be mediated by a GTP-binding protein other than G(s).	UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106	University of California System; University of California San Francisco; Case Western Reserve University	BARBER, DL (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,HSW 604,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040259, R01DK041371, R29DK040259] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40259, DK41371] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBER DL, 1989, J BIOL CHEM, V264, P21038; BARBER DL, 1987, AM J PHYSIOL, V253, pG684, DOI 10.1152/ajpgi.1987.253.5.G684; BARBER DL, 1986, AM J PHYSIOL, V250, pG374, DOI 10.1152/ajpgi.1986.250.3.G374; BARBER DL, 1992, MOL PHARMACOL, V41, P1056; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BICKER P, 1980, NATURE, V287, P607; BIERMAN AJ, 1990, J CELL PHYSIOL, V142, P441, DOI 10.1002/jcp.1041420302; BORLE AB, 1982, SCIENCE, V217, P252, DOI 10.1126/science.6806904; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; DOLPHIN AC, 1988, PFLUG ARCH EUR J PHY, V411, P628, DOI 10.1007/BF00580858; GANZ MB, 1990, J BIOL CHEM, V265, P8989; GANZ MB, 1989, NATURE, V337, P648, DOI 10.1038/337648a0; GANZ MB, 1989, KIDNEY INT, V35, P298; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOMPERTS BD, 1983, NATURE, V306, P64, DOI 10.1038/306064a0; GRINSTEIN S, 1987, J BIOL CHEM, V262, P15277; GRINSTEIN S, 1986, BIOCHIM BIOPHYS ACTA, V889, P301, DOI 10.1016/0167-4889(86)90192-8; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HUANG CL, 1987, J BIOL CHEM, V262, P14134; Johnson G L, 1980, Adv Cyclic Nucleotide Res, V13, P1; KAHN AM, 1985, AM J PHYSIOL, V248, pF212, DOI 10.1152/ajprenal.1985.248.2.F212; KAMEYAMA M, 1985, PFLUG ARCH EUR J PHY, V405, P285, DOI 10.1007/BF00582573; MAGUIRE ME, 1980, J BIOL CHEM, V255, P1030; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; PARIS S, 1987, J BIOL CHEM, V262, P1977; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; PARIS S, 1990, J BIOL CHEM, V265, P11567; POLLOCK AS, 1986, AM J PHYSIOL, V250, pF217, DOI 10.1152/ajprenal.1986.250.2.F217; ROONEY TA, 1991, J BIOL CHEM, V266, P15068; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; ROSS EM, 1978, J BIOL CHEM, V253, P6401; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SCHUBERT B, 1989, SCIENCE, V245, P516, DOI 10.1126/science.2547248; SIFFERT W, 1990, J BIOL CHEM, V265, P15441; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRADER CD, 1987, J BIOL CHEM, V262, P16439; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VOLPI M, 1985, P NATL ACAD SCI USA, V82, P2708, DOI 10.1073/pnas.82.9.2708; WEINMAN EJ, 1987, AM J PHYSIOL, V252, pF19, DOI 10.1152/ajprenal.1987.252.1.F19; WEINMAN EJ, 1989, J MEMBRANE BIOL, V109, P233, DOI 10.1007/BF01870280; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390	41	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20607	20612						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328204				2022-12-27	WOS:A1992JT97800019
J	LIPKOWITZ, S; GOBEL, V; VARTERASIAN, ML; NAKAHARA, K; TCHORZ, K; KIRSCH, IR				LIPKOWITZ, S; GOBEL, V; VARTERASIAN, ML; NAKAHARA, K; TCHORZ, K; KIRSCH, IR			A COMPARATIVE STRUCTURAL CHARACTERIZATION OF THE HUMAN NSCL-1 AND NSCL-2 GENES - 2 BASIC HELIX-LOOP-HELIX GENES EXPRESSED IN THE DEVELOPING NERVOUS-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; MESSENGER-RNA; DROSOPHILA-MELANOGASTER; NEGATIVE REGULATOR; ENHANCER-BINDING; POINT MUTATIONS; N-MYC; SEQUENCE; ACHAETE; COMPLEX	Human cDNA clones for NSCL-1 and NSCL-2, two basic domain helix-loop-helix (bHLH) genes expressed predominantly in the developing nervous system, were obtained from a fetal brain cDNA library. The full-length transcripts and the genomic structures were determined. The cDNAs for the two genes encode predicted proteins of similar size (133 and 135 amino acids for NSCL-1 and NSCL-2, respectively) and structure. The carboxyl-terminal 75 amino acids of the two proteins contain the bHLH motif and differ from each other by only three conservative amino acid changes, while the amino-terminal portions are markedly divergent from each other. In addition to the similar protein structure, the genes have a similar genomic organization, suggesting a close evolutionary relationship. The 5'-regulatory regions of the two genes share some features (i.e. potential TATA, CCAAT, and GATA binding sites) but also differ significantly in their G+C content. NSCL-1 is relatively G+C-rich (63%) in the sequences upstream of transcription initiation and has multiple potential binding sites for transcription factors that bind to G+C-rich sequences (e.g. AP-2). NSCL-2 is relatively A+T-rich (63%) in this region and has a potential binding site for AP1. Studies of expression in normal tissues demonstrated expression of NSCL-1 and NSCL-2 in the developing central and peripheral nervous system, most likely in developing neurons. Additional Northern analysis studies in cell lines revealed expression of these genes in some cell lines derived from tumors with neural or neuroendocrine features such as neuroblastoma, PNET, and small cell lung cancer. NSCL-1 is expressed in a larger number of these cell lines. The differences in expression may parallel differences in developmental regulation.			LIPKOWITZ, S (corresponding author), NCI,USN,MED ONCOL BRANCH,BETHESDA,MD 20892, USA.							APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Battey, 1986, BASIC METHODS MOL BI; BEGLEY CG, 1992, P NATL ACAD SCI USA, V89, P38, DOI 10.1073/pnas.89.1.38; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CARNEY DN, 1985, CANCER RES, V45, P2913; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GOBEL V, 1992, CELL GROWTH DIFFER, V3, P143; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HIRVONEN H, 1990, ONCOGENE, V5, P1787; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KATO KJ, 1989, MOL CELL BIOL, V10, P5914; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAWRENCE JB, 1988, CELL, V52, P51; LEDOUARIN NM, 1984, DEV BIOL, P318; MARTINEZ C, 1991, SCIENCE, V251, P1485, DOI 10.1126/science.1900954; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; REYNOLDS CP, 1988, ADV NEUROBLASTOMA RE, V2, P291; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SORGE J, 1989, STRATEGIES, V1, P3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILUSZ J, 1989, NUCLEIC ACIDS RES, V17, P3899, DOI 10.1093/nar/17.10.3899; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10642, DOI 10.1073/pnas.88.23.10642	50	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21065	21071						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328219				2022-12-27	WOS:A1992JT97800087
J	TOBE, K; KADOWAKI, T; HARA, K; GOTOH, Y; KOSAKO, H; MATSUDA, S; TAMEMOTO, H; UEKI, K; AKANUMA, Y; NISHIDA, E; YAZAKI, Y				TOBE, K; KADOWAKI, T; HARA, K; GOTOH, Y; KOSAKO, H; MATSUDA, S; TAMEMOTO, H; UEKI, K; AKANUMA, Y; NISHIDA, E; YAZAKI, Y			SEQUENTIAL ACTIVATION OF MAP KINASE ACTIVATOR, MAP KINASES, AND S6 PEPTIDE KINASE IN INTACT RAT-LIVER FOLLOWING INSULIN INJECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; STIMULATED PROTEIN-KINASE; CHICKEN-EMBRYO FIBROBLASTS; SERINE THREONINE KINASES; SWISS 3T3 CELLS; TYROSINE-PHOSPHORYLATION; RIBOSOMAL PROTEIN-S6; RECEPTOR KINASE; RABBIT LIVER; INVITRO	An insulin-stimulated phosphorylation cascade was examined in rat liver after insulin injection via a portal vein by the use of immune complex kinase assays specific to the mitogen-activated protein (MAP) kinase and S6 kinase II homologue (rsk) kinase. We have prepared an antibody against the peptide consisting of a carboxyl-terminal portion of the extracellular signal-regulated kinase 1 (alphaC92), one of the MAP kinases, and an antibody against the peptide consisting of the carboxyl terminus of the mouse S6 kinase II homologue (alpharsk(m)C). In alphaC92 immune complex assay, maximal activation of rat liver MAP kinases (approximately 4.3-fold) were observed 4.5 min after insulin injection. We also observed an insulin-stimulated MAP kinase activity (approximately 3-fold) in liver extracts from insulin-treated rat in fractions eluted from phenyl-Sepharose with 30-50% ethylene glycol. Kinase assay in myelin basic protein (MBP)-containing gel after sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by denaturation with 6 M guanidine HCl, and renaturation revealed that insulin injection stimulated the kinase activity of the 42- and 44-kDa proteins, which corresponded to the two distinct MAP kinases. In alpharsk(m)C immune complex assay, maximal stimulation (approximately 5-fold) of the S6 peptide (Arg-Arg-Leu-Ser-Ser-Leu-Arg-Ala) kinase activity was observed 7.5 min after insulin injection. In addition, MAP kinases purified from insulin-treated rat liver were able to activate S6 peptide kinase activity in vitro in alpharsk(m)C immunoprecipitates from untreated rat liver, accompanied by the appearance of several phosphorylated bands including a major band at 88 kDa. We also examined whether insulin injection stimulates the MAP kinase activator (Ahn, N. G., Seger, R., Bratlien, R. L., Diltz, C. D., Tonks, N. K., and Krebs, E. G. (1991) J. Biol. Chem. 266, 4220-4227) in rat liver. Using recombinant Xenopus MAP kinase, fractions of Q-Sepharose eluted early in the NaCl gradient were found to have MAP kinase activator activity accompanied by the phosphorylation of 42-kDa recombinant Xenopus MAP kinase. From these data, we demonstrate three tiers of a cascade composed of the MAP kinase activator, MAP kinases, and an S6 peptide kinase activity in rat liver under physiological conditions in the intact animal.	UNIV TOKYO, FAC MED,DEPT INTERNAL MED 3,7-3-1 HONGO,BUNKYO KU, TOKYO 113, JAPAN; ASAHI LIFE FDN, INST DIABET CARE & RES, CHIYODA KU, TOKYO 100, JAPAN; UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, TOKYO 113, JAPAN	University of Tokyo; Asahi Life Foundation; University of Tokyo								AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDO A, 1992, J BIOL CHEM, V267, P12788; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRANDT H, 1975, J BIOL CHEM, V250, P8038; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DENTON RM, 1986, ADV CYCLIC NUCL PROT, V20, P293; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ERICKSON E, 1987, MOL CELL BIOL, V7, P3147; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; IZUMI T, 1988, J BIOL CHEM, V263, P10386; JENO P, 1989, J BIOL CHEM, V264, P1293; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KABURAGI Y, 1991, 73RD ANN M END SOC W, P309; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KLARLUND JK, 1990, J BIOL CHEM, V265, P227; KREBS EG, 1964, BIOCHEMISTRY-US, V3, P1022, DOI 10.1021/bi00896a003; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LEVOINNE A, 1991, EUR J BIOCHEM, V199, P723; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; PELECH SL, 1987, INSULIN INSULIN LIKE, P27; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P1844; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STURGILL TW, 1988, NATURE, V344, P7150; SWEET LJ, 1990, MOL CELL BIOL, V10, P2787, DOI 10.1128/MCB.10.6.2787; SWEET LJ, 1990, MOL CELL BIOL, V10, P2413, DOI 10.1128/MCB.10.5.2413; TASHIROHASHIMOTO Y, 1989, J BIOL CHEM, V264, P6879; TOBE K, 1991, J BIOL CHEM, V266, P24793; TOBE K, 1990, DIABETES, V39, P528, DOI 10.2337/diabetes.39.5.528; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WEIEL JE, 1990, ADV SEC MESS PHOSPH, V24, P182; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0	56	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21089	21097						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328222				2022-12-27	WOS:A1992JT97800090
J	HATTORI, S; FUKUDA, M; YAMASHITA, T; NAKAMURA, S; GOTOH, Y; NISHIDA, E				HATTORI, S; FUKUDA, M; YAMASHITA, T; NAKAMURA, S; GOTOH, Y; NISHIDA, E			ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE AND ITS ACTIVATOR BY RAS IN INTACT-CELLS AND IN A CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MURINE SARCOMA-VIRUS; XENOPUS OOCYTES; STIMULATED PROTEIN; MAP KINASE; PC12 CELLS; TYROSINE PHOSPHORYLATION; GUANINE-NUCLEOTIDES; FIBROBLASTIC CELLS; ONCOGENE PRODUCTS	Mitogen-activated protein (MAP) kinase is a serine/threonine kinase whose function is thought to be essential for the transduction of mitogenic signals. MAP kinase is activated by phosphorylation induced by a variety of extracellular stimuli, and its direct upstream activator has been identified. Using amphibian and mammalian systems, we show here that ras can activate MAP kinase and its activator. Injection of v-Ha-ras p21 into Xenopus immature oocytes activated both MAP kinase and maturation-promoting factor (MPF) activities. The activation of MAP kinase preceded that of MPF, demonstrating that ras activates MAP kinase in an MPF-independent pathway. Moreover, we found that the MAP kinase activator is also activated in ras-injected oocytes. Activation of MAP kinase and its activator occurred also when the v-Ki-ras gene was conditionally induced in rat fibroblastic 3Y1 cells. Furthermore, we observed that ras activated MAP kinase and its activator in a cell-free system prepared from Xenopus oocytes. Using an antibody against the Xenopus 45-kDa MAP kinase activator, we demonstrated that the 45-kDa activator molecule was activated by ras. These findings suggest that the MAP kinase activator/MAP kinase system may be the downstream components of ras signal transduction pathways.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN; NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,KODAIRA,TOKYO 187,JAPAN	University of Tokyo; National Center for Neurology & Psychiatry - Japan			Fukuda, Makoto/C-9745-2009; Fukuda, Makoto/I-7915-2014; Fukuda, Makoto/S-9748-2019	Fukuda, Makoto/0000-0003-0112-9925; Fukuda, Makoto/0000-0003-0112-9925; Fukuda, Makoto/0000-0003-0112-9925				AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11495; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P671, DOI 10.1111/j.1432-1033.1990.tb19385.x; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HATTORI S, 1985, MOL CELL BIOL, V5, P1449, DOI 10.1128/MCB.5.6.1449; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; HOSHINO M, 1987, J BIOCHEM-TOKYO, V102, P503, DOI 10.1093/oxfordjournals.jbchem.a122082; KAMATA T, 1990, MOL CELL BIOL, V10, P880, DOI 10.1128/MCB.10.3.880; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUROYA K, 1992, ONCOGENE, V7, P1001; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SATOH T, 1988, BIOCHIM BIOPHYS ACTA, V949, P97, DOI 10.1016/0167-4781(88)90059-0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSUCHIDA N, 1982, SCIENCE, V217, P937, DOI 10.1126/science.6287573	48	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20346	20351						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328197				2022-12-27	WOS:A1992JR85800094
J	OOKAWARA, T; KAWAMURA, N; KITAGAWA, Y; TANIGUCHI, N				OOKAWARA, T; KAWAMURA, N; KITAGAWA, Y; TANIGUCHI, N			SITE-SPECIFIC AND RANDOM FRAGMENTATION OF CU,ZN-SUPEROXIDE DISMUTASE BY GLYCATION REACTION - IMPLICATION OF REACTIVE OXYGEN SPECIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC SUPEROXIDE-DISMUTASE; METAL-CATALYZED OXIDATION; HYDROGEN-PEROXIDE; AMINO-GROUPS; COPPER; INACTIVATION; PROTEIN; GLUCOSYLATION; MECHANISM; GLUCOSE	Site-specific and random fragmentation of human Cu,Zn-superoxide dismutase (Cu,Zn-SOD) was observed following the glycation reaction (the early stage of the Maillard reaction). The fragmentation proceeded in two steps. In the first step, Cu,Zn-SOD was cleaved at a peptide bond between Pro62 and His63, as judged by amino acid analysis and sequencing of fragment peptides, yielding a large (15 kDa) and a small (5 kDa) fragment. In the second step, random fragmentation occurred. The ESR spectrum of the glycated Cu,Zn-SOD suggested that reactive oxygen species was implicated in the both steps of fragmentation. The same fragmentations were seen upon exposure of the enzyme to an H2O2 bolus. Catalase completely blocked both steps of the fragmentation process, whereas EDTA blocked only the second step. Incubation with glucose resulted in a time-dependent release of Cu2+ from the Cu,Zn-SOD molecule. The released CU2+ then likely participated in a Fenton's type of reaction to produce hydroxyl radical, which may cause the nonspecific fragmentation. Evidence that EDTA abolished only the second step of fragmentation induced by an H2O2 bolus supports this mechanism. This is the first report that a site-specific fragmentation of a protein is caused by reactive oxygen species formed by the Maillard reaction.	OSAKA UNIV, SCH MED, DEPT BIOCHEM, 2-2 YAMADAOKA, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, INST PROT RES, SUITA, OSAKA 565, JAPAN	Osaka University; Osaka University			Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; 				ACHARYA AS, 1983, J BIOL CHEM, V258, P2296; AMICI A, 1989, J BIOL CHEM, V264, P3341; ARAI K, 1987, J BIOL CHEM, V262, P16969; ARAI K, 1987, BIOCHIM BIOPHYS ACTA, V924, P292, DOI 10.1016/0304-4165(87)90025-0; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; JABUSCH JR, 1980, BIOCHEMISTRY-US, V19, P2310, DOI 10.1021/bi00552a005; JEWETT SL, 1989, EUR J BIOCHEM, V180, P569, DOI 10.1111/j.1432-1033.1989.tb14683.x; KASHIMURA N, 1979, CARBOHYD RES, V70, pC3, DOI 10.1016/S0008-6215(00)83286-3; KAWAKISHI S, 1991, CARBOHYD RES, V211, P167, DOI 10.1016/0008-6215(91)84156-9; KAWAMURA N, 1992, J CLIN ENDOCR METAB, V74, P1352, DOI 10.1210/jc.74.6.1352; KINOSHITA N, 1990, ADV LIF SCI, P443; KITAGAWA Y, 1991, J BIOCHEM-TOKYO, V109, P477, DOI 10.1093/oxfordjournals.jbchem.a123407; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1989, PRACTICAL GUIDE PROT, P66; LERCH K, 1981, J BIOL CHEM, V256, P1545; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MONNIER VM, 1989, MAILLARD REACTION AG, P1; MULLARKEY CJ, 1990, BIOCHEM BIOPH RES CO, V173, P932, DOI 10.1016/S0006-291X(05)80875-7; NEY KA, 1981, ANAL BIOCHEM, V118, P294, DOI 10.1016/0003-2697(81)90585-6; SAKURAI T, 1988, FEBS LETT, V236, P406, DOI 10.1016/0014-5793(88)80066-8; SALO DC, 1990, J BIOL CHEM, V265, P11919; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; TAINER JA, 1983, NATURE, V306, P284, DOI 10.1038/306284a0; Taniguchi N., 1989, MAILLARD REACTION AG, P277; WATKINS NG, 1985, J BIOL CHEM, V260, P629; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006	28	219	227	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18505	18510						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326527				2022-12-27	WOS:A1992JN50200043
J	GOODE, N; HUGHES, K; WOODGETT, JR; PARKER, PJ				GOODE, N; HUGHES, K; WOODGETT, JR; PARKER, PJ			DIFFERENTIAL REGULATION OF GLYCOGEN-SYNTHASE KINASE-3-BETA BY PROTEIN-KINASE-C ISOTYPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF RECEPTOR; PHOSPHORYLATION; ACTIVATION; FAMILY; GENE; EXPRESSION; SEQUENCE; PRODUCT; ALPHA; GAMMA	In cells, stimulation of protein kinase C (PKC) results in the dephosphorylation of specific residues proximal to the DNA binding domain of c-Jun, a major component of the AP-1 transcription factor. Since phosphorylation of this region of c-Jun inhibits interaction with DNA, this pathway may contribute to PKC activation of AP-1. To determine the mechanism(s) underlying this pathway, possible interactions between PKC and proteins implicated in c-Jun regulation are being investigated. Here it is shown that glycogen synthase kinase-3-beta (GSK-3-beta), a serine/threonine kinase that specifically targets the inhibitory c-Jun phosphorylation sites, is phosphorylated in vitro by particular forms of PKC (alpha, beta-1, gamma > beta-2; not epsilon). By contrast, the related GSK-3-alpha is not a substrate for any of these PKC isotypes. Phosphorylation of GSK-3-beta by PKC results in its specific inactivation. These results are consistent with a model in which activation of PKC stimulates c-Jun DNA binding by inhibiting its phosphorylation by GSK-3-beta.	IMPERIAL CANC RES FUND, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Cancer Research UK; Ludwig Institute for Cancer Research			Woodgett, Jim/F-1087-2010; Parker, Peter j/D-5192-2013	Woodgett, Jim/0000-0003-3731-5797; parker, peter/0000-0002-6218-2933				ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COUSSENS L, 1987, DNA-J MOLEC CELL BIO, V6, P389, DOI 10.1089/dna.1987.6.389; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; HUGHES K, 1992, EUR J BIOCHEM, V203, P305, DOI 10.1111/j.1432-1033.1992.tb19860.x; HUGHES K, 1991, ADV PROTEIN PHOSPHAT, V7, P483; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; IDO M, 1987, FEBS LETT, V219, P215, DOI 10.1016/0014-5793(87)81219-X; KARIN M, 1991, MOL ASPECTS CELLULAR, V6, P143; KUBO K, 1987, NUCLEIC ACIDS RES, V15, P7179, DOI 10.1093/nar/15.17.7179; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MARAIS RM, 1990, FEBS LETT, V277, P151, DOI 10.1016/0014-5793(90)80831-3; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PARKER PJ, 1991, METHOD ENZYMOL, V200, P234; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SHEU FS, 1990, BIOCHEM BIOPH RES CO, V171, P1236, DOI 10.1016/0006-291X(90)90818-8; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; STABEL S, 1991, METHOD ENZYMOL, V200, P670; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; Woodgett J R, 1990, Semin Cancer Biol, V1, P389; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; YANG SD, 1991, ADV PROT PHOSPHATASE, V6, P133	39	347	351	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16878	16882						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324914				2022-12-27	WOS:A1992JL05300026
J	LIU, JW; MODRELL, B; ARUFFO, A; MARKEN, JS; TAGA, T; YASUKAWA, K; MURAKAMI, M; KISHIMOTO, T; SHOYAB, M				LIU, JW; MODRELL, B; ARUFFO, A; MARKEN, JS; TAGA, T; YASUKAWA, K; MURAKAMI, M; KISHIMOTO, T; SHOYAB, M			INTERLEUKIN-6 SIGNAL TRANSDUCER GP130 MEDIATES ONCOSTATIN-M SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COLONY-STIMULATING FACTOR; MOLECULAR-CLONING; GROWTH-REGULATOR; GM-CSF; RECEPTOR; EXPRESSION; SUBUNIT; CELLS; CDNA	Oncostatin M (OM) is a multifunctional cytokine that is structurally and functionally related to interleukin 6 (IL-6) and leukemia inhibitory factor (LIF). The specific receptor for OM has been demonstrated (by chemical cross-linking) to be a 150-kDa protein in a number of cell lines. The IL-6 signal transducer, gp130, is also an affinity converter for the LIF receptor. It does not bind to either IL-6 or LIF, but associates with the alpha-subunits of the receptors and transduces the signals. We examined the possible involvement of gp130 in OM binding and signaling. We demonstrate that: (a) anti-gp130 monoclonal antibodies (mAbs) block the inhibitory effect of OM on A375 cell growth, (b) the binding and cross-linking of I-125-OM to H2981 cells are completely abolished by anti-gp130 mAbs, (c) the cross-linked OM-receptor complex is immunoprecipitated by anti-gp130 mAbs, and (d) COS-7 cells transfected with the full-length cDNA encoding gp130 exhibit increased OM binding and cross-linking, which are also blocked by anti-gp130 mAbs. Therefore, we conclude that the 150-kDa OM binding protein previously characterized in a variety of cell lines is gp130. OM is the natural ligand for gp130 and gp130 mediates the biological responses of OM.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,3005 1ST AVE,SEATTLE,WA 98121; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; TOSOH CORP,BIOTECHNOL RES LAB,KANAGAWA,JAPAN	Bristol-Myers Squibb; Osaka University; Tosoh Corporation			Kishimoto, Tadamitsu/C-8470-2009					ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BROWN TJ, 1991, J IMMUNOL, V147, P2175; DEVOS R, 1991, EMBO J, V10, P2133, DOI 10.1002/j.1460-2075.1991.tb07747.x; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GROVE RI, 1991, J BIOL CHEM, V266, P18194; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LINSLEY PS, 1989, J BIOL CHEM, V264, P4282; LIU JW, 1992, CELL GROWTH DIFFER, V3, P307; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MALIK N, 1992, DNA CELL BIOL, V11, P453, DOI 10.1089/dna.1992.11.453; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	22	155	163	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16763	16766						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324910				2022-12-27	WOS:A1992JL05300005
J	COOK, WJ; JEFFREY, LC; CARSON, M; CHEN, ZJ; PICKART, CM				COOK, WJ; JEFFREY, LC; CARSON, M; CHEN, ZJ; PICKART, CM			STRUCTURE OF A DIUBIQUITIN CONJUGATE AND A MODEL FOR INTERACTION WITH UBIQUITIN CONJUGATING ENZYME (E2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE MUTANT TS85; MULTIUBIQUITIN CHAIN; CARRIER PROTEIN; DEGRADATION; REFINEMENT; CLONING; INVITRO; WHEAT	Covalent ligation of multiubiquitin chains targets eukaryotic proteins for degradation. In such multiubiquitin chains, successive ubiquitins are linked by an isopeptide bond involving the side chain of Lys48 and the carboxyl group of Gly76. The crystal structure of a diubiquitin conjugate has been determined and refined at 2.3-angstrom resolution. The molecule has internal approximate 2-fold symmetry with multiple hydrophobic and hydrophilic contacts along the 2-fold axis. The structure of the diubiquitin conjugate suggests determinants for recognition of multiubiquitin chains. A model for the interaction of diubiquitin and a ubiquitin conjugating enzyme (E2) is proposed.	UNIV ALABAMA, CTR MACROMOLEC CRYSTALLOG, BIRMINGHAM, AL 35294 USA; SUNY BUFFALO, DEPT BIOCHEM, BUFFALO, NY 14214 USA	University of Alabama System; University of Alabama Birmingham; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	COOK, WJ (corresponding author), UNIV ALABAMA, DEPT PATHOL, BIRMINGHAM, AL 35294 USA.		Chen, Zhijian/C-6039-2012	Chen, Zhijian/0000-0002-8475-8251	NINDS NIH HHS [NS-30374] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030374] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; COOK WJ, 1992, J BIOL CHEM, V267, P15116; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HAAS AL, 1991, J BIOL CHEM, V266, P5104; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Rechsteiner M., 1988, UBIQUITIN; SULLIVAN ML, 1991, J BIOL CHEM, V266, P23878; VANNOCKER S, 1991, P NATL ACAD SCI USA, V88, P10297, DOI 10.1073/pnas.88.22.10297; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6	21	168	188	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16467	16471						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322903				2022-12-27	WOS:A1992JJ45800075
J	WANG, JS; TSAI, AL; HELDT, J; PALMER, G; VANWART, HE				WANG, JS; TSAI, AL; HELDT, J; PALMER, G; VANWART, HE			TEMPERATURE-DEPENDENT AND PH-DEPENDENT CHANGES IN THE COORDINATION SPHERE OF THE HEME-C GROUP IN THE MODEL PEROXIDASE N(ALPHA)-ACETYL MICROPEROXIDASE-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTRA; MAGNETIC CIRCULAR-DICHROISM; SPIN-STATE; HORSERADISH-PEROXIDASE; CYTOCHROME-C; OCTAPEPTIDE MICROPEROXIDASE-8; VIBRATIONAL-MODES; FERRICYTOCHROME-C; AQUEOUS-SOLUTION; ALKALINE FORMS	The pH- and temperature-dependent changes in the coordination sphere of the heme c group of N(alpha)-acetyl microperoxidase-8 (Ac-MP-8) have been studied by examining its optical, resonance Raman, electron paramagnetic resonance, and magnetic circular dichroism spectra. An optical titration indicates that Ac-MP-8 exists in three major ionization forms over the pH 1-12 range that are linked by pK(a) values of approximately 3 and 9. The acid form that is present at pH 1.5 exists as a mixture of five- and six-coordinate high-spin species and most likely has water or buffer ions as axial ligand(s). On titration to pH 7, the His18 residue is deprotonated and becomes the proximal ligand to the iron to give a six-coordinate neutral form that has water as the sixth ligand. This form exists in a thermal high-spin intermediate-spin state equilibrium. On raising the pH to 10, an alkaline form is generated which is predominantly a five-coordinate high-spin species. It is formed by ionization of the proximal His18 residue to its imidazolate form with concomitant dissociation of the water ligand at the sixth site. At concentrations of Ac-MP-8 greater than 10-mu-M, some six-coordinate low-spin species are formed that are attributed to a dimer in which a His18 residue from a second molecule of Ac-MP-8 coordinates to the sixth site of another to give a bis-His complex. Raising the pH to 11.5 does not produce an appreciable amount of the six-coordinate complex with hydroxide as the sixth ligand. These studies show that Ac-MP-8 is a good water-soluble model for the peroxidases that exhibits minimal aggregation at concentrations below 10-mu-M in the neutral and alkaline pH regions.	FLORIDA STATE UNIV,DEPT CHEM,TALLAHASSEE,FL 32306; FLORIDA STATE UNIV,INST MOLEC BIOPHYS,TALLAHASSEE,FL 32306; UNIV TEXAS,HLTH SCI CTR,DIV HEMATOL & ONCOL,HOUSTON,TX 77030; RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	State University System of Florida; Florida State University; State University System of Florida; Florida State University; University of Texas System; University of Texas Health Science Center Houston; Rice University					NIGMS NIH HHS [GM21337, GM27276] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027276, R37GM021337, R01GM021337] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ADAMS PA, 1990, J CHEM SOC CHEM COMM, P97, DOI 10.1039/c39900000097; ANDERSSON LA, 1989, J BIOL CHEM, V264, P19099; ARON J, 1986, J INORG BIOCHEM, V27, P227, DOI 10.1016/0162-0134(86)80064-2; ASHER SA, 1977, BIOCHEMISTRY-US, V16, P5849, DOI 10.1021/bi00645a032; ASHER SA, 1979, BIOCHEMISTRY-US, V18, P5377, DOI 10.1021/bi00591a019; BALDWIN DA, 1986, J INORG BIOCHEM, V27, P245, DOI 10.1016/0162-0134(86)80065-4; BALDWIN DA, 1985, FEBS LETT, V183, P309, DOI 10.1016/0014-5793(85)80799-7; BALDWIN DA, 1987, J INORG BIOCHEM, V30, P203, DOI 10.1016/0162-0134(87)80064-8; BELL SEJ, 1990, J CHEM SOC FARADAY T, V86, P4017, DOI 10.1039/ft9908604017; BURKE JM, 1978, J AM CHEM SOC, V100, P6077, DOI 10.1021/ja00487a017; CHOI S, 1982, J AM CHEM SOC, V104, P4345, DOI 10.1021/ja00380a006; CHUANG WJ, 1989, J BIOL CHEM, V264, P14209; DESBOIS A, 1979, BIOCHEMISTRY-US, V18, P1510, DOI 10.1021/bi00575a019; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; EHRENBERG A, 1955, ACTA CHEM SCAND, V9, P1193, DOI 10.3891/acta.chem.scand.09-1193; KAJIYOSHI M, 1975, J BIOCHEM-TOKYO, V78, P1087, DOI 10.1093/oxfordjournals.jbchem.a130986; KOBAYASHI N, 1977, BIOCHIM BIOPHYS ACTA, V493, P340, DOI 10.1016/0005-2795(77)90190-8; LAMAR GN, 1990, J BIOL CHEM, V265, P16173; LANIR A, 1979, BIOCHEMISTRY-US, V18, P1656, DOI 10.1021/bi00576a004; LINDER RE, 1980, BIOPHYS CHEM, V12, P143, DOI 10.1016/0301-4622(80)80047-0; MALTEMPO MM, 1979, BIOCHEMISTRY-US, V18, P2935, DOI 10.1021/bi00581a003; MALTEMPO MM, 1974, BIOCHIM BIOPHYS ACTA, V342, P290, DOI 10.1016/0005-2795(74)90084-1; MYER YP, 1990, J PROTEIN CHEM, V9, P379, DOI 10.1007/BF01024613; NOZAWA T, 1976, BIOCHIM BIOPHYS ACTA, V427, P652, DOI 10.1016/0005-2795(76)90209-9; OGOSHI H, 1981, B CHEM SOC JPN, V54, P3414, DOI 10.1246/bcsj.54.3414; PALMER G, 1985, BIOCHEM SOC T, V13, P548, DOI 10.1042/bst0130548; Palmer G., 1979, PORPHYRINS, P313; REED CA, 1979, J AM CHEM SOC, V101, P2948, DOI 10.1021/ja00505a023; REED RA, 1990, INORG CHEM, V29, P2881, DOI 10.1021/ic00341a003; SITTER AJ, 1988, J BIOL CHEM, V263, P13032; TAKANO T, 1981, J MOL BIOL, V153, P95, DOI 10.1016/0022-2836(81)90529-5; TU AT, 1968, EXPERIENTIA, V24, P219, DOI 10.1007/BF02152778; TUPPY H, 1955, ACTA CHEM SCAND, V9, P353, DOI 10.3891/acta.chem.scand.09-0353; URRY DW, 1967, J AM CHEM SOC, V89, P5276, DOI 10.1021/ja00996a034; VICKERY L, 1976, J AM CHEM SOC, V98, P351, DOI 10.1021/ja00418a006; VICKERY L, 1976, J AM CHEM SOC, V98, P343, DOI 10.1021/ja00418a005; WANG JS, 1989, J PHYS CHEM-US, V93, P7925, DOI 10.1021/j100360a038; WANG JS, 1991, BIOCHEM BIOPH RES CO, V179, P1320, DOI 10.1016/0006-291X(91)91717-Q; WILSON MT, 1977, EUR J BIOCHEM, V77, P193, DOI 10.1111/j.1432-1033.1977.tb11657.x	40	39	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15310	15318						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322395				2022-12-27	WOS:A1992JG11300012
J	HARRIS, KW; MITCHELL, RA; WINKELMANN, JC				HARRIS, KW; MITCHELL, RA; WINKELMANN, JC			LIGAND-BINDING PROPERTIES OF THE HUMAN ERYTHROPOIETIN RECEPTOR EXTRACELLULAR DOMAIN EXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; MURINE INTERLEUKIN-4 RECEPTOR; CELL-LINE; BETA-CHAIN; CLONING; GENE; GROWTH; FAMILY; VIRUS; IDENTIFICATION	We developed an assay to directly measure the ligand binding properties of the cloned human erythropoietin receptor (EpoR). The cDNA encoding the extracellular domain of the human EpoR was amplified by polymerase chain reaction and ligated into the prokaryotic expression vector pGEX3X. Synthesis in Escherichia coli was induced and a soluble glutathione S-transferase fusion protein, EREx, was purified by erythropoietin affinity chromatography. Purified EREx was bound to GSH agarose beads and used in a solid phase ligand binding assay. Specific binding of I-125-erythropoietin to EREx beads was demonstrated. A single affinity class (K(d) = 1.5 nM) of the binding site was evident on Scatchard analysis. The K(d) of this site is quantitatively equivalent to that of the "low" affinity cellular binding site. Kinetic analysis of ligand binding to EREx revealed both the on and off rates to be rapid, with t1/2 of 60 and 40 s, respectively. EREx ligand binding exhibits no obvious metal ion dependence or cross-competition by other hemopoietins. Antibodies to EREx block the binding of erythropoietin to the cellular EpoR. We conclude that the 66-kDa EpoR protein is capable of specific ligand binding and that no covalent modifications or associated molecules are required for this interaction. We speculate that the "high" affinity cellular binding site (K(d) < 0.2 nM) results from the interaction of the EpoR with another molecule, either additional EpoR or associated subunits, that decreases the ligand off rate.	UNIV MINNESOTA, DEPT MED, BOX 480 UMHC, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, INST HUMAN GENET, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NHLBI NIH HHS [HL39834] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL039834] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; Bennett J., 1985, NEUROTRANSMITTER REC, V2nd, P61; BROUDY VC, 1990, BLOOD, V75, P1622; BROUDY VC, 1988, P NATL ACAD SCI USA, V85, P6513, DOI 10.1073/pnas.85.17.6513; CHENG JB, 1986, J PHARMACOL EXP THER, V236, P126; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1990, PROG CLIN BIOL RES, V352, P153; DANDREA AD, 1990, J CLIN INVEST, V86, P681, DOI 10.1172/JCI114763; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DIPERSIO JF, 1991, J BIOL CHEM, V266, P279; ERSLEV A, 1953, BLOOD, V8, P349, DOI 10.1182/blood.V8.4.349.349; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; Harlow E., 1988, ANTIBODIES LABORATOR, P511; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JONES SS, 1990, BLOOD, V76, P31; KITAMURA T, 1989, BLOOD, V73, P375; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRANTZ SB, 1991, BLOOD, V77, P419; KRANTZ SB, 1984, P NATL ACAD SCI-BIOL, V81, P7574, DOI 10.1073/pnas.81.23.7574; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MAYEUX P, 1991, J BIOL CHEM, V266, P23380; MIYAKE T, 1977, J BIOL CHEM, V252, P5558; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; PERRINE SP, 1989, BIOCHEM BIOPH RES CO, V164, P857, DOI 10.1016/0006-291X(89)91537-4; SAWYER ST, 1990, PROG CLIN BIOL RES, V352, P145; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SHIOZAKI M, 1990, LEUKEMIA RES, V14, P287, DOI 10.1016/0145-2126(90)90137-X; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPIVAK JL, 1991, BLOOD, V77, P1228; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TSUDA H, 1989, EXP HEMATOL, V17, P211; URDAL DL, 1989, HEMATOPOIETIC GROWTH; WINKELMANN JC, 1990, BLOOD, V76, P24; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675	41	35	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15205	15209						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321832				2022-12-27	WOS:A1992JF08800102
J	VONECHE, V; CALLEBAUT, I; KETTMANN, R; BRASSEUR, R; BURNY, A; PORTETELLE, D				VONECHE, V; CALLEBAUT, I; KETTMANN, R; BRASSEUR, R; BURNY, A; PORTETELLE, D			THE 19-27 AMINO-ACID SEGMENT OF GP51 ADOPTS AN AMPHIPHILIC STRUCTURE AND PLAYS A KEY ROLE IN THE FUSION EVENTS INDUCED BY BOVINE LEUKEMIA-VIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEMAGGLUTININ MEMBRANE GLYCOPROTEIN; INFLUENZA-VIRUS; MONOCLONAL-ANTIBODIES; ENVELOPE GLYCOPROTEIN; PROTEIN; PEPTIDE; TYPE-1; GP120; EPITOPES	Previous results indicate that the external glycoprotein gp51 of bovine leukemia virus plays an important role in the process of cell fusion induced by bovine leukemia virus (Bruck, C., Mathot, S., Portetelle, D., Berte, C., Franssen, J. D., Herion, P., and Burny, A. (1982) Virology 122, 342-352; Voneche, V., Portetelle., D., Kettmann, R., Willems, L., Limbach, K., Paoletti, E., Ruysschaert, J. M., Burny, A., and Brasseur, R. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 3810-3814) and suggest that a region encompassing residues 23 and 25 of gp51 is involved in this process (Portetelle, D., Couez, D., Bruck, C., Kettmann, R., Mammerickx, M., Van der Maaten, M., Brasseur, R., and Burny, A. (1989) Virology 169, 27-33; Mamoun, R., Morisson, M., Rebeyrotte, N., Busetta, B., Couez, D., Kettmann, R., Hospital, M., and Guillemain, B. (1990) J. Virol. 64, 4180-4188). X-ray diffraction studies performed on envelope glycoproteins of influenza virus indicate that the NH2-terminal part of the external glycoprotein lies very close to the fusion peptide. The same overall structure seems to exist in human immunodeficiency virus as suggested by site-directed mutagenesis followed by syncytia induction assays. Our theoretical studies indicate that a segment expanding between residues 19 and 27 of gp5l probably adopts an amphipathic beta-strand structure. We hypothesize that the amphipathic 19-27 structure of gp51 plays an important role in the process of membrane fusion by interacting with the fusion peptide or with another region of gp30. Mutational analysis disrupting the amphipathy of the 19-27 region strongly altered the fusogenic capacity of the gp51-gp30 complex.	FAC AGRON GEMBLOUX,MICROBIOL LAB,B-5030 GEMBLOUX,BELGIUM; UNIV BRUSSELS,BIOL CHEM LAB,B-1640 RHODE ST GENESE,BELGIUM; UNIV BRUSSELS,MACROMOLEC INTERFACES LAB,B-1050 BRUSSELS,BELGIUM; UNIV LIEGE,B-4000 LIEGE,BELGIUM	University of Liege; University of Liege	VONECHE, V (corresponding author), FAC AGRON GEMBLOUX,MOLEC BIOL & ANIM PHYSIOL LAB,13 AVE MARECHAL JUIN,B-5030 GEMBLOUX,BELGIUM.							BOSCH ML, 1989, SCIENCE, V244, P694, DOI 10.1126/science.2541505; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1029, P267, DOI 10.1016/0005-2736(90)90163-I; BRUCK C, 1984, VIROLOGY, V136, P20, DOI 10.1016/0042-6822(84)90244-7; BRUCK C, 1982, VIROLOGY, V122, P342, DOI 10.1016/0042-6822(82)90234-3; BRUCK C, 1982, VIROLOGY, V122, P353, DOI 10.1016/0042-6822(82)90235-5; BURNY A, 1988, J ACQ IMMUN DEF SYND, V1, P579; BURNY A, 1987, CANCER SURV, V6, P139; BUSETTA B, 1989, BIOCHIM BIOPHYS ACTA, V998, P301, DOI 10.1016/0167-4838(89)90289-6; CALLEBAUT I, 1991, VIROLOGY, V185, P48, DOI 10.1016/0042-6822(91)90752-W; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; FISCHINGER PJ, 1974, J VIROL, V14, P177, DOI 10.1128/JVI.14.1.177-179.1974; FREED EO, 1990, P NATL ACAD SCI USA, V87, P4650, DOI 10.1073/pnas.87.12.4650; GALLAHER WR, 1987, CELL, V50, P327, DOI 10.1016/0092-8674(87)90485-5; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRAVES DC, 1981, J VIROL, V38, P1055, DOI 10.1128/JVI.38.3.1055-1063.1981; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; HO DD, 1988, SCIENCE, V239, P1021, DOI 10.1126/science.2830667; HORTH M, 1991, EMBO J, V10, P2747, DOI 10.1002/j.1460-2075.1991.tb07823.x; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; MAMOUN RZ, 1990, J VIROL, V64, P4180, DOI 10.1128/JVI.64.9.4180-4188.1990; MARTIN I, 1991, BIOCHEM BIOPH RES CO, V175, P872, DOI 10.1016/0006-291X(91)91646-T; MEULEMANS G, 1978, ANN MED VET, V122, P45; RICHARDSON CD, 1980, VIROLOGY, V105, P205, DOI 10.1016/0042-6822(80)90168-3; SCHEID A, 1977, VIROLOGY, V80, P54, DOI 10.1016/0042-6822(77)90380-4; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; SKINNER MA, 1988, J VIROL, V62, P4195, DOI 10.1128/JVI.62.11.4195-4200.1988; VONECHE V, 1992, P NATL ACAD SCI USA, V89, P3810, DOI 10.1073/pnas.89.9.3810; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WEIS WI, 1990, EMBO J, V9, P17, DOI 10.1002/j.1460-2075.1990.tb08075.x; WHITE J, 1983, Q REV BIOPHYS, V16, P151, DOI 10.1017/S0033583500005072; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	35	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15193	15197						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321831				2022-12-27	WOS:A1992JF08800100
J	WRIGHT, CS				WRIGHT, CS			CRYSTAL-STRUCTURE OF A WHEAT-GERM-AGGLUTININ GLYCOPHORIN-SIALOGLYCOPEPTIDE RECEPTOR COMPLEX - STRUCTURAL BASIS FOR COOPERATIVE LECTIN-CELL BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROCYTE GLYCOPHORIN; AMINO-ACID SEQUENCE; SIALIC-ACID; MACROMOLECULAR STRUCTURES; PLANT-LECTINS; SUGAR BINDING; ISOLECTIN; SITES; OLIGOSACCHARIDE; RESOLUTION	The crystal structure of wheat germ agglutinin isolectin 1 (WGA1) complexed with a tryptic sialoglycopeptide fragment (T-5) from its erythrocyte receptor glycophorin A, which contains the O-linked tetrasaccharide NeuNAc-alpha-2,3-Gal-beta-1,3-(alpha-2,6-NeuNAc) Gal-NAc-alpha-1-O-Thr, has been determined by molecular replacement techniques and refined at 2.0-angstrom resolution (R = 18.1%). The structure reveals that association between WGA1 dimers, composed of two identical four-domain (A-D) monomers, and T-5 is asymmetric and involves sialic acid binding at three nonequivalent aromatic residue-rich sites. Two independent binding modes are observed. In the dominant ("major") binding mode, the two highest affinity sites are utilized to cross-link neighboring crystallographically related WGA1 dimers. The branched tetrasaccharide has an extended rigid conformation, and its terminal alpha-2,6-NeuNac and alpha-2,3-NeuNAc residues occupy specificity sites in domains B1 (monomer 1) and C2 (monomer 2) on opposing dimers, respectively. This asymmetric selection of binding sites leads to infinite open-ended arrays of interlinked lectin molecules. In the subsidiary "minor" binding mode, only the terminal alpha-2,6-NeuNac, anchored to the aromatic residue-rich binding site in domain A2, is clearly visible. The remaining portion of T-5 is disordered. This structure presents the first evidence for NeuNAc binding in the aromatic residue-rich sites of domains A and C and suggests a preference of WGA for alpha-2,6-linked NeuNAc. Moreover, the unusual asymmetric WGA1-tetrasaccharide association, involving domain binding sites that differ in their binding affinities for NeuNAc, offers explanations for the widely observed cooperative cell binding behavior of WGA.			WRIGHT, CS (corresponding author), VIRGINIA COMMONWEALTH UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, RICHMOND, VA 23298 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017992] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-17992] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAIR WL, 1974, J BIOL CHEM, V249, P4696; ALLEN AK, 1973, BIOCHEM J, V131, P155, DOI 10.1042/bj1310155; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BHAVANANDAN VP, 1979, J BIOL CHEM, V254, P4000; BOURNE Y, 1992, J BIOL CHEM, V267, P197; BRILES EB, 1977, J BIOL CHEM, V252, P1107; Brunger AT, 1988, CRYSTALLOGRAPHIC COM, V3, P126; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; CUATRECA.P, 1973, BIOCHEMISTRY-US, V12, P1312, DOI 10.1021/bi00731a011; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; ETZLER ME, 1985, ANNU REV PLANT PHYS, V36, P209, DOI 10.1146/annurev.pp.36.060185.001233; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GANGULY P, 1979, BIOCHEM BIOPH RES CO, V89, P1154, DOI 10.1016/0006-291X(79)92129-6; GOLDSTEIN IJ, 1986, LECTINS PROPERTIES F, P43; GROB PM, 1983, J BIOL CHEM, V258, P4136; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JOHNSON LN, 1988, CURR TOP MICROBIOL, V139, P81; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KETIS NV, 1980, P NATL ACAD SCI-BIOL, V77, P3788, DOI 10.1073/pnas.77.7.3788; KRONIS KA, 1982, BIOCHEMISTRY-US, V21, P3050, DOI 10.1021/bi00256a003; KRONIS KA, 1985, BIOCHEMISTRY-US, V24, P826, DOI 10.1021/bi00325a003; Lis H., 1981, The biochemistry of plants. A comprehensive treatise. Volume 6. Proteins and nucleic acids., P371; LIS H, 1977, ANTIGENS, V4, P465; LOVRIEN RE, 1980, J CELL BIOL, V85, P534, DOI 10.1083/jcb.85.3.534; MANSFIELD MA, 1988, PLANTA, V173, P482, DOI 10.1007/BF00958961; MARCHESI VT, 1972, P NATL ACAD SCI USA, V69, P1445, DOI 10.1073/pnas.69.6.1445; MONSIGNY M, 1980, EUR J BIOCHEM, V104, P147, DOI 10.1111/j.1432-1033.1980.tb04410.x; NAGATA Y, 1974, J BIOL CHEM, V249, P3116; NICOLSON GL, 1974, INT REV CYTOL, V39, P89, DOI 10.1016/S0074-7696(08)60939-0; OIKAWA T, 1973, NATURE, V241, P256, DOI 10.1038/241256a0; PETERS BP, 1979, BIOCHEMISTRY-US, V18, P5505, DOI 10.1021/bi00591a038; PRIVAT JP, 1974, FEBS LETT, V46, P224, DOI 10.1016/0014-5793(74)80373-X; PRUJANSKY A, 1978, BIOCHIM BIOPHYS ACTA, V508, P137, DOI 10.1016/0005-2736(78)90195-5; QUIOCHO FA, 1988, CURR TOP MICROBIOL, V139, P135; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; RAIKHEL NV, 1987, P NATL ACAD SCI USA, V84, P6745, DOI 10.1073/pnas.84.19.6745; REEKE GN, 1988, CURR TOP MICROBIOL, V139, P35; REISNER Y, 1976, EXP CELL RES, V97, P445, DOI 10.1016/0014-4827(76)90640-6; RICE RH, 1975, BIOCHEMISTRY-US, V14, P4093, DOI 10.1021/bi00689a027; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SMITH JJ, 1989, PLANT MOL BIOL, V13, P601, DOI 10.1007/BF00027321; SOBOTTKA SE, 1984, NUCL INSTRUM METH A, V220, P575, DOI 10.1016/0167-5087(84)90325-9; STANLEY P, 1977, P NATL ACAD SCI USA, V74, P5056, DOI 10.1073/pnas.74.11.5056; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; THOMAS DB, 1969, J BIOL CHEM, V244, P5943; TOMITA M, 1975, P NATL ACAD SCI USA, V72, P2964, DOI 10.1073/pnas.72.8.2964; TOMITA M, 1978, BIOCHEMISTRY-US, V17, P4756, DOI 10.1021/bi00615a025; WRIGHT CS, 1987, J MOL BIOL, V194, P353, DOI 10.1016/0022-2836(87)90383-4; WRIGHT CS, 1989, J MOL BIOL, V209, P475, DOI 10.1016/0022-2836(89)90011-9; WRIGHT CS, 1980, J MOL BIOL, V141, P267, DOI 10.1016/0022-2836(80)90181-3; WRIGHT CS, 1990, J MOL BIOL, V215, P635, DOI 10.1016/S0022-2836(05)80174-3; WRIGHT CS, 1984, J MOL BIOL, V178, P91, DOI 10.1016/0022-2836(84)90232-8; WRIGHT CS, 1987, J MOL BIOL, V194, P501, DOI 10.1016/0022-2836(87)90678-4; WRIGHT CS, 1977, J MOL BIOL, V111, P439, DOI 10.1016/S0022-2836(77)80063-6; WRIGHT CS, 1989, J MOL EVOL, V28, P327, DOI 10.1007/BF02103429; WRIGHT CS, 1984, BIOCHEMISTRY-US, V23, P280, DOI 10.1021/bi00297a017; WRIGHT HT, 1991, J MOL EVOL, V33, P283, DOI 10.1007/BF02100680; WRIGHT HT, 1985, J MOL EVOL, V21, P133, DOI 10.1007/BF02100087	59	128	129	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14345	14352						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321144				2022-12-27	WOS:A1992JD32500085
J	MANNHERZ, HG				MANNHERZ, HG			CRYSTALLIZATION OF ACTIN IN COMPLEX WITH ACTIN-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SKELETAL-MUSCLE ACTIN; PANCREATIC DNASE-I; X-RAY-DIFFRACTION; F-ACTIN; DEOXYRIBONUCLEASE-I; 3-DIMENSIONAL STRUCTURE; MAGNETIC-RESONANCE; CYTOPLASMIC ACTIN; PLASMA GELSOLIN; RESOLUTION				MANNHERZ, HG (corresponding author), UNIV MARBURG,INST ANAT & ZELLBIOL,W-3550 MARBURG,GERMANY.		Mannherz, Hans Georg/HHM-2867-2022	Mannherz, Hans Georg/0000-0001-8158-5722				ANDRE E, 1988, J BIOL CHEM, V263, P722; BRAY D, 1975, BIOCHEM J, V147, P221, DOI 10.1042/bj1470221; BRENNER SL, 1980, J BIOL CHEM, V255, P841; CARLIER MF, 1984, J BIOL CHEM, V259, P9983; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CARLSSON L, 1976, J MOL BIOL, V105, P353, DOI 10.1016/0022-2836(76)90098-X; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DEROSIER DJ, 1990, NATURE, V347, P21; ELZINGA M, 1984, P NATL ACAD SCI-BIOL, V81, P6599, DOI 10.1073/pnas.81.21.6599; ELZINGA M, 1973, P NATL ACAD SCI USA, V70, P2687, DOI 10.1073/pnas.70.9.2687; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; GOODY RS, 1983, BIOCHIM BIOPHYS ACTA, V726, P11; HIRONO M, 1990, J BIOCHEM-TOKYO, V107, P32, DOI 10.1093/oxfordjournals.jbchem.a123007; HITCHCOCK SE, 1976, CELL, V7, P531, DOI 10.1016/0092-8674(76)90203-8; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; HUXLEY H, 1954, NATURE, V173, P973, DOI 10.1038/173973a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KABSCH W, 1985, EMBO J, V4, P2113, DOI 10.1002/j.1460-2075.1985.tb03900.x; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KREUDER V, 1984, EUR J BIOCHEM, V139, P389, DOI 10.1111/j.1432-1033.1984.tb08018.x; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; MANNHERZ HG, 1976, ANNU REV BIOCHEM, V45, P427, DOI 10.1146/annurev.bi.45.070176.002235; MANNHERZ HG, 1980, EUR J BIOCHEM, V104, P367, DOI 10.1111/j.1432-1033.1980.tb04437.x; MANNHERZ HG, 1975, FEBS LETT, V60, P34, DOI 10.1016/0014-5793(75)80412-1; MANNHERZ HG, 1985, BIOCHEM J, V225, P517, DOI 10.1042/bj2250517; MANNHERZ HG, 1977, FEBS LETT, V73, P141, DOI 10.1016/0014-5793(77)80966-6; MANNHERZ HG, 1983, ACTIN STRUCTURE FUNC, P35; MANNHERZ HG, 1992, IN PRESS J MOL BIOL; MEZA I, 1983, J BIOL CHEM, V258, P3936; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MOMMAERTS WF, 1992, BIOESSAYS, V14, P57, DOI 10.1002/bies.950140112; MORNET D, 1981, NATURE, V292, P301, DOI 10.1038/292301a0; ORIOL C, 1977, FEBS LETT, V73, P89, DOI 10.1016/0014-5793(77)80022-7; PODOLSKI JL, 1988, J BIOL CHEM, V263, P638; Pollard TD, 1990, CURR OPIN CELL BIOL, V2, P33, DOI 10.1016/S0955-0674(05)80028-6; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1984, FEBS LETT, V170, P94, DOI 10.1016/0014-5793(84)81376-9; POLZAR B, 1989, EUR J BIOCHEM, V182, P267, DOI 10.1111/j.1432-1033.1989.tb14826.x; POLZAR B, 1992, EUR J CELL BIOL S36, V57, P62; POPP D, 1987, J MOL BIOL, V197, P679, DOI 10.1016/0022-2836(87)90474-8; RAYMENT I, 1984, P NATL ACAD SCI-BIOL, V81, P4378; ROHR G, 1978, EUR J BIOCHEM, V89, P151, DOI 10.1111/j.1432-1033.1978.tb20907.x; RUBENSTEIN PA, 1990, BIOESSAYS, V12, P309, DOI 10.1002/bies.950120702; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; SAKABE N, 1983, J BIOCHEM-TOKYO, V93, P299, DOI 10.1093/oxfordjournals.jbchem.a134168; SCHUTT CE, 1989, J MOL BIOL, V209, P735, DOI 10.1016/0022-2836(89)90603-7; SELDEN LA, 1989, J BIOL CHEM, V264, P9271; Straub F.B., 1942, STUDIES I MED CHEM U, P3; Straub FB., 1943, STUDIES I MED CHEM U, VIII, P23; SUCK D, 1981, P NATL ACAD SCI-BIOL, V78, P4319, DOI 10.1073/pnas.78.7.4319; SUCK D, 1984, EMBO J, V3, P2423, DOI 10.1002/j.1460-2075.1984.tb02149.x; SUGINO H, 1979, J BIOCHEM-TOKYO, V86, P257; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; TRAYER IP, 1987, EUR J BIOCHEM, V164, P259, DOI 10.1111/j.1432-1033.1987.tb11019.x; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; VANDEKERCKHOVE J, 1984, J MOL BIOL, V179, P391, DOI 10.1016/0022-2836(84)90072-X; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3; WEGNER A, 1983, P NATL ACAD SCI-BIOL, V80, P4922, DOI 10.1073/pnas.80.16.4922; WINKELMANN DA, 1991, J CELL BIOL, V114, P701, DOI 10.1083/jcb.114.4.701; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YIN HL, 1985, BIOESSAYS, V7, P176; ZARBOCK J, 1990, BIOCHEMISTRY-US, V29, P7814, DOI 10.1021/bi00486a006	69	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11661	11664						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1318297				2022-12-27	WOS:A1992HY94700001
J	CAI, DY; TIEN, M				CAI, DY; TIEN, M			KINETIC-STUDIES ON THE FORMATION AND DECOMPOSITION OF COMPOUND-II AND COMPOUND-III - REACTIONS OF LIGNIN PEROXIDASE WITH H2O2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHANEROCHAETE-CHRYSOSPORIUM; SPECTRAL CHARACTERIZATION; HORSERADISH-PEROXIDASE; HYDROGEN-PEROXIDE; STEADY-STATE; HEME ENZYME; AUTOXIDATION; OXIDATION; MECHANISM; GENERATION	The present study characterizes the serial reactions of H2O2 with compounds I and II of lignin peroxidase isozyme H1. These two reactions constitute part of the pathway leading to formation of the oxy complex (compound III) from the ferric enzyme. Compounds II and III are the only complexes observed; no compound III* is observed. Compound III* is proposed to be an adduct of compound III with H2O2, formed from the complexation of compound III with H2O2 (Wariishi, H., and Gold, M. H. (1990) J. Biol. Chem. 265, 2070-2077). We provide evidence that demonstrates that the spectral data, on which the formation of compound III* is based, are merely an artifact caused by enzyme instability and, therefore, rule out the existence of compound III*. The reactions of compounds II and III with H2O2 are pH-dependent, similar to that observed for reactions of compounds I and II with the reducing substrate veratryl alcohol. The spontaneous decay of the compound III of lignin peroxidase results in the reduction of ferric cytochrome c. The reduction is inhibited by superoxide dismutase, indicating that superoxide is released during the decay. Therefore, the lignin peroxidase compound III decays to the ferric enzyme through the dissociation of superoxide. This mechanism is identical with that observed with oxymyoglobin and oxyhemoglobin but different from that for horseradish peroxidase. Compound III is capable of reacting with small molecules, such as tetranitromethane (a superoxide scavenger) and fluoride (a ligand for the ferric enzyme), resulting in ferric enzyme and fluoride complex formation, respectively.	PENN STATE UNIV, DEPT MOLEC & CELL BIOL, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004922] Funding Source: NIH RePORTER; NIEHS NIH HHS [1-P42ES04922-01] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSSON LA, 1985, J BIOL CHEM, V260, P6080; ANDRAWIS A, 1988, J BIOL CHEM, V263, P1195; BANCI L, 1991, P NATL ACAD SCI USA, V88, P6956, DOI 10.1073/pnas.88.16.6956; CAI D, 1991, ACS SYM SER, V460, P180; CAI DY, 1989, BIOCHEM BIOPH RES CO, V162, P464, DOI 10.1016/0006-291X(89)92020-2; CAI DY, 1990, BIOCHEMISTRY-US, V29, P2085, DOI 10.1021/bi00460a018; FARRELL RL, 1989, ENZYME MICROB TECH, V11, P322, DOI 10.1016/0141-0229(89)90014-8; GOTOH T, 1976, J BIOCHEM-TOKYO, V80, P397, DOI 10.1093/oxfordjournals.jbchem.a131289; GREEN MJ, 1984, METHOD ENZYMOL, V105, P3; HARVEY PJ, 1989, BIOCHIM BIOPHYS ACTA, V994, P59, DOI 10.1016/0167-4838(89)90062-9; HOOGLAND H, 1988, BIOCHIM BIOPHYS ACTA, V955, P337, DOI 10.1016/0167-4838(88)90213-0; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; KERSTEN PJ, 1985, J BIOL CHEM, V260, P2609; MANSOURI A, 1973, BIOCHEMISTRY-US, V12, P4946, DOI 10.1021/bi00748a020; MARQUEZ L, 1988, J BIOL CHEM, V263, P10549; MISRA HP, 1972, J BIOL CHEM, V247, P6960; MUTHUSAMY M, 1990, BIOCHEMISTRY-US, V29, P9617; NAKAJIMA R, 1987, J BIOL CHEM, V262, P2576; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; NOBLE RW, 1970, J BIOL CHEM, V245, P2409; RENGANATHAN V, 1986, BIOCHEMISTRY-US, V25, P1626, DOI 10.1021/bi00355a027; ROMAN R, 1972, BIOCHEMISTRY-US, V11, P2076, DOI 10.1021/bi00761a013; SHAH MM, 1991, ARCH BIOCHEM BIOPHYS, V290, P173, DOI 10.1016/0003-9861(91)90604-H; SHIMIZU N, 1989, BIOCHIM BIOPHYS ACTA, V995, P133, DOI 10.1016/0167-4838(89)90071-X; SUTTON HC, 1976, BIOCHEM J, V155, P503, DOI 10.1042/bj1550503; TAMURA M, 1972, J BIOCHEM-TOKYO, V71, P311, DOI 10.1093/oxfordjournals.jbchem.a129768; TIEN M, 1988, METHOD ENZYMOL, V161, P238; TIEN M, 1986, J BIOL CHEM, V261, P1687; TIEN M, 1990, APPL ENVIRON MICROB, V56, P2540, DOI 10.1128/AEM.56.8.2540-2544.1990; WALLACE WJ, 1982, J BIOL CHEM, V257, P4966; WARIISHI H, 1990, J BIOL CHEM, V265, P2070; WARIISHI H, 1990, J BIOL CHEM, V265, P11137; WARIISHI H, 1989, FEBS LETT, V243, P165, DOI 10.1016/0014-5793(89)80122-X; WITTENBERG JB, 1967, J BIOL CHEM, V242, P626	34	67	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11149	11155						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317857				2022-12-27	WOS:A1992HX16900036
J	JANSSEN, YMW; MARSH, JP; ABSHER, MP; HEMENWAY, D; VACEK, PM; LESLIE, KO; BORM, PJA; MOSSMAN, BT				JANSSEN, YMW; MARSH, JP; ABSHER, MP; HEMENWAY, D; VACEK, PM; LESLIE, KO; BORM, PJA; MOSSMAN, BT			EXPRESSION OF ANTIOXIDANT ENZYMES IN RAT LUNGS AFTER INHALATION OF ASBESTOS OR SILICA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; CONTAINING SUPEROXIDE-DISMUTASE; TRACHEAL EPITHELIAL-CELLS; HYDROGEN-PEROXIDE; ALVEOLAR MACROPHAGES; CYTO-TOXICITY; INTERLEUKIN-1; EXPOSURE; PROTEIN; CRISTOBALITE	Several studies indicate that active oxygen species play an important role in the development of pulmonary disease (asbestosis and silicosis) after exposure to mineral dust. The present study was conducted to determine if inhaled fibrogenic minerals induced changes in gene expression and activities of antioxidant enzymes (AOE) in rat lung. Two different fibrogenic minerals were compared, crocidolite, an amphibole asbestos fiber, and cristobalite, a crystalline silicon dioxide particle. Steady-state mRNA levels, immunoreactive protein, and activities of selected AOE were measured in lungs 1-10 days after initiation of exposure and at 14 days after cessation of a 10-day exposure period. Exposure to asbestos resulted in significant increases in steady-state mRNA levels of manganese-containing superoxide dismutase (MnSOD) at 3 and 9 days and of glutathione peroxidase at 6 and 9 days. An increase in steady-state mRNA levels of copper, zinc-containing superoxide dismutase (CuZnSOD), was observed at 6 days. Exposure to asbestos also resulted in overall increased enzyme activities of catalase, glutathione peroxidase and total superoxide dismutase in lung. In contrast, silica caused a dramatic increase in steady-state levels of MnSOD mRNA at all time periods and an increase in glutathione peroxidase mRNA levels at 9 days. Activities of AOE remained unchanged in silica-exposed lungs. In both models, increases in gene expression of MnSOD correlated with increased amounts of MnSOD immunoreactive protein in lung and the pattern and extent of inflammation. These data indicate that the profiles of AOE are dissimilar during the development of experimental asbestosis or silicosis and suggest different mechanisms of lung defense in response to these minerals.	UNIV VERMONT,COLL MED,DEPT PATHOL,BURLINGTON,VT 05405; UNIV VERMONT,COLL MED,DEPT MED,BURLINGTON,VT 05405; UNIV VERMONT,COLL MED,DEPT MED BIOSTAT,BURLINGTON,VT 05405; UNIV VERMONT,COLL MED,DEPT CIVIL & MECH ENGN,BURLINGTON,VT 05405; UNIV LIMBURG,DEPT OCCUPAT & ENVIRONM HLTH & TOXICOL,6200 MD MAASTRICHT,NETHERLANDS	University of Vermont; University of Vermont; University of Vermont; University of Vermont; Hasselt University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039469] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 39469] Funding Source: Medline; PHPPO CDC HHS [PHS 14212] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHPPO CDC HHS		ABSHER MP, 1989, AM J PATHOL, V134, P1243; Bergmeyer HU., 1974, METHODS ENZYMATIC AN, P574, DOI [10.1016/B978-0-12-091302-2.50010-4, DOI 10.1016/B978-0-12-091302-2.50010-4]; BORM P, 1989, EFFECTS MINERAL DUST, P173; BORM PJA, 1988, AM REV RESPIR DIS, V138, P1589, DOI 10.1164/ajrccm/138.6.1589; BOWDEN DH, 1987, EXP LUNG RES, V12, P89, DOI 10.3109/01902148709062834; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALAL NS, 1989, EFFECTS MINERAL DUST, P265; DRISCOLL KE, 1989, EFFECTS MINERAL DUST, P101; DUBOIS C, 1989, EFFECTS MINERAL DUST, P359; EBERHARDT MK, 1985, ENVIRON RES, V37, P287, DOI 10.1016/0013-9351(85)90108-2; EDMONDSON SW, 1990, J CELL PHYSIOL, V142, P21, DOI 10.1002/jcp.1041420104; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORMAN HJ, 1981, LAB INVEST, V45, P1; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FREEMAN BA, 1986, EXP LUNG RES, V10, P203, DOI 10.3109/01902148609061493; FUBINI B, 1989, EFFECTS MINERAL DUST, P205; FURATA S, 1986, P NATL ACAD SCI USA, V83, P313; GOODGLICK LA, 1986, CANCER RES, V46, P5558; GOODGLICK LA, 1989, AM REV RESPIR DIS, V139, P1265, DOI 10.1164/ajrccm/139.5.1265; HANSEN K, 1987, CANCER RES, V47, P1681; HASS MA, 1982, J BIOL CHEM, V257, P9379; HEFFNER JE, 1989, AM REV RESPIR DIS, V140, P531, DOI 10.1164/ajrccm/140.2.531; HEMENWAY DR, 1986, AM IND HYG ASSOC J, V47, P301; HEMENWAY DR, 1982, AM IND HYG ASSOC J, V43, P874, DOI 10.1202/0002-8894(1982)043<0874:DDATRO>2.3.CO;2; HEMENWAY DR, 1990, AM IND HYG ASSOC J, V51, P363, DOI 10.1080/15298669091369790; HENDERSON RF, 1984, ENVIRON HEALTH PERSP, V56, P115, DOI 10.2307/3429841; HO YS, 1987, NUCLEIC ACIDS RES, V15, P10070, DOI 10.1093/nar/15.23.10070; HO YS, 1987, NUCLEIC ACIDS RES, V15, P6746, DOI 10.1093/nar/15.16.6746; HO YS, 1991, AM J RESP CELL MOL, V4, P278, DOI 10.1165/ajrcmb/4.3.278; HOLLEY JA, 1992, IN PRESS AM J PATHOL; JANSSEN YMW, 1990, FREE RADICAL RES COM, V11, P53, DOI 10.3109/10715769009109667; KONO Y, 1982, J BIOL CHEM, V257, P5751; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; MOSSMAN BT, 1986, LAB INVEST, V54, P204; MOSSMAN BT, 1987, DRUG CHEM TOXICOL, V10, P157, DOI 10.3109/01480548709042587; MOSSMAN BT, 1989, ENVIRON HEALTH PERSP, V81, P91, DOI 10.2307/3430811; MOSSMAN BT, 1990, BIOLOGY, TOXICOLOGY, AND CARCINOGENESIS OF RESPIRATORY EPITHELIUM, P145; MOSSMAN BT, 1990, AM REV RESPIR DIS, V141, P1266, DOI 10.1164/ajrccm/141.5_Pt_1.1266; MOSSMAN BT, 1990, J AEROSOL MED, V3, pS75, DOI 10.1089/jam.1990.3.Suppl_1.S-75; MULLENBACH GT, 1988, OXYRADICALS MOL BIOL, P313; OBERLEY TD, 1990, AM J PATHOL, V137, P199; OLIVER CN, 1987, ARCH BIOCHEM BIOPHYS, V253, P62, DOI 10.1016/0003-9861(87)90637-0; PANUS PC, 1988, EXP LUNG RES, V14, P959, DOI 10.3109/01902148809064186; PANUS PC, 1989, IN VITRO CELL DEV B, V25, P821; PIQUET PF, 1990, NATURE, V344, P245; RADOSEVICH CA, 1989, CARCINOGENESIS, V10, P1943, DOI 10.1093/carcin/10.10.1943; Reid T.W., 1971, ENZYMES, V4, P373; ROM WN, 1991, AM REV RESPIR DIS, V143, P408, DOI 10.1164/ajrccm/143.2.408; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT JA, 1984, J CLIN INVEST, V73, P1462, DOI 10.1172/JCI111350; SHAFFER JB, 1990, FREE RADICAL BIO MED, V8, P497, DOI 10.1016/0891-5849(90)90064-P; SHATOS MA, 1987, ENVIRON RES, V44, P103, DOI 10.1016/S0013-9351(87)80090-7; SHULL S, 1991, J BIOL CHEM, V266, P24398; VISNER GA, 1990, J BIOL CHEM, V265, P2856; VOISIN C, 1987, B EUR PHYSIOPATH RES, V23, P309; WEITZMAN SA, 1984, ARCH BIOCHEM BIOPHYS, V228, P373, DOI 10.1016/0003-9861(84)90078-X; WHITE CW, 1985, EXP LUNG RES, V8, P81, DOI 10.3109/01902148509057515; WISPE JR, 1989, BIOCHIM BIOPHYS ACTA, V994, P30, DOI 10.1016/0167-4838(89)90058-7; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; ZALMA R, 1987, CAN J CHEM, V65, P2338, DOI 10.1139/v87-390	63	139	140	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10625	10630						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1316905				2022-12-27	WOS:A1992HV09000063
J	CHE, MX; NISHIDA, T; GATMAITAN, Z; ARIAS, IM				CHE, MX; NISHIDA, T; GATMAITAN, Z; ARIAS, IM			A NUCLEOSIDE TRANSPORTER IS FUNCTIONALLY LINKED TO ECTONUCLEOTIDASES IN RAT-LIVER CANALICULAR MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; HUMAN-ERYTHROCYTES; MAMMALIAN-CELLS; ANIMAL-CELLS; ECTO-ATPASE; VESICLES; ADENOSINE; NITROBENZYLTHIOINOSINE; URIDINE	Prevention of nucleoside loss in bile is physiologically desirable because hepatocytes are the main source of nucleosides for animal cells which lack de novo nucleoside biosynthesis. We have demonstrated a Na+ gradient-energized, concentrative nucleoside transport system in canalicular membrane vesicles (CMV) from rat liver by studying [H-3]adenosine uptake using a rapid filtration technique. The Na+-dependent nucleoside transporter accepts purine, analogues of purine nucleosides and uridine; exhibits high affinity for adenosine (apparent K(m), 14-mu-M); is not inhibited by nitrobenzylthioinosine or dipyridamole, and is present in CMV but not in rat liver sinusoidal membrane vesicles. Adenosine transport in right side-out CMV was substantially greater than with inside-out CMV. CMV also contain abundant ecto-ATPase and ecto-AMPase (5'-nucleotidase). These ectoenzymes were shown to degrade nucleotides into nucleosides which were conserved by the Na+-dependent nucleoside transport system.			CHE, MX (corresponding author), TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111, USA.				NIDDK NIH HHS [DK-35652] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035652, R01DK035652] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEHHFELD G, 1989, J PHYSL, V418, P88; CASS CE, 1972, J BIOL CHEM, V247, P3314; CRAWFORD CR, 1990, J BIOL CHEM, V265, P9732; FORRESTER T, 1990, ANN NY ACAD SCI, V603, P335; FORRESTER T, 1977, J PHYSIOL-LONDON, V268, P371, DOI 10.1113/jphysiol.1977.sp011862; FOX IH, 1978, ANNU REV BIOCHEM, V47, P655, DOI 10.1146/annurev.bi.47.070178.003255; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HARDEN TK, 1990, ANN NY ACAD SCI, V603, P256; HIR ML, 1985, EUR J CLIN INVEST, V15, P121; INOUE M, 1982, HEPATOLOGY, V2, P572; INOUE M, 1983, J BIOL CHEM, V258, P5183; JARVIS SM, 1989, BIOCHIM BIOPHYS ACTA, V979, P132, DOI 10.1016/0005-2736(89)90533-6; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KITAMURA T, 1991, HEPATOLOGY, V14, P640, DOI 10.1016/0270-9139(91)90051-V; LEE CW, 1988, BIOCHIM BIOPHYS ACTA, V942, P139, DOI 10.1016/0005-2736(88)90283-0; LIN SH, 1989, J BIOL CHEM, V264, P14408; LIN SH, 1989, J BIOL CHEM, V264, P14403; LIN SH, 1985, J BIOL CHEM, V260, P976; LIN SH, 1990, ANN NY ACAD SCI, V603, P394; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIRASPORTUGAL MT, 1986, J BIOL CHEM, V261, P1712; MOSELEY RH, 1991, AM J PHYSIOL, V261, pG716, DOI 10.1152/ajpgi.1991.261.5.G716; MURRAY AW, 1971, ANNU REV BIOCHEM, V40, P811, DOI 10.1146/annurev.bi.40.070171.004115; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; Plagemann P.G.W., 1980, CURR TOP MEMBR TRANS, P225; PLAGEMANN PGW, 1982, J BIOL CHEM, V257, P2069; PLAGEMANN PGW, 1990, BIOCHIM BIOPHYS ACTA, V1028, P289, DOI 10.1016/0005-2736(90)90178-Q; PLAGEMANN PGW, 1984, BIOCHIM BIOPHYS ACTA, V773, P39, DOI 10.1016/0005-2736(84)90548-0; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; PLAGEMANN PGW, 1985, BIOCHIM BIOPHYS ACTA, V816, P387, DOI 10.1016/0005-2736(85)90506-1; RODEN M, 1991, GASTROENTEROLOGY, V100, P1553, DOI 10.1016/0016-5085(91)90652-2; SEMENZA G, 1985, ANN NY ACAD SCI, V456, P83, DOI 10.1111/j.1749-6632.1985.tb14848.x; VIJAYALAKSHMI D, 1988, J BIOL CHEM, V263, P19419; WILLIAMS TC, 1991, BIOCHEM J, V274, P27, DOI 10.1042/bj2740027	34	67	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9684	9688						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315767				2022-12-27	WOS:A1992HT96500037
J	WU, ZG; CHACONAS, G				WU, ZG; CHACONAS, G			FLANKING HOST SEQUENCES CAN EXERT AN INHIBITORY EFFECT ON THE CLEAVAGE STEP OF THE INVITRO MU-DNA STRAND TRANSFER-REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE-LIKE PROTEINS; BACTERIOPHAGE-MU; B-PROTEIN; TRANSPOSITION; ENDS; MECHANISM; ENHANCER; BINDING; SITE	The effect of flanking host sequences on the cleavage step of the in vitro Mu DNA strand transfer reaction was investigated. Insertion of a mini-Mu molecule into certain sites in pUC19 results in insertions that demonstrate a decreased ability to form Type 1 complexes in subsequent rounds of transposition. Similarly, changes in the flanking host sequences directly adjacent to the Mu ends by in vitro mutagenesis can also result in Type 1-deficient mini-Mu molecules. Further examination of the inhibition revealed that Type 1 deficient mini-Mu molecules are capable of forming uncut synaptic complexes at normal levels but are compromised in their ability to serve as substrates for phosphodiester bond hydrolysis at the Mu ends. This cleavage defect can be overcome by addition of the Mu B protein and ATP to the reaction. Our data suggest that one of the roles of the B protein may be to provide a mechanism whereby Mu prophages with inhibitory flanking sequences can overcome this obstacle and avoid being trapped at unproductive locations.			WU, ZG (corresponding author), UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON N6A 5C1,ONTARIO,CANADA.			Wu, Zhenguo/0000-0003-3049-8324				ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; CHACONAS G, 1988, BIOESSAYS, V9, P205, DOI 10.1002/bies.950090606; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CHURCHWARD G, 1984, GENE, V31, P165, DOI 10.1016/0378-1119(84)90207-5; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; FUJIMOTO BS, 1990, NATURE, V344, P175, DOI 10.1038/344175a0; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; KAMP D, 1980, COLD SPRING HARB SYM, V45, P329; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MILLER JL, 1986, GENE, V48, P101, DOI 10.1016/0378-1119(86)90356-2; MIZUUCHI K, 1986, ANNU REV GENET, V20, P385; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; Pato ML, 1989, MOBILE DNA, P23; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SCHMID MB, 1990, CELL, V63, P451, DOI 10.1016/0092-8674(90)90438-K; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; SURETTE MG, 1991, J BIOL CHEM, V266, P17306; SYMONDS N, 1987, PHAGE MU, P1; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; VANGIJSEGEM F, 1987, PHAGE MU, P215	34	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9552	9558						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315758				2022-12-27	WOS:A1992HT96500019
J	SHUMAN, S				SHUMAN, S			DNA STRAND TRANSFER-REACTIONS CATALYZED BY VACCINIA TOPOISOMERASE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; TYPE-1 TOPOISOMERASE; ESCHERICHIA-COLI; CLEAVAGE SITES; BREAKAGE; RESOLUTION	Vaccinia virus DNA topoisomerase I forms a 3'-phosphoryl intermediate with duplex DNAs containing the conserved binding/cleavage motif 5'CCCTT down. Covalently bound enzyme is capable of transferring the incised DNA strand to a heterologous DNA acceptor containing a 5'OH terminus. Both intramolecular and intermolecular religation reactions are catalyzed. Intramolecular strand transfer occurs to the noncleaved strand of the DNA duplex and results in formation of a hairpin loop. Intermolecular religation to an exogenous DNA strand is favored over hairpin formation and requires the potential for base pairing between the acceptor and the noncleaved strand of the donor complex. As few as 4 potential base pairs are sufficient to support intermolecular transfer. These results in vitro are consistent with the proposal that vaccinia topoisomerase can catalyze sequence-specific strand transfer during genetic recombination in vivo (Shuman, S. (1991) Proc. Natl. Acad. Sci. U.S.A. 88, 10104-10108).			SHUMAN, S (corresponding author), SLOAN KETTERING MEM CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046330, R01GM046330] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 46330] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEEN MD, 1981, P NATL ACAD SCI-BIOL, V78, P2883, DOI 10.1073/pnas.78.5.2883; BEEN MD, 1984, J MOL BIOL, V180, P515, DOI 10.1016/0022-2836(84)90025-1; BULLOCK P, 1985, SCIENCE, V230, P954, DOI 10.1126/science.2997924; BULLOCK P, 1984, J MOL BIOL, V174, P3948; CHAMPOUX JJ, 1984, COLD SPRING HARB SYM, V49, P435, DOI 10.1101/SQB.1984.049.01.049; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; EDWARDS KA, 1982, NUCLEIC ACIDS RES, V10, P2565, DOI 10.1093/nar/10.8.2565; HALLIGAN BD, 1982, J BIOL CHEM, V257, P3995; Hatfull GF, 1988, GENETIC RECOMBINATIO, P357; KROGH S, 1991, NUCLEIC ACIDS RES, V19, P1235, DOI 10.1093/nar/19.6.1235; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; MCFADDEN G, 1988, CANCER CELL, V6, P77; MERCHLINSKY M, 1990, J VIROL, V64, P3437, DOI 10.1128/JVI.64.7.3437-3446.1990; NASH HA, 1989, EMBO J, V8, P3523, DOI 10.1002/j.1460-2075.1989.tb08518.x; NUNESDUBY SE, 1989, CELL, V59, P197, DOI 10.1016/0092-8674(89)90881-7; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P3489, DOI 10.1073/pnas.86.10.3489; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1991, P NATL ACAD SCI USA, V88, P10104, DOI 10.1073/pnas.88.22.10104; SHUMAN S, 1989, VIROLOGY, V170, P302, DOI 10.1016/0042-6822(89)90384-X; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; TAPPER DP, 1981, NUCLEIC ACIDS RES, V9, P6787, DOI 10.1093/nar/9.24.6787; WANG HP, 1991, J VIROL, V65, P2381, DOI 10.1128/JVI.65.5.2381-2392.1991	25	87	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8620	8627						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314832				2022-12-27	WOS:A1992HQ18500099
J	CHIBALIN, AV; VASILETS, LA; HENNEKES, H; PRALONG, D; GEERING, K				CHIBALIN, AV; VASILETS, LA; HENNEKES, H; PRALONG, D; GEERING, K			PHOSPHORYLATION OF NA,K-ATPASE ALPHA-SUBUNITS IN MICROSOMES AND IN HOMOGENATES OF XENOPUS OOCYTES RESULTING FROM THE STIMULATION OF PROTEIN KINASE-A AND PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; CATALYTIC SUBUNIT; PHORBOL ESTER; BETA-SUBUNITS; CELLS; TRANSPORT; MEMBRANE; SEQUENCE; NA+,K+-ATPASE; BLADDER	The phosphorylation of the alpha-subunit of Na+/K+-transporting ATPase (Na,K-ATPase) by cAMP-dependent protein kinase (PKA) and protein kinase C (PKC) was characterized in purified enzyme preparations of Bufo marinus kidney and duck salt gland and in microsomes of Xenopus oocytes. In addition, we have examined cAMP and phorbol esters, which are stimulators of PKA and PKC, respectively, for their ability to provoke the phosphorylation of alpha-subunits of Na,K-ATPase in homogenates of Xenopus oocytes. In the enzyme from the duct salt gland, phosphorylation by PKA and PKC occurs on serine and threonine residues, whereas in the enzyme from B. marinus kidney and Xenopus oocytes, phosphorylation by PKA occurs only on serine residues. Phosphopeptide analysis indicates that a site phosphorylated by PKA resides in a 12-kDa fragment comprising the C terminus of the polypeptide. Studies of phosphorylation performed on homogenates of Xenopus oocytes show that not only endogenous oocyte Na,K-ATPase but also exogenous Xenopus Na,K-ATPase expressed in the oocyte by microinjection of cRNA can be phosphorylated in response to stimulation of oocyte PKA and PKC. In conclusion, these data are consistent with the possibility that the alpha-subunit of Na,K-ATPase can serve as a substrate for PKA and PKC in vivo.	UNIV LAUSANNE, INST PHARMACOL & TOXICOL, RUE BUGNON 27, CH-1005 LAUSANNE, SWITZERLAND; SWISS INST EXPTL CANC RES, CH-1066 EPALINGES, SWITZERLAND; RUSSIAN ACAD SCI, INST CHEM PHYS, MOSCOW 142432, USSR	University of Lausanne; Swiss Institute Experimental Cancer Research; Russian Academy of Sciences; N.N. Semenov Federal Research Centre for Chemical Physics, Russian Academy of Sciences				Vasilets, Larisa/0000-0001-5980-4423; Chibalin, Alexander/0000-0002-6339-6271				ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; ANTOLOVIC R, 1991, EUR J BIOCHEM, V199, P195, DOI 10.1111/j.1432-1033.1991.tb16109.x; APERIA A, 1987, AM J PHYSIOL, V252, pF39, DOI 10.1152/ajprenal.1987.252.1.F39; BAYER R, 1990, BIOCHEMISTRY-US, V29, P2251, DOI 10.1021/bi00461a007; BEACH RE, 1987, AM J PHYSIOL, V252, pF215, DOI 10.1152/ajprenal.1987.252.2.F215; BERTORELLO A, 1988, AM J PHYSIOL, V254, pF795, DOI 10.1152/ajprenal.1988.254.6.F795; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHIBALIN AV, 1991, BIOL MEMBRANY, V8, P1140; CHIBALIN AV, 1992, IN PRESS J BIOENERG; GEERING K, 1979, BIOCHIM BIOPHYS ACTA, V566, P157, DOI 10.1016/0005-2744(79)90258-4; GEERING K, 1982, J BIOL CHEM, V257, P338; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; GEERING K, 1985, J BIOL CHEM, V260, P5154; GIRARDET M, 1981, BIOCHEMISTRY-US, V20, P6684, DOI 10.1021/bi00526a025; HERNANDEZ J, 1992, NEUROCHEM INT, V20, P1, DOI 10.1016/0197-0186(92)90119-C; JAUNIN P, 1992, J BIOL CHEM, V267, P577; LAMB JF, 1990, INT J BIOCHEM, V22, P1365, DOI 10.1016/0020-711X(90)90224-Q; LING L, 1984, J BIOL CHEM, V259, P4089; LOWNDES JM, 1990, BIOCHIM BIOPHYS ACTA, V1052, P143, DOI 10.1016/0167-4889(90)90069-P; MARDH S, 1983, CURR TOP MEMBR TRANS, V19, P999; MARVER D, 1986, J MEMBRANE BIOL, V94, P205, DOI 10.1007/BF01869716; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NAVRAN SS, 1991, J PHARMACOL EXP THER, V256, P297; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; ROSSIER BC, 1987, TRENDS BIOCHEM SCI, V12, P483, DOI 10.1016/0968-0004(87)90235-0; SATOH T, 1990, AM J PHYSIOL, V259, pF425, DOI 10.1152/ajprenal.1990.259.3.F425; SMART JL, 1988, PHARMACOLOGY, V37, P94, DOI 10.1159/000138452; VASILETS LA, 1992, J MEMBRANE BIOL, V125, P119; VASILETS LA, 1990, J MEMBRANE BIOL, V118, P131, DOI 10.1007/BF01868470; VASILETS LA, 1991, SOC GENERAL PHYSL 2, V46; VERREY F, 1989, AM J PHYSIOL, V256, pF1034, DOI 10.1152/ajprenal.1989.256.6.F1034	32	116	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22378	22384						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331053				2022-12-27	WOS:A1992JW71900062
J	GUAN, XM; KOBILKA, TS; KOBILKA, BK				GUAN, XM; KOBILKA, TS; KOBILKA, BK			ENHANCEMENT OF MEMBRANE INSERTION AND FUNCTION IN A TYPE IIIB MEMBRANE-PROTEIN FOLLOWING INTRODUCTION OF A CLEAVABLE SIGNAL PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-ADRENERGIC-RECEPTOR; GLYCOSYLATION; TRANSLOCATION; TOPOGRAPHY; MECHANISMS; SEQUENCE; BINDING; SITES; GENE	The human beta2 adrenergic receptor is a type IIIb membrane protein. It has a putative seven-transmembrane topology but lacks an amino-terminal cleavable signal sequence. The mechanism by which the amino terminus of the beta2 receptor is translocated across the endoplasmic reticulum membrane is unknown. Furthermore, it is not known if translocation as a type IIIb protein is essential for the proper folding. Our studies indicate that conversion of beta2 receptor from a type IIIb to a type IIIa membrane protein by introducing an NH2-terminal cleavable signal sequence enhances translocation of the receptor into the endoplasmic reticulum membrane, thereby facilitating expression of functional receptor.	STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305; STANFORD UNIV,DIV CARDIOVASC,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University				Kobilka, Brian/0000-0001-5958-3990	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028471] Funding Source: NIH RePORTER; NINDS NIH HHS [5 RO1 NS28471] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Blobel G, 1982, Cold Spring Harb Symp Quant Biol, V46 Pt 1, P7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; JOU WM, 1980, CELL, V19, P683, DOI 10.1016/S0092-8674(80)80045-6; KOBILKA BK, 1990, J BIOL CHEM, V265, P7610; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU JTY, 1983, J BIOL CHEM, V258, P5255; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; SUMMERS MD, 1987, TEXAS AGR EXP STN B, V1555; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WANG HY, 1989, J BIOL CHEM, V264, P14424; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938	18	227	233	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					21995	21998						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331042				2022-12-27	WOS:A1992JW71900003
J	TOMAVO, S; DUBREMETZ, JF; SCHWARZ, RT				TOMAVO, S; DUBREMETZ, JF; SCHWARZ, RT			BIOSYNTHESIS OF GLYCOLIPID PRECURSORS FOR GLYCOSYLPHOSPHATIDYLINOSITOL MEMBRANE ANCHORS IN A TOXOPLASMA-GONDII CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEINS; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; DECAY-ACCELERATING FACTOR; TRYPANOSOMA-BRUCEI; PHOSPHOLIPASE-C; STRUCTURAL CHARACTERIZATION; THY-1 GLYCOPROTEIN; LEISHMANIA-MAJOR; N-GLYCOSYLATION; PHOSPHATIDYLINOSITOL	Toxoplasmosis, a disease that affects humans and a wide variety of mammals is caused by Toxoplasma gondii, the obligate intracellular coccidian protozoan parasite. Most T. gondii research has focused on the rapidly growing invasive form, the tachyzoite, which expresses five major surface proteins attached to the parasite membrane by glycosylphosphatidylinositol (GPI) anchors. We have recently reported the purification and partial characterization of candidate precursor glycolipids (GPIs) from metabolically labeled parasites and have presented evidence that these GPIs have a linear glycan backbone sequence indistinguishable from the GPI core glycan of the major tachyzoite surface protein, P30. In this report, we describe a cell-free system derived from tachyzoite membranes which is capable of catalyzing GPI biosynthesis. Incubation of the membrane preparations with radioactive sugar nucleotides (GDP-[H-3]mannose or UDP-[H-3]GlcNAc) resulted in incorporation of radiolabel into numerous glycolipids. By using a combination of chemical/enzymatic tests and chromatographic analysis, a series of incompletely glycosylated lipid species and mature GPIs have been identified. We have also established the involvement of Dol-P-mannose in the synthesis of T. gondii GPIs by demonstrating that the incorporation of [H-3]mannose into the mannosylated GPIs is stimulated by dolichylphosphate and inhibited by amphomycin. In addition, increasing the concentration of nonradioactive GDP mannose resulted in a loss of radiolabel from the first easily detectable GPI precursor, GlcN-PI, and a concomittant appearance of the radioactivity into mannosylated glycolipids. Altogether, our data suggest that the GPI core glycan in T. gondii is assembled via sequential glycosylation of phosphatidylinositol, as proposed for the biosynthesis of GPIs in Trypanosoma brucei. In contrast to T. brucei, preliminary experiments indicate that the core glycan of some GPIs synthesized by the T. gondii cell-free system is modified by N-acetylgalactosamine similar to the situation for mammalian Thy-1.	UNIV MARBURG,MED ZENTRUM HYG & MED MIKROBIOL,W-3550 MARBURG,GERMANY; INSERM,U42,F-59650 VILLENEUVE DASCQ,FRANCE	Philipps University Marburg; Institut National de la Sante et de la Recherche Medicale (Inserm)								BANERJEE DK, 1981, BIOCHEMISTRY-US, V20, P1561, DOI 10.1021/bi00509a024; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BOOTHROYD JC, 1981, NUCLEIC ACIDS RES, V9, P4735, DOI 10.1093/nar/9.18.4735; CLAYTON CE, 1989, J BIOL CHEM, V264, P15088; CONZELMANN A, 1987, BIOCHEM J, V246, P605, DOI 10.1042/bj2460605; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; DOERING TL, 1989, J BIOL CHEM, V264, P11168; DOERING TL, 1990, J BIOL CHEM, V265, P611; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FASEL N, 1989, P NATL ACAD SCI USA, V86, P6858, DOI 10.1073/pnas.86.18.6858; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIELD MC, 1991, J BIOL CHEM, V266, P8392; HARDY MR, 1988, P NATL ACAD SCI USA, V85, P3289, DOI 10.1073/pnas.85.10.3289; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; KANG MS, 1978, J BIOL CHEM, V253, P8860; KASPER LH, 1983, J IMMUNOL, V130, P2407; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, Methods (Orlando), V1, P297, DOI 10.1016/S1046-2023(05)80331-7; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; NAGEL SD, 1989, J BIOL CHEM, V264, P5569; PFEFFERKORN ER, 1983, CIBA F SYMP, V99, P74; PFEFFERKORN ER, 1978, EXP PARASITOL, V44, P26, DOI 10.1016/0014-4894(78)90077-2; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SCHWARZ RT, 1982, METHOD ENZYMOL, V83, P432; SHARMA CB, 1974, EUR J BIOCHEM, V46, P35, DOI 10.1111/j.1432-1033.1974.tb03594.x; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; TOMAVO S, 1989, MOL CELL BIOL, V9, P4576, DOI 10.1128/MCB.9.10.4576; TOMAVO S, 1992, J BIOL CHEM, V267, P11721; TOMAVO S, 1992, Biochemical Society Transactions, V20, p166S; TOMAVO S, 1991, BIOL CHEM H-S, V372, P769; WALTER EI, 1990, J IMMUNOL, V144, P1030	46	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21446	21458						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328232				2022-12-27	WOS:A1992JV01100031
J	FOSANG, AJ; NEAME, PJ; LAST, K; HARDINGHAM, TE; MURPHY, G; HAMILTON, JA				FOSANG, AJ; NEAME, PJ; LAST, K; HARDINGHAM, TE; MURPHY, G; HAMILTON, JA			THE INTERGLOBULAR DOMAIN OF CARTILAGE AGGRECAN IS CLEAVED BY PUMP, GELATINASES, AND CATHEPSIN-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; GLOBULAR PROTEIN DOMAINS; 72 KDA PROGELATINASE; LINK-PROTEIN; PROTEOGLYCANS INVITRO; TISSUE INHIBITOR; BINDING REGION; G2 DOMAIN; DEGRADATION; STROMELYSIN	The action of three matrix metalloproteinases (MMPs), 72- and 95-kDa gelatinases (MMP-2 and MMP-9) and PUMP (MMP-7), and a cysteine proteinase, cathepsin B, were investigated on aggrecan the major proteoglycan of cartilage. All the enzymes cleaved aggrecan although the activity of the 95-kDa gelatinase was very low. Specific cleavage sites were investigated following incubation with a purified aggrecan G1-G2 domain fragment (150 kDa). Both gelatinases produced 110-kDa G2 and 56-kDa G1 products by a single cleavage at an Asn-Phe bond within the interglobular domain close to the G1 domain. This was similar to the action of stromelysin (MMP-3) (Fosang, A. J., Neame, P. J., Hardingham, T. E., Murphy, G., and Hamilton, J. A. (1991) J. Biol. Chem. 266, 15579-15582). Cathepsin B also produced two fragments from a single cleavage at a Gly-Val bond only three amino acids C-terminal to the metalloproteinase cleavage site. PUMP cleaved at the metalloproteinase Asn-Phe site, but in addition produced a low yield of a smaller G2 fragment (56 kDa) corresponding to cleavage between Asp441 and Leu442 (human sequence), within the interglobular domain, close to the G2 domain. The apparent difference in size between the two G2 fragments released by PUMP (110 and 56 kDa) was much greater than predicted from the peptide length between the cleavage sites (100 amino acids). However, keratanase digestion greatly reduced the size of the 110-kDa G2 fragment, while producing only a small reduction in size of the 56-kDa product, showing that there was approximately 30-40 kDa of keratan sulfate attached to the interglobular domain between the PUMP cleavage sites. This new structural information on aggrecan may account for the previously observed stiffness of the interglobular domains when viewed by rotary shadowing electron microscopy (Paulsson, M., Morgelin, M., Wiedemann, H., Beardmore-Gray, M., Dunham, D. G., Hardingham, T. E., Heinegard, D., Timpl, R., and Engel, J. (1987) Biochem. J. 245, 763-772). These results show that in spite of a high keratan sulfate content the interglobular domain provides important sites for cleavage by different proteinases, including several members of the matrix metalloproteinase family.	SHRINERS HOSP CRIPPLED CHILDREN,TAMPA,FL 33612; KENNEDY INST,LONDON W6 7DW,ENGLAND; STRANGEWAYS RES LAB,CAMBRIDGE CB1 4RN,ENGLAND	University of Oxford	FOSANG, AJ (corresponding author), UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT MED,ROYAL PARADE,PARKVILLE,VIC 3050,AUSTRALIA.			Hamilton, John A/0000-0002-9493-9224; Last, Karena/0000-0002-4396-8404; Fosang, Amanda/0000-0002-5523-5427; Hardingham, Timothy/0000-0001-8271-6763				ALLAN JA, 1991, J CELL SCI, V99, P789; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BAYLISS MT, 1985, BIOCHEM J, V232, P111, DOI 10.1042/bj2320111; BROWN CC, 1989, J BONE JOINT SURG AM, V71A, P580, DOI 10.2106/00004623-198971040-00014; CAMPBELL IK, 1986, BIOCHEM J, V237, P117, DOI 10.1042/bj2370117; CARNEY SL, 1986, ANAL BIOCHEM, V156, P38, DOI 10.1016/0003-2697(86)90150-8; CASE JP, 1990, J IMMUNOL, V145, P3755; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FOSANG AJ, 1989, BIOCHEM J, V261, P801, DOI 10.1042/bj2610801; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; FOSANG AJ, 1991, BIOCHEM J, V273, P369, DOI 10.1042/bj2730369; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HASTY KA, 1990, ARTHRITIS RHEUM, V33, P388, DOI 10.1002/art.1780330312; LEE X, 1990, J BIOL CHEM, V265, P5950; LEFEBVRE V, 1991, BIOCHIM BIOPHYS ACTA, V1094, P8, DOI 10.1016/0167-4889(91)90020-X; MACIEWICZ RA, 1988, BIOCHEM SOC T, V16, P812, DOI 10.1042/bst0160812; MACIEWICZ RA, 1990, FEBS LETT, V269, P189, DOI 10.1016/0014-5793(90)81151-D; MOK MT, 1992, ARCH BIOCHEM BIOPHYS, V292, P442, DOI 10.1016/0003-9861(92)90014-N; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MORT JS, 1984, ARTHRITIS RHEUM, V27, P509, DOI 10.1002/art.1780270505; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; MURPHY G, 1986, COLLAGEN REL RES, V6, P351; NGUYEN Q, 1992, J CLIN INVEST, V89, P1189, DOI 10.1172/JCI115702; OGATA Y, 1992, J BIOL CHEM, V267, P3581; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; PERKINS SJ, 1989, J MOL BIOL, V206, P737, DOI 10.1016/0022-2836(89)90580-9; POOLE AR, 1987, J RHEUMATOL, V14, P80; RATCLIFFE A, 1983, BIOCHEM J, V213, P371, DOI 10.1042/bj2130371; RATCLIFFE A, 1986, BIOCHEM J, V238, P571, DOI 10.1042/bj2380571; SAKLATVALA J, 1984, BIOCHEM J, V224, P461, DOI 10.1042/bj2240461; SANDY JD, 1978, BIOCHIM BIOPHYS ACTA, V543, P536, DOI 10.1016/0304-4165(78)90308-2; SANDY JD, 1991, J BIOL CHEM, V266, P8683; SANDY JD, 1990, J BIOL CHEM, V265, P21108; TRECHSEL U, 1982, BIOCHIM BIOPHYS ACTA, V720, P364, DOI 10.1016/0167-4889(82)90113-6; TYLER JA, 1985, BIOCHEM J, V225, P493, DOI 10.1042/bj2250493; VANRANST M, 1991, CYTOKINE, V3, P231, DOI 10.1016/1043-4666(91)90021-5; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J	44	273	283	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19470	19474						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326552				2022-12-27	WOS:A1992JP59300069
J	WILLARD, JM; OSWALD, RE				WILLARD, JM; OSWALD, RE			INTERACTION OF THE FROG BRAIN KAINATE RECEPTOR EXPRESSED IN CHINESE-HAMSTER OVARY CELLS WITH A GTP-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HIPPOCAMPAL-NEURONS; METHYL-D-ASPARTATE; GLUTAMATE RECEPTOR; GUANINE-NUCLEOTIDES; MOLECULAR-CLONING; SUBUNIT; ASTROCYTES; INDUCTION; INVITRO; FAMILY	A protein that binds kainate with high affinity has been purified and cloned from frog brain (Rana pipiens) and has approximately 35% sequence homology with mammalian non-N-methyl-D-aspartate glutamate receptors, some of which have been shown to be ligand-gated ion channels. Frog brain membranes and membranes from Chinese hamster ovary (CHO) cells transfected with the cDNA coding for the frog kainate-binding protein (CHO-4 cells) bound kainate with essentially identical affinity (K(D) values of 1.9 and 2.1 nm, respectively). In both tissues, the affinity for kainate decreased 9-fold in the presence of 100 muM GTPgammaS (guanosine 5'-O-(3-thio)triphosphate). No specific kainate binding to nontransfected CHO cell membranes was observed. GTPgammaS and GDP were effective inhibitors of kainate binding, while cGMP and adenosine 5'-O-(3-thio)triphosphate had no effect in either frog brain membranes or CHO-4 membranes. Pretreatment of CHO-4 cell membranes with pertussis toxin led to a 34% decrease in kainate binding. Kainate increased the binding of [H-3]5'-guanylyl imidodiphosphate by 61%, and the rate of GTP hydrolysis by up to 5-fold. These results indicate that the kainate receptor cloned from frog brain can interact functionally with a G protein present in CHO-4 cell membranes.	CORNELL UNIV,COLL VET MED,DEPT PHARMACOL,ITHACA,NY 14853	Cornell University								ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; BARON BM, 1989, J PHARMACOL EXP THER, V250, P162; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; CHERUBINI E, 1990, EPILEPSY RES, V5, P18, DOI 10.1016/0920-1211(90)90062-Z; COCKCROFT S, 1987, J CELL BIOL, V105, P2745, DOI 10.1083/jcb.105.6.2745; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FOSTER AC, 1984, BRAIN RES REV, V7, P103, DOI 10.1016/0165-0173(84)90020-1; GARTHWAITE J, 1989, J NEUROCHEM, V53, P1952, DOI 10.1111/j.1471-4159.1989.tb09266.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; IMAMURA K, 1988, J BIOL CHEM, V263, P14093; JENSEN AM, 1990, J NEUROSCI, V10, P1165; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; MILLER RJ, 1991, TRENDS NEUROSCI, V14, P477, DOI 10.1016/0166-2236(91)90054-X; MONAHAN JB, 1988, MOL PHARMACOL, V34, P111; MOTT DD, 1991, SCIENCE, V252, P1718, DOI 10.1126/science.1675489; NISTRI A, 1991, J PHYSIOL-LONDON, V435, P465, DOI 10.1113/jphysiol.1991.sp018519; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; PUCKETT C, 1991, P NATL ACAD SCI USA, V88, P7557, DOI 10.1073/pnas.88.17.7557; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; ROVIRA C, 1990, PFLUG ARCH EUR J PHY, V415, P471, DOI 10.1007/BF00373625; SCHUSTER CM, 1991, SCIENCE, V254, P112, DOI 10.1126/science.1681587; STERNWEIS PC, 1990, TRENDS NEUROSCI, V13, P122, DOI 10.1016/0166-2236(90)90002-R; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; WADA K, 1989, NATURE, V342, P684, DOI 10.1038/342684a0; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; WILLARD JM, 1991, J BIOL CHEM, V266, P10196; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZIEGRA CJ, 1992, P NATL ACAD SCI USA, V89, P4134, DOI 10.1073/pnas.89.9.4134; ZIEGRA CJ, 1992, IN PRESS MOL PHARM	37	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19112	19116						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326545				2022-12-27	WOS:A1992JP59300019
J	BIRD, GS; OBIE, JF; PUTNEY, JW				BIRD, GS; OBIE, JF; PUTNEY, JW			SUSTAINED CA(2+) SIGNALING IN MOUSE LACRIMAL ACINAR-CELLS DUE TO PHOTOLYSIS OF CAGED GLYCEROPHOSPHORYL-MYO-INOSITOL 4,5-BISPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM; 1,4,5-TRISPHOSPHATE; TRISPHOSPHATE; KINETICS; TETRAKISPHOSPHATE; PERMEABILITY; HEPATOCYTES; GLAND; CA-2+	In saponin-permeabilized mouse lacrimal acinar cells, glycerophosphoryl-myo-inositol 4,5-bisphosphate (GPIP2) activated the release of sequestered Ca2+ to the same extent as inositol 1,4,5-trisphosphate ((1,4,5)IP3) but with a potency about 1/10 that of (1,4,5)IP3. In lacrimal gland homogenates, [H-3]GPIP2 was metabolized to two compounds which upon anion exchange high performance liquid chromatography eluted at positions indicating that they were [H-3]GPIP and [H-3]GPIP3. The rate of metabolism of [H-3]GPIP2 was much slower than that of [H-3](1,4,5)IP3, and its rate of phosphorylation was less than 1% of that of [H-3] (1,4,5)IP3. In intact lacrimal cells, photolysis of a microinjected "caged" derivative of GPIP2, 1-(alpha-glycero-phosphoryl)-myo-inositol 4,5-bisphoshhate p4(5)-1-(2-nitrophenyl)ethyl ester, resulted in sustained activation of Ca2+ signaling; i.e. intracellular Ca2+ release followed by increased entry of Ca2+ across the plasma membrane. These findings indicate that caged GPIP2 should provide a useful tool for producing photolytically initiated, sustained activation of intracellular (1,4,5)IP3 receptors. They also provide strong support for the idea that sustained Ca2+ signaling can be achieved in lacrimal acinar cells by activation of intracellular receptors for (1,4,5)IP3 in the absence of stimulated production of inositol 1,3,4,5-tetrakisphoshate.			BIRD, GS (corresponding author), NIEHS, CELLULAR & MOLEC PHARMACOL LAB, CALCIUM REGULAT SECT, POB 12233, RES TRIANGLE PK, NC 27709 USA.		Bird, Gary/AAI-8186-2021; Putney, James/F-7247-2019	Bird, Gary/0000-0003-1389-8748; Putney, James/0000-0002-3379-4789				BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GSJ, 1991, BIOCHEM J, V273, P541, DOI 10.1042/bj2730541; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; IRVINE RF, 1991, NATURE, V352, P115, DOI 10.1038/352115a0; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORRIS AJ, 1988, BIOCHEM J, V251, P157, DOI 10.1042/bj2510157; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NAHORSKI SR, 1989, TRENDS PHARMACOL SCI, V10, P139, DOI 10.1016/0165-6147(89)90165-X; OGDEN DC, 1990, J PHYSIOL-LONDON, V422, P585, DOI 10.1113/jphysiol.1990.sp018002; PAROD RJ, 1978, J PHYSIOL-LONDON, V281, P371, DOI 10.1113/jphysiol.1978.sp012428; PAROD RJ, 1980, AM J PHYSIOL, V239, pG99, DOI 10.1152/ajpgi.1980.239.2.G99; PUTNEY JW, 1981, PHILOS T ROY SOC B, V296, P37, DOI 10.1098/rstb.1981.0169; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; WALKER JW, 1987, NATURE, V327, P249, DOI 10.1038/327249a0; WALKER JW, 1989, BIOCHEMISTRY-US, V28, P3272, DOI 10.1021/bi00434a023	21	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17722	17725						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325446				2022-12-27	WOS:A1992JM22300039
J	BEULLENS, M; VAN EYNDE, A; STALMANS, W; BOLLEN, M				BEULLENS, M; VAN EYNDE, A; STALMANS, W; BOLLEN, M			THE ISOLATION OF NOVEL INHIBITORY POLYPEPTIDES OF PROTEIN PHOSPHATASE-1 FROM BOVINE THYMUS NUCLEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR-REGULATION; RAT-LIVER; TYPE-1; PURIFICATION; ENCODES; GENE; IDENTIFICATION; PHOSPHOPROTEIN; CHROMATOGRAPHY; DROSOPHILA	Nuclei from bovine thymus contain a high level of partially latent protein phosphatase 1 (PP-1). More than 90% of this PP-1 is associated with the insoluble chromatin/matrix fraction and can be extracted with 0.3 M NaCl. The salt extract also contains three heat- and acid-stable inhibitory proteins of PP-1 that can be resolved on Mono Q. We have purified two of these nuclear inhibitors of PP-1 (NIPP-1a and NIPP-1b) until homogeneity. They are acidic proteins (pI = 4.4) with a molecular mass of 18 kDa (NIPP-1a) and 16 kDa (NIPP-1b) on SDS-PAGE. Judged from the larger molecular mass that was deduced from gel filtration (35 kDa), NIPP-1a and NIPP-1b appear to be asymmetric or dimeric proteins. The nuclear inhibitors totally inhibited the phosphorylase phosphatase activity of PP-1, but even at a 250-fold higher concentration they did not affect the activities of the other major serine/threonine protein phosphatases (PP-2A, PP-2B, and PP-2C). NIPP-1a and NIPP-1b inhibited the catalytic subunit of PP-1 with an extrapolated K(i) of about 1 pM, which is some three orders of magnitude better than the cytoplasmic proteins inhibitor 1/DARPP-32 and modulator. The nuclear inhibitors were not inactivated by incubation with protein phosphatases that inactivate inhibitor 1 and DARPP-32. Unlike modulator, they were not able to convert the catalytic subunit of PP-1 into a MgATP-dependent form. Remarkably, the extent of inhibition of PP-1 by NIPP-1b depended on the nature of the substrate. The phosphorylase phosphatase and casein phosphatase activities of PP-1 were completely blocked by NIPP-1b, whereas the dephosphorylation of basic proteins was either not at all inhibited (histone IIA) or only partially (myelin basic protein). These data may indicate that the acidic NIPP-1b is inactivated through complexation by basic proteins. Indeed, nonphosphorylated histone IIA antagonized the inhibitory effect of NIPP-1b on the casein phosphatase activity of PP-1. Our data show that the nucleus contains specific and potent inhibitory proteins of PP-1 that differ from earlier described cytoplasmic inhibitors. We suggest that these novel proteins may control the activity of nuclear PP-1 on its natural substrate(s).	CATHOLIC UNIV LEUVEN, FAK GENEESKUNDE, AFDELING BIOCHEM, CAMPUS GASTHUISBERG, B-3000 LOUVAIN, BELGIUM	KU Leuven								AITKEN A, 1982, EUR J BIOCHEM, V126, P235, DOI 10.1111/j.1432-1033.1982.tb06771.x; ANTONIW JF, 1977, BIOCHEM J, V162, P423, DOI 10.1042/bj1620423; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; DEJONG L, 1990, CELL BIOL INT REP, V14, P1051, DOI 10.1016/0309-1651(90)90014-P; DOMBRADI V, 1990, FEBS LETT, V275, P39, DOI 10.1016/0014-5793(90)81434-P; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; DOPERE F, 1982, BIOCHEM BIOPH RES CO, V104, P443, DOI 10.1016/0006-291X(82)90657-X; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; FOULKES JG, 1983, EUR J BIOCHEM, V132, P309, DOI 10.1111/j.1432-1033.1983.tb07363.x; FRIEDMAN DL, 1986, BIOCHEM BIOPH RES CO, V134, P1372, DOI 10.1016/0006-291X(86)90401-8; GOODWIN GH, 1973, EUR J BIOCHEM, V40, P215, DOI 10.1111/j.1432-1033.1973.tb03188.x; GOODWIN GH, 1973, EUR J BIOCHEM, V38, P14, DOI 10.1111/j.1432-1033.1973.tb03026.x; GOODWIN GH, 1989, PROTEIN PURIFICATION, P97; GORIS J, 1984, ADV ENZYME REGUL, V22, P467, DOI 10.1016/0065-2571(84)90026-8; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HOLMES CFB, 1986, EUR J BIOCHEM, V155, P173, DOI 10.1111/j.1432-1033.1986.tb09473.x; JAKES S, 1986, BIOCHIM BIOPHYS ACTA, V888, P135, DOI 10.1016/0167-4889(86)90079-0; JESSUS C, 1989, BIOCHEM J, V260, P45, DOI 10.1042/bj2600045; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; KURET J, 1986, FEBS LETT, V203, P197, DOI 10.1016/0014-5793(86)80741-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERCIER JC, 1968, B SOC CHIM BIOL, V50, P521; MERLEVEDE W, 1985, ADV PROTEIN PHOSPHAT, V1, P1; OHKURA H, 1991, CELL, V64, P149, DOI 10.1016/0092-8674(91)90216-L; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; PELECH S, 1985, EUR J BIOCHEM, V148, P245, DOI 10.1111/j.1432-1033.1985.tb08832.x; RAMACHANDRAN C, 1987, J BIOL CHEM, V262, P3210; STEWART AA, 1983, EUR J BIOCHEM, V132, P289, DOI 10.1111/j.1432-1033.1983.tb07361.x; TAKAI A, 1991, BIOCHEM J, V275, P233, DOI 10.1042/bj2750233; TSUIKI S, 1988, METHOD ENZYMOL, V159, P437; VANDENHEEDE JR, 1987, FEBS LETT, V211, P190, DOI 10.1016/0014-5793(87)81434-5; VANFLETEREN JR, 1989, ANAL BIOCHEM, V178, P385, DOI 10.1016/0003-2697(89)90657-X; WILLIAMS KR, 1986, J BIOL CHEM, V261, P1890; YANG SD, 1981, FEBS LETT, V132, P293, DOI 10.1016/0014-5793(81)81182-9	40	116	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16538	16544						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322907				2022-12-27	WOS:A1992JJ45800085
J	EASON, MG; KUROSE, H; HOLT, BD; RAYMOND, JR; LIGGETT, SB				EASON, MG; KUROSE, H; HOLT, BD; RAYMOND, JR; LIGGETT, SB			SIMULTANEOUS COUPLING OF ALPHA-2-ADRENERGIC RECEPTORS TO 2 G-PROTEINS WITH OPPOSING EFFECTS - SUBTYPE-SELECTIVE COUPLING OF ALPHA-2C10, ALPHA-2C4, AND ALPHA-2C2 ADRENERGIC-RECEPTORS TO G(I) AND G(S)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; HAMSTER OVARY CELLS; ADENYLATE-CYCLASE; PHOSPHOLIPID-VESICLES; CYTOPLASMIC DOMAINS; EXPRESSION; CLONING; IDENTIFICATION; GENE; PHOSPHORYLATION	Coupling of the three alpha-2-adrenergic receptor (alpha-2AR) subtypes to G(i) and G(s) was studied in membranes from transfected CHO cells. We observed that in the presence of low concentrations of the alpha-2AR agonist UK-14304, alpha-2C10 mediated inhibition of adenylyl cyclase activity, whereas at high concentrations of agonist, alpha-2C10 mediated stimulation of adenylyl cyclase activity. We considered that this biphasic response was due to the coupling of alpha-2C10 to both G(i) and G(s). To isolate functional G(s) and G(i) coupling, cells were treated with pertussis toxin or cholera toxin in doses sufficient to fully ADP-ribosylate the respective G-proteins. Following treatment with cholera toxin, agonists elicited only alpha-2C10-mediated inhibition (approximately 50%) of adenylyl cyclase while after pertussis toxin treatment, agonists elicited only alpha-2C10-mediated stimulation (approximately 60%) of adenylyl cyclase. Incubation of membranes with antisera directed against the carboxyl-terminal portion of G(s-alpha) blocked this functional alpha-2AR.G(s) coupling to the same extent as that found for beta-2AR.G(s) coupling. In addition to functional G(s) coupling, we also verified direct, agonist-dependent, physical coupling of alpha-2AR to G(s-alpha). In agonist-treated membranes, an agonist-receptor-G(s-alpha) complex was immunoprecipitated with a specific alpha-2C10 antibody, and the G(s) component identified by both western blots using G(s-alpha) antibody, and cholera toxin mediated ADP-ribosylation. Due to the differences in primary amino acid structure in a number of regions of the alpha-2AR subtypes, we investigated whether G-protein coupling was subtype-selective, using UK-14304 and cells with the same alpha-2AR expression levels (approximately 5 pmol/mg). Coupling to G(i) was equivalent for alpha-2C10, alpha-2C4, and alpha-2C2: 53.4 +/- 8.9% versus 54.9 +/- 1.0% versus 47.6 +/- 3.5% inhibition of adenylyl cyclase, respectively. In marked contrast, distinct differences in coupling to G(s) were found between the three alpha-2AR subtypes: stimulation of adenylyl cyclase was 57.9 +/- 6.3 % versus 30.7 +/- 1.1% versus 21.8 +/- 1.7% for alpha-2C10, alpha-2C4, and alpha-2C2, respectively. Thus, alpha-2AR have the potential to couple physically and functionally to both G(i) and G(s); for G(i) coupling we found a rank order of alpha-2C10 = alpha-2C4 = alpha-2C2, while for G(s) coupling, alpha-2C10 > alpha-2C4 > alpha-2C2.	DUKE UNIV,MED CTR,DEPT MED PULM & NEPHROL,POB 3177,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Duke University; Duke University			liggett, stephen b/E-7453-2012		NHLBI NIH HHS [HL45967] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL045967, R01HL045967] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CERIONE RA, 1986, J BIOL CHEM, V261, P3901; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DELEAN A, 1981, MOL PHARMACOL, V21, P5; DUMAN RS, 1986, J NEUROCHEM, V47, P800; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GUYER CA, 1990, J BIOL CHEM, V265, P17307; JONES SB, 1991, MOL PHARMACOL, V39, P239; JONES SB, 1990, J PHARMACOL EXP THER, V254, P294; JONES SVP, 1991, MOL PHARMACOL, V40, P242; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LIGGETT SB, 1989, BIOCHEM BIOPH RES CO, V165, P257, DOI 10.1016/0006-291X(89)91063-2; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LIMBIRD LE, 1985, RECEPTORS, V2, P281; LOMASNEY JW, 1991, BIOCHIM BIOPHYS ACTA, V1095, P127, DOI 10.1016/0167-4889(91)90075-9; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; RIBEIRONETO FAP, 1985, METHOD ENZYMOL, V109, P566; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRADER CD, 1987, J BIOL CHEM, V262, P16439; ULLRICH S, 1984, J BIOL CHEM, V259, P4111	31	327	331	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15795	15801						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322406				2022-12-27	WOS:A1992JG11300082
J	SCHOEPPER, B; WEGNER, A				SCHOEPPER, B; WEGNER, A			GELSOLIN BINDS TO POLYMERIC ACTIN AT A LOW RATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-GELSOLIN; DEOXYRIBONUCLEASE-I; RATE CONSTANTS; SMOOTH-MUSCLE; POINTED ENDS; BARBED ENDS; F-ACTIN; FILAMENTS; COMPLEX; CALCIUM	Association of gelsolin with actin filament subunits was investigated by the decrease of the fluorescence intensity of a 7-nitro-2-oxa-1,3-diazole (NBD) label covalently linked to gelsolin. The rate constant of this reaction was found to be 4 x 10(3) M-1 s-1. Binding of NBD-labeled gelsolin to monomeric actin proceeds at a similar low rate. The rate of association of gelsolin that was unmodified to actin filament subunits was estimated too. Unmodified gelsolin was added to a mixture of actin filaments and actin-DNase I complex. The fractions of gelsolin that bound to actin filament subunits or to actin-DNase I complex depended on the relative rates of these two competing reactions. In this way it was possible to estimate the rate constant of association of unmodified gelsolin with actin filament subunits (2 x 10(4) M-1 s-1 ). Thus, gelsolin associates with actin filament subunits at a rate that is considerably slower than diffusion-controlled and similar to the rate of binding of gelsolin to monomeric actin.	RUHR UNIV BOCHUM,INST PHYSIOL CHEM,W-4630 BOCHUM,GERMANY	Ruhr University Bochum								ABODERIN AA, 1973, BIOCHIM BIOPHYS ACTA, V328, P20, DOI 10.1016/0005-2795(73)90325-5; BRYAN J, 1984, J BIOL CHEM, V259, P7480; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; COLOMBO R, 1991, J MOL BIOL, V217, P401, DOI 10.1016/0022-2836(91)90742-O; COUE M, 1986, J BIOL CHEM, V261, P1588; COUE M, 1985, J BIOL CHEM, V260, P5033; DETMERS P, 1981, J BIOL CHEM, V256, P99; DOI Y, 1991, EUR J BIOCHEM, V199, P277, DOI 10.1111/j.1432-1033.1991.tb16121.x; EDGAR AJ, 1990, J MUSCLE RES CELL M, V11, P323, DOI 10.1007/BF01766670; HINSSEN H, 1984, FEBS LETT, V166, P90, DOI 10.1016/0014-5793(84)80051-4; ITO H, 1990, J CHROMATOGR-BIOMED, V526, P397, DOI 10.1016/S0378-4347(00)82523-2; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; KONDO H, 1976, J BIOCHEM-TOKYO, V79, P159, DOI 10.1093/oxfordjournals.jbchem.a131043; KURTH MC, 1984, J BIOL CHEM, V259, P7473; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; LIND SE, 1982, J CLIN INVEST, V69, P1384, DOI 10.1172/JCI110578; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNHERZ HG, 1980, EUR J BIOCHEM, V104, P367, DOI 10.1111/j.1432-1033.1980.tb04437.x; NISHIDA E, 1981, J BIOCHEM-TOKYO, V89, P1655, DOI 10.1093/oxfordjournals.jbchem.a133363; NODES BR, 1987, J BIOL CHEM, V262, P5422; NORBERG R, 1979, EUR J BIOCHEM, V100, P575, DOI 10.1111/j.1432-1033.1979.tb04204.x; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POPE B, 1991, FEBS LETT, V280, P70, DOI 10.1016/0014-5793(91)80206-I; PORTE F, 1986, EUR J BIOCHEM, V154, P87, DOI 10.1111/j.1432-1033.1986.tb09362.x; REES MK, 1967, J BIOL CHEM, V242, P4449; SCHOEPPER B, 1991, EUR J BIOCHEM, V202, P1127, DOI 10.1111/j.1432-1033.1991.tb16480.x; SELVE N, 1986, EUR J BIOCHEM, V155, P397, DOI 10.1111/j.1432-1033.1986.tb09504.x; SELVE N, 1986, J MOL BIOL, V187, P627, DOI 10.1016/0022-2836(86)90341-4; SELVE N, 1986, EUR J BIOCHEM, V160, P379, DOI 10.1111/j.1432-1033.1986.tb09982.x; SELVE N, 1987, EUR J BIOCHEM, V168, P111, DOI 10.1111/j.1432-1033.1987.tb13394.x; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; WEBER A, 1991, BIOCHEMISTRY-US, V30, P9327, DOI 10.1021/bi00102a027; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3; WEIGT C, 1990, FEBS LETT, V260, P266, DOI 10.1016/0014-5793(90)80119-4; WEIGT C, 1991, BIOCHEMISTRY-US, V30, P10700, DOI 10.1021/bi00108a014; WOODRUM DT, 1975, J CELL BIOL, V67, P231, DOI 10.1083/jcb.67.1.231; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0	38	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13924	13927						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321131				2022-12-27	WOS:A1992JD32500024
J	CHOI, EJ; WONG, ST; HINDS, TR; STORM, DR				CHOI, EJ; WONG, ST; HINDS, TR; STORM, DR			CALCIUM AND MUSCARINIC AGONIST STIMULATION OF TYPE-I ADENYLYLCYCLASE IN WHOLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SENSITIVE ADENYLATE-CYCLASE; CALMODULIN; RECEPTOR; ASSAY; ACID	The type I adenylylcyclase which was originally purified and cloned from bovine brain is stimulated by Ca2+ and calmodulin in vitro. Although it has been proposed that this enzyme may couple elevations in intracellular Ca2+ to increases in cAMP in whole cells, this has not been demonstrated in vivo. In this study, the type I adenylylcyclase was expressed in human 293 cells, and the influence of extracellular Ca2+ and Ca2+ ionophore on intracellular cAMP levels was examined. The cAMP levels of control cells were unaffected by Ca2+ and A23187. In contrast, intracellular cAMP in 293 cells expressing type I adenylylcyclase was markedly elevated by addition of A23187 and extracellular Ca2+. In the presence of forskolin, the muscarinic agonist carbachol also increased cAMP in 293 cells expressing the type I adenylylcyclase. These data indicate that the type I adenylylcyclase can be stimulated by Ca2+ in vivo, and that muscarinic agonists may indirectly stimulate the enzyme by increasing intracellular free Ca2+.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NINDS NIH HHS [NS 20498] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020498] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEUNG WY, 1982, HDB EXP PHARM, V58, P301; FELDER CC, 1989, J BIOL CHEM, V264, P20356; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; HASSID A, 1986, AM J PHYSIOL, V251, pC681, DOI 10.1152/ajpcell.1986.251.5.C681; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; MINOCHERHOMJEE AEVM, 1987, BIOCHEMISTRY-US, V26, P4444, DOI 10.1021/bi00388a038; OLIANAS MC, 1991, J PHARMACOL EXP THER, V259, P673; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; TANG WJ, 1991, J BIOL CHEM, V266, P8595; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; YEAGER RE, 1986, J NEUROCHEM, V47, P139	18	91	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12440	12442						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1319996				2022-12-27	WOS:A1992HZ48300013
J	VANLEEUWEN, JPTM; BIRKENHAGER, JC; VANDENBEMD, GJCM; BUURMAN, CJ; STAAL, A; BOS, MP; POLS, HAP				VANLEEUWEN, JPTM; BIRKENHAGER, JC; VANDENBEMD, GJCM; BUURMAN, CJ; STAAL, A; BOS, MP; POLS, HAP			EVIDENCE FOR THE FUNCTIONAL INVOLVEMENT OF PROTEIN-KINASE-C IN THE ACTION OF 1,25-DIHYDROXYVITAMIN-D(3) IN BONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTORS; OSTEOBLAST-LIKE CELLS; CALCIUM-UPTAKE; UP-REGULATION; METABOLITES; BINDING; INVITRO; "1-ALPHA,25-DIHYDROXYCHOLECALCIFEROL; STAUROSPORINE; PURIFICATION	In the present study the involvement of protein kinase C in the action of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) on osteoblast-like cells and in the stimulation of in vitro bone resorption by 1,25(OH)2D3 was examined. Incubation for 24 h with 1,25(OH)2D3 potently stimulated osteocalcin synthesis by ROS 17/2.8 cells. This stimulation was inhibited (30-70% inhibition) by 25-mu-M of the protein kinase C (PKC) inhibitors 1-O-hexadecyl-2-O-methyl-rac-glycerol (AMG) and sphingosine without affecting basal osteocalcin synthesis. 1,25(OH)2D3-stimulated osteocalcin secretion by nontransformed isolated fetal rat osteoblasts was also inhibited (30-55%) by AMG. Also, AMG inhibited 10(-9) M 1,25(OH)2D3-induced up-regulation of vitamin D receptor in ROS 17/2.8 cells. Activation of PKC with phorbol 12-myristate 13-acetate (PMA) did not cause an increase in osteocalcin secretion, while only a small increase in cellular content of osteocalcin in ROS 17/2.8 cells was observed. Addition of PMA together with 1,25(OH)2D3 did not change the response to 1,25(OH)2D3. The PKC inhibitors were not toxic for the cells. 1,25(OH)2D3 did not stimulate diacylglycerol production in ROS 17/2.8 cells up to 5 min after administration. However, 4- and 24-h incubation with 10 nM 1,25(OH)2D3 increased phorbol ester binding in ROS 17/2.8 cells. 1,25(OH)2D3 potently stimulated bone resorption after 3 and 6 days of culture in fetal mouse long bones and calvaria. Both the PKC inhibitors AMG (25-mu-M) and staurosporine (50 nM) strongly inhibited (60-86% inhibition) 1,25(OH)2D3-stimulated bone resorption without affecting basal Ca-45 release. These effects were not due to a cytotoxic effect of both PKC inhibitors. Nor is it likely that the effects of AMG and staurosporine are due to inhibition of cell proliferation as hydroxyurea did not affect 1,25(OH)2D3-stimulated bone resorption. The inhibition of 1,25(OH)2D3-stimulated bone resorption by PKC inhibitors suggests that besides osteocalcin synthesis PKC is also involved in other responses of 1,25(OH)2D3 in bone. 1,25(OH)2D3 does not directly activate PKC via an increase in diacylglycerol production but more likely via an increase in PKC. Together, the present study demonstrates a functional involvement of PKC in the action of 1,25(OH)2D3 in bone and bone cells which may have consequences for the development of 1,25(OH)2D3 analogs, e.g. with less hypercalcemic and relatively more antiproliferative activity.	LAB CELL BIOL & HISTOL, 2333 AA LEIDEN, NETHERLANDS		VANLEEUWEN, JPTM (corresponding author), ERASMUS UNIV, DEPT INTERNAL MED 3, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.		van Leeuwen, Johannes/D-5015-2014	van Leeuwen, Johannes/0000-0002-2282-4006				BARSONY J, 1988, P NATL ACAD SCI USA, V85, P1223, DOI 10.1073/pnas.85.4.1223; BERDEL WE, 1985, PHOSPHOLIPIDS CELLUL, V2, P41; BOONEKAMP PM, 1985, BONE, V6, P37, DOI 10.1016/8756-3282(85)90405-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGER EH, 1982, J EXP MED, V156, P1604, DOI 10.1084/jem.156.6.1604; CHEN TL, 1979, J BIOL CHEM, V254, P7491; CIVITELLI R, 1990, ENDOCRINOLOGY, V127, P2253, DOI 10.1210/endo-127-5-2253; COHN DV, 1979, SKELETAL RES, P3; DEBOLAND AR, 1987, ENDOCRINOLOGY, V120, P1858, DOI 10.1210/endo-120-5-1858; DREHER ML, 1988, TRENDS PHARMACOL SCI, V9, P114, DOI 10.1016/0165-6147(88)90184-8; EISMAN JA, 1989, J CELL PHYSIOL, V138, P611, DOI 10.1002/jcp.1041380323; FARACHCARSON MC, 1991, ENDOCRINOLOGY, V129, P1876, DOI 10.1210/endo-129-4-1876; FELDMAN D, 1979, J BIOL CHEM, V254, P378; FRAMPTON RJ, 1983, CANCER RES, V43, P4443; GAMETCHU B, 1991, STEROIDS, V56, P411, DOI 10.1016/0039-128X(91)90029-U; GAMETCHU B, 1991, STEROIDS, V56, P402, DOI 10.1016/0039-128X(91)90028-T; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; JAKEN S, 1987, METHOD ENZYMOL, V141, P275; JAKEN S, 1987, P NATL ACAD SCI USA, V84, P4418, DOI 10.1073/pnas.84.13.4418; JOHNSONWINT B, 1982, ANAL BIOCHEM, V122, P338, DOI 10.1016/0003-2697(82)90292-5; LIEBERHERR M, 1989, J BIOL CHEM, V264, P20403; LIEBERHERR M, 1987, J BIOL CHEM, V262, P13168; MARTELL RE, 1987, J BIOL CHEM, V262, P5570; MASMOUDI A, 1989, J BIOL CHEM, V264, P1172; MEZZETTI G, 1988, ENDOCRINOLOGY, V122, P389, DOI 10.1210/endo-122-2-389; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAOR Z, 1988, MOL ENDOCRINOL, V2, P1043, DOI 10.1210/mend-2-11-1043; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; NORMAN AW, 1990, NATO ADV SCI I A-LIF, V184, P93; OBEID LM, 1990, J BIOL CHEM, V265, P2370; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; PARTRIDGE NC, 1980, FEBS LETT, V115, P139, DOI 10.1016/0014-5793(80)80744-7; PAUL DC, 1990, J BONE MINER RES, V6, pS148; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; POLS HAP, 1990, J STEROID BIOCHEM, V37, P873, DOI 10.1016/0960-0760(90)90435-N; POLS HAP, 1988, BIOCHIM BIOPHYS ACTA, V970, P122, DOI 10.1016/0167-4889(88)90170-X; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAISZ LG, 1965, J CLIN INVEST, V44, P103, DOI 10.1172/JCI105117; REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SCHEVEN BAA, 1986, ANAT RECORD, V214, P418, DOI 10.1002/ar.1092140413; SIMPSON RU, 1989, J BIOL CHEM, V264, P19710; SU Y, 1990, J BONE MINER RES, V5, pS2; SU Y, 1990, J BONE MINER RES, V5, P60; Suda T., 1986, BONE MINERAL RES, V4, P1; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; VANBLITTERSWIJK WJ, 1987, LIPIDS, V22, P842, DOI 10.1007/BF02535541; VANLEEUWEN JPTM, 1990, FEBS LETT, V270, P165, DOI 10.1016/0014-5793(90)81258-P; VANLEEUWEN JPTM, 1992, ENDOCRINOLOGY, V130, P2259, DOI 10.1210/en.130.4.2259; VANLEEUWEN JPTM, 1990, CELL CALCIUM, V11, P281, DOI 10.1016/0143-4160(90)90005-F; VERHAEGHE J, 1989, J ENDOCRINOL, V120, P143, DOI 10.1677/joe.0.1200143	52	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12562	12569						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1320001				2022-12-27	WOS:A1992HZ48300031
J	LIU, QY; SUMMERS, WC				LIU, QY; SUMMERS, WC			IDENTIFICATION OF THE 12-O-TETRADECANOYLPHORBOL-13-ACETATE-RESPONSIVE ENHANCER OF THE MS GENE OF THE EPSTEIN-BARR-VIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN; TRANS; EXPRESSION; PROMOTER; BZLF1; TRANSCRIPTION; ACTIVATOR; ELEMENTS; BMLF1; DNA	We previously located two 12-O-tetradecanoylphorbol-13-acetate (TPA)-responsive enhancers, MSTRE-I and MSTRE-II, in the upstream sequence of the MS gene of Epstein-Barr virus (Liu, Q., and Summers, W. C. (1989) J. Virol. 63, 5062-5068). The core sequence of the MSTRE-I enhancer is now determined to be between -718 and -708 of the upstream sequence of the MS gene. The activity of the enhancer is also sensitive to its immediate surrounding sequence on either side. A single copy of a 30-base pair (bp) fragment containing the MSTRE-I sequence was able to confer TPA responsiveness upon the MS promoter even in the absence of an AP-1 binding site. Multiple tandem copies of this 30-bp fragment, regardless of their relative orientations to each other, could function synergistically to enhance the MS promoter activity. At least two copies of the 30-bp fragment were required to bestow TPA induction upon the thymidine kinase gene promoter of herpes simplex virus type 1. The MSTRE-I sequence could also be bound by a Fos-GCN4 chimeric protein but with an affinity much lower than that between the chimeric protein and the AP-1 binding site. This MSTRE-I region has strong homology to one of the TPA-responsive elements (the ZII domain) in the upstream sequence of the EBV BZLF1 gene. In addition, a putative negative regulatory region or silencer was found immediately downstream of the MSTRE-I enhancer. This potential silencer region contains a 14-bp sequence that is homologous to the silencer consensus sequence of the BZLF1 gene. Therefore, the regulation of the MS gene may share the same pathway with the immediate early gene BZLF1.	YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT THERAPEUT RADIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University					NCI NIH HHS [CA39238] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA039238] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIZUMI K, 1989, MOL CELL BIOL, V9, P4032; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BIGGIN M, 1987, J VIROL, V61, P3120, DOI 10.1128/JVI.61.10.3120-3132.1987; BUISSON M, 1989, J VIROL, V63, P5276, DOI 10.1128/JVI.63.12.5276-5284.1989; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; CHO MS, 1985, J VIROL, V56, P852, DOI 10.1128/JVI.56.3.852-859.1985; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; FLEMINGTON E, 1990, J VIROL, V64, P1217, DOI 10.1128/JVI.64.3.1217-1226.1990; FLEMINGTON E, 1990, J VIROL, V64, P1227, DOI 10.1128/JVI.64.3.1227-1232.1990; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; KENNEY S, 1989, J VIROL, V63, P3870, DOI 10.1128/JVI.63.9.3870-3877.1989; KENNEY S, 1989, J VIROL, V63, P3878, DOI 10.1128/JVI.63.9.3878-3883.1989; LIEBERMAN PM, 1986, J VIROL, V60, P140, DOI 10.1128/JVI.60.1.140-148.1986; LIU Q, 1990, THESIS YALE U; LIU QY, 1989, J VIROL, V63, P5062, DOI 10.1128/JVI.63.12.5062-5068.1989; MANIATIS T, 1982, MOL CLONING LABORATO, P363; MARSCHALL M, 1989, J VIROL, V63, P938, DOI 10.1128/JVI.63.2.938-942.1989; OGURO MO, 1987, J VIROL, V61, P3310, DOI 10.1128/JVI.61.10.3310-3313.1987; ROONEY CM, 1989, J VIROL, V63, P3109, DOI 10.1128/JVI.63.7.3109-3116.1989; SAMBROOK J, 1990, MOL CLONING LABORATO; SAMPLE J, 1984, VIROLOGY, V139, P1, DOI 10.1016/0042-6822(84)90324-6; SAMPLE J, 1986, J VIROL, V57, P145, DOI 10.1128/JVI.57.1.145-154.1986; TAYLOR N, 1991, J VIROL, V65, P4033, DOI 10.1128/JVI.65.8.4033-4041.1991; URIER G, 1989, EMBO J, V8, P1447, DOI 10.1002/j.1460-2075.1989.tb03527.x; WONG KM, 1989, VIROLOGY, V168, P101, DOI 10.1016/0042-6822(89)90408-X; WONG KM, 1986, J VIROL, V60, P149, DOI 10.1128/JVI.60.1.149-156.1986	27	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12049	12054						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1318308				2022-12-27	WOS:A1992HY94700062
J	SEBAG, M; HENDERSON, J; RHIM, J; KREMER, R				SEBAG, M; HENDERSON, J; RHIM, J; KREMER, R			RELATIVE RESISTANCE TO 1,25-DIHYDROXYVITAMIN-D3 IN A KERATINOCYTE MODEL OF TUMOR PROGRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC GENE; FACTOR-ALPHA; CELLS; DIFFERENTIATION; RECEPTOR; GROWTH; DNA; INHIBITION; EXPRESSION; ONCOGENES	We have examined the effect of 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) on mitogen-stimulated growth and on c-myc proto-oncogene expression in a keratinocyte model of tumor progression. A dose-dependent inhibition of cell growth by 1,25-(OH)2D3 was demonstrated in both established (HPK1A) and malignant (HPK1A-ras) cells. However, this inhibition was observed with the addition of 1,25-(OH)2D3 at a higher concentration in HPK1A-ras cells than in HPK1A cells. Cell cycle analysis revealed a blockage of the normal progression of the cell cycle from G0 to S phase in the presence of 1,25-(OH)2D3. A higher concentration of 1,25-(OH)2D3 was required in HPK1A-ras cells to overcome the mitogen-stimulated progression into S phase, when compared with HPK1A cells. Analysis of c-myc messenger RNA revealed a strong inhibition of its expression at early time points with higher concentrations of 1,25-(OH)2D3 being required to obtain an inhibition in HPK1A-ras cells similar to that obtained in HPK1A cells. 1,25-(OH)2D3 receptor characterization by sucrose gradient analysis and equilibrium binding demonstrated the presence of a single 3.7 S protein with similar receptor numbers and affinity in both cell lines. These observations therefore demonstrate that an alteration of the growth inhibitory response to 1,25-(OH)2D3 occurs when keratinocytes acquire the malignant phenotype and suggest that the alteration lies beyond the interaction of the ligand with its receptor. In addition, relative resistance to 1,25-(OH)2D3 was also observed in the expression of the cell-cycle associated oncogene c-myc. These studies may therefore have important implications in vivo in the development and growth of epithelial cell cancers.	MCGILL UNIV, DEPT MED, MONTREAL H3A 1A1, QUEBEC, CANADA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20812 USA	McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Kremer, Richard/0000-0002-7053-2139				ALLENHOFFMANN BL, 1991, 1ST P WORKSH NEOPL T, P25; ALT FW, 1986, MOL BIOL HOMO SAPIEN, V6, P931; BARSHAVIT Z, 1983, P NATL ACAD SCI-BIOL, V80, P5907, DOI 10.1073/pnas.80.19.5907; BEEBE JS, 1991, MOL ENDOCRINOL, V5, P85, DOI 10.1210/mend-5-1-85; BIKLE DD, 1986, BIOCHEMISTRY-US, V25, P1545, DOI 10.1021/bi00355a013; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; CLEMENS TL, 1981, FEBS LETT, V134, P203, DOI 10.1016/0014-5793(81)80602-3; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DURST M, 1987, ONCOGENE, V1, P251; DURST M, 1989, VIROLOGY, V173, P767, DOI 10.1016/0042-6822(89)90595-3; FELDMAN D, 1980, J CLIN ENDOCR METAB, V51, P1463, DOI 10.1210/jcem-51-6-1463; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; HENDERSON J, 1991, CANCER RES, V51, P6521; HOSOMI J, 1983, ENDOCRINOLOGY, V113, P1950, DOI 10.1210/endo-113-6-1950; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; KATAKAMI Y, 1988, BIOCHEM BIOPH RES CO, V152, P1151, DOI 10.1016/S0006-291X(88)80405-4; KREMER R, 1989, ENDOCRINOLOGY, V125, P935, DOI 10.1210/endo-125-2-935; KREMER R, 1991, J CLIN INVEST, V87, P884, DOI 10.1172/JCI115094; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MALLOY PJ, 1989, J CLIN ENDOCR METAB, V68, P263, DOI 10.1210/jcem-68-2-263; MATSUMOTO K, 1990, BIOCHEM BIOPH RES CO, V166, P916, DOI 10.1016/0006-291X(90)90898-W; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Peto R, 1977, ORIGINS HUMAN CANC C, P1403; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PIKE JW, 1985, BIOCHEM BIOPH RES CO, V131, P378, DOI 10.1016/0006-291X(85)91813-3; PILLAI S, 1988, J BIOL CHEM, V263, P5390; RIGBY WFC, 1984, J CLIN INVEST, V74, P1451, DOI 10.1172/JCI111557; SCUDIERO DA, 1988, CANCER RES, V48, P4827; SHILO BZ, 1981, P NATL ACAD SCI-BIOL, V78, P6789, DOI 10.1073/pnas.78.11.6789; SIMPSON RU, 1980, P NATL ACAD SCI-BIOL, V77, P5822, DOI 10.1073/pnas.77.10.5822; SIMPSON RU, 1987, J BIOL CHEM, V262, P4104; SMITH EL, 1986, J INVEST DERMATOL, V86, P709, DOI 10.1111/1523-1747.ep12276343; TRAMONTANO D, 1986, J BIOL CHEM, V261, P3919; VINDELOV LL, 1977, VIRCHOWS ARCH B, V24, P227; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WOODWORTH CD, 1991, 1ST P WORKSH NEOPL T, P153	41	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12162	12167						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1318311				2022-12-27	WOS:A1992HY94700076
J	FURUHASHI, K; HATANO, S; ANDO, S; NISHIZAWA, K; INAGAKI, M				FURUHASHI, K; HATANO, S; ANDO, S; NISHIZAWA, K; INAGAKI, M			PHOSPHORYLATION BY ACTIN KINASE OF THE POINTED END DOMAIN ON THE ACTIN MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NUCLEOTIDE-SEQUENCE; BINDING PROTEINS; SKELETAL-MUSCLE; BARBED END; F-ACTIN; FRAGMIN; POLYMERIZATION; GELSOLIN; FILAMENT	Fragmin from plasmodium of Physarum polycephalum binds G-actin and severs F-actin in the presence of Ca2+ over 10(-6) M. The fragmin-actin complex consisting of fragmin and G-actin nucleates actin polymerization and caps the barbed (fast growing) end of F-actin, regardless of the concentrations of Ca2+, and the actin filaments are shortened. Actin kinase purified from plasmodium abolishes the nucleation and capping activities of the complex by phosphorylating actin of the fragmin-actin complex (Furuhashi, K., and Hatano, S. (1990) J. Cell. Biol. 111, 1081-1087). This inactivation of the complex leads to production of long actin filaments. We obtained evidence that Physarum actin is phosphorylated by actin kinase at Thr-201, and probably at Thr-202 and/or Thr-203, with 1 mol of phosphate distributed among them. This finding raises the possibility that the site of phosphorylation, Thr-201 to Thr-203, is positioned on the pointed (slow growing) end domain of the actin molecule, because growth of actin filaments from the fragmin-actin complex occurs only from the pointed end. These observations are consistent with a model of the three-dimensional structure of G-actin. Inactivation of the fragmin-actin complex may follow phosphorylation of the pointed end domain of actin.	AICHI CANC CTR,RES INST,EXPTL RADIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Aichi Cancer Center	FURUHASHI, K (corresponding author), NAGOYA UNIV,SCH SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA 46401,JAPAN.		Inagaki, Masaki/B-9920-2016					BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; COLLINS JH, 1975, J BIOL CHEM, V250, P5915; COOPER AD, 1982, NUCLEIC ACIDS RES, V10, P4081, DOI 10.1093/nar/10.13.4081; COOPER JA, 1987, J CELL BIOL, V104, P491, DOI 10.1083/jcb.104.3.491; ELZINGA M, 1984, P NATL ACAD SCI-BIOL, V81, P6599, DOI 10.1073/pnas.81.21.6599; FURUHASHI K, 1989, J BIOCHEM-TOKYO, V106, P311, DOI 10.1093/oxfordjournals.jbchem.a122850; FURUHASHI K, 1990, J CELL BIOL, V111, P1081, DOI 10.1083/jcb.111.3.1081; GIFFARD RG, 1982, J CELL BIOL, V93, P205; HASEGAWA T, 1980, BIOCHEMISTRY-US, V19, P2677, DOI 10.1021/bi00553a021; HATANO S, 1977, J BIOCHEM, V82, P201, DOI 10.1093/oxfordjournals.jbchem.a131670; HATANO S, 1986, MOL BIOL PHYSARUM PO, P165; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; NELLEN W, 1982, J MOL BIOL, V159, P1, DOI 10.1016/0022-2836(82)90028-6; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; ROMANS P, 1985, J MOL BIOL, V186, P321, DOI 10.1016/0022-2836(85)90108-1; SONOBE S, 1986, J BIOL CHEM, V261, P4837; SUGINO H, 1982, CELL MOTIL CYTOSKEL, V2, P457, DOI 10.1002/cm.970020505; SUTOH K, 1986, BIOCHEMISTRY-US, V25, P435, DOI 10.1021/bi00350a024; TAKAGI T, 1990, EUR J BIOCHEM, V192, P777, DOI 10.1111/j.1432-1033.1990.tb19289.x; VANDEKERCKHOVE J, 1980, NATURE, V284, P475, DOI 10.1038/284475a0; VANDEKERCKHOVE J, 1979, DIFFERENTIATION, V14, P123, DOI 10.1111/j.1432-0436.1979.tb01021.x; VANDEKERCKHOVE J, 1984, J MOL BIOL, V172, P141, DOI 10.1016/0022-2836(84)90418-2; VANDEKERCKHOVE J, 1978, NATURE, V276, P720, DOI 10.1038/276720a0; WANG YH, 1986, J BIOL CHEM, V261, P6909; WEEDS A, 1982, NATURE, V296, P811, DOI 10.1038/296811a0; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0	33	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9326	9330						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1315751				2022-12-27	WOS:A1992HR85400095
J	THIGPEN, AE; RUSSELL, DW				THIGPEN, AE; RUSSELL, DW			4-AMINO ACID SEGMENT IN STEROID 5-ALPHA-REDUCTASE-1 CONFERS SENSITIVITY TO FINASTERIDE, A COMPETITIVE INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BENIGN PROSTATIC HYPERPLASIA; LDL RECEPTOR; RAT; BINDING; ENZYME; MUTAGENESIS; EXPRESSION; CLONING	The 4-azasteroid 17-beta-(N-t-butyl)carbamoyl-4-aza-5-alpha-androst-1-en-3-one (finasteride) is 100-fold more potent as a competitive inhibitor of the rat NADPH:DELTA-4-3-oxosteroid-5-alpha-oxidoreductase (steroid 5-alpha-reductase) type 1 enzyme (K(i) = 3-5 nM) than of the human type 1 enzyme (K(i) greater-than-or-equal-to 300 nM). In this study, we exploit this differential sensitivity to map a major determinant of finasteride sensitivity in steroid 5-alpha-reductase. Chimeric steroid 5-alpha-reductase cDNAs composed of different combinations of rat and human exon sequences were created by genetic engineering, expressed in human embryonic kidney 293 cells, and assayed for their sensitivity to finasteride. Hybrid proteins containing sequences encoded by rat exon 1 were found to be as sensitive to finasteride as the parental enzyme. The exchange of progressively smaller protein segments encoded within exon 1 identified a tetrapeptide sequence (Val-Ser-Ile-Val) in the rat enzyme that conferred sensitivity to finasteride. The analogous sequence in the human enzyme (Ala-Val-Phe-Ala) conferred partial resistance to the drug. Finasteride was a competitive inhibitor of the native and all chimeric enzymes tested, suggesting that the tetrapeptide segments form a portion of the substrate-binding domain of steroid 5-alpha-reductase.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,5323 HARRY HINES BLVD,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Russell, David/0000-0002-0277-403X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043753] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07504] Funding Source: Medline; NIGMS NIH HHS [GM43753] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1990, P NATL ACAD SCI USA, V87, P3640, DOI 10.1073/pnas.87.10.3640; ANDERSSON S, 1989, J BIOL CHEM, V264, P16249; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDERSSON S, 1991, NATURE, V354, P159, DOI 10.1038/354159a0; [Anonymous], METABOLIC BASIS INHE; BROOKS JR, 1981, ENDOCRINOLOGY, V109, P830, DOI 10.1210/endo-109-3-830; IMPERATOMCGINLEY J, 1985, ENDOCRINOLOGY, V116, P807, DOI 10.1210/endo-116-2-807; JENKINS EP, 1992, J CLIN INVEST, V89, P293, DOI 10.1172/JCI115574; JENKINS EP, 1991, GENOMICS, V11, P1102, DOI 10.1016/0888-7543(91)90038-G; KOVACS WJ, 1983, ENDOCRINOLOGY, V113, P1574, DOI 10.1210/endo-113-5-1574; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEVY MA, 1991, BIOORG CHEM, V19, P245, DOI 10.1016/0045-2068(91)90050-Y; LIANG T, 1983, ENDOCRINOLOGY, V112, P1460, DOI 10.1210/endo-112-4-1460; LIANG T, 1985, ENDOCRINOLOGY, V117, P571, DOI 10.1210/endo-117-2-571; LIANG T, 1981, J BIOL CHEM, V256, P7998; METCALF BW, 1989, TRENDS PHARMACOL SCI, V10, P491, DOI 10.1016/0165-6147(89)90048-5; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; VERMEULEN A, 1989, PROSTATE, V14, P45, DOI 10.1002/pros.2990140106; WILSON JD, 1980, AM J MED, V68, P745, DOI 10.1016/0002-9343(80)90267-3; WILSON JD, 1975, HDB PHYSL 7, V5, P491; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	23	95	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8577	8583						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314830				2022-12-27	WOS:A1992HQ18500093
J	RYTOMAA, M; MUSTONEN, P; KINNUNEN, PKJ				RYTOMAA, M; MUSTONEN, P; KINNUNEN, PKJ			REVERSIBLE, NONIONIC, AND PH-DEPENDENT ASSOCIATION OF CYTOCHROME-C WITH CARDIOLIPIN-PHOSPHATIDYLCHOLINE LIPOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; CONFORMATIONAL-CHANGES; FERRICYTOCHROME-C; ESCHERICHIA-COLI; DNAA PROTEIN; MITOCHONDRIAL-MEMBRANES; PHOSPHOLIPID MONOLAYERS; CHARGED INTERFACES; INITIATION PROTEIN; APOCYTOCHROME-C	Membrane association of cytochrome c (cyt c) was monitored by the efficiency of resonance energy transfer from a pyrene-fatty acid containing phospholipid derivative (1-palmitoyl-2[6-(pyren-1-yl)]hexanoyl-sn-glycero-3-phosphocholine (PPHPC)) to the heme of cyt c. Liposomes consisted of 85 mol% egg phosphatidylcholine (egg PC), 10 mol% cardiolipin, and 5 mol% PPHPC. Cardiolipin was necessary for the membrane binding of cyt c over the pH range studied, from 4 to 7. In accordance with the electrostatic nature of the membrane association of cyt c at neutral pH both 2 mM MgCl2 and 80 mM NaCl dissociated cyt c from the vesicles completely. At neutral pH also adenine nucleotides in millimolar concentrations were able to displace cyt c from liposomes, their efficiency decreasing in the sequence ATP > ADP > AMP. In addition, both CTP and GTP were equally effective as ATP. The detachment of cyt c from liposomes by nucleotides is likely to result from a competition between cardiolipin and the nucleotides for a common binding site in cyt c. When pH was decreased to 4 there was a small yet significant increase in the apparent affinity of cyt c to cardiolipin containing liposomes. Notably, at pH 4 the above nucleotides as well as NaCl and MgCl2 were no longer able to dissociate cyt c and, on the contrary, they slightly enhanced the quenching of pyrene fluorescence by cyt c. The above results do suggest that the membrane association of cyt c at acidic pH was nonionic and presumably due to hydrogen bonding. The pH-dependent binding of cyt c to membranes was fully reversible. Accordingly, in the presence of sufficient concentrations of either nucleotides or salts rapid detachment and membrane association of cyt c could be induced by varying pH between neutral and acidic values, respectively.	UNIV HELSINKI,DEPT MED CHEM,SILTAVUORENPENGER 10A,SF-00170 HELSINKI 17,FINLAND	University of Helsinki								BROWN LR, 1977, BIOCHIM BIOPHYS ACTA, V468, P389, DOI 10.1016/0005-2736(77)90290-5; DEJONGH HHJ, 1990, BIOCHIM BIOPHYS ACTA, V1029, P105, DOI 10.1016/0005-2736(90)90442-Q; DEMEL RA, 1989, J BIOL CHEM, V264, P3988; DICKERSON RE, 1971, J BIOL CHEM, V246, P1511; FERGUSONMILLER S, 1976, J BIOL CHEM, V251, P1104; HAVERSTICK DM, 1989, BIOPHYS J, V55, P677, DOI 10.1016/S0006-3495(89)82866-8; HEIMBURG T, 1991, BIOCHEMISTRY-US, V30, P9084, DOI 10.1021/bi00101a025; HILDEBRANDT P, 1989, BIOCHEMISTRY-US, V28, P6710, DOI 10.1021/bi00442a026; HILDEBRANDT P, 1989, BIOCHEMISTRY-US, V28, P6722, DOI 10.1021/bi00442a027; HOCHMAN JH, 1982, P NATL ACAD SCI-BIOL, V79, P6866, DOI 10.1073/pnas.79.22.6866; JORI G, 1974, PHOTOCHEM PHOTOBIOL, V19, P337, DOI 10.1111/j.1751-1097.1974.tb06521.x; KAIHOVAARA P, 1991, BIOCHEMISTRY-US, V30, P8380, DOI 10.1021/bi00098a015; KIMELBERG HK, 1969, BIOCHEM BIOPH RES CO, V34, P784, DOI 10.1016/0006-291X(69)90248-4; KONTTILA R, 1988, BIOCHEMISTRY-US, V27, P7443, DOI 10.1021/bi00419a040; KOZARAC Z, 1988, FEBS LETT, V229, P372, DOI 10.1016/0014-5793(88)81159-1; LEE S, 1989, ARCH BIOCHEM BIOPHYS, V271, P188, DOI 10.1016/0003-9861(89)90269-5; MACDONALD PM, 1987, BIOCHEMISTRY-US, V26, P6292, DOI 10.1021/bi00393a050; MITCHELL P, 1983, FEBS LETT, V151, P167, DOI 10.1016/0014-5793(83)80063-5; MOSIOR M, 1992, BIOCHEMISTRY-US, V31, P1767, DOI 10.1021/bi00121a026; MUGA A, 1991, BIOCHEMISTRY-US, V30, P7219, DOI 10.1021/bi00243a025; MUSTONEN P, 1987, BIOCHEMISTRY-US, V26, P2991, DOI 10.1021/bi00385a006; NICHOLLS P, 1974, BIOCHIM BIOPHYS ACTA, V346, P261, DOI 10.1016/0304-4173(74)90003-2; NICHOLLS P, 1973, T BIOCHEM SOC, V1, P372; QUINN PJ, 1969, BIOCHEM J, V115, P65, DOI 10.1042/bj1150065; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SJOSTRAND FS, 1983, CONCEPTS MEMBRANE ST, V1, P83; SOUSSI B, 1990, BIOCHEM J, V265, P227, DOI 10.1042/bj2650227; SPECK SH, 1983, FEBS LETT, V164, P379, DOI 10.1016/0014-5793(83)80321-4; SPOONER PJR, 1991, BIOCHEMISTRY-US, V30, P3871, DOI 10.1021/bi00230a010; STEINEMANN A, 1971, J MEMBRANE BIOL, V4, P74, DOI 10.1007/BF02431963; STELLWAGEN E, 1975, BIOCHEMISTRY-US, V14, P5135, DOI 10.1021/bi00694a018; SZEBENI J, 1988, BIOCHIM BIOPHYS ACTA, V932, P153, DOI 10.1016/0005-2728(88)90150-8; VANDERKOOI J, 1973, ARCH BIOCHEM BIOPHYS, V154, P219, DOI 10.1016/0003-9861(73)90052-0; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P1456, DOI 10.1073/pnas.78.3.1456; WALTHAM MC, 1986, BIOCHIM BIOPHYS ACTA, V862, P451, DOI 10.1016/0005-2736(86)90250-6; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202	38	151	153	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22243	22248						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331048				2022-12-27	WOS:A1992JW71900041
J	ROSS, TS; MAJERUS, PW				ROSS, TS; MAJERUS, PW			IDENTIFICATION OF A PHOSPHODIESTERASE THAT CONVERTS INOSITOL CYCLIC 1/2-PHOSPHATE TO INOSITOL 2-PHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-2-CYCLIC PHOSPHATE 2-PHOSPHOHYDROLASE; 1,2-CYCLIC PHOSPHATE; 2-INOSITOLPHOSPHOHYDROLASE; PHOSPHOLIPIDS	Inositol 2-phosphate (Ins(2)P) has been identified in several cell types. The cellular levels of Ins(2)P appear to be directly correlated with the levels of inositol 1:2-cyclic phosphate (cIns(1:2)P) (Ross, T. S., Wang, F. P., and Majerus, P. W. (1992) J. Biol. Chem. 267, 19919-19923). In this study we have detected an enzyme in extracts from CV-1 cells and rat cerebellum that converts cIns(1:2)P to Ins(2)P and inositol I-phosphate. This enzyme (designated cyclic hydrolase II) is not the same protein previously designated cIns(1:2)P 2-phosphohydrolase (cyclic hydrolase I). The products, heat inactivation curves, pH optima, and metal dependence of these two activities are different, and the two activities were separated by DEAE and gel filtration chromatography. Mixing of cyclic hydrolase I with cyclic hydrolase II does not effect the activity of either. The K(m) of the CV-1 cyclic hydrolase II for D-cIns(1:2)P is 10 muM. The enzyme is approximately 55 kDa as estimated by gel filtration analysis in the presence of sodium chloride and 120 kDa in its absence.			ROSS, TS (corresponding author), WASHINGTON UNIV,DIV HEMATOL ONCOL,ST LOUIS,MO 63130, USA.			Ross, Theodora/0000-0002-9166-1802	NHLBI NIH HHS [HLBI 14147, HLBI 16634] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R37HL016634, R01HL016634] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMES BN, 1960, J BIOL CHEM, V235, P769; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; DAWSON RMC, 1973, BIOCHEM J, V134, P59, DOI 10.1042/bj1340059; DAWSON RMC, 1972, BIOCHEM J, V127, P113, DOI 10.1042/bj1270113; EISENBER.F, 1967, J BIOL CHEM, V242, P1375; Ikezawa H, 1981, METHODS ENZYMOLOGY C, P731, DOI [10.1016/0076-6879(81)71086-3, DOI 10.1016/0076-6879(81)71086-3]; KIM JW, 1989, BIOCHEM BIOPH RES CO, V163, P177, DOI 10.1016/0006-291X(89)92117-7; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; RAGAN CI, 1988, BIOCHEM J, V249, P143, DOI 10.1042/bj2490143; ROSS TS, 1992, J BIOL CHEM, V267, P19919; ROSS TS, 1991, J BIOL CHEM, V266, P9086; ROSS TS, 1991, J BIOL CHEM, V266, P851; ROSS TS, 1986, J BIOL CHEM, V261, P1119; ROSS TS, 1990, SCIENCE, V248, P605, DOI 10.1126/science.2159184	16	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19924	19928						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328187				2022-12-27	WOS:A1992JR85800031
J	NEUBERT, TA; JOHNSON, RS; HURLEY, JB; WALSH, KA				NEUBERT, TA; JOHNSON, RS; HURLEY, JB; WALSH, KA			THE ROD TRANSDUCIN ALPHA SUBUNIT AMINO TERMINUS IS HETEROGENEOUSLY FATTY ACYLATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEIN; GAMMA-SUBUNIT; ACID SEQUENCE; PHOTORECEPTOR-MEMBRANES; MASS-SPECTROMETRY; OUTER SEGMENTS; CDNA SEQUENCE; MYRISTOYLATION	Rod transducin (T(r)), a heterotrimeric GTP-binding protein composed of alpha, beta, and gamma-subunits, couples photolysis of rhodopsin to the activation of cyclic GMP phosphodiesterase in the vertebrate visual signal transduction cascade. To determine if T-alpha(r) is covalently modified, we analyzed tryptic fragments of bovine retinal T-alpha(r) using electrospray mass spectrometry, liquid chromatography/mass spectrometry, tandem mass spectrometry, and gas chromatography. A novel heterogeneous fatty acylation was detected at the NH2 terminus. Four types of NH2-terminal tryptic fragments of T-alpha(r) were isolated, and each contained either a lauroyl (C12:0), myristoyl (C14:0), (cis-DELTA-5)-tetradecaenoyl (C14:1) or (cis,cis-DELTA-5,DELTA-8)-tetradecadienoyl (C14:2) fatty acyl residue amide-linked to the NH2-terminal glycine residue. NH2-terminal fatty acylation does not anchor T-alpha(r) permanently in the membrane, since T-alpha(r) used in these experiments was eluted without detergent from rod outer segment membranes.	UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NATIONAL EYE INSTITUTE [R01EY006641] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040990] Funding Source: NIH RePORTER; NCRR NIH HHS [RR0553] Funding Source: Medline; NEI NIH HHS [R01 EY006641, EY06641] Funding Source: Medline; NHLBI NIH HHS [HL40990] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HO YK, 1989, CURR TOP CELL REGUL, V30, P171; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LIPKIN VM, 1987, RETINAL PROTEINS, P39; McConnell D.G., 1984, FED PROC, V43, P1585; MCDOWELL JH, 1977, BIOCHEMISTRY-US, V16, P4054, DOI 10.1021/bi00637a018; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; OVCHINNIKOV YA, 1985, FEBS LETT, V179, P107, DOI 10.1016/0014-5793(85)80201-5; PAPPAS JJ, 1966, TETRAHEDRON LETT, P4273; SANFORD J, 1991, J BIOL CHEM, V266, P9570; STRYER L, 1991, J BIOL CHEM, V266, P10711; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; WENSEL T G, 1992, Biophysical Journal, V61, pA98; YAMAZAKI A, 1988, METHOD ENZYMOL, V159, P702; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P4316, DOI 10.1073/pnas.82.13.4316; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936	30	164	166	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18274	18277						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326520				2022-12-27	WOS:A1992JN50200007
J	SCIMECA, JC; NGUYEN, TT; FILLOUX, C; VANOBBERGHEN, E				SCIMECA, JC; NGUYEN, TT; FILLOUX, C; VANOBBERGHEN, E			NERVE GROWTH FACTOR-INDUCED PHOSPHORYLATION CASCADE IN PC12 PHEOCHROMOCYTOMA CELLS - ASSOCIATION OF S6 KINASE-II WITH THE MICROTUBULE-ASSOCIATED PROTEIN-KINASE, ERK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASES; TYROSINE PHOSPHORYLATION; SIGNALING COMPLEX; SWISS 3T3-CELLS; SKELETAL-MUSCLE; INSULIN; ACTIVATION; INVITRO; MECHANISM; AUTOPHOSPHORYLATION	Microtubule-associated protein (MAP) kinases form a group of serine/threonine kinases stimulated by various growth factors such as nerve growth factor (NGF) and hormones such as insulin. Interestingly, MAP kinases are thought to participate in a protein kinase cascade leading to cell growth as they have been shown to phosphorylate and activate ribosomal protein S6 kinase. To further evaluate the interactions between the different components of this cascade, we looked at the possible coprecipitation of MAP kinase activator(s) or MAP kinase substrate(s) with MAP kinase. Using antipeptides to the C terminus of the M(r) 44,000 MAP kinase, ERK1, and cell extracts from unstimulated or NGF-treated PC12 cells, we obtained in addition to MAP kinase itself coprecipitation of a protein with a M(r) in the 90,000 range. We further show that this protein is a protein kinase since it becomes phosphorylated on serine residues, after sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transfer to a polyvinylidene difluoride membrane. In vitro phosphorylation performed before sodium dodecyl sulfate-polyacrylamide gel electrophoresis demonstrates NGF-sensitive phosphorylation of this 90-kDa protein on both serine and threonine; the serine phosphorylation is likely to be due to autophosphorylation, and the threonine phosphorylation due to phosphorylation by the copurifying MAP kinase. Furthermore, immunoprecipitation of this 90-kDa protein was obtained with antibodies to S6 kinase II. Finally, using in situ chemical cross-linking, we were able to demonstrate in intact cells the occurrence of an anti-ERK1 immunoreactive species with a molecular mass of approximately 125,000 compatible with a complex between ERK1 and a 90-kDa S6 kinase. Taken together, our observations demonstrate that the 44-kDa MAP kinase is associated, in intact PC12 cells, with a protein kinase which is very likely to be S6 kinase II. In conclusion, our data represent strong evidence for a physiological role of the MAP kinase-S6 kinase cascade in PC12 cells. Finally, our antipeptides provide us with a powerful tool to search for additional physiologically relevant substrates for MAP kinase, a key integrator enzyme for growth factors and hormones.			SCIMECA, JC (corresponding author), FAC MED NICE,INSERM,U145,F-06107 NICE 2,FRANCE.		Scimeca, Jean-Claude/P-3830-2016	Scimeca, Jean-Claude/0000-0003-3773-6110				AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; HACCARD O, 1990, EUR J BIOCHEM, V192, P633, DOI 10.1111/j.1432-1033.1990.tb19270.x; HARI J, 1987, ENDOCRINOLOGY, V120, P829, DOI 10.1210/endo-120-2-829; HOSHI M, 1988, J BIOL CHEM, V263, P5396; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SCIMECA JC, 1991, BIOCHEMISTRY-US, V30, P9313, DOI 10.1021/bi00102a025; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	27	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17369	17374						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324933				2022-12-27	WOS:A1992JL05300095
J	OLDERSHAW, KA; RICHARDSON, A; TAYLOR, CW				OLDERSHAW, KA; RICHARDSON, A; TAYLOR, CW			PROLONGED EXPOSURE TO INOSITOL 1,4,5-TRISPHOSPHATE DOES NOT CAUSE INTRINSIC DESENSITIZATION OF THE INTRACELLULAR CA2+-MOBILIZING RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM RELEASE; CA-2+ RELEASE; TRISPHOSPHATE; HEPATOCYTES; CELLS; DECAVANADATE; PHOSPHATES; INHIBITION; STORES	The rapid release of Ca2+ from intracellular stores stimulated with inositol 1,4,5-trisphosphate (InsP3) has required superfusion or stopped-flow techniques to resolve the kinetics of Ca2+ mobilization and made it difficult to determine whether the InSP3 receptor desensitizes during prolonged stimulation. Here we have overloaded the intracellular Ca2+ stores of permeabilized rat hepatocytes by incubating them with ATP and Ca-45(2+) in the presence of pyrophosphate, which precipitates Ca2+ within the lumen of the stores. Subsequent ATP removal initiated slow Ca-45(2+) efflux that followed zero-order kinetics, allowing us to examine the effects of InSP3 over a prolonged time course. InsP3 produced a concentration-dependent increase in the C-45(2+) efflux rate that was sustained for several min. The rate rapidly returned to the unstimulated level after the addition of decavanadate, a competitive antagonist of InsP3 at its receptor. Prior incubation with a submaximal concentration of InSP3 (1-mu-M) did not affect the subsequent enhanced rate of Ca-45(2+) efflux stimulated by a higher, but still submaximal, concentration of InSP3 (3-mu-M). We conclude that prolonged exposure to InsP3 does not desensitize the InsP3 receptor and that intrinsic receptor desensitization cannot provide an explanation for the quantal responses to InsP3 observed in several cell types.	UNIV CAMBRIDGE, DEPT PHARMACOL, TENNIS COURT RD, CAMBRIDGE CB2 1QJ, ENGLAND	University of Cambridge			Richardson, Alan/E-7615-2010; Richardson, Alan/I-4631-2015; Taylor, Colin/G-2447-2010	Richardson, Alan/0000-0003-1825-3375; Taylor, Colin/0000-0001-7771-1044				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOHR KJ, 1989, BIOCHEM J, V262, P83; FOHR KJ, 1991, CELL CALCIUM, V12, P735, DOI 10.1016/0143-4160(91)90042-D; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; LESLIE BA, 1988, CELL CALCIUM, V9, P9, DOI 10.1016/0143-4160(88)90033-4; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MISSIAEN L, 1992, BIOCHEM J, V282, P306, DOI 10.1042/bj2820306; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NUNN DL, 1990, BIOCHEM J, V270, P227, DOI 10.1042/bj2700227; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; PALADE P, 1989, MOL PHARMACOL, V36, P673; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PIETRI F, 1990, J BIOL CHEM, V265, P17478; STRUPISH J, 1991, Molecular Neuropharmacology, V1, P111; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; TAYLOR CW, 1989, BIOCHEM J, V259, P645, DOI 10.1042/bj2590645	22	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16312	16316						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322898				2022-12-27	WOS:A1992JJ45800051
J	YOSHIKAWA, S; TANIMURA, T; MIYAWAKI, A; NAKAMURA, M; YUZAKI, M; FURUICHI, T; MIKOSHIBA, K				YOSHIKAWA, S; TANIMURA, T; MIYAWAKI, A; NAKAMURA, M; YUZAKI, M; FURUICHI, T; MIKOSHIBA, K			MOLECULAR-CLONING AND CHARACTERIZATION OF THE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR IN DROSOPHILA-MELANOGASTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE ADENYLATE-CYCLASE; RYANODINE RECEPTOR; MOUSE CEREBELLUM; P-400 PROTEIN; TRISPHOSPHATE RECEPTOR; PHOSPHOLIPASE-C; PURKINJE-CELLS; INSP3 RECEPTOR; LIMULUS PHOTORECEPTORS; FUNCTIONAL EXPRESSION	We isolated a cDNA encoding an inositol 1,4,5-trisphosphate receptor (InSP3R) of Drosophila melanogaster. The predicted Drosophila InsP3R (2,833 amino acids) has extensive sequence similarity to the mouse InSP3R. The polypeptide encoded by the cDNA was functionally expressed and showed characteristic InsP3-binding activity. The Drosophila InsP3R gene is located at the region 83A5-9 on the third chromosome and expresses throughout development but predominantly in the adult. Localization of the InSP3R mRNA in adult tissues suggests strong expression in the retina and antenna, indicating the involvement of the InSP3R in visual and olfactory transduction. In addition, the InsP3R mRNA is abundant in the legs and thorax, which are enriched with a muscular system. Such localization is apparently consistent with the quantitatively predominant sites for [H-3]InsP3 binding in Drosophila and the fleshfly (Boettcherisca peregrina). The present study points to the likely functional importance of the InsP3/Ca2+ signaling system in Drosophila.	NATL INST BASIC BIOL, DIV BEHAV & NEUROBIOL, OKAZAKI, AICHI 444, JAPAN; OSAKA UNIV, INST PROT RES, DIV REGULAT MACROMOLEC FUNCT, SUITA, OSAKA 565, JAPAN; KYUSHU UNIV, BIOL LAB, CHUO KU, FUKUOKA 810, JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Osaka University; Kyushu University			Miyawaki, Atsushi/K-3569-2014; Mikoshiba, Katsuhiko/N-7943-2015; Yuzaki, Michisuke/K-5328-2013	Miyawaki, Atsushi/0000-0002-2329-3235; Yuzaki, Michisuke/0000-0002-5750-3544; Furuichi, Teiichi/0000-0002-9676-1888				ASHBURNER M, 1989, DROSOPHILA LABORATOR; BAINES RA, 1990, J COMP NEUROL, V297, P479, DOI 10.1002/cne.902970402; BARNARD EA, 1990, TRENDS PHARMACOL SCI, V11, P500, DOI 10.1016/0165-6147(90)90051-9; BASLER K, 1988, CELL, V54, P299; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BOEKHOFF I, 1990, CELL SIGNAL, V2, P49, DOI 10.1016/0898-6568(90)90032-6; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BROWN JE, 1984, NATURE, V311, P160, DOI 10.1038/311160a0; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; DEVARY O, 1987, P NATL ACAD SCI USA, V84, P6939, DOI 10.1073/pnas.84.19.6939; EVANS PD, 1984, J EXP BIOL, V110, P231; FASMAN GD, 1990, TRENDS BIOCHEM SCI, V15, P89, DOI 10.1016/0968-0004(90)90187-G; FEIN A, 1986, TRENDS NEUROSCI, V9, P110, DOI 10.1016/0166-2236(86)90037-8; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FURUICHI T, 1989, NUCLEIC ACIDS RES, V17, P5385, DOI 10.1093/nar/17.13.5385; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1990, FEBS LETT, V267, P85, DOI 10.1016/0014-5793(90)80294-S; FYRBERG EA, 1983, CELL, V33, P115, DOI 10.1016/0092-8674(83)90340-9; HUGANIR RL, 1983, P NATL ACAD SCI USA, V81, P6963; KLEIN P, 1984, BIOCHIM BIOPHYS ACTA, V787, P221, DOI 10.1016/0167-4838(84)90312-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; MAEDA N, 1989, DEV BIOL, V133, P67, DOI 10.1016/0012-1606(89)90297-2; Maniatis T., 1982, MOL CLONING; MARKS AR, 1990, J BIOL CHEM, V265, P20719; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIKOSHIBA K, 1978, BRAIN RES, V142, P487, DOI 10.1016/0006-8993(78)90911-3; MIKOSHIBA K, 1979, DEV NEUROSCI-BASEL, V2, P254, DOI 10.1159/000112489; MIKOSHIBA K, 1985, DEV NEUROSCI-BASEL, V7, P179, DOI 10.1159/000112286; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; MONTELL C, 1989, BIOESSAYS, V11, P43, DOI 10.1002/bies.950110202; MORIYOSHI M, 1991, NATURE, V354, P665; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; Oliver D., 1970, DROS INFORM SERV, V45, P58; OTSU H, 1990, CELL STRUCT FUNCT, V15, P163, DOI 10.1247/csf.15.163; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; Pak W.L., 1979, P67; PAYNE R, 1986, PHOTOBIOCH PHOTOBIOP, V13, P373; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; STERNBERG MJE, 1984, FEBS LETT, V175, P387, DOI 10.1016/0014-5793(84)80774-7; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; THAMBI NC, 1989, J BIOL CHEM, V264, P18552; TOYOSHIMA S, 1990, J BIOL CHEM, V265, P14842; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; YAMAMOTO H, 1989, J NEUROCHEM, V53, P917, DOI 10.1111/j.1471-4159.1989.tb11792.x; YOSHIOKA T, 1985, J BIOCHEM-TOKYO, V97, P1251, DOI 10.1093/oxfordjournals.jbchem.a135171; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	61	141	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16613	16619						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322910				2022-12-27	WOS:A1992JJ45800096
J	SANJOSE, E; BENGURIA, A; GELLER, P; VILLALOBO, A				SANJOSE, E; BENGURIA, A; GELLER, P; VILLALOBO, A			CALMODULIN INHIBITS THE EPIDERMAL GROWTH-FACTOR RECEPTOR TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR; BINDING PROTEINS; EGF RECEPTOR; A431 CELLS; PHOSPHORYLATION; GENE	We demonstrate in this report that the epidermal growth factor (EGF) receptor from rat liver can be isolated by calmodulin affinity chromatography by binding in the presence of Ca2+ and elution with a Ca2+-chelating agent. The bulk of the EGF receptor is not eluted by a NaCl gradient in the presence of Ca2+. We ascertained the identity of the isolated receptor by immunoblot and immunoprecipitation using a polyclonal antibody against an EGF receptor from human origin. The purified receptor is autophosphorylated in tyrosine residues in an EGF-stimulated manner, and EGF-dependent phosphorylation of serine residues was also detected. Both the EGF and the transforming growth factor-alpha stimulate the tyrosine-directed protein kinase activity of the isolated receptor with similar affinities. Furthermore, we demonstrate that calmodulin inhibits the EGF-dependent tyrosine-directed protein kinase activity associated to the receptor in a concentration-dependent manner. This inhibition is partially Ca2+ dependent and is not displaced by increasing the concentration of EGF up to an EGF/calmodulin ratio of 10 (mol/mol). In addition, calmodulin was phosphorylated in an EGF-stimulated manner in the presence of a basic protein (histone) as cofactor and in the absence, but not in the presence, of Ca2+.	CSIC, INST INVEST BIOMED, ARTURO DUPERIER 4, E-28029 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Villalobo, Antonio/O-9621-2019; Villalobo, Antonio/K-2902-2017; Benguria, Alberto/M-9911-2014	Villalobo, Antonio/0000-0002-4200-374X; Benguria, Alberto/0000-0002-5536-566X				ANDERSON WB, 1985, CURR TOP CELL REGUL, V27, P455; BROWN AE, 1976, BIOCHIM BIOPHYS ACTA, V426, P418, DOI 10.1016/0005-2736(76)90387-4; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; COHEN P, 1978, FEBS LETT, V92, P287, DOI 10.1016/0014-5793(78)80772-8; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; GOLDSTEIN DA, 1979, BIOPHYS J, V26, P235, DOI 10.1016/S0006-3495(79)85247-9; GRAVES CB, 1985, SCIENCE, V230, P827, DOI 10.1126/science.3904001; GRAVES CB, 1986, J BIOL CHEM, V261, P429; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JOSE ES, 1990, J BIOL CHEM, V265, P20653; KING MJ, 1988, BIOCHEM J, V256, P893, DOI 10.1042/bj2560893; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1980, ANNU REV BIOCHEM, V49, P489, DOI 10.1146/annurev.bi.49.070180.002421; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANALAN AS, 1984, ADV CYCLIC NUCL PROT, V18, P227; MEANS AR, 1980, NATURE, V285, P73, DOI 10.1038/285073a0; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; PANDIELLA A, 1987, BIOCHEM BIOPH RES CO, V149, P145, DOI 10.1016/0006-291X(87)91616-0; PANDIELLA A, 1988, BIOCHEM J, V254, P223, DOI 10.1042/bj2540223; PARKER PJ, 1984, J BIOL CHEM, V259, P9906; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SACKS DB, 1988, J BIOL CHEM, V263, P2377; SACKS DB, 1989, BIOCHEM J, V263, P803, DOI 10.1042/bj2630803; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WANG KKW, 1989, BIOCHEM CELL BIOL, V67, P703, DOI 10.1139/o89-105; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; ZHAO D, 1991, BIOCHEM J, V277, P445, DOI 10.1042/bj2770445	31	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15237	15245						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321833				2022-12-27	WOS:A1992JF08800107
J	STIRDIVANT, SM; AHERN, JD; OLIFF, A; HEIMBROOK, DC				STIRDIVANT, SM; AHERN, JD; OLIFF, A; HEIMBROOK, DC			RETINOBLASTOMA PROTEIN-BINDING PROPERTIES ARE DEPENDENT ON 4 CYSTEINE RESIDUES IN THE PROTEIN-BINDING POCKET	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 T-ANTIGEN; GENE-PRODUCT; SUSCEPTIBILITY GENE; CELL-CYCLE; TRANSCRIPTION FACTOR; ENCODED PROTEIN; RB PROTEIN; EXPRESSION; PHOSPHORYLATION; SUBSTITUTION	The retinoblastoma gene product (pRB) participates in regulating mammalian cell replication. The mechanism responsible for pRB's growth regulatory activity is uncertain. However, pRB is known to bind viral transforming proteins including the papilloma virus E7 protein, cellular proteins, and DNA. pRB contains a critical domain termed the "binding pocket" which is required for binding activities. This binding pocket contains 8 cysteine residues. A naturally occurring mutation affecting one of these cysteines is known to eliminate pRB's protein and DNA binding activities. To investigate the cysteine residues in pRB's binding pocket, each residue was mutated to alanine, phenylalanine, or serine. These mutant genes were used to prepare pRBs harboring specific amino acid substitutions. Individual mutations at positions 407, 553, 666, and 706 depressed pRB binding to E7 protein, DNA, and a conformation-specific anti-pRB antibody, XZ133. Combinations of these inhibitory mutations exhibited additive inhibitory effects on pRB's binding properties. Mutations at positions 438, 489, 590, 712, and 853 did not affect pRB binding to E7 protein, DNA, or the XZ133 antibody. Combination of these five neutral mutations yielded a pRB species with full E7 protein, DNA, and XZ133 binding activities. These studies indicate that the cysteine residues at positions 407, 553, 666, and 706 contribute to the E7 protein and DNA binding properties of pRB and appear to do so by maintaining pRB's normal conformation.	MERCK SHARP & DOHME LTD,DEPT CANC RES,BLDG 16,RM 101,W POINT,PA 19486	Merck & Company								BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BIGNON YJ, 1990, CELL GROWTH DIFFER, V1, P647; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; JONES RE, 1992, J BIOL CHEM, V267, P908; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; PATRICK DR, 1992, J BIOL CHEM, V267, P6910; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; STIRDIVANT SM, 1992, MOL CELL BIOL, V12, P1905, DOI 10.1128/MCB.12.5.1905; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	32	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14846	14851						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321820				2022-12-27	WOS:A1992JF08800053
J	HARDING, PP; DUESTER, G				HARDING, PP; DUESTER, G			RETINOIC ACID ACTIVATION AND THYROID-HORMONE REPRESSION OF THE HUMAN ALCOHOL-DEHYDROGENASE GENE ADH3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE ELEMENT; LIVER ALCOHOL; HEPATOCELLULAR-CARCINOMA; BETA-GENE; RECEPTOR; IDENTIFICATION; EXPRESSION; REGION; CELLS; TRANSCRIPTION	Mammalian alcohol dehydrogenase (ADH) catalyzes the oxidation of retinol to retinaldehyde, the rate-limiting step in the synthesis of retinoic acid. There exists a family of ADH isozymes encoded by unique genes, and it is unclear which isozymes are most important for regulation of retinoic acid synthesis during differentiation or development. A region in the human ADH3 promoter from -328 to -272 base pairs was shown previously to function as a retinoic acid response element (RARE), prompting an hypothesis for a positive feedback mechanism controlling retinoic acid synthesis (Duester, G., Shean, M. L., McBride, M. S., and Stewart, M. J. (1991) Mol. Cell. Biol. 11, 1638-1646). The ADH3 RARE contains three direct AGGTCA repeats which constitute the critical nucleotides of RAREs present in other genes. We dissected the ADH3 RARE and determined that receptor binding as well as transactivation are dependent upon only the two downstream AGGTCA motifs separated by 5 base pairs, a structure noticed previously for a RARE in the promoter for the retinoic acid receptor-beta (RAR-beta) gene. ADH3 and RAR-beta RAREs functioned similarly in transfection assays, suggesting that the feedback mechanisms controlling ADH3 and RAR-beta utilize a common RARE. We also found that the normal functioning of the ADH3 RARE was abrogated by thyroid hormone receptor in the presence of thyroid hormone. A negative thyroid hormone response element in the human ADH3 promoter was found to colocalize with the RARE. Since ADH production in rat liver is known to be repressed by thyroid hormone, these findings suggest that human ADH production may also be subject to thyroid hormone repression and that the mechanism involves an interference with retinoic acid induction.	LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA; COLORADO STATE UNIV, DEPT BIOCHEM, FT COLLINS, CO 80523 USA	Sanford Burnham Prebys Medical Discovery Institute; Colorado State University					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K02AA000119, R01AA007261] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA07261, K02 AA00119] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CRABB DW, 1986, BIOCHEM PHARMACOL, V35, P1527, DOI 10.1016/0006-2952(86)90120-6; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; DUESTER G, 1986, J BIOL CHEM, V261, P2027; DUESTER G, 1991, ALCOHOL CLIN EXP RES, V15, P568, DOI 10.1111/j.1530-0277.1991.tb00562.x; Duester G., 1991, LIVER PATHOLOGY ALCO, P375; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HILLBOM ME, 1970, BIOCHEM PHARMACOL, V19, P2097, DOI 10.1016/0006-2952(70)90308-4; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; ISRAEL Y, 1975, J PHARMACOL EXP THER, V192, P565; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; li T K, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P427; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Maxam A M, 1980, Methods Enzymol, V65, P499; MEZEY E, 1971, EXP MOL PATHOL, V15, P148, DOI 10.1016/0014-4800(71)90095-5; MEZEY E, 1981, GASTROENTEROLOGY, V80, P566; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; OLIVER G, 1990, EMBO J, V9, P3093, DOI 10.1002/j.1460-2075.1990.tb07506.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; POSCH KC, 1989, ARCH BIOCHEM BIOPHYS, V274, P171, DOI 10.1016/0003-9861(89)90428-1; ROBERTS AB, 1984, RETINOIDS, V2, P209; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; Sambrook J, 1989, MOL CLONING LABORATO; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SMITH M, 1986, ADV HUM GENET, V15, P249; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STEWART MJ, 1991, J BIOL CHEM, V266, P11594; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WOLF G, 1984, PHYSIOL REV, V64, P873, DOI 10.1152/physrev.1984.64.3.873; YOSHIDA A, 1991, PROG NUCLEIC ACID RE, V40, P255; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	55	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14145	14150						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321136				2022-12-27	WOS:A1992JD32500057
J	KO, K; KO, ZW				KO, K; KO, ZW			CARBOXYL-TERMINAL SEQUENCES CAN INFLUENCE THE INVITRO IMPORT AND INTRAORGANELLAR TARGETING OF CHLOROPLAST PROTEIN PRECURSORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL-A/B PROTEIN; TRANSIT PEPTIDE; FOREIGN PROTEIN; ISOLATED-MITOCHONDRIA; THYLAKOID MEMBRANE; BINDING PROTEIN; TRANSLOCATION; PLASTOCYANIN; INTEGRATION; ENVELOPE	The transit peptide of the lumenal 33-kDa oxygen-evolving polypeptide (OEE1) is capable of directing the import and targeting of the foreign protein dihydrofolate reductase (DHFR) to the thylakoid lumen. The import results from the first part of this study indicate that methotrexate cannot block the import or intraorganellar targeting of OEE1-DHFR in chloroplasts in contrast to that reported for the import of cytochrome oxidase subunit IV (COXIV)-DHFR in mitochondria. These results suggest that the fusion of the OEE1 transit sequence to DHFR affected the protein's methotrexate binding properties. We further examined and compared the transport characteristics of a number of carboxyl-terminal truncated native chloroplast precursors to determine whether carboxyl domains contribute to the import and intraorganellar targeting mechanism of these proteins. The plastid precursors chosen for this study are targeted to one of the following chloroplast compartments: the stroma, the thylakoid membrane, and the lumen. In most cases, removal of carboxyl domains had a dramatic effect on one or more stages of the translocation pathway, such as import, processing, and intraorganellar targeting. The effects of carboxyl deletions varied from precursor to precursor and were dependent on the extent of the deletion. These combined results suggest that carboxyl domains in the mature part of the proteins can influence the function of the transit peptide, and as a result play an important role in determining the import and targeting competence of chloroplast precursors.			KO, K (corresponding author), QUEENS UNIV,DEPT BIOL,KINGSTON K7L 3N6,ONTARIO,CANADA.							ANDERSON CM, 1991, FEBS LETT, V280, P383, DOI 10.1016/0014-5793(91)80337-3; BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; CLINE K, 1988, PLANT PHYSIOL, V86, P1120, DOI 10.1104/pp.86.4.1120; CLINE K, 1985, J BIOL CHEM, V260, P3691; DEBOER D, 1991, EMBO J, V10, P2765, DOI 10.1002/j.1460-2075.1991.tb07825.x; DEBOER D, 1988, EMBO J, V7, P2631, DOI 10.1002/j.1460-2075.1988.tb03115.x; DELLACIOPPA G, 1988, EMBO J, V7, P1299, DOI 10.1002/j.1460-2075.1988.tb02944.x; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; EILERS M, 1988, CELL, V52, P481, DOI 10.1016/0092-8674(88)90458-8; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; KAVANAGH TA, 1988, MOL GEN GENET, V215, P38, DOI 10.1007/BF00331300; KIRWIN PM, 1989, EMBO J, V8, P2251, DOI 10.1002/j.1460-2075.1989.tb08349.x; KO K, 1990, PLANT MOL BIOL, V14, P217, DOI 10.1007/BF00018562; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; KOHORN BD, 1989, PLANT CELL, V1, P159; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LUBBEN TH, 1988, PHOTOSYNTH RES, V17, P173, DOI 10.1007/BF00047688; MEADOWS JW, 1989, FEBS LETT, V253, P244, DOI 10.1016/0014-5793(89)80968-8; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NESS SA, 1987, P NATL ACAD SCI USA, V84, P6692, DOI 10.1073/pnas.84.19.6692; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1987, PLANT MOL BIOL, V9, P377, DOI 10.1007/BF00014912; VANDENBROECK G, 1985, NATURE, V313, P358, DOI 10.1038/313358a0; VANDENBROECK G, 1988, PLANT SCI, V58, P171, DOI 10.1016/0168-9452(88)90006-4; VERNER K, 1987, EMBO J, V6, P2449, DOI 10.1002/j.1460-2075.1987.tb02524.x; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VERNER K, 1989, EMBO J, V8, P1491, DOI 10.1002/j.1460-2075.1989.tb03533.x; VESTWEBER D, 1988, EMBO J, V7, P1147, DOI 10.1002/j.1460-2075.1988.tb02924.x; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; WASMANN CC, 1986, MOL GEN GENET, V205, P446, DOI 10.1007/BF00338081; WIENHUES U, 1991, J CELL BIOL, V115, P1601, DOI 10.1083/jcb.115.6.1601	40	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13910	13916						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321129				2022-12-27	WOS:A1992JD32500022
J	WAHL, MI; JONES, GA; NISHIBE, S; RHEE, SG; CARPENTER, G				WAHL, MI; JONES, GA; NISHIBE, S; RHEE, SG; CARPENTER, G			GROWTH-FACTOR STIMULATION OF PHOSPHOLIPASE-C-GAMMA-1 ACTIVITY - COMPARATIVE PROPERTIES OF CONTROL AND ACTIVATED ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; FACTOR RECEPTOR; INTRACELLULAR STORES; INOSITOL PHOSPHATES; KINETIC-ANALYSIS; CYTOSOLIC CA-2+; MIXED MICELLES; BOVINE BRAIN; A-431 CELLS	We demonstrated previously tyrosine phosphorylation-dependent modulation of phospholipase C-gamma-1 (PLC-gamma-1) catalytic activity (Nishibe, S., Wahl, M. I., Hernandez-Sotomayor, S. M. T., Tonks, N. K., Rhee, S. G., and Carpenter, G. (1990) Science 250, 1253-1256). The increase in PLC-gamma-1 catalytic activity in A-431 cells occurs rapidly, with maximal activation 5 min after epidermal growth factor (EGF) stimulation. Certain other growth factors (fibroblast growth factor, platelet-derived growth factor) also stimulate PLC-gamma-1 catalytic activity, whereas insulin does not. A similar increase in PLC-gamma-1 specific activity (2-3-fold) was observed in both soluble (cytosol) and particulate (membrane) preparations from EGF-treated cells. Tyrosine-phosphorylated PLC-gamma-1 was detected in both cytosol and membrane fractions in lysates from EGF-treated A-431 cells, but the proportion of tyrosine-phosphorylated PLC-gamma-1 was higher in the cytosol (approximately 50%) than in the membrane (approximately 20%). Because a micellar concentration of the non-ionic detergent Triton X-100 allows detection of the tyrosine phosphorylation-dependent increase in PLC-gamma-1 catalytic activity in this assay, we evaluated the kinetic properties of PLC-gamma-1, immunoprecipitated from cytosol of control or EGF-treated cells, using substrate, phosphatidylinositol 4,5-bisphosphate (PtdIns 4,5-P2), solubilized in Triton X-100 at various molar ratios. The behavior of the control enzyme differed from the EGF-activated enzyme with respect to both K8 and K(m). The control enzyme has a 7.5-fold higher K8 value than the activated enzyme (1.5 mm as compared with 0.22 mm). Activation by EGF is also a positive allosteric modifier of PLC-gamma-1-catalyzed PtdIns 4,5-P2 hydrolysis, i.e. the activated enzyme displayed apparent Michalis-Menton kinetics, with a K(m) of 0.6 mol fraction PtdIns 4,5-P2, whereas the control enzyme displayed sigmoidal kinetics with respect to PtdIns 4,5-P2 hydrolysis. At low substrate mol fractions (e.g. 0.07), the reaction velocity of the control enzyme was 4-fold lower than the activated enzyme. However, at a high substrate mol fraction (e.g. 0.33), the estimated maximal reaction velocities (V(max)) for both forms of PLC-gamma-1 were equivalent. PLC-gamma-1 activity from both control and EGF-treated cells was stimulated by increasing nanomolar Ca2+ concentrations. Although the catalytic activity of PLC-gamma-1 from EGF-treated cells was greater than control PLC-gamma-1 at every Ca2+ concentration tested, the relative stimulation of activity was markedly greater at Ca2+ concentrations above approximately 300 nM.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,DEPT MED,NASHVILLE,TN 37232; NHLBI,BIOCHEM LAB,BETHESDA,MD 20892	Vanderbilt University; Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)					NCI NIH HHS [CA43720, CA09582] Funding Source: Medline; NIGMS NIH HHS [GM07347] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA043720, T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANNO Y, 1988, J BIOL CHEM, V263, P11459; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DENNIS E A, 1974, Journal of Supramolecular Structure, V2, P682, DOI 10.1002/jss.400020513; Dennis EA, 1983, ENZYMES, P307; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FRACKELTON AR, 1983, MOL CELL BIOL, V3, P1353; FUKUI T, 1988, J BIOL CHEM, V263, P17730; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HEPLER JR, 1987, J BIOL CHEM, V262, P2951; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; HOFMANN SL, 1982, J BIOL CHEM, V257, P4359; IRVINE RF, 1984, BIOCHEM J, V218, P177, DOI 10.1042/bj2180177; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1990, J BIOL CHEM, V265, P3940; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PANDIELLA A, 1987, EXP CELL RES, V170, P175, DOI 10.1016/0014-4827(87)90127-3; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RIDGWAY ND, 1988, J BIOL CHEM, V263, P16864; ROBSON RJ, 1983, ACCOUNTS CHEM RES, V16, P251, DOI 10.1021/ar00091a003; RYU SH, 1987, J BIOL CHEM, V262, P12511; SANDERMANN H, 1983, BIOCHIM BIOPHYS ACTA, V732, P332, DOI 10.1016/0005-2736(83)90223-7; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SUH PG, 1988, J BIOL CHEM, V263, P14497; TILLY BC, 1988, BIOCHEM J, V252, P857, DOI 10.1042/bj2520857; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WAHL M, 1988, J BIOL CHEM, V263, P7581; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WAHL MI, 1989, CANCER CELL-MON REV, V1, P101; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WHEELER LA, 1990, J MEMBRANE BIOL, V118, P77, DOI 10.1007/BF01872206; WILSON DB, 1984, J BIOL CHEM, V259, P1718	48	153	153	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10447	10456						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1316902				2022-12-27	WOS:A1992HV09000039
J	CHAMULITRAT, W; MASON, RP; RIENDEAU, D				CHAMULITRAT, W; MASON, RP; RIENDEAU, D			NITROXIDE METABOLITES FROM ALKYLHYDROXYLAMINES AND N-HYDROXYUREA DERIVATIVES RESULTING FROM REDUCTIVE INHIBITION OF SOYBEAN LIPOXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN RESONANCE; 5-LIPOXYGENASE; ACID; DESFERRIOXAMINE; BIOSYNTHESIS; INACTIVATION; OXIDATION; POTENT; DRUGS; ESR	One proposed mechanism of the inactivation of lipoxygenase by inhibitors is the reduction of the catalytically active ferric form of the enzyme to its ferrous form. Recent studies have shown that compounds containing the hydroxamate moiety are potent inhibitors of lipoxygenase. The hydroxamate portion of the inhibitor is thought to bind to iron at the catalytic site of the enzyme. We now report evidence that the NOH of the hydroxamate group of N-(4-chlorophenyl)-N-hydroxy-N'-(3-chlorophenyl)urea, N-[(E)-3-(3-phenoxyphenyl)prop-2-enyl]acetohydroxamic (BW A4C), and N-(1-benzo(b)thien-2-ylethyl)-N-hydroxyurea (Zileuton) is oxidized by lipoxygenase to form their corresponding nitroxides, which are directly detected by electron paramagnetic resonance spectroscopy. It is consistently found that the selected NOH-containing compounds, e.g. alkylhydroxylamines or N-hydroxyureas, are also oxidized by lipoxygenase to form their corresponding nitroxides.	MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM,POINTE CLAIRE H9R 4P8,QUEBEC,CANADA	Merck & Company	CHAMULITRAT, W (corresponding author), NIEHS,POB 12233,RES TRIANGLE PK,NC 27709, USA.		Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109				[Anonymous], CHEM BIOL HYDROXAMIC; BARRADAS MA, 1989, FEBS LETT, V245, P105, DOI 10.1016/0014-5793(89)80201-7; CARTER GW, 1991, J PHARMACOL EXP THER, V256, P929; CHAMULITRAT W, 1989, J BIOL CHEM, V264, P20968; CLAPP CH, 1985, BIOCHEMISTRY-US, V24, P1826, DOI 10.1021/bi00329a004; COREY EJ, 1984, J AM CHEM SOC, V106, P1503, DOI 10.1021/ja00317a064; DARLEYUSMAR VM, 1989, BIOCHEM PHARMACOL, V38, P1465, DOI 10.1016/0006-2952(89)90186-X; FORRESTER AR, 1979, LANDOLTBORNSTEIN NUM, V9, P778; GRADY RW, 1976, J PHARMACOL EXP THER, V196, P478; HINOJOSA O, 1989, PHOTOCHEM PHOTOBIOL, V49, P1, DOI 10.1111/j.1751-1097.1989.tb04069.x; HIRSCHELMANN R, 1988, BIOMED BIOCHIM ACTA, V47, pS256; Hirschelmann R, 1986, Free Radic Res Commun, V2, P125, DOI 10.3109/10715768609088063; JACKSON WP, 1988, J MED CHEM, V31, P499, DOI 10.1021/jm00398a001; KEMAL C, 1987, BIOCHEMISTRY-US, V26, P7064, DOI 10.1021/bi00396a031; KERDESKY FAJ, 1985, TETRAHEDRON LETT, V26, P2143, DOI 10.1016/S0040-4039(00)98946-9; LASSMANN G, 1989, FREE RADICAL BIO MED, V6, P241, DOI 10.1016/0891-5849(89)90050-6; LAUGHTON MJ, 1989, BIOCHEM PHARMACOL, V38, P189, DOI 10.1016/0006-2952(89)90167-6; MANSUY D, 1988, BIOCHEM BIOPH RES CO, V151, P339, DOI 10.1016/0006-291X(88)90599-2; MASSICOT JG, 1986, PROSTAGLANDINS, V32, P481, DOI 10.1016/0090-6980(86)90031-6; MOREHOUSE KM, 1987, FEBS LETT, V222, P246, DOI 10.1016/0014-5793(87)80379-4; MOTTLEY C, 1987, MOL PHARMACOL, V31, P417; NELSON MJ, 1991, J BIOL CHEM, V266, P8225; NELSON MJ, 1988, BIOCHEMISTRY-US, V27, P4273, DOI 10.1021/bi00412a011; REYNOLDS CH, 1988, BIOCHEM PHARMACOL, V37, P4531, DOI 10.1016/0006-2952(88)90669-7; RIENDEAU D, 1991, BIOCHEM J, V274, P287, DOI 10.1042/bj2740287; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SUMMERS JB, 1987, J MED CHEM, V30, P574, DOI 10.1021/jm00386a022; VANDERZEE J, 1989, BIOCHEMISTRY-US, V28, P8363, DOI 10.1021/bi00447a015; Vliegenthart J. F. G., 1982, FREE RADICAL BIO MED, P29	29	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9574	9579						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315759				2022-12-27	WOS:A1992HT96500022
J	GARDNER, PR; FRIDOVICH, I				GARDNER, PR; FRIDOVICH, I			INACTIVATION-REACTIVATION OF ACONITASE IN ESCHERICHIA-COLI - A SENSITIVE MEASURE OF SUPEROXIDE RADICAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISMUTASE; BIOSYNTHESIS; INVIVO; OXYGEN; DYE	The rapid inactivation of aconitase by O2-, previously seen to occur in vitro, was explored in vivo. A fraction of the aconitase in growing, aerobic, Escherichia coli is inactive at any instant but can be activated by imposition of anaerobic conditions. This reactivation occurred in the absence of protein synthesis and was inhibited by the ferrous chelator alpha,alpha'-dipyridyl. This fraction of inactive, but activatable, aconitase was increased by augmenting O2- production with paraquat, decreased by elevation of superoxide dismutase, and increased by inhibiting reactivation with alpha,alpha'-dipyridyl. The balance between inactive and active aconitase thus represented a pseudoequilibrium between inactivation by O2- and reactivation by restoration of Fe(II), and it provided, for the first time, a measure of the steady-state concentration of O2- within E. coli. On this basis, [O2-] was estimated to be approximately 20-40 pm in aerobic log phase E. coli containing wild type levels of superoxide dismutase and approximately 300 pm in a mutant strain lacking superoxide dismutase.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University				Gardner, Paul/0000-0001-8189-0903				ARCHIBALD FS, 1982, ARCH BIOCHEM BIOPHYS, V214, P452, DOI 10.1016/0003-9861(82)90049-2; BEERS RF, 1952, J BIOL CHEM, V195, P133; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; Boveris A., 1982, SUPEROXIDE DISMUTASE, VII, P15, DOI DOI 10.1007/978-1-4615-9035-4_5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; FLINT D H, 1990, P285; FRIDOVICH I, 1986, ARCH BIOCHEM BIOPHYS, V247, P1, DOI 10.1016/0003-9861(86)90526-6; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GRAY CT, 1966, BIOCHIM BIOPHYS ACTA, V117, P33, DOI 10.1016/0304-4165(66)90149-8; HASSAN HM, 1977, J BACTERIOL, V132, P505, DOI 10.1128/JB.132.2.505-510.1977; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; IMLAY JA, 1987, JBACTERIOL, V169, P2697; IUCHI S, 1988, P NATL ACAD SCI USA, V85, P1888, DOI 10.1073/pnas.85.6.1888; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KUO CF, 1987, J BIOL CHEM, V262, P4724; LOEWEN PC, 1985, ARCH BIOCHEM BIOPHYS, V243, P144, DOI 10.1016/0003-9861(85)90782-9; LOWRY OH, 1971, J BIOL CHEM, V246, P6511; Maniatis T., 1982, MOL CLONING; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MOODY CS, 1984, J BIOL CHEM, V259, P2821; NIEDERHOFFER EC, 1990, J BACTERIOL, V172, P1930, DOI 10.1128/jb.172.4.1930-1938.1990; NOHL H, 1978, EUR J BIOCHEM, V82, P563, DOI 10.1111/j.1432-1033.1978.tb12051.x; NORROD P, 1979, BIOCHEM BIOPH RES CO, V90, P1287, DOI 10.1016/0006-291X(79)91176-8; PHILLIPS JP, 1989, P NATL ACAD SCI USA, V86, P2761, DOI 10.1073/pnas.86.8.2761; PUGH SYR, 1985, J BACTERIOL, V162, P196, DOI 10.1128/JB.162.1.196-202.1985; TARDAT B, 1991, MOL MICROBIOL, V5, P455, DOI 10.1111/j.1365-2958.1991.tb02129.x; TOUATI D, 1988, J BACTERIOL, V170, P2511, DOI 10.1128/jb.170.6.2511-2520.1988; TYLER DD, 1975, BIOCHEM J, V147, P493, DOI 10.1042/bj1470493; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; VERNIQUET F, 1991, BIOCHEM J, V276, P643, DOI 10.1042/bj2760643	33	311	313	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8757	8763						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1315737				2022-12-27	WOS:A1992HR85400011
J	YASUMOTO, K; OKAMOTO, S; MUKAIDA, N; MURAKAMI, S; MAI, M; MATSUSHIMA, K				YASUMOTO, K; OKAMOTO, S; MUKAIDA, N; MURAKAMI, S; MAI, M; MATSUSHIMA, K			TUMOR-NECROSIS-FACTOR-ALPHA AND INTERFERON-GAMMA SYNERGISTICALLY INDUCE INTERLEUKIN-8 PRODUCTION IN A HUMAN GASTRIC-CANCER CELL-LINE THROUGH ACTING CONCURRENTLY ON AP-1 AND NF-KB-LIKE BINDING-SITES OF THE INTERLEUKIN-8 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-ANALYSIS; MONONUCLEAR-CELLS; INFILTRATING LYMPHOCYTES; SELECTIVE DEPLETION; MONOCLONAL-ANTIBODY; DISTANT SITE; T-CELL; EXPRESSION; IMMUNE; RATS	Interleukin 8 (IL-8) is a novel cytokine which possesses neutrophil chemotactic and activating activities in addition to chemotactic activity for basophils and T lymphocytes. It has been shown that IL-8 is produced by a variety of human somatic cells including monocytes/macrophages, dermal fibroblasts, vascular endothelial cells, keratinocytes, mesangeal cells, and several types of tumor cell lines. We have examined here whether or not human gastric cancer cell lines produce IL-8 in vitro. The production of IL-8 protein was detected by enzyme-linked immunosorbent assay in the culture supernatants derived from eight of nine human gastric cancer cell lines stimulated with either interleukin 1alpha (IL-1alpha), tumor necrosis factor alpha (TNFalpha), or TNFalpha plus interferon gamma (IFNgamma). In some of the gastric cancer cell lines such as MKN 45 and KATO, TNFalpha plus IFNgamma synergistically induced the production of IL-8. In MKN 45 cells, synergistic increase of the steady state level of IL-8 mRNA by TNFalpha plus IFNgamma was not inhibited by cycloheximide treatment. Scatchard analysis revealed that IFNgamma changed neither the number nor the affinity constant of TNFalpha binding sites on a gastric cancer cell line, suggesting that the synergism was a post-receptor event. Furthermore, synergistic induction of chloramphenicol acetyltransferase activity by TNFalpha plus IFNgamma was observed in MKN 45 that were transiently transfected with chimeric chloramphenicol acetyltransferase reporter genes driven by the transcriptional regulatory region of human IL-8 gene. Through the mutation of the regulatory region of the IL-8 gene, both AP-1- and NF-kB-like factor binding elements were presumed to be involved in conferring the responsiveness to TNFalpha plus IFNgamma. Moreover, gel retardation analyses revealed that TNFalpha and IFNgamma synergistically induced the binding of NF-kB like as well as AP-1 like proteins bound to these sites. These results indicated that IFNgamma synergistically enhanced TNFalpha-induced IL-8 production in a human gastric cancer cell line through synergistic activation of transcription factors without up-regulating TNFalpha receptor.	KANAZAWA UNIV, CANC RES INST, DEPT PHARMACOL, 13-1 TAKARA MACHI, KANAZAWA, ISHIKAWA 920, JAPAN; KANAZAWA UNIV, DEPT BIOPHYS, KANAZAWA, ISHIKAWA 920, JAPAN; KANAZAWA UNIV, DEPT SURG, KANAZAWA, ISHIKAWA 920, JAPAN	Kanazawa University; Kanazawa University; Kanazawa University			Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851				AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EBINA T, 1990, JPN J CANCER RES, V81, P1307, DOI 10.1111/j.1349-7006.1990.tb02695.x; EBINA T, 1991, JPN J CANCER RES, V82, P1292, DOI 10.1111/j.1349-7006.1991.tb01795.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hojo H., 1997, NIIGATA IGAKKAI ZASS, V91, P737; HUNG CD, 1991, HUMAN CELL S, V4, P51; IBAYASHI Y, 1985, J IMMUNOL, V134, P648; IOACHIM HL, 1976, J NATL CANCER I, V57, P465, DOI 10.1093/jnci/57.3.465; ITOH K, 1986, CANCER RES, V46, P3011; JOHNSON DR, 1990, P NATL ACAD SCI USA, V87, P5183, DOI 10.1073/pnas.87.13.5183; KIKUCHI K, 1976, ANN NY ACAD SCI, V276, P188, DOI 10.1111/j.1749-6632.1976.tb41646.x; KO YC, 1992, J IMMUNOL METHODS, V149, P227, DOI 10.1016/0022-1759(92)90254-Q; KRADIN RL, 1989, LANCET, V1, P577; KUDO C, 1991, J IMMUNOL, V147, P2196; LARSEN CG, 1989, IMMUNOLOGY, V68, P31; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEE SH, 1984, J IMMUNOL, V133, P1083; MAHE Y, 1991, J BIOL CHEM, V266, P13759; MATSUSHIMA K, 1992, CHEM IMMUNOL, V51, P236; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MIDORIKAWA Y, 1990, CANCER RES, V50, P6243; MINAMOTO T, 1990, CANCER-AM CANCER SOC, V66, P945, DOI 10.1002/1097-0142(19900901)66:5<945::AID-CNCR2820660523>3.0.CO;2-X; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; NAKAMURA H, 1991, J BIOL CHEM, V266, P19611; ROSENBERG SA, 1988, ANN SURG, V208, P121, DOI 10.1097/00000658-198808000-00001; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; RUGGIERO V, 1986, J IMMUNOL, V136, P2445; SAWAGUCHI K, 1991, HUMAN CELL S, V4, P50; SAWAGUCHI S, 1989, HUMAN CELL S, V2, P87; SEKIGUCHI M, 1978, JPN J EXP MED, V48, P61; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIJUBO N, 1989, J IMMUNOL, V142, P2961; SHIMOKAWARA I, 1982, CANCER, V49, P1456, DOI 10.1002/1097-0142(19820401)49:7<1456::AID-CNCR2820490724>3.0.CO;2-#; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TSUJIMOTO M, 1986, J IMMUNOL, V136, P2441; UEDE T, 1985, J IMMUNOL, V135, P3243; UNDERWOOD JCE, 1974, BRIT J CANCER, V30, P538, DOI 10.1038/bjc.1974.233; VOSE BM, 1979, INT J CANCER, V24, P579, DOI 10.1002/ijc.2910240510; WATANABE H, 1976, CANCER, V38, P232, DOI 10.1002/1097-0142(197607)38:1<232::AID-CNCR2820380135>3.0.CO;2-4; WILLIAMSON BD, 1983, P NATL ACAD SCI-BIOL, V80, P5397, DOI 10.1073/pnas.80.17.5397; YAMAKI T, 1988, J IMMUNOL, V140, P4388; YAMANO S, 1989, HUMAN CELL S, V2, P93; ZACHARIAE COC, 1992, IN PRESS INVEST DERM	46	430	435	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22506	22511						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331059				2022-12-27	WOS:A1992JW71900081
J	YASUDA, K; RENSDOMIANO, S; BREDER, CD; LAW, SF; SAPER, CB; REISINE, T; BELL, GI				YASUDA, K; RENSDOMIANO, S; BREDER, CD; LAW, SF; SAPER, CB; REISINE, T; BELL, GI			CLONING OF A NOVEL SOMATOSTATIN RECEPTOR, SSTR3, COUPLED TO ADENYLYLCYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; PITUITARY-CELLS; RAT-BRAIN; DESENSITIZATION; SUBTYPES; ANALOGS; PROTEIN; CAMP; SMS-201-995; SPECIFICITY	The gene encoding a novel mouse somatostatin receptor termed mSSTR3 was isolated and characterized. The sequence of mSSTR3 shows 46 and 47% identity with mSSTR1 and mSSTR2, respectively. mSSTR3 binds somatostatin-14 and somatostatin-28 with high affinity, but shows very low affinity for the somatostatin analogs MK-678 and SMS-201-995. In addition, mSSTR3 is coupled to pertussis toxin-sensitive G proteins and mediates somatostatin inhibition of forskolin-stimulated and dopamine D1 receptor-stimulated cAMP formation, indicating that it is coupled to adenylylcyclase. The pharmacological properties of mSSTR3 and its ability to couple with adenylylcyclase distinguish SSTR3 from the other cloned somatostatin receptors and indicates that it mediates biological functions different from SSTR1 or SSTR2. In situ hybridization indicates that SSTR3 mRNA is widely distributed in the mouse brain, and its expression in the nucleus of the lateral olfactory tract and in the piriform cortex, the primary olfactory cortex in the rodent brain, suggests that SSTR3 may participate in the processing and modulation of primary sensory information.	UNIV CHICAGO,HOWARD HUGHES MED INST,5841 S MARYLAND AVE,MC1028,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,COMM NEUROBIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637; UNIV CHICAGO,DEPT NEUROL,CHICAGO,IL 60637; UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Pennsylvania			Saper, Clifford/L-3815-2019		NIDDK NIH HHS [DK-20595, DK-42086] Funding Source: Medline; NIMH NIH HHS [MH-45533] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086, P60DK020595] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBER DL, 1989, J BIOL CHEM, V264, P21038; BRAZEAU P, 1973, SCIENCE, V179, P77, DOI 10.1126/science.179.4068.77; CARPENTER MB, 1987, HDB CLIN NEUROLOGY, P1; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EPELBAUM J, 1986, PROG NEUROBIOL, V27, P63, DOI 10.1016/0301-0082(86)90012-2; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; JAKOBS KH, 1983, NATURE, V303, P177, DOI 10.1038/303177a0; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LAMBERTS SWJ, 1991, ENDOCR REV, V12, P450, DOI 10.1210/edrv-12-4-450; MAHY N, 1988, J PHARMACOL EXP THER, V246, P779; MAHY N, 1988, J PHARMACOL EXP THER, V247, P390; MALM D, 1991, ACTA PHYSIOL SCAND, V143, P305, DOI 10.1111/j.1748-1716.1991.tb09237.x; MARKSTEIN R, 1989, NEUROSCI LETT, V104, P13, DOI 10.1016/0304-3940(89)90321-2; MARTIN JL, 1991, NEUROSCIENCE, V41, P581, DOI 10.1016/0306-4522(91)90351-N; MORIIZUMI T, 1991, NEUROSCI LETT, V132, P69, DOI 10.1016/0304-3940(91)90435-V; PITTMAN QJ, 1981, BRAIN RES, V221, P402, DOI 10.1016/0006-8993(81)90791-5; PLESS J, 1986, SCAND J GASTROENTERO, V21, P54, DOI 10.3109/00365528609087432; PRESKY DH, 1988, J BIOL CHEM, V263, P714; Price J. L., 1987, HDB CHEM NEUROANATOM, V5, P279; PRIESTLEY T, 1992, NEUROPHARMACOLOGY, V31, P103, DOI 10.1016/0028-3908(92)90018-K; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RAYNOR K, 1989, J PHARMACOL EXP THER, V251, P510; RAYNOR K, 1991, MOL PHARMACOL, V40, P248; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REICHLIN S, 1983, NEW ENGL J MED, V309, P1556, DOI 10.1056/NEJM198312223092506; REISINE T, 1984, J PHARMACOL EXP THER, V229, P14; RENSDOMIANO S, 1991, J BIOL CHEM, V266, P20094; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH MA, 1984, MOL CELL ENDOCRINOL, V37, P311, DOI 10.1016/0303-7207(84)90101-1; SPANN BM, 1991, J COMP NEUROL, V311, P375, DOI 10.1002/cne.903110308; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; TALLENT M, 1992, MOL PHARMACOL, V41, P452; THEVENIAU M, 1992, P NATL ACAD SCI USA, V89, P4314, DOI 10.1073/pnas.89.10.4314; TOTTERDELL S, 1984, J NEUROCYTOL, V13, P593, DOI 10.1007/BF01148081; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VEBER DF, 1984, LIFE SCI, V34, P1371, DOI 10.1016/0024-3205(84)90009-2; VIGUERIE N, 1989, ENDOCRINOLOGY, V124, P1017, DOI 10.1210/endo-124-2-1017; WANG H, 1990, NEUROSCIENCE, V342, P335; WANG HL, 1989, P NATL ACAD SCI USA, V86, P9616, DOI 10.1073/pnas.86.23.9616; YAJIMA Y, 1986, J BIOL CHEM, V261, P2684; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251	44	336	349	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20422	20428						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328199				2022-12-27	WOS:A1992JR85800105
J	LIN, K; CORREIA, JJ; PILKIS, SJ				LIN, K; CORREIA, JJ; PILKIS, SJ			ARG-257 AND ARG-307 OF 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE BIND THE C-2 PHOSPHO GROUP OF FRUCTOSE-2,6-BISPHOSPHATE IN THE FRUCTOSE-2,6-BISPHOSPHATASE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RAT-LIVER; FRUCTOSE 2,6-BISPHOSPHATASE; HEPATIC GLUCONEOGENESIS; SUBSTRATE CYCLE; ENZYME; EXPRESSION; DNA; FRUCTOSE-6-PHOSPHATE; INTERMEDIATE	Rat liver fructose-2,6-bisphosphatase, which catalyzes its reaction via a phosphoenzyme intermediate, is evolutionarily related to the phosphoglycerate mutase enzyme family (Bazan, F., Fletterick, R., and Pilkis, S. J. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 9642-9646). Arg-7 and Arg-59 of the yeast phosphoglycerate mutase have been postulated to be substrate-binding residues based on the x-ray crystal structure. The corresponding residues in rat liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase, Arg-257 and Arg-307, were mutated to alanine. The Arg257Ala and Arg307Ala mutants and the wild-type enzyme were expressed in Escherichia coli and then purified to homogeneity. Both mutant enzymes had identical far and near UV circular dichroism spectra and 6-phosphofructo-2-kinase activities when compared with the wild-type enzyme. However, the Arg257Ala and Arg307Ala mutants had altered steady state fructose-2,6-bisphosphatase kinetic properties; the K(m) values for fructose-2,6-bisphosphate of the Arg257Ala and Arg307Ala mutants were increased by 12,500 and 760-fold, whereas the K(i) values for inorganic phosphate were increased 7.4- and 147-fold, respectively, as compared with the wild-type values. However, the K(i) values for the other product, fructose-6-phosphate, were unchanged for the mutant enzymes. Although both mutants exhibited parallel changes in kinetic parameters that reflect substrate/product binding, they had opposing effects on their respective maximal velocities; the maximal velocity of Arg257Ala was 11-fold higher, whereas that for Arg307Ala was 700-fold lower, than that of the wild-type enzyme. Pre-steady state kinetic studies demonstrated that the rate of phosphoenzyme formation for Arg307Ala was at least 4000-fold lower than that of the wild-type enzyme, whereas the rate for Arg257Ala was similar to the wild-type enzyme. Furthermore, consistent with the V(max) changes, the rate constant for phosphoenzyme breakdown for Arg257Ala was increased 9-fold, whereas that for Arg307Ala was decreased by a factor of 500-fold, as compared with the wild-type value. The results indicate that both Arg-257 and Arg-307 interact with the reactive C-2 phospho group of fructose 2,6-bisphosphate and that Arg-307 stabilizes this phospho group in the transition state during phosphoenzyme breakdown, whereas Arg-257 stabilizes the phospho group of the ground state phosphoenzyme intermediate.	UNIV MISSISSIPPI, MED CTR, DEPT BIOCHEM, JACKSON, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center	LIN, K (corresponding author), SUNY STONY BROOK, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA.				NIDDK NIH HHS [DK 38354] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK038354, R01DK038354] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; BENKOVIC SJ, 1990, ENZYMES, V19, P159; COLOSIA AD, 1988, J BIOL CHEM, V263, P18669; COLOSIA AD, 1987, BIOCHEM BIOPH RES CO, V143, P1092, DOI 10.1016/0006-291X(87)90364-0; DARVILLE MI, 1989, P NATL ACAD SCI USA, V86, P6543, DOI 10.1073/pnas.86.17.6543; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; ELMAGHRABI MR, 1984, J BIOL CHEM, V259, P3096; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; FERSHT AR, 1985, ENZYME STRUCTURE FUN, P331; FOTHERGILLGILMORE LA, 1989, ADV ENZYMOL RAMB, V62, P227; HACKNEY DD, 1990, ENZYMES, V19, P1; HENDERSON R, 1970, Journal of Molecular Biology, V54, P341, DOI 10.1016/0022-2836(70)90434-1; KITAJIMA S, 1984, J BIOL CHEM, V259, P6896; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KRETSCHMER M, 1991, BIOCHEMISTRY-US, V30, P10663, DOI 10.1021/bi00108a009; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANGE AJ, 1991, ARCH BIOCHEM BIOPHYS, V290, P258, DOI 10.1016/0003-9861(91)90617-R; LANGE AJ, 1990, NUCLEIC ACIDS RES, V18, P3652, DOI 10.1093/nar/18.12.3652; LI L, 1992, J BIOL CHEM, V267, P16669; LIN K, 1992, J BIOL CHEM, V267, P6556; Lin K, 1990, Protein Expr Purif, V1, P169, DOI 10.1016/1046-5928(90)90012-N; LIVELY MO, 1988, J BIOL CHEM, V263, P839; LOWRY OH, 1951, J BIOL CHEM, V267, P4386; Maniatis T., 1982, MOL CLONING; PILKIS SJ, 1983, J BIOL CHEM, V258, P6135; PILKIS SJ, 1984, J BIOL CHEM, V259, P949; PILKIS SJ, 1982, MOL CELL ENDOCRINOL, V25, P245, DOI 10.1016/0303-7207(82)90082-X; PILKIS SJ, 1991, ANNU REV NUTR, V11, P465, DOI 10.1146/annurev.nu.11.070191.002341; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PILKIS SJ, 1990, DIABETES CARE, V13, P582, DOI 10.2337/diacare.13.6.582; PILKIS SJ, 1990, FRUCTOSE 2 6 BISPHOS, P17; SAKATA J, 1991, J BIOL CHEM, V266, P15764; SAKATA J, 1990, P NATL ACAD SCI USA, V87, P4951, DOI 10.1073/pnas.87.13.4951; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFTINGEN EV, 1982, EUR J BIOCHEM, V124, P143; STEWART HB, 1985, J BIOL CHEM, V260, P2935; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAULER A, 1989, P NATL ACAD SCI USA, V86, P7316, DOI 10.1073/pnas.86.19.7316; TAULER A, 1990, J BIOL CHEM, V265, P15617; WELLS TNC, 1985, NATURE, V316, P656, DOI 10.1038/316656a0; WINN SI, 1981, PHILOS T ROY SOC B, V293, P121, DOI 10.1098/rstb.1981.0066	43	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19163	19171						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326547				2022-12-27	WOS:A1992JP59300026
J	DURR, JA; HENSEN, J; SCHRIER, RW				DURR, JA; HENSEN, J; SCHRIER, RW			HIGH SPECIFIC ACTIVITY I-125 LABELED AND S-35 LABELED VASOPRESSIN ANALOGS WITH HIGH-AFFINITY FOR THE V1 AND V2 VASOPRESSIN ISORECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROHYPOPHYSEAL HORMONES; 8-LYSINE VASOPRESSIN; BINDING-SITES; RECEPTOR; PURIFICATION; ANTAGONISTS	Since iodination of the tyrosine residue in the pressin ring of vasopressins abolishes binding to the V2 (renal) isoreceptor, the low specific activity tritiated vasopressins have been the only radioligands available for this receptor. Alternative vasopressin radioligands are described in the present study. N-tert-Butoxycarbonyl-(N-t-Boc) I-125-tyrosine or [S-35]methionine were conjugated to the 8th amino acid of lysine- (LVP) or deamino-ornithine-vasopressin via active succinimidyl esters. Following the purification on C-18 reverse-phase high pressure liquid chromatography, t-Boc removal, and a second high pressure liquid chromatography purification, specific activities of 2200 and 1300 Ci/mmol were obtained for the I-125 and the S-35-labeled ligands, respectively. These vasopressin analogues, conjugated outside the pressin ring, were found to bind with high affinity to the V1A (Vascular) and V2 vasopressin isoreceptors (K(d) less-than-or-equal-to 10(-9) M) and to retain the full biological activity of intact vasopressin. The present study demonstrates the possibility of producing high specific activity radioligands with high affinity for the V1A and V2 Vasopressin isoreceptors by conjugating labeled moieties to the 8th amino acid of vasopressin analogues. Since these new radioligands have specific activities much higher than the tritiated ligands (1300-2200 versus 10-30 Ci/mmol), they should provide considerable advantages in the future study of the physiology and biochemistry of the AVP receptors.			DURR, JA (corresponding author), UNIV COLORADO,SCH MED,DEPT MED,DIV RENAL DIS,BOX C-281,DENVER,CO 80262, USA.				NIDDK NIH HHS [DK 38468, DK 19928] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928, R29DK038468] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASSOIAN RK, 1980, ANAL BIOCHEM, V103, P70, DOI 10.1016/0003-2697(80)90238-9; BURLET C, 1980, J PHYSIOL-PARIS, V76, P249; DILLINGHAM MA, 1986, SCIENCE, V231, P1572, DOI 10.1126/science.3006248; FAHRENHOLZ F, 1986, EUR J BIOCHEM, V161, P321, DOI 10.1111/j.1432-1033.1986.tb10450.x; FAHRENHOLZ F, 1985, EUR J BIOCHEM, V152, P589, DOI 10.1111/j.1432-1033.1985.tb09236.x; FLOURET G, 1977, BIOCHEMISTRY-US, V16, P2119, DOI 10.1021/bi00629a011; GEORGOUSSI Z, 1990, BIOCHIM BIOPHYS ACTA, V1055, P69, DOI 10.1016/0167-4889(90)90092-R; GUILLON G, 1984, MOL PHARMACOL, V26, P241; HAVRAN RT, 1969, J AM CHEM SOC, V91, P2696, DOI 10.1021/ja01038a048; HECHTER O, 1978, J BIOL CHEM, V253, P3230; JARD S, 1981, J PHYSIOL-PARIS, V77, P621; JARD S, 1987, MOL PHARMACOL, V32, P369; JI I, 1985, ANAL BIOCHEM, V151, P348, DOI 10.1016/0003-2697(85)90186-1; KIM JK, 1977, KIDNEY INT, V12, P172, DOI 10.1038/ki.1977.98; LANGONE JL, 1981, METHOD ENZYMOL, V71, P112; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDT BF, 1978, INT J PEPT PROT RES, V12, P258; MOORE ML, 1984, BIOCHEM BIOPH RES CO, V121, P878, DOI 10.1016/0006-291X(84)90759-9; MOREL F, 1983, RECENT PROG HORM RES, V39, P271; MOREL F, 1976, METHODS PHARM RENAL, P297; MORRIS BJ, 1976, CLIN CHIM ACTA, V73, P213, DOI 10.1016/0009-8981(76)90328-4; MUJAIS SK, 1986, J CLIN INVEST, V77, P315, DOI 10.1172/JCI112293; PRADELLE.P, 1972, FEBS LETT, V26, P189, DOI 10.1016/0014-5793(72)80570-2; RAGGENBASS M, 1987, P NATL ACAD SCI USA, V84, P7778, DOI 10.1073/pnas.84.21.7778; RATTRAY M, 1990, MOL BRAIN RES, V7, P249, DOI 10.1016/0169-328X(90)90035-C; Roy C, 1981, Ann N Y Acad Sci, V372, P92, DOI 10.1111/j.1749-6632.1981.tb15463.x; ROY C, 1981, J BIOL CHEM, V256, P3415; ROY C, 1975, J BIOL CHEM, V250, P3157; ROY C, 1982, INSERM S, V21, P41; SMIGEL M, 1977, J BIOL CHEM, V252, P3689; STASSEN FL, 1987, MOL PHARMACOL, V31, P267; ULLIAN ME, 1989, J CLIN INVEST, V84, P840, DOI 10.1172/JCI114244; WALTER R, 1967, AM J MED, V42, P653, DOI 10.1016/0002-9343(67)90087-3; WATSON S, 1991, TRENDS PHARMS CI S1, V12, P28; WEITZMAN RE, 1978, AM J PHYSIOL, V235, pE591, DOI 10.1152/ajpendo.1978.235.6.E591; YAMASHIRO D, 1967, P NATL ACAD SCI USA, V57, P1058, DOI 10.1073/pnas.57.4.1058	36	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18453	18458						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326525				2022-12-27	WOS:A1992JN50200036
J	ZHANG, B; ROTH, RA				ZHANG, B; ROTH, RA			THE INSULIN RECEPTOR-RELATED RECEPTOR - TISSUE EXPRESSION, LIGAND-BINDING SPECIFICITY, AND SIGNALING CAPABILITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR-I RECEPTOR; HAMSTER OVARY CELLS; TYROSINE KINASE; MONOCLONAL-ANTIBODIES; PROTEIN; PHOSPHORYLATION; SUBSTRATE; REGIONS; DOMAIN	In 1989, Shier and Watt identified a gene which was predicted to encode a new member of the insulin receptor (IR) family, and they called it the insulin receptor-related receptor (IRR) (Shier, P., and Watt, V. M. (1989) J. Biol. Chem. 264, 14605-14608). However, the tissues expressing this receptor, its ligand binding specificity and its signaling capability have remained unknown. In the present studies we report Northern blot analyses and polymerase chain reaction data, which indicate that the IRR mRNA is expressed in a variety of tissues, including the human kidney, heart, skeletal muscle, liver, and pancreas. In order to examine the ligand(s) recognized by IRR, we constructed a chimeric receptor with the extracellular domain of the IR replaced with that of IRR. This chimera was found not to bind radioactively labeled insulin, insulin-like growth factor I (IGF-I), or IGF-II. These ligands and relaxin, the only other known member of the mammalian insulin family, also failed to stimulate the tyrosine kinase activity of this chimeric receptor. A second chimeric receptor with the extracellular domain of IR and the kinase domain of IRR was also constructed and utilized to study the signaling capabilities of the kinase domain of IRR. This chimera exhibited high affinity insulin binding and insulin-stimulated tyrosine kinase activity. The kinase domains of the IR and IRR were found capable of phosphorylating the same spectrum of exogenous and endogenous substrates. However, Chinese hamster ovary (CHO) cells stably overexpressing the kinase domain of IRR exhibited elevated basal thymidine incorporation and 2-deoxyglucose uptake compared with CHO cells and CHO cells overexpressing wild-type IR. We conclude that: 1) IRR is expressed in the human kidney, heart, skeletal muscle, liver, and pancreas, 2) IRR does not appear to be the receptor of any known member of the insulin family, and 3) the tyrosine kinase of IRR appears to be similar to that of IR in both the spectrum of substrates phosphorylated and the biological responses stimulated.	STANFORD UNIV, MED CTR, SCH MED, DEPT PHARMACOL, STANFORD, CA 94305 USA	Stanford University					NIDDK NIH HHS [DK 34926, DK 4175] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034926, R01DK034926] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHIN JE, 1991, J BIOL CHEM, V266, P15587; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS L, 1986, P NATL ACAD SCI USA, V83, P8137, DOI 10.1073/pnas.83.21.8137; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ELLIS L, 1987, P NATL ACAD SCI USA, V84, P5101, DOI 10.1073/pnas.84.15.5101; ELLIS L, 1986, COLD SPRING HARB SYM, V51, P773, DOI 10.1101/SQB.1986.051.01.090; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GERAERTS WPM, 1991, CURRENT ASPECTS NEUR, V3, P255; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; HERBST R, 1991, J BIOL CHEM, V266, P19908; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LAMMERS R, 1991, METHOD ENZYMOL, V198, P225; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MARUYAMA K, 1988, AGR BIOL CHEM TOKYO, V52, P3035, DOI 10.1080/00021369.1988.10869178; MORGAN DO, 1986, BIOCHEMISTRY-US, V25, P1364, DOI 10.1021/bi00354a026; MYERS MG, 1991, J BIOL CHEM, V266, P10616; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; ROTH RA, 1983, BIOCHEM BIOPH RES CO, V115, P245, DOI 10.1016/0006-291X(83)90996-8; ROTH RA, 1991, MODERN CONCEPTS INSU, P505; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SCHWABE C, 1990, COMP BIOCHEM PHYS B, V96, P15, DOI 10.1016/0305-0491(90)90335-Q; SHIER P, 1990, CYTOGENET CELL GENET, V54, P80, DOI 10.1159/000132963; SHIER P, 1989, J BIOL CHEM, V264, P14605; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEELEPERKINS G, 1990, BIOCHEM BIOPH RES CO, V171, P1244, DOI 10.1016/0006-291X(90)90819-9; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAMURA S, 1983, BIOCHEM BIOPH RES CO, V113, P80, DOI 10.1016/0006-291X(83)90434-5; THIES RS, 1989, J BIOL CHEM, V264, P12820; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; YAMAMOTO K, 1992, ENDOCRINOLOGY, V130, P1490, DOI 10.1210/en.130.3.1490; ZHANG B, 1991, J BIOL CHEM, V266, P990; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	44	84	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18320	18328						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326521				2022-12-27	WOS:A1992JN50200015
J	CHAKRABORTY, T; MARTIN, JF; OLSON, EN				CHAKRABORTY, T; MARTIN, JF; OLSON, EN			ANALYSIS OF THE OLIGOMERIZATION OF MYOGENIN AND E2A PRODUCTS INVIVO USING A 2-HYBRID ASSAY SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LOOP-HELIX PROTEINS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; HETERO-OLIGOMERIZATION; REGULATORY PROTEIN; LEUCINE ZIPPER; MYOD; DOMAIN; EXPRESSION; ENHANCER	Members of the helix-loop-helix (HLH) family of proteins bind DNA and activate transcription as homo- and heterodimers. Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the E2A gene products E12 and E47. We describe a method for detection of protein-protein interactions among HLH proteins in vivo in which dimerization through the HLH motif reconstructs a hybrid transcription factor containing the DNA-binding domain of yeast GAL4 linked to one HLH motif and the activation domain of VP-16 linked to another. We have used this assay to investigate whether myogenin forms homomeric or heteromeric complexes in vivo and to determine whether growth factors and oncogenes that inhibit myogenesis influence myogenin's ability to dimerize. The results show that myogenin heterodimerizes with E12 and E47 in vivo, but it does not homodimerize to a measurable extent. Peptide growth factors, as well as the immediate early gene products c-Jun, v-Fos, and c-Myc, inhibit the activity of myogenin through a mechanism independent of its association with E2A products.	UNIV TEXAS, MD ANDERSON CANC CTR,DEPT BIOCHEM,BOX 117, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039849, R01AR040339] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39849, AR40339] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRAUN T, 1990, NATURE, V346, P663, DOI 10.1038/346663a0; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1991, J BIOL CHEM, V266, P21343; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FARMER K, 1992, J BIOL CHEM, V267, P5631; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; GOODRICH J, 1992, CELL, V68, P955, DOI 10.1016/0092-8674(92)90038-E; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN H, 1992, J BIOL CHEM, V267, P4773; MARTIN JF, 1992, J BIOL CHEM, V267, P10956; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; SCHAFER BW, 1990, NATURE, V344, P454, DOI 10.1038/344454a0; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; VASAVADA HA, 1991, P NATL ACAD SCI USA, V88, P10686, DOI 10.1073/pnas.88.23.10686; VISVADER J, 1991, TRENDS BIOCHEM SCI, V16, P330, DOI 10.1016/0968-0004(91)90137-K; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	47	16	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17498	17501						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325437				2022-12-27	WOS:A1992JM22300006
J	SCHEIBE, RJ; WAGNER, JA				SCHEIBE, RJ; WAGNER, JA			RETINOIC ACID REGULATES BOTH EXPRESSION OF THE NERVE GROWTH-FACTOR RECEPTOR AND SENSITIVITY TO NERVE GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 PHEOCHROMOCYTOMA CELLS; HIGH-AFFINITY RECEPTORS; NGF RECEPTOR; TERATOCARCINOMA CELLS; MOLECULAR-CLONING; TRK PROTOONCOGENE; NEURITE OUTGROWTH; GENE-TRANSFER; DEVELOPMENTAL EXPRESSION; TYROSINE PHOSPHORYLATION	In PC12 cells, retinoic acid (RA) stimulates the expression of p75NGFR, a component of the nerve growth factor (NGF) receptor, as indicated by a rapid increase in p75NGFR mRNA, an increase in the binding of I-125-labeled NGF to p75NGFR, and an increase in the binding of NGF to low affinity sites. RA-treated cells are more sensitive to NGF, but not to either fibroblast growth factor or phorbol 12-myristate 13-acetate, showing that RA has a specific effect on the responsiveness of PC12 cells to NGF. Exposure to RA leads neither to an increase in the expression of mRNA for trk, another component of the NGF receptor, nor to an increase in binding to high affinity receptors, suggesting that an increase in the expression of p75NGFR is sufficient to make cells more sensitive to NGF. This work suggests that, in addition to having direct effects on gene expression, RA can indirectly modulate differentiation of neurons by modifying their expression of cell surface receptors to peptide growth factors.	CORNELL UNIV, SCH MED, DEPT CELL BIOL & ANAT, NEW YORK, NY 10021 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Cornell University; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL CANCER INSTITUTE [P01CA022427, R01CA040929] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40929, CA 22427] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BERG MM, 1991, P NATL ACAD SCI USA, V88, P7106, DOI 10.1073/pnas.88.16.7106; BLOCK T, 1983, J NEUROCHEM, V40, P1654, DOI 10.1111/j.1471-4159.1983.tb08139.x; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BUXSER S, 1990, J BIOL CHEM, V265, P12701; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHO KO, 1989, MOL CELL BIOL, V9, P135, DOI 10.1128/MCB.9.1.135; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DAMON DH, 1990, J CELL BIOL, V110, P1333, DOI 10.1083/jcb.110.4.1333; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; ERIKSSON U, 1986, CANCER RES, V46, P717; EVELETH DD, 1988, NEURON, V1, P929, DOI 10.1016/0896-6273(88)90150-X; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJITA K, 1989, ENVIRON HEALTH PERSP, V80, P127, DOI 10.2307/3430738; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HASKELL BE, 1987, CELL TISSUE RES, V247, P67, DOI 10.1007/BF00216548; HAUSSLER M, 1983, P NATL ACAD SCI-BIOL, V80, P5525, DOI 10.1073/pnas.80.18.5525; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEUER JG, 1990, DEV BIOL, V137, P287, DOI 10.1016/0012-1606(90)90255-H; HOSANG M, 1987, EMBO J, V6, P1197, DOI 10.1002/j.1460-2075.1987.tb02354.x; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LANDRETH GE, 1987, NEUROCHEM RES, V12, P943, DOI 10.1007/BF00966317; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEVI-MONTALCINI R, 1968, Physiological Reviews, V48, P535; MADEN M, 1989, DEV BIOL, V135, P124, DOI 10.1016/0012-1606(89)90163-2; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; REES JL, 1989, BIOCHEM J, V259, P917, DOI 10.1042/bj2590917; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SCHEIBE RJ, 1991, J CELL BIOL, V113, P1173, DOI 10.1083/jcb.113.5.1173; SEEGER RC, 1977, CANCER RES, V37, P1364; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; STONER CM, 1989, CANCER RES, V49, P1497; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUTTER A, 1979, J BIOL CHEM, V254, P5972; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; VALE RD, 1985, METHOD ENZYMOL, V109, P21; VANBUSKIRK R, 1985, MOL CELL BIOL, V5, P1984, DOI 10.1128/MCB.5.8.1984; WAGNER JA, 1986, J CELL BIOL, V103, P1363, DOI 10.1083/jcb.103.4.1363; WANG SY, 1985, DEV BIOL, V107, P75, DOI 10.1016/0012-1606(85)90377-X; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P159, DOI 10.1073/pnas.88.1.159; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	67	63	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17611	17616						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325442				2022-12-27	WOS:A1992JM22300023
J	HASHIMOTO, Y; OGIHARA, A; NAKANISHI, S; MATSUDA, Y; KUROKAWA, K; NONOMURA, Y				HASHIMOTO, Y; OGIHARA, A; NAKANISHI, S; MATSUDA, Y; KUROKAWA, K; NONOMURA, Y			2 THROMBIN-ACTIVATED CA2+ CHANNELS IN HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; SMOOTH-MUSCLE CELLS; INOSITOL 1,4,5-TRISPHOSPHATE; FREE CALCIUM; CA-2+; RELEASE; MEMBRANES; KINETICS; PHOSPHORYLATION; TRIPHOSPHATE	The regulation of extracellular Ca2+ entry into fura-2-loaded human platelets was examined following stimulation with thrombin. In the presence of external Ca2+, stimulation of platelets with thrombin resulted in a rapid increase, followed by a plateau, in intracellular Ca2+ concentration ([Ca2+]i). Pretreatment with wortmannin, a specific inhibitor of myosin light chain kinase, suppressed only the plateau phase and had no effect on the initial rapid increase in [Ca2+]i. In Ca2+-free EGTA buffer, thrombin induced a transient and relatively small increase in [Ca2+]i caused by Ca2+ release from internal stores. When Ca2+ was added subsequently to the Ca2+-free medium within 10 min after thrombin activation, a marked increase in [Ca2+]i was seen, reflecting thrombin-stimulated external Ca2+ entry. With the Ca2+-free medium, wortmannin did not affect either the Ca2+ mobilization from the internal stores or the rapid external Ca2+ entry at early time points (within 5 s) after thrombin stimulation, whereas it significantly inhibited Ca2+ entry when Ca2+ was added later (at 3 min). Wortmannin inhibition of this late Ca2+ entry and that of 20-kDa myosin light chain phosphorylation after thrombin stimulation were dose- and preincubation time-dependent and correlated well with each other. These results suggest that two different channels are responsible for Ca2+ entry in human platelets at the early and late phases of thrombin stimulation and that the channel responsible for the late phase of Ca2+ entry may be activated by a mechanism involving myosin light chain kinase.	KYOWA HAKKO KOGYO,RES LABS,MACHIDA,TOKYO 194,JAPAN; NIHON UNIV,SCH MED,DEPT INTERNAL MED 3,ITABASHI KU,TOKYO 173,JAPAN; UNIV TOKYO,FAC MED,DEPT PHARMACOL,BUNKYO KU,TOKYO 113,JAPAN	Kyowa Kirin Ltd; Nihon University; University of Tokyo	HASHIMOTO, Y (corresponding author), UNIV TOKYO,FAC MED,DEPT INTERNAL MED 1,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN.							ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; ADUNYAH SE, 1985, BIOCHEM BIOPH RES CO, V128, P1274, DOI 10.1016/0006-291X(85)91078-2; ADUNYAH SE, 1986, J BIOL CHEM, V261, P3122; AUTHI KS, 1985, BIOCHEM J, V230, P247, DOI 10.1042/bj2300247; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BRASS LF, 1985, J BIOL CHEM, V260, P5172; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; ENOUF J, 1987, BIOCHIM BIOPHYS ACTA, V928, P76, DOI 10.1016/0167-4889(87)90087-5; HASHIMOTO Y, 1985, BIOCHIM BIOPHYS ACTA, V841, P283, DOI 10.1016/0304-4165(85)90070-4; ITOH T, 1989, NATURE, V338, P164, DOI 10.1038/338164a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1984, P NATL ACAD SCI-BIOL, V81, P7431, DOI 10.1073/pnas.81.23.7431; MAHAUTSMITH MP, 1990, J BIOL CHEM, V265, P10479; MAMIYA S, 1989, J BIOL CHEM, V264, P8575; MOORE EDW, 1990, CELL CALCIUM, V11, P157, DOI 10.1016/0143-4160(90)90068-6; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; OROURKE FA, 1985, J BIOL CHEM, V260, P956; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RINK TJ, 1990, ANNU REV PHYSIOL, V52, P431, DOI 10.1146/annurev.ph.52.030190.002243; ROGERS JC, 1989, BIOCHEM BIOPH RES CO, V164, P419, DOI 10.1016/0006-291X(89)91736-1; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; TAKEUCHI K, 1989, TOHOKU J EXP MED, V159, P23, DOI 10.1620/tjem.159.23; ZSCHAUER A, 1988, NATURE, V334, P703, DOI 10.1038/334703a0	28	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17078	17081						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324922				2022-12-27	WOS:A1992JL05300055
J	HUANG, MN; HUNG, HL; STANFIELDOAKLEY, SA; HIGH, KA				HUANG, MN; HUNG, HL; STANFIELDOAKLEY, SA; HIGH, KA			CHARACTERIZATION OF THE HUMAN BLOOD-COAGULATION FACTOR-X PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; ENHANCER BINDING-PROTEIN; ALBUMIN GENE; FACTOR-IX; TRANSCRIPTION FACTOR; HEPATOMA-CELLS; HEMOPHILIA-B; DNA; PROTHROMBIN; HORMONE	Blood coagulation Factor X is a serine protease required for both the intrinsic and extrinsic pathways of coagulation. The gene for Factor X spans 27 kilobases and is located on chromosome 13, in close proximity to the gene encoding Factor VII. Expression of Factor X is restricted to the liver. We have characterized the human Factor X promoter by mapping the start sites of transcription and carrying out a functional analysis of the promoter. The first 279 base pairs (bp) of 5'-flanking sequence upstream from the first AUG are sufficient to confer maximal promoter activity in HepG2 cells. Protein-binding sites within the 279-bp fragment are defined using gel mobility shift assays. Mutagenesis of two specific sequences within the 279-bp fragment (CCAAT at -120 to -116, and ACTTTG at -56 to -51), results in loss of ability to bind proteins from a HepG2 nuclear extract, and profound reduction in promoter activity of the 279-bp fragment. We conclude that these two protein-binding sites are critical for the activity of the Factor X promoter.	UNIV N CAROLINA, DEPT MED, DIV HEMATOL, CAMPUS BOX 7035, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PATHOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, CTR THROMBOSIS & HEMOSTASIS, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			High, Katherine A./AAB-9322-2020		NHLBI NIH HHS [KO8-HL01922, P01-HL06350] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL001922, P01HL006350] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANSON DS, 1984, EMBO J, V3, P1053, DOI 10.1002/j.1460-2075.1984.tb01926.x; BANCROFT JD, 1990, GENE, V95, P253, DOI 10.1016/0378-1119(90)90368-2; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAIR DS, 1984, BLOOD, V64, P194; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HUANG MN, 1990, BIOTECHNIQUES, V9, P710; JAGADEESWARAN P, 1989, GENE, V84, P517, DOI 10.1016/0378-1119(89)90529-5; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; REITSMA PH, 1989, BLOOD, V73, P743; SALIER JP, 1990, J BIOL CHEM, V265, P7062; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Sharp P A, 1980, Methods Enzymol, V65, P750; SHINICHI A, 1987, METHOD ENZYMOL, V151, P38; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291	32	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15440	15446						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322399				2022-12-27	WOS:A1992JG11300030
J	JACKIW, V; HUNZICKERDUNN, M				JACKIW, V; HUNZICKERDUNN, M			LUTEINIZATION-ASSOCIATED CHANGES IN PROTEIN STABILITY OF THE REGULATORY SUBUNIT OF THE TYPE-I CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN GRANULOSA-CELLS; BOVINE CARDIAC-MUSCLE; CATALYTIC SUBUNIT; MOLECULAR-CLONING; MESSENGER-RNA; CYCLIC-AMP; HUMAN TESTIS; HORMONAL-REGULATION; SKELETAL-MUSCLE; CDNA STRUCTURE	The purpose of this study was to determine how RI-alpha, the R subunit of the type I cAMP-dependent protein kinase, is regulated in rabbit ovarian follicles in response to the preovulatory luteinizing hormone surge. When soluble extracts from rabbit preovulatory follicles and 7-day-old corpora lutea were photoaffinity-labeled with 8-N3-[P-32]cAMP, 3-fold more RI-alpha was detected in corpora lutea than in follicles. Based on DEAE-cellulose chromatography, both type I holoenzyme and free RI-alpha increased during luteinization. Western blot analysis of soluble extracts obtained from follicles and corpora lutea at various time points after human chorionic gonadotropin (hCG) injection revealed a 6-10-fold increase in RI-alpha protein by 5 h after hCG injection. However, based on Northern blot analysis and solution hybridization/RNase protection assays, this increase in RI-alpha protein was not due to an increase in RI-alpha mRNA. These results suggested that RI-alpha subunit levels were post-transcriptionally regulated. Half-life determinations indicated a 2.1-fold increase in the stability of RI-alpha when follicles were incubated in the presence of hCG. The effect of hCG on the stability of RI-alpha could also be mimicked by forskolin, thus suggesting that a rise in cAMP levels in follicles during the luteinizing hormone surge plays a role in RI-alpha subunit stability. We conclude that RI-alpha protein is stabilized in follicles by hCG treatment and the consequent rise in follicular cAMP levels.	NORTHWESTERN UNIV,SCH MED,DEPT CELL MOLEC & STRUCT BIOL,303 E CHICAGO AVE,CHICAGO,IL 60611	Northwestern University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021921] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD011356] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-11356, HD-21921] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEAVO JA, 1982, HDB EXPT PHARM, V581, P363; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P3478, DOI 10.1021/bi00386a035; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUTLEY MS, 1984, J BIOL CHEM, V259, P6001; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; COSTA RH, 1986, MOL CELL BIOL, V6, P4697, DOI 10.1128/MCB.6.12.4697; DRUBIN DG, 1984, J CELL BIOL, V98, P1090, DOI 10.1083/jcb.98.3.1090; ERLICHMAN J, 1984, J BIOL CHEM, V259, P289; ERLICHMAN J, 1980, J BIOL CHEM, V255, P8179; HEDIN L, 1987, ENDOCRINOLOGY, V120, P1928, DOI 10.1210/endo-120-5-1928; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; HUNZICKERDUNN M, 1978, ENDOCRINOLOGY, V103, P420, DOI 10.1210/endo-103-2-420; HUNZICKERDUNN M, 1978, ENDOCRINOLOGY, V103, P441, DOI 10.1210/endo-103-2-441; HUNZICKERDUNN M, 1984, ENDOCRINOLOGY, V115, P302, DOI 10.1210/endo-115-1-302; HUNZICKERDUNN M, 1981, J BIOL CHEM, V256, P2185; HUNZICKERDUNN M, 1985, J BIOL CHEM, V260, P3360; HUNZICKERDUNN M, 1991, J BIOL CHEM, V266, P7166; HUNZICKERDUNN M, 1978, ENDOCRINOLOGY, V103, P431, DOI 10.1210/endo-103-2-431; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; JAHNSEN T, 1986, J BIOL CHEM, V261, P6637; JAHNSEN T, 1985, J BIOL CHEM, V260, P5980; KAPOOR CL, 1979, J BIOL CHEM, V254, P2427; KERLAVAGE AR, 1980, J BIOL CHEM, V255, P8483; KNUTSEN HK, 1991, ENDOCRINOLOGY, V129, P2496, DOI 10.1210/endo-129-5-2496; KURTEN RC, 1988, ENDOCRINOLOGY, V123, P2408, DOI 10.1210/endo-123-5-2408; LEE DC, 1983, P NATL ACAD SCI-BIOL, V80, P3608, DOI 10.1073/pnas.80.12.3608; LIU AYC, 1987, BIOCHEM BIOPH RES CO, V148, P350, DOI 10.1016/0006-291X(87)91117-X; LORIMER IAJ, 1987, J BIOL CHEM, V262, P17200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHMOUDI M, 1989, BIOTECHNIQUES, V7, P331; MAIZELS ET, 1990, SERONO S, P54; Maniatis T, 1982, MOL CLONING LABORATO; MARSH JM, 1973, BIOCHIM BIOPHYS ACTA, V304, P197, DOI 10.1016/0304-4165(73)90128-1; ORELLANA SA, 1990, J BIOL CHEM, V265, P3048; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; OYEN O, 1987, BIOL REPROD, V37, P947, DOI 10.1095/biolreprod37.4.947; OYEN O, 1988, ENDOCRINOLOGY, V122, P2658; POTTER RL, 1979, J BIOL CHEM, V254, P2413; RANGELALDAO R, 1979, J BIOL CHEM, V254, P2499; RATOOSH SL, 1987, J BIOL CHEM, V262, P7306; ROSEN OM, 1975, J BIOL CHEM, V250, P7788; RUBIN CS, 1979, J BIOL CHEM, V254, P3797; Rudolph S A, 1979, Adv Cyclic Nucleotide Res, V10, P107; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SANDBERG M, 1990, BIOCHEM BIOPH RES CO, V167, P323, DOI 10.1016/0006-291X(90)91768-N; SCHWARTZ DA, 1985, J BIOL CHEM, V260, P6296; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; STEINBERG RA, 1981, J BIOL CHEM, V256, P731; STEINBERG RA, 1984, ARCH BIOCHEM BIOPHYS, V234, P546, DOI 10.1016/0003-9861(84)90302-3; SUDGEN PH, 1976, BIOCHEM J, V159, P423; TASKEN KA, 1991, MOL ENDOCRINOL, V5, P21, DOI 10.1210/mend-5-1-21; TAYLOR SS, 1988, FASEB J, V2, P2677, DOI 10.1096/fasebj.2.11.3294077; UHLER MD, 1986, J BIOL CHEM, V261, P5360; UHLER MD, 1987, J BIOL CHEM, V262, P15202; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WELDON SL, 1985, J BIOL CHEM, V260, P6640; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; WIEMANN S, 1991, J BIOL CHEM, V266, P5140	61	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14335	14344						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321143				2022-12-27	WOS:A1992JD32500084
J	TSAI, YJ; AOKI, T; MARUTA, H; ABE, H; SAKAGAMI, H; HATANO, T; OKUDA, T; TANUMA, S				TSAI, YJ; AOKI, T; MARUTA, H; ABE, H; SAKAGAMI, H; HATANO, T; OKUDA, T; TANUMA, S			MOUSE MAMMARY-TUMOR VIRUS GENE-EXPRESSION IS SUPPRESSED BY OLIGOMERIC ELLAGITANNINS, NOVEL INHIBITORS OF POLY(ADP-RIBOSE) GLYCOHYDROLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADENOSINE DIPHOSPHATE RIBOSE); ENDOGENOUS ADP-RIBOSYLATION; S3 CELL-CYCLE; (ADP-RIBOSE)N GLYCOHYDROLASE; CHROMOSOMAL-PROTEINS; HYDROLYZABLE TANNINS; ACCEPTOR PROTEINS; REGULATORY ROLE; INTACT-CELLS; PURIFICATION	Oligomeric ellagitannins (nobotanins B, E, and K) were found to be potent inhibitors of poly(ADP-ribose) glycohydrolase purified from mouse mammary tumor 34I cells. Kinetic analysis revealed that the inhibition of nobotanin B (dimer) was competitive with respect to the substrate poly(ADP-ribose), whereas nobotanin E (trimer) and nobotanin K (tetramer) exhibited mixed-type inhibition. These results suggest that the dimeric structure of ellagitannin may have a functional domain that competes with poly(ADP-ribose) on the poly(ADP-ribose) glycohydrolase molecule. To determine the inhibitory effects of oligomeric ellagitannins on poly(ADP-ribose) glycohydrolase in vivo, we examined their effects on de-poly(ADP-ribosyl)ation of some chromosomal proteins in intact 34I cells that was induced by glucocorticoid treatment. Nobotanin B caused concentration-dependent inhibition of glucocorticoid-induced de-poly(ADP-ribosyl)ation of HMG 14 and 17 and histone H1 in intact 34I cells. Interestingly, this inhibition was associated with suppression of the glucocorticoid-sensitive mouse mammary tumor virus (MMTV) mRNA synthesis. In contrast, nobotanin E and K had little inhibitory effect on either depoly(ADP-ribosyl)ation of these proteins or induction of MMTV transcription after glucocorticoid treatment. Nobotanin B but not E and K was taken into 34I cells. These results may suggest that the suppression of glucocorticoid-sensitive MMTV transcription results from in vivo inhibition of poly(ADP-ribose) glycohydrolase by nobotanin B. These results also indicate the importance of de-poly(ADP-ribosyl)ation of HMG 14 and 17 and histone H1 in regulation of transcription of the glucocorticoid-sensitive MMTV gene.	TAIPEI MED COLL,FAC MED SCI,DEPT PHARMACOL,TAIPEI,TAIWAN; SHOWA UNIV,SCH MED,DEPT BIOCHEM 1,SHINAGAWA KU,TOKYO 142,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT LIFE SCI,YOKOHAMA,KANAGAWA 227,JAPAN; OKAYAMA UNIV,FAC PHARMACEUT SCI,OKAYAMA 700,JAPAN	Taipei Medical University; Showa University; Tokyo Institute of Technology; Okayama University			Hatano, Tsutomu/B-1645-2011	Hatano, Tsutomu/0000-0002-5593-8827				ALTHAUS FR, 1982, NATURE, V300, P366, DOI 10.1038/300366a0; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; HATAKEYAMA K, 1986, J BIOL CHEM, V261, P4902; HATANO T, 1989, CHEM PHARM BULL, V37, P2083; HATANO T, 1986, CHEM PHARM BULL, V34, P4092; HATANO T, 1989, CHEM PHARM BULL, V37, P2016; KREIMEYER A, 1984, J BIOL CHEM, V259, P890; LONN U, 1985, P NATL ACAD SCI USA, V82, P104, DOI 10.1073/pnas.82.1.104; LUCAS DL, 1984, J CELL PHYSIOL, V121, P334, DOI 10.1002/jcp.1041210210; MANDEL P, 1982, PROG NUCLEIC ACID RE, V27, P1, DOI 10.1016/S0079-6603(08)60596-6; MARUTA H, 1991, BIOCHEMISTRY-US, V30, P5907, DOI 10.1021/bi00238a014; MIWA M, 1974, J BIOL CHEM, V249, P3475; OKA J, 1984, J BIOL CHEM, V259, P986; Okuda T., 1983, J CHEM SOC P1, V1, P1765; SUGIMURA T, 1983, CARCINOGENESIS, V4, P1503, DOI 10.1093/carcin/4.12.1503; TANUMA S, 1986, J BIOCHEM, V99, P915, DOI 10.1093/oxfordjournals.jbchem.a135553; TANUMA S, 1987, BIOCHIM BIOPHYS ACTA, V910, P197, DOI 10.1016/0167-4781(87)90073-X; TANUMA S, 1989, BIOCHEM BIOPH RES CO, V163, P1047, DOI 10.1016/0006-291X(89)92327-9; TANUMA S, 1989, BIOCHEM INT, V18, P701; TANUMA S, 1982, J BIOL CHEM, V257, P6565; TANUMA S, 1990, EUR J BIOCHEM, V191, P57, DOI 10.1111/j.1432-1033.1990.tb19093.x; TANUMA S, 1989, BIOCHEM INT, V19, P1395; TANUMA S, 1983, J BIOL CHEM, V258, P5371; TANUMA S, 1983, J BIOL CHEM, V258, P4067; TANUMA SI, 1985, ARCH BIOCHEM BIOPHYS, V237, P38, DOI 10.1016/0003-9861(85)90251-6; TANUMA SI, 1986, BIOCHEM BIOPH RES CO, V135, P979, DOI 10.1016/0006-291X(86)91024-7; TANUMA SI, 1986, J BIOL CHEM, V261, P965; TAVASSOLI M, 1983, EUR J BIOCHEM, V135, P449, DOI 10.1111/j.1432-1033.1983.tb07672.x; TAVASSOLI M, 1985, BIOCHIM BIOPHYS ACTA, V827, P228, DOI 10.1016/0167-4838(85)90207-9; THOMASSIN H, 1990, NUCLEIC ACIDS RES, V18, P4691, DOI 10.1093/nar/18.16.4691; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; YOSHIDA T, 1989, J CHROMATOGR, V467, P139, DOI 10.1016/S0021-9673(01)93958-5; YOSHIDA T, 1987, HETEROCYCLES, V26, P2845; YOSHIDA T, 1987, NATURAL PRODUCTS, V29, P676	34	72	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14436	14442						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321148				2022-12-27	WOS:A1992JD32500098
J	PANG, XP; ROSS, NS; PARK, M; JUILLARD, GJF; STANLEY, TM; HERSHMAN, JM				PANG, XP; ROSS, NS; PARK, M; JUILLARD, GJF; STANLEY, TM; HERSHMAN, JM			TUMOR-NECROSIS-FACTOR-ALPHA ACTIVATES NUCLEAR FACTOR-KAPPA-B AND INDUCES MANGANOUS SUPEROXIDE-DISMUTASE AND PHOSPHODIESTERASE MESSENGER-RNA IN HUMAN PAPILLARY THYROID-CARCINOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SUBUNIT; TRANSCRIPTION FACTOR; PROGNOSTIC FACTORS; CANCER; PROTEIN; INTERLEUKIN-1; INVOLVEMENT; CACHECTIN; RECEPTORS; SURVIVAL	Human papillary thyroid carcinoma (PTC) has a relatively benign prognosis despite a high frequency of lymphatic metastasis. This suggests that local antieancer factors, generated in lymph nodes, control PTC progression. The cytokine, tumor necrosis factor-alpha (TNF-alpha), may be one such factor. We have previously shown that a human PTC cell line (NP-PTC) has high affinity TNF-alpha receptors. We now report on the action of TNF-alpha in these cells. TNF-alpha decreased [H-3]thymidine incorporation as well as cellular DNA content and cell number in a dose-dependent manner. The abundance of phosphodiesterase and manganous superoxide dismutase mRNA species was increased in a time- and dose-dependent manner in the NP-PTC cells after TNF-alpha treatment. TNF-alpha activated NF-kappa-B, a nuclear factor thought to mediate multiple actions of TNF-alpha, in these cells with a maximum effect observed after 30 min of treatment. Thus, TNF-alpha has an antiproliferative action on NP-PTC cells, despite its ability to induce the accumulation of mRNA that encodes an enzyme (manganous superoxide dismutase), thought to be cytoprotective. The net antiproliferative effect must therefore be explained by a balance of protective and tumoricidal or static effects that ultimately result in control of tumor spread. These antiproliferative effects may be in part mediated by NF-kappa-B and PDE.	VET ADM MED CTR BRENTWOOD, DEPT MED, DIV ENDOCRINOL, ENDOCRINE RES LAB, W111D, LOS ANGELES, CA 90073 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT RADIOL, LOS ANGELES, CA 90073 USA; VET ADM MED CTR BRENTWOOD, DEPT PATHOL, LOS ANGELES, CA 90073 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD025299] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25299] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; ATTIE JN, 1988, EUR J CANCER CLIN ON, V24, P315, DOI 10.1016/0277-5379(88)90274-X; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BERKOW RL, 1987, J IMMUNOL, V139, P3783; BEUTLER B, 1987, NEW ENGL J MED, V316, P379; BLOCK BL, 1990, OTOLARYNG CLIN N AM, V23, P403; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CLARK MA, 1988, BIOCHEM J, V250, P125, DOI 10.1042/bj2500125; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; CONTI M, 1986, ENDOCRINOLOGY, V118, P901, DOI 10.1210/endo-118-3-901; CONTI M, 1984, ENDOCRINOLOGY, V114, P2361, DOI 10.1210/endo-114-6-2361; DEGROOT LJ, 1990, J CLIN ENDOCR METAB, V71, P414, DOI 10.1210/jcem-71-2-414; DEKEYSER LFM, 1985, HEAD NECK SURG, V8, P100, DOI 10.1002/hed.2890080207; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HANNEQUIN P, 1986, CANCER, V58, P1749; HARDEN TK, 1983, PHARMACOL REV, V35, P5; HERSHMAN JM, 1991, MOL CLIN ADV PITUITA, P153; HERSHMAN JM, 1990, CANCER TREATMENT, P406; HILL BT, 1975, FEBS LETT, V56, P20, DOI 10.1016/0014-5793(75)80102-5; HOFFMANN HP, 1991, MOL CELL BIOL, V11, P259; HOFFMANN HP, 1990, J BIOL CHEM, V265, P15183; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MANGANIELLO V, 1972, P NATL ACAD SCI USA, V69, P269; MARINO MW, 1989, P NATL ACAD SCI USA, V86, P8417, DOI 10.1073/pnas.86.21.8417; MAZZAFERRI EL, 1986, WERNERS THYROID, P1329; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; NEALE ML, 1988, IMMUNOLOGY, V64, P81; OERTEL JE, 1986, WERNERS THYROID FUND, P651; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; SELDEN RF, 1987, CURRENT PROTOCOLS MO; SIMPSON WJ, 1987, AM J MED, V83, P479, DOI 10.1016/0002-9343(87)90758-3; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; THORESEN SO, 1989, BRIT J CANCER, V59, P231, DOI 10.1038/bjc.1989.47; VILCEK J, 1991, J BIOL CHEM, V266, P7313; VISNER GA, 1990, J BIOL CHEM, V265, P2856; WANG AM, 1985, SCIENCE, V228, P149, DOI 10.1126/science.3856324; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; YAMAUCHI N, 1989, CANCER RES, V49, P1671; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802; ZIMMERMAN RJ, 1989, J IMMUNOL, V142, P1405; ZIMMERMAN RJ, 1989, CANCER RES, V49, P1644	53	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12826	12830						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1320006				2022-12-27	WOS:A1992HZ48300067
J	KALIMAN, P; BARON, V; GAUTIER, N; VANOBBERGHEN, E				KALIMAN, P; BARON, V; GAUTIER, N; VANOBBERGHEN, E			ANTIPEPTIDE ANTIBODY TO THE INSULIN-LIKE GROWTH FACTOR-I RECEPTOR SEQUENCE-1232-1246 INHIBITS THE RECEPTOR KINASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOMA-CELLS; TYROSINE KINASE; PHORBOL ESTERS; PROTEIN-KINASES; BETA-SUBUNIT; OBESE MICE; PHOSPHORYLATION; SPECIFICITY; STIMULATE; POLYMERS	To approach the question of why insulin-like growth factor-I (IGF-I) and insulin have different physiological actions, we developed antibodies directed against cytoplasmic regions of the IGF-I receptor exhibiting a low degree of homology with the corresponding sequences of the insulin receptor. We found that an antipeptide antibody directed against the beta-subunit carboxyl-terminal sequence (1232-1246) of the IGF-I receptor significantly reduced the in vitro receptor autophosphorylation. The ability of the synthetic peptide corresponding to the IGF-I receptor sequence 1232-1246 to abolish this inhibitory effect reflects the specific nature of the antibody interaction with the targeted domain in the receptor. Antipeptide antibody to IGF-I receptor sequence 1232-1246 also decreased receptor phosphorylation activity toward the exogenous substrate poly(Glu/Tyr). The reduction in poly(Glu/Tyr) phosphorylation was seen even when the antibody was incubated with a receptor previously activated and phosphorylated. Therefore, the inhibitory action on substrate phosphorylation is likely to be unrelated to the antibody reduction of receptor autophosphorylation but rather results from a global decrease in receptor enzymatic activity. The effect of the antipeptide antibody on receptor tyrosine kinase cannot be accounted for by a lowering of the receptor K(m) for ATP or of its affinity for the substrate poly(Glu/Tyr). Moreover, the interaction of the antibody with the receptor had no repercussion on the ligand binding site as shown by the unaltered IGF-I binding. Taken together our data suggest that the beta-subunit carboxyl-terminal domain of the IGF-I receptor plays a key role in regulating its kinase activity and that the particular sequence recognized by our antipeptide antibody could be involved in negative regulation of receptor functioning.	FAC MED NICE,INSERM,U145,AVE VALOMBROSE,F-06107 NICE 2,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur								BARON V, 1989, BIOCHEM J, V260, P749, DOI 10.1042/bj2600749; BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; BRAUN S, 1984, J BIOL CHEM, V259, P2051; CASCIERI MA, 1986, BIOCHIM BIOPHYS ACTA, V886, P491, DOI 10.1016/0167-4889(86)90186-2; COCHET C, 1984, J BIOL CHEM, V259, P2553; DESBUQUOIS B, 1971, J CLIN ENDOCR METAB, V33, P732, DOI 10.1210/jcem-33-5-732; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; IWASHITA S, 1984, J BIOL CHEM, V259, P2559; JACOBS S, 1986, J BIOL CHEM, V261, P934; JACOBS S, 1983, P NATL ACAD SCI-BIOL, V80, P6211, DOI 10.1073/pnas.80.20.6211; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; KRETT NL, 1987, ENDOCRINOLOGY, V120, P401, DOI 10.1210/endo-120-1-401; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LEMARCHANDBRUSTEL Y, 1985, NATURE, V315, P676, DOI 10.1038/315676a0; MAMOUNAS M, 1989, P NATL ACAD SCI USA, V86, P9294, DOI 10.1073/pnas.86.23.9294; MASSAGUE J, 1982, J BIOL CHEM, V257, P3958; MCCLAIN DA, 1990, J BIOL CHEM, V265, P1678; POGGI C, 1979, ENDOCRINOLOGY, V105, P723, DOI 10.1210/endo-105-3-723; Roth J, 1975, Methods Enzymol, V37, P223; SAHAL D, 1988, ARCH BIOCHEM BIOPHYS, V260, P416, DOI 10.1016/0003-9861(88)90465-1; SASAKI N, 1985, J BIOL CHEM, V260, P9793; STADTMAUER L, 1986, J BIOL CHEM, V261, P3402; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANOBBERGHEN E, 1981, P NATL ACAD SCI-BIOL, V78, P1052; VERSPOHL EJ, 1984, J CLIN INVEST, V74, P1436, DOI 10.1172/JCI111555; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; YOSHITAKE S, 1982, ANAL LETT PT B, V15, P147, DOI 10.1080/00032718208064372; YU KT, 1986, J BIOL CHEM, V261, P1341; ZAPF J, 1981, CURR TOP CELL REGUL, V19, P257	37	9	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10645	10651						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1316907				2022-12-27	WOS:A1992HV09000066
J	WIKSTROM, M; MORGAN, JE				WIKSTROM, M; MORGAN, JE			THE DIOXYGEN CYCLE - SPECTRAL, KINETIC, AND THERMODYNAMIC CHARACTERISTICS OF FERRYL AND PEROXY INTERMEDIATES OBSERVED BY REVERSAL OF THE CYTOCHROME-OXIDASE REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-OXIDASE; OXYGEN; MITOCHONDRIA; REDUCTION	The catalytic mechanism of O2 reduction by cytochrome oxidase was studied in isolated mitochondria and mitoplasts by partial reversal of the reaction. At a high redox potential (E(h)) of cytochrome c, high pH, and a high electrochemical proton gradient (DELTA-mu(H+)) across the inner mitochondrial membrane, the initial ferric-cupric state (O) of the oxidized enzyme's bimetallic oxygen reaction center is converted to ferryl (F) and peroxy (P) intermediates, the optical spectroscopic properties of which are reported in detail. This is associated with reversed electron transfer from the bimetallic center to ferricytochrome c. The kinetics of reduction of ferricytochrome c by the reversed electron transfer process are compared with the kinetics of formation of F and P. The results are consistent with transfer of one electron from the ferric-cupric bimetallic center (O) to cytochrome c, yielding the F intermediate, followed by transfer of one electron from the latter to cytochrome c, yielding the P state. In the absence of an effective redox buffer, poising cytochrome c highly oxidized, these primary events are immediately followed by reoxidation of cytochrome c, which is ascribed to forward electron transfer to enzyme molecules still in the O state. This forward reaction also results in accumulation of the P intermediate. Kinetic simulations of the data predict equilibrium constants for the reversed electron transfer steps, and E(m,7) values of approximately 1.1 and 1.2 V may be calculated for the F/O and P/F redox couples, respectively, at DELTA-mu(H+) and DELTA-psi equal to zero. Taken together with previously measured E(m,7) values, these data indicate that it is the two-electron reduction of bound dioxygen to bound peroxide that is responsible for the irreversibility of the catalytic dioxygen cycle of cell respiration.			WIKSTROM, M (corresponding author), UNIV HELSINKI, DEPT MED CHEM, HELSINKI BIOENERGET GRP, SILTAVUORENPENGER 10, SF-00170 HELSINKI 17, FINLAND.		Wikstrom, Marten KF/A-4403-2008					BICKAR D, 1982, BIOCHEMISTRY-US, V21, P2661, DOI 10.1021/bi00540a013; BLAIR DF, 1985, J AM CHEM SOC, V107, P7389, DOI 10.1021/ja00311a029; CHANCE B, 1975, J BIOL CHEM, V250, P9226; GEORGE P, 1964, OXIDASES RELATED RED, V1, P3; Greenawalt J W, 1974, Methods Enzymol, V31, P310; HAN S, 1990, P NATL ACAD SCI USA, V87, P8408, DOI 10.1073/pnas.87.21.8408; HAN SW, 1990, NATURE, V348, P89, DOI 10.1038/348089a0; Hinkle P, 1970, J Bioenerg, V1, P45, DOI 10.1007/BF01516088; KLINGENBERG M, 1975, CIBA F S, V31, P105; MALMSTROM BG, 1982, ANNU REV BIOCHEM, V51, P21, DOI 10.1146/annurev.bi.51.070182.000321; MORGAN JE, 1991, BIOCHEMISTRY-US, V30, P948, DOI 10.1021/bi00218a010; MURAOKA S, 1969, BIOCHIM BIOPHYS ACTA, V180, P227, DOI 10.1016/0005-2728(69)90109-1; OGURA T, 1990, J BIOL CHEM, V265, P14721; ORII Y, 1988, ANN NY ACAD SCI, V550, P105, DOI 10.1111/j.1749-6632.1988.tb35327.x; RICH PR, 1988, FEBS LETT, V233, P25, DOI 10.1016/0014-5793(88)81349-8; SLATER EC, 1990, BIOENERGETICS, P163; Vanderkooi J., 1976, ENZYMES BIOL MEMBR, V4, P43; VAROTSIS C, 1990, BIOCHEMISTRY-US, V29, P7357, DOI 10.1021/bi00484a001; VAROTSIS C, 1989, J AM CHEM SOC, V111, P6439, DOI 10.1021/ja00198a075; VYGODINA T, 1987, FEBS LETT, V219, P387, DOI 10.1016/0014-5793(87)80258-2; WIKSTROM M, 1987, CHEM SCRIPTA, V27B, P53; WIKSTROM M, 1985, FEBS LETT, V183, P293, DOI 10.1016/0014-5793(85)80796-1; WIKSTROM M, 1981, P NATL ACAD SCI-BIOL, V78, P4051, DOI 10.1073/pnas.78.7.4051; WIKSTROM M, 1988, CHEM SCRIPTA, V28A, P71; WIKSTROM M, 1988, FEBS LETT, V231, P247, DOI 10.1016/0014-5793(88)80741-5; WIKSTROM M, 1981, ANNU REV BIOCHEM, V50, P623, DOI 10.1146/annurev.bi.50.070181.003203; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; WIKSTROM M, 1975, BIOCHIM BIOPHYS ACTA, V408, P170, DOI 10.1016/0005-2728(75)90009-2; WIKSTROM M, 1976, GENETICS BIOGENESIS, P325; Wikstrom M., 1981, CYTOCHROME OXIDASE S; WIKSTROM MKF, 1976, FEBS LETT, V65, P259, DOI 10.1016/0014-5793(76)80127-5; WILSON DF, 1972, BIOCHIM BIOPHYS ACTA, V256, P277, DOI 10.1016/0005-2728(72)90058-8; WILSON MT, 1982, BIOCHEM J, V203, P483, DOI 10.1042/bj2030483	33	141	143	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10266	10273						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1316895				2022-12-27	WOS:A1992HV09000013
J	AKIYAMA, M; CROOKE, E; KORNBERG, A				AKIYAMA, M; CROOKE, E; KORNBERG, A			THE POLYPHOSPHATE KINASE GENE OF ESCHERICHIA-COLI - ISOLATION AND SEQUENCE OF THE PPK GENE AND MEMBRANE LOCATION OF THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; PROMOTERS; MAP	Polyphosphate kinase (PPK) catalyzes the reversible transfer of the terminal phosphate of ATP to form a long-chain polyphosphate (polyP) (Ahn, K., and Kornberg, A. (1990) J. Biol. Chem. 265, 11734-11739). The Escherichia coli gene (ppk) encoding PPK has been cloned, sequenced, and overexpressed (about 100-fold). The gene possesses an open reading frame for 687 amino acids (mass of 80,278 Da). PPK has been purified from overproducing cells after release from attachment to the cell outer membrane; the purified soluble PPK reassociates with cell membrane fractions. About 850 molecules of PPK are found in a wild type cell.			AKIYAMA, M (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM007581, R01GM007581] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07581] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN KH, 1990, J BIOL CHEM, V265, P11734; AIBA H, 1981, J BIOL CHEM, V256, P1905; AKIYAMA Y, 1985, EMBO J, V4, P3351, DOI 10.1002/j.1460-2075.1985.tb04088.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANSORGE W, 1983, ELECTROPHORESIS 82, P235; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BAYER MH, 1982, J BACTERIOL, V149, P758, DOI 10.1128/JB.149.2.758-767.1982; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CSONKA LN, 1980, J BACTERIOL, V143, P529, DOI 10.1128/JB.143.1.529-530.1980; DIRHEIMER G, 1968, B SOC CHIM BIOL, V50, P1933; HARE JF, 1974, P NATL ACAD SCI USA, V71, P4843, DOI 10.1073/pnas.71.12.4843; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; ITO K, 1980, J BIOL CHEM, V255, P2123; KASSAVETIS GA, 1982, EMBO J, V1, P107, DOI 10.1002/j.1460-2075.1982.tb01132.x; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KORNBERG A, 1956, BIOCHIM BIOPHYS ACTA, V20, P215, DOI 10.1016/0006-3002(56)90280-3; KORNBERG SR, 1957, BIOCHIM BIOPHYS ACTA, V26, P294, DOI 10.1016/0006-3002(57)90008-2; Kulaev IS, 1979, BIOCH INORGANIC POLY; NAKABEPPU Y, 1985, J BIOL CHEM, V260, P7281; OHTAKE H, 1985, WATER RES, V19, P1587, DOI 10.1016/0043-1354(85)90404-X; Osborn M J, 1974, Methods Enzymol, V31, P642; PEPIN CA, 1987, J BIOL CHEM, V262, P5223; REUSCH RN, 1989, P SOC EXP BIOL MED, V191, P377; REUSCH RN, 1988, P NATL ACAD SCI USA, V85, P4176, DOI 10.1073/pnas.85.12.4176; Sambrook J, 1989, MOL CLONING LABORATO; SMITH JM, 1987, J BIOL CHEM, V262, P10565; SZYMONA M, 1977, ACTA BIOCHIM POL, V24, P133; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOOD HG, 1988, ANNU REV BIOCHEM, V57, P235, DOI 10.1146/annurev.bi.57.070188.001315	29	176	190	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22556	22561						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331061				2022-12-27	WOS:A1992JW71900088
J	SHAH, MM; GROVER, TA; BARR, DP; AUST, SD				SHAH, MM; GROVER, TA; BARR, DP; AUST, SD			ON THE MECHANISM OF INHIBITION OF THE VERATRYL ALCOHOL OXIDASE ACTIVITY OF LIGNIN PEROXIDASE H2 BY EDTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHITE-ROT FUNGUS; PHANEROCHAETE-CHRYSOSPORIUM; ENVIRONMENTAL-POLLUTANTS; STEADY-STATE; OXALIC-ACID; COMPOUND-II; OXIDATION; DEGRADATION; OXYGEN; PURIFICATION	The mechanism of inhibition of the veratryl alcohol oxidase activity of lignin peroxidase H2 (LiPH2) by EDTA was investigated. It was found that EDTA was decarboxylated and that cytochrome c, nitro blue tetrazolium, ferric iron, and molecular oxygen were reduced in a reaction mixture containing LiPH2, H2O2, veratryl alcohol, and EDTA. The reductive activity observed with LiPH2 followed first order kinetics with respect to the concentration of EDTA. Stoichiometry studies showed that in the presence of sufficient EDTA, 1.7 mol of ferric iron were reduced per mole of H2O2 added to the reaction mixture. Superoxide- and EDTA-derived radicals were detected by ESR spin trapping upon incubation of LiPH2 with H2O2, veratryl alcohol, and EDTA. The K(m) values of veratryl alcohol and H2O2 remained the same for both the oxidative and reductive activities of LiPH2. Reductive activity was also observed with LiPH2 and EDTA using other free radical mediators in the place of veratryl alcohol, such as 1,4-dimethoxybenzene, 1,2,3- and 1,2,4-trimethoxybenzenes, and 1,2,4,5-tetramethoxybenzene. EDTA reduced the cation radical of 1,2,4,5-tetramethoxybenzene formed by LiPH2 in the presence of H2O2. Hence, it is proposed that the apparent inhibition of the veratryl alcohol oxidase activity of LiPH2 by EDTA is due to the reduction of the veratryl alcohol cation radical intermediate back to veratryl alcohol by EDTA. The reduction of cytochrome c, nitro blue tetrazolium, ferric ion, and molecular oxygen appears to be mediated by the EDTA radical formed by reduction of the veratryl alcohol cation radical.	UTAH STATE UNIV, CTR BIOTECHNOL, LOGAN, UT 84322 USA	Utah System of Higher Education; Utah State University					NIEHS NIH HHS [ES04922] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004922] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKAMATSU Y, 1990, FEBS LETT, V269, P261, DOI 10.1016/0014-5793(90)81169-O; ANDERSON NH, 1971, J CHEM SOC B, P993, DOI 10.1039/j29710000993; ARJMAND M, 1985, J AGR FOOD CHEM, V33, P1055, DOI 10.1021/jf00066a011; AUST SD, 1990, MICROB ECOL, V20, P197, DOI 10.1007/BF02543877; BANERJEE RK, 1989, J BIOL CHEM, V264, P9188; BANERJEE RK, 1986, J BIOL CHEM, V261, P592; BARLEV SS, 1981, BIOCHEM BIOPH RES CO, V99, P373, DOI 10.1016/0006-291X(81)91755-1; BARR DP, 1992, ARCH BIOCHEM BIOPHYS, V298, P480, DOI 10.1016/0003-9861(92)90438-3; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; BUMPUS JA, 1985, SCIENCE, V228, P1434, DOI 10.1126/science.3925550; DEMELO PM, 1992, ARCH BIOCHEM BIOPHYS, V296, P34; FAISON BD, 1983, APPL ENVIRON MICROB, V46, P1140, DOI 10.1128/AEM.46.5.1140-1145.1983; FIFE DJ, 1979, PHOTOCHEM PHOTOBIOL, V29, P43, DOI 10.1111/j.1751-1097.1979.tb09257.x; FORNEY LJ, 1982, J BIOL CHEM, V257, P1455; GILARDI G, 1990, BIOCHIM BIOPHYS ACTA, V1041, P129, DOI 10.1016/0167-4838(90)90055-K; GOLD MH, 1983, PHOTOCHEM PHOTOBIOL, V38, P617; GREENWALD RA, 1985, CRC HDB METHODS OXYG, P121; GROVER TA, 1987, FREE RADICAL BIO MED, V3, P27, DOI 10.1016/0891-5849(87)90036-0; HAEMMERLI SD, 1986, J BIOL CHEM, V261, P6900; HALL PL, 1980, ENZYME MICROB TECH, V2, P170, DOI 10.1016/0141-0229(80)90043-5; HAMMEL KE, 1986, J BIOL CHEM, V261, P6948; HARVEY PJ, 1986, FEBS LETT, V195, P242, DOI 10.1016/0014-5793(86)80168-5; HARVEY PJ, 1989, BIOCHIM BIOPHYS ACTA, V994, P59, DOI 10.1016/0167-4838(89)90062-9; HEELIS PF, 1982, CHEM SOC REV, V11, P15, DOI 10.1039/cs9821100015; KELLEY RL, 1986, J BACTERIOL, V166, P269, DOI 10.1128/jb.166.1.269-274.1986; KERNSTEN PJ, 1985, J BIOL CHEM, V260, P2609; KIRK TK, 1978, ARCH MICROBIOL, V117, P277, DOI 10.1007/BF00738547; METODIEWA D, 1992, ARCH BIOCHEM BIOPHYS, V296, P27, DOI 10.1016/0003-9861(92)90540-D; PHILIP JK, 1987, J BACTERIOL, V169, P2195; POPP JL, 1991, ARCH BIOCHEM BIOPHYS, V288, P145, DOI 10.1016/0003-9861(91)90176-J; POPP JL, 1990, BIOCHEMISTRY-US, V29, P10475, DOI 10.1021/bi00498a008; SAWYER DT, 1984, OXYGEN RADICALS CHEM; SHAH MM, 1991, ARCH BIOCHEM BIOPHYS, V290, P173, DOI 10.1016/0003-9861(91)90604-H; SHIMADA MF, 1981, ARCH MICROBIOL, V1129, P321; SHOEMAKER HE, 1990, RECL TRAV CHIM PAY B, V109, P255; TAKAO S, 1965, APPL MICROBIOL, V13, P732, DOI 10.1128/AEM.13.5.732-737.1965; TIEN M, 1986, J BIOL CHEM, V261, P1687; TIEN M, 1987, CRIT REV MICROBIOL, V15, P141, DOI 10.3109/10408418709104456; TUISEL H, 1990, ARCH BIOCHEM BIOPHYS, V279, P158, DOI 10.1016/0003-9861(90)90476-F; TUISEL H, 1991, ARCH BIOCHEM BIOPHYS, V293, P287; WARIISHI H, 1991, J BIOL CHEM, V266, P20694; WAYNER DDM, 1988, J AM CHEM SOC, V110, P132, DOI 10.1021/ja00209a021; YAMAZAKI I, 1960, ARCH BIOCHEM BIOPHYS, V86, P294, DOI 10.1016/0003-9861(60)90421-5	43	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21564	21569						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328238				2022-12-27	WOS:A1992JV01100048
J	LEMAS, MV; TAKEYASU, K; FAMBROUGH, DM				LEMAS, MV; TAKEYASU, K; FAMBROUGH, DM			THE CARBOXYL-TERMINAL-161 AMINO-ACIDS OF THE NA,K-ATPASE ALPHA-SUBUNIT ARE SUFFICIENT FOR ASSEMBLY WITH THE BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; NA+-K+-ATPASE; SKELETAL-MUSCLE; INTRACELLULAR-TRANSPORT; SODIUM-PUMP; SARCOPLASMIC-RETICULUM; EXPRESSION; NA+,K+-ATPASE; CELLS; CA-2+-ATPASE	Chimeric cDNAs encoding regions of the Na,K-ATPase alpha-subunit and a sarcoplasmic reticulum Ca2+-ATPase were constructed and expressed together with the avian Na,K-ATPase beta-subunit cDNA in COS-1 cells to determine which regions of the alpha-subunit are required for assembly with the beta-subunit. Assembly was assayed by immune precipitation of the chimeric subunit with a monoclonal antibody to the avian beta-subunit. A chimera composed of the amino-terminal two-thirds of the Na,K-ATPase and carboxyl-terminal one-third of the Ca2+-ATPase did not assemble with the avian beta-subunit. In contrast, the reciprocal chimera, containing the carboxyl-terminal one-third of the Na,K-ATPase, assembled with the beta-subunit. A third chimera, in which 161 amino acids of the Na,K-ATPase carboxyl terminus replaced the corresponding amino acids of the Ca2+-ATPase carboxyl terminus, also assembled with the beta-subunit. These results suggest that the aminoacyl residues of the Na,K-ATPase alpha-subunit critical for subunit assembly lie within the carboxyl-terminal 16% of the sequence.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; OHIO STATE UNIV, DEPT MED BIOCHEM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, CTR BIOTECHNOL, COLUMBUS, OH 43210 USA	Johns Hopkins University; Ohio State University; Ohio State University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044373, R21GM044373] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-27867] Funding Source: Medline; NIGMS NIH HHS [GM-44373] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CAMPBELL AM, 1992, J BIOL CHEM, V267, P9321; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; FAMBROUGH DM, 1983, J BIOL CHEM, V258, P3926; FAMBROUGH DM, 1988, TRENDS NEUROSCI, V11, P325, DOI 10.1016/0166-2236(88)90096-3; FAMBROUGH DM, 1983, COLD SPRING HARB SYM, V48, P297, DOI 10.1101/SQB.1983.048.01.032; FAMBROUGH DM, 1992, IN PRESS CURR TOP ME, V40; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GEERING K, 1987, J CELL BIOL, V105, P2613, DOI 10.1083/jcb.105.6.2613; Hall Z W, 1992, Trends Cell Biol, V2, P66, DOI 10.1016/0962-8924(92)90058-U; HORISBERGER JD, 1991, ANNU REV PHYSIOL, V53, P565, DOI 10.1146/annurev.physiol.53.1.565; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JAUNIN P, 1992, J BIOL CHEM, V267, P577; KAPRIELIAN Z, 1987, DEV BIOL, V124, P490, DOI 10.1016/0012-1606(87)90502-1; KARIN NJ, 1989, MOL CELL BIOL, V9, P1978, DOI 10.1128/MCB.9.5.1978; KAWAKAMI K, 1988, J BIOCHEM-TOKYO, V103, P54, DOI 10.1093/oxfordjournals.jbchem.a122239; KONE BC, 1990, SODIUM PUMP RECENT D, V46, P263; KURT AE, 1992, P NATL ACAD SCI USA, V89, P2834; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LUCKIE DB, 1992, BIOPHYS J, V62, P220, DOI 10.1016/S0006-3495(92)81807-6; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NOGUCHI S, 1990, BIOCHIM BIOPHYS ACTA, V1023, P247, DOI 10.1016/0005-2736(90)90420-S; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; STULTS NL, 1989, ANAL BIOCHEM, V180, P114, DOI 10.1016/0003-2697(89)90097-3; TAKEYASU K, 1990, AM J PHYSIOL, V259, pC619, DOI 10.1152/ajpcell.1990.259.4.C619; TAKEYASU K, 1989, CURR TOP MEMBR TRANS, V34, P143; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; TAKEYASU K, 1987, J BIOL CHEM, V262, P10733; TAMKUN MM, 1986, J BIOL CHEM, V261, P1009	38	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20987	20991						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328216				2022-12-27	WOS:A1992JT97800075
J	PEPPER, MS; MATSUMOTO, K; NAKAMURA, T; ORCI, L; MONTESANO, R				PEPPER, MS; MATSUMOTO, K; NAKAMURA, T; ORCI, L; MONTESANO, R			HEPATOCYTE GROWTH-FACTOR INCREASES UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (U-PA) AND U-PA RECEPTOR EXPRESSION IN MADIN-DARBY CANINE KIDNEY EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCATTER FACTOR; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; C-MET; INVITRO; IDENTIFICATION; MORPHOGENESIS; INDUCTION; MONOCYTES; BINDING	We have recently demonstrated that fibroblast-conditioned medium induces Madin-Darby canine kidney (MDCK) epithelial cells to form branching tubules when grown in three-dimensional collagen or fibrin gels (Montesano, R., Schaller, G., and Orci, L. (1991) Cell 66, 697-711), and that this morphogenetic effect is mediated by hepatocyte growth factor (HGF), also known as scatter factor (Montesano, R., Matsumoto, K., Nakamura, T., and Orci, L. (1991) Cell 67, 901-908). In fibrin gels, this effect is inhibited by addition of exogenous serine protease inhibitors, which suggests a role for plasminogen activators (PAs) in the matrix remodeling required for tubulogenesis. In the studies reported in this paper, we have investigated the effect of fibroblast-conditioned medium (CM) and HGF on the production of PAs by MDCK cells. We have found that urokinase-type PA (u-PA) activity and mRNA are increased 4.9-fold by CM from human MRC-5 fibroblasts, which has tubulogenic activity, but not by CM from human Detroit-550 fibroblasts, which lacks tubulogenic activity. The u-PA inductive property of MRC-5 CM was completely inhibited by preincubation with antibodies to recombinant human HGF (rhHGF). Exogenously added rhHGF also increased u-PA activity and mRNA 5.9-fold in MDCK cells, with an optimal effect at approximately 10 ng/ml. MRC-5 CM also increased u-PA receptor mRNA 34.9-fold in MDCK cells, an effect which was inhibited by 71% by preincubating the CM with antibodies to rhHGF, and which was mimicked by exogenously added rhHGF (31.3-fold increase). These results demonstrate that HGF, which induces tubulogenesis by MDCK cells in vitro, also increases u-PA and u-PA receptor expression in these cells. Taken together with our previous observations, this suggests that the resulting increase in extracellular proteolysis, appropriately localized to the cell surface, is required for epithelial morphogenesis.	KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN	Kyushu University	PEPPER, MS (corresponding author), UNIV GENEVA,MED CTR,DEPT MORPHOL,INST HISTOL & EMBRYOL,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND.		Pepper, Michael S./M-6143-2014	Pepper, Michael S./0000-0001-6406-2380				Alexander CM, 1991, CELL BIOL EXTRACELLU, P255; BELIN D, 1985, EUR J BIOCHEM, V148, P225, DOI 10.1111/j.1432-1033.1985.tb08829.x; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSO N, 1986, J BIOL CHEM, V261, P9309; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FURLONG RA, 1991, J CELL SCI, V100, P173; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; KONISHI T, 1991, BIOCHEM BIOPH RES CO, V180, P765, DOI 10.1016/S0006-291X(05)81131-3; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MICHALOPOULOS GK, 1992, HEPATOLOGY, V15, P149, DOI 10.1002/hep.1840150125; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1991, Progress in Growth Factor Research, V3, P67, DOI 10.1016/0955-2235(91)90014-U; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PEPPER MS, 1990, CELL DIFFER DEV, V32, P319, DOI 10.1016/0922-3371(90)90046-Y; PEPPER MS, 1987, J CELL BIOL, V105, P2535, DOI 10.1083/jcb.105.6.2535; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; VASSALLI JD, 1977, CELL, V11, P695, DOI 10.1016/0092-8674(77)90086-1; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001	34	215	218	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20493	20496						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328201				2022-12-27	WOS:A1992JR85800115
J	CHEIFETZ, S; BELLON, T; CALES, C; VERA, S; BERNABEU, C; MASSAGUE, J; LETARTE, M				CHEIFETZ, S; BELLON, T; CALES, C; VERA, S; BERNABEU, C; MASSAGUE, J; LETARTE, M			ENDOGLIN IS A COMPONENT OF THE TRANSFORMING GROWTH-FACTOR-BETA RECEPTOR SYSTEM IN HUMAN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BINDING-PROTEINS; SURFACE PROTEINS; IDENTIFICATION; EXPRESSION; PURIFICATION; ANTIGEN; CLONING; KINASE	Endoglin, a dimeric membrane glycoprotein expressed at high levels on human vascular endothelial cells, shares regions of sequence identity with beta-glycan, a major binding protein for transforming growth factor-beta (TGF-beta) that co-exists with TGF-beta receptors I and II in a variety of cell lines but is low or absent in endothelial cells. We have examined whether endoglin also binds TGF-beta and demonstrate here that the major TGF-beta1-binding protein co-existing with TGF-beta receptors I and II on human umbilical vein endothelial cells is endoglin, as determined by specific immunoprecipitation of endoglin affinity-labeled with I-125-TGF-beta. Furthermore, endoglin ectopically expressed in COS cells binds TGF-beta1. Competition affinity-labeling experiments showed that endoglin binds TGF-beta1 (K(D) approximately 50 pM) and TGF-beta3 with high affinity but fails to bind TGF-beta2. This difference in affinity of endoglin for the TGF-beta isoforms is in contrast to beta-glycan which recognizes all three isoforms. TGF-beta however is binding with high affinity to only a small fraction of the available endoglin molecules, suggesting that some rate-limiting event is required to sustain TGF-beta binding to endoglin.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,BOX 116,1275 YORK AVE,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; CSIC,CTR INVEST BIOL,E-28006 MADRID,SPAIN; HOSP SICK CHILDREN,DIV IMMUNOL & CANC RES,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,TORONTO M5G LX8,ONTARIO,CANADA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto			Bellón, Teresa/ABF-4916-2020; Calés, Carmela/AAB-1595-2019; Bernabeu, Carmelo/L-3226-2014; Bernabeu, Carmelo/P-4662-2019	Bellón, Teresa/0000-0002-0138-6879; Bernabeu, Carmelo/0000-0002-1563-6162; Bernabeu, Carmelo/0000-0002-1563-6162; Cales, Carmela/0000-0002-6987-2259; Massague, Joan/0000-0001-9324-8408				ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; BUHRING HJ, 1991, LEUKEMIA, V5, P841; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; Fafeur V, 1990, GROWTH FACTORS, V3, P237, DOI 10.3109/08977199009043908; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOUGOS A, 1988, J IMMUNOL, V141, P1925; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; GOUGOS A, 1988, J IMMUNOL, V141, P1935; GOUGOS A, 1992, J INT IMMUNOL, V4, P83; ICHIJO H, 1991, J BIOL CHEM, V266, P22459; JENNINGS JC, 1988, J CELL PHYSIOL, V137, P167, DOI 10.1002/jcp.1041370120; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MACKAY K, 1990, J BIOL CHEM, V265, P9351; MACKAY K, 1991, J BIOL CHEM, V266, P9907; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MERWIN JR, 1991, AM J PATHOL, V138, P37; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; QUACKENBUSH EJ, 1985, J IMMUNOL, V134, P1276; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SEGARINI PR, 1992, J BIOL CHEM, V267, P1048; WANG XF, 1991, CELL, V67, P796	31	706	739	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19027	19030						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326540				2022-12-27	WOS:A1992JP59300002
J	OH, Y; MATALON, S; KLEYMAN, TR; BENOS, DJ				OH, Y; MATALON, S; KLEYMAN, TR; BENOS, DJ			BIOCHEMICAL-EVIDENCE FOR THE PRESENCE OF AN AMILORIDE BINDING-PROTEIN IN ADULT ALVEOLAR TYPE-II PNEUMOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLADDER MEMBRANE-VESICLES; EPITHELIAL SODIUM-CHANNEL; ISOLATED RAT LUNG; ION-TRANSPORT; NA+ CHANNELS; CELLS; LOCALIZATION; ANTIBODIES; ANALOGS; ABSORPTION	An amiloride binding protein in adult rat and rabbit alveolar type II (ATII) cells was characterized using three different antibodies against epithelial Na+ channel proteins. We found that 1) polyclonal antibodies raised against epithelial Na+ channel proteins from bovine kidney cross-react with a 135-kDa protein in ATII membrane vesicles on Western blots; 2) using the photoreactive amiloride analog, 2'-methoxy-5'-nitrobenzamil (NMBA), in combination with anti-amiloride antibodies, we found that NMBA specifically labeled the same M(r) protein; and 3) monoclonal anti-idiotypic antibodies directed against anti-amiloride antibodies also recognized this same M(r) protein on Western blots. We also demonstrated a low benzamil affinity binding site (apparent K(d) = 370 nM) in rabbit ATII cell membranes and both high and low benzamil affinity binding sites (apparent K(d) = 6 nM and 230 nM) in bovine kidney membranes using [H-3]Br-benzamil as a ligand. Pharmacological inhibitory profiles for displacing bound [H-3]Br-benzamil were also different between ATII cells and bovine kidneys. These observations indicate that adult ATII pneumocytes express a population of epithelial Na+ channels having a low affinity to benzamil and amiloride and a pharmacological inhibitory profile different from that in bovine kidney.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT ANESTHESIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PEDIAT,BIRMINGHAM,AL 35294; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PHYSIOL,PHILADELPHIA,PA 19104; VET AFFAIRS MED CTR,PHILADELPHIA,PA 19104	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL031197, R01HL031197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK037206, R01DK037206] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-31197] Funding Source: Medline; NIDDK NIH HHS [DK-37206] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMSON IYR, 1974, LAB INVEST, V30, P35; ASHER C, 1987, J BIOL CHEM, V262, P8566; BARBRY P, 1989, BIOCHEMISTRY-US, V28, P3744, DOI 10.1021/bi00435a018; BASSET G, 1987, J PHYSIOL-LONDON, V384, P325, DOI 10.1113/jphysiol.1987.sp016457; BASSET G, 1987, J PHYSIOL-LONDON, V384, P311, DOI 10.1113/jphysiol.1987.sp016456; Bennett J., 1985, NEUROTRANSMITTER REC, V2nd, P61; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; BENOS DJ, 1992, IN PRESS REV PHYSL B; BRIDGES RJ, 1988, AM J PHYSIOL, V254, pC484, DOI 10.1152/ajpcell.1988.254.4.C484; BRIDGES RJ, 1989, AM J PHYSIOL, V256, pC67, DOI 10.1152/ajpcell.1989.256.1.C67; BROWN D, 1989, AM J PHYSIOL, V256, pF366, DOI 10.1152/ajprenal.1989.256.2.F366; BRUNS RF, 1983, ANAL BIOCHEM, V132, P74, DOI 10.1016/0003-2697(83)90427-X; CHEEK JM, 1989, AM J PHYSIOL, V256, pC688, DOI 10.1152/ajpcell.1989.256.3.C688; CRAPO JD, 1978, LAB INVEST, V39, P640; DOBBS LG, 1990, AM J PHYSIOL, V258, pL134, DOI 10.1152/ajplung.1990.258.4.L134; EVANS MJ, 1975, EXP MOL PATHOL, V22, P142, DOI 10.1016/0014-4800(75)90059-3; GARTY H, 1984, J MEMBRANE BIOL, V82, P269, DOI 10.1007/BF01871636; GOODMAN BE, 1987, J APPL PHYSIOL, V62, P2460, DOI 10.1152/jappl.1987.62.6.2460; HACKNEY CM, 1991, SCANNING MICROSCOPY, V5, P741; HAIES DM, 1981, AM REV RESPIR DIS, V123, P533; KLEYMAN TR, 1986, AM J PHYSIOL, V250, pC165, DOI 10.1152/ajpcell.1986.250.1.C165; KLEYMAN TR, 1991, J BIOL CHEM, V266, P3907; KLEYMAN TR, 1989, J BIOL CHEM, V264, P11995; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P51; MASON RJ, 1982, P NATL ACAD SCI-BIOL, V79, P6033, DOI 10.1073/pnas.79.19.6033; MATALON S, 1991, AM J PHYSIOL, V260, pL90, DOI 10.1152/ajplung.1991.260.2.L90; MATALON S, 1991, AM J PHYSIOL, V261, pC727, DOI 10.1152/ajpcell.1991.261.5.C727; MATALON S, 1992, AM J PHYSIOL, V262, pC1228, DOI 10.1152/ajpcell.1992.262.5.C1228; MORAN A, 1988, J BIOL CHEM, V263, P19586; NIELSON DW, 1990, AM J PHYSIOL, V258, pL215, DOI 10.1152/ajplung.1990.258.4.L215; NIJJAR MS, 1980, BIOCHIM BIOPHYS ACTA, V600, P238, DOI 10.1016/0005-2736(80)90429-0; OH Y, 1992, IN PRESS AMILORIDE I; SARIBANSOHRABY S, 1986, BIOCHEMISTRY-US, V25, P4639, DOI 10.1021/bi00364a028; SIMON SA, 1992, IN PRESS J ELECTRON; SMITH PR, 1991, ANNU REV PHYSIOL, V53, P509, DOI 10.1146/annurev.ph.53.030191.002453; SORSCHER EJ, 1988, AM J PHYSIOL, V255, pC835, DOI 10.1152/ajpcell.1988.255.6.C835; TIERNEY DF, 1989, AM J PHYSIOL, V257, pL1, DOI 10.1152/ajplung.1989.257.2.L1; TOUSSON A, 1989, J CELL SCI, V93, P349; [No title captured]	41	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18498	18504						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326526				2022-12-27	WOS:A1992JN50200042
J	REPASKE, DR; SWINNEN, JV; JIN, SLC; VANWYK, JJ; CONTI, M				REPASKE, DR; SWINNEN, JV; JIN, SLC; VANWYK, JJ; CONTI, M			A POLYMERASE CHAIN-REACTION STRATEGY TO IDENTIFY AND CLONE CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE CDNAS - MOLECULAR-CLONING OF THE CDNA-ENCODING THE 63-KDA CALMODULIN-DEPENDENT PHOSPHODIESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY CAMP PHOSPHODIESTERASE; AMINO-ACID-SEQUENCE; DROSOPHILA DUNCE+ GENE; PROTEOLYTIC ACTIVATION; MESSENGER-RNA; ALPHA-SUBUNIT; BOVINE BRAIN; IDENTIFICATION; PHYTOHEMAGGLUTININ; ISOZYMES	Multiple isozymes of cyclic nucleotide phosphodiesterases (PDEs) are expressed simultaneously in mammalian tissues. To identify and clone these PDEs, a polymerase chain reaction (PCR) strategy was developed using degenerate oligonucleotide primers designed to hybridize with highly conserved PDE DNA domains. Both known and novel PDEs were cloned from rat liver, the mouse K30a-3.3 lymphoma cell line, and a human hypothalamus cDNA library, demonstrating that these PCR primers can be used to amplify the cDNA of multiple PDE isozymes. One unique mouse PDE clone was found to encode a polypeptide identical with the corresponding portion of the bovine brain 63-kDa calmodulin-dependent PDE as reported in the companion article (Bentley, J. K., Kadlecek, A., Sherbert, C. H., Seger, D., Sonnenburg, W. K., Charbonneau, H., Novack, J. P., and Beavo, J. A. (1992) J. Biol. Chem. 267, 18676-18682). This mouse clone was used as a probe to screen a rat brain cDNA library for a full-length clone. The conceptual translation of the nucleotide sequence of the resulting rat clone has an open reading frame of 535 amino acids and maintains a high degree of homology with the bovine 63-kDa calmodulin-dependent PDE, indicating that this protein is likely to be the rat homolog of the 63-kDa calmodulin-dependent PDE. Expression of the full-length clone in Escherichia coli yielded a cGMP hydrolyzing activity that was stimulated severalfold by calmodulin. Northern blot analysis demonstrated that the mRNA encoding this PDE is highly expressed in rat brain and also in the S49.1 T-lymphocyte cell line. These data demonstrate that the PCR method described is a viable strategy to isolate cDNA clones of known and novel members of different families of PDE isozymes. Molecular cloning of these PDEs will provide valuable tools for investigating the roles of these isozymes in regulation of intracellular concentrations of the cyclic nucleotides.	UNIV N CAROLINA, DEPT PEDIAT, REPROD BIOL LABS, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DIV PEDIAT ENDOCRINOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PHYSIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Swinnen, Johannes V/AAA-2214-2022; Repaske, David/W-5603-2019; Repaske, David/E-3939-2011	Swinnen, Johannes V/0000-0002-7720-5077; Repaske, David/0000-0002-5417-0967; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007129] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20788] Funding Source: Medline; NIDDK NIH HHS [5 T32 DK07129] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAEHR W, 1991, FEBS LETT, V278, P107, DOI 10.1016/0014-5793(91)80095-K; Beavo J., 1990, CYCLIC NUCLEOTIDE PH, P3; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BENTLEY JK, 1992, J BIOL CHEM, V267, P18676; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BROTHERS VM, 1982, J BIOL CHEM, V257, P9349; CHARBONNEAU H, 1991, BIOCHEMISTRY-US, V30, P7931, DOI 10.1021/bi00246a009; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; EPSTEIN PM, 1984, ADV CYCLIC NUCL PROT, V16, P303; FRANCIS SH, 1990, CYCLIC NUCLEOTIDE PH, P117; Gillespie P.G., 1990, CYCLIC NUCLEOTIDE PH, P163; HOUSLAY MD, 1990, CYCLIC NUCLEOTIDE PH, P185; HURWITZ RL, 1990, J BIOL CHEM, V265, P8901; KINCAID RL, 1985, J BIOL CHEM, V260, P9009; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIVI GP, 1990, MOL CELL BIOL, V10, P2678, DOI 10.1128/MCB.10.6.2678; NOVACK JP, 1991, BIOCHEMISTRY-US, V30, P7940, DOI 10.1021/bi00246a010; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; RALPH P, 1973, J IMMUNOL, V110, P1470; RALPH P, 1973, J NATL CANCER I, V51, P883, DOI 10.1093/jnci/51.3.883; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; SONNENBURG WK, 1991, J BIOL CHEM, V266, P17655; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; TANAKA T, 1991, SEC MESS PHOSPHOPROT, V13, P87; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; TRONG HL, 1990, BIOCHEMISTRY-US, V29, P10280, DOI 10.1021/bi00496a018; Wang J.H., 1990, CYCLIC NUCLEOTIDE PH, P19	38	55	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18683	18688						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326532				2022-12-27	WOS:A1992JN50200067
J	NISHIKAWA, A; IHARA, Y; HATAKEYAMA, M; KANGAWA, K; TANIGUCHI, N				NISHIKAWA, A; IHARA, Y; HATAKEYAMA, M; KANGAWA, K; TANIGUCHI, N			PURIFICATION, CDNA CLONING, AND EXPRESSION OF UDP-N-ACETYLGLUCOSAMINE - BETA-D-MANNOSIDE BETA-1,4N-ACETYLGLUCOSAMINYLTRANSFERASE-III FROM RAT-KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FULL-LENGTH CDNA; GLYCOPROTEIN-SYNTHESIS; LINKED OLIGOSACCHARIDES; LIVER CARCINOGENESIS; HEPATOMA TISSUES; MESSENGER-RNA; SUGAR CHAINS; HEN OVIDUCT; CELLS; SEQUENCE	UDP-N-acetylglucosamine:beta-D-mannoside beta-1,4N-acetylglucosaminyltransferase III (GnT-III: EC 2.4.1.144) catalyzes the addition of N-acetylglucosamine in beta-1-4 linkage to the beta-linked mannose of the trimannosyl core of N-linked sugar chains. The enzyme has been purified over 153,000-fold in 1.5% yield from a Triton X-100 extract of rat kidney by fractionation procedures utilizing QAE-Sepharose, Cu2+-chelating Sepharose, and affinity chromatography on UDP-hexanolamine and substrate-conjugated Sepharose. The purified protein migrates as one major and one minor band with apparent molecular masses of 62 kDa and 52 kDa, respectively. The purified enzyme was digested with trypsin, and the amino acid sequences of four peptides were determined. Oligonucleotide primers were designed according to those amino acid sequences and used in the polymerase chain reaction. Screening for the cDNA for GnT-III was carried out by plaque hybridization using a rat kidney cDNA library (lambda-gt10) and a polymerase chain reaction product as the probe. Rat kidney GnT-III has 536 amino acids and three putative N-glycosylation sites. There is no sequence homology to other previously cloned glycosyltransferases, but the enzyme appears to be a type II transmembrane protein like the other glycosyltransferases. The GnT-III activity in transiently transfected COS-1 cells was found to be about 500-3600-fold as compared to that in non- or mock-transfected cells.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,2-2 YAMADAOKA,SUITA,OSAKA 565,JAPAN; INST MOLEC & CELLULAR BIOL,DIV MOLEC BIOL,SUITA,OSAKA 565,JAPAN; MIYAZAKI MED COLL,DEPT BIOCHEM,MIYAZAKI 88916,JAPAN	Osaka University; University of Miyazaki			Taniguchi, Naoyuki/I-4182-2014; Nishikawa, Atsushi/E-6766-2013; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; Nishikawa, Atsushi/0000-0003-4325-1160; 				BAENZIGER J, 1974, J BIOL CHEM, V249, P7260; BARKER R, 1972, J BIOL CHEM, V247, P7135; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P3680, DOI 10.1021/bi00284a022; CARVER JP, 1981, BIOCHEMISTRY-US, V20, P6600, DOI 10.1021/bi00526a013; CARVER JP, 1987, PURE APPL CHEM, V59, P1465, DOI 10.1351/pac198759111465; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; ERNST LK, 1989, J BIOL CHEM, V264, P3436; FUJII S, 1990, J BIOL CHEM, V265, P6009; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HULL E, 1991, BIOCHEM BIOPH RES CO, V176, P608, DOI 10.1016/S0006-291X(05)80227-X; IRIMURA T, 1981, BIOCHEMISTRY-US, V20, P560, DOI 10.1021/bi00506a018; ISHIBASHI K, 1989, CLIN CHIM ACTA, V185, P325, DOI 10.1016/0009-8981(89)90223-4; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KOENDERMAN AHL, 1987, FEBS LETT, V222, P42, DOI 10.1016/0014-5793(87)80188-6; KOENDERMAN AHL, 1989, EUR J BIOCHEM, V181, P651, DOI 10.1111/j.1432-1033.1989.tb14772.x; KORNFELD R, 1976, ANNU REV BIOCHEM, V45, P217, DOI 10.1146/annurev.bi.45.070176.001245; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; NAKAZAWA K, 1988, J BIOCHEM-TOKYO, V104, P165, DOI 10.1093/oxfordjournals.jbchem.a122434; NARASIMHAN S, 1986, CARBOHYD RES, V149, P65, DOI 10.1016/S0008-6215(00)90370-7; NARASIMHAN S, 1985, BIOCHEMISTRY-US, V24, P1694, DOI 10.1021/bi00328a019; NARASIMHAN S, 1988, BIOCHEM CELL BIOL, V66, P889, DOI 10.1139/o88-101; NARASIMHAN S, 1988, J BIOL CHEM, V263, P1273; NARASIMHAN S, 1982, J BIOL CHEM, V257, P235; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; NISHIKAWA A, 1988, BIOCHEM BIOPH RES CO, V152, P107, DOI 10.1016/S0006-291X(88)80686-7; NISHIKAWA A, 1990, BIOCHIM BIOPHYS ACTA, V1035, P313, DOI 10.1016/0304-4165(90)90094-D; NISHIKAWA A, 1988, ANAL BIOCHEM, V170, P349, DOI 10.1016/0003-2697(88)90641-0; PASCALE R, 1989, CARCINOGENESIS, V10, P961, DOI 10.1093/carcin/10.5.961; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; WIENSTEIN J, 1987, J BIOL CHEM, V262, P17735; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146; YAMASHITA K, 1983, J BIOL CHEM, V258, P1098; YAMASHITA K, 1983, CANCER RES, V43, P5059	48	176	183	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18199	18204						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325461				2022-12-27	WOS:A1992JM22300109
J	ELIAS, P; GUSTAFSSON, CM; HAMMARSTEN, O; STOW, ND				ELIAS, P; GUSTAFSSON, CM; HAMMARSTEN, O; STOW, ND			STRUCTURAL ELEMENTS REQUIRED FOR THE COOPERATIVE BINDING OF THE HERPES-SIMPLEX VIRUS ORIGIN BINDING-PROTEIN TO ORIS RESIDE IN THE N-TERMINAL PART OF THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; VIRAL-DNA REPLICATION; TYPE-1 ORIGIN; SV40 ORIGIN; UL9 PROTEIN; SEQUENCE; ANTIGEN; SITES; SP1; INITIATION	The origin binding protein (OBP) of herpes simplex virus type 1 is required to activate a viral origin of replication in vivo. We have used intact OBP as well as a truncated form of the protein expressed in Escherichia coli to investigate the protein-protein interactions, as well as the protein-DNA interactions involved in the formation of a nucleoprotein complex at a viral origin of replication (oriS) in vitro. The salient findings demonstrate that the N-terminal part of OBP is required for the cooperative binding of OBP to three sites (boxes I, II, and III) within oriS. A detailed model for the interaction of OBP with the viral origins of replication oriS and oriL is presented.	INST VIROL,MRC,VIROL UNIT,GLASGOW G11 5JR,SCOTLAND	University of Glasgow	ELIAS, P (corresponding author), UNIV GOTEBORG,DEPT MED BIOCHEM,MEDICINAREGATAN 9,S-41390 GOTHENBURG,SWEDEN.		Hammarsten, Ola/A-2791-2012	Gustafsson, Claes/0000-0003-3531-8468				ARNDTJOVIN DJ, 1975, EUR J BIOCHEM, V54, P411, DOI 10.1111/j.1432-1033.1975.tb04151.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; DABROWSKI CE, 1991, J VIROL, V65, P3140, DOI 10.1128/JVI.65.6.3140-3150.1991; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DEB S, 1991, J VIROL, V65, P2829, DOI 10.1128/JVI.65.6.2829-2838.1991; ELIAS P, 1986, P NATL ACAD SCI USA, V83, P6322, DOI 10.1073/pnas.83.17.6322; ELIAS P, 1990, J BIOL CHEM, V265, P17167; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; HAZUDA DJ, 1991, J BIOL CHEM, V266, P24621; HERNANDEZ TR, 1991, J VIROL, V65, P1649, DOI 10.1128/JVI.65.3.1649-1652.1991; HODGMAN TC, 1988, NATURE, V333, P578, DOI 10.1038/333578a0; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KOFF A, 1991, J VIROL, V65, P3284, DOI 10.1128/JVI.65.6.3284-3292.1991; Kornberg A., 1992, DNA REPLICATION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOCKSHON D, 1988, MOL CELL BIOL, V8, P4018, DOI 10.1128/MCB.8.10.4018; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; RABKIN SD, 1991, P NATL ACAD SCI USA, V88, P10946, DOI 10.1073/pnas.88.23.10946; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STOW ND, 1983, VIROLOGY, V130, P427, DOI 10.1016/0042-6822(83)90097-1; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; WEIR HM, 1989, NUCLEIC ACIDS RES, V17, P1409, DOI 10.1093/nar/17.4.1409; WEIR HM, 1990, J GEN VIROL, V71, P1379, DOI 10.1099/0022-1317-71-6-1379; WELLER SK, 1985, MOL CELL BIOL, V5, P930, DOI 10.1128/MCB.5.5.930; WONG SW, 1991, J VIROL, V65, P2601, DOI 10.1128/JVI.65.5.2601-2611.1991; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	35	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17424	17429						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324937				2022-12-27	WOS:A1992JL05300103
J	JORDANOV, J; COURTOISVERNIQUET, F; NEUBURGER, M; DOUCE, R; DIAKUN, G				JORDANOV, J; COURTOISVERNIQUET, F; NEUBURGER, M; DOUCE, R; DIAKUN, G			STRUCTURAL INVESTIGATIONS BY EXTENDED X-RAY ABSORPTION FINE-STRUCTURE SPECTROSCOPY OF THE IRON CENTER OF MITOCHONDRIAL ACONITASE IN HIGHER-PLANT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DOUBLE-RESONANCE SPECTROSCOPY; SULFUR CLUSTERS; AZOTOBACTER-VINELANDII; DESULFOVIBRIO-GIGAS; <4FE-4S>+ CLUSTER; FERREDOXIN-II; EXAFS; PROTEINS; BINDING; INACTIVATION	We have obtained iron K-edge extended x-ray absorption fine structure spectra of the plant mitochondrial aconitase in its active state, in the presence (aconitase (+)) and absence (aconitase (-)) of the substrate citrate. Analysis of the data indicates that oxygens are present in the first coordination shell, at an average Fe-O distance of 1.96/1.98 angstrom (aconitase (+)/aconitase(-)). Part of these oxygens is provided by the citrate, which binds at 1.99 angstrom from the iron in aconitase (+). The second shell (sulfur) contribution is split and is consistent with Fe-S distances of 2.30/2.29 and 2.56/2.59 angstrom, and the third shell (iron) is consistent with an Fe-Fe distance of 2.83/2.84 angstrom. Both Fe-S and Fe-Fe distances are longer than similar distances found in most Fe-S centers. A strong scattering at approximately 5 angstrom has been identified as originating from an iron atom which is near to, but not part of, the Fe-S cluster. These data indicate that active plant mitochondrial aconitase contains a novel type of iron center.	CEN,DEPT BIOL MOLEC & STRUCT,PHYSIOL CELLULAIRE VEGETALE LAB,CNRS,F-38041 GRENOBLE,FRANCE; CEN,DEPT RECH FONDAMENTALE MAT CONDENSEE,F-38041 GRENOBLE,FRANCE; SERC,DARESBURY LAB,WARRINGTON WA4 4AD,CHESHIRE,ENGLAND	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); STFC Daresbury Laboratory				Courtois, Florence/0000-0003-0357-9401				ANTONIO MR, 1982, J BIOL CHEM, V257, P6646; BACKES G, 1991, J AM CHEM SOC, V113, P2055, DOI 10.1021/ja00006a027; BEINERT H, 1983, P NATL ACAD SCI-BIOL, V80, P393, DOI 10.1073/pnas.80.2.393; BEINERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P333, DOI 10.1016/0003-9861(83)90531-3; BLACKBURN NJ, 1983, BIOCHEM J, V213, P765, DOI 10.1042/bj2130765; BROUQUISSE R, 1987, PLANT PHYSIOL, V84, P1402, DOI 10.1104/pp.84.4.1402; BROUQUISSE R, 1985, PLANT PHYSIOL, V81, P247; CARTER CW, 1977, J BIOL CHEM, V252, P7802; DOUCE R, 1987, METHOD ENZYMOL, V148, P403; Fansler B., 1969, METHODS ENZYMOL, V13, P26; FUKUYAMA K, 1988, J MOL BIOL, V199, P183, DOI 10.1016/0022-2836(88)90388-9; GARRATT RC, 1986, BIOCHEM J, V233, P479, DOI 10.1042/bj2330479; GURMAN SJ, 1984, J PHYS C SOLID STATE, V17, P143, DOI 10.1088/0022-3719/17/1/019; JOYNER RW, 1987, J PHYS C SOLID STATE, V20, P4005, DOI 10.1088/0022-3719/20/25/028; KENNEDY MC, 1987, P NATL ACAD SCI USA, V84, P8854, DOI 10.1073/pnas.84.24.8854; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KENT TA, 1985, J BIOL CHEM, V260, P6871; KENT TA, 1982, P NATL ACAD SCI-BIOL, V79, P1096, DOI 10.1073/pnas.79.4.1096; KISSINGER CR, 1991, J MOL BIOL, V219, P693, DOI 10.1016/0022-2836(91)90665-S; LINDAHL PA, 1987, INORG CHEM, V26, P3912, DOI 10.1021/ic00270a018; MARONEY MJ, 1991, J AM CHEM SOC, V113, P3962, DOI 10.1021/ja00010a044; MCREE DE, 1986, J BIOL CHEM, V261, P277; PERUTZ MF, 1982, NATURE, V295, P535, DOI 10.1038/295535a0; POGANIUCH P, 1991, J AM CHEM SOC, V113, P4645, DOI 10.1021/ja00012a037; RAO CP, 1986, INORG CHEM, V25, P428, DOI 10.1021/ic00224a011; STEPHENS PJ, 1985, P NATL ACAD SCI USA, V82, P5661, DOI 10.1073/pnas.82.17.5661; TEO BK, 1979, J AM CHEM SOC, V101, P5624, DOI 10.1021/ja00513a029; VANDERHOEK MJ, 1986, NUCL INSTRUM METH A, V246, P380, DOI 10.1016/0168-9002(86)90113-0; VERNIQUET F, 1991, BIOCHEM J, V276, P643, DOI 10.1042/bj2760643; WERST MM, 1990, BIOCHEMISTRY-US, V29, P10533, DOI 10.1021/bi00498a016	30	4	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16775	16778						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324911				2022-12-27	WOS:A1992JL05300008
J	RUSCITTI, T; POLAYES, DA; KARU, AE; LINN, S				RUSCITTI, T; POLAYES, DA; KARU, AE; LINN, S			SELECTIVE IMMUNONEUTRALIZATION OF THE MULTIPLE ACTIVITIES OF ESCHERICHIA-COLI DNA-POLYMERASE-I SUPPORTS THE MODEL FOR SEPARATE ACTIVE-SITES AND INDICATES A COMPLEX 5' TO 3' EXONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLENOW FRAGMENT; BINDING; CULTURES; SERUM; FORM	DNA polymerase I (pol I) from Escherichia coli has three well-defined activities: DNA polymerase, 3'-5' exonuclease, and 5'-3' exonuclease. We have raised monoclonal antibodies to pol I which selectively neutralize each of these three activities, thus supporting the model of separate active sites for each activity, heretofore exclusively demonstrated with proteolytic fragments of pol I. Antibodies from each class could bind pol I in the presence of antibodies of another class, indicating the existence of significant spatial separation between each of the three sites. In addition, several of the neutralizing antibodies were able to distinguish particular activities of the 5'-3' exonuclease. One of them, for example, inhibited the RNase H activity but not the DNase activity. Two other antibodies could, in addition to inhibiting the polymerase and the 3'-5' exonuclease, either stimulate or inhibit the 5'-3' exonuclease depending upon the assay conditions, particularly the ionic strength.			RUSCITTI, T (corresponding author), UNIV CALIF BERKELEY, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019020, R01GM030415, R01GM019020] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19020, GM30415] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN DJ, 1989, BIOCHEMISTRY-US, V28, P9586, DOI 10.1021/bi00451a006; BERNARDI F, 1979, J MOL BIOL, V129, P93, DOI 10.1016/0022-2836(79)90062-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUTLAG D, 1969, BIOCHEM BIOPH RES CO, V37, P982, DOI 10.1016/0006-291X(69)90228-9; CATALANO CE, 1989, BIOCHEMISTRY-US, V28, P4374, DOI 10.1021/bi00436a038; COOPER PK, 1982, MOL GEN GENET, V185, P189, DOI 10.1007/BF00330785; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; DESTGROTH SF, 1980, J IMMUNOL METHODS, V35, P1, DOI 10.1016/0022-1759(80)90146-5; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FREEMANWITTIG MJ, 1986, BIOCHIM BIOPHYS ACTA, V867, P107, DOI 10.1016/0167-4781(86)90070-9; FREEMONT P S, 1986, Proteins Structure Function and Genetics, V1, P66, DOI 10.1002/prot.340010111; HARLOW E, 1988, ANTIBODIES LABORATOR, P311; ISCOVE NN, 1978, J EXP MED, V147, P923, DOI 10.1084/jem.147.3.923; ITOH T, 1979, COLD SPRING HARB SYM, V43, P409, DOI 10.1101/SQB.1979.043.01.047; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; KARU AE, 1985, J IMMUNOL METHODS, V76, P145, DOI 10.1016/0022-1759(85)90487-9; KLENOW H, 1970, P NATL ACAD SCI USA, V65, P168, DOI 10.1073/pnas.65.1.168; KORNBERG A, 1956, BIOCHIM BIOPHYS ACTA, V21, P197, DOI 10.1016/0006-3002(56)90127-5; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; LACKEY D, 1985, J BIOL CHEM, V260, P3178; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LINN S, 1976, P NATL ACAD SCI USA, V73, P2818, DOI 10.1073/pnas.73.8.2818; MORENO MR, 1985, ANAL BIOCHEM, V151, P466; NIWA O, 1981, P NATL ACAD SCI-BIOL, V78, P7024, DOI 10.1073/pnas.78.11.7024; PAPANICOLAOU C, 1984, BIOCHIMIE, V66, P115, DOI 10.1016/0300-9084(84)90199-8; ROSS M, 1990, BIOTECHNIQUES, V9, P532; STEITZ TA, 1992, J CELL BIOCH B S, V16, P3; SUGASAWARA RJ, 1985, J IMMUNOL METHODS, V79, P263, DOI 10.1016/0022-1759(85)90106-1; SYVAOJA J, 1989, J BIOL CHEM, V264, P2489; Voller A., 1976, MANUAL CLIN IMMUNOLO	31	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16806	16811						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324912				2022-12-27	WOS:A1992JL05300014
J	WEBER, DJ; BHATNAGAR, SK; BULLIONS, LC; BESSMAN, MJ; MILDVAN, AS				WEBER, DJ; BHATNAGAR, SK; BULLIONS, LC; BESSMAN, MJ; MILDVAN, AS			NMR AND ISOTOPIC EXCHANGE STUDIES OF THE SITE OF BOND-CLEAVAGE IN THE MUTT REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MUTATOR GENE; NUCLEOSIDE TRIPHOSPHATASE; PYROPHOSPHORYL GROUP; MOLECULAR-CLONING; IDENTIFICATION	The MutT protein, which prevents AT --> CG transversions during DNA replication, hydrolyzes nucleoside triphosphates to yield nucleoside monophosphates and pyrophosphate. The hydrolysis of dGTP by the MutT protein in (H2O)-O-18-enriched water, when monitored by high resolution P-31 NMR spectroscopy at 242.9 MHz, showed O-18 labeling of the pyrophosphate product, as manifested by a 0.010 +/- 0.002 ppm upfield shift of the pyrophosphate resonance, and no labeling of the dGMP product. This establishes that the reaction proceeds via a nucleophilic substitution at the beta-phosphorus of dGTP with displacement of dGMP as the leaving group. No exchange of P-32-labeled dGMP into dGTP was detected, indicating that water attacks dGTP directly or, less likely, an irreversibly formed pyrophosphoryl-enzyme intermediate. No exchange of P-32-labeled pyrophosphate into dGTP was observed, consistent with nucleophilic substitution at the beta-phosphorus of dGTP. Only six enzymes, all synthetases, have previously been shown to catalyze nucleophilic substitution at the beta-phosphorus of nucleoside triphosphate substrates. The MutT protein is the first hydrolase shown to do so.	JOHNS HOPKINS UNIV, SCH MED, SCH MED, DEPT BIOL CHEM, 725 N WOLFE ST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Johns Hopkins University; Johns Hopkins University			Weber, David J/B-5349-2011	Weber, David J/0000-0002-8824-1110	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028616, R37DK028616] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013324] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28616] Funding Source: Medline; NIGMS NIH HHS [GM18649, F32 GM13324] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA M, 1987, MOL GEN GENET, V206, P9, DOI 10.1007/BF00326530; BERMAN K, 1967, BIOCHIM BIOPHYS ACTA, V141, P214, DOI 10.1016/0304-4165(67)90270-X; BERTANI LE, 1961, J BIOL CHEM, V236, pPC67; BHATNAGAR SK, 1990, J BACTERIOL, V172, P2802, DOI 10.1128/jb.172.5.2802-2803.1990; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; COHN M, 1959, J CELL COMPAR PHYSL, V54, P17, DOI 10.1002/jcp.1030540405; COOPER RA, 1967, BIOCHEM J, V105, pC49; COX EC, 1973, GENETICS, V73, P67; EVANS HJ, 1968, P NATL ACAD SCI USA, V61, P1448, DOI 10.1073/pnas.61.4.1448; GIROIR IE, 1987, J BIOL CHEM, V262, P130; KAZIRO Y, 1961, J BIOCHEM-TOKYO, V49, P472, DOI 10.1093/oxfordjournals.jbchem.a127330; KHORANA HG, 1958, J BIOL CHEM, V230, P941; LI TM, 1978, J BIOL CHEM, V253, P3918; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Mildvan A.S., 1970, ENZYMES, P445; MILLER GA, 1975, ARCH BIOCHEM BIOPHYS, V171, P732, DOI 10.1016/0003-9861(75)90086-7; MILNER Y, 1972, P NATL ACAD SCI USA, V9, P2463; ROSCOE DH, 1969, VIROLOGY, V38, P520, DOI 10.1016/0042-6822(69)90172-X; Saenger W., 1984, PRINCIPLES NUCLEIC A, P76; SCHLOMAI J, 1978, J BIOL CHEM, V253, P3305; SHIOTA T, 1969, BIOCHEMISTRY-US, V8, P5022, DOI 10.1021/bi00840a052; SY J, 1973, P NATL ACAD SCI USA, V70, P306, DOI 10.1073/pnas.70.2.306; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274; ZIMMERMAN S, 1961, J BIOL CHEM, V236, P1480	27	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16939	16942						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324915				2022-12-27	WOS:A1992JL05300035
J	HIGMAN, MA; BOURGEOIS, N; NILES, EG				HIGMAN, MA; BOURGEOIS, N; NILES, EG			THE VACCINIA VIRUS MESSENGER-RNA (GUANINE-N7-)-METHYLTRANSFERASE REQUIRES BOTH SUBUNITS OF THE MESSENGER-RNA CAPPING ENZYME FOR ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PURIFICATION; VIRIONS; TRANSCRIPTION; POLYMERASE; INITIATION; PROTEINS; GENES; ACID	Plasmid vectors capable of expressing the large and small subunits of the vaccinia virus mRNA capping enzyme were constructed and used to transform Escherichia coli. Conditions for the induction of the dimeric enzyme or the individual subunits in a soluble form were identified, and the capping enzyme was purified to near homogeneity. Proteolysis of the capping enzyme in bacteria yields a 60-kDa product shown previously to possess the mRNA triphosphatase and guanyltransferase activities (Shuman, S. (1990) J. Biol. Chem. 265, 11960-11966) was isolated and shown by amino acid sequence analysis to be derived from the NH2 terminus of D1R. The individual subunits lacked methyltransferase activity when assayed alone. However, mixing the D1R and D12L subunits permitted reconstitution of the methyltransferase activity, and this appearance in activity accompanied the association of the subunits. In contrast, mixing the D12L subunit with the D1R-60K proteolytic fragment failed to yield methyltransferase activity or result in a physical association of the two proteins. These results demonstrate that the methyltransferase active site requires the presence of the D12L subunit with the carboxyl-terminal portion of the D1R subunit. Furthermore, since the mRNA triphosphatase and guanyltransferase active sites reside in the NH2-terminal domain of the D1R subunit, and the methyltransferase activity is found in the carboxyl-terminal portion of this subunit and D12L, there must be at least two separate active sites in this enzyme.	SUNY BUFFALO, SCH MED & BIOMED SCI, DEPT BIOCHEM, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIAID NIH HHS [AI28824] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028824] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBOSA E, 1978, J BIOL CHEM, V253, P7692; BAROUDY BM, 1980, J BIOL CHEM, V255, P4372; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; CONG PJ, 1992, J BIOL CHEM, V267, P16424; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; FURUICHI Y, 1989, METHOD ENZYMOL, V180, P164; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GUO PX, 1990, P NATL ACAD SCI USA, V87, P4023, DOI 10.1073/pnas.87.11.4023; KATES J, 1970, J MOL BIOL, V50, P19, DOI 10.1016/0022-2836(70)90101-4; KATES JR, 1967, P NATL ACAD SCI USA, V57, P314, DOI 10.1073/pnas.57.2.314; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin K, 1990, Protein Expr Purif, V1, P169, DOI 10.1016/1046-5928(90)90012-N; MARTIN SA, 1975, J BIOL CHEM, V250, P9322; MORGAN JR, 1984, J VIROL, V52, P206, DOI 10.1128/JVI.52.1.206-214.1984; MOSS B, 1975, J BIOL CHEM, V250, P4722; NILES EG, 1989, VIROLOGY, V172, P513, DOI 10.1016/0042-6822(89)90194-3; PAOLETTI E, 1974, J BIOL CHEM, V249, P3273; SHUMAN S, 1990, J BIOL CHEM, V265, P11960; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1990, J BIOL CHEM, V265, P11967; SHUMAN S, 1989, J BIOL CHEM, V264, P9690; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; Steczko J, 1991, Protein Expr Purif, V2, P221, DOI 10.1016/1046-5928(91)90075-T; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TUTAS DJ, 1977, J BIOL CHEM, V252, P3092; VENKATESAN S, 1980, J BIOL CHEM, V255, P903; VOS JC, 1991, EMBO J, V10, P2553, DOI 10.1002/j.1460-2075.1991.tb07795.x; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6069, DOI 10.1073/pnas.84.17.6069; [No title captured]	29	58	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16430	16437						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322902				2022-12-27	WOS:A1992JJ45800070
J	NAKANISHI, H; EXTON, JH				NAKANISHI, H; EXTON, JH			PURIFICATION AND CHARACTERIZATION OF THE ZETA-ISOFORM OF PROTEIN-KINASE-C FROM BOVINE KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; ACTIVATION; CALCIUM; RAF-1; PHOSPHORYLATION; ONCOGENE; IDENTIFICATION; EXPRESSION	The zeta-isoform of protein kinase C (PKC-zeta) was purified to near homogeneity from the cytosolic fraction of bovine kidney by successive chromatography on DEAE-Sephacel, heparin-Sepharose, phenyl-5PW, hydroxyapatite, and Mono Q. The purified enzyme had a molecular mass of 78 kDa on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The protein was recognized by an antibody raised against a synthetic oligopeptide corresponding to the deduced amino acid sequence of rat PKC-zeta. The enzymatic properties of PKC-zeta were examined and compared with conventional protein kinase C purified from rat brain. The activity of PKC-zeta was stimulated by phospholipid but was unaffected by phorbol ester, diacylglycerol, or Ca2+. PKC-zeta did not bind phorbol ester, and autophosphorylation was not affected by phorbol ester. Unsaturated fatty acid activated PKC-zeta, but this activation was neither additive nor synergistic with phospholipid. These results indicate that regulation of PKC-zeta is distinct from that of other isoforms and suggest that hormone-stimulated increases in diacylglycerol and Ca2+ do not activate this isoform in cells. It is possible that PKC-zeta belongs to another enzyme family, in which regulation is by a different mechanism from that for other isoforms of protein kinase C.	VANDERBILT UNIV, MED CTR, SCH MED, HOWARD HUGHES MED INST, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University				Nakanishi, Hiroyuki/0000-0002-9765-0266				BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BELL RM, 1991, J BIOL CHEM, V266, P4661; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DELL KR, 1988, BIOCHEM J, V254, P455, DOI 10.1042/bj2540455; EXTON JH, 1990, J BIOL CHEM, V265, P1; HUANG KP, 1988, J BIOL CHEM, V263, P14839; INOUE M, 1977, J BIOL CHEM, V252, P7610; ISHIKAWA F, 1987, ONCOGENE RES, V1, P243; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; KAIBUCHI K, 1981, J BIOL CHEM, V256, P7146; Kitano T, 1986, Methods Enzymol, V124, P349; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1990, J BIOL CHEM, V265, P22434; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; TANAKA Y, 1986, J BIOCHEM-TOKYO, V99, P257, DOI 10.1093/oxfordjournals.jbchem.a135467; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; WAYS DK, 1992, J BIOL CHEM, V267, P4799	34	303	304	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16347	16354						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322899				2022-12-27	WOS:A1992JJ45800057
J	AUBERTFOUCHER, E; FONT, B; EICHENBERGER, D; GOLDSCHMIDT, D; LETHIAS, C; VANDERREST, M				AUBERTFOUCHER, E; FONT, B; EICHENBERGER, D; GOLDSCHMIDT, D; LETHIAS, C; VANDERREST, M			PURIFICATION AND CHARACTERIZATION OF NATIVE TYPE-XIV COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IX COLLAGEN; EXTRACELLULAR-MATRIX; II COLLAGEN; PROTEINS; MOLECULE; DOMAIN; IDENTIFICATION; CARTILAGE; CLONING; CDNA	A new molecule, type XIV collagen, with domains homologous to type IX and XII collagens has been recently discovered in pepsin extracts of fetal bovine tissues (Dublet, B., and van der Rest, M. (1991) J. Biol. Chem. 266, 6853-6858). In the present study, we describe the purification and the characterization of the intact native form of this newly discovered collagen. By using only two chromatographic steps we were able to obtain pure type XIV collagen. Furthermore, minor modifications of the protocol allowed us to perform the simultaneous large scale purification of type XII and type XIV collagens from the same tissue. Intact type XIV collagen migrates on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as two bands of 220 and 290 kDa (reducing conditions). After collagenase treatment, a single band of 190 kDa is observed, which represents the large non-collagenous domain of the molecule (NC3). Rotary shadowing electron micrographs of intact type XIV collagen show a cross-shaped structure formed by a thin tail attached through a central globule to three identical "fingers." These properties are similar to those previously described for intact chicken type XII collagen (Dublet, B., Oh, S., Sugrue, S. P., Gordon, M. K., Gerecke, D. R., Olsen, B. R., and van der Rest, M. (1989) J. Biol. Chem. 264, 13150-13156), but the two molecules are different gene products and have charge and glycosylation differences. Finally, we show that the three chains of purified type XIV collagen have an apparent molecular mass of approximately 220 kDa and are not cross-linked to each other by bonds other than disulfide bridges. The same observation was made for type XII collagen. In both cases, the 290-kDa migrating band in SDS-PAGE is due to incomplete denaturation in electrophoresis sample buffer in the absence of urea.	ECOLE NORMALE SUPER LYON, 46 ALLEE DITALIE, F-69364 LYON, FRANCE; CNRS, UPR 412, INST BIOL & CHEM PROT, F-69364 LYON, FRANCE; UNIV LYON 1, F-69622 VILLEURBANNE, FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUBLET B, 1990, ANN NY ACAD SCI, V580, P436, DOI 10.1111/j.1749-6632.1990.tb17953.x; DUBLET B, 1989, J BIOL CHEM, V264, P13150; DUBLET B, 1991, J BIOL CHEM, V266, P6853; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; Gordon MK, 1990, CURR OPIN CELL BIOL, V2, P833, DOI 10.1016/0955-0674(90)90080-X; GORDON MK, 1989, CONNECT TISSUE RES, V20, P179, DOI 10.3109/03008208909023886; GORDON MK, 1989, J BIOL CHEM, V264, P19772; GORDON MK, 1991, EUR J BIOCHEM, V201, P333, DOI 10.1111/j.1432-1033.1991.tb16290.x; GORDON MK, 1987, P NATL ACAD SCI USA, V84, P6040, DOI 10.1073/pnas.84.17.6040; KEENE DR, 1991, J CELL BIOL, V113, P971, DOI 10.1083/jcb.113.4.971; KUHN K, 1981, FEBS LETT, V125, P123, DOI 10.1016/0014-5793(81)81012-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINSENMAYER TF, 1982, IMMUNOCHEMISTRY EXTR, V1, P179; LUNSTRUM G P, 1991, Journal of Cell Biology, V115, p106A; LUNSTRUM GP, 1991, J CELL BIOL, V113, P963, DOI 10.1083/jcb.113.4.963; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; SUGRUE SP, 1989, J CELL BIOL, V109, P939, DOI 10.1083/jcb.109.2.939; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VANDERREST M, 1990, BIOCHIMIE, V72, P473, DOI 10.1016/0300-9084(90)90071-N; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; YAMAGATA M, 1991, J CELL BIOL, V115, P209, DOI 10.1083/jcb.115.1.209	23	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15759	15764						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322405				2022-12-27	WOS:A1992JG11300077
J	FRIDMAN, R; FUERST, TR; BIRD, RE; HOYHTYA, M; OELKUCT, M; KRAUS, S; KOMAREK, D; LIOTTA, LA; BERMAN, ML; STETLERSTEVENSON, WG				FRIDMAN, R; FUERST, TR; BIRD, RE; HOYHTYA, M; OELKUCT, M; KRAUS, S; KOMAREK, D; LIOTTA, LA; BERMAN, ML; STETLERSTEVENSON, WG			DOMAIN-STRUCTURE OF HUMAN 72-KDA GELATINASE TYPE-IV COLLAGENASE CHARACTERIZATION OF PROTEOLYTIC ACTIVITY AND IDENTIFICATION OF THE TISSUE INHIBITOR OF METALLOPROTEINASE-2 (TIMP-2) BINDING REGIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; RHEUMATOID SYNOVIAL FIBROBLASTS; BRONCHIAL EPITHELIAL-CELLS; MATRIX METALLOPROTEINASES; INTERSTITIAL COLLAGENASE; EXPRESSION; PURIFICATION; ACTIVATION; STROMELYSIN; INVASION	The 72-kDa gelatinase/type IV collagenase, a metalloproteinase thought to play a role in metastasis and in angiogenesis, forms a noncovalent stoichiometric complex with the tissue inhibitor of metalloproteinase-2 (TIMP-2), a potent inhibitor of enzyme activity. To define the regions of the 72-kDa gelatinase responsible for TIMP-2 binding, a series of NH2- and COOH-terminal deletions of the enzyme were constructed using the polymerase chain reaction technique. The full-length and the truncated enzymes were expressed in a recombinant vaccinia virus mammalian cell expression system (Vac/T7). Two truncated enzymes ending at residues 425 (DELTA-426-631) and 454 (DELTA-455-631) were purified. Like the full-length recombinant 72-kDa gelatinase, both COOH-terminally truncated enzymes were activated with organomercurial and digested gelatin and native collagen type IV. In contrast to the full-length enzyme, DELTA-426-631 and DELTA-455-631 enzymes were less sensitive to TIMP-2 inhibition requiring 10 mol of TIMP-2/mol of enzyme to achieve maximal inhibition of enzymatic activity. The activated but not the latent forms of the DELTA-426-631 and DELTA-455-631 proteins formed a complex with TIMP-2 only when excess molar concentrations of inhibitor were used. We also expressed the 205-amino acid COOH-terminal fragment, DELTA-1-426, and found that it binds TIMP-2. In addition, a truncated version of the 72-kDa gelatinase lacking the NH2-terminal 78 amino acids (DELTA-1-78) of the proenzyme retained the ability to bind TIMP-2. These studies demonstrate that 72-kDa gelatinases lacking the COOH-terminal domain retain full enzymatic activity but acquire a reduced sensitivity to TIMP-2 inhibition. These data suggest that both the active site and the COOH-terminal tail of the 72-kDa gelatinase independently and cooperatively participate in TIMP-2 binding.	MEDIMMUNE,GAITHERSBURG,MD 20878; NCI,PATHOL LAB,BETHESDA,MD 20892	AstraZeneca; Medimmune; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	FRIDMAN, R (corresponding author), MOLEC ONCOL INC,19 FIRSTFIELD RD,GAITHERSBURG,MD 20878, USA.		Stetler-Stevenson, William/AAE-3501-2020; Stetler-Stevenson, William G/H-6956-2012	Stetler-Stevenson, William/0000-0002-5500-5808; Stetler-Stevenson, William G/0000-0002-5500-5808	NATIONAL CANCER INSTITUTE [R43CA056257] Funding Source: NIH RePORTER; NCI NIH HHS [1R43CA56257-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; BANYAI L, 1991, FEBS LETT, V282, P23, DOI 10.1016/0014-5793(91)80436-7; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BROWN PD, 1990, CANCER RES, V50, P6184; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CAWSTON TE, 1983, BIOCHEM J, V211, P313, DOI 10.1042/bj2110313; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; DECLERCK YA, 1991, CANCER RES, V51, P2151; DECLERCK YA, 1989, J BIOL CHEM, V264, P17445; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; KLEINER DE, 1992, BIOCHEMISTRY-US, V31, P1665, DOI 10.1021/bi00121a013; KOLKENBROCK H, 1991, EUR J BIOCHEM, V198, P775, DOI 10.1111/j.1432-1033.1991.tb16080.x; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MARCY AI, 1991, BIOCHEMISTRY-US, V30, P6476, DOI 10.1021/bi00240a018; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OKADA Y, 1986, J BIOL CHEM, V261, P14245; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTZ RM, 1988, CANCER RES, V48, P5539; SELTZER JL, 1990, J BIOL CHEM, V265, P20409; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; TRYGGVASON K, 1980, BIOCHEMISTRY-US, V19, P1284, DOI 10.1021/bi00548a003; URA H, 1989, CANCER RES, V49, P4615; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	40	210	219	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15398	15405						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322396				2022-12-27	WOS:A1992JG11300024
J	LUSSKA, A; WU, L; WHITLOCK, JP				LUSSKA, A; WU, L; WHITLOCK, JP			SUPERINDUCTION OF CYP1A1 TRANSCRIPTION BY CYCLOHEXIMIDE - ROLE OF THE DNA-BINDING SITE FOR THE LIGANDED AH RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-P1-450 GENE-TRANSCRIPTION; DIOXIN-RESPONSIVE ENHANCER; MOUSE HEPATOMA-CELLS; PROTEIN-SYNTHESIS; WILD-TYPE; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; ACTIVATION; EXPRESSION; MECHANISM; INDUCTION	Nuclear run-off experiments reveal that four distinct DNA domains, each of which contains a binding site for the liganded Ah receptor, can mediate the super-induction of transcription by 2,3,7.8-tetrachlorodibenzo-p-dioxin plus cycloheximide. Superinduction requires substantial inhibition of protein synthesis by cycloheximide. Gel retardation analyses of nuclear extracts and methylation protection studies in intact cells reveal no evidence for cycloheximide-sensitive protein-DNA interactions that might mediate the superinduction response. These observations suggest the existence of a labile protein(s) that acts to inhibit the function of the dioxin-responsive receptor/enhancer regulatory system via protein-protein interactions.	STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305	Stanford University					NATIONAL CANCER INSTITUTE [R35CA053887, R01CA053887] Funding Source: NIH RePORTER; NCI NIH HHS [CA53887] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DURRIN LK, 1989, MOL CELL BIOL, V9, P5733, DOI 10.1128/MCB.9.12.5733; ELFERINK CJ, 1990, J BIOL CHEM, V265, P5718; FISHER JM, 1990, J BIOL CHEM, V265, P9676; FISHER JM, 1989, MOL CARCINOGEN, V1, P216, DOI 10.1002/mc.2940010403; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; GONZALEZ FJ, 1985, NUCLEIC ACIDS RES, V13, P7269, DOI 10.1093/nar/13.20.7269; HANKINSON O, 1985, J BIOL CHEM, V260, P1790; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; ISRAEL DI, 1985, J BIOL CHEM, V260, P5648; ISRAEL DI, 1984, J BIOL CHEM, V259, P5400; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES PBC, 1986, P NATL ACAD SCI USA, V83, P2802, DOI 10.1073/pnas.83.9.2802; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KIMBROUGH RD, 1989, HALOGENATED BIPHENYL, P1; KLEIN E, 1988, THESIS STANFORD U; LILIENFELD DE, 1989, EPIDEMIOL REV, V11, P28, DOI 10.1093/oxfordjournals.epirev.a036044; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1976, J BIOL CHEM, V251, P4936; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; SAATCIOGLU F, 1990, MOL CELL BIOL, V10, P6408, DOI 10.1128/MCB.10.12.6408; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; WEN LP, 1990, P NATL ACAD SCI USA, V87, P8545, DOI 10.1073/pnas.87.21.8545; WHITLOCK JP, 1973, J BIOL CHEM, V248, P6114; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251	42	93	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15146	15151						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321828				2022-12-27	WOS:A1992JF08800094
J	ROSENBERG, AH; PATEL, SS; JOHNSON, KA; STUDIER, FW				ROSENBERG, AH; PATEL, SS; JOHNSON, KA; STUDIER, FW			CLONING AND EXPRESSION OF GENE-4 OF BACTERIOPHAGE-T7 AND CREATION AND ANALYSIS OF T7 MUTANTS LACKING THE 4A-PRIMASE HELICASE OR THE 4B-HELICASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; ESCHERICHIA-COLI; LAC REPRESSOR; NUCLEOTIDE-SEQUENCE; REPLICATION INVITRO; CLONED FRAGMENTS; DNA; PROTEIN; PRIMASE; SYSTEM	T7 gene 4, which is required for DNA replication, specifies two proteins whose coding sequences overlap in the same reading frame: the 4A protein, a 566-amino acid primase/helicase, and the 4B protein, a 503-amino acid helicase whose initiation codon is the 64th codon of the 4A protein. To study better the individual functions of these two overlapping proteins, we made clones that express both 4A and 4B proteins, only 4B protein, or only what we refer to as the 4A' protein, in which methionine 64 is replaced by leucine, thereby eliminating the 4B initiation codon. These clones provide considerably more gene 4 protein for biochemical analysis than do infected cells. They can also be used to isolate and propagate T7 gene 4 deletion mutants, and we have made T7 mutants which lack all gene 4 coding sequences, or which express 4A' protein but no 4B protein, or 4B protein but no 4A protein. Analysis of these phage mutants shows that 4A' protein without any 4B protein can support essentially normal replication and growth, whereas 4B protein without any 4A protein supports little replication or growth. Apparently, the primase activity of the 4A protein is essential for replication, but the 4B protein is dispensable, presumably because the 4A protein also supplies helicase activity. The mutation at amino acid 64 of 4A' appears to have little effect on 4A function. The rate of replication during normal T7 infection appears to be limited by the amount of gene 4 protein, but too high a level of either 4A or 4B protein is inhibitory to growth.	PENN STATE UNIV,DEPT MOLEC & CELL BIOL,UNIV PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	ROSENBERG, AH (corresponding author), BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044613, R01GM021872, F32GM013135] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44613, GM21872, GM13135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; CAMPBELL JL, 1978, P NATL ACAD SCI USA, V75, P2276, DOI 10.1073/pnas.75.5.2276; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEUSCHLE U, 1986, EMBO J, V5, P2987, DOI 10.1002/j.1460-2075.1986.tb04596.x; DEUSCHLE U, 1986, P NATL ACAD SCI USA, V83, P4134, DOI 10.1073/pnas.83.12.4134; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; DUNN JJ, 1981, J MOL BIOL, V148, P303, DOI 10.1016/0022-2836(81)90178-9; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; DUNN JJ, 1984, J MOL BIOL, V175, P111; FISCHER H, 1980, J BIOL CHEM, V255, P7956; GIORDANO TJ, 1989, GENE, V84, P209, DOI 10.1016/0378-1119(89)90494-0; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; KOLODNER R, 1978, J BIOL CHEM, V253, P566; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MCALLISTER WT, 1981, J MOL BIOL, V153, P527, DOI 10.1016/0022-2836(81)90406-X; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NAKAMURA K, 1982, EMBO J, V1, P771, DOI 10.1002/j.1460-2075.1982.tb01244.x; PATEL SS, 1992, J BIOL CHEM, V267, P15013; RICHARDSON CC, 1987, UCLA S MOL CELL BIOL, V47, P151; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SILBERSTEIN S, 1975, J MOL BIOL, V96, P1, DOI 10.1016/0022-2836(75)90178-3; STUDIER FW, 1975, J MOL BIOL, V94, P283, DOI 10.1016/0022-2836(75)90083-2; STUDIER FW, 1972, SCIENCE, V176, P367, DOI 10.1126/science.176.4033.367; STUDIER FW, 1981, J MOL BIOL, V153, P503, DOI 10.1016/0022-2836(81)90405-8; STUDIER FW, 1973, J MOL BIOL, V79, P237, DOI 10.1016/0022-2836(73)90003-X; STUDIER FW, 1981, J MOL BIOL, V153, P493, DOI 10.1016/0022-2836(81)90404-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STUDIER FW, 1969, VIROLOGY, V39, P562, DOI 10.1016/0042-6822(69)90104-4; STUDIER FW, 1973, J MOL BIOL, V79, P227, DOI 10.1016/0022-2836(73)90002-8	34	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15005	15012						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321823				2022-12-27	WOS:A1992JF08800075
J	SEGER, R; AHN, NG; POSADA, J; MUNAR, ES; JENSEN, AM; COOPER, JA; COBB, MH; KREBS, EG				SEGER, R; AHN, NG; POSADA, J; MUNAR, ES; JENSEN, AM; COOPER, JA; COBB, MH; KREBS, EG			PURIFICATION AND CHARACTERIZATION OF MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATOR(S) FROM EPIDERMAL GROWTH FACTOR-STIMULATED A431 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; POLYACRYLAMIDE GELS; SWISS 3T3-CELLS; S6 KINASE; INSULIN; PHOSPHORYLATES; INVITRO; ACID	Two peaks of mitogen-activated protein (MAP) kinase activator activity are resolved upon ion exchange chromatography of cytosolic extracts from epidermal growth factor-stimulated A431 cells. Two forms of the activator (1 and 2) have been purified from these peaks, using chromatography on Q-Sepharose, heparin-agarose, hydroxylapatite, ATP-agarose, Sephacryl S-300, Mono S, and Mono Q. The two preparations each contained one major protein band with an apparent molecular mass of 46 or 45 kDa, respectively, on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Evidence identifying the MAP kinase activators as the 46- and 45-kDa proteins is presented. Using inactive mutants of MAP kinase as potential substrates, it was found that each preparation of MAP kinase activator catalyzes phosphorylation of the regulatory residues, threonine 188 and tyrosine 190, of Xenopus MAP kinase. These results support the concept that the MAP kinase activators are protein kinases. These MAP kinase kinases demonstrate an apparent high degree of specificity toward the native conformation of MAP kinase, although slow autophosphorylation on serine, threonine, and tyrosine residues and phosphorylation of myelin basic protein on serine and threonine residues is detected as well.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Cobb, Melanie/0000-0003-0833-5473; Posada, James/0000-0003-3582-9612	NIDDK NIH HHS [DK 42528] Funding Source: Medline; NIGMS NIH HHS [GM 42508] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; AHN NG, 1992, IN PRESS J NEUROCHEM; AHN NG, 1992, IN PRESS CIBA F; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; WU T, 1991, P NATL ACAD SCI USA, V88, P9508	41	342	348	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14373	14381						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321146				2022-12-27	WOS:A1992JD32500089
J	DEREMER, MF; SAELI, RJ; BRAUTIGAN, DL; EDELMAN, AM				DEREMER, MF; SAELI, RJ; BRAUTIGAN, DL; EDELMAN, AM			CA2+-CALMODULIN-DEPENDENT PROTEIN KINASE-IA AND KINASE-IB FROM RAT-BRAIN .2. ENZYMATIC CHARACTERISTICS AND REGULATION OF ACTIVITIES BY PHOSPHORYLATION AND DEPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOPHOSPHORYLATION; CA-2+; ACTIVATION; PURIFICATION; ACID; FORM	In addition to physical properties (DeRemer, M. F., Saeli, R. J., and Edelman, A. M. (1992) J. Biol. Chem. 267, 13460-13465), enzymatic and regulatory characteristics indicate that calmodulin (CaM) kinase Ia and CaM kinase Ib are distinct entities. The K(m) values for ATP and site 1 peptide were similar between the two kinases, however, CaM kinase Ib is approximately 20-fold more sensitive to CaM than is CaM kinase Ia. The kinases also displayed differential sensitivities to divalent metal ions. For both kinases, site 1 peptide, synapsin I, and syntide-2 were highly preferred substrates relative to others tested. A 72-kDa protein from a heat-treated extract of rat pancreas was phosphorylated by CaM kinase Ib but not by CaM kinase Ia. CaM kinase Ia activity displayed a pronounced lag in its time course suggesting enzyme activation over time. Preincubation of CaM kinase Ia in the combined presence of Ca2+-CaM and MgATP led to a time-dependent increase in its site 1 peptide kinase activity of up to 15-fold. The extent of activation of CaM kinase Ia correlated with the extent of autophosphorylation. The enzyme retained full Ca2+-CaM dependence in the activated state which was rapidly reversible by treatment with protein phosphatase 2A catalytic subunit. Thus, the activation of CaM kinase Ia is a result of its Ca2+-CaM-dependent autophosphorylation. CaM kinase Ib was not activated by preincubation under autophosphorylating conditions yet lost approximately 90% of its activity toward either an exogenous substrate (site 1 peptide) or itself (autophosphorylation) after incubation with protein phosphatase 2A catalytic subunit. The deactivated state was not reversed by subsequent incubations under autophosphorylating conditions. Thus, CaM kinase Ib activity is dependent upon phosphorylation by a regulating kinase(s) which is resolved from CaM kinase Ib during purification of the latter.	SUNY BUFFALO,DEPT PHARMACOL & THERAPEUT,102 FARBER HALL,BUFFALO,NY 14260; SUNY BUFFALO,DEPT BIOL SCI,BUFFALO,NY 14260; BROWN UNIV,BIOCHEM SECT,PROVIDENCE,RI 02912	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Brown University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024738, R29NS024738] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 31374] Funding Source: Medline; NINDS NIH HHS [NS24738] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRAUTIGAN DL, 1985, J BIOL CHEM, V260, P4295; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DEREMER MF, 1992, J BIOL CHEM, V267, P13460; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P11309; HATHAWAY DR, 1983, ANAL BIOCHEM, V135, P37, DOI 10.1016/0003-2697(83)90726-1; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KING MM, 1981, J BIOL CHEM, V256, P1058; KWIATKOWSKI AP, 1988, J BIOL CHEM, V263, P6484; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MILLER SG, 1985, J BIOL CHEM, V260, P9039; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; O'Sullivan W J, 1979, Methods Enzymol, V63, P294; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; WANG JH, 1976, J BIOL CHEM, V251, P4521	21	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13466	13471						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320022				2022-12-27	WOS:A1992JB74600060
J	PACHTER, JA; PAI, JK; MAYEREZELL, R; PETRIN, JM; DOBEK, E; BISHOP, WR				PACHTER, JA; PAI, JK; MAYEREZELL, R; PETRIN, JM; DOBEK, E; BISHOP, WR			DIFFERENTIAL REGULATION OF PHOSPHOINOSITIDE AND PHOSPHATIDYLCHOLINE HYDROLYSIS BY PROTEIN-KINASE C-BETA-1 OVEREXPRESSION - EFFECTS ON STIMULATION BY ALPHA-THROMBIN, GUANOSINE 5'-0-(THIOTRIPHOSPHATE), AND CALCIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL TRISPHOSPHATE FORMATION; PHOSPHOLIPASE-D; PHORBOL ESTER; HUMAN-PLATELETS; CULTURED FIBROBLASTS; SIGNAL TRANSDUCTION; FEEDBACK-REGULATION; CELLS; ACTIVATION; RECEPTOR	Rat 6 fibroblasts that stably overexpress cDNA for the beta-1 isozyme of protein kinase C (PKC3 cells) were used to determine the effect of protein kinase C (PKC) overexpression on hormonal stimulation of phospholipid hydrolysis. In control Rat 6 cells, inositol trisphosphate levels (InsP3) were increased 9-fold in 15 s in response to 10 nM alpha-thrombin, compared with only a 2-fold increase in PKC3 cells. PKC overexpression also inhibited thrombin-stimulated production of 1,2-diacylglycerol, the other product of phosphatidylinositol 4,5-bisphosphate hydrolysis, by 73% at 15 s. In permeabilized cells, PKC overexpression greatly reduced guanosine thiotriphosphate-stimulated InsP3 accumulation, but did not affect InsP3 stimulation by increased free calcium concentration. These data suggest that desensitization of thrombin-stimulated phosphoinositide-phospholipase C is enhanced by PKC-beta-1 overexpression and may involve modulation of G-protein/phospholipase C coupling. In contrast, thrombin was 4.5-fold more effective in stimulation of phosphatidylcholine-phospholipase D activity in PKC3 cells than in control cells, as determined by phosphatidylethanol formation. In permeabilized cells, guanosine thiotriphosphate also stimulated phospholipase D activity more effectively in PKC3 cells than in control cells, suggesting that up-regulation of phospholipase D activity by PKC over-expression occurs distal to the thrombin receptor. These results suggest that PKC may act as a switch to up-regulate phosphatidylcholine-phospholipase D and down-regulate phosphoinositide-phospholipase C stimulations.			PACHTER, JA (corresponding author), SCHERING PLOUGH CORP,MOLEC PHARMACOL SECT,B-9-1,60 ORANGE ST,BLOOMFIELD,NJ 07003, USA.							AMES BN, 1960, J BIOL CHEM, V235, P769; BELL RM, 1991, J BIOL CHEM, V266, P4661; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BHAVE SV, 1990, J PHYSIOL-LONDON, V425, P335, DOI 10.1113/jphysiol.1990.sp018106; BILLAH MM, 1981, J BIOL CHEM, V256, P5399; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BISHOP WR, 1990, BIOCHEM J, V269, P465, DOI 10.1042/bj2690465; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN KD, 1990, BIOCHEM J, V270, P557, DOI 10.1042/bj2700557; CAO YZ, 1990, BIOCHEM BIOPH RES CO, V171, P955, DOI 10.1016/0006-291X(90)90777-K; FURKAMI K, 1989, J BIOL CHEM, V264, P14985; HOCKBERGER P, 1989, NATURE, V338, P340, DOI 10.1038/338340a0; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; JONES LG, 1988, CIRC RES, V62, P299, DOI 10.1161/01.RES.62.2.299; LO WWY, 1988, BIOCHEM J, V251, P625, DOI 10.1042/bj2510625; MARTIN TW, 1989, BIOCHEM BIOPH RES CO, V165, P319, DOI 10.1016/0006-291X(89)91072-3; MAU SE, 1990, MOL CELL ENDOCRINOL, V69, P69, DOI 10.1016/0303-7207(90)90090-U; ORELLANA S, 1987, J BIOL CHEM, V262, P1638; PACHTER JA, 1988, BIOCHEM BIOPH RES CO, V154, P654, DOI 10.1016/0006-291X(88)90189-1; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PAI JK, 1988, J BIOL CHEM, V263, P12472; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; PLEVIN R, 1990, BIOCHEM J, V268, P605, DOI 10.1042/bj2680605; PREISS J, 1986, J BIOL CHEM, V261, P8597; QIAN Z, 1989, J BIOL CHEM, V264, P21720; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1990, J BIOL CHEM, V265, P17941; SANDO JJ, 1983, P NATL ACAD SCI-BIOL, V80, P2642, DOI 10.1073/pnas.80.9.2642; SHAAFI RI, 1989, BIOCHEM J, V261, P688, DOI 10.1042/bj2610688; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; TAKAI Y, 1979, BIOCHEM BIOPH RES CO, V91, P1218, DOI 10.1016/0006-291X(79)91197-5; TAKAMURA H, 1987, J BIOL CHEM, V262, P2262; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WATSON SP, 1985, P NATL ACAD SCI USA, V82, P2623, DOI 10.1073/pnas.82.9.2623; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374	40	77	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9826	9830						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315771				2022-12-27	WOS:A1992HT96500061
J	RAJOTTE, D; HADDAD, P; HAMAN, A; CRAGOE, EJ; HOANG, T				RAJOTTE, D; HADDAD, P; HAMAN, A; CRAGOE, EJ; HOANG, T			ROLE OF PROTEIN-KINASE-C AND THE NA+/H+ ANTIPORTER IN SUPPRESSION OF APOPTOSIS BY GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR AND INTERLEUKIN-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; GM-CSF RECEPTOR; PHORBOL-ESTER; HEMATOPOIETIC-CELLS; GROWTH-FACTORS; PROLIFERATION; BINDING; HETEROGENEITY; CLONING; IDENTIFICATION	Granulocyte macrophage colony-stimulating factor (GM-CSF) or interleukin-3 (IL-3) suppress apoptosis in hemopoietic cell, a process of active cell death characterized by the degradation of genomic DNA into oligonucleosomic fragments. The present study was therefore initiated with the view that the two growth factors may trigger the same early events in the cell, leading to suppression of apoptosis. We provide evidence here for a role of protein kinase C and of the Na+/H+ antiporter in the signal transduction pathways activated by binding of GM-CSF or IL-3 to their respective receptors, resulting in suppression of apoptosis in target cells. First, kinetic studies indicate that the process is irreversible after two hours of deprivation. The suppression of apoptosis by GM-CSF and IL-3 is dose-dependent, with half-efficient concentrations that are in the range of the dissociation constants of the high affinity GM-CSF or EL-3 receptor, respectively. Second, the use of three inhibitors of protein kinase C (PKC), H7, staurosporine, and sphingosine, in concentrations that are below their toxicity limits, revert the suppression of apoptosis by EL-3 and GM-CSF. Conversely, the use of 12-O-tetradecanoylphorbol-13-acetate (TPA), a PKC activator, allows a bypass of receptor activation in suppression of apoptosis. Western blotting of cytosolic and membrane proteins indicate that exposure of the cells to GM-CSF, IL-3, or TPA results in translocation of PKC to the cell membrane. Our data, therefore, indicate that the activation of PKC is important in suppression of apoptosis by GM-CSF and IL-3. Third, the two amiloride derivatives 5-(N,N-hexamethylene) and 5-(N-ethyl-N-isopropyl)amiloride that specifically block the function of the Na+/H+ antiport also revert the protective effect of GM-CSF, IL-3, and TPA on MO7-E cells. Further, exposure of the cells to GM-CSF, IL-3, or TPA results in sustained pH(i) alkalinization, which is abrogated when the cells are preincubated with 5-(N-ethyl-N-isopropyl)amiloride, a specific inhibitor of the antiport. Preincubation of the cells with staurosporine, a PKC inhibitor, also significantly reduces the effect of GM-CSF or IL-3 on pH(i). Taken together, our data indicate that a functional antiport is required in suppression of apoptosis by GM-CSF, IL-3, or TPA. Furthermore, our results are consistent with the view that GM-CSF or IL-3 receptor activation initiates the sequential activation of PKC and of the Na+/H+ antiporter, resulting in suppression of apoptosis in target cells.	CLIN RES INST MONTREAL,HEMOPOIESIS & LEUKEMIA LAB,110 PINE AVE W,MONTREAL H2W 1R7,QUEBEC,CANADA; UNIV MONTREAL,DEPT MED,MONTREAL H3C 3J7,QUEBEC,CANADA; UNIV MONTREAL,DEPT PHARMACOL,MONTREAL H3C 3J7,QUEBEC,CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal								ADAMS JC, 1989, BIOCHEM J, V257, P905, DOI 10.1042/bj2570905; ADUNYAH SE, 1991, J BIOL CHEM, V266, P5670; ALVAREZ J, 1989, EUR J BIOCHEM, V183, P709, DOI 10.1111/j.1432-1033.1989.tb21102.x; ARENDS MJ, 1990, AM J PATHOL, V136, P593; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS G, 1991, CANCER RES, V51, P3281; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; BUSSOLINO F, 1989, J BIOL CHEM, V264, P18284; CHIBA S, 1990, CELL REGUL, V1, P327, DOI 10.1091/mbc.1.4.327; CRAGOE EJ, 1967, J MED CHEM, V10, P66, DOI 10.1021/jm00313a014; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GESNER T, 1989, BLOOD, V74, P2652; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; INAGAKI M, 1984, J BIOL CHEM, V259, P1431; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KILEY S, 1990, J BIOL CHEM, V265, P15704; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LIU JW, 1991, J BIOL CHEM, V266, P5929; LOTEM J, 1991, BLOOD, V78, P953; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MCCONKEY DJ, 1990, IMMUNOL TODAY, V11, P120, DOI 10.1016/0167-5699(90)90048-E; MOOLENAAR WH, 1984, NATURE, V312, P371, DOI 10.1038/312371a0; NICOLA NA, 1986, J CELL PHYSIOL, V128, P180, DOI 10.1002/jcp.1041280207; ONETTOPOTHIER N, 1990, BLOOD, V75, P59; ONETTOPOTHIER N, 1990, LEUKEMIA, V4, P329; PARK LS, 1989, BLOOD, V74, P56; PARK LS, 1989, J BIOL CHEM, V264, P5420; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; Schreurs J, 1990, GROWTH FACTORS, V2, P221, DOI 10.3109/08977199009071508; SCHWARTZ EL, 1991, BLOOD, V77, P2716; STRASSER A, 1990, NATURE, V348, P31; TAKETAZU F, 1991, J CELL PHYSIOL, V146, P251, DOI 10.1002/jcp.1041460209; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; VALLANCE SJ, 1990, BIOCHEM J, V265, P359, DOI 10.1042/bj2650359; WALKER F, 1985, EMBO J, V4, P933, DOI 10.1002/j.1460-2075.1985.tb03721.x; WHETTON AD, 1988, P NATL ACAD SCI USA, V85, P3284, DOI 10.1073/pnas.85.10.3284; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	49	173	173	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9980	9987						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315776				2022-12-27	WOS:A1992HT96500081
J	BRUBAKER, PL; LEE, YC; DRUCKER, DJ				BRUBAKER, PL; LEE, YC; DRUCKER, DJ			ALTERATIONS IN PROGLUCAGON PROCESSING AND INHIBITION OF PROGLUCAGON GENE-EXPRESSION IN TRANSGENIC MICE WHICH CONTAIN A CHIMERIC PROGLUCAGON-SV40 T-ANTIGEN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET CELL-LINE; GLUCAGON GENE; PEPTIDE-I; PRO-OPIOMELANOCORTIN; DEPENDENT PATHWAY; INSULIN RELEASE; RAT INTESTINE; PANCREAS; PROHORMONE; PITUITARY	The proglucagon gene is expressed in A cells of the pancreas and L cells of the large and small intestine. Transgenic mice expressing SV40 large T antigen under the control of proglucagon regulatory sequences develop neuroendocrine carcinoma of the large intestine. To determine the consequences of coexpression of SV40 large T antigen and proglucagon in different cell types, the levels of proglucagon mRNA transcripts and proglucagon-derived peptides were determined in tumor-bearing transgenic mice and in age-matched paired controls. Plasma levels of proglucagon-derived peptides (glicentin, oxyntomodulin, and glucagon, as determined by high pressure liquid chromatography and radioimmunoassay) were markedly elevated in association with tumor growth (p < 0.001). Northern blot analysis demonstrated that the increased concentration of proglucagon-derived peptides was associated with significant inhibition of the endogenous proglucagon gene in pancreas, and to a lesser extent, small intestine. Concomitantly, the concentrations of proglucagon-derived peptides fell to 1-10% of control values in pancreas (p < 0.001) and to 62% of control values in small intestine (p < 0.001). Analysis of proglucagon-derived peptides in mice of different ages demonstrated that tumor growth was associated with a switch in the post-translational processing of proglucagon. Compared with normal mouse intestine, tumors contained increased proportions of glucagon and glucagon-like peptide-1(7-37) relative to glicentin, oxyntomodulin, and glucagon-like peptide-1(1-37). The results of these studies provide evidence for humorally-mediated tissue-specific inhibition of proglucagon gene expression.	UNIV TORONTO, BANTING & BEST DIABET CTR, TORONTO M5S 1A8, ONTARIO, CANADA; UNIV TORONTO, DEPT MED, TORONTO M5S 1A8, ONTARIO, CANADA; UNIV TORONTO, DEPT CLIN BIOCHEM, TORONTO M5S 1A8, ONTARIO, CANADA	University of Toronto; University of Toronto; University of Toronto	BRUBAKER, PL (corresponding author), UNIV TORONTO, DEPT PHYSIOL, RM 3366, MED SCI BLDG, TORONTO M5S 1A8, ONTARIO, CANADA.		Drucker, Daniel J/A-4092-2010					ALARCON C, 1991, HORM METAB RES, V23, P290, DOI 10.1055/s-2007-1003677; BATAILLE D, 1988, ANN NY ACAD SCI, V527, P168; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BRUBAKER PL, 1987, ENDOCRINOLOGY, V120, P1976, DOI 10.1210/endo-120-5-1976; BRUBAKER PL, 1988, ENDOCRINOLOGY, V123, P220, DOI 10.1210/endo-123-1-220; BRUBAKER PL, 1989, ENDOCRINOLOGY, V124, P3003, DOI 10.1210/endo-124-6-3003; BRUBAKER PL, 1991, ENDOCRINOLOGY, V128, P3175, DOI 10.1210/endo-128-6-3175; CANNY BJ, 1988, NEUROENDOCRINOLOGY, V48, P603, DOI 10.1159/000125069; DRUCKER DJ, 1990, CANCER, V65, P1762, DOI 10.1002/1097-0142(19900415)65:8<1762::AID-CNCR2820650817>3.0.CO;2-Q; DRUCKER DJ, 1989, P NATL ACAD SCI USA, V86, P3953, DOI 10.1073/pnas.86.11.3953; DRUCKER DJ, 1987, J BIOL CHEM, V262, P15659; DRUCKER DJ, 1988, J BIOL CHEM, V263, P13475; DRUCKER DJ, 1988, ENDOCRINOLOGY, V123, P1861, DOI 10.1210/endo-123-4-1861; DRUCKER DJ, 1991, ENDOCRINOLOGY, V128, P394, DOI 10.1210/endo-128-1-394; DRUCKER DJ, 1986, J BIOL CHEM, V261, P9637; FALOONA GR, 1974, METHOD HORM RADIOIMM, P317; FEHMANN HC, 1991, ENDOCRINOLOGY, V128, P2880, DOI 10.1210/endo-128-6-2880; FEHMANN HC, 1992, ENDOCRINOLOGY, V130, P159, DOI 10.1210/en.130.1.159; FUKUSHIMA H, 1981, ENDOCRINOL JAPON, V28, P575; HEDING LG, 1971, DIABETOLOGIA, V7, P10, DOI 10.1007/BF02346248; HOLST JJ, 1987, FEBS LETT, V211, P169, DOI 10.1016/0014-5793(87)81430-8; HOLST JJ, 1983, DIABETOLOGIA, V24, P359; KAWAI K, 1989, ENDOCRINOLOGY, V124, P1768, DOI 10.1210/endo-124-4-1768; KERVRAN A, 1990, REGUL PEPTIDES, V31, P41, DOI 10.1016/0167-0115(90)90194-2; KERVRAN A, 1987, ENDOCRINOLOGY, V121, P704, DOI 10.1210/endo-121-2-704; KOMATSU R, 1989, DIABETES, V38, P902, DOI 10.2337/diabetes.38.7.902; KREYMANN B, 1987, LANCET, V2, P1300; LEE YC, 1992, J BIOL CHEM, V267, P10705; LIU EY, 1990, ENDOCRINOLOGY, V126, P110; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOJSOV S, 1990, J BIOL CHEM, V265, P8001; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172/JCI112855; MURPHY GJ, 1987, BIOCHEM J, V243, P39, DOI 10.1042/bj2430039; NOEL G, 1991, ENDOCRINOLOGY, V129, P1317, DOI 10.1210/endo-129-3-1317; OCONNOR KJ, 1976, BIOCHEM J, V156, P265, DOI 10.1042/bj1560265; OHNEDA A, 1986, DIABETOLOGIA, V29, P397, DOI 10.1007/BF00903352; PATZELT C, 1984, P NATL ACAD SCI-BIOL, V81, P5007, DOI 10.1073/pnas.81.16.5007; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1986, ENDOCRINOLOGY, V119, P2833, DOI 10.1210/endo-119-6-2833; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; SCHMIDT WE, 1985, DIABETOLOGIA, V28, P704, DOI 10.1007/BF00291980; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; TANAKA R, 1979, ENDOCRINOL JAPON, V26, P59; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; ZAKARIAN S, 1989, NATURE, V339, P553, DOI 10.1038/339553a0	49	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20728	20733						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328210				2022-12-27	WOS:A1992JT97800035
J	MIKI, T; FUJII, H; KAKINUMA, K				MIKI, T; FUJII, H; KAKINUMA, K			EPR SIGNALS OF CYTOCHROME-B558 PURIFIED FROM PORCINE NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; ELECTRON-PARAMAGNETIC RESONANCE; 2 CYTOSOLIC COMPONENTS; NADPH OXIDASE; SPIN-RESONANCE; SUPEROXIDE PRODUCTION; RESPIRATORY BURST; PLASMA-MEMBRANE; SYSTEM; OXIDOREDUCTASE	Cytochrome b558 of pig blood neutrophils was partially purified, and its EPR spectra were measured. The cytochrome b558 was solubilized from membranes with the detergent n-heptyl-beta-thioglucoside and purified by DEAE-Sepharose and heparin-Sepharose chromatographies. The small and large subunits of cytochrome b558 were detected on gel by immunoblotting. A solution of the purified, undenatured cytochrome b558 at 85-108 muM concentration was obtained. The concentrated cytochrome b558 showed an EPR signal at a g value of 3.26 with a bandwidth of 100 G at 10 K. Addition of 2 mM KCN had no effect on the low spin signal at g = 3.26 but caused disappearance of a minor high spin signal. The cyanide-insensitive signal at g = 3.26 disappeared completely on reduction with Na2S2O4. These results suggest that the g = 3.26 signal is characteristic of the low spin heme in cytochrome b558 of neutrophils.	TOKYO METROPOLITAN INST MED SCI,DEPT INFLAMMAT RES,HONKOMAGOME 3-18-22,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science								BABIOR BM, 1984, BLOOD, V64, P959; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; CHIBA T, 1990, BIOCHEM BIOPH RES CO, V173, P376, DOI 10.1016/S0006-291X(05)81068-X; CLARK RA, 1989, NEW ENGL J MED, V321, P647, DOI 10.1056/NEJM198909073211005; CROSS AR, 1981, BIOCHEM J, V194, P599, DOI 10.1042/bj1940599; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; FRIDEN H, 1990, BIOCHIM BIOPHYS ACTA, V1041, P207, DOI 10.1016/0167-4838(90)90067-P; FUJII H, 1992, IN PRESS BIOCH BIOPH; GABELLINI N, 1986, EUR J BIOCHEM, V154, P569, DOI 10.1111/j.1432-1033.1986.tb09437.x; GABIG TG, 1982, J BIOL CHEM, V257, P4114; HATATANAKA A, 1987, FEBS LETT, V214, P279, DOI 10.1016/0014-5793(87)80070-4; HURST JK, 1991, J BIOL CHEM, V266, P1627; IIZUKA T, 1985, J BIOL CHEM, V260, P2049; KAKINUMA K, 1986, J BIOL CHEM, V261, P9426; KAKINUMA K, 1989, 3RD P INT C BIOPH 19; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKERT M, 1985, P NATL ACAD SCI USA, V82, P3144, DOI 10.1073/pnas.82.10.3144; MCCURLEY JP, 1990, BIOCHIM BIOPHYS ACTA, V1020, P176, DOI 10.1016/0005-2728(90)90049-A; MIKI T, 1992, J BIOL CHEM, V267, P18695; NUGENT JHA, 1989, BIOCHEM J, V264, P921, DOI 10.1042/bj2640921; PALMER G, 1985, BIOCHEM SOC T, V13, P548, DOI 10.1042/bst0130548; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SALERNO JC, 1984, J BIOL CHEM, V259, P2331; SEGAL AW, 1978, NATURE, V276, P515, DOI 10.1038/276515a0; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UENO I, 1991, FEBS LETT, V281, P130, DOI 10.1016/0014-5793(91)80375-D; WAKEYAMA H, 1982, BIOCHEM J, V205, P593, DOI 10.1042/bj2050593; WALKER FA, 1984, J AM CHEM SOC, V106, P6888, DOI 10.1021/ja00335a003	34	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19673	19675						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326560				2022-12-27	WOS:A1992JP59300097
J	UMBARGER, KO; YAMAZAKI, M; HUTSON, LD; HAYASHI, F; YAMAZAKI, A				UMBARGER, KO; YAMAZAKI, M; HUTSON, LD; HAYASHI, F; YAMAZAKI, A			HETEROGENEITY OF THE RETINAL G-PROTEIN TRANSDUCIN FROM FROG ROD PHOTORECEPTORS - BIOCHEMICAL-IDENTIFICATION AND CHARACTERIZATION OF NEW SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; CYCLIC-GMP PHOSPHODIESTERASE; CGMP PHOSPHODIESTERASE; ADP-RIBOSYLATION; PERTUSSIS TOXIN; OUTER SEGMENTS; GAMMA-SUBUNITS; ALPHA-SUBUNIT; VISUAL EXCITATION; CYCLASE	Transducin, a retinal G-protein, has been shown to exist as heterotrimers of alpha (39,000), beta (36,000), and gamma (approximately 7,000) subunits. Blue Sepharose CL-6B column chromatography of a transducin preparation extracted with a metal-free, low salt buffer containing GTP showed three distinct alpha and two distinct betagamma activities in frog (Rana catesbiana) rod outer segment. The binding of a hydrolysis-resistant GTP analog in these alpha fractions was proportional to the amount of the M(r) 39,000 protein. The first alpha was eluted in a complex with an inhibitory subunit of cGMP phosphodiesterase, but alpha subunits in the second and the third fractions were not complexed with any proteins. Two-dimensional gel electrophoresis and characterization with regard to the interaction with the inhibitory subunit of cGMP phoshodiesterase suggested that the first and the second alphas were the same protein; however, the third alpha showed different characters as follows. We designated alpha in the first two fractions as alpha1, and alpha in the third fraction as alpha2. Nonlinear regression analysis for the binding of a hydrolysis-resistant GTP analog to both alpha subunits revealed a single class of GTP binding sites with an apparent stoichiometry of 1 mol of GTP/mol of alpha. Compared with alpha1, alpha2 required larger amounts of rhodopsin and betagamma for the binding of a hydrolysis-resistant GTP analog. Alpha2 also showed less binding with the inhibitory subunit of cGMP phosphodiesterase. Both alpha1 and alpha2 complexed with betagamma or betadelta (described below) were substrates for pertussis toxin-dependent ADP-ribosylation. The protein profiles of two betagamma fractions revealed that the main fraction was composed of a betagamma complex; however, the second active fraction was composed of beta complexed with delta (M(r) 12,000). Compared with betagamma, betadelta stimulated GTP binding to alpha1 at approximately 10-fold higher concentration. Two-dimensional gel electrophoresis revealed five beta and two gamma isoforms in betagamma. Only one beta isoform was present in betadelta. The diversity of transducin subunits may reflect different signaling pathways in visual signal transduction.	WAYNE STATE UNIV, SCH MED,KRESGE EYE INST,DEPT OPHTHALMOL, 4717 ST ANTOINE ST, DETROIT, MI 48201 USA; LOS ALAMOS NATL LAB, DIV LIFE SCI, LOS ALAMOS, NM 87545 USA; WAYNE STATE UNIV, SCH MED, DEPT PHARMACOL, DETROIT, MI 48201 USA	Wayne State University; United States Department of Energy (DOE); Los Alamos National Laboratory; Wayne State University					NATIONAL EYE INSTITUTE [R01EY007546, R01EY009631] Funding Source: NIH RePORTER; NEI NIH HHS [EY09631, EY07546] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		APPLEBURY ML, 1986, VISION RES, V26, P1881, DOI 10.1016/0042-6989(86)90115-X; BIRNBAUMER L, 1987, KIDNEY INT, V32, pS14; BRAVO R, 1984, 2 DIMENSIONAL GEL EL, P3; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; FUKADA Y, 1989, J BIOL CHEM, V264, P5937; FUKADA Y, 1986, PHOTOBIOCH PHOTOBIOP, V11, P269; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GRUNWALD GB, 1986, SCIENCE, V231, P856, DOI 10.1126/science.3080807; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4333, DOI 10.1073/pnas.88.10.4333; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4746, DOI 10.1073/pnas.88.11.4746; HILDEBRANDT JD, 1985, J BIOL CHEM, V260, P4867; HO YK, 1989, CURR TOP CELL REGUL, V30, P171; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; LIEBMAN PA, 1968, VISION RES, V8, P761, DOI 10.1016/0042-6989(68)90128-4; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; MANNING DR, 1984, J BIOL CHEM, V259, P749; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MILLER WH, 1990, INVEST OPHTH VIS SCI, V31, P1664; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; NEUBERT TA, 1992, INVEST OPHTH VIS SCI, V33, P872; OKABE K, 1990, J BIOL CHEM, V265, P12854; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STRYER L, 1991, J BIOL CHEM, V266, P10711; TAMIR H, 1991, BIOCHEMISTRY-US, V30, P3929, DOI 10.1021/bi00230a018; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; VANDOP C, 1984, J BIOL CHEM, V259, P23; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; YAMAZAKI A, 1992, ADV SEC MESS PHOSPH, V25, P135; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9324	38	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19494	19502						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326554				2022-12-27	WOS:A1992JP59300073
J	BENTLEY, JK; KADLECEK, A; SHERBERT, CH; SEGER, D; SONNENBURG, WK; CHARBONNEAU, H; NOVACK, JP; BEAVO, JA				BENTLEY, JK; KADLECEK, A; SHERBERT, CH; SEGER, D; SONNENBURG, WK; CHARBONNEAU, H; NOVACK, JP; BEAVO, JA			MOLECULAR-CLONING OF CDNA-ENCODING A 63-KDA CALMODULIN-STIMULATED PHOSPHODIESTERASE FROM BOVINE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; DEPENDENT PROTEIN-KINASE; RAT-BRAIN; SUBSTRATE-SPECIFICITY; RNA-POLYMERASE; EXPRESSION; SEQUENCE; IDENTIFICATION; LOCALIZATION; ISOZYMES	Partially degenerate oligonucleotides based on peptide sequence were used to isolate cDNA to a 63-kDa bovine brain calmodulin-stimulated phosphodiesterase (CaM-PDE) isozyme. A 412-base pair polymerase chain reaction fragment was obtained and used along with the oligonucleotides to isolate several cDNAs each encoding sequence identical to known peptide sequences from the 63-kDa CaM-PDE. The largest cDNA contained a full-length open reading frame (ORF) encoding a 534 amino acid, 61,005-dalton protein. It had 59% amino acid identity to the 61-kDa bovine brain CaM-PDE and included a carboxyl-terminal conserved domain containing the PDE catalytic domain consensus sequences. The NH2-terminal region fits the criteria for a calmodulin-binding domain. When its expression was driven by a cytomegalogvirus promoter on a pCDM8 vector in COS-7 cells, the cDNA encoded a catalytically active, calmodulin-stimulated PDE. Northern analysis of RNA from several tissues with a probe containing much of the conserved PDE catalytic domain showed only a single band of 4.0 kilobases. Hybridization was seen in mRNA from several regions of the central nervous system with the greatest signal in basal ganglia. Strong signals also were seen in other tissues including kidney papilla and adrenal medulla. Antisense RNA probes were used in RNase-protection assays to look for evidence of multiple 63-kDa CaM-PDE transcripts. A catalytic domain probe was fully protected by RNA from cerebral cortex, basal ganglia, cerebellum, hippocampus, adrenal medulla, and kidney papilla. However, a probe to the NH2-terminal region was fully protected only by brain and adrenal medullary RNA indicating the likelihood of one or more isozyme(s) divergent in this region in the kidney papilla.	UNIV WASHINGTON,DEPT PHARMACOL,SJ-30,SEATTLE,WA 98195; PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	University of Washington; University of Washington Seattle; Purdue University System; Purdue University; Purdue University West Lafayette Campus				Bentley, John Kelley/0000-0001-8865-7979	NEI NIH HHS [EY 08197] Funding Source: Medline; NIDDK NIH HHS [DK 21723] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021723] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSIELLO DA, 1984, SEMIN NEPHROL, V4, P134; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; Beavo JA, 1990, CYCLIC NUCLEOTIDE PH, P1; BELTZ GA, 1983, METHOD ENZYMOL, V100, P266; BENTLEY J K, 1992, Current Opinion in Cell Biology, V4, P233; BILLINGSLEY ML, 1990, DEV BRAIN RES, V53, P253, DOI 10.1016/0165-3806(90)90015-Q; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; CHARBONNEAU H, 1991, BIOCHEMISTRY-US, V30, P7981; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDWARDS RM, 1981, AM J PHYSIOL, V240, pF311, DOI 10.1152/ajprenal.1981.240.4.F311; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; HANSEN RS, 1986, J BIOL CHEM, V261, P4636; HANSEN RS, 1982, P NATL ACAD SCI-BIOL, V79, P2788, DOI 10.1073/pnas.79.9.2788; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P10884; HURWITZ RL, 1990, J BIOL CHEM, V265, P8901; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KINCAID RL, 1987, P NATL ACAD SCI USA, V84, P1118, DOI 10.1073/pnas.84.4.1118; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LUDVIG N, 1991, NEUROSCIENCE, V44, P491, DOI 10.1016/0306-4522(91)90072-V; MARRIOTT D, 1988, J NEUROCHEM, V50, P616, DOI 10.1111/j.1471-4159.1988.tb02955.x; MORRIS CE, 1986, GENE, V41, P193, DOI 10.1016/0378-1119(86)90098-3; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NOVACK JP, 1991, BIOCHEMISTRY-US, V30, P7940, DOI 10.1021/bi00246a010; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; REPASKE DR, 1992, J BIOL CHEM, V267, P18683; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHARMA RK, 1991, BIOCHEMISTRY-US, V30, P5963, DOI 10.1021/bi00238a021; SHARMA RK, 1985, P NATL ACAD SCI USA, V82, P2603, DOI 10.1073/pnas.82.9.2603; SHARMA RK, 1984, J BIOL CHEM, V259, P9248; SHENOLIKAR S, 1985, BIOCHEMISTRY-US, V24, P672, DOI 10.1021/bi00324a020; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SMITH WL, 1989, ADV EXP MED BIOL, V259, P131; SONNENBURG WK, 1991, J BIOL CHEM, V266, P17655; SONNENBURG WK, 1992, IN PRESS CYCLIC GMP; TIRRELL JG, 1983, ARCH BIOCHEM BIOPHYS, V222, P380, DOI 10.1016/0003-9861(83)90534-9	40	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18676	18682						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326531				2022-12-27	WOS:A1992JN50200066
J	REALINI, CA; ALTHAUS, FR				REALINI, CA; ALTHAUS, FR			HISTONE SHUTTLING BY POLY(ADP-RIBOSYLATION)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA EXCISION REPAIR; ADP-RIBOSYLATION; MAMMALIAN-CELLS; POLYMERASE; INVITRO; RIBOSE; ACTIVATION; BREAKS; INHIBITION; MOLECULES	We have found that two nuclear enzymes, i.e. poly(ADP-ribose) polymerase (EC 2.4.2.30) and poly(ADP-ribose) glycohydrolase, may cooperate to function as a histone shuttle mechanism on DNA. The mechanism involves four distinct reaction intermediates that were analyzed in a reconstituted in vitro system. In the first step, the enzyme poly(ADP-ribose) polymerase is activated in the presence of histone-DNA complexes and converts itself into a protein carrying multiple ADP-ribose polymers. These polymers attract histones that dissociate from the DNA as a histone-polymer-polymerase complex. The DNA assumes the electrophoretic mobility of free DNA and becomes susceptible to nuclease digestion (second step). In the third step, poly(ADP-ribose) glycohydrolase degrades ADP-ribose polymers and thereby eliminates the binding sites for histones. In the fourth step, histones reassociate with DNA, and the histone-DNA complexes exhibit the electrophoretic mobilities and nuclease susceptibilities of the original complexes prior to dissociation. Our results are compatible with the view that the poly(ADP-ribosylation) system acts as a catalyst of nucleosomal unfolding of chromatin in DNA excision repair.	UNIV ZURICH, TIERSPITAL, INST PHARMACOL & BIOCHEM, WINTERTHURERSTR 260, CH-8057 ZURICH, SWITZERLAND	University of Zurich								Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BENJAMIN RC, 1980, J BIOL CHEM, V255, P493; BERGER NA, 1981, BIOCHEMISTRY-US, V20, P3610, DOI 10.1021/bi00515a047; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN JJ, 1981, BIOCHEM BIOPH RES CO, V98, P268, DOI 10.1016/0006-291X(81)91898-2; COHEN JJ, 1982, BIOCHEMISTRY-US, V21, P4931, DOI 10.1021/bi00263a016; COLE GA, 1991, BIOCHEM BIOPH RES CO, V180, P504, DOI 10.1016/S0006-291X(05)81093-9; DEMURCIA G, 1988, BIOCHEM CELL BIOL, V66, P626, DOI 10.1139/o88-072; FERRO AM, 1982, J BIOL CHEM, V257, P7808; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; HATAKEYAMA K, 1986, J BIOL CHEM, V261, P4902; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; JUAREZSALINAS H, 1982, J BIOL CHEM, V257, P607; KUPPER JH, 1990, J BIOL CHEM, V265, P18721; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT WM, 1989, DNA REPAIR MECHANISM, P667; LOEB LA, 1969, J BIOL CHEM, V244, P1672; LUTTER LC, 1978, J MOL BIOL, V124, P391, DOI 10.1016/0022-2836(78)90306-6; MALANGA M, 1992, Experientia (Basel), V48, pA82; MANIATIS T, 1975, BIOCHEMISTRY-US, V14, P3787, DOI 10.1021/bi00688a010; MANIATIS T, 1982, MOL CLONING LABORATO, P122; MATHIS G, 1990, CARCINOGENESIS, V11, P1237, DOI 10.1093/carcin/11.7.1237; MATHIS G, 1987, BIOCHEM BIOPH RES CO, V143, P1049, DOI 10.1016/0006-291X(87)90358-5; MCCURRY LS, 1981, J BIOL CHEM, V256, P551; NAEGELI H, 1989, J BIOL CHEM, V264, P14382; NAEGELI H, 1991, J BIOL CHEM, V266, P10596; OHASHI Y, 1983, P NATL ACAD SCI-BIOL, V80, P3604, DOI 10.1073/pnas.80.12.3604; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PANZETER PL, 1992, BIOCHEMISTRY-US, V31, P1379, DOI 10.1021/bi00120a014; PANZETER PL, 1990, NUCLEIC ACIDS RES, V18, P2194, DOI 10.1093/nar/18.8.2194; PEACOCK AC, 1967, BIOCHEMISTRY-US, V6, P1818, DOI 10.1021/bi00858a033; SHALL S, 1984, ADV RADIAT BIOL, V11, P1; SIDIK K, 1992, CARCINOGENESIS, V13, P135, DOI 10.1093/carcin/13.1.135; SMERDON MJ, 1989, NATO ADV SCI I A-LIF, V182, P271; THOMASSIN H, 1990, NUCLEIC ACIDS RES, V18, P4691, DOI 10.1093/nar/18.16.4691; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; van Holde KE., 1989, SPRINGER SERIES MOL; ZAHRADKA P, 1982, EUR J BIOCHEM, V127, P3471	43	165	167	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18858	18865						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326536				2022-12-27	WOS:A1992JN50200092
J	XU, JM; NAKAHARA, M; CRABB, JW; SHI, EG; MATUO, Y; FRASER, M; KAN, M; HOU, JZ; MCKEEHAN, WL				XU, JM; NAKAHARA, M; CRABB, JW; SHI, EG; MATUO, Y; FRASER, M; KAN, M; HOU, JZ; MCKEEHAN, WL			EXPRESSION AND IMMUNOCHEMICAL ANALYSIS OF RAT AND HUMAN FIBROBLAST GROWTH-FACTOR RECEPTOR (FLG) ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE MUTATION SUPPRESSES; 3-DIMENSIONAL STRUCTURE; BINDING; CELL; PROTEINS; DOMAINS; FAMILY; FORMS; HETERODIMERIZATION; ARRANGEMENT	Potentially 96 splice variants among four genes that code for the human heparin-binding fibroblast growth factor receptor family complicate study of structure, metabolism, and function of single isoforms in mammalian cells. As an alternative, we expressed structural subdomains and isoforms of the flg receptor gene in bacteria and baculoviral-infected insect cells. We developed and characterized a panel of 16 isoform and domain-specific polyclonal and monoclonal antibodies. The panel of antibodies was used to distinguish mature glycosylated ligand-binding and kinase-active and -inactive recombinant isoforms in baculoviral insect cells and transfected mammalian cells and natural isoforms in rat prostate and human liver cells. The results revealed a cell type-specific expression of the flg gene and isoforms that result from combinations of splice variations. Reactive epitopes of monoclonal antibodies against both the three (alpha) and two (beta) immunoglobulin-like disulfide loop extracellular domain isoforms were mapped by cross-reactivity with synthetic polypeptide sequences and deletion mutants expressed in bacteria. The native alpha and beta-receptor isoforms differed in display of shared epitopes and suggested that the NH2-terminal Loop I and COOH-terminal Loops II and III of the alpha-isoform are interactive. Although the common Loops II and III appear qualitatively sufficient for ligand binding, the results suggest that tertiary relationships among loops in the three and two loop isoforms are distinct and, therefore, the two isoforms may have distinct activities. Spatial models for arrangement of immunoglobulin-like loops in the extracellular domain of the two isoforms are presented.	W ALTON JONES CELL SCI CTR, 10 OLD BARN RD, LAKE PLACID, NY 12946 USA; UPSTATE BIOTECHNOL INC, LAKE PLACID, NY 12946 USA; UNIV NOTRE DAME, DEPT BIOL, NOTRE DAME, IN 46556 USA	University of Notre Dame			Fraser, Malcolm J/C-9100-2009		NCI NIH HHS [CA37589] Funding Source: Medline; NIDDK NIH HHS [DK40739, DK35310] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA037589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040739, R01DK035310] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BECKER JW, 1989, P NATL ACAD SCI USA, V86, P1088, DOI 10.1073/pnas.86.3.1088; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CRABB JW, 1986, BIOCHEMISTRY-US, V25, P4988, DOI 10.1021/bi00366a003; CRABB JW, 1991, J BIOL CHEM, V266, P16674; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EISEMANN A, 1991, ONCOGENE, V6, P1195; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; HARLOW E, 1988, ANTIBODIES LABORATOR; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HIGGINS RC, 1979, ANAL BIOCHEM, V93, P257, DOI 10.1016/S0003-2697(79)80077-9; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOU JZ, 1992, J BIOL CHEM, V267, P17804; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAN M, 1988, J BIOL CHEM, V263, P11306; KAN M, 1991, METHOD ENZYMOL, V198, P158; KAN M, 1992, IN PRESS IN VITRO CE; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MANSSON PE, 1989, CANCER RES, V49, P2485; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; SHI E, 1991, J BIOL CHEM, V266, P5774; SHI E, 1991, Journal of Cell Biology, V115, p416A; SHI E, 1991, Journal of Cell Biology, V115, p417A; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; SUMMERS MD, 1988, TEXAS AGR EXPT STATI, V1555; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YAN GC, 1992, BIOCHEM BIOPH RES CO, V183, P423, DOI 10.1016/0006-291X(92)90498-A	37	90	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17792	17803						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325449				2022-12-27	WOS:A1992JM22300051
J	CONG, PJ; SHUMAN, S				CONG, PJ; SHUMAN, S			METHYLTRANSFERASE AND SUBUNIT ASSOCIATION DOMAINS OF VACCINIA VIRUS MESSENGER-RNA CAPPING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLATE INTERMEDIATE; ESCHERICHIA-COLI; GUANYLYLTRANSFERASE; TRANSCRIPTION; MECHANISM	RNA triphosphatase, RNA guanylyltransferase, and RNA (guanine-N7-)-methyltransferase activities are associated with the vaccinia virus mRNA capping enzyme, a heterodimeric protein containing polypeptides of M(r) 95,000 and 31,000. Although the RNA triphosphatase and RNA guanylyltransferase domains have been localized to a M(r) 59,000 fragment of the capping enzyme large subunit, the location of the methyltransferase domain within the protein and the catalytic role of individual subunits in methyl group transfer remain unclear. In the present work, through the study of methyltransferase activity of truncated forms of capping enzyme translated in vitro in a rabbit reticulocyte lysate, we have localized the methyltransferase domain to a complex consisting of the small subunit and the carboxyl-terminal portion of the large subunit. The M(r) 31,000 subunit translated alone was not sufficient for methyltransferase activity. This requirement for both subunits may explain the tight physical association of the two polypeptides in vivo. We have recreated the association of the large and small enzyme subunits in vitro through the translation of synthetic mRNAs encoding the two polypeptides. Study of the ability of deleted versions of the large subunit to bind the small subunit, as detected by co-immunoprecipitation, defined a 347-amino acid carboxyl-terminal region of the large subunit that was sufficient for heterodimerization. Colocalization within the large subunit of the methyltransferase and subunit association domains suggests that dimerization of the subunits may be required for methyltransferase activity.			CONG, PJ (corresponding author), SLOAN KETTERING MEM CANC CTR, PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA.				NIGMS NIH HHS [GM 42498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		GUO PX, 1990, P NATL ACAD SCI USA, V87, P4023, DOI 10.1073/pnas.87.11.4023; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; LUO Y, 1991, J BIOL CHEM, V266, P13303; MORGAN JR, 1984, J VIROL, V52, P206, DOI 10.1128/JVI.52.1.206-214.1984; MOSS B, 1976, VIROLOGY, V72, P341, DOI 10.1016/0042-6822(76)90163-X; NILES EG, 1989, VIROLOGY, V172, P513, DOI 10.1016/0042-6822(89)90194-3; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROTH MJ, 1984, J BIOL CHEM, V259, P3488; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1990, J BIOL CHEM, V265, P11960; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1990, J BIOL CHEM, V265, P11967; SHUMAN S, 1989, J BIOL CHEM, V264, P9690; TOYAMA R, 1983, EMBO J, V2, P2195, DOI 10.1002/j.1460-2075.1983.tb01723.x; VENKATESAN S, 1980, J BIOL CHEM, V255, P903; VOS JC, 1991, EMBO J, V10, P2553, DOI 10.1002/j.1460-2075.1991.tb07795.x	17	42	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16424	16429						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322901				2022-12-27	WOS:A1992JJ45800069
J	LI, L; LIN, K; CORREIA, JJ; PILKIS, SJ				LI, L; LIN, K; CORREIA, JJ; PILKIS, SJ			LYSINE-356 IS A CRITICAL RESIDUE FOR BINDING THE C-6 PHOSPHO GROUP OF FRUCTOSE 2,6-BISPHOSPHATE TO THE FRUCTOSE-2,6-BISPHOSPHATASE DOMAIN OF RAT-LIVER 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC GLUCONEOGENESIS; ESCHERICHIA-COLI; SUBSTRATE CYCLE; EXPRESSION; 2-KINASE; INTERMEDIATE; GLYCOLYSIS; SEQUENCE; ENZYME; KINASE	Lysine 356 has been implicated by protein modification studies as a fructose-2,6-bisphosphate binding site residue in the 6-phosphofructo-2-kinase domain of rat liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (Kitajima, S., Thomas, H., and Uyeda, K. (1985) J. Biol. Chem. 260, 13995-14002). However, Lys-356 is found in the fructose-2,6-bisphosphatase domain (Bazan, F., Fletterick, R., and Pilkis, S. J. (1989) Proc. Natl. Acad. Sci. U. S. A. 86,9642-9646). In order to ascertain whether Lys-356 is involved in fructose-2,6-bisphosphatase catalysis and/or domain/domain interactions of the bifunctional enzyme, Lys-356 was mutated to Ala, expressed in Escherichia coli, and then purified to homogeneity. Circular dichroism experiments indicated that the secondary structure of the Lys-356-Ala mutant was not significantly different from that of the wild-type enzyme. The K(m) for fructose 2,6-bisphosphate and the K(i) for the noncompetitive inhibitor, fructose 6-phosphate, for the fructose-2,6-bisphosphatase of the Lys-356-Ala mutant were 2700- and 2200-fold higher, respectively, than those of the wild-type enzyme. However, the maximal velocity and the K(i) for the competitive product inhibitor, inorganic phosphate, were unchanged compared to the corresponding values of the wild-type enzyme. Furthermore, in contrast to the wild-type enzyme, which exhibits substrate inhibition, there was no inhibition by substrate of the Lys-356-Ala mutant. In the presence of saturating substrate, inorganic phosphate, which acts by relieving fructose-6-phosphate and substrate inhibition, is an activator of the bisphosphatase. The K(a) for inorganic phosphate of the Lys-356-Ala mutant was 1300-fold higher than that of the wild-type enzyme. The kinetic properties of the 6-phosphofructo-2-kinase of the Lys-356-Ala mutant were essentially identical with that of the wild-type enzyme. The results demonstrate that: 1) Lys-356 is a critical residue in fructose-2,6-bisphosphatase for binding the 6-phospho group of fructose 6-phosphate/fructose 2,6-bisphosphate; 2) the fructose 6-phosphate binding site is responsible for substrate inhibition; 3) Inorganic phosphate activates fructose-2,6-bisphosphatase by competing with fructose 6-phosphate for the same site; and 4) Lys-356 is not involved in 6-phosphofructo-2-kinase substrate/product binding or catalysis.	SUNY STONY BROOK, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA; UNIV MISSISSIPPI, MED CTR, DEPT BIOCHEM, JACKSON, MS 39216 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Mississippi; University of Mississippi Medical Center					NIDDK NIH HHS [DK 38354] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038354, R37DK038354] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; CLAUS TH, 1984, CURR TOP CELL REGUL, V23, P57; COLOSIA AD, 1987, BIOCHEM BIOPH RES CO, V143, P1092, DOI 10.1016/0006-291X(87)90364-0; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; ELMAGHRABI MR, 1982, BIOCHEM BIOPH RES CO, V106, P794, DOI 10.1016/0006-291X(82)91780-6; ELMAGHRABI MR, 1984, J BIOL CHEM, V259, P3096; HERS HG, 1982, BIOCHEM J, V206, P1; KITAJIMA S, 1985, J BIOL CHEM, V260, P3995; KITAJIMA S, 1984, J BIOL CHEM, V259, P6896; LI L, 1992, J BIOL CHEM, V267, P4386; LIN K, 1992, J BIOL CHEM, V267, P6556; Lin K, 1990, Protein Expr Purif, V1, P169, DOI 10.1016/1046-5928(90)90012-N; LIN K, 1992, IN PRESS J BIOL CHEM, V267; LIVELY MO, 1988, J BIOL CHEM, V263, P839; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PILKIS SJ, 1983, J BIOL CHEM, V258, P6135; PILKIS SJ, 1984, J BIOL CHEM, V259, P949; PILKIS SJ, 1982, MOL CELL ENDOCRINOL, V25, P245, DOI 10.1016/0303-7207(82)90082-X; PILKIS SJ, 1991, ANNU REV NUTR, V11, P465, DOI 10.1146/annurev.nu.11.070191.002341; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PILKIS SJ, 1990, DIABETES CARE, V13, P582, DOI 10.2337/diacare.13.6.582; PILKIS SJ, 1987, J BIOL CHEM, V262, P12672; PILKIS SJ, 1990, FRUCTOSE 2 6 BISPHOS; PILKIS SJ, 1981, ENZYMES, V16, P3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEITZ TA, 1982, ANNU REV BIOPHYS BIO, V11, P419, DOI 10.1146/annurev.bb.11.060182.002223; STEWART HB, 1985, J BIOL CHEM, V260, P2935; STEWART HB, 1986, J BIOL CHEM, V261, P8793; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAULER A, 1989, P NATL ACAD SCI USA, V86, P7316, DOI 10.1073/pnas.86.19.7316; TAULER A, 1988, P NATL ACAD SCI USA, V85, P6642, DOI 10.1073/pnas.85.18.6642; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V124, P143; WINN SL, 1983, PHILOS T R SOC LON B, V293, P121	34	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16669	16675						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322913				2022-12-27	WOS:A1992JJ45800103
J	LEEBEEK, FWG; KARIYA, K; SCHWABE, M; FOWLKES, DM				LEEBEEK, FWG; KARIYA, K; SCHWABE, M; FOWLKES, DM			IDENTIFICATION OF A RECEPTOR-BINDING SITE IN THE CARBOXYL TERMINUS OF HUMAN INTERLEUKIN-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GROWTH-FACTOR; MONOCLONAL-ANTIBODY; LYMPHOCYTES-T; AMINO-ACIDS; HUMAN IL-6; PROTEIN; INTERFERON-BETA-2; MUTAGENESIS; EXPRESSION	To identify a receptor binding site of human interleukin-6 (IL-6), we created a library of IL-6 variants with single amino acid substitutions in the last 15 residues (171-185) in the COOH terminus of IL-6. Twenty-seven IL-6 variants were tested for biological activity on a human hepatoma and a mouse hybridoma cell line. Most variants were additionally tested in a receptor binding assay using a human myeloma cell line. Several single amino acid substitutions in the COOH terminus of IL-6 were found to decrease biological activity significantly. This is especially seen in variants with amino acid substitutions that alter the postulated amphipathical alpha-helix structure between residues 178 and 183. The two highly conserved Arg residues at positions 180 and 183 seem to play a very important role in biological activity. The loss of biological activity in all inactive variants is completely paralleled by a decrease of IL-6 receptor binding, as determined by competition binding experiments. One mutant (Leu171) displayed a higher activity on human cells and a higher binding affinity to the receptor and can be considered an IL-6 agonist. It is concluded that the amphipathical alpha-helix structure in the COOH terminus of IL-6 is critical for ligand receptor interaction. Furthermore, the region between residues Ser178 and Arg183 (Ser-Leu-Arg-Ala-X-Arg) is identified as a receptor binding site in the COOH terminus of human IL-6.	UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599; NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21701	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NHLBI NIH HHS [HL31012] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL031012, R01HL031012] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; BATAILLE R, 1991, BLOOD S, V78, pA129; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BRAKENHOFF JPJ, 1989, J IMMUNOL, V143, P1175; CHEN L, 1988, P NATL ACAD SCI USA, V85, P8037, DOI 10.1073/pnas.85.21.8037; COLLINS L, 1988, P NATL ACAD SCI USA, V85, P7709, DOI 10.1073/pnas.85.20.7709; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; DINARELLO CA, 1991, BLOOD, V77, P1627; FALTYNEK CR, 1986, J IMMUNOL, V136, P4134; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; HACK CE, 1989, BLOOD, V74, P1704; HIBI M, 1991, CELL, V63, P1049; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HORII Y, 1989, J IMMUNOL, V143, P3949; HUTCHISON CA, 1986, P NATL ACAD SCI USA, V83, P710, DOI 10.1073/pnas.83.3.710; IDA N, 1989, BIOCHEM BIOPH RES CO, V165, P728, DOI 10.1016/S0006-291X(89)80027-0; IKEBUCHI K, P NATL ACAD SCI USA, V84, P9305; ISHIBASHI T, 1989, P NATL ACAD SCI USA, V86, P5953, DOI 10.1073/pnas.86.15.5953; JAMBOU RC, 1988, P NATL ACAD SCI USA, V139, P4116; JANIN J, 1976, J MOL BIOL, V100, P197, DOI 10.1016/S0022-2836(76)80148-9; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KAUSHANSKY K, 1989, P NATL ACAD SCI USA, V86, P1213, DOI 10.1073/pnas.86.4.1213; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KLEIN B, 1991, BLOOD, V78, P1198; KRUEGER J, 1991, J CELL BIOCHEM, V45, P327, DOI 10.1002/jcb.240450404; KRUTTGEN A, 1990, FEBS LETT, V273, P95, DOI 10.1016/0014-5793(90)81059-W; KUGA T, 1989, BIOCHEM BIOPH RES CO, V159, P103, DOI 10.1016/0006-291X(89)92410-8; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LOKKER NA, 1991, EMBO J, V10, P2125, DOI 10.1002/j.1460-2075.1991.tb07746.x; LOKKER NA, 1991, J BIOL CHEM, V266, P10624; LOTZ M, 1988, J EXP MED, V167, P1253, DOI 10.1084/jem.167.3.1253; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; RENNICK D, 1989, BLOOD, V73, P1828; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SNOUWAERT J, 1987, NUCLEIC ACIDS RES, V15, P8293, DOI 10.1093/nar/15.20.8293; SNOUWAERT JN, 1991, J BIOL CHEM, V266, P23097; SNOUWAERT JN, 1991, J IMMUNOL, V146, P585; VANDAMME J, 1987, J EXP MED, V165, P914, DOI 10.1084/jem.165.3.914; VANSNICK J, 1986, P NATL ACAD SCI USA, V83, P9679; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZHANG XG, 1989, BLOOD, V74, P11; ZURAWSKI SM, 1990, EMBO J, V9, P3899, DOI 10.1002/j.1460-2075.1990.tb07610.x	53	64	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14832	14838						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321818				2022-12-27	WOS:A1992JF08800051
J	PATEL, KD; ZIMMERMAN, GA; PRESCOTT, SM; MCINTYRE, TM				PATEL, KD; ZIMMERMAN, GA; PRESCOTT, SM; MCINTYRE, TM			NOVEL LEUKOCYTE AGONISTS ARE RELEASED BY ENDOTHELIAL-CELLS EXPOSED TO PEROXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; MYOCARDIAL REPERFUSION INJURY; PLASMA-MEMBRANE VESICULATION; FREE-RADICAL GENERATION; INDUCED LUNG INJURY; ISCHEMIA-REPERFUSION; FACTOR ACETYLHYDROLASE; NEUTROPHIL ADHERENCE; INTESTINAL ISCHEMIA; RAT-LIVER	Reactive oxygen species do not activate isolated neutrophils, yet in vivo, such oxidants promote their adhesion to, and subsequent migration through, the vascular wall. We show human endothelial cells exposed to t-butylhydroperoxide shed large, sealed membrane vesicles that contained potent neutrophil agonists. This activity migrated on TLC like platelet-activating factor (PAF). Since neutrophils have a receptor for this phospholipid, which recognizes its unique characteristics including the short sn-2 acetyl residue, we examined the effect of PAF receptor antagonists and PAF acetylhydrolase on this activity. Structurally unrelated PAF receptor antagonists blocked neutrophil stimulation by vesicular phospholipids, and digestion with PAF acetylhydrolase, which is specific for short sn-2 residues, destroyed this activity. However, metabolic labeling, inhibition of synthesis, phospholipase A, digestion, and high performance liquid chromatographic studies demonstrated that the vesicles did not contain PAF. Instead, the bioactivity migrated on high performance liquid chromatography like the phospholipids generated by oxidative fragmentation of synthetic arachidonoyl phosphatidylcholine that we have shown previously (Smiley, P. L., Stremler, K. E., Prescott, S. M., Zimmerman, G. A., and McIntyre, T. M. (1991) J. Biol. Chem. 266, 11104-11110) to stimulate neutrophils through their receptor for PAF. Thus, peroxide treatment of endothelial cells fragments cellular phosphatidylcholines, forming novel PAF-like phospholipids, and induces the shedding of membrane vesicles that contain these bioactive phospholipids.	UNIV UTAH, SCH MED, NORA ECCLES HARRISON CARDIOVASC RES & TRAINING INS, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, SCH MED, DEPT BIOCHEM, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, SCH MED, DEPT MED, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah			Patel, Kamala D/AAX-1245-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044513, R01HL035828, R01HL044525, R37HL044525] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35828, HL44525, HL44513] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER JE, 1988, P NATL ACAD SCI USA, V85, P2786, DOI 10.1073/pnas.85.8.2786; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BERTI F, 1990, J CARDIOVASC PHARM, V16, P727, DOI 10.1097/00005344-199011000-00006; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAQUET P, 1989, TRENDS PHARMACOL SCI, V10, P23, DOI 10.1016/0165-6147(89)90103-X; DELMAESTRO RF, 1982, INT J MICROCIRC, V1, P105; DELMAESTRO RF, 1980, ACTA PHYSIOL SCAND, P43; DREYER WJ, 1989, CIRC RES, V65, P1751, DOI 10.1161/01.RES.65.6.1751; GASIC AC, 1991, CIRCULATION, V84, P2154, DOI 10.1161/01.CIR.84.5.2154; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GO LO, 1988, AM J PHYSIOL, V255, pH1188, DOI 10.1152/ajpheart.1988.255.5.H1188; GOLDMAN G, 1990, ANN SURG, V211, P196, DOI 10.1097/00000658-199002000-00012; GORES GJ, 1989, AM J PHYSIOL, V257, pC347, DOI 10.1152/ajpcell.1989.257.2.C347; GRISHAM MB, 1986, AM J PHYSIOL, V251, pG567, DOI 10.1152/ajpgi.1986.251.4.G567; GROVES RW, 1991, BRIT J DERMATOL, V124, P117, DOI 10.1111/j.1365-2133.1991.tb00419.x; HERNANDEZ LA, 1987, AM J PHYSIOL, V253, pH699, DOI 10.1152/ajpheart.1987.253.3.H699; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; INGRAHAM LM, 1982, BLOOD, V59, P1259; JAESCHKE H, 1990, FASEB J, V4, P3355, DOI 10.1096/fasebj.4.15.2253850; JANOS F, 1989, BIOCHEM BIOPH RES CO, V158, P353; JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412; KLAUSNER JM, 1989, SURGERY, V105, P192; KLAUSNER JM, 1988, ANN SURG, V208, P761, DOI 10.1097/00000658-198812000-00015; KOHLER HR, 1990, ULTRASTRUCT PATHOL, V14, P513; KUBES P, 1990, AM J PHYSIOL, V259, pG300, DOI 10.1152/ajpgi.1990.259.2.G300; LASKY LA, 1991, J CELL BIOCHEM, V45, P139, DOI 10.1002/jcb.240450204; LEMASTERS JJ, 1983, J CELL BIOL, V97, P778, DOI 10.1083/jcb.97.3.778; LEWIS MS, 1988, J CLIN INVEST, V82, P2045, DOI 10.1172/JCI113825; LOPEZFARRE A, 1988, BIOCHEM BIOPH RES CO, V152, P129, DOI 10.1016/S0006-291X(88)80689-2; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; MCEVER RP, 1991, THROMB HAEMOSTASIS, V65, P223; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; MEEUSEN E, 1987, IMMUNOLOGY, V61, P321; MOLDOVAN NI, 1987, EXP CELL RES, V170, P499, DOI 10.1016/0014-4827(87)90324-7; MORGAN BP, 1987, J IMMUNOL, V138, P246; MUELLER HW, 1991, BIOCHEM BIOPH RES CO, V176, P1557, DOI 10.1016/0006-291X(91)90465-J; PATEL KD, 1991, J CELL BIOL, V112, P749, DOI 10.1083/jcb.112.4.749; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; ROMASCHIN AD, 1990, AM J PHYSIOL, V259, pH116, DOI 10.1152/ajpheart.1990.259.1.H116; ROMSON JL, 1983, CIRCULATION, V67, P1016, DOI 10.1161/01.CIR.67.5.1016; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; SATOUCHI K, 1985, BIOCHEM BIOPH RES CO, V128, P1409, DOI 10.1016/0006-291X(85)91097-6; SCHMELING DJ, 1989, SURGERY, V106, P195; SCOTT RE, 1979, J CELL SCI, V35, P229; SCOTT RE, 1979, J CELL SCI, V35, P245; SIMPSON PJ, 1988, J CLIN INVEST, V81, P624, DOI 10.1172/JCI113364; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; SNYDER F, 1985, MED RES REV, V5, P107, DOI 10.1002/med.2610050105; SPRAGG RG, 1991, LUNG SCI F, P2003; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; VEDDER NB, 1990, P NATL ACAD SCI USA, V87, P2643, DOI 10.1073/pnas.87.7.2643; VERCELLOTTI GM, 1988, BLOOD, V71, P1100; WHATLEY RE, 1992, PROSTAGLANDINS, V43, P21, DOI 10.1016/0090-6980(92)90061-W; WRIGHT SD, 1988, J CELL SCI, P99; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529; ZIMMERMAN GA, 1988, J CLIN INVEST, V81, P531, DOI 10.1172/JCI113351; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046	62	114	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15168	15175						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321830				2022-12-27	WOS:A1992JF08800097
J	KONG, SK; CHOCK, PB				KONG, SK; CHOCK, PB			PROTEIN UBIQUITINATION IS REGULATED BY PHOSPHORYLATION - AN INVITRO STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; HISTONES; IDENTIFICATION; DISAPPEARANCE; PURIFICATION; MECHANISM; ISOZYMES; SPLEEN; ENZYME; CELLS	Protein ubiquitination has been implicated in ATP-dependent protein turnover and in a number of biological processes in eukaryotic cells. The ubiquitination activating enzyme, E1, and ubiquitin carrier protein, E2, are two essential enzymes in the protein ubiquitination machinery. Using purified E1 and E2 from rabbit reticulocytes and various protein kinases, which include cAMP-dependent protein kinase, protein kinase C, and protein tyrosine kinase, we demonstrated that E1 is phosphorylated by protein kinase C, with a stoichiometry of 0.65 mol of phosphate/mol of E1, and one of the E2 isoforms, E2(32kDa), is phosphorylated by protein tyrosine kinase to 2 eq of phosphate/mol of protein. Phosphorylation of E1 causes a 2- fold enhancement of its activity as monitored by ubiquitin-dependent ATP half arrow left over half arrow right PP(i) exchange. When 1 eq of phosphate was incorporated into E2(32kDa), a 2.4-fold activation was also observed for its activity to catalyze the ubiquitination of histone H2A. The regulatory significance of this finding is discussed.			KONG, SK (corresponding author), NHLBI,BIOCHEM LAB,BETHESDA,MD 20892, USA.							CARLSON N, 1987, J CELL BIOL, V104, P547, DOI 10.1083/jcb.104.3.547; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; CIECHANOYER A, 1980, J BIOL CHEM, V255, P7525; COOK J, 1988, Biofactors, V1, P133; COOK JC, 1991, P NATL ACAD SCI USA, V88, P11388, DOI 10.1073/pnas.88.24.11388; COOK JC, 1991, BIOCHEM BIOPH RES CO, V174, P564, DOI 10.1016/0006-291X(91)91454-K; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDSTEIN G, 1975, P NATL ACAD SCI USA, V72, P11, DOI 10.1073/pnas.72.1.11; HAAS AL, 1991, J BIOL CHEM, V266, P5104; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HERSHKO A, 1982, ANNU REV BIOCHEM, V51, P335, DOI 10.1146/annurev.bi.51.070182.002003; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; KONG SK, 1988, J BIOL CHEM, V263, P14523; KONG SK, 1987, J BIOL CHEM, V262, P2597; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITWIN CME, 1991, J BIOL CHEM, V266, P2557; MATSUI SI, 1979, P NATL ACAD SCI USA, V76, P6386, DOI 10.1073/pnas.76.12.6386; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MUELLER RD, 1985, J BIOL CHEM, V260, P5147; PICKART CM, 1988, J BIOL CHEM, V263, P15076; SCHAFFNER M, 1990, CELL, V63, P1129; SHACHTER E, 1986, ENZYMES A, V17, P21; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; TOKUDA M, 1987, BIOCHEMISTRY-US, V26, P5226, DOI 10.1021/bi00391a002; WANG CY, 1988, BIOCHEMISTRY-US, V27, P1254, DOI 10.1021/bi00404a027; WU RS, 1981, J BIOL CHEM, V256, P5916	31	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14189	14192						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321138				2022-12-27	WOS:A1992JD32500063
J	MOONEY, RA; BORDWELL, KL				MOONEY, RA; BORDWELL, KL			DIFFERENTIAL DEPHOSPHORYLATION OF THE INSULIN-RECEPTOR AND ITS 160-KDA SUBSTRATE (PP160) IN RAT ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; FACTOR-I STIMULATE; HUMAN-PLACENTA; 3T3-L1 ADIPOCYTES; KINASE-ACTIVITY; PERMEABILIZED ADIPOCYTES; ENDOGENOUS SUBSTRATE; DIABETIC RATS; INTACT-CELLS; PHOSPHORYLATION	A permeabilized rat adipocyte model was developed which permitted an examination of: 1) insulin receptor autophosphorylation, 2) phosphorylation of a putative insulin receptor substrate of 160 kDa, pp160, and 3) the dephosphorylation reactions associated with each of these phosphoproteins. Rat adipocytes, preincubated with [P-32]orthophosphate for 2 h, were exposed to insulin (10(-7) M) at the time of digitonin permeabilization. Phosphorylation of pp160 and autophosphorylation of the insulin receptor increased as a function of Mn2+ concentration in the media with near maximum responses at 10 mM. Maximum response was at least as large as the intact cell response to 10(-7) M insulin. In contrast, magnesium did not increase phosphorylation of pp160 although an increase in receptor autophosphorylation was observed. Autophosphorylation was preserved at digitonin concentrations of 20-100-mu-g/ml, but pp160 phosphorylation was negligible beyond 40-mu-g/ml. Our previous work demonstrated that the insulin receptor was associated with a phosphotyrosine phosphatase activity in permeabilized adipocytes (Mooney, R., and Anderson, D. (1989) J. Biol. Chem. 264,6850-6857). The current permeabilized adipocyte model made possible an examination of the effects of phosphotyrosine phosphatase inhibitors, including several divalent metal cations (Zn2+, Co2+, and Ni2+), vanadate, and molybdate on both net phosphorylation of pp160 and autophosphorylation of the insulin receptor. Zn2+ at 100-mu-M, Ni2+ at 1 mM and Co2+ at 1 or 5 mM increased insulin-dependent phosphorylation of pp160 at least 5-fold and autophosphorylation 2-fold. At higher concentrations of Zn2+ (1 mM) and Ni2+ (5 mM), however, no increase in phosphorylation of pp160 was observed and autophosphorylation was inhibited. Vanadate (I mM) and molybdate (100-mu-M) increased insulin-dependent phosphorylation of pp160 by 3-fold when tested separately and 7-fold in combination. Insulin receptor autophosphorylation was increased 50% by each and 3-fold when the agents were combined. Dephosphorylation of pp 1 60 and the insulin receptor was analyzed directly by permeabilizing prelabeled insulin-treated adipocytes in the presence of EDTA (10 mM). Dephosphorylation of pp 1 60 was especially rapid with a t1/2 of approximately 10 s. The t1/2 for the insulin receptor was 37 s. Zn2+ at 1 mM (a concentration that inhibited the insulin receptor kinase) was a strong inhibitor of dephosphorylation, prolonging the rate of PP160 dephosphorylation more than 12-fold and insulin receptor dephosphorylation 3-fold. Inhibition by Zn2+ was reversible with EDTA. These results demonstrate that phosphorylation by the insulin receptor tyrosine kinase of its substrate, pp160, is acutely sensitive to modulation by phosphotyrosine phosphatase activity. The observation that pp160 is more rapidly dephosphorylated and more sensitive to phosphatase inhibitors than the insulin receptor may suggest a phosphatase-dependent mechanism for rapid reversal of insulin signal propagation and is consistent with a role for pp160 in insulin signal transduction.			MOONEY, RA (corresponding author), UNIV ROCHESTER, SCH MED & DENT, DEPT PATHOL & LAB MED, ROCHESTER, NY 14642 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038138] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38138] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRICHARD SM, 1988, ENDOCRINOLOGY, V123, P2048, DOI 10.1210/endo-123-4-2048; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; DEGANI H, 1981, BIOCHEMISTRY-US, V20, P5795, DOI 10.1021/bi00523a023; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; EZAKI O, 1989, J BIOL CHEM, V264, P16118; GIBBS EM, 1986, J BIOL CHEM, V261, P6597; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KING MJ, 1988, BIOCHEM J, V256, P893, DOI 10.1042/bj2560893; KOWALSKI A, 1983, BIOCHEM BIOPH RES CO, V117, P885, DOI 10.1016/0006-291X(83)91679-0; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUSTIN K, 1982, COMMENTS INORG CHEM, V2, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1977, FEBS LETT, V82, P314, DOI 10.1016/0014-5793(77)80609-1; MACHICAO F, 1987, BIOCHEM J, V243, P797, DOI 10.1042/bj2430797; MADOFF DH, 1988, BIOCHEM J, V252, P7, DOI 10.1042/bj2520007; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEYEROVITCH J, 1989, J CLIN INVEST, V84, P976, DOI 10.1172/JCI114261; MEYEROVITCH J, 1987, J BIOL CHEM, V262, P6658; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MOONEY RA, 1989, ENDOCRINOLOGY, V124, P422, DOI 10.1210/endo-124-1-422; MOONEY RA, 1983, EUR J BIOCHEM, V136, P603, DOI 10.1111/j.1432-1033.1983.tb07783.x; MOONEY RA, 1989, J BIOL CHEM, V264, P6850; MOONEY RA, 1989, BIOCHEM BIOPH RES CO, V162, P1200, DOI 10.1016/0006-291X(89)90801-2; MOONEY RA, 1992, ENDOCRINOLOGY, V130, P1533, DOI 10.1210/en.130.3.1533; PANG DT, 1985, J BIOL CHEM, V260, P7131; PANG DT, 1985, J BIOL CHEM, V260, P5126; PETRUZZELLI LM, 1982, P NATL ACAD SCI-BIOL, V79, P6792, DOI 10.1073/pnas.79.22.6792; ROOME J, 1988, BIOCHEM J, V256, P493, DOI 10.1042/bj2560493; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SMITH JB, 1983, P NATL ACAD SCI-BIOL, V80, P6162, DOI 10.1073/pnas.80.20.6162; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TAMURA S, 1983, BIOCHEM BIOPH RES CO, V113, P80, DOI 10.1016/0006-291X(83)90434-5; THIES RS, 1990, DIABETES, V39, P250, DOI 10.2337/diabetes.39.2.250; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0	43	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14054	14060						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321133				2022-12-27	WOS:A1992JD32500044
J	CASCIOLAROSEN, LA; RENFREW, CA; HUBBARD, AL				CASCIOLAROSEN, LA; RENFREW, CA; HUBBARD, AL			LUMENAL LABELING OF RAT HEPATOCYTE ENDOCYTIC COMPARTMENTS - DISTRIBUTION OF SEVERAL ACID-HYDROLASES AND MEMBRANE-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MEDIATED ENDOCYTOSIS; MORPHOLOGICAL CHARACTERIZATION; MACROPHAGE ENDOSOMES; LYSOSOMAL-ENZYMES; HUMAN-FIBROBLASTS; PLASMA-MEMBRANE; LIVER ENDOSOMES; CATHEPSIN-D; TRANSPORT	We used a combination of subcellular fractionation and lactoperoxidase-mediated iodination to examine the polypeptide compositions of three hepatocyte endocytic compartments: early endosomes, late endosomes, and lysosomes. A chemical conjugate of asialoorosomucoid and lactoperoxidase which binds specifically to asialoglycoprotein receptors was perfused through isolated rat livers at 37-degrees-C. Subcellular fractions enriched in various endocytic compartments were then isolated by differential and isopycnic centrifugation, and the lactoperoxidase moiety of the internalized conjugate was used to catalyze the iodination of lumenal-facing proteins. The I-125 profiles of early and late endosomes were strikingly similar after gel electrophoresis. Using immunoprecipitation, we directly identified and compared the relative amounts of the Na+,K+-ATPase and several different acid hydrolases and membrane receptors in all three fractions. The asialoglycoprotein receptor and the low density lipoprotein related protein were approximately nine times more abundant in early endosomes than late endosomes, suggesting that they recycle from early endosomes. In addition, cathepsin D, but not cathepsin L, beta-glucuronidase, and lgp120, was detected in early endosomes; however, all of these molecules were detected in lysosomes. Our findings provide strong evidence that early endosomes mature into late endosomes and that there is either selective delivery or selective retention of hydrolases at discrete points in the endocytic pathway.	JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,725 N WOLFE ST,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM129133, R01GM029133] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29133] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BAENZIGER JU, 1986, J BIOL CHEM, V261, P7445; BARRETT AJ, 1979, PROTEINASES MAMMALIA, P181; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BEAUMELLE BD, 1990, J CELL BIOL, V111, P1811, DOI 10.1083/jcb.111.5.1811; BOWSER R, 1990, J CELL PHYSIOL, V143, P110, DOI 10.1002/jcp.1041430115; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; CASCIOLAROSEN LA, 1992, J BIOL CHEM, V267, P8213; CASCIOLAROSEN LAF, 1991, J BIOL CHEM, V266, P4341; CHANDLER LP, 1985, J BIOL CHEM, V260, P3360; CHIACCHIA KB, 1984, J BIOL CHEM, V259, P5440; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DIMENT S, 1985, J BIOL CHEM, V260, P5311; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; DUNN WA, 1983, METHOD ENZYMOL, V98, P225; DUNN WA, 1984, J CELL BIOL, V98, P2148, DOI 10.1083/jcb.98.6.2148; DUNN WA, 1980, J BIOL CHEM, V255, P5971; EHRENREICH JH, 1973, J CELL BIOL, V59, P45, DOI 10.1083/jcb.59.1.45; EHRENREICH JH, 1973, J CELL BIOL, V59, P73; FUCHS R, 1989, J BIOL CHEM, V264, P2212; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; Griffiths G, 1991, Trends Cell Biol, V1, P5, DOI 10.1016/0962-8924(91)90047-D; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HERTZ J, 1990, J BIOL CHEM, V265, P21355; HERTZ J, 1988, EMBO J, V7, P4119; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOPPE CA, 1985, J CELL BIOL, V101, P2113, DOI 10.1083/jcb.101.6.2113; Hubbard AL, 1989, CURR OPIN CELL BIOL, V1, P675, DOI 10.1016/0955-0674(89)90033-1; HUBBARD AL, 1979, J CELL BIOL, V83, P47, DOI 10.1083/jcb.83.1.47; HUBBARD AL, 1983, J CELL BIOL, V96, P230, DOI 10.1083/jcb.96.1.230; HUBBARD AL, 1976, BIOCH ANAL MEMBRANES, P427; HUBBARD AL, 1983, J CELL BIOL, V61, P188; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; KHAN MN, 1986, J BIOL CHEM, V261, P8462; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MERION M, 1983, J CELL BIOL, V96, P644, DOI 10.1083/jcb.96.3.644; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MUELLER SC, 1986, J CELL BIOL, V102, P932, DOI 10.1083/jcb.102.3.932; MULLOCK BM, 1989, J CELL BIOL, V108, P2093, DOI 10.1083/jcb.108.6.2093; Murphy R F, 1991, Trends Cell Biol, V1, P77, DOI 10.1016/0962-8924(91)90022-2; NEWSHOLME EA, 1961, BIOCHEM J, V80, P649; RENFREW CA, 1991, J BIOL CHEM, V266, P21265; RENFREW CA, 1991, J BIOL CHEM, V266, P4348; RENFREW CA, 1992, IN PRESS METHODS MOL; RUNQUIST EA, 1991, J BIOL CHEM, V266, P22557; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; WALL DA, 1985, J CELL BIOL, V101, P2104, DOI 10.1083/jcb.101.6.2104; WATTS C, 1984, EMBO J, V3, P1965, DOI 10.1002/j.1460-2075.1984.tb02077.x	65	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11856	11864						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1318303				2022-12-27	WOS:A1992HY94700035
J	SOMA, MR; MIMS, MP; CHARI, MV; REES, D; MORRISETT, JD				SOMA, MR; MIMS, MP; CHARI, MV; REES, D; MORRISETT, JD			TRIGLYCERIDE-METABOLISM IN 3T3-L1 CELLS - AN INVIVO C-13 NMR-STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; NUCLEAR MAGNETIC-RESONANCE; RAT ADIPOSE-TISSUE; LIPOPROTEIN-LIPASE; ADIPOCYTES; INSULIN; TRIACYLGLYCEROLS; ACTIVATION; PROTEIN	C-13 nuclear magnetic resonance spectroscopy has been used to study triglyceride metabolism in 3T3-L1 cells incubated with [1-C-13/14] acetate, myristate, palmitate, stearate, or oleate. Labeled cells embedded in agarose filaments were perfused in a specially fitted NMR tube within the spectrometer magnet. Incubation of 3T3-L1 cells with a specific fatty acid enriched the cellular triglycerides with that fatty acid; the NMR signal observed in the carbonyl region of the cell spectrum was due in large part to that fatty acid. NMR data demonstrated that cellular enzymes preferentially esterified saturated fatty acids at the glyceride sn-1,3 position and unsaturated fatty acids at the sn-2 position. Cellular triglyceride hydrolysis by hormone-sensitive lipase was monitored by measuring the decrease in the integrated intensities of resonances arising from fatty acyl carbonyls esterified at glycerol carbons sn-1,3 and sn-2. Under basal conditions, the time courses were first-order, and the average rates were 0.14% of signal/min at both carbonyl positions. Under isoproterenol stimulated conditions, these rates were still first-order and increased 6.4-fold at the sn-1,3 position and 2.4-fold at the sn-2 position. The observation that the hydrolysis time courses were first-order suggested that only a small amount of cellular triglyceride was available to hormone-sensitive lipase, supporting the view that lipolytic enzymes operate at lipid surfaces where only small amounts of neutral lipid may be soluble. Attempts to correlate the measured rates with the rates of hydrolysis at the sn-1,3 and sn-2 positions were hindered by the fact that the chemical shifts of the carbonyl carbons of the diglyceride hydrolysis product did not overlie those of the triglyceride. Analysis of hydrolysis kinetics revealed that hormone-sensitive lipase exhibited little preference for a particular esterified fatty acid under basal conditions; however, under stimulated conditions, the enzyme exhibited a preference for certain triglyceride species.	BAYLOR COLL MED,CTR MAGNET RESONANCE,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT RADIOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL027341, P50HL027341] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL27341] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belfrage P., 1984, P365; BELFRAGE P, 1983, ADIPOCYTE OBESITY CE, P217; BERGLUND L, 1980, J BIOL CHEM, V255, P5420; BRAINARD JR, 1980, BIOCHEMISTRY-US, V19, P4266, DOI 10.1021/bi00559a019; CHERNICK SS, 1986, J LIPID RES, V27, P286; DIMAND RJ, 1989, MAGN RESON MED, V9, P273, DOI 10.1002/mrm.1910090212; EISEN EJ, 1982, LIPIDS, V17, P136, DOI 10.1007/BF02535093; FOXALL DL, 1983, J MAGN RESON, V52, P346, DOI 10.1016/0022-2364(83)90210-X; FREDRIKSON G, 1983, J BIOL CHEM, V258, P4253; HAMILTON JA, 1984, P NATL ACAD SCI-BIOL, V81, P3718, DOI 10.1073/pnas.81.12.3718; HARCUCHKURI W, 1978, CELL, V14, P53; HOMAN R, 1989, ANAL BIOCHEM, V178, P166, DOI 10.1016/0003-2697(89)90374-6; HUTTUNEN JK, 1971, BIOCHIM BIOPHYS ACTA, V239, P411, DOI 10.1016/0005-2760(71)90034-8; KAWAMURA M, 1981, P NATL ACAD SCI-BIOL, V78, P732, DOI 10.1073/pnas.78.2.732; Khoo J.C., 1983, ENZYMES, V16, P183; KHOO JC, 1974, J CLIN INVEST, V53, P1124, DOI 10.1172/JCI107650; KHOO JC, 1983, ADIPOCYTE OBESITY CE, P225; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Rodbell M., 1965, HANDB PHYSIOL, P471; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SILLERUD LO, 1986, J BIOL CHEM, V261, P4380; SOMA MR, 1989, BIOCHIM BIOPHYS ACTA, V1003, P307, DOI 10.1016/0005-2760(89)90237-3; SPOONER PM, 1979, J BIOL CHEM, V254, P21; SPOONER PM, 1978, J BIOL CHEM, V254, P1305; Steinberg D, 1976, Adv Cyclic Nucleotide Res, V7, P157; STRALFORS P, 1984, P NATL ACAD SCI-BIOL, V81, P3317, DOI 10.1073/pnas.81.11.3317; TORNQVIST H, 1976, J BIOL CHEM, V251, P813; VANNIER C, 1986, BIOCHIM BIOPHYS ACTA, V875, P344, DOI 10.1016/0005-2760(86)90185-2; VAUGHAN M, 1965, HANDB PHYSIOL, P239; VOLD RL, 1968, J CHEM PHYS, V48, P3831, DOI 10.1063/1.1669699; WILLIAMS E, 1973, SCIENCE, V181, P869, DOI 10.1126/science.181.4102.869; ZASS M, 1977, J MAGN RESON, V25, P263	32	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11168	11175						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317859				2022-12-27	WOS:A1992HX16900039
J	MIZUNO, T; KAIBUCHI, K; ANDO, S; MUSHA, T; HIRAOKA, K; TAKAISHI, K; ASADA, M; NUNOI, H; MATSUDA, I; TAKAI, Y				MIZUNO, T; KAIBUCHI, K; ANDO, S; MUSHA, T; HIRAOKA, K; TAKAISHI, K; ASADA, M; NUNOI, H; MATSUDA, I; TAKAI, Y			REGULATION OF THE SUPEROXIDE-GENERATING NADPH OXIDASE BY A SMALL GTP-BINDING PROTEIN AND ITS STIMULATORY AND INHIBITORY GDP/GTP EXCHANGE PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL-FREE SYSTEM; CHRONIC GRANULOMATOUS-DISEASE; BOVINE BRAIN CYTOSOL; RESPIRATORY BURST OXIDASE; SODIUM DODECYL-SULFATE; HUMAN-NEUTROPHILS; SUBSEQUENT BINDING; MOLECULAR-CLONING; ACTIVATION; PURIFICATION	The superoxide-generating NADPH oxidase system in phagocytes consists of at least membrane-associated cytochrome b558 and three cytosolic components named SOCI/NCF-3/sigma-1/C1, SOCII/NCF-1/p47-phox, and SOCIII/NCF-2/p67-phox. p47-phox and p67-phox were isolated, and their primary structures were determined, but SOCI has not been well characterized. In the present study, we first purified SOCI to homogeneity from the cytosol fraction of the differentiated HL-60 cells. The purified SOCI was a small GTP-binding protein (G protein) with a M(r) of about 22,000. The guanosine 5'-(3-O-thio)triphosphate-bound form, but not the GDP-bound form, of this small G protein showed the SOCI activity. The partial amino acid sequence of SOCI thus far determined was identical to the amino acid sequence deduced from the cDNA encoding rac2 p21. None of the purified small G proteins, including Ki-ras p21, smg p21B/rap1B p21, rhoA p21, and rac1 p21, showed the SOCI activity. These results indicate that SOCI is a small G protein very similar, if not identical, to rac2 p21. The GDP/GTP exchange reaction of SOCI was stimulated and inhibited by stimulatory and inhibitory GDP/GTP exchange proteins for small G proteins, named smg GDS and rho GDI, respectively. The NADPH oxidase activity was also stimulated and inhibited by smg GDS and rho GDI, respectively. These results indicate that the superoxide-generating NADPH oxidase system is regulated by both smg GDS and rho GDI through rac2 p21 or the rac2-related small G protein in phagocytes.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; EISAI & CO LTD,TSUKUBA RES LAB,TSUKUBA 30026,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT PEDIAT,KUMAMOTO 860,JAPAN	Kobe University; Eisai Co Ltd; Kumamoto University								ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AMBRUSO DR, 1990, J BIOL CHEM, V265, P924; BOLSCHER BGJM, 1990, J BIOL CHEM, V265, P15782; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CURNUTTE JT, 1987, J BIOL CHEM, V262, P6450; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; FUJITA I, 1987, BIOCHIM BIOPHYS ACTA, V931, P41, DOI 10.1016/0167-4889(87)90048-6; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GABIG TG, 1987, J BIOL CHEM, V262, P1685; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; ISHIDA K, 1989, FEBS LETT, V243, P169, DOI 10.1016/0014-5793(89)80123-1; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1991, J BIOL CHEM, V266, P19812; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; PICK E, 1989, J IMMUNOL, V143, P4180; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; UEDA T, 1990, J BIOL CHEM, V265, P9373; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	29	151	153	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10215	10218						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1316893				2022-12-27	WOS:A1992HV09000005
J	KLEYMAN, TR; COUPAYEGERARD, B; ERNST, SA				KLEYMAN, TR; COUPAYEGERARD, B; ERNST, SA			ALDOSTERONE DOES NOT ALTER APICAL CELL-SURFACE EXPRESSION OF EPITHELIAL NA+ CHANNELS IN THE AMPHIBIAN CELL LINE-A6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED KIDNEY-CELLS; PROTEIN KINASE-C; TOAD BLADDER; SODIUM-TRANSPORT; HORMONAL-REGULATION; TIGHT EPITHELIA; AMILORIDE; SUBUNIT; MECHANISMS; A6	The steroid hormone aldosterone regulates reabsorptive Na+ transport across specific high resistance epithelia. The increase in Na+ transport induced by aldosterone is dependent on protein synthesis and is due, in part, to an increase in Na+ conductance of the apical membrane mediated by amiloride-sensitive Na+ channels. To examine whether an increment in the biochemical pool of Na+ channels expressed at the apical cell surface is a mechanism by which aldosterone increases apical membrane Na+ conductance, apical cell-surface proteins from the epithelial cell line A6 were specifically labeled by an enzyme-catalyzed radioiodination procedure following exposure of cells to aldosterone. Labeled Na+ channels were immunoprecipitated to quantify the biochemical pool of Na+ channels at the apical cell surface. The activation of Na+ transport across A6 cells by aldosterone was not accompanied by alterations in the biochemical pool of Na+ channels at the apical plasma membrane, despite a 3.7-4.2-fold increase in transepithelial Na+ transport. Similarly, no change in the distribution of immunoreactive protein was resolved by immunofluorescence microscopy. The oligomeric subunit composition of the channel remained unaltered, with one exception. A 75,000-Da polypeptide and a broad 70,000-Da polypeptide were observed in controls. Following addition of aldosterone, the 75,000-Da polypeptide was not resolved, and the 70,000-Da polypeptide was the major polypeptide found in this molecular mass region. Aldosterone did not alter rates of Na+ channel biosynthesis. These data suggest that neither changes in rates of Na+ channel biosynthesis nor changes in its apical cell-surface expression are required for activation of transepithelial Na+ transport by aldosterone. Post-translational modification of the Na+ channel, possibly the 75,000 or 70,000-Da polypeptide, may be one of the cellular events required for Na+ channel activation by aldosterone.	VET AFFAIRS MED CTR,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PHYSIOL,PHILADELPHIA,PA 19104; UNIV MICHIGAN,DEPT ANAT & CELL BIOL,ANN ARBOR,MI 48109	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; University of Michigan System; University of Michigan	KLEYMAN, TR (corresponding author), UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104, USA.				NIDDK NIH HHS [DK 34933] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHER C, 1988, P NATL ACAD SCI USA, V85, P7413, DOI 10.1073/pnas.85.19.7413; BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738; BENOS DJ, 1983, BIOCHIM BIOPHYS ACTA, V734, P99, DOI 10.1016/0005-2736(83)90080-9; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; CRABBE J, 1964, NATURE, V202, P298, DOI 10.1038/202298a0; CUTHBERT AW, 1975, PROC R SOC SER B-BIO, V189, P543, DOI 10.1098/rspb.1975.0072; DAVIS RJ, 1985, J BIOL CHEM, V260, P2543; EDELMAN IS, 1963, P NATL ACAD SCI USA, V50, P1169, DOI 10.1073/pnas.50.6.1169; GARTY H, 1983, J GEN PHYSIOL, V81, P785, DOI 10.1085/jgp.81.6.785; GARTY H, 1989, AM J PHYSIOL, V256, pF965, DOI 10.1152/ajprenal.1989.256.5.F965; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; GARTY H, 1986, J MEMBRANE BIOL, V90, P193, DOI 10.1007/BF01870126; GEERING K, 1982, J BIOL CHEM, V257, P338; GEHEB M, 1981, J BIOL CHEM, V256, P1716; KEMENDY A E, 1989, FASEB Journal, V3, pA861; KIPNOWSKI J, 1983, AM J PHYSIOL, V245, pF726, DOI 10.1152/ajprenal.1983.245.6.F726; KIRSTEN E, 1968, PFLUEGERS ARCH, V316, P26; KLEYMAN TR, 1989, AM J PHYSIOL, V257, pC1135, DOI 10.1152/ajpcell.1989.257.6.C1135; KLEYMAN TR, 1991, J BIOL CHEM, V266, P3907; KLEYMAN TR, 1989, J BIOL CHEM, V264, P11995; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; LIGHT DB, 1989, SCIENCE, V243, P383, DOI 10.1126/science.2463673; LING BN, 1989, AM J PHYSIOL, V256, pF1094, DOI 10.1152/ajprenal.1989.256.6.F1094; LIU AYC, 1974, P NATL ACAD SCI USA, V71, P3869, DOI 10.1073/pnas.71.10.3869; Maizel JV, 1971, METHOD VIROL, V5, P179; MARUNAKA Y, 1991, AM J PHYSIOL, V260, pC1071, DOI 10.1152/ajpcell.1991.260.5.C1071; MOREL F, 1986, PHYSIOL REV, V66, P377, DOI 10.1152/physrev.1986.66.2.377; PALEVSKY P, 1990, KIDNEY INT, V37, P233; PALMER LG, 1990, J GEN PHYSIOL, V96, P23, DOI 10.1085/jgp.96.1.23; SARIBANSOHRABY S, 1984, SCIENCE, V225, P745, DOI 10.1126/science.6463652; SARIBANSOHRABY S, 1988, J BIOL CHEM, V263, P13875; SARIBANSOHRABY S, 1986, AM J PHYSIOL, V250, pC175, DOI 10.1152/ajpcell.1986.250.2.C175; SHARP GWG, 1964, P NATL ACAD SCI USA, V52, P1114, DOI 10.1073/pnas.52.4.1114; SIMCHOWITZ L, 1987, J BIOL CHEM, V262, P15875; SPOONER PM, 1975, BIOCHIM BIOPHYS ACTA, V406, P304, DOI 10.1016/0005-2736(75)90012-7; TOUSSON A, 1989, J CELL SCI, V93, P349; VERREY F, 1987, J CELL BIOL, V104, P1231, DOI 10.1083/jcb.104.5.1231; VERREY F, 1990, SEMIN NEPHROL, V10, P410; WATLINGTON CO, 1982, AM J PHYSIOL, V242, pF610, DOI 10.1152/ajprenal.1982.242.6.F610; YANASE M, 1986, AM J PHYSIOL, V250, pC517, DOI 10.1152/ajpcell.1986.250.3.C517	41	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9622	9628						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315763				2022-12-27	WOS:A1992HT96500029
J	MURPHY, G; ALLAN, JA; WILLENBROCK, F; COCKETT, MI; OCONNELL, JP; DOCHERTY, AJP				MURPHY, G; ALLAN, JA; WILLENBROCK, F; COCKETT, MI; OCONNELL, JP; DOCHERTY, AJP			THE ROLE OF THE C-TERMINAL DOMAIN IN COLLAGENASE AND STROMELYSIN SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; POLYACRYLAMIDE GELS; PURIFICATION; PROCOLLAGENASE; ACTIVATION; ENZYME; METALLOPROTEINASES; COMPONENTS; INHIBITORS; EFFICIENT	Recombinant human interstitial collagenase, an N-terminal truncated form, DELTA-243-450 collagenase, recombinant human stromelysin-1, and an N-terminal truncated form, DELTA-248-460 stromelysin, have been stably expressed in myeloma cells and purified. The truncated enzymes were similar in properties to their wild-type counterparts with respect to activation requirements and the ability to degrade casein, gelatin, and a peptide substrate, but truncated collagenase failed to cleave native collagen. Removal of the C-terminal domain from collagenase also modified its interaction with tissue inhibitor of metalloproteinases-1. Hybrid enzymes consisting of N-terminal (1-242) collagenase.C-terminal (248-460) stromelysin and N-terminal (1-238) stromelysin.C-terminal (229-450) collagenase, representing an exchange of the complete catalytic and C-terminal domains of the two enzymes, were expressed in a transient system using Chinese hamster ovary cells and purified. Both proteins showed similar activity to their N-terminal parent and neither was able to degrade collagen. Analysis of the ability of the different forms of recombinant enzyme to bind to collagen by ELISA showed that both pro and active stromelysin and N-terminal collagenase.C-terminal stromelysin bound to collagen equally well. In contrast, only the active forms of collagenase and N-terminal stromelysin.C-terminal collagenase bound well to collagen, as compared with their pro forms.	CELLTECH LTD, SLOUGH SL1 4EN, ENGLAND	Celltech Group Ltd	MURPHY, G (corresponding author), STRANGEWAYS RES LAB, WORTS CAUSEWAY, CAMBRIDGE CB1 4RN, ENGLAND.							ALLAN JA, 1991, J CELL SCI, V99, P789; Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; BIRKEDALHANSEN B, 1988, BIOCHEMISTRY-US, V27, P6751, DOI 10.1021/bi00418a016; Bos E S, 1981, J Immunoassay, V2, P187, DOI 10.1080/15321818108056977; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; COCKETT MI, 1991, NUCLEIC ACIDS RES, V19, P319, DOI 10.1093/nar/19.2.319; COOKSLEY S, 1990, MATRIX, V10, P285, DOI 10.1016/S0934-8832(11)80183-6; DOCHERTY AJP, 1990, ANN RHEUM DIS, P469; GALLOWAY WA, 1983, BIOCHEM J, V209, P741, DOI 10.1042/bj2090741; GRANT GA, 1987, J BIOL CHEM, V262, P5886; HEMBRY RM, 1986, J CELL SCI, V81, P105; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEATHERBARROW RJ, 1987, ENZFITTER SOFTWARE; MARCY AI, 1991, BIOCHEMISTRY-US, V30, P6476, DOI 10.1021/bi00240a018; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; MURPHY G, 1981, BIOCHEM J, V199, P807, DOI 10.1042/bj1990807; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; OKADA Y, 1986, J BIOL CHEM, V261, P14245; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STACK MS, 1989, J BIOL CHEM, V264, P4277; STEPHENS PE, 1989, NUCLEIC ACIDS RES, V17, P7110, DOI 10.1093/nar/17.17.7110; TEAHAN JA, 1990, FASEB J, V4, pA1977; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VATER CA, 1978, BIOCHIM BIOPHYS ACTA, V539, P238, DOI 10.1016/0304-4165(78)90010-7; WELGUS HG, 1985, COLLAGEN REL RES, V5, P167; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008	36	288	292	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9612	9618						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315762				2022-12-27	WOS:A1992HT96500027
J	CIOE, L; MUKHOPADHYAY, S; ROVERA, G				CIOE, L; MUKHOPADHYAY, S; ROVERA, G			SELECTIVE-INHIBITION OF PROLIFERATION IN V-ABL-TRANSFORMED AND BCR-ABL-TRANSFORMED CELLS BY A NUCLEOSIDE ANALOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; PHILADELPHIA-CHROMOSOME; GENE-PRODUCT; GRANULOCYTIC DIFFERENTIATION; KINASE-ACTIVITY; LINE; EXPRESSION; 9-(2-HYDROXYETHOXYMETHYL)GUANINE; INTERLEUKIN-3; SEQUENCE	The nucleoside analog acyclovir (9-[2-hydroxyethoxy)methyl]guanine or acycloguanosine; ACV) inhibited the in vitro transformation of NIH 3T3 cells by Abelson murine leukemia virus and the proliferation of abl- and bcr-abl-transformed hemopoietic murine cell lines. This effect is selective since ACV at the same concentration had no effect on the src and Ha-ras transformation of NIH 3T3 cells or on the proliferation of hemopoietic cells transformed by those oncogenes. The inhibitory effect on proliferation of abl-transformed cells correlated with the extent of ACV triphosphate formation and incorporation into cellular DNA that was greater than that in normal or other oncogene-transformed cells. The increased ACV triphosphate formation might be due to a higher level of 5'-nucleotidase, the enzyme responsible for trace levels of ACV phosphorylation in uninfected cells.	WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute					NATIONAL CANCER INSTITUTE [P30CA010815, P01CA052009] Funding Source: NIH RePORTER; NCI NIH HHS [CA 52009, CA 10815] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORELLI E, 1988, P NATL ACAD SCI USA, V85, P7572; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1585, DOI 10.1073/pnas.88.4.1585; ELION GB, 1977, P NATL ACAD SCI USA, V74, P5716, DOI 10.1073/pnas.74.12.5716; FYFE JA, 1978, J BIOL CHEM, V253, P8721; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; ISCOVE NN, 1971, BLOOD-J HEMATOL, V37, P1; JACKSON P, 1989, EMBO J, V8, P49; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KELLER PM, 1985, J BIOL CHEM, V260, P8664; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KRUGER A, 1991, ONCOGENE, V6, P245; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LARSSON A, 1981, ANTIVIR RES, V1, P55, DOI 10.1016/0166-3542(81)90032-2; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MAVILIO F, 1989, ONCOGENE, V4, P301; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; REDDY EP, 1988, ONCOGENE HDB, P3; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; ROVERA G, 1987, ONCOGENE, V1, P29; SANDBERG AA, 1986, CANCER GENET CYTOGEN, V21, P129, DOI 10.1016/0165-4608(86)90039-7; SCHER CD, 1975, P NATL ACAD SCI USA, V72, P1932; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SEGEL IH, 1975, BEHAVIOR ANAL RAPID, P810; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; STEMBERG K, 1986, J BIOL CHEM, V261, P2134; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WITTE ON, 1980, NATURE, V332, P2269; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	38	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22178	22182						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331046				2022-12-27	WOS:A1992JW71900031
J	TAANMAN, JW; CAPALDI, RA				TAANMAN, JW; CAPALDI, RA			PURIFICATION OF YEAST CYTOCHROME-C-OXIDASE WITH A SUBUNIT COMPOSITION RESEMBLING THE MAMMALIAN ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-CODED SUBUNITS; AMINO-ACID-SEQUENCE; MITOCHONDRIAL-MEMBRANE SYSTEM; GEL-ELECTROPHORESIS; SKELETAL-MUSCLE; DNA-SEQUENCE; BOVINE HEART; PROTEINS; COMPLEX; NITROCELLULOSE	Yeast cytochrome c oxidase has been isolated by ion exchange chromatography using lauryl maltoside (n-dodecyl beta-D-maltoside) as the solubilizing detergent. The enzyme prepared in this way has a heme aa3 concentration of 8-9 nmol/mg of protein and a turnover number in the range of 180-210 s-1 at pH 6.2 in 0.01% lauryl maltoside at 20-degrees-C. Yeast cytochrome c oxidase prepared by any of several previously published methods which use Triton X-100 contains nine subunits. The enzyme isolated in lauryl maltoside contains these same nine different polypeptides and three others, including homologues of subunits VIa and VIb of the mammalian enzyme.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA	University of Oregon			Taanman, Jan W/A-5379-2011	Taanman, Jan W/0000-0002-5476-9785	NHLBI NIH HHS [HL 22050] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022050] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AGGELER R, 1990, J BIOL CHEM, V265, P16389; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CAPALDI RA, 1977, BIOCHEM BIOPH RES CO, V74, P425, DOI 10.1016/0006-291X(77)90321-7; COOPER CE, 1991, BIOCH CELL BIOL, V69, P589; CORUZZI G, 1979, J BIOL CHEM, V254, P9324; CUMSKY MG, 1987, MOL CELL BIOL, V7, P3511, DOI 10.1128/MCB.7.10.3511; DAUM G, 1982, J BIOL CHEM, V257, P3028; EWART GD, 1991, FEBS LETT, V292, P79, DOI 10.1016/0014-5793(91)80839-U; FINEL M, 1987, BIOCHIM BIOPHYS ACTA, V894, P174, DOI 10.1016/0005-2728(87)90187-3; GATTI DL, 1989, J MOL BIOL, V205, P421, DOI 10.1016/0022-2836(89)90352-5; JACOBS EE, 1960, J BIOL CHEM, V235, P531; KADENBACH B, 1981, FEBS LETT, V135, P1, DOI 10.1016/0014-5793(81)80932-5; KADENBACH B, 1987, CURR TOP BIOENERG, V15, P113; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMARCHE AEP, 1992, J BIOL CHEM, V267, P22473; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LIGHTOWLERS R, 1991, J BIOL CHEM, V266, P7688; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4128, DOI 10.1021/bi00313a018; LUDWIG B, 1987, FEMS MICROBIOL LETT, V46, P41, DOI 10.1111/j.1574-6968.1987.tb02451.x; MASON TL, 1973, J BIOL CHEM, V248, P1346; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; PATTERSON TE, 1986, J BIOL CHEM, V261, P7192; PENTTILA T, 1983, EUR J BIOCHEM, V133, P355, DOI 10.1111/j.1432-1033.1983.tb07470.x; PLANQUES Y, 1989, FEBS LETT, V258, P285, DOI 10.1016/0014-5793(89)81675-8; POWER SD, 1984, J BIOL CHEM, V259, P6571; POWER SD, 1986, J BIOL CHEM, V261, P9206; POWER SD, 1984, J BIOL CHEM, V259, P6575; POWER SD, 1984, J BIOL CHEM, V259, P6564; POYTON RO, 1978, J BIOL CHEM, V253, P6303; POYTON RO, 1988, ANN NY ACAD SCI, V550, P284; RUBIN MS, 1973, J BIOL CHEM, V248, P4269; SINJORGO KMC, 1987, BIOCHIM BIOPHYS ACTA, V893, P251, DOI 10.1016/0005-2728(87)90046-6; STEFFENS GCM, 1979, H-S Z PHYSIOL CHEM, V360, P1641, DOI 10.1515/bchm2.1979.360.2.1641; STIGGALL DL, 1978, J BIOL CHEM, V253, P956; TAANMAN JW, 1990, GENE, V93, P285, DOI 10.1016/0378-1119(90)90237-L; THOMPSON DA, 1985, J INORG BIOCHEM, V23, P357, DOI 10.1016/0162-0134(85)85046-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANGELDER BF, 1966, BIOCHIM BIOPHYS ACTA, V118, P36, DOI 10.1016/S0926-6593(66)80142-X; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; YONETANI T, 1965, J BIOL CHEM, V240, P4509	44	74	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22481	22485						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331058				2022-12-27	WOS:A1992JW71900077
J	SCOTT, DJ; DEAN, DR; NEWTON, WE				SCOTT, DJ; DEAN, DR; NEWTON, WE			NITROGENASE-CATALYZED ETHANE PRODUCTION AND CO-SENSITIVE HYDROGEN EVOLUTION FROM MOFE PROTEINS HAVING AMINO-ACID SUBSTITUTIONS IN AN ALPHA-SUBUNIT FEMO COFACTOR-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; KLEBSIELLA-PNEUMONIAE NITROGENASE; AZOTOBACTER-VINELANDII NITROGENASE; ELECTRON-PARAMAGNETIC RESONANCE; SUBSTRATE REDUCTION PROPERTIES; CONSERVED CYSTEINE RESIDUES; SITE-DIRECTED MUTAGENESIS; WILD-TYPE; VANADIUM-NITROGENASE; BETA-SUBUNIT	Unlike wild type, certain Mo-dependent nitrogenases, which are expressed in non-N2-fixing mutant strains of Azotobacter vinelandii and have single amino acid substitutions within a region of the MoFe protein alpha-subunit proposed to encompass an FeMo cofactor-binding domain, are able to catalyze the reduction of acetylene by both two and four electrons to yield ethylene and ethane, respectively (Scott, D. J., May, H. D., Newton, W. E., Brigle, K. E., and Dean, D. R. (1990) Nature 343, 188-190). Although the V-dependent nitrogenase is also able to catalyze the reduction of acetylene to the same two- and four-electron products (Dilworth, M. J., Eady, R. R., Robson, R. L., and Miller, R. W. (1987) Nature 327, 167-168), we find that ethane formation from acetylene catalyzed by the altered Mo-dependent nitrogenases occurs by a different mechanism, which is distinguished by: (i) an increased sensitivity to CO; (ii) the absence of a lag; and (iii) no temperature dependence of product distribution among ethylene and ethane during acetylene reduction. An altered MoFe protein, which was purified from one such mutant strain having the alpha-subunit glutaminyl 191 residue substituted by lysyl, exhibited both a changed S = 3/2 EPR spectrum and changes in the distribution of electrons to various products when compared to wild type. Also, unlike wild type, this altered MoFe protein catalyzed proton reduction that is inhibited by carbon monoxide (CO). Because proton reduction catalyzed by a nitrogenase that has a FeMo cofactor with citrate rather than homocitrate as its organic constituent (Liang, J., Madden, M., Shah, V. K., and Burris, R. H. (1990) Biochemistry 29, 8577-8581) is also inhibited by CO, the possibility arose that changes in the polypeptide environment of FeMo cofactor might have caused a rearrangement in its molecular structure or composition. However, this possibility was ruled out by biochemical reconstitution studies (using FeMo cofactor isolated from both the wild-type and altered MoFe proteins), which were monitored by EPR spectroscopy and resulting catalytic activity.	VIRGINIA POLYTECH INST & STATE UNIV, DEPT BIOCHEM & NUTR, BLACKSBURG, VA 24061 USA; USDA ARS, WESTERN REG RES CTR, BERKELEY, CA 94710 USA; VIRGINIA POLYTECH INST & STATE UNIV, DEPT ANAEROB MICROBIOL, BLACKSBURG, VA 24061 USA	Virginia Polytechnic Institute & State University; United States Department of Agriculture (USDA); Virginia Polytechnic Institute & State University					NIDDK NIH HHS [DK-37255] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037255] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALT HG, 1982, ANGEW CHEM INT EDIT, V21, P78, DOI 10.1002/anie.198200781; ASHBY GA, 1987, BIOCHEM J, V247, P547, DOI 10.1042/bj2470547; BISHOP PE, 1980, P NATL ACAD SCI-BIOL, V77, P7342, DOI 10.1073/pnas.77.12.7342; Bishop PE, 1992, BIOL NITROGEN FIXATI, P736; BOLIN JT, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P117; BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; BRIGLE KE, 1987, P NATL ACAD SCI USA, V84, P7066, DOI 10.1073/pnas.84.20.7066; Bulen W., 1965, NONHEMA IRON PROTEIN, P261; BULEN WA, 1966, P NATL ACAD SCI USA, V56, P979, DOI 10.1073/pnas.56.3.979; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURNS R. C., 1965, BIOCHIM BIOPHYS ACTA, V105, P437; CORBIN JL, 1984, APPL ENVIRON MICROB, V47, P1027, DOI 10.1128/AEM.47.5.1027-1030.1984; Dean D.R., 1992, BIOL NITROGEN FIXATI, P763; DEAN DR, 1990, MOL MICROBIOL, V4, P1505, DOI 10.1111/j.1365-2958.1990.tb02061.x; DEAN DR, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P95; DILWORTH MJ, 1991, BIOCHEM J, V277, P465, DOI 10.1042/bj2770465; DILWORTH MJ, 1988, BIOCHEM J, V249, P745, DOI 10.1042/bj2490745; DILWORTH MJ, 1987, NATURE, V327, P167, DOI 10.1038/327167a0; EADY RR, 1987, BIOCHEM J, V244, P197, DOI 10.1042/bj2440197; EIDSNESS MK, 1986, J AM CHEM SOC, V108, P2746, DOI 10.1021/ja00270a039; EULER WB, 1984, BIOCHEMISTRY-US, V23, P3021, DOI 10.1021/bi00308a027; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HAGEMAN RV, 1980, BIOCHIM BIOPHYS ACTA, V591, P63, DOI 10.1016/0005-2728(80)90220-0; HAGEN WR, 1987, EUR J BIOCHEM, V169, P457, DOI 10.1111/j.1432-1033.1987.tb13633.x; HALES BJ, 1986, BIOCHEMISTRY-US, V25, P7253, DOI 10.1021/bi00371a001; HARDY RWF, 1965, BIOCHEM BIOPH RES CO, V20, P539, DOI 10.1016/0006-291X(65)90431-6; HARRIS GS, 1990, J BIOL CHEM, V265, P15909; HAWKES TR, 1983, BIOCHEM J, V209, P43, DOI 10.1042/bj2090043; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HEDMAN B, 1988, J AM CHEM SOC, V110, P3798, DOI 10.1021/ja00220a013; HOOVER TR, 1988, BIOCHEMISTRY-US, V27, P3647, DOI 10.1021/bi00410a019; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; IMPERIAL J, 1989, BIOCHEMISTRY-US, V28, P7796, DOI 10.1021/bi00445a040; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; KENT HM, 1990, MOL MICROBIOL, V4, P1497, DOI 10.1111/j.1365-2958.1990.tb02060.x; KENT HM, 1989, BIOCHEM J, V264, P257, DOI 10.1042/bj2640257; KURTZ DM, 1979, P NATL ACAD SCI USA, V76, P4986, DOI 10.1073/pnas.76.10.4986; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG JH, 1990, BIOCHEMISTRY-US, V29, P8577, DOI 10.1021/bi00489a011; LOWE DJ, 1984, BIOCHEM J, V224, P877, DOI 10.1042/bj2240877; MADDEN MS, 1990, P NATL ACAD SCI USA, V87, P6517, DOI 10.1073/pnas.87.17.6517; MAY HD, 1991, BIOCHEM J, V277, P457, DOI 10.1042/bj2770457; MCLEAN PA, 1987, J AM CHEM SOC, V109, P943, DOI 10.1021/ja00237a075; MCLEAN PA, 1981, NATURE, V292, P655, DOI 10.1038/292655a0; MCLEAN PA, 1989, BIOCHEMISTRY-US, V28, P9402, DOI 10.1021/bi00450a023; MORTENSON LE, 1973, BIOCHIM BIOPHYS ACTA, V292, P422, DOI 10.1016/0005-2728(73)90048-0; MUNCK E, 1975, BIOCHIM BIOPHYS ACTA, V400, P32, DOI 10.1016/0005-2795(75)90124-5; NAGATANI HH, 1974, J BACTERIOL, V120, P697, DOI 10.1128/JB.120.2.697-701.1974; NAKAMURA A, 1972, J AM CHEM SOC, V94, P1886, DOI 10.1021/ja00761a017; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ORMEJOHNSON WH, 1972, P NATL ACAD SCI USA, V69, P3142, DOI 10.1073/pnas.69.11.3142; PAU RN, 1989, J BACTERIOL, V171, P124, DOI 10.1128/jb.171.1.124-129.1989; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; ROBERTS GP, 1978, J BACTERIOL, V136, P267, DOI 10.1128/JB.136.1.267-279.1978; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBSON RL, 1986, NATURE, V322, P388, DOI 10.1038/322388a0; SCOTT DJ, 1990, NATURE, V343, P188, DOI 10.1038/343188a0; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V292, P246, DOI 10.1016/0005-2728(73)90269-7; SMITH BE, 1973, BIOCHEM J, V135, P331, DOI 10.1042/bj1350331; STRANDBERG GW, 1968, CAN J MICROBIOL, V14, P25, DOI 10.1139/m68-005; THOMANN H, 1987, J AM CHEM SOC, V109, P7913, DOI 10.1021/ja00259a067; THOMANN H, 1991, P NATL ACAD SCI USA, V88, P6620, DOI 10.1073/pnas.88.15.6620; TRUE AE, 1990, J AM CHEM SOC, V112, P651, DOI 10.1021/ja00158a024; WHERLAND S, 1981, BIOCHEMISTRY-US, V20, P5132, DOI 10.1021/bi00521a006; ZIMMERMANN R, 1978, BIOCHIM BIOPHYS ACTA, V537, P185, DOI 10.1016/0005-2795(78)90504-4	66	65	68	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20002	20010						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328190				2022-12-27	WOS:A1992JR85800042
J	DEEG, MA; MURRAY, NR; ROSENBERRY, TL				DEEG, MA; MURRAY, NR; ROSENBERRY, TL			IDENTIFICATION OF GLYCOINOSITOL PHOSPHOLIPIDS IN RAT-LIVER BY REDUCTIVE RADIOMETHYLATION OF AMINES BUT NOT IN H4IIE HEPATOMA-CELLS OR ISOLATED HEPATOCYTES BY BIOSYNTHETIC LABELING WITH GLUCOSAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; VARIANT SURFACE GLYCOPROTEINS; GLYCOSYL-PHOSPHATIDYLINOSITOL; TRYPANOSOMA-BRUCEI; MEMBRANE ANCHOR; LEISHMANIA-MAJOR; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR; INSULIN MEDIATORS; PRECURSOR; PROTEINS	The identification of free glycoinositol phospholipids (GPIs) following biosynthetic labeling with [H-3]glucosamine in cultured cells has been reported by several laboratories. We applied this procedure to two of the cell types used in these studies, H4IIE hepatoma cells and isolated hepatocytes, but were unable to detect a [H-3]glucosamine-containing lipid that met any of the criteria for GPIs, including sensitivity to phosphatidylinositol-specific phospholipase C (PIPLC) or GPI-specific phospholipase D. Part of the difficulty in radiolabeling a GPI by this procedure was the rapid metabolic conversion of [H-3]glucosamine to galactosamine and neutral or anionic derivatives. A PIPLC-sensitive radiolabeled lipid was detected only after 16 h of labeling. The water-soluble fragments released from this lipid by PIPLC corresponded largely to myoinositol 1,2-cyclic phosphate and myo-inositol 1-phosphate, products expected from PIPLC cleavage of phosphatidylinositol or lyso-phosphatidylinositol. In an alternative approach that we introduce here, free GPIs in lipid extracts from rat liver plasma membranes were labeled by reductive radiomethylation. This procedure, which radiomethylates primary and secondary amines, has been shown to label a glucosamine residue adjacent to inositol in all GPIs characterized to date. The labeled extracts were fractionated by two-dimensional thin-layer chromatography, and a cluster of polar labeled lipids were assigned as GPIs based upon the following observations. 1) They were cleaved by PIPLC, 2) after hydrolysis in 6 N HCl, both radiomethylated glucosamine and a glucosamine-inositol conjugate were identified by cation exchange chromatography, and 3) hydrolysis in 4 M trifluoroacetic acid generated a fragment consistent with glucosamine-inositol-phosphate. These results illustrate new criteria for the identification of GPIs. The labeled GPIs also contained radiomethylated ethanolamine, another component found in GPI anchors of proteins and in mature lipid precursors of GPI anchors, suggesting that the liver plasma membrane GPIs retained considerable structural homology to GPI anchors.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHARMACOL, CLEVELAND, OH 44106 USA	Case Western Reserve University					NIDDK NIH HHS [DK 08441, DK38181] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038181, F32DK008441] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARR K, 1984, BIOCHEMISTRY-US, V23, P5581, DOI 10.1021/bi00318a031; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASS EP, 1984, FEBS LETT, V169, P293, DOI 10.1016/0014-5793(84)80336-1; DAVITZ MA, 1989, J BIOL CHEM, V264, P13760; DEEG MA, 1992, J BIOL CHEM, V267, P18573; DOERING TL, 1990, J BIOL CHEM, V265, P611; EARDLEY DD, 1991, SCIENCE, V251, P78, DOI 10.1126/science.1824727; FATEMI SH, 1987, J BIOL CHEM, V262, P4728; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIELD MC, 1991, J BIOL CHEM, V266, P8392; GAULTON GN, 1991, DIABETES, V40, P1297, DOI 10.2337/diabetes.40.10.1297; GAULTON GN, 1988, CELL, V53, P963, DOI 10.1016/S0092-8674(88)90509-0; HAAS R, 1985, ANAL BIOCHEM, V148, P154, DOI 10.1016/0003-2697(85)90640-2; HAAS R, 1986, BIOCHEMISTRY-US, V25, P3098, DOI 10.1021/bi00359a005; HANSON BA, 1980, J LIPID RES, V21, P309; HARMS E, 1973, EUR J BIOCHEM, V32, P254, DOI 10.1111/j.1432-1033.1973.tb02605.x; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; IGARASHI Y, 1987, BIOCHEM BIOPH RES CO, V145, P249, DOI 10.1016/0006-291X(87)91313-1; LARNER J, 1988, COLD SPRING HARB SYM, V53, P965, DOI 10.1101/SQB.1988.053.01.111; LEE HC, 1992, BIOCHEMISTRY-US, V31, P3236, DOI 10.1021/bi00127a027; MACAULAY SL, 1990, BIOCHEM J, V271, P427, DOI 10.1042/bj2710427; MALEY F, 1959, BIOCHIM BIOPHYS ACTA, V31, P577, DOI 10.1016/0006-3002(59)90047-2; MATO JM, 1987, BIOCHEM BIOPH RES CO, V146, P764, DOI 10.1016/0006-291X(87)90595-X; MATO JM, 1987, J BIOL CHEM, V262, P2131; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; MCCONVILLE MJ, 1990, MOL BIOCHEM PARASIT, V38, P57, DOI 10.1016/0166-6851(90)90205-Z; MEDOF ME, 1986, BIOCHEMISTRY-US, V25, P6740, DOI 10.1021/bi00370a003; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; MERIDA I, 1988, FEBS LETT, V236, P251, DOI 10.1016/0014-5793(88)80325-9; MISUMI Y, 1990, J BIOL CHEM, V265, P2178; NEVILLE DM, 1968, BIOCHIM BIOPHYS ACTA, V154, P540, DOI 10.1016/0005-2795(68)90014-7; PERELMAN A, 1989, EUR J BIOCHEM, V182, P203, DOI 10.1111/j.1432-1033.1989.tb14818.x; PUOTI A, 1991, J BIOL CHEM, V266, P21051; RAY TK, 1969, J BIOL CHEM, V244, P5528; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROMERO G, 1991, CELL BIOL INT REP, V15, P827, DOI 10.1016/0309-1651(91)90036-I; ROSENBERRY TL, 1989, METHOD CELL BIOL, V32, P231; ROSS GAM, 1990, ANN REV CELL BIOL, V6, P1; SALTIEL AR, 1986, P NATL ACAD SCI USA, V83, P5793, DOI 10.1073/pnas.83.16.5793; SALTIEL AR, 1988, AM J PHYSIOL, V255, pC1, DOI 10.1152/ajpcell.1988.255.1.C1; SEYFRED MA, 1984, J BIOL CHEM, V259, P7659; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; SUZUKI S, 1991, J BIOL CHEM, V266, P8115; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; THAKKAR JK, 1990, J BIOL CHEM, V265, P5475; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; VARELA I, 1990, EUR J BIOCHEM, V188, P213, DOI 10.1111/j.1432-1033.1990.tb15392.x	52	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18581	18588						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326529				2022-12-27	WOS:A1992JN50200053
J	HOSODA, K; NAKAO, K; TAMURA, N; ARAI, H; OGAWA, Y; SUGA, S; NAKANISHI, S; IMURA, H				HOSODA, K; NAKAO, K; TAMURA, N; ARAI, H; OGAWA, Y; SUGA, S; NAKANISHI, S; IMURA, H			ORGANIZATION, STRUCTURE, CHROMOSOMAL ASSIGNMENT, AND EXPRESSION OF THE GENE ENCODING THE HUMAN ENDOTHELIN-A RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CDNA; SEQUENCE; RAT; PROMOTER; CELLS; DNA; PROTEINS; REGIONS; SITES	We have isolated and characterized the gene for the human endothelin-A receptor. Southern blot analyses demonstrated a single copy gene for the receptor. The gene spans more than 40 kilobases and contains eight exons and seven introns. Intron 1 exists in the 5'-noncoding region, and introns 2-7 occur in the coding region. The locations of introns 2-7 exist before or after the regions encoding the membrane-spanning domains. The transcription start site, determined by primer extension experiments, is 502 base pairs upstream of the methionine initiation codon. The 5'-flanking region lacks a typical TATA box but contains a potential SP-1-binding site 27 base pairs upstream of the transcription start site. Using human-rodent somatic hybrid cell DNA, the gene was assigned to human chromosome 4. Northern blot analyses revealed a 4.3-kilobase mRNA in a wide variety of human tissues, at the highest level in the aorta and at a substantial level in the cultured human mesangial cells. This is the first report of cloning of a gene for a member of the endothelin receptor family. The present study should give a clue to the discovery of possible disorders of the endothelin-A receptor, as well as facilitate the elucidation of the mechanisms by which the gene expression is regulated.	KYOTO UNIV,SCH MED,DEPT MED,DIV 2,54 SHOGOIN KAWAHARA CHO,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,SCH MED,INST IMMUNOL,KYOTO 606,JAPAN	Kyoto University; Kyoto University				Ogawa, Yoshihiro/0000-0002-0834-2836				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BLOCH KD, 1989, J BIOL CHEM, V264, P10851; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; FOWLKES DM, 1984, P NATL ACAD SCI-BIOL, V81, P2313, DOI 10.1073/pnas.81.8.2313; GERARD NP, 1990, J BIOL CHEM, V265, P20455; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; HERSHEY AD, 1991, J BIOL CHEM, V266, P4366; HORI S, 1992, ENDOCRINOLOGY, V130, P1885, DOI 10.1210/en.130.4.1885; HOSODA K, 1991, FEBS LETT, V287, P23, DOI 10.1016/0014-5793(91)80007-P; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; INOUE A, 1989, J BIOL CHEM, V264, P14954; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; LEE ME, 1990, J BIOL CHEM, V265, P10446; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; MARTIN ER, 1990, J BIOL CHEM, V265, P14044; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MIWA T, 1987, P NATL ACAD SCI USA, V84, P6702, DOI 10.1073/pnas.84.19.6702; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; Nayler W G, 1990, Trends Pharmacol Sci, V11, P96, DOI 10.1016/0165-6147(90)90188-E; NICOSIA RF, 1990, LAB INVEST, V63, P115; OGAWA Y, 1991, BIOCHEM BIOPH RES CO, V178, P248, DOI 10.1016/0006-291X(91)91806-N; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITO Y, 1991, J BIOL CHEM, V266, P23433; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sambrook J, 1989, MOL CLONING LABORATO; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; TAKAHASHI K, 1992, EUR J BIOCHEM, V204, P1025, DOI 10.1111/j.1432-1033.1992.tb16724.x; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; WARNER TD, 1989, EUR J PHARMACOL, V159, P325, DOI 10.1016/0014-2999(89)90167-2; WATANABE H, 1989, BIOCHEM BIOPH RES CO, V161, P1252, DOI 10.1016/0006-291X(89)91377-6; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; YANAGISAWA M, 1989, TRENDS PHARMACOL SCI, V10, P374; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	41	165	169	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18797	18804						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326535				2022-12-27	WOS:A1992JN50200083
J	SNOW, JW; GLICK, JM; PHILLIPS, MC				SNOW, JW; GLICK, JM; PHILLIPS, MC			THE PHASE-BEHAVIOR OF CHOLESTERYL ESTERS IN INTRACELLULAR INCLUSIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; TISSUE-CULTURE CELLS; ATHEROSCLEROTIC LESIONS; PHYSICAL STATE; LIPID DEPOSITS; FOAM CELLS; METABOLISM; MACROPHAGES; DISPERSIONS; MODEL	Differential scanning calorimetry and polarizing light microscopy have been used to investigate kinetic and thermodynamic properties of the phase behavior of cholesteryl ester contained in Fu5AH rat hepatoma cells and J774 murine macrophages. These cultured cells store cholesteryl esters as cytoplasmic inclusions of approximately 1-mu-m diameter and thus are models of the foam cells characteristic of atherosclerotic plaque. Simple binary mixtures of cholesteryl palmitate and cholesteryl oleate, the predominant cholesteryl esters in cellular inclusions in both cell types serve as models to explain important aspects of the phase behavior of these inclusions. Although inclusions should exist as stable crystals at 37-degrees-C under conditions of thermodynamic equilibrium, microscopic examination of cells indicates that inclusions exist as metastable liquid crystals at 37-degrees-C for extended periods of time. Using an analytical model based on nucleation theory, we predict that the cholesteryl ester inclusions should be liquid-crystalline in the cytoplasm of living cells. This may not be true either for lysosomal cholesteryl ester or for extracellular cholesteryl ester present in advanced atherosclerotic plaque where fusion of droplets can enhance the possibility of crystallization. The enhanced metastability of the relatively fluid liquid-crystalline state in cellular inclusions should result in increased activity of the neutral cholesteryl ester hydrolase in living cells.	MED COLL PENN, DEPT PHYSIOL BIOCHEM, PHILADELPHIA, PA 19129 USA	Drexel University	SNOW, JW (corresponding author), PHILADELPHIA COLL PHARM & SCI, DEPT CHEM, PHILADELPHIA, PA 19104 USA.			Phillips, Michael/0000-0002-7147-8007	NHLBI NIH HHS [HL 22633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELMAN SJ, 1984, J BIOL CHEM, V259, P3844; BILLHEIMER JT, 1983, J LIPID RES, V24, P1646; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CARROLL RM, 1981, J LIPID RES, V22, P359; CROLL DH, 1985, BIOCHEMISTRY-US, V24, P7971, DOI 10.1021/bi00348a020; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; Eyring H., 1963, MODERN CHEM KINETICS; GINSBURG GS, 1984, PROG LIPID RES, V23, P135, DOI 10.1016/0163-7827(84)90002-X; GLICK JM, 1983, J BIOL CHEM, V258, P3425; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Hatch F T, 1968, Adv Lipid Res, V6, P1; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; KATZ S S, 1976, Journal of Clinical Investigation, V58, P200; KATZ SS, 1977, J CLIN INVEST, V59, P1045, DOI 10.1172/JCI108727; KROON PA, 1981, J BIOL CHEM, V256, P5332; LUNDBERG B, 1985, ATHEROSCLEROSIS, V56, P93, DOI 10.1016/0021-9150(85)90087-5; LUPU F, 1987, ATHEROSCLEROSIS, V67, P127, DOI 10.1016/0021-9150(87)90273-5; MAHLBERG FH, 1990, BIOCHIM BIOPHYS ACTA, V1045, P291, DOI 10.1016/0005-2760(90)90133-I; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCLOSKEY HM, 1987, BIOCHIM BIOPHYS ACTA, V921, P320, DOI 10.1016/0005-2760(87)90033-6; MINOR LK, 1989, J LIPID RES, V30, P189; NOBLE RP, 1968, J LIPID RES, V9, P693; OLIVER MJ, 1975, J CRYST GROWTH, V30, P343, DOI 10.1016/0022-0248(75)90010-X; PITOT H. C., 1964, NAT CANCER INST MONOGR, V13, P229; RALPH P, 1975, J IMMUNOL, V114, P898; ROTHBLAT GH, 1977, EXP MOL PATHOL, V26, P318, DOI 10.1016/0014-4800(77)90059-4; ROTHBLAT GH, 1974, LIPIDS, V9, P526, DOI 10.1007/BF02532500; SKODA W, 1963, J COLL SCI IMP U TOK, V18, P568, DOI 10.1016/0095-8522(63)90049-7; SMALL DM, 1974, SCIENCE, V185, P222, DOI 10.1126/science.185.4147.222; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; SMALL DM, 1986, HDB LIPID RES, V4, P395; SNOW J, 1990, BIOCHEMISTRY-US, V29, P2464, DOI 10.1021/bi00462a005; SNOW JW, 1988, BIOCHEMISTRY-US, V27, P3640, DOI 10.1021/bi00410a018; TURNBULL D, 1949, J CHEM PHYS, V17, P71, DOI 10.1063/1.1747055; TURNBULL D, 1952, J CHEM PHYS, V20, P411, DOI 10.1063/1.1700435; WERB Z, 1972, J EXP MED, V135, P21, DOI 10.1084/jem.135.1.21; YAUYOUNG AO, 1982, BIOCHIM BIOPHYS ACTA, V710, P181, DOI 10.1016/0005-2760(82)90148-5	38	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18564	18572						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326528				2022-12-27	WOS:A1992JN50200051
J	RANDAZZO, PA; NORTHUP, JK; KAHN, RA				RANDAZZO, PA; NORTHUP, JK; KAHN, RA			REGULATORY GTP-BINDING PROTEINS (ADP-RIBOSYLATION-FACTOR, G(T), AND RAS) ARE NOT ACTIVATED DIRECTLY BY NUCLEOSIDE DIPHOSPHATE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; ADENYLATE-CYCLASE; TRIPHOSPHATE CONFORMATION; TUMOR-METASTASIS; ESCHERICHIA-COLI; BOUND GDP; P21; CELLS; GS; RHODOPSIN	The expression of nucleoside diphosphate kinase (NDK) genes has been implicated as a negative regulator of murine and human tumor metastases and is critical to proper development in Drosophilia melanogaster. Molecular mechanisms for the role(s) of NDK in these complex processes have not yet been elucidated, but several reports have suggested that these and many other signal transduction pathways may be activated by NDK acting directly on a regulatory GTP-binding protein(s). To test this hypothesis, we examined the ability of NDK to catalyze the phosphorylation of the GDP bound to the following three members of the superfamily of regulatory GTP-binding proteins: G(t), Ha-ras p21, and ARF. We have found no evidence to support the hypothesis that NDK can directly activate any GTP-binding protein. Rather, evidence is presented which clearly shows that all of the GTP formed upon incubation of GTP-binding proteins with NDK is the result of NDK utilizing free GDP as substrate. The GDP bound to the regulatory proteins is not a substrate for NDK under conditions in which free nucleotides are rapidly and efficiently phosphorylated. The importance of appropriate controls for dissociation of GDP from the regulatory proteins both during the NDK reaction and during the analysis of product is demonstrated. We believe there is currently no experimental evidence to support the hypothesis that NDK can directly activate a regulatory GTP-binding protein.	NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,BIOL CHEM LAB,BETHESDA,MD 20892; NIMH,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)			Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				Agarwal R P, 1978, Methods Enzymol, V51, P376; BERG P, 1953, NATURE, V172, P1008, DOI 10.1038/1721008a0; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BRANDT DR, 1985, J BIOL CHEM, V260, P266; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; FUNG BKK, 1980, P NATL ACAD SCI-BIOL, V77, P2500, DOI 10.1073/pnas.77.5.2500; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; HAMEL E, 1984, J BIOL CHEM, V259, P1060; JACOBS M, 1979, EUR J BIOCHEM, V99, P613, DOI 10.1111/j.1432-1033.1979.tb13294.x; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIKKAWA S, 1991, J BIOL CHEM, V266, P12795; KIMURA N, 1990, BIOCHEM BIOPH RES CO, V168, P99, DOI 10.1016/0006-291X(90)91680-Q; KIMURA N, 1983, J BIOL CHEM, V258, P2609; KREBS HA, 1953, BIOCHIM BIOPHYS ACTA, V12, P172, DOI 10.1016/0006-3002(53)90136-X; LACOMBE M L, 1992, Trends in Pharmacological Sciences, V13, P46, DOI 10.1016/0165-6147(92)90020-7; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MANNE V, 1984, P NATL ACAD SCI-BIOL, V81, P6953, DOI 10.1073/pnas.81.22.6953; MOURAD N, 1966, J BIOL CHEM, V241, P271; NICKERSON JA, 1984, J BIOL CHEM, V259, P1297; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OHTSUKI K, 1985, BIOCHEM INT, V11, P719; OHTSUKI K, 1987, BIOCHIM BIOPHYS ACTA, V929, P231, DOI 10.1016/0167-4889(87)90248-5; OHTSUKI K, 1987, BIOCHEM BIOPH RES CO, V148, P300, DOI 10.1016/0006-291X(87)91110-7; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; OTERO AS, 1988, SCIENCE, V242, P443, DOI 10.1126/science.3051383; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; PENNINGROTH SM, 1977, J MOL BIOL, V115, P643, DOI 10.1016/0022-2836(77)90108-5; POE M, 1985, J BIOL CHEM, V260, P3906; RANDAZZO PA, 1991, SCIENCE, V254, P850, DOI 10.1126/science.1658935; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SEIFERT R, 1988, EUR J BIOCHEM, V175, P51, DOI 10.1111/j.1432-1033.1988.tb14165.x; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; WEISS O, 1989, J BIOL CHEM, V264, P21066; WIELAND T, 1989, FEBS LETT, V245, P189, DOI 10.1016/0014-5793(89)80219-4; WIELAND T, 1991, EUR J PHARM-MOLEC PH, V208, P17, DOI 10.1016/0922-4106(91)90046-K	48	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18182	18189						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325460				2022-12-27	WOS:A1992JM22300107
J	SPRING, DJ; CHENLIU, LW; CHATTERTON, JE; ELOVSON, J; SCHUMAKER, VN				SPRING, DJ; CHENLIU, LW; CHATTERTON, JE; ELOVSON, J; SCHUMAKER, VN			LIPOPROTEIN ASSEMBLY - APOLIPOPROTEIN-B SIZE DETERMINES LIPOPROTEIN CORE CIRCUMFERENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LIVER-CELL; ELECTRON-MICROSCOPY; RAT-LIVER; PLASMA; LINE; CHOLESTEROL; APOPROTEIN; PROTEIN; B-100	Apolipoprotein B (apoB) is an essential structural protein for the two triglyceride-rich lipoproteins synthesized by humans: chylomicrons and very low density lipoproteins. Although much is known about the role of apoB in clearance of lipoproteins from the circulation, relatively little is known about its role in the assembly of nascent lipoproteins. Therefore, we have investigated the relationship between the length of various N-terminal apoB fragments and the characteristics of the lipoproteins with which these fragments were associated. After the addition of puromycin, HepG2 cells secreted a discrete series of C-terminally truncated apoB fragments on lipoprotein particles including apoB25, apoB29, apoB31, apoB33, apoB36, apoB38, apoB42, apoB45, apoB49, apoB51, apoB55, apoB70, and apoB80. Also, using plasmids encoding apoB26, apoB33, apoB37, apoB42, and apoB48, C-terminally truncated apoB fragments were expressed and secreted after transient transfection of HepG2 cells. Lipoproteins bearing the metabolically labeled apoB fragments were isolated from the cell culture media and characterized in terms of size, density, flotation coefficient, and composition. Lipoprotein radii, calculated from their flotation coefficients and buoyant densities, were used to derive the circumference of the non-polar core of each lipoprotein species. When plotted as a function of apoB size, core circumference defined a straight line of near-zero intercept. The slope of this line was approximately 1 angstrom of core circumference/1 kDa of apoB molecular mass. A model for the mechanism of lipoprotein assembly in HepG2 cells, consistent with the concept that apoB size determines lipoprotein core circumference, is proposed.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,405 HILGARD AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; WADSWORTH VET ADM MED CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				Spring, Denise J./0000-0002-4593-0901	NHLBI NIH HHS [HL07386, HL28481] Funding Source: Medline; NIGMS NIH HHS [1 P41 GM 27556] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; BROWN MS, 1984, SCI AM, V251, P58, DOI 10.1038/scientificamerican1184-58; BUSCH SJ, 1989, LIFE SCI, V45, P615, DOI 10.1016/0024-3205(89)90047-7; CHAPMAN MJ, 1988, J LIPID RES, V29, P442; CHATTERTON JE, 1991, J BIOL CHEM, V266, P5955; CHEN GC, 1989, J BIOL CHEM, V264, P14369; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CLAUDE A, 1970, J CELL BIOL, V47, P745, DOI 10.1083/jcb.47.3.745; FISHER WR, 1971, BIOCHEMISTRY-US, V10, P1622, DOI 10.1021/bi00785a019; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; GULIKKRZYWICKI T, 1979, J MOL BIOL, V131, P475, DOI 10.1016/0022-2836(79)90003-2; HABERLAND ME, 1973, P NATL ACAD SCI USA, V70, P2313, DOI 10.1073/pnas.70.8.2313; HAUSER H, 1972, Z PHYSL CHEM, V353, P1579; JANERO DR, 1983, J BIOL CHEM, V258, P4496; JONES AL, 1967, J LIPID RES, V8, P429; KANE JP, 1980, P NATL ACAD SCI-BIOL, V77, P2465, DOI 10.1073/pnas.77.5.2465; LABELLE M, 1991, BIOCHIM BIOPHYS ACTA, V1046, P288; LEE DM, 1987, BIOCHEM BIOPH RES CO, V144, P210, DOI 10.1016/S0006-291X(87)80497-7; LUZZATI V, 1979, J MOL BIOL, V131, P435, DOI 10.1016/0022-2836(79)90002-0; OLOFSSON SO, 1987, ATHEROSCLEROSIS, V68, P1, DOI 10.1016/0021-9150(87)90088-8; PEASE RJ, 1990, J BIOL CHEM, V265, P553; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; PHILLIPS ML, 1989, J LIPID RES, V30, P415; POLLARD H, 1969, P NATL ACAD SCI USA, V64, P304, DOI 10.1073/pnas.64.1.304; SHEN BW, 1977, P NATL ACAD SCI USA, V74, P837, DOI 10.1073/pnas.74.3.837; SIUTAMANGANO P, 1981, J BIOL CHEM, V256, P2094; SMALL D, 1978, HDB LIPID RES, P386; SPRING DJ, 1992, J LIPID RES, V33, P233; STEELE JCH, 1979, J BIOL CHEM, V254, P1639; THRIFT RN, 1986, J LIPID RES, V27, P236; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96; YAO ZM, 1991, J BIOL CHEM, V266, P3300	35	129	130	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14839	14845						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321819				2022-12-27	WOS:A1992JF08800052
J	URADE, R; NASU, M; MORIYAMA, T; WADA, K; KITO, M				URADE, R; NASU, M; MORIYAMA, T; WADA, K; KITO, M			PROTEIN-DEGRADATION BY THE PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE-C-ALPHA FAMILY FROM RAT-LIVER ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSOMAL-MEMBRANES; DISULFIDE-ISOMERASE; IDENTIFICATION; SEQUENCE; BINDING; CARBOXYLESTERASES; PURIFICATION; INVIVO; ER	A 60-kDa protein homologous to phosphoinositide-specific phospholipase C-alpha was purified to apparent homogeneity on sodium dodecyl sulfate-polyacrylamide gel electrophoresis from the rough endoplasmic reticulum of rat liver through three sequential chromatographies on DEAE Toyopearl 650, AF-heparin Toyopearl 650M, and TSK gel G3000SW. The purified protein was monomeric, with an M(r) of 60,000. Eight types of protein were further separated from the 60-kDa protein and named ER60A-ER60H according to the order of their elution from a TSK gel DEAE-5PW column. They were essentially identical in terms of immunochemical properties and the NH2-terminal amino acid sequence. The partial amino acid sequence of ER60F showed homology to that of phosphoinositide-specific phospholipase C-alpha. ER60A-ER60H showed no phosphoinositide-specific phospholipase C activity. However, ER60A-ER60H catalyzed cleavage of themselves and the endoplasmic reticulum proteins protein disulfide-isomerase and calreticulin. Proteolytic degradation was inhibited by p-chloromercuribenzoate. These results indicate that ER60A-ER60H comprise a group of endoplasmic reticulum resident proteins and show thiol group-related proteolytic activity.	KYOTO UNIV,FOOD SCI RES INST,UJI,KYOTO 611,JAPAN	Kyoto University								BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BENNETT CF, 1987, J BIOL CHEM, V262, P13789; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; CHUN KT, 1990, J BIOL CHEM, V265, P22004; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HAUGEJORDEN SM, 1991, J BIOL CHEM, V266, P6015; INOUE S, 1992, J BIOL CHEM, V267, P9080; INOUE S, 1991, J BIOL CHEM, V266, P13311; KASCHNITZ R, 1969, ANAL BIOCHEM, V30, P148; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KLAUSNER RD, 1991, CELL, V113, P997; KOCH GLE, 1987, J CELL SCI, V87, P491; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACER DRJ, 1988, J CELL SCI, V91, P61; MARTIN JL, 1991, BIOCHEM BIOPH RES CO, V178, P679, DOI 10.1016/0006-291X(91)90161-Y; MENTLEIN R, 1987, BIOCHIM BIOPHYS ACTA, V913, P27, DOI 10.1016/0167-4838(87)90228-7; MENTLEIN R, 1988, BIOCHIM BIOPHYS ACTA, V964, P319, DOI 10.1016/0304-4165(88)90032-3; MILLS ENC, 1983, BIOCHEM J, V213, P245, DOI 10.1042/bj2130245; MOORE S, 1963, J BIOL CHEM, V238, P235; MORIYAMA T, 1990, J BIOCHEM-TOKYO, V108, P414, DOI 10.1093/oxfordjournals.jbchem.a123215; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; MURTHY KK, 1990, NUCLEIC ACIDS RES, V18, P4933, DOI 10.1093/nar/18.16.4933; MURTHY LR, 1991, ANAL BIOCHEM, V193, P299, DOI 10.1016/0003-2697(91)90025-O; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAJOT P, 1976, EUR J BIOCHEM, V63, P263, DOI 10.1111/j.1432-1033.1976.tb10228.x; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; SHELNESS GS, 1988, J BIOL CHEM, V263, P17063; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; SRIVASTAVA SP, 1991, J BIOL CHEM, V266, P20337; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; TOMPKINS TA, 1991, J BIOL CHEM, V266, P4228	35	110	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15152	15159						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321829				2022-12-27	WOS:A1992JF08800095
J	KAHAN, C; SEUWEN, K; MELOCHE, S; POUYSSEGUR, J				KAHAN, C; SEUWEN, K; MELOCHE, S; POUYSSEGUR, J			COORDINATE, BIPHASIC ACTIVATION OF P44 MITOGEN-ACTIVATED PROTEIN-KINASE AND S6 KINASE BY GROWTH-FACTORS IN HAMSTER FIBROBLASTS - EVIDENCE FOR THROMBIN-INDUCED SIGNALS DIFFERENT FROM PHOSPHOINOSITIDE TURNOVER AND ADENYLYLCYCLASE INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL PROTEIN-S6; ADENYLATE-CYCLASE; LUNG FIBROBLASTS; PERTUSSIS TOXIN; LATE PHASE; PHOSPHORYLATION; INSULIN; STIMULATION; CAMP; EXPRESSION	In CCL39 cells transfected with m1-muscarinic receptors, carbachol stimulates phosphoinositide turnover and early events associated with mitogenesis as efficiently as thrombin but, in contrast to thrombin, fails to induce cell proliferation (Seuwen, K., Kahan, C., Hartmann, T., and Pouyssegur, J. (1990) J. Biol. Chem. 265, 22292-22299). We show here that the action of the two agents can be dissociated at the level of S6 kinase and mitogen-activated protein kinase (MAP kinase) activation. Mitogenic concentrations of thrombin and basic FGF were found to stimulate S6 kinase activity, measured in whole cell lysates, with a biphasic time course; an early peak of activity is induced 10 min following stimulation and a sustained phase of activity can be measured over several hours. A very similar profile emerged for p44 MAP kinase (p44mapk), assayed in immunoprecipitates. In this case, the activity first peaks at 6-8 min, preceding S6 kinase. In contrast to thrombin and FGF, carbachol stimulates S6 kinase and MAP kinase only transiently, corresponding to the first peak of activity, but the sustained phase is not observed. Similarly, phorbol dibutyrate induces an early phase of activity only. Pertussis toxin (PTX), which is known to block thrombin mitogenicity efficiently, inhibited the first peak of thrombin-induced S6 kinase and MAP kinase activity only partially, but totally blocked the sustained phase. The toxin had no effect on FGF-induced kinase activities. The cAMP elevating hormone PGE1 did not inhibit p44mapk or S6 kinase activation by thrombin or FGF, demonstrating that the PTX-sensitive signal generated by thrombin does not depend on a G(i)-mediated sustained inhibition of adenylylcyclase. Surprisingly, PGE1 was found to stimulate sustained phase S6 kinase activity both alone and in synergy with FGF or thrombin. This result, as well as the biphasic activation of S6 kinase by thrombin, could be qualitatively reproduced in immunocomplex kinase assays using an antiserum immunoprecipitating p70 S6 kinase (p70S6k). Our data show that activation of phosphoinositide turnover and PKC does not quantitatively explain thrombin action, in particular the sustained phase of kinase activities, which critically depends on a PTX-sensitive signal different from adenylylcyclase inhibition. We postulate that this signal does not exclusively originate from the recently identified G protein-coupled thrombin receptor.			KAHAN, C (corresponding author), FAC SCI NICE,CNRS,CTR BIOCHIM,PARC VALROSE,F-06108 NICE 2,FRANCE.							AHN NG, 1991, J BIOL CHEM, V266, P4220; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; ELBRECHT A, 1990, J BIOL CHEM, V265, P13415; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FERRARI S, 1991, J BIOL CHEM, V266, P22770; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KAHAN C, 1992, IN PRESS EXP CELL RE; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOHNO M, 1986, BIOCHEM J, V238, P451, DOI 10.1042/bj2380451; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LANE HA, 1992, IN PRESS EMBO J; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAGNALDO I, 1989, CELL SIGNAL, V1, P507, DOI 10.1016/0898-6568(89)90035-1; MAGNALDO I, 1988, BIOCHEM J, V253, P711, DOI 10.1042/bj2530711; MAGNALDO I, 1989, FEBS LETT, V245, P65, DOI 10.1016/0014-5793(89)80193-0; MANGALDO I, 1986, J BIOL CHEM, V261, P16916; MARTINPEREZ J, 1984, CELL, V36, P287, DOI 10.1016/0092-8674(84)90222-8; MECHTA F, 1989, New Biologist, V1, P297; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; PALEN E, 1987, J BIOL CHEM, V262, P3518; PARIS S, 1988, J BIOL CHEM, V263, P12893; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; PARIS S, 1988, J BIOL CHEM, V263, P11250; PEREZRODRIGUEZ R, 1981, CELL BIOL INT REP, V5, P347, DOI 10.1016/0309-1651(81)90004-7; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; RANGAN LA, 1991, CELL REGUL, V2, P311, DOI 10.1091/mbc.2.4.311; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RUOSS SJ, 1991, J CLIN INVEST, V88, P493, DOI 10.1172/JCI115330; SEUWEN K, 1992, ADV CANCER RES, V58, P75, DOI 10.1016/S0065-230X(08)60291-2; SEUWEN K, 1990, BIOCHEM PHARMACOL, V39, P985, DOI 10.1016/0006-2952(90)90276-Q; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUSA M, 1990, P NATL ACAD SCI USA, V87, P7040, DOI 10.1073/pnas.87.18.7040; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; SWEET LJ, 1990, MOL CELL BIOL, V10, P2787, DOI 10.1128/MCB.10.6.2787; THOMAS G, 1978, J BIOL CHEM, V253, P1101; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; VANOBBERGHENSCHILLING E, 1991, MOL ENDOCRINOL, V5, P881, DOI 10.1210/mend-5-7-881; VANOBBERGHENSCHILLING E, 1985, EMBO J, V4, P2927, DOI 10.1002/j.1460-2075.1985.tb04025.x; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WETTENHALL REH, 1984, J BIOL CHEM, V259, P2084	56	239	239	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13369	13375						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320018				2022-12-27	WOS:A1992JB74600045
J	MARTIN, JF; LI, L; OLSON, EN				MARTIN, JF; LI, L; OLSON, EN			REPRESSION OF MYOGENIN FUNCTION BY TGF-BETA-1 IS TARGETED AT THE BASIC HELIX-LOOP-HELIX MOTIF AND IS INDEPENDENT OF E2A PRODUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH-FACTOR; BRONCHIAL EPITHELIAL-CELLS; CREATINE-KINASE GENE; FACTOR-BETA; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; NUCLEAR FACTOR; SERUM FACTOR; EXPRESSION; DIFFERENTIATION	The muscle-specific helix-loop-helix (HLH) proteins myogenin, MyoD, myf5, and MRF4 form hetero-oligomers with ubiquitous HLH proteins encoded by the E2A gene and activate muscle transcription by binding to a DNA sequence known as an E-box (CANNTG). Transforming growth factor-beta (TGF-beta) can inhibit muscle differentiation by silencing the transcription-activating potential of myogenic HLH proteins without affecting their ability to bind DNA. We show that repression by TGF-beta is directed at the basic-HLH motif of myogenin and is independent of E2A products. Using a series of reporter genes as targets for trans-activation by myogenin, transcriptional repression by TGF-beta is also shown to map to the E-box motif and to not require heterologous DNA sequence elements. These results demonstrate that TGF-beta represses muscle-specific transcription through a post-translational mechanism that renders the basic-HLH regions of the myogenic regulators nonfunctional. The selective repression of myogenic HLH proteins by TGF-beta indicates that the TGF-beta signaling system can discriminate between different classes of HLH proteins and implies that myogenic HLH proteins activate muscle-specific transcription through a unique mechanism.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center								BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLACKWELL TK, 1990, SCIENCE, V251, P1211; BRAUN T, 1990, NATURE, V346, P663, DOI 10.1038/346663a0; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN T, 1991, P NATL ACAD SCI USA, V88, P929; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1991, J BIOL CHEM, V266, P21343; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FAUSTO N, 1987, S FUNDAM CANCER RES, V39, P69; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FLORINI JR, 1986, J BIOL CHEM, V261, P6509; HEIMARK RL, 1986, SCIENCE, V233, P1078, DOI 10.1126/science.3461562; HEINO J, 1990, J BIOL CHEM, V265, P10181; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HOLLEY RW, 1983, CELL BIOL INT REP, V7, P141, DOI 10.1016/0309-1651(83)90027-9; HOOSEIN NM, 1987, CANCER RES, V47, P2950; IGNOTZ RA, 1985, P NATL ACAD SCI USA, V82, P8530, DOI 10.1073/pnas.82.24.8530; KEHRL JH, 1986, J IMMUNOL, V137, P3855; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIM SJ, 1989, J BIOL CHEM, V264, P7041; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1990, J BIOL CHEM, V265, P1556; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1986, J BIOL CHEM, V261, P9483; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SAUDNERS KB, 1991, CRIT REV EUKARYOTIC, V1, P157; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; SEONGJIN K, 1990, MOL CELL BIOL, V10, P1492; SPIZZ G, 1987, DEV BIOL, V123, P500, DOI 10.1016/0012-1606(87)90408-8; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YUTZEY EE, 1991, MOL CELL BIOL, V10, P3934	52	74	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10956	10960						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317849				2022-12-27	WOS:A1992HX16900007
J	ABBOTT, AM; BUENO, R; PEDRINI, MT; MURRAY, JM; SMITH, RJ				ABBOTT, AM; BUENO, R; PEDRINI, MT; MURRAY, JM; SMITH, RJ			INSULIN-LIKE GROWTH FACTOR-I RECEPTOR GENE STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; SEQUENCE; PROMOTER; FAMILY	The insulin-like growth factor I (IGF I) receptor is a tyrosine kinase-containing transmembrane protein that plays an important role in cell growth control. We have isolated and characterized human genomic DNA clones containing the entire coding sequence of the IGF I receptor. Results of restriction analysis and sequencing of multiple overlapping clones were consistent with the existence of a single IGF I receptor gene. The complete receptor coding sequence is contained in 21 exons. There is striking homology with the insulin receptor gene in overall size (approximately 100 kilobases) and in the number and size of individual exons. An exon analogous to the alternatively spliced exon 11 of the insulin receptor gene could not be detected. An alternative internal splice site corresponding to a known alternatively spliced mRNA transcript was shown to be located at the 5' end of exon 14. Knowledge of the structure of the IGF I receptor gene should facilitate further studies on the structural determinants of receptor function, the relationships between insulin and IGF I receptors, and the molecular basis for multiple IGF I receptor species.	JOSLIN DIABET CTR,DIV RES,ELLIOT P JOSLIN RES LAB,1 JOSLIN PL,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK36836, DK07260] Funding Source: Medline; NIGMS NIH HHS [GM36428] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, T32DK007260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM036428] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDRIDES TK, 1989, J BIOL CHEM, V264, P12922; ARAKI E, 1991, J BIOL CHEM, V266, P3944; BARNES WM, 1983, METHOD ENZYMOL, V101, P98; CHERNAUSEK SD, 1981, BIOCHEMISTRY-US, V20, P7345, DOI 10.1021/bi00529a004; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOKE DW, 1991, BIOCHEM BIOPH RES CO, V177, P1113, DOI 10.1016/0006-291X(91)90654-P; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; LIM HM, 1988, GENE ANAL TECH, V5, P32, DOI 10.1016/0735-0651(88)90024-6; MAMULA PW, 1988, DIABETES, V37, P1241, DOI 10.2337/diabetes.37.9.1241; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; MOSTHAF L, 1991, P NATL ACAD SCI USA, V88, P4728, DOI 10.1073/pnas.88.11.4728; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEINO S, 1989, BIOCHEM BIOPH RES CO, V159, P312, DOI 10.1016/0006-291X(89)92439-X; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SHIER P, 1989, J BIOL CHEM, V264, P14605; SORGE JA, 1988, VECTORS SURVEY MOL C, P43; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; YEE D, 1989, J BIOL CHEM, V264, P21439	26	119	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10759	10763						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1316909				2022-12-27	WOS:A1992HV09000083
J	GRINDE, B; CAMERON, CE; LEIS, J; WEBER, IT; WLODAWER, A; BURSTEIN, H; BIZUB, D; SKALKA, AM				GRINDE, B; CAMERON, CE; LEIS, J; WEBER, IT; WLODAWER, A; BURSTEIN, H; BIZUB, D; SKALKA, AM			MUTATIONS THAT ALTER THE ACTIVITY OF THE ROUS-SARCOMA VIRUS PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; AVIAN RETROVIRAL PROTEASE; SYNTHETIC HIV-1 PROTEASE; CRYSTAL-STRUCTURE; ASPARTIC PROTEASES; POL POLYPROTEINS; ESCHERICHIA-COLI; 2-A RESOLUTION; INHIBITOR; COMPLEX	Mutations designed by analysis of the Rous sarcoma virus (RSV) and human immunodeficiency virus (HIV)-1 protease (PR) crystal structures were introduced into 1) the substrate binding pocket, 2) the substrate enclosing "flaps," and 3) surface loops of RSV PR. Each mutant PR was expressed in Escherichia coli. Changes in activity were detected by following cleavage of a truncated (NC-PR) precursor polypeptide in E. coli and cleavage of synthetic peptide substrates representing RSV and HIV-1 PR cleavage sites in vitro. Mutations in the substrate binding pocket exchanged amino acid residues located close to the substrate in the HIV-1 PR for structurally equivalent residues in the RSV PR. Changing histidine 65 to glycine (H65G) gave an inactive enzyme, while a double mutant R105P,G106V, as well as the triple mutant, H65G,R105P,G106V, produced enzymes which showed significant activity toward a substrate that represented a HIV-1 cleavage site. Mutating the catalytic aspartate (D37S) or an adjacent conserved alanine to threonine (A40T), produced inactive enzymes. In contrast, the substitution A40S was active, but showed a reduced rate of catalysis. Mutations in the flaps of conserved glycines (G69L, G70L) produced inactive PRs. Two extended RSV PR surface loops were shortened to the size found in HIV-1 PR and resulted in drastically reduced activity. These results have confirmed some of the basic predictions made from structural models but have also revealed unexpected roles and interactions in the protein.	CASE WESTERN RESERVE UNIV, SCH MED, CLEVELAND, OH 44106 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA; FOX CHASE CANC INST, INST CANC RES, PHILADELPHIA, PA 19111 USA	Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Fox Chase Cancer Center					NATIONAL CANCER INSTITUTE [P30CA006927, R01CA038046, R35CA047486] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927, CA47486, CA38046] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER F, 1987, J VIROL, V61, P534, DOI 10.1128/JVI.61.2.534-542.1987; ANDREEVA NS, 1984, J BIOL CHEM, V259, P1353; BIZUB D, 1991, J BIOL CHEM, V266, P4951; BLUNDELL TL, 1985, ASPARTIC PROTEINASES, P151; CRAVEN RC, 1991, J VIROL, V65, P6205, DOI 10.1128/JVI.65.11.6205-6217.1991; CRAWFORD S, 1985, J VIROL, V53, P899, DOI 10.1128/JVI.53.3.899-907.1985; DARKE PL, 1988, BIOCHEM BIOPH RES CO, V156, P297, DOI 10.1016/S0006-291X(88)80839-8; DICKSON C, 1984, RNA TUMOR VIRUSES, V1, P513; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; FOLTMANN B, 1988, 18TH P LIND LANG C A, P7; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GRINDE B, 1992, J BIOL CHEM, V267, P9491; GUSTCHINA A, 1990, FEBS LETT, V269, P269, DOI 10.1016/0014-5793(90)81171-J; JASKOLSKI M, 1990, BIOCHEMISTRY-US, V29, P5889, DOI 10.1021/bi00477a002; JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KOHL N, 1988, P NATL ACAD SCI USA, V85, P4185; KOTLER M, 1989, J BIOL CHEM, V264, P3428; KOTLER M, 1988, J VIROL, V62, P2696, DOI 10.1128/JVI.62.8.2696-2700.1988; KOTLER M, 1988, P NATL ACAD SCI USA, V85, P4185, DOI 10.1073/pnas.85.12.4185; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPATTO P, 1989, NATURE, V342, P299; LEIS J, 1989, CURRENT COMMUNICATIO, P235; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; MANTAFOUNIS D, 1990, PROTEIN ENG, V3, P605, DOI 10.1093/protein/3.7.605; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; MOUS J, 1988, J VIROL, V62, P1433, DOI 10.1128/JVI.62.4.1433-1436.1988; OROSZLAN S, 1990, SEMINARS VIROL, V1, P369; SEELMEIER S, 1988, P NATL ACAD SCI USA, V85, P6612, DOI 10.1073/pnas.85.18.6612; SIELECKI AR, 1989, SCIENCE, V243, P1346, DOI 10.1126/science.2493678; SKALKA AM, 1989, CELL, V56, P911, DOI 10.1016/0092-8674(89)90621-1; STROP P, 1991, BIOCHEMISTRY-US, V30, P3437, DOI 10.1021/bi00228a013; SUGUNA K, 1987, J MOL BIOL, V196, P877, DOI 10.1016/0022-2836(87)90411-6; SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P14675; WEBER IT, 1989, SCIENCE, V243, P928, DOI 10.1126/science.2537531; WEBER IT, 1990, J BIOL CHEM, V265, P10492; WEBER IT, 1989, GENE, V85, P565, DOI 10.1016/0378-1119(89)90453-8; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; WLODAWER A, 1991, ADV LIF SCI, P215	42	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9481	9490						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315755				2022-12-27	WOS:A1992HT96500009
J	PORT, JD; HADCOCK, JR; MALBON, CC				PORT, JD; HADCOCK, JR; MALBON, CC			CROSS-REGULATION BETWEEN G-PROTEIN-MEDIATED PATHWAYS - ACUTE ACTIVATION OF THE INHIBITORY PATHWAY OF ADENYLYLCYCLASE REDUCES BETA-2-ADRENERGIC RECEPTOR PHOSPHORYLATION AND INCREASES BETA-ADRENERGIC RESPONSIVENESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; DESENSITIZATION	Cross-regulation from the stimulatory to the inhibitory adenylylcyclase pathways has been described (Hadcock, J. R., Ros, M., Watkins, D. C., and Malbon, C. C. (1990) J. Biol. Chem. 265,14784-14790). More recently, persistent activation (48 h) of the inhibitory adenylylcyclase pathway has been shown to cross-regulate the stimulatory pathway (i) enhancing the maximal response of beta-adrenergic agonists, (ii) increasing the expression of beta-adrenergic receptor, and (iii) reducing the ED50 for the isoproterenol-stimulated response by 50-fold (Hadcock, J. R., Port, J. D., and Malbon, C. C. (1991) J. Biol. Chem. 266, 11915-11922). Here, we report that short term activation (60 min) of the inhibitory adenylylcyclase pathway of hamster smooth muscle DDT1MF-2 cells with the A1-adenosine receptor agonist N6-phenylisopropyladenosine (PIA) likewise enhances the stimulatory adenylylcyclase response to the beta-adrenergic agonist isoproterenol. The PIA effect was exerted at the level of the receptor, i.e. the beta-adrenergic receptor-mediated response was enhanced, whereas the guanosine 5'-O-(thiotriphosphate)- and forskolin-stimulated adenylylcyclase activities were largely unaffected. In contrast to longer term persistent activation of the inhibitory pathway, receptor number and affinity for I-125-labeled cyanopindolol were unaffected. Metabolic labeling of cells with [P-32]orthophosphate and immuneprecipitation of beta-adrenergic receptors detected phosphorylation of the receptor in unstimulated cells and marked phosphorylation in cells challenged with epinephrine. When cells were challenged short term with PIA, the basal state of beta-adrenergic receptor phosphorylation was reduced by 75%. Treating cells with PIA in combination with the cAMP analog 8-(4-chlorophenylthio)adenosine cyclic AMP attenuated the enhanced receptor-mediated adenylylcyclase response observed in cells treated with PIA alone. These data suggest that short term cross-regulation from the inhibitory to stimulatory adenylylcyclase pathways results in the following: (i) decreased intracellular cAMP levels and protein kinase A activity, (ii) reduced phosphorylation of the beta-2-adrenergic receptor in the "basal" (i.e. unstimulated) state, and (iii) enhanced receptor-mediated activation of G(s).	SUNY STONY BROOK,HLTH SCI CTR,SCH MED,DEPT PHARMACOL DIABET & METAB DIS,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			malbon, craig/ABF-3604-2020	Port, Jonathan D./0000-0001-7048-3544	NIADDK NIH HHS [K04 AM00786] Funding Source: Medline; NIDDK NIH HHS [T32 DK07521, DK25410] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007521, R01DK025410] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CLARK RB, 1988, P NATL ACAD SCI USA, V85, P5021; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HADCOCK JR, 1991, J BIOL CHEM, V266, P11915; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; HADCOCK JR, 1989, J BIOL CHEM, V264, P13956; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HADCOCK JR, 1991, TRENDS NEUROSCI, V14, P242, DOI 10.1016/0166-2236(91)90124-D; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORRIS GM, 1991, J BIOL CHEM, V266, P2233; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; SAKAUE M, 1991, J BIOL CHEM, V266, P5743; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCARPACE PJ, 1985, MOL PHARMACOL, V28, P495; SMITH DE, 1987, J CELL BIOL, V105, P771, DOI 10.1083/jcb.105.2.771; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; Wang H Y, 1990, Receptor, V1, P13; WANG HY, 1989, BIOCHEM J, V263, P519, DOI 10.1042/bj2630519; WANG HY, 1989, J BIOL CHEM, V264, P14424; WATKINS DC, 1989, J BIOL CHEM, V264, P4186	22	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8468	8472						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314828				2022-12-27	WOS:A1992HQ18500079
J	KAMIBAYASHI, C; LICKTEIG, RL; ESTES, R; WALTER, G; MUMBY, MC				KAMIBAYASHI, C; LICKTEIG, RL; ESTES, R; WALTER, G; MUMBY, MC			EXPRESSION OF THE A-SUBUNIT OF PROTEIN PHOSPHATASE-2A AND CHARACTERIZATION OF ITS INTERACTIONS WITH THE CATALYTIC AND REGULATORY SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; LIGHT CHAIN KINASE; DNA-REPLICATION INVITRO; MEDIUM TUMOR-ANTIGEN; MOLECULAR-CLONING; CELLULAR-REGULATION; SEQUENCE-ANALYSIS; CDNA; PURIFICATION; FORMS	The alpha form of the A subunit of human protein phosphatase 2A was expressed in insect cells following infection with a recombinant baculovirus. Aalpha was expressed as a soluble protein that comprised approximately 10% of total cellular protein. The expressed Aalpha subunit was purified by chromatography on amino-hexyl-Sepharose and Mono Q with a yield of 2 mg/500-ml culture. The recombinant protein had the same apparent molecular mass as the bovine cardiac protein and was devoid of myosin light chain phosphatase activity. Biological activity of expressed A was assessed by assays of complex formation with the catalytic (C) and B subunits, purified from bovine cardiac tissue, and by inhibition of phosphatase activity. Purified Aalpha had a high apparent affinity for C (IC50 = 0.10 nM) and bound with a stoichiometry of 1 mol of A/mol of C. Interaction of Aalpha with the catalytic subunit caused a maximal inhibition of myosin light chain and phosphorylase phosphatase activities of 50 and 79%, respectively. The AC complex prepared by reconstitution of recombinant Aalpha with C had the same electrophoretic mobility in nondenaturing polyacrylamide gels and the same elution volume when chromatographed on a size exclusion column as the native AC complex purified from cardiac muscle. Similar chromatographic profiles were also observed for the heterotrimer reconstituted from recombinant Aalpha, purified B and C, and the native bovine cardiac heterotrimeric holoenzyme. Cross-linking of the native enzyme and the reconstituted hetero-trimer generated the same pattern of high molecular weight species. Immunological analyses of these complexes demonstrated that distinct cross-linked forms composed of ABC, AC, AB, and BC were obtained. These results suggest that each of the three subunits of protein phosphatase 2A forms direct contacts with both of the others.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R01CA054726] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031107] Funding Source: NIH RePORTER; NCI NIH HHS [CA54726] Funding Source: Medline; NHLBI NIH HHS [HL31107] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; BERNDT N, 1990, EUR J BIOCHEM, V190, P291, DOI 10.1111/j.1432-1033.1990.tb15575.x; BLISS CI, 1970, STATISTICS BIOL; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BLUMENTHAL DK, 1982, BIOCHEMISTRY-US, V21, P2386, DOI 10.1021/bi00539a017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN SC, 1989, J BIOL CHEM, V264, P7267; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; IMAOKA T, 1983, J BIOL CHEM, V258, P1526; IMAOKA T, 1980, BIOCHIM BIOPHYS ACTA, V612, P73, DOI 10.1016/0005-2744(80)90280-6; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; KITAGAWA Y, 1988, BIOCHIM BIOPHYS ACTA, V951, P123, DOI 10.1016/0167-4781(88)90032-2; KITAGAWA Y, 1988, BIOCHEM BIOPH RES CO, V157, P821, DOI 10.1016/S0006-291X(88)80323-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; MUMBY MC, 1985, J BIOL CHEM, V260, P3763; NUNNALLY MH, 1985, J BIOL CHEM, V260, P1020; ORGAD S, 1990, FEBS LETT, V275, P44, DOI 10.1016/0014-5793(90)81435-Q; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PARIS H, 1984, J BIOL CHEM, V259, P7510; PATO MD, 1986, J BIOL CHEM, V261, P3770; REED L. J., 1938, AMER JOUR HYG, V27, P493; Sambrook J, 1989, MOL CLONING LABORATO; SHENOLIKAR S, 1991, ADV 2ND MESSENGER PH, V23, P1; SILVA OBD, 1987, FEBS LETT, V221, P415, DOI 10.1016/0014-5793(87)80966-3; SILVA OBDC, 1987, FEBS LETT, V226, P176; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; STONE SR, 1988, NUCLEIC ACIDS RES, V16, P11365, DOI 10.1093/nar/16.23.11365; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TAMARU S, 1980, EUR J BIOCHEM, V104, P347; THOEN C, 1987, EUR J BIOCHEM, V163, P503, DOI 10.1111/j.1432-1033.1987.tb10897.x; TUNG HYL, 1984, EUR J BIOCHEM, V145, P57, DOI 10.1111/j.1432-1033.1984.tb08521.x; TUNG HYL, 1985, EUR J BIOCHEM, V148, P253, DOI 10.1111/j.1432-1033.1985.tb08833.x; USUI H, 1988, J BIOL CHEM, V263, P3752; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; VIRSHUP DM, 1989, P NATL ACAD SCI USA, V86, P3584, DOI 10.1073/pnas.86.10.3584; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	49	68	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21864	21872						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328247				2022-12-27	WOS:A1992JV01100093
J	KIMURA, S; NAKAMURA, H; HASHIMOTO, T; OOBATAKE, M; KANAYA, S				KIMURA, S; NAKAMURA, H; HASHIMOTO, T; OOBATAKE, M; KANAYA, S			STABILIZATION OF ESCHERICHIA-COLI RIBONUCLEASE HI BY STRATEGIC REPLACEMENT OF AMINO-ACID-RESIDUES WITH THOSE FROM THE THERMOPHILIC COUNTERPART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCED PROTEIN THERMOSTABILITY; SITE-DIRECTED MUTAGENESIS; L-LACTATE DEHYDROGENASES; DISULFIDE BOND; RNASE-H; ENGINEERING THERMOSTABILITY; MESOPHILIC BACTERIA; STABILITY; BINDING; GENE	Thermus thermophilus ribonuclease H is exceptionally stable against thermal and guanidine hydrochloride denaturations as compared to Escherichia coli ribonuclease HI (Kanaya, S., and Itaya, M. (1992) J. Biol. Chem. 267, 10184-10192). The identity in the amino acid sequences of these enzymes is 52%. As an initial step to elucidate the stabilization mechanism of the thermophilic RNase H, we examined whether certain regions in its amino acid sequence confer the thermostability. A variety of mutant proteins of E. coli RNase HI were constructed and analyzed for protein stability. In these mutant proteins, amino acid sequences in loops or terminal regions were systematically replaced with the corresponding sequences from T. thermophilus RNase H. Of the nine regions examined, replacement of the amino acid sequence in each of four regions (R4-R7) resulted in an increase in protein stability. Simultaneous replacements of these amino acid sequences revealed that the effect of each replacement on protein stability is independent of each other and cumulative. Replacement of all four regions (R4-R7) gave the most stable mutant protein. The temperature of the midpoint of the transition in the thermal unfolding curve and the free energy change of unfolding in the absence of denaturant of this mutant protein were increased by 16.7-degrees-C and 3.66 kcal/mol, respectively, as compared to those of E. coli RNase HI. These results suggest that individual local interactions contribute to the stability of thermophilic proteins in an independent manner, rather than in a cooperative manner.	PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN				Nakamura, Haruki/O-4028-2014					ALBER T, 1987, NATURE, V330, P41, DOI 10.1038/330041a0; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BERKOWER I, 1973, J BIOL CHEM, V248, P5914; BIRO J, 1990, FEBS LETT, V275, P130, DOI 10.1016/0014-5793(90)81456-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P863; CARUTHERS MH, 1985, SCIENCE, V230, P281, DOI 10.1126/science.3863253; Crouch R. J., 1982, NUCLEASES, P211; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; IMANAKA T, 1986, NATURE, V324, P695, DOI 10.1038/324695a0; ITAYA M, 1991, NUCLEIC ACIDS RES, V19, P4443, DOI 10.1093/nar/19.16.4443; ITAYA M, 1990, P NATL ACAD SCI USA, V87, P8587, DOI 10.1073/pnas.87.21.8587; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KANAYA S, 1992, J BIOL CHEM, V267, P10184; KANAYA S, 1989, J BIOL CHEM, V264, P11546; KANAYA S, 1983, J BIOL CHEM, V258, P1276; KANAYA S, 1991, J BIOL CHEM, V266, P6038; KANAYA S, 1991, EUR J BIOCHEM, V198, P437, DOI 10.1111/j.1432-1033.1991.tb16033.x; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KIMURA S, 1992, EUR J BIOCHEM, V206, P337, DOI 10.1111/j.1432-1033.1992.tb16932.x; KUROKI R, 1989, P NATL ACAD SCI USA, V86, P6903, DOI 10.1073/pnas.86.18.6903; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MATSUMURA M, 1986, NATURE, V323, P356, DOI 10.1038/323356a0; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MILLER HI, 1973, J BIOL CHEM, V248, P2621; Miller J. H., 1972, EXPT MOL GENETICS, P433; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; NICHOLSON H, 1988, NATURE, V336, P651, DOI 10.1038/336651a0; OSHIMA T, 1986, PROTEIN ENG APPLICAT, P81; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; PAKULA AA, 1990, NATURE, V344, P363, DOI 10.1038/344363a0; PANTOLIANO MW, 1989, BIOCHEMISTRY-US, V28, P7205, DOI 10.1021/bi00444a012; PERRY LJ, 1984, SCIENCE, V226, P555, DOI 10.1126/science.6387910; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; STEARMAN RS, 1988, BIOCHEMISTRY-US, V27, P7571, DOI 10.1021/bi00419a059; SUZUKI Y, 1989, J BIOL CHEM, V264, P18933; TAKAGI H, 1990, J BIOL CHEM, V265, P6874; TOGAYA M, 1989, J BIOL CHEM, V264, P990; TOMA S, 1991, BIOCHEMISTRY-US, V30, P97, DOI 10.1021/bi00215a015; WATANABE K, 1991, J BIOL CHEM, V266, P24287; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; YUTANI K, 1991, PROTEINS, V9, P90, DOI 10.1002/prot.340090203; ZULLI F, 1990, BIOL CHEM H-S, V371, P655, DOI 10.1515/bchm3.1990.371.2.655; ZULLI F, 1991, BIOL CHEM H-S, V372, P363, DOI 10.1515/bchm3.1991.372.1.363	50	69	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21535	21542						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328237				2022-12-27	WOS:A1992JV01100044
J	HACKER, KJ; ALBERTS, BM				HACKER, KJ; ALBERTS, BM			OVEREXPRESSION, PURIFICATION, SEQUENCE-ANALYSIS, AND CHARACTERIZATION OF THE BACTERIOPHAGE-T4 DDA DNA HELICASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-RECOMBINATION; ESCHERICHIA-COLI; REPLICATION APPARATUS; RNA REPLICATION; GENE-41 PROTEIN; BINDING; SYSTEM; MUTANTS; SUPERFAMILY; EXPRESSION	The bacteriophage T4 dda protein is a 5'-3' DNA helicase that stimulates DNA replication and recombination reactions in vitro and seems to play a role in the initiation of T4 DNA replication in vivo. Oligonucleotide probes based on NH2-terminal amino acid sequence were used to precisely map the location of the dda gene on the T4 chromosome. Using polymerase chain reaction techniques, the dda gene was then cloned into an expression vector, and the overproduced protein was purified in two chromatography steps. Both the genomic and cloned dda genes were sequenced and found to be identical, encoding a protein of 439 amino acids. The dda protein contains amino acid sequences resembling those of other known helicases, and is most homologous to the Escherichia coli recD protein. Protein affinity chromatography was used to show a direct interaction between the dda protein and the T4 uvsX protein (a rec A-type DNA recombinase).	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [T32CA009270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024020, R37GM024020] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA09270] Funding Source: Medline; NIGMS NIH HHS [GM24020] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ALBERTS BM, 1980, ICN UCLA S MOL CELL, V19, P449; ALTSCHUL SF, 1986, B MATH BIOL, V48, P603, DOI 10.1016/S0092-8240(86)90010-8; ARGOS P, 1990, METHOD ENZYMOL, V183, P352; BARKER WC, 1972, ATLAS PROTEIN SEQUEN, P101; BEHME MT, 1975, J VIROL, V15, P50, DOI 10.1128/JVI.15.1.50-54.1975; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUDHURY AM, 1984, P NATL ACAD SCI-BIOL, V81, P7850, DOI 10.1073/pnas.81.24.7850; CUNNINGHAM RP, 1977, VIROLOGY, V80, P67, DOI 10.1016/0042-6822(77)90381-6; DEBRECENI N, 1970, BIOCHEM BIOPH RES CO, V41, P115, DOI 10.1016/0006-291X(70)90476-6; DOHERTY DH, 1982, MOL GEN GENET, V188, P77, DOI 10.1007/BF00332998; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FORMOSA T, 1984, COLD SPRING HARB SYM, V49, P363, DOI 10.1101/SQB.1984.049.01.043; FORMOSA T, 1985, THESIS U CALIFORNIA; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GAUSS P, 1987, MOL GEN GENET, V206, P24, DOI 10.1007/BF00326532; GORBALENYA AE, 1988, FEBS LETT, V235, P16, DOI 10.1016/0014-5793(88)81226-2; HODGMAN TC, 1986, NUCLEIC ACIDS RES, V14, P6769, DOI 10.1093/nar/14.16.6769; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; JONGENEEL CV, 1984, J BIOL CHEM, V259, P2933; JONGENEEL CV, 1984, J BIOL CHEM, V259, P2925; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KODADEK T, 1987, NATURE, V326, P312, DOI 10.1038/326312a0; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; KRELL H, 1979, J BIOL CHEM, V93, P387; KREUZER KN, 1985, P NATL ACAD SCI USA, V82, P3345, DOI 10.1073/pnas.82.10.3345; KREUZER KN, 1988, J BIOL CHEM, V263, P11348; Kutter E., 1983, BACTERIOPHAGE T4, P277; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LIN TC, 1987, P NATL ACAD SCI USA, V84, P7000, DOI 10.1073/pnas.84.20.7000; LITTLE JW, 1973, VIROLOGY, V53, P47, DOI 10.1016/0042-6822(73)90464-9; LIU CC, 1981, J BIOL CHEM, V256, P2813; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; LIU CC, 1981, J BIOL CHEM, V256, P2821; LOVETT ST, 1988, GENETICS, V120, P37; Maniatis T., 1982, MOL CLONING; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; Maxam A M, 1980, Methods Enzymol, V65, P499; MCPHEETERS DS, 1986, NUCLEIC ACIDS RES, V14, P5813, DOI 10.1093/nar/14.14.5813; MENKENS AE, 1988, J BIOL CHEM, V263, P11358; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; NEIDHARDT FC, 1984, ANNU REV GENET, V18, P295, DOI 10.1146/annurev.ge.18.120184.001455; NELSON MA, 1982, MOL GEN GENET, V188, P69, DOI 10.1007/BF00332997; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; PRIBNOW D, 1981, J MOL BIOL, V149, P337, DOI 10.1016/0022-2836(81)90477-0; PURKEY RM, 1977, EUR J BIOCHEM, V75, P303, DOI 10.1111/j.1432-1033.1977.tb11530.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELICK HE, 1988, J BIOL CHEM, V263, P11336; SHINEDLING S, 1987, J VIROL, V61, P3790, DOI 10.1128/JVI.61.12.3790-3794.1987; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; TELANDERMUSKAVI.KM, 1981, ENZYMES, V14, P233; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	56	33	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20674	20681						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328208				2022-12-27	WOS:A1992JT97800027
J	LEE, YS; MARKS, AR; GURECKAS, N; LACRO, R; NADALGINARD, B; KIM, DH				LEE, YS; MARKS, AR; GURECKAS, N; LACRO, R; NADALGINARD, B; KIM, DH			PURIFICATION, CHARACTERIZATION, AND MOLECULAR-CLONING OF A 60-KDA PHOSPHOPROTEIN IN RABBIT SKELETAL SARCOPLASMIC-RETICULUM WHICH IS AN ISOFORM OF PHOSPHOGLUCOMUTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CHANNEL RYANODINE RECEPTOR; AMINO-ACID-SEQUENCE; CALCIUM RELEASE; COMPLEMENTARY-DNA; CA2+ TRANSPORT; MUSCLE TRIADS; CALMODULIN; CDNA; COMPLEX	A 60-kDa substrate of calmodulin-dependent protein kinase in rabbit "heavy" skeletal sarcoplasmic reticulum (SR) was characterized by purification and cDNA cloning. Purification was achieved by column chromatography using DEAE-Sephacel, heparin-agarose, and hydroxylapatite in 0.5% 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonic acid (CHAPS). Analyses of amino acid sequence and composition indicated that the CHAPS-soluble 60-kDa protein is an isoform of phosphoglucomutase (PGM). cDNAs encoding two isoforms of PGM were isolated from rabbit skeletal muscles. The translated amino acid sequences show that the isoforms, PGM1 and PGM2, differ in the N-terminal 77 amino acids and that PGM2 is identical to the 60-kDa protein in the SR. Northern blot analysis showed that the size of the mRNA encoding PGM2 is 2.4 kilobases. The PGM enzyme activity was markedly inhibited in SR membranes, while perturbation of the membranes with CHAPS or guanidine-HCl recovered the enzyme activity. KCl (0.15-1 M) led to a partial recovery of the enzyme activity suggesting that the charge interaction is not the primary force for PGM-SR interaction. PGM is localized in the heavy fraction of SR, where calsequestrin and Ca2+ release channel are enriched. Our results demonstrate that an isoform of PGM localized in junctional skeletal SR is the 60-kDa substrate of calmodulin-dependent protein kinase.	UNIV CONNECTICUT,CTR HLTH,DEPT MED,DIV CARDIOL,FARMINGTON,CT 06030; CHILDRENS HOSP MED CTR,DEPT CARDIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115	University of Connecticut; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute					NHLBI NIH HHS [HL 33026] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033026] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDT NR, 1990, J MEMBRANE BIOL, V113, P237, DOI 10.1007/BF01870075; BURN P, 1988, TRENDS BIOCHEM SCI, V13, P79, DOI 10.1016/0968-0004(88)90043-6; CAMPBELL KP, 1982, J BIOL CHEM, V257, P1238; CASWELL A H, 1989, Biophysical Journal, V55, p478A; CHIESI M, 1982, J BIOL CHEM, V257, P984; CHU A, 1990, BIOCHEMISTRY-US, V29, P5899, DOI 10.1021/bi00477a003; DAWSON DM, 1975, ISOZYMES, V1, P381; ENTMAN ML, 1980, J BIOL CHEM, V255, P6245; ENTMAN ML, 1976, J BIOL CHEM, V251, P3140; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HEILMEYER LMG, 1990, MOL CELL BIOCHEM, V99, P111; HORL WH, 1978, BIOCHEMISTRY-US, V17, P759; IKEMOTO N, 1974, J BIOL CHEM, V249, P649; KIM DH, 1983, J BIOL CHEM, V258, P9662; KIM DH, 1986, J BIOL CHEM, V261, P1674; KORZA G, 1988, J BIOL CHEM, V263, P3486; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1969, J BIOL CHEM, V244, P910; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1984, ADV CYCLIC NUCL PROT, V17, P393; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; MEYER F, 1970, J BIOL CHEM, V245, P6642; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OTSU K, 1990, J BIOL CHEM, V265, P13472; PIERCE GN, 1985, J BIOL CHEM, V260, P6862; RAY WJ, 1983, J BIOL CHEM, V258, P9166; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; Sambrook J, 1989, MOL CLONING LABORATO; SATO H, 1988, ARCH BIOCHEM BIOPHYS, V260, P443, DOI 10.1016/0003-9861(88)90468-7; SEILER S, 1984, J BIOL CHEM, V259, P8550; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; THIELECZEK R, 1989, J BIOL CHEM, V264, P7349; TUANA BS, 1988, FEBS LETT, V235, P219, DOI 10.1016/0014-5793(88)81266-3; VALE MGP, 1988, J BIOL CHEM, V263, P12872; WADDELL ID, 1991, BIOCHEM J, V275, P133, DOI 10.1042/bj2750133; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	43	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21080	21088						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328221				2022-12-27	WOS:A1992JT97800089
J	CHAO, TSO; BYRON, KL; LEE, KM; VILLEREAL, M; ROSNER, MR				CHAO, TSO; BYRON, KL; LEE, KM; VILLEREAL, M; ROSNER, MR			ACTIVATION OF MAP KINASES BY CALCIUM-DEPENDENT AND CALCIUM-INDEPENDENT PATHWAYS - STIMULATION BY THAPSIGARGIN AND EPIDERMAL GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; SIGNAL-REGULATED KINASES; SERINE THREONINE KINASES; TYROSINE PHOSPHORYLATION; HUMAN-FIBROBLASTS; SWISS 3T3-CELLS; FACTOR RECEPTOR; TUMOR PROMOTER; 3T3-L1 CELLS; INSULIN	In order to determine the effect of calcium mobilization on mitogen-activated protein (MAP) kinase activation, we have treated human foreskin fibroblasts (HSWP cells) and human epidermal carcinoma (A431) cells with thapsigargin. Intracellular free calcium was monitored by single cell image analysis using fura-2 and correlated with MAP kinase stimulation as assessed by immunoprecipitation, kinase renaturation assays and immunoblotting. Thapsigargin stimulated the 44- and 42-kDa MAP kinase isozymes in both cell types with kinetics that were slightly delayed relative to enzyme stimulated by epidermal growth factor. Removal of external calcium did not significantly affect the activation of the MAP kinases by thapsigargin-indicating that intracellular calcium mobilization is sufficient to stimulate the enzymes. However, treatment of cells with EGTA under conditions which deplete both intra- and extracellular calcium inhibited stimulation by thapsigargin but not epidermal growth factor. Stimulation of the MAP kinases by the calcium ionophore ionomycin paralleled the activation observed with thapsigargin in both calcium-containing and calcium-free conditions. These results indicate that there are at least two independent pathways for stimulation of MAP kinase: one that is dependent on intracellular calcium mobilization, and one that is mediated by the tyrosine kinase epidermal growth factor receptor and is calcium-independent.	UNIV CHICAGO,BEN MAY INST,5841 S MARYLAND AVE,M-C 6027,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637	University of Chicago; University of Chicago				Byron, Kenneth/0000-0002-3875-9667	NCI NIH HHS [CA35541] Funding Source: Medline; NIGMS NIH HHS [GM28359] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028359] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDERSON NG, 1991, J BIOL CHEM, V266, P10131; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BESTERMAN JM, 1986, J BIOL CHEM, V261, P723; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRON KL, 1989, J BIOL CHEM, V264, P18234; BYRON KL, 1992, J BIOL CHEM, V267, P108; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; FRIEDMAN B, 1989, P NATL ACAD SCI USA, V86, P812, DOI 10.1073/pnas.86.3.812; GEAHLEN RL, 1986, ANAL BIOCHEM, V153, P151, DOI 10.1016/0003-2697(86)90074-6; GEISSLER JF, 1990, J BIOL CHEM, V265, P22255; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HUGHES AR, 1991, MOL PHARMACOL, V40, P254; KAUFFMAN RF, 1980, J BIOL CHEM, V255, P2735; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MCCAFFREY P, 1987, J BIOL CHEM, V262, P1442; MULDOON LL, 1987, AM J PHYSIOL, V253, pC219, DOI 10.1152/ajpcell.1987.253.2.C219; NEL AE, 1990, J IMMUNOL, V145, P971; PALFREY HC, 1987, J BIOL CHEM, V262, P9785; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POLLACK S, 1991, BIOCHEM J, V276, P481, DOI 10.1042/bj2760481; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RASMUSSEN U, 1978, ACTA PHARM SUEC, V15, P133; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1988, J BIOL CHEM, V263, P12721; SCIMECA JC, 1991, BIOCHEMISTRY-US, V30, P9313, DOI 10.1021/bi00102a025; STURGILL TW, 1986, BIOCHEM BIOPH RES CO, V134, P565, DOI 10.1016/S0006-291X(86)80457-0; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAKISHIMA K, 1988, BIOCHEM BIOPH RES CO, V157, P740, DOI 10.1016/S0006-291X(88)80312-7; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TOBE K, 1991, J BIOL CHEM, V266, P24793	38	255	256	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19876	19883						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328184				2022-12-27	WOS:A1992JR85800023
J	AMIN, AA; HURWITZ, J				AMIN, AA; HURWITZ, J			POLAR ARREST OF THE SIMIAN-VIRUS 40 TUMOR ANTIGEN-MEDIATED REPLICATION FORK MOVEMENT INVITRO BY THE TUS PROTEIN-TERB COMPLEX OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 DNA-REPLICATION; LARGE-T-ANTIGEN; CELL NUCLEAR ANTIGEN; POLYMERASE-ALPHA; ENZYMATIC-SYNTHESIS; TERMINATOR PROTEIN; ACCESSORY PROTEINS; PURIFIED PROTEINS; HELICASE ACTIVITY; BINDING PROTEIN	The effect of the tus protein-terB sequence complex of Escherichia coli on the movement of the SV40 large tumor antigen (T antigen)-mediated replication fork during SV40 DNA replication in vitro has been examined. In the monopolymerase and dipolymerase systems, the tus protein-terB complex efficiently blocked the replication fork movement in a polar fashion, as observed in prokaryotic replication systems. With crude cytosolic extracts of HeLa cells, the same polarity of fork arrest was observed, but the block of replication fork movement was inefficient. These results indicate that the structure of the prokaryotic tus protein-terB complex allows it to block replication fork movement in an orientation-dependent manner. We also show that the tus protein-terB complex blocks the 3' --> 5' helicase action of T antigen in a polar fashion, using substrates comprised of single-stranded M13 DNA with either a 52-base pair (bp) or 29-bp duplex containing the terB sequence. The tus protein-terB complex formed on the 52-bp duplex was less effective than the complex formed on the 29-bp duplex in blocking the helicase action of T antigen. With the 52-bp duplex substrate, T antigen movement was only partially (30%) blocked by the tus protein-terB sequence complex in the active orientation, whereas the E. coli dnaB helicase moving 5' --> 3' was blocked more than 90% by the complex in the active orientation. However, with the shorter 29-bp duplex substrate, the complex blocked the T antigen helicase activity about 75%, whereas the dnaB helicase activity was completely blocked. Altogether, these results suggest that the T antigen helicase activity, when coupled to DNA replication, is more susceptible to arrest by the tus protein-terB complex than the T antigen functioning as a helicase alone.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NIGMS NIH HHS [5R0 GM34559] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034559, R01GM034559] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEDROSIAN CL, 1991, P NATL ACAD SCI USA, V88, P2618, DOI 10.1073/pnas.88.7.2618; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOROWIEC JA, 1988, P NATL ACAD SCI USA, V85, P64, DOI 10.1073/pnas.85.1.64; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BULLOCK PA, 1989, P NATL ACAD SCI USA, V86, P3944, DOI 10.1073/pnas.86.11.3944; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; EKI T, 1991, J BIOL CHEM, V266, P3087; EKI T, 1992, J BIOL CHEM, V267, P7284; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GOTTLIEB PA, 1992, J BIOL CHEM, V267, P7434; HIASA H, 1992, J BIOL CHEM, V267, P11379; HIDAKA M, 1992, J BIOL CHEM, V267, P5361; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; HORIUCHI T, 1988, CELL, V54, P515, DOI 10.1016/0092-8674(88)90073-6; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KUEMPEL PL, 1989, CELL, V59, P581, DOI 10.1016/0092-8674(89)90001-9; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LEE SH, 1988, P NATL ACAD SCI USA, V85, P9469, DOI 10.1073/pnas.85.24.9469; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1991, J BIOL CHEM, V266, P594; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LOEBER G, 1991, J VIROL, V65, P3167, DOI 10.1128/JVI.65.6.3167-3174.1991; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; SEO YS, 1991, J BIOL CHEM, V266, P13161; SISTA PR, 1989, P NATL ACAD SCI USA, V86, P3026, DOI 10.1073/pnas.86.9.3026; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; STAHL MH, 1988, EMBO J, V7, P3149; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TACK LC, 1987, J BIOL CHEM, V262, P6339; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; WOBBE CR, 1987, PHILOS T ROY SOC B, V317, P439, DOI 10.1098/rstb.1987.0071; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710	53	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18612	18622						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326530				2022-12-27	WOS:A1992JN50200057
J	PAYET, MD; DUPUIS, G				PAYET, MD; DUPUIS, G			DUAL REGULATION OF THE N-TYPE K+ CHANNEL IN JURKAT LYMPHOCYTES-T BY PROTEIN KINASE-A AND KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SENSITIVE ION CHANNELS; POTASSIUM CHANNEL; SIGNAL TRANSDUCTION; CHLORIDE CHANNELS; CHOLERA-TOXIN; CELLS; MODULATION; FAMILY; INTERLEUKIN-2; PHOSPHATASES	We have measured the activity of the n type K+ channel present in human (Jurkat) T lymphocytes using the patch clamp technique in the whole-cell configuration. We report that protein kinase A (PKA) and protein kinase C (PKC) modulate, in a dual manner, the K+ conductance in these cells. Activation of PKA decreases the amplitude of the current, as previously reported (Bastin, B., Payet, M. D., and Dupuis, G. (1990) Cell. Immunol. 128, 385-399), and this is also the case for 12-O-tetradecanoylphorbol-13-acetate-dependent activation of PKC. In contrast, inhibitors of PKC (H7, staurosporine, polymixin B, and anti-PKC antibody) increase the current amplitude. Of importance, down-regulation of PKC or its inhibition prevented the PKA-dependent inhibition of the K+ channels. Addition of alkaline phosphatase via the patch pipette increased the K+ conductance under basal conditions and reversed the inhibition produced by PKA. The dual modulation of K+ channels in Jurkat T cells is in agreement with the presence of consensus sequences in the primary structure of the n type K+ channel.	UNIV SHERBROOKE, FAC MED, DEPT BIOCHEM, SHERBROOKE J1H 5N4, QUEBEC, CANADA	University of Sherbrooke	PAYET, MD (corresponding author), UNIV SHERBROOKE, FAC MED, DEPT PHYSIOL & BIOPHYS, SHERBROOKE J1H 5N4, QUEBEC, CANADA.							Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; ASANO T, 1984, J PHARMACOL EXP THER, V231, P141; ATTALI B, 1992, J BIOL CHEM, V267, P8650; BASTIN B, 1990, CELL IMMUNOL, V128, P385, DOI 10.1016/0008-8749(90)90035-P; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BUBIEN JK, 1990, SCIENCE, V248, P1416, DOI 10.1126/science.2162561; CAI YC, 1992, DNA CELL BIOL, V11, P163, DOI 10.1089/dna.1992.11.163; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; CHOQUET D, 1987, SCIENCE, V235, P1211, DOI 10.1126/science.2434998; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; DECOURSEY TE, 1987, J GEN PHYSIOL, V89, P405, DOI 10.1085/jgp.89.3.405; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DEUTSCH C, 1986, J PHYSIOL-LONDON, V372, P405, DOI 10.1113/jphysiol.1986.sp016016; DOUGLASS J, 1990, J IMMUNOL, V144, P4841; DUPUIS G, 1989, J PHYSIOL-LONDON, V412, P135, DOI 10.1113/jphysiol.1989.sp017608; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GALLIN EK, 1991, PHYSIOL REV, V71, P775, DOI 10.1152/physrev.1991.71.3.775; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; ICHINOSE M, 1991, BRAIN RES, V549, P146, DOI 10.1016/0006-8993(91)90611-X; IMBODEN JB, 1986, P NATL ACAD SCI USA, V83, P5673, DOI 10.1073/pnas.83.15.5673; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; KACZMAREK LK, 1988, ADV SEC MESS PHOSPH, V22, P113; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KRAUSE D, 1988, PFLUG ARCH EUR J PHY, V412, P133, DOI 10.1007/BF00583742; LAI CY, 1980, CRC CR REV BIOCH MOL, V9, P171, DOI 10.3109/10409238009105434; LAI WS, 1990, BIOCHEM J, V267, P23, DOI 10.1042/bj2670023; LEWIS RS, 1990, ANNU REV PHYSIOL, V52, P415; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; LUCAS S, 1990, FEBS LETT, V260, P53, DOI 10.1016/0014-5793(90)80064-P; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MALDONADO D, 1991, FASEB J, V5, P2965, DOI 10.1096/fasebj.5.14.1721593; MARY D, 1987, J IMMUNOL, V139, P1179; MATTESON DR, 1984, NATURE, V307, P468, DOI 10.1038/307468a0; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; ROTHERMEL JD, 1984, J BIOL CHEM, V259, P5294; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SIEGELBAUM SA, 1982, NATURE, V299, P413, DOI 10.1038/299413a0; TAMIR A, 1991, IMMUNOL LETT, V27, P95, DOI 10.1016/0165-2478(91)90134-V; VALGE VE, 1988, CELL, V55, P101, DOI 10.1016/0092-8674(88)90013-X; WALSH KB, 1991, AM J PHYSIOL, V261, pC1081, DOI 10.1152/ajpcell.1991.261.6.C1081; WANG WH, 1991, P NATL ACAD SCI USA, V88, P9722, DOI 10.1073/pnas.88.21.9722; WIENER E, 1989, J BIOL CHEM, V264, P4324; WITTKA R, 1991, FEBS LETT, V286, P193, DOI 10.1016/0014-5793(91)80972-6; YAZAWA K, 1990, J PHYSIOL-LONDON, V421, P135, DOI 10.1113/jphysiol.1990.sp017937; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	47	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18270	18273						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326519				2022-12-27	WOS:A1992JN50200006
J	TSAI, AL; PALMER, G; KULMACZ, RJ				TSAI, AL; PALMER, G; KULMACZ, RJ			PROSTAGLANDIN-H SYNTHASE - KINETICS OF TYROSYL RADICAL FORMATION AND OF CYCLOOXYGENASE CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER OXIDATION-STATES; PEROXIDASE REACTION; ENDOPEROXIDE SYNTHETASE; VESICULAR GLAND; HYDROPEROXIDE; SPECTROSCOPY; PURIFICATION; BIOSYNTHESIS; SUBSTRATE; ENZYME	Hydroperoxides are known to induce the formation of tyrosyl free radicals in prostaglandin (PG) H synthase. To evaluate the role of these radicals in cyclooxygenase catalysis we have analyzed the temporal correlation between radical formation and substrate conversion during reaction of the synthase with arachidonic acid. PGH synthase reacted with equimolar levels of arachidonic acid generated sequentially the wide doublet (34 G peak-to-trough) and wide singlet (32 G peak-to-trough) tyrosyl radical signals previously reported for reaction with hydroperoxide. The kinetics of formation and decay of the doublet signal corresponded reasonably well with those of cyclooxygenase activity. However, the wide singlet free radical signal accumulated only after prostaglandin formation had ceased, indicating that the wide singlet is not likely to be an intermediate in cyclooxygenase catalysis. When PGH synthase was reacted with 25 equivalents of arachidonic acid, the wide doublet and wide singlet radical signals were not observed. Instead, a narrower singlet (24 G peak-to-trough) tyrosyl radical was generated, similar to that found upon reaction of indomethacin-treated synthase with hydroperoxide. Only about 11 mol of prostaglandin were formed per mol of synthase before complete self-inactivation of the cyclooxygenase, far less than the 170 mol/mol synthase produced under standard assay conditions. Phenol (0.5 mM) increased the extent of cyclooxygenase reaction by only about 50%, in contrast to the 460% stimulation seen under standard assay conditions. These results indicate that the narrow singlet tyrosyl radical observed in the reaction with high levels of arachidonate in this study and by Lassmann et al. (Lassmann, G., Odenwaller, R., Curtis, J. F., DeGray, J. A., Mason, R. P., Marnett, L. J., and Eling, T. E. (1991) J. Biol. Chem. 266 20045-20055) is associated with abnormal cyclooxygenase activity and is probably nonphysiological. In titrations of the synthase with arachidonate or with hydroperoxide, the loss of enzyme activity and destruction of heme were linear functions of the amount of titrant added. Complete inactivation of cyclooxygenase activity was found at about 10 mol of arachidonate, ethyl hydrogen peroxide, or hydrogen peroxide per mol of synthase heme; maximal bleaching of the heme Soret absorbance peak was found with 10 mol of ethyl hydroperoxide or 20 mol of either arachidonate or hydrogen peroxide per mol of synthase heme. The peak concentration of the wide doublet tyrosyl radical did not change appreciably with increased levels of ethyl hydroperoxide. In contrast, higher levels of hydroperoxide gave higher levels of the wide singlet radical species, in parallel with enzyme inactivation. We conclude that the wide doublet tyrosyl radical species is kinetically competent for participation in cyclooxygenase catalysis, whereas both the wide and narrow singlet free radical species are probably involved in self-inactivation processes.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Rice University	TSAI, AL (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV HEMATOL & ONCOL,6431 FANNIN ST,HOUSTON,TX 77030, USA.				NIGMS NIH HHS [GM21337, GM30509] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021337, R01GM021337, R01GM030509] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABCOCK GT, 1992, J AM CHEM SOC, V114, P3727, DOI 10.1021/ja00036a023; BALLOU DP, 1974, ANAL CHEM, V46, P1248, DOI 10.1021/ac60345a034; BARRY BA, 1990, J BIOL CHEM, V265, P20139; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; ELING TE, 1986, J BIOL CHEM, V261, P5023; GRAFF G, 1982, METHOD ENZYMOL, V86, P376; HEMLER ME, 1978, BIOCHEM BIOPH RES CO, V85, P1325, DOI 10.1016/0006-291X(78)91148-8; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KULMACZ RJ, 1985, BIOCHEM BIOPH RES CO, V130, P918, DOI 10.1016/0006-291X(85)90504-2; KULMACZ RJ, 1991, MOL PHARMACOL, V40, P833; KULMACZ RJ, 1985, PROSTAGLANDINS, V29, P175, DOI 10.1016/0090-6980(85)90200-X; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1987, J BIOL CHEM, V262, P10524; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; KULMACZ RJ, 1986, ARCH BIOCHEM BIOPHYS, V249, P273, DOI 10.1016/0003-9861(86)90003-2; KULMACZ RJ, 1989, PROSTAGLANDINS, V38, P277, DOI 10.1016/0090-6980(89)90133-0; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; MIKI H, 1989, ARCH BIOCHEM BIOPHYS, V275, P354, DOI 10.1016/0003-9861(89)90382-2; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; ZHANG XH, 1992, BIOCHEMISTRY-US, V31, P2528, DOI 10.1021/bi00124a013	27	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17753	17759						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325448				2022-12-27	WOS:A1992JM22300045
J	JACKSON, TR; STEPHENS, LR; HAWKINS, PT				JACKSON, TR; STEPHENS, LR; HAWKINS, PT			RECEPTOR SPECIFICITY OF GROWTH FACTOR-STIMULATED SYNTHESIS OF 3-PHOSPHORYLATED INOSITOL LIPIDS IN SWISS 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I PHOSPHATIDYLINOSITOL KINASE; PHOSPHOLIPASE-C; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; PHOSPHOINOSITIDE KINASES; ACTIVATED NEUTROPHILS; HUMAN PLATELETS; A431 CELLS; G-PROTEINS; PDGF	We have investigated synthesis of 3-phosphorylated inositol lipids in growth factor-stimulated Swiss 3T3 cells. Those growth factors tested which act via tyrosine kinase-containing receptors (platelet-derived growth factor (PDGF), insulin growth factor I (IGF-I), epidermal growth factor (EGF), and basic fibroblast growth factor (bFGF)) caused the rapid synthesis of [P-32]PtdIns(3,4)P2 and [P-32]PtdIns(3,4,5)P3 (PtdIns is phosphatidylinositol) in [P-32]P(i)-prelabeled cells and the appearance of an inositol lipid 3-OH kinase in antiphosphotyrosine immunoprecipates. In contrast, those growth factors tested which act via G-protein-coupled receptors (bombesin, vasopressin, prostaglandin E1) were unable to stimulate either of the above responses. Furthermore, while PDGF was able to increase the formation of PtdIns(3,4)P2 and PtdIns(3,4,5)P3 in streptolysin-permeabilized cells, guanosine 5'-3-(thio)triphosphate and guanyl-5'-yl imidodiphosphate were not. These results suggest that Swiss 3T3 cells possess the machinery for tyrosine kinase but not G-protein-mediated activation of PtdIns(4, 5)P2 3-OH kinase; a situation which is the inverse to that recently described for human neutrophils. The tyrosine kinase-containing receptors differed markedly in their relative abilities to elevate the levels of [P-32] PtdIns(3,4,5)P3 (ranked in the order PDGF greater-than-or-equal-to IGF-I > EGF > bFGF), [P-32]Ptd-OH (PDGF > EGF > bFGF; undetectable for IGF-I), and [P-32]PtdIns4P (EGF > bFGF > PDGF; undetectable for IGF-I) in [P-32]P(i)-prelabeled cells. These differences are epitomized by IGF-I, which was the joint most powerful stimulus for [P-32]ptdIns(3,4,5)P3 formation, but was unable to stimulate a measurable accumulation of [P-32]Ptd-OH (and hence, by deduction, was unable to stimulate phospholipase C). These results indicate that there is a differential ability among the tyrosine kinase-containing receptors present in a single cell to recruit phospholipase C and PtdIns(4, 5)P2 3-OH kinase into their signalling complexes and further emphasizes the notion that the rapid synthesis of PtdIns(3,4,5)P3 may be a signalling event.			JACKSON, TR (corresponding author), INST ANIM PHYSIOL & GENET RES, DEPT BIOCHEM, CAMBRIDGE CB2 4AT, ENGLAND.			Hawkins, Phillip/0000-0002-6979-0464; stephens, len/0000-0002-2771-3487				ALLEN D, 1978, BIOCHIM BIOPHYS ACTA, V508, P277; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BLAKELEY DM, 1989, BIOCHEM J, V258, P177, DOI 10.1042/bj2580177; BOYER JL, 1989, TRENDS PHARMACOL SCI, V10, P360, DOI 10.1016/0165-6147(89)90008-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN KD, 1983, BIOCHEM J, V212, P465, DOI 10.1042/bj2120465; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; COCHET C, 1991, J BIOL CHEM, V266, P637; CORPS AN, 1988, BIOCHEM J, V252, P119, DOI 10.1042/bj2520119; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; CUNNINGHAM TW, 1991, BIOCHEM BIOPH RES CO, V175, P568, DOI 10.1016/0006-291X(91)91603-A; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; EBERLE M, 1990, J BIOL CHEM, V265, P16725; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FOLCH J, 1949, J BIOL CHEM, V177, P497; FOLCH J, 1957, J BIOL CHEM, V226, P497; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HARDEN TK, 1991, BIOCHEM SOC T, V19, P342, DOI 10.1042/bst0190342; HESKETH TR, 1988, J BIOL CHEM, V263, P11879; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; IRVINE RF, 1984, BIOCHEM J, V218, P177, DOI 10.1042/bj2180177; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LOGAN A, 1991, CELL SIGNAL, V3, P171; MILLER ES, 1990, BIOCHEM BIOPH RES CO, V173, P289, DOI 10.1016/S0006-291X(05)81055-1; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NOLAN RD, 1991, BIOCHEM BIOPH RES CO, V174, P524, DOI 10.1016/0006-291X(91)91448-L; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PALMER S, 1986, BIOCHEM J, V238, P491, DOI 10.1042/bj2380491; PAYRASTRE B, 1990, BIOCHEM J, V272, P665, DOI 10.1042/bj2720665; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RHEE SG, 1991, BIOCHEM SOC T, V19, P337, DOI 10.1042/bst0190337; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS L, 1989, BIOCHEM J, V259, P267, DOI 10.1042/bj2590267; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TALMAGE DA, 1989, CELL, V59, P5; TAYLOR CW, 1990, BIOCHEM J, V272, P1; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VADNAL RE, 1989, BIOCHEM BIOPH RES CO, V163, P995, DOI 10.1016/0006-291X(89)92320-6; Vallance SJ, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104813; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VERHEIJDEN GF, 1990, CELL REGUL, V1, P615, DOI 10.1091/mbc.1.9.615; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577	63	122	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16627	16636						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322911				2022-12-27	WOS:A1992JJ45800098
J	ROTMAN, EI; DEJONGH, KS; FLORIO, V; LAI, Y; CATTERALL, WA				ROTMAN, EI; DEJONGH, KS; FLORIO, V; LAI, Y; CATTERALL, WA			SPECIFIC PHOSPHORYLATION OF A COOH-TERMINAL SITE ON THE FULL-LENGTH FORM OF THE ALPHA-1-SUBUNIT OF THE SKELETAL-MUSCLE CALCIUM-CHANNEL BY CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 SIZE FORMS; DIHYDROPYRIDINE RECEPTOR; CYCLIC-AMP; 1,4-DIHYDROPYRIDINE RECEPTOR; ANTAGONIST RECEPTOR; BINDING POLYPEPTIDE; TRANSVERSE TUBULES; CATALYTIC SUBUNIT; IDENTIFICATION; MODULATION	The primary (alpha-1) subunit of purified skeletal muscle dihydropyridine-sensitive calcium channels is present in full-length (212 kDa) and truncated (190 kDa) forms which are both phosphorylated by cAMP-dependent protein kinase (cA-PK) in vitro. In the present study, phosphorylation of the purified calcium channel by cA-PK followed by immunoprecipitation, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and two-dimensional phosphopeptide mapping revealed differential phosphorylation of the related 190- and 212-kDa forms. The 190-kDa form of the alpha-1 subunit was phosphorylated on three major and three minor tryptic phosphopeptides; the 212-kDa form was phosphorylated on all six of these phosphopeptides plus two that were unique. Time course experiments showed that a single site on the COOH-terminal portion of the full-length form of the alpha-1 subunit is most intensely and rapidly (within 10 s) phosphorylated. Phosphorylation occurs almost exclusively on this COOH-terminal site unless harsh conditions such as treatment with denaturing detergents are employed to expose phosphorylation sites within the 190-kDa segment of the molecule. Elution of phosphopeptides from the second dimension chromatograph followed by immunoprecipitation with an anti-peptide antibody (anti-CP1) directed against the COOH-terminal amino acid sequence enabled us to identify this major phosphorylation site as serine 1854. The nearby consensus sites for cA-PK phosphorylation at serines 1757 and 1772 were phosphorylated only after denaturation or proteolytic cleavage. Phosphorylation of serine 1854 may play a pivotal role in the regulation of calcium channel function by cA-PK.			ROTMAN, EI (corresponding author), UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA.		Mackie, Ken/E-3384-2013		NINDS NIH HHS [R01-NS22625] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022625] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARREOLA J, 1987, J PHYSIOL-LONDON, V393, P307, DOI 10.1113/jphysiol.1987.sp016825; BRUM G, 1983, PFLUG ARCH EUR J PHY, V398, P147, DOI 10.1007/BF00581064; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; CURTIS BM, 1984, BIOCHEMISTRY-US, V23, P2113, DOI 10.1021/bi00305a001; CURTIS BM, 1986, BIOCHEMISTRY-US, V25, P3077, DOI 10.1021/bi00359a002; CURTIS BM, 1985, P NATL ACAD SCI USA, V82, P2528, DOI 10.1073/pnas.82.8.2528; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FERNANDEZ JL, 1980, BIOCHIM BIOPHYS ACTA, V599, P552, DOI 10.1016/0005-2736(80)90199-6; FLOCKERZI V, 1986, NATURE, V323, P66, DOI 10.1038/323066a0; HOSEY MM, 1988, J MEMBRANE BIOL, V104, P81, DOI 10.1007/BF01870922; HUTTNER WB, 1979, P NATL ACAD SCI USA, V76, P5402, DOI 10.1073/pnas.76.10.5402; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P4290, DOI 10.1073/pnas.85.12.4290; JAHN H, 1988, EUR J BIOCHEM, V178, P535, DOI 10.1111/j.1432-1033.1988.tb14480.x; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1990, J BIOL CHEM, V265, P20839; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MUSZYNSKA G, 1986, BIOCHEMISTRY-US, V25, P6850, DOI 10.1021/bi00370a018; NUNOKI K, 1989, P NATL ACAD SCI USA, V86, P6816, DOI 10.1073/pnas.86.17.6816; OCALLAHAN CM, 1988, BIOCHEMISTRY-US, V27, P6071, DOI 10.1021/bi00416a036; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; ROHRKASTEN A, 1988, J BIOL CHEM, V263, P15325; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID A, 1985, J BIOL CHEM, V260, P3041; SHARP AH, 1987, J BIOL CHEM, V262, P12309; SIEBER M, 1987, EUR J BIOCHEM, V167, P117, DOI 10.1111/j.1432-1033.1987.tb13311.x; STRIESSNIG J, 1990, J BIOL CHEM, V265, P363; STRIESSNIG J, 1987, FEBS LETT, V212, P247, DOI 10.1016/0014-5793(87)81354-6; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TSIEN RW, 1986, J MOL CELL CARDIOL, V18, P691, DOI 10.1016/S0022-2828(86)80941-5; TSIEN RW, 1983, ANNU REV PHYSIOL, V45, P341, DOI 10.1146/annurev.ph.45.030183.002013; VAGHY PL, 1987, J BIOL CHEM, V262, P14337	40	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16100	16105						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322891				2022-12-27	WOS:A1992JJ45800021
J	OHMICHI, M; PANG, L; DECKER, SJ; SALTIEL, AR				OHMICHI, M; PANG, L; DECKER, SJ; SALTIEL, AR			NERVE GROWTH-FACTOR STIMULATES THE ACTIVITIES OF THE RAF-1 AND THE MITOGEN-ACTIVATED PROTEIN-KINASES VIA THE TRK PROTOONCOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 CELLS; C-RAF; TYROSINE PHOSPHORYLATION; PHEOCHROMOCYTOMA CELLS; NGF RECEPTOR; PC-12 CELLS; V-RAF; SERINE; ONCOGENE; INSULIN	Nerve growth factor (NGF) binds to two structurally unrelated transmembrane proteins on the surface of PC-12 cells, a 75-kDa glycoprotein with a short cytoplasmic sequence, and the trk protooncogene (pp140c-trk), a protein tyrosine kinase activated by NGF. Immediately after binding to cells, NGF induces changes in serine/threonine phosphorylation of several proteins. We have explored the relative roles of these two NGF binding proteins in mediating the activation of two intracellular kinases that may be responsible for some of these phosphorylations. The raf-1 protooncogene is a serine/threonine kinase activated by several growth factors and oncogenic proteins. Treatment of PC-12 cells with NGF increases the serine and threonine phosphorylation of raf-1 in an anti-raf-1 immunoprecipitate kinase assay. This increased phosphorylation observed in vitro is dose-dependent and transient and is accompanied by the NGF-dependent shift in the mobility of immunoblotted raf-1 on SDS sodium dodecyl sulfate-polyacrylamide gel electrophoresis, an effect thought to reflect phosphorylation. NGF-dependent activation of raf-1 is not dependent on protein kinase C, since prolonged exposure to phorbol esters under conditions that cause down-regulation of cellular protein kinase C activity has no effect on the NGF response. Expression of pp140c-trk in 3T3 fibroblasts (3T3-c-trk), as evidenced by cross-linking of I-125-NGF to the 140-kDa protein, permits the NGF-dependent activation of raf-1 kinase, detected in the immunoprecipitate kinase assay, anti-raf immunoblot shift on gel electrophoresis, and incorporation of [P-32]orthophosphate into the raf-1 protein. The concentration dependence of raf-1 activation is identical in 3T3-c-trk and PC-12 cells, despite the absence of the 75-kDa NGF binding protein in 3T3-c-trk cells. NGF is without effect in untransfected 3T3 cells or in Chinese hamster ovary cells overexpressing p75, although raf-1 is present in these cells. Similarly, the NGF-dependent activation of mitogen-activated protein (MAP) kinase is detected in 3T3-c-trk cells, but not in untransfected 3T3 or Chinese hamster ovary cells overexpressing p75. As described for raf-1 activation, the NGF dose responses for MAP kinase activation in 3T3-c-trk and PC-12 cells are virtually superimposable. These data indicate that the activation of these two serine/threonine kinases by NGF is mediated solely by binding to and activating the pp140c-trk receptor.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105; UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT MICROBIOL,ANN ARBOR,MI 48109	Pfizer; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Saltiel, Alan/L-3632-2019		NATIONAL CANCER INSTITUTE [R01CA037754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R23DK033804, R01DK033804] Funding Source: NIH RePORTER; NCI NIH HHS [CA37754] Funding Source: Medline; NIDDK NIH HHS [DK33804] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALETTA JM, 1988, J CELL BIOL, V106, P1573, DOI 10.1083/jcb.106.5.1573; BERG MM, 1991, P NATL ACAD SCI USA, V86, P1756; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; DECKER SJ, 1984, MOL CELL BIOL, V4, P1719; HAMA T, 1986, P NATL ACAD SCI USA, V83, P2353, DOI 10.1073/pnas.83.8.2353; HEASLEY LE, 1989, MOL PHARMACOL, V35, P331; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; IZUMI T, 1991, J BIOL CHEM, V266, P7933; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOIZUMI S, 1988, J NEUROSCI, V8, P715; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KY, 1985, MOL PHARMACOL, V28, P220; LEE RM, 1991, J BIOL CHEM, V266, P10351; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MARGOLIS B, 1990, MOL CELL BIOL, V4, P571; MATSUDA Y, 1987, J BIOL CHEM, V262, P2832; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MIYASAKA T, 1990, BIOCHEM BIOPH RES CO, V168, P1237, DOI 10.1016/0006-291X(90)91161-K; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; OHMICHI M, 1992, BIOCHEMISTRY-US, V31, P4034, DOI 10.1021/bi00131a019; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; OHMICHI M, 1991, CELL REGUL, V2, P691, DOI 10.1091/mbc.2.9.691; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAWLAND EA, 1987, J BIOL CHEM, V262, P7504; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; VULLIET PR, 1989, J BIOL CHEM, V264, P16292	44	70	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14604	14610						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321811				2022-12-27	WOS:A1992JF08800020
J	BRASS, LF; VASSALLO, RR; BELMONTE, E; AHUJA, M; CICHOWSKI, K; HOXIE, JA				BRASS, LF; VASSALLO, RR; BELMONTE, E; AHUJA, M; CICHOWSKI, K; HOXIE, JA			STRUCTURE AND FUNCTION OF THE HUMAN PLATELET THROMBIN RECEPTOR - STUDIES USING MONOCLONAL-ANTIBODIES DIRECTED AGAINST A DEFINED DOMAIN WITHIN THE RECEPTOR N-TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL-LINE	Based upon its recently cloned nucleotide sequence, the human platelet thrombin receptor is thought to be formed by a single polypeptide chain with seven transmembrane domains and an extracellular N terminus that can be cleaved by thrombin. As yet, however, little is known from studies of the receptor protein itself. To obtain such information, we have prepared monoclonal antibodies against a peptide corresponding to receptor residues Ser42 through Phe55, the domain immediately distal to the site of cleavage by thrombin. By flow cytometry, all of the antibodies reacted with the thrombin-responsive megakaryoblastic CHRF-288 and HEL cell lines, but not with the T-lymphoid Sup-T1 cell line. Functionally, the antibodies inhibited platelet responses to alpha-thrombin, gamma-thrombin, and trypsin, but had no effect on platelet activation by ADP, epinephrine, or the thromboxane analog U46619. Radioiodinated antibody bound to almost-equal-to 1,800 sites/platelet, a value similar to the reported number of moderate affinity thrombin binding sites per platelet. On Western blots, the antibodies recognized a 66-kDa protein in platelet, HEL, and CHRF-288 membranes. The discrepancy between this apparent size and the predicted mass of the receptor suggests that, as with other G protein-coupled receptors, one or more of the potential sites for N-linked glycosylation have been utilized. Therefore, these results suggest that: 1) the cloned thrombin receptor is involved in a broad range of platelet responses to thrombin, as well as gamma-thrombin and trypsin; 2) as predicted, the N terminus of the receptor is accessible on the platelet surface; 3) the moderate affinity thrombin binding site noted in earlier studies may be the receptor; 4) potentially as much as one third of the mass of the receptor is carbohydrate.	UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104	University of Pennsylvania	BRASS, LF (corresponding author), UNIV PENN,DEPT MED,HEMATOL ONCOL SECT,SILVERSTEIN 7,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL40387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRASS LF, 1992, BIOCHEM J, V281, P73, DOI 10.1042/bj2810073; BRASS LF, 1992, J BIOL CHEM, V267, P6044; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; FROST GH, 1991, BIOCHEM BIOPH RES CO, V180, P349, DOI 10.1016/S0006-291X(05)81299-9; FUGMAN DA, 1990, BLOOD, V75, P1252; GAGNON AW, 1991, BLOOD, V78, P1247; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GRECO NJ, 1991, P SOC EXP BIOL MED, V198, P792; GRIFFITH L, 1991, BLOOD, V78, P1753; HARMON JT, 1986, J BIOL CHEM, V261, P5928; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; LIU LW, 1991, J BIOL CHEM, V266, P16977; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; NGAIZA JR, 1991, BIOCHEM BIOPH RES CO, V179, P1656, DOI 10.1016/0006-291X(91)91765-5; RANDS E, 1990, J BIOL CHEM, V265, P10759; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; ROSENFELD SI, 1985, J CLIN INVEST, V76, P2317, DOI 10.1172/JCI112242; SEILER SM, 1992, BIOCHEM BIOPH RES CO, V182, P1296, DOI 10.1016/0006-291X(92)91873-O; SMITH SD, 1984, CANCER RES, V44, P5657; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	25	182	186	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13795	13798						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321125				2022-12-27	WOS:A1992JD32500002
J	KAHLE, P; HERTEL, C				KAHLE, P; HERTEL, C			NERVE GROWTH-FACTOR (NGF) RECEPTOR ON RAT GLIAL-CELL LINES - EVIDENCE FOR NGF INTERNALIZATION VIA P75(NGFR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 PHEOCHROMOCYTOMA CELLS; HIGH-AFFINITY RECEPTORS; SCHWANN-CELLS; BINDING-PROPERTIES; EXPRESSION; ASSOCIATION; DEGRADATION; CONVERSION; TRANSPORT; NEURONS	Two types of nerve growth factor (NGF) receptors have been described: high affinity (class I) and low affinity (class II). Biological responses to NGF are thought to be mediated by class I receptors, whereas the role of class II receptors is less clear. While some neuronal cells express both receptor types, only class II receptors have been detected on glial cells. Two glial cell lines, peripheral Schwannoma D6P2T and central 33B glioma cells, were employed to investigate the properties of class II receptors in the absence of class I receptors. These cell lines were found to express NGF receptors identified as class II by a low nanomolar dissociation constant, rapid dissociation kinetics at 4-degrees-C, and trypsin sensitivity. The receptor was found to bind brain-derived neurotrophic factor with similar affinity as NGF. The responsible binding molecule appeared in sodium dodecyl sulfate-polyacrylamide gel electrophoresis as a heterogeneously glycosylated protein of 60-80 kDa with a tendency to aggregate. All receptor bands affinity-labeled with radioiodinated NGF were immunoprecipitated with anti-p75NGFR antibody, but not with anti-p140prototrk antiserum. In these cells, which express p75NGFR as only NGF receptor, a time- and temperature-dependent appearance of a nondisplaceable, trypsin-resistant, acid wash-stable ligand fraction, followed by an increase of trichloroacetic acid-soluble radiolabel in the medium was observed. This sequestration resembled receptor-mediated internalization with subsequent degradation of NGF. Whether this ligand processing indicates a functional role of p75NGFR in glial cells remains to be shown.	F HOFFMANN LA ROCHE & CO LTD,PRECLIN RES,DIV PHARMA,GRENZACHERSTR 124,CH-4002 BASEL,SWITZERLAND	Roche Holding								BERND P, 1984, J BIOL CHEM, V259, P5509; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; DISTEFANO PS, 1988, J NEUROSCI, V8, P231; FIELDS KL, 1975, P NATL ACAD SCI USA, V72, P1296, DOI 10.1073/pnas.72.4.1296; FIELDS KL, 1985, NEUROSCIENCE, V15, P877, DOI 10.1016/0306-4522(85)90085-5; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GROB PM, 1983, P NATL ACAD SCI-BIOL, V80, P6819, DOI 10.1073/pnas.80.22.6819; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HERTEL C, 1983, BIOCHEM J, V216, P669, DOI 10.1042/bj2160669; HEUMANN R, 1987, J CELL BIOL, V104, P1623, DOI 10.1083/jcb.104.6.1623; HOSANG M, 1987, EMBO J, V6, P1197, DOI 10.1002/j.1460-2075.1987.tb02354.x; IMADA M, 1978, DEV BIOL, V66, P97, DOI 10.1016/0012-1606(78)90276-2; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KASAIAN MT, 1988, J BIOL CHEM, V263, P5083; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNUSEL B, 1991, P NATL ACAD SCI USA, V88, P961, DOI 10.1073/pnas.88.3.961; KUMAR S, 1990, J NEUROSCI RES, V27, P408, DOI 10.1002/jnr.490270320; LANDRETH GE, 1980, P NATL ACAD SCI-BIOL, V77, P4751, DOI 10.1073/pnas.77.8.4751; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LAYER PG, 1983, J BIOL CHEM, V258, P3012; LEMKE G, 1988, DEVELOPMENT, V102, P499; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; PERIOSO PM, 1988, AM J PATHOL, V132, P152; PFEIFFER SE, 1972, P NATL ACAD SCI USA, V69, P2885, DOI 10.1073/pnas.69.10.2885; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RAIVICH G, 1991, NEURON, V7, P151, DOI 10.1016/0896-6273(91)90083-C; RAKOWICZSZULCZYNSKA EM, 1989, MOL CARCINOGEN, V2, P47, DOI 10.1002/mc.2940020108; Rodbard D, 1975, Methods Enzymol, V37, P3; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; SAAD B, 1991, J CELL BIOL, V115, P473, DOI 10.1083/jcb.115.2.473; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SEILHEIMER B, 1987, EMBO J, V6, P1611, DOI 10.1002/j.1460-2075.1987.tb02408.x; SONNENFELD KH, 1986, CANCER RES, V46, P1446; STACH RW, 1984, J NEUROSCI RES, V11, P215, DOI 10.1002/jnr.490110302; TANIUCHI M, 1985, J CELL BIOL, V101, P1100, DOI 10.1083/jcb.101.3.1100; TANIUCHI M, 1988, J NEUROSCI, V8, P664; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; VALE RD, 1985, METHOD ENZYMOL, V109, P21; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WILEY HS, 1981, CELL, V25, P433, DOI 10.1016/0092-8674(81)90061-1; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551; YAN Q, 1988, J NEUROSCI, V8, P3481; ZIEMIECKI A, 1990, EMBO J, V9, P191, DOI 10.1002/j.1460-2075.1990.tb08095.x; ZIMMERMANN A, 1983, EMBO J, V2, P879, DOI 10.1002/j.1460-2075.1983.tb01517.x	50	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13917	13923						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321130				2022-12-27	WOS:A1992JD32500023
J	WENNSTROM, S; LANDGREN, E; JENSEN, PB; CLAESSONWELSH, L				WENNSTROM, S; LANDGREN, E; JENSEN, PB; CLAESSONWELSH, L			THE PLATELET-DERIVED GROWTH-FACTOR BETA-RECEPTOR KINASE INSERT CONFERS SPECIFIC SIGNALING PROPERTIES TO A CHIMERIC FIBROBLAST GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; GTPASE ACTIVATING PROTEIN; TYROSINE PHOSPHORYLATION; PDGF RECEPTOR; PHOSPHATIDYLINOSITOL KINASE; CDNA CLONING; BINDING; ASSOCIATION; INDUCTION; FAMILY	Signal transduction by tyrosine kinase growth factor receptors involves ligand-induced phosphorylation of substrates for the kinase, resulting in mediation of common or receptor-specific biological signals. We have compared signal transduction pathways for the fibroblast growth factor receptor-1 (FGFR-1), the platelet-derived growth factor-beta-receptor (PDGFR-beta), and a chimeric FGFR-1 molecule, FGFRchim, in which the FGFR-1 kinase insert was replaced with that of the PDGFR-beta. The different receptors were characterized and found to be functional as ligand-stimulatable kinases, after expression of the respective human cDNAs in porcine aortic endothelial cells. Substrates for the receptors were analyzed by ligand stimulation of [P-32]orthophosphate-labeled cells and immunoprecipitation with phosphotyrosine antiserum. A number of phosphoproteins were induced in all the different types of cells, but components specifically induced after stimulation of FGFR-1 and PDGFR-beta expressing cells could also be detected. Examination of receptor-associated substrates by in vitro kinase assays revealed phosphoproteins of 65 and 85 kDa, which were associated with PDGFR-beta and FGFRchim, but not with FGFR-1. The 85-kDa phosphoprotein could correspond to the regulatory subunit of phosphatidylinositol 3' kinase (PI3-K), since phosphatidylinositol 3' kinase activity was detected after ligand stimulation of FGFRchim- and PDGFR-beta- but not FGFR-1-expressing cells. In addition, ligand stimulation of FGFRchim- and PDGFR-beta-expressing cells, but not FGFR-1-expressing cells, led to induction of actin reorganization in the form of circular membrane ruffling. Thus, replacement of a discrete segment of the intracellular domain of the FGFR-1 with the corresponding stretch from the PDGFR-beta resulted in transfer of PDGFR-beta-specific signaling properties to the chimeric molecule.	BIOMED CTR,LUDWIG INST CANC RES,UPPSALA BRANCH,BOX 595,S-75124 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research								ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EK B, 1984, J BIOL CHEM, V259, P1145; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; MELLSTROM K, 1983, J MUSCLE RES CELL M, V4, P589, DOI 10.1007/BF00712117; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANZOELEN EJJ, 1989, BIOCHEM J, V262, P549, DOI 10.1042/bj2620549; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	53	33	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13749	13756						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320030				2022-12-27	WOS:A1992JB74600102
J	TANSEY, MG; WORD, RA; HIDAKA, H; SINGER, HA; SCHWORER, CM; KAMM, KE; STULL, JT				TANSEY, MG; WORD, RA; HIDAKA, H; SINGER, HA; SCHWORER, CM; KAMM, KE; STULL, JT			PHOSPHORYLATION OF MYOSIN LIGHT CHAIN KINASE BY THE MULTIFUNCTIONAL CALMODULIN-DEPENDENT PROTEIN KINASE-II IN SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; SITES; HEAVY	Stimulation of tracheal smooth muscle cells in culture with ionomycin resulted in a rapid increase in cytosolic free Ca2+ concentration ([Ca2+]i) and an increase in both myosin light chain kinase and myosin light chain phosphorylation. These responses were markedly inhibited in the absence of extracellular Ca2+. Pretreatment of cells with 1-[N-O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine (KN-62), a specific inhibitor of the multifunctional calmodulin-dependent protein kinase II (CaM kinase II), did not affect the increase in [Ca2+]i but inhibited ionomycin-induced phosphorylation of myosin light chain kinase at the regulatory site near the calmodulin-binding domain. KN-62 inhibited CaM kinase II activity toward purified myosin light chain kinase. Phosphorylation of myosin light chain kinase decreased its sensitivity to activation by Ca2+ in cell lysates. Pretreatment of cells with KN-62 prevented this desensitization to Ca2+ and potentiated myosin light chain phosphorylation. We propose that the Ca2+-dependent phosphorylation of myosin light chain kinase by CaM kinase II decreases the Ca2+ sensitivity of myosin light chain phosphorylation in smooth muscle.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,CECIL H & IDA GREEN CTR REPROD BIOL SCI,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT OBSTET & GYNECOL,DALLAS,TX 75235; NAGOYA UNIV,SCH MED,DEPT PHARMACOL,NAGOYA,AICHI 466,JAPAN; GEISINGER MED CLIN,SIEGFRIED & JANET WEIS CTR RES,DANVILLE,PA 17822	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Nagoya University; Geisinger Medical Center					NHLBI NIH HHS [HL26043, HL32607] Funding Source: Medline; NIGMS NIH HHS [GM07062] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026043, R23HL032607, R01HL026043, R01HL032607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HASHIMOTO Y, 1990, ARCH BIOCHEM BIOPHYS, V278, P41, DOI 10.1016/0003-9861(90)90228-Q; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIMPENS B, 1989, J PHYSIOL-LONDON, V413, P489, DOI 10.1113/jphysiol.1989.sp017665; IKEBE M, 1985, J BIOL CHEM, V260, P4547; IKEBE M, 1990, J BIOL CHEM, V265, P8975; ISHII A, 1991, BIOCHEM BIOPH RES CO, V176, P1051, DOI 10.1016/0006-291X(91)90389-O; KAMM KE, 1986, SCIENCE, V232, P80, DOI 10.1126/science.3754063; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KAMM KE, 1989, J BIOL CHEM, V264, P21223; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KARAKI H, 1989, TRENDS PHARMACOL SCI, V10, P320; KAWAMOTO S, 1988, J BIOL CHEM, V263, P1099; MILLER JR, 1983, MOL PHARMACOL, V24, P235; MORGAN JP, 1984, J PHYSIOL-LONDON, V351, P155, DOI 10.1113/jphysiol.1984.sp015239; NISHIKAWA M, 1985, J BIOL CHEM, V260, P8978; PAYNE ME, 1983, J BIOL CHEM, V258, P2376; REMBOLD CM, 1988, CIRC RES, V63, P593, DOI 10.1161/01.RES.63.3.593; STULL JT, 1990, J BIOL CHEM, V265, P16683; STULL JT, 1991, HYPERTENSION, V17, P723, DOI 10.1161/01.HYP.17.6.723; STULL JT, 1986, ENZYMES, P113; TANG DC, 1992, J BIOL CHEM, V267, P11839; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; TOHDA M, 1991, NEUROSCI LETT, V129, P47, DOI 10.1016/0304-3940(91)90717-8; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; YAGI S, 1988, P NATL ACAD SCI USA, V85, P4109, DOI 10.1073/pnas.85.11.4109	28	121	123	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12511	12516						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1319999				2022-12-27	WOS:A1992HZ48300024
J	VALTORTA, F; GREENGARD, P; FESCE, R; CHIEREGATTI, E; BENFENATI, F				VALTORTA, F; GREENGARD, P; FESCE, R; CHIEREGATTI, E; BENFENATI, F			EFFECTS OF THE NEURONAL PHOSPHOPROTEIN SYNAPSIN-I ON ACTIN POLYMERIZATION .1. EVIDENCE FOR A PHOSPHORYLATION-DEPENDENT NUCLEATING EFFECT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-II; SQUID GIANT SYNAPSE; NEUROTRANSMITTER RELEASE; F-ACTIN; VESICLES; BINDING; PURIFICATION; ASSOCIATION; CONTRACTION; FRAGMENTS	Synapsin I is a synaptic vesicle-specific phosphoprotein which is able to bind and bundle actin filaments in a phosphorylation-dependent fashion. In the present paper we have analyzed the effects of synapsin I on the kinetics of actin polymerization and their modulation by site-specific phosphorylation of synapsin I. We found that dephosphorylated synapsin I accelerates the initial rate of actin polymerization and decreases the rate of filament elongation. The effect was observed at both low and high ionic strength, was specific for synapsin I, and was still present when polymerization was triggered by F-actin seeds. Dephosphorylated synapsin I was also able to induce actin polymerization and bundle formation in the absence of KCl and MgCl2. The effects of synapsin I were strongly decreased after its phosphorylation by Ca2+/calmodulin-dependent protein kinase II. These observations suggest that synapsin I has a phosphorylation-dependent nucleating effect on actin polymerization. The data are compatible with the view that changes in the phosphorylation state of synapsin I play a functional role in regulating the interactions between the nerve terminal cytoskeleton and synaptic vesicles in various stages of the exoendocytotic cycle.	ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021; UNIV MODENA,INST HUMAN PHYSIOL,I-41100 MODENA,ITALY	Rockefeller University; Universita di Modena e Reggio Emilia	VALTORTA, F (corresponding author), UNIV MILAN,SAN RAFFAELE SCI INST,NATL RES COUNCIL,CTR CYTOPHARMACOL,I-20129 MILAN,ITALY.		Chieregatti, Evelina/G-2917-2013; fesce, riccardo/A-6317-2008; Flavia, Valtorta/F-3450-2012	Flavia, Valtorta/0000-0001-9556-4746; Chieregatti, Evelina/0000-0001-9066-3606; fesce, riccardo/0000-0001-9473-896X	NIMH NIH HHS [MH 39327] Funding Source: Medline; Telethon [112] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039327, R01MH039327] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ATTRI AK, 1991, J BIOL CHEM, V266, P6815; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAHLER M, 1989, J CELL BIOL, V108, P1841, DOI 10.1083/jcb.108.5.1841; BAHLER M, 1990, BIOESSAYS, V12, P259, DOI 10.1002/bies.950120603; BENFENATI F, 1991, P NATL ACAD SCI USA, V88, P575, DOI 10.1073/pnas.88.2.575; BENFENATI F, 1992, NEURON, V8, P377, DOI 10.1016/0896-6273(92)90303-U; BERNSTEIN BW, 1989, NEURON, V3, P257, DOI 10.1016/0896-6273(89)90039-1; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; FESCE R, 1980, J BIOL CHEM, V267, P11289; FRIEDEN C, 1980, J BIOL CHEM, V255, P8991; GLENNEY JR, 1981, CELL, V24, P471, DOI 10.1016/0092-8674(81)90338-X; GRAZI E, 1985, BIOCHEM BIOPH RES CO, V128, P1058, DOI 10.1016/0006-291X(85)91047-2; HAN HQ, 1991, NATURE, V349, P697, DOI 10.1038/349697a0; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LIN JW, 1990, P NATL ACAD SCI USA, V87, P8257, DOI 10.1073/pnas.87.21.8257; LINSTEDT AD, 1987, TRENDS NEUROSCI, V10, P446, DOI 10.1016/0166-2236(87)90095-6; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU B, 1992, IN PRESS NEURON; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Martell A. E., 1974, CRITICAL STABILITY C; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; Nestler E. J., 1984, PROTEIN PHOSPHORYLAT; PETRUCCI TC, 1987, J CELL BIOL, V105, P1355, DOI 10.1083/jcb.105.3.1355; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1976, J CELL BIOL, V68, P579, DOI 10.1083/jcb.68.3.579; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TASHIRO T, 1978, EUR J BIOCHEM, V90, P479, DOI 10.1111/j.1432-1033.1978.tb12627.x; TOBACMAN LS, 1983, J BIOL CHEM, V258, P3207; UEDA T, 1977, J BIOL CHEM, V252, P5155; VALTORTA F, 1990, NEUROSCIENCE, V35, P477, DOI 10.1016/0306-4522(90)90323-V	39	67	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11281	11288						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317863				2022-12-27	WOS:A1992HX16900056
J	YE, J; LIU, LW; ESMON, CT; JOHNSON, AE				YE, J; LIU, LW; ESMON, CT; JOHNSON, AE			THE 5TH AND 6TH GROWTH FACTOR-LIKE DOMAINS OF THROMBOMODULIN BIND TO THE ANION-BINDING EXOSITE OF THROMBIN AND ALTER ITS SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-C; RABBIT THROMBOMODULIN; ANTICOAGULANT ACTIVITY; PROTEOLYTIC FORMATION; FUNCTIONAL DOMAINS; BLOOD-COAGULATION; HOMOLOGY DOMAIN; ALPHA-THROMBIN; HIRUDIN; INHIBITION	The domain of thrombomodulin that binds to the anion-binding exosite of thrombin was identified by comparing the binding of fragments of thrombomodulin to thrombin with that of Hirugen, a 12-residue peptide of hirudin that is known to bind to the anion-binding exosite of thrombin. Three soluble fragments of thrombomodulin, containing (i) the six repeated growth factor-like domains of thrombomodulin (GF1-6), (ii) one-half of the second through the sixth growth factor-like repeats (GF2.5-6), or (iii) the fifth and sixth such domains (GF5-6), were examined. Hirugen was a competitive inhibitor for either GF1-6 or GF2.5-6 stimulation of thrombin activation of protein C. GF5-6, which binds to thrombin without altering its ability to activate protein C, competed with fluorescein-labeled Hirugen for binding to thrombin. Therefore, all three thrombomodulin fragments, each of which lacked the chondroitin sulfate moiety, competed with Hirugen for binding to thrombin. To determine whether GF5-6 and Hirugen were binding to overlapping sites on thrombin or were interfering allosterically with each other's binding to thrombin, the effects of each thrombomodulin fragment and of Hirugen on the active site conformation of thrombin were compared using two different approaches: fluorescence-detected changes in the structure of the active site and the hydrolysis of chromogenic substrates. The GF5-6 and Hirugen peptides affected these measures of active site conformation very similarly, and hence GF5-6 and Hirugen contact residues on the surface of thrombin that allosterically alter the active site structure to a similar extent. Full-length thrombomodulin and GF1-6 alter the active site structure to comparable extents, but the amidolytic activity of thrombin complexed to thrombomodulin or GF1-6 differs significantly from that of thrombin complexed to GF5-6 or Hirugen. Taken together, these results indicate that the GF5-6 domain of thrombomodulin binds to the anion-binding exosite of thrombin. Furthermore, the binding of GF5-6 to the anion-binding exosite alters thrombin specificity, as evidenced by GF5-6-dependent changes in both the k(cat) and K(m) of synthetic substrate hydrolysis by thrombin. The contact sites on thrombin for the GF4 domain and the chondroitin sulfate moiety of thrombomodulin are still unknown.	UNIV OKLAHOMA, DEPT CHEM & BIOCHEM, NORMAN, OK 73019 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT PATHOL, OKLAHOMA CITY, OK 73190 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, OKLAHOMA CITY, OK 73190 USA; OKLAHOMA MED RES FDN, CARDIOVASC BIOL RES PROGRAM, OKLAHOMA CITY, OK 73104 USA; HOWARD HUGHES MED INST, OKLAHOMA CITY, OK 73104 USA	University of Oklahoma System; University of Oklahoma - Norman; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; Howard Hughes Medical Institute			Johnson, Arthur E/G-3457-2012		NHLBI NIH HHS [R01 HL 32934, R01 HL 29807, R37 HL 30340] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029807, R37HL030340, R01HL032934] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERLINER LJ, 1978, THROMB RES, V12, P15, DOI 10.1016/0049-3848(78)90081-6; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; BOURIN MC, 1986, P NATL ACAD SCI USA, V83, P5924, DOI 10.1073/pnas.83.16.5924; DELL VA, 1990, BIOCHEMISTRY-US, V29, P1757, DOI 10.1021/bi00459a014; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON CT, 1991, ANN NY ACAD SCI, V614, P30; ESMON NL, 1982, J BIOL CHEM, V257, P859; ESMON NL, 1983, J BIOL CHEM, V258, P5548; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HAYASHI T, 1990, J BIOL CHEM, V265, P20156; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HORTIN GL, 1990, BIOCHEM BIOPH RES CO, V169, P437, DOI 10.1016/0006-291X(90)90350-V; HORTIN GL, 1991, J BIOL CHEM, V266, P6866; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; JAKUBOWSKI HV, 1989, J BIOL CHEM, V264, P11117; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4893, DOI 10.1021/bi00667a022; KOYAMA T, 1991, BRIT J HAEMATOL, V78, P515, DOI 10.1111/j.1365-2141.1991.tb04481.x; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; KUROSAWA S, 1987, J BIOL CHEM, V262, P2206; LIU LW, 1991, J BIOL CHEM, V266, P16977; LIU LW, 1991, J BIOL CHEM, V266, P23632; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; MUSCI G, 1988, BIOCHEMISTRY-US, V27, P769, DOI 10.1021/bi00402a042; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NOE G, 1988, J BIOL CHEM, V263, P11729; PREISSNER KT, 1987, BIOCHEMISTRY-US, V26, P2521, DOI 10.1021/bi00383a018; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; STEARNS DJ, 1989, J BIOL CHEM, V264, P3352; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; SUZUKI K, 1990, J BIOL CHEM, V265, P13263; SUZUKI K, 1991, J BIOL CHEM, V266, P18498; THOMPSON AR, 1977, ARCH BIOCHEM BIOPHYS, V178, P356, DOI 10.1016/0003-9861(77)90204-1; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; YE J, 1991, J BIOL CHEM, V266, P23016; ZUSHI M, 1989, J BIOL CHEM, V264, P10351	39	105	108	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11023	11028						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317850				2022-12-27	WOS:A1992HX16900017
J	SUGUMARAN, M; SEMENSI, V; KALYANARAMAN, B; BRUCE, JM; LAND, EJ				SUGUMARAN, M; SEMENSI, V; KALYANARAMAN, B; BRUCE, JM; LAND, EJ			EVIDENCE FOR THE FORMATION OF A QUINONE METHIDE DURING THE OXIDATION OF THE INSECT CUTICULAR SCLEROTIZING PRECURSOR 1,2-DEHYDRO-N-ACETYLDOPAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDOLIC MELANIN PRECURSORS; N-ACETYLDOPAMINE QUINONE; PULSE-RADIOLYSIS; SARCOPHAGA-BULLATA; 3,4-DIHYDROXYPHENYLALANINE DOPA; ENZYMATIC-ACTIVITIES; BETA-SCLEROTIZATION; CUTICLE; MECHANISM; RADICALS	1,2-Dehydro-N-acetyldopamine (dehydro-NADA) is an important catecholamine derivative involved in the cross-linking of insect cuticular components during sclerotization. Since sclerotization is a vital process for the survival of insects, and is closely related to melanogenesis, it is of interest to unravel the chemical mechanisms participating in this process. The present paper reports on the mechanism by which dehydro-NADA is oxidatively activated to form reactive intermediate(s) as revealed by pulse radiolysis, electron spin resonance spectroscopy, high performance liquid chromatography, and ultraviolet-visible spectroscopic analysis. Pulse radiolytic one-electron oxidation of dehydro-NADA by N3. (k = 5.3 x 10(9) M-1 s-1) or Br2 radical-anion (k = 7.5 x 10(8) M-1 s-1) at pH 6 resulted in the rapid generation of the corresponding semiquinone radical, lambda(max) 400 nm, epsilon = 20,700 M-1 cm-1. This semiquinone decayed to form a second transient intermediate, lambda(max) 485 nm, epsilon = 8000 M-1 cm-1, via a second order disproportionation process, k = 6.2 x 10(8) M-1 s-1. At pH 6 in the presence of azide, the first order decay of this second intermediate occurred over milliseconds; the rate decreases at higher pH. At pH 6 in the presence of bromide, the intermediate decayed much more slowly over seconds, k = 0.15 s-1. Under such conditions, the dependence of the first order decay constant upon parent dehydro-NADA concentration led to a second order rate constant of 8.5 x 10(2) M-1 s-1 for reaction of the intermediate with the parent, probably to form benzodioxan "dimers." (The term dimer is used for convenience; the products are strictly bisdehydrodimers of dehydro-NADA (see "Discussion" and Fig. 11)) Rate constants of 5.9 x 10(5), 4.5 x 10(5), 2.8 x 10(4) and 3.5 x 10(4) M-1 s-1 were also obtained for decay of the second intermediate in the presence of cysteine, cysteamine, o-phenylenediamine, and p-aminophenol, respectively. By comparison with the UV-visible spectroscopic properties of the two-electron oxidized species derived from dehydro-NADA and from 1,2-dehydro-N-acetyldopa methyl ester, it is concluded that the transient intermediate exhibiting absorbance at 485 nm is the quinone methide tautomer of the o-quinone of dehydro-NADA. Sclerotization of insect cuticle is discussed in the light of these findings.	MED COLL WISCONSIN,NATL BIOMED ESR CTR,DEPT RADIOL,MILWAUKEE,WI 53226; UNIV MANCHESTER,DEPT CHEM,MANCHESTER M13 9PL,LANCS,ENGLAND; CHRISTIE HOSP TRUST,PATERSON INST CANC RES,DEPT BIOPHYS CHEM,MANCHESTER M20 9BX,ENGLAND	Medical College of Wisconsin; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	SUGUMARAN, M (corresponding author), UNIV MASSACHUSETTS,DEPT BIOL,HARBOR CAMPUS,BOSTON,MA 02125, USA.				NCRR NIH HHS [RR-01008] Funding Source: Medline; NIAID NIH HHS [R01 AI-14753] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014753] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS GE, 1965, PULSE RADIOLYSIS, P117; ANDERSEN SO, 1989, INSECT BIOCHEM, V19, P375, DOI 10.1016/0020-1790(89)90042-5; ANDERSEN SO, 1989, INSECT BIOCHEM, V19, P59, DOI 10.1016/0020-1790(89)90009-7; ANDERSEN SO, 1982, INSECT BIOCHEM, V12, P269, DOI 10.1016/0020-1790(82)90085-3; BOUHEROUM M, 1989, BIOCHIM BIOPHYS ACTA, V998, P57, DOI 10.1016/0167-4838(89)90118-0; BUTLER J, 1984, RADIAT PHYS CHEM, V23, P265, DOI 10.1016/0146-5724(84)90118-3; CHAPMAN DF, 1980, INSECTS STRUCTURE FU, P501; CHEDEKEL MR, 1984, J CHEM SOC CHEM COMM, P1170, DOI 10.1039/c39840001170; Cooksey C J, 1987, Free Radic Res Commun, V4, P131, DOI 10.3109/10715768709088098; DALI H, 1988, ORG PREP PROCED INT, V20, P191, DOI 10.1080/00304948809355808; FELIX CC, 1981, J AM CHEM SOC, V103, P2831, DOI 10.1021/ja00400a056; KALYANARAMAN B, 1985, ENVIRON HEALTH PERSP, V64, P185, DOI 10.2307/3430009; LAMBERT C, 1989, BIOCHIM BIOPHYS ACTA, V993, P12, DOI 10.1016/0304-4165(89)90136-0; LAMBERT C, 1991, J CHEM SOC FARADAY T, V87, P2939, DOI 10.1039/ft9918702939; LAMBERT C, 1990, BIOCHIM BIOPHYS ACTA, V1035, P319, DOI 10.1016/0304-4165(90)90095-E; LAND EJ, 1990, BIOCHEM PHARMACOL, V39, P1133, DOI 10.1016/0006-2952(90)90294-U; LAND EJ, 1988, REV CHEM INTERMED, V10, P219, DOI 10.1007/BF03155994; Lipke H., 1983, Advances in Insect Physiology, V17, P1, DOI 10.1016/S0065-2806(08)60216-7; PATEL KB, 1973, J CHEM SOC FARAD T 1, V69, P814, DOI 10.1039/f19736900814; Pryor MGM, 1940, PROC R SOC SER B-BIO, V128, P393, DOI 10.1098/rspb.1940.0018; Pryor MGM, 1940, PROC R SOC SER B-BIO, V128, P378, DOI 10.1098/rspb.1940.0017; RAMAMURTHY B, 1987, SYNTHESIS-STUTTGART, V5, P523; RAO PS, 1973, J PHYS CHEM-US, V77, P2274, DOI 10.1021/j100638a003; SAUL S, 1988, FEBS LETT, V237, P155, DOI 10.1016/0014-5793(88)80191-1; SAUL SJ, 1990, ARCH INSECT BIOCHEM, V15, P237, DOI 10.1002/arch.940150405; SAUL SJ, 1989, FEBS LETT, V255, P340, DOI 10.1016/0014-5793(89)81117-2; SAUL SJ, 1989, FEBS LETT, V251, P69, DOI 10.1016/0014-5793(89)81430-9; SAUL SJ, 1990, J BIOL CHEM, V265, P16992; SAUL SJ, 1989, FEBS LETT, V249, P155, DOI 10.1016/0014-5793(89)80614-3; Sugumaran M., 1988, Advances in Insect Physiology, V21, P179, DOI 10.1016/S0065-2806(08)60124-1; SUGUMARAN M, 1989, ARCH INSECT BIOCHEM, V11, P109, DOI 10.1002/arch.940110205; SUGUMARAN M, 1988, ARCH INSECT BIOCHEM, V8, P73, DOI 10.1002/arch.940080202; SUGUMARAN M, 1988, ARCH INSECT BIOCHEM, V9, P269, DOI 10.1002/arch.940090403; SUGUMARAN M, 1987, BIOORG CHEM, V15, P194, DOI 10.1016/0045-2068(87)90019-8; SUGUMARAN M, 1983, FEBS LETT, V155, P65, DOI 10.1016/0014-5793(83)80210-5; SUGUMARAN M, 1990, ARCH INSECT BIOCHEM, V14, P93, DOI 10.1002/arch.940140205; SUGUMARAN M, 1987, J BIOL CHEM, V262, P10546; SUGUMARAN M, 1988, ARCH INSECT BIOCHEM, V8, P89, DOI 10.1002/arch.940080203; SUGUMARAN M, 1987, UCLA S, V49, P357; SUGUMARAN M, 1991, INSECT EPIDERMIS, P141; THOMPSON A, 1985, BIOCHIM BIOPHYS ACTA, V843, P49, DOI 10.1016/0304-4165(85)90048-0; [No title captured]	42	54	55	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10355	10361						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1316899				2022-12-27	WOS:A1992HV09000026
J	MULLERSTEFFNER, HM; MALVER, O; HOSIE, L; OPPENHEIMER, NJ; SCHUBER, F				MULLERSTEFFNER, HM; MALVER, O; HOSIE, L; OPPENHEIMER, NJ; SCHUBER, F			SLOW-BINDING INHIBITION OF NAD+ GLYCOHYDROLASE BY ARABINO ANALOGS OF BETA-NAD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE-ADENINE-DINUCLEOTIDE; MECHANISM; CHYMOTRYPSIN; ENZYME; GLUCOSIDASE; THERMOLYSIN; HYDROLYSIS; LIPOSOMES	Modifications at the 2'-position of the nicotinamide-ribosyl moiety influence dramatically the nature of the interactions of the modified beta-NAD+ with calf spleen NAD+ glycohydrolase (EC 3.2.2.6), an enzyme that cleaves the nicotinamide-ribose bound in NAD(P)+. Nicotinamide arabinoside adenine dinucleotide (ara-NAD+) and nicotinamide 2'-deoxy-2'-fluoroarabinoside adenine dinucleotide (araF-NAD+) are not hydrolyzed at measurable rates and are the first documented examples of reversible slow binding inhibitors of this class of enzyme. The kinetic data obtained are consistent with both slow k(on) and k(off) rate constants in the formation of an enzyme-inhibitor complex, i.e. the association rate constants are about 10(4) and 10(6) slower than diffusion rates, respectively, for araF-NAD+ and ara-NAD+, and the half-life of the complex is about 3-10 min for both analogues. The kinetic model does not account for a slow turnover of an ADP-ribosyl-enzyme intermediary complex. AraF-NAD+ is one of the most potent inhibitors described for NAD+ glycohydrolase.	UNIV LOUIS PASTEUR STRASBOURG,FAC PHARM,CHIM BIOORGAN LAB,CNRS,UNITE RECH,74 ROUTE RHIN,F-67400 ILLKIRCH GRAFFENS,FRANCE; UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of California System; University of California San Francisco								BARTLETT PA, 1987, BIOCHEMISTRY-US, V26, P8553, DOI 10.1021/bi00400a009; BRADY K, 1990, BIOCHEMISTRY-US, V29, P7608, DOI 10.1021/bi00485a010; BULL HG, 1978, J BIOL CHEM, V253, P5186; DUGGLEBY RG, 1982, BIOCHEMISTRY-US, V21, P3364, DOI 10.1021/bi00257a018; FRICK L, 1986, BIOCHEMISTRY-US, V25, P1616, DOI 10.1021/bi00355a025; HANDLON AL, 1991, J ORG CHEM, V56, P5009, DOI 10.1021/jo00017a004; HOLDEN HM, 1987, BIOCHEMISTRY-US, V26, P8542, DOI 10.1021/bi00400a008; Jencks W. P., 1969, CATALYSIS CHEM ENZYM, P282; KAM BL, 1987, BIOCHEMISTRY-US, V26, P3453, DOI 10.1021/bi00386a031; KNOWLES JR, 1965, BIOCHEM J, V95, P180, DOI 10.1042/bj0950180; LONGSTAFF C, 1990, BIOCHEMISTRY-US, V29, P7339, DOI 10.1021/bi00483a025; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MULLER HM, 1983, BIOCHEM J, V212, P459, DOI 10.1042/bj2120459; MULLER HM, 1987, BIOCHEM J, V246, P319, DOI 10.1042/bj2460319; PASCAL M, 1976, FEBS LETT, V66, P107, DOI 10.1016/0014-5793(76)80596-0; RICH DH, 1985, J MED CHEM, V28, P263, DOI 10.1021/jm00381a001; SALORD J, 1986, BIOCHIM BIOPHYS ACTA, V886, P64, DOI 10.1016/0167-4889(86)90212-0; SCHLOSS JV, 1988, ACCOUNTS CHEM RES, V21, P348, DOI 10.1021/ar00153a005; SCHUBER F, 1977, BIOCHIMIE, V59, P735, DOI 10.1016/S0300-9084(77)80254-X; SCHUBER F, 1978, EUR J BIOCHEM, V83, P205, DOI 10.1111/j.1432-1033.1978.tb12085.x; SCHUBER F, 1976, EUR J BIOCHEM, V69, P593, DOI 10.1111/j.1432-1033.1976.tb10945.x; SCHUBER F, 1979, BIOORG CHEM, V8, P83, DOI 10.1016/0045-2068(79)90039-7; SLAMA JT, 1989, BIOCHEMISTRY-US, V28, P7688, DOI 10.1021/bi00445a025; SLAMA JT, 1988, BIOCHEMISTRY-US, V27, P183, DOI 10.1021/bi00401a028; SLEATH PR, 1991, J ORG CHEM, V56, P3608, DOI 10.1021/jo00011a029; STEIN RL, 1987, BIOCHEMISTRY-US, V26, P2611, DOI 10.1021/bi00383a030; TARNUS C, 1987, BIOORG CHEM, V15, P31, DOI 10.1016/0045-2068(87)90004-6; TARNUS C, 1988, BIOORG CHEM, V16, P38, DOI 10.1016/0045-2068(88)90036-3; TARNUS C, 1985, THESIS U L PASTEUR S; WENTWORTH DF, 1974, BIOCHEMISTRY-US, V13, P4715, DOI 10.1021/bi00720a006; Williams J W, 1979, Methods Enzymol, V63, P437; WILLIAMS JW, 1979, BIOCHEMISTRY-US, V18, P2567, DOI 10.1021/bi00579a021; WITHERS SG, 1988, J AM CHEM SOC, V110, P8551, DOI 10.1021/ja00233a045; WITHERS SG, 1988, J BIOL CHEM, V263, P7929; WITHERS SG, 1987, J AM CHEM SOC, V109, P7530, DOI 10.1021/ja00258a047	35	43	44	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9606	9611						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315761				2022-12-27	WOS:A1992HT96500026
J	MINNITI, CP; KOHN, EC; GRUBB, JH; SLY, WS; OH, Y; MULLER, HL; ROSENFELD, RG; HELMAN, LJ				MINNITI, CP; KOHN, EC; GRUBB, JH; SLY, WS; OH, Y; MULLER, HL; ROSENFELD, RG; HELMAN, LJ			THE INSULIN-LIKE GROWTH FACTOR-II (IGF-II) MANNOSE 6-PHOSPHATE RECEPTOR MEDIATES IGF-II-INDUCED MOTILITY IN HUMAN RHABDOMYOSARCOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MELANOMA CELLS; AUTOCRINE GROWTH; TUMOR CELLS; CLONING; BINDING; PROTEIN; HETEROGENEITY; EXPRESSION; AFFINITY; SEQUENCE	Insulin-like growth factor-II (IGF-II) is an autocrine growth and motility factor for human rhabdomyosarcoma. It interacts with three different receptors: the IGF-I, the IGF-II, and the insulin receptor. A specific function of the IGF-II receptor in mediating IGF-II responses has not been defined. In this report we investigate the mechanism of IGF-II-mediated motility in rhabdomyosarcoma cells. We demonstrate that IGF-II and [Leu27]IGF-II, an analog selective for the IGF-II receptor, stimulate motility at concentrations in which they interact only with their own receptor. An antibody that blocks the IGF-I receptor does not inhibit either peptide activity, while an antibody specific for the IGF-II receptor suppresses the IGF-II-induced motility. This antibody does not interfere with rhabdomyosarcoma cell proliferation. We conclude that in rhabdomyosarcoma cells IGF-II stimulates two different responses mediated by distinct receptors: 1) a mitogenic response through the type I receptor and 2) a motility response through the type II receptor.	ST LOUIS UNIV,SCH MED,DEPT BIOCHEM,ST LOUIS,MO 63104; STANFORD UNIV,MED CTR,STANFORD,CA 94305	Saint Louis University; Stanford University	MINNITI, CP (corresponding author), NCI,PEDIAT BRANCH,MOLEC GENET SECT,BLDG 10,RM 13N240,BETHESDA,MD 20892, USA.		müller, Hermann l/AAC-1637-2020; Minniti, Caterina/AAX-3187-2021	Muller, Hermann L./0000-0003-4929-9966				BEUKERS MW, 1991, ENDOCRINOLOGY, V128, P1201, DOI 10.1210/endo-128-2-1201; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAUGHADAY WH, 1990, ENDOCRINOLOGY, V127, P1; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; ELBADRY OM, 1989, J CLIN INVEST, V84, P829, DOI 10.1172/JCI114243; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EWTON DZ, 1987, ENDOCRINOLOGY, V120, P115, DOI 10.1210/endo-120-1-115; FISCHER HD, 1980, J BIOL CHEM, V255, P5069; HARI J, 1987, EMBO J, V6, P3367, DOI 10.1002/j.1460-2075.1987.tb02658.x; KIESS W, 1988, J BIOL CHEM, V263, P9339; KOHN EC, 1990, INT J CANCER, V46, P287, DOI 10.1002/ijc.2910460225; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING N, 1984, P NATL ACAD SCI-BIOL, V81, P4302, DOI 10.1073/pnas.81.14.4302; LIOTTA LA, 1986, CANCER RES, V46, P1; LOBEL P, 1987, P NATL ACAD SCI USA, V84, P2233, DOI 10.1073/pnas.84.8.2233; LOBEL P, 1987, P NATL ACAD SCI USA, V84, P7523; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MASSAGUE J, 1982, J BIOL CHEM, V257, P5038; MCALLISTER RM, 1969, CANCER-AM CANCER SOC, V24, P520, DOI 10.1002/1097-0142(196909)24:3<520::AID-CNCR2820240313>3.0.CO;2-M; MELLAS J, 1986, J BIOL CHEM, V261, P4437; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; NISSLEY SP, 1984, HORMONAL PROTEINS PE, V12, P127; NOLAN CM, 1987, J CELL BIOCHEM, V35, P137, DOI 10.1002/jcb.240350207; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; RANEY B, 1981, PRINCIPLES PRACTICE, P635; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; RECHLER MM, 1990, HDB EXPT PHARM, V95, P317; RINDERKNECHT E, 1978, FEBS LETT, V89, P283, DOI 10.1016/0014-5793(78)80237-3; RINDERKNECHT E, 1976, P NATL ACAD SCI USA, V73, P2365, DOI 10.1073/pnas.73.7.2365; ROSENFELD RG, 1987, BIOCHEM BIOPH RES CO, V143, P199, DOI 10.1016/0006-291X(87)90650-4; RUFF M, 1985, CLIN IMMUNOL IMMUNOP, V37, P387, DOI 10.1016/0090-1229(85)90108-4; STRACKE ML, 1987, BIOCHEM BIOPH RES CO, V146, P339, DOI 10.1016/0006-291X(87)90730-3; STRACKE ML, 1988, BIOCHEM BIOPH RES CO, V153, P1076, DOI 10.1016/S0006-291X(88)81338-X; TALLY M, 1987, BIOCHEM BIOPH RES CO, V148, P811, DOI 10.1016/0006-291X(87)90948-X; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; YEE D, 1988, CANCER RES, V48, P6691	41	115	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9000	9004						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1315746				2022-12-27	WOS:A1992HR85400047
J	KIMURA, S; KANAYA, S; NAKAMURA, H				KIMURA, S; KANAYA, S; NAKAMURA, H			THERMOSTABILIZATION OF ESCHERICHIA-COLI RIBONUCLEASE HI BY REPLACING LEFT-HANDED HELICAL LYS(95) WITH GLY OR ASN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MALATE-DEHYDROGENASE; CRYSTAL-STRUCTURE; SEQUENCE-ANALYSIS; STABILITY; RESIDUES; PROTEINS; MUTAGENESIS; RESOLUTION; CLONING	From the systematic replacements of amino acid residues of Escherichia coli ribonuclease HI with those of its thermophilic counterpart, the basic protrusion domain including region 6 (R6) from residues 91 to 95 was found to increase the structural stability of the mutant protein (Kimura, S., Nakamura, H., Hashimoto, T., Oobatake, M., and Kanaya, S. (1992) J. Biol. Chem. 267, 21535-21542). Further mutagenesis concentrating in the R6 region has revealed that replacements of Lys95 at the left-handed structure with Gly or Asn essentially enhances the protein stability. Gly and Asn substitutions stabilize the protein up to 1.9 kcal/mol and 0.9 kcal/mol in the free energy changes of unfolding, respectively. We propose that the amino acid substitution of left-handed non-Gly residue with Gly or Asn residue can be used as one of the general strategies to enhance protein stability, when such a non-Gly residue itself does not seriously contribute to protein stability.	PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN				Nakamura, Haruki/O-4028-2014					[Anonymous], INTRO PROTEIN STRUCT; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BETZEL C, 1988, ACTA CRYSTALLOGR B, V44, P163, DOI 10.1107/S010876818700939X; BIRKTOFT JJ, 1989, BIOCHEMISTRY-US, V28, P6065, DOI 10.1021/bi00440a051; Crouch R. J., 1982, NUCLEASES, P211; HEADGORDON T, 1991, J AM CHEM SOC, V113, P5989, DOI 10.1021/ja00016a010; HOLMES MA, 1982, J MOL BIOL, V160, P623, DOI 10.1016/0022-2836(82)90319-9; HYDE CC, 1990, BIO-TECHNOL, V8, P27, DOI 10.1038/nbt0190-27; JOH T, 1987, J BIOL CHEM, V262, P15127; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KANAYA S, 1989, J BIOL CHEM, V264, P11546; KANAYA S, 1991, J BIOL CHEM, V266, P6038; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KIMURA S, 1992, J BIOL CHEM, V267, P21535; KIMURA S, 1992, EUR J BIOCHEM, V206, P337, DOI 10.1111/j.1432-1033.1992.tb16932.x; KOYAMA Y, 1990, J BACTERIOL, V172, P3490, DOI 10.1128/jb.172.6.3490-3495.1990; KWON ST, 1988, EUR J BIOCHEM, V173, P491, DOI 10.1111/j.1432-1033.1988.tb14025.x; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MENENDEZARIAS L, 1989, J MOL BIOL, V206, P397, DOI 10.1016/0022-2836(89)90488-9; NICHOLSON H, 1989, J MOL BIOL, V210, P181, DOI 10.1016/0022-2836(89)90299-4; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; THORNTON JM, 1988, BIOESSAYS, V8, P63, DOI 10.1002/bies.950080205; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; ZIMMERMAN SS, 1977, MACROMOLECULES, V10, P1, DOI 10.1021/ma60055a001	28	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22014	22017						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331044				2022-12-27	WOS:A1992JW71900008
J	SAMPATH, TK; MALIAKAL, JC; HAUSCHKA, PV; JONES, WK; SASAK, H; TUCKER, RF; WHITE, KH; COUGHLIN, JE; TUCKER, MM; PANG, RHL; CORBETT, C; OZKAYNAK, E; OPPERMANN, H; RUEGER, DC				SAMPATH, TK; MALIAKAL, JC; HAUSCHKA, PV; JONES, WK; SASAK, H; TUCKER, RF; WHITE, KH; COUGHLIN, JE; TUCKER, MM; PANG, RHL; CORBETT, C; OZKAYNAK, E; OPPERMANN, H; RUEGER, DC			RECOMBINANT HUMAN OSTEOGENIC PROTEIN-1 (HOP-1) INDUCES NEW BONE-FORMATION INVIVO WITH A SPECIFIC ACTIVITY COMPARABLE WITH NATURAL BOVINE OSTEOGENIC PROTEIN AND STIMULATES OSTEOBLAST PROLIFERATION AND DIFFERENTIATION INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; RAT OSTEOCALCIN GENE; MORPHOGENETIC PROTEIN-2; AFFINITY-CHROMATOGRAPHY; COLLAGEN-SYNTHESIS; INDUCTIVE PROTEIN; SKELETAL GROWTH; CALVARIA CELLS; CULTURES; FAMILY	We reported previously that a 32-36-kDa osteogenic protein purified from bovine bone matrix is composed of dimers of two members of the transforming growth factor (TGF)-beta superfamily: the bovine equivalent of human osteogenic protein-1 (OP-1) and bone morphogenetic protein-2a, BMP-2a (BMP-2). In the present study, we produced the recombinant human OP-1 (hOP-1) in mammalian cells as a processed mature disulfide-linked homodimer with an apparent molecular weight of 36,000. Examination of hOP-1 in the rat subcutaneous bone induction model demonstrated that hOP-1 was capable of inducing new bone formation with a specific activity comparable with that exhibited by highly purified bovine osteogenic protein preparations. The half-maximal bone-inducing activity of hOP-1 in combination with a rat collagen matrix preparation was 50-100 ng/25 mg of matrix as determined by the calcium content of day 12 implants. Evaluation of hOP-1 effects on cell growth and collagen synthesis in rat osteoblast-enriched bone cell cultures showed that both cell proliferation and collagen synthesis were stimulated in a dose-dependent manner and increased 3-fold in response to 40 ng of hOP-1/ml. Examination of the expression of markers characteristic of the osteoblast phenotype showed that hOP-1 specifically stimulated the induction of alkaline phosphatase (4-fold increase at 40 ng of hOP-1/ml), parathyroid hormone-mediated intracellular cAMP production (4-fold increase at 40 ng of hOP-1/ml), and osteocalcin synthesis (5-fold increase at 25 ng of hOP-1/ml). In long-term (11-17 day) cultures of osteoblasts in the presence of beta-glycerophosphate and L(+)-ascorbate, hOP-1 markedly increased the rate of mineralization as measured by the number of mineral nodules per well (20-fold increase at 20 ng of hOP-1/ml). Direct comparison of TGF-beta1 and hOP-1 in these bone cell cultures indicated that, although both hOP-1 and TGF-beta1 promoted cell proliferation and collagen synthesis, only hOP-1 was effective in specifically stimulating markers of the osteoblast phenotype.	CHILDRENS HOSP MED CTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH DENT MED, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard School of Dental Medicine	SAMPATH, TK (corresponding author), CREAT BIOMOLECULES INC, 35 SOUTH ST, HOPKINTON, MA 01748 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038349] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 38349] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARONOW MA, 1990, J CELL PHYSIOL, V143, P213, DOI 10.1002/jcp.1041430203; AUFMKOLK B, 1985, CALCIFIED TISSUE INT, V37, P228, DOI 10.1007/BF02554868; BELLOWS CG, 1989, CELL TISSUE RES, V256, P145; BELLOWS CG, 1987, ENDOCRINOLOGY, V121, P1985, DOI 10.1210/endo-121-6-1985; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CENTRELLA M, 1985, ENDOCR REV, V6, P544, DOI 10.1210/edrv-6-4-544; CENTRELLA M, 1987, J BIOL CHEM, V262, P2869; CHEN TL, 1991, J BONE MINER RES, V6, P1387; COOK SD, 1992, IN PRESS J BONE J SU; FELIX R, 1988, J BONE MINER RES, V3, P27; GLASS WF, 1981, ANAL BIOCHEM, V115, P219, DOI 10.1016/0003-2697(81)90549-2; GUNDBERG CM, 1984, METHOD ENZYMOL, V107, P516; HAMMONDS RG, 1990, MOL ENDOCRINOL, V150, P149; HAUSCHKA PV, 1988, CIBA F SYMP, V136, P207; HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665; Hauschka PV, 1990, BONE OSTEOBLAST OSTE, V1, P103; HOCK JM, 1988, ENDOCRINOLOGY, V122, P254, DOI 10.1210/endo-122-1-254; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; KBENOIT R, 1987, SCIENCE, V238, P1216; LIAN J, 1989, P NATL ACAD SCI USA, V86, P1143, DOI 10.1073/pnas.86.4.1143; LUYTEN FP, 1989, J BIOL CHEM, V264, P13377; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MCDONNELL DP, 1989, MOL ENDOCRINOL, V3, P635, DOI 10.1210/mend-3-4-635; MOHAN S, 1988, BIOCHIM BIOPHYS ACTA, V966, P44, DOI 10.1016/0304-4165(88)90127-4; MOHAN S, 1991, CLIN ORTHOP RELAT R, V263, P30; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; PARALKAR VM, 1991, P NATL ACAD SCI USA, V88, P3397, DOI 10.1073/pnas.88.8.3397; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; REDDI AH, 1972, P NATL ACAD SCI USA, V69, P1601, DOI 10.1073/pnas.69.6.1601; ROBEY PG, 1987, J CELL BIOL, V105, P457, DOI 10.1083/jcb.105.1.457; RODAN SB, 1987, ENDOCRINOLOGY, V121, P1917, DOI 10.1210/endo-121-6-1917; SAMPATH TK, 1987, P NATL ACAD SCI USA, V84, P7109, DOI 10.1073/pnas.84.20.7109; SAMPATH TK, 1981, P NATL ACAD SCI-BIOL, V78, P7599, DOI 10.1073/pnas.78.12.7599; SAMPATH TK, 1990, J BIOL CHEM, V265, P13198; SEDIVY JM, 1988, BIO-TECHNOL, V6, P1192, DOI 10.1038/nbt1088-1192; SEYEDIN SM, 1985, P NATL ACAD SCI USA, V82, P2267, DOI 10.1073/pnas.82.8.2267; TAKUWA Y, 1991, BIOCHEM BIOPH RES CO, V174, P96, DOI 10.1016/0006-291X(91)90490-X; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; VUKICEVIC S, 1990, BIOCHEM BIOPH RES CO, V166, P750, DOI 10.1016/0006-291X(90)90873-L; VUKICEVIC S, 1989, P NATL ACAD SCI USA, V86, P8793, DOI 10.1073/pnas.86.22.8793; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; WONG GL, 1975, P NATL ACAD SCI USA, V72, P3167, DOI 10.1073/pnas.72.8.3167; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; YOON K, 1988, BIOCHEMISTRY-US, V27, P8521, DOI 10.1021/bi00423a003	50	603	649	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20352	20362						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328198				2022-12-27	WOS:A1992JR85800095
J	SHATTIL, SJ; CUNNINGHAM, M; WIEDMER, T; ZHAO, J; SIMS, PJ; BRASS, LF				SHATTIL, SJ; CUNNINGHAM, M; WIEDMER, T; ZHAO, J; SIMS, PJ; BRASS, LF			REGULATION OF GLYCOPROTEIN-IIB-IIIA RECEPTOR FUNCTION STUDIED WITH PLATELETS PERMEABILIZED BY THE PORE-FORMING COMPLEMENT PROTEINS C5B-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPIIB-IIIA; FIBRINOGEN RECEPTOR; MONOCLONAL-ANTIBODY; ACTIVATED PLATELETS; KINASE INHIBITORS; IIB/IIIA COMPLEX; PLASMA-MEMBRANE; BINDING DOMAIN; FACTOR-VA; EXPRESSION	Recent evidence suggests that the cytoplasmic domains of platelet glycoprotein (GP) IIb-IIIa are involved in the agonist-initiated transformation of this integrin into a receptor for fibrinogen. To identify intracellular reactions that regulate the receptor function of GP IIb-IIIa, membrane-impermeable agonists and antagonists were introduced into the platelet by permeabilizing the plasma membrane with the pore-forming complement proteins C5b-9. Platelet responses were then analyzed by flow cytometry. Non-lytic concentrations of C5b-9 caused permeabilization of the platelet plasma membrane, as determined by uptake of a water-soluble fluorescent tracer dye. The complement pores were large enough to permit the entry of fluorescein isothiocyanate (FITC)-labeled oligopeptides in a size-dependent manner. Under conditions of low external Ca2+, C5b-9 treatment per se did not activate GP IIb-IIIa, as measured by binding of the activation-dependent antibody FITC-PAC1. However, FITC-PAC1 binding to C5b-9-permeabilized platelets was stimulated by a thrombin receptor agonist acting at the cell surface and by guanosine 5'-O-(thiotriphosphate), a membrane-impermeable activator of G proteins. Permeabilization also permitted the entry of cyclic AMP and the peptide, RFARKGALRQKNV, a pseudo-substrate inhibitor of protein kinase C. Each of these inhibited agonist-induced FITC-PAC1 binding to permeabilized platelets but not to intact platelets. Agonist-induced GP IIb-IIIa activation in permeabilized platelets was also inhibited by tyrphostin-23, a protein tyrosine kinase inhibitor. Thus, C5b-9 can be used to permeabilize the plasma membrane to permit the selective entry of small peptides and other bioactive compounds into permeabilized platelets. Results obtained with these platelets indicate that GP IIb-IIIa receptor function is regulated by a network of signaling reactions involving G proteins, serine/threonine kinases, and tyrosine kinases.	UNIV PENN, SCH MED, DEPT MED, DIV HEMATOL ONCOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, DIV HEMATOL ONCOL, PHILADELPHIA, PA 19104 USA; OKLAHOMA MED RES FDN, OKLAHOMA CITY, OK 73104 USA	University of Pennsylvania; University of Pennsylvania; Oklahoma Medical Research Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036946, R01HL036061, R37HL036061, P01HL040387] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL40387, HL36946, HL36061] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1992, J BIOL CHEM, V267, P2775; ABRAMS CS, 1990, BLOOD, V75, P128; ANDO B, 1989, BLOOD, V73, P462; ANDO B, 1988, J BIOL CHEM, V263, P11907; ANDRIEUX A, 1991, J BIOL CHEM, V266, P14202; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAMSON HN, 1991, J BIOL CHEM, V266, P16219; Brass L F, 1991, Prog Hemost Thromb, V10, P127; BRASS LF, 1982, J BIOL CHEM, V257, P4000; BRASS LF, 1985, J BIOL CHEM, V260, P5172; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; CHEN Y, 1991, BLOOD, V78, P279; CHUNG DL, 1991, ANTICANCER RES, V11, P1373; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FISHER GJ, 1985, BIOCHEM BIOPH RES CO, V129, P958, DOI 10.1016/0006-291X(85)91984-9; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GILBERT GE, 1991, J BIOL CHEM, V266, P17261; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GRABER SE, 1982, J BIOL CHEM, V257, P4606; HERSEY SJ, 1990, ANNU REV PHYSIOL, V52, P345; HILLERY CA, 1991, J BIOL CHEM, V266, P14663; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; ISRAELS SJ, 1985, THROMB RES, V40, P499, DOI 10.1016/0049-3848(85)90287-7; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LEVITZKI A, 1991, TRENDS PHARMACOL SCI, V12, P171, DOI 10.1016/0165-6147(91)90538-4; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1989, BLOOD, V74, P14; PARISE LV, 1985, J BIOL CHEM, V260, P698; PHILLIPS DR, 1987, ANN NY ACAD SCI, V509, P177, DOI 10.1111/j.1749-6632.1987.tb30994.x; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PONCZ M, 1987, J BIOL CHEM, V262, P8476; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHATTIL SJ, 1987, BLOOD, V70, P307; SHATTIL SJ, 1986, BLOOD, V68, P1224; SHIRATAKI H, 1991, J BIOL CHEM, V266, P20672; SIMS PJ, 1980, J IMMUNOL, V125, P2617; SIMS PJ, 1983, BIOCHIM BIOPHYS ACTA, V732, P541, DOI 10.1016/0005-2736(83)90230-4; SIMS PJ, 1989, J BIOL CHEM, V264, P19228; SIMS PJ, 1991, IMMUNOL TODAY, V12, P338, DOI 10.1016/0167-5699(91)90012-I; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; SIMS PJ, 1981, P NATL ACAD SCI-BIOL, V78, P1838, DOI 10.1073/pnas.78.3.1838; SMYTH SS, 1991, BLOOD, V78, P278; TORTI M, 1991, BIOCHIM BIOPHYS ACTA, V1070, P20, DOI 10.1016/0005-2736(91)90141-T; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; WEISS HJ, 1991, THROMB HAEMOSTASIS, V65, P202; WIEDMER T, 1990, BIOCHEMISTRY-US, V29, P623, DOI 10.1021/bi00455a005; WIEDMER T, 1987, J BIOL CHEM, V262, P13674; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702	64	76	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18424	18431						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326524				2022-12-27	WOS:A1992JN50200032
J	FROLAND, WA; ANDERSSON, KK; LEE, SK; LIU, Y; LIPSCOMB, JD				FROLAND, WA; ANDERSSON, KK; LEE, SK; LIU, Y; LIPSCOMB, JD			METHANE MONOOXYGENASE COMPONENT-B AND REDUCTASE ALTER THE REGIOSELECTIVITY OF THE HYDROXYLASE COMPONENT-CATALYZED REACTIONS - A NOVEL ROLE FOR PROTEIN-PROTEIN INTERACTIONS IN AN OXYGENASE MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOCOCCUS-CAPSULATUS-BATH; METHYLOSINUS-TRICHOSPORIUM OB3B; ALKANE HYDROXYLATION; MONO-OXYGENASE; SATURATED-HYDROCARBONS; CYTOCHROME P-450CAM; UTILIZING BACTERIA; GENE-CLUSTER; IRON CENTER; PURIFICATION	The soluble methane monooxygenase (MMO) system, consisting of reductase, component B, and hydroxylase (MMOH), catalyzes NADH and O2-dependent monooxygenation of many hydrocarbons. MMOH contains 2-mu-(H or R)oxo-bridged dinuclear iron clusters thought to be the sites of catalysis. Although rapid NADH-coupled turnover requires all three protein components, three less complex systems are also functional: System I, NADH, O2, reductase, and MMOH; System II, H2O2 and oxidized MMOH; System III, MMOH reduced nonenzymatically by 2e- and then exposed to O2 (single turnover). All three systems give the same products, suggesting a common reactive oxygen species. However, the distribution of products observed for most substrates that are hydroxylated in more than one position is different for each system. For several of these substrates, addition of component B to Systems I, II, or III causes the product distributions to shift dramatically. These shifts result in identical product distributions for Systems I and III in which MMOH passes through the 2e- reduced state ([Fe(II)-Fe(II)]) during catalysis. In contrast, System II (in which MMOH probably does not become reduced) generally gives a unique product distribution. It is proposed that changes in MMOH structure occurring upon diiron cluster reduction and/or component complex formation cause substrates to be presented differently to the activated oxygen species. Kinetic studies show that component B strongly activates System I and, in most cases, strongly deactivates System II. The effect of component B on product distribution of System I (and III) occurs at <5% of the MMOH concentration, while nearly stoichiometric concentrations are required to maximize the rate of System I. This shows that component B has at least two roles in catalysis. EPR monitored titration of reduced MMOH ([Fe(II).Fe(II)]) with component B suggests that the effect of substoichiometric component B on product distribution is due to hysteresis in the MMOH conformational changes.	UNIV MINNESOTA, SCH MED, DEPT BIOCHEM, 4-225 MILLARD HALL, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities			Andersson, K Kristoffer/F-9624-2010	Lipscomb, John/0000-0002-8158-5594	NIGMS NIH HHS [GM40466, GM08277, R01 GM040466] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040466, T32GM008277] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON KK, 1991, NEW J CHEM, V15, P411; ANDERSSON KK, 1981, BIOCHEM BIOPH RES CO, V98, P311, DOI 10.1016/0006-291X(81)91904-5; Anthony C., 1982, BIOCH METHYLOTROPHS; ATKINS WM, 1989, J AM CHEM SOC, V111, P2715, DOI 10.1021/ja00189a057; BARTON DHR, 1990, P NATL ACAD SCI USA, V87, P3401, DOI 10.1073/pnas.87.9.3401; BARTON DHR, 1986, NEW J CHEM, V10, P387; BARTON DHR, 1992, J AM CHEM SOC, V114, P2147, DOI 10.1021/ja00032a032; CARDY DLN, 1991, MOL MICROBIOL, V5, P335, DOI 10.1111/j.1365-2958.1991.tb02114.x; COLBY J, 1978, BIOCHEM J, V171, P461, DOI 10.1042/bj1710461; COOK BR, 1986, J AM CHEM SOC, V108, P7281, DOI 10.1021/ja00283a024; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; ENHALT DH, 1978, PAGEOPH, V116, P452; ERICSON A, 1988, J AM CHEM SOC, V110, P2330, DOI 10.1021/ja00215a070; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013; FOX BG, 1989, J BIOL CHEM, V264, P10023; FOX BG, 1990, METHOD ENZYMOL, V188, P191; FROMMER U, 1970, H-S Z PHYSIOL CHEM, V351, P903, DOI 10.1515/bchm2.1970.351.2.903; GREEN J, 1989, J BIOL CHEM, V264, P17698; GROVES JT, 1983, J AM CHEM SOC, V105, P6243, DOI 10.1021/ja00358a009; GROVES JT, 1983, J AM CHEM SOC, V105, P5791, DOI 10.1021/ja00356a016; HENDRICH MP, 1990, J AM CHEM SOC, V112, P5861, DOI 10.1021/ja00171a029; HENDRICH MP, 1992, J BIOL CHEM, V267, P261; HIGGINS IJ, 1980, NATURE, V286, P561, DOI 10.1038/286561a0; HOA GHB, 1990, BIOCHEMISTRY-US, V29, P6810, DOI 10.1021/bi00481a008; HRYCAY EG, 1976, EUR J BIOCHEM, V61, P43, DOI 10.1111/j.1432-1033.1976.tb09995.x; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; KITAJIMA N, 1988, J CHEM SOC CHEM COMM, P485, DOI 10.1039/c39880000485; Leak D. J., 1987, BIOCATALYSIS, V1, P23; LEISING RA, 1990, INORG CHEM, V29, P2553, DOI 10.1021/ic00339a003; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; LIU KE, 1991, J BIOL CHEM, V266, P12836; MANSUY D, 1982, TETRAHEDRON LETT, V23, P2781, DOI 10.1016/S0040-4039(00)87457-2; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; McMurry T. J., 1986, CYTOCHROME P450 STRU, P1; MURCH BP, 1986, J AM CHEM SOC, V108, P5027, DOI 10.1021/ja00276a065; PATEL RN, 1987, J BACTERIOL, V169, P2313, DOI 10.1128/jb.169.5.2313-2317.1987; RATAJ MJ, 1991, J BIOL CHEM, V266, P18684; ROSENZWEIG AC, 1991, IND UNIV C, P69; SHEU C, 1990, J AM CHEM SOC, V112, P1936, DOI 10.1021/ja00161a045; SHEU CH, 1989, J AM CHEM SOC, V111, P8030, DOI 10.1021/ja00202a063; SLIGAR SG, 1976, BIOCHEMISTRY-US, V15, P5399, DOI 10.1021/bi00669a029; STAINTHORPE AC, 1990, GENE, V91, P27, DOI 10.1016/0378-1119(90)90158-N; STANLEY SH, 1983, BIOTECHNOL LETT, V5, P487, DOI 10.1007/BF00132233; Trotman-Dickenson A. F., 1965, ADVAN FREE RADICAL C, V1, P1; VINCENT JB, 1988, J AM CHEM SOC, V110, P6898, DOI 10.1021/ja00228a057; WALLING C, 1975, ACCOUNTS CHEM RES, V8, P125, DOI 10.1021/ar50088a003; WHITTENB.R, 1970, J GEN MICROBIOL, V61, P205, DOI 10.1099/00221287-61-2-205; WOODLAND MP, 1984, J BIOL CHEM, V259, P53	49	147	147	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17588	17597						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325441				2022-12-27	WOS:A1992JM22300020
J	VENTURA, F; ROSA, JL; AMBROSIO, S; PILKIS, SJ; BARTRONS, R				VENTURA, F; ROSA, JL; AMBROSIO, S; PILKIS, SJ; BARTRONS, R			BOVINE BRAIN 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE - EVIDENCE FOR A NEURAL-SPECIFIC ISOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER 6-PHOSPHOFRUCTO-2-KINASE; AMINO-ACID-SEQUENCE; FRUCTOSE 2,6-BISPHOSPHATE; HEPATIC GLUCONEOGENESIS; GENE-EXPRESSION; PROTEIN-KINASE; HEART; GLYCOLYSIS; PHOSPHORYLATION; ENZYMES	Bovine brain 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase was purified to homogeneity and characterized. This bifunctional enzyme is a homodimer with a subunit molecular weight of 120,000, which is twice that of all other known bifunctional enzyme isozymes. The kinase/bisphosphatase activity ratio was 3.0. The K(m) values for fructose 6-phosphate and ATP of the 6-phosphofructo-2-kinase were 27 and 55-mu-M, respectively. The K(m) for fructose 2,6-bisphosphate and the K(i) for fructose 6-phosphate for the bisphosphatase were 70 and 20-mu-M, respectively. Physiologic concentrations of citrate had reciprocal effects on the enzyme's activities, i.e. inhibiting the kinase (K(i) of 35-mu-M) and activating the bisphosphatase (K(a) of 16-mu-M). Phosphorylation of the brain enzyme was catalyzed by the cyclic AMP-dependent protein kinase with a stoichiometry of 0.9 mol of phosphate/mol of subunit and at a rate similar to that seen with the liver isozyme. In contrast to the liver isozyme, the kinetic properties of the brain enzyme were unaffected by cyclic AMP-dependent protein kinase phosphorylation, and also was not a substrate for protein kinase C. The brain isozyme formed a labeled phosphoenzyme intermediate and cross-reacted with antibodies raised against the liver isozyme. However, the NH2-terminal amino acid sequence of a peptide generated by cyanogen bromide cleavage of the enzyme had no identity with any known bifunctional enzyme sequences. These results indicate that a novel isozyme, which is related to other 6-phosphofructose-2,6-bisphosphatase isozymes, is expressed specifically in neural tissues.	UNIV BARCELONA,DEPT CIENCIES FISIOL HUMANES & NUTR,UNITAT BIOQUIM,CAMPUS BELLVITGE,E-08907 LHOSPITALET LLOBR,SPAIN; SUNY STONY BROOK,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794	University of Barcelona; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Rosa, Jose Luis/K-6685-2014; Ventura, Francesc/K-9700-2014; Ambrosio, Santiago/ABC-8753-2021; Ventura, Francesc/ABG-2285-2020	Rosa, Jose Luis/0000-0002-6161-5688; Ventura, Francesc/0000-0001-9673-9405; Ventura, Francesc/0000-0001-9673-9405; Bartrons, Ramon/0000-0001-9349-5847	NIDDK NIH HHS [DK-38354] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK038354, R01DK038354] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMBROSIO S, 1991, J NEUROCHEM, V57, P200, DOI 10.1111/j.1471-4159.1991.tb02116.x; BARTRONS R, 1983, BIOCHEM J, V136, P115; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CIFUENTES ME, 1991, J BIOL CHEM, V266, P1557; COLOSIA AD, 1988, J BIOL CHEM, V263, P18669; DARVILLE MI, 1987, FEBS LETT, V224, P317, DOI 10.1016/0014-5793(87)80476-3; DARVILLE MI, 1989, P NATL ACAD SCI USA, V86, P6543, DOI 10.1073/pnas.86.17.6543; DARVILLE MI, 1991, FEBS LETT, V288, P91, DOI 10.1016/0014-5793(91)81009-W; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; ELMAGHRABI MR, 1982, J BIOL CHEM, V257, P7603; ELMAGHRABI MR, 1980, J BIOL CHEM, V255, P668; FOE LG, 1985, J BIOL CHEM, V260, P726; FRANCOIS J, 1988, EUR J BIOCHEM, V171, P599, DOI 10.1111/j.1432-1033.1988.tb13830.x; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; KITAMURA K, 1989, J BIOL CHEM, V264, P9799; KITAMURA K, 1988, J BIOL CHEM, V263, P9027; KRETSCHMER M, 1991, BIOCHEMISTRY-US, V30, P10663, DOI 10.1021/bi00108a009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE AJ, 1991, ARCH BIOCHEM BIOPHYS, V290, P258, DOI 10.1016/0003-9861(91)90617-R; LEMAIGRE FP, 1991, MOL CELL BIOL, V11, P1099, DOI 10.1128/MCB.11.2.1099; LIVELY MO, 1988, J BIOL CHEM, V263, P839; MARKER AJ, 1989, J BIOL CHEM, V264, P7000; NEWSHOLME EA, 1977, BIOCHEM J, V166, P123, DOI 10.1042/bj1660123; PAUWELS PJ, 1984, NEUROSCI LETT, V46, P173, DOI 10.1016/0304-3940(84)90437-3; PILKIS SJ, 1991, ANNU REV NUTR, V11, P465, DOI 10.1146/annurev.nu.11.070191.002341; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; RIDER MH, 1985, BIOCHEM J, V231, P193, DOI 10.1042/bj2310193; RIDER MH, 1986, BIOCHEM J, V240, P57, DOI 10.1042/bj2400057; RUDERMAN NB, 1974, BIOCHEM J, V138, P1; SAKATA J, 1991, J BIOL CHEM, V266, P15764; SAKATA J, 1991, BIOCHEM BIOPH RES CO, V180, P470, DOI 10.1016/S0006-291X(05)81088-5; SAKATA J, 1990, P NATL ACAD SCI USA, V87, P4951, DOI 10.1073/pnas.87.13.4951; VANSCHAFTINGEN E, 1987, ADV ENZYMOL RAMB, V59, P315; VENTURA F, 1991, BIOCHEM J, V276, P455, DOI 10.1042/bj2760455; VORA S, 1985, BIOCHEM J, V229, P333, DOI 10.1042/bj2290333; WALL SR, 1989, FEBS LETT, V257, P211, DOI 10.1016/0014-5793(89)81536-4; YAMAMOTO M, 1990, J NEUROCHEM, V54, P592, DOI 10.1111/j.1471-4159.1990.tb01912.x	39	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17939	17943						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325453				2022-12-27	WOS:A1992JM22300070
J	CAMERON, KE; RESNIK, J; WEBSTER, NJG				CAMERON, KE; RESNIK, J; WEBSTER, NJG			TRANSCRIPTIONAL REGULATION OF THE HUMAN INSULIN-RECEPTOR PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE; BINDING-PROTEIN; MESSENGER-RNAS; CELLS; EXPRESSION; SEQUENCE; REGION; INITIATOR; ELEMENT; MOUSE	The ability of the human insulin receptor promoter to direct expression of a linked chloramphenicol acetyltransferase gene was assessed in transient transfections into HepG2 and Hela cells. A 5'-deletional analysis of the promoter showed that regions between -646 and -489 were important for the activity of the proximal promoter. In addition, a possible negative regulatory element was identified between -1311 and -877 and a positive element between -1823 and -1311. DNase I footprint and gel retardation analysis showed that multiple factors bind to the human insulin receptor promoter. In particular, DNase I protection patterns were observed over the Sp1 sites at -620 to -599 and -438 to -392, a TC box at -533, four homopyrimidine/homopurine sites clustered around -1150, and a site at -1420 that contains the motif TGGCCC which has been shown to bind the liver-specific transcription factor LF-A1.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; VET ADM MED CTR,DEPT VET AFFAIRS,MED RES SERV,SAN DIEGO,CA 92161; UNIV CALIF SAN DIEGO,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego			Webster, Nick/AAI-8410-2021					ARAKI E, 1991, J BIOL CHEM, V266, P3944; ARAKI E, 1987, J BIOL CHEM, V262, P16186; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; CRABB DW, 1987, ANAL BIOCHEM, V163, P88, DOI 10.1016/0003-2697(87)90096-0; CZECH MP, 1985, ANNU REV PHYSIOL, V47, P357, DOI 10.1146/annurev.ph.47.030185.002041; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GROSSCHEDL R, 1980, P NATL ACAD SCI-BIOL, V77, P1432, DOI 10.1073/pnas.77.3.1432; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; IWAMA N, 1989, DIABETOLOGIA, V32, P877, DOI 10.1007/BF00297453; KAHN CR, 1985, ANNU REV MED, V36, P429; KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4; KAUFMAN RJ, 1987, EMBO J, V6, P187, DOI 10.1002/j.1460-2075.1987.tb04737.x; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEE JK, 1992, J BIOL CHEM, V267, P4638; LEROITH D, 1991, TRENDS ENDOCRIN MET, V2, P134, DOI 10.1016/1043-2760(91)90003-6; LEVY JR, 1991, DIABETES, V40, P58, DOI 10.2337/diabetes.40.1.58; MACE HAF, 1983, NATURE, V304, P555, DOI 10.1038/304555a0; MAMULA PW, 1990, DIABETES CARE, V13, P288, DOI 10.2337/diacare.13.3.288; MAMULA PW, 1988, DIABETES, V37, P1241, DOI 10.2337/diabetes.37.9.1241; MCKEON C, 1991, BIOCHEM BIOPH RES CO, V174, P721, DOI 10.1016/0006-291X(91)91477-T; MCKEON C, 1984, J BIOL CHEM, V259, P6636; MCKEON C, 1990, MOL ENDOCRINOL, V4, P647, DOI 10.1210/mend-4-4-647; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAFFER JD, 1989, MOL CELL BIOL, V9, P355, DOI 10.1128/MCB.9.2.355; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SIBLEY E, 1989, P NATL ACAD SCI USA, V86, P9732, DOI 10.1073/pnas.86.24.9732; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TANG A, 1989, ONCOGENE, V4, P401; TEWARI DS, 1989, J BIOL CHEM, V264, P16238; TEWARI M, 1991, MOL ENDOCRINOL, V5, P653, DOI 10.1210/mend-5-5-653; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WU J, 1990, MOL CELL BIOL, V10, P1209, DOI 10.1128/MCB.10.3.1209	41	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17375	17383						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324934				2022-12-27	WOS:A1992JL05300096
J	LAMA, J; CARRASCO, L				LAMA, J; CARRASCO, L			EXPRESSION OF POLIOVIRUS NONSTRUCTURAL PROTEINS IN ESCHERICHIA-COLI-CELLS - MODIFICATION OF MEMBRANE-PERMEABILITY INDUCED BY 2B AND 3A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTED HELA-CELLS; RNA-POLYMERASE; PURIFICATION; GENOME; REPLICATION; TRANSLATION; SEQUENCE; PEPTIDES; CDNA; GENE	The poliovirus nonstructural proteins 2B, 2C, 2C3A, 2C3AB, 3A, and 3AB have been cloned and efficiently expressed in Escherichia coli cells. Each individual protein, or combinations of some of them, were cloned using polymerase chain reaction techniques and correspond to the genuine poliovirus protein plus an additional methionine. The system used to express them uses pET vectors containing the promoter of gene 10 of phage T7. Expression of protein 2C in BL21(DE3) pLysS cells, which express the T7 lysozyme, is not toxic, and the bacteria synthesize this protein for several hours after induction. In contrast, the expression of proteins 2B, 3A, or 3AB is not tolerated by BL21(DE3) pLysS cells which could make them only for a limited period of time. Protein 3AB was particularly toxic and induced a rapid lysis of the recombinant clone after its induction with isopropyl-1-thio-beta-D-galactopyranoside alone or with both isopropyl-1-thio-beta-D-galactopyranoside and rifampicin. Further analyses showed that 3AB induced profound modifications in membrane permeability to o-nitrophenyl-beta-D-galactopyranoside, labeled uridine, and nonpermeant translation inhibitors. Cloning and expression of proteins 2B, 3A, and 3AB in BL21(DE3) cells that do not contain the T7 lysozyme lead to a more sustained expression of these proteins without detectable cell lysis. Changes in permeability to low molecular weight compounds such as radioactive uridine, o-nitrophenyl-beta-D-galactopyranoside, and hygromycin B readily appeared upon induction of 2B, 3A, and 3AB. Our results indicate that the poliovirus nonstructural polypeptides 2B and 3A (or 3AB) are lytic for the bacteria. In fact, both proteins 2B and 3A contain hydrophobic domains in a potential amphipathic helix; this is one characteristic shared with a number of membrane-active peptides.			LAMA, J (corresponding author), UNIV AUTONOMA MADRID, CTR BIOL MOLEC, CANTO BLANCO, E-28049 MADRID, SPAIN.		Carrasco, Luis/E-2435-2012; Carrasco, Luis/H-3001-2017	Carrasco, Luis/0000-0003-3833-8835				AGAWA Y, 1991, J BIOL CHEM, V266, P20218; BAUM EZ, 1991, VIROLOGY, V185, P140, DOI 10.1016/0042-6822(91)90762-Z; BIENZ K, 1990, J VIROL, V64, P1156, DOI 10.1128/JVI.64.3.1156-1163.1990; CARRASCO L, 1978, NATURE, V272, P694, DOI 10.1038/272694a0; CARRASCO L, 1976, NATURE, V264, P807, DOI 10.1038/264807a0; CARRASCO L, 1989, PHARMACOL THERAPEUT, V40, P171, DOI 10.1016/0163-7258(89)90096-X; CARRASCO L, 1987, MECHANISM VIRAL TOXI, P1; CARRASCO L, 1983, ANTIBIOTICS, V6, P279; CASTRILLO JL, 1988, J GEN VIROL, V69, P583, DOI 10.1099/0022-1317-69-3-583; CONTRERAS A, 1979, J VIROL, V29, P114, DOI 10.1128/JVI.29.1.114-122.1979; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; FERNANDEZPUENTES C, 1980, CELL, V20, P769, DOI 10.1016/0092-8674(80)90323-2; GARRETT J, 1981, MOL GEN GENET, V182, P326, DOI 10.1007/BF00269678; GARRETT JM, 1982, J VIROL, V44, P886, DOI 10.1128/JVI.44.3.886-892.1982; GOESSENS WHF, 1988, EMBO J, V7, P867, DOI 10.1002/j.1460-2075.1988.tb02886.x; GUINEA R, 1989, J BIOL CHEM, V264, P21923; GUINEA R, 1990, EMBO J, V9, P2011, DOI 10.1002/j.1460-2075.1990.tb08329.x; HELLEN CUT, 1991, J VIROL, V65, P4226, DOI 10.1128/JVI.65.8.4226-4231.1991; INNIS AM, 1989, PCR PROTOCOLS GUIDE; Koch G., 1985, MOL BIOL POLIOVIRUS; LACAL JC, 1983, J GEN VIROL, V64, P787, DOI 10.1099/0022-1317-64-4-787; LI JP, 1988, J VIROL, V62, P4016, DOI 10.1128/JVI.62.11.4016-4021.1988; LOPEZRIVAS A, 1987, J GEN VIROL, V68, P335, DOI 10.1099/0022-1317-68-2-335; Maniatis T., 1982, MOL CLONING; MINOR PD, 1986, J GEN VIROL, V67, P1283, DOI 10.1099/0022-1317-67-7-1283; MUNOZ A, 1983, EUR J BIOCHEM, V137, P623, DOI 10.1111/j.1432-1033.1983.tb07871.x; MUNOZ A, 1985, VIROLOGY, V146, P203, DOI 10.1016/0042-6822(85)90004-2; NICKLIN MJH, 1988, J VIROL, V62, P4586, DOI 10.1128/JVI.62.12.4586-4593.1988; PAGE GS, 1988, J VIROL, V62, P1781, DOI 10.1128/JVI.62.5.1781-1794.1988; PALMENBERG AC, 1990, ANNU REV MICROBIOL, V44, P603, DOI 10.1146/annurev.mi.44.100190.003131; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PELLETIER J, 1989, J VIROL, V63, P441, DOI 10.1128/JVI.63.1.441-444.1989; PLOTCH SJ, 1989, J VIROL, V63, P216, DOI 10.1128/JVI.63.1.216-225.1989; RACANIELLO VR, 1981, P NATL ACAD SCI-BIOL, V78, P4887, DOI 10.1073/pnas.78.8.4887; ROTHSTEIN MA, 1988, VIROLOGY, V164, P301, DOI 10.1016/0042-6822(88)90542-9; SEMLER BL, 1988, RNA GENETICS, P23; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKAHARA Y, 1989, GENE, V79, P249; TAKEGAMI T, 1983, VIROLOGY, V128, P33, DOI 10.1016/0042-6822(83)90316-1; TAKEGAMI T, 1983, P NATL ACAD SCI-BIOL, V80, P7447, DOI 10.1073/pnas.80.24.7447; TRONO D, 1988, SCIENCE, V241, P445, DOI 10.1126/science.2839901; URZAINQUI A, 1989, BIOCHEM BIOPH RES CO, V158, P263, DOI 10.1016/S0006-291X(89)80207-4; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; WIMMER E, 1987, J CELL SCI, P251; YOUNG KD, 1982, J VIROL, V44, P993, DOI 10.1128/JVI.44.3.993-1002.1982; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	48	101	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15932	15937						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322409				2022-12-27	WOS:A1992JG11300100
J	CARTER, AN; DOWNES, CP				CARTER, AN; DOWNES, CP			PHOSPHATIDYLINOSITOL 3-KINASE IS ACTIVATED BY NERVE GROWTH-FACTOR AND EPIDERMAL GROWTH-FACTOR IN PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRK PROTOONCOGENE PRODUCT; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; TYROSINE PHOSPHORYLATION; INOSITOL 3-PHOSPHATE; RECEPTOR; PROTEIN; TRANSFORMATION; POLYPHOSPHOINOSITIDES; DIFFERENTIATION	The effects of nerve growth factor (NGF) and epidermal growth factor (EGF) on the regulation of phosphatidylinositol 3-kinase (PtdIns 3-kinase) activity were assessed in rat pheochromocytoma (PC12) cells. Both NGF and EGF induced a rapid activation of PtdIns 3-kinase as assessed by a dramatic rise in growth factor-induced PtdIns 3-kinase activity found in antiphosphotyrosine immunoprecipitates. The intracellular levels of two of the lipid products of PtdIns 3-kinase, phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) and phosphatidylinositol 3,4-bisphosphate PtdIns(3,4)P2), also rose dramatically, exhibiting time courses very similar to the appearance of PtdIns 3-kinase in immunoprecipitates. The activation of PtdIns 3-kinase is, therefore, a common event in the signal transduction processes elicited by growth factors stimulating distinct cellular end points in PC12 cells, namely the NGF-induced neuronal differentiation and EGF-stimulated mitogenesis. Thus the intracellular products of this enzyme may function in early biochemical events that are common components of the pathways controlling both differentiation and proliferation.			CARTER, AN (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND.							ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; COCHET C, 1991, J BIOL CHEM, V266, P637; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; CUNNINGHAM TW, 1991, BIOCHEM BIOPH RES CO, V175, P568, DOI 10.1016/0006-291X(91)91603-A; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; MILLER ES, 1990, BIOCHEM BIOPH RES CO, V173, P289, DOI 10.1016/S0006-291X(05)81055-1; PAYRASTRE B, 1990, BIOCHEM J, V272, P665, DOI 10.1042/bj2720665; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; QUI MS, 1991, J CELL BIOL, V115, P795; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; STEPHENS L, 1989, BIOCHEM J, V259, P267, DOI 10.1042/bj2590267; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; VADNAL RE, 1989, BIOCHEM BIOPH RES CO, V163, P995, DOI 10.1016/0006-291X(89)92320-6; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	38	142	146	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14563	14567						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321809				2022-12-27	WOS:A1992JF08800013
J	YU, FX; SUN, HQ; JANMEY, PA; YIN, HL				YU, FX; SUN, HQ; JANMEY, PA; YIN, HL			IDENTIFICATION OF A POLYPHOSPHOINOSITIDE-BINDING SEQUENCE IN AN ACTIN MONOMER-BINDING DOMAIN OF GELSOLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; DEOXYRIBONUCLEASE-I; CAPPING PROTEIN; PLASMA GELSOLIN; HUMAN-PLATELET; PROFILIN; INHIBITION; FILAMENTS; COFILIN	Gelsolin is an actin filament-severing and -capping protein that has profound effects on actin filament organization and assembly. It is activated by Ca2+ and inhibited by polyphosphoinositides (PPI). We have previously shown that PPI inhibit actin filament severing by the amino-terminal half of gelsolin and hypothesized that this is mediated through inhibition of actin filament side binding (by domains II-III of gelsolin), a requisite first step in severing. In this paper, we report that the subsequent step in severing, which is mediated by an actin monomer binding site located in domain I of gelsolin, is also regulated by PPI. We used deletional mutagenesis and a synthetic peptide to locate the sequence required for high affinity PPI binding in domain I. Our results show that the PPI-binding sequence has a basic charge distribution that is also present in the PPI-regulated actin filament side binding domain, and the two gelsolin PPI-binding sites have similar PPI-binding affinities. In addition, a similar motif is present in several other PPI-binding proteins, including a highly conserved region in the phospholipase C family. We propose that the sequences identified in gelsolin may represent a consensus for PPI binding in a variety of proteins.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV EXPTL MED,BOSTON,MA 02115	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038910, R29AR038910] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29113] Funding Source: Medline; NIAMS NIH HHS [AR38910] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMPE C, 1988, FEBS LETT, V228, P17, DOI 10.1016/0014-5793(88)80575-1; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; BUBB MR, 1991, J BIOL CHEM, V266, P3820; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HARTWIG JH, 1989, J CELL BIOL, V109, P1571, DOI 10.1083/jcb.109.4.1571; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; HEISS SG, 1991, BIOCHEMISTRY-US, V30, P8753, DOI 10.1021/bi00100a006; ISENBERG G, 1991, J MUSCLE RES CELL M, V142, P4319; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JANMEY PA, 1992, IN PRESS J BIOL CHEM, V267; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1985, J BIOL CHEM, V260, P5232; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MAEKAWA S, 1990, J BIOL CHEM, V265, P10940; MATSUDAIRA P, 1988, CELL, V54, P139, DOI 10.1016/0092-8674(88)90542-9; MATSUZAKI F, 1988, J BIOL CHEM, V263, P11564; POPE B, 1991, FEBS LETT, V280, P70, DOI 10.1016/0014-5793(91)80206-I; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WAY M, 1992, J CELL BIOL, V116, P1135, DOI 10.1083/jcb.116.5.1135; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; XIAN W, 1992, FASEB J, V6, pA87; YIN HL, 1988, J CELL BIOL, V106, P805, DOI 10.1083/jcb.106.3.805; YIN HL, 1990, FEBS LETT, V264, P78, DOI 10.1016/0014-5793(90)80769-F; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; YU FX, 1991, J BIOL CHEM, V266, P19269	38	213	218	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14616	14621						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321812				2022-12-27	WOS:A1992JF08800022
J	SIEGAL, G; TURCHI, JJ; JESSEE, CB; MYERS, TW; BAMBARA, RA				SIEGAL, G; TURCHI, JJ; JESSEE, CB; MYERS, TW; BAMBARA, RA			A NOVEL DNA HELICASE FROM CALF THYMUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE FM3A CELLS; ESCHERICHIA-COLI; POLYMERASE-I; ADENOSINE-TRIPHOSPHATASE; PURIFICATION; PROTEIN; ENZYME; GENE	We report the purification and characterization of a novel DNA helicase from calf thymus tissue. This enzyme partially copurifies with DNA polymerase epsilon* through many of the chromatographic procedures used to isolate it. The enzyme contains an intrinsic DNA-dependent ATPase activity. It can displace short oligonucleotides annealed to long single stranded substrates, in an ATP-dependent reaction. Use of this assay indicates that the DNA helicase translocates in a 3' to 5' direction with respect to the substrate strand to which it is bound. Maximal efficiency of displacement is accomplished by hydrolysis of (d)ATP as cofactor, however, (d)CTP can also be utilized resulting in a 5-fold decrease in the level of displacement. Displacement activity is enhanced by the presence of saturating amounts of Escherichia coli single stranded DNA-binding protein, not affected by the presence of phage T4 gene 32 protein, and inhibited by human replication factor A. The DNA helicase has a molecular mass of approximately 104 kDa as measured by denaturing gel electrophoresis, and an S value of 5.4 obtained from glycerol gradient sedimentation. Direct [alpha-P-32]ATP cross-linking labels a protein of molecular mass approximately 105 kDa, providing further evidence that this polypeptide contains the helicase active site. In view of the differences in the properties of this helicase from four others recently identified in calf and designated A through D, we propose the name helicase E.	UNIV ROCHESTER,SCH MED & DENT,MED CTR,DEPT BIOCHEM,BOX 607,601 ELMWOOD AVE,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester			Turchi, John J/B-5807-2015	Turchi, John J/0000-0001-5375-2992; Siegal, Gregg/0000-0003-3806-4811	NATIONAL CANCER INSTITUTE [T32CA009363, R01CA046148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER; NCI NIH HHS [CA 46148, T32-CA09363] Funding Source: Medline; NIGMS NIH HHS [GM 24441] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; CRUTE JJ, 1986, BIOCHEMISTRY-US, V25, P26, DOI 10.1021/bi00349a005; DOWNEY KM, 1990, MOL MECHANISMS DNA R; DUGUET M, 1978, COLD SPRING HARB SYM, V43, P335; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; Kornberg A., 1991, DNA REPLICATION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; LU AL, 1984, COLD SPRING HARB SYM, V49, P589, DOI 10.1101/SQB.1984.049.01.066; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; SEKI M, 1986, BIOCHEMISTRY-US, V25, P3239, DOI 10.1021/bi00359a024; SEKI M, 1987, BIOCHEMISTRY-US, V26, P2924, DOI 10.1021/bi00384a038; SEO YS, 1991, J BIOL CHEM, V266, P13161; SIEGAL G, 1992, J BIOL CHEM, V267, P3991; SUGINO A, 1986, J BIOL CHEM, V261, P1744; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; THOMMES P, 1990, J BIOL CHEM, V265, P14347; THOMMES P, 1992, J BIOL CHEM, V267, P6063; ZHANG SS, 1991, J BIOL CHEM, V266, P20483	20	26	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13629	13635						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320024				2022-12-27	WOS:A1992JB74600084
J	WILLIAMS, KJ; FLESS, GM; PETRIE, KA; SNYDER, ML; BROCIA, RW; SWENSON, TL				WILLIAMS, KJ; FLESS, GM; PETRIE, KA; SNYDER, ML; BROCIA, RW; SWENSON, TL			MECHANISMS BY WHICH LIPOPROTEIN-LIPASE ALTERS CELLULAR-METABOLISM OF LIPOPROTEIN(A), LOW-DENSITY-LIPOPROTEIN, AND NASCENT LIPOPROTEINS - ROLES FOR LOW-DENSITY-LIPOPROTEIN RECEPTORS AND HEPARAN-SULFATE PROTEOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; APOLIPOPROTEIN-B; FAMILIAL HYPERCHOLESTEROLEMIA; MEDIATED ENDOCYTOSIS; CHOLESTERYL ESTER; MISSENSE MUTATION; CULTURED-CELLS; HEPATIC LIPASE; PLASMA; BINDING	We sought to investigate effects of lipoprotein lipase (LpL) on cellular catabolism of lipoproteins rich in apolipoprotein B-100. LpL increased cellular degradation of lipoprotein(a) (Lp(a)) and low density lipoprotein (LDL) by 277% +/- 3.8% and 32.5% +/- 4.1%, respectively, and cell association by 509% +/- 8.7% and 83.9% +/- 4.0%. The enhanced degradation was entirely lysosomal. Enhanced degradation of Lp(a) had at least two components, one LDL receptor-dependent and unaffected by heparitinase digestion of the cells, and the other LDL receptor-independent and heparitinase-sensitive. The effect of LpL on LDL degradation was entirely LDL receptor-independent, heparitinase-sensitive, and essentially absent from mutant Chinese hamster ovary cells that lack cell surface heparan sulfate proteoglycans. Enhanced cell association of Lp(a) and LDL was largely LDL receptor-independent and heparitinase-sensitive. The ability of LpL to reduce net secretion of apolipoprotein B-100 by HepG2 cells by enhancing cellular reuptake of nascent lipoproteins was also LDL receptor-independent and heparitinase-sensitive. None of these effects on Lp(a), LDL, or nascent lipoproteins required LpL enzymatic activity. We conclude that LpL promotes binding of apolipoprotein B-100-rich lipoproteins to cell surface heparan sulfate proteoglycans. LpL also enhanced the otherwise weak binding of Lp(a) to LDL receptors. The heparan sulfate proteoglycan pathway represents a novel catabolic mechanism that may allow substantial cellular and interstitial accumulation of cholesteryl ester-rich lipoproteins, independent of feedback inhibition by cellular sterol content.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; MERCK SHARP & DOHME LTD,RAHWAY,NJ 07065	University of Chicago; Merck & Company	WILLIAMS, KJ (corresponding author), MED COLL PENN,DEPT BIOL,3300 HENRY AVE,PHILADELPHIA,PA 19129, USA.				NHLBI NIH HHS [HL18577, HL38956] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038956, P01HL018577, R29HL038956] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIRAM M, 1988, J BIOL CHEM, V263, P15416; AVIRAM M, 1988, J BIOL CHEM, V263, P16842; BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BABIRAK SP, 1989, CIRCULATION S2, V80, P79; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BEISIEGEL U, 1991, CURR OPIN LIPIDOL, V2, P317; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BISGAIER CL, 1991, J LIPID RES, V32, P21; BLISS CI, 1967, STATISTICS BIOL, V1, P213; BORENSZTAJN J, 1988, J LIPID RES, V29, P1087; BOSNER MS, 1988, P NATL ACAD SCI USA, V85, P7438, DOI 10.1073/pnas.85.20.7438; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY WA, 1984, J BIOL CHEM, V259, P4728; BRANDAN E, 1989, J BIOL CHEM, V264, P10520; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BUSCH SJ, 1989, J BIOL CHEM, V264, P9527; CAMEJO G, 1990, CURR OPIN LIPIDOL, V1, P431; CAMPS L, 1991, J LIPID RES, V32, P1877; Capriotti A, 1986, J TISSUE CULTURE MET, V10, P219, DOI 10.1007/BF01404480; CATAPANO AL, 1979, J BIOL CHEM, V254, P1007; CHAJEKSHAUL T, 1989, BIOCHIM BIOPHYS ACTA, V1014, P178, DOI 10.1016/0167-4889(89)90031-1; CHAN BL, 1988, SCIENCE, V241, P1670, DOI 10.1126/science.2843987; CISAR LA, 1989, J BIOL CHEM, V264, P1767; EMI M, 1990, J BIOL CHEM, V265, P5910; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P9481; FELTS JM, 1975, BIOCHEM BIOPH RES CO, V66, P1467, DOI 10.1016/0006-291X(75)90524-0; FLESS GM, 1986, J BIOL CHEM, V261, P8712; FRIEDMAN G, 1982, BIOCHIM BIOPHYS ACTA, V711, P114, DOI 10.1016/0005-2760(82)90016-9; GOLDBERG IJ, 1986, J CLIN INVEST, V78, P1523, DOI 10.1172/JCI112744; GOLDSTEIN JL, 1975, P NATL ACAD SCI USA, V72, P1092, DOI 10.1073/pnas.72.3.1092; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1976, CELL, V7, P85, DOI 10.1016/0092-8674(76)90258-0; GRUNDY SM, 1987, ARTERIOSCLEROSIS, V7, P203; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HOWARD AN, 1971, ATHEROSCLEROSIS, V14, P17, DOI 10.1016/0021-9150(71)90035-9; HUMPHRIES DE, 1988, BIOCHEM BIOPH RES CO, V154, P365, DOI 10.1016/0006-291X(88)90694-8; ISHIBASHI S, 1990, J BIOL CHEM, V265, P3040; ISHIHARA M, 1987, J BIOL CHEM, V262, P4708; JONASSON L, 1987, J LIPID RES, V28, P437; JONES PH, 1991, CIRCULATION S, V84, P483; KERN PA, 1990, J LIPID RES, V31, P17; KJELLEN L, 1981, P NATL ACAD SCI-BIOL, V78, P5371, DOI 10.1073/pnas.78.9.5371; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLINGER MM, 1985, J BIOL CHEM, V260, P4082; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LUNDKATZ S, 1991, J BIOL CHEM, V266, P2701; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MULDER M, 1991, BIOCHIM BIOPHYS ACTA, V1081, P308, DOI 10.1016/0005-2760(91)90287-R; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; Olivecrona T., 1987, LIPOPROTEIN LIPASE, P15; OSTLUNDLINDQVIST AM, 1983, ARTERIOSCLEROSIS, V3, P433, DOI 10.1161/01.ATV.3.5.433; PETERSON J, 1985, BIOCHIM BIOPHYS ACTA, V837, P262, DOI 10.1016/0005-2760(85)90049-9; PITAS RE, 1990, J BIOL CHEM, V265, P12722; POSNER I, 1983, ARCH BIOCHEM BIOPHYS, V226, P306, DOI 10.1016/0003-9861(83)90297-7; QUINN DM, 1985, BIOCHIM BIOPHYS ACTA, V834, P267, DOI 10.1016/0005-2760(85)90165-1; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROBINSON DS, 1963, ADV LIPID RES, V1, P133; ROTHBLAT GH, 1977, BIOCHEM BIOPH RES CO, V78, P45, DOI 10.1016/0006-291X(77)91219-0; SAXENA U, 1991, J BIOL CHEM, V266, P17516; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SEGUCHI T, 1991, ARCH BIOCHEM BIOPHYS, V284, P245, DOI 10.1016/0003-9861(91)90292-Q; SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354; SHIRAI K, 1981, BIOCHIM BIOPHYS ACTA, V665, P504; SNYDER ML, 1992, J BIOL CHEM, V267, P339; STEIN O, 1984, BIOCHIM BIOPHYS ACTA, V795, P47, DOI 10.1016/0005-2760(84)90103-6; VILARO S, 1988, BIOCHIM BIOPHYS ACTA, V959, P106, DOI 10.1016/0005-2760(88)90021-5; WALLINDER L, 1984, BIOCHIM BIOPHYS ACTA, V795, P513, DOI 10.1016/0005-2760(84)90181-4; WEISWEILER P, 1990, CIRCULATION, V82, P6; WIKLUND O, 1991, CIRCULATION S2, V84, P258; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P16741; WILLIAMS KJ, 1988, P NATL ACAD SCI USA, V85, P242, DOI 10.1073/pnas.85.1.242; WILLIAMS KJ, 1991, J CLIN INVEST, V88, P1300, DOI 10.1172/JCI115434; Williams KJ, 1991, CIRCULATION S2, V84, P566; WILSON DE, 1990, J CLIN INVEST, V86, P735, DOI 10.1172/JCI114770; WOLFBAUER G, 1986, P NATL ACAD SCI USA, V83, P7760, DOI 10.1073/pnas.83.20.7760; XU XX, 1991, J BIOL CHEM, V266, P24849; YLAHERTTUALA S, 1991, CIRCULATION S2, V84, P258; ZAWADZKI Z, 1988, BIOCHEMISTRY-US, V27, P8474, DOI 10.1021/bi00422a027; ZILVERSMIT DB, 1973, CIRC RES, V33, P633, DOI 10.1161/01.RES.33.6.633; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473; ZOLFAGHARI R, 1989, P NATL ACAD SCI USA, V86, P6913, DOI 10.1073/pnas.86.18.6913; 1991, LANCET, V337, P397; 1988, LANCET, V1, P1141	86	238	247	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13284	13292						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320015				2022-12-27	WOS:A1992JB74600033
J	CAMPBELL, GS; YU, JH; OXENDER, DL				CAMPBELL, GS; YU, JH; OXENDER, DL			CHEMICAL MODIFICATION OF THE NEUTRAL AMINO-ACID-TRANSPORT SYSTEM-L OF CHINESE-HAMSTER OVARY CELLS WITH PARA-CHLOROMERCURIBENZENE SULFONATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL BRUSH-BORDERS; CONFORMATIONAL-CHANGES; SUBSTRATE PROTECTION; GLUCOSE TRANSPORTER; MEMBRANE-VESICLES; RAT HEPATOCYTES; A-SYSTEM; INACTIVATION; REAGENTS; CARRIER	Branched-chain and aromatic neutral amino acids enter mammalian cells predominantly through a Na+-independent transport agency called System L. The sulfhydryl specific reagent p-chloromercuribenzene sulfonate (pCMBS) has been shown to be a potent inactivator of System L transport activity in Chinese hamster ovary cells, however, inactivation by pCMBS can be prevented by the presence of System L-specific substrate amino acids during the inactivation reaction. In addition, the presence of amino acids that are not substrates for System L have no effect on pCMBS inactivation of System L. Inactivation of System L activity by pCMBS was sensitive to pH and reversible by incubation with dithiothreitol. These findings suggest that there is a sulfhydryl group in, or very near, the amino acid-binding site of the System L transporter of CHO cells. Substrate protection, however, could be explained by conformational changes in the transporter associated with substrate binding. The presence of a substrate protectable sulfhydryl group on the System L transporter would aid in the attempt to identify this transporter using the technique of differential labeling.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIGMS NIH HHS [GM20737] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALY DL, 1988, BIOCHIM BIOPHYS ACTA, V947, P571, DOI 10.1016/0304-4157(88)90008-1; BASS R, 1981, J BIOL CHEM, V256, P259; CHILES TC, 1986, J CELL PHYSIOL, V129, P321, DOI 10.1002/jcp.1041290309; CHILES TC, 1988, AM J PHYSIOL, V255, pC340, DOI 10.1152/ajpcell.1988.255.3.C340; DUDECK KL, 1987, J BIOL CHEM, V262, P12565; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; HARE JD, 1975, ARCH BIOCHEM BIOPHYS, V170, P347, DOI 10.1016/0003-9861(75)90128-9; HARE JD, 1967, CANCER RES, V27, P2357; HAYES MR, 1983, BIOCHEM J, V214, P489, DOI 10.1042/bj2140489; KLIP A, 1982, J CELL PHYSIOL, V113, P56, DOI 10.1002/jcp.1041130111; LIEB WR, 1976, BIOCHIM BIOPHYS ACTA, V455, P913, DOI 10.1016/0005-2736(76)90060-2; MCCORMICK J, 1990, BIOCHEM CELL BIOL, V68, P512, DOI 10.1139/o90-073; PEERCE BE, 1985, ANN NY ACAD SCI, V456, P118, DOI 10.1111/j.1749-6632.1985.tb14854.x; PEERCE BE, 1985, J BIOL CHEM, V260, P6026; PEERCE BE, 1984, J BIOL CHEM, V259, P4105; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; SHOTWELL MA, 1983, J BIOL CHEM, V258, P8183; SHOTWELL MA, 1981, J BIOL CHEM, V256, P5422; SIPS HJ, 1981, J MEMBRANE BIOL, V62, P231, DOI 10.1007/BF01998168; WRIGHT EM, 1984, J BIOL CHEM, V259, P4993; ZAK B, 1961, CLIN CHIM ACTA, V6, P665, DOI 10.1016/0009-8981(61)90112-7	21	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12496	12500						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1319998				2022-12-27	WOS:A1992HZ48300021
J	KIRBY, MS; SAGARA, Y; GAA, S; INESI, G; LEDERER, WJ; ROGERS, TB				KIRBY, MS; SAGARA, Y; GAA, S; INESI, G; LEDERER, WJ; ROGERS, TB			THAPSIGARGIN INHIBITS CONTRACTION AND CA2+ TRANSIENT IN CARDIAC-CELLS BY SPECIFIC-INHIBITION OF THE SARCOPLASMIC-RETICULUM CA2+ PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; INTRACELLULAR CA-2+; ANGIOTENSIN-II; TUMOR PROMOTER; CALCIUM; ACTIVATION; MYOCYTES; MUSCLE; RELEASE; ACETYLCHOLINE	Regulation of the level of ionized calcium, [Ca2+]i, is critical for its use as an important intracellular signal. In cardiac and skeletal muscle the control of fluctuations of [Ca2+]i depend on sarcolemmal and sarcoplasmic reticulum ion channels and transporters. We have investigated the sesquiterpine lactone, thapsigargin (TG), because of its reported action to alter cellular calcium regulation in diverse cell types, including striated muscle cells. We have combined biochemical and physiological methods at the cellular level to determine the site of action of this agent, its specificity, and its cellular effects. Using a patch-clamp method in whole cell configuration while measuring [Ca2+]i with Indo-1 salt, we find that TG (100 nM) largely blocks the contraction and the [Ca2+]i transient in rat ventricular myocytes. Analysis of these data indicate that no sarcolemmal current or transport system is directly altered by TG, although indirect [Ca2+]i-dependent processes are affected. In permeabilized myocytes, TG blocked oxalate-stimulated calcium uptake (half-maximal effect at 10 nM) into the SR. However, TG (100-mu-M) had no effect on Ca2+-induced Ca2+-release in purified muscle (ryanodine-receptor enriched) vesicles while clearly blocking Ca2+-ATPase activity in purified (longitudinal SR) vesicles. We conclude that in striated muscle TG markedly alters calcium metabolism and thus alters contractile function only by its direct action on the Ca2+-ATPase.	UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore			Lederer, William/B-1285-2010		NHLBI NIH HHS [HL28131, HL25765, HL36974] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036974, R37HL036974] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELLES B, 1988, PFLUG ARCH EUR J PHY, V412, P554, DOI 10.1007/BF00582548; BERLIN JR, 1990, CELL CALCIUM, V11, P371, DOI 10.1016/0143-4160(90)90040-2; BERS DM, 1990, AM J PHYSIOL, V258, pC944, DOI 10.1152/ajpcell.1990.258.5.C944; BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; BERS DM, 1985, AM J PHYSIOL, V248, pH366, DOI 10.1152/ajpheart.1985.248.3.H366; BOYETT MR, 1988, J PHYSIOL-LONDON, V404, P613, DOI 10.1113/jphysiol.1988.sp017309; CAMPBELL AM, 1991, J BIOL CHEM, V266, P16050; CANNELL MB, 1986, PFLUG ARCH EUR J PHY, V406, P536, DOI 10.1007/BF00583378; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CARROLL S, 1991, ARCH BIOCHEM BIOPHYS, V290, P239, DOI 10.1016/0003-9861(91)90615-P; CHU A, 1990, BIOCHEMISTRY-US, V29, P5899, DOI 10.1021/bi00477a003; COHEN P, 1989, J BIOL CHEM, V264, P21435; CRESPO LM, 1990, NATURE, V345, P618, DOI 10.1038/345618a0; DOSEMECI A, 1988, CIRC RES, V62, P347, DOI 10.1161/01.RES.62.2.347; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KIRTLEY ME, 1990, INTRACELLULAR CALCIU, P249; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NIGGLI E, 1991, NATURE, V349, P621, DOI 10.1038/349621a0; ROGERS TB, 1990, J BIOL CHEM, V265, P4302; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SEI CA, 1991, J BIOL CHEM, V266, P15910; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; WEISHAAR RE, 1985, J MED CHEM, V28, P537, DOI 10.1021/jm50001a001	30	155	157	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12545	12551						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1320000				2022-12-27	WOS:A1992HZ48300028
J	ZHUO, SQ; GARROD, S; MILLER, P; ALLISON, WS				ZHUO, SQ; GARROD, S; MILLER, P; ALLISON, WS			IRRADIATION OF THE BOVINE MITOCHONDRIAL F1-ATPASE PREVIOUSLY INACTIVATED WITH 5'-P-FLUOROSULFONYLBENZOYL-8-AZIDO-[H-3]ADENOSINE CROSS-LINKS HIS-BETA-427 TO TYR-BETA-345 WITHIN THE SAME BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; NUCLEOTIDE BINDING-SITES; COUPLING FACTOR-I; ADENOSINE-TRIPHOSPHATASE; ALPHA-SUBUNIT; ATP SYNTHASE; CATALYTIC SITES; THERMOPHILIC BACTERIUM; RAT-LIVER; IDENTIFICATION	The bovine heart mitochondrial F1-ATPase (MF1) is inactivated by 5'-p'-fluorosulfonylbenzoyl-8-azidoadenosine (8-N3-FSBA) with an apparent K(d) of 0.47 mM at pH 8.0 and 23-degrees-C in the absence of light. Irradiation of dark-inactivated enzyme with long-wavelength UV light produced cross-linked dimers and, to a lesser extent, trimers made up of alpha and beta-subunits. Two major radioactive peptides were resolved by high-performance liquid chromatography from tryptic digests of MF1 which had been inactivated with 8-N3-FSB[H-3]A at pH 8.0 in the dark. Sequence analysis revealed that one contained Tyr-beta-368 and the other contained His-beta-427 which were labeled in the ratio of 18:15. Sequence analysis of radioactive tryptic peptides isolated from digests of irradiated MF1 derivatized with 8-N3-FSB[H-3]A showed that photolysis induced cross-linking of His-427 to Tyr-345 within the same beta-subunit in high yield. When MF1 derivatized with 8-N3-FSB[H-3]A was irradiated in the presence of beta-mercaptoethanol, alpha-beta cross-links were eliminated, whereas those between His-beta-427 and Tyr-beta-345 were unaffected. Analysis of radioactive peptides in tryptic digests of MF1 derivatized with 8-N3-FSB[H-3]A and then irradiated in the presence or absence of beta-mercaptoethanol showed that the nitrene generated from reagent attached to Tyr-beta-368 participates in formation of alpha-beta cross-links in the absence of beta-mercaptoethanol. Therefore, the nitrene generated from reagent tethered to His-beta-427 is shielded from solvent and reacts with the side chain of Tyr-beta-345. In contrast, the nitrene generated from reagent attached to Tyr-beta-368 is exposed to solvent, but in the absence of scavengers reacts with side chains present in the alpha-subunit. Irradiation of MF1, partially inactivated with 8-N3-FSBA, led to loss of residual ATPase activity without affecting residual ITPase activity. The amount of photoinactivation was greater when partial dark inactivation was performed at pH 6.9, where modification of His-beta-427 predominates, than when performed at pH 8.0, where modification of Tyr-beta-368 predominates. This suggests that cross-linking of His-beta-427 to Tyr-beta-345, and not cross-linking of alpha and beta-subunits, is responsible for the augmented inactivation induced by irradiation.			ZHUO, SQ (corresponding author), UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA.				NIGMS NIH HHS [GM-16974] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOUGH DA, 1986, J BIOL CHEM, V261, P5722; BULLOUGH DA, 1988, J BIOL CHEM, V263, P14053; BULLOUGH DA, 1986, J BIOL CHEM, V261, P14171; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; Czarnecki J, 1979, Methods Enzymol, V56, P642; DOMBROWSKI KE, 1989, ARCH BIOCHEM BIOPHYS, V275, P302, DOI 10.1016/0003-9861(89)90377-9; DUNN SD, 1980, J BIOL CHEM, V255, P113; ESCH FS, 1978, J BIOL CHEM, V253, P6100; FEINSTEIN DL, 1984, ANAL BIOCHEM, V136, P362, DOI 10.1016/0003-2697(84)90231-8; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GARBOCZI DN, 1988, BIOCHEMISTRY-US, V27, P553, DOI 10.1021/bi00402a008; GARIN J, 1986, BIOCHEMISTRY-US, V25, P4431, DOI 10.1021/bi00363a039; GARIN J, 1988, FEBS LETT, V242, P178, DOI 10.1016/0014-5793(88)81011-1; GARRETT NE, 1975, J BIOL CHEM, V250, P6640; Guggenheim EA, 1926, PHILOS MAG, V2, P538; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V504, P364, DOI 10.1016/0005-2728(78)90060-9; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V463, P245, DOI 10.1016/0304-4173(78)90002-2; JACOBSON MA, 1984, J BIOL CHEM, V259, P1454; KIRONDE FAS, 1989, BIOCHEM J, V259, P421, DOI 10.1042/bj2590421; KNOWLES AF, 1972, J BIOL CHEM, V247, P6617; MAGGIO MB, 1987, J BIOL CHEM, V262, P8981; MILGROM YM, 1991, J BIOL CHEM, V266, P11551; OHTA S, 1980, J BIOCHEM-TOKYO, V87, P1609, DOI 10.1093/oxfordjournals.jbchem.a132904; PAGAN J, 1990, ARCH BIOCHEM BIOPHYS, V277, P283, DOI 10.1016/0003-9861(90)90580-R; Penefsky H S, 1979, Methods Enzymol, V56, P527; PENIN F, 1984, BIOCHIM BIOPHYS ACTA, V775, P239, DOI 10.1016/0005-2736(84)90175-5; PERLIN DS, 1984, BIOCHEMISTRY-US, V23, P4998, DOI 10.1021/bi00316a026; RAO R, 1988, J BIOL CHEM, V263, P5640; RIMKE T, 1989, BIOL CHEM H-S, V370, P949; SCHAFER HJ, 1984, J BIOL CHEM, V259, P5301; SCHAFER HJ, 1989, FEBS LETT, V253, P264, DOI 10.1016/0014-5793(89)80972-X; SCHAFER HJ, 1985, FEBS LETT, V186, P275, DOI 10.1016/0014-5793(85)80724-9; SCHEURICH P, 1978, EUR J BIOCHEM, V88, P253, DOI 10.1111/j.1432-1033.1978.tb12445.x; SCHUSTER SM, 1975, J BIOL CHEM, V250, P7848; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SWENSON RP, 1983, J BIOL CHEM, V258, P497; TAGAYA M, 1988, FEBS LETT, V233, P347, DOI 10.1016/0014-5793(88)80457-5; VERBURG JG, 1990, J BIOL CHEM, V265, P8065; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; VOGEL PD, 1991, J BIOL CHEM, V266, P6101; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WISE JG, 1990, J BIOL CHEM, V265, P10403; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YOSHIDA M, 1986, J BIOL CHEM, V261, P5714; YSERN X, 1988, J BIOENERG BIOMEMBR, V20, P423, DOI 10.1007/BF00762202; [No title captured]	49	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12916	12927						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1320008				2022-12-27	WOS:A1992HZ48300079
J	POSAS, F; CASAMAYOR, A; MORRAL, N; ARINO, J				POSAS, F; CASAMAYOR, A; MORRAL, N; ARINO, J			MOLECULAR-CLONING AND ANALYSIS OF A YEAST PROTEIN PHOSPHATASE WITH AN UNUSUAL AMINO-TERMINAL REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE PHOSPHATASES; CATALYTIC SUBUNIT; ACID SEQUENCE; ESCHERICHIA-COLI; CELLS; CDNA; GENE; TRANSFORMATION; ISOFORMS; HOMOLOGY	DNA fragments containing structural characteristics found in Ser/Thr protein phosphatases were amplified by polymerase chain reaction from yeast genome. Amplification was carried out by using degenerate oligonucleotides encoding conserved sequences found in type 1, 2A, and 2B phosphatases. A 215-base pair amplification fragment was used to screen a size-selected library, and a positive clone was isolated and sequenced. Nucleotide sequencing revealed a 2076-base pair open reading frame encoding a 692-amino acid protein. The carboxyl half of the protein is structurally related to type 1 phosphatases and virtually identical with the sequence reported as PPZ1, whereas the amino-terminal half of the protein is unrelated to sequences found in other protein phosphatases. This region is very rich in Ser residues and presents a high number of basic amino acids. Therefore, the gene product, on the basis of its unique structure, would represent a novel class of protein phosphatase. The gene, which is located at chromosome XIII, is transcribed as a mRNA of about 2.7 kilobases, and the amount of message has been found to increase 3- to 4-fold during the culture. The product of the gene PPZ1 was identified by immunoblot analysis of cell extracts as a 75-kDa protein, and the amount of immunoreactive protein was increased in cells carrying multiple copies of the gene. Disruption of the gene resulted in viable cells, with no detectable phenotypic change, indicating that the gene is not essential for growth.	UNIV AUTONOMA BARCELONA,FAC VET,DEPT BIOQUIM & BIOL MOLEC,E-08193 BARCELONA,SPAIN; HOSP DURAN & REINALS,INST REC ONCOL,DEPT GENET MOLEC,E-08907 LHOSPITALET LLOBR,SPAIN	Autonomous University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals			Arino, Joaquin/D-3756-2011; Casamayor, Antonio/A-3190-2012; Morral, Nuria/AAC-7149-2020; Posas, Francesc/K-1364-2013; Casamayor, Antonio/C-2509-2017	Arino, Joaquin/0000-0002-6774-2987; Casamayor, Antonio/0000-0003-2788-7329; Posas, Francesc/0000-0002-4164-7076; Arino Carmona, Joaquin/0000-0002-0390-4270; Morral, Nuria/0000-0002-8932-2887				ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; BERNDT N, 1987, FEBS LETT, V223, P340, DOI 10.1016/0014-5793(87)80316-2; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; CIGAN AM, 1987, GENE, V59, P1; CLOTET J, 1991, CURR GENET, V19, P339, DOI 10.1007/BF00309593; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, FEBS LETT, V250, P601, DOI 10.1016/0014-5793(89)80804-X; COHEN PTW, 1990, FEBS LETT, V268, P355, DOI 10.1016/0014-5793(90)81285-V; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; DOMBRADI V, 1989, FEBS LETT, V247, P391, DOI 10.1016/0014-5793(89)81377-8; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HOLZER H, 1987, ADV PROTEIN PHOSPHAT, V4, P153; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINKAID RL, 1989, P NATL ACAD SCI USA, V85, P8983; KITAGAWA Y, 1988, BIOCHEM BIOPH RES CO, V157, P821, DOI 10.1016/S0006-291X(88)80323-1; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; POSAS F, 1991, FEBS LETT, V279, P341, DOI 10.1016/0014-5793(91)80183-4; RITTENHOUSE J, 1986, J BIOL CHEM, V261, P3939; RONNE H, 1991, MOL CELL BIOL, V11, P4876, DOI 10.1128/MCB.11.10.4876; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1986, METHODS YEAST GENETI; SILVA EFDE, 1991, BIOCHIM BIOPHYS ACTA, V1089, P269, DOI 10.1016/0167-4781(91)90023-F; SILVA OBDE, 1988, FEBS LETT, V242, P106, DOI 10.1016/0014-5793(88)80995-5; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; SNEDDON AA, 1991, ADV PROTEIN PHOSPHAT, V6, P307; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAMURA S, 1989, P NATL ACAD SCI USA, V86, P1796, DOI 10.1073/pnas.86.6.1796; VANHETSCHIP FD, 1987, J MOL BIOL, V196, P245, DOI 10.1016/0022-2836(87)90688-7; WADZINSKI BE, 1990, J BIOL CHEM, V265, P21504; WALSH DA, 1991, PHYSIOL REV, V71, P285, DOI 10.1152/physrev.1991.71.1.285	43	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11734	11740						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1318299				2022-12-27	WOS:A1992HY94700017
J	MACPHEE, CH; CARTER, AN; RUIZLARREA, F; WARD, JG; YOUNG, RC; DOWNES, CP				MACPHEE, CH; CARTER, AN; RUIZLARREA, F; WARD, JG; YOUNG, RC; DOWNES, CP			THE STEREOSELECTIVE RECOGNITION OF SUBSTRATES BY PHOSPHOINOSITIDE KINASES - STUDIES USING SYNTHETIC STEREOISOMERS OF DIPALMITOYL PHOSPHATIDYLINOSITOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHOLIPIDS; PURIFICATION; 4-KINASE; CELLS; POLYPHOSPHOINOSITIDE; ERYTHROCYTES; METABOLITES; PHOSPHATE; RECEPTOR; LIVER	Soluble phosphatidylinositol (PtdIns) 4- and 3-kinase activities were partially purified and characterized from human placental extracts. The placental ptdIns 4-kinase (type 3) has a K(m) for ATP of 460-mu-M and is kinetically different to a partially purified human erythrocyte, membrane-bound, PtdIns 4-kinase (type 2). These three inositol lipid kinases were then used to compare their substrate specificities against the four synthetic stereoisomers of dipalmitoyl PtdIns. Only the placental 4-kinase was influenced by the chirality of the glycerol moiety of PtdIns. However, neither of the 4-kinases was able to phosphorylate L-PtdIns and, therefore, these kinases have an absolute requirement for the inositol ring to be linked to the glyceryl backbone of the lipid through the D-1 position. Phosphoinositide 3-kinase, on the other hand, was found to phosphorylate both D- and L-PtdIns. While the 3-kinase phosphorylated exclusively the D-3 position of D-PtdIns, further analyses demonstrated that the same enzyme phosphorylated two sites on L-PtdIns, namely the D-6 and D-5 positions of the inositol ring. Some implications of these findings are discussed.	LUDWIG INST CANC RES,LONDON,ENGLAND; UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	Ludwig Institute for Cancer Research; University of Dundee	MACPHEE, CH (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,WELWYN GARDEN CIT AL6 9AR,HERTS,ENGLAND.			Ruiz Larrea, Fernanda/0000-0001-5610-7745				BATTY IH, 1989, BIOCHEM J, V258, P23, DOI 10.1042/bj2580023; BERRIDGE MJ, 1989, NATURE, V315, P239; BROWN DM, 1966, BIOCHIM BIOPHYS ACTA, V125, P413, DOI 10.1016/0005-2760(66)90029-4; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; CUNNINGHAM TW, 1991, BIOCHEM BIOPH RES CO, V175, P568, DOI 10.1016/0006-291X(91)91603-A; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; HAWKINS PT, 1984, BIOCHEM J, V218, P785, DOI 10.1042/bj2180785; HOU WM, 1988, BIOCHIM BIOPHYS ACTA, V959, P67; LI YS, 1989, BIOCHEM BIOPH RES CO, V160, P202, DOI 10.1016/0006-291X(89)91641-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MICHELL RH, 1975, BIOCHIM BIOPHYS ACTA, V415, P81, DOI 10.1016/0304-4157(75)90017-9; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PORTER FD, 1988, J BIOL CHEM, V263, P8989; SHARPS ES, 1982, ANAL BIOCHEM, V124, P421, DOI 10.1016/0003-2697(82)90059-8; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS L, 1989, BIOCHEM J, V259, P267, DOI 10.1042/bj2590267; STEPHENS LR, 1988, BIOCHEM J, V249, P283, DOI 10.1042/bj2490283; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; WALKER DH, 1988, BIOCHEMISTRY-US, V27, P6504, DOI 10.1021/bi00417a046; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YOUNG RC, 1990, J MED CHEM, V33, P2073, DOI 10.1021/jm00170a005; YOUNG RC, 1990, J MED CHEM, V33, P641, DOI 10.1021/jm00164a027	29	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11137	11143						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317855				2022-12-27	WOS:A1992HX16900034
J	PINNER, E; PADAN, E; SCHULDINER, S				PINNER, E; PADAN, E; SCHULDINER, S			CLONING, SEQUENCING, AND EXPRESSION OF THE NHAB GENE, ENCODING A NA+/H+ ANTIPORTER IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; BACTERIA; PROTON; GRADIENT; CELLS; PUMP; ANT	In Escherichia coli, expulsion of sodium ions is driven by proton flux via at least two distinct Na+/H+ antiporters, NhaA and NhaB. When the nhaA gene is deleted from the chromosome, the cell becomes sensitive to high salinity and alkaline pH (Padan, E., Maisler, N., Taglicht, D., Karpel, R., and Schuldiner, S. (1989) J. Biol. Chem. 264, 20297-20302). In the current work we cloned the nhaB gene by complementation of the DELTA-nhaA strain. The gene codes for a membrane protein 504 amino acids long. Hydropathic analysis of the sequence indicates the presence of 12 putative transmembrane helices. NhaB has been specifically labeled with [S-35]methionine; it is a membrane protein and displays an apparent M(r) of 47,000, slightly lower than that predicted from its amino acid sequence. Membranes from cells containing multiple dose of nhaB display enhanced Na+/H+ antiporter activity, as measured by the ability of Na+ to collapse a preformed pH gradient or by direct measurement of Na-22(+) fluxes. In contrast to NhaA, whose activity increases with pH, NhaB is practically insensitive to pH. Limited homologies with Na+ transporters have been identified.			PINNER, E (corresponding author), HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT MOLEC & MICROBIAL ECOL,IL-91904 JERUSALEM,ISRAEL.		Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237				BACHMAN BJ, 1990, MICROBIOL REV, V54, P197; BOOTH IR, 1985, MICROBIOL REV, V49, P395; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENDEL V, 1984, NUCLEIC ACIDS RES, V12, P4411, DOI 10.1093/nar/12.10.4411; BROWN II, 1983, EUR J BIOCHEM, V134, P345, DOI 10.1111/j.1432-1033.1983.tb07573.x; DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; DELSAL G, 1988, NUCLEIC ACIDS RES, V16, P1978; DIMROTH P, 1987, MICROBIOL REV, V51, P320, DOI 10.1128/MMBR.51.3.320-340.1987; DIRUSSO CC, 1988, NUCLEIC ACIDS RES, V16, P7995, DOI 10.1093/nar/16.16.7995; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GILLEN JR, 1981, J BACTERIOL, V145, P521, DOI 10.1128/JB.145.1.521-532.1981; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; Harold F. M., 1974, CURR TOP MEMBR TRANS, V5, P1; HEEFNER DL, 1982, P NATL ACAD SCI-BIOL, V79, P2798, DOI 10.1073/pnas.79.9.2798; HIROTA N, 1981, FEBS LETT, V132, P278, DOI 10.1016/0014-5793(81)81178-7; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KARPEL R, 1988, J BIOL CHEM, V263, P10408; KARPEL R, 1991, J BIOL CHEM, V266, P21753; KITAGAWA Y, 1985, P NATL ACAD SCI USA, V82, P4336, DOI 10.1073/pnas.82.13.4336; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KRULWICH TA, 1986, J MEMBRANE BIOL, V89, P113, DOI 10.1007/BF01869707; LANYI JK, 1979, BIOCHIM BIOPHYS ACTA, V559, P377, DOI 10.1016/0304-4157(79)90011-X; LeBlanc G, 1988, NA PLUS H PLUS EXCHA, p[103, Na+/H+exchange]; OSTERHELT D, 1978, ENERGY CONSERVATION, P140; PADAN E, 1989, J BIOL CHEM, V264, P20297; PADAN E, 1981, BIOCHIM BIOPHYS ACTA, V650, P151, DOI 10.1016/0304-4157(81)90004-6; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; PADAN E, 1992, IN PRESS ALKALIC ATI; RAHAVMANOR O, 1992, IN PRESS J BIOL CHEM, V267; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SCHULDINER S, 1978, BIOCHEMISTRY-US, V17, P706, DOI 10.1021/bi00597a023; SKULACHEV VP, 1987, ION TRANSPORT PROKAR, P131; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TOKUDA H, 1982, J BIOL CHEM, V257, P7; WEST IC, 1974, BIOCHEM J, V144, P87, DOI 10.1042/bj1440087	37	130	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11064	11068						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317851				2022-12-27	WOS:A1992HX16900023
J	YAMAMOTO, K; ALTSCHULER, D; WOOD, E; HORLICK, K; JACOBS, S; LAPETINA, EG				YAMAMOTO, K; ALTSCHULER, D; WOOD, E; HORLICK, K; JACOBS, S; LAPETINA, EG			ASSOCIATION OF PHOSPHORYLATED INSULIN-LIKE GROWTH FACTOR-I RECEPTOR WITH THE SH2 DOMAINS OF PHOSPHATIDYLINOSITOL 3-KINASE P85	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLATELETS; PROTEIN; BINDING; PURIFICATION; KINASE; SIGNAL; SRC; GAP	Insulin-like growth factor-I (IGF-I) stimulates the production of 3-inositides and markedly increases the phosphatidylinositol 3-kinase activity that is immunoprecipitated by anti-phosphotyrosine antibodies, a portion of which is also associated with the IGF-I receptor. In this study, recombinant p85, the regulatory subunit of phosphatidylinositol 3-kinase, and fusion proteins containing various subdomains were used to investigate the association of p85 with the IGF-I receptor and to demonstrate that p85 is a direct in vitro substrate of the IGF-I receptor kinase. Solubilized IGF-I receptor was immobilized on antireceptor antibody-agarose beads. Following in vitro receptor phosphorylation and incubation with cell lysate, immobilized receptor became associated with phosphatidylinositol 3-kinase activity and with protein bands with molecular masses of 85 and 110 kDa, which correspond to the known molecular masses of the subunits of phosphatidylinositol 3-kinase. These associations were inhibited by the addition of recombinant intact p85 or SH2-containing fusion proteins, but not by fusion proteins containing its SH3 domain or breakpoint cluster homology region. A fusion protein containing the SH2 domains of Ras GTPase-activating protein also inhibited the association of phosphatidylinositol 3-kinase activity with immobilized IGF-I receptor, although less effectively than p85, whereas a similar construct containing the SH2 domain of pp60src was without effect. When immobilized phosphorylated IGF-I receptor was incubated with intact p85 or the SH2-containing fusion proteins, it became associated with and phosphorylated these proteins. These results demonstrate that at least in vitro, a tight association occurs between phosphorylated IGF-I receptor and phosphatidylinositol 3-kinase, that the region of phosphatidylinositol 3-kinase that contains its SH2 domains is directly involved in this association, and that this region is a direct substrate for IGF-I receptor tyrosine kinase. Furthermore, these results suggest that Ras GTPase-activating protein can also interact with the IGF-I receptor and that different SH2 domain-containing proteins interact with the IGF-I receptor with widely differing affinities.			YAMAMOTO, K (corresponding author), BURROUGHS WELLCOME CO,DIV CELL BIOL,RES TRIANGLE PK,NC 27709, USA.							ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KULL FC, 1983, J BIOL CHEM, V258, P6561; LAPETINA EG, 1986, BIOCHIM BIOPHYS ACTA, V884, P219, DOI 10.1016/0304-4165(86)90166-2; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; MYERS MG, 1991, J BIOL CHEM, V266, P10616; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PIGNATARO OP, 1990, MOL ENDOCRINOL, V4, P758, DOI 10.1210/mend-4-5-758; PILLAY TS, 1991, FEBS LETT, V288, P206, DOI 10.1016/0014-5793(91)81035-7; ROTH RA, 1991, MODERN CONCEPTS INSU, P505; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEELEPERKINS G, 1990, BIOCHEM BIOPH RES CO, V171, P1244, DOI 10.1016/0006-291X(90)90819-9; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; YAMAMOTO K, 1992, ENDOCRINOLOGY, V130, P1490, DOI 10.1210/en.130.3.1490; YAMAMOTO K, 1990, J BIOL CHEM, V265, P22086	34	73	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11337	11343						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317864				2022-12-27	WOS:A1992HX16900063
J	YOSHIMURA, A; ZIMMERS, T; NEUMANN, D; LONGMORE, G; YOSHIMURA, Y; LODISH, HF				YOSHIMURA, A; ZIMMERS, T; NEUMANN, D; LONGMORE, G; YOSHIMURA, Y; LODISH, HF			MUTATIONS IN THE TRP-SER-X-TRP-SER MOTIF OF THE ERYTHROPOIETIN RECEPTOR ABOLISH PROCESSING, LIGAND-BINDING, AND ACTIVATION OF THE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; BETA-CHAIN; INSULIN PRORECEPTOR; GLYCOPROTEIN; SUPERFAMILY; ACQUISITION; CLONING; HORMONE; FAMILY; GROWTH	The erythropoietin receptor (EPOR) is a member of the newly identified cytokine receptor superfamily. A common sequence motif, Trp-Ser-X-Trp-Ser (WSXWS), near the transmembrane domain is highly conserved in this family. To determine the function of this motif, we constructed deletion and insertion mutations in this part of the EPOR and introduced them into an interleukin-3 (IL-3)-dependent hematopoietic Ba/F3 cell line. Cells expressing the wild-type EPOR displayed 1500 erythropoietin (EPO)-binding sites/cell with a single affinity of about 300 pM and proliferate in the presence of IL-3 or EPO. Ba/F3 cells expressing receptors mutated in the WSXWS motif displayed little EPO binding on the cell surface and did not grow in the presence of EPO. The mutant receptors were retained in the endoplasmic reticulum (ER) and, as such, were unable to bind EPO. A single Gly insertion between the two WS sequences caused defects in receptor structure and function similar to mutations lacking all or part of the WSXWS motif. The EPOR can be activated, resulting in proliferation independent of EPO either by an Arg129 to Cys point mutation or by association with the Friend spleen focus-forming virus (SFFV) envelope glycoprotein gp55. Introduction of the point mutation (Arg129 to Cys) did not activate any of the receptors mutated in the WSXWS motif. Moreover, gp55 did not activate the mutant receptors in Ba/F3 cells. Our study indicates that the WSXWS motif is critical for protein folding, ligand-binding, and signal transduction.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Massachusetts Institute of Technology (MIT)	YOSHIMURA, A (corresponding author), WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.		Zimmers, Teresa/AAD-5461-2019; Zimmers, Teresa/H-5892-2011; Yoshimura, Akihiko/K-5515-2013	Zimmers, Teresa/0000-0001-7872-0540; Neumann, Drorit/0000-0002-4805-7511	NHLBI NIH HHS [HL-32253] Funding Source: Medline; NIA NIH HHS [AG 00294] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K12AG000294] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; D'Andrea AD, 1990, CURR OPIN CELL BIOL, V2, P648, DOI 10.1016/0955-0674(90)90106-O; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Honjo T, 1991, Curr Biol, V1, P201, DOI 10.1016/0960-9822(91)90055-2; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MAINS PE, 1983, J BIOL CHEM, V258, P5027; MAYEUX P, 1990, EUR J BIOCHEM, V194, P271, DOI 10.1111/j.1432-1033.1990.tb19453.x; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; OLSON TS, 1987, J BIOL CHEM, V262, P6816; OLSON TS, 1988, J BIOL CHEM, V263, P7342; OLSON TS, 1989, FASEB J, V3, P1618, DOI 10.1096/fasebj.3.5.2537774; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; TAKAKI S, 1991, EMBO J, V10, P2833, DOI 10.1002/j.1460-2075.1991.tb07832.x; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WOGNUM AW, 1990, BLOOD, V76, P697; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706	35	105	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11619	11625						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1317872				2022-12-27	WOS:A1992HX16900104
J	COLBRAN, JL; FRANCIS, SH; LEACH, AB; THOMAS, MK; JIANG, H; MCALLISTER, LM; CORBIN, JD				COLBRAN, JL; FRANCIS, SH; LEACH, AB; THOMAS, MK; JIANG, H; MCALLISTER, LM; CORBIN, JD			A PHENYLALANINE IN PEPTIDE-SUBSTRATES PROVIDES FOR SELECTIVITY BETWEEN CGMP-DEPENDENT AND CAMP-DEPENDENT PROTEIN-KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC PEPTIDE; RAT-LIVER; PHOSPHORYLATION; SITE; SPECIFICITY; PHOSPHODIESTERASE	Bovine lung cGMP-binding cGMP-specific phosphodiesterase (cG-BPDE) is a potent and relatively specific substrate for cGMP-dependent protein kinase (cGK) as compared to cAMP-dependent protein kinase (cAK) (Thomas, M. K., Francis, S. H., and Corbin J. D. (1990) J. Biol. Chem. 265, 14971-14978). A synthetic peptide, RKISASEFDRPLR (BPDEtide), was synthesized corresponding to the sequence surrounding the phosphorylation site in cG-BPDE. BPDEtide retained the cGK/cAK kinase specificity demonstrated by native cG-BPDE: the apparent K(m) of BPDEtide for cGK was 5-fold lower than that for cAK (K(m) = 68 and 320-mu-M, respectively). V(max) values were 11-mu-mol/min/mg for cGK and 3.2-mu-mol/min/mg for cAK. The peptide was not phosphorylated to a measurable extent by protein kinase C or by calcium/calmodulin-dependent protein kinase II. Thus, the primary amino acid sequence of the peptide substrate was sufficient to confer kinase specificity. Studies in crude tissue extracts indicated that BPDEtide was the most selective peptide substrate documented for measuring cGK activity. Peptide analogs of BPDEtide were synthesized to determine the contribution of specific residues to cGK or cAK substrate specificity. Substitution of a Lys for the amino-terminal Arg did not reduce cGK/cAK specificity; neither did the exchange of an Ala for the nonphosphorylated Ser nor the removal of the 3 carboxyl-terminal residues. A truncated BPDEtide (RKISASE) served equally well as substrate (K(m) approximately 90-mu-M) for both kinases. However, restoration of the Phe, to yield RKI-SASEF, reproduced the original cGK/cAK specificity for BPDEtide (K(m) = 120 and 480-mu-M, respectively), primarily by decreasing the affinity of cAK. Addition of a carboxyl-terminal Phe to the peptide RKRSRAE (derived from the sequence of the cGK phosphorylation site in histone H2B) or to the peptide LRRASLG (derived from the sequence of the cAK phosphorylation site in pyruvate kinase) also improved the cGK/cAK specificity by decreasing the affinity of cAK. These data suggested that the Phe in each substrate tested is a negative determinant for cAK.	VANDERBILT UNIV, SCH MED, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA	Vanderbilt University					NIDDK NIH HHS [DK-40029] Funding Source: Medline; NIGMS NIH HHS [GM-41269] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041269] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CORBIN JD, 1983, J BIOL CHEM, V258, P1391; CORBIN JD, 1990, ADV SEC MESS PHOSPH, V24, P411; DAILE P, 1975, NATURE, V257, P416, DOI 10.1038/257416a0; FLOCKHART DA, 1984, BRAIN RECEPTOR MET A, P209; GEAHLEN RL, 1980, J BIOL CHEM, V255, P1164; GLASS DB, 1982, J BIOL CHEM, V257, P1196; GLASS DB, 1979, J BIOL CHEM, V254, P9728; GLASS DB, 1990, PEPT PROT PHOSPH, P209; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; JIANG H, 1992, J BIOL CHEM, V267, P1015; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LINCOLN TM, 1977, P NATL ACAD SCI USA, V74, P3239, DOI 10.1073/pnas.74.8.3239; MASARACCHIA RA, 1977, J BIOL CHEM, V252, P7109; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; PIERCE MW, 1982, J BIOL CHEM, V257, P681; SODERLING TR, 1986, C INSERM, V139, P141; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; Walter U, 1989, REV PHYSL BIOCH PHAR, V113, P41; WRETBORN M, 1980, BIOCHEM BIOPH RES CO, V93, P403, DOI 10.1016/0006-291X(80)91091-8; ZETTERQVIST O, 1976, BIOCHEM BIOPH RES CO, V70, P696, DOI 10.1016/0006-291X(76)90648-3; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171	24	72	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9589	9594						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315760				2022-12-27	WOS:A1992HT96500024
J	MILLER, VP; DEPILLIS, GD; FERRER, JC; MAUK, AG; DEMONTELLANO, PRO				MILLER, VP; DEPILLIS, GD; FERRER, JC; MAUK, AG; DEMONTELLANO, PRO			MONOOXYGENASE ACTIVITY OF CYTOCHROME-C PEROXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON HEME COMPLEX; HORSERADISH-PEROXIDASE; SODIUM-AZIDE; FERROCYTOCHROME-C; HYDROGEN-PEROXIDE; CRYSTAL-STRUCTURE; OXYGEN-TRANSFER; RADICAL SITE; MODEL SYSTEM; COMPOUND-I	Recombinant cytochrome c peroxidase (CcP) and a W51A mutant of CcP, in contrast to other classical peroxidases, react with phenylhydrazine to give sigma-bonded phenyl-iron complexes. The conclusion that the heme iron is accessible to substrates is supported by the observation that CcP and W51A CcP oxidize thioanisole to the racemic sulfoxide with quantitative incorporation of oxygen from H2O2. Definitive evidence for an open active site is provided by stereoselective epoxidation by both enzymes of styrene, cis-beta-methylstyrene, and trans-beta-methylstyrene. trans-beta-methylstyrene yields exclusively the trans-epoxide, but styrene yields the epoxide and phenylacetaldehyde, and cis-beta-methylstyrene yields both the cis- and trans-epoxides and 1-phenyl-2-propanone. The sulfoxide, stereoretentive epoxides, and 1-phenyl-2-propanone are formed by ferryl oxygen transfer mechanisms because their oxygen atom derives from H2O2. In contrast, the oxygen in the trans-epoxide from the cis-olefin derives primarily from molecular oxygen and is probably introduced by a protein cooxidation mechanism. cis-[1,2-H-2]-l-Phenyl-1-propene is oxidized to [1,1-H-2]-1-phenyl-2-propanone without a detectable isotope effect on the epoxide:ketone product ratio. The phenyl-iron complex is not formed and substrate oxidation is not observed when the prosthetic group is replaced by delta-meso-ethylheme. CcP thus has a sufficiently open active site to form a phenyl-iron complex, to oxidize thioanisole to the sulfoxide, and to epoxidize styrene and beta-methylstyrene. The results indicate that a ferryl (Fe(IV) = O)/protein radical pair can be coupled to achieve two-electron oxidations. The unique ability of CcP to catalyze monooxygenation reactions does not conflict with its peroxidase function because cytochrome c is oxidized at a distinct surface site (DePillis, G. D., Sishta, B. P., Mauk, A. G., and Ortiz de Montellano, P. R. (1991) J. BioL Chem. 266,19334-19341).	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1Z3,BC,CANADA	University of California System; University of California San Francisco; University of British Columbia			Ferrer, Joan C./AAP-2145-2021	Ferrer, Joan C./0000-0003-1212-5161	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081, P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-1081, RR-01614] Funding Source: Medline; NIGMS NIH HHS [GM32488] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATOR MA, 1987, J BIOL CHEM, V262, P14954; ATOR MA, 1987, J BIOL CHEM, V262, P1542; AUGUSTO O, 1982, J BIOL CHEM, V257, P6231; BOSSHARD HR, 1991, PEROXIDASES CHEM BIO, V2, P51; BRUICE TC, 1991, ACCOUNTS CHEM RES, V24, P243, DOI 10.1021/ar00008a004; CATALANO CE, 1987, BIOCHEMISTRY-US, V26, P8373, DOI 10.1021/bi00399a052; COLLMAN JP, 1986, J AM CHEM SOC, V108, P2588, DOI 10.1021/ja00270a016; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DEMONTELLANO PRO, 1987, BIOCHEMISTRY-US, V26, P5310, DOI 10.1021/bi00391a014; DEMONTELLANO PRO, 1983, J BIOL CHEM, V258, P558; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; DEMONTELLANO PRO, 1987, J BIOL CHEM, V262, P11641; DEMONTELLANO PRO, 1988, BIOCHEMISTRY-US, V27, P5470, DOI 10.1021/bi00415a013; DEMONTELLANO PRO, 1992, IN PRESS ANN REV PHA; DEPILLIS GD, 1991, J BIOL CHEM, V266, P19334; DEPILLIS GD, 1989, BIOCHEMISTRY-US, V28, P7947, DOI 10.1021/bi00445a059; DEPILLIS GD, 1990, ARCH BIOCHEM BIOPHYS, V280, P217, DOI 10.1016/0003-9861(90)90539-B; DOERGE DR, 1991, BIOCHEMISTRY-US, V30, P8960, DOI 10.1021/bi00101a007; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; ELFARRA AA, 1991, ARCH BIOCHEM BIOPHYS, V286, P244, DOI 10.1016/0003-9861(91)90036-I; ERMAN JE, 1989, BIOCHEMISTRY-US, V28, P7992, DOI 10.1021/bi00446a004; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FISHEL LA, 1991, BIOCHEMISTRY-US, V30, P1986, DOI 10.1021/bi00221a036; GARRISON JM, 1989, J AM CHEM SOC, V111, P4960, DOI 10.1021/ja00195a060; GOODIN DB, 1991, BIOCHEMISTRY-US, V30, P4953, DOI 10.1021/bi00234a017; GROVES JT, 1986, INORG CHEM, V25, P123, DOI 10.1021/ic00222a003; GROVES JT, 1988, J AM CHEM SOC, V110, P8443, DOI 10.1021/ja00233a021; GROVES JT, 1983, J AM CHEM SOC, V105, P5791, DOI 10.1021/ja00356a016; HARRIS RZ, 1991, J BIOL CHEM, V266, P8751; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; KOBAYASHI S, 1987, BIOCHEMISTRY-US, V26, P5019, DOI 10.1021/bi00390a020; KOBAYASHI S, 1986, BIOCHEM BIOPH RES CO, V135, P166, DOI 10.1016/0006-291X(86)90957-5; MANSUY D, 1984, BIOCHEM BIOPH RES CO, V119, P319, DOI 10.1016/0006-291X(84)91654-1; MAURO JM, 1988, BIOCHEMISTRY-US, V27, P6243, DOI 10.1021/bi00417a008; NARUTA Y, 1991, J AM CHEM SOC, V113, P6865, DOI 10.1021/ja00018a024; Ortiz de Montellano PR, 1986, CYTOCHROME P450 STRU, P217; PLE P, 1989, J BIOL CHEM, V264, P13983; RAAG R, 1990, BIOCHEMISTRY-US, V29, P8119, DOI 10.1021/bi00487a019; RINGE D, 1984, BIOCHEMISTRY-US, V23, P2, DOI 10.1021/bi00296a001; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SUMMERS FE, 1988, J BIOL CHEM, V263, P14267; SWANSON BA, 1991, J AM CHEM SOC, V113, P8146, DOI 10.1021/ja00021a046; SWANSON BA, 1991, J BIOL CHEM, V266, P19258; YONETANI T, 1966, J BIOL CHEM, V241, P3240; YONETANI T, 1966, BIOCHEM PREP, V11, P14	45	80	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8936	8942						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1315745				2022-12-27	WOS:A1992HR85400038
J	LIUZZI, M; PATERSON, MC				LIUZZI, M; PATERSON, MC			ENZYMATIC ANALYSIS OF OLIGONUCLEOTIDES CONTAINING CYCLOBUTANE PYRIMIDINE PHOTODIMERS WITH A CLEAVED INTRADIMER PHOSPHODIESTER LINKAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DNA PHOTOLYASE; ESCHERICHIA-COLI; ISOMERIC TRITHYMIDYLATES; MICROCOCCUS-LUTEUS; DIMERS; REPAIR; INHIBITION; EXCISION	Our recent studies indicate that enzymatic hydrolysis of the intradimer phosphodiester linkage constitutes an early reaction in processing UV light-induced cis-syn-cyclobutane pyrimidine dimers in cultured human fibroblasts. Before characterizing the resultant modified dimer sites in cellular DNA, it is necessary to establish experimental conditions that can distinguish backbone-nicked from intact dimers. We thus constructed a model substrate, i.e. p(dT)10<>p(dT)10 containing a dimer with a ruptured sugar-phosphate bond, and determined the products of its reaction with snake venom phosphodiesterase and alkaline phosphatase, an enzymatic digestion mixture known to release dimers from UV-treated poly(dA) . poly(dT) within trinucleotides with the photoproduct intact at the 3'-end (d-TpT<p>T). The model substrate was prepared by (i) end labeling p(dT)9 using terminal deoxynucleotidyltransferase and [H-3]thymine-labeled TTP; and (ii) annealing the chromatographically purified p(dT)10 oligomers to poly(dA) followed by UV (290 nm)-induced ligation. Photoligated 20-mers with one radioactive and modified internal dimer were isolated and enzymatically digested. High performance liquid chromatographic analysis of the reaction products revealed a novel trithymidylate with its backbone severed at the 3'-terminus (d-TpT<>dT), demonstrating that this procedure could discriminate between intact and modified dimers. The procedure was then exploited to show that (i) Escherichia coli DNA photolyase can monomerize, albeit inefficiently, backbone-ruptured dimers; and (ii) phage T4 polynucleotide kinase can catalyze the phosphorylation of d-TpT<>dT, thus facilitating the development of a sensitive postlabeling assay suitable for modified dimer detection under biologically relevant conditions.	CROSS CANC INST, DEPT MED, MOLEC ONCOL PROGRAM, EDMONTON T6G 1Z2, ALBERTA, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON T6G 2E1, ALBERTA, CANADA	University of Alberta; University of Alberta								[Anonymous], 1985, DNA REPAIR; CADET J, 1983, J CHROMATOGR, V280, P99, DOI 10.1016/S0021-9673(00)91543-7; CARRIER WL, 1981, DNA REPAIR A, V1, P1; DEERING RA, 1963, BIOCHIM BIOPHYS ACTA, V68, P526; HANAWALT PC, 1979, ANNU REV BIOCHEM, V48, P783, DOI 10.1146/annurev.bi.48.070179.004031; HUSAIN I, 1987, J BIOL CHEM, V262, P13188; KIM ST, 1991, BIOCHEMISTRY-US, V30, P8623, DOI 10.1021/bi00099a019; LABELLE M, 1982, PHOTOCHEM PHOTOBIOL, V36, P319, DOI 10.1111/j.1751-1097.1982.tb04381.x; LEWIS RJ, 1982, NATURE, V298, P393, DOI 10.1038/298393a0; LIUZZI M, 1987, BIOCHEMISTRY-US, V26, P3315, DOI 10.1021/bi00386a011; LIUZZI M, 1989, J BIOL CHEM, V264, P6355; LIUZZI M, 1988, J CELL BIOCH A S, V12, P271; MOORE P, 1979, NATURE, V278, P664, DOI 10.1038/278664a0; PATERSON MC, 1987, J CELL SCI, P161; PATERSON MC, 1992, ADP RIBOSYLATION REA, P97; Patrick MH., 1976, PHOTOCHEM PHOTOBIOL, V2, P35, DOI [10.1016/B978-0-12-734602-1.50008-3, DOI 10.1016/B978-0-12-734602-1.50008-3]; RICHARDSON CC, 1965, P NATL ACAD SCI USA, V54, P158, DOI 10.1073/pnas.54.1.158; SANCAR A, 1984, J BIOL CHEM, V259, P6028; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANCAR GB, 1987, TRENDS BIOCHEM SCI, V12, P259, DOI 10.1016/0968-0004(87)90130-7; SAUERBIER W, 1978, ANNU REV GENET, V12, P329, DOI 10.1146/annurev.ge.12.120178.001553; SCHOTT H, 1984, EUR J BIOCHEM, V143, P613, DOI 10.1111/j.1432-1033.1984.tb08414.x; SETLOW RB, 1964, BIOCHIM BIOPHYS ACTA, V91, P446, DOI 10.1016/0926-6550(64)90075-1; SMITH CA, 1990, ADV MUTAGENESIS RES, V1, P153; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WEINFELD M, 1989, J BIOL CHEM, V264, P6364; WEINFELD M, 1986, BIOCHEMISTRY-US, V25, P2656, DOI 10.1021/bi00357a055; WEINFELD M, 1988, NUCLEIC ACIDS RES, V16, P5693, DOI 10.1093/nar/16.12.5693	28	4	4	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22421	22427						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331055				2022-12-27	WOS:A1992JW71900068
J	CREPIN, KM; DECLOEDT, M; VERTOMMEN, D; FORET, D; MICHEL, A; RIDER, MH; ROUSSEAU, GG; HUE, L				CREPIN, KM; DECLOEDT, M; VERTOMMEN, D; FORET, D; MICHEL, A; RIDER, MH; ROUSSEAU, GG; HUE, L			MOLECULAR-FORMS OF 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE EXPRESSED IN RAT SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED BOVINE HEART; ESCHERICHIA-COLI; LIVER 6-PHOSPHOFRUCTO-2-KINASE; FRUCTOSE 2,6-BISPHOSPHATE; PLASMID VECTORS; MESSENGER-RNAS; CLONING; PROTEIN; DNA; SEQUENCE	The rat cDNA for the muscle-type (M) isozyme of 6-phosphofructo-2-kinase(PFK-2)/fructose-2,6-bisphosphatase (FBPase-2) contains two putative translation initiation sites. To determine whether the M isozyme expressed in rat skeletal muscle corresponds to the short (PFK2M-sf) or the long (PFK2M-lf) isoform, we have expressed them in Escherichia coli. A third construction was also expressed in which the second ATG codon was deleted (PFK2M-lfDELTAATG) to ensure that initiation started at the first ATG. The properties of these recombinant proteins were compared with those of the PFK-2/FBPase-2 present in rat skeletal muscle and liver. The recombinant proteins displayed PFK-2 and FBPase-2 activities and the M(r) values of the subunits measured by SDS-polyacrylamide gel electrophoresis were compatible with the calculated ones. The purified recombinant lf form contained not only the expected If band (54,500 M(r)) but also the sf band (52,000 M(r)), indicating that the expression system could synthesize the long and the short isoforms from the same mRNA. The kinetic properties of the recombinant sf form were not different from those of the rat muscle enzyme. By contrast, lfDELTAATG PFK-2 displayed a higher K(m) for its substrates and a lower V(max). Immunoblotting with an antibody directed against the long isoform revealed a 54,500 M(r) band both in the If and the lfDELTAATG recombinant, but no band in rat skeletal muscle extracts. In these extracts, one band of 52,000 and a minor one of 54,500 M(r) were detected by an anti PFK-2/FBPase-2 antibody. The 54,500 M(r) band was recognized by an antibody directed against the L isozyme, suggesting that a small amount of the latter is expressed in skeletal muscle. Thus, the M isozyme differs from the L isozyme by replacement of the first 32 amino acids of the L isozyme by an unrelated nonapeptide.	CATHOLIC UNIV LOUVAIN,SCH MED,HORMONE & METAB RES UNIT,B-1200 BRUSSELS,BELGIUM; CATHOLIC UNIV LOUVAIN,INT INST CELLULAR & MOLEC PATHOL,B-1200 BRUSSELS,BELGIUM; UNIV MONS,FAC SCI,BIOL CHEM LAB,B-7000 MONS,BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; University of Mons				Vertommen, Didier/0000-0001-7648-8282				BARTRONS R, 1983, BIOCHEM J, V214, P829, DOI 10.1042/bj2140829; BOLLAG DM, 1991, PROTEIN METHODS, P118; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CREPIN KM, 1989, BIOCHEM J, V264, P151, DOI 10.1042/bj2640151; CREPIN KM, 1989, EUR J BIOCHEM, V183, P433, DOI 10.1111/j.1432-1033.1989.tb14946.x; DARVILLE MI, 1987, FEBS LETT, V224, P317, DOI 10.1016/0014-5793(87)80476-3; DARVILLE MI, 1989, P NATL ACAD SCI USA, V86, P6543, DOI 10.1073/pnas.86.17.6543; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; KITAMURA K, 1989, J BIOL CHEM, V264, P9799; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MARCHAND MJ, 1992, BIOCHEM J, V285, P413, DOI 10.1042/bj2850413; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; REMAUT E, 1987, METHOD ENZYMOL, V153, P416; REMAUT E, 1983, GENE, V22, P103, DOI 10.1016/0378-1119(83)90069-0; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; RIDER MH, 1984, FEBS LETT, V176, P484, DOI 10.1016/0014-5793(84)81223-5; RIDER MH, 1985, BIOCHEM J, V231, P193, DOI 10.1042/bj2310193; RIDER MH, 1986, BIOCHEM J, V240, P57, DOI 10.1042/bj2400057; RIDER MH, 1992, BIOCHEM J, V285, P405, DOI 10.1042/bj2850405; SAKATA J, 1991, J BIOL CHEM, V266, P15764; SAKATA J, 1990, P NATL ACAD SCI USA, V87, P4951, DOI 10.1073/pnas.87.13.4951; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; TANIYAMA M, 1988, BIOCHEM BIOPH RES CO, V157, P949, DOI 10.1016/S0006-291X(88)80966-5; van Schaftingen E., 1984, METHODS ENZYMATIC AN, P335; VANSCHAFTINGEN E, 1986, EUR J BIOCHEM, V159, P359; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V124, P143	34	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21698	21704						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328243				2022-12-27	WOS:A1992JV01100069
J	GAFVELS, ME; COUKOS, G; SAYEGH, R; COUTIFARIS, C; STRICKLAND, DK; STRAUSS, JF				GAFVELS, ME; COUKOS, G; SAYEGH, R; COUTIFARIS, C; STRICKLAND, DK; STRAUSS, JF			REGULATED EXPRESSION OF THE TROPHOBLAST ALPHA-2-MACROGLOBULIN RECEPTOR LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN - DIFFERENTIATION AND CAMP MODULATE PROTEIN AND MESSENGER-RNA LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANCY; BINDING; SYNCYTIOTROPHOBLAST; IDENTIFICATION; CLEARANCE; ANTIGEN; INVITRO	The alpha2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha2MR/LRP) has several ligands including activated alpha2-macroglobulin, pregnancy zone protein, and very low density lipoproteins enriched with apolipoprotein E. The diversity of ligands suggests a role for the alpha2MR/LRP in a variety of processes including tissue remodeling and lipoprotein metabolism. We examined alpha2MR/LRP in placental trophoblasts, invasive cells that also function in lipid transport and cholesterol metabolism. Alpha2MR/LRP protein was localized by immunohistochemistry in the syncytiotrophoblast of term placenta. Cytotrophoblasts did not stain prominently. Alpha2MR/LRP (protein and message) in primary cultures of human trophoblast cells increased as cytotrophoblasts differentiated into syncytiotrophoblast. 8-Bromo-cAMP prevented this increase and suppressed alpha2MR/LRP expression. The cyclic nucleotide had similar suppressive effects on alpha2MR/LRP in BeWo choriocarcinoma cells. In contrast, low density lipoprotein receptor gene expression was increased. We conclude that: 1) there is a differentiation-dependent pattern of alpha2MR/LRP expression in the human trophoblast; 2) cAMP negatively regulates alpha2MR/LRP; 3) there is an inverse relationship between alpha2MR/LRP and low density lipoprotein receptor gene expression in trophoblast cells.	AMER RED CROSS LABS, BIOCHEM LAB, ROCKVILLE, MD 20855 USA	American Red Cross	GAFVELS, ME (corresponding author), UNIV PENN, SCH MED, DEPT OBSTET & GYNECOL, 778 CLIN RES BLDG, 422 CURIE BLVD, PHILADELPHIA, PA 19104 USA.		Coukos, George/ABG-7389-2020	Coukos, George/0000-0001-8813-7367	NICHD NIH HHS [HD-06274, HD-29946] Funding Source: Medline; NIGMS NIH HHS [GM-42581] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029946, P01HD006274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUTIFARIS C, 1991, DEVELOPMENT, V113, P767; Daiter E, 1992, REPROD MED REV, V1, P83; FURUHASHI M, 1989, MOL ENDOCRINOL, V3, P1252, DOI 10.1210/mend-3-8-1252; GLIEMANN J, 1986, BIOCHIM BIOPHYS ACTA, V883, P400, DOI 10.1016/0304-4165(86)90276-X; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARTMANN KKP, 1990, ENDOCRINOLOGY, V127, P2038, DOI 10.1210/endo-127-4-2038; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; HUSSAINI IM, 1990, J BIOL CHEM, V265, P19441; JENSEN PH, 1988, PLACENTA, V9, P463, DOI 10.1016/0143-4004(88)90019-7; KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KUTT H, 1989, BIOCHIM BIOPHYS ACTA, V1009, P229, DOI 10.1016/0167-4781(89)90107-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMARRE J, 1991, LAB INVEST, V65, P3; MOESTRUP SK, 1990, EXP CELL RES, V190, P195, DOI 10.1016/0014-4827(90)90185-D; POTTER JM, 1979, AM J OBSTET GYNECOL, V133, P165, DOI 10.1016/0002-9378(79)90469-1; RINDLER MJ, 1991, PLACENTA, V12, P615, DOI 10.1016/0143-4004(91)90496-3; Sambrook J, 1989, MOL CLONING LABORATO; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WICE B, 1990, EXP CELL RES, V186, P306, DOI 10.1016/0014-4827(90)90310-7	28	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21230	21234						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328226				2022-12-27	WOS:A1992JT97800111
J	HOLMES, SE; SINGER, MF; SWERGOLD, GD				HOLMES, SE; SINGER, MF; SWERGOLD, GD			STUDIES ON P40, THE LEUCINE ZIPPER MOTIF-CONTAINING PROTEIN ENCODED BY THE 1ST OPEN READING FRAME OF AN ACTIVE HUMAN LINE-1 TRANSPOSABLE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED-COIL; SEQUENCE; FAMILY; CELLS; END; DNA	Full-length human LINE-1 retrotransposons encode p40 proteins with varying electrophoretic mobilities under denaturing conditions. The p40 expressed from the first open reading frame in the LINE-1 copy designated L1.2A co-electrophoreses with the endogenous p40 in human teratocarcinoma cells. This finding is consistent with previous data indicating that L1.2A is an active element. The amino acid sequence in the central region of the L1.2A p40 accounts, at least in part, for its characteristic mobility. This region includes sequences which can, in principle, form a leucine zipper.	NCI,BIOCHEM LAB,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,CTR MED GENET,DEPT PEDIAT & MED,BALTIMORE,MD 21205; CARNEGIE INST WASHINGTON,WASHINGTON,DC 20005	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; Carnegie Institution for Science								BRATTHAUER GL, 1992, ONCOGENE, V7, P507; DEMERS GW, 1989, J MOL EVOL, V29, P3, DOI 10.1007/BF02106177; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; FURANO AV, 1988, NUCLEIC ACIDS RES, V16, P9215, DOI 10.1093/nar/16.19.9215; GRIMALDI G, 1984, EMBO J, V3, P1753, DOI 10.1002/j.1460-2075.1984.tb02042.x; HODGES R S, 1988, Peptide Research, V1, P19; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; LIEBOLD DM, 1990, P NATL ACAD SCI USA, V87, P6990; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARINAS MG, 1977, J MOL BIOL, V85, P309; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MATHIAS SL, 1992, THESIS J HOPKINS U B; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; NOEL D, 1979, BIOCHEMISTRY-US, V18, P4159, DOI 10.1021/bi00586a017; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; SCOTT A F, 1987, Genomics, V1, P113, DOI 10.1016/0888-7543(87)90003-6; SHEHEE WR, 1987, J MOL BIOL, V196, P757, DOI 10.1016/0022-2836(87)90402-5; SKOWRONSKI J, 1985, P NATL ACAD SCI USA, V82, P6050, DOI 10.1073/pnas.82.18.6050; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718	27	97	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19765	19768						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328181				2022-12-27	WOS:A1992JR85800004
J	RAISHER, BD; GULICK, T; ZHANG, ZF; STRAUSS, AW; MOORE, DD; KELLY, DP				RAISHER, BD; GULICK, T; ZHANG, ZF; STRAUSS, AW; MOORE, DD; KELLY, DP			IDENTIFICATION OF A NOVEL RETINOID-RESPONSIVE ELEMENT IN THE PROMOTER REGION OF THE MEDIUM CHAIN ACYL-COENZYME-A DEHYDROGENASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR SUPERFAMILY; ACID RECEPTOR; COA DEHYDROGENASE; THYROID-HORMONE; MOLECULAR CHARACTERIZATION; MITOCHONDRIAL PROTEINS; BINDING PROTEIN; I GENE; EXPRESSION; DEFICIENCY	To study the mechanisms involved in regulation of nuclear genes encoding mitochondrial enzymes in oxidative energy pathways, the promoter region of the medium-chain acyl-CoA dehydrogenase (MCAD) gene was analyzed. A series of hexamer sequences known to bind and confer responsiveness to a subset of members of the nuclear receptor superfamily of transcription factors was identified. Cotransfection of an MCAD promoter-chloramphenicol acetyltransferase (CAT) reporter plasmid with retinoic acid receptor (RAR)alpha, beta, or retinoid X receptor alpha (RXRalpha) resulted in 10-15-fold transcriptional activation in response to retinoic acid. The retinoic acid-induced activation was 3-4-fold higher with RXRalpha than with either RARalpha or RARbeta. Deletional analysis confirmed that a region between -341 and -308 base pairs upstream of the MCAD gene cap site conferred the RA-responsive transcriptional activation to homologous and heterologous promoters. Gel mobility shift assays demonstrated that the MCAD RARE interacted directly with overexpressed receptors. Mutational analysis of the RARE delineated three hexamer binding sequences with unique orientation and spacing compared to other reported retinoid responsive elements. These results indicate that the MCAD gene promoter region contains a novel regulatory element that interacts with members of the retinoid receptor family, with preferential activation by RXRalpha. This element likely plays a role in the transcriptional regulation of this gene and perhaps others involved in oxidative energy metabolism.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV CARDIOVASC,660 S EUCLID AVE,BOX 8086,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Kelly, Daniel/ABG-2056-2021					ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; AUSIBEL FM, 1987, CURRENT PROTOCOLS MO, V2, P1612; Beinert H., 1963, ENZYMES, P447; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BONDMATTHEWS B, 1988, GENE, V62, P289, DOI 10.1016/0378-1119(88)90566-5; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; DORSMAN JC, 1988, NUCLEIC ACIDS RES, V16, P7287, DOI 10.1093/nar/16.15.7287; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREGERSEN N, 1991, HUM GENET, V86, P545; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KELLY DP, 1990, P NATL ACAD SCI USA, V87, P9236, DOI 10.1073/pnas.87.23.9236; KELLY DP, 1987, P NATL ACAD SCI USA, V84, P4068, DOI 10.1073/pnas.84.12.4068; KELLY DP, 1989, J BIOL CHEM, V264, P18921; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MATSUBARA Y, 1990, BIOCHEM BIOPH RES CO, V171, P498, DOI 10.1016/0006-291X(90)91421-N; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; REVZIN A, 1989, BIOTECHNIQUES, V7, P346; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SAMBROOK J, 1989, MOL CLONING LABORATO, P114; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STANLEY CA, 1983, PEDIATR RES, V17, P872; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUZUKI H, 1990, J BIOL CHEM, V265, P8159; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YOKOTA I, 1990, J CLIN INVEST, V86, P1000, DOI 10.1172/JCI114761; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG ZF, 1992, BIOCHEMISTRY-US, V31, P81, DOI 10.1021/bi00116a013	45	64	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20264	20269						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328196				2022-12-27	WOS:A1992JR85800081
J	MIKI, T; YOSHIDA, LS; KAKINUMA, K				MIKI, T; YOSHIDA, LS; KAKINUMA, K			RECONSTITUTION OF SUPEROXIDE-FORMING NADPH OXIDASE ACTIVITY WITH CYTOCHROME-B558 PURIFIED FROM PORCINE NEUTROPHILS - REQUIREMENT OF A MEMBRANE-BOUND FLAVIN ENZYME FOR RECONSTITUTION OF ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; CELL-FREE SYSTEM; POLYACRYLAMIDE GELS; GENERATING OXIDASE; PHAGOCYTIC-CELLS; FATTY-ACIDS; C REDUCTASE; ACTIVATION; BINDING	Cytochrome b558 of pig blood neutrophils was purified from the membranes of resting cells to examine its ability to reconstitute superoxide (O2-)-forming NADPH oxidase activity in a cell-free assay system containing cytosol and fatty acid. The membrane-associated cytochrome b558 was solubilized with a detergent, n-heptyl beta-thioglucoside, and purified by DEAE-Sepharose, heparin-Sepharose, and Mono Q column chromatography. The final preparation of cytochrome containing 11.5 nmol of protoheme/mg of protein gave bands of the large and small subunits on immunoblotted gel. The cell-free system with the purified cytochrome alone as a membrane component showed little O2--generating activity in the absence of exogenous FAD. However, the system showed high O2--generating activity of 31.8 mol/s/mol of cytochrome b558 (52.5% of the original O2--generating activity of the solubilized membranes) in the presence of a nitro blue tetrazolium (NBT) reductase fraction that was separated from the cytochrome b fraction by heparin-Sepharose chromatography. Heat treatment of the NBT reductase fraction resulted in loss of the O2--generating activity in the reconstituted system. The O2--forming activity of the reconstituted system was markedly decreased by removal of FAD from the NBT reductase fraction and was restored by readdition of FAD to the FAD-depleted reductase. The reconstituted system containing purified cytochrome b558 plus the NBT reductase showed approximately 100 times higher O2--generating activity than a system containing rabbit liver NADPH-cytochrome P-450 reductase instead. These results suggest that both the FAD-dependent NBT reductase and cytochrome b558 are required as membrane redox components for O2--forming NADPH oxidase activity. The present data are discussed in comparison with previously reported results on reconstituted systems containing added free FAD.	TOKYO METROPOLITAN INST MED SCI,DEPT INFLAMMAT RES,HONKOMAGOME 3-18-22,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science								ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BABIOR BM, 1990, SEMIN HEMATOL, V27, P247; BALLOU D, 1969, BIOCHEM BIOPH RES CO, V36, P898, DOI 10.1016/0006-291X(69)90288-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; CHIBA T, 1990, BIOCHEM BIOPH RES CO, V173, P376, DOI 10.1016/S0006-291X(05)81068-X; CLARK RA, 1989, NEW ENGL J MED, V321, P647, DOI 10.1056/NEJM198909073211005; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; FUJII H, 1991, BIOCHIM BIOPHYS ACTA, V1095, P201, DOI 10.1016/0167-4889(91)90100-C; GABIG TG, 1987, J BIOL CHEM, V262, P1685; GROVER TA, 1981, ARCH BIOCHEM BIOPHYS, V212, P105, DOI 10.1016/0003-9861(81)90348-9; ISOGAI Y, 1991, J BIOL CHEM, V266, P13481; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; KAKINUMA K, 1978, BIOCHIM BIOPHYS ACTA, V538, P50, DOI 10.1016/0304-4165(78)90251-9; KAKINUMA K, 1986, J BIOL CHEM, V261, P9426; KAKINUMA K, 1987, J BIOL CHEM, V262, P12316; KISHORE GM, 1979, BIOCHEM BIOPH RES CO, V87, P518, DOI 10.1016/0006-291X(79)91826-6; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGETI E, 1989, BIOCHEMISTRY-US, V28, P7116, DOI 10.1021/bi00443a050; MASSEY V, 1966, J BIOL CHEM, V241, P3417; MICHELSON AM, 1977, SUPEROXIDE SUPEROXID, P87; MISRA HP, 1972, J BIOL CHEM, V247, P188; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PARKINSON JF, 1988, J BIOENERG BIOMEMBR, V20, P653, DOI 10.1007/BF00762547; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; SMITH RM, 1989, J BIOL CHEM, V264, P1958; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TU SC, 1981, ARCH BIOCHEM BIOPHYS, V209, P423, DOI 10.1016/0003-9861(81)90299-X; UMEI T, 1991, J BIOL CHEM, V266, P6019; WAKEYAMA H, 1982, BIOCHEM J, V205, P593, DOI 10.1042/bj2050593; YOSHIDA LS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P245	39	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18695	18701						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326533				2022-12-27	WOS:A1992JN50200069
J	FIORE, S; RYEOM, SW; WELLER, PF; SERHAN, CN				FIORE, S; RYEOM, SW; WELLER, PF; SERHAN, CN			LIPOXIN RECOGNITION SITES - SPECIFIC BINDING OF LABELED LIPOXIN-A4 WITH HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHONUCLEAR LEUKOCYTE RECEPTORS; ARACHIDONIC-ACID; LEUKOTRIENE-B4 RECEPTORS; STIMULATED NEUTROPHILS; LIGAND-BINDING; LUNG MEMBRANES; G-PROTEINS; METABOLISM; RESPONSES; RELEASE	Lipoxin A4 stimulates rapid lipid remodeling and a pertussis toxin-sensitive release of arachidonic acid in Polymorphonuclear leukocytes (PMN) (Nigam, S., Fiore, S., Luscinskas, F. W., and Serhan, C. N. (1990) J. Cell. Physiol. 143, 512-523) and has been shown to inhibit leukocyte responses in several systems. To examine the basis underlying these actions, we have prepared [11,12-H-3]lipoxin A4 (LXA4) and characterized its interactions with human PMN. Time course studies (0-90 min) with intact PMN demonstrated cell association of H-3 label which was specific and reversible. PMN bound [H-3]LXA4 with a K(d) of 0.5 +/- 0.3 nm, representing approximately 1,830 sites/PMN, and the Hill plot value of 1.9 suggests cooperative binding. [H-3]LXA4 binding was stereoselective since neither leukotriene B4 (LTB4), lipoxin B4 (LXB4), (6S)-LXA4, 11-trans-LXA4, nor SKF 104353 competed for [H-3]LXA4-specific binding while LTD4 and LTC4 partially competed. Subcellular fractionation revealed that specific binding with [H-3]LXA4 was associated with membrane (42.1%)-, granule (34.5%)-, and nuclear (23.3%)-enriched fractions, a distribution distinct from that of [14,15-H-3] LTB4 binding. [11,12-H-3]LXA4-specific binding was modulated by guanosine analogs, suggesting the involvement of G proteins. A fluorescent LXA4 derivative (methyl-7-methoxycoumarin-LXA4) competed with [H-3]LXA4 binding to intact PMN and showed specific and reversible binding as monitored by flow cytometric analysis. These results indicate that PMN possess specific recognition sites for LXA4 which may mediate its actions.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV HEMATOL, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED,DIV INFECT DIS, BOSTON, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School					NIAID NIH HHS [AI22571, AI20241] Funding Source: Medline; NIGMS NIH HHS [GM38765] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020241, R01AI022571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038765, R29GM038765, R01GM038765] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADR KF, 1989, P NATL ACAD SCI USA, V86, P3438, DOI 10.1073/pnas.86.9.3438; BAUD L, 1987, IMMUNOLOGY, V62, P53; BERGMEYER HU, 1963, METHOD ENZYMAT AN, P737; BOEYNAEMS JM, 1975, J CYCLIC NUCL PROT, V1, P123; BOYUN A, 1986, SCAND J CLIN LAB S97, V21, P77; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASSEUR R, 1988, BIOCHIM BIOPHYS ACTA, V960, P245, DOI 10.1016/0005-2760(88)90070-7; BREZINSKI DA, 1991, BIOL MASS SPECTROM, V20, P45, DOI 10.1002/bms.1200200202; CANNISTRA SA, 1990, J BIOL CHEM, V265, P12656; CANONICO PG, 1978, J RETICULOENDOTH SOC, V24, P115; Dahlen S E, 1988, Adv Exp Med Biol, V229, P107; DAHLEN SE, 1991, LIPOXYGENASES THEIR, P235; DECHATELET LR, 1970, BIOCHEM MED METAB B, V4, P61, DOI 10.1016/0006-2944(70)90103-1; DUNGES W, 1977, ANAL CHEM, V49, P442; FALCONE RC, 1990, J PHARMACOL EXP THER, V255, P565; GOLDMAN DW, 1987, FASEB J, V46, P200; GRANDORDY BM, 1990, BIOCHEM BIOPH RES CO, V167, P1022, DOI 10.1016/0006-291X(90)90625-W; HAVUNJIAN RH, 1990, J BIOL CHEM, V265, P22181; HEDQVIST P, 1989, ACTA PHYSIOL SCAND, V137, P571, DOI 10.1111/j.1748-1716.1989.tb08805.x; HERRMANN T, 1988, J CHROMATOGR-BIOMED, V428, P237, DOI 10.1016/S0378-4347(00)83914-6; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; IYENGAR R, 1980, J BIOL CHEM, V255, P312; LEE TH, 1989, CLIN SCI, V77, P195, DOI 10.1042/cs0770195; LINDHART K, 1974, METHOD ENZYMAT AN, P856; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MIGLER R, 1978, BIOCHEM MED METAB B, V19, P16, DOI 10.1016/0006-2944(78)90003-0; MONG S, 1990, METHOD ENZYMOL, V187, P421; MONG S, 1987, MOL PHARMACOL, V32, P223; MONG S, 1991, LIPOXYGENASES THEIR, P185; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NICOLAOU KC, 1985, J AM CHEM SOC, V107, P7515, DOI 10.1021/ja00311a048; NIGAM S, 1990, J CELL PHYSIOL, V143, P512, DOI 10.1002/jcp.1041430316; OFLAHERTY JT, 1990, J CELL PHYSIOL, V142, P299, DOI 10.1002/jcp.1041420212; Palmblad J, 1988, Adv Exp Med Biol, V229, P137; PARIS S, 1990, J BIOL CHEM, V265, P11567; RODBELL M, 1974, J BIOL CHEM, V249, P59; ROSSI AG, 1989, PROSTAGLANDINS, V37, P641, DOI 10.1016/0090-6980(89)90102-0; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHAAF TK, 1983, ADV PROSTAG THROMB L, V11, P313; SERHAN CN, 1990, METHOD ENZYMOL, V187, P167; SERHAN CN, 1982, BIOCHEM BIOPH RES CO, V107, P951, DOI 10.1016/0006-291X(82)90615-5; SERHAN CN, 1984, P NATL ACAD SCI-BIOL, V81, P5335, DOI 10.1073/pnas.81.17.5335; SHAK S, 1985, J CLIN INVEST, V76, P1218, DOI 10.1172/JCI112077; STENKE L, 1991, BIOCHEM BIOPH RES CO, V180, P255, DOI 10.1016/S0006-291X(05)81285-9; TODA M, 1985, ADV PROSTAG THROMB L, V14, P427; UESAKA H, 1987, BIOCHEM BIOPH RES CO, V143, P552, DOI 10.1016/0006-291X(87)91389-1; VOTTA B, 1990, BIOCHEM J, V265, P841, DOI 10.1042/bj2650841; WALKER BAM, 1991, LAB INVEST, V64, P105; WALSH CE, 1981, J BIOL CHEM, V256, P7228; Wasserman MA, 1991, LIPOXYGENASES THEIR, P1; WEISSMANN G, 1980, NEW ENGL J MED, V303, P27; WRIGHT DG, 1977, AM J PATHOL, V87, P273; YAMAZAKI M, 1989, P NATL ACAD SCI USA, V86, P5791, DOI 10.1073/pnas.86.15.5791	56	122	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16168	16176						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322894				2022-12-27	WOS:A1992JJ45800031
J	JONES, KS; COLEMAN, J; MERKEL, GW; LAUE, TM; SKALKA, AM				JONES, KS; COLEMAN, J; MERKEL, GW; LAUE, TM; SKALKA, AM			RETROVIRAL INTEGRASE FUNCTIONS AS A MULTIMER AND CAN TURN OVER CATALYTICALLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GAMMA-DELTA RESOLVASE; HIV-1 PROTEASE; DNA; RECOMBINATION; ENZYME; VIRUS	A number of studies have demonstrated that the retroviral protein integrase (IN) alone is sufficient to carry out two discrete steps required for retroviral integration: the endonucleolytic processing of viral DNA ends and the cleavage and joining of host DNA to the processed viral DNA termini. Little is known about the biochemical and biophysical mechanisms involved in these reactions. Here, we employ in vitro assays of Rous sarcoma virus IN to demonstrate for the first time that IN is capable of multiple turnover in both the processing and joining reactions. The turnover number calculated for the processing reaction is 0.26 cleavages/min/mol of IN. Our steady state kinetic studies indicate that both the processing and joining activities require a multimeric form of IN. Ultracentrifugation analyses reveal a substrate-independent reversible equilibrium among the monomeric, dimeric, and tetrameric forms of this protein. From these results we conclude that the minimal functional unit for both the processing and joining of each viral DNA end is an IN dimer.	UNIV NEW HAMPSHIRE, DEPT BIOCHEM, DURHAM, NH 03824 USA	University System Of New Hampshire; University of New Hampshire	JONES, KS (corresponding author), FOX CHASE CANC INST, INST CANC RES, PHILADELPHIA, PA 19111 USA.		Laue, Tom/AAI-5136-2020	Laue, Tom/0000-0003-3571-9368	NCI NIH HHS [CA-47486, CA-06927] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R35CA047486] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BROWN PO, 1990, CURR TOP MICROBIOL, V157, P19; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CHRISTOPHERSON RI, 1979, ANAL BIOCHEM, V100, P184, DOI 10.1016/0003-2697(79)90130-1; ENGLEMAN A, 1991, CELL, V67, P1211; Friedberg E C, 1980, Methods Enzymol, V65, P191; GATES CA, 1988, P NATL ACAD SCI USA, V85, P4628, DOI 10.1073/pnas.85.13.4628; GRANDGENETT DP, 1990, CELL, V60, P3, DOI 10.1016/0092-8674(90)90707-L; GRANDGENETT DP, 1978, VIROLOGY, V89, P119, DOI 10.1016/0042-6822(78)90046-6; HUGHES RE, 1990, CELL, V63, P1331, DOI 10.1016/0092-8674(90)90428-H; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; KATZ RA, 1992, IN PRESS P NATL ACAD; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KOTLER M, 1989, P NATL ACAD SCI USA, V85, P4185; KULKOSKY J, 1990, J ACQ IMMUN DEF SYND, V3, P839; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; Laue T. M, 1981, THESIS U CONNECTICUT; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; LAUE TM, 1992, IN PRESS ANAL ULTRAC; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; MCMEEKIN TL, 1952, SCIENCE, V116, P142, DOI 10.1126/science.116.3006.142; PERLMANN GE, 1948, J AM CHEM SOC, V70, P2719, DOI 10.1021/ja01188a027; ROARK DE, 1969, ANN NY ACAD SCI, V164, P245, DOI 10.1111/j.1749-6632.1969.tb14043.x; SANDERSON MR, 1990, CELL, V63, P1323, DOI 10.1016/0092-8674(90)90427-G; SCHRAMM HJ, 1991, BIOCHEM BIOPH RES CO, V179, P847, DOI 10.1016/0006-291X(91)91895-J; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SKALKA AM, 1989, CELL, V56, P911, DOI 10.1016/0092-8674(89)90621-1; SKALKA AM, 1988, GENETIC RECOMBINATIO, P701; TERRY R, 1988, J VIROL, V62, P2358, DOI 10.1128/JVI.62.7.2358-2365.1988; VARMUS HE, 1985, RNA TUMOR VIRUSES, V2, P75; WEAST RC, 1986, HDB CHEM PHYSICS, V67; YPHANTIS DA, 1960, ANN NY ACAD SCI, V88, P586, DOI 10.1111/j.1749-6632.1960.tb20055.x; YPHANTIS DA, 1987, BIOCHEMISTRY-US, V26, P5422, DOI 10.1021/bi00391a031; YPHANTIS DA, 1956, J PHYS CHEM-US, V60, P623; ZHANG ZY, 1991, J BIOL CHEM, V266, P15591	36	134	135	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16037	16040						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322888				2022-12-27	WOS:A1992JJ45800009
J	SAKAKI, T; AKIYOSHISHIBATA, M; YABUSAKI, Y; OHKAWA, H				SAKAKI, T; AKIYOSHISHIBATA, M; YABUSAKI, Y; OHKAWA, H			ORGANELLA-TARGETED EXPRESSION OF RAT-LIVER CYTOCHROME-P450C27 IN YEAST - GENETICALLY ENGINEERED ALTERATION OF MITOCHONDRIAL-P450 INTO A MICROSOMAL FORM CREATES A NOVEL FUNCTIONAL ELECTRON-TRANSPORT CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NADPH-CYTOCHROME-P450 REDUCTASE; VITAMIN-D3 25-HYDROXYLASE; ENDOPLASMIC-RETICULUM; GENE; CDNA; DEHYDROGENASE; PURIFICATION; ORIENTATION; PROTEINS	A modified rat cytochrome P450c27, whose mitochondrial targeting signal had been replaced by a possible microsomal targeting signal of bovine cytochrome P450c17, was expressed in yeast. The modified P450c27 hemoprotein was correctly localized on yeast microsomes and exhibited the P450c27-dependent monooxygenase activity by addition of bovine adrenodoxin (ADX) and NADPH-adrenodoxin reductase (ADR). Considering the previous observation that P450c27 with its own mitochondrial targeting signal was imported into yeast mitochondria (Akiyoshi-Shibata, M., Usui, E., Sakaki, T., Yabusaki, Y., Noshiro, M., Okuda, K., and Ohkawa, H. (1991) FEBS Lett. 280, 367-370), it is now suggested that the destination of P450c27 to either mitochondria or microsomes in yeast depends solely on the amino-terminal targeting signal. In addition, the modified P450c27 was simultaneously expressed in yeast with mature forms of bovine ADX and ADR. The recombinant yeast produced the P450 on the microsomes and mature forms of ADX and ADR in the cytoplasm, and showed the monooxygenase activity. Accordingly, a novel type of functional electron transport chain has been established between the cytoplasm and the microsomes in yeast.			SAKAKI, T (corresponding author), SUMITOMO CHEM CO LTD, TAKARAZUKA RES CTR, BIOTECHNOL LAB, 4-2-1 TAKATSUKASA, TAKARAZUKA, HYOGO 665, JAPAN.							AKIYOSHISHIBATA M, 1991, DNA CELL BIOL, V10, P613, DOI 10.1089/dna.1991.10.613; AKIYOSHISHIBATA M, 1991, FEBS LETT, V280, P367, DOI 10.1016/0014-5793(91)80333-X; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; EDWARDS RJ, 1991, BIOCHEMISTRY-US, V30, P71, DOI 10.1021/bi00215a011; HITZEMAN RA, 1980, J BIOL CHEM, V255, P2073; IMURA T, 1987, AGR BIOL CHEM TOKYO, V51, P1641, DOI 10.1080/00021369.1987.10868270; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASUMOTO O, 1988, J BIOL CHEM, V263, P14256; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; MURAKAMI H, 1986, DNA-J MOLEC CELL BIO, V5, P1, DOI 10.1089/dna.1986.5.1; MURAKAMI H, 1990, J BIOCHEM, V108, P859, DOI 10.1093/oxfordjournals.jbchem.a123293; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; OEDA K, 1985, DNA-J MOLEC CELL BIO, V4, P203, DOI 10.1089/dna.1985.4.203; OHYAMA Y, 1991, J BIOCHEM-TOKYO, V63, P389; OKUDA K, 1988, J BIOL CHEM, V263, P18138; OMURA T, 1964, J BIOL CHEM, V239, P2370; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; SAKAKI T, 1984, J BIOCHEM-TOKYO, V96, P117, DOI 10.1093/oxfordjournals.jbchem.a134803; SAKAKI T, 1990, DNA CELL BIOL, V9, P603, DOI 10.1089/dna.1990.9.603; SAKAKI T, 1991, PHARMACOGENETICS, V1, P86, DOI 10.1097/00008571-199111000-00005; SAKAKI T, 1989, DNA-J MOLEC CELL BIO, V8, P409, DOI 10.1089/dna.1.1989.8.409; SAKAKI T, 1987, DNA-J MOLEC CELL BIO, V6, P31, DOI 10.1089/dna.1987.6.31; SAKAKI T, 1985, J BIOCHEM-TOKYO, V98, P167, DOI 10.1093/oxfordjournals.jbchem.a135255; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USUI E, 1990, FEBS LETT, V262, P135, DOI 10.1016/0014-5793(90)80172-F; VERGERES G, 1989, BIOCHEMISTRY-US, V28, P3650, DOI 10.1021/bi00435a005; YABUSAKI Y, 1991, FRONTIERS BIOTRANSFO, V4, P169; ZUBER MX, 1986, J BIOL CHEM, V261, P2475	30	55	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16497	16502						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322905				2022-12-27	WOS:A1992JJ45800079
J	SCARBOROUGH, RM; NAUGHTON, MA; TENG, W; HUNG, DT; ROSE, J; VU, TKH; WHEATON, VI; TURCK, CW; COUGHLIN, SR				SCARBOROUGH, RM; NAUGHTON, MA; TENG, W; HUNG, DT; ROSE, J; VU, TKH; WHEATON, VI; TURCK, CW; COUGHLIN, SR			TETHERED LIGAND AGONIST PEPTIDES - STRUCTURAL REQUIREMENTS FOR THROMBIN RECEPTOR ACTIVATION REVEAL MECHANISM OF PROTEOLYTIC UNMASKING OF AGONIST FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SURFACE; BINDING	The human platelet thrombin receptor is activated when thrombin cleaves its receptor's amino-terminal extension to reveal a new amino terminus that functions as a tethered peptide ligand. Exactly how this "agonist peptide domain" remains cryptic within the uncleaved receptor and becomes functional after receptor cleavage is unknown. In this report we define the structural features of the thrombin receptor's agonist peptide domain important for receptor activation. Studies with mutant thrombin receptors have suggested that agonist peptide domain residues 2-6 contained determinants critical for receptor activation, and the synthetic peptide SFLLR-NH2 representing the 1st 5 amino-terminal residues of the agonist peptide domain was sufficient to specify agonist activity. Acetylating or removing the agonist peptide's amino-terminal ammonium group greatly attenuated agonist activity. Agonist peptide residue Phe2 was vital for agonist function; residues Leu4 and Arg5 individually played less important roles. These structure-function relationships held for both platelet activation and activation of the cloned receptor expressed in transfected mammalian cells. Our studies suggest that structures at the extreme amino terminus of the thrombin receptor's agonist peptide domain, in particular the free ammonium group of Ser1 and the phenyl ring of Phe2, are critical for receptor activation and that the agonist function of this domain is expressed when receptor proteolysis unmasks such determinants. In addition to revealing details of the thrombin receptor's proteolytic triggering mechanism, these studies open avenues to the development of drugs targeting the thrombin receptor and to further definition for the role of the thrombin receptor in cellular regulation.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT LAB MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	SCARBOROUGH, RM (corresponding author), COR THERAPEUT, S SAN FRANCISCO, CA 94080 USA.				NHLBI NIH HHS [HL44907, HL43821] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907, P01HL043821] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; CHARO IF, 1977, J CLIN INVEST, V60, P866, DOI 10.1172/JCI108841; CHEN LB, 1976, EXP CELL RES, V101, P41, DOI 10.1016/0014-4827(76)90409-2; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; EIDT JF, 1989, J CLIN INVEST, V84, P18, DOI 10.1172/JCI114138; FITZGERALD DJ, 1989, P NATL ACAD SCI USA, V86, P7585, DOI 10.1073/pnas.86.19.7585; HANSON SR, 1988, P NATL ACAD SCI USA, V85, P3184, DOI 10.1073/pnas.85.9.3184; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HUANG RS, 1991, J BIOL CHEM, V266, P18435; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; Muszbek L, 1984, THROMBIN, P83; NGAIZA JR, 1991, BIOCHEM BIOPH RES CO, V179, P1656, DOI 10.1016/0006-291X(91)91765-5; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; Sambrook J, 1989, MOL CLONING LABORATO; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRADER CD, 1991, J BIOL CHEM, V266, P5; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0	26	292	301	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13146	13149						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320011				2022-12-27	WOS:A1992JB74600009
J	KELLER, U; SCHLUMBOHM, W				KELLER, U; SCHLUMBOHM, W			PURIFICATION AND CHARACTERIZATION OF ACTINOMYCIN SYNTHETASE-I, A 4-METHYL-3-HYDROXYANTHRANILIC ACID-AMP LIGASE FROM STREPTOMYCES-CHRYSOMALLUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA SYNTHETASES; ACTIVATING ENZYME; ENNIATIN SYNTHETASE; BIOSYNTHESIS; BINDING; GENES; EXPRESSION; ISOENZYMES; PROTEINS	Actinomycin synthetase I was purified to homogeneiety from actinomycin-producing Streptomyces chrysomallus. The purified enzyme is a single polypeptide chain of M(r) 45,000. It catalyzes the formation of the adenylate of 4-methyl-3-hydroxyanthranilic acid (4-MHA) from the free acid and ATP in an equilibrium reaction. 4-MHA is the precursor of the chromophoric part of actinomycin. By using the 4-MHA analogue, 4-methyl-3-hydroxybenzoic acid, as a model substrate it could be established that the equilibrium constant K(eq) is independent on enzyme concentration, which suggests that no stoichiometric acyladenylate-enzyme complex is formed in contrast to observations made with aminoacyl adenylates formed by aminoacyl-tRNA synthetases or multifunctional peptide synthetases. Actinomycin synthetase I does not charge itself with substrate carboxylic acid via a covalent thioester bond as is usual for amino acid activation in non-ribosomal peptide synthesis. In addition, the enzyme does not act as an acyl-coenzyme A ligase as revealed by its inability to release AMP in the presence of 4-MHA or other structurally related aromatic carboxylic acids, coenzyme A and ATP. Additional analysis of the activation reaction showed that it is exothermic, whereas the free enthalpy change DELTA-G0 is positive due to a negative entropy change indicating a strong influence of restriction of random motion on the course of the reaction. Determinations of K(m) and k(cat), of various substrate carboxylic acids revealed the highest k(cat)/K(m) ratio for the natural substrate 4-MHA. From these properties, actinomycin synthetase I represents the prototype of novel chromophore activating enzymes involved in non-ribosomal synthesis of chromopeptide lactones in streptomycetes.			KELLER, U (corresponding author), TECH UNIV BERLIN,INST BIOCHEM & MOLEK BIOL,FRANKLINSTR 29,W-1000 BERLIN 10,GERMANY.							Allende JE, 1971, METHOD ENZYMOL, V20, P210; BARTMANN P, 1976, ANAL BIOCHEM, V70, P174, DOI 10.1016/S0003-2697(76)80059-0; BILLICH A, 1987, BIOL CHEM H-S, V368, P521, DOI 10.1515/bchm3.1987.368.1.521; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DELUCA M, 1978, METHOD ENZYMOL, V42, P3; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIEZ B, 1990, J BIOL CHEM, V265, P16358; Eigner E A, 1974, Methods Enzymol, V29, P601; FAWAZ F, 1988, J BIOL CHEM, V263, P4602; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P5, DOI 10.1021/bi00672a002; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P1, DOI 10.1021/bi00672a001; GLUND K, 1990, BIOCHEMISTRY-US, V29, P3522, DOI 10.1021/bi00466a015; HAESE A, 1988, J BACTERIOL, V170, P1360, DOI 10.1128/jb.170.3.1360-1368.1988; HINZ HJ, 1976, EUR J BIOCHEM, V71, P437, DOI 10.1111/j.1432-1033.1976.tb11131.x; Hopwood D.A., 1985, GENETIC MANIPULATION; JAKUBOWSKI HZ, 1977, ANAL BIOCHEM, V82, P29, DOI 10.1016/0003-2697(77)90130-0; KELLER U, 1987, J BIOL CHEM, V262, P5852; KELLER U, 1984, BIOCHEMISTRY-US, V23, P1479, DOI 10.1021/bi00302a022; KELLER U, 1985, J GEN MICROBIOL, V131, P1181; KELLER U, 1984, J BIOL CHEM, V259, P8226; KLEINKAUF H, 1979, PLANTA MED, V35, P1, DOI 10.1055/s-0028-1097178; KLEINKAUF H, 1980, MULTIFUNCTIONAL PROT, P217; KNOBLOCH KH, 1975, EUR J BIOCHEM, V52, P311, DOI 10.1111/j.1432-1033.1975.tb03999.x; KRATZSCHMAR J, 1989, J BACTERIOL, V171, P5422; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOZOYA E, 1988, EUR J BIOCHEM, V176, P661, DOI 10.1111/j.1432-1033.1988.tb14328.x; MULVEY RS, 1977, BIOCHEMISTRY-US, V16, P4005, DOI 10.1021/bi00637a011; RUSNAK F, 1989, BIOCHEMISTRY-US, V28, P6827, DOI 10.1021/bi00443a008; SCHLUMBOHM W, 1985, BIOL CHEM H-S, V366, P925, DOI 10.1515/bchm3.1985.366.2.925; SCHLUMBOHM W, 1990, J BIOL CHEM, V265, P2156; SMITH DJ, 1990, EMBO J, V9, P2743, DOI 10.1002/j.1460-2075.1990.tb07461.x; VATER J, 1976, BIOCHIM BIOPHYS ACTA, V429, P1062, DOI 10.1016/0005-2744(76)90351-X; Warburg O., 1942, BIOCHEM Z, V310, P384; WECKERMANN R, 1988, NUCLEIC ACIDS RES, V16, P11841, DOI 10.1093/nar/16.24.11841; WOOD KV, 1985, BIOCHEM BIOPH RES CO, V124, P592; YARUS M, 1969, J MOL BIOL, V42, P171, DOI 10.1016/0022-2836(69)90037-0; ZOCHER R, 1982, BIOCHEMISTRY-US, V21, P43, DOI 10.1021/bi00530a008	38	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11745	11752						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1318300				2022-12-27	WOS:A1992HY94700019
J	BARGER, SW; VANELDIK, LJ				BARGER, SW; VANELDIK, LJ			S100-BETA STIMULATES CALCIUM FLUXES IN GLIAL AND NEURONAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONERGIC GROWTH-FACTOR; NEURITE EXTENSION FACTOR; NERVOUS-SYSTEM; PROTEIN S-100; BRAIN; RAT; DIFFERENTIATION; PROLIFERATION; NEUROTOXICITY; INHIBITORS	The glial-derived protein S-100-beta can act as a mitogen or a neurotrophic factor, stimulating proliferation of glial cells or differentiation of immature neurons. We report here that dimeric S100-beta evokes increases in intracellular free calcium concentrations ([Ca2+]i) in both glial cells and neuronal cells. The [Ca2+]i increase exhibited a rapid transient component which was not affected by removal of extracellular calcium and a sustained component which appeared to require influx of extracellular calcium through Ni2+-sensitive channels. S100-beta also stimulated hydrolysis of phosphoinositides, suggesting a mobilization of calcium from intracellular stores. These data suggest that although the final biological responses of neuronal and glial cells to S100-beta are different, transduction of the S100-beta signal in both cell types involves changes in [Ca2+]i.	VANDERBILT UNIV,DEPT PHARMACOL,406 MED RES BLDG,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University				Barger, Steven/0000-0001-6049-6480	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R55NS029215] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05424] Funding Source: Medline; NINDS NIH HHS [NS29215] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; AZMITIA EC, 1990, BRAIN RES, V516, P354, DOI 10.1016/0006-8993(90)90942-5; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BHATTACHARYYA A, 1992, IN PRESS J NEUROBIOL; CALISSANO P, 1969, BIOCHEMISTRY-US, V8, P4318, DOI 10.1021/bi00839a015; CALISSANO P, 1971, BIOCHEM BIOPH RES CO, V43, P504, DOI 10.1016/0006-291X(71)90642-5; CAMPOCHIARO P, 1978, P NATL ACAD SCI USA, V75, P2025, DOI 10.1073/pnas.75.4.2025; CHAN CC, 1987, EUR J PHARMACOL, V139, P11, DOI 10.1016/0014-2999(87)90492-4; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; COLLINS F, 1991, J NEUROSCI, V11, P2582; DEAN NM, 1987, BIOCHEM J, V242, P361, DOI 10.1042/bj2420361; DONATO R, 1991, CELL CALCIUM, V12, P713, DOI 10.1016/0143-4160(91)90040-L; DUNCAN AMV, 1989, CYTOGENET CELL GENET, V50, P234, DOI 10.1159/000132767; FAZELI MS, 1990, EXCITATORY AMINO ACI, P369; GALLO V, 1980, LIFE SCI, V27, P761, DOI 10.1016/0024-3205(80)90330-6; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNDERSEN RW, 1980, J CELL BIOL, V87, P546, DOI 10.1083/jcb.87.3.546; GUREVICH V S, 1982, Byulleten' Eksperimental'noi Biologii i Meditsiny, V94, P118; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HYDEN H, 1970, P NATL ACAD SCI USA, V67, P1959, DOI 10.1073/pnas.67.4.1959; IRVINE RF, 1985, BIOCHEM J, V229, P505, DOI 10.1042/bj2290505; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KLIGMAN D, 1987, DEV BRAIN RES, V33, P296, DOI 10.1016/0165-3806(87)90163-5; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS D, 1986, BRAIN RES, V383, P159, DOI 10.1016/0006-8993(86)90016-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCKASEN JR, 1974, P NATL ACAD SCI USA, V71, P5088, DOI 10.1073/pnas.71.12.5088; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MARSHAK DR, 1990, PROG BRAIN RES, V86, P169; MATTSON MP, 1990, DEV BRAIN RES, V52, P201, DOI 10.1016/0165-3806(90)90236-R; MATTSON MP, 1987, J NEUROSCI, V7, P4034; NITECKA L, 1984, NEUROSCIENCE, V13, P1073, DOI 10.1016/0306-4522(84)90289-6; POZDNYAKOVA AL, 1987, B EXP BIOL MED+, V103, P1, DOI 10.1007/BF00840118; REBOULLEAU CP, 1986, J NEUROCHEM, V46, P920, DOI 10.1111/j.1471-4159.1986.tb13058.x; Schweber M S, 1989, Prog Clin Biol Res, V317, P247; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; SELINFREUND RH, 1990, J CELL BIOL, V111, P2021, DOI 10.1083/jcb.111.5.2021; SHASHOUA VE, 1984, J NEUROCHEM, V42, P1536, DOI 10.1111/j.1471-4159.1984.tb12739.x; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SIESJO BK, 1989, MAGNESIUM, V8, P223; Snapes Dr., 1991, GIRLFRENZY; SUZUKI F, 1987, J NEUROCHEM, V49, P1557, DOI 10.1111/j.1471-4159.1987.tb01027.x; VANELDIK LJ, 1987, BRAIN RES, V436, P367, DOI 10.1016/0006-8993(87)91681-7; VANELDIK LJ, 1988, J BIOL CHEM, V263, P7830; VANELDIK LJ, 1991, BRAIN RES, V542, P280, DOI 10.1016/0006-8993(91)91579-P; VEDIA LMY, 1988, BIOCHEM J, V255, P795, DOI 10.1042/bj2550795; WALENGA R, 1980, J BIOL CHEM, V255, P6024; WEI Q, 1991, SOC NEUROSCI, V17, P1123; WHITAKERAZMITIA PM, 1990, BRAIN RES, V528, P155, DOI 10.1016/0006-8993(90)90210-3; WHITFIELD JF, 1990, CALCIUM CELL CYCLES; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V107, P729	57	183	195	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9689	9694						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315768				2022-12-27	WOS:A1992HT96500038
J	OLSON, D; POLLANEN, J; HOYERHANSEN, G; RONNE, E; SAKAGUCHI, K; WUN, TC; APPELLA, E; DANO, K; BLASI, F				OLSON, D; POLLANEN, J; HOYERHANSEN, G; RONNE, E; SAKAGUCHI, K; WUN, TC; APPELLA, E; DANO, K; BLASI, F			INTERNALIZATION OF THE UROKINASE-PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 COMPLEX IS MEDIATED BY THE UROKINASE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX DEGRADATION; BOUND UROKINASE; CELL-SURFACE; U937 MONOCYTES; PRO-UROKINASE; SARCOMA-CELLS; BINDING; PROUROKINASE; SYSTEM; PURIFICATION	The role of the urokinase receptor (uPAR) in the internalization of the urokinase-plasminogen activator inhibitor type-1 (uPA.PAI-1) complex has been investigated. First, exploiting the species specificity of uPA binding, we show that mouse LB6 cells (that express a mouse uPAR) were unable to bind or degrade the human uPA.PAI-1 complex. On the other hand, LB6 clone 19 cells, which express a transfected human uPAR, degraded uPA.PAI-1 complexes with kinetics identical to the human monocytic U937 cells. We also show by immunofluorescence experiments with anti-uPA antibodies that in LB6 clone 19 cells, the uPA.PAI-1 complex is indeed internalized. While at 4-degrees-C uPA fluorescence was visible at the cell surface, shift of the temperature to 37-degrees-C caused a displacement of the immunoreactivity to the cytoplasmic compartment, with a pattern indicating lysosomal localization. If uPA.PAI-1 internalization/degradation is mediated by uPAR, inhibition of uPA.PAI-1 binding to uPAR should block degradation. Three different treatments, competition with the agonist amino-terminal fragment of uPA, treatment with a monoclonal antibody directed toward the binding domain of uPAR or release of uPAR from the cell surface with phosphatidylinositol-specific phospholipase C completely prevented uPA.PAI-1 degradation. The possibility that a serpin-enzyme complex receptor might be primarily or secondarily involved in the internalization process was excluded since a serpin-enzyme complex peptide failed to inhibit uPA.PAI-1 binding and degradation. Similarly, complexes of PAI-1 with low molecular mass uPA (33 kDa uPA), which lacks the uPAR binding domain, were neither bound nor degraded. Finally we also show that treatment of cells with uPA.PAI-1 complex caused a specific but partial down-regulation of uPAR. A similar result was obtained when PAI-1 was allowed to complex to uPA that had been previously bound to the receptor. The possibility therefore exists that the entire complex uPA.PAI-1-uPAR is internalized. All these data allow us to conclude that internalization of the uPA.PAI-1 complex is mediated by uPAR.	UNIV COPENHAGEN,INST MICROBIOL,OSTER FARIMAGSGADE 2A,DK-1353 COPENHAGEN,DENMARK; MONSANTO CO,CHESTERFIELD,MO 63198; FINSEN INST,DK-2100 COPENHAGEN,DENMARK; NCI,CELL BIOL LAB,BETHESDA,MD 20892	University of Copenhagen; Monsanto; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Sakaguchi, Kazuyasu/0000-0002-8434-4171; Blasi, Francesco/0000-0001-9406-1784				BERKENPAS MB, 1991, P NATL ACAD SCI USA, V88, P7768, DOI 10.1073/pnas.88.17.7768; Blasi F, 1990, Semin Cancer Biol, V1, P117; BLASI F, 1991, CELL DIFF DEV, V32, P247; CAJOT JF, 1989, J CELL BIOL, V109, P915, DOI 10.1083/jcb.109.2.915; CAJOT JF, 1990, P NATL ACAD SCI USA, V87, P6939, DOI 10.1073/pnas.87.18.6939; CUBELLIS MV, 1986, J BIOL CHEM, V261, P5819; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; HEARING VJ, 1988, CANCER RES, V48, P1270; HOLMBERG L, 1976, BIOCHIM BIOPHYS ACTA, V445, P215, DOI 10.1016/0005-2744(76)90174-1; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; NUSRAT AR, 1991, J CLIN INVEST, V87, P1091, DOI 10.1172/JCI115070; OSSOWSKI L, 1991, CANCER RES, V51, P274; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; PERLMUTTER DH, 1990, J BIOL CHEM, V265, P16713; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; POLLANEN J, 1990, P NATL ACAD SCI USA, V87, P2230, DOI 10.1073/pnas.87.6.2230; QUAX PHA, 1991, CELL REGUL, V2, P793, DOI 10.1091/mbc.2.10.793; REICH E, 1978, MOL BASIS BIOL DEGRA, P115; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WUN TC, 1989, J BIOL CHEM, V264, P7862	38	177	181	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9129	9133						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1315748				2022-12-27	WOS:A1992HR85400066
J	ABDULLAH, M; HUGHES, PJ; CRAXTON, A; GIGG, R; DESAI, T; MARECEK, JF; PRESTWICH, GD; SHEARS, SB				ABDULLAH, M; HUGHES, PJ; CRAXTON, A; GIGG, R; DESAI, T; MARECEK, JF; PRESTWICH, GD; SHEARS, SB			PURIFICATION AND CHARACTERIZATION OF INOSITOL-1,3,4-TRISPHOSPHATE 5 6-KINASE FROM RAT-LIVER USING AN INOSITOL HEXAKISPHOSPHATE AFFINITY COLUMN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL GLOMERULOSA CELLS; MYOINOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE; 1,3,4-TRISPHOSPHATE PHOSPHORYLATION; AVIAN ERYTHROCYTES; ACINAR-CELLS; 1,3,4,6-TETRAKISPHOSPHATE; TETRAKISPHOSPHATE; 1,3,4,5-TETRAKISPHOSPHATE; 1,4,5-TRISPHOSPHATE; PHOSPHATES	The metabolism of inositol 1,3,4-trisphosphate is a pivotal branch point of inositol phosphate turnover; its dephosphorylation replenishes cellular inositol pools, its phosphorylation at the 6-position supports the synthesis of inositol pentakisphosphate, and its phosphorylation at the 5-position produces inositol 1,3,4,5-tetrakisphosphate Shears, S. B. (1989) J. Biol. Chem. 264, 19879-19886). In order to increase understanding of the control of inositol-1,3,4-trisphosphate kinase activity, the enzyme was highly purified from rat liver by precipitation with polyethylene glycol, MonoQ ion-exchange chromatography, heparin-agarose affinity chromatography, and a novel affinity chromatography procedure that utilized Affi-Gel resin to which InSP6 was coupled (Marecek, J. F., and Prestwich, G. D. (1991) Tetrahedron Lett. 32, 1863-1866). The final purification was about 26,000-fold, with a 6% yield. This final preparation performed both 5- and 6-kinase activities in the ratio of approximately 1:5. The affinity of the enzyme for inositol 1,3,4-trisphosphate was 0.04 muM, the highest yet determined for an inositol phosphate kinase. Both inositol 1,3,4,5-tetrakisphosphate and inositol 1,3,4,6-tetrakisphosphate were competitive inhibitors of the kinase (K(i) values of 2-4 muM). The enzyme was determined to have a molecular mass of 36 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Kinase activity was unaffected by Ca2+/calmodulin, protein kinase A, or protein kinase C.	NIEHS, INOSITOL LIPID SECT, CELLULAR & MOLEC PHARMACOL LAB, RES TRIANGLE PK, NC 27709 USA; NATL INST MED RES, LONDON NW7 1AA, ENGLAND; SUNY STONY BROOK, DEPT CHEM, STONY BROOK, NY 11794 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); MRC National Institute for Medical Research; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916	NINDS NIH HHS [NS 29632] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALLA T, 1987, J BIOL CHEM, V262, P9952; BALLA T, 1989, J BIOL CHEM, V264, P13605; BANSAL VS, 1990, J BIOL CHEM, V265, P1806; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDWELL KK, 1991, J BIOL CHEM, V266, P18378; DESAI T, 1992, CARBOHYD RES, V228, P65, DOI 10.1016/S0008-6215(00)90549-4; GAWLER DJ, 1991, BIOCHEM J, V276, P163, DOI 10.1042/bj2760163; HANSEN CA, 1988, FEBS LETT, V236, P53, DOI 10.1016/0014-5793(88)80284-9; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HIRATA M, 1990, BIOCHEM BIOPH RES CO, V168, P379, DOI 10.1016/0006-291X(90)91719-9; HUGHES PJ, 1989, J BIOL CHEM, V264, P19871; INHORN RC, 1988, J BIOL CHEM, V263, P14559; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; IVORRA I, 1991, BIOCHEM J, V273, P317, DOI 10.1042/bj2730317; KING WG, 1990, BIOCHEM J, V270, P125, DOI 10.1042/bj2700125; Kirk CJ., 1990, PEPTIDE HORMONE ACTI, P151; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SY, 1990, J BIOL CHEM, V265, P9434; LI GD, 1992, J BIOL CHEM, V267, P4349; MARECEK JF, 1991, TETRAHEDRON LETT, V32, P1863, DOI 10.1016/S0040-4039(00)85982-1; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; PITTET D, 1989, J BIOL CHEM, V264, P18489; PRESTWICH GD, 1991, ACS SYM SER, V463, P122; PRESTWICH GD, 1991, J AM CHEM SOC, V113, P1822, DOI 10.1021/ja00005a055; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; SHEARS SB, 1989, J BIOL CHEM, V264, P19879; SHEARS SB, 1987, BIOCHEM J, V246, P139, DOI 10.1042/bj2460139; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; STEPHENS LR, 1989, BIOCHEM J, V262, P727, DOI 10.1042/bj2620727; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; 1989, BIOCHEM J, V258, P1	34	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22340	22345						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331051				2022-12-27	WOS:A1992JW71900056
J	PENNICA, D; LAM, VT; MIZE, NK; WEBER, RF; LEWIS, M; FENDLY, BM; LIPARI, MT; GOEDDEL, DV				PENNICA, D; LAM, VT; MIZE, NK; WEBER, RF; LEWIS, M; FENDLY, BM; LIPARI, MT; GOEDDEL, DV			BIOCHEMICAL-PROPERTIES OF THE 75-KDA TUMOR-NECROSIS-FACTOR RECEPTOR - CHARACTERIZATION OF LIGAND-BINDING, INTERNALIZATION, AND RECEPTOR PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CELL-SURFACE RECEPTORS; FACTOR TNF RECEPTOR; PROTEIN KINASE-C; HIGH-AFFINITY BINDING; MOLECULAR-CLONING; SOLUBLE FORM; FACTOR-ALPHA; MONOCLONAL-ANTIBODIES; ACTIVATION MOLECULE	An expression plasmid encoding the human 75-kDa tumor necrosis factor (TNF) type 2 receptor (TNF-R2) was constructed and used to generate a stable human cell line (293/TNF-R2) overexpressing TNF-R2. Ligand binding analysis revealed high affinity binding (K(d) = 0.2 nM) with approximately 94,000 +/- 7,500 sites/cell for I-125-TNF-alpha and approximately 5-fold lower affinity for TNF-beta (K(d) = 1.1 nM) with 264,000 +/- 2,000 sites/cell. Cross-linking of I-125-TNF-alpha and I-125-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules. Immunoprecipitation of TNF-R2 from P-32-labeled 293/TNF-R2 cells demonstrated that the receptor is phosphorylated. The majority (97%) of P-32i incorporation was found in serine residues with a very low level of incorporation (3%) in threonine residues. TNF-alpha treatment of 293/TNF-R2 cells did not significantly affect the degree or pattern of phosphorylation. Cell surface-bound I-125-TNF-alpha was slowly internalized by the 293/TNF-R2 cell line with a t1/2 = 25 min. Shedding of the extracellular domain of TNF-R2 was induced by 4beta-phorbol 12-myristate 13-acetate but not by TNF-alpha or TNF-beta.	GENENTECH INC,DEPT MED & ANALYT CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech	PENNICA, D (corresponding author), GENENTECH INC,DEPT MOLEC BIOL,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							ADERKA D, 1991, CANCER RES, V51, P5602; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; AGGARWAL BB, 1987, J BIOL CHEM, V262, P16450; BAGLIONI C, 1985, J BIOL CHEM, V260, P3395; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CAMERINI D, 1991, J IMMUNOL, V147, P3165; CAMUSSI G, 1991, EUR J BIOCHEM, V202, P3, DOI 10.1111/j.1432-1033.1991.tb16337.x; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAY PW, 1990, P NATL ACAD SCI USA, V87, P7380, DOI 10.1073/pnas.87.19.7380; HATEKAYEMA M, 1989, CELL, V59, P837; HAYAKAWA M, 1991, ARCH BIOCHEM BIOPHYS, V286, P323, DOI 10.1016/0003-9861(91)90047-M; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HIMMLER A, 1990, DNA CELL BIOL, V9, P705, DOI 10.1089/dna.1990.9.705; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; HOHMANN HP, 1992, J BIOL CHEM, V267, P2065; HOLTMANN H, 1987, J IMMUNOL, V139, P1161; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JAATTELA M, 1991, LAB INVEST, V64, P724; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KULL FC, 1985, P NATL ACAD SCI USA, V82, P5756, DOI 10.1073/pnas.82.17.5756; LANTZ M, 1990, J CLIN INVEST, V86, P1396, DOI 10.1172/JCI114853; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, J BIOL CHEM, V265, P20131; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOETSCHER H, 1992, TUMOR NECROSIS FACTO, P160; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MIYATA A, 1985, BIOCHEM BIOPH RES CO, V129, P248, DOI 10.1016/0006-291X(85)91429-9; MOSSELMANS R, 1988, J IMMUNOL, V141, P3096; NAUME B, 1991, J IMMUNOL, V146, P3045; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; OPPERMANN H, 1981, VIROLOGY, V108, P47, DOI 10.1016/0042-6822(81)90526-2; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; PORTEU F, 1991, J BIOL CHEM, V266, P18846; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUBIN BY, 1985, J EXP MED, V162, P1099, DOI 10.1084/jem.162.3.1099; Sambrook J, 1989, MOL CLONING LABORATO; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SEED B, 1987, P NATL ACAD SCI USA, V84, P8573; SHALABY MR, 1990, J EXP MED, V172, P15617; SHYJAN AW, 1989, BIOCHEMISTRY-US, V28, P4531, DOI 10.1021/bi00437a002; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH RA, 1992, TUMOR NECROSIS FACTO, P131; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; UNGLAUB R, 1987, J EXP MED, V166, P1788, DOI 10.1084/jem.166.6.1788; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WATANABE N, 1989, CANCER IMMUNOL IMMUN, V28, P157; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YOSHIE O, 1986, J BIOCHEM-TOKYO, V100, P531, DOI 10.1093/oxfordjournals.jbchem.a121744	73	83	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21172	21178						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328224				2022-12-27	WOS:A1992JT97800102
J	NAKANISHI, A; IMAJOHOHMI, S; FUJINAWA, T; KIKUCHI, H; KANEGASAKI, S				NAKANISHI, A; IMAJOHOHMI, S; FUJINAWA, T; KIKUCHI, H; KANEGASAKI, S			DIRECT EVIDENCE FOR INTERACTION BETWEEN COOH-TERMINAL REGIONS OF CYTOCHROME-B558 SUBUNITS AND CYTOSOLIC 47-KDA PROTEIN DURING ACTIVATION OF AN O2(-)-GENERATING SYSTEM IN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; RESPIRATORY BURST OXIDASE; DEPENDENT SUPEROXIDE PRODUCTION; ADENINE-DINUCLEOTIDE PHOSPHATE; CHRONIC GRANULOMATOUS-DISEASE; NADPH OXIDASE; FATTY-ACIDS; LEUKOCYTES; NUCLEOTIDE; COMPONENT	Cytochrome b558 in phagocytes is a transmembrane protein composed of large and small subunits and considered to play a key role in O2- generation during the respiratory burst. The COOH-terminal regions of the cytochrome subunits protrude to the cytoplasmic side and are assumed to be the sites for association with cytosolic components to form an active O2--generating complex (Imajoh-Ohmi, S., Tokita, K., Ochiai, H., Nakamura, M., and Kanegasaki, S. (1992) J. Biol. Chem. 267, 180-184). We show here that two synthetic peptides corresponding to the COOH-terminal region of each subunit inhibit NADPH-dependent oxygen uptake induced by sodium dodecyl sulfate (SDS) in a cell-free system consisting of plasma membrane and cytosol. The inhibition was observed when either peptide was added to the system before, but not after, the activation with SDS suggesting that interaction between the COOH-terminal regions of the cytochrome subunits and cytosolic components is important for the assembly and the activity of the O2--generating system. Using the cross-linking reagent dimethyl 3,3'-dithiobis-propionimidate, we found that the cytosolic 47-kDa protein, an essential component of the O2--generating system, interacted with the synthetic peptides in the presence of SDS. In addition to the 47-kDa protein, a 17-kDa protein was found to be associated with the peptide corresponding to the COOH-terminal region of the small subunit. These results indicate that the cytosolic COOH-terminal regions of cytochrome b558 subunits are the binding sites for both the cytosolic 47-kDa protein and the 17-kDa protein and that the binding takes place during activation of the system.	UNIV TOKYO,INST MED SCI,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN	University of Tokyo			Kanegasaki, Shiro/AAM-4921-2021					BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BOLSCHER BGJM, 1990, J BIOL CHEM, V265, P15782; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DOUSSIERE J, 1988, BIOCHEM BIOPH RES CO, V152, P993, DOI 10.1016/S0006-291X(88)80382-6; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1991, J BIOL CHEM, V266, P19812; LOMAX KJ, 1989, BLOOD REV, V3, P94, DOI 10.1016/0268-960X(89)90004-0; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LOMAX KJ, 1989, SCIENCE, V246, P987, DOI 10.1126/science.2587992; MAKINO R, 1986, J BIOL CHEM, V261, P1444; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; SMITH RM, 1991, BLOOD, V77, P673; SMITH RM, 1989, J BIOL CHEM, V264, P1958; TANAKA T, 1987, BIOCHEM BIOPH RES CO, V144, P606, DOI 10.1016/S0006-291X(87)80009-8; TANAKA T, 1988, J BIOL CHEM, V263, P13670; UMEI T, 1991, J BIOL CHEM, V266, P6019; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P9563	28	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19072	19074						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326544				2022-12-27	WOS:A1992JP59300012
J	ULMER, JB; BURKE, CJ; SHI, CY; FRIEDMAN, A; DONNELLY, JJ; LIU, MA				ULMER, JB; BURKE, CJ; SHI, CY; FRIEDMAN, A; DONNELLY, JJ; LIU, MA			PORE FORMATION AND MITOGENICITY IN BLOOD-CELLS BY THE CLASS-2 PROTEIN OF NEISSERIA-MENINGITIDIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEINS; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; MATRIX PORIN; GENE; PERMEABILITY; GONORRHOEAE; SEQUENCE	The class 2 outer membrane protein (MIEP) of Neisseria meningitidis has recently been shown to be mitogenic for lymphocytes (Liu, M. A., Friedman, A., Tai, J., Martinez, D., Deck, R. R., Hawe, L. A., Shieh, J. T.-C., Jenkins, T. D., Donnelly, J. J., and Oliff, A. 1. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 4633-4637. In this study, a possible connection between MIEP's mitogenicity and its possible action as a porin was investigated. MIEP, purified from the bacterial outer membrane protein complex under denaturing conditions, caused a modest but specific release of ions (Rb-86) from both erythrocytes and lymphocytes, ultimately resulting in cell lysis. The dose-response of MIEP on erythrocyte lysis was qualitatively similar to a known porin (protein I from Neisseria gonorrhoeae) but was much less efficient. Induction or preservation of native structure in MIEP increased pore formation, resulting in levels comparable to that of the protein I porin. These observations suggest that native MIEP, free of the other outer membrane proteins of Neisseria meningitidis, can efficiently form pores in cells, but that denatured MIEP is variably and marginally effective. However, pore formation by MIEP was not related to its mitogenicity in lymphocytes, based on: (i) native MIEP was not mitogenic; (ii) denatured MIEP was highly mitogenic; and (iii) denatured MIEP was mitogenic at concentrations below the threshold level for pore formation. Therefore, mitogenicity is dependent upon MIEP being in a denatured, monomeric state and is masked by native conformation.	MERCK RES LABS,DEPT PHARMACEUT RES,W POINT,PA 19486	Merck & Company	ULMER, JB (corresponding author), MERCK RES LABS,DEPT CANC RES,BLDG 16-3,W POINT,PA 19486, USA.							AHONKAI VI, 1990, PEDIATRICS, V85, P668; BARLOW AK, 1989, MOL MICROBIOL, V3, P131, DOI 10.1111/j.1365-2958.1989.tb01802.x; BLAKE MS, 1982, INFECT IMMUN, V36, P277, DOI 10.1128/IAI.36.1.277-283.1982; DIHANICH M, 1990, EXPERIENTIA, V46, P146, DOI 10.1007/BF02027310; DONNELLY JJ, 1990, J IMMUNOL, V145, P3071; DORNMAIR K, 1990, J BIOL CHEM, V265, P18907; DORSET DL, 1983, J MOL BIOL, V165, P701, DOI 10.1016/S0022-2836(83)80275-7; EISELE JL, 1990, J BIOL CHEM, V265, P10217; FORBUSH B, 1987, J BIOL CHEM, V262, P11104; FRASCH CE, 1978, J BACTERIOL, V136, P1127, DOI 10.1128/JB.136.3.1127-1134.1978; FRASCH CE, 1986, CLIN INVEST MED, V9, P101; GELFAND EW, 1990, LIGANDS RECEPTORS SI, P359; HANCOCK REW, 1987, J BACTERIOL, V169, P929, DOI 10.1128/jb.169.3.929-933.1987; JAP BK, 1990, Q REV BIOPHYS, V23, P367, DOI 10.1017/S003358350000559X; JAP BK, 1990, J STRUCT BIOL, V103, P57, DOI 10.1016/1047-8477(90)90086-R; Levitt D, 1990, CURR OPIN CELL BIOL, V2, P689, DOI 10.1016/0955-0674(90)90112-R; LIU MA, 1992, P NATL ACAD SCI USA, V89, P4633, DOI 10.1073/pnas.89.10.4633; LYNCH EC, 1984, BIOPHYS J, V45, P104, DOI 10.1016/S0006-3495(84)84127-2; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MARKOVICHOUSLEY Z, 1986, BIOCHIM BIOPHYS ACTA, V869, P158, DOI 10.1016/0167-4838(86)90290-6; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MIZUNO T, 1983, J BIOL CHEM, V258, P6932; MURAKAMI K, 1989, INFECT IMMUN, V57, P2318, DOI 10.1128/IAI.57.8.2318-2323.1989; NAKAE T, 1979, J BIOL CHEM, V254, P1457; PARR TR, 1986, J BACTERIOL, V165, P523, DOI 10.1128/jb.165.2.523-526.1986; PERUTZ MF, 1968, NATURE, V219, P29, DOI 10.1038/219029a0; TSAI CM, 1981, J BACTERIOL, V146, P69, DOI 10.1128/JB.146.1.69-78.1981; WEISS A, 1987, ADV IMMUNOL, P1; YOSHIHARA E, 1991, J BIOL CHEM, V266, P952	29	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19266	19271						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326549				2022-12-27	WOS:A1992JP59300040
J	KESSLER, D; HERTH, W; KNAPPE, J				KESSLER, D; HERTH, W; KNAPPE, J			ULTRASTRUCTURE AND PYRUVATE FORMATE-LYASE RADICAL QUENCHING PROPERTY OF THE MULTIENZYMATIC ADHE PROTEIN OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED ALCOHOL-DEHYDROGENASE; ZYMOMONAS-MOBILIS; ADENINE-DINUCLEOTIDE; ACETYL-COA; HYPOPHOSPHITE; CLONING; ENZYME; ANALOG; GENE	The AdhE protein of Escherichia coli is a homopolymer of 96-kDa subunits harboring three Fe2+-dependent catalytic functions: acetaldehyde-CoA dehydrogenase, alcohol dehydrogenase, and pyruvate formatelyase (PFL) deactivase. By negative staining electron microscopy, we determined a helical assembly of 20-60 subunits into rods of 45-120 nm in length. The subunit packing is widened along the helix axis when Fe2+ and NAD are present. Chymotrypsin dissects the AdhE polypeptide between Phe762 and Ser763, thereby retaining the alcohol dehydrogenase activity on the NH2-terminal core, but destroying all other activities. PFL deactivation, i.e. quenching of the glycyl radical in PFL by the AdhE protein, was examined with respect to cofactor involvements (Fe2+, NAD, and CoA). This process is coupled to NAD reduction and requires the intact CoA sulfhydryl group. Pyruvate and NADH are inhibitors that affect the steady-state level of the radical form of PFL in a reconstituted interconversion cycle. Studies of cell cultures found that PFL deactivation in situ is initiated at redox potentials of greater-than-or-equal-to +100 mV. Our results provide insights into the structure/function organization of the AdhE multienzyme and give a rationale for how its PFL radical quenching activity may be suppressed in situ to enable effective glucose fermentation.	UNIV HEIDELBERG,INST BIOL CHEM,NEUENHEIMER FELD 501,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg								CONRADT H, 1984, ARCH BIOCHEM BIOPHYS, V228, P133, DOI 10.1016/0003-9861(84)90054-7; CONWAY T, 1987, J BACTERIOL, V169, P2591, DOI 10.1128/jb.169.6.2591-2597.1987; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FISHER TL, 1973, J BIOL CHEM, V248, P4293; GOODLOVE PE, 1989, GENE, V85, P209, DOI 10.1016/0378-1119(89)90483-6; HARVEY HE, 1955, ANAL CHEM, V27, P26; KESSLER D, 1991, FEBS LETT, V281, P59, DOI 10.1016/0014-5793(91)80358-A; KNAPPE J, 1990, FEMS MICROBIOL LETT, V75, P383, DOI 10.1111/j.1574-6968.1990.tb04108.x; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATAYOSHI S, 1989, J GEN MICROBIOL, V135, P525; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; PLAGA W, 1988, EUR J BIOCHEM, V178, P445, DOI 10.1111/j.1432-1033.1988.tb14468.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STANDRING DN, 1980, BIOCHEMISTRY-US, V19, P2811, DOI 10.1021/bi00553a042; TSE P, 1989, J AM CHEM SOC, V111, P8703, DOI 10.1021/ja00205a021; UNKRIG V, 1989, EUR J BIOCHEM, V184, P723, DOI 10.1111/j.1432-1033.1989.tb15072.x; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WILLIAMSON VM, 1987, MOL GEN GENET, V209, P374, DOI 10.1007/BF00329668; WIMPENNY JW, 1971, BIOCHIM BIOPHYS ACTA, V253, P352, DOI 10.1016/0005-2728(71)90039-9	22	98	99	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18073	18079						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325457				2022-12-27	WOS:A1992JM22300091
J	NIRANJANAKUMARI, S; GOPINATHAN, KP				NIRANJANAKUMARI, S; GOPINATHAN, KP			DNA POLYMERASE-DELTA FROM THE SILK GLANDS OF BOMBYX-MORI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; CALF THYMUS; AUXILIARY PROTEIN; HUMAN-FIBROBLASTS; REPAIR SYNTHESIS; HELA-CELLS; RAT-LIVER; 2 FORMS; ALPHA; PURIFICATION	The silk gland of Bombyx mori is a terminally differentiated tissue in which DNA replication continues without cell or nuclear division during larval development. DNA polymerase-delta activity increases in the posterior and middle silk glands during the development period, reaching maximal levels in the middle of the fifth instar larvae. The enzyme has been purified to homogeneity by a series of column chromatographic and affinity purification steps. It is a multimer comprising of three heterogeneous subunits, M(r) 170,000, 70,000, and 42,000. An auxiliary protein from B. mori silk glands, analogous to the proliferating cell nuclear antigen, enhances the processivity of the enzyme and stimulates catalytic activity by 3-fold. This auxiliary protein has also been purified to homogeneity. It is a dimer comprised of a single type M(r) 40,000 subunit. Polymerase-delta possesses an intrinsic 3' --> 5' exonuclease activity which participates in proofreading by mismatch match repair during DNA synthesis and is devoid of any primase activity. DNA polymerase-delta activity could be further distinguished from polymerase-alpha from the same tissue based on its sensitivity to various inhibitors and polyclonal antibodies to the individual enzymes. Like DNA polymerase-alpha, polymerase-delta is also tightly associated with the nuclear matrix. The polymerase alpha-primase complex could be readily separated from polymerase-delta (exonuclease) in the purification protocol adopted. DNA polymerase-delta from B. mori silk glands resembles the mammalian delta-polymerases. Considering that both DNA polymerase-delta and -alpha are present in nearly equal amounts in this highly replicative tissue and their close association with the nuclear matrix, the involvement of both the enzymes in the chromosomal endoreplication process in B. mori is strongly implicated.	INDIAN INST SCI,DEPT MICROBIOL & CELL BIOL,BANGALORE 560012,KARNATAKA,INDIA; INDIAN INST SCI,CTR GENET ENGN,BANGALORE 560012,KARNATAKA,INDIA	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore								BAUER GA, 1988, J BIOL CHEM, V263, P917; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRNES JJ, 1985, BIOCHEM BIOPH RES CO, V132, P628, DOI 10.1016/0006-291X(85)91179-9; BYRNES JJ, 1976, BIOCHEMISTRY-US, V15, P2817, DOI 10.1021/bi00658a018; CRUTE JJ, 1986, BIOCHEMISTRY-US, V25, P26, DOI 10.1021/bi00349a005; DECKER RS, 1987, J BIOL CHEM, V262, P10863; DOWNEY KM, 1990, BIOESSAYS, V12, P231, DOI 10.1002/bies.950120507; DOWNEY KM, 1988, CANCER CELLS EUKARYO, V6, P403; DRESLER SL, 1986, NUCLEIC ACIDS RES, V14, P7093, DOI 10.1093/nar/14.17.7093; FOCHER F, 1988, NUCLEIC ACIDS RES, V16, P6279, DOI 10.1093/nar/16.14.6279; FRY M, 1986, ANIMAL CELL DNA POLY; GAGE LP, 1974, CHROMOSOMA, V45, P27; GOULIAN M, 1990, J BIOL CHEM, V265, P16402; HAMMOND RA, 1987, BIOCHEMISTRY-US, V26, P6817, DOI 10.1021/bi00395a035; HOLMES AM, 1974, EUR J BIOCHEM, V43, P487, DOI 10.1111/j.1432-1033.1974.tb03436.x; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; Lee M Y, 1981, Prog Nucleic Acid Res Mol Biol, V26, P83; LEE MYWT, 1987, BIOCHEMISTRY-US, V26, P1076, DOI 10.1021/bi00378a014; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LEE MYWT, 1985, NUCLEIC ACIDS RES, V13, P8623, DOI 10.1093/nar/13.23.8623; LONGIARU M, 1979, NUCLEIC ACIDS RES, V6, P3369, DOI 10.1093/nar/6.10.3369; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MECHALI M, 1980, J BIOL CHEM, V255, P2114; NASHEUER HP, 1987, BIOCHEMISTRY-US, V26, P8458, DOI 10.1021/bi00399a064; NIRANJANAKUMARI S, 1991, EUR J BIOCHEM, V202, P431; NISHIDA C, 1988, J BIOL CHEM, V263, P501; OHASHI M, 1978, BIOCHEM BIOPH RES CO, V82, P1084, DOI 10.1016/0006-291X(78)90298-X; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; REYLAND ME, 1988, J BIOL CHEM, V263, P6518; SYVAOJA J, 1989, J BIOL CHEM, V264, P2489; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TAN CK, 1986, J BIOL CHEM, V261, P2310; TANAKA S, 1982, J BIOL CHEM, V257, P8386; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAHL AF, 1986, BIOCHEMISTRY-US, V25, P7821, DOI 10.1021/bi00372a006	35	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17531	17539						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325438				2022-12-27	WOS:A1992JM22300012
J	ADLER, V; POLOTSKAYA, A; WAGNER, F; KRAFT, AS				ADLER, V; POLOTSKAYA, A; WAGNER, F; KRAFT, AS			AFFINITY-PURIFIED C-JUN AMINO-TERMINAL PROTEIN-KINASE REQUIRES SERINE THREONINE PHOSPHORYLATION FOR ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC INHIBITOR; MONOCYTIC DIFFERENTIATION; REGULATORY DOMAIN; FOS; EXPRESSION; ACTIVATION; INDUCTION; ONCOGENE	The addition of phorbol esters to U937 leukemic cells stimulates the phosphorylation of c-Jun on serines 63 and 73. To isolate the protein kinase which stimulates this phosphorylation, we have used heparin-Sepharose chromatography followed by affinity chromatography over glutathione-Sepharose beads bound with a fusion protein of glutathione S-transferase and amino acids 5-89 of c-Jun (GST-c-Jun). Using this procedure we purify a 67-kDa protein which is capable of phosphorylating GST-c-Jun as well as the complete c-Jun protein. By making mutations in serines 63 and 73 and then creating a fusion protein with GST (GST-c-Jun mut), we demonstrate that this protein kinase specifically phosphorylates these sites in the c-Jun amino terminus. Treatment of purified c-Jun amino-terminal protein kinase (cJAT-PK) with phosphatase 2A inhibits its ability to phosphorylate GST-c-Jun. This inactivated enzyme can be reactivated by phosphorylation with protein kinase C (PKC), although PKC is not capable of phosphorylating the GST-c-Jun substrate. Because v-Jun cannot be phosphorylated in vivo, we compared the ability of cJAT-PK to bind to GST-v-Jun or GST-c-Jun mut. The cJAT-PK bound 50-fold better to GST-c-Jun mut than GST-v-Jun suggesting that the delta-domain which is missing in v-Jun plays a role in binding the cJAT-PK. These results suggest that there is a protein kinase cascade mediated by protein phosphatases and PKC which regulates c-Jun phosphorylation.	UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER; NCI NIH HHS [R0-1 CA-42533] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; DATTA R, 1991, CELL GROWTH DIFFER, V2, P43; FRANKLIN CC, IN PRESS P NATL ACAD; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KRAFT AS, 1983, J BIOL CHEM, V258, P9178; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; UNLAP T, 1992, NUCLEIC ACIDS RES, V20, P897, DOI 10.1093/nar/20.4.897; WILLIAM F, 1990, J BIOL CHEM, V265, P18166	22	103	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17001	17005						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324919				2022-12-27	WOS:A1992JL05300044
J	MAIZELS, ET; MILLER, JB; CUTLER, RE; JACKIW, V; CARNEY, EM; MIZUNO, K; OHNO, S; HUNZICKERDUNN, M				MAIZELS, ET; MILLER, JB; CUTLER, RE; JACKIW, V; CARNEY, EM; MIZUNO, K; OHNO, S; HUNZICKERDUNN, M			ESTROGEN MODULATES CA2+-INDEPENDENT LIPID-STIMULATED KINASE IN THE RABBIT CORPUS-LUTEUM OF PSEUDOPREGNANCY - IDENTIFICATION OF LUTEAL ESTROGEN-MODULATED LIPID-STIMULATED KINASE AS PROTEIN-KINASE C-DELTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTOR; STEROL CARRIER PROTEIN-2; 2 DISTINCT CLASSES; 17 BETA-ESTRADIOL; CORPORA-LUTEA; RAT-BRAIN; DEPENDENT PHOSPHORYLATION; SIGNAL TRANSDUCTION; PKC-EPSILON; FAMILY	Rabbit corpora lutea were tested for the presence of phosphorylative responses sensitive to estrogen. Luteal Ca2+-independent lipid-stimulated kinase activity was detected by phosphorylation of the endogenous substrate, p76. Estrogen treatment, by way of estradiol-17-beta implant, increased levels of the lipid-stimulated phosphoprotein 2-3-fold throughout pseudopregnancy. Midpseudopregnant rabbit luteal extracts were further evaluated to determine the identity of the lipid-stimulated kinase. Results of low pH-activated phosphorylation were consistent with the identification of p76 as an autophosphorylated member of the protein kinase C (PKC) family. Partial purification of the luteal lipid-stimulated kinase was performed using sequential DEAE-cellulose/hydroxylapatite chromatographies and using gel filtration. Western immunoblot with type-specific anti-PKC-delta antiserum showed coelution of kinase p76 activity with immunoreactive PKC-delta. Immunoblot analysis confirmed that luteal levels of PKC-delta were increased by estrogen treatment.	NORTHWESTERN UNIV, SCH MED, DEPT CELL MOLEC & STRUCT BIOL, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA; UNIV ILLINOIS, SCH MED, DEPT OBSTET & GYNECOL, CHICAGO, IL 60612 USA; YOKOHAMA CITY UNIV, SCH MED, DEPT MOLEC BIOL, YOKOHAMA 236, JAPAN	Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Yokohama City University			Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269; Maizels, Evelyn/0000-0001-9072-1095	NICHD NIH HHS [HD-11356, HD-28472] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028472, R01HD011356] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKITA Y, 1990, J BIOL CHEM, V265, P354; ALESSENKO A, 1992, BIOCHEM BIOPH RES CO, V182, P1333, DOI 10.1016/0006-291X(92)91879-U; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BELL RM, 1991, J BIOL CHEM, V266, P4661; BENDER EM, 1978, ENDOCRINOLOGY, V103, P1937, DOI 10.1210/endo-103-5-1937; BERNARDS R, 1991, EMBO J, V10, P1119, DOI 10.1002/j.1460-2075.1991.tb08052.x; BIGNON E, 1989, BIOCHEM BIOPH RES CO, V163, P1377, DOI 10.1016/0006-291X(89)91131-5; BILL CH, 1983, BIOL REPROD, V28, P608, DOI 10.1095/biolreprod28.3.608; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DEMANNO DA, 1992, IN PRESS MOL CELL EN; GADSBY JE, 1983, ENDOCRINOLOGY, V113, P2255, DOI 10.1210/endo-113-6-2255; GSCHWENDT M, 1989, BIOCHEM BIOPH RES CO, V164, P974, DOI 10.1016/0006-291X(89)91765-8; GSCHWENDT M, 1986, BIOCHEM BIOPH RES CO, V137, P766, DOI 10.1016/0006-291X(86)91145-9; HEIDENREICH KA, 1990, J BIOL CHEM, V265, P15076; HOLT JA, 1975, ENDOCRINOLOGY, V97, P76, DOI 10.1210/endo-97-1-76; HOLT JA, 1988, ENDOCRINOLOGY, V122, P1948, DOI 10.1210/endo-122-5-1948; HOLT JA, 1985, ENDOCRINOLOGY, V117, P2462, DOI 10.1210/endo-117-6-2462; HOLT JA, 1989, BIOL REPROD, V40, P201, DOI 10.1095/biolreprod40.2.201; HOMAN EC, 1991, J BIOL CHEM, V266, P5676; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; HUANG KP, 1986, J BIOL CHEM, V261, P4781; HUNZICKERDUNN M, 1984, ENDOCRINOLOGY, V115, P302, DOI 10.1210/endo-115-1-302; KEYES PL, 1967, ENDOCRINOLOGY, V80, P938, DOI 10.1210/endo-80-5-938; KEYES PL, 1990, ENDOCRINOLOGY, V127, P1186, DOI 10.1210/endo-127-3-1186; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; KILEY S, 1990, J BIOL CHEM, V265, P15704; LEACH KL, 1988, ADV 2ND MESSENGER A, V21, P182; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maizels E T, 1989, J Reprod Fertil Suppl, V37, P311; MAIZELS E T, 1987, Biology of Reproduction, V36, P124; MAIZELS ET, 1990, BIOCHIM BIOPHYS ACTA, V1054, P285, DOI 10.1016/0167-4889(90)90099-Y; MAIZELS ET, 1983, ENDOCRINOLOGY, V112, P1895, DOI 10.1210/endo-112-6-1895; MAIZELS ET, 1991, REGULATORY PROCESSES, P54; MCFADDEN PN, 1989, J BIOL CHEM, V264, P12765; MCLEAN MP, 1989, ENDOCRINOLOGY, V125, P1337, DOI 10.1210/endo-125-3-1337; MILLER JB, 1983, BIOL REPROD, V29, P620, DOI 10.1095/biolreprod29.3.620; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1990, J BIOL CHEM, V265, P22434; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PELECH SL, 1991, J BIOL CHEM, V266, P8696; RAO MC, 1987, ENDOCRINOLOGY, V120, P1010, DOI 10.1210/endo-120-3-1010; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; STEINSCHNEIDER A, 1991, ENDOCRINOLOGY, V128, P263, DOI 10.1210/endo-128-1-263; STEINSCHNEIDER A, 1989, ENDOCRINOLOGY, V125, P569, DOI 10.1210/endo-125-1-569; SU HD, 1985, BIOCHEM PHARMACOL, V34, P3649; WOOTEN MW, 1992, FEBS LETT, V298, P74, DOI 10.1016/0014-5793(92)80025-C	58	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17061	17068						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324921				2022-12-27	WOS:A1992JL05300052
J	RICHARDS, OC; YU, P; NEUFELD, KL; EHRENFELD, E				RICHARDS, OC; YU, P; NEUFELD, KL; EHRENFELD, E			NUCLEOTIDE BINDING BY THE POLIOVIRUS RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS REVERSE-TRANSCRIPTASE; COLI DNA-POLYMERASE; ESCHERICHIA-COLI; CROSS-LINKING; ELECTROPHORETIC TRANSFER; FUNCTIONAL TOPOGRAPHY; POLYACRYLAMIDE GELS; ENZYMATIC-ACTIVITY; SUBSTRATE-BINDING; VIRAL CDNA	Cross-linking of ribonucleoside triphosphates (NTPs) to specific binding sites on the poliovirus RNA-dependent RNA polymerase has been performed by ultraviolet irradiation and by reduction of oxidized nucleotide-protein complexes. The latter method approached a cross-linking efficiency of 1 NTP/molecule of enzyme. Nucleotide competition experiments suggested that the same binding site is occupied by all NTPs. Analysis of peptides produced by proteinase Glu-C and trypsin digestion and labeled with [P-32]GTP indicated that a lysine residue between Met-189 and Lys-228 in the polymerase was cross-linked to NTP. Nucleotide binding was exploited for rapid purification of the enzyme by GTP-agarose affinity chromatography. In addition, a set of cloned, modified polymerase molecules with reduced or absent polymerization activity was analyzed for binding efficiency to a GTP-agarose column. Some mutations eliminated GTP binding, whereas others generated proteins with varying affinities for GTP. Incubation of the poliovirus polymerase with high concentrations of NTP, particularly GTP, resulted in a dramatic protection against heat denaturation and activity loss. These data suggest that nucleotide binding results in an alteration of the enzyme conformation or the stabilization of an ordered conformation.	UNIV UTAH, DEPT CELLULAR VIRAL & MOLEC BIOL, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, SCH MED, DEPT BIOCHEM, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah				Neufeld, Kristi/0000-0003-3653-9385	NATIONAL CANCER INSTITUTE [P30CA042014, T32CA009602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017386, R37AI017386] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09602, CA 42014] Funding Source: Medline; NIAID NIH HHS [AI 17386] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM KI, 1984, BIOCHEMISTRY-US, V23, P1176, DOI 10.1021/bi00301a023; BASU A, 1988, J BIOL CHEM, V263, P1648; BASU A, 1990, J BIOL CHEM, V265, P17162; BASU A, 1987, BIOCHEMISTRY-US, V26, P1704, DOI 10.1021/bi00380a032; BASU A, 1989, J BIOL CHEM, V264, P8746; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BURNS CC, 1989, J VIROL, V63, P4866, DOI 10.1128/JVI.63.11.4866-4874.1989; CHARBONNEAU H, 1989, PRACTICAL GUIDE PROT, P23; CLERTANT P, 1982, J BIOL CHEM, V257, P6300; FRISCHAUF AM, 1973, BIOCHEM BIOPH RES CO, V53, P1227, DOI 10.1016/0006-291X(73)90596-2; GRACHEV MA, 1987, EUR J BIOCHEM, V163, P113, DOI 10.1111/j.1432-1033.1987.tb10743.x; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; HANNA MM, 1989, METHOD ENZYMOL, V180, P383; HARTMANN GR, 1988, BIOL CHEM H-S, V369, P775; HEY TD, 1986, J VIROL, V58, P790, DOI 10.1128/JVI.58.3.790-796.1986; JABLONSKI SA, 1991, J VIROL, V65, P4565, DOI 10.1128/JVI.65.9.4565-4572.1991; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; KELLY S, 1990, J BIOL CHEM, V265, P7787; Kuhn R. J., 1987, The molecular biology of the positive strand RNA viruses, P17; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORROW CD, 1987, P NATL ACAD SCI USA, V84, P6050, DOI 10.1073/pnas.84.17.6050; NANDURI VB, 1990, BIOCHEMISTRY-US, V29, P5258, DOI 10.1021/bi00474a006; NEUFELD KL, 1991, J BIOL CHEM, V266, P24212; NEUFELD KL, 1991, VIRUS RES, V19, P173, DOI 10.1016/0168-1702(91)90044-V; OBERSTE MS, 1988, NUCLEIC ACIDS RES, V16, P10338; PANDEY V, 1987, BIOCHEMISTRY-US, V26, P2033, DOI 10.1021/bi00381a036; PANDEY V, 1988, J BIOL CHEM, V263, P3744; PANDEY VN, 1987, BIOCHEMISTRY-US, V26, P7744, DOI 10.1021/bi00398a031; PLOTCH SJ, 1989, J VIROL, V63, P216, DOI 10.1128/JVI.63.1.216-225.1989; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; RICHARDS OC, 1990, CURR TOP MICROBIOL, V161, P89; RICHARDS OC, 1987, VIROLOGY, V161, P348, DOI 10.1016/0042-6822(87)90127-9; RIVA M, 1990, J BIOL CHEM, V265, P16498; ROTHSTEIN MA, 1988, VIROLOGY, V164, P301, DOI 10.1016/0042-6822(88)90542-9; RUSH J, 1990, J BIOL CHEM, V265, P4821; Sambrook J, 1989, MOL CLONING LABORATO; SEMLER BL, 1988, RNA GENETICS, P23; SPERLING J, 1976, BIOCHEMISTRY-US, V15, P1489, DOI 10.1021/bi00652a020; SUN S, 1990, J VIROL, V64, P5093, DOI 10.1128/JVI.64.10.5093-5105.1990; TIRUMALAI RS, 1991, BIOCHEMISTRY-US, V30, P6436, DOI 10.1021/bi00240a014; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDYKE TA, 1980, J VIROL, V35, P732, DOI 10.1128/JVI.35.3.732-740.1980	43	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17141	17146						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324924				2022-12-27	WOS:A1992JL05300065
J	FONDA, ML				FONDA, ML			PURIFICATION AND CHARACTERIZATION OF VITAMIN-B(6)-PHOSPHATE PHOSPHATASE FROM HUMAN ERYTHROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WEIGHT ACID-PHOSPHATASE; HUMAN SERUM-ALBUMIN; PYRIDOXAL 5'-PHOSPHATE; ALKALINE-PHOSPHATASE; PROTEIN-BINDING; VITAMIN-B6 METABOLISM; RAT-LIVER; PLASMA; LOCALIZATION; PYRIDOXAL-5'-PHOSPHATE	Human erythrocytes rapidly convert vitamin B-6 to pyridoxal-P and contain soluble phosphatase activity which dephosphorylates pyridoxal-P at a pH optimum of 6-6.5. This phosphatase was purified 51,000-fold with a yield of 39% by ammonium sulfate precipitation and chromatography on DEAE-Sepharose, Sephacryl S-200, hydroxylapatite, and reactive yellow 86-agarose. Sephacryl S-200 chromatography and sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed that the enzyme was a dimer with a molecular mass of approximately 64 kDa. The phosphatase required Mg2+ for activity. It specifically catalyzed the removal of phosphate from pyridoxal-P, pyridoxine-P, pyridoxamine-P, 4-pyridoxic acid-P, and 4-deoxypyridoxine-P at pH 7.4. Nucleotide phosphates, phosphoamino acids, and other phosphorylated compounds were not hydrolyzed significantly nor were they effective inhibitors of the enzyme. The phosphatase showed Michaelis-Menten kinetics with its substrates. It had a K(m) of 1.5-mu-M and a V(max) of 3.2-mu-mol/min/mg with pyridoxal-P. The V(max)/K(m) was greatest with pyridoxal-P > 4-pyridoxic acid-P > pyridoxine-P > pyridoxamine-P. The phosphatase was competitively inhibited by the product, inorganic phosphate, with a K(i) of 0.8 mM, and weakly inhibited by pyridoxal. It was also inhibited by Zn2+, fluoride, molybdate, and EDTA, but was not inhibited by levamisole, L-phenylalanine, or L(+)-tartrate. These properties of the purified enzyme suggest that it is a unique acid phosphatase that specifically dephosphorylates vitamin B-6-phosphates.			FONDA, ML (corresponding author), UNIV LOUISVILLE, SCH MED, DEPT BIOCHEM, LOUISVILLE, KY 40292 USA.				NIAAA NIH HHS [AA06861] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006861] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANDERSON BB, 1980, GUT, V21, P192, DOI 10.1136/gut.21.3.192; BOIVIN P, 1986, BIOCHEM BIOPH RES CO, V134, P557, DOI 10.1016/S0006-291X(86)80456-9; COBURN SP, 1986, METHOD ENZYMOL, V122, P102, DOI 10.1016/0076-6879(86)22155-2; Coburn SP, 1988, CLIN PHYSL APPLICATI, P65; COLEMAN JE, 1983, ADV ENZYMOL RAMB, V55, P381; COLEMAN RA, 1980, J HISTOCHEM CYTOCHEM, V28, P115, DOI 10.1177/28.2.7354210; DISSING J, 1990, BIOCHIM BIOPHYS ACTA, V1041, P232, DOI 10.1016/0167-4838(90)90277-M; EBADI M, 1979, INT J BIOCHEM, V10, P705, DOI 10.1016/0020-711X(79)90216-7; Ebadi M., 1986, VITAMIN B6 PYRIDOXAL, P449; FONDA M, 1987, BIOCH VITAMIN B6, P399; FONDA ML, 1982, AM J CLIN NUTR, V35, P1391, DOI 10.1093/ajcn/35.6.1391; FONDA ML, 1991, ARCH BIOCHEM BIOPHYS, V288, P79, DOI 10.1016/0003-9861(91)90167-H; FONDA ML, 1990, ANN NY ACAD SCI, V585, P483, DOI 10.1111/j.1749-6632.1990.tb28082.x; FONDA ML, 1989, ALCOHOL CLIN EXP RES, V13, P804, DOI 10.1111/j.1530-0277.1989.tb00426.x; FUJIMOTO S, 1984, J BIOCHEM, V96, P1079, DOI 10.1093/oxfordjournals.jbchem.a134925; HARRIS H, 1990, CLIN CHIM ACTA, V186, P133, DOI 10.1016/0009-8981(90)90031-M; HENDERSON JM, 1986, HEPATOLOGY, V6, P464, DOI 10.1002/hep.1840060324; HILL DW, 1979, ANAL CHEM, V51, P1338, DOI 10.1021/ac50044a055; KYAW A, 1980, BIOCHEM MED METAB B, V24, P27, DOI 10.1016/0006-2944(80)90083-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE H, 1971, BIOCHIM BIOPHYS ACTA, V242, P519, DOI 10.1016/0005-2744(71)90144-6; LI TK, 1974, BIOCHEM BIOPH RES CO, V61, P677, DOI 10.1016/0006-291X(74)91010-9; LUMENG L, 1980, J CLIN INVEST, V66, P688, DOI 10.1172/JCI109906; LUMENG L, 1974, J CLIN INVEST, V53, P693, DOI 10.1172/JCI107607; LUMENG L, 1974, J LAB CLIN MED, V84, P334; LUMENG L, 1975, J BIOL CHEM, V250, P8126; LUMENG L, 1986, HEPATOLOGY, V6, P330; MIDDLETON HM, 1986, GASTROENTEROLOGY, V91, P343, DOI 10.1016/0016-5085(86)90567-6; MURAKAMI K, 1986, CHEM PHARM BULL, V34, P3320; NATTA CL, 1984, AM J CLIN NUTR, V40, P235, DOI 10.1093/ajcn/40.2.235; RAIBAUD O, 1974, FEBS LETT, V40, P41, DOI 10.1016/0014-5793(74)80889-6; REYNOLDS RD, 1991, AM J CLIN NUTR, V53, P698, DOI 10.1093/ajcn/53.3.698; ROSE ZB, 1981, ARCH BIOCHEM BIOPHYS, V208, P602, DOI 10.1016/0003-9861(81)90549-X; SARASWATHI S, 1963, J NEUROCHEM, V10, P127, DOI 10.1111/j.1471-4159.1963.tb11473.x; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH GP, 1981, BIOCHIM BIOPHYS ACTA, V661, P287, DOI 10.1016/0005-2744(81)90017-6; SMITH GP, 1981, CLIN CHIM ACTA, V114, P257, DOI 10.1016/0009-8981(81)90398-3; SPATER HW, 1978, J HISTOCHEM CYTOCHEM, V26, P809, DOI 10.1177/26.10.31396; STOCK A, 1966, BIOCHEM Z, V344, P353; WADA H, 1961, J BIOL CHEM, V236, P2089; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WILSON PD, 1983, HISTOCHEM J, V15, P257, DOI 10.1007/BF01006240; ZECHER R, 1980, BIOCHEM J, V191, P117, DOI 10.1042/bj1910117	43	45	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15978	15983						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322411				2022-12-27	WOS:A1992JG11300107
J	DAHL, MK; MSADEK, T; KUNST, F; RAPOPORT, G				DAHL, MK; MSADEK, T; KUNST, F; RAPOPORT, G			THE PHOSPHORYLATION STATE OF THE DEGU RESPONSE REGULATOR ACTS AS A MOLECULAR SWITCH ALLOWING EITHER DEGRADATIVE ENZYME-SYNTHESIS OR EXPRESSION OF GENETIC COMPETENCE IN BACILLUS-SUBTILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; ESCHERICHIA-COLI; MUTATIONS; PHOSPHOTRANSFER; PROTEINS; SYSTEMS	Two classes of mutations were identified in the degS and degU regulatory genes of Bacillus subtilis, leading either to deficiency of degradative enzyme synthesis (degS or degU mutations) or to a pleiotropic phenotype which includes overproduction of degradative enzymes and the loss of genetic competence (degS(Hy) or degU(Hy) mutations). We have shown previously that the DegS protein kinase and the DegU response regulator form a signal transduction system in B. subtilis. We now demonstrate that the DegS protein kinase also acts as a DegU phosphatase. We present evidence that the DegU response regulator has two active conformations: a phosphorylated form which is necessary for degradative enzyme synthesis and a nonphosphorylated form required for expression of genetic competence. The degU146-encoded response regulator, allowing expression of genetic competence, has been purified and seems to be modified within the putative phosphorylation site (D56-->N) since it is no longer phosphorylated by DegS. Both the degU146 mutation as well as the degS220 mutation, which essentially abolishes DegS protein kinase activity, lead to deficiency of degradative enzyme synthesis, indicating the requirement of phosphorylated DegU for the expression of this phenotype. We also purified the degU32(Hy)-encoded protein and showed that this response regulator is phosphorylated by the DegS protein kinase in vitro. In addition, the phosphorylated form of the degU32(Hy)-encoded protein presented a strongly increased stability as compared with the wild type DegU protein, thus leading to hyperproduction of degradative enzymes in vivo.			DAHL, MK (corresponding author), INST PASTEUR,CNRS,CNRS,URA 1300,UNITE BIOCHIM MICROBIENNE,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							AIBA H, 1989, J BIOL CHEM, V264, P14090; AIBA H, 1989, J BIOL CHEM, V264, P8563; AMORY A, 1987, J BACTERIOL, V169, P324, DOI 10.1128/jb.169.1.324-333.1987; AYUSAWA D, 1975, J BACTERIOL, V124, P459, DOI 10.1128/JB.124.1.459-469.1975; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; DAHL MK, 1991, J BACTERIOL, V173, P2539, DOI 10.1128/jb.173.8.2539-2547.1991; DUBNAU D, 1991, MICROBIOL REV, V55, P395, DOI 10.1128/MMBR.55.3.395-424.1991; Gibson T., 1984, THESIS U CAMBRIDGE C; HENNER DJ, 1988, J BACTERIOL, V170, P5102, DOI 10.1128/jb.170.11.5102-5109.1988; JIN SG, 1990, J BACTERIOL, V172, P525, DOI 10.1128/jb.172.2.525-530.1990; KUNST F, 1988, J BACTERIOL, V170, P5093, DOI 10.1128/jb.170.11.5093-5101.1988; KUNST F, 1974, BIOCHIMIE, V56, P1481; LUKAT GS, 1991, J BIOL CHEM, V266, P8348; MSADEK T, 1991, J BACTERIOL, V173, P2366, DOI 10.1128/JB.173.7.2366-2377.1991; MSADEK T, 1990, J BACTERIOL, V172, P824, DOI 10.1128/jb.172.2.824-834.1990; MUKAI K, 1990, J BIOL CHEM, V265, P20000; NINFA AJ, 1988, P NATL ACAD SCI USA, V85, P5492, DOI 10.1073/pnas.85.15.5492; ROGGIANI M, 1990, J BACTERIOL, V172, P4056, DOI 10.1128/jb.172.7.4056-4063.1990; Sambrook J, 1989, MOL CLONING LABORATO; Silhavy T. J., 1984, EXPT GENE FUSIONS; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TANAKA T, 1988, J BACTERIOL, V170, P3593, DOI 10.1128/jb.170.8.3593-3600.1988; TANAKA T, 1991, J BACTERIOL, V173, P5507, DOI 10.1128/jb.173.17.5507-5515.1991; YANG M, 1986, J BACTERIOL, V166, P113, DOI 10.1128/jb.166.1.113-119.1986	26	133	143	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14509	14514						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321152				2022-12-27	WOS:A1992JD32500109
J	ABE, T; SUGIHARA, H; NAWA, H; SHIGEMOTO, R; MIZUNO, N; NAKANISHI, S				ABE, T; SUGIHARA, H; NAWA, H; SHIGEMOTO, R; MIZUNO, N; NAKANISHI, S			MOLECULAR CHARACTERIZATION OF A NOVEL METABOTROPIC GLUTAMATE RECEPTOR MGLUR5 COUPLED TO INOSITOL PHOSPHATE/CA2+ SIGNAL TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID RECEPTORS; STIMULATED PHOSPHOINOSITIDE HYDROLYSIS; PHOSPHOLIPID-METABOLISM; FUNCTIONAL EXPRESSION; RECOGNITION SITES; STRIATAL NEURONS; RAT HIPPOCAMPUS; PROTEIN-KINASE; FAMILY; BRAIN	A cDNA clone for a new metabotropic glutamate receptor, mGluR5, was isolated through polymerase chain reaction-mediated DNA amplification by using primer sequences conserved among the metabotropic glutamate receptor (mGluR) family and by the subsequent screening of a rat brain cDNA library. The cloned receptor consists of 1171 amino acid residues and exhibits a structural architecture common to the mGluR family, possessing a large extracellular domain preceding the seven putative membrane-spanning segments. mGluR5 shows the highest sequence similarity to mGluR1 among the mGluR members and is coupled to the stimulation of phosphatidylinositol hydrolysis/Ca2+ signal transduction in Chinese hamster ovary cells transfected with the cloned cDNA. This receptor also resembles mGluR1 in its agonist selectivity and antagonist responses; the potency rank order of agonists for mGluR5 was determined to be quisqualate > L-glutamate greater-than-or-equal-to ibotenate > trans-1-aminocyclopentane-1,3-dicarboxylate. Blot and in situ hybridization analyses indicated that mGluR5 mRNA is widely distributed in neuronal cells of the central nervous system and is expressed differently from mGluR1 mRNA in many brain regions. This investigation thus demonstrates that there is an additional mGluR subtype which closely resembles mGluR1 in its signal transduction and pharmacological properties and is expressed in specialized neuronal cells in the central nervous system.	KYOTO UNIV,FAC MED,DEPT MORPHOL BRAIN SCI,KYOTO 606,JAPAN	Kyoto University	ABE, T (corresponding author), KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN.		Shigemoto, Ryuichi/E-3628-2013	Shigemoto, Ryuichi/0000-0001-8761-9444				ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; GODFREY PP, 1988, BRIT J PHARMACOL, V95, P131, DOI 10.1111/j.1476-5381.1988.tb16556.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; ITO S, 1991, J NEUROCHEM, V56, P531, DOI 10.1111/j.1471-4159.1991.tb08182.x; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MILLER RJ, 1991, TRENDS PHARMACOL SCI, V12, P365, DOI 10.1016/0165-6147(91)90604-Q; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; Nakanishi S, 1990, Recent Prog Horm Res, V46, P59; NICOLETTI F, 1986, J NEUROCHEM, V46, P40, DOI 10.1111/j.1471-4159.1986.tb12922.x; NICOLETTI F, 1986, P NATL ACAD SCI USA, V83, P1931, DOI 10.1073/pnas.83.6.1931; NICOLETTI F, 1990, J NEUROCHEM, V54, P771, DOI 10.1111/j.1471-4159.1990.tb02317.x; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; RECASENS M, 1987, EUR J PHARMACOL, V141, P87, DOI 10.1016/0014-2999(87)90413-4; RECASENS M, 1991, CURRENT ASPECTS NEUR, V3, P103; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; SCHOEPP DD, 1989, J NEUROCHEM, V53, P273, DOI 10.1111/j.1471-4159.1989.tb07324.x; SCHOEPP DD, 1989, J NEUROCHEM, V53, P1865, DOI 10.1111/j.1471-4159.1989.tb09254.x; SHIGEMOTO R, 1992, IN PRESS J COMP NEUR; SLADECZEK F, 1985, NATURE, V317, P717, DOI 10.1038/317717a0; STRATTON KR, 1990, EUR J PHARMACOL, V186, P357, DOI 10.1016/0014-2999(90)90461-E; SUGIYAMA H, 1987, NATURE, V325, P531, DOI 10.1038/325531a0; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WEISS S, 1989, BRAIN RES, V491, P189, DOI 10.1016/0006-8993(89)90104-2; YOUNG AB, 1990, TRENDS PHARMACOL SCI, V11, P126, DOI 10.1016/0165-6147(90)90199-I	44	793	831	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13361	13368						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1320017				2022-12-27	WOS:A1992JB74600044
J	GILGENKRANTZ, H; HUGNOT, JP; LAMBERT, M; CHAFEY, P; KAPLAN, JC; KAHN, A				GILGENKRANTZ, H; HUGNOT, JP; LAMBERT, M; CHAFEY, P; KAPLAN, JC; KAHN, A			POSITIVE AND NEGATIVE REGULATORY DNA ELEMENTS INCLUDING A CCARGG BOX ARE INVOLVED IN THE CELL TYPE-SPECIFIC EXPRESSION OF THE HUMAN MUSCLE DYSTROPHIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC ACTIN GENE; C-FOS; PROMOTER ELEMENTS; MAMMALIAN-CELLS; BINDING-FACTOR; TRANSCRIPTION; ENHANCER; ACTIVATION; MYOGENIN; REGIONS	The muscle-specific promoter of the dystrophin gene is active in skeletal, cardiac, and smooth muscles and is specifically stimulated during differentiation of myoblasts into multinucleated myotubes. An 850-base pair (bp) DNA fragment upstream from the cap site is able to confer a partial muscle specificity to a reporter gene. The region between -850 and -140 bp includes nonspecific negative and positive regulatory sequences. A continuous stretch of 140 bp upstream from the cap site exhibits a striking conservation between rodents and human (93% homology) and still retains muscle preference of expression. It contains two putative binding sites for factors involved in regulation of other muscle-specific genes, a CCArGG box and an E box. This latter element, however, is unable to confer the ability to be transactivated by MyoD1 to the dystrophin promoter. The -140-bp promoter fragment exhibits antagonist effects contributed by one inhibiting sequence (nucleotide -140/-96), active in all cell types, and one activating region, from nucleotide -96 to the cap site, sufficient to confer a muscle preference of expression, in which the CCArGG box seems to play a major role.			GILGENKRANTZ, H (corresponding author), INSERM,U129,INST COCHIN GENET MOLEC,RECH GENET & PATHOL MOLEC LAB,F-75014 PARIS,FRANCE.		Gilgenkrantz, Helene/G-5534-2017	gilgenkrantz, helene/0000-0001-6770-4561				AKLI S, 1991, GENOMICS, V11, P124, DOI 10.1016/0888-7543(91)90109-R; BOYCE FM, 1991, P NATL ACAD SCI USA, V88, P1276, DOI 10.1073/pnas.88.4.1276; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; CHELLY J, 1990, NATURE, V344, P64, DOI 10.1038/344064a0; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOFFMAN EP, 1988, NEURON, V1, P411, DOI 10.1016/0896-6273(88)90191-2; KLAMUT HJ, 1990, MOL CELL BIOL, V10, P193, DOI 10.1128/MCB.10.1.193; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; NUDEL U, 1989, NATURE, V337, P76, DOI 10.1038/337076a0; NUDEL U, 1988, NATURE, V331, P635, DOI 10.1038/331635a0; PHANDINHTUY F, 1988, EUR J BIOCHEM, V173, P507, DOI 10.1111/j.1432-1033.1988.tb14027.x; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; ROSENTHAL N, 1990, NUCLEIC ACIDS RES, V18, P6239, DOI 10.1093/nar/18.21.6239; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; TAYLOR M, 1989, DEVELOPMENT, V106, P67; TAYLOR MV, 1991, NUCLEIC ACIDS RES, V19, P2669, DOI 10.1093/nar/19.10.2669; THOMPSON WR, 1990, MOL CELL BIOL, V266, P22678; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TUIL D, 1990, J MOL BIOL, V213, P677, DOI 10.1016/S0022-2836(05)80255-4; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934	32	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10823	10830						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1316911				2022-12-27	WOS:A1992HV09000093
J	RAHAVMANOR, O; CARMEL, O; KARPEL, R; TAGLICHT, D; GLASER, G; SCHULDINER, S; PADAN, E				RAHAVMANOR, O; CARMEL, O; KARPEL, R; TAGLICHT, D; GLASER, G; SCHULDINER, S; PADAN, E			NHAR, A PROTEIN HOMOLOGOUS TO A FAMILY OF BACTERIAL REGULATORY PROTEINS (LYSR), REGULATES NHAA, THE SODIUM PROTON ANTIPORTER GENE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; PH HOMEOSTASIS; TRANSPORT; SEQUENCES; FRAGMENTS; PROMOTER; DELETION; ANT	On the basis of protein homology, nhaR has previously been shown to belong to a large family of regulatory proteins, the LysR family (Henikoff, S., Haughn, G. W., Calvo, J. M., and Wallace, J. C. (1988) Proc. Natl. Acad. Sci. U.S.A. 85, 6602-6606). In this work we show that nhaR is a regulator of nhaA, a gene encoding a Na+/H+ antiporter in Escherichia coli. Multicopy plasmid bearing nhaR enhances the Na+-dependent induction of a chromosomal nhaA'-'lacZ fusion. Extracts derived from cells overexpressing nhaR exhibit specific DNA binding capacity to the upstream sequences of nhaA. Construction of an nhaR deletion mutant (OR100) shows that nhaR is required in addition to nhaA to tolerate the extreme conditions under which nhaA is indispensable. Whereas OR100 grows like the wild type at neutral pH even at high Na+ concentrations (700 mm), it becomes much more sensitive to Na+ (> 300 mm) at pH 8.5; furthermore, OR100 is more sensitive to Li+ (100 mm) than the wild type. Nevertheless, the phenotype of OR100, which is more resistant to Na+, Li+, and alkaline pH than a DELTA-nhaA strain (NM81), implies that the regulation exerted by nhaR is not complete and that some expression of nhaA exists in OR100. Accordingly, the effect of nhaR in cells is dependent on the level of nhaA. OR200, a nhaA and nhaR deletion mutant, has the same phenotype as NM81. Multicopy plasmid bearing nhaR does not change the phenotype of either OR200 or NM81. On the other hand, multicopy nhaA renders the cells Li+- and Ne-resistant even without nhaR.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT CELLULAR BIOCHEM,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem	RAHAVMANOR, O (corresponding author), HEBREW UNIV JERUSALEM,HADASSAH MED SCH,INST LIFE SCI,DIV MICROBIAL & MOLEC ECOL,IL-91904 JERUSALEM,ISRAEL.		Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237				BAKKER EP, 1990, FEMS MICROBIOL LETT, V75, P319, DOI 10.1111/j.1574-6968.1990.tb04105.x; BOOTH IR, 1985, MICROBIOL REV, V49, P359, DOI 10.1128/MMBR.49.4.359-378.1985; BORON WF, 1983, J MEMBRANE BIOL, V72, P1, DOI 10.1007/BF01870311; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTLE AM, 1986, J BIOL CHEM, V261, P7797; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GILLEN JR, 1981, J BACTERIOL, V145, P521, DOI 10.1128/JB.145.1.521-532.1981; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; HAUSSINGER D, 1988, PH HOMEOSTASIS MECHA; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; KARPEL R, 1988, J BIOL CHEM, V263, P10408; KARPEL R, 1991, J BIOL CHEM, V266, P21753; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; MACKIE GA, 1982, CAN J BIOCHEM CELL B, V60, P338, DOI 10.1139/o82-040; MACKIE GA, 1986, NUCLEIC ACIDS RES, V14, P6965, DOI 10.1093/nar/14.17.6965; MACKIE GA, 1980, J BIOL CHEM, V255, P8928; NACHALIEL N, 1989, NUCLEIC ACIDS RES, V17, P9811, DOI 10.1093/nar/17.23.9811; PADAN E, 1989, J BIOL CHEM, V264, P20297; PADAN E, 1981, BIOCHIM BIOPHYS ACTA, V650, P151, DOI 10.1016/0304-4157(81)90004-6; PAN JW, 1990, J BIOL CHEM, V265, P9247; PINNER E, 1992, J BIOL CHEM, V267, P11064; POUYSSEGUR J, 1988, NAPLUS HPLUS EXCHANG, P337; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; RUTHER U, 1980, MOL GEN GENET, V178, P475, DOI 10.1007/BF00270503; SLONCZEWSKI JL, 1981, P NATL ACAD SCI-BIOL, V78, P6271, DOI 10.1073/pnas.78.10.6271; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985	31	74	78	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10433	10438						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1316901				2022-12-27	WOS:A1992HV09000037
J	HIGASHI, H; YAMAGATA, T				HIGASHI, H; YAMAGATA, T			MECHANISM FOR GANGLIOSIDE-MEDIATED MODULATION OF A CALMODULIN-DEPENDENT ENZYME - MODULATION OF CALMODULIN-DEPENDENT CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE ACTIVITY THROUGH BINDING OF GANGLIOSIDES TO CALMODULIN AND THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; BRAIN; ACTIVATION; GLYCOSPHINGOLIPIDS; PROTEOLYSIS	Gangliosides were recently shown to bind to calmodulin (Higashi, H., Omori, A., and Yamagata, T. (1992) J. Biol. Chem. 267, 9831-9838). This prompted us to investigate the effects of gangliosides on the calmodulin-dependent enzyme, cyclic nucleotide phosphodiesterase. Several species of gangliosides competitively inhibited calmodulin-stimulated phosphodiesterase activity, with G(D1b), G(T1b), and G(D1a) being noted to do so particularly (group 1). G(M1), G(Q1b), and G(M2) (group 2) were less inhibitory, and G(M3), G(M3)(NeuGc), GalCer, sulfatide, GgOse4Cer, and oligosacharide portions of inhibitory gangliosides showed no inhibition in accordance with the binding specificity of calmodulin to gangliosides. Trypsin-activated phosphodiesterase was inhibited by gangliosides with similar specificity, indicating interactions of gangliosides with the enzyme. Inhibition, however, was less than that of calmodulin-dependent activity by these compounds and, in both cases, was eliminated by excess calmodulin. In the absence of calmodulin, group 1 gangliosides at lower concentrations activated the intact enzyme but inhibited, it over a certain range of increase in concentration. Ganglioside-dependent modulation of calmodulin-dependent phosphodiesterase activity is thus shown to be due to interactions of gangliosides with both calmodulin and the enzyme, and consequently, ganglioside-calmodulin binding is likely the mechanism for regulation of the enzyme.			HIGASHI, H (corresponding author), MITSUBISHI KASEI INST LIFE SCI,GLYCOCONJUGATE RES LAB,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							BENFENATI F, 1991, NEUROCHEM INT, V19, P271, DOI 10.1016/0197-0186(91)90011-2; CHEUNG WY, 1971, J BIOL CHEM, V246, P2859; COMTE M, 1983, BIOCHEM J, V209, P269, DOI 10.1042/bj2090269; COX JA, 1981, J BIOL CHEM, V256, P3218; DAVIS CW, 1980, MOL PHARMACOL, V17, P206; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; Fiske CH, 1925, J BIOL CHEM, V66, P375; FUKUNAGA K, 1990, J NEUROCHEM, V54, P102, DOI 10.1111/j.1471-4159.1990.tb13288.x; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HIGASHI H, 1992, J BIOL CHEM, V267, P9831; HIGASHI H, 1988, BIOCHIM BIOPHYS ACTA, V963, P333, DOI 10.1016/0005-2760(88)90299-8; ITO M, 1989, J BIOL CHEM, V264, P9510; JARRETT HW, 1991, J BIOL CHEM, V266, P362; JOURDIAN GW, 1971, J BIOL CHEM, V246, P430; KAKIUCHI S, 1982, J BIOCHEM-TOKYO, V92, P1041, DOI 10.1093/oxfordjournals.jbchem.a134019; KRINKS MH, 1984, ADV CYCLIC NUCL PROT, V16, P31; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; MASSOM L, 1990, BIOCHEMISTRY-US, V29, P671, DOI 10.1021/bi00455a012; SONNINO S, 1979, J NEUROCHEM, V33, P117, DOI 10.1111/j.1471-4159.1979.tb11713.x; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; TUCKER MM, 1981, J BIOL CHEM, V256, P9051; YATES AJ, 1989, J NEUROCHEM, V53, P162, DOI 10.1111/j.1471-4159.1989.tb07308.x	22	61	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9839	9843						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315772				2022-12-27	WOS:A1992HT96500063
J	MUSHA, T; KAWATA, M; TAKAI, Y				MUSHA, T; KAWATA, M; TAKAI, Y			THE GERANYLGERANYL MOIETY BUT NOT THE METHYL MOIETY OF THE SMG-25A RAB3A PROTEIN IS ESSENTIAL FOR THE INTERACTIONS WITH MEMBRANE AND ITS INHIBITORY GDP GTP EXCHANGE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; BOVINE BRAIN; SMG P25A; REGULATORY PROTEIN; RAS; PURIFICATION; DISSOCIATION; SEQUENCES; FARNESYL; P21RAS	The smg-25A/rab3A protein (smg p25A), a member of the small GTP-binding protein superfamily, has a C-terminal structure of Cys-Ala-Cys which is posttranslationally processed: both cysteine residues are geranylgeranylated followed by the carboxyl methylation of the C-terminal cysteine residue. We reported previously that this posttranslational processing is essential for the interactions of smg p25A with membrane and its inhibitory GDP/GTP exchange protein, named smg p25A GDP dissociation inhibitor (GDI). In this study, we examined which posttranslational modification of smg p25A is necessary for these interactions. The smg p25A which was not posttranslationally processed was produced in Escherichia coli and purified. This protein was then geranylgeranylated at both of the 2 cysteine residues by use of a bovine brain geranylgeranyltransferase in a cell-free system (recombinant 8mg p25A-GG). By use of this recombinant smg p25A-GG, its membrane-binding activity and its sensitivity to smg p25A GDI were compared with those of the fully posttranslationally processed form of bovine brain smg p25A (smg p25A-GG-Me) and the posttranslationally unprocessed form of bacterial smg p25A (recombinant smg p25A). The membrane-binding activity and sensitivity to smg p25A GDI were similar between the recombinant smg p25A-GG and smg p25A-GG-Me, although recombinant smg p25A lacked both activities. These results indicate that the geranylgeranyl moiety of smg p25A is essential and sufficient for its interactions with membrane and smg p25A GDI and that the methyl moiety is not essential for these interactions.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University								ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FISCHER V, 1990, P NATL ACAD SCI USA, V87, P1988; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KIM S, 1989, MOL BRAIN RES, V6, P167, DOI 10.1016/0169-328X(89)90051-X; MARR RS, 1990, J BIOL CHEM, V265, P20057; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SASAKI T, 1991, MOL CELL BIOL, V11, P2909, DOI 10.1128/MCB.11.5.2909; SASAKI T, 1990, J BIOL CHEM, V265, P2333; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; UEDA T, 1991, BIOCHEMISTRY-US, V30, P909, DOI 10.1021/bi00218a005; YOSHIDA Y, 1991, BIOCHEM BIOPH RES CO, V175, P720, DOI 10.1016/0006-291X(91)91625-M; ZAHRAOUI A, 1988, NUCLEIC ACIDS RES, V16, P1204, DOI 10.1093/nar/16.3.1204	31	83	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9821	9825						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1315770				2022-12-27	WOS:A1992HT96500060
J	SIMONSON, MS; JONES, JM; DUNN, MJ				SIMONSON, MS; JONES, JM; DUNN, MJ			DIFFERENTIAL REGULATION OF FOS AND JUN GENE-EXPRESSION AND AP-1 CIS-ELEMENT ACTIVITY BY ENDOTHELIN ISOPEPTIDES - POSSIBLE IMPLICATIONS FOR MITOGENIC SIGNALING BY ENDOTHELIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; DNA-BINDING ACTIVITY; PROTO-ONCOGENE; GROWTH-FACTORS; 3T3 CELLS; C-JUN; VASOCONSTRICTOR PEPTIDE; MEMBRANE DEPOLARIZATION; MESANGIAL CELLS; LEUCINE ZIPPER	Endothelins (ET) are potent vasoconstrictor peptides that also function as mitogens for numerous cell types. Although regulation of second messenger pathways by ET peptides has been extensively investigated, little is known about the pathways of nuclear signaling by which ET controls gene expression. The present experiments investigated whether fos and jun contribute to nuclear signaling and gene regulation by ET isopeptides. ET isopeptides induced a subset of fos and jun mRNAs in mesangial cells, including c-fos, fra-1, c-jun, and JunB. fos and jun mRNAs were induced as members of the immediate-early gene response. Activation of the high affinity ET receptor moderately increased c-fos and fra-1 mRNA, whereas activation of the low affinity receptor markedly induced both fos and jun mRNAs. Thus, different ET receptor subtypes evoke distinct patterns of fos and jun induction. Prominent isopeptide- and cell-specific differences in the magnitude and kinetics of fos andjun expression were observed. Most striking was the marked elevation of c-fos steady-state mRNA and protein by ET-1, as compared with ET-3. In addition, ET-1, but not ET-3, increased transcriptional activity conferred by an AP-1 cis-element and directed collagenase gene expression. These results suggest that differential regulation of fos and jun expression and of AP-1 cis-element activity by ET isopeptides contributes to regulation of gene expression by ET. Furthermore, a role for AP-1 in mitogenic signaling by ET is suggested by the close correlation between AP-1 cis-element activity and cell growth.	CASE WESTERN RESERVE UNIV, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA; UNIV HOSP CLEVELAND, DIV NEPHROL, CLEVELAND, OH 44106 USA	Case Western Reserve University; University Hospitals of Cleveland	SIMONSON, MS (corresponding author), CASE WESTERN RESERVE UNIV, DEPT MED, WEARN 433, 2065 ADELBERT RD, CLEVELAND, OH 44106 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022563, R37HL022563] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-22563] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BADR KF, 1989, BIOCHEM BIOPH RES CO, V161, P776, DOI 10.1016/0006-291X(89)92667-3; BALDI E, 1991, J PHARMACOL EXP THER, V256, P581; BALDINO F, 1989, NEUROENDOCRINE PEPTI, P79; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1988, COLD SPRING HARB SYM, V53, P695, DOI 10.1101/SQB.1988.053.01.079; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1987, ONCOGENE, V2, P79; Curran T, 1988, ONCOGENE HDB, P307; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; KARIN M, 1990, MOL ASPECTS CELLULAR, P143; KLOOG Y, 1988, SCIENCE, V242, P268, DOI 10.1126/science.2845579; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARTIN ER, 1990, J BIOL CHEM, V265, P14044; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; QUINN CO, 1990, J BIOL CHEM, V265, P22342; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; SIMONSON MS, 1990, METHOD ENZYMOL, V187, P544; SIMONSON MS, 1991, LAB INVEST, V64, P1; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; SIMONSON MS, 1990, FASEB J, V4, P2989, DOI 10.1096/fasebj.4.12.2168326; SIMONSON MS, 1991, MOL ENDOCRINOL, V5, P441, DOI 10.1210/mend-5-3-441; SIMONSON MS, 1991, EXP CELL RES, V192, P148, DOI 10.1016/0014-4827(91)90169-U; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; VOGT PK, 1991, ADV CANCER RES, V55, P1; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; YANAGISAWA M, 1989, BIOCHEM PHARMACOL, V38, P1877; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	57	88	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8643	8649						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314833				2022-12-27	WOS:A1992HQ18500102
